description,curated_by,variant_id,cell_id,assay_tax_id,assay_subcellular_fraction,src_assay_id,assay_id,chembl_id,assay_tissue,confidence_score,src_id,assay_category,bao_format,assay_test_type,assay_organism,doc_id,tid,assay_type,relationship_type,assay_cell_type,tissue_id,assay_strain
The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,Autocuration,,,,,,1,CHEMBL615117,,8,1,,BAO_0000019,,,11087,12052,B,H,,,
Compound was evaluated for its ability to mobilize calcium in 1321NI cells,Autocuration,,,,,,2,CHEMBL615118,,0,1,,BAO_0000219,,,684,22226,F,U,,,
,Autocuration,,,,,,3,CHEMBL615119,,0,1,,BAO_0000019,,,15453,22226,B,U,,,
Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,Autocuration,,,9913.0,,,4,CHEMBL615120,,4,1,,BAO_0000249,,Bos taurus,17841,104729,B,H,,,
In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,,163.0,9606.0,,,5,CHEMBL615121,,1,1,,BAO_0000219,,Homo sapiens,17430,80001,F,N,143B,,
In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,,163.0,9606.0,,,6,CHEMBL615122,,1,1,,BAO_0000219,,Homo sapiens,17430,80001,F,N,143B,,
Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Intermediate,,163.0,10090.0,,,7,CHEMBL615123,,1,1,,BAO_0000219,,Mus musculus,13799,80001,F,N,143B,,
In vitro cell cytotoxicity was determined against 143B cell line,Expert,,163.0,9606.0,,,8,CHEMBL615124,,1,1,,BAO_0000219,,Homo sapiens,17774,80001,F,N,143B,,
Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,Intermediate,,163.0,9606.0,,,9,CHEMBL615125,,1,1,,BAO_0000219,,Homo sapiens,3801,80001,F,N,143B,,
In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,,163.0,9606.0,,,10,CHEMBL615126,,1,1,,BAO_0000219,,Homo sapiens,17430,80001,F,N,143B,,
In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,,163.0,9606.0,,,11,CHEMBL615127,,1,1,,BAO_0000219,,Homo sapiens,17430,80001,F,N,143B,,
In vitro cell cytotoxicity was determined against 143B-LTK cell line,Expert,,163.0,9606.0,,,12,CHEMBL615128,,1,1,,BAO_0000219,,Homo sapiens,17774,80001,F,N,143B,,
"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,1280.0,,,13,CHEMBL857900,,1,1,,BAO_0000218,,Staphylococcus aureus,11324,50185,F,N,,,
"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,1280.0,,,14,CHEMBL615129,,1,1,,BAO_0000218,,Staphylococcus aureus,11324,50185,F,N,,,
"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,1280.0,,,15,CHEMBL615130,,1,1,,BAO_0000218,,Staphylococcus aureus,11324,50185,F,N,,,
"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,,1280.0,,,16,CHEMBL615131,,1,1,,BAO_0000218,,Staphylococcus aureus,11324,50185,F,N,,,
Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,Expert,,,10116.0,,,17,CHEMBL884521,,9,1,,BAO_0000357,,Rattus norvegicus,11347,100122,A,D,,,
Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,,18,CHEMBL615132,,8,1,,BAO_0000357,,,16474,12054,B,H,,,
Inhibition of partially purified 15-lipoxygenase from human leukocytes,Autocuration,,,,,,19,CHEMBL615133,,8,1,,BAO_0000019,,,10091,12054,B,H,,,
Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,,20,CHEMBL615134,,8,1,,BAO_0000357,,,16474,12054,B,H,,,
Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,,21,CHEMBL615135,,8,1,,BAO_0000357,,,16474,12054,B,H,,,
Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,,,,,22,CHEMBL615136,,8,1,,BAO_0000357,,,16474,12054,B,H,,,
Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,,,,,23,CHEMBL615137,,8,1,,BAO_0000357,,,16474,12054,B,H,,,
Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,,,,,24,CHEMBL615138,,8,1,,BAO_0000357,,,16474,12054,B,H,,,
"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",Autocuration,,,,,,25,CHEMBL836324,,0,1,,BAO_0000219,,,14352,22226,B,U,,,
In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,Autocuration,,,9986.0,,,26,CHEMBL615139,,8,1,,BAO_0000357,,Oryctolagus cuniculus,5646,12054,B,H,,,
Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),Autocuration,,,9986.0,,,27,CHEMBL615140,,8,1,,BAO_0000357,,Oryctolagus cuniculus,5646,12054,B,H,,,
Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,,,,,28,CHEMBL615141,,8,1,,BAO_0000219,,,10997,12426,B,H,,,
Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,Autocuration,,,3847.0,,,29,CHEMBL615142,,8,1,,BAO_0000357,,soya bean,6309,12054,B,H,,,
Inhibitory activity against soybean 15-lipoxygenase was evaluated,Autocuration,,,3847.0,,,30,CHEMBL615143,,8,1,,BAO_0000357,,Glycine max,167,12054,B,H,,,
Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,Autocuration,,,3847.0,,,31,CHEMBL615144,,8,1,,BAO_0000357,,Glycine max,167,12054,B,H,,,
The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,Autocuration,,,3847.0,,,32,CHEMBL872867,,8,1,,BAO_0000357,,Glycine max,11087,12054,B,H,,,
The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,Autocuration,,,3847.0,,,33,CHEMBL615145,,8,1,,BAO_0000357,,Glycine max,11087,12054,B,H,,,
Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,,,3847.0,,,34,CHEMBL615146,,8,1,,BAO_0000357,,Glycine max,13622,12054,B,H,,,
Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,,,3847.0,,,35,CHEMBL615147,,8,1,,BAO_0000357,,Glycine max,13622,12054,B,H,,,
Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,Autocuration,,,10116.0,,,36,CHEMBL615148,,0,1,,BAO_0000019,,Rattus norvegicus,11347,22226,A,U,,,
Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,Autocuration,,,562.0,,,37,CHEMBL615149,,0,1,,BAO_0000019,,Escherichia coli,5926,22226,B,U,,,
Dissociation constant with dimeric 16S rRNA RNA construct B,Autocuration,,,,,,38,CHEMBL615150,,0,1,,BAO_0000019,,,4567,22226,B,U,,,
Dissociation constant towards 16S rRNA construct A,Intermediate,,,,,,39,CHEMBL615151,,3,1,,BAO_0000225,,,3782,22222,B,M,,,
Dissociation constant towards 16S rRNA construct B,Intermediate,,,,,,40,CHEMBL615152,,3,1,,BAO_0000225,,,3782,22222,B,M,,,
Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,Expert,,,562.0,,,41,CHEMBL615153,,3,1,,BAO_0000225,,Escherichia coli,4466,100263,B,M,,,
Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,Expert,,,562.0,,,42,CHEMBL615154,,3,1,,BAO_0000225,,Escherichia coli,6592,100263,B,M,,,
Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,,,,43,CHEMBL615155,,8,1,,BAO_0000019,,,898,13053,B,H,,,
Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,,,,44,CHEMBL615156,,8,1,,BAO_0000019,,,898,13053,B,H,,,
The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,,,9606.0,,,45,CHEMBL615157,,8,1,,BAO_0000019,,Homo sapiens,13163,20001,B,H,,,
The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,,,9606.0,,,46,CHEMBL615158,,8,1,,BAO_0000019,,Homo sapiens,13163,20001,B,H,,,
"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,,,10116.0,,,47,CHEMBL615159,,9,1,,BAO_0000019,,Rattus norvegicus,10691,12971,B,D,,,
"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,,,10116.0,,,48,CHEMBL615172,,9,1,,BAO_0000019,,Rattus norvegicus,10691,12971,B,D,,,
"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,,,10116.0,,,49,CHEMBL615173,,9,1,,BAO_0000019,,Rattus norvegicus,10691,12971,B,D,,,
"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,,,10116.0,,,50,CHEMBL615174,,9,1,,BAO_0000019,,Rattus norvegicus,10691,12971,B,D,,,
Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,,,,,51,CHEMBL884518,,8,1,,BAO_0000019,,,898,13053,B,H,,,
Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),Autocuration,,,,,,52,CHEMBL615175,,8,1,,BAO_0000357,,,912,11512,B,H,,,
Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,Autocuration,,,,,,53,CHEMBL615176,,8,1,,BAO_0000357,,,912,11512,B,H,,,
Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,Autocuration,,,,,,54,CHEMBL615177,,8,1,,BAO_0000357,,,912,11512,B,H,,,
Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Autocuration,,,10116.0,Membranes,,55,CHEMBL615178,,5,1,,BAO_0000249,,Rattus norvegicus,15103,104740,B,D,,,
Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Intermediate,,506.0,9606.0,,,56,CHEMBL615179,,1,1,,BAO_0000219,,Homo sapiens,5116,80002,F,N,1A9,,
Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Autocuration,,,10116.0,,,57,CHEMBL615180,,7,1,,BAO_0000219,,Rattus norvegicus,14578,104835,F,D,Oocytes,,
Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Autocuration,,,10116.0,,,58,CHEMBL615181,,7,1,,BAO_0000219,,Rattus norvegicus,14578,104821,F,D,Oocytes,,
Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Autocuration,,,10116.0,,,59,CHEMBL615182,,7,1,,BAO_0000219,,Rattus norvegicus,14578,104848,F,D,Oocytes,,
In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,Expert,,506.0,9606.0,,,60,CHEMBL615183,,1,1,,BAO_0000219,,Homo sapiens,4787,80002,F,N,1A9,,
In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,Intermediate,,506.0,9606.0,,,61,CHEMBL615184,,1,1,,BAO_0000219,,Homo sapiens,4787,80002,F,N,1A9,,
Cytotoxic activity against human ovarian cancer (1A9) cell line,Intermediate,,506.0,9606.0,,,62,CHEMBL615185,,1,1,,BAO_0000219,,Homo sapiens,3547,80002,F,N,1A9,,
Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,Intermediate,,506.0,9606.0,,,63,CHEMBL615186,,1,1,,BAO_0000219,,Homo sapiens,3547,80002,F,N,1A9,,
Effective dose of compound against replication of 1A9 cell line was evaluated,Intermediate,,506.0,9606.0,,,64,CHEMBL615187,,1,1,,BAO_0000219,,Homo sapiens,6726,80002,F,N,1A9,,
In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,Expert,,506.0,9606.0,,,65,CHEMBL885343,,1,1,,BAO_0000219,,Homo sapiens,3455,80002,F,N,1A9,,
In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),Intermediate,,506.0,9606.0,,,66,CHEMBL615188,,1,1,,BAO_0000219,,Homo sapiens,5726,80002,F,N,1A9,,
In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,Intermediate,,506.0,9606.0,,,67,CHEMBL615189,,1,1,,BAO_0000219,,Homo sapiens,5726,80002,F,N,1A9,,
In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,Intermediate,,506.0,9606.0,,,68,CHEMBL615190,,1,1,,BAO_0000219,,Homo sapiens,5726,80002,F,N,1A9,,
Inhibitory activity against Taxol resistant 1A9 cell lines,Intermediate,,506.0,9606.0,,,69,CHEMBL615191,,1,1,,BAO_0000219,,Homo sapiens,3395,80002,F,N,1A9,,
Cytotoxicity against human ovarian cancer (1A9) cell lines.,Expert,,506.0,9606.0,,,70,CHEMBL615192,,1,1,,BAO_0000219,,Homo sapiens,3415,80002,F,N,1A9,,
Percentage inhibition of human ovarian cancer (1A9) cell lines.,Expert,,506.0,9606.0,,,71,CHEMBL827083,,1,1,,BAO_0000219,,Homo sapiens,3415,80002,F,N,1A9,,
Effective dose required for inhibitory activity against 1A9 human tumor cell line.,Expert,,506.0,9606.0,,,72,CHEMBL615193,,1,1,,BAO_0000219,,Homo sapiens,17099,80002,F,N,1A9,,
Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,Intermediate,,506.0,9606.0,,,73,CHEMBL615194,,1,1,,BAO_0000219,,Homo sapiens,17099,80002,F,N,1A9,,
Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,Intermediate,,506.0,9606.0,,,74,CHEMBL615195,,1,1,,BAO_0000219,,Homo sapiens,17099,80002,F,N,1A9,,
Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,Intermediate,,506.0,9606.0,,,75,CHEMBL615196,,1,1,,BAO_0000219,,Homo sapiens,17099,80002,F,N,1A9,,
Inhibitory concentration against Jurkat cells,Intermediate,,503.0,9606.0,,,76,CHEMBL615197,,1,1,,BAO_0000219,,Homo sapiens,17721,81072,F,N,Jurkat,,
In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,Intermediate,,,,,,77,CHEMBL615198,,0,1,,BAO_0000019,,,1229,22226,F,U,,,
Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,Expert,,,10116.0,,,78,CHEMBL615199,,9,1,,BAO_0000357,,Rattus norvegicus,11347,100121,A,D,,,
"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,,,,,79,CHEMBL615200,,8,1,,BAO_0000357,,,17117,11231,B,H,,,
"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,,,,,80,CHEMBL615201,,8,1,,BAO_0000357,,,17117,11231,B,H,,,
"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",Expert,,,,,,81,CHEMBL615202,,8,1,,BAO_0000357,,,17117,11231,B,H,,,
"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Autocuration,,,5476.0,Microsomes,,82,CHEMBL615203,,8,1,,BAO_0000251,,Candida albicans,11375,11231,B,H,,,
"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Autocuration,,,5476.0,Microsomes,,83,CHEMBL615204,,8,1,,BAO_0000251,,Candida albicans,11375,11231,B,H,,,
"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Autocuration,,,4932.0,Microsomes,,84,CHEMBL615205,,8,1,,BAO_0000251,,Saccharomyces cerevisiae,11375,11231,B,H,,,
"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Autocuration,,,4932.0,Microsomes,,85,CHEMBL615206,,8,1,,BAO_0000251,,Saccharomyces cerevisiae,11375,11231,B,H,,,
"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Autocuration,,,9823.0,Microsomes,,86,CHEMBL615207,Liver,8,1,,BAO_0000251,,Sus scrofa,11375,12083,B,H,,2107.0,
"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",Autocuration,,,10116.0,,,87,CHEMBL827084,,8,1,,BAO_0000019,,Rattus norvegicus,791,11231,B,H,,,
"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",Autocuration,,,10116.0,,,88,CHEMBL615208,,8,1,,BAO_0000019,,Rattus norvegicus,791,11231,B,H,,,
"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",Autocuration,,,10116.0,,,89,CHEMBL615209,,8,1,,BAO_0000019,,Rattus norvegicus,791,11231,B,H,,,
"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Autocuration,,,10116.0,Microsomes,,90,CHEMBL615210,Liver,9,1,,BAO_0000251,,Rattus norvegicus,11375,12083,B,D,,2107.0,
"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,,,10116.0,Microsomes,,91,CHEMBL615211,Liver,9,1,,BAO_0000251,,Rattus norvegicus,11375,12083,B,D,,2107.0,
"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,,,10116.0,Microsomes,,92,CHEMBL615212,Liver,9,1,,BAO_0000251,,Rattus norvegicus,153,12083,B,D,,2107.0,
Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),Expert,,,,,,93,CHEMBL615213,,8,1,,BAO_0000357,,,8269,11377,B,H,,,
Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,Expert,,,,,,94,CHEMBL615273,,8,1,,BAO_0000357,,,8269,11377,B,H,,,
In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,,726.0,9606.0,,,95,CHEMBL615274,,1,1,,BAO_0000219,,Homo sapiens,17653,81020,F,N,HepG2,,
50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,Intermediate,,726.0,9606.0,,,96,CHEMBL615275,,1,1,,BAO_0000219,,Homo sapiens,14277,81020,F,N,HepG2,,
Antiviral activity against Hepatitis B virus in 2.2.15 cell line,Intermediate,,726.0,9606.0,,,97,CHEMBL615276,,1,1,,BAO_0000219,,Homo sapiens,1717,81020,F,N,HepG2,,
In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,Intermediate,,726.0,9606.0,,,98,CHEMBL615277,,1,1,,BAO_0000219,,Homo sapiens,14091,81020,F,N,HepG2,,
In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,Intermediate,,726.0,9606.0,,,99,CHEMBL615326,,1,1,,BAO_0000219,,Homo sapiens,14091,81020,F,N,HepG2,,
In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,,,10407.0,,,100,CHEMBL883130,,1,1,,BAO_0000218,,Hepatitis B virus,17653,50606,F,N,,,
Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,Intermediate,,726.0,9606.0,,,101,CHEMBL884519,,1,1,,BAO_0000219,,Homo sapiens,13105,81020,F,N,HepG2,,
Concentration required to inhibit 50% of 2.2.15 cell line,Intermediate,,726.0,9606.0,,,102,CHEMBL615327,,1,1,,BAO_0000219,,Homo sapiens,1717,81020,F,N,HepG2,,
Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,Intermediate,,726.0,9606.0,,,103,CHEMBL615328,,1,1,,BAO_0000219,,Homo sapiens,13105,81020,A,N,HepG2,,
Cytotoxic activity of compound against uninfected 2.2.15 cells.,Intermediate,,,9606.0,,,104,CHEMBL615329,,1,1,,BAO_0000218,,Homo sapiens,13600,50587,F,N,2.2.15,,
Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,Intermediate,,,9606.0,,,105,CHEMBL615330,,1,1,,BAO_0000218,,Homo sapiens,13467,50587,F,N,2.2.15,,
"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",Expert,,,10407.0,,,106,CHEMBL615331,,1,1,,BAO_0000218,,Hepatitis B virus,17477,50606,F,N,2.2.15,,
In vitro anti-HBV activity in 2.2.15 cells,Intermediate,,,9606.0,,,107,CHEMBL615332,,1,1,,BAO_0000218,,Homo sapiens,1593,50587,F,N,2.2.15,,
In vitro anti-HBV activity in 2.2.15 cells; Not determined,Intermediate,,,9606.0,,,108,CHEMBL615333,,1,1,,BAO_0000218,,Homo sapiens,1593,50587,F,N,2.2.15,,
The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,Intermediate,,,9606.0,,,109,CHEMBL615334,,1,1,,BAO_0000218,,Homo sapiens,15089,50587,F,N,2.2.15,,
The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,Intermediate,,,9606.0,,,110,CHEMBL615335,,1,1,,BAO_0000218,,Homo sapiens,15089,50587,F,N,2.2.15,,
Cytotoxicity in 2.2.15 cells,Intermediate,,,9606.0,,,111,CHEMBL615336,,1,1,,BAO_0000218,,Homo sapiens,1593,50587,F,N,2.2.15,,
Cytotoxicity in 2.2.15 cells; Not determined,Intermediate,,,9606.0,,,112,CHEMBL615337,,1,1,,BAO_0000218,,Homo sapiens,1593,50587,F,N,2.2.15,,
Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,Intermediate,,,9606.0,,,113,CHEMBL615338,,1,1,,BAO_0000218,,Homo sapiens,13600,50587,F,N,2.2.15,,
The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,Intermediate,,,9606.0,,,114,CHEMBL615339,,1,1,,BAO_0000218,,Homo sapiens,13467,50587,F,N,2.2.15,,
Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,Intermediate,,,9606.0,,,115,CHEMBL615340,,1,1,,BAO_0000218,,Homo sapiens,13467,50587,F,N,2.2.15,,
Antiviral activity against HBV was determined in 2.215 cell line,Intermediate,,726.0,9606.0,,,116,CHEMBL615341,,1,1,,BAO_0000219,,Homo sapiens,14764,81020,F,N,HepG2,,
Inhibition of 20-HETE synthesis in human renal microsomes,Autocuration,,,9606.0,Microsomes,,117,CHEMBL615342,,0,1,,BAO_0000251,,Homo sapiens,6531,22226,B,U,,,
Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,Autocuration,,,,,,118,CHEMBL615343,,0,1,,BAO_0000019,,,17322,22226,B,U,,,
Inhibitory concentration against 2008 (ovarian) cells,Intermediate,,388.0,9606.0,,,119,CHEMBL615344,,1,1,,BAO_0000219,,Homo sapiens,17072,80612,F,N,2008,,
50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,Intermediate,,388.0,9606.0,,,120,CHEMBL615345,,1,1,,BAO_0000219,,Homo sapiens,16936,80612,F,N,2008,,
Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),Intermediate,,388.0,9606.0,,,121,CHEMBL615346,,1,1,,BAO_0000219,,Homo sapiens,16936,80612,F,N,2008,,
Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,Intermediate,,388.0,9606.0,,,122,CHEMBL615347,,1,1,,BAO_0000219,,Homo sapiens,17146,80612,F,N,2008,,
Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,Intermediate,,388.0,9606.0,,,123,CHEMBL615348,,1,1,,BAO_0000219,,Homo sapiens,17146,80612,F,N,2008,,
In vitro inhibition of 2008/R ovarian cancer cell line,Intermediate,,561.0,9606.0,,,124,CHEMBL827085,,1,1,,BAO_0000219,,Homo sapiens,10797,80613,F,N,2008/R,,
In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Intermediate,,561.0,9606.0,,,125,CHEMBL615349,,1,1,,BAO_0000219,,Homo sapiens,10797,80613,F,N,2008/R,,
In vitro inhibition of 2008/S ovarian cancer cell line,Intermediate,,389.0,9606.0,,,126,CHEMBL615350,,1,1,,BAO_0000219,,Homo sapiens,10797,80614,F,N,2008/S,,
In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Intermediate,,389.0,9606.0,,,127,CHEMBL615351,,1,1,,BAO_0000219,,Homo sapiens,10797,80614,F,N,2008/S,,
Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,Expert,,,9606.0,,,128,CHEMBL615352,,2,1,,BAO_0000220,,Homo sapiens,4823,100256,B,S,,,
Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,Intermediate,,,9606.0,,,129,CHEMBL615353,,2,1,,BAO_0000220,,Homo sapiens,12912,100256,B,S,,,
Inhibition of chymotrypsin-like activity of 20S proteasome,Expert,,,,,,130,CHEMBL615354,,2,1,,BAO_0000220,,,2957,100256,B,S,,,
Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,Expert,,,,,,131,CHEMBL615355,,2,1,,BAO_0000220,,,2957,100256,B,S,,,
Inhibitory activity against 20S proteosome,Intermediate,,,,,,132,CHEMBL615356,,2,1,,BAO_0000220,,,3260,100256,B,S,,,
Compound was tested for inhibitory activity against tryptase,Autocuration,,,9606.0,,,133,CHEMBL615357,,0,1,,BAO_0000019,,Homo sapiens,3451,22226,B,U,,,
Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,Intermediate,,726.0,9606.0,,,134,CHEMBL615358,,1,1,,BAO_0000219,,Homo sapiens,13885,81020,F,N,HepG2,,
Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,Intermediate,,726.0,9606.0,,,135,CHEMBL827086,,1,1,,BAO_0000219,,Homo sapiens,13885,81020,F,N,HepG2,,
Compound was tested for the inhibition of Alpha-glucosidase,Autocuration,,,,,,136,CHEMBL615359,,0,1,,BAO_0000019,,,3676,22226,B,U,,,
Inhibitory concentration against human neutrophil elastase (HNE),Autocuration,,,,,,137,CHEMBL615360,,8,1,,BAO_0000357,,,6043,235,B,H,,,
Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Autocuration,,,10116.0,,,138,CHEMBL615361,Heart,0,1,,BAO_0000218,,Rattus norvegicus,11140,22226,F,U,,948.0,
90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,,,,,139,CHEMBL615362,,8,1,,BAO_0000019,,,10543,19640,F,H,,,
Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,,,,,140,CHEMBL615363,,8,1,,BAO_0000019,,,10543,19640,F,H,,,
Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,,,,,141,CHEMBL615364,,8,1,,BAO_0000357,,,10543,19640,B,H,,,
90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,,,,,142,CHEMBL615365,,8,1,,BAO_0000019,,,10543,19640,F,H,,,
In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,Intermediate,,524.0,10090.0,,,143,CHEMBL615366,,1,1,,BAO_0000219,,Mus musculus,11365,80360,F,N,P338,,
In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,Intermediate,,524.0,10090.0,,,144,CHEMBL615367,,1,1,,BAO_0000219,,Mus musculus,11365,80360,F,N,P338,,
Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Intermediate,,554.0,9606.0,,,145,CHEMBL615368,,1,1,,BAO_0000219,,Homo sapiens,11803,80384,F,N,PBL,,
Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,Autocuration,,,9940.0,,,146,CHEMBL615369,,0,1,,BAO_0000019,,Ovis aries,11803,22226,F,U,,,
Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Autocuration,,,9940.0,,,147,CHEMBL615370,,0,1,,BAO_0000019,,Ovis aries,11803,22226,F,U,,,
Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),Autocuration,,,,,,148,CHEMBL615673,,8,1,,BAO_0000357,,,12278,191,B,H,,,
Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,Autocuration,,,9606.0,,,149,CHEMBL615674,,0,1,,BAO_0000019,,Homo sapiens,8249,22226,F,U,,,
Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,Autocuration,,,9606.0,,,150,CHEMBL615675,,0,1,,BAO_0000019,,Homo sapiens,8249,22226,F,U,,,
Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,Autocuration,,635.0,9606.0,,,151,CHEMBL615676,,0,1,,BAO_0000219,,Homo sapiens,8249,22226,F,U,CCRF-CEM,,
Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,Autocuration,,635.0,9606.0,,,152,CHEMBL615677,,0,1,,BAO_0000219,,Homo sapiens,8249,22226,F,U,CCRF-CEM,,
Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,Autocuration,,635.0,9606.0,,,153,CHEMBL615678,,0,1,,BAO_0000219,,Homo sapiens,8249,22226,F,U,CCRF-CEM,,
Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,Autocuration,,635.0,9606.0,,,154,CHEMBL615679,,0,1,,BAO_0000219,,Homo sapiens,8249,22226,F,U,CCRF-CEM,,
Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,Autocuration,,,9606.0,,,155,CHEMBL615680,,0,1,,BAO_0000019,,Homo sapiens,8249,22226,F,U,,,
Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,Autocuration,,,9606.0,,,156,CHEMBL615681,,0,1,,BAO_0000019,,Homo sapiens,8249,22226,F,U,,,
In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,Autocuration,,,,,,157,CHEMBL857972,,6,1,,BAO_0000249,,,16992,104290,B,H,,,
Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,Intermediate,,,1314.0,,,158,CHEMBL857899,,1,1,,BAO_0000218,,Streptococcus pyogenes,10543,50264,F,N,,,
Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Intermediate,,,10335.0,,,159,CHEMBL615371,,1,1,,BAO_0000218,,Human herpesvirus 3,17833,50527,F,N,,,
Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,Expert,,468.0,10335.0,,,160,CHEMBL615372,,1,1,,BAO_0000218,,vericilla zoster virus,17290,50527,F,N,HEL,,
Antiviral activity against 07/1 strain of VZV; ND: No data,Intermediate,,,10335.0,,,161,CHEMBL615373,,1,1,,BAO_0000218,,vericilla zoster virus,17290,50527,F,N,,,
Antiviral activity against 07/1 strain of VZV; ND=No data,Intermediate,,,10335.0,,,162,CHEMBL615374,,1,1,,BAO_0000218,,vericilla zoster virus,17290,50527,F,N,,,
"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",Intermediate,,,561.0,,,163,CHEMBL615375,,1,1,,BAO_0000218,,escherichia cloac,10932,50145,F,N,,,
Ratio of Ki at A2 to Ki at A1 receptors,Autocuration,,,,,,164,CHEMBL615376,,0,1,,BAO_0000019,,,9707,22226,B,U,,,
"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",Expert,,,5476.0,,,165,CHEMBL615377,,8,1,,BAO_0000249,,Candida albicans,2346,11143,B,H,,,
"Inhibition of 1,3-beta-glucan synthase",Expert,,,284593.0,,,166,CHEMBL615378,,8,1,,BAO_0000357,,Candida glabrata CBS 138,2205,18077,B,H,,,
Inhibition of growth of 1-87 human tumor cell line,Intermediate,,832.0,9606.0,,,167,CHEMBL615379,,1,1,,BAO_0000219,,Homo sapiens,11900,80609,F,N,1-87 tumor cell line,,
Inhibition of 1-lipoxygenase (LOX)in RBL cells,Expert,,,10116.0,,,168,CHEMBL615380,,9,1,,BAO_0000219,,Rattus norvegicus,14864,12166,B,D,,,
Inhibitory activity against soybean 1-lipoxygenase (SLO),Autocuration,,,3847.0,,,169,CHEMBL615381,,9,1,,BAO_0000357,,Glycine max,16474,100171,B,D,,,
Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,Autocuration,,,3847.0,,,170,CHEMBL615382,,9,1,,BAO_0000357,,Glycine max,16474,100171,B,D,,,
% inhibition against soybean 1-lipoxygenase (SLO),Autocuration,,,3847.0,,,171,CHEMBL615383,,9,1,,BAO_0000357,,Glycine max,16474,100171,B,D,,,
percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,Autocuration,,,3847.0,,,172,CHEMBL615384,,9,1,,BAO_0000357,,Glycine max,16474,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,Autocuration,,,3847.0,,,173,CHEMBL615385,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,Autocuration,,,3847.0,,,174,CHEMBL615386,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,Autocuration,,,3847.0,,,175,CHEMBL615387,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,Autocuration,,,3847.0,,,176,CHEMBL615388,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,Autocuration,,,3847.0,,,177,CHEMBL615214,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,Autocuration,,,3847.0,,,178,CHEMBL827087,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,Autocuration,,,3847.0,,,179,CHEMBL615215,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,Autocuration,,,3847.0,,,180,CHEMBL615216,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,Autocuration,,,3847.0,,,181,CHEMBL615217,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,Autocuration,,,3847.0,,,182,CHEMBL615218,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,Autocuration,,,3847.0,,,183,CHEMBL615219,,9,1,,BAO_0000357,,Glycine max,3094,100171,B,D,,,
Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,Autocuration,,,10090.0,,,184,CHEMBL615220,,0,1,,BAO_0000019,,Mus musculus,10413,22226,B,U,,,
Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),Intermediate,,294.0,10090.0,,,185,CHEMBL615221,,1,1,,BAO_0000219,,Mus musculus,16929,80049,F,N,C3H 10T1/2,,
In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,Intermediate,,,,,,186,CHEMBL615222,,0,1,,BAO_0000019,,,1229,22226,F,U,,,
In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,,,,,187,CHEMBL615223,,8,1,,BAO_0000357,,,16587,11489,B,H,,,
In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,,,,,188,CHEMBL615224,,8,1,,BAO_0000357,,,16587,11862,B,H,,,
In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,Autocuration,,,,,,189,CHEMBL615225,,8,1,,BAO_0000357,,,16587,11862,B,H,,,
Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,Autocuration,,,,,,190,CHEMBL615226,,8,1,,BAO_0000357,,,16587,11489,B,H,,,
Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,Autocuration,,,,,,191,CHEMBL615227,,8,1,,BAO_0000357,,,16587,11862,B,H,,,
Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,Expert,,,9913.0,,,192,CHEMBL615228,,9,1,,BAO_0000019,,Bos taurus,8058,12347,F,D,,,
Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,Expert,,,10116.0,,,193,CHEMBL615229,,9,1,,BAO_0000357,,Rattus norvegicus,9065,100120,B,D,,,
Inhibition of 11 beta-hydroxylase from rat adrenal gland,Expert,,,10116.0,,,194,CHEMBL615230,Adrenal gland,9,1,,BAO_0000357,,Rattus norvegicus,8865,100120,B,D,,2369.0,
Inhibition of rat adrenal 11-beta-hydroxylase,Expert,,,10116.0,,,195,CHEMBL615231,,9,1,,BAO_0000357,,Rattus norvegicus,9066,100120,B,D,,,
Inhibition of rat adrenal 11-beta-hydroxylase,Expert,,,10116.0,,,196,CHEMBL884520,,9,1,,BAO_0000357,,Rattus norvegicus,8394,100120,B,D,,,
Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,Expert,,,10116.0,,,197,CHEMBL615232,,9,1,,BAO_0000357,,Rattus norvegicus,8394,100120,B,D,,,
Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,Autocuration,,,,,,198,CHEMBL615233,,8,1,,BAO_0000019,,,6431,10328,B,H,,,
Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,,,,,199,CHEMBL827088,,8,1,,BAO_0000357,,,6431,11490,B,H,,,
Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,,,,,200,CHEMBL615234,,8,1,,BAO_0000357,,,6431,11490,B,H,,,
Compound was tested for the percent of inhibition against 12-LO at 10 uM,Autocuration,,,,,,201,CHEMBL615235,,8,1,,BAO_0000019,,,9295,11134,F,H,,,
In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,,,,202,CHEMBL615236,,8,1,,BAO_0000019,,,10193,12052,B,H,,,
Compound was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,,,,,203,CHEMBL615237,,8,1,,BAO_0000019,,,13622,11134,B,H,,,
Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,,,,,,204,CHEMBL615238,,8,1,,BAO_0000019,,,12079,11134,F,H,,,
Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,,,,,205,CHEMBL615239,,8,1,,BAO_0000019,,,13622,11134,B,H,,,
Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,,,9606.0,,,206,CHEMBL615240,,9,1,,BAO_0000019,,Homo sapiens,12079,11134,F,D,,,
Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,Expert,,,,,,207,CHEMBL615241,,8,1,,BAO_0000019,,,13500,11835,B,H,,,
Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,Expert,,,,,,208,CHEMBL615242,,8,1,,BAO_0000357,,,13723,11601,B,H,,,
Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),Autocuration,,,,,,209,CHEMBL615243,,8,1,,BAO_0000019,,,16474,11134,B,H,,,
Inhibitory activity against human platelet 12-lipoxygenase,Autocuration,,,,,,210,CHEMBL615244,,8,1,,BAO_0000019,,,1630,11134,B,H,,,
Inhibitory activity against human platelet 12-lipoxygenase was evaluated,Autocuration,,,,,,211,CHEMBL615245,,8,1,,BAO_0000019,,,167,11134,B,H,,,
% inhibition against human platelet 12-lipoxygenase (12-HLO),Autocuration,,,,,,212,CHEMBL615246,,8,1,,BAO_0000019,,,16474,11134,B,H,,,
Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,Autocuration,,,,,,213,CHEMBL615247,,8,1,,BAO_0000019,,,167,11134,B,H,,,
percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,Autocuration,,,,,,214,CHEMBL615248,,8,1,,BAO_0000019,,,16474,11134,B,H,,,
Inhibitory activity towards porcine 12-lipoxygenase,Autocuration,,,,,,215,CHEMBL615249,,8,1,,BAO_0000357,,,10091,11601,B,H,,,
Tested for inhibition against porcine 12-LO,Autocuration,,,,,,216,CHEMBL615250,,8,1,,BAO_0000357,,,11966,11601,B,H,,,
Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,Autocuration,,,,,,217,CHEMBL615251,,8,1,,BAO_0000019,,,951,12052,B,H,,,
Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,Autocuration,,,,,,218,CHEMBL615252,,8,1,,BAO_0000019,,,10997,12052,B,H,,,
In vitro inhibition of rat platelet 12-lipoxygenase,Expert,,,,,,219,CHEMBL828340,,8,1,,BAO_0000019,,,10193,12052,B,H,,,
In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,,,,220,CHEMBL615253,,8,1,,BAO_0000019,,,10193,12052,B,H,,,
In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,Autocuration,,,,,,221,CHEMBL615254,,8,1,,BAO_0000019,,,10193,12052,B,H,,,
In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,Autocuration,,,,,,222,CHEMBL615255,,8,1,,BAO_0000019,,,10193,12052,B,H,,,
In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,,,,,223,CHEMBL615256,,8,1,,BAO_0000019,,,10193,12052,B,H,,,
In vitro inhibitory activity against rat platelet 12-lipoxygenase,Autocuration,,,,,,224,CHEMBL615257,,8,1,,BAO_0000019,,,10193,12052,B,H,,,
The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,Autocuration,,,,,,225,CHEMBL615258,,8,1,,BAO_0000019,,,11087,12052,B,H,,,
Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,Intermediate,,621.0,9606.0,,,226,CHEMBL615259,,1,1,,BAO_0000219,,Homo sapiens,15569,80007,F,N,41M,,
In vitro antitumor activity against 41M cell line.,Expert,,621.0,9606.0,,,227,CHEMBL615260,,1,1,,BAO_0000219,,Homo sapiens,12989,80007,F,N,41M,,
cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,Intermediate,,621.0,9606.0,,,228,CHEMBL615261,,1,1,,BAO_0000219,,Homo sapiens,16745,80007,F,N,41M,,
Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,Intermediate,,621.0,9606.0,,,229,CHEMBL615262,,1,1,,BAO_0000219,,Homo sapiens,15569,80007,F,N,41M,,
In vitro antitumor activity against 41McisR cell line.,Expert,,621.0,9606.0,,,230,CHEMBL615263,,1,1,,BAO_0000219,,Homo sapiens,12989,80007,F,N,41M,,
Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,Expert,,621.0,9606.0,,,231,CHEMBL838393,,1,1,,BAO_0000219,,Homo sapiens,12989,80007,F,N,41M,,
cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,Intermediate,,621.0,9606.0,,,232,CHEMBL615264,,1,1,,BAO_0000219,,Homo sapiens,16745,80007,F,N,41M,,
Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),Expert,,,9606.0,,,233,CHEMBL615265,,9,1,,BAO_0000357,,Homo sapiens,6210,84,B,D,,,
Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,,,9606.0,,,234,CHEMBL615266,,9,1,,BAO_0000357,,Homo sapiens,6210,68,B,D,,,
Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,,,,,,235,CHEMBL615267,,8,1,,BAO_0000357,,,6226,68,B,H,,,
Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,,,,,236,CHEMBL615268,,8,1,,BAO_0000357,,,17855,10201,B,H,,,
Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,Expert,,,,,,237,CHEMBL615269,,8,1,,BAO_0000357,,,17855,10201,B,H,,,
Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,,,,,238,CHEMBL615270,,8,1,,BAO_0000357,,,17855,10201,B,H,,,
"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,,,,239,CHEMBL615271,,8,1,,BAO_0000357,,,10413,12220,B,H,,,
"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,,,562.0,,,240,CHEMBL615272,,8,1,,BAO_0000357,,Escherichia coli,10413,11303,B,H,,,
"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,,,562.0,,,241,CHEMBL615103,,8,1,,BAO_0000357,,Escherichia coli,10413,11303,B,H,,,
"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",Autocuration,,,562.0,,,242,CHEMBL615104,,8,1,,BAO_0000357,,Escherichia coli,10413,11303,B,H,,,
"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,,,,243,CHEMBL615105,,8,1,,BAO_0000357,,,10413,12220,B,H,,,
"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",Autocuration,,,,,,244,CHEMBL872866,,8,1,,BAO_0000357,,,10413,12220,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,9823.0,,,245,CHEMBL615106,,8,1,,BAO_0000357,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",Autocuration,,,9823.0,,,246,CHEMBL615107,,8,1,,BAO_0000019,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,9823.0,,,247,CHEMBL615108,,8,1,,BAO_0000357,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",Autocuration,,,9823.0,,,248,CHEMBL615109,,8,1,,BAO_0000357,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,9823.0,,,249,CHEMBL615110,,8,1,,BAO_0000357,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,9823.0,,,250,CHEMBL840105,,8,1,,BAO_0000019,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",Autocuration,,,9823.0,,,251,CHEMBL615111,,8,1,,BAO_0000019,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,9823.0,,,252,CHEMBL615112,,8,1,,BAO_0000019,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",Autocuration,,,9823.0,,,253,CHEMBL615113,,8,1,,BAO_0000019,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",Autocuration,,,9823.0,,,254,CHEMBL615114,,8,1,,BAO_0000019,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,,9823.0,,,255,CHEMBL615115,,8,1,,BAO_0000357,,Sus scrofa,7587,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,9823.0,,,256,CHEMBL615116,,8,1,,BAO_0000019,,Sus scrofa,7587,11303,B,H,,,
"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",Autocuration,,,,,,257,CHEMBL615698,,8,1,,BAO_0000357,,,7323,11303,B,H,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",Autocuration,,,9823.0,,,258,CHEMBL615699,,0,1,,BAO_0000019,,Sus scrofa,7587,22226,B,U,,,
"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",Autocuration,,,9823.0,,,259,CHEMBL615700,,0,1,,BAO_0000019,,Sus scrofa,7587,22226,B,U,,,
Inhibition of 5-Desaturase involved in ergosterol biosynthesis,Expert,,,4932.0,,,260,CHEMBL615701,,8,1,,BAO_0000357,,Saccharomyces cerevisiae,13750,100249,B,H,,,
Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,,,10116.0,,,261,CHEMBL615702,,0,1,,BAO_0000019,,Rattus norvegicus,7662,22226,B,U,,,
Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,,,10116.0,,,262,CHEMBL615703,,0,1,,BAO_0000019,,Rattus norvegicus,7662,22226,B,U,,,
"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",Autocuration,,,10116.0,,,263,CHEMBL615704,,0,1,,BAO_0000019,,Rattus norvegicus,7662,22226,B,U,,,
"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,,,,,264,CHEMBL615705,,6,1,,BAO_0000019,,,12211,104698,F,H,,,
"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,,,,,265,CHEMBL615706,,6,1,,BAO_0000019,,,12211,104698,F,H,,,
Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Intermediate,,,10141.0,,,266,CHEMBL615707,Ileum,9,1,,BAO_0000221,,Cavia porcellus,12211,20033,F,D,,2116.0,
Stimulatory activity of intragastric pressure was tested in the rat,Expert,,,,,,267,CHEMBL615708,,8,1,,BAO_0000019,,,12211,10623,F,H,,,
% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,Autocuration,,,,,,268,CHEMBL615709,,8,1,,BAO_0000357,,,15453,121,B,H,,,
Dose to reduce neuronal firing against 5-HT cells in rats (iv),Autocuration,,,10116.0,,,269,CHEMBL615710,,0,1,,BAO_0000218,,Rattus norvegicus,11884,22226,F,U,,,
Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,,,,,270,CHEMBL615711,,8,1,,BAO_0000019,,,7185,12688,F,H,,,
Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,Expert,,,9606.0,,,271,CHEMBL615712,,9,1,,BAO_0000357,,Homo sapiens,6876,121,B,D,,,
Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,Expert,,,9606.0,,,272,CHEMBL836325,,9,1,,BAO_0000357,,Homo sapiens,6876,121,B,D,,,
Inhibition of high affinity 5-HT uptake at concentration of 1 uM,Autocuration,,,,,,273,CHEMBL615713,,8,1,,BAO_0000019,,,11863,12198,F,H,,,
Inhibition constant of high-affinity 5-HT uptake,Autocuration,,,,,,274,CHEMBL615714,,8,1,,BAO_0000357,,,11863,12198,B,H,,,
Michaelis-Menten constant was reported for high affinity transport of 5-HT,Autocuration,,,,,,275,CHEMBL615715,,8,1,,BAO_0000019,,,11863,12198,F,H,,,
Maximum rate was determined for high affinity transport of 5-HT,Autocuration,,,,,,276,CHEMBL615716,,8,1,,BAO_0000019,,,11863,12198,F,H,,,
Compound was tested for agonistic activity against 5-HT uptake,Autocuration,,,,,,277,CHEMBL615717,,4,1,,BAO_0000019,,,4639,104714,F,H,,,
Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,Expert,,,,,,278,CHEMBL881818,,8,1,,BAO_0000019,,,15796,10577,B,H,,,
Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,Expert,,,9913.0,,,279,CHEMBL884540,,8,1,,BAO_0000357,,Bos taurus,15796,105,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,,,10116.0,,,280,CHEMBL615718,,5,1,,BAO_0000224,,Rattus norvegicus,12801,104744,B,D,,,
The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,Autocuration,,,,,,281,CHEMBL615719,,4,1,,BAO_0000224,,,12801,104744,B,H,,,
Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Autocuration,,,,Membranes,,282,CHEMBL615720,,4,1,,BAO_0000249,,,12120,104744,B,H,,,
Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Autocuration,,,,Membranes,,283,CHEMBL615721,,4,1,,BAO_0000249,,,12120,104744,B,H,,,
Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,,284,CHEMBL615722,,4,1,,BAO_0000019,,,11963,104744,B,H,,,
Dose required to reduce neuronal firing of 5-HT1A cells by 50%,Autocuration,,,,,,285,CHEMBL615723,,8,1,,BAO_0000019,,,11701,51,F,H,,,
In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,,,286,CHEMBL615724,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,,,287,CHEMBL615725,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,,,288,CHEMBL615726,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),Autocuration,,,,,,289,CHEMBL615727,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,Intermediate,,,10141.0,,,290,CHEMBL615728,,9,1,,BAO_0000019,,Cavia porcellus,11574,105570,F,D,,,
Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,449.0,,,,291,CHEMBL857971,,8,1,,BAO_0000219,,,15779,279,B,H,CHO,,
Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,292,CHEMBL615729,,8,1,,BAO_0000357,,,15363,107,B,H,,,
Efficacy against 5-hydroxytryptamine 2A receptor,Expert,,,10116.0,,,293,CHEMBL615730,,9,1,,BAO_0000019,,Rattus norvegicus,15363,12687,F,D,,,
Intrinsic activity towards 5-HT2A receptor of rat tail artery,Expert,,,,,,294,CHEMBL615731,,8,1,,BAO_0000019,,,15329,12687,F,H,,,
Relative potency towards 5-HT2A receptor of rat tail artery,Expert,,,,,,295,CHEMBL615732,,8,1,,BAO_0000019,,,15329,12687,F,H,,,
Blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,,,,,296,CHEMBL615733,,8,1,,BAO_0000019,,,15329,12687,F,H,,,
Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,Expert,,,,,,297,CHEMBL615734,,8,1,,BAO_0000019,,,15329,12687,F,H,,,
Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,Autocuration,,,,,,298,CHEMBL615735,,8,1,,BAO_0000019,,,15329,12687,F,H,,,
Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,,,,,299,CHEMBL615736,,8,1,,BAO_0000019,,,15329,12687,F,H,,,
Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,10141.0,,,300,CHEMBL615737,Ileum,9,1,,BAO_0000221,,Cavia porcellus,273,20033,F,D,,2116.0,
Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Intermediate,,,10141.0,,,301,CHEMBL615738,Ileum,9,1,,BAO_0000221,,Cavia porcellus,273,20033,F,D,,2116.0,
Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,10141.0,,,302,CHEMBL615739,Ileum,9,1,,BAO_0000221,,Cavia porcellus,273,20033,F,D,,2116.0,
The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,Autocuration,,,,,,303,CHEMBL615278,,8,1,,BAO_0000357,,,12092,10623,B,H,,,
Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Expert,,,10116.0,,,304,CHEMBL615279,,9,1,,BAO_0000019,,Rattus norvegicus,1317,10623,F,D,,,
Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,,,,,305,CHEMBL615280,,8,1,,BAO_0000357,,,12409,168,B,H,,,
Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,Autocuration,,,9031.0,,,306,CHEMBL615281,,0,1,,BAO_0000019,,Gallus gallus,11126,22226,B,U,,,
Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,Autocuration,,,9606.0,,,307,CHEMBL615282,,0,1,,BAO_0000019,,Homo sapiens,11126,22226,F,U,,,
25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,,,9606.0,,,308,CHEMBL615283,,0,1,,BAO_0000019,,Homo sapiens,11126,22226,F,U,,,
Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,Autocuration,,649.0,9606.0,,,309,CHEMBL615284,,1,1,,BAO_0000219,,Homo sapiens,11126,80156,B,N,HL-60,,
Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,Autocuration,,,9606.0,,,310,CHEMBL615285,,0,1,,BAO_0000019,,Homo sapiens,11126,22226,B,U,,,
25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,,,9606.0,,,311,CHEMBL615286,,0,1,,BAO_0000019,,Homo sapiens,11126,22226,B,U,,,
Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Autocuration,,,9606.0,,,312,CHEMBL615287,,7,1,,BAO_0000219,,Homo sapiens,17807,104703,B,D,Oocytes,,
Chymotryptic inhibitory activity against 26S proteasome,Intermediate,,,,,,313,CHEMBL615288,,2,1,,BAO_0000220,,,16575,100256,F,S,,,
Inhibitory activity against 26S proteasome degradation of IkB,Intermediate,,,,,,314,CHEMBL615289,,2,1,,BAO_0000220,,,15407,100256,B,S,,,
In vitro inhibition of 2780/DOX ovarian cancer cell line,Intermediate,,478.0,9606.0,,,315,CHEMBL615290,,1,1,,BAO_0000219,,Homo sapiens,10797,81034,F,N,A2780,,
In vitro inhibition of 2780/S ovarian cancer cell line,Intermediate,,478.0,9606.0,,,316,CHEMBL884522,,1,1,,BAO_0000219,,Homo sapiens,10797,81034,F,N,A2780,,
Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,Autocuration,,,9606.0,,,317,CHEMBL615291,,0,1,,BAO_0000019,,Homo sapiens,3469,22226,F,U,,,
Association constant for binding to AATT 28-mer AATT hairpin,Intermediate,,,,,,318,CHEMBL615292,,3,1,,BAO_0000225,,,16037,22222,B,M,,,
Kinetically Defined Association Constant for 28-mer AATT hairpin.,Intermediate,,,,,,319,CHEMBL615293,,3,1,,BAO_0000225,,,16037,22222,B,M,,,
Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,,,,,320,CHEMBL615294,,3,1,,BAO_0000225,,,16037,22222,B,M,,,
Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,,,,,321,CHEMBL615295,,3,1,,BAO_0000225,,,16037,22222,B,M,,,
Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),Autocuration,,,9606.0,,,322,CHEMBL825021,,0,1,,BAO_0000019,,Homo sapiens,16524,22226,F,U,,,
Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),Autocuration,,,9606.0,,,323,CHEMBL615296,,0,1,,BAO_0000019,,Homo sapiens,16524,22226,F,U,,,
Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,Autocuration,,,9606.0,,,324,CHEMBL615297,,0,1,,BAO_0000019,,Homo sapiens,16524,22226,F,U,,,
Cytotoxicity against cell line 2SC/20 determined by MTT test,Autocuration,,,10029.0,,,325,CHEMBL615298,,0,1,,BAO_0000019,,Cricetulus griseus,16758,22226,F,U,,,
Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,Autocuration,,,10029.0,,,326,CHEMBL615299,,0,1,,BAO_0000019,,Cricetulus griseus,16758,22226,F,U,,,
Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Autocuration,,,10029.0,,,327,CHEMBL615300,,0,1,,BAO_0000019,,Cricetulus griseus,16758,22226,F,U,,,
Binding affinity on 3 beta-hydroxysteroid dehydrogenase,Autocuration,,,,,,328,CHEMBL615301,,8,1,,BAO_0000357,,,14360,241,B,H,,,
Binding affinity for 3-beta-hydroxysteroid dehydrogenase,Expert,,,9606.0,,,329,CHEMBL615302,,9,1,,BAO_0000357,,Homo sapiens,14360,241,B,D,,,
Selectivity ratio of ID50 in liver and heart,Autocuration,,,10116.0,,,330,CHEMBL615303,,0,1,,BAO_0000019,,Rattus norvegicus,9964,22226,B,U,,,
"Selectivity, ratio of relative ID50 in liver and heart",Autocuration,,,,,,331,CHEMBL615304,,8,1,,BAO_0000019,,,9964,12132,B,H,,,
Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,Autocuration,,,,,,332,CHEMBL615305,,8,1,,BAO_0000019,,,9964,12132,B,H,,,
"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,,333,CHEMBL615306,,8,1,,BAO_0000218,,,9964,12132,B,H,,,
"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,,334,CHEMBL615307,,8,1,,BAO_0000218,,,9964,12132,B,H,,,
"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,,335,CHEMBL615308,,8,1,,BAO_0000218,In vivo,,9964,12132,B,H,,,
"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,,336,CHEMBL615309,,8,1,,BAO_0000218,In vivo,,9964,12132,F,H,,,
"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",Autocuration,,,,,,337,CHEMBL615310,,0,1,,BAO_0000019,,,9964,22226,B,U,,,
Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,Autocuration,,,,,,338,CHEMBL615311,,8,1,,BAO_0000019,,,9964,12132,B,H,,,
"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",Autocuration,,,9606.0,,,339,CHEMBL615312,,0,1,,BAO_0000019,,Homo sapiens,9964,22226,B,U,,,
In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,,,,,340,CHEMBL615313,,8,1,,BAO_0000019,,,9964,12132,B,H,,,
In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,,,,,341,CHEMBL615314,,8,1,,BAO_0000019,,,9964,12132,F,H,,,
"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,,342,CHEMBL615315,,8,1,,BAO_0000019,,,9964,12132,B,H,,,
"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",Autocuration,,,10116.0,,,343,CHEMBL615316,,0,1,,BAO_0000218,,Rattus norvegicus,9964,22226,B,U,,,
Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,Autocuration,,,,,,344,CHEMBL615317,,8,1,,BAO_0000218,In vivo,,9964,12132,B,H,,,
"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,,345,CHEMBL615318,,8,1,,BAO_0000218,,,9964,12132,B,H,,,
"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",Autocuration,,,10116.0,,,346,CHEMBL615319,,0,1,,BAO_0000218,,Rattus norvegicus,9964,22226,B,U,,,
"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,,347,CHEMBL615320,,8,1,,BAO_0000019,,,9964,12132,B,H,,,
"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,,,,,348,CHEMBL615321,,8,1,,BAO_0000019,,,9964,12132,F,H,,,
"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",Autocuration,,,10116.0,,,349,CHEMBL615322,,0,1,,BAO_0000019,,Rattus norvegicus,3796,22226,B,U,,,
Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,,,562.0,,,350,CHEMBL615323,,8,1,,BAO_0000357,,Escherichia coli,4251,19690,B,H,,,
Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,,,562.0,,,351,CHEMBL615407,,8,1,,BAO_0000357,,Escherichia coli,4251,19690,B,H,,,
Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,,,562.0,,,352,CHEMBL857267,,8,1,,BAO_0000357,,Escherichia coli,4251,19690,B,H,,,
Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,,,562.0,,,353,CHEMBL615408,,8,1,,BAO_0000357,,Escherichia coli,4251,19690,B,H,,,
Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,Autocuration,,,,,,354,CHEMBL615409,,8,1,,BAO_0000357,,,166,19690,B,H,,,
Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,Autocuration,,,,,,355,CHEMBL615410,,8,1,,BAO_0000357,,,17861,19690,B,H,,,
Inhibition constant against 3-dehydroquinate synthase,Autocuration,,,,,,356,CHEMBL615411,,8,1,,BAO_0000357,,,166,19690,B,H,,,
Association rate constant against 3-dehydroquinate synthase,Autocuration,,,,,,357,CHEMBL615412,,8,1,,BAO_0000357,,,166,19690,B,H,,,
Rate constant against 3-dehydroquinate synthase,Autocuration,,,,,,358,CHEMBL615413,,8,1,,BAO_0000357,,,166,19690,B,H,,,
Inhibitory activity against fuc-TVII,Autocuration,,,,,,359,CHEMBL615414,,0,1,,BAO_0000019,,,3548,22226,B,U,,,
Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,10116.0,Microsomes,,360,CHEMBL615415,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,10116.0,Microsomes,,361,CHEMBL615416,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,10116.0,Microsomes,,362,CHEMBL615417,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,10116.0,Microsomes,,363,CHEMBL615418,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,,10116.0,Microsomes,,364,CHEMBL615419,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Autocuration,,,10116.0,Microsomes,,365,CHEMBL615420,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Autocuration,,,10116.0,Microsomes,,366,CHEMBL615421,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Autocuration,,,10116.0,Microsomes,,367,CHEMBL615422,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Autocuration,,,10116.0,Microsomes,,368,CHEMBL615423,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Autocuration,,,10116.0,Microsomes,,369,CHEMBL872868,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Autocuration,,,10116.0,Microsomes,,370,CHEMBL615424,Liver,9,1,,BAO_0000251,,Rattus norvegicus,9877,12236,B,D,,2107.0,
Inhibitory activity against 3-phosphoglycerate kinase.,Autocuration,,,,,,371,CHEMBL825022,,4,1,,BAO_0000224,,,3003,104832,B,H,,,
Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,Autocuration,,,,,,372,CHEMBL615425,,4,1,,BAO_0000224,,,3003,104832,B,H,,,
"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",Autocuration,,,,,,373,CHEMBL615426,,4,1,,BAO_0000224,,,3003,104832,B,H,,,
Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,Expert,,,9606.0,,,374,CHEMBL615427,,9,1,,BAO_0000357,,Homo sapiens,17185,10612,B,D,,,
Cytotoxicity on 3677 melanoma cells,Intermediate,,844.0,9606.0,,,375,CHEMBL615428,,1,1,,BAO_0000219,,Homo sapiens,6072,80616,F,N,3677 melanoma cell line,,
Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,Intermediate,,844.0,9606.0,,,376,CHEMBL615429,,1,1,,BAO_0000219,,Homo sapiens,6072,80616,F,N,3677 melanoma cell line,,
Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,Intermediate,,700.0,10090.0,,,377,CHEMBL615430,,1,1,,BAO_0000219,,Mus musculus,5018,80617,F,N,MC-38,,
Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,Intermediate,,,9606.0,,,378,CHEMBL615431,,0,1,,BAO_0000019,,Homo sapiens,2852,22226,F,U,,,
In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,Autocuration,,798.0,,,,379,CHEMBL615432,,0,1,,BAO_0000218,,,8663,22226,F,U,B16,,
In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,Autocuration,,798.0,,,,380,CHEMBL615433,,0,1,,BAO_0000218,,,8663,22226,F,U,B16,,
Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,Expert,,,12131.0,,,381,CHEMBL615434,,9,1,,BAO_0000019,,Human rhinovirus 14,3245,12464,F,D,,,
Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,Intermediate,,,169066.0,,,382,CHEMBL615435,,1,1,,BAO_0000218,,Human rhinovirus sp.,3245,50085,F,N,,,
Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,Intermediate,,,169066.0,,,383,CHEMBL615436,,1,1,,BAO_0000218,,human rhinovirus type 14,3877,50679,F,N,,,
Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,Intermediate,,,169066.0,,,384,CHEMBL615437,,1,1,,BAO_0000218,,human rhinovirus type 14,3877,50679,F,N,,,
Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,,12131.0,,,385,CHEMBL615438,,9,1,,BAO_0000019,,Human rhinovirus 14,5861,12464,F,D,,,
Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,,12131.0,,,386,CHEMBL615439,,9,1,,BAO_0000019,,Human rhinovirus 14,5861,12464,F,D,,,
Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,,12131.0,,,387,CHEMBL615440,,9,1,,BAO_0000019,,Human rhinovirus 14,5861,12464,F,D,,,
Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,Expert,,,12131.0,,,388,CHEMBL615441,,9,1,,BAO_0000019,,Human rhinovirus 14,5861,12464,F,D,,,
Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,Intermediate,,,12059.0,,,389,CHEMBL615641,,1,1,,BAO_0000218,,Enterovirus,13748,50665,F,N,,,
Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,Intermediate,,,12059.0,,,390,CHEMBL872065,,1,1,,BAO_0000218,,Enterovirus,13748,50665,F,N,,,
Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,Intermediate,,,12059.0,,,391,CHEMBL825023,,1,1,,BAO_0000218,,Enterovirus,13748,50665,F,N,,,
Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,Intermediate,,,12059.0,,,392,CHEMBL615642,,1,1,,BAO_0000218,,Enterovirus,13748,50665,F,N,,,
Inhibition of human rhinovirus 3C protease,Expert,,,147712.0,,,393,CHEMBL615643,,8,1,,BAO_0000357,,Human rhinovirus B,13748,12464,B,H,,,
Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,Autocuration,,,9606.0,,,394,CHEMBL615644,,0,1,,BAO_0000019,,Homo sapiens,17699,22226,B,U,,,
Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),Intermediate,,833.0,10090.0,,,395,CHEMBL615645,,1,1,,BAO_0000218,,Mus musculus,7145,80619,F,N,3EM 37,,
Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),Intermediate,,833.0,10090.0,,,396,CHEMBL615646,,1,1,,BAO_0000218,,Mus musculus,7145,80619,F,N,3EM 37,,
Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),Intermediate,,833.0,10090.0,,,397,CHEMBL615647,,1,1,,BAO_0000218,,Mus musculus,7145,80619,F,N,3EM 37,,
Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),Intermediate,,833.0,10090.0,,,398,CHEMBL615648,,1,1,,BAO_0000218,,Mus musculus,7145,80619,F,N,3EM 37,,
Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,Intermediate,,833.0,10090.0,,,399,CHEMBL615649,,1,1,,BAO_0000218,,Mus musculus,7145,80619,F,N,3EM 37,,
Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,Intermediate,,833.0,10090.0,,,400,CHEMBL615650,,1,1,,BAO_0000218,,Mus musculus,7145,80619,F,N,3EM 37,,
In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,,847.0,10090.0,,,401,CHEMBL615651,,1,1,,BAO_0000218,,Mus musculus,5325,80620,F,N,3LL cell line,,
In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,,847.0,10090.0,,,402,CHEMBL615652,,1,1,,BAO_0000218,,Mus musculus,5325,80620,F,N,3LL cell line,,
In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,Expert,,847.0,10090.0,,,403,CHEMBL615653,,1,1,,BAO_0000218,,Mus musculus,5325,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,Intermediate,,847.0,10090.0,,,404,CHEMBL615654,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,Intermediate,,847.0,10090.0,,,405,CHEMBL615655,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,Intermediate,,847.0,10090.0,,,406,CHEMBL825024,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,Intermediate,,847.0,10090.0,,,407,CHEMBL615656,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,Intermediate,,847.0,10090.0,,,408,CHEMBL615657,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,Intermediate,,847.0,10090.0,,,409,CHEMBL615658,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,Intermediate,,847.0,10090.0,,,410,CHEMBL615659,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,Intermediate,,847.0,10090.0,,,411,CHEMBL615660,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,,847.0,10090.0,,,412,CHEMBL615661,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,Intermediate,,847.0,10090.0,,,413,CHEMBL615662,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,Intermediate,,847.0,10090.0,,,414,CHEMBL615663,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,Intermediate,,847.0,10090.0,,,415,CHEMBL615664,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,Intermediate,,847.0,10090.0,,,416,CHEMBL615665,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,,847.0,10090.0,,,417,CHEMBL615666,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
putrescine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,,847.0,10090.0,,,418,CHEMBL615667,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
putrescine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,,847.0,10090.0,,,419,CHEMBL615668,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
putrescine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,,847.0,10090.0,,,420,CHEMBL615669,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
putrescine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,,847.0,10090.0,,,421,CHEMBL615670,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
spermidine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,,847.0,10090.0,,,422,CHEMBL836739,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
spermidine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,,847.0,10090.0,,,423,CHEMBL615671,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
spermidine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,,847.0,10090.0,,,424,CHEMBL615672,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
spermidine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,,847.0,10090.0,,,425,CHEMBL615791,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
spermine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,,847.0,10090.0,,,426,CHEMBL615792,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
spermine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,,847.0,10090.0,,,427,CHEMBL615793,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
spermine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,,847.0,10090.0,,,428,CHEMBL615794,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
spermine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,,847.0,10090.0,,,429,CHEMBL615795,,1,1,,BAO_0000219,,Mus musculus,16169,80620,F,N,3LL cell line,,
Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,Intermediate,,971.0,9606.0,,,430,CHEMBL615590,,1,1,,BAO_0000219,,Homo sapiens,15547,80621,F,N,3LLD122,,
In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,Autocuration,,,,,,431,CHEMBL615591,,0,1,,BAO_0000218,,,8663,22226,F,U,,,
In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,Autocuration,,,,,,432,CHEMBL615592,,0,1,,BAO_0000218,,,8663,22226,F,U,,,
In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,Autocuration,,,,,,433,CHEMBL615593,,0,1,,BAO_0000218,,,8663,22226,F,U,,,
In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,Autocuration,,,,,,434,CHEMBL615594,,0,1,,BAO_0000218,,,8663,22226,F,U,,,
Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,,723.0,10090.0,,,435,CHEMBL615595,,1,1,,BAO_0000219,,Mus musculus,4504,80951,F,N,NIH3T3,,
Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,,723.0,10090.0,,,436,CHEMBL615596,,1,1,,BAO_0000219,,Mus musculus,4504,80951,F,N,NIH3T3,,
Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,Expert,,723.0,,,,437,CHEMBL615597,,8,1,,BAO_0000219,,,12695,11169,F,H,NIH3T3,,
Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,Intermediate,,723.0,10090.0,,,438,CHEMBL615598,,1,1,,BAO_0000219,,Mus musculus,12695,80951,F,N,NIH3T3,,
Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,Intermediate,,723.0,10090.0,,,439,CHEMBL615599,,1,1,,BAO_0000219,,Mus musculus,12695,80951,F,N,NIH3T3,,
Effective dose against murine 3T3 fibroblasts cells,Expert,,723.0,10090.0,,,440,CHEMBL615600,,1,1,,BAO_0000219,,Mus musculus,17642,80951,F,N,NIH3T3,,
Dose required against murine 3T3 fibroblasts cells; 1-10 uM,Expert,,723.0,10090.0,,,441,CHEMBL615601,,1,1,,BAO_0000219,,Mus musculus,17642,80951,F,N,NIH3T3,,
Cytotoxic effect on 3T3 cells,Expert,,723.0,10090.0,,,442,CHEMBL615602,,1,1,,BAO_0000219,,Mus musculus,12340,80951,F,N,NIH3T3,,
Cytotoxic effect on 3T3 cells,Expert,,723.0,10090.0,,,443,CHEMBL615603,,1,1,,BAO_0000219,,Mus musculus,12340,80951,F,N,NIH3T3,,
Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,Intermediate,,723.0,10090.0,,,444,CHEMBL615604,,1,1,,BAO_0000219,,Mus musculus,12716,80951,F,N,NIH3T3,,
Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,,723.0,10090.0,,,445,CHEMBL615605,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,Intermediate,,723.0,10090.0,,,446,CHEMBL615606,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,Expert,,723.0,10090.0,,,447,CHEMBL884526,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,Expert,,723.0,10090.0,,,448,CHEMBL615607,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,Intermediate,,723.0,10090.0,,,449,CHEMBL615608,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,Expert,,723.0,10090.0,,,450,CHEMBL615609,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,Expert,,723.0,10090.0,,,451,CHEMBL615682,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,Intermediate,,723.0,10090.0,,,452,CHEMBL615683,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,Expert,,723.0,10090.0,,,453,CHEMBL615684,,1,1,,BAO_0000218,,Mus musculus,17780,80951,F,N,NIH3T3,,
Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,Autocuration,,,10090.0,,,454,CHEMBL615685,,7,1,,BAO_0000219,,Mus musculus,12751,104860,F,D,,,
Inhibition of Swiss 3T3 Mouse fibroblast proliferation,Expert,,723.0,10090.0,,,455,CHEMBL615686,,1,1,,BAO_0000219,,Mus musculus,12380,80951,F,N,NIH3T3,,
Inhibitory activity against 3T3 cell line,Intermediate,,723.0,10090.0,,,456,CHEMBL615687,,1,1,,BAO_0000219,,Mus musculus,14892,80951,F,N,NIH3T3,,
The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,Intermediate,,723.0,10090.0,,,457,CHEMBL884523,,1,1,,BAO_0000219,,Mus musculus,12695,80951,F,N,NIH3T3,,
Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,Expert,,,,,,458,CHEMBL615688,,8,1,,BAO_0000019,,,12695,11169,F,H,,,
The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,Intermediate,,723.0,10090.0,,,459,CHEMBL615689,,1,1,,BAO_0000219,,Mus musculus,12695,80951,F,N,NIH3T3,,
The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,Intermediate,,723.0,10090.0,,,460,CHEMBL615690,,1,1,,BAO_0000219,,Mus musculus,12695,80951,F,N,NIH3T3,,
The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,Expert,,,,,,461,CHEMBL615691,,8,1,,BAO_0000019,,,12695,11169,F,H,,,
The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,Expert,,,,,,462,CHEMBL615692,,8,1,,BAO_0000019,,,12695,11169,F,H,,,
Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,,723.0,10090.0,,,463,CHEMBL615693,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,Expert,,723.0,10090.0,,,464,CHEMBL615324,,1,1,,BAO_0000219,,Mus musculus,6277,80951,F,N,NIH3T3,,
Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Expert,,723.0,9606.0,,,465,CHEMBL615325,,9,1,,BAO_0000219,,Homo sapiens,4959,9,F,D,NIH3T3,,
Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),Expert,,723.0,9606.0,,,466,CHEMBL615490,,9,1,,BAO_0000219,,Homo sapiens,4959,9,F,D,NIH3T3,,
Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,Expert,,723.0,9606.0,,,467,CHEMBL615491,,9,1,,BAO_0000219,,Homo sapiens,4959,188,F,D,NIH3T3,,
Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),Expert,,723.0,9606.0,,,468,CHEMBL615492,,9,1,,BAO_0000219,,Homo sapiens,4959,188,F,D,NIH3T3,,
Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,Intermediate,,723.0,10090.0,,,469,CHEMBL615493,,1,1,,BAO_0000219,,Mus musculus,12082,80951,F,N,NIH3T3,,
Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,Intermediate,,723.0,10090.0,,,470,CHEMBL615494,,1,1,,BAO_0000219,,Mus musculus,12082,80951,F,N,NIH3T3,,
Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,Intermediate,,723.0,10090.0,,,471,CHEMBL615495,,1,1,,BAO_0000219,,Mus musculus,12082,80951,F,N,NIH3T3,,
Inhibitory concentration was calculated on 3T3 cells by using growth assay,Intermediate,,723.0,10090.0,,,472,CHEMBL615496,,1,1,,BAO_0000219,,Mus musculus,12082,80951,F,N,NIH3T3,,
In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,Intermediate,,723.0,10090.0,,,473,CHEMBL615497,,1,1,,BAO_0000219,,Mus musculus,2643,80951,F,N,NIH3T3,,
Inhibition of Swiss 3T3 mouse fibroblast proliferation,Expert,,723.0,10090.0,,,474,CHEMBL615498,,1,1,,BAO_0000219,,Mus musculus,11926,80951,F,N,NIH3T3,,
The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,Intermediate,,723.0,10090.0,,,475,CHEMBL615499,,1,1,,BAO_0000219,,Mus musculus,15204,80951,A,N,NIH3T3,,
Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Expert,,723.0,10090.0,,,476,CHEMBL835522,,1,1,,BAO_0000219,,Mus musculus,15992,80951,F,N,NIH3T3,,
Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,Intermediate,,723.0,10090.0,,,477,CHEMBL615500,,1,1,,BAO_0000219,,Mus musculus,16279,80951,F,N,NIH3T3,,
Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,723.0,10090.0,,,478,CHEMBL615501,,1,1,,BAO_0000219,,Mus musculus,16279,80951,F,N,NIH3T3,,
Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,723.0,10090.0,,,479,CHEMBL615502,,1,1,,BAO_0000219,,Mus musculus,16279,80951,F,N,NIH3T3,,
cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,723.0,10090.0,,,480,CHEMBL615503,,1,1,,BAO_0000219,,Mus musculus,16279,80951,F,N,NIH3T3,,
Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,723.0,10090.0,,,481,CHEMBL615504,,1,1,,BAO_0000219,,Mus musculus,16279,80951,F,N,NIH3T3,,
Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,,723.0,10090.0,,,482,CHEMBL615505,,1,1,,BAO_0000219,,Mus musculus,16279,80951,F,N,NIH3T3,,
Inhibition of swiss 3T3 mouse fibroblast proliferation,Expert,,723.0,10090.0,,,483,CHEMBL615506,,1,1,,BAO_0000219,,Mus musculus,12831,80951,F,N,NIH3T3,,
Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,Intermediate,,723.0,10090.0,,,484,CHEMBL615507,,1,1,,BAO_0000219,,Mus musculus,13497,80951,F,N,NIH3T3,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,,620.0,,,,485,CHEMBL615508,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,Intermediate,,620.0,10090.0,,,486,CHEMBL615509,,1,1,,BAO_0000219,,Mus musculus,13618,80006,F,N,3T3-L1,,
Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,Intermediate,,620.0,10090.0,,,487,CHEMBL615510,,1,1,,BAO_0000219,,Mus musculus,11902,80006,F,N,3T3-L1,,
Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,Intermediate,,620.0,10090.0,,,488,CHEMBL615511,,1,1,,BAO_0000219,,Mus musculus,11902,80006,F,N,3T3-L1,,
Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,Intermediate,,620.0,10090.0,,,489,CHEMBL615512,,1,1,,BAO_0000219,,Mus musculus,11902,80006,F,N,3T3-L1,,
"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",Intermediate,,620.0,10090.0,,,490,CHEMBL615513,,1,1,,BAO_0000218,,Mus musculus,14840,80006,F,N,3T3-L1,,
"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",Intermediate,,620.0,10090.0,,,491,CHEMBL615514,,1,1,,BAO_0000218,,Mus musculus,14840,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,Intermediate,,620.0,,,,492,CHEMBL615515,,1,1,,BAO_0000219,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,,620.0,,,,493,CHEMBL615516,,1,1,,BAO_0000219,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,620.0,,,,494,CHEMBL615517,,1,1,,BAO_0000219,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,,620.0,,,,495,CHEMBL615518,,1,1,,BAO_0000219,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,620.0,,,,496,CHEMBL615519,,1,1,,BAO_0000219,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,Intermediate,,620.0,,,,497,CHEMBL615520,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,Intermediate,,620.0,,,,498,CHEMBL615521,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,,620.0,,,,499,CHEMBL615522,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,,620.0,,,,500,CHEMBL615523,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Expert,,620.0,,,,501,CHEMBL615524,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Expert,,620.0,,,,502,CHEMBL615525,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,,620.0,,,,503,CHEMBL615526,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,,620.0,,,,504,CHEMBL615527,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,Intermediate,,620.0,,,,505,CHEMBL615528,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Expert,,620.0,,,,506,CHEMBL615529,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Expert,,620.0,,,,507,CHEMBL615530,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Expert,,620.0,,,,508,CHEMBL615531,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,,620.0,,,,509,CHEMBL615532,,1,1,,BAO_0000219,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,,620.0,,,,510,CHEMBL615533,,1,1,,BAO_0000219,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,,620.0,,,,511,CHEMBL615534,,1,1,,BAO_0000219,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Intermediate,,620.0,,,,512,CHEMBL615535,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,,620.0,,,,513,CHEMBL615536,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,,620.0,,,,514,CHEMBL615537,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,,620.0,,,,515,CHEMBL615538,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Intermediate,,620.0,,,,516,CHEMBL836166,,1,1,,BAO_0000218,,,13715,80006,F,N,3T3-L1,,
Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,Expert,,620.0,,,,517,CHEMBL615539,,8,1,,BAO_0000219,,,6411,11214,F,H,3T3-L1,,
Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,Intermediate,,620.0,10090.0,,,518,CHEMBL615540,,1,1,,BAO_0000219,,Mus musculus,6411,80006,F,N,3T3-L1,,
Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,Expert,,620.0,,,,519,CHEMBL615541,,8,1,,BAO_0000219,,,6411,11214,F,H,3T3-L1,,
Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,Expert,,620.0,10090.0,,,520,CHEMBL615542,,1,1,,BAO_0000219,,Mus musculus,3966,80006,F,N,3T3-L1,,
Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,Intermediate,,620.0,10090.0,,,521,CHEMBL615543,,1,1,,BAO_0000219,,Mus musculus,3966,80006,F,N,3T3-L1,,
Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,Expert,,620.0,10090.0,,,522,CHEMBL615544,,1,1,,BAO_0000219,,Mus musculus,15556,80006,F,N,3T3-L1,,
Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,,620.0,10090.0,,,523,CHEMBL615545,,1,1,,BAO_0000219,,Mus musculus,5845,80006,F,N,3T3-L1,,
Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,,620.0,10090.0,,,524,CHEMBL615546,,1,1,,BAO_0000219,,Mus musculus,14422,80006,F,N,3T3-L1,,
Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,Expert,,620.0,10090.0,,,525,CHEMBL615547,,1,1,,BAO_0000219,,Mus musculus,5845,80006,F,N,3T3-L1,,
In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,Expert,,620.0,10090.0,,,526,CHEMBL615548,,1,1,,BAO_0000219,,Mus musculus,14508,80006,F,N,3T3-L1,,
In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,Expert,,620.0,10090.0,,,527,CHEMBL615549,,1,1,,BAO_0000219,,Mus musculus,14508,80006,F,N,3T3-L1,,
In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,Expert,,620.0,10090.0,,,528,CHEMBL615550,,1,1,,BAO_0000219,,Mus musculus,14508,80006,F,N,3T3-L1,,
Inhibitory activity against rat fibroblast (3Y1) cell line,Intermediate,,1118.0,10116.0,,,529,CHEMBL615551,,1,1,,BAO_0000219,,Rattus norvegicus,6349,80622,F,N,3Y1 cell line,,
Mean concentration causing inhibition of cell growth in 3Y1 cells.,Expert,,1118.0,10116.0,,,530,CHEMBL615552,,1,1,,BAO_0000219,,Rattus norvegicus,15899,80622,F,N,3Y1 cell line,,
Cytotoxicity in 3Y1 cells.,Expert,,1118.0,10116.0,,,531,CHEMBL615553,,1,1,,BAO_0000219,,Rattus norvegicus,15899,80622,F,N,3Y1 cell line,,
Cytostatic effect in 3Y1 cells.,Expert,,1118.0,10116.0,,,532,CHEMBL615554,,1,1,,BAO_0000219,,Rattus norvegicus,15899,80622,F,N,3Y1 cell line,,
"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",Intermediate,,1118.0,10116.0,,,533,CHEMBL615555,,1,1,,BAO_0000219,,Rattus norvegicus,15899,80622,F,N,3Y1 cell line,,
Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,Expert,,1118.0,10116.0,,,534,CHEMBL615556,,1,1,,BAO_0000219,,Rattus norvegicus,17038,80622,F,N,3Y1 cell line,,
In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,Autocuration,,,,,,535,CHEMBL615557,,0,1,,BAO_0000019,,,12421,22226,B,U,,,
Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,,,,,536,CHEMBL615558,,0,1,,BAO_0000019,,,12947,22226,B,U,,,
Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,,,,,537,CHEMBL872066,,0,1,,BAO_0000019,,,12947,22226,B,U,,,
In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,Expert,,,9823.0,,,538,CHEMBL615559,,9,1,,BAO_0000019,,Sus scrofa,4896,11607,B,D,,,
In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,Autocuration,,,,,,539,CHEMBL615560,,8,1,,BAO_0000019,,,6148,11607,B,H,,,
Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,Autocuration,,,,,,540,CHEMBL615561,,8,1,,BAO_0000019,,,16432,11607,B,H,,,
Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,Expert,,,,,,541,CHEMBL857062,,8,1,,BAO_0000019,,,4978,11607,B,H,,,
Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),Expert,,,,,,542,CHEMBL615562,,8,1,,BAO_0000019,,,4978,11607,B,H,,,
In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,Autocuration,,,,,,543,CHEMBL615563,,8,1,,BAO_0000019,,,3723,11607,B,H,,,
Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),Autocuration,,,,,,544,CHEMBL615564,,8,1,,BAO_0000357,,,3518,11607,B,H,,,
In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,Autocuration,,,,,,545,CHEMBL615565,,8,1,,BAO_0000019,,,4164,11607,B,H,,,
Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,Autocuration,,,,,,546,CHEMBL615566,,8,1,,BAO_0000019,,,3518,11607,B,H,,,
Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,Expert,,,9823.0,,,547,CHEMBL615567,,9,1,,BAO_0000019,,Sus scrofa,4164,11607,B,D,,,
The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,Autocuration,,,,,,548,CHEMBL615568,,8,1,,BAO_0000019,,,3518,11607,B,H,,,
Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),Autocuration,,,,,,549,CHEMBL615569,,8,1,,BAO_0000357,,,3518,11607,B,H,,,
Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,Autocuration,,,,,,550,CHEMBL615570,,8,1,,BAO_0000019,,,4978,11607,B,H,,,
Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),Autocuration,,,,,,551,CHEMBL615571,,8,1,,BAO_0000019,,,4978,11607,B,H,,,
Binding affinity against melatonin (MT1) receptor (pC1),Autocuration,,,,,,552,CHEMBL615572,,4,1,,BAO_0000224,,,6455,104733,B,H,,,
Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,,553,CHEMBL615573,,0,1,,BAO_0000019,,,2222,22226,B,U,,,
Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,Autocuration,,,,,,554,CHEMBL615574,,0,1,,BAO_0000019,,,13020,22226,B,U,,,
Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,Autocuration,,,,,,555,CHEMBL615575,,0,1,,BAO_0000019,,,13021,22226,B,U,,,
Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,Autocuration,,,,,,556,CHEMBL615576,,8,1,,BAO_0000357,,,14532,10619,B,H,,,
Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,,,,,,557,CHEMBL615577,,8,1,,BAO_0000357,,,14118,10619,B,H,,,
Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Autocuration,,,,,,558,CHEMBL615578,Hippocampus,8,1,,BAO_0000221,,,11884,51,B,H,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,Expert,,,,,,559,CHEMBL615579,,8,1,,BAO_0000357,,,13969,51,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,,,,,,560,CHEMBL615580,,8,1,,BAO_0000357,,,13392,51,B,H,,,
Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,Expert,,,,,,561,CHEMBL615581,,8,1,,BAO_0000019,,,14430,51,B,H,,,
Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,,,,562,CHEMBL615582,Hippocampus,8,1,,BAO_0000221,,,12248,51,B,H,,10000000.0,
Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,,,,563,CHEMBL615583,Hippocampus,8,1,,BAO_0000221,,,12249,51,B,H,,10000000.0,
In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,,,564,CHEMBL615584,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,,,565,CHEMBL833691,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,,,566,CHEMBL615585,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,,,567,CHEMBL615586,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,,,568,CHEMBL884524,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,,,,,569,CHEMBL615587,Hippocampus,8,1,,BAO_0000221,,,12249,51,B,H,,10000000.0,
"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Autocuration,,,,,,570,CHEMBL615588,Hippocampus,8,1,,BAO_0000221,,,11799,51,B,H,,10000000.0,
Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Expert,,,10116.0,Membranes,,571,CHEMBL615589,,9,1,,BAO_0000249,,Rattus norvegicus,14331,10576,B,D,,,
Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Expert,,,9913.0,,,572,CHEMBL615442,Hippocampus,8,1,,BAO_0000221,,Bos taurus,11884,51,B,H,,10000000.0,
Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Autocuration,,,,,,573,CHEMBL615443,Hippocampus,8,1,,BAO_0000221,,,14331,51,B,H,,10000000.0,
Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Autocuration,,,,,,574,CHEMBL615444,Hippocampus,8,1,,BAO_0000221,,,11701,51,B,H,,10000000.0,
Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Expert,,,,,,575,CHEMBL615445,Hippocampus,8,1,,BAO_0000221,,,11701,51,B,H,,10000000.0,
Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Autocuration,,,,,,576,CHEMBL615446,Hippocampus,8,1,,BAO_0000221,,,12248,51,B,H,,10000000.0,
Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,Autocuration,,449.0,,,,577,CHEMBL615447,,8,1,,BAO_0000219,,,12248,51,B,H,CHO,,
Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,,,,,578,CHEMBL615448,Hippocampus,8,1,,BAO_0000221,,,12248,51,B,H,,10000000.0,
Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,,,,,579,CHEMBL615449,Hippocampus,8,1,,BAO_0000221,,,12249,51,B,H,,10000000.0,
Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,449.0,,,,580,CHEMBL615450,,8,1,,BAO_0000219,,,12248,51,B,H,CHO,,
"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Expert,,,,,,581,CHEMBL615451,Hippocampus,8,1,,BAO_0000221,,,11799,51,B,H,,10000000.0,
Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,,,,,582,CHEMBL615452,,8,1,,BAO_0000357,,,634,51,B,H,,,
In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,,,583,CHEMBL615453,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,,,584,CHEMBL615454,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,,,585,CHEMBL615455,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,,,586,CHEMBL615456,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,,,,,587,CHEMBL615457,Hippocampus,8,1,,BAO_0000221,,,9995,51,B,H,,10000000.0,
In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Expert,,,,,,588,CHEMBL615458,Hippocampus,8,1,,BAO_0000218,,,12210,51,B,H,,10000000.0,
Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Expert,,,,,,589,CHEMBL615459,Hippocampus,8,1,,BAO_0000221,,,13311,51,B,H,,10000000.0,
"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",Expert,,449.0,9606.0,,,590,CHEMBL615460,,9,1,,BAO_0000219,,Homo sapiens,2331,51,B,D,CHO,,
Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,Autocuration,,,10141.0,,,591,CHEMBL615461,,8,1,,BAO_0000019,,Cavia porcellus,1375,51,F,H,,,
Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Autocuration,,,10141.0,,,592,CHEMBL615462,,8,1,,BAO_0000019,,Cavia porcellus,1375,51,F,H,,,
Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Autocuration,,,10141.0,,,593,CHEMBL615463,Hippocampus,8,1,,BAO_0000221,,Cavia porcellus,11574,51,F,H,,10000000.0,
Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,,,10141.0,,,594,CHEMBL615464,Ileum,8,1,,BAO_0000221,,Cavia porcellus,12867,51,B,H,,2116.0,
Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,,10141.0,,,595,CHEMBL615465,Ileum,8,1,,BAO_0000221,,Cavia porcellus,12867,51,B,H,,2116.0,
Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,,,10141.0,,,596,CHEMBL615466,Ileum,8,1,,BAO_0000221,,Cavia porcellus,12867,51,B,H,,2116.0,
Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,,10141.0,,,597,CHEMBL615467,Ileum,8,1,,BAO_0000221,,Cavia porcellus,12867,51,B,H,,2116.0,
Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,,10141.0,,,598,CHEMBL615468,Ileum,8,1,,BAO_0000221,,Cavia porcellus,12867,51,B,H,,2116.0,
Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Autocuration,,,10141.0,,,599,CHEMBL615469,Ileum,8,1,,BAO_0000221,,Cavia porcellus,12867,51,B,H,,2116.0,
Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,10141.0,,,600,CHEMBL615470,,8,1,,BAO_0000357,,Cavia porcellus,11574,51,B,H,,,
Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,10141.0,,,601,CHEMBL615471,,8,1,,BAO_0000357,,Cavia porcellus,13114,51,B,H,,,
Binding affinity was determined against 5-hydroxytryptamine 1A receptor,Autocuration,,,10141.0,,,602,CHEMBL615472,,8,1,,BAO_0000357,,Cavia porcellus,13181,51,B,H,,,
Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,,,10141.0,,,603,CHEMBL883242,Hippocampus,8,1,,BAO_0000221,,Cavia porcellus,10639,106,B,H,,10000000.0,
Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,,,10141.0,,,604,CHEMBL615473,Hippocampus,8,1,,BAO_0000221,,Cavia porcellus,10639,106,F,H,,10000000.0,
In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,,449.0,10029.0,,,605,CHEMBL615474,,8,1,,BAO_0000218,,Cricetulus griseus,11883,11863,B,H,CHO,,
Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,606,CHEMBL615475,,8,1,,BAO_0000357,,,17785,51,B,H,,,
Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,Autocuration,,308.0,,,,607,CHEMBL615476,,8,1,,BAO_0000219,,,1558,51,F,H,HeLa,,
Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,Autocuration,,308.0,,,,608,CHEMBL615477,,8,1,,BAO_0000219,,,1558,51,F,H,HeLa,,
EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,609,CHEMBL615478,,8,1,,BAO_0000019,,,15740,51,F,H,,,
Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Autocuration,,449.0,,,,610,CHEMBL615160,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Expert,,449.0,,,,611,CHEMBL615161,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,Autocuration,,449.0,,,,612,CHEMBL615162,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,Autocuration,,449.0,,,,613,CHEMBL615163,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,,449.0,,,,614,CHEMBL615164,,8,1,,BAO_0000219,,,17624,51,B,H,CHO,,
Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,,449.0,,,,615,CHEMBL615165,,8,1,,BAO_0000219,,,17624,51,B,H,CHO,,
Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,Autocuration,,449.0,,,,616,CHEMBL615166,,8,1,,BAO_0000219,,,17624,51,B,H,CHO,,
In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,Autocuration,,,,,,617,CHEMBL615167,,8,1,,BAO_0000219,,,14256,51,F,H,,,
Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,,308.0,9606.0,,,618,CHEMBL615168,,9,1,,BAO_0000219,,Homo sapiens,3445,51,B,D,HeLa,,
Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,Expert,,308.0,9606.0,,,619,CHEMBL615169,,9,1,,BAO_0000219,,Homo sapiens,3445,51,B,D,HeLa,,
Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,Expert,,449.0,9606.0,,,620,CHEMBL615170,,9,1,,BAO_0000219,,Homo sapiens,17200,51,B,D,CHO,,
Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,Expert,,449.0,9606.0,,,621,CHEMBL615171,,9,1,,BAO_0000219,,Homo sapiens,17200,51,B,D,CHO,,
Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,622,CHEMBL615694,,8,1,,BAO_0000019,,,15180,51,F,H,,,
Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,623,CHEMBL615695,,8,1,,BAO_0000019,,,15180,51,F,H,,,
"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,,,,624,CHEMBL615696,,8,1,,BAO_0000019,,,16026,51,F,H,,,
Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,449.0,,,,625,CHEMBL615697,,8,1,,BAO_0000219,,,2759,51,F,H,CHO,,
Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,,449.0,9606.0,,,626,CHEMBL859410,,9,1,,BAO_0000219,,Homo sapiens,2759,51,F,D,CHO,,
Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,,449.0,,,,627,CHEMBL615841,,8,1,,BAO_0000219,,,2759,51,F,H,CHO,,
Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,,449.0,9606.0,,,628,CHEMBL615842,,9,1,,BAO_0000219,,Homo sapiens,2759,51,F,D,CHO,,
Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,449.0,,,,629,CHEMBL835003,,8,1,,BAO_0000219,,,2759,51,F,H,CHO,,
Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),Autocuration,,449.0,,,,630,CHEMBL615843,,8,1,,BAO_0000219,,,2759,51,F,H,CHO,,
Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,,449.0,9606.0,,,631,CHEMBL615979,,9,1,,BAO_0000219,,Homo sapiens,2759,51,F,D,CHO,,
Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,,449.0,,,,632,CHEMBL615980,,8,1,,BAO_0000219,,,2759,51,F,H,CHO,,
Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,,449.0,9606.0,,,633,CHEMBL615981,,9,1,,BAO_0000219,,Homo sapiens,2759,51,F,D,CHO,,
Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,Expert,,,9606.0,,,634,CHEMBL615982,,9,1,,BAO_0000019,,Homo sapiens,3445,51,F,D,,,
"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,,9606.0,,,635,CHEMBL615983,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",Expert,,,9606.0,,,636,CHEMBL615984,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",Expert,,,9606.0,,,637,CHEMBL615985,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,,449.0,,,,638,CHEMBL615986,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,,449.0,,,,639,CHEMBL615987,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,,449.0,,,,640,CHEMBL615988,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Expert,,449.0,,,,641,CHEMBL615989,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,,449.0,,,,642,CHEMBL615990,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,Autocuration,,449.0,,,,643,CHEMBL615991,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,,449.0,,,,644,CHEMBL615992,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,,449.0,,,,645,CHEMBL615993,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Expert,,449.0,,,,646,CHEMBL615994,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,Autocuration,,449.0,,,,647,CHEMBL615995,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,,449.0,,,,648,CHEMBL615996,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,,449.0,,,,649,CHEMBL615997,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,,650,CHEMBL615998,,8,1,,BAO_0000019,,,6563,51,F,H,,,
"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,,651,CHEMBL615999,,8,1,,BAO_0000019,,,6563,51,F,H,,,
Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,,,,,652,CHEMBL616000,,8,1,,BAO_0000019,,,6563,51,F,H,,,
Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,722.0,,,,653,CHEMBL616001,,8,1,,BAO_0000219,,,17296,51,F,H,HEK293,,
"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",Expert,,,9606.0,,,654,CHEMBL616002,,9,1,,BAO_0000019,,Homo sapiens,6876,51,F,D,,,
"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",Expert,,,,,,655,CHEMBL616003,,8,1,,BAO_0000019,,,6876,51,F,H,,,
In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,Expert,,,9606.0,,,656,CHEMBL616004,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,Expert,,,9606.0,,,657,CHEMBL616005,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,,,,658,CHEMBL616006,,8,1,,BAO_0000019,,,5548,51,F,H,,,
"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",Expert,,,,,,659,CHEMBL616007,,8,1,,BAO_0000019,,,5548,51,F,H,,,
"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,,,,660,CHEMBL616008,,8,1,,BAO_0000019,,,5548,51,F,H,,,
"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,,,,,661,CHEMBL616009,,8,1,,BAO_0000019,,,5548,51,F,H,,,
"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",Expert,,,,,,662,CHEMBL616010,,8,1,,BAO_0000019,,,5929,51,F,H,,,
"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",Expert,,,9606.0,,,663,CHEMBL616011,,9,1,,BAO_0000019,,Homo sapiens,5929,51,F,D,,,
"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",Expert,,,9606.0,,,664,CHEMBL615740,,9,1,,BAO_0000019,,Homo sapiens,5929,51,F,D,,,
"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",Autocuration,,,,,,665,CHEMBL615741,,8,1,,BAO_0000019,,,16245,51,F,H,,,
"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,,,,,666,CHEMBL615742,,8,1,,BAO_0000019,,,5640,51,F,H,,,
"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",Autocuration,,,,,,667,CHEMBL615743,,8,1,,BAO_0000019,,,5640,51,F,H,,,
Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,Autocuration,,449.0,,,,668,CHEMBL615744,,8,1,,BAO_0000219,,,14509,51,F,H,CHO,,
Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,Expert,,449.0,,,,669,CHEMBL615745,,8,1,,BAO_0000219,,,14509,51,F,H,CHO,,
Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,,,,670,CHEMBL615746,,8,1,,BAO_0000357,,,15331,51,B,H,,,
Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,,,,671,CHEMBL615747,,8,1,,BAO_0000357,,,15331,51,B,H,,,
"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,,672,CHEMBL615748,,8,1,,BAO_0000019,,,6563,51,F,H,,,
"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",Autocuration,,,,,,673,CHEMBL615749,,8,1,,BAO_0000019,,,6563,51,F,H,,,
Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,,,,,674,CHEMBL615750,,8,1,,BAO_0000019,,,6563,51,F,H,,,
Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,Expert,,,9606.0,,,675,CHEMBL616259,,9,1,,BAO_0000019,,Homo sapiens,6563,51,F,D,,,
"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,,676,CHEMBL616260,,8,1,,BAO_0000019,,,6563,51,F,H,,,
Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,Expert,,,9606.0,,,677,CHEMBL616261,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,,9606.0,,,678,CHEMBL616262,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,,,9606.0,,,679,CHEMBL616263,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,Expert,,,9606.0,,,680,CHEMBL616264,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,Expert,,,9606.0,,,681,CHEMBL616265,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,,9606.0,,,682,CHEMBL616266,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,,,9606.0,,,683,CHEMBL616267,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,Expert,,,9606.0,,,684,CHEMBL616268,,9,1,,BAO_0000019,,Homo sapiens,5272,51,F,D,,,
Inhibition of human 5-hydroxytryptamine 1A receptor,Expert,,,9606.0,,,685,CHEMBL616269,,9,1,,BAO_0000357,,Homo sapiens,16146,51,B,D,,,
Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,449.0,,,,686,CHEMBL884528,,8,1,,BAO_0000219,,,17624,51,B,H,CHO,,
Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,Expert,,722.0,,,,687,CHEMBL616270,,9,1,,BAO_0000219,,,13706,105,B,D,HEK293,,
Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,Autocuration,,449.0,,,,688,CHEMBL616271,,8,1,,BAO_0000219,,,15250,51,B,H,CHO,,
Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,449.0,,,,689,CHEMBL616272,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,Expert,,,,,,690,CHEMBL616273,,8,1,,BAO_0000357,,,6861,51,B,H,,,
In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,,,9606.0,,,691,CHEMBL616274,,9,1,,BAO_0000357,,Homo sapiens,17200,51,B,D,,,
Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,449.0,,,,692,CHEMBL616275,,8,1,,BAO_0000219,,,17624,51,B,H,CHO,,
Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,449.0,,,,693,CHEMBL616276,,8,1,,BAO_0000219,,,17624,51,B,H,CHO,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,,,10116.0,,,694,CHEMBL616277,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,Autocuration,,,10116.0,,,695,CHEMBL616278,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,Autocuration,,,10116.0,,,696,CHEMBL616279,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,,,10116.0,,,697,CHEMBL616280,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,Autocuration,,,10116.0,,,698,CHEMBL616281,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,,,10116.0,,,699,CHEMBL616282,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,Autocuration,,,10116.0,,,700,CHEMBL616283,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,Autocuration,,,10116.0,,,701,CHEMBL616284,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,Autocuration,,,10116.0,,,702,CHEMBL616285,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,Autocuration,,,10116.0,,,703,CHEMBL616286,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,Autocuration,,,10116.0,,,704,CHEMBL616287,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,Autocuration,,,10116.0,,,705,CHEMBL616288,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,Autocuration,,,10116.0,,,706,CHEMBL616289,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,Autocuration,,,10116.0,,,707,CHEMBL615610,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,Autocuration,,,10116.0,,,708,CHEMBL615611,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,Autocuration,,,10116.0,,,709,CHEMBL615612,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,Autocuration,,,10116.0,,,710,CHEMBL615613,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,Autocuration,,,10116.0,,,711,CHEMBL615614,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,,,10116.0,,,712,CHEMBL615615,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,22226,F,U,,,
Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,Autocuration,,,,,,713,CHEMBL615616,,4,1,,BAO_0000019,,,11440,105093,B,H,,,
Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Autocuration,,,,,,714,CHEMBL615617,Hypothalamus,8,1,,BAO_0000249,,,6238,11923,B,H,,1898.0,
Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,Autocuration,,,,,,715,CHEMBL615618,,8,1,,BAO_0000019,,,10046,10577,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,Autocuration,,,,,,716,CHEMBL615619,,8,1,,BAO_0000019,,,10046,10577,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Expert,,,,,,717,CHEMBL615620,,8,1,,BAO_0000019,,,10046,10577,B,H,,,
"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",Autocuration,,,,,,718,CHEMBL615621,,8,1,,BAO_0000357,,,167,55,B,H,,,
"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,,,,,719,CHEMBL615622,,8,1,,BAO_0000357,,,167,55,B,H,,,
Compound was evaluated for the inhibition of 5-LO (lipoxygenase),Autocuration,,,,,,720,CHEMBL615623,,8,1,,BAO_0000019,,,11520,12166,F,H,,,
Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,,,,721,CHEMBL615624,,8,1,,BAO_0000019,,,11520,12166,F,H,,,
Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,,,,722,CHEMBL615625,,8,1,,BAO_0000019,,,11520,12166,F,H,,,
Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,,,,,723,CHEMBL767045,,8,1,,BAO_0000019,,,11520,12166,F,H,,,
Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,Autocuration,,,10141.0,,,724,CHEMBL615626,,8,1,,BAO_0000019,,Cavia porcellus,135,55,F,H,,,
Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,Autocuration,,,10141.0,,,725,CHEMBL615627,,8,1,,BAO_0000019,,Cavia porcellus,135,55,F,H,,,
The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,Autocuration,,,10141.0,,,726,CHEMBL615628,,8,1,,BAO_0000019,,Cavia porcellus,11311,55,B,H,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,,,10141.0,,,727,CHEMBL615629,,8,1,,BAO_0000357,,Cavia porcellus,10193,55,B,H,,,
Inhibitory concentration against 5-lipoxygenase from human whole blood,Expert,,,9606.0,,,728,CHEMBL615630,,9,1,,BAO_0000357,,Homo sapiens,12281,55,B,D,,,
The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,,,,,729,CHEMBL615631,,8,1,,BAO_0000219,,,11311,55,B,H,,,
In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,,,,,730,CHEMBL615632,,8,1,,BAO_0000218,,,12576,17087,F,H,,,
Inhibitory concentration against 5-lipoxygenase from mouse macrophage,Autocuration,,,,,,731,CHEMBL615633,,8,1,,BAO_0000357,,,12281,17087,B,H,,,
In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,,,,,732,CHEMBL615634,,8,1,,BAO_0000218,,,12576,17087,F,H,,,
Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,Expert,,,9823.0,,,733,CHEMBL615635,,8,1,,BAO_0000019,,Sus scrofa,11089,55,B,H,,,
In vitro inhibition of rat 5-Lipoxygenase,Expert,,,,,,734,CHEMBL615636,,8,1,,BAO_0000357,,,11006,12166,B,H,,,
Inhibitory activity against 5-Lipoxygenase,Expert,,,10116.0,,,735,CHEMBL615637,,9,1,,BAO_0000357,,Rattus norvegicus,11481,12166,B,D,,,
Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,Expert,,702.0,,,,736,CHEMBL615638,,8,1,,BAO_0000219,,,10864,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,,702.0,,,,737,CHEMBL615639,,8,1,,BAO_0000219,,,3595,12166,B,H,RBL-1,,
The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,Autocuration,,702.0,,,,738,CHEMBL615640,,8,1,,BAO_0000219,,,11311,12166,B,H,RBL-1,,
The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,Autocuration,,,,,,739,CHEMBL615796,,8,1,,BAO_0000019,,,11311,12166,B,H,,,
The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,,740,CHEMBL615845,,8,1,,BAO_0000219,,,11311,12166,B,H,,,
Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,,,,,741,CHEMBL615846,,8,1,,BAO_0000357,,,11006,12166,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Autocuration,,702.0,,,,742,CHEMBL615847,,8,1,,BAO_0000219,,,3595,12166,B,H,RBL-1,,
The compound was tested for inhibition of isolated 5-Lipoxygenase,Autocuration,,,,,,743,CHEMBL615848,,8,1,,BAO_0000357,,,11311,12166,B,H,,,
Ratio of IC50 against 5-LO and COX,Autocuration,,,10116.0,,,744,CHEMBL615849,,0,1,,BAO_0000019,,Rattus norvegicus,11481,22226,B,U,,,
Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,,,,,745,CHEMBL615850,,8,1,,BAO_0000357,,,11006,12166,B,H,,,
Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,Autocuration,,,,,,746,CHEMBL615851,,8,1,,BAO_0000357,,,11006,12166,B,H,,,
The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,Autocuration,,,,,,747,CHEMBL615852,,8,1,,BAO_0000219,,,11311,12166,B,H,,,
Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,Autocuration,,,,,,748,CHEMBL615853,,8,1,,BAO_0000019,,,11006,12166,F,H,,,
Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Autocuration,,,,,,749,CHEMBL884527,Prostate gland,8,1,,BAO_0000357,,,4288,120,B,H,,2367.0,
Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,Autocuration,,,8932.0,,,750,CHEMBL872871,,0,1,,BAO_0000019,,Columba livia,7587,22226,B,U,,,
Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,Autocuration,,,8932.0,,,751,CHEMBL615854,,0,1,,BAO_0000019,,Columba livia,7587,22226,B,U,,,
Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,Autocuration,,,8932.0,,,752,CHEMBL767046,,0,1,,BAO_0000019,,Columba livia,7587,22226,B,U,,,
Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,Autocuration,,,,,,753,CHEMBL615855,,8,1,,BAO_0000357,,,11249,10732,B,H,,,
Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,Expert,,,10116.0,,,754,CHEMBL615856,,9,1,,BAO_0000019,,Rattus norvegicus,8003,12198,F,D,,,
Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,,,10116.0,,,755,CHEMBL615857,,9,1,,BAO_0000019,,Rattus norvegicus,8003,12198,F,D,,,
Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,,,10116.0,,,756,CHEMBL615858,,9,1,,BAO_0000019,,Rattus norvegicus,8003,12198,F,D,,,
In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Expert,,,,,,757,CHEMBL615859,Hippocampus,8,1,,BAO_0000221,,,12416,10576,B,H,,10000000.0,
Binding affinity towards human 5-hydroxytryptamine 1 receptor,Autocuration,,,,,,758,CHEMBL615860,,8,1,,BAO_0000357,,,16293,51,B,H,,,
Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,759,CHEMBL615861,,0,1,,BAO_0000019,,Oryctolagus cuniculus,13047,22226,B,U,,,
Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,760,CHEMBL615862,,0,1,,BAO_0000019,,Oryctolagus cuniculus,13047,22226,B,U,,,
Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,761,CHEMBL615863,,0,1,,BAO_0000019,,Oryctolagus cuniculus,13047,22226,B,U,,,
Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,762,CHEMBL615864,,0,1,,BAO_0000019,,Oryctolagus cuniculus,13047,22226,B,U,,,
Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,,,,763,CHEMBL615865,Hippocampus,4,1,,BAO_0000221,,,10085,104744,B,H,,10000000.0,
Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,,,,764,CHEMBL615866,Hippocampus,4,1,,BAO_0000221,,,10085,104744,B,H,,10000000.0,
Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,,,,,765,CHEMBL615867,Hippocampus,4,1,,BAO_0000221,,,10085,104744,B,H,,10000000.0,
Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Autocuration,,,,Membranes,,766,CHEMBL615868,,4,1,,BAO_0000249,,,9841,104744,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,Autocuration,,,10116.0,,,767,CHEMBL615869,,5,1,,BAO_0000249,,Rattus norvegicus,8822,104744,B,D,,,
Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,Autocuration,,,10116.0,,,768,CHEMBL615870,,5,1,,BAO_0000019,,Rattus norvegicus,9806,104744,B,D,,,
Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,Autocuration,,,10116.0,,,769,CHEMBL615871,,5,1,,BAO_0000019,,Rattus norvegicus,9806,104744,B,D,,,
Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,Autocuration,,,,,,770,CHEMBL615872,,4,1,,BAO_0000224,,,8868,104744,B,H,,,
Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Autocuration,,,,,,771,CHEMBL833492,Hippocampus,4,1,,BAO_0000221,,,9036,104744,B,H,,10000000.0,
Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Autocuration,,,,,,772,CHEMBL615873,Hippocampus,4,1,,BAO_0000221,,,11374,104744,B,H,,10000000.0,
Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,Autocuration,,,,,,773,CHEMBL615479,,4,1,,BAO_0000224,,,10881,104744,B,H,,,
Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,Autocuration,,,,,,774,CHEMBL615480,,4,1,,BAO_0000019,,,8822,104744,B,H,,,
Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,Autocuration,,,10116.0,,,775,CHEMBL615481,,5,1,,BAO_0000249,,Rattus norvegicus,9806,104744,B,D,,,
Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,,776,CHEMBL872869,,4,1,,BAO_0000019,,,15463,104744,B,H,,,
Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,,777,CHEMBL615482,,4,1,,BAO_0000019,,,15463,104744,B,H,,,
Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,,,,778,CHEMBL615483,Brain,4,1,,BAO_0000221,,,14542,104744,B,H,,955.0,
Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,,,,779,CHEMBL615484,Brain,4,1,,BAO_0000221,,,14542,104744,B,H,,955.0,
Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,Autocuration,,,,,,780,CHEMBL615485,,4,1,,BAO_0000019,,,8569,104744,B,H,,,
Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,Autocuration,,,10116.0,,,781,CHEMBL615486,,5,1,,BAO_0000224,,Rattus norvegicus,10062,104744,B,D,,,
Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,Autocuration,,,,,,782,CHEMBL615487,,4,1,,BAO_0000224,,,4771,104744,B,H,,,
Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,,783,CHEMBL615488,,4,1,,BAO_0000224,,,10062,104744,B,H,,,
Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,,784,CHEMBL615489,,4,1,,BAO_0000224,,,10062,104744,B,H,,,
Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,,785,CHEMBL615389,,4,1,,BAO_0000224,,,10062,104744,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,,,,,786,CHEMBL615390,,4,1,,BAO_0000019,,,15463,104744,B,H,,,
Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,,,,,787,CHEMBL615391,,4,1,,BAO_0000019,,,15463,104744,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,Autocuration,,,,,,788,CHEMBL615392,,4,1,,BAO_0000224,,,9098,104744,B,H,,,
Affinity for 5-hydroxytryptamine 1 receptor,Autocuration,,,10116.0,,,789,CHEMBL615393,,0,1,,BAO_0000019,,Rattus norvegicus,3070,22226,B,U,,,
Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Autocuration,,,,,,790,CHEMBL615394,Brain,4,1,,BAO_0000221,,,14542,104744,B,H,,955.0,
Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,,,,,791,CHEMBL615395,Brain,4,1,,BAO_0000221,,,14542,104744,B,H,,955.0,
Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,Autocuration,,,,,,792,CHEMBL615396,,4,1,,BAO_0000224,,,6398,104744,B,H,,,
Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Autocuration,,,,,,793,CHEMBL615397,Brain,4,1,,BAO_0000221,,,1344,104744,B,H,,955.0,
Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,,,,,794,CHEMBL615398,,4,1,,BAO_0000019,,,11963,104744,B,H,,,
Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,Autocuration,,,10116.0,,,795,CHEMBL615399,,0,1,,BAO_0000019,,Rattus norvegicus,8908,22226,B,U,,,
Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,Autocuration,,,,,,796,CHEMBL615400,,4,1,,BAO_0000019,,,9098,104744,B,H,,,
Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,Autocuration,,,10116.0,,,797,CHEMBL615401,,5,1,,BAO_0000019,,Rattus norvegicus,8841,104744,B,D,,,
Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,Autocuration,,,10116.0,,,798,CHEMBL615402,,0,1,,BAO_0000019,,Rattus norvegicus,8814,22226,B,U,,,
The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,Autocuration,,,,,,799,CHEMBL615403,,4,1,,BAO_0000019,,,11752,104744,B,H,,,
The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Autocuration,,,,,,800,CHEMBL615404,Brain,4,1,,BAO_0000221,,,11642,104744,B,H,,955.0,
The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,Autocuration,,,,,,801,CHEMBL615781,,4,1,,BAO_0000019,,,11642,104744,B,H,,,
Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Autocuration,,,,,,802,CHEMBL615782,Brain,4,1,,BAO_0000220,,,9231,104744,B,H,,955.0,
Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Autocuration,,,,,,803,CHEMBL615783,Brain,4,1,,BAO_0000221,,,11351,104744,B,H,,955.0,
Compound was tested for binding affinity against 5-HT1 receptor,Autocuration,,,,,,804,CHEMBL873481,,0,1,,BAO_0000019,,,4639,22226,B,U,,,
Inhibitory concentration against 5-hydroxytryptamine 1 receptor,Autocuration,,,,,,805,CHEMBL615784,,0,1,,BAO_0000019,,,1205,22226,B,U,,,
Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,,,,,806,CHEMBL615785,,8,1,,BAO_0000357,,,10025,10576,B,H,,,
"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,,,,,807,CHEMBL615786,,8,1,,BAO_0000249,,,13241,10576,F,H,,,
Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,,,,,808,CHEMBL615787,,8,1,,BAO_0000218,In vivo,,16245,10576,F,H,,,
Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,,,,,809,CHEMBL615788,,8,1,,BAO_0000218,In vivo,,16245,10576,F,H,,,
Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,810,CHEMBL767044,,8,1,,BAO_0000019,,,12438,10576,F,H,,,
Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,,,,,811,CHEMBL615789,,8,1,,BAO_0000218,In vivo,,16245,10576,F,H,,,
Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,,,,,812,CHEMBL615790,,8,1,,BAO_0000218,In vivo,,16245,10576,F,H,,,
Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,Autocuration,,,,,,813,CHEMBL615813,,8,1,,BAO_0000019,,,15740,10576,F,H,,,
Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,Autocuration,,,,,,814,CHEMBL615814,,8,1,,BAO_0000219,,,15535,10576,F,H,,,
Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,Expert,,,,,,815,CHEMBL615815,,8,1,,BAO_0000219,,,15535,51,F,H,,,
Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,Autocuration,,,,,,816,CHEMBL615816,,8,1,,BAO_0000219,,,15535,10576,F,H,,,
Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,Expert,,,,,,817,CHEMBL615817,,8,1,,BAO_0000249,,,9888,10576,B,H,,,
Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,,,,,818,CHEMBL615818,Hippocampus,8,1,,BAO_0000221,,,10085,10576,B,H,,10000000.0,
Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,,,,,819,CHEMBL615819,Hippocampus,8,1,,BAO_0000221,,,10085,10576,B,H,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Expert,,,,Membranes,,820,CHEMBL615820,,8,1,,BAO_0000249,,,17331,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Expert,,,10116.0,,,821,CHEMBL615821,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,10845,10576,B,D,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,,,10116.0,,,822,CHEMBL615822,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,10845,10576,B,D,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Expert,,,,,,823,CHEMBL615823,Hippocampus,8,1,,BAO_0000221,,,10845,10576,B,H,,10000000.0,
Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Expert,,,10116.0,,,824,CHEMBL615824,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,10845,10576,B,D,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,,,10116.0,,,825,CHEMBL615825,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,10845,10576,B,D,,10000000.0,
Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,Expert,,,,,,826,CHEMBL615826,,8,1,,BAO_0000357,,,13730,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,Expert,,,,,,827,CHEMBL615827,,8,1,,BAO_0000249,,,13508,10576,B,H,,,
Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Expert,,,,,,828,CHEMBL615828,Hippocampus,8,1,,BAO_0000249,,,13508,10576,B,H,,10000000.0,
Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,,,829,CHEMBL615829,Hippocampus,8,1,,BAO_0000221,,,12073,10576,B,H,,10000000.0,
Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,830,CHEMBL615830,Hippocampus,8,1,,BAO_0000221,,,4671,10576,B,H,,10000000.0,
Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Expert,,,,,,831,CHEMBL615831,Hippocampus,8,1,,BAO_0000221,,,13631,10576,B,H,,10000000.0,
Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,832,CHEMBL615832,,8,1,,BAO_0000357,,,12438,10576,B,H,,,
Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,Autocuration,,,,,,833,CHEMBL615833,,8,1,,BAO_0000019,,,10483,10576,B,H,,,
Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Autocuration,,,,,,834,CHEMBL615834,Hippocampus,8,1,,BAO_0000221,,,10483,10576,B,H,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,Intermediate,,,,,,835,CHEMBL615835,,8,1,,BAO_0000249,,,12352,10576,B,H,,,
Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Autocuration,,,,,,836,CHEMBL615836,Hippocampus,8,1,,BAO_0000249,,,14732,10576,B,H,,10000000.0,
Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Expert,,,10116.0,,,837,CHEMBL615837,,9,1,,BAO_0000019,,Rattus norvegicus,11049,10576,B,D,,,
Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,Expert,,,10116.0,,,838,CHEMBL615838,,9,1,,BAO_0000019,,Rattus norvegicus,11049,10576,B,D,,,
"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",Expert,,,,,,839,CHEMBL615839,,8,1,,BAO_0000249,,,13657,10576,B,H,,,
Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,Autocuration,,,,,,840,CHEMBL884525,,8,1,,BAO_0000019,,,11473,10576,B,H,,,
Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Autocuration,,,,,,841,CHEMBL615840,,8,1,,BAO_0000249,,,2014,10576,B,H,,,
Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,,,842,CHEMBL615405,Hippocampus,8,1,,BAO_0000221,,,3086,10576,B,H,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,,,,843,CHEMBL615406,,8,1,,BAO_0000019,,,15854,10576,B,H,,,
Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Expert,,,,,,844,CHEMBL615900,Hippocampus,8,1,,BAO_0000221,,,10922,10576,B,H,,10000000.0,
Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Expert,,,,,,845,CHEMBL615901,Hippocampus,8,1,,BAO_0000221,,,13346,10576,B,H,,10000000.0,
In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,Expert,,,,,,846,CHEMBL615902,,8,1,,BAO_0000357,,,15311,10576,B,H,,,
Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Autocuration,,,,,,847,CHEMBL615903,Hippocampus,8,1,,BAO_0000221,,,10922,10576,B,H,,10000000.0,
Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,Autocuration,,,,,,848,CHEMBL615904,,8,1,,BAO_0000357,,,10025,10576,B,H,,,
Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,,,,,849,CHEMBL615905,,8,1,,BAO_0000357,,,10025,10576,B,H,,,
In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,,,,850,CHEMBL615906,,8,1,,BAO_0000019,,,9742,10576,B,H,,,
In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,,,,851,CHEMBL615907,,8,1,,BAO_0000019,,,9742,10576,F,H,,,
In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Expert,,,,,,852,CHEMBL615908,,8,1,,BAO_0000019,,,12304,10576,B,H,,,
In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Autocuration,,,,,,853,CHEMBL615909,Hippocampus,8,1,,BAO_0000221,,,15789,10576,B,H,,10000000.0,
"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",Autocuration,,,,,,854,CHEMBL615910,,8,1,,BAO_0000019,,,9912,10576,B,H,,,
"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",Autocuration,,,,,,855,CHEMBL615911,,8,1,,BAO_0000019,,,9912,10576,B,H,,,
"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",Autocuration,,,,,,856,CHEMBL615912,,8,1,,BAO_0000019,,,9912,10576,B,H,,,
In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Expert,,,,,,857,CHEMBL615913,,8,1,,BAO_0000019,,,16693,10576,B,H,,,
In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,,,,,858,CHEMBL615914,,8,1,,BAO_0000357,,,13276,10576,B,H,,,
In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,,,,,859,CHEMBL615915,Hippocampus,8,1,,BAO_0000221,,,12678,10576,B,H,,10000000.0,
In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,Autocuration,,,,,,860,CHEMBL615916,,8,1,,BAO_0000357,,,11825,10576,B,H,,,
In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,Expert,,,,,,861,CHEMBL615917,,8,1,,BAO_0000357,,,12443,10576,B,H,,,
In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,,,,,,862,CHEMBL615918,,8,1,,BAO_0000357,,,13830,10576,B,H,,,
In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Expert,,,,,,863,CHEMBL615919,Hippocampus,8,1,,BAO_0000249,,,14286,10576,B,H,,10000000.0,
In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Expert,,,10116.0,,,864,CHEMBL615920,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,14356,10576,B,D,,10000000.0,
Inhibition concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,865,CHEMBL615921,,8,1,,BAO_0000357,,,15306,10576,B,H,,,
Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),Expert,,,,,,866,CHEMBL615922,,8,1,,BAO_0000357,,,15306,10576,B,H,,,
"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,,,10116.0,,,867,CHEMBL881290,,9,1,,BAO_0000249,,Rattus norvegicus,16616,10576,F,D,,,
"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Autocuration,,,,,,868,CHEMBL615923,Hippocampus,8,1,,BAO_0000221,,,3651,10576,B,H,,10000000.0,
Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,,,869,CHEMBL615924,Hippocampus,8,1,,BAO_0000221,,,14331,10576,F,H,,10000000.0,
Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,,,870,CHEMBL615925,Hippocampus,8,1,,BAO_0000221,,,14331,10576,F,H,,10000000.0,
Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,871,CHEMBL615926,,9,1,,BAO_0000357,,Rattus norvegicus,14178,10576,B,D,,,
Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,872,CHEMBL615927,,9,1,,BAO_0000019,,Rattus norvegicus,10639,10576,B,D,,,
Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,,,873,CHEMBL615928,Hippocampus,8,1,,BAO_0000221,,,12306,10576,B,H,,10000000.0,
Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,Expert,,,10116.0,,,874,CHEMBL615929,,9,1,,BAO_0000357,,Rattus norvegicus,1348,10576,B,D,,,
Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Autocuration,,,,,,875,CHEMBL615930,Hippocampus,8,1,,BAO_0000221,,,13605,10576,B,H,,10000000.0,
Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,,449.0,,,,876,CHEMBL615931,,8,1,,BAO_0000219,,,17624,51,B,H,CHO,,
Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,449.0,,,,877,CHEMBL615932,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,,449.0,,,,878,CHEMBL615933,,8,1,,BAO_0000219,,,17624,51,F,H,CHO,,
Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,879,CHEMBL615934,,8,1,,BAO_0000357,,,15267,51,B,H,,,
The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,Autocuration,,,,,,880,CHEMBL615935,,8,1,,BAO_0000357,,,16532,51,B,H,,,
"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,,,,,881,CHEMBL615936,,8,1,,BAO_0000019,,,6563,51,F,H,,,
Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,Autocuration,,449.0,,,,882,CHEMBL615937,,8,1,,BAO_0000219,,,4751,51,B,H,CHO,,
Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,883,CHEMBL615938,,8,1,,BAO_0000357,,,15463,51,B,H,,,
In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),Autocuration,,,,,,884,CHEMBL615797,,8,1,,BAO_0000357,,,3805,51,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,885,CHEMBL615798,,8,1,,BAO_0000357,,,5640,51,B,H,,,
Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,Autocuration,,,,,,886,CHEMBL872870,,8,1,,BAO_0000357,,,6563,51,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,Autocuration,,,,,,887,CHEMBL615799,,8,1,,BAO_0000357,,,5548,51,B,H,,,
Percent binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,888,CHEMBL615800,,8,1,,BAO_0000357,,,6347,51,B,H,,,
Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,722.0,,,,889,CHEMBL615801,,8,1,,BAO_0000219,,,17296,51,F,H,HEK293,,
Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,Autocuration,,,,,,890,CHEMBL615802,,8,1,,BAO_0000019,,,13047,51,B,H,,,
Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,,,,891,CHEMBL615803,,8,1,,BAO_0000357,,,15740,51,B,H,,,
"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,,,,,892,CHEMBL835002,,8,1,,BAO_0000019,,,5640,51,F,H,,,
"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",Autocuration,,,,,,893,CHEMBL615804,,8,1,,BAO_0000019,,,5640,51,F,H,,,
Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,Expert,,308.0,,,,894,CHEMBL615805,,8,1,,BAO_0000219,,,17211,51,B,H,HeLa,,
Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,Autocuration,,449.0,,,,895,CHEMBL615806,,8,1,,BAO_0000219,,,4751,51,B,H,CHO,,
Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,Expert,,,9606.0,,,896,CHEMBL615807,,9,1,,BAO_0000357,,Homo sapiens,6491,51,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,Autocuration,,,,,,897,CHEMBL615808,,8,1,,BAO_0000357,,,4707,51,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,,,9606.0,,,898,CHEMBL615809,,9,1,,BAO_0000357,,Homo sapiens,13910,51,B,D,,,
Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,Autocuration,,308.0,,,,899,CHEMBL615810,,8,1,,BAO_0000219,,,16190,51,B,H,HeLa,,
Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,900,CHEMBL615811,,8,1,,BAO_0000357,,,16633,51,B,H,,,
Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,Autocuration,,449.0,,,,901,CHEMBL615812,,8,1,,BAO_0000219,,,11898,51,B,H,CHO,,
Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,449.0,,,,902,CHEMBL615751,,8,1,,BAO_0000219,,,11898,51,B,H,CHO,,
Binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,903,CHEMBL615752,,8,1,,BAO_0000357,,,14331,51,B,H,,,
Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,Expert,,449.0,,,,904,CHEMBL615753,,8,1,,BAO_0000219,,,17624,51,B,H,CHO,,
Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,Autocuration,,449.0,,,,905,CHEMBL615754,,8,1,,BAO_0000219,,,17624,51,B,H,CHO,,
Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,906,CHEMBL615755,,8,1,,BAO_0000357,,,3307,51,B,H,,,
Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,,449.0,9606.0,,,907,CHEMBL615756,,9,1,,BAO_0000219,,Homo sapiens,6563,51,B,D,CHO,,
Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,908,CHEMBL615757,,8,1,,BAO_0000019,,,14165,51,B,H,,,
Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,,909,CHEMBL615758,,8,1,,BAO_0000357,,,5732,51,B,H,,,
In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,,,,,910,CHEMBL615759,,8,1,,BAO_0000357,,,13366,51,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,911,CHEMBL615760,,8,1,,BAO_0000357,,,17626,51,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,Expert,,308.0,,,,912,CHEMBL615761,,8,1,,BAO_0000219,,,6588,51,B,H,HeLa,,
Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,Autocuration,,,,,,913,CHEMBL872104,,8,1,,BAO_0000357,,,16209,51,B,H,,,
Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,914,CHEMBL615762,,8,1,,BAO_0000357,,,15463,51,B,H,,,
Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,915,CHEMBL615763,,8,1,,BAO_0000357,,,15463,51,B,H,,,
Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,Autocuration,,,,,,916,CHEMBL615764,,8,1,,BAO_0000357,,,14770,51,B,H,,,
Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),Autocuration,,1167.0,,,,917,CHEMBL615765,,8,1,,BAO_0000219,,,16245,51,B,H,Cell line,,
Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),Autocuration,,,,,,918,CHEMBL615766,,8,1,,BAO_0000019,,,16245,51,B,H,,,
Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,919,CHEMBL615767,,8,1,,BAO_0000357,,,5548,51,B,H,,,
Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,,,,,920,CHEMBL615768,,8,1,,BAO_0000357,,,5548,51,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,921,CHEMBL615769,,8,1,,BAO_0000357,,,5548,51,B,H,,,
Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,Expert,,,,,,922,CHEMBL615770,,8,1,,BAO_0000357,,,6876,51,B,H,,,
Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,923,CHEMBL615771,,8,1,,BAO_0000357,,,2598,51,B,H,,,
Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,Expert,,,,,,924,CHEMBL615772,,8,1,,BAO_0000357,,,17785,51,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,925,CHEMBL615773,,8,1,,BAO_0000357,,,6013,51,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Expert,,,,,,926,CHEMBL615774,,8,1,,BAO_0000357,,,5929,51,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,927,CHEMBL615775,,8,1,,BAO_0000357,,,16633,51,B,H,,,
Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,,928,CHEMBL615776,,8,1,,BAO_0000357,,,1558,51,B,H,,,
Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,,,,,929,CHEMBL615777,,8,1,,BAO_0000357,,,16026,51,B,H,,,
Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,Autocuration,,,,,,930,CHEMBL615778,,8,1,,BAO_0000219,,,12469,51,B,H,,,
Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Expert,,,9606.0,,,931,CHEMBL615779,,9,1,,BAO_0000357,,Homo sapiens,15874,51,B,D,,,
Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,,,,,932,CHEMBL615780,,8,1,,BAO_0000357,,,15874,51,B,H,,,
Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,933,CHEMBL616298,,8,1,,BAO_0000357,,,3935,51,B,H,,,
Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,934,CHEMBL616299,,8,1,,BAO_0000357,,,15818,51,B,H,,,
Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,Autocuration,,485.0,,,,935,CHEMBL616300,,8,1,,BAO_0000219,,,13706,51,B,H,CHO-K1,,
Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,Expert,,485.0,,,,936,CHEMBL616301,,8,1,,BAO_0000219,,,13729,51,F,H,CHO-K1,,
In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,937,CHEMBL616302,,8,1,,BAO_0000019,,,15413,51,B,H,,,
In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),Autocuration,,,,,,938,CHEMBL616117,,8,1,,BAO_0000019,,,15413,51,B,H,,,
In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),Autocuration,,,,,,939,CHEMBL616118,,8,1,,BAO_0000019,,,15413,51,B,H,,,
In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,Autocuration,,,,,,940,CHEMBL616119,,8,1,,BAO_0000019,,,15413,51,B,H,,,
Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,,308.0,9606.0,,,941,CHEMBL616120,,9,1,,BAO_0000219,,Homo sapiens,3445,51,B,D,HeLa,,
Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,942,CHEMBL616121,,8,1,,BAO_0000357,,,15740,51,B,H,,,
Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,,,,943,CHEMBL616122,,8,1,,BAO_0000357,,,15740,51,B,H,,,
In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,944,CHEMBL616123,,8,1,,BAO_0000357,,,17626,51,B,H,,,
In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,Expert,,,9606.0,,,945,CHEMBL616124,,9,1,,BAO_0000357,,Homo sapiens,4234,51,B,D,,,
In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,,,,,946,CHEMBL616125,,8,1,,BAO_0000357,,,5640,51,B,H,,,
In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,Expert,,,10116.0,,,947,CHEMBL616126,,8,1,,BAO_0000357,,Rattus norvegicus,5272,51,B,H,,,
In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,Autocuration,,449.0,,,,948,CHEMBL616127,,8,1,,BAO_0000219,,,4622,51,B,H,CHO,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,Expert,,,,,,949,CHEMBL616128,,8,1,,BAO_0000019,,,17085,51,B,H,,,
In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,,,,,950,CHEMBL616129,,8,1,,BAO_0000357,,,3025,51,B,H,,,
In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,,951,CHEMBL616130,,8,1,,BAO_0000357,,,15315,51,B,H,,,
Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,Autocuration,,,,,,952,CHEMBL616131,,8,1,,BAO_0000357,,,15267,51,B,H,,,
Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,Autocuration,,308.0,,,,953,CHEMBL616132,,8,1,,BAO_0000219,,,17158,51,B,H,HeLa,,
Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,Expert,,308.0,9606.0,,,954,CHEMBL616133,,9,1,,BAO_0000219,,Homo sapiens,14214,51,B,D,HeLa,,
Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,955,CHEMBL616134,,8,1,,BAO_0000357,,,17133,51,B,H,,,
The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,Autocuration,,,,,,956,CHEMBL616135,,8,1,,BAO_0000357,,,16532,51,B,H,,,
Affinity for 5-hydroxytryptamine 1A receptor subtype,Expert,,,9606.0,,,957,CHEMBL616136,,9,1,,BAO_0000357,,Homo sapiens,2391,51,B,D,,,
The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,Autocuration,,,,,,958,CHEMBL616137,,8,1,,BAO_0000019,,,14447,51,B,H,,,
The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,Autocuration,,,,,,959,CHEMBL872105,,8,1,,BAO_0000019,,,14447,51,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,Autocuration,,,,,,960,CHEMBL616138,,8,1,,BAO_0000357,,,15086,51,B,H,,,
Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,,,9606.0,,,961,CHEMBL616139,,9,1,,BAO_0000357,,Homo sapiens,13051,51,B,D,,,
"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",Autocuration,,,,,,962,CHEMBL616140,,8,1,,BAO_0000019,,,16026,51,F,H,,,
In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,Expert,,,,,,963,CHEMBL616141,,8,1,,BAO_0000019,,,17085,51,B,H,,,
Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,964,CHEMBL616142,,8,1,,BAO_0000357,,,17133,51,B,H,,,
Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,Autocuration,,,,,,965,CHEMBL616143,,8,1,,BAO_0000357,,,17133,51,B,H,,,
Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,308.0,,,,966,CHEMBL616144,,8,1,,BAO_0000219,,,17211,51,B,H,HeLa,,
Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,Autocuration,,308.0,,,,967,CHEMBL616145,,8,1,,BAO_0000219,,,17211,51,B,H,HeLa,,
Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,308.0,,,,968,CHEMBL616012,,8,1,,BAO_0000219,,,17211,51,B,H,HeLa,,
Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,,308.0,,,,969,CHEMBL616013,,8,1,,BAO_0000219,,,17211,51,B,H,HeLa,,
"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,,,,970,CHEMBL616014,,8,1,,BAO_0000019,,,16394,51,F,H,,,
"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,,,,971,CHEMBL616015,,8,1,,BAO_0000019,,,16394,51,F,H,,,
"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,,,,,972,CHEMBL616016,,8,1,,BAO_0000019,,,16394,51,F,H,,,
Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,Autocuration,,,,,,973,CHEMBL616017,,8,1,,BAO_0000218,In vivo,,16394,51,F,H,,,
Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,Autocuration,,,,,,974,CHEMBL616018,,8,1,,BAO_0000019,,,16394,51,B,H,,,
EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,Autocuration,,,,,,975,CHEMBL616019,,8,1,,BAO_0000019,,,15740,51,F,H,,,
EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,,,,,976,CHEMBL616020,,8,1,,BAO_0000019,,,15740,51,F,H,,,
Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,977,CHEMBL858018,,8,1,,BAO_0000357,,,15740,51,B,H,,,
Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,722.0,,,,978,CHEMBL616021,,8,1,,BAO_0000219,,,17296,51,F,H,HEK293,,
"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",Expert,,,,,,979,CHEMBL616022,,8,1,,BAO_0000019,,,5640,51,F,H,,,
"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",Autocuration,,,,,,980,CHEMBL616023,,8,1,,BAO_0000019,,,5640,51,F,H,,,
"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",Autocuration,,,,,,981,CHEMBL616024,,8,1,,BAO_0000019,,,5640,51,F,H,,,
"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",Autocuration,,,,,,982,CHEMBL616025,,8,1,,BAO_0000019,,,5640,51,F,H,,,
Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,,449.0,,,,983,CHEMBL616026,,8,1,,BAO_0000219,,,2759,51,F,H,CHO,,
"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",Autocuration,,,,,,984,CHEMBL616027,,8,1,,BAO_0000019,,,16394,51,F,H,,,
"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",Expert,,,9606.0,,,985,CHEMBL616028,,9,1,,BAO_0000019,,Homo sapiens,16394,51,F,D,,,
Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,Expert,,,9606.0,,,986,CHEMBL616029,,9,1,,BAO_0000019,,Homo sapiens,3445,51,F,D,,,
Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,Expert,,449.0,,,,987,CHEMBL616030,,8,1,,BAO_0000219,,,4316,51,B,H,CHO,,
In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,Expert,,,,,,988,CHEMBL616031,,8,1,,BAO_0000019,,,4316,51,B,H,,,
Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,,,9606.0,,,989,CHEMBL616032,,9,1,,BAO_0000019,,Homo sapiens,15180,51,F,D,,,
Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,,,9606.0,,,990,CHEMBL616033,,9,1,,BAO_0000019,,Homo sapiens,15180,51,F,D,,,
Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,,991,CHEMBL616034,,8,1,,BAO_0000019,,,15042,51,F,H,,,
Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,,992,CHEMBL616035,,8,1,,BAO_0000019,,,15042,51,F,H,,,
Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,993,CHEMBL616036,,8,1,,BAO_0000019,,,15042,51,F,H,,,
Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,,994,CHEMBL616037,,8,1,,BAO_0000019,,,15042,51,F,H,,,
Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,,995,CHEMBL616038,,8,1,,BAO_0000019,,,15042,51,F,H,,,
Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,,,,,996,CHEMBL616039,,8,1,,BAO_0000019,,,15042,51,F,H,,,
Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,997,CHEMBL616040,,8,1,,BAO_0000019,,,15042,51,F,H,,,
Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,,308.0,9606.0,,,998,CHEMBL616041,,9,1,,BAO_0000219,,Homo sapiens,15180,51,F,D,HeLa,,
Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,,308.0,9606.0,,,999,CHEMBL616042,,9,1,,BAO_0000219,,Homo sapiens,15180,51,F,D,HeLa,,
Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,,308.0,9606.0,,,1000,CHEMBL616043,,9,1,,BAO_0000219,,Homo sapiens,15180,51,F,D,HeLa,,
"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",Autocuration,,,,,,1001,CHEMBL616044,,8,1,,BAO_0000019,,,16245,51,F,H,,,
"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,,,,1002,CHEMBL616045,,8,1,,BAO_0000019,,,16026,51,F,H,,,
Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,,722.0,,,,1003,CHEMBL616046,,8,1,,BAO_0000219,,,17296,51,F,H,HEK293,,
Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,,449.0,,,,1004,CHEMBL616047,,8,1,,BAO_0000219,,,2759,51,F,H,CHO,,
Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Autocuration,,449.0,,,,1005,CHEMBL616048,,8,1,,BAO_0000219,,,2759,51,F,H,CHO,,
Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),Expert,,449.0,9606.0,,,1006,CHEMBL616049,,9,1,,BAO_0000219,,Homo sapiens,2759,51,F,D,CHO,,
Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,,449.0,,,,1007,CHEMBL616050,,8,1,,BAO_0000219,,,2759,51,F,H,CHO,,
In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,Expert,,,,,,1008,CHEMBL616051,,8,1,,BAO_0000219,,,15419,51,F,H,,,
In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,Autocuration,,,,,,1009,CHEMBL616212,,8,1,,BAO_0000219,,,15419,51,F,H,,,
"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,,,,,1010,CHEMBL616213,,8,1,,BAO_0000019,,,16026,51,F,H,,,
Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,Expert,,,,,,1011,CHEMBL616214,,8,1,,BAO_0000219,In vitro,,1414,51,B,H,,,
Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,Expert,,,,,,1012,CHEMBL616215,,8,1,,BAO_0000219,In vitro,,1414,51,B,H,,,
Binding activity radioligand.,Autocuration,,,,,,1013,CHEMBL616216,,8,1,,BAO_0000357,,,12861,51,B,H,,,
Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,,,,1014,CHEMBL616217,,8,1,,BAO_0000019,,,12861,51,B,H,,,
Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1015,CHEMBL616218,,8,1,,BAO_0000357,,,5104,51,B,H,,,
Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1016,CHEMBL616219,,8,1,,BAO_0000357,,,5105,51,B,H,,,
binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1017,CHEMBL616220,,8,1,,BAO_0000357,,,16312,51,B,H,,,
Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,Expert,,,9606.0,,,1018,CHEMBL833493,,9,1,,BAO_0000357,,Homo sapiens,15180,51,B,D,,,
Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1019,CHEMBL616221,,8,1,,BAO_0000357,,,5033,51,B,H,,,
Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,,449.0,9606.0,,,1020,CHEMBL616222,,9,1,,BAO_0000219,,Homo sapiens,16909,51,B,D,CHO,,
Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1021,CHEMBL616223,,8,1,,BAO_0000019,,,2590,51,F,H,,,
Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,Autocuration,,,,,,1022,CHEMBL616224,,8,1,,BAO_0000019,,,2590,51,F,H,,,
Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,Expert,,,,,,1023,CHEMBL616225,,8,1,,BAO_0000019,,,16394,51,B,H,,,
Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,Expert,,722.0,9606.0,,,1024,CHEMBL616226,,9,1,,BAO_0000219,,Homo sapiens,4540,51,B,D,HEK293,,
Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,Autocuration,,722.0,,,,1025,CHEMBL616227,,8,1,,BAO_0000219,,,17296,51,B,H,HEK293,,
Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,Autocuration,,722.0,,,,1026,CHEMBL616228,,8,1,,BAO_0000219,,,17296,51,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,,722.0,,,,1027,CHEMBL616229,,8,1,,BAO_0000219,,,15779,51,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,Autocuration,,722.0,,,,1028,CHEMBL616230,,8,1,,BAO_0000219,,,15779,51,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,Autocuration,,722.0,,,,1029,CHEMBL616231,,8,1,,BAO_0000219,,,15779,51,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1030,CHEMBL616232,,8,1,,BAO_0000357,,,6166,51,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,,722.0,,,,1031,CHEMBL616233,,8,1,,BAO_0000219,,,15779,51,B,H,HEK293,,
Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,Autocuration,,722.0,,,,1032,CHEMBL857973,,8,1,,BAO_0000219,,,4199,51,B,H,HEK293,,
Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,Autocuration,,,,,,1033,CHEMBL616234,,8,1,,BAO_0000219,,,15316,51,B,H,,,
Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1034,CHEMBL616235,,8,1,,BAO_0000357,,,14875,51,B,H,,,
Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,,308.0,,,,1035,CHEMBL616236,,8,1,,BAO_0000219,,,14727,51,B,H,HeLa,,
Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,,,,,,1036,CHEMBL616237,,8,1,,BAO_0000019,,,14727,51,B,H,,,
Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,Autocuration,,722.0,,,,1037,CHEMBL616238,,8,1,,BAO_0000219,,,15146,51,B,H,HEK293,,
Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,Autocuration,,722.0,,,,1038,CHEMBL616239,,8,1,,BAO_0000219,,,5213,51,B,H,HEK293,,
In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,Autocuration,,,,,,1039,CHEMBL616240,,8,1,,BAO_0000219,,,16429,51,B,H,,,
The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,Expert,,308.0,9606.0,,,1040,CHEMBL616241,,9,1,,BAO_0000219,,Homo sapiens,15042,51,B,D,HeLa,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,Autocuration,,722.0,,,,1041,CHEMBL616242,,8,1,,BAO_0000219,,,14818,51,B,H,HEK293,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",Autocuration,,722.0,,,,1042,CHEMBL616243,,8,1,,BAO_0000219,,,4829,51,B,H,HEK293,,
In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,,,,,,1043,CHEMBL616244,,9,1,,BAO_0000357,,,17200,51,B,D,,,
The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,,9606.0,,,1044,CHEMBL616245,,9,1,,BAO_0000357,,Homo sapiens,13051,51,B,D,,,
Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,,,,,1045,CHEMBL616246,,8,1,,BAO_0000357,,,5486,106,B,H,,,
Binding affinity against 5-HT1D receptor,Autocuration,,,,,,1046,CHEMBL616247,,8,1,,BAO_0000357,,,5254,105,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1047,CHEMBL616248,,8,1,,BAO_0000357,,,5254,105,B,H,,,
Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,,,,,1048,CHEMBL616249,,8,1,,BAO_0000357,,,15331,107,B,H,,,
Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,,,9606.0,,,1049,CHEMBL616250,,8,1,,BAO_0000357,,Homo sapiens,13506,10576,B,H,,,
Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1050,CHEMBL616251,,8,1,,BAO_0000357,,,15267,51,B,H,,,
Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,Autocuration,,,,,,1051,CHEMBL616252,,8,1,,BAO_0000218,In vivo,,16616,11863,F,H,,,
Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,Autocuration,,,,,,1052,CHEMBL616253,,8,1,,BAO_0000218,In vivo,,16616,11863,F,H,,,
Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,Autocuration,,,,,,1053,CHEMBL616254,,8,1,,BAO_0000218,In vivo,,16616,11863,F,H,,,
Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,Expert,,,10090.0,,,1054,CHEMBL616255,,9,1,,BAO_0000218,,Mus musculus,16616,11863,F,D,,,
Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,Expert,,,10090.0,,,1055,CHEMBL832872,,9,1,,BAO_0000218,,Mus musculus,16616,11863,F,D,,,
Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,Expert,,,10090.0,,,1056,CHEMBL616256,,9,1,,BAO_0000218,,Mus musculus,16616,11863,F,D,,,
Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,Expert,,,10090.0,,,1057,CHEMBL616257,,9,1,,BAO_0000218,,Mus musculus,16616,11863,F,D,,,
Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,Expert,,,10090.0,,,1058,CHEMBL616258,,9,1,,BAO_0000218,,Mus musculus,16616,11863,F,D,,,
Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,Expert,,,10090.0,,,1059,CHEMBL616384,,9,1,,BAO_0000218,,Mus musculus,16616,11863,F,D,,,
Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Autocuration,,,,,,1060,CHEMBL616385,Hippocampus,8,1,,BAO_0000221,,,10297,11863,B,H,,10000000.0,
Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,Expert,,,,,,1061,CHEMBL616386,,8,1,,BAO_0000357,,,13704,11863,B,H,,,
Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,,,10090.0,,,1062,CHEMBL616387,Hippocampus,9,1,,BAO_0000221,,Mus musculus,10297,11863,B,D,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,,,,,1063,CHEMBL616388,Hippocampus,8,1,,BAO_0000221,,,10297,11863,B,H,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,,,10090.0,,,1064,CHEMBL616389,Hippocampus,9,1,,BAO_0000221,,Mus musculus,10297,11863,B,D,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,,,,,1065,CHEMBL616390,Hippocampus,8,1,,BAO_0000221,,,10297,11863,B,H,,10000000.0,
Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,Autocuration,,,,,,1066,CHEMBL616391,,8,1,,BAO_0000357,,,217,11863,B,H,,,
Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Expert,,,10090.0,,,1067,CHEMBL616392,Hippocampus,9,1,,BAO_0000221,,Mus musculus,10297,11863,B,D,,10000000.0,
Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,Autocuration,,,9823.0,,,1068,CHEMBL616393,,8,1,,BAO_0000357,,Sus scrofa,4921,51,B,H,,,
Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Autocuration,,,9823.0,,,1069,CHEMBL616394,,8,1,,BAO_0000357,,Sus scrofa,4921,51,B,H,,,
Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,Autocuration,,,9823.0,,,1070,CHEMBL616395,,8,1,,BAO_0000019,,Sus scrofa,4996,51,B,H,,,
Compound was evaluated for the binding affinity at 5- HT1A receptor,Autocuration,,,9823.0,,,1071,CHEMBL616396,,8,1,,BAO_0000357,,Sus scrofa,12918,51,B,H,,,
Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,,,9823.0,,,1072,CHEMBL872907,,8,1,,BAO_0000019,,Sus scrofa,5333,51,B,H,,,
In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,,,9823.0,,,1073,CHEMBL616397,,8,1,,BAO_0000019,,Sus scrofa,4437,51,B,H,,,
Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,Autocuration,,,9823.0,,,1074,CHEMBL616398,,8,1,,BAO_0000019,,Sus scrofa,1742,51,B,H,,,
Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,Expert,,,9823.0,,,1075,CHEMBL616399,,8,1,,BAO_0000357,,Sus scrofa,16688,51,B,H,,,
Binding activity radioligand.,Autocuration,,,9823.0,,,1076,CHEMBL857065,,8,1,,BAO_0000357,,Sus scrofa,12861,51,B,H,,,
Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Expert,,,9823.0,,,1077,CHEMBL616400,,8,1,,BAO_0000019,,Sus scrofa,12861,51,B,H,,,
Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,,,9823.0,,,1078,CHEMBL616401,,8,1,,BAO_0000019,,Sus scrofa,12861,51,B,H,,,
Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,Expert,,,,,,1079,CHEMBL616402,,8,1,,BAO_0000019,,,12490,10624,B,H,,,
Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,Expert,,,9823.0,,,1080,CHEMBL616403,,8,1,,BAO_0000019,,Sus scrofa,11828,51,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Autocuration,,,9823.0,,,1081,CHEMBL616404,Hippocampus,8,1,,BAO_0000221,,Sus scrofa,11866,51,B,H,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,Autocuration,,,9823.0,,,1082,CHEMBL616405,,8,1,,BAO_0000249,,Sus scrofa,12827,51,B,H,,,
Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,Autocuration,,,9823.0,,,1083,CHEMBL616406,,8,1,,BAO_0000019,,Sus scrofa,12918,51,B,H,,,
Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,Expert,,,9823.0,,,1084,CHEMBL616407,,8,1,,BAO_0000019,,Sus scrofa,12919,51,F,H,,,
Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,Autocuration,,,9986.0,,,1085,CHEMBL616408,,8,1,,BAO_0000019,,Oryctolagus cuniculus,13047,51,B,H,,,
Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,Expert,,,10116.0,,,1086,CHEMBL616409,,9,1,,BAO_0000249,,Rattus norvegicus,15796,10576,B,D,,,
"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Expert,,,10116.0,,,1087,CHEMBL616410,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,3651,10576,B,D,,10000000.0,
Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,Autocuration,,,,,,1088,CHEMBL616411,,8,1,,BAO_0000357,,,188,10576,B,H,,,
"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,,,10116.0,Membranes,,1089,CHEMBL616412,,9,1,,BAO_0000249,,Rattus norvegicus,16616,10576,F,D,,,
"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,,,10116.0,Membranes,,1090,CHEMBL616413,Hippocampus,9,1,,BAO_0000249,,Rattus norvegicus,16616,10576,F,D,,10000000.0,
The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,,,1091,CHEMBL616414,Hippocampus,8,1,,BAO_0000221,,,12306,10576,B,H,,10000000.0,
Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Expert,,,10116.0,,,1092,CHEMBL616415,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,17167,10576,B,D,,10000000.0,
Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,Autocuration,,,,,,1093,CHEMBL616416,,8,1,,BAO_0000019,,,14776,10576,B,H,,,
Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,Expert,,,,,,1094,CHEMBL616417,,8,1,,BAO_0000357,,,12158,10576,B,H,,,
Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,,,,,1095,CHEMBL616418,,8,1,,BAO_0000357,,,13481,10576,B,H,,,
Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,,,,1096,CHEMBL616419,,8,1,,BAO_0000219,In vitro,,13427,10576,B,H,,,
Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,Autocuration,,,,,,1097,CHEMBL616420,,8,1,,BAO_0000357,,,10210,10576,B,H,,,
Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,,,Membranes,,1098,CHEMBL616421,,8,1,,BAO_0000249,,,10205,10576,B,H,,,
Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,,,Membranes,,1099,CHEMBL616422,,8,1,,BAO_0000249,,,10205,10576,B,H,,,
Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Expert,,,,Membranes,,1100,CHEMBL616423,,8,1,,BAO_0000249,,,10205,10576,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,Expert,,,10116.0,,,1101,CHEMBL616424,,9,1,,BAO_0000357,,Rattus norvegicus,12280,10576,B,D,,,
Binding affinity to the rat 5-hydroxytryptamine 1A receptor,Expert,,,,,,1102,CHEMBL616425,,8,1,,BAO_0000357,,,17386,10576,B,H,,,
Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,Expert,,,,,,1103,CHEMBL616426,,8,1,,BAO_0000357,,,13654,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Autocuration,,,,,,1104,CHEMBL616427,Hippocampus,8,1,,BAO_0000221,,,14423,10576,B,H,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Autocuration,,,,,,1105,CHEMBL616428,Hippocampus,8,1,,BAO_0000221,,,15412,10576,B,H,,10000000.0,
Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,,,1106,CHEMBL616290,Hippocampus,8,1,,BAO_0000221,,,12073,10576,B,H,,10000000.0,
Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,1107,CHEMBL616052,,9,1,,BAO_0000357,,Rattus norvegicus,4101,10576,B,D,,,
Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1108,CHEMBL616053,,8,1,,BAO_0000357,,,10062,10576,B,H,,,
Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1109,CHEMBL616054,,8,1,,BAO_0000249,,,6238,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1110,CHEMBL616055,,8,1,,BAO_0000357,,,16273,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,Autocuration,,,,,,1111,CHEMBL616056,,8,1,,BAO_0000357,,,11139,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Expert,,,,,,1112,CHEMBL616057,,8,1,,BAO_0000019,,,16796,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,,,10116.0,,,1113,CHEMBL616058,Brain,9,1,,BAO_0000221,,Rattus norvegicus,9548,10576,B,D,,955.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Autocuration,,,,,,1114,CHEMBL616059,Brain,8,1,,BAO_0000221,,,10381,10576,B,H,,955.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1115,CHEMBL616060,,8,1,,BAO_0000249,,,13408,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Expert,,,10116.0,,,1116,CHEMBL616061,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,13825,10576,B,D,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Expert,,,,,,1117,CHEMBL616062,Hippocampus,8,1,,BAO_0000221,,,11147,10576,B,H,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1118,CHEMBL616063,,8,1,,BAO_0000249,,,10552,10576,B,H,,,
"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,,,,,1119,CHEMBL616064,Striatum,8,1,,BAO_0000249,,,10552,10576,B,H,,2435.0,
Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Expert,,,10116.0,Membranes,,1120,CHEMBL616065,,9,1,,BAO_0000249,,Rattus norvegicus,17136,10576,B,D,,,
Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Expert,,,10116.0,Membranes,,1121,CHEMBL616066,,9,1,,BAO_0000249,,Rattus norvegicus,5778,10576,B,D,,,
Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1122,CHEMBL616067,Hippocampus,8,1,,BAO_0000221,,,13481,10576,B,H,,10000000.0,
Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Autocuration,,,,,,1123,CHEMBL616068,Hippocampus,8,1,,BAO_0000221,,,13481,10576,B,H,,10000000.0,
Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Intermediate,,,,,,1124,CHEMBL616069,Hippocampus,8,1,,BAO_0000221,,,13630,10576,B,H,,10000000.0,
Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,,,,1125,CHEMBL616070,,8,1,,BAO_0000249,,,16245,10576,B,H,,,
Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1126,CHEMBL616071,Hippocampus,8,1,,BAO_0000221,,,14509,10576,B,H,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Expert,,,,,,1127,CHEMBL616072,Hippocampus,8,1,,BAO_0000221,,,14509,10576,B,H,,10000000.0,
Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Autocuration,,,,,,1128,CHEMBL616073,Hippocampus,8,1,,BAO_0000221,,,14509,10576,B,H,,10000000.0,
Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Autocuration,,,,,,1129,CHEMBL616074,Hippocampus,8,1,,BAO_0000221,,,14509,10576,B,H,,10000000.0,
Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,Expert,,,,,,1130,CHEMBL616075,,8,1,,BAO_0000019,,,14256,10576,B,H,,,
Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1131,CHEMBL616076,,8,1,,BAO_0000357,,,11139,10576,B,H,,,
Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,Expert,,,10116.0,,,1132,CHEMBL616077,,9,1,,BAO_0000019,,Rattus norvegicus,11047,10576,B,D,,,
Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,Expert,,,10116.0,,,1133,CHEMBL616078,,9,1,,BAO_0000019,,Rattus norvegicus,11047,10576,B,D,,,
Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,Expert,,,10116.0,,,1134,CHEMBL616079,,9,1,,BAO_0000019,,Rattus norvegicus,11047,10576,B,D,,,
Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,,485.0,10116.0,,,1135,CHEMBL616080,,9,1,,BAO_0000219,,Rattus norvegicus,2395,10576,B,D,CHO-K1,,
Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1136,CHEMBL616081,,8,1,,BAO_0000357,,,9699,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Expert,,,10116.0,,,1137,CHEMBL616082,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,12028,10576,B,D,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Autocuration,,,,,,1138,CHEMBL616083,Hippocampus,8,1,,BAO_0000221,,,12028,10576,B,H,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,,,,,1139,CHEMBL616084,,8,1,,BAO_0000019,,,5815,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,Expert,,,,,,1140,CHEMBL616085,,8,1,,BAO_0000019,,,16616,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,Autocuration,,,,,,1141,CHEMBL616086,,8,1,,BAO_0000019,,,5815,10576,B,H,,,
"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Autocuration,,,,,,1142,CHEMBL616087,Hippocampus,8,1,,BAO_0000221,,,2761,10576,B,H,,10000000.0,
Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,Expert,,,,,,1143,CHEMBL616088,,8,1,,BAO_0000357,,,13133,10576,B,H,,,
Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,,,,1144,CHEMBL616089,,8,1,,BAO_0000019,,,10444,10576,B,H,,,
Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,Expert,,,10116.0,,,1145,CHEMBL616090,,9,1,,BAO_0000357,,Rattus norvegicus,13278,10576,B,D,,,
Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,,,,,1146,CHEMBL616091,,8,1,,BAO_0000357,,,15874,10576,B,H,,,
"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,,,Membranes,,1147,CHEMBL616092,Striatum,8,1,,BAO_0000249,,,10552,10576,B,H,,2435.0,
Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),Autocuration,,,,,,1148,CHEMBL616093,,8,1,,BAO_0000357,,,11130,10576,B,H,,,
Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),Autocuration,,,,,,1149,CHEMBL616094,,8,1,,BAO_0000218,In vivo,,11130,10576,B,H,,,
Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Autocuration,,,,,,1150,CHEMBL616095,Brain,8,1,,BAO_0000221,,,14542,10576,B,H,,955.0,
Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,1151,CHEMBL616096,,9,1,,BAO_0000357,,Rattus norvegicus,13670,10576,B,D,,,
Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,Expert,,,,,,1152,CHEMBL616097,,8,1,,BAO_0000249,,,9888,10576,B,H,,,
Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Expert,,,10116.0,Membranes,,1153,CHEMBL616098,,9,1,,BAO_0000249,,Rattus norvegicus,3678,10576,B,D,,,
Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1154,CHEMBL616099,Hippocampus,8,1,,BAO_0000221,,,11332,10576,B,H,,10000000.0,
Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1155,CHEMBL616100,Hippocampus,8,1,,BAO_0000221,,,11332,10576,B,H,,10000000.0,
Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Expert,,,,,,1156,CHEMBL616101,,8,1,,BAO_0000357,,,1185,10576,B,H,,,
Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,Expert,,,,,,1157,CHEMBL616102,,8,1,,BAO_0000249,,,2014,10576,B,H,,,
Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1158,CHEMBL616103,,8,1,,BAO_0000357,,,1185,10576,B,H,,,
Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,Expert,,,,,,1159,CHEMBL616104,,8,1,,BAO_0000019,,,14429,10576,B,H,,,
"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",Expert,,,,,,1160,CHEMBL616105,,8,1,,BAO_0000019,,,16288,10576,B,H,,,
Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,1161,CHEMBL616106,,9,1,,BAO_0000019,,Rattus norvegicus,5432,10576,B,D,,,
Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,Autocuration,,,,,,1162,CHEMBL616107,,8,1,,BAO_0000019,,,14429,10576,B,H,,,
Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,Expert,,,,,,1163,CHEMBL616108,,8,1,,BAO_0000357,,,13672,10576,B,H,,,
In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,,,,,1164,CHEMBL616109,Hippocampus,8,1,,BAO_0000221,,,11296,10576,B,H,,10000000.0,
In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,Autocuration,,,,,,1165,CHEMBL616110,,8,1,,BAO_0000357,,,11296,10576,B,H,,,
Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,Expert,,449.0,,,,1166,CHEMBL616111,,8,1,,BAO_0000219,,,14749,10576,B,H,CHO,,
Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,Expert,,,,,,1167,CHEMBL616112,,8,1,,BAO_0000019,,,15086,10576,B,H,,,
Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Autocuration,,,,,,1168,CHEMBL616113,Hippocampus,8,1,,BAO_0000221,,,13462,10576,B,H,,10000000.0,
Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1169,CHEMBL616114,,8,1,,BAO_0000019,,,15363,10576,B,H,,,
Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1170,CHEMBL616115,,8,1,,BAO_0000019,,,15363,10576,B,H,,,
Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1171,CHEMBL616116,,8,1,,BAO_0000357,,,10796,10576,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Expert,,,,,,1172,CHEMBL615844,Brain,8,1,,BAO_0000221,,,12816,10576,B,H,,955.0,
In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,,,,1173,CHEMBL615939,Hippocampus,8,1,,BAO_0000221,,,13542,10576,B,H,,10000000.0,
In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,Expert,,,,,,1174,CHEMBL615940,,8,1,,BAO_0000019,,,13308,10576,B,H,,,
In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Expert,,,,,,1175,CHEMBL615941,Hippocampus,8,1,,BAO_0000221,,,13541,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Autocuration,,,,,,1176,CHEMBL615942,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Autocuration,,,,,,1177,CHEMBL615943,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Autocuration,,,,,,1178,CHEMBL615944,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Autocuration,,,,,,1179,CHEMBL615945,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Autocuration,,,,,,1180,CHEMBL615946,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Autocuration,,,,,,1181,CHEMBL615947,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Autocuration,,,,,,1182,CHEMBL615948,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Autocuration,,,,,,1183,CHEMBL615949,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Autocuration,,,,,,1184,CHEMBL615950,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Autocuration,,,,,,1185,CHEMBL615951,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Autocuration,,,,,,1186,CHEMBL615952,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Autocuration,,,,,,1187,CHEMBL615953,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Autocuration,,,,,,1188,CHEMBL615954,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,,,10116.0,,,1189,CHEMBL615955,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,10058,10576,B,D,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Autocuration,,,,,,1190,CHEMBL615956,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Autocuration,,,,,,1191,CHEMBL615957,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,Expert,,,,,,1192,CHEMBL615958,,8,1,,BAO_0000019,,,12879,10576,B,H,,,
Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,Expert,,,,,,1193,CHEMBL615959,,8,1,,BAO_0000019,,,11964,10576,B,H,,,
Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),Autocuration,,,,,,1194,CHEMBL615960,,8,1,,BAO_0000019,,,11964,10576,B,H,,,
Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),Autocuration,,,,,,1195,CHEMBL615961,,8,1,,BAO_0000019,,,11964,10576,B,H,,,
Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,,,,,,1196,CHEMBL615962,Brain,8,1,,BAO_0000221,,,9548,10576,B,H,,955.0,
Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,Expert,,,,,,1197,CHEMBL615963,,8,1,,BAO_0000019,,,9098,10576,B,H,,,
Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,Autocuration,,,,,,1198,CHEMBL615964,,8,1,,BAO_0000019,,,9098,10576,B,H,,,
Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,Autocuration,,,,,,1199,CHEMBL615965,,8,1,,BAO_0000019,,,9098,10576,B,H,,,
In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,Expert,,449.0,,,,1200,CHEMBL615966,,8,1,,BAO_0000219,,,13248,10576,B,H,CHO,,
In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,Expert,,,,,,1201,CHEMBL615967,,8,1,,BAO_0000249,,,3147,10576,B,H,,,
In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,,,,,1202,CHEMBL615968,,8,1,,BAO_0000019,,,13949,10576,B,H,,,
In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,,449.0,,,,1203,CHEMBL615969,,8,1,,BAO_0000218,,,11883,10576,B,H,CHO,,
In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),Autocuration,,,,,,1204,CHEMBL615970,,8,1,,BAO_0000218,,,11883,10576,B,H,,,
In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,Expert,,,10116.0,,,1205,CHEMBL615971,,9,1,,BAO_0000357,,Rattus norvegicus,11883,10576,B,D,,,
In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,,Membranes,,1206,CHEMBL615972,,8,1,,BAO_0000249,,,15535,10576,B,H,,,
In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,Autocuration,,,,,,1207,CHEMBL615973,,8,1,,BAO_0000249,,,15535,10576,B,H,,,
In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,Autocuration,,,,,,1208,CHEMBL615974,,8,1,,BAO_0000249,,,15535,10576,B,H,,,
Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,,449.0,9606.0,,,1209,CHEMBL615975,,9,1,,BAO_0000219,,Homo sapiens,16372,51,B,D,CHO,,
In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,Expert,,,,,,1210,CHEMBL615976,,8,1,,BAO_0000249,,,14608,10576,B,H,,,
Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,,,10116.0,,,1211,CHEMBL872106,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,4795,10576,B,D,,10000000.0,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1212,CHEMBL615977,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,Autocuration,,,,,,1213,CHEMBL615978,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,Autocuration,,,,,,1214,CHEMBL616166,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,Autocuration,,,,,,1215,CHEMBL616167,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,Autocuration,,,,,,1216,CHEMBL616168,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,Autocuration,,,,,,1217,CHEMBL616169,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,Autocuration,,,,,,1218,CHEMBL616170,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,Autocuration,,,,,,1219,CHEMBL616171,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,Autocuration,,,,,,1220,CHEMBL616172,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,Autocuration,,,,,,1221,CHEMBL616173,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,Autocuration,,,,,,1222,CHEMBL616174,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,Autocuration,,,,,,1223,CHEMBL616175,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,Autocuration,,,,,,1224,CHEMBL616176,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,Autocuration,,,,,,1225,CHEMBL616177,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,Autocuration,,,,,,1226,CHEMBL616178,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,,,,,1227,CHEMBL616179,,8,1,,BAO_0000019,,,9742,10576,B,H,,,
Inhibitory concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1228,CHEMBL616180,,8,1,,BAO_0000357,,,12073,10576,B,H,,,
Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,Autocuration,,,,,,1229,CHEMBL616181,,8,1,,BAO_0000357,,,4101,10576,B,H,,,
Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,Autocuration,,,,,,1230,CHEMBL616182,,8,1,,BAO_0000019,,,15360,10576,B,H,,,
Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1231,CHEMBL616183,Hippocampus,8,1,,BAO_0000221,,,11576,10576,B,H,,10000000.0,
Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,Expert,,,,,,1232,CHEMBL615874,,8,1,,BAO_0000019,,,5834,10576,B,H,,,
Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,,485.0,10116.0,,,1233,CHEMBL615875,,9,1,,BAO_0000219,,Rattus norvegicus,2395,10576,B,D,CHO-K1,,
Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,Autocuration,,,,,,1234,CHEMBL615876,,8,1,,BAO_0000019,,,1375,10576,B,H,,,
Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,Autocuration,,,,,,1235,CHEMBL615877,,8,1,,BAO_0000019,,,1375,10576,B,H,,,
The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),Autocuration,,,,,,1236,CHEMBL615878,,8,1,,BAO_0000357,,,3967,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,Expert,,,,,,1237,CHEMBL615879,,8,1,,BAO_0000357,,,12884,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,Expert,,,,,,1238,CHEMBL615880,,8,1,,BAO_0000357,,,2343,10576,B,H,,,
"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Autocuration,,,,,,1239,CHEMBL615881,,8,1,,BAO_0000019,,,11511,10576,B,H,,,
"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Expert,,,10116.0,,,1240,CHEMBL615882,,9,1,,BAO_0000019,,Rattus norvegicus,11511,10576,B,D,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,Autocuration,,,,,,1241,CHEMBL615883,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),Autocuration,,,,,,1242,CHEMBL615884,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),Autocuration,,,,,,1243,CHEMBL615885,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),Autocuration,,,,,,1244,CHEMBL615886,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),Autocuration,,,,,,1245,CHEMBL615887,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),Autocuration,,,,,,1246,CHEMBL615888,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),Autocuration,,,,,,1247,CHEMBL615889,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),Autocuration,,,,,,1248,CHEMBL615890,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),Autocuration,,,,,,1249,CHEMBL615891,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),Autocuration,,,,,,1250,CHEMBL615892,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),Autocuration,,,,,,1251,CHEMBL615893,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),Autocuration,,,,,,1252,CHEMBL615894,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),Autocuration,,,,,,1253,CHEMBL615895,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),Autocuration,,,,,,1254,CHEMBL615896,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,Autocuration,,,,,,1255,CHEMBL615897,,8,1,,BAO_0000218,In vivo,,16394,10576,F,H,,,
"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,,,10116.0,Membranes,,1256,CHEMBL615898,,9,1,,BAO_0000249,,Rattus norvegicus,16616,10576,F,D,,,
% inhibition towards 5-HT1A receptor from rat hippocampal membranes,Autocuration,,,,,,1257,CHEMBL615899,,8,1,,BAO_0000019,,,16796,10576,B,H,,,
% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Autocuration,,,,,,1258,CHEMBL616291,,8,1,,BAO_0000019,,,16796,10576,B,H,,,
Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,Autocuration,,,,,,1259,CHEMBL616292,,8,1,,BAO_0000357,,,15629,10576,B,H,,,
"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,,,,,1260,CHEMBL616293,,8,1,,BAO_0000249,,,13241,10576,F,H,,,
Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,,,1261,CHEMBL616294,Hippocampus,8,1,,BAO_0000221,,,12073,10576,B,H,,10000000.0,
Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Autocuration,,,,,,1262,CHEMBL616295,Hippocampus,8,1,,BAO_0000249,,,14286,10576,B,H,,10000000.0,
Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Autocuration,,,,,,1263,CHEMBL616296,Brain,8,1,,BAO_0000221,,,14542,10576,B,H,,955.0,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,,,,,1264,CHEMBL616297,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,Autocuration,,,,,,1265,CHEMBL616605,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,Autocuration,,,,,,1266,CHEMBL616606,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Autocuration,,,,,,1267,CHEMBL616607,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Expert,,,,,,1268,CHEMBL616608,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,Autocuration,,,,,,1269,CHEMBL616609,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,Expert,,,10116.0,,,1270,CHEMBL616610,,9,1,,BAO_0000019,,Rattus norvegicus,13630,10576,F,D,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,,,,,1271,CHEMBL616611,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,Expert,,,,,,1272,CHEMBL616612,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,Autocuration,,,,,,1273,CHEMBL616613,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,Expert,,,,,,1274,CHEMBL616614,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,Autocuration,,,,,,1275,CHEMBL616615,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Expert,,,,,,1276,CHEMBL616616,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,Autocuration,,,,,,1277,CHEMBL616617,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,,,,,1278,CHEMBL616618,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,Autocuration,,,,,,1279,CHEMBL616619,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,Expert,,,,,,1280,CHEMBL616620,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Expert,,,,,,1281,CHEMBL616621,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,Autocuration,,,,,,1282,CHEMBL616622,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,Expert,,,,,,1283,CHEMBL616146,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,Autocuration,,,,,,1284,CHEMBL832873,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,Autocuration,,,,,,1285,CHEMBL616147,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,,,,,1286,CHEMBL872872,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Autocuration,,,,,,1287,CHEMBL616148,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Autocuration,,,,,,1288,CHEMBL616149,Hippocampus,8,1,,BAO_0000221,,,9783,10576,B,H,,10000000.0,
In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Expert,,,,,,1289,CHEMBL616150,Hippocampus,8,1,,BAO_0000221,,,9783,10576,B,H,,10000000.0,
Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Expert,,,10116.0,Membranes,,1290,CHEMBL616151,,9,1,,BAO_0000249,,Rattus norvegicus,14331,10576,B,D,,,
Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Expert,,,,,,1291,CHEMBL872873,Hippocampus,8,1,,BAO_0000221,,,15260,10576,B,H,,10000000.0,
Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Autocuration,,,,,,1292,CHEMBL616670,Hippocampus,8,1,,BAO_0000221,,,15260,10576,B,H,,10000000.0,
Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Autocuration,,,,,,1293,CHEMBL616671,Hippocampus,8,1,,BAO_0000221,,,15260,10576,B,H,,10000000.0,
"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,,,10116.0,,,1294,CHEMBL884861,,9,1,,BAO_0000249,,Rattus norvegicus,16616,10576,F,D,,,
Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,Autocuration,,,,,,1295,CHEMBL616672,,8,1,,BAO_0000357,,,15629,10576,B,H,,,
The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,,,,,1296,CHEMBL616673,,8,1,,BAO_0000019,,,15086,10576,B,H,,,
Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,,,,,1297,CHEMBL616674,,8,1,,BAO_0000019,,,5717,10576,F,H,,,
Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,,,,,1298,CHEMBL616675,,8,1,,BAO_0000357,,,12652,10576,B,H,,,
In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Autocuration,,,,,,1299,CHEMBL616676,Hippocampus,8,1,,BAO_0000221,,,14608,10576,B,H,,10000000.0,
Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,,,1300,CHEMBL616677,Hippocampus,8,1,,BAO_0000221,,,12306,10576,B,H,,10000000.0,
The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,,,1301,CHEMBL616678,Hippocampus,8,1,,BAO_0000221,,,12306,10576,B,H,,10000000.0,
Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,1302,CHEMBL616679,,9,1,,BAO_0000357,,Rattus norvegicus,15247,10576,B,D,,,
Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Expert,,,,,,1303,CHEMBL616680,Hippocampus,8,1,,BAO_0000221,,,17529,10576,B,H,,10000000.0,
Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,,,1304,CHEMBL616681,Hippocampus,8,1,,BAO_0000221,,,14826,10576,B,H,,10000000.0,
Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,,,1305,CHEMBL616682,Hippocampus,8,1,,BAO_0000221,,,14826,10576,B,H,,10000000.0,
Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1306,CHEMBL616683,Hippocampus,8,1,,BAO_0000221,,,13241,10576,B,H,,10000000.0,
Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1307,CHEMBL616684,Hippocampus,8,1,,BAO_0000221,,,14093,10576,B,H,,10000000.0,
Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,,,,,1308,CHEMBL616685,Hippocampus,8,1,,BAO_0000221,,,14093,10576,B,H,,10000000.0,
Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Autocuration,,,,,,1309,CHEMBL616686,Brain,8,1,,BAO_0000221,,,14442,10576,B,H,,955.0,
Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,,,,,1310,CHEMBL616687,,8,1,,BAO_0000357,,,9919,10576,B,H,,,
Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,,,,,1311,CHEMBL616688,,8,1,,BAO_0000357,,,9919,10576,B,H,,,
Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Autocuration,,,,,,1312,CHEMBL616689,Hippocampus,8,1,,BAO_0000221,,,11440,10576,B,H,,10000000.0,
Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,Autocuration,,,,,,1313,CHEMBL616690,,8,1,,BAO_0000357,,,11257,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,Expert,,,,,,1314,CHEMBL616691,,8,1,,BAO_0000357,,,10330,10576,B,H,,,
Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Expert,,,10116.0,,,1315,CHEMBL616692,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,17331,10576,B,D,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,Expert,,,,,,1316,CHEMBL616693,,8,1,,BAO_0000249,,,16567,10576,B,H,,,
"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Expert,,,10116.0,,,1317,CHEMBL616694,,9,1,,BAO_0000019,,Rattus norvegicus,12058,10576,B,D,,,
Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Autocuration,,,,,,1318,CHEMBL616695,Hippocampus,8,1,,BAO_0000221,,,9699,10576,B,H,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,Autocuration,,,,,,1319,CHEMBL616696,,8,1,,BAO_0000357,,,9547,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,Autocuration,,,,,,1320,CHEMBL616697,,8,1,,BAO_0000357,,,10330,10576,B,H,,,
Binding affinity against rat 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1321,CHEMBL616698,,8,1,,BAO_0000357,,,14331,10576,B,H,,,
Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,1322,CHEMBL616949,,9,1,,BAO_0000019,,Rattus norvegicus,14060,10576,B,D,,,
Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Autocuration,,,,,,1323,CHEMBL616950,Hippocampus,8,1,,BAO_0000221,,,14744,10576,B,H,,10000000.0,
Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,,,,,,1324,CHEMBL832875,,8,1,,BAO_0000357,,,13506,10576,B,H,,,
Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,,,,,1325,CHEMBL616951,Brain,8,1,,BAO_0000221,,,10862,10576,B,H,,955.0,
Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,,,,,1326,CHEMBL616952,Brain,8,1,,BAO_0000221,,,10862,10576,B,H,,955.0,
Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,Expert,,,,,,1327,CHEMBL616953,,8,1,,BAO_0000357,,,10062,10576,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,Autocuration,,,,,,1328,CHEMBL616954,,8,1,,BAO_0000357,,,12073,10576,B,H,,,
GTPgammaS radioligand binding assay,Autocuration,,,,,,1329,CHEMBL616955,,8,1,,BAO_0000357,,,14875,106,B,H,,,
The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,,,,,1330,CHEMBL616956,,8,1,,BAO_0000357,,,2391,106,B,H,,,
The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,Autocuration,,,,,,1331,CHEMBL616957,,8,1,,BAO_0000019,,,2391,106,F,H,,,
The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,Autocuration,,,,,,1332,CHEMBL616958,,8,1,,BAO_0000019,,,2391,106,F,H,,,
The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1333,CHEMBL616959,,8,1,,BAO_0000357,,,2391,106,B,H,,,
The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,,,,,1334,CHEMBL616960,,8,1,,BAO_0000357,,,2391,106,B,H,,,
The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,Autocuration,,,,,,1335,CHEMBL616961,,8,1,,BAO_0000019,,,2391,106,F,H,,,
Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,Expert,,308.0,,,,1336,CHEMBL616962,,8,1,,BAO_0000219,,,17211,106,B,H,HeLa,,
Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,Autocuration,,308.0,,,,1337,CHEMBL616963,,8,1,,BAO_0000219,,,17211,106,B,H,HeLa,,
Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,Expert,,,9606.0,,,1338,CHEMBL616524,,9,1,,BAO_0000357,,Homo sapiens,6491,106,B,D,,,
Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,449.0,,,,1339,CHEMBL616525,,8,1,,BAO_0000219,,,16190,106,B,H,CHO,,
Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,Autocuration,,,,,,1340,CHEMBL872908,,8,1,,BAO_0000019,,,14165,106,B,H,,,
Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,Autocuration,,,,,,1341,CHEMBL616526,,8,1,,BAO_0000019,,,14165,106,B,H,,,
Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,Expert,,,9606.0,,,1342,CHEMBL616527,,9,1,,BAO_0000357,,Homo sapiens,4234,106,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,,,,,1343,CHEMBL616528,,8,1,,BAO_0000219,,,6328,106,B,H,,,
Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,,,,1344,CHEMBL616529,,8,1,,BAO_0000357,,,14770,106,B,H,,,
Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,Autocuration,,,,,,1345,CHEMBL616530,,8,1,,BAO_0000357,,,2598,106,B,H,,,
Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,,1346,CHEMBL616531,,8,1,,BAO_0000357,,,6897,106,B,H,,,
Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1347,CHEMBL616532,,8,1,,BAO_0000357,,,6897,106,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1348,CHEMBL616533,,8,1,,BAO_0000357,,,6013,106,B,H,,,
Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,,1349,CHEMBL616534,,8,1,,BAO_0000357,,,5843,106,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,,,,,1350,CHEMBL616535,,8,1,,BAO_0000357,,,14454,106,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,Autocuration,,,,,,1351,CHEMBL616536,,8,1,,BAO_0000357,,,16209,106,B,H,,,
Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1352,CHEMBL616537,,8,1,,BAO_0000357,,,3935,106,B,H,,,
Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,Expert,,485.0,,,,1353,CHEMBL616538,,8,1,,BAO_0000219,,,13729,106,F,H,CHO-K1,,
Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,Expert,,,,,,1354,CHEMBL616539,,8,1,,BAO_0000019,,,14251,106,F,H,,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,Expert,,,,,,1355,CHEMBL616540,,8,1,,BAO_0000019,,,17085,106,B,H,,,
In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,,,,,1356,CHEMBL616429,,8,1,,BAO_0000357,,,3025,106,B,H,,,
In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,Expert,,,,,,1357,CHEMBL616430,,8,1,,BAO_0000357,,,15315,106,B,H,,,
Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,Expert,,,9606.0,,,1358,CHEMBL616431,,9,1,,BAO_0000219,,Homo sapiens,14214,106,B,D,,,
Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,,,9606.0,,,1359,CHEMBL616432,,9,1,,BAO_0000357,,Homo sapiens,3804,106,B,D,,,
Affinity for 5-hydroxytryptamine 1B receptor subtype,Expert,,,9606.0,,,1360,CHEMBL616433,,9,1,,BAO_0000357,,Homo sapiens,2391,106,B,D,,,
Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,,,9606.0,,,1361,CHEMBL616434,,9,1,,BAO_0000357,,Homo sapiens,4175,106,B,D,,,
Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,Autocuration,,449.0,,,,1362,CHEMBL616435,,8,1,,BAO_0000219,,,17296,106,B,H,CHO,,
In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,Expert,,,,,,1363,CHEMBL616436,,8,1,,BAO_0000019,,,17085,106,B,H,,,
Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,,308.0,,,,1364,CHEMBL616437,,8,1,,BAO_0000219,,,17211,106,B,H,HeLa,,
Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,Autocuration,,308.0,,,,1365,CHEMBL616438,,8,1,,BAO_0000219,,,17211,106,B,H,HeLa,,
Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,,308.0,,,,1366,CHEMBL616439,,8,1,,BAO_0000219,,,17211,106,B,H,HeLa,,
Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,Expert,,,9606.0,,,1367,CHEMBL616440,,9,1,,BAO_0000357,,Homo sapiens,15926,106,B,D,,,
Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,Autocuration,,485.0,,,,1368,CHEMBL616441,,8,1,,BAO_0000219,,,16312,106,B,H,CHO-K1,,
Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,Expert,,,,,,1369,CHEMBL616442,,8,1,,BAO_0000357,,,5843,106,B,H,,,
Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1370,CHEMBL616443,,8,1,,BAO_0000357,,,5843,106,B,H,,,
Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,Expert,,485.0,,,,1371,CHEMBL616444,,8,1,,BAO_0000219,,,16312,106,B,H,CHO-K1,,
Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,,,9606.0,,,1372,CHEMBL616445,,9,1,,BAO_0000357,,Homo sapiens,15926,106,B,D,,,
Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,,,9606.0,,,1373,CHEMBL616446,,9,1,,BAO_0000357,,Homo sapiens,15926,106,B,D,,,
Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Expert,,449.0,9606.0,,,1374,CHEMBL616447,,9,1,,BAO_0000219,,Homo sapiens,4540,106,B,D,CHO,,
Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,,,,1375,CHEMBL616448,,8,1,,BAO_0000357,,,6166,106,B,H,,,
Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,Autocuration,,449.0,,,,1376,CHEMBL616449,,8,1,,BAO_0000219,,,17296,106,B,H,CHO,,
Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,Autocuration,,449.0,,,,1377,CHEMBL616450,,8,1,,BAO_0000219,,,17296,106,B,H,CHO,,
Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,Autocuration,,449.0,,,,1378,CHEMBL857974,,8,1,,BAO_0000219,,,17296,106,B,H,CHO,,
Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,449.0,,,,1379,CHEMBL616451,,8,1,,BAO_0000219,,,15779,106,B,H,CHO,,
Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,449.0,,,,1380,CHEMBL616452,,8,1,,BAO_0000219,,,15779,106,B,H,CHO,,
Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,,449.0,,,,1381,CHEMBL616453,,8,1,,BAO_0000219,,,15779,106,B,H,CHO,,
Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,449.0,,,,1382,CHEMBL616454,,8,1,,BAO_0000219,,,4199,106,B,H,CHO,,
Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,,,9606.0,,,1383,CHEMBL616455,,9,1,,BAO_0000357,,Homo sapiens,14875,106,B,D,,,
Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,,449.0,,,,1384,CHEMBL616456,,8,1,,BAO_0000219,,,15146,106,B,H,CHO,,
Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,,1385,CHEMBL616457,,8,1,,BAO_0000357,,,5213,106,B,H,,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,,449.0,,,,1386,CHEMBL616458,,8,1,,BAO_0000219,,,14818,106,B,H,CHO,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,449.0,,,,1387,CHEMBL616459,,8,1,,BAO_0000219,,,4829,106,B,H,CHO,,
Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,Expert,,,,,,1388,CHEMBL616460,,8,1,,BAO_0000019,,,14454,106,F,H,,,
Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,Expert,,,,,,1389,CHEMBL616461,,8,1,,BAO_0000019,,,14454,106,F,H,,,
"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,,449.0,,,,1390,CHEMBL616462,,8,1,,BAO_0000219,,,14875,106,F,H,CHO,,
"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,,449.0,,,,1391,CHEMBL616463,,8,1,,BAO_0000219,,,14875,106,F,H,CHO,,
"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",Autocuration,,,,,,1392,CHEMBL616464,,8,1,,BAO_0000019,,,15250,105,F,H,,,
Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,Autocuration,,449.0,,,,1393,CHEMBL616465,,8,1,,BAO_0000219,,,15250,105,B,H,CHO,,
The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1394,CHEMBL832874,,8,1,,BAO_0000357,,,15086,17105,B,H,,,
5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,Autocuration,,,9986.0,,,1395,CHEMBL616184,,8,1,,BAO_0000019,,Oryctolagus cuniculus,3025,106,F,H,,,
The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,Autocuration,,,9986.0,,,1396,CHEMBL616185,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14998,106,B,H,,,
"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",Intermediate,,,9986.0,,,1397,CHEMBL616186,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14998,106,B,H,,,
The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,Autocuration,,,9986.0,,,1398,CHEMBL616187,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14998,106,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,Expert,,,,,,1399,CHEMBL616188,,8,1,,BAO_0000357,,,13969,10577,B,H,,,
Binding affinity for 5-hydroxytryptamine 1B receptor,Intermediate,,,,,,1400,CHEMBL873475,,9,1,,BAO_0000357,,,13392,10577,B,D,,,
Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Expert,,,10116.0,,,1401,CHEMBL616189,Striatum,9,1,,BAO_0000019,,Rattus norvegicus,3651,10577,B,D,,2435.0,
Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Expert,,,,,,1402,CHEMBL616190,,8,1,,BAO_0000357,,,10025,10577,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,Autocuration,,,,,,1403,CHEMBL616191,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,Autocuration,,,,,,1404,CHEMBL616192,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,Autocuration,,,,,,1405,CHEMBL616193,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,Autocuration,,,,,,1406,CHEMBL616194,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,Autocuration,,,,,,1407,CHEMBL616195,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,Autocuration,,,,,,1408,CHEMBL616196,,8,1,,BAO_0000357,,,13863,10576,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Autocuration,,,,,,1409,CHEMBL616197,Hippocampus,8,1,,BAO_0000249,,,4622,10576,B,H,,10000000.0,
Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Intermediate,,,,,,1410,CHEMBL616198,,8,1,,BAO_0000019,,,14911,10576,B,H,,,
In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,,,,,1411,CHEMBL616199,Hippocampus,8,1,,BAO_0000221,,,12678,10576,B,H,,10000000.0,
In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Expert,,,,,,1412,CHEMBL616200,Hippocampus,8,1,,BAO_0000221,,,12678,10576,B,H,,10000000.0,
In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Expert,,,,,,1413,CHEMBL616201,Hippocampus,8,1,,BAO_0000221,,,14235,10576,B,H,,10000000.0,
In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,,,,,1414,CHEMBL616202,Hippocampus,8,1,,BAO_0000221,,,14949,10576,B,H,,10000000.0,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,,,,,1415,CHEMBL616203,Hippocampus,8,1,,BAO_0000221,,,14949,10576,B,H,,10000000.0,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Expert,,,,,,1416,CHEMBL616204,Hippocampus,8,1,,BAO_0000221,,,14949,10576,B,H,,10000000.0,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Expert,,,,,,1417,CHEMBL616205,Hippocampus,8,1,,BAO_0000221,,,14949,10576,B,H,,10000000.0,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Expert,,,,,,1418,CHEMBL616206,Hippocampus,8,1,,BAO_0000221,,,14949,10576,B,H,,10000000.0,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Expert,,,,,,1419,CHEMBL616207,,8,1,,BAO_0000249,,,16118,10576,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,Autocuration,,,,,,1420,CHEMBL616208,,8,1,,BAO_0000249,,,3268,10576,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,Autocuration,,,,,,1421,CHEMBL616209,,8,1,,BAO_0000249,,,3268,10576,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,Expert,,,,,,1422,CHEMBL616210,,8,1,,BAO_0000357,,,16117,10576,B,H,,,
In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Expert,,,,,,1423,CHEMBL616211,Hippocampus,8,1,,BAO_0000221,,,9783,10576,B,H,,10000000.0,
In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Autocuration,,,,,,1424,CHEMBL616504,Hippocampus,8,1,,BAO_0000221,,,9783,10576,B,H,,10000000.0,
Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,1425,CHEMBL616505,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,14356,10576,B,D,,10000000.0,
Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1426,CHEMBL616506,,8,1,,BAO_0000019,,,15740,10576,F,H,,,
Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,,,,,1427,CHEMBL872107,Hippocampus,8,1,,BAO_0000221,,,12306,10576,B,H,,10000000.0,
Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Expert,,,10116.0,,,1428,CHEMBL616507,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,13348,10576,B,D,,10000000.0,
Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,Autocuration,,,,,,1429,CHEMBL616303,,8,1,,BAO_0000249,,,10394,10576,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Autocuration,,,,,,1430,CHEMBL616304,Hippocampus,8,1,,BAO_0000221,,,15260,10576,B,H,,10000000.0,
Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Expert,,,,,,1431,CHEMBL616305,Hippocampus,8,1,,BAO_0000221,,,10046,10576,B,H,,10000000.0,
Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Intermediate,,,,,,1432,CHEMBL616306,Hippocampus,8,1,,BAO_0000221,,,15260,10576,F,H,,10000000.0,
Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1433,CHEMBL616307,,8,1,,BAO_0000357,,,12851,10576,B,H,,,
Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Expert,,,10116.0,,,1434,CHEMBL881829,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,2148,10576,B,D,,10000000.0,
Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,Expert,,,,,,1435,CHEMBL616308,,8,1,,BAO_0000357,,,13134,10576,B,H,,,
Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,Autocuration,,,,,,1436,CHEMBL616309,,8,1,,BAO_0000019,,,12462,10576,B,H,,,
Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,Expert,,,,,,1437,CHEMBL616310,,8,1,,BAO_0000019,,,12462,10576,B,H,,,
Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,Autocuration,,449.0,,,,1438,CHEMBL616311,,8,1,,BAO_0000219,,,12462,10576,B,H,CHO,,
Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,Expert,,,,,,1439,CHEMBL616312,,8,1,,BAO_0000357,,,11933,10576,B,H,,,
Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,Autocuration,,,,,,1440,CHEMBL616313,,8,1,,BAO_0000357,,,11933,10576,B,H,,,
Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,1441,CHEMBL616314,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,403,10576,B,D,,10000000.0,
Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,,,1442,CHEMBL616315,Hippocampus,8,1,,BAO_0000221,,,15538,10576,B,H,,10000000.0,
Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Autocuration,,,,,,1443,CHEMBL616567,Hippocampus,8,1,,BAO_0000221,,,15538,10576,B,H,,10000000.0,
Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Autocuration,,,,,,1444,CHEMBL616568,Hippocampus,8,1,,BAO_0000221,,,15538,10576,B,H,,10000000.0,
Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,Intermediate,,,,,,1445,CHEMBL616569,,8,1,,BAO_0000019,,,12464,10576,B,H,,,
Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,Expert,,,,,,1446,CHEMBL616570,,8,1,,BAO_0000357,,,1455,10576,B,H,,,
Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,,,,,1447,CHEMBL616571,,8,1,,BAO_0000357,,,12652,10576,B,H,,,
Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Autocuration,,,,,,1448,CHEMBL616572,Hippocampus,8,1,,BAO_0000221,,,12639,10576,B,H,,10000000.0,
Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,Expert,,,,,,1449,CHEMBL616573,,8,1,,BAO_0000249,,,13949,10576,B,H,,,
Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,Expert,,,10116.0,,,1450,CHEMBL616574,,9,1,,BAO_0000357,,Rattus norvegicus,12463,10576,B,D,,,
The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Expert,,,,,,1451,CHEMBL616575,Hippocampus,8,1,,BAO_0000221,,,14829,10576,B,H,,10000000.0,
The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Autocuration,,,,,,1452,CHEMBL872108,Hippocampus,8,1,,BAO_0000221,,,14829,10576,B,H,,10000000.0,
The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,Autocuration,,,,,,1453,CHEMBL616576,,8,1,,BAO_0000357,,,12092,10576,B,H,,,
The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,Autocuration,,,,,,1454,CHEMBL616577,,8,1,,BAO_0000249,,,403,10576,B,H,,,
The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,Autocuration,,,,,,1455,CHEMBL616578,,8,1,,BAO_0000249,,,403,10576,B,H,,,
Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,Expert,,,,,,1456,CHEMBL616579,,8,1,,BAO_0000357,,,3967,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Expert,,,10116.0,,,1457,CHEMBL616580,,9,1,,BAO_0000019,,Rattus norvegicus,12771,10576,B,D,,,
The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,,,,,1458,CHEMBL616581,,8,1,,BAO_0000019,,,15086,10576,B,H,,,
The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,,,,,1459,CHEMBL616582,Hippocampus,8,1,,BAO_0000221,,,14909,10576,B,H,,10000000.0,
The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,,,,,1460,CHEMBL616583,Hippocampus,8,1,,BAO_0000221,,,14949,10576,B,H,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Expert,,,10116.0,,,1461,CHEMBL616584,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,2309,10576,B,D,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,,,,1462,CHEMBL616585,,8,1,,BAO_0000357,,,4170,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Expert,,,10116.0,,,1463,CHEMBL616586,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,11642,10576,B,D,,10000000.0,
The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Autocuration,,,,,,1464,CHEMBL616587,Hippocampus,8,1,,BAO_0000221,,,11642,10576,B,H,,10000000.0,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Autocuration,,,,,,1465,CHEMBL616588,Hippocampus,8,1,,BAO_0000221,,,12953,10576,B,H,,10000000.0,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Autocuration,,,,,,1466,CHEMBL616589,Hippocampus,8,1,,BAO_0000221,,,12953,10576,B,H,,10000000.0,
Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Expert,,,,,,1467,CHEMBL616590,Hippocampus,8,1,,BAO_0000221,,,12953,10576,B,H,,10000000.0,
"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",Expert,,449.0,,,,1468,CHEMBL616591,,8,1,,BAO_0000219,,,12903,10576,B,H,CHO,,
Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,,,,,,1469,CHEMBL616592,,8,1,,BAO_0000357,,,12536,10576,B,H,,,
The inhibition activity of 5-HT1A at 1 uM,Autocuration,,,,,,1470,CHEMBL616593,,8,1,,BAO_0000357,,,10058,10576,B,H,,,
"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",Expert,,485.0,,,,1471,CHEMBL616594,,8,1,,BAO_0000219,,,12902,10576,B,H,CHO-K1,,
Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,Expert,,,,,,1472,CHEMBL616595,,8,1,,BAO_0000249,,,14057,10576,B,H,,,
Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,Autocuration,,,,,,1473,CHEMBL616596,,8,1,,BAO_0000357,,,11296,10576,B,H,,,
Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Autocuration,,,,,,1474,CHEMBL616597,Hippocampus,8,1,,BAO_0000221,,,11296,10576,B,H,,10000000.0,
Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,,,,,1475,CHEMBL616598,Hippocampus,8,1,,BAO_0000221,,,11296,10576,B,H,,10000000.0,
Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Expert,,,10116.0,Membranes,,1476,CHEMBL616599,,9,1,,BAO_0000249,,Rattus norvegicus,16616,10576,F,D,,,
"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,,,10116.0,Membranes,,1477,CHEMBL616600,Hippocampus,9,1,,BAO_0000249,,Rattus norvegicus,16616,10576,F,D,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,Autocuration,,,,,,1478,CHEMBL616601,,8,1,,BAO_0000019,,,16567,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,Autocuration,,,,,,1479,CHEMBL616602,,8,1,,BAO_0000019,,,16567,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,Autocuration,,,,,,1480,CHEMBL616603,,8,1,,BAO_0000019,,,16567,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,Autocuration,,,,,,1481,CHEMBL616604,,8,1,,BAO_0000019,,,16567,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,Autocuration,,,,,,1482,CHEMBL616316,,8,1,,BAO_0000249,,,17136,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,Autocuration,,,,,,1483,CHEMBL616317,,8,1,,BAO_0000249,,,17136,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,Expert,,,10116.0,,,1484,CHEMBL616318,,9,1,,BAO_0000019,,Rattus norvegicus,16616,10576,B,D,,,
Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Autocuration,,,,,,1485,CHEMBL616319,Hippocampus,8,1,,BAO_0000221,,,17331,10576,B,H,,10000000.0,
Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Autocuration,,,,,,1486,CHEMBL616320,Hippocampus,8,1,,BAO_0000221,,,17331,10576,B,H,,10000000.0,
Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Expert,,,10116.0,,,1487,CHEMBL616321,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,17167,10576,B,D,,10000000.0,
Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,,,,,1488,CHEMBL616322,,8,1,,BAO_0000019,,,15740,10576,F,H,,,
Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,Autocuration,,,,,,1489,CHEMBL616323,,8,1,,BAO_0000019,,,15740,10576,F,H,,,
Ratio of binding affinity to 5-HT 1A and D2 receptor,Autocuration,,,,,,1490,CHEMBL616324,,8,1,,BAO_0000357,,,4671,10576,B,H,,,
In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,,,,,1491,CHEMBL616325,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,,,,,1492,CHEMBL616326,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Autocuration,,,,,,1493,CHEMBL616327,Hippocampus,8,1,,BAO_0000221,,,10058,10576,B,H,,10000000.0,
Percentage inhibition against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1494,CHEMBL616328,,8,1,,BAO_0000357,,,12073,10576,B,H,,,
Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,,,,,1495,CHEMBL858110,,8,1,,BAO_0000249,,,2759,10576,B,H,,,
Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,,,,,1496,CHEMBL616329,,8,1,,BAO_0000249,,,2759,10576,F,H,,,
Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,,,,,1497,CHEMBL616330,,8,1,,BAO_0000249,,,2759,10576,B,H,,,
Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,,,,,1498,CHEMBL616331,,8,1,,BAO_0000249,,,2759,10576,F,H,,,
Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,,,,,1499,CHEMBL616332,,8,1,,BAO_0000249,,,2759,10576,F,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,,,1500,CHEMBL857063,Brain,8,1,,BAO_0000249,,,9737,10576,B,H,,955.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,Autocuration,,,,,,1501,CHEMBL616333,,8,1,,BAO_0000019,,,9737,10576,B,H,,,
Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,Expert,,,,,,1502,CHEMBL616334,,8,1,,BAO_0000019,,,5717,10576,F,H,,,
Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,,,,,1503,CHEMBL616335,Hippocampus,8,1,,BAO_0000221,,,12253,10576,B,H,,10000000.0,
Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,Autocuration,,,,,,1504,CHEMBL616336,,8,1,,BAO_0000019,,,14025,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,Expert,,,,,,1505,CHEMBL616337,,8,1,,BAO_0000249,,,10425,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,Autocuration,,,,,,1506,CHEMBL616338,,8,1,,BAO_0000019,,,14998,10576,B,H,,,
Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Autocuration,,,,,,1507,CHEMBL616339,Hippocampus,8,1,,BAO_0000221,,,13694,10576,B,H,,10000000.0,
Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Autocuration,,,,,,1508,CHEMBL616340,Hippocampus,8,1,,BAO_0000221,,,13694,10576,B,H,,10000000.0,
Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,,1509,CHEMBL616341,,8,1,,BAO_0000357,,,4342,10576,B,H,,,
Binding affinity against rat 5-hydroxytryptamine 1A receptor,Expert,,,10116.0,,,1510,CHEMBL616342,,9,1,,BAO_0000357,,Rattus norvegicus,12936,10576,B,D,,,
Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,Expert,,,10116.0,,,1511,CHEMBL616343,,9,1,,BAO_0000019,,Rattus norvegicus,13144,10576,B,D,,,
Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,Expert,,,,,,1512,CHEMBL616344,,8,1,,BAO_0000019,,,13343,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,,,,,1513,CHEMBL616345,,8,1,,BAO_0000357,,,12132,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,Expert,,,,,,1514,CHEMBL616346,,8,1,,BAO_0000019,,,15419,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,,,,,1515,CHEMBL616347,Hippocampus,8,1,,BAO_0000221,,,1479,10576,B,H,,10000000.0,
In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,Expert,,,,,,1516,CHEMBL616348,,8,1,,BAO_0000019,,,14287,10576,B,H,,,
Binding affinity at 5-hydroxytryptamine 1A receptor,Expert,,,,,,1517,CHEMBL616349,,8,1,,BAO_0000357,,,13116,10576,B,H,,,
Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Expert,,,10116.0,Membranes,,1518,CHEMBL616152,,9,1,,BAO_0000249,,Rattus norvegicus,2759,10576,B,D,,,
Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,,,,,1519,CHEMBL616153,,8,1,,BAO_0000249,,,2759,10576,B,H,,,
"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",Expert,,,,,,1520,CHEMBL616154,,8,1,,BAO_0000019,,,14748,10576,B,H,,,
In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,,,,,1521,CHEMBL616155,,8,1,,BAO_0000019,,,12304,10576,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Expert,,,10116.0,,,1522,CHEMBL616156,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,12409,10576,B,D,,10000000.0,
Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Expert,,,10116.0,,,1523,CHEMBL616157,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,12409,10576,B,D,,10000000.0,
The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Autocuration,,,,,,1524,CHEMBL616158,Hippocampus,8,1,,BAO_0000221,,,13267,10576,B,H,,10000000.0,
The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Autocuration,,,,,,1525,CHEMBL616159,,8,1,,BAO_0000357,,,15194,10576,B,H,,,
pKi value against rat 5-hydroxytryptamine 1A receptor.,Expert,,,,,,1526,CHEMBL616160,,8,1,,BAO_0000357,,,14256,10576,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,Autocuration,,,,,,1527,CHEMBL616161,,8,1,,BAO_0000019,,,16567,10576,B,H,,,
Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,,,,,1528,CHEMBL616162,,8,1,,BAO_0000019,,,15740,10576,F,H,,,
Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,,,10116.0,,,1529,CHEMBL616163,,9,1,,BAO_0000357,,Rattus norvegicus,13278,12687,B,D,,,
Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,,,Membranes,,1530,CHEMBL616164,,8,1,,BAO_0000249,,,1970,10626,B,H,,,
Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Autocuration,,,,,,1531,CHEMBL616165,Brain,8,1,,BAO_0000221,,,10034,10576,B,H,,955.0,
Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,Autocuration,,,10116.0,,,1532,CHEMBL616355,,8,1,,BAO_0000019,,Rattus norvegicus,13348,51,B,H,,,
Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Autocuration,,,,,,1533,CHEMBL616356,,8,1,,BAO_0000019,,,13630,10576,F,H,,,
Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Autocuration,,,,,,1534,CHEMBL616357,Brain,8,1,,BAO_0000221,,,10862,10576,B,H,,955.0,
"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Autocuration,,,,,,1535,CHEMBL616358,,8,1,,BAO_0000019,,,12058,10576,B,H,,,
Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1536,CHEMBL616359,,8,1,,BAO_0000357,,,4639,51,B,H,,,
Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,Expert,,,,,,1537,CHEMBL616360,,8,1,,BAO_0000357,,,15453,51,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,,,,1538,CHEMBL616361,,8,1,,BAO_0000357,,,4820,51,B,H,,,
Tested for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1539,CHEMBL616362,,8,1,,BAO_0000357,,,1089,51,B,H,,,
The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Autocuration,,,,Brain membranes,,1540,CHEMBL616363,,8,1,,BAO_0000249,,,386,51,B,H,,,
Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,Autocuration,,,,,,1541,CHEMBL616364,,8,1,,BAO_0000357,,,6011,51,B,H,,,
Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1542,CHEMBL616365,,8,1,,BAO_0000357,,,5014,51,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,Expert,,,,,,1543,CHEMBL616366,,8,1,,BAO_0000357,,,4402,51,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,,,,,1544,CHEMBL872906,,8,1,,BAO_0000357,,,17066,51,B,H,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,Autocuration,,,,,,1545,CHEMBL616367,,8,1,,BAO_0000357,,,17515,51,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1546,CHEMBL616368,,8,1,,BAO_0000357,,,2474,51,B,H,,,
Binding affinity to 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,,1547,CHEMBL616369,,8,1,,BAO_0000357,,,4775,51,B,H,,,
Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,Expert,,,9606.0,,,1548,CHEMBL616370,,9,1,,BAO_0000357,,Homo sapiens,14294,51,B,D,,,
Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,Expert,,,9606.0,,,1549,CHEMBL616371,,9,1,,BAO_0000357,,Homo sapiens,14294,51,B,D,,,
Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,449.0,,,,1550,CHEMBL616372,,8,1,,BAO_0000219,,,12249,51,B,H,CHO,,
Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,Expert,,,,,,1551,CHEMBL616373,,8,1,,BAO_0000219,,,11376,51,B,H,,,
Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1552,CHEMBL616374,,8,1,,BAO_0000218,In vivo,,2474,51,B,H,,,
Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,,,,,1553,CHEMBL616375,Hippocampus,8,1,,BAO_0000221,,,13311,51,B,H,,10000000.0,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,,1554,CHEMBL616376,,8,1,,BAO_0000357,,,4373,51,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,Expert,,,,,,1555,CHEMBL857064,,8,1,,BAO_0000357,,,1633,51,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,,1556,CHEMBL616377,,8,1,,BAO_0000357,,,11866,51,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,,,,,1557,CHEMBL616378,,8,1,,BAO_0000357,,,4373,51,B,H,,,
Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1558,CHEMBL616379,,8,1,,BAO_0000357,,,4687,51,B,H,,,
Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1559,CHEMBL616380,,8,1,,BAO_0000357,,,16946,11863,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,Autocuration,,,,,,1560,CHEMBL616381,,8,1,,BAO_0000357,,,13291,11863,B,H,,,
Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1561,CHEMBL616382,,8,1,,BAO_0000357,,,14159,11863,B,H,,,
Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,Autocuration,,,,,,1562,CHEMBL616383,,8,1,,BAO_0000357,,,10812,11863,B,H,,,
In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,Expert,,449.0,10090.0,,,1563,CHEMBL616350,,9,1,,BAO_0000219,,Mus musculus,3032,11863,B,D,CHO,,
Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1564,CHEMBL616351,,8,1,,BAO_0000357,,,16655,11863,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,Autocuration,,,,,,1565,CHEMBL616352,,8,1,,BAO_0000357,,,14532,11863,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1566,CHEMBL616353,,8,1,,BAO_0000357,,,13944,11863,B,H,,,
Binding affinity against serotonergic 5-HT1a receptor,Autocuration,,,,,,1567,CHEMBL616354,,8,1,,BAO_0000357,,,13033,11863,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,1568,CHEMBL616508,,8,1,,BAO_0000357,,,10321,11863,B,H,,,
Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,,,10090.0,,,1569,CHEMBL616559,,9,1,,BAO_0000357,,Mus musculus,2968,11863,B,D,,,
Binding affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1570,CHEMBL616560,,8,1,,BAO_0000357,,,13964,11863,B,H,,,
"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",Autocuration,,,,,,1571,CHEMBL616561,,8,1,,BAO_0000357,,,15527,11863,B,H,,,
Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,449.0,,,,1572,CHEMBL616562,,8,1,,BAO_0000219,,,12248,11863,B,H,CHO,,
Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,,449.0,,,,1573,CHEMBL616563,,8,1,,BAO_0000219,,,12249,11863,B,H,CHO,,
Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1574,CHEMBL616564,,8,1,,BAO_0000357,,,15120,11863,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,Autocuration,,,,,,1575,CHEMBL616565,,8,1,,BAO_0000357,,,13313,11863,B,H,,,
In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1576,CHEMBL616566,,8,1,,BAO_0000218,,,2613,11863,B,H,,,
The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,Autocuration,,,,,,1577,CHEMBL616989,,8,1,,BAO_0000357,,,16700,11863,B,H,,,
Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1578,CHEMBL857975,,8,1,,BAO_0000357,,,2201,11863,B,H,,,
Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,,,10090.0,,,1579,CHEMBL616990,,9,1,,BAO_0000357,,Mus musculus,1274,11863,B,D,,,
Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,,,,,1580,CHEMBL616991,,8,1,,BAO_0000357,,,1317,11863,B,H,,,
Tested against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1581,CHEMBL616992,,8,1,,BAO_0000357,,,12146,11863,B,H,,,
The compound's binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,1582,CHEMBL616993,,8,1,,BAO_0000357,,,14059,11863,B,H,,,
Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,Expert,,,9986.0,,,1583,CHEMBL616994,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14025,106,B,H,,,
The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,Autocuration,,,9986.0,,,1584,CHEMBL616995,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14025,106,B,H,,,
The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Intermediate,,722.0,9593.0,,,1585,CHEMBL616996,,9,1,,BAO_0000219,,Gorilla gorilla,14447,105571,B,D,HEK293,,
5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,,,10141.0,,,1586,CHEMBL616997,,8,1,,BAO_0000218,In vivo,Cavia porcellus,3025,106,F,H,,,
5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,,,10141.0,,,1587,CHEMBL616998,,8,1,,BAO_0000218,In vivo,Cavia porcellus,3025,106,F,H,,,
Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,Autocuration,,,10141.0,,,1588,CHEMBL616999,,8,1,,BAO_0000019,,Cavia porcellus,15329,106,F,H,,,
Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,Autocuration,,,10141.0,,,1589,CHEMBL617000,,8,1,,BAO_0000019,,Cavia porcellus,15329,106,F,H,,,
Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,Autocuration,,,10141.0,,,1590,CHEMBL617001,,8,1,,BAO_0000019,,Cavia porcellus,15847,106,F,H,,,
Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,Autocuration,,,10141.0,,,1591,CHEMBL858111,,8,1,,BAO_0000019,,Cavia porcellus,15847,106,F,H,,,
Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,Autocuration,,,,,,1592,CHEMBL617002,,8,1,,BAO_0000019,,,14165,106,F,H,,,
Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),Autocuration,,,,,,1593,CHEMBL617003,,8,1,,BAO_0000019,,,14214,106,F,H,,,
Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),Autocuration,,,,,,1594,CHEMBL617004,,8,1,,BAO_0000019,,,14214,106,F,H,,,
Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,Expert,,,9606.0,,,1595,CHEMBL617005,,9,1,,BAO_0000019,,Homo sapiens,14214,106,F,D,,,
Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,Expert,,485.0,9606.0,,,1596,CHEMBL616623,,9,1,,BAO_0000219,,Homo sapiens,13729,106,F,D,CHO-K1,,
Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,Autocuration,,449.0,,,,1597,CHEMBL616624,,8,1,,BAO_0000219,,,3025,106,F,H,CHO,,
The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1598,CHEMBL883243,,8,1,,BAO_0000357,,,2391,106,B,H,,,
The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,Autocuration,,,,,,1599,CHEMBL616625,,8,1,,BAO_0000019,,,2391,106,F,H,,,
"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",Expert,,449.0,,,,1600,CHEMBL616626,,8,1,,BAO_0000219,,,14956,106,F,H,CHO,,
The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,Autocuration,,449.0,,,,1601,CHEMBL616627,,8,1,,BAO_0000219,,,2598,106,F,H,CHO,,
The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,Autocuration,,449.0,,,,1602,CHEMBL616628,,8,1,,BAO_0000219,,,2598,106,F,H,CHO,,
The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,Autocuration,,449.0,,,,1603,CHEMBL616629,,8,1,,BAO_0000219,,,2598,106,F,H,CHO,,
The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,Autocuration,,449.0,,,,1604,CHEMBL616630,,8,1,,BAO_0000219,,,2598,106,F,H,CHO,,
"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",Expert,,,,,,1605,CHEMBL616631,,8,1,,BAO_0000019,,,14956,106,F,H,,,
"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",Autocuration,,,,,,1606,CHEMBL616632,,8,1,,BAO_0000019,,,14956,106,F,H,,,
Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,Expert,,,9606.0,,,1607,CHEMBL616633,,9,1,,BAO_0000357,,Homo sapiens,14214,106,B,D,,,
Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,Expert,,449.0,,,,1608,CHEMBL616634,,8,1,,BAO_0000219,,,3463,106,B,H,CHO,,
Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,Autocuration,,,,,,1609,CHEMBL616635,,8,1,,BAO_0000357,,,15331,106,B,H,,,
Binding affinity against 5-hydroxytryptamine 1B receptor,Expert,,,9606.0,,,1610,CHEMBL885358,,9,1,,BAO_0000357,,Homo sapiens,16146,106,B,D,,,
Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,,449.0,9606.0,,,1611,CHEMBL616636,,9,1,,BAO_0000219,,Homo sapiens,14159,106,B,D,CHO,,
Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,Expert,,449.0,,,,1612,CHEMBL616637,,8,1,,BAO_0000219,,,14158,106,B,H,CHO,,
Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1613,CHEMBL616638,,8,1,,BAO_0000357,,,14159,106,B,H,,,
Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,,449.0,,,,1614,CHEMBL616639,,8,1,,BAO_0000219,,,15250,106,B,H,CHO,,
Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,,449.0,,,,1615,CHEMBL616640,,8,1,,BAO_0000219,,,15250,106,B,H,CHO,,
Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,,449.0,,,,1616,CHEMBL616641,,8,1,,BAO_0000219,,,15331,106,B,H,CHO,,
Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,Expert,,449.0,,,,1617,CHEMBL616642,,8,1,,BAO_0000219,,,15332,106,B,H,CHO,,
Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,,449.0,,,,1618,CHEMBL616643,,8,1,,BAO_0000219,,,14956,106,B,H,CHO,,
In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),Autocuration,,,,,,1619,CHEMBL616644,,8,1,,BAO_0000357,,,3805,106,B,H,,,
Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,Autocuration,,,,,,1620,CHEMBL616645,,8,1,,BAO_0000357,,,14875,106,B,H,,,
Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,,,9986.0,,,1621,CHEMBL616646,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14454,105,F,H,,,
Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Expert,,,9986.0,,,1622,CHEMBL616647,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14454,105,F,H,,,
Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),Autocuration,,,,,,1623,CHEMBL616509,,8,1,,BAO_0000357,,,16288,105,B,H,,,
Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),Autocuration,,,,,,1624,CHEMBL616510,,8,1,,BAO_0000357,,,16288,105,B,H,,,
Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1625,CHEMBL616511,,8,1,,BAO_0000357,,,16312,105,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,Expert,,,9913.0,,,1626,CHEMBL616512,,8,1,,BAO_0000357,,Bos taurus,1348,105,B,H,,,
Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,Autocuration,,,9913.0,,,1627,CHEMBL616513,,8,1,,BAO_0000357,,Bos taurus,5834,105,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,,,9913.0,,,1628,CHEMBL616514,Striatum,8,1,,BAO_0000019,,Bos taurus,13366,105,B,H,,2435.0,
Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,Expert,,,9913.0,,,1629,CHEMBL616515,,8,1,,BAO_0000357,,Bos taurus,1414,105,B,H,,,
Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,Autocuration,,,9913.0,,,1630,CHEMBL616516,,8,1,,BAO_0000019,,Bos taurus,14998,105,B,H,,,
Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,,,9913.0,,,1631,CHEMBL616517,,8,1,,BAO_0000357,,Bos taurus,11473,105,B,H,,,
Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,,,9913.0,,,1632,CHEMBL616518,,8,1,,BAO_0000357,,Bos taurus,11473,105,B,H,,,
Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,,,9913.0,,,1633,CHEMBL616519,,8,1,,BAO_0000357,,Bos taurus,10639,105,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,,,9913.0,,,1634,CHEMBL616520,,8,1,,BAO_0000357,,Bos taurus,10639,105,B,H,,,
Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,Autocuration,,,9913.0,,,1635,CHEMBL616521,,8,1,,BAO_0000357,,Bos taurus,1375,105,B,H,,,
Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Autocuration,,,9913.0,,,1636,CHEMBL616522,,8,1,,BAO_0000357,,Bos taurus,1375,105,B,H,,,
The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,,,9913.0,,,1637,CHEMBL884531,,8,1,,BAO_0000357,,Bos taurus,16532,105,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,Autocuration,,,9913.0,,,1638,CHEMBL616523,,8,1,,BAO_0000357,,Bos taurus,11147,105,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,,,9913.0,,,1639,CHEMBL616731,Striatum,8,1,,BAO_0000019,,Bos taurus,13366,105,B,H,,2435.0,
Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,Autocuration,,,9913.0,,,1640,CHEMBL616732,,8,1,,BAO_0000019,,Bos taurus,10444,105,B,H,,,
The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,Autocuration,,,9913.0,,,1641,CHEMBL616733,,8,1,,BAO_0000357,,Bos taurus,16532,105,B,H,,,
The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,,,9913.0,,,1642,CHEMBL616734,,8,1,,BAO_0000357,,Bos taurus,16532,105,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,Autocuration,,,9913.0,,,1643,CHEMBL616735,,8,1,,BAO_0000249,,Bos taurus,12827,105,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,Autocuration,,,9913.0,,,1644,CHEMBL616736,,8,1,,BAO_0000249,,Bos taurus,12827,105,B,H,,,
Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,9913.0,,,1645,CHEMBL616737,,8,1,,BAO_0000019,,Bos taurus,12919,105,F,H,,,
Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,Autocuration,,,9913.0,,,1646,CHEMBL616738,,8,1,,BAO_0000019,,Bos taurus,14025,105,B,H,,,
Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,9913.0,,,1647,CHEMBL616739,,8,1,,BAO_0000019,,Bos taurus,12919,105,F,H,,,
Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,9913.0,,,1648,CHEMBL616740,,8,1,,BAO_0000019,,Bos taurus,12919,105,F,H,,,
Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,,9913.0,,,1649,CHEMBL616741,,8,1,,BAO_0000019,,Bos taurus,12919,105,F,H,,,
The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Autocuration,,722.0,9593.0,,,1650,CHEMBL616742,,8,1,,BAO_0000219,,Gorilla gorilla,14447,105,B,H,HEK293,,
Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,Intermediate,,,10141.0,,,1651,CHEMBL616743,,9,1,,BAO_0000019,,Cavia porcellus,1375,105570,B,D,,,
Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Intermediate,,,10141.0,,,1652,CHEMBL616744,,9,1,,BAO_0000019,,Cavia porcellus,1375,105570,B,D,,,
Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,Intermediate,,,10141.0,,,1653,CHEMBL616745,,9,1,,BAO_0000019,,Cavia porcellus,12409,105570,F,D,,,
Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,10141.0,,,1654,CHEMBL616746,,9,1,,BAO_0000019,,Cavia porcellus,12409,105570,F,D,,,
Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,Intermediate,,,10141.0,,,1655,CHEMBL616747,,9,1,,BAO_0000019,,Cavia porcellus,12409,105570,F,D,,,
Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,Intermediate,,,10141.0,,,1656,CHEMBL616748,,9,1,,BAO_0000019,,Cavia porcellus,12409,105570,F,D,,,
Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,Intermediate,,,10141.0,,,1657,CHEMBL616648,,9,1,,BAO_0000019,,Cavia porcellus,12409,105570,F,D,,,
Binding affinity against 5-hydroxytryptamine 1D receptor,Intermediate,,,10141.0,,,1658,CHEMBL616649,,9,1,,BAO_0000357,,Cavia porcellus,11574,105570,B,D,,,
Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,Intermediate,,,10141.0,,,1659,CHEMBL616650,,9,1,,BAO_0000357,,Cavia porcellus,1558,105570,B,D,,,
Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,10141.0,,,1660,CHEMBL616651,,9,1,,BAO_0000218,,Cavia porcellus,12409,105570,F,D,,,
Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,10141.0,,,1661,CHEMBL616652,,9,1,,BAO_0000218,,Cavia porcellus,12409,105570,F,D,,,
Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,,10141.0,,,1662,CHEMBL616653,,9,1,,BAO_0000218,,Cavia porcellus,12409,105570,F,D,,,
Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,Intermediate,,,10141.0,,,1663,CHEMBL616654,,9,1,,BAO_0000218,,Cavia porcellus,12409,105570,F,D,,,
Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,Intermediate,,,10141.0,,,1664,CHEMBL616655,,9,1,,BAO_0000019,,Cavia porcellus,12253,105570,B,D,,,
Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,Intermediate,,,10141.0,,,1665,CHEMBL616656,,9,1,,BAO_0000357,,Cavia porcellus,12936,105570,B,D,,,
Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,Autocuration,,,10141.0,,,1666,CHEMBL616657,,8,1,,BAO_0000019,,Cavia porcellus,13181,105,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Intermediate,,,10141.0,,,1667,CHEMBL616658,Striatum,9,1,,BAO_0000357,,Cavia porcellus,12409,105570,B,D,,2435.0,
Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,Intermediate,,,10141.0,,,1668,CHEMBL616659,,9,1,,BAO_0000357,,Cavia porcellus,10639,105570,B,D,,,
Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1669,CHEMBL616660,,8,1,,BAO_0000357,,,5254,51,B,H,,,
The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,Autocuration,,,,,,1670,CHEMBL616661,,8,1,,BAO_0000357,,,13051,106,B,H,,,
Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,Expert,,,,,,1671,CHEMBL616662,,8,1,,BAO_0000019,,,3463,105,F,H,,,
Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1672,CHEMBL616663,,8,1,,BAO_0000019,,,15315,105,F,H,,,
Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1673,CHEMBL616664,,8,1,,BAO_0000019,,,6011,105,F,H,,,
"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",Expert,,449.0,9606.0,,,1674,CHEMBL881820,,9,1,,BAO_0000219,,Homo sapiens,14159,105,F,D,CHO,,
"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",Autocuration,,449.0,,,,1675,CHEMBL616665,,8,1,,BAO_0000219,,,14159,105,F,H,CHO,,
Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,,449.0,,,,1676,CHEMBL616666,,8,1,,BAO_0000219,,,15250,105,B,H,CHO,,
Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,Autocuration,,449.0,,,,1677,CHEMBL616667,,8,1,,BAO_0000219,,,15250,105,B,H,CHO,,
"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,,449.0,,,,1678,CHEMBL616668,,8,1,,BAO_0000219,,,15331,105,F,H,CHO,,
"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,,449.0,9606.0,,,1679,CHEMBL616669,,9,1,,BAO_0000219,,Homo sapiens,15332,105,F,D,CHO,,
"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",Expert,,449.0,,,,1680,CHEMBL617040,,8,1,,BAO_0000219,,,15332,105,F,H,CHO,,
"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",Autocuration,,449.0,,,,1681,CHEMBL617041,,8,1,,BAO_0000219,,,3294,105,F,H,CHO,,
"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",Expert,,449.0,,,,1682,CHEMBL617042,,8,1,,BAO_0000219,,,14158,105,F,H,CHO,,
"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",Expert,,449.0,,,,1683,CHEMBL617043,,8,1,,BAO_0000219,,,14956,105,F,H,CHO,,
Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1684,CHEMBL617044,,8,1,,BAO_0000019,,,12469,105,F,H,,,
Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,,449.0,,,,1685,CHEMBL617045,,8,1,,BAO_0000219,,,3463,105,F,H,CHO,,
"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,,449.0,9606.0,,,1686,CHEMBL617046,,9,1,,BAO_0000219,,Homo sapiens,15250,105,F,D,CHO,,
"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,,449.0,9606.0,,,1687,CHEMBL617047,,9,1,,BAO_0000219,,Homo sapiens,15250,105,F,D,CHO,,
"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",Expert,,,,,,1688,CHEMBL617048,,8,1,,BAO_0000019,,,14956,105,F,H,,,
"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",Autocuration,,,,,,1689,CHEMBL616897,,8,1,,BAO_0000019,,,14159,105,F,H,,,
"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",Expert,,,9606.0,,,1690,CHEMBL616898,,9,1,,BAO_0000019,,Homo sapiens,14159,105,F,D,,,
Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,Expert,,449.0,9606.0,,,1691,CHEMBL858201,,9,1,,BAO_0000219,,Homo sapiens,14499,105,F,D,CHO,,
Intrinsic activity for 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1692,CHEMBL616899,,8,1,,BAO_0000019,,,15315,105,F,H,,,
Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),Autocuration,,,,,,1693,CHEMBL616900,,8,1,,BAO_0000219,In vitro,,3294,105,B,H,,,
Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,Expert,,449.0,,,,1694,CHEMBL616901,,8,1,,BAO_0000219,,,3463,105,B,H,CHO,,
Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,Autocuration,,,,,,1695,CHEMBL616902,,8,1,,BAO_0000357,,,15331,105,B,H,,,
Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,449.0,9606.0,,,1696,CHEMBL616903,,9,1,,BAO_0000219,,Homo sapiens,14159,105,B,D,CHO,,
Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,Expert,,449.0,,,,1697,CHEMBL616904,,8,1,,BAO_0000219,,,14158,105,B,H,CHO,,
Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1698,CHEMBL616905,,8,1,,BAO_0000357,,,14159,105,B,H,,,
Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,,449.0,,,,1699,CHEMBL616906,,8,1,,BAO_0000219,,,15250,105,B,H,CHO,,
Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,449.0,,,,1700,CHEMBL616907,,8,1,,BAO_0000219,,,15250,105,B,H,CHO,,
Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,449.0,,,,1701,CHEMBL616908,,8,1,,BAO_0000219,,,15331,105,B,H,CHO,,
Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,449.0,9606.0,,,1702,CHEMBL616909,,9,1,,BAO_0000219,,Homo sapiens,15332,105,B,D,CHO,,
Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,449.0,9606.0,,,1703,CHEMBL616910,,9,1,,BAO_0000219,,Homo sapiens,14499,105,B,D,CHO,,
Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,,449.0,,,,1704,CHEMBL616911,,8,1,,BAO_0000219,,,15332,105,B,H,CHO,,
Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,,449.0,,,,1705,CHEMBL616912,,8,1,,BAO_0000219,,,14956,105,B,H,CHO,,
In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),Autocuration,,,,,,1706,CHEMBL616913,,8,1,,BAO_0000357,,,3805,105,B,H,,,
Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,Expert,,449.0,9606.0,,,1707,CHEMBL616914,,9,1,,BAO_0000219,,Homo sapiens,6011,105,B,D,CHO,,
Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,449.0,,,,1708,CHEMBL616915,,8,1,,BAO_0000219,,,16190,105,B,H,CHO,,
Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,Autocuration,,,,,,1709,CHEMBL616916,,8,1,,BAO_0000019,,,14165,105,B,H,,,
Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,Expert,,,9606.0,,,1710,CHEMBL616917,,9,1,,BAO_0000357,,Homo sapiens,4234,105,B,D,,,
"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",Autocuration,,,,,,1711,CHEMBL616918,,8,1,,BAO_0000357,,,15527,105,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,,,,,1712,CHEMBL616919,,8,1,,BAO_0000219,,,6328,105,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,Autocuration,,,,,,1713,CHEMBL616920,,8,1,,BAO_0000357,,,16209,105,B,H,,,
Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,Autocuration,,,,,,1714,CHEMBL872914,,8,1,,BAO_0000357,,,14770,105,B,H,,,
Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,Autocuration,,,,,,1715,CHEMBL616921,,8,1,,BAO_0000357,,,2598,105,B,H,,,
Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,,1716,CHEMBL616922,,8,1,,BAO_0000357,,,6897,105,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1717,CHEMBL616923,,8,1,,BAO_0000357,,,6013,105,B,H,,,
Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,,1718,CHEMBL616924,,8,1,,BAO_0000357,,,5843,105,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,,,,,1719,CHEMBL875909,,8,1,,BAO_0000357,,,14454,105,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,Autocuration,,,,,,1720,CHEMBL616925,,8,1,,BAO_0000357,,,14454,105,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,Autocuration,,,,,,1721,CHEMBL616926,,8,1,,BAO_0000357,,,14454,105,B,H,,,
Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1722,CHEMBL616927,,8,1,,BAO_0000357,,,15818,105,B,H,,,
Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,Expert,,485.0,,,,1723,CHEMBL616928,,8,1,,BAO_0000219,,,13729,105,F,H,CHO-K1,,
Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),Expert,,,9606.0,,,1724,CHEMBL616929,,9,1,,BAO_0000219,In vitro,Homo sapiens,6011,105,B,D,,,
In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,Expert,,,9606.0,,,1725,CHEMBL616930,,9,1,,BAO_0000357,,Homo sapiens,4234,105,B,D,,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Expert,,,,,,1726,CHEMBL616931,,8,1,,BAO_0000019,,,17085,105,B,H,,,
In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,,,,,1727,CHEMBL616932,,8,1,,BAO_0000357,,,3025,105,B,H,,,
In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,Expert,,,,,,1728,CHEMBL616933,,8,1,,BAO_0000357,,,15315,105,B,H,,,
Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,Expert,,,9606.0,,,1729,CHEMBL616934,,9,1,,BAO_0000219,,Homo sapiens,14214,105,B,D,,,
Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,,9606.0,,,1730,CHEMBL616935,,9,1,,BAO_0000357,,Homo sapiens,3804,105,B,D,,,
The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,Autocuration,,,,,,1731,CHEMBL616936,,8,1,,BAO_0000357,,,16700,105,B,H,,,
Affinity for 5-hydroxytryptamine 1D receptor subtype,Expert,,,9606.0,,,1732,CHEMBL616937,,9,1,,BAO_0000357,,Homo sapiens,2391,105,B,D,,,
Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,,9606.0,,,1733,CHEMBL616938,,9,1,,BAO_0000357,,Homo sapiens,4175,105,B,D,,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1734,CHEMBL616939,,8,1,,BAO_0000019,,,17085,105,B,H,,,
In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,Expert,,,,,,1735,CHEMBL616940,,8,1,,BAO_0000019,,,17085,105,B,H,,,
Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,Expert,,,9606.0,,,1736,CHEMBL616941,,9,1,,BAO_0000357,,Homo sapiens,15926,105,B,D,,,
Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,Autocuration,,485.0,,,,1737,CHEMBL616942,,8,1,,BAO_0000219,,,16312,105,B,H,CHO-K1,,
Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,Autocuration,,485.0,,,,1738,CHEMBL616943,,8,1,,BAO_0000219,,,16312,105,B,H,CHO-K1,,
Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,Autocuration,,449.0,,,,1739,CHEMBL616944,,4,1,,BAO_0000219,,,14956,104802,B,H,CHO,,
"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",Autocuration,,,,,,1740,CHEMBL616945,,8,1,,BAO_0000019,,,3294,105,F,H,,,
Binding activity radioligand.,Autocuration,,,,,,1741,CHEMBL616946,,8,1,,BAO_0000357,,,12861,105,B,H,,,
Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,,,,1742,CHEMBL616947,,8,1,,BAO_0000019,,,12861,105,B,H,,,
Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,Expert,,485.0,,,,1743,CHEMBL616948,,8,1,,BAO_0000219,,,16312,105,B,H,CHO-K1,,
Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1744,CHEMBL616851,,8,1,,BAO_0000357,,,5104,105,B,H,,,
Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1745,CHEMBL616852,,8,1,,BAO_0000357,,,5105,105,B,H,,,
Measured as -log Ka on 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1746,CHEMBL616853,,8,1,,BAO_0000357,,,14499,105,B,H,,,
Binding activity against human 5-hydroxytryptamine 1D receptor,Expert,,,9606.0,,,1747,CHEMBL616854,,9,1,,BAO_0000357,,Homo sapiens,15926,105,B,D,,,
Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Expert,,449.0,9606.0,,,1748,CHEMBL616855,,9,1,,BAO_0000219,,Homo sapiens,4540,105,B,D,CHO,,
Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,Autocuration,,449.0,,,,1749,CHEMBL616856,,8,1,,BAO_0000219,,,15779,105,B,H,CHO,,
Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,449.0,,,,1750,CHEMBL616857,,8,1,,BAO_0000219,,,15779,105,B,H,CHO,,
Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1751,CHEMBL616858,,8,1,,BAO_0000357,,,6166,105,B,H,,,
Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,,449.0,,,,1752,CHEMBL616859,,8,1,,BAO_0000219,,,15779,105,B,H,CHO,,
Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,Autocuration,,449.0,,,,1753,CHEMBL616860,,8,1,,BAO_0000219,,,15779,105,B,H,CHO,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,,722.0,,,,1754,CHEMBL616861,,8,1,,BAO_0000219,,,17451,105,B,H,HEK293,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,,722.0,,,,1755,CHEMBL616541,,8,1,,BAO_0000219,,,17451,105,B,H,HEK293,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,Autocuration,,722.0,,,,1756,CHEMBL616542,,8,1,,BAO_0000219,,,17451,105,B,H,HEK293,,
Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,449.0,,,,1757,CHEMBL616543,,8,1,,BAO_0000219,,,4199,105,B,H,CHO,,
Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,,9606.0,,,1758,CHEMBL616544,,9,1,,BAO_0000357,,Homo sapiens,14875,105,B,D,,,
Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,Autocuration,,449.0,,,,1759,CHEMBL616545,,8,1,,BAO_0000219,,,15146,105,B,H,CHO,,
Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,,1760,CHEMBL616546,,8,1,,BAO_0000357,,,5213,105,B,H,,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,Autocuration,,449.0,,,,1761,CHEMBL616547,,8,1,,BAO_0000219,,,14818,105,B,H,CHO,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,449.0,,,,1762,CHEMBL616548,,8,1,,BAO_0000219,,,4829,105,B,H,CHO,,
Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,Expert,,,,,,1763,CHEMBL616549,,8,1,,BAO_0000019,,,14454,105,F,H,,,
Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,Expert,,,,,,1764,CHEMBL616550,,8,1,,BAO_0000019,,,14454,105,F,H,,,
Binding affinity against 5-HT2C receptor,Autocuration,,,,,,1765,CHEMBL857066,,8,1,,BAO_0000357,,,5254,108,B,H,,,
Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1766,CHEMBL616551,,8,1,,BAO_0000357,,,5254,108,B,H,,,
Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,,,,,1767,CHEMBL616552,,8,1,,BAO_0000357,,,10639,10577,B,H,,,
Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,,,,,1768,CHEMBL832876,,8,1,,BAO_0000019,,,10639,10577,F,H,,,
"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",Expert,,,,,,1769,CHEMBL616553,,8,1,,BAO_0000019,,,12352,10577,B,H,,,
Binding affinity towards 5-HT1B was determined,Autocuration,,,,,,1770,CHEMBL616554,,8,1,,BAO_0000357,,,9098,10577,B,H,,,
Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,Expert,,,,,,1771,CHEMBL616555,,8,1,,BAO_0000019,,,14430,10577,B,H,,,
"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",Expert,,,,,,1772,CHEMBL616556,,8,1,,BAO_0000019,,,13657,10577,B,H,,,
"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",Autocuration,,,,,,1773,CHEMBL616557,,8,1,,BAO_0000019,,,13657,10577,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,,,,1774,CHEMBL616558,,8,1,,BAO_0000019,,,15854,10577,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,Expert,,,10116.0,,,1775,CHEMBL616749,,9,1,,BAO_0000019,,Rattus norvegicus,10639,10577,B,D,,,
Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Autocuration,,,,,,1776,CHEMBL616750,,8,1,,BAO_0000357,,,10025,10577,B,H,,,
"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",Autocuration,,,,,,1777,CHEMBL616751,,8,1,,BAO_0000357,,,10025,10577,B,H,,,
In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,,,,,1778,CHEMBL616752,,8,1,,BAO_0000249,,,14286,10577,B,H,,,
Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Autocuration,,,,,,1779,CHEMBL616753,Striatum,8,1,,BAO_0000019,,,3651,10577,B,H,,2435.0,
Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,Expert,,,10116.0,,,1780,CHEMBL616754,,9,1,,BAO_0000357,,Rattus norvegicus,14178,10577,B,D,,,
Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,Autocuration,,,,,,1781,CHEMBL616755,,8,1,,BAO_0000019,,,10639,10577,B,H,,,
Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Autocuration,,,,,,1782,CHEMBL616756,Striatum,8,1,,BAO_0000019,,,13605,10577,B,H,,2435.0,
Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Autocuration,,,,,,1783,CHEMBL616757,Striatum,8,1,,BAO_0000019,,,5834,10577,B,H,,2435.0,
compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Autocuration,,,,,,1784,CHEMBL616758,Striatum,8,1,,BAO_0000357,,,10922,10577,B,H,,2435.0,
Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,,,,,1785,CHEMBL616759,,8,1,,BAO_0000249,,,14286,10577,B,H,,,
In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,Autocuration,,,,,,1786,CHEMBL616760,,8,1,,BAO_0000357,,,11825,10577,B,H,,,
Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Autocuration,,,,,,1787,CHEMBL616761,Striatum,8,1,,BAO_0000019,,,14826,10577,B,H,,2435.0,
Binding affinity against 5-HT1B serotonin receptor in rat striatum,Autocuration,,,,,,1788,CHEMBL616762,Striatum,8,1,,BAO_0000019,,,9699,10577,B,H,,2435.0,
Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,Autocuration,,,,,,1789,CHEMBL616763,,8,1,,BAO_0000019,,,14423,10577,B,H,,,
Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,Expert,,,,,,1790,CHEMBL872909,,8,1,,BAO_0000357,,,10062,10577,B,H,,,
Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1791,CHEMBL616764,,8,1,,BAO_0000357,,,10062,10577,B,H,,,
Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,Expert,,,10116.0,,,1792,CHEMBL616765,,9,1,,BAO_0000357,,Rattus norvegicus,12280,10577,B,D,,,
Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Autocuration,,,,,,1793,CHEMBL616766,Striatum,8,1,,BAO_0000357,,,15412,10577,B,H,,2435.0,
Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Autocuration,,,,,,1794,CHEMBL616767,Striatum,8,1,,BAO_0000357,,,15412,10577,B,H,,2435.0,
Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1795,CHEMBL616768,,8,1,,BAO_0000357,,,10062,10577,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,,,,,1796,CHEMBL616769,,8,1,,BAO_0000357,,,11147,10577,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,Autocuration,,,,,,1797,CHEMBL616770,,8,1,,BAO_0000019,,,9547,10577,B,H,,,
Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,,,,1798,CHEMBL616771,,8,1,,BAO_0000019,,,10444,10577,B,H,,,
Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Autocuration,,,,,,1799,CHEMBL616772,Striatum,8,1,,BAO_0000019,,,12469,10577,B,H,,2435.0,
Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,Expert,,,,,,1800,CHEMBL616773,,8,1,,BAO_0000019,,,9098,10577,B,H,,,
Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,Autocuration,,,,,,1801,CHEMBL616774,,8,1,,BAO_0000019,,,9098,10577,B,H,,,
Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1802,CHEMBL616775,,8,1,,BAO_0000357,,,9699,10577,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,,,,,1803,CHEMBL616776,,8,1,,BAO_0000249,,,10394,10577,B,H,,,
The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,Autocuration,,,,,,1804,CHEMBL616777,,8,1,,BAO_0000357,,,12092,10577,B,H,,,
The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,Autocuration,,,,,,1805,CHEMBL616778,,8,1,,BAO_0000357,,,16700,10577,B,H,,,
Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,Expert,,,10116.0,,,1806,CHEMBL616779,,9,1,,BAO_0000249,,Rattus norvegicus,403,10577,B,D,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor,Expert,,,10116.0,,,1807,CHEMBL616780,,9,1,,BAO_0000357,,Rattus norvegicus,12771,10577,B,D,,,
The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,Autocuration,,,,,,1808,CHEMBL616781,,8,1,,BAO_0000019,,,11642,10577,B,H,,,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,Autocuration,,,,,,1809,CHEMBL616782,,8,1,,BAO_0000357,,,12953,10577,B,H,,,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,Autocuration,,,,,,1810,CHEMBL616783,,8,1,,BAO_0000357,,,12953,10577,B,H,,,
Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Expert,,,,,,1811,CHEMBL616784,Striatum,8,1,,BAO_0000019,,,12953,10577,B,H,,2435.0,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,Autocuration,,,,,,1812,CHEMBL616785,,8,1,,BAO_0000357,,,12953,10577,B,H,,,
Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,,,1813,CHEMBL857067,Brain,8,1,,BAO_0000249,,,9737,10577,B,H,,955.0,
Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,Autocuration,,,,,,1814,CHEMBL616786,,8,1,,BAO_0000019,,,9737,10577,B,H,,,
Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,,,1815,CHEMBL616787,Brain,8,1,,BAO_0000249,,,9737,10577,B,H,,955.0,
Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,Autocuration,,,,,,1816,CHEMBL616788,,8,1,,BAO_0000357,,,12827,10577,B,H,,,
Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1817,CHEMBL616789,,8,1,,BAO_0000357,,,5033,10577,B,H,,,
Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,Expert,,,10116.0,,,1818,CHEMBL616790,,9,1,,BAO_0000019,,Rattus norvegicus,9786,10577,B,D,,,
Binding affinity at 5-hydroxytryptamine 1B receptor,Expert,,,,,,1819,CHEMBL616791,,8,1,,BAO_0000357,,,13116,10577,B,H,,,
In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,Autocuration,,,,,,1820,CHEMBL616792,,8,1,,BAO_0000019,,,16429,10577,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,Expert,,,10116.0,,,1821,CHEMBL616793,,9,1,,BAO_0000249,,Rattus norvegicus,12409,10577,B,D,,,
The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,,,,,1822,CHEMBL616794,,8,1,,BAO_0000357,,,15194,10577,B,H,,,
The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,,,,1823,CHEMBL616795,,8,1,,BAO_0000357,,,15194,10577,B,H,,,
Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,Autocuration,,,,,,1824,CHEMBL616796,,4,1,,BAO_0000019,,,5486,104686,B,H,,,
Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1825,CHEMBL616797,,8,1,,BAO_0000357,,,4639,106,B,H,,,
The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Autocuration,,,,Brain membranes,,1826,CHEMBL616798,,8,1,,BAO_0000249,,,386,106,B,H,,,
Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,Autocuration,,,,,,1827,CHEMBL616799,,8,1,,BAO_0000357,,,2474,106,B,H,,,
Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,Autocuration,,,,,,1828,CHEMBL616800,,8,1,,BAO_0000357,,,6011,106,B,H,,,
Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1829,CHEMBL616801,,8,1,,BAO_0000357,,,5014,106,B,H,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,Autocuration,,,,,,1830,CHEMBL616802,,8,1,,BAO_0000357,,,17515,106,B,H,,,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,,,,1831,CHEMBL616803,,8,1,,BAO_0000357,,,4373,106,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,Expert,,,,,,1832,CHEMBL857068,,8,1,,BAO_0000357,,,1633,106,B,H,,,
Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,Autocuration,,,,,,1833,CHEMBL616804,,8,1,,BAO_0000357,,,1633,106,B,H,,,
Binding affinity for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,,,,,1834,CHEMBL616805,,8,1,,BAO_0000357,,,4373,106,B,H,,,
Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1835,CHEMBL616806,,8,1,,BAO_0000357,,,4687,106,B,H,,,
Binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,,,,,1836,CHEMBL616807,,8,1,,BAO_0000357,,,11574,106,B,H,,,
Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,Autocuration,,,,,,1837,CHEMBL616808,,8,1,,BAO_0000357,,,10321,106,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,,,,,1838,CHEMBL616809,,8,1,,BAO_0000357,,,15527,106,B,H,,,
Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,Autocuration,,,,,,1839,CHEMBL616810,,8,1,,BAO_0000357,,,17200,106,B,H,,,
Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,Autocuration,,,,,,1840,CHEMBL616811,,4,1,,BAO_0000224,,,14423,104802,B,H,,,
Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,Autocuration,,,9913.0,,,1841,CHEMBL616812,,8,1,,BAO_0000357,,Bos taurus,5834,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,,,9823.0,,,1842,CHEMBL616813,,8,1,,BAO_0000357,,Sus scrofa,11473,108,B,H,,,
Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,Autocuration,,,9823.0,,,1843,CHEMBL616814,,8,1,,BAO_0000357,,Sus scrofa,11473,108,B,H,,,
Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,,,9823.0,,,1844,CHEMBL616815,,8,1,,BAO_0000357,,Sus scrofa,10639,108,B,H,,,
inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,,,9823.0,,,1845,CHEMBL616816,,8,1,,BAO_0000357,,Sus scrofa,10639,108,B,H,,,
Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,Autocuration,,,9823.0,,,1846,CHEMBL616817,,8,1,,BAO_0000357,,Sus scrofa,14331,108,B,H,,,
Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,Autocuration,,,9823.0,,,1847,CHEMBL616818,,8,1,,BAO_0000357,,Sus scrofa,10796,108,B,H,,,
Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,Expert,,,9823.0,,,1848,CHEMBL616819,,8,1,,BAO_0000357,,Sus scrofa,9098,108,B,H,,,
Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,Expert,,,9823.0,,,1849,CHEMBL616820,,8,1,,BAO_0000357,,Sus scrofa,14331,108,B,H,,,
Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,Expert,,,9823.0,,,1850,CHEMBL616821,,8,1,,BAO_0000019,,Sus scrofa,11828,108,B,H,,,
Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,Autocuration,,,9823.0,,,1851,CHEMBL616822,,8,1,,BAO_0000357,,Sus scrofa,11866,108,B,H,,,
Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,1852,CHEMBL616823,,8,1,,BAO_0000019,,Oryctolagus cuniculus,13047,108,B,H,,,
Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,Autocuration,,,10116.0,,,1853,CHEMBL616824,,9,1,,BAO_0000357,,Rattus norvegicus,188,12689,B,D,,,
In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,,,10116.0,,,1854,CHEMBL616825,,9,1,,BAO_0000357,,Rattus norvegicus,11825,12689,B,D,,,
In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,,,10116.0,,,1855,CHEMBL616826,,9,1,,BAO_0000357,,Rattus norvegicus,11825,12689,B,D,,,
Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,Expert,,,10116.0,,,1856,CHEMBL616827,,9,1,,BAO_0000019,,Rattus norvegicus,11624,12689,B,D,,,
Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,Autocuration,,,10116.0,,,1857,CHEMBL616828,,9,1,,BAO_0000357,,Rattus norvegicus,11139,12689,B,D,,,
Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,,,10116.0,,,1858,CHEMBL616829,,9,1,,BAO_0000357,,Rattus norvegicus,11147,12689,B,D,,,
Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,,10116.0,,,1859,CHEMBL616830,,9,1,,BAO_0000019,,Rattus norvegicus,10444,12689,B,D,,,
Binding affinity against 5-hydroxytryptamine 1C receptor,Expert,,,10116.0,,,1860,CHEMBL616831,,9,1,,BAO_0000357,,Rattus norvegicus,11624,12689,B,D,,,
"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,,10116.0,,,1861,CHEMBL616832,,9,1,,BAO_0000019,,Rattus norvegicus,11662,12689,B,D,,,
"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,,10116.0,,,1862,CHEMBL616833,,9,1,,BAO_0000019,,Rattus norvegicus,11662,12689,B,D,,,
"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Expert,,,10116.0,,,1863,CHEMBL616834,,9,1,,BAO_0000019,,Rattus norvegicus,11662,12689,B,D,,,
"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,,10116.0,,,1864,CHEMBL829595,,9,1,,BAO_0000019,,Rattus norvegicus,11662,12689,B,D,,,
Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,Autocuration,,,10116.0,,,1865,CHEMBL616835,,9,1,,BAO_0000357,,Rattus norvegicus,9098,12689,B,D,,,
Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Autocuration,,,10116.0,,,1866,CHEMBL872910,,9,1,,BAO_0000249,,Rattus norvegicus,10394,12689,B,D,,,
Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,Expert,,,,,,1867,CHEMBL616836,,8,1,,BAO_0000357,,,11933,12689,B,H,,,
The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,Autocuration,,,10116.0,,,1868,CHEMBL616837,,9,1,,BAO_0000357,,Rattus norvegicus,12092,12689,B,D,,,
Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,,,10116.0,,,1869,CHEMBL616466,,9,1,,BAO_0000019,,Rattus norvegicus,12253,12689,B,D,,,
Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,Autocuration,,722.0,10116.0,,,1870,CHEMBL616467,,9,1,,BAO_0000219,,Rattus norvegicus,12253,12689,B,D,HEK293,,
Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,,,,,1871,CHEMBL616468,,8,1,,BAO_0000357,,,1558,108,B,H,,,
Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,,,,,1872,CHEMBL616469,,8,1,,BAO_0000357,,,2474,108,B,H,,,
Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,,,,,1873,CHEMBL616470,,8,1,,BAO_0000357,,,2474,108,B,H,,,
Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,,,,,1874,CHEMBL616471,,8,1,,BAO_0000357,,,11574,12689,B,H,,,
Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,,,,,1875,CHEMBL616472,,8,1,,BAO_0000357,,,1558,12689,B,H,,,
Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,,,,,1876,CHEMBL616473,,8,1,,BAO_0000357,,,13944,12689,B,H,,,
Binding affinity against serotonergic 5-HT1c receptor,Autocuration,,,,,,1877,CHEMBL616474,,8,1,,BAO_0000357,,,13033,12689,B,H,,,
Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,Autocuration,,,,,,1878,CHEMBL616475,,8,1,,BAO_0000357,,,10321,12689,B,H,,,
Binding affinity for 5-hydroxytryptamine 1C receptor was determined,Autocuration,,,,,,1879,CHEMBL616476,,8,1,,BAO_0000357,,,11866,12689,B,H,,,
Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,,,9986.0,,,1880,CHEMBL616477,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14454,105,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,Autocuration,,,,,,1881,CHEMBL616478,,4,1,,BAO_0000224,,,11574,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,Autocuration,,,,,,1882,CHEMBL616479,,4,1,,BAO_0000224,,,11574,104686,B,H,,,
Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,Autocuration,,,,,,1883,CHEMBL616480,,4,1,,BAO_0000019,,,13631,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,Autocuration,,,10116.0,,,1884,CHEMBL616481,,5,1,,BAO_0000019,,Rattus norvegicus,9630,104686,B,D,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,Autocuration,,,10116.0,,,1885,CHEMBL616482,,5,1,,BAO_0000249,,Rattus norvegicus,8822,104686,B,D,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Autocuration,,,10116.0,,,1886,CHEMBL884713,Brain,5,1,,BAO_0000221,,Rattus norvegicus,9064,104686,B,D,,955.0,
Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,Autocuration,,,,,,1887,CHEMBL616483,,4,1,,BAO_0000224,,,8868,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,Autocuration,,,,,,1888,CHEMBL616484,,4,1,,BAO_0000224,,,9064,104686,B,H,,,
Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,Autocuration,,,,,,1889,CHEMBL616485,,4,1,,BAO_0000019,,,9806,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,,1890,CHEMBL616486,,4,1,,BAO_0000224,,,9098,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,Autocuration,,,,,,1891,CHEMBL616487,,4,1,,BAO_0000224,,,8868,104686,B,H,,,
Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,,,,,1892,CHEMBL616488,,4,1,,BAO_0000224,,,12765,104686,B,H,,,
Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,,1893,CHEMBL616489,,4,1,,BAO_0000019,,,11049,104686,B,H,,,
Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,,1894,CHEMBL616490,,4,1,,BAO_0000019,,,11049,104686,B,H,,,
Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,Autocuration,,,,,,1895,CHEMBL616491,,4,1,,BAO_0000019,,,11049,104686,B,H,,,
Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,Autocuration,,,,,,1896,CHEMBL616492,,4,1,,BAO_0000019,,,11049,104686,B,H,,,
Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,,1897,CHEMBL616493,,4,1,,BAO_0000019,,,11049,104686,B,H,,,
Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,Autocuration,,,,,,1898,CHEMBL616494,,4,1,,BAO_0000019,,,11473,104686,B,H,,,
Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,Autocuration,,,,,,1899,CHEMBL616495,,4,1,,BAO_0000019,,,11473,104686,B,H,,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,Autocuration,,,,,,1900,CHEMBL616496,,4,1,,BAO_0000019,,,3086,104686,B,H,,,
Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,,1901,CHEMBL616497,,4,1,,BAO_0000019,,,11049,104686,B,H,,,
Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,,,,,1902,CHEMBL616498,,4,1,,BAO_0000019,,,11049,104686,B,H,,,
Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,Autocuration,,,,,,1903,CHEMBL616499,,4,1,,BAO_0000019,,,10639,104686,B,H,,,
Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,Autocuration,,,,,,1904,CHEMBL616500,,4,1,,BAO_0000019,,,10922,104686,B,H,,,
Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,,,10116.0,,,1905,CHEMBL616501,Brain,5,1,,BAO_0000221,,Rattus norvegicus,9064,104686,B,D,,955.0,
Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Autocuration,,,,,,1906,CHEMBL616502,Brain,4,1,,BAO_0000221,,,10748,104686,B,H,,955.0,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,,,Membranes,,1907,CHEMBL884529,,4,1,,BAO_0000249,,,11614,104686,B,H,,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,,,Membranes,,1908,CHEMBL616503,,4,1,,BAO_0000249,,,11615,104686,B,H,,,
Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,1909,CHEMBL616964,,4,1,,BAO_0000224,,,11615,104686,B,H,,,
Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,,,Membranes,,1910,CHEMBL616965,,4,1,,BAO_0000249,,,11614,104686,B,H,,,
Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,Autocuration,,,,,,1911,CHEMBL616966,,4,1,,BAO_0000224,,,11702,104686,B,H,,,
Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,,,,1912,CHEMBL616967,,4,1,,BAO_0000224,,,11702,104686,B,H,,,
Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Autocuration,,,10116.0,,,1913,CHEMBL616968,,5,1,,BAO_0000224,,Rattus norvegicus,11702,104686,B,D,,,
Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,,,,1914,CHEMBL616969,,4,1,,BAO_0000224,,,11702,104686,B,H,,,
Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,Autocuration,,,,,,1915,CHEMBL884530,,4,1,,BAO_0000019,,,13346,104686,B,H,,,
Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,1916,CHEMBL616970,,4,1,,BAO_0000224,,,10025,104686,B,H,,,
Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,,,,,1917,CHEMBL616971,,4,1,,BAO_0000224,,,10025,104686,B,H,,,
"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,,,,,1918,CHEMBL616972,,4,1,,BAO_0000224,,,10025,104686,B,H,,,
Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,Autocuration,,,,,,1919,CHEMBL616973,,4,1,,BAO_0000224,,,9036,104686,B,H,,,
Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,Autocuration,,,,,,1920,CHEMBL616974,,4,1,,BAO_0000224,,,9036,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,Autocuration,,,,,,1921,CHEMBL616975,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,Autocuration,,,,,,1922,CHEMBL616976,,4,1,,BAO_0000019,,,12304,104686,B,H,,,
In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,Autocuration,,,,,,1923,CHEMBL616977,,4,1,,BAO_0000224,,,13276,104686,B,H,,,
In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,,,,,1924,CHEMBL616978,,4,1,,BAO_0000224,,,11825,104686,B,H,,,
In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,Autocuration,,,,,,1925,CHEMBL616979,,4,1,,BAO_0000224,,,12443,104686,B,H,,,
In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,1926,CHEMBL616980,,4,1,,BAO_0000224,,,13830,104686,B,H,,,
Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Autocuration,,,,Membranes,,1927,CHEMBL616981,,4,1,,BAO_0000249,,,9592,104686,B,H,,,
Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Autocuration,,,,Membranes,,1928,CHEMBL616982,,4,1,,BAO_0000249,,,9592,104686,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,Autocuration,,,,,,1929,CHEMBL616983,,4,1,,BAO_0000224,,,10881,104686,B,H,,,
Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,Autocuration,,,,,,1930,CHEMBL616984,,4,1,,BAO_0000019,,,13605,104686,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,,,10116.0,,,1931,CHEMBL616985,,5,1,,BAO_0000224,,Rattus norvegicus,11624,104686,B,D,,,
Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,,,,,1932,CHEMBL616986,,4,1,,BAO_0000224,,,4101,104686,B,H,,,
Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,,,,,1933,CHEMBL616987,,4,1,,BAO_0000224,,,4101,104686,B,H,,,
Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,Autocuration,,,,,,1934,CHEMBL616988,,4,1,,BAO_0000019,,,15360,104686,B,H,,,
Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,,,,1935,CHEMBL617243,,4,1,,BAO_0000019,,,11576,104686,B,H,,,
Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,Autocuration,,,,,,1936,CHEMBL617244,,4,1,,BAO_0000019,,,5834,104686,B,H,,,
Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,,485.0,10116.0,,,1937,CHEMBL617245,,5,1,,BAO_0000219,,Rattus norvegicus,2395,104686,B,D,CHO-K1,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,,,Membranes,,1938,CHEMBL617246,,4,1,,BAO_0000249,,,11965,104686,B,H,,,
The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),Autocuration,,,,,,1939,CHEMBL617546,,4,1,,BAO_0000224,,,3967,104686,B,H,,,
The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Autocuration,,,,Brain membranes,,1940,CHEMBL617547,,4,1,,BAO_0000249,,,11130,104686,B,H,,,
Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,,,,1941,CHEMBL617548,,4,1,,BAO_0000219,In vitro,,13427,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,1942,CHEMBL617549,,4,1,,BAO_0000224,,,9443,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,,,,,1943,CHEMBL617550,,4,1,,BAO_0000224,,,9443,104686,B,H,,,
In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,,,,,1944,CHEMBL617551,,4,1,,BAO_0000224,,,11825,104686,B,H,,,
Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Autocuration,,,,Membranes,,1945,CHEMBL617552,,4,1,,BAO_0000249,,,12120,104686,B,H,,,
Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Autocuration,,,,Membranes,,1946,CHEMBL617553,,4,1,,BAO_0000249,,,12120,104686,B,H,,,
Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Autocuration,,,,,,1947,CHEMBL617554,Thoracic aorta,4,1,,BAO_0000019,,,11963,104686,F,H,,1515.0,
Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,1948,CHEMBL617555,,4,1,,BAO_0000019,,,9069,104686,B,H,,,
Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,,,,,1949,CHEMBL617556,,4,1,,BAO_0000224,,,8868,104686,B,H,,,
Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,,,,,1950,CHEMBL617557,,8,1,,BAO_0000357,,,17200,10624,B,H,,,
Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,,,,,1951,CHEMBL617558,,8,1,,BAO_0000357,,,17200,10624,B,H,,,
Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,Expert,,,,,,1952,CHEMBL617559,,8,1,,BAO_0000357,,,13969,17106,B,H,,,
Binding affinity for 5-hydroxytryptamine 1D receptor,Expert,,,,,,1953,CHEMBL617560,,9,1,,BAO_0000357,,,13392,17106,B,D,,,
Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,,,,1954,CHEMBL617561,,8,1,,BAO_0000249,,,1742,17106,B,H,,,
Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,,,,1955,CHEMBL617562,,8,1,,BAO_0000249,,,1742,17106,B,H,,,
Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Autocuration,,,,,,1956,CHEMBL617563,Striatum,8,1,,BAO_0000357,,,14331,17106,B,H,,2435.0,
Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1957,CHEMBL617564,,8,1,,BAO_0000019,,,12861,17106,F,H,,,
Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,Expert,,,,,,1958,CHEMBL617565,,8,1,,BAO_0000019,,,12861,17106,B,H,,,
Binding activity radioligand.,Autocuration,,,,,,1959,CHEMBL856076,,8,1,,BAO_0000357,,,12861,17106,B,H,,,
Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,,,,1960,CHEMBL617566,,8,1,,BAO_0000019,,,12861,17106,B,H,,,
Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Expert,,,,,,1961,CHEMBL875911,,8,1,,BAO_0000019,,,12861,17106,B,H,,,
Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,,,,,1962,CHEMBL617567,,8,1,,BAO_0000019,,,12861,17106,B,H,,,
Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,,,,,1963,CHEMBL617568,,8,1,,BAO_0000249,,,675,17106,B,H,,,
Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,Expert,,,,,,1964,CHEMBL617569,,8,1,,BAO_0000019,,,12490,17106,B,H,,,
Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,Expert,,,,,,1965,CHEMBL617570,,8,1,,BAO_0000249,,,11828,17106,B,H,,,
Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,Autocuration,,,,,,1966,CHEMBL617571,,8,1,,BAO_0000357,,,11866,17106,B,H,,,
In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,Autocuration,,,9823.0,,,1967,CHEMBL617572,,8,1,,BAO_0000357,,Sus scrofa,773,105,B,H,,,
The compound was tested for intrinsic activity against 5-HT1D receptor,Expert,,,9986.0,,,1968,CHEMBL617573,,8,1,,BAO_0000357,,Oryctolagus cuniculus,13047,105,B,H,,,
Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,1969,CHEMBL617574,,8,1,,BAO_0000019,,Oryctolagus cuniculus,13047,105,B,H,,,
The compound was tested for binding affinity against 5-HT1D receptor,Expert,,,9986.0,,,1970,CHEMBL617575,,8,1,,BAO_0000357,,Oryctolagus cuniculus,13047,105,B,H,,,
Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,Autocuration,,,,,,1971,CHEMBL617576,,8,1,,BAO_0000357,,,188,10578,B,H,,,
Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,Autocuration,,,,,,1972,CHEMBL617577,,8,1,,BAO_0000019,,,10639,10578,F,H,,,
Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1973,CHEMBL617578,,8,1,,BAO_0000019,,,12438,10578,F,H,,,
Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1974,CHEMBL617579,,8,1,,BAO_0000357,,,12438,10578,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,,,,,1975,CHEMBL617580,,8,1,,BAO_0000019,,,15854,10578,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,,,,,1976,CHEMBL617581,,8,1,,BAO_0000249,,,10394,10578,B,H,,,
The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,Autocuration,,,,,,1977,CHEMBL617582,,8,1,,BAO_0000357,,,12092,10578,B,H,,,
Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,Expert,,,,,,1978,CHEMBL617583,,8,1,,BAO_0000019,,,3389,10578,B,H,,,
Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,Autocuration,,,,,,1979,CHEMBL617584,,8,1,,BAO_0000357,,,6011,105,B,H,,,
Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1980,CHEMBL617585,,8,1,,BAO_0000357,,,4639,105,B,H,,,
Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,Autocuration,,,,,,1981,CHEMBL875912,,8,1,,BAO_0000357,,,2474,105,B,H,,,
Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1982,CHEMBL617586,,8,1,,BAO_0000357,,,5014,105,B,H,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,Autocuration,,,,,,1983,CHEMBL617587,,8,1,,BAO_0000357,,,17515,105,B,H,,,
Binding affinity for 5-hydroxytryptamine 1D receptor was determined,Autocuration,,,,,,1984,CHEMBL617588,,8,1,,BAO_0000357,,,11866,105,B,H,,,
Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1985,CHEMBL857980,,8,1,,BAO_0000357,,,4687,105,B,H,,,
Tested against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,1986,CHEMBL617589,,8,1,,BAO_0000357,,,12146,105,B,H,,,
Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,Autocuration,,,,,,1987,CHEMBL617590,,8,1,,BAO_0000357,,,10321,105,B,H,,,
Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,,722.0,,,,1988,CHEMBL617591,,8,1,,BAO_0000219,,,13267,105,B,H,HEK293,,
Binding affinity against 5-Hydroxytryptamine 1D receptor,Expert,,,9606.0,,,1989,CHEMBL617592,,9,1,,BAO_0000357,,Homo sapiens,1274,105,B,D,,,
,Autocuration,,,,,,1990,CHEMBL617593,,8,1,,BAO_0000357,,,15250,105,B,H,,,
Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,485.0,,,,1991,CHEMBL617594,,8,1,,BAO_0000219,,,13706,106,B,H,CHO-K1,,
Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,485.0,,,,1992,CHEMBL617595,,8,1,,BAO_0000219,,,13706,105,B,H,CHO-K1,,
Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,,722.0,,,,1993,CHEMBL617596,,8,1,,BAO_0000219,,,13706,105,B,H,HEK293,,
Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,,722.0,,,,1994,CHEMBL617597,,8,1,,BAO_0000219,,,13706,105,B,H,HEK293,,
Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,,,,,1995,CHEMBL617598,,8,1,,BAO_0000019,,,13047,105,B,H,,,
Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,Autocuration,,,,,,1996,CHEMBL872916,,8,1,,BAO_0000357,,,13366,105,B,H,,,
In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,Expert,,,,,,1997,CHEMBL617599,,8,1,,BAO_0000357,,,13366,105,B,H,,,
Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,Autocuration,,,,,,1998,CHEMBL617091,,8,1,,BAO_0000357,,,1558,105,B,H,,,
"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",Expert,,485.0,,,,1999,CHEMBL617092,,8,1,,BAO_0000219,,,12902,105,B,H,CHO-K1,,
Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,,485.0,,,,2000,CHEMBL617093,,8,1,,BAO_0000219,,,13706,105,B,H,CHO-K1,,
Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,,2001,CHEMBL617094,,8,1,,BAO_0000019,,,13706,105,F,H,,,
Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,,2002,CHEMBL617095,,8,1,,BAO_0000019,,,13706,105,F,H,,,
Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,,,,2003,CHEMBL617096,,8,1,,BAO_0000019,,,14251,105,F,H,,,
Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,,,,2004,CHEMBL617097,,8,1,,BAO_0000019,,,14251,105,F,H,,,
Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,,,,,2005,CHEMBL617098,,8,1,,BAO_0000019,,,14251,105,F,H,,,
In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,Autocuration,,,,,,2006,CHEMBL617301,,8,1,,BAO_0000357,,,13313,105,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,Autocuration,,,,,,2007,CHEMBL617302,,8,1,,BAO_0000357,,,13313,105,B,H,,,
Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,,2008,CHEMBL617303,,8,1,,BAO_0000357,,,13366,105,B,H,,,
Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,Expert,,,,,,2009,CHEMBL617304,,8,1,,BAO_0000357,,,13051,105,B,H,,,
"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,,449.0,,,,2010,CHEMBL617305,,8,1,,BAO_0000219,,,12903,105,B,H,CHO,,
Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,Autocuration,,,9606.0,,,2011,CHEMBL617306,,9,1,,BAO_0000219,,Homo sapiens,12469,105,B,D,,,
Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,Autocuration,,,,,,2012,CHEMBL617307,,8,1,,BAO_0000357,,,5619,17106,B,H,,,
Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,2013,CHEMBL617308,,8,1,,BAO_0000019,,Oryctolagus cuniculus,13047,105,B,H,,,
Binding affinities against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,,2014,CHEMBL617309,,8,1,,BAO_0000357,,,16633,105,B,H,,,
Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,,2015,CHEMBL617310,,8,1,,BAO_0000357,,,16633,105,B,H,,,
Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,,2016,CHEMBL617311,,8,1,,BAO_0000357,,,16633,105,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,2017,CHEMBL617312,,8,1,,BAO_0000357,,,16633,105,B,H,,,
Affinity against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,,,,,2018,CHEMBL617313,,8,1,,BAO_0000357,,,3269,105,B,H,,,
Binding affinity against 5-hydroxytryptamine 1D receptor alpha,Expert,,,,,,2019,CHEMBL617314,,8,1,,BAO_0000357,,,12409,105,B,H,,,
Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,,2020,CHEMBL617315,,8,1,,BAO_0000019,,,13706,106,F,H,,,
Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,,722.0,,,,2021,CHEMBL617316,,8,1,,BAO_0000219,,,13706,106,B,H,HEK293,,
Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,,722.0,,,,2022,CHEMBL617317,,8,1,,BAO_0000219,,,13706,106,B,H,HEK293,,
"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Autocuration,,449.0,,,,2023,CHEMBL617318,,8,1,,BAO_0000219,,,12903,106,B,H,CHO,,
Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,,,,,2024,CHEMBL617319,,8,1,,BAO_0000019,,,13047,106,B,H,,,
Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,,2025,CHEMBL617320,,9,1,,BAO_0000357,,,13366,106,B,D,,,
Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,,2026,CHEMBL617321,,9,1,,BAO_0000357,,,13366,106,B,D,,,
Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,,2027,CHEMBL617322,,9,1,,BAO_0000357,,,13366,106,B,D,,,
Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,2028,CHEMBL616862,,8,1,,BAO_0000357,,,13366,106,B,H,,,
Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,2029,CHEMBL616863,,8,1,,BAO_0000357,,,13366,106,B,H,,,
Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,Autocuration,,449.0,,,,2030,CHEMBL616864,,8,1,,BAO_0000219,,,12469,106,B,H,CHO,,
Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,Autocuration,,485.0,,,,2031,CHEMBL616865,,8,1,,BAO_0000219,,,13706,106,B,H,CHO-K1,,
Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,Autocuration,,485.0,,,,2032,CHEMBL616866,,8,1,,BAO_0000219,,,13706,106,B,H,CHO-K1,,
Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,,,,,2033,CHEMBL616867,,8,1,,BAO_0000019,,,13706,106,F,H,,,
"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",Expert,,485.0,,,,2034,CHEMBL616868,,8,1,,BAO_0000219,,,12902,106,B,H,CHO-K1,,
Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,Expert,,,,,,2035,CHEMBL616869,,8,1,,BAO_0000357,,,13051,105,B,H,,,
"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,,449.0,,,,2036,CHEMBL616870,,8,1,,BAO_0000219,,,12903,106,B,H,CHO,,
Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,Autocuration,,485.0,,,,2037,CHEMBL616871,,8,1,,BAO_0000219,,,1558,105,F,H,CHO-K1,,
Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,Autocuration,,485.0,,,,2038,CHEMBL616872,,8,1,,BAO_0000219,,,1558,105,F,H,CHO-K1,,
Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,Autocuration,,485.0,,,,2039,CHEMBL616873,,8,1,,BAO_0000219,,,1558,105,F,H,CHO-K1,,
Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,Autocuration,,485.0,,,,2040,CHEMBL616838,,8,1,,BAO_0000219,,,1558,105,F,H,CHO-K1,,
Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,Autocuration,,,,,,2041,CHEMBL616839,,8,1,,BAO_0000357,,,1558,105,B,H,,,
Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,2042,CHEMBL616840,,8,1,,BAO_0000019,,Oryctolagus cuniculus,13047,106,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,Autocuration,,,,,,2043,CHEMBL616841,,8,1,,BAO_0000357,,,13313,105,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,Autocuration,,,,,,2044,CHEMBL616842,,8,1,,BAO_0000357,,,13313,105,B,H,,,
Binding affinity against 5-hydroxytryptamine 1D receptor beta,Expert,,,,,,2045,CHEMBL857976,,8,1,,BAO_0000357,,,12409,105,B,H,,,
Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,Autocuration,,449.0,,,,2046,CHEMBL616843,,8,1,,BAO_0000219,,,15250,10618,B,H,CHO,,
Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,Expert,,,9606.0,,,2047,CHEMBL616844,,9,1,,BAO_0000357,,Homo sapiens,1348,10618,B,D,,,
Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,Autocuration,,,,,,2048,CHEMBL616845,,8,1,,BAO_0000357,,,1348,10618,B,H,,,
Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,Expert,,,9606.0,,,2049,CHEMBL616846,,9,1,,BAO_0000357,,Homo sapiens,4234,10618,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,Autocuration,,,,,,2050,CHEMBL616847,,8,1,,BAO_0000357,,,16209,10618,B,H,,,
Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,Autocuration,,,,,,2051,CHEMBL616848,,8,1,,BAO_0000019,,,10444,10618,B,H,,,
Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,,2052,CHEMBL616849,,8,1,,BAO_0000357,,,3935,10618,B,H,,,
Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,,2053,CHEMBL872911,,8,1,,BAO_0000357,,,15818,10618,B,H,,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,,2054,CHEMBL616850,,8,1,,BAO_0000019,,,17085,10618,B,H,,,
Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,Expert,,449.0,9606.0,,,2055,CHEMBL616699,,9,1,,BAO_0000219,,Homo sapiens,12936,10618,B,D,CHO,,
Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,,,,2056,CHEMBL616700,,8,1,,BAO_0000357,,,6166,10618,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,449.0,,,,2057,CHEMBL616701,,8,1,,BAO_0000219,,,15779,10618,B,H,CHO,,
Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,,449.0,,,,2058,CHEMBL616702,,8,1,,BAO_0000219,,,15779,10618,B,H,CHO,,
Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,,449.0,,,,2059,CHEMBL616703,,8,1,,BAO_0000219,,,15779,10618,B,H,CHO,,
Binding affinity was determined against 5-hydroxytryptamine 1D receptor,Autocuration,,,,,,2060,CHEMBL616704,,8,1,,BAO_0000357,,,13181,10618,B,H,,,
Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,,449.0,,,,2061,CHEMBL616705,,8,1,,BAO_0000219,,,4199,10618,B,H,CHO,,
Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,Autocuration,,,,,,2062,CHEMBL616706,,8,1,,BAO_0000357,,,14875,10618,B,H,,,
Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,Autocuration,,449.0,,,,2063,CHEMBL616707,,8,1,,BAO_0000219,,,15146,10618,B,H,CHO,,
Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,,2064,CHEMBL616708,,8,1,,BAO_0000357,,,5213,10618,B,H,,,
Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,Autocuration,,,,,,2065,CHEMBL616709,,8,1,,BAO_0000357,,,12146,10618,B,H,,,
The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,Autocuration,,449.0,,,,2066,CHEMBL616710,,8,1,,BAO_0000219,,,13267,10618,B,H,CHO,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,Autocuration,,449.0,,,,2067,CHEMBL616711,,8,1,,BAO_0000219,,,14818,10618,B,H,CHO,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,449.0,,,,2068,CHEMBL616712,,8,1,,BAO_0000219,,,4829,10618,B,H,CHO,,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,,,,2069,CHEMBL616713,,8,1,,BAO_0000357,,,4373,10618,B,H,,,
Binding affinity for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,,,,,2070,CHEMBL616714,,8,1,,BAO_0000357,,,4373,10618,B,H,,,
Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,Autocuration,,,,,,2071,CHEMBL616715,,8,1,,BAO_0000357,,,14159,10618,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1E receptor,Autocuration,,,,,,2072,CHEMBL616716,,8,1,,BAO_0000357,,,16633,10618,B,H,,,
"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",Autocuration,,,,,,2073,CHEMBL616717,,8,1,,BAO_0000019,,,17085,279,F,H,,,
"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",Expert,,,,,,2074,CHEMBL616718,,8,1,,BAO_0000019,,,17085,279,F,H,,,
In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,,2075,CHEMBL875905,,8,1,,BAO_0000019,,,16209,279,F,H,,,
In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,,2076,CHEMBL616719,,8,1,,BAO_0000019,,,16209,279,F,H,,,
"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",Expert,,,,,,2077,CHEMBL616720,,8,1,,BAO_0000019,,,17085,279,F,H,,,
Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,Autocuration,,,,,,2078,CHEMBL616721,,8,1,,BAO_0000357,,,14159,279,B,H,,,
Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,Autocuration,,449.0,,,,2079,CHEMBL616722,,8,1,,BAO_0000219,,,15250,279,B,H,CHO,,
In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),Autocuration,,,,,,2080,CHEMBL616723,,8,1,,BAO_0000357,,,3805,279,B,H,,,
Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,Autocuration,,449.0,,,,2081,CHEMBL616724,,8,1,,BAO_0000219,,,16190,279,B,H,CHO,,
Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,Autocuration,,,,,,2082,CHEMBL616725,,8,1,,BAO_0000357,,,16190,279,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,,2083,CHEMBL616726,,8,1,,BAO_0000357,,,16209,279,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,,2084,CHEMBL616727,,8,1,,BAO_0000357,,,16209,279,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,Autocuration,,,,,,2085,CHEMBL616728,,8,1,,BAO_0000357,,,16209,279,B,H,,,
In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,,2086,CHEMBL616729,,8,1,,BAO_0000357,,,6866,279,B,H,,,
In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,Expert,,,,,,2087,CHEMBL616730,,8,1,,BAO_0000019,,,17085,279,B,H,,,
Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,Autocuration,,,,,,2088,CHEMBL617125,,8,1,,BAO_0000357,,,16312,279,B,H,,,
Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,,2089,CHEMBL857977,,8,1,,BAO_0000357,,,6166,279,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,,449.0,,,,2090,CHEMBL617126,,8,1,,BAO_0000219,,,15779,279,B,H,CHO,,
Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,Autocuration,,449.0,,,,2091,CHEMBL617127,,8,1,,BAO_0000219,,,4199,279,B,H,CHO,,
Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,Autocuration,,,,,,2092,CHEMBL617128,,8,1,,BAO_0000357,,,14875,279,B,H,,,
Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,Autocuration,,449.0,,,,2093,CHEMBL617129,,8,1,,BAO_0000219,,,15146,279,B,H,CHO,,
Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,,,,,2094,CHEMBL617130,,8,1,,BAO_0000357,,,5213,279,B,H,,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,Autocuration,,449.0,,,,2095,CHEMBL617131,,8,1,,BAO_0000219,,,14818,279,B,H,CHO,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,449.0,,,,2096,CHEMBL617132,,8,1,,BAO_0000219,,,4829,279,B,H,CHO,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,,449.0,,,,2097,CHEMBL617133,,8,1,,BAO_0000219,,,4829,279,B,H,CHO,,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,,2098,CHEMBL617134,,8,1,,BAO_0000357,,,4373,279,B,H,,,
Binding affinity for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,,,,,2099,CHEMBL617135,,8,1,,BAO_0000357,,,4373,279,B,H,,,
Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,Autocuration,,,,,,2100,CHEMBL617136,,8,1,,BAO_0000357,,,5014,279,B,H,,,
"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",Autocuration,,,,,,2101,CHEMBL617137,,4,1,,BAO_0000019,,,11662,104686,B,H,,,
"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,,,,,2102,CHEMBL617138,,4,1,,BAO_0000019,,,11662,104686,B,H,,,
"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,,,,2103,CHEMBL617139,,4,1,,BAO_0000019,,,11662,104686,B,H,,,
Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2104,CHEMBL617140,,8,1,,BAO_0000019,,,14093,12687,B,H,,,
"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",Autocuration,,,,,,2105,CHEMBL617141,,4,1,,BAO_0000218,In vivo,,11200,104686,F,H,,,
In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,,2106,CHEMBL858112,,4,1,,BAO_0000019,,,11200,104686,F,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,Intermediate,,,,,,2107,CHEMBL617142,,8,1,,BAO_0000019,,,12352,17005,B,H,,,
"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",Autocuration,,,9913.0,,,2108,CHEMBL617143,,0,1,,BAO_0000019,,Bos taurus,13657,22226,B,U,,,
Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,Autocuration,,,9913.0,,,2109,CHEMBL617144,,0,1,,BAO_0000019,,Bos taurus,14331,22226,B,U,,,
Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,Autocuration,,,9913.0,,,2110,CHEMBL617145,,0,1,,BAO_0000019,,Bos taurus,14331,22226,B,U,,,
Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,Autocuration,,,,,,2111,CHEMBL617146,,0,1,,BAO_0000019,,,14331,22226,B,U,,,
Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,Autocuration,,,10141.0,,,2112,CHEMBL617147,,4,1,,BAO_0000019,,Cavia porcellus,12685,104784,B,H,,,
Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Autocuration,,,10141.0,,,2113,CHEMBL617148,,4,1,,BAO_0000019,,Cavia porcellus,14389,104784,B,H,,,
Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Autocuration,,,10141.0,,,2114,CHEMBL617149,,4,1,,BAO_0000019,,Cavia porcellus,14386,104784,B,H,,,
Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,,2115,CHEMBL617150,,4,1,,BAO_0000224,,,5732,104784,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,,2116,CHEMBL617151,,4,1,,BAO_0000224,,,16293,104784,B,H,,,
In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2117,CHEMBL617201,,4,1,,BAO_0000224,,,2078,104784,B,H,,,
Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,,,,,2118,CHEMBL617202,,8,1,,BAO_0000357,,,5486,10209,B,H,,,
Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,,,,,2119,CHEMBL617203,,4,1,,BAO_0000218,In vivo,,11820,104826,B,H,,,
Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,,,,,,2120,CHEMBL617204,,4,1,,BAO_0000019,,,10297,104826,B,H,,,
Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,Autocuration,,,,,,2121,CHEMBL617205,,4,1,,BAO_0000224,,,13704,104826,B,H,,,
Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,Autocuration,,,10090.0,,,2122,CHEMBL617206,,5,1,,BAO_0000019,,Mus musculus,10297,104826,B,D,,,
Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,,,,,2123,CHEMBL617207,,4,1,,BAO_0000218,In vivo,,11820,104826,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,Autocuration,,,10090.0,,,2124,CHEMBL617208,,5,1,,BAO_0000019,,Mus musculus,10297,104826,B,D,,,
The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2125,CHEMBL617209,,4,1,,BAO_0000224,,,11555,104826,B,H,,,
In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,Autocuration,,,,,,2126,CHEMBL617210,,4,1,,BAO_0000224,,,11555,104826,B,H,,,
The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,Autocuration,,,,,,2127,CHEMBL617211,,4,1,,BAO_0000224,,,11555,104826,B,H,,,
Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,,,10090.0,,,2128,CHEMBL617212,,5,1,,BAO_0000019,,Mus musculus,10297,104826,B,D,,,
Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,Autocuration,,,9823.0,,,2129,CHEMBL617213,,4,1,,BAO_0000224,,Sus scrofa,16688,104784,B,H,,,
Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,Autocuration,,,9823.0,,,2130,CHEMBL617214,,4,1,,BAO_0000224,,Sus scrofa,16688,104784,B,H,,,
Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,,,,,2131,CHEMBL617215,,0,1,,BAO_0000221,,,5333,22226,B,U,,,
In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,,,,,2132,CHEMBL617216,,0,1,,BAO_0000221,,,4437,22226,B,U,,,
Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,Autocuration,,,9823.0,,,2133,CHEMBL617217,,8,1,,BAO_0000357,,Sus scrofa,5033,17005,B,H,,,
Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2134,CHEMBL617218,,4,1,,BAO_0000019,,,15267,104686,B,H,,,
Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2135,CHEMBL872913,,4,1,,BAO_0000019,,,15267,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,Autocuration,,,,,,2136,CHEMBL617219,,4,1,,BAO_0000019,,,11820,104826,B,H,,,
Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2137,CHEMBL873482,,4,1,,BAO_0000224,,,9069,104686,B,H,,,
Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,Autocuration,,,10116.0,,,2138,CHEMBL617220,,5,1,,BAO_0000019,,Rattus norvegicus,9162,104686,B,D,,,
Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,Autocuration,,,,,,2139,CHEMBL617221,,4,1,,BAO_0000019,,,9162,104686,B,H,,,
Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,Autocuration,,,,,,2140,CHEMBL617222,,4,1,,BAO_0000019,,,9162,104686,B,H,,,
Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,Autocuration,,,,,,2141,CHEMBL875906,,4,1,,BAO_0000019,,,10428,104686,F,H,,,
Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,Autocuration,,,,,,2142,CHEMBL617223,,4,1,,BAO_0000019,,,9628,104686,B,H,,,
Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2143,CHEMBL617224,,4,1,,BAO_0000224,,,12704,104686,B,H,,,
Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,,,10116.0,,,2144,CHEMBL617225,,5,1,,BAO_0000224,,Rattus norvegicus,15453,104686,B,D,,,
Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,Autocuration,,,,,,2145,CHEMBL617226,,4,1,,BAO_0000224,,,188,104686,B,H,,,
Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,,,,,2146,CHEMBL617227,,4,1,,BAO_0000224,,,10349,104686,B,H,,,
Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,,,,,2147,CHEMBL617228,,4,1,,BAO_0000224,,,10349,104686,B,H,,,
Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,,,,,2148,CHEMBL617229,,4,1,,BAO_0000224,,,8868,104686,B,H,,,
Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,,,,,2149,CHEMBL617230,,4,1,,BAO_0000224,,,10025,104686,B,H,,,
"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,,,,,2150,CHEMBL617231,,4,1,,BAO_0000224,,,10025,104686,B,H,,,
Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,Autocuration,,,,,,2151,CHEMBL617232,,4,1,,BAO_0000224,,,11702,104686,B,H,,,
Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2152,CHEMBL617233,,4,1,,BAO_0000224,,,11702,104686,B,H,,,
Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,,,,,2153,CHEMBL617234,,4,1,,BAO_0000224,,,11702,104686,B,H,,,
Compound was tested for the inhibition of quipazine induced head twitches in rats,Autocuration,,,,,,2154,CHEMBL617235,,4,1,,BAO_0000019,,,11702,104686,F,H,,,
Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,Autocuration,,,,,,2155,CHEMBL617236,,4,1,,BAO_0000019,,,11702,104686,F,H,,,
Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Autocuration,,,,,,2156,CHEMBL617237,Hippocampus,4,1,,BAO_0000221,,,10085,104686,B,H,,10000000.0,
Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Autocuration,,,,,,2157,CHEMBL617238,Hippocampus,4,1,,BAO_0000221,,,10085,104686,B,H,,10000000.0,
Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Autocuration,,,10116.0,,,2158,CHEMBL617239,Brain,5,1,,BAO_0000221,,Rattus norvegicus,9630,104686,B,D,,955.0,
Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,,,,2159,CHEMBL617240,,4,1,,BAO_0000019,,,11070,104686,B,H,,,
Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,,,Membranes,,2160,CHEMBL617241,,4,1,,BAO_0000249,,,9841,104686,B,H,,,
Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,,,Membranes,,2161,CHEMBL875907,,4,1,,BAO_0000249,,,9841,104686,B,H,,,
Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,Autocuration,,,,,,2162,CHEMBL617242,,4,1,,BAO_0000019,,,13291,104686,B,H,,,
Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,Autocuration,,,,,,2163,CHEMBL617152,,4,1,,BAO_0000019,,,10590,104686,F,H,,,
Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,,,10116.0,,,2164,CHEMBL617153,Brain,5,1,,BAO_0000221,,Rattus norvegicus,9064,104686,B,D,,955.0,
Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Autocuration,,,10116.0,Membranes,,2165,CHEMBL617154,,5,1,,BAO_0000249,,Rattus norvegicus,12268,104686,B,D,,,
Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Autocuration,,,,,,2166,CHEMBL617155,Brain,4,1,,BAO_0000221,,,13508,104686,B,H,,955.0,
5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,,,,,2167,CHEMBL617156,,4,1,,BAO_0000019,,,11279,104686,F,H,,,
In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,Autocuration,,,,,,2168,CHEMBL617157,,4,1,,BAO_0000019,,,11200,104686,F,H,,,
In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,,2169,CHEMBL617158,,4,1,,BAO_0000019,,,11200,104686,F,H,,,
In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,,,,,2170,CHEMBL617159,,4,1,,BAO_0000019,,,11200,104686,F,H,,,
In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,,,,,2171,CHEMBL617160,,4,1,,BAO_0000019,,,11200,104686,F,H,,,
In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,,2172,CHEMBL858113,,4,1,,BAO_0000019,,,11200,104686,F,H,,,
Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Autocuration,,,,,,2173,CHEMBL617247,Brain,4,1,,BAO_0000220,,,9231,104686,B,H,,955.0,
Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,,,,,2174,CHEMBL617248,,4,1,,BAO_0000019,,,9737,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,,,,,2175,CHEMBL617249,Brain,4,1,,BAO_0000249,,,9737,104686,B,H,,955.0,
Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,Autocuration,,,,,,2176,CHEMBL617250,,4,1,,BAO_0000019,,,9737,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,,,,,2177,CHEMBL617251,,4,1,,BAO_0000019,,,9737,104686,B,H,,,
isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,Autocuration,,,10116.0,,,2178,CHEMBL617252,,5,1,,BAO_0000019,,Rattus norvegicus,11828,104686,B,D,,,
Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,,,,,,2179,CHEMBL617006,,4,1,,BAO_0000019,,,12253,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,Autocuration,,,,,,2180,CHEMBL617007,,4,1,,BAO_0000019,,,12253,104686,B,H,,,
"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",Autocuration,,,,,,2181,CHEMBL617008,,4,1,,BAO_0000019,,,11279,104686,F,H,,,
Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,Autocuration,,,,,,2182,CHEMBL617009,,4,1,,BAO_0000019,,,11866,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,Autocuration,,,10116.0,,,2183,CHEMBL617010,,5,1,,BAO_0000224,,Rattus norvegicus,14424,104686,B,D,,,
Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,10116.0,,,2184,CHEMBL857978,,5,1,,BAO_0000019,,Rattus norvegicus,15180,104686,B,D,,,
Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,,10116.0,,,2185,CHEMBL617011,,5,1,,BAO_0000019,,Rattus norvegicus,15180,104686,B,D,,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,Autocuration,,,10116.0,,,2186,CHEMBL617012,,5,1,,BAO_0000019,,Rattus norvegicus,9786,104686,B,D,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,Autocuration,,,,,,2187,CHEMBL617013,,4,1,,BAO_0000224,,,12132,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,Autocuration,,,,,,2188,CHEMBL617014,,4,1,,BAO_0000249,,,5486,104686,B,H,,,
Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2189,CHEMBL617015,,4,1,,BAO_0000019,,,15316,104686,B,H,,,
In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,Autocuration,,,,,,2190,CHEMBL617016,,4,1,,BAO_0000019,,,16429,104686,B,H,,,
pKi value for 5-hydroxytryptamine 2 receptor binding site,Autocuration,,,,,,2191,CHEMBL617017,,4,1,,BAO_0000224,,,14617,104686,B,H,,,
Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Autocuration,,,,,,2192,CHEMBL617018,Brain,4,1,,BAO_0000221,,,11351,104686,B,H,,955.0,
5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,,,,,2193,CHEMBL617019,,4,1,,BAO_0000019,,,11279,104686,F,H,,,
Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,,2194,CHEMBL617020,,4,1,,BAO_0000019,,,9523,105075,B,H,,,
Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,,2195,CHEMBL617021,,4,1,,BAO_0000019,,,9523,105075,B,H,,,
Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,,2196,CHEMBL617022,,4,1,,BAO_0000019,,,9523,105075,B,H,,,
Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,,2197,CHEMBL617023,,4,1,,BAO_0000019,,,9523,105075,B,H,,,
Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,,2198,CHEMBL617024,,4,1,,BAO_0000019,,,9523,105075,B,H,,,
Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,,,,,2199,CHEMBL617025,,4,1,,BAO_0000019,,,9523,105075,B,H,,,
Hill coefficient of compound was determined,Autocuration,,,,,,2200,CHEMBL617026,,4,1,,BAO_0000224,,,9523,105075,B,H,,,
Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2201,CHEMBL617027,,0,1,,BAO_0000019,,,4771,22226,B,U,,,
Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,Autocuration,,,10116.0,,,2202,CHEMBL617028,,5,1,,BAO_0000019,,Rattus norvegicus,5033,104686,B,D,,,
Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,Expert,,,,,,2203,CHEMBL617029,,8,1,,BAO_0000019,,,10845,12687,B,H,,,
Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,Expert,,,,,,2204,CHEMBL875908,,8,1,,BAO_0000019,,,10845,12687,B,H,,,
Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),Autocuration,,,,,,2205,CHEMBL617030,,8,1,,BAO_0000357,,,16288,12687,B,H,,,
Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),Autocuration,,,,,,2206,CHEMBL617031,,8,1,,BAO_0000019,,,16288,12687,B,H,,,
Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,Autocuration,,,,,,2207,CHEMBL617032,,8,1,,BAO_0000019,,,16190,12687,B,H,,,
Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,Autocuration,,,10116.0,,,2208,CHEMBL617033,,5,1,,BAO_0000224,,Rattus norvegicus,12463,104686,B,D,,,
"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",Autocuration,,,,,,2209,CHEMBL617034,,4,1,,BAO_0000224,,,9699,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,Autocuration,,,,,,2210,CHEMBL617035,,4,1,,BAO_0000224,,,9699,104686,B,H,,,
"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,,,,2211,CHEMBL617036,,4,1,,BAO_0000019,,,11662,104686,B,H,,,
Inhibitory concentration against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2212,CHEMBL617037,,4,1,,BAO_0000224,,,1205,104784,B,H,,,
Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,Autocuration,,,,,,2213,CHEMBL617038,,0,1,,BAO_0000219,,,11376,22226,B,U,,,
"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",Autocuration,,,,,,2214,CHEMBL617039,,4,1,,BAO_0000219,,,11376,104784,B,H,,,
Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2215,CHEMBL617161,,4,1,,BAO_0000224,,,4639,104784,B,H,,,
Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2216,CHEMBL617162,,4,1,,BAO_0000224,,,2222,104784,B,H,,,
Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2217,CHEMBL617163,,4,1,,BAO_0000224,,,1558,104784,B,H,,,
Tested for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2218,CHEMBL617164,,4,1,,BAO_0000224,,,1089,104784,B,H,,,
The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Autocuration,,,,Brain membranes,,2219,CHEMBL617165,,4,1,,BAO_0000249,,,386,104784,B,H,,,
Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,Autocuration,,,,,,2220,CHEMBL617166,,4,1,,BAO_0000224,,,2474,104784,B,H,,,
Binding affinity towards 5-HT2 receptor,Autocuration,,,,,,2221,CHEMBL617167,,4,1,,BAO_0000224,,,17066,104784,B,H,,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2222,CHEMBL872912,,4,1,,BAO_0000224,,,959,104784,B,H,,,
Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,Autocuration,,,,,,2223,CHEMBL617168,,4,1,,BAO_0000224,,,6398,104784,B,H,,,
In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,Autocuration,,,,,,2224,CHEMBL617169,,4,1,,BAO_0000224,,,11889,104686,B,H,,,
In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2225,CHEMBL617170,,4,1,,BAO_0000224,,,4221,104784,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,Autocuration,,,,,,2226,CHEMBL617171,,4,1,,BAO_0000224,,,11026,104784,B,H,,,
Binding affinity for 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,,2227,CHEMBL617172,,4,1,,BAO_0000224,,,11866,104784,B,H,,,
In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2228,CHEMBL617173,,4,1,,BAO_0000224,,,4221,104784,B,H,,,
In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2229,CHEMBL617174,,0,1,,BAO_0000019,,,13950,22226,B,U,,,
5-hydroxytryptamine 2 receptor binding affinity,Autocuration,,,,,,2230,CHEMBL617175,,4,1,,BAO_0000224,,,1263,104784,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,Autocuration,,,,,,2231,CHEMBL617176,,8,1,,BAO_0000357,,,13291,17005,B,H,,,
Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,Autocuration,,,,,,2232,CHEMBL617177,,8,1,,BAO_0000357,,,10812,17005,B,H,,,
Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,,,,,2233,CHEMBL617178,,4,1,,BAO_0000224,,,13020,104784,B,H,,,
Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,Autocuration,,,,,,2234,CHEMBL617179,,4,1,,BAO_0000224,,,13021,104784,B,H,,,
Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,,,,,2235,CHEMBL617180,,4,1,,BAO_0000224,,,13020,104784,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,Autocuration,,,,,,2236,CHEMBL617181,,8,1,,BAO_0000357,,,14532,17005,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2237,CHEMBL617182,,8,1,,BAO_0000357,,,13944,17005,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2238,CHEMBL617183,,8,1,,BAO_0000357,,,14331,17005,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,,,,,2239,CHEMBL617184,,8,1,,BAO_0000357,,,14118,17005,B,H,,,
Binding affinity against serotonergic 5-HT2 receptor,Autocuration,,,,,,2240,CHEMBL617185,,8,1,,BAO_0000357,,,13033,17005,B,H,,,
Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,Autocuration,,,,,,2241,CHEMBL617186,,8,1,,BAO_0000357,,,10321,17005,B,H,,,
Compound was evaluated for the binding affinity at 5- HT2 receptor,Autocuration,,,,,,2242,CHEMBL617187,,8,1,,BAO_0000357,,,12918,17005,B,H,,,
Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2243,CHEMBL617188,,8,1,,BAO_0000357,,,15120,17005,B,H,,,
In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2244,CHEMBL617189,,8,1,,BAO_0000218,,,2613,17005,B,H,,,
Inhibitory activity against cloned human 5-HT2 receptor,Autocuration,,,9606.0,,,2245,CHEMBL617190,,5,1,,BAO_0000224,,Homo sapiens,13378,104784,B,D,,,
"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",Autocuration,,449.0,9606.0,,,2246,CHEMBL617191,,5,1,,BAO_0000219,,Homo sapiens,2331,104784,B,D,CHO,,
"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",Autocuration,,449.0,9606.0,,,2247,CHEMBL617192,,5,1,,BAO_0000219,,Homo sapiens,2331,104784,B,D,CHO,,
"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",Autocuration,,449.0,9606.0,,,2248,CHEMBL617193,,5,1,,BAO_0000219,,Homo sapiens,2331,104784,B,D,CHO,,
"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",Autocuration,,449.0,9606.0,,,2249,CHEMBL617194,,5,1,,BAO_0000219,,Homo sapiens,2331,104784,B,D,CHO,,
Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2250,CHEMBL617195,,4,1,,BAO_0000224,,,4170,104784,B,H,,,
Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,,,,,,2251,CHEMBL881830,,4,1,,BAO_0000224,,,15453,104784,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2252,CHEMBL617196,,8,1,,BAO_0000357,,,1479,17005,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,Autocuration,,,,,,2253,CHEMBL617197,,4,1,,BAO_0000224,,,11139,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,Expert,,,,,,2254,CHEMBL617198,,8,1,,BAO_0000357,,,13969,17005,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,,,,2255,CHEMBL873476,,8,1,,BAO_0000357,,,13392,17005,B,H,,,
Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,Expert,,,,,,2256,CHEMBL617199,,8,1,,BAO_0000019,,,14430,17005,B,H,,,
Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,,,10141.0,,,2257,CHEMBL617200,,8,1,,BAO_0000357,,Cavia porcellus,13181,107,B,H,,,
Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,,2258,CHEMBL617484,,8,1,,BAO_0000357,,,17200,51,B,H,,,
Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,,2259,CHEMBL617485,,8,1,,BAO_0000357,,,17200,107,B,H,,,
Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,,2260,CHEMBL617486,,8,1,,BAO_0000357,,,17200,51,B,H,,,
Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,Autocuration,,,,,,2261,CHEMBL858022,,8,1,,BAO_0000357,,,13463,107,B,H,,,
Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,,449.0,,,,2262,CHEMBL617049,,8,1,,BAO_0000219,,,6347,107,B,H,CHO,,
Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,,449.0,9606.0,,,2263,CHEMBL617050,,9,1,,BAO_0000219,,Homo sapiens,6857,107,F,D,CHO,,
Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,,,,,2264,CHEMBL617051,,8,1,,BAO_0000219,,,4176,107,F,H,,,
Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,Autocuration,,,,,,2265,CHEMBL617052,,8,1,,BAO_0000219,,,4176,107,F,H,,,
Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,,,,,2266,CHEMBL617053,,8,1,,BAO_0000219,,,4176,107,F,H,,,
"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",Autocuration,,449.0,,,,2267,CHEMBL617054,,8,1,,BAO_0000219,,,6347,107,B,H,CHO,,
"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",Autocuration,,449.0,,,,2268,CHEMBL617055,,8,1,,BAO_0000219,,,6347,107,B,H,CHO,,
Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,Autocuration,,,,,,2269,CHEMBL882924,,8,1,,BAO_0000357,,,15331,107,B,H,,,
Inhibition of human 5-hydroxytryptamine 2A receptor,Expert,,,9606.0,,,2270,CHEMBL617056,,9,1,,BAO_0000357,,Homo sapiens,16146,107,B,D,,,
Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Autocuration,,449.0,,,,2271,CHEMBL617057,,8,1,,BAO_0000219,,,15250,107,B,H,CHO,,
Inhibitory concentration against human 5-HT2A receptor in BEK cells,Expert,,,,,,2272,CHEMBL617058,,8,1,,BAO_0000219,,,13631,107,B,H,,,
In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),Autocuration,,,,,,2273,CHEMBL617059,,8,1,,BAO_0000357,,,3805,107,B,H,,,
Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,Autocuration,,449.0,,,,2274,CHEMBL617060,,8,1,,BAO_0000219,,,4011,107,B,H,CHO,,
Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,Expert,,449.0,,,,2275,CHEMBL617061,,8,1,,BAO_0000219,,,4012,107,B,H,CHO,,
Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,Expert,,307.0,,,,2276,CHEMBL617062,,8,1,,BAO_0000219,,,6366,107,B,H,L929,,
Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,449.0,,,,2277,CHEMBL617063,,8,1,,BAO_0000219,,,15949,107,B,H,CHO,,
Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,Autocuration,,,,,,2278,CHEMBL617064,,8,1,,BAO_0000019,,,14093,107,F,H,,,
Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,,2279,CHEMBL617065,,8,1,,BAO_0000019,,,13481,107,F,H,,,
Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,,449.0,,,,2280,CHEMBL617066,,8,1,,BAO_0000219,,,6347,107,B,H,CHO,,
Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,Autocuration,,449.0,,,,2281,CHEMBL617067,,8,1,,BAO_0000219,,,6347,107,B,H,CHO,,
Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,Autocuration,,,,,,2282,CHEMBL617068,,8,1,,BAO_0000019,,,14093,107,F,H,,,
Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,Autocuration,,,,,,2283,CHEMBL617069,,8,1,,BAO_0000019,,,14093,107,F,H,,,
Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,,2284,CHEMBL617070,,8,1,,BAO_0000019,,,13481,107,F,H,,,
Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,Autocuration,,,,,,2285,CHEMBL617071,,8,1,,BAO_0000357,,,14442,107,B,H,,,
Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,,2286,CHEMBL872915,,8,1,,BAO_0000357,,,14442,107,B,H,,,
Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,Autocuration,,,,,,2287,CHEMBL617072,,8,1,,BAO_0000357,,,14755,107,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor in humans,Autocuration,,,,,,2288,CHEMBL617073,,8,1,,BAO_0000357,,,16441,107,B,H,,,
Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,Autocuration,,,,,,2289,CHEMBL617074,,8,1,,BAO_0000357,,,14744,107,B,H,,,
Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,449.0,,,,2290,CHEMBL617075,,8,1,,BAO_0000219,,,16659,107,B,H,CHO,,
Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2291,CHEMBL617076,,8,1,,BAO_0000357,,,3307,107,B,H,,,
Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,Expert,,,9606.0,,,2292,CHEMBL617077,,9,1,,BAO_0000019,,Homo sapiens,6857,107,B,D,,,
Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,Expert,,,,,,2293,CHEMBL617078,,8,1,,BAO_0000357,,,5635,107,B,H,,,
Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,Expert,,,9606.0,,,2294,CHEMBL617079,,9,1,,BAO_0000357,,Homo sapiens,4234,107,B,D,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,,,,,2295,CHEMBL617080,,8,1,,BAO_0000357,,,15527,107,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,Expert,,449.0,,,,2296,CHEMBL617081,,8,1,,BAO_0000219,,,6588,107,B,H,CHO,,
Binding affinity towards human 5-HT2A receptor in BEK cells,Expert,,,,,,2297,CHEMBL617082,,8,1,,BAO_0000219,,,13631,107,B,H,,,
Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2298,CHEMBL617083,,8,1,,BAO_0000357,,,17723,107,B,H,,,
Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,,,,,2299,CHEMBL617084,,8,1,,BAO_0000357,,,14770,107,B,H,,,
Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,,,9606.0,,,2300,CHEMBL617085,,9,1,,BAO_0000357,,Homo sapiens,16293,107,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,,2301,CHEMBL617086,,8,1,,BAO_0000357,,,16209,107,B,H,,,
Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,Autocuration,,,,,,2302,CHEMBL617087,,8,1,,BAO_0000219,,,12469,107,B,H,,,
Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2303,CHEMBL617088,,8,1,,BAO_0000357,,,15363,107,B,H,,,
Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2304,CHEMBL617089,,8,1,,BAO_0000357,,,15363,107,B,H,,,
"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",Expert,,,,,,2305,CHEMBL617090,,8,1,,BAO_0000019,,,16441,107,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,Autocuration,,,,,,2306,CHEMBL617513,,8,1,,BAO_0000357,,,8,107,B,H,,,
In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,Autocuration,,722.0,,,,2307,CHEMBL617514,,8,1,,BAO_0000219,,,4176,107,B,H,HEK293,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2308,CHEMBL617515,,8,1,,BAO_0000019,,,17085,107,B,H,,,
Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,,,,,2309,CHEMBL617516,,8,1,,BAO_0000357,,,17200,107,B,H,,,
Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Expert,,,9606.0,,,2310,CHEMBL617517,,9,1,,BAO_0000357,,Homo sapiens,17200,107,B,D,,,
Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,Expert,,449.0,9606.0,,,2311,CHEMBL617518,,9,1,,BAO_0000219,,Homo sapiens,4013,107,B,D,CHO,,
Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2312,CHEMBL617519,,8,1,,BAO_0000357,,,5088,107,B,H,,,
Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,Expert,,,9606.0,,,2313,CHEMBL617520,,9,1,,BAO_0000357,,Homo sapiens,5088,107,B,D,,,
Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,Autocuration,,,,,,2314,CHEMBL617521,,8,1,,BAO_0000357,,,5088,107,B,H,,,
Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,Expert,,,9606.0,,,2315,CHEMBL617522,,9,1,,BAO_0000357,,Homo sapiens,5088,107,B,D,,,
Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,Autocuration,,,,,,2316,CHEMBL617523,,8,1,,BAO_0000357,,,5088,107,B,H,,,
Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,,,,,2317,CHEMBL617524,,8,1,,BAO_0000357,,,5088,107,B,H,,,
Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,Autocuration,,,,,,2318,CHEMBL617525,,4,1,,BAO_0000019,,,9786,104686,B,H,,,
Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Autocuration,,,10116.0,,,2319,CHEMBL617526,,5,1,,BAO_0000019,,Rattus norvegicus,9205,104686,B,D,,,
Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,Autocuration,,,,,,2320,CHEMBL617527,,4,1,,BAO_0000224,,,11257,104686,B,H,,,
Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,,,,,2321,CHEMBL617528,,4,1,,BAO_0000019,,,9362,104686,B,H,,,
Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,,,,,2322,CHEMBL617529,,4,1,,BAO_0000019,,,9362,104686,B,H,,,
Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,Autocuration,,,,,,2323,CHEMBL617530,,4,1,,BAO_0000224,,,10590,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,,,,,2324,CHEMBL617531,,4,1,,BAO_0000019,,,10468,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,Autocuration,,,,,,2325,CHEMBL617532,,4,1,,BAO_0000019,,,13050,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,Autocuration,,,,,,2326,CHEMBL617533,,4,1,,BAO_0000019,,,11624,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,,,,,2327,CHEMBL617534,,4,1,,BAO_0000019,,,10468,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,,,,,2328,CHEMBL617535,,4,1,,BAO_0000224,,,10330,104686,B,H,,,
Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,,,,,2329,CHEMBL617536,,4,1,,BAO_0000224,,,10062,104686,B,H,,,
Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2330,CHEMBL617537,,4,1,,BAO_0000224,,,11642,104686,B,H,,,
Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2331,CHEMBL617538,,4,1,,BAO_0000224,,,10062,104686,B,H,,,
Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,,,,,2332,CHEMBL617539,,4,1,,BAO_0000219,In vitro,,13427,104686,B,H,,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,10116.0,,,2333,CHEMBL617540,,5,1,,BAO_0000224,,Rattus norvegicus,12280,104686,B,D,,,
Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Autocuration,,,10116.0,,,2334,CHEMBL617541,,5,1,,BAO_0000224,,Rattus norvegicus,4101,104686,B,D,,,
Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2335,CHEMBL617542,,4,1,,BAO_0000224,,,10062,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,Autocuration,,,,,,2336,CHEMBL617543,,4,1,,BAO_0000224,,,11147,104686,B,H,,,
Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,,485.0,10116.0,,,2337,CHEMBL617544,,5,1,,BAO_0000219,,Rattus norvegicus,2395,104686,B,D,CHO-K1,,
Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,,485.0,10116.0,,,2338,CHEMBL617545,,5,1,,BAO_0000219,,Rattus norvegicus,2395,104686,B,D,CHO-K1,,
Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,Autocuration,,,10116.0,,,2339,CHEMBL617413,,5,1,,BAO_0000019,,Rattus norvegicus,9098,104686,B,D,,,
Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,Autocuration,,,,,,2340,CHEMBL617414,,4,1,,BAO_0000019,,,9098,104686,B,H,,,
Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,Autocuration,,,10116.0,,,2341,CHEMBL617415,,5,1,,BAO_0000019,,Rattus norvegicus,9098,104686,B,D,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2342,CHEMBL617416,,4,1,,BAO_0000224,,,9443,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,,,,,2343,CHEMBL617417,,4,1,,BAO_0000224,,,9443,104686,B,H,,,
"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",Autocuration,,,,,,2344,CHEMBL617418,,4,1,,BAO_0000019,,,9699,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,Autocuration,,,,,,2345,CHEMBL617419,,4,1,,BAO_0000019,,,9699,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,,,,,2346,CHEMBL617420,,4,1,,BAO_0000224,,,9098,104686,B,H,,,
Affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,10116.0,,,2347,CHEMBL617421,,5,1,,BAO_0000224,,Rattus norvegicus,3070,104686,B,D,,,
Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,Autocuration,,,,,,2348,CHEMBL617422,,4,1,,BAO_0000224,,,9547,104686,B,H,,,
Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,Autocuration,,,,,,2349,CHEMBL617423,,4,1,,BAO_0000019,,,10444,104686,B,H,,,
Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,Autocuration,,,,,,2350,CHEMBL617424,,4,1,,BAO_0000019,,,14617,104686,B,H,,,
Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,Autocuration,,,,,,2351,CHEMBL617425,,4,1,,BAO_0000019,,,14617,104686,B,H,,,
Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),Autocuration,,,,,,2352,CHEMBL617426,,4,1,,BAO_0000224,,,11130,104686,B,H,,,
Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),Autocuration,,,,,,2353,CHEMBL617427,,4,1,,BAO_0000218,In vivo,,11130,104686,B,H,,,
Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Autocuration,,,,,,2354,CHEMBL617428,Brain,4,1,,BAO_0000221,,,14542,104686,B,H,,955.0,
Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,Autocuration,,,,,,2355,CHEMBL617429,,4,1,,BAO_0000224,,,2797,104686,B,H,,,
Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,,,,,2356,CHEMBL617430,,4,1,,BAO_0000019,,,11332,104686,B,H,,,
Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,,,,,2357,CHEMBL617431,,4,1,,BAO_0000019,,,11332,104686,B,H,,,
Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Autocuration,,,,,,2358,CHEMBL617432,Frontal cortex,4,1,,BAO_0000019,,,10752,104686,B,H,,1870.0,
Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2359,CHEMBL617433,,4,1,,BAO_0000224,,,1185,104686,B,H,,,
Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2360,CHEMBL617434,,4,1,,BAO_0000224,,,1185,104686,B,H,,,
Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,Autocuration,,,10116.0,,,2361,CHEMBL617435,,5,1,,BAO_0000224,,Rattus norvegicus,11624,104686,B,D,,,
Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,Autocuration,,,,,,2362,CHEMBL617436,,4,1,,BAO_0000019,,,1344,104686,B,H,,,
Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Autocuration,,,10116.0,,,2363,CHEMBL617437,Striatum,5,1,,BAO_0000019,,Rattus norvegicus,15453,104686,B,D,,2435.0,
"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,,,,,2364,CHEMBL617438,,4,1,,BAO_0000019,,,11662,104686,B,H,,,
"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,,,,,2365,CHEMBL617439,,4,1,,BAO_0000019,,,11662,104686,B,H,,,
Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2366,CHEMBL617440,,4,1,,BAO_0000224,,,10796,104686,B,H,,,
Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2367,CHEMBL617441,,4,1,,BAO_0000224,,,9069,104686,B,H,,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,Autocuration,,,10116.0,,,2368,CHEMBL872918,,5,1,,BAO_0000019,,Rattus norvegicus,8814,104686,B,D,,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,Autocuration,,,10116.0,,,2369,CHEMBL617442,,5,1,,BAO_0000019,,Rattus norvegicus,8908,104686,B,D,,,
Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,,,,,2370,CHEMBL617443,,4,1,,BAO_0000019,,,9098,104686,B,H,,,
Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,Autocuration,,,,,,2371,CHEMBL617444,,4,1,,BAO_0000019,,,9098,104686,B,H,,,
Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,,,,,2372,CHEMBL617445,,4,1,,BAO_0000019,,,9098,104686,B,H,,,
Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,Autocuration,,,,,,2373,CHEMBL617446,,4,1,,BAO_0000019,,,9098,104686,B,H,,,
Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,Autocuration,,,,,,2374,CHEMBL617447,,4,1,,BAO_0000249,,,9098,104686,B,H,,,
Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,Autocuration,,,,,,2375,CHEMBL617448,,4,1,,BAO_0000019,,,9098,104686,B,H,,,
Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,Autocuration,,,,,,2376,CHEMBL617449,,4,1,,BAO_0000019,,,9098,104686,B,H,,,
In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,Autocuration,,,,,,2377,CHEMBL617450,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,Autocuration,,,,,,2378,CHEMBL617451,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,Autocuration,,,,,,2379,CHEMBL617452,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,Autocuration,,,,,,2380,CHEMBL617453,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,Autocuration,,,,,,2381,CHEMBL617660,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,Autocuration,,,,,,2382,CHEMBL617661,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,Autocuration,,,,,,2383,CHEMBL617662,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,Autocuration,,,,,,2384,CHEMBL872919,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,Autocuration,,,,,,2385,CHEMBL617663,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,Autocuration,,,,,,2386,CHEMBL617664,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,Autocuration,,,,,,2387,CHEMBL617665,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,Autocuration,,,,,,2388,CHEMBL617666,,4,1,,BAO_0000019,,,9161,104686,B,H,,,
In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,Autocuration,,,,,,2389,CHEMBL617667,,4,1,,BAO_0000019,,,12094,104686,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,Autocuration,,,,,,2390,CHEMBL617668,,4,1,,BAO_0000249,,,12018,104686,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,Autocuration,,,,,,2391,CHEMBL617669,,4,1,,BAO_0000249,,,10394,104686,B,H,,,
Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2392,CHEMBL617670,,4,1,,BAO_0000224,,,15260,104686,B,H,,,
Inhibitory constant against 5-hydroxytryptamine 2 receptor,Autocuration,,,10116.0,,,2393,CHEMBL617671,,5,1,,BAO_0000224,,Rattus norvegicus,11624,104686,B,D,,,
Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2394,CHEMBL617672,,4,1,,BAO_0000224,,,13654,104686,B,H,,,
Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,Autocuration,,,,,,2395,CHEMBL617673,,4,1,,BAO_0000019,,,9541,104686,B,H,,,
Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,Autocuration,,,,,,2396,CHEMBL617674,,4,1,,BAO_0000224,,,11933,104686,B,H,,,
Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,,,,,2397,CHEMBL617675,,4,1,,BAO_0000019,,,15538,104686,B,H,,,
Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,Autocuration,,,,,,2398,CHEMBL617676,,4,1,,BAO_0000019,,,15538,104686,B,H,,,
Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,Autocuration,,,,,,2399,CHEMBL617677,,4,1,,BAO_0000019,,,15538,104686,B,H,,,
Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2400,CHEMBL617678,,5,1,,BAO_0000019,,,8841,104686,B,D,,,
Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,Autocuration,,,,,,2401,CHEMBL617679,,4,1,,BAO_0000224,,,1455,104686,B,H,,,
Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,Autocuration,,,,,,2402,CHEMBL617680,,4,1,,BAO_0000224,,,1455,104686,B,H,,,
The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,Autocuration,,,,,,2403,CHEMBL617681,,4,1,,BAO_0000019,,,11752,104686,B,H,,,
The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Autocuration,,,,,,2404,CHEMBL617682,Brain,4,1,,BAO_0000221,,,11642,104686,B,H,,955.0,
The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,Autocuration,,,,,,2405,CHEMBL617683,,4,1,,BAO_0000224,,,12092,104686,B,H,,,
Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,Autocuration,,,,,,2406,CHEMBL617684,,4,1,,BAO_0000224,,,3967,104686,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,,10116.0,,,2407,CHEMBL617685,,5,1,,BAO_0000224,,Rattus norvegicus,12771,104686,B,D,,,
The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,Autocuration,,,,,,2408,CHEMBL617686,,4,1,,BAO_0000019,,,11642,104686,B,H,,,
The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,Autocuration,,,,,,2409,CHEMBL617687,,4,1,,BAO_0000224,,,11628,104686,B,H,,,
Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,,,,,2410,CHEMBL617688,,4,1,,BAO_0000224,,,13654,104686,B,H,,,
In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,,2411,CHEMBL617689,,4,1,,BAO_0000019,,,11200,104686,F,H,,,
In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,,,,,2412,CHEMBL617690,,4,1,,BAO_0000019,,,11200,104686,F,H,,,
"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,,,,,2413,CHEMBL617691,,4,1,,BAO_0000218,In vivo,,11200,104686,F,H,,,
"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,,,,,2414,CHEMBL617692,,4,1,,BAO_0000218,In vivo,,11200,104686,F,H,,,
"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,,,,,2415,CHEMBL617693,,4,1,,BAO_0000218,In vivo,,11200,104686,F,H,,,
"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,,,,,2416,CHEMBL617694,,4,1,,BAO_0000218,In vivo,,11200,104686,F,H,,,
Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Expert,,,,,,2417,CHEMBL857985,Brain,8,1,,BAO_0000221,,,15436,12687,B,H,,955.0,
Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,,10116.0,,,2418,CHEMBL617695,,9,1,,BAO_0000019,,Rattus norvegicus,15436,12687,B,D,,,
Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,Autocuration,,,,,,2419,CHEMBL617696,,8,1,,BAO_0000019,,,14025,12687,B,H,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,,2420,CHEMBL617697,,8,1,,BAO_0000357,,,4342,12687,B,H,,,
Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,Expert,,,10116.0,,,2421,CHEMBL617257,,9,1,,BAO_0000019,,Rattus norvegicus,13735,12687,B,D,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,,,10116.0,,,2422,CHEMBL617258,,9,1,,BAO_0000357,,Rattus norvegicus,5816,12687,B,D,,,
Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,Expert,,,,,,2423,CHEMBL617259,,8,1,,BAO_0000019,,,14287,12687,B,H,,,
In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,Autocuration,,,,,,2424,CHEMBL617260,,8,1,,BAO_0000357,,,15738,12687,B,H,,,
In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Expert,,,10116.0,,,2425,CHEMBL617261,,9,1,,BAO_0000357,,Rattus norvegicus,15738,12687,B,D,,,
Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,Autocuration,,,,,,2426,CHEMBL617262,,8,1,,BAO_0000019,,,15026,12687,B,H,,,
Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,,,,,2427,CHEMBL617263,,8,1,,BAO_0000019,,,16647,12687,B,H,,,
Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,Autocuration,,,,,,2428,CHEMBL617264,,8,1,,BAO_0000019,,,16647,12687,B,H,,,
Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Expert,,,10116.0,,,2429,CHEMBL617265,,9,1,,BAO_0000019,,Rattus norvegicus,13345,12687,B,D,,,
Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Autocuration,,,,Membranes,,2430,CHEMBL617266,,8,1,,BAO_0000249,,,1543,12687,B,H,,,
Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,Autocuration,,,,,,2431,CHEMBL617267,,8,1,,BAO_0000019,,,12444,12687,B,H,,,
Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,Expert,,,,,,2432,CHEMBL617268,,8,1,,BAO_0000019,,,16404,12687,B,H,,,
Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Autocuration,,449.0,,,,2433,CHEMBL617269,,8,1,,BAO_0000219,,,16404,12687,B,H,CHO,,
Kinetic inhibition constant evaluated by measuring serotonergic activity,Expert,,,,,,2434,CHEMBL617323,,8,1,,BAO_0000357,,,15577,12687,B,H,,,
Serotonergic activity of the compound.,Autocuration,,,,,,2435,CHEMBL617324,,8,1,,BAO_0000357,,,15577,12687,B,H,,,
Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,Autocuration,,,,,,2436,CHEMBL617325,,8,1,,BAO_0000249,,,2495,12687,B,H,,,
The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,Expert,,,10116.0,,,2437,CHEMBL617326,,9,1,,BAO_0000019,,Rattus norvegicus,15042,12687,B,D,,,
In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,Expert,,,,,,2438,CHEMBL617327,,8,1,,BAO_0000249,,,15026,12687,B,H,,,
Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,10116.0,,,2439,CHEMBL617328,,9,1,,BAO_0000019,,Rattus norvegicus,12919,12687,F,D,,,
Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,10116.0,,,2440,CHEMBL617329,,9,1,,BAO_0000019,,Rattus norvegicus,12919,12687,F,D,,,
Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,10116.0,,,2441,CHEMBL617330,,9,1,,BAO_0000019,,Rattus norvegicus,12919,12687,F,D,,,
The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,,2442,CHEMBL617331,,8,1,,BAO_0000357,,,15194,12687,B,H,,,
The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,Autocuration,,,,,,2443,CHEMBL617332,,8,1,,BAO_0000357,,,15194,12687,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,,,,2444,CHEMBL617333,,8,1,,BAO_0000357,,,4820,107,B,H,,,
Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,Autocuration,,,,,,2445,CHEMBL617334,,8,1,,BAO_0000357,,,6736,107,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,,,,,2446,CHEMBL617335,,8,1,,BAO_0000357,,,5163,107,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,,,,,2447,CHEMBL617336,,8,1,,BAO_0000357,,,5163,107,B,H,,,
Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,Autocuration,,,,,,2448,CHEMBL617337,,8,1,,BAO_0000357,,,6011,107,B,H,,,
Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,Expert,,,9606.0,,,2449,CHEMBL617338,,9,1,,BAO_0000357,,Homo sapiens,14294,107,B,D,,,
Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2450,CHEMBL617339,,8,1,,BAO_0000357,,,5014,107,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,,,,,2451,CHEMBL617340,,8,1,,BAO_0000357,,,17066,107,B,H,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,Autocuration,,,,,,2452,CHEMBL617341,,8,1,,BAO_0000357,,,17515,107,B,H,,,
Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,,2453,CHEMBL617342,,8,1,,BAO_0000357,,,6736,107,B,H,,,
Affinity for 5-hydroxytryptamine 2A receptor,Expert,,,,,,2454,CHEMBL617343,,8,1,,BAO_0000357,,,5163,107,B,H,,,
Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,Expert,,723.0,,,,2455,CHEMBL617344,,8,1,,BAO_0000219,,,16911,107,B,H,NIH3T3,,
Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,,,,,,2456,CHEMBL617345,,8,1,,BAO_0000357,,,6841,107,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,Expert,,,,,,2457,CHEMBL617346,,8,1,,BAO_0000357,,,6119,107,B,H,,,
Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2458,CHEMBL617347,,8,1,,BAO_0000357,,,3962,107,B,H,,,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,,2459,CHEMBL617348,,8,1,,BAO_0000357,,,4373,107,B,H,,,
Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,,2460,CHEMBL617349,,8,1,,BAO_0000357,,,4373,107,B,H,,,
Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2461,CHEMBL617350,,8,1,,BAO_0000019,,,3962,107,F,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,Expert,,,,,,2462,CHEMBL872339,,8,1,,BAO_0000357,,,1633,107,B,H,,,
Binding affinity for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,,2463,CHEMBL617351,,8,1,,BAO_0000357,,,4373,107,B,H,,,
Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,,2464,CHEMBL617352,,8,1,,BAO_0000357,,,6576,107,B,H,,,
Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2465,CHEMBL617353,,8,1,,BAO_0000357,,,4687,107,B,H,,,
Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2466,CHEMBL617354,,8,1,,BAO_0000357,,,16946,107,B,H,,,
Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2467,CHEMBL617355,,8,1,,BAO_0000357,,,14159,107,B,H,,,
In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,Expert,,449.0,10090.0,,,2468,CHEMBL617356,,8,1,,BAO_0000219,,Mus musculus,3032,107,B,H,CHO,,
Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2469,CHEMBL617357,,8,1,,BAO_0000357,,,16655,107,B,H,,,
Binding affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2470,CHEMBL617358,,8,1,,BAO_0000357,,,13964,107,B,H,,,
Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,,2471,CHEMBL617359,,8,1,,BAO_0000357,,,16989,107,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,Autocuration,,,,,,2472,CHEMBL617360,,8,1,,BAO_0000357,,,16117,107,B,H,,,
The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,Autocuration,,,,,,2473,CHEMBL875913,,8,1,,BAO_0000357,,,16700,107,B,H,,,
Affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2474,CHEMBL617361,,8,1,,BAO_0000357,,,3269,107,B,H,,,
Binding affinity against 5-Hydroxytryptamine 2A receptor,Expert,,,9606.0,,,2475,CHEMBL617362,,9,1,,BAO_0000357,,Homo sapiens,1274,107,B,D,,,
Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,,,,,2476,CHEMBL617363,,8,1,,BAO_0000357,,,1317,107,B,H,,,
Tested against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2477,CHEMBL617364,,8,1,,BAO_0000357,,,12146,107,B,H,,,
Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,,,,,2478,CHEMBL617365,,4,1,,BAO_0000224,,,12652,105075,B,H,,,
Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,Autocuration,,,,,,2479,CHEMBL617366,,4,1,,BAO_0000224,,,12652,105075,B,H,,,
Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,Autocuration,,,,,,2480,CHEMBL617367,,4,1,,BAO_0000224,,,12652,105075,B,H,,,
Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,,,,,2481,CHEMBL617368,,4,1,,BAO_0000224,,,12652,105075,B,H,,,
Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),Autocuration,,,,,,2482,CHEMBL617369,,8,1,,BAO_0000357,,,16647,107,B,H,,,
Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,Expert,,722.0,9606.0,,,2483,CHEMBL617370,,9,1,,BAO_0000219,,Homo sapiens,15851,227,B,D,HEK293,,
Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,,449.0,9606.0,,,2484,CHEMBL617371,,9,1,,BAO_0000219,,Homo sapiens,6857,227,F,D,CHO,,
In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),Autocuration,,,,,,2485,CHEMBL617372,,8,1,,BAO_0000357,,,3805,227,B,H,,,
Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,Expert,,,9606.0,,,2486,CHEMBL617373,,9,1,,BAO_0000357,,Homo sapiens,6491,227,B,D,,,
Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,Autocuration,,,,,,2487,CHEMBL617374,,8,1,,BAO_0000019,,,14093,227,F,H,,,
Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,Autocuration,,,,,,2488,CHEMBL617375,,8,1,,BAO_0000019,,,13481,227,F,H,,,
Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,Autocuration,,,,,,2489,CHEMBL617376,,8,1,,BAO_0000019,,,14093,227,F,H,,,
Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,Autocuration,,,,,,2490,CHEMBL617377,,8,1,,BAO_0000019,,,14093,227,F,H,,,
Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,Autocuration,,,,,,2491,CHEMBL617378,,8,1,,BAO_0000019,,,14093,227,F,H,,,
Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,,,,,2492,CHEMBL617379,,8,1,,BAO_0000019,,,13481,227,F,H,,,
Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,Autocuration,,,,,,2493,CHEMBL617380,,8,1,,BAO_0000357,,,14442,227,B,H,,,
Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,Autocuration,,,,,,2494,CHEMBL617381,,8,1,,BAO_0000357,,,14442,227,B,H,,,
Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,,,,,2495,CHEMBL617382,,8,1,,BAO_0000357,,,14442,227,B,H,,,
The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2496,CHEMBL617383,,8,1,,BAO_0000357,,,12369,107,B,H,,,
Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,Expert,,,,,,2497,CHEMBL617384,,8,1,,BAO_0000357,,,12369,107,B,H,,,
Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,Expert,,,,,,2498,CHEMBL617385,,8,1,,BAO_0000357,,,12369,107,B,H,,,
The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,Autocuration,,,,,,2499,CHEMBL617386,,8,1,,BAO_0000019,,,14447,107,B,H,,,
The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,Autocuration,,,,,,2500,CHEMBL617387,,8,1,,BAO_0000019,,,14447,107,B,H,,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,723.0,,,,2501,CHEMBL617388,,8,1,,BAO_0000219,,,17451,107,B,H,NIH3T3,,
Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Autocuration,,449.0,,,,2502,CHEMBL617389,,8,1,,BAO_0000219,,,6857,107,F,H,CHO,,
Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,449.0,9606.0,,,2503,CHEMBL617390,,9,1,,BAO_0000219,,Homo sapiens,6857,107,F,D,CHO,,
Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,Autocuration,,,,,,2504,CHEMBL617391,,4,1,,BAO_0000224,,,5635,104817,B,H,,,
Binding activity radioligand.,Autocuration,,,,,,2505,CHEMBL617392,,8,1,,BAO_0000357,,,12861,107,B,H,,,
Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,,,,2506,CHEMBL617393,,8,1,,BAO_0000019,,,12861,107,B,H,,,
Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Autocuration,,307.0,,,,2507,CHEMBL617394,,8,1,,BAO_0000219,,,5105,107,B,H,L929,,
Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Expert,,307.0,,,,2508,CHEMBL617395,,8,1,,BAO_0000219,,,5104,107,B,H,L929,,
Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,Expert,,307.0,,,,2509,CHEMBL617396,,8,1,,BAO_0000219,,,5105,107,B,H,L929,,
Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,Autocuration,,307.0,,,,2510,CHEMBL617397,,8,1,,BAO_0000219,,,5105,107,B,H,L929,,
Binding affinity against 5-HT2A receptor,Autocuration,,,,,,2511,CHEMBL617398,,8,1,,BAO_0000357,,,5254,107,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2512,CHEMBL617399,,8,1,,BAO_0000357,,,5254,107,B,H,,,
Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,,722.0,,,,2513,CHEMBL617400,,8,1,,BAO_0000219,,,13267,107,B,H,HEK293,,
Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,,722.0,,,,2514,CHEMBL617401,,8,1,,BAO_0000219,,,13267,107,B,H,HEK293,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,Expert,,722.0,9606.0,,,2515,CHEMBL617402,,9,1,,BAO_0000219,,Homo sapiens,14157,107,B,D,HEK293,,
Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,722.0,9606.0,,,2516,CHEMBL617403,,9,1,,BAO_0000219,,Homo sapiens,12936,107,B,D,HEK293,,
Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,Expert,,,,,,2517,CHEMBL617404,,8,1,,BAO_0000357,,,14068,107,B,H,,,
Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,722.0,9606.0,,,2518,CHEMBL857981,,9,1,,BAO_0000219,,Homo sapiens,12936,107,B,D,HEK293,,
Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,722.0,9606.0,,,2519,CHEMBL617405,,9,1,,BAO_0000219,,Homo sapiens,12936,107,B,D,HEK293,,
Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,Expert,,722.0,9606.0,,,2520,CHEMBL617253,,9,1,,BAO_0000219,,Homo sapiens,4540,107,B,D,HEK293,,
Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,Expert,,,,,,2521,CHEMBL617254,,8,1,,BAO_0000357,,,6166,107,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,722.0,,,,2522,CHEMBL617255,,8,1,,BAO_0000219,,,17296,107,B,H,HEK293,,
Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,722.0,,,,2523,CHEMBL617256,,8,1,,BAO_0000219,,,17296,107,B,H,HEK293,,
Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,,722.0,,,,2524,CHEMBL616874,,8,1,,BAO_0000219,,,17296,107,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,Expert,,722.0,9606.0,,,2525,CHEMBL616875,,9,1,,BAO_0000219,,Homo sapiens,15779,107,B,D,HEK293,,
Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,Expert,,722.0,,,,2526,CHEMBL616876,,8,1,,BAO_0000219,,,14391,107,B,H,HEK293,,
"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",Expert,,722.0,,,,2527,CHEMBL616877,,8,1,,BAO_0000219,,,15851,107,B,H,HEK293,,
Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,Expert,,722.0,9606.0,,,2528,CHEMBL616878,,9,1,,BAO_0000219,,Homo sapiens,15851,107,B,D,HEK293,,
Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,Expert,,722.0,,,,2529,CHEMBL616879,,8,1,,BAO_0000219,,,3832,107,B,H,HEK293,,
In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,Expert,,722.0,,,,2530,CHEMBL616880,,8,1,,BAO_0000219,,,3833,107,B,H,HEK293,,
Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,,722.0,9606.0,,,2531,CHEMBL616881,,9,1,,BAO_0000219,,Homo sapiens,12936,107,B,D,HEK293,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,,723.0,,,,2532,CHEMBL616882,,8,1,,BAO_0000219,,,17451,107,B,H,NIH3T3,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,723.0,,,,2533,CHEMBL616883,,8,1,,BAO_0000219,,,17451,107,B,H,NIH3T3,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,723.0,,,,2534,CHEMBL616884,,8,1,,BAO_0000219,,,17451,107,B,H,NIH3T3,,
Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,Autocuration,,722.0,,,,2535,CHEMBL616885,,8,1,,BAO_0000219,,,4199,107,B,H,HEK293,,
Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,Autocuration,,485.0,,,,2536,CHEMBL616886,,8,1,,BAO_0000219,,,1883,107,B,H,CHO-K1,,
Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,Expert,,485.0,,,,2537,CHEMBL616887,,8,1,,BAO_0000219,,,1883,107,B,H,CHO-K1,,
Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,,,9606.0,,,2538,CHEMBL616888,,9,1,,BAO_0000357,,Homo sapiens,14875,107,B,D,,,
Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,Autocuration,,722.0,,,,2539,CHEMBL616889,,8,1,,BAO_0000219,,,15146,107,B,H,HEK293,,
Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,,722.0,,,,2540,CHEMBL616890,,8,1,,BAO_0000219,,,5213,107,B,H,HEK293,,
Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Expert,,449.0,9606.0,,,2541,CHEMBL616891,,9,1,,BAO_0000219,,Homo sapiens,16404,107,B,D,CHO,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,Autocuration,,722.0,,,,2542,CHEMBL616892,,8,1,,BAO_0000219,,,14818,107,B,H,HEK293,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",Autocuration,,722.0,,,,2543,CHEMBL616893,,8,1,,BAO_0000219,,,4829,107,B,H,HEK293,,
Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,Autocuration,,723.0,,,,2544,CHEMBL616894,,8,1,,BAO_0000219,,,12652,10620,F,H,NIH3T3,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,Expert,,723.0,,,,2545,CHEMBL616895,,8,1,,BAO_0000219,,,4682,107,B,H,NIH3T3,,
The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2546,CHEMBL616896,,8,1,,BAO_0000019,,,12652,10620,F,H,,,
Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2547,CHEMBL617099,,8,1,,BAO_0000357,,,4921,10621,B,H,,,
Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,Autocuration,,,,,,2548,CHEMBL617100,,8,1,,BAO_0000357,,,4921,10621,B,H,,,
Binding affinity against rabbit aorta 5-HT2A receptor,Autocuration,,,9986.0,,,2549,CHEMBL884532,,8,1,,BAO_0000357,,Oryctolagus cuniculus,16312,107,B,H,,,
Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,Expert,,,9986.0,,,2550,CHEMBL617101,,8,1,,BAO_0000357,,Oryctolagus cuniculus,14998,107,B,H,,,
Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,Expert,,,9986.0,,,2551,CHEMBL617102,,8,1,,BAO_0000357,,Oryctolagus cuniculus,14025,107,B,H,,,
Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,2552,CHEMBL617103,,8,1,,BAO_0000019,,Oryctolagus cuniculus,13047,107,B,H,,,
The compound was tested for binding affinity against 5-HT2A receptor,Expert,,,9986.0,,,2553,CHEMBL617104,,8,1,,BAO_0000357,,Oryctolagus cuniculus,13047,107,B,H,,,
Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,Autocuration,,485.0,,,,2554,CHEMBL857979,,8,1,,BAO_0000219,,,1883,10576,B,H,CHO-K1,,
Binding affinity analysed towards 5-HT 2A in rat jugular vein,Autocuration,,,,,,2555,CHEMBL857502,,8,1,,BAO_0000019,,,13463,12687,B,H,,,
Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,,,,,2556,CHEMBL617105,,8,1,,BAO_0000019,,,13463,12687,B,H,,,
Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Autocuration,,,,,,2557,CHEMBL858021,Stomach,8,1,,BAO_0000019,,,13463,12687,B,H,,945.0,
Binding affinity for 5-HT 2A in rat stomach fundus,Expert,,,10116.0,,,2558,CHEMBL875910,Stomach,9,1,,BAO_0000019,,Rattus norvegicus,13463,12687,B,D,,945.0,
Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,,,,,2559,CHEMBL617106,,8,1,,BAO_0000019,,,13463,12687,B,H,,,
Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,Expert,,723.0,,,,2560,CHEMBL617107,,8,1,,BAO_0000219,,,16326,12687,B,H,NIH3T3,,
Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2561,CHEMBL617108,,8,1,,BAO_0000019,,,14093,12687,F,H,,,
Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2562,CHEMBL617109,,8,1,,BAO_0000019,,,14093,12687,F,H,,,
Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2563,CHEMBL617110,,8,1,,BAO_0000357,,,15740,12687,B,H,,,
Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,Autocuration,,,,,,2564,CHEMBL617111,,8,1,,BAO_0000357,,,16633,12687,B,H,,,
In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,Expert,,,10116.0,,,2565,CHEMBL617112,,9,1,,BAO_0000019,,Rattus norvegicus,17200,12687,F,D,,,
Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2566,CHEMBL617113,,8,1,,BAO_0000357,,,17133,12687,B,H,,,
Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2567,CHEMBL617114,,8,1,,BAO_0000357,,,17133,12687,B,H,,,
Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2568,CHEMBL617115,,8,1,,BAO_0000357,,,17133,12687,B,H,,,
The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,,,,,2569,CHEMBL617116,,8,1,,BAO_0000219,,,17200,12687,F,H,,,
Efficacy at 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2570,CHEMBL617117,,8,1,,BAO_0000019,,,15363,12687,F,H,,,
In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Autocuration,,,,,,2571,CHEMBL617118,,8,1,,BAO_0000357,,,17200,12687,B,H,,,
In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Expert,,,10116.0,,,2572,CHEMBL617119,,9,1,,BAO_0000357,,Rattus norvegicus,17200,12687,B,D,,,
In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),Expert,,,10116.0,,,2573,CHEMBL617120,,9,1,,BAO_0000357,,Rattus norvegicus,17200,12687,B,D,,,
The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Expert,,,10116.0,,,2574,CHEMBL617121,,9,1,,BAO_0000219,,Rattus norvegicus,17200,12687,F,D,,,
The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,,,,,2575,CHEMBL617122,,8,1,,BAO_0000219,,,17200,12687,F,H,,,
Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2576,CHEMBL617123,,8,1,,BAO_0000019,,,17211,12687,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,,,,,2577,CHEMBL617124,,8,1,,BAO_0000019,,,17331,12687,B,H,,,
Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,Expert,,,,,,2578,CHEMBL617600,,8,1,,BAO_0000249,,,13565,12687,B,H,,,
Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,Expert,,,,,,2579,CHEMBL617601,,8,1,,BAO_0000357,,,13730,12687,B,H,,,
In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,Expert,,,,,,2580,CHEMBL882923,,8,1,,BAO_0000019,,,12416,12687,B,H,,,
Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2581,CHEMBL617602,,8,1,,BAO_0000357,,,15295,12687,B,H,,,
Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,Autocuration,,,,,,2582,CHEMBL617603,,8,1,,BAO_0000019,,,1742,12687,B,H,,,
Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2583,CHEMBL617604,,8,1,,BAO_0000357,,,15295,12687,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,Expert,,,,,,2584,CHEMBL617605,,8,1,,BAO_0000019,,,14970,12687,B,H,,,
In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,Expert,,,,,,2585,CHEMBL617606,,8,1,,BAO_0000019,,,16693,12687,B,H,,,
Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Expert,,,10116.0,,,2586,CHEMBL617607,,9,1,,BAO_0000019,,Rattus norvegicus,14776,12687,B,D,,,
In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,,2587,CHEMBL617455,,8,1,,BAO_0000249,,,14286,12687,B,H,,,
In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,,,10116.0,,,2588,CHEMBL617456,,9,1,,BAO_0000019,,Rattus norvegicus,17200,12687,B,D,,,
Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),Expert,,,,,,2589,CHEMBL617457,,8,1,,BAO_0000357,,,15306,12687,B,H,,,
Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,Expert,,,10116.0,,,2590,CHEMBL617458,,9,1,,BAO_0000357,,Rattus norvegicus,14178,12687,B,D,,,
Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Expert,,,10116.0,,,2591,CHEMBL617459,,9,1,,BAO_0000019,,Rattus norvegicus,14229,12687,B,D,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,Expert,,,,,,2592,CHEMBL617460,,8,1,,BAO_0000357,,,12884,12687,B,H,,,
"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",Expert,,,,,,2593,CHEMBL617461,,8,1,,BAO_0000357,,,13149,12687,B,H,,,
Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,Expert,,,10116.0,,,2594,CHEMBL617462,,9,1,,BAO_0000019,,Rattus norvegicus,15295,12687,B,D,,,
Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,Autocuration,,,,,,2595,CHEMBL617463,,8,1,,BAO_0000357,,,15740,12687,B,H,,,
"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",Autocuration,,,,,,2596,CHEMBL617464,,8,1,,BAO_0000019,,,15185,12687,B,H,,,
"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",Autocuration,,,,,,2597,CHEMBL617465,,8,1,,BAO_0000019,,,15185,12687,B,H,,,
Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,Expert,,,,,,2598,CHEMBL617466,,8,1,,BAO_0000019,,,17529,12687,B,H,,,
Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,,,,,2599,CHEMBL617467,,8,1,,BAO_0000019,,,14826,12687,B,H,,,
Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,Expert,,,,,,2600,CHEMBL617468,,8,1,,BAO_0000019,,,17211,12687,B,H,,,
Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,,,,,2601,CHEMBL617469,,8,1,,BAO_0000019,,,14826,12687,B,H,,,
Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2602,CHEMBL617470,,8,1,,BAO_0000019,,,14093,12687,B,H,,,
Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,Autocuration,,,,,,2603,CHEMBL617471,,8,1,,BAO_0000019,,,14093,12687,B,H,,,
Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,Expert,,723.0,,,,2604,CHEMBL617472,,8,1,,BAO_0000219,,,13246,12687,B,H,NIH3T3,,
Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,Expert,,,,,,2605,CHEMBL617473,,8,1,,BAO_0000357,,,13246,12687,B,H,,,
Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,,10116.0,,,2606,CHEMBL617474,,9,1,,BAO_0000019,,Rattus norvegicus,15436,12687,B,D,,,
Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,,10116.0,,,2607,CHEMBL617475,,9,1,,BAO_0000019,,Rattus norvegicus,15436,12687,B,D,,,
Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Autocuration,,,,,,2608,CHEMBL617476,Brain,8,1,,BAO_0000221,,,14442,12687,B,H,,955.0,
Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,Expert,,,,,,2609,CHEMBL617477,,8,1,,BAO_0000357,,,12457,12687,B,H,,,
Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,Expert,,723.0,,,,2610,CHEMBL617478,,8,1,,BAO_0000219,,,12457,12687,B,H,NIH3T3,,
"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",Autocuration,,,,,,2611,CHEMBL617479,,8,1,,BAO_0000221,,,14755,12687,F,H,,,
Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,Autocuration,,,,,,2612,CHEMBL617480,,8,1,,BAO_0000357,,,4707,12687,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor,Expert,,,,,,2613,CHEMBL617481,,8,1,,BAO_0000357,,,13297,12687,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,,,,,2614,CHEMBL617482,,8,1,,BAO_0000019,,,17331,12687,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,Autocuration,,,,,,2615,CHEMBL617483,,8,1,,BAO_0000019,,,4664,12687,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,,2616,CHEMBL621528,,8,1,,BAO_0000357,,,16633,12687,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,Expert,,723.0,10116.0,,,2617,CHEMBL621529,,9,1,,BAO_0000219,,Rattus norvegicus,4664,12687,B,D,NIH3T3,,
Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,,,,,2618,CHEMBL621530,,8,1,,BAO_0000357,,,16133,12687,B,H,,,
Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Expert,,,,,,2619,CHEMBL621531,,8,1,,BAO_0000357,,,16133,12687,B,H,,,
Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,Expert,,,10116.0,,,2620,CHEMBL621532,,9,1,,BAO_0000019,,Rattus norvegicus,14060,12687,B,D,,,
Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,,,,,2621,CHEMBL621533,,8,1,,BAO_0000357,,,16326,12687,B,H,,,
Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,,449.0,,,,2622,CHEMBL621534,,8,1,,BAO_0000219,,,16659,12687,B,H,CHO,,
Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,Autocuration,,,,,,2623,CHEMBL621535,,8,1,,BAO_0000019,,,14776,12687,B,H,,,
Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,,,,,2624,CHEMBL621536,,8,1,,BAO_0000357,,,13481,12687,B,H,,,
Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2625,CHEMBL621537,,8,1,,BAO_0000357,,,17386,12687,B,H,,,
Binding affinity for 5-hydroxytryptamine 2A receptor,Expert,,,10116.0,,,2626,CHEMBL621538,,9,1,,BAO_0000357,,Rattus norvegicus,6611,12687,B,D,,,
Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,Autocuration,,,,,,2627,CHEMBL621539,,8,1,,BAO_0000019,,,14423,12687,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,Autocuration,,,,,,2628,CHEMBL621540,,8,1,,BAO_0000019,,,15412,12687,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,Autocuration,,,,,,2629,CHEMBL621541,,8,1,,BAO_0000019,,,15412,12687,B,H,,,
Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,Autocuration,,,,,,2630,CHEMBL621542,,8,1,,BAO_0000019,,,6238,12687,B,H,,,
Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,Expert,,,,,,2631,CHEMBL621543,,8,1,,BAO_0000357,,,6648,12687,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,Expert,,,,,,2632,CHEMBL621544,,8,1,,BAO_0000357,,,5667,12687,B,H,,,
Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,Expert,,,10116.0,,,2633,CHEMBL621545,,9,1,,BAO_0000357,,Rattus norvegicus,6611,12687,B,D,,,
Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,,2634,CHEMBL621546,,8,1,,BAO_0000357,,,13481,12687,B,H,,,
Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,Autocuration,,,,,,2635,CHEMBL621547,,8,1,,BAO_0000357,,,13481,12687,B,H,,,
Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,Expert,,723.0,,,,2636,CHEMBL618692,,8,1,,BAO_0000219,,,15558,12687,B,H,NIH3T3,,
Binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2637,CHEMBL618693,,8,1,,BAO_0000357,,,6013,12687,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,,,,,2638,CHEMBL872922,,8,1,,BAO_0000357,,,16633,12687,B,H,,,
Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,Autocuration,,,,,,2639,CHEMBL618694,,8,1,,BAO_0000357,,,6013,12687,B,H,,,
Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,Expert,,,10116.0,,,2640,CHEMBL618695,,9,1,,BAO_0000357,,Rattus norvegicus,6013,12687,B,D,,,
Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,Autocuration,,,,,,2641,CHEMBL618696,,8,1,,BAO_0000357,,,6013,12687,B,H,,,
Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,Expert,,,,,,2642,CHEMBL618697,,8,1,,BAO_0000357,,,6013,12687,B,H,,,
Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,Autocuration,,,,,,2643,CHEMBL618892,,8,1,,BAO_0000357,,,6013,12687,B,H,,,
Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,Autocuration,,,,,,2644,CHEMBL618893,,8,1,,BAO_0000357,,,6013,12687,B,H,,,
Binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2645,CHEMBL618894,,8,1,,BAO_0000357,,,16293,12687,B,H,,,
Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,Expert,,723.0,,,,2646,CHEMBL618895,,8,1,,BAO_0000219,,,17175,12687,B,H,NIH3T3,,
Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,,,10116.0,,,2647,CHEMBL618896,,9,1,,BAO_0000357,,Rattus norvegicus,13278,12687,B,D,,,
Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,,,,,2648,CHEMBL618897,Caudate-putamen,8,1,,BAO_0000019,,,3682,12687,B,H,,5383.0,
Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,Autocuration,,,,,,2649,CHEMBL618898,,8,1,,BAO_0000357,,,2014,12687,B,H,,,
Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,Autocuration,,,,,,2650,CHEMBL618899,,8,1,,BAO_0000357,,,2014,12687,B,H,,,
Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,Autocuration,,,,,,2651,CHEMBL618900,,8,1,,BAO_0000357,,,4932,12687,B,H,,,
Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,Autocuration,,,,,,2652,CHEMBL618901,,8,1,,BAO_0000019,,,4932,12687,B,H,,,
Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2653,CHEMBL618902,,8,1,,BAO_0000357,,,3935,12687,B,H,,,
Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Expert,,,10116.0,,,2654,CHEMBL618903,Hippocampus,9,1,,BAO_0000221,,Rattus norvegicus,5432,12687,B,D,,10000000.0,
Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2655,CHEMBL618904,,8,1,,BAO_0000357,,,15818,12687,B,H,,,
Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,Autocuration,,,,,,2656,CHEMBL618905,,8,1,,BAO_0000357,,,13672,12687,B,H,,,
Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,Autocuration,,,,,,2657,CHEMBL618906,,8,1,,BAO_0000357,,,13672,12687,B,H,,,
Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,Expert,,723.0,,,,2658,CHEMBL618907,,8,1,,BAO_0000219,,,14749,12687,B,H,NIH3T3,,
Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,Autocuration,,,,,,2659,CHEMBL618908,,8,1,,BAO_0000019,,,13462,12687,B,H,,,
Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2660,CHEMBL617909,,8,1,,BAO_0000357,,,15740,12687,B,H,,,
Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,,,,,2661,CHEMBL617910,,8,1,,BAO_0000019,,,16647,12687,B,H,,,
In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Autocuration,,,,,,2662,CHEMBL617911,Brain,8,1,,BAO_0000221,,,13345,12687,B,H,,955.0,
In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,,2663,CHEMBL872923,,8,1,,BAO_0000249,,,16740,12687,B,H,,,
In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,,2664,CHEMBL617912,,8,1,,BAO_0000249,,,16740,12687,B,H,,,
In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,Expert,,,10116.0,,,2665,CHEMBL617913,,9,1,,BAO_0000019,,Rattus norvegicus,15535,12687,B,D,,,
In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Expert,,,,,,2666,CHEMBL617914,,8,1,,BAO_0000249,,,16740,12687,B,H,,,
In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,,2667,CHEMBL617915,,8,1,,BAO_0000249,,,16740,12687,B,H,,,
In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,,,,,2668,CHEMBL617916,,8,1,,BAO_0000249,,,16740,12687,B,H,,,
Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,Expert,,,10116.0,,,2669,CHEMBL617917,,9,1,,BAO_0000019,,Rattus norvegicus,4795,12687,B,D,,,
In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,Expert,,,,,,2670,CHEMBL617918,,8,1,,BAO_0000019,,,8,12687,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,Autocuration,,,,,,2671,CHEMBL617919,,8,1,,BAO_0000019,,,8,12687,B,H,,,
In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,,,10116.0,,,2672,CHEMBL617920,,9,1,,BAO_0000019,,Rattus norvegicus,17200,12687,B,D,,,
Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Expert,,,10116.0,,,2673,CHEMBL617921,,9,1,,BAO_0000019,,Rattus norvegicus,2148,12687,B,D,,,
"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Expert,,,10116.0,,,2674,CHEMBL617922,,5,1,,BAO_0000224,,Rattus norvegicus,13345,105102,B,D,,,
Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,,,,,2675,CHEMBL617923,,8,1,,BAO_0000357,,,5088,12687,B,H,,,
Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,,,,,2676,CHEMBL617924,,8,1,,BAO_0000357,,,5088,12687,B,H,,,
Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,Autocuration,,,,,,2677,CHEMBL617925,,8,1,,BAO_0000357,,,17133,12687,B,H,,,
In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,Expert,,,10116.0,,,2678,CHEMBL617926,,9,1,,BAO_0000357,,Rattus norvegicus,17133,12687,B,D,,,
The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,Autocuration,,,,,,2679,CHEMBL617927,,8,1,,BAO_0000357,,,16532,12687,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,,,,,2680,CHEMBL617928,,8,1,,BAO_0000357,,,15086,12687,B,H,,,
Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,,10116.0,,,2681,CHEMBL617929,,9,1,,BAO_0000019,,Rattus norvegicus,2309,12687,B,D,,,
Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,Expert,,,,,,2682,CHEMBL617930,,8,1,,BAO_0000019,,,12953,12687,B,H,,,
The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,Autocuration,,,,,,2683,CHEMBL617931,,8,1,,BAO_0000019,,,12953,12687,B,H,,,
The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,Autocuration,,,,,,2684,CHEMBL617932,,8,1,,BAO_0000019,,,12953,12687,B,H,,,
Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,Autocuration,,449.0,,,,2685,CHEMBL617933,,8,1,,BAO_0000219,,,16659,12687,B,H,CHO,,
In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,,,,,2686,CHEMBL617934,,8,1,,BAO_0000019,,,16740,12687,B,H,,,
In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,,,,,2687,CHEMBL617935,,8,1,,BAO_0000019,,,16740,12687,B,H,,,
Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,Autocuration,,,,,,2688,CHEMBL617936,,8,1,,BAO_0000357,,,17133,12687,B,H,,,
Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,Autocuration,,,,,,2689,CHEMBL617937,,8,1,,BAO_0000019,,,17211,12687,B,H,,,
Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,Autocuration,,,,,,2690,CHEMBL617938,,8,1,,BAO_0000019,,,17331,12687,B,H,,,
Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,Autocuration,,,,,,2691,CHEMBL617939,,8,1,,BAO_0000218,,,16633,12687,B,H,,,
Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,Autocuration,,,,,,2692,CHEMBL617940,,8,1,,BAO_0000218,,,16633,12687,B,H,,,
Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,Autocuration,,,,,,2693,CHEMBL617941,,8,1,,BAO_0000218,,,16633,12687,B,H,,,
Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,Expert,,,,,,2694,CHEMBL617942,,8,1,,BAO_0000357,,,15026,12687,B,H,,,
Ratio of pKi of 5-HT2A to that of D2 receptor,Expert,,,,,,2695,CHEMBL617943,,8,1,,BAO_0000357,,,15026,12687,B,H,,,
Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,,,,,2696,CHEMBL617944,,4,1,,BAO_0000224,,,16404,105093,B,H,,,
Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,,,,,2697,CHEMBL617945,,4,1,,BAO_0000224,,,16404,105093,B,H,,,
Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,Expert,,,,,,2698,CHEMBL617946,,4,1,,BAO_0000224,,,16404,105075,B,H,,,
Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,Autocuration,,,,,,2699,CHEMBL617947,,8,1,,BAO_0000357,,,16404,12687,B,H,,,
Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,Expert,,,,,,2700,CHEMBL617948,,8,1,,BAO_0000357,,,16326,12687,B,H,,,
Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,Autocuration,,,,,,2701,CHEMBL858116,,8,1,,BAO_0000019,,,15847,12687,F,H,,,
Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,Autocuration,,,,,,2702,CHEMBL617949,,8,1,,BAO_0000019,,,15847,12687,F,H,,,
Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,Autocuration,,,,,,2703,CHEMBL617950,,8,1,,BAO_0000019,,,15329,12687,F,H,,,
Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Expert,,,,,,2704,CHEMBL617951,Thoracic aorta,8,1,,BAO_0000019,,,16404,12687,F,H,,1515.0,
Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Expert,,,,,,2705,CHEMBL617952,Thoracic aorta,8,1,,BAO_0000019,,,16404,12687,F,H,,1515.0,
Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Autocuration,,,,,,2706,CHEMBL617953,Thoracic aorta,8,1,,BAO_0000019,,,16404,12687,F,H,,1515.0,
Binding activity radioligand.,Autocuration,,,,,,2707,CHEMBL617954,,8,1,,BAO_0000357,,,12861,12687,B,H,,,
Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,,,,,2708,CHEMBL617955,,8,1,,BAO_0000019,,,12861,12687,B,H,,,
Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,,,,,2709,CHEMBL857071,,8,1,,BAO_0000019,,,12861,12687,B,H,,,
Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,Expert,,,,,,2710,CHEMBL617270,,8,1,,BAO_0000019,,,12490,12687,B,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,Autocuration,,339.0,,,,2711,CHEMBL617271,,8,1,,BAO_0000219,,,12827,12687,B,H,N1E-115,,
Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,Autocuration,,339.0,,,,2712,CHEMBL617272,,8,1,,BAO_0000219,,,12827,12687,B,H,N1E-115,,
Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,Autocuration,,,,,,2713,CHEMBL617273,,8,1,,BAO_0000019,,,12918,12687,B,H,,,
Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,Expert,,,10116.0,,,2714,CHEMBL617274,,9,1,,BAO_0000019,,Rattus norvegicus,12919,12687,F,D,,,
Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2715,CHEMBL617275,,8,1,,BAO_0000357,,,17723,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2716,CHEMBL617276,,8,1,,BAO_0000357,,,6013,108,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2717,CHEMBL617277,,8,1,,BAO_0000357,,,16293,108,B,H,,,
Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,,,,,2718,CHEMBL617278,,8,1,,BAO_0000019,,,3857,108,B,H,,,
Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,Expert,,,,,,2719,CHEMBL617279,,8,1,,BAO_0000019,,,3857,108,B,H,,,
Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,,,,,2720,CHEMBL617280,,8,1,,BAO_0000019,,,3857,108,B,H,,,
Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2721,CHEMBL617281,,8,1,,BAO_0000357,,,15363,108,B,H,,,
Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2722,CHEMBL617282,,8,1,,BAO_0000357,,,15363,108,B,H,,,
Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,Expert,,,,,,2723,CHEMBL617283,,8,1,,BAO_0000019,,,16441,108,B,H,,,
Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,Expert,,,,,,2724,CHEMBL617284,,8,1,,BAO_0000019,,,16441,108,B,H,,,
In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,Autocuration,,722.0,,,,2725,CHEMBL617285,,8,1,,BAO_0000219,,,4176,108,B,H,HEK293,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2726,CHEMBL617286,,8,1,,BAO_0000019,,,17085,108,B,H,,,
Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,Expert,,,9606.0,,,2727,CHEMBL617287,,9,1,,BAO_0000357,,Homo sapiens,17200,108,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 2C receptor.,Expert,,,,,,2728,CHEMBL617288,,8,1,,BAO_0000357,,,5088,108,B,H,,,
Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,Autocuration,,,,,,2729,CHEMBL617289,,8,1,,BAO_0000357,,,5088,108,B,H,,,
Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,,2730,CHEMBL872917,,8,1,,BAO_0000357,,,5088,108,B,H,,,
Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,,,,,2731,CHEMBL617290,,8,1,,BAO_0000357,,,5088,108,B,H,,,
Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Autocuration,,449.0,,,,2732,CHEMBL617291,,8,1,,BAO_0000219,,,16659,108,B,H,CHO,,
Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,Autocuration,,449.0,,,,2733,CHEMBL617292,,8,1,,BAO_0000219,,,16659,108,B,H,CHO,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,,723.0,,,,2734,CHEMBL617293,,8,1,,BAO_0000219,,,17451,108,B,H,NIH3T3,,
Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,449.0,9606.0,,,2735,CHEMBL617294,,9,1,,BAO_0000219,,Homo sapiens,6857,108,F,D,CHO,,
Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Expert,,,,,,2736,CHEMBL617295,,8,1,,BAO_0000019,,,3857,108,B,H,,,
Binding activity radioligand.,Autocuration,,,,,,2737,CHEMBL617296,,8,1,,BAO_0000357,,,12861,108,B,H,,,
Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,,,,,2738,CHEMBL617297,,8,1,,BAO_0000019,,,12861,108,B,H,,,
Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,Expert,,449.0,,,,2739,CHEMBL617298,,8,1,,BAO_0000219,,,5104,108,B,H,CHO,,
Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,Expert,,449.0,,,,2740,CHEMBL617299,,8,1,,BAO_0000219,,,5105,108,B,H,CHO,,
Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,Autocuration,,449.0,,,,2741,CHEMBL617300,,8,1,,BAO_0000219,,,5105,108,B,H,CHO,,
Binding affinity against 5-HT2C receptor,Autocuration,,,,,,2742,CHEMBL617454,,8,1,,BAO_0000357,,,5254,108,B,H,,,
Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,,722.0,,,,2743,CHEMBL617505,,8,1,,BAO_0000219,,,13267,108,B,H,HEK293,,
Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,Expert,,722.0,9606.0,,,2744,CHEMBL617506,,9,1,,BAO_0000219,,Homo sapiens,14157,108,B,D,HEK293,,
Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,,722.0,9606.0,,,2745,CHEMBL617507,,9,1,,BAO_0000219,,Homo sapiens,12936,108,B,D,HEK293,,
Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,Expert,,,,,,2746,CHEMBL617508,,8,1,,BAO_0000357,,,14068,108,B,H,,,
Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,,722.0,9606.0,,,2747,CHEMBL857982,,9,1,,BAO_0000219,,Homo sapiens,12936,108,B,D,HEK293,,
Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,Expert,,722.0,9606.0,,,2748,CHEMBL617509,,9,1,,BAO_0000219,,Homo sapiens,4540,108,B,D,HEK293,,
Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,Expert,,722.0,9606.0,,,2749,CHEMBL617510,,9,1,,BAO_0000219,,Homo sapiens,4540,108,B,D,HEK293,,
Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,,2750,CHEMBL617511,,8,1,,BAO_0000357,,,6166,108,B,H,,,
Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,,722.0,,,,2751,CHEMBL617512,,8,1,,BAO_0000219,,,17296,108,B,H,HEK293,,
Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,,722.0,,,,2752,CHEMBL617749,,8,1,,BAO_0000219,,,17296,108,B,H,HEK293,,
Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,722.0,,,,2753,CHEMBL617750,,8,1,,BAO_0000219,,,15779,108,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,722.0,,,,2754,CHEMBL617751,,8,1,,BAO_0000219,,,15779,108,B,H,HEK293,,
Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,Expert,,722.0,,,,2755,CHEMBL617752,,8,1,,BAO_0000219,,,14391,108,B,H,HEK293,,
"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",Autocuration,,722.0,,,,2756,CHEMBL617753,,8,1,,BAO_0000219,,,15779,108,B,H,HEK293,,
"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",Expert,,722.0,,,,2757,CHEMBL617754,,8,1,,BAO_0000219,,,15851,108,B,H,HEK293,,
Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,Expert,,722.0,9606.0,,,2758,CHEMBL617755,,9,1,,BAO_0000219,,Homo sapiens,15851,108,B,D,HEK293,,
"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",Autocuration,,722.0,,,,2759,CHEMBL617756,,8,1,,BAO_0000219,,,15779,108,B,H,HEK293,,
Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,Expert,,722.0,,,,2760,CHEMBL617757,,8,1,,BAO_0000219,,,3832,108,B,H,HEK293,,
In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,Expert,,722.0,,,,2761,CHEMBL617758,,8,1,,BAO_0000219,,,3833,108,B,H,HEK293,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,,723.0,,,,2762,CHEMBL617759,,8,1,,BAO_0000219,,,17451,108,B,H,NIH3T3,,
Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,Autocuration,,722.0,,,,2763,CHEMBL617760,,8,1,,BAO_0000219,,,4199,108,B,H,HEK293,,
Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,Expert,,485.0,,,,2764,CHEMBL617761,,8,1,,BAO_0000219,,,1883,108,B,H,CHO-K1,,
Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,9606.0,,,2765,CHEMBL617762,,9,1,,BAO_0000357,,Homo sapiens,4321,108,B,D,,,
Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2766,CHEMBL617763,,8,1,,BAO_0000357,,,14875,108,B,H,,,
Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,Autocuration,,722.0,,,,2767,CHEMBL857983,,8,1,,BAO_0000219,,,15146,108,B,H,HEK293,,
Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,Autocuration,,722.0,,,,2768,CHEMBL617764,,8,1,,BAO_0000219,,,5213,108,B,H,HEK293,,
Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,Autocuration,,308.0,,,,2769,CHEMBL617765,,8,1,,BAO_0000219,,,16404,108,B,H,HeLa,,
Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,Autocuration,,,,,,2770,CHEMBL617766,,8,1,,BAO_0000019,,,13267,108,F,H,,,
The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Autocuration,,,,,,2771,CHEMBL617767,Hippocampus,8,1,,BAO_0000221,,,13267,108,F,H,,10000000.0,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,Autocuration,,722.0,,,,2772,CHEMBL617768,,8,1,,BAO_0000219,,,14818,108,B,H,HEK293,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",Autocuration,,722.0,,,,2773,CHEMBL617769,,8,1,,BAO_0000219,,,4829,108,B,H,HEK293,,
Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,Autocuration,,,,,,2774,CHEMBL858023,,8,1,,BAO_0000357,,,13463,11864,B,H,,,
Binding affinity analysed on 5-HT 2C in rat stomach fundus,Autocuration,,,,,,2775,CHEMBL617770,Stomach,8,1,,BAO_0000019,,,13463,11864,B,H,,945.0,
Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Autocuration,,,,,,2776,CHEMBL617771,Stomach,8,1,,BAO_0000019,,,13463,11864,B,H,,945.0,
Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,Autocuration,,625.0,,,,2777,CHEMBL617772,,8,1,,BAO_0000219,,,12652,11864,F,H,A9,,
Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,,723.0,,,,2778,CHEMBL617773,,8,1,,BAO_0000219,,,4682,11864,B,H,NIH3T3,,
Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,Autocuration,,723.0,,,,2779,CHEMBL617850,,8,1,,BAO_0000219,,,4682,11864,B,H,NIH3T3,,
Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,,723.0,,,,2780,CHEMBL617851,,8,1,,BAO_0000219,,,4682,11864,B,H,NIH3T3,,
The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2781,CHEMBL617852,,8,1,,BAO_0000019,,,12652,11864,F,H,,,
Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Autocuration,,,10090.0,,,2782,CHEMBL858024,Stomach,8,1,,BAO_0000019,,Mus musculus,13463,12689,B,H,,945.0,
Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Expert,,,10116.0,,,2783,CHEMBL617853,Stomach,9,1,,BAO_0000019,,Rattus norvegicus,13463,12689,B,D,,945.0,
Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,Expert,,,,,,2784,CHEMBL617854,,8,1,,BAO_0000357,,,13969,108,B,H,,,
Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,9823.0,,,2785,CHEMBL873477,,8,1,,BAO_0000357,,Sus scrofa,13392,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,,,,,2786,CHEMBL617855,,8,1,,BAO_0000357,,,13392,108,B,H,,,
Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,Expert,,,,,,2787,CHEMBL617856,,8,1,,BAO_0000019,,,14430,108,B,H,,,
Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,Autocuration,,,,,,2788,CHEMBL617857,,8,1,,BAO_0000019,,,1742,108,B,H,,,
In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,Autocuration,,,,,,2789,CHEMBL617858,,8,1,,BAO_0000249,,,14286,108,B,H,,,
Binding affinity towards pig 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2790,CHEMBL617859,,8,1,,BAO_0000357,,,5619,108,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2791,CHEMBL617860,,8,1,,BAO_0000357,,,15086,108,B,H,,,
Binding activity radioligand.,Autocuration,,,,,,2792,CHEMBL617861,,8,1,,BAO_0000357,,,12861,108,B,H,,,
Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,,,,,2793,CHEMBL617862,,8,1,,BAO_0000019,,,12861,108,B,H,,,
Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,,,,,2794,CHEMBL617863,,8,1,,BAO_0000019,,,12861,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,Autocuration,,,,,,2795,CHEMBL617864,,8,1,,BAO_0000249,,,12827,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,Autocuration,,,,,,2796,CHEMBL617649,,8,1,,BAO_0000249,,,12827,108,B,H,,,
Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,,,9823.0,,,2797,CHEMBL617650,,8,1,,BAO_0000019,,Sus scrofa,12919,108,F,H,,,
Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,,,9823.0,,,2798,CHEMBL617651,,8,1,,BAO_0000019,,Sus scrofa,12919,108,F,H,,,
In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,Autocuration,,,9823.0,,,2799,CHEMBL617652,,8,1,,BAO_0000357,,Sus scrofa,16429,108,B,H,,,
In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,Autocuration,,,9823.0,,,2800,CHEMBL857072,,8,1,,BAO_0000019,,Sus scrofa,773,108,B,H,,,
Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,Autocuration,,,9823.0,,,2801,CHEMBL617653,,8,1,,BAO_0000357,,Sus scrofa,5033,108,B,H,,,
Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Autocuration,,,,,,2802,CHEMBL617654,,8,1,,BAO_0000019,,,12861,12687,B,H,,,
Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2803,CHEMBL617655,,8,1,,BAO_0000019,,,14093,12689,F,H,,,
Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,Expert,,,,,,2804,CHEMBL617656,,8,1,,BAO_0000357,,,14970,12689,B,H,,,
Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,Autocuration,,,,,,2805,CHEMBL617657,,8,1,,BAO_0000357,,,14970,12689,B,H,,,
Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,Autocuration,,,,,,2806,CHEMBL617658,,8,1,,BAO_0000357,,,14970,12689,B,H,,,
Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,Expert,,,10116.0,,,2807,CHEMBL617659,,9,1,,BAO_0000357,,Rattus norvegicus,14178,12689,B,D,,,
Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,Expert,,,10116.0,,,2808,CHEMBL617838,,9,1,,BAO_0000357,,Rattus norvegicus,14178,12689,B,D,,,
Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Expert,,,10116.0,Brain membranes,,2809,CHEMBL617839,,9,1,,BAO_0000249,,Rattus norvegicus,14229,12689,B,D,,,
The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,Autocuration,,,,,,2810,CHEMBL617840,,8,1,,BAO_0000357,,,16532,12689,B,H,,,
Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,Autocuration,,,,,,2811,CHEMBL617841,,8,1,,BAO_0000019,,,14826,12689,B,H,,,
Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,Autocuration,,,,,,2812,CHEMBL875915,,8,1,,BAO_0000019,,,17211,12689,B,H,,,
Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,Expert,,,,,,2813,CHEMBL617842,,8,1,,BAO_0000219,In vitro,,17211,12689,B,H,,,
Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,Expert,,723.0,,,,2814,CHEMBL617843,,8,1,,BAO_0000219,,,13246,12689,B,H,NIH3T3,,
Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,Expert,,,,,,2815,CHEMBL617844,,8,1,,BAO_0000357,,,13246,12689,B,H,,,
Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,Expert,,,,,,2816,CHEMBL617845,,8,1,,BAO_0000357,,,12457,12689,B,H,,,
Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,Expert,,723.0,,,,2817,CHEMBL617846,,8,1,,BAO_0000219,,,12457,12689,B,H,NIH3T3,,
Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,,,,,2818,CHEMBL617847,,8,1,,BAO_0000357,,,4707,12689,B,H,,,
Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,,,,2819,CHEMBL617848,,8,1,,BAO_0000357,,,13297,12689,B,H,,,
Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,,,,2820,CHEMBL617849,,8,1,,BAO_0000357,,,16633,12689,B,H,,,
Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Expert,,,,,,2821,CHEMBL621507,,8,1,,BAO_0000357,,,16133,12689,B,H,,,
Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,Expert,,,,,,2822,CHEMBL621508,,8,1,,BAO_0000357,,,16326,12689,B,H,,,
Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,Autocuration,,,,,,2823,CHEMBL621509,,8,1,,BAO_0000019,,,14423,12689,B,H,,,
Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,Autocuration,,,,,,2824,CHEMBL621510,,8,1,,BAO_0000019,,,15412,12689,B,H,,,
Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,Autocuration,,,,,,2825,CHEMBL621511,,8,1,,BAO_0000019,,,15412,12689,B,H,,,
Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,Expert,,625.0,,,,2826,CHEMBL621512,,8,1,,BAO_0000219,,,15558,12689,B,H,A9,,
Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,,,,2827,CHEMBL621513,,8,1,,BAO_0000357,,,16633,12689,B,H,,,
Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,Expert,,,,,,2828,CHEMBL621514,,8,1,,BAO_0000357,,,6013,12689,B,H,,,
Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,Expert,,,,,,2829,CHEMBL621515,,8,1,,BAO_0000219,In vitro,,17175,12689,B,H,,,
Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,Autocuration,,,,,,2830,CHEMBL621516,,8,1,,BAO_0000219,,,12469,12689,B,H,,,
Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,,,,,2831,CHEMBL621517,Caudate-putamen,8,1,,BAO_0000019,,,3682,12689,B,H,,5383.0,
Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,Autocuration,,,,,,2832,CHEMBL621518,,8,1,,BAO_0000357,,,4932,12689,B,H,,,
Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,Autocuration,,,,,,2833,CHEMBL621519,,8,1,,BAO_0000019,,,4932,12689,B,H,,,
Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2834,CHEMBL621520,,8,1,,BAO_0000357,,,3935,12689,B,H,,,
Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2835,CHEMBL621521,,8,1,,BAO_0000357,,,15818,12689,B,H,,,
Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2836,CHEMBL621522,,8,1,,BAO_0000357,,,15818,12689,B,H,,,
Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,Expert,,,,,,2837,CHEMBL621523,,8,1,,BAO_0000219,,,14749,12689,B,H,,,
Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2838,CHEMBL621524,,8,1,,BAO_0000357,,,15740,12689,B,H,,,
In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,Expert,,,10116.0,,,2839,CHEMBL621525,,9,1,,BAO_0000357,,Rattus norvegicus,17133,12689,B,D,,,
The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,Autocuration,,,,,,2840,CHEMBL872921,,8,1,,BAO_0000357,,,16532,12689,B,H,,,
The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2841,CHEMBL621526,,8,1,,BAO_0000357,,,12369,12689,B,H,,,
Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,Expert,,,,,,2842,CHEMBL621527,,8,1,,BAO_0000219,,,12369,12689,B,H,,,
Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,Expert,,,10116.0,,,2843,CHEMBL617865,,9,1,,BAO_0000019,,Rattus norvegicus,2309,12689,B,D,,,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2844,CHEMBL617866,,8,1,,BAO_0000357,,,12953,12689,B,H,,,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,Autocuration,,,,,,2845,CHEMBL617867,,8,1,,BAO_0000019,,,12953,12689,B,H,,,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,Autocuration,,,,,,2846,CHEMBL617487,,8,1,,BAO_0000357,,,12953,12689,B,H,,,
Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,,2847,CHEMBL617488,,8,1,,BAO_0000357,,,12953,12689,B,H,,,
Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,Autocuration,,,,,,2848,CHEMBL617489,,8,1,,BAO_0000357,,,17133,12689,B,H,,,
Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,Autocuration,,,,,,2849,CHEMBL617490,,8,1,,BAO_0000019,,,17211,12689,B,H,,,
Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,Autocuration,,,,,,2850,CHEMBL617491,,8,1,,BAO_0000019,,,17211,12689,B,H,,,
Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,Autocuration,,,,,,2851,CHEMBL617492,,8,1,,BAO_0000019,,,14025,12689,B,H,,,
Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,Autocuration,,,,,,2852,CHEMBL617493,,8,1,,BAO_0000019,,,14998,12689,B,H,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,,2853,CHEMBL617494,,8,1,,BAO_0000357,,,4342,12689,B,H,,,
Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,Expert,,,10116.0,,,2854,CHEMBL617495,,9,1,,BAO_0000019,,Rattus norvegicus,13735,12689,B,D,,,
Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,,,,,2855,CHEMBL617496,,8,1,,BAO_0000357,,,13181,12689,B,H,,,
Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,Autocuration,,485.0,,,,2856,CHEMBL617497,,8,1,,BAO_0000219,,,1883,12689,B,H,CHO-K1,,
The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,,2857,CHEMBL617498,,8,1,,BAO_0000357,,,15194,12689,B,H,,,
The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,Autocuration,,,,,,2858,CHEMBL617499,,8,1,,BAO_0000357,,,15194,12689,B,H,,,
Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2859,CHEMBL617500,,8,1,,BAO_0000019,,,14579,12689,F,H,,,
Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2860,CHEMBL617501,,8,1,,BAO_0000357,,,4639,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,,,,,2861,CHEMBL617502,,8,1,,BAO_0000357,,,4820,108,B,H,,,
Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,Autocuration,,,,,,2862,CHEMBL617503,,8,1,,BAO_0000357,,,14442,227,B,H,,,
Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,Autocuration,,,,,,2863,CHEMBL617504,,8,1,,BAO_0000357,,,14755,227,B,H,,,
Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,Autocuration,,,,,,2864,CHEMBL617406,,8,1,,BAO_0000357,,,14744,227,B,H,,,
Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,Expert,,,9606.0,,,2865,CHEMBL617407,,9,1,,BAO_0000019,,Homo sapiens,6857,227,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,Autocuration,,,,,,2866,CHEMBL617408,,8,1,,BAO_0000357,,,16209,227,B,H,,,
Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,,2867,CHEMBL617409,,8,1,,BAO_0000357,,,15363,227,B,H,,,
Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,,2868,CHEMBL617410,,8,1,,BAO_0000357,,,15363,227,B,H,,,
Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,,2869,CHEMBL617411,,8,1,,BAO_0000357,,,15363,227,B,H,,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,Autocuration,,,,,,2870,CHEMBL617412,,8,1,,BAO_0000019,,,17085,227,B,H,,,
Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,Expert,,,9606.0,,,2871,CHEMBL617774,,9,1,,BAO_0000357,,Homo sapiens,17200,227,B,D,,,
Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,,722.0,9606.0,,,2872,CHEMBL617775,,9,1,,BAO_0000219,,Homo sapiens,15851,227,B,D,HEK293,,
Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,,722.0,9606.0,,,2873,CHEMBL617776,,9,1,,BAO_0000219,,Homo sapiens,15851,227,B,D,HEK293,,
Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,449.0,9606.0,,,2874,CHEMBL617777,,9,1,,BAO_0000219,,Homo sapiens,6857,227,F,D,CHO,,
Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,,449.0,9606.0,,,2875,CHEMBL617778,,9,1,,BAO_0000219,,Homo sapiens,6857,227,F,D,CHO,,
"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,722.0,,,,2876,CHEMBL617779,,8,1,,BAO_0000219,,,15779,227,B,H,HEK293,,
Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,Expert,,722.0,,,,2877,CHEMBL617780,,8,1,,BAO_0000219,,,15851,227,B,H,HEK293,,
"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",Autocuration,,722.0,,,,2878,CHEMBL617781,,8,1,,BAO_0000219,,,15779,227,B,H,HEK293,,
Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,Expert,,722.0,9606.0,,,2879,CHEMBL617782,,9,1,,BAO_0000219,,Homo sapiens,14157,227,B,D,HEK293,,
Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,Expert,,722.0,9606.0,,,2880,CHEMBL617783,,9,1,,BAO_0000219,,Homo sapiens,4540,227,B,D,HEK293,,
Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,,,,2881,CHEMBL617784,,8,1,,BAO_0000357,,,6166,227,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,Autocuration,,722.0,,,,2882,CHEMBL617785,,8,1,,BAO_0000219,,,15779,227,B,H,HEK293,,
Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,Expert,,722.0,,,,2883,CHEMBL857984,,8,1,,BAO_0000219,,,14391,227,B,H,HEK293,,
Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,Expert,,722.0,,,,2884,CHEMBL617786,,8,1,,BAO_0000219,,,3832,227,B,H,HEK293,,
In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,Expert,,722.0,,,,2885,CHEMBL617787,,8,1,,BAO_0000219,,,3833,227,B,H,HEK293,,
Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,Expert,,722.0,9606.0,,,2886,CHEMBL617788,,9,1,,BAO_0000219,,Homo sapiens,15851,227,B,D,HEK293,,
Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,Expert,,722.0,9606.0,,,2887,CHEMBL617789,,9,1,,BAO_0000219,,Homo sapiens,15851,227,B,D,HEK293,,
Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,Autocuration,,722.0,,,,2888,CHEMBL617790,,8,1,,BAO_0000219,,,4199,227,B,H,HEK293,,
Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,Expert,,485.0,,,,2889,CHEMBL617791,,8,1,,BAO_0000219,,,1883,227,B,H,CHO-K1,,
Binding affinity against 5-hydroxytryptamine 2B receptor,Expert,,,,,,2890,CHEMBL617608,,8,1,,BAO_0000357,,,4321,227,B,H,,,
Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,Autocuration,,722.0,,,,2891,CHEMBL617609,,8,1,,BAO_0000219,,,15146,227,B,H,HEK293,,
Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,,722.0,,,,2892,CHEMBL617610,,8,1,,BAO_0000219,,,5213,227,B,H,HEK293,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,Autocuration,,722.0,,,,2893,CHEMBL617611,,8,1,,BAO_0000219,,,14818,227,B,H,HEK293,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,722.0,,,,2894,CHEMBL617612,,8,1,,BAO_0000219,,,4829,227,B,H,HEK293,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,,722.0,,,,2895,CHEMBL617613,,8,1,,BAO_0000219,,,4829,227,B,H,HEK293,,
The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,Autocuration,,,9986.0,,,2896,CHEMBL617614,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14025,227,B,H,,,
Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Expert,,,,,,2897,CHEMBL617615,Stomach,8,1,,BAO_0000019,,,13463,12688,B,H,,945.0,
Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Expert,,,,,,2898,CHEMBL858114,Stomach,8,1,,BAO_0000357,,,7259,12688,B,H,,945.0,
Affinity against serotonergic receptor in the isolated rat stomach fundus,Autocuration,,,,,,2899,CHEMBL617616,Stomach,8,1,,BAO_0000357,,,7259,12688,B,H,,945.0,
Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Expert,,,10116.0,,,2900,CHEMBL617617,Stomach,9,1,,BAO_0000019,,Rattus norvegicus,7185,12688,F,D,,945.0,
Antagonistic against 5-hydroxytryptamine 2B receptor,Expert,,,10116.0,,,2901,CHEMBL875914,,9,1,,BAO_0000019,,Rattus norvegicus,7185,12688,F,D,,,
Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Autocuration,,,,,,2902,CHEMBL617618,Stomach,8,1,,BAO_0000019,,,13267,12688,F,H,,945.0,
Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Expert,,,10116.0,,,2903,CHEMBL617619,Stomach,9,1,,BAO_0000357,,Rattus norvegicus,13735,12688,B,D,,945.0,
Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,Autocuration,,,,,,2904,CHEMBL617620,,8,1,,BAO_0000019,,,15738,12688,F,H,,,
Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,Autocuration,,,,,,2905,CHEMBL617621,,8,1,,BAO_0000019,,,15738,12688,F,H,,,
Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,Autocuration,,,,,,2906,CHEMBL617622,,8,1,,BAO_0000019,,,15738,12688,F,H,,,
Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,10116.0,,,2907,CHEMBL617623,Stomach,9,1,,BAO_0000357,,Rattus norvegicus,12936,12688,B,D,,945.0,
Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,10116.0,,,2908,CHEMBL617624,Stomach,9,1,,BAO_0000357,,Rattus norvegicus,12936,12688,B,D,,945.0,
Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,10116.0,,,2909,CHEMBL617625,Stomach,9,1,,BAO_0000357,,Rattus norvegicus,12936,12688,B,D,,945.0,
Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,,10116.0,,,2910,CHEMBL617626,Stomach,9,1,,BAO_0000357,,Rattus norvegicus,12936,12688,B,D,,945.0,
Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,,,,,,2911,CHEMBL617627,Stomach,8,1,,BAO_0000019,,,16404,12688,F,H,,945.0,
Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Expert,,,,,,2912,CHEMBL617628,Stomach,8,1,,BAO_0000019,,,16404,12688,F,H,,945.0,
Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Autocuration,,,,,,2913,CHEMBL617629,Stomach,8,1,,BAO_0000019,,,16404,12688,F,H,,945.0,
Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Autocuration,,,,,,2914,CHEMBL858115,Stomach,8,1,,BAO_0000019,,,16404,12688,F,H,,945.0,
Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Expert,,,10116.0,,,2915,CHEMBL617630,Stomach,9,1,,BAO_0000019,,Rattus norvegicus,16404,12688,F,D,,945.0,
Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Autocuration,,,,,,2916,CHEMBL617631,Thoracic aorta,8,1,,BAO_0000019,,,16404,12688,F,H,,1515.0,
The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,,,,2917,CHEMBL617632,,8,1,,BAO_0000357,,,7483,12688,B,H,,,
The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,Expert,,,,,,2918,CHEMBL617633,,8,1,,BAO_0000357,,,7483,12688,B,H,,,
The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,,,,2919,CHEMBL617634,,8,1,,BAO_0000357,,,7483,12688,B,H,,,
The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,,,,,2920,CHEMBL617635,,8,1,,BAO_0000357,,,7483,12688,B,H,,,
Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,,,10116.0,,,2922,CHEMBL617637,Stomach,9,1,,BAO_0000019,,Rattus norvegicus,16404,12688,F,D,,945.0,
Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,,,,,2923,CHEMBL617638,,8,1,,BAO_0000357,,,6347,227,B,H,,,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,,,,2924,CHEMBL617639,,8,1,,BAO_0000357,,,4373,227,B,H,,,
Binding affinity for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,,,,,2925,CHEMBL617640,,8,1,,BAO_0000357,,,4373,227,B,H,,,
Evaluated for the binding affinity to 5-HT 2B receptor,Autocuration,,,,,,2926,CHEMBL617641,,8,1,,BAO_0000357,,,4687,227,B,H,,,
Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,Autocuration,,,,,,2927,CHEMBL617642,,8,1,,BAO_0000357,,,16946,227,B,H,,,
Binding affinities against 5-hydroxytryptamine 2B receptor,Autocuration,,,,,,2928,CHEMBL617643,,8,1,,BAO_0000357,,,16633,227,B,H,,,
Binding affinities towards 5-hydroxytryptamine 2B receptor,Autocuration,,,,,,2929,CHEMBL617644,,8,1,,BAO_0000357,,,16633,227,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,Autocuration,,,,,,2930,CHEMBL617645,,8,1,,BAO_0000357,,,16633,227,B,H,,,
In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,,,,,,2931,CHEMBL617646,,8,1,,BAO_0000357,,,15026,108,B,H,,,
In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,,,9913.0,,,2932,CHEMBL617647,,8,1,,BAO_0000357,,Bos taurus,15738,108,B,H,,,
In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,Autocuration,,,9913.0,,,2933,CHEMBL617648,,8,1,,BAO_0000357,,Bos taurus,15738,108,B,H,,,
In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,Autocuration,,,9913.0,,,2934,CHEMBL617875,,8,1,,BAO_0000357,,Bos taurus,15738,108,B,H,,,
In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,Autocuration,,,9913.0,,,2935,CHEMBL617876,,8,1,,BAO_0000357,,Bos taurus,15738,108,B,H,,,
Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Expert,,,9913.0,,,2936,CHEMBL617877,,8,1,,BAO_0000357,,Bos taurus,16404,108,B,H,,,
In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,,,9913.0,,,2937,CHEMBL617878,,8,1,,BAO_0000357,,Bos taurus,15026,108,B,H,,,
In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,,,9913.0,,,2938,CHEMBL617879,,8,1,,BAO_0000357,,Bos taurus,15738,108,B,H,,,
Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,Autocuration,,,10141.0,,,2939,CHEMBL617880,,8,1,,BAO_0000019,,Cavia porcellus,16312,108,B,H,,,
Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Intermediate,,,10141.0,,,2940,CHEMBL617881,Striatum,9,1,,BAO_0000357,,Cavia porcellus,5486,20033,B,D,,2435.0,
Binding affinity against 5-HT1A receptor,Autocuration,,,,,,2941,CHEMBL857073,,8,1,,BAO_0000357,,,5254,51,B,H,,,
Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,Expert,,449.0,,,,2942,CHEMBL617882,,8,1,,BAO_0000219,,,3857,108,F,H,CHO,,
Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,,449.0,9606.0,,,2943,CHEMBL617883,,9,1,,BAO_0000219,,Homo sapiens,6857,108,F,D,CHO,,
Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,Autocuration,,,,,,2944,CHEMBL617884,,8,1,,BAO_0000219,,,4176,108,F,H,,,
Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,Autocuration,,449.0,,,,2945,CHEMBL617885,,8,1,,BAO_0000219,,,6347,108,B,H,CHO,,
"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",Autocuration,,449.0,,,,2946,CHEMBL617886,,8,1,,BAO_0000219,,,6347,108,B,H,CHO,,
Inhibition of human 5-hydroxytryptamine 2C receptor,Expert,,,9606.0,,,2947,CHEMBL617887,,9,1,,BAO_0000357,,Homo sapiens,16146,108,B,D,,,
In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),Autocuration,,,,,,2948,CHEMBL617888,,8,1,,BAO_0000357,,,3805,108,B,H,,,
Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Autocuration,,,,,,2949,CHEMBL617889,,8,1,,BAO_0000019,,,3857,108,B,H,,,
Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,2950,CHEMBL617890,,8,1,,BAO_0000357,,,5635,108,B,H,,,
Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,,,,,2951,CHEMBL617891,,8,1,,BAO_0000357,,,5635,108,B,H,,,
Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,,,,,2952,CHEMBL617892,,8,1,,BAO_0000357,,,5635,108,B,H,,,
Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,Expert,,449.0,,,,2953,CHEMBL617893,,8,1,,BAO_0000219,,,4012,108,B,H,CHO,,
Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,Expert,,449.0,,,,2954,CHEMBL617894,,8,1,,BAO_0000219,,,6366,108,B,H,CHO,,
Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,,449.0,,,,2955,CHEMBL617895,,8,1,,BAO_0000219,,,15949,108,B,H,CHO,,
Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,Autocuration,,449.0,,,,2956,CHEMBL617896,,8,1,,BAO_0000219,,,17211,108,B,H,CHO,,
Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,Expert,,,9606.0,,,2957,CHEMBL617897,,9,1,,BAO_0000357,,Homo sapiens,6491,108,B,D,,,
Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,Autocuration,,,,,,2958,CHEMBL617898,,8,1,,BAO_0000019,,,14093,108,F,H,,,
Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,,,,,2959,CHEMBL617899,,8,1,,BAO_0000019,,,13481,108,F,H,,,
Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,Expert,,449.0,10116.0,,,2960,CHEMBL617900,,8,1,,BAO_0000219,,Rattus norvegicus,6347,108,B,H,CHO,,
Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,Autocuration,,,,,,2961,CHEMBL617901,,8,1,,BAO_0000019,,,14093,108,F,H,,,
Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,Autocuration,,,,,,2962,CHEMBL617902,,8,1,,BAO_0000019,,,14093,108,F,H,,,
Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,,2963,CHEMBL617903,,8,1,,BAO_0000019,,,13481,108,F,H,,,
Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,Autocuration,,,,,,2964,CHEMBL617904,,8,1,,BAO_0000357,,,14442,108,B,H,,,
Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,Autocuration,,,,,,2965,CHEMBL617905,,8,1,,BAO_0000357,,,14442,108,B,H,,,
Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,Autocuration,,,,,,2966,CHEMBL617906,,8,1,,BAO_0000357,,,14442,108,B,H,,,
Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,Autocuration,,,,,,2967,CHEMBL617907,,8,1,,BAO_0000357,,,14755,108,B,H,,,
Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,Autocuration,,,,,,2968,CHEMBL617908,,8,1,,BAO_0000357,,,14744,108,B,H,,,
Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,,449.0,,,,2969,CHEMBL620617,,8,1,,BAO_0000219,,,16659,108,B,H,CHO,,
Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,Expert,,,9606.0,,,2970,CHEMBL620618,,9,1,,BAO_0000019,,Homo sapiens,6857,108,B,D,,,
Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,Expert,,,,,,2971,CHEMBL620619,,8,1,,BAO_0000357,,,5635,108,B,H,,,
Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,Expert,,,9606.0,,,2972,CHEMBL620620,,9,1,,BAO_0000357,,Homo sapiens,4234,108,B,D,,,
Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,,,,,2973,CHEMBL620621,,8,1,,BAO_0000357,,,16209,108,B,H,,,
Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Autocuration,,,10116.0,Membranes,,2974,CHEMBL872920,,7,1,,BAO_0000249,,Rattus norvegicus,5778,104698,B,D,,,
Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,Autocuration,,,,,,2975,CHEMBL620622,,6,1,,BAO_0000223,,,5094,104698,B,H,,,
Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,Autocuration,,,10116.0,,,2976,CHEMBL620623,,7,1,,BAO_0000019,,Rattus norvegicus,809,104698,B,D,,,
Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,Autocuration,,,,,,2977,CHEMBL620624,,6,1,,BAO_0000019,,,1578,104698,B,H,,,
Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,Autocuration,,,,,,2978,CHEMBL620625,,6,1,,BAO_0000019,,,809,104698,B,H,,,
Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,Autocuration,,,,,,2979,CHEMBL620626,,6,1,,BAO_0000219,,,12469,104698,B,H,,,
Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,Autocuration,,,,,,2980,CHEMBL621307,,6,1,,BAO_0000019,,,14290,104698,B,H,,,
Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,Autocuration,,,,,,2981,CHEMBL621308,,6,1,,BAO_0000019,,,14290,104698,B,H,,,
Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,Autocuration,,,,,,2982,CHEMBL621309,,6,1,,BAO_0000223,,,10609,104698,B,H,,,
Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,Autocuration,,,,,,2983,CHEMBL621310,,6,1,,BAO_0000223,,,10609,104698,B,H,,,
Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,Autocuration,,,,,,2984,CHEMBL621311,,6,1,,BAO_0000223,,,10609,104698,B,H,,,
"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,,,,,2985,CHEMBL621502,,6,1,,BAO_0000249,,,15253,104698,B,H,,,
"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,,,,,2986,CHEMBL621503,,6,1,,BAO_0000249,,,15253,104698,B,H,,,
Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Autocuration,,,,Membranes,,2987,CHEMBL621504,,6,1,,BAO_0000249,,,11683,104698,B,H,,,
Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,2988,CHEMBL621505,,6,1,,BAO_0000223,,,12092,104698,B,H,,,
Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,,,,,2989,CHEMBL621506,,6,1,,BAO_0000019,,,1946,104698,B,H,,,
Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,Autocuration,,,,,,2990,CHEMBL619781,,6,1,,BAO_0000223,,,11623,104698,B,H,,,
Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,Autocuration,,,,,,2991,CHEMBL619782,,6,1,,BAO_0000223,,,11623,104698,B,H,,,
Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,Autocuration,,,,,,2992,CHEMBL619783,,6,1,,BAO_0000019,,,14788,104698,B,H,,,
Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,Autocuration,,,10116.0,,,2993,CHEMBL619784,,7,1,,BAO_0000019,,Rattus norvegicus,5432,104698,B,D,,,
Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,,,,2994,CHEMBL619785,,6,1,,BAO_0000249,,,14826,104698,B,H,,,
Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,2995,CHEMBL619786,,6,1,,BAO_0000223,,,2222,104698,B,H,,,
Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,Autocuration,,,,,,2996,CHEMBL619787,,6,1,,BAO_0000019,,,11963,104698,B,H,,,
In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,Autocuration,,,,,,2997,CHEMBL872925,,6,1,,BAO_0000019,,,14145,104698,B,H,,,
In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,Autocuration,,,,,,2998,CHEMBL619788,,6,1,,BAO_0000019,,,17819,104698,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,,,,,2999,CHEMBL619789,,6,1,,BAO_0000249,,,10394,104698,B,H,,,
Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,,,,,3000,CHEMBL619790,,6,1,,BAO_0000249,,,10394,104698,B,H,,,
Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,,,,,3001,CHEMBL619791,,6,1,,BAO_0000019,,,15034,104698,B,H,,,
Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,,,,,3002,CHEMBL619792,,6,1,,BAO_0000019,,,691,104698,B,H,,,
Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Autocuration,,,,Membranes,,3003,CHEMBL619793,,6,1,,BAO_0000249,,,12092,104698,B,H,,,
Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3004,CHEMBL619794,,7,1,,BAO_0000223,,Rattus norvegicus,11752,104698,B,D,,,
The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Autocuration,,,,,,3005,CHEMBL619795,Brain,6,1,,BAO_0000221,,,11752,104698,B,H,,955.0,
Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,Autocuration,,,,,,3006,CHEMBL619796,,6,1,,BAO_0000019,,,301,104698,B,H,,,
The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,Autocuration,,,,,,3007,CHEMBL620448,,6,1,,BAO_0000223,,,16532,104698,B,H,,,
The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,,,,,3008,CHEMBL620449,,6,1,,BAO_0000223,,,16532,104698,B,H,,,
The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,Autocuration,,,,,,3009,CHEMBL620450,,6,1,,BAO_0000223,,,12092,104698,B,H,,,
The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,Autocuration,,,,,,3010,CHEMBL620451,,6,1,,BAO_0000223,,,11684,104698,B,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,Autocuration,,,,,,3011,CHEMBL620631,,6,1,,BAO_0000223,,,11684,104698,B,H,,,
Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,Autocuration,,,,,,3012,CHEMBL620632,,6,1,,BAO_0000019,,,12953,104698,B,H,,,
The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,Autocuration,,,,,,3013,CHEMBL620633,,6,1,,BAO_0000019,,,12953,104698,B,H,,,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,Autocuration,,,,,,3014,CHEMBL620634,,6,1,,BAO_0000223,,,12953,104698,B,H,,,
Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,,,,,3015,CHEMBL620635,,6,1,,BAO_0000019,,,12861,104698,B,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,,3016,CHEMBL620636,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,,3017,CHEMBL620637,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,,3018,CHEMBL620638,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,,,,3019,CHEMBL620639,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,,3020,CHEMBL620640,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,,3021,CHEMBL620641,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,Autocuration,,,,,,3022,CHEMBL620642,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,,3023,CHEMBL620643,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,,,,3024,CHEMBL620644,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,,3025,CHEMBL620645,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,,3026,CHEMBL620646,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,,3027,CHEMBL620647,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,,,,,3028,CHEMBL620648,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,,,,,3029,CHEMBL620649,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,,3030,CHEMBL620650,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,,3031,CHEMBL620651,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,,,,,3032,CHEMBL872875,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,,,,,3033,CHEMBL620652,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,Autocuration,,,,,,3034,CHEMBL620653,,6,1,,BAO_0000019,,,10609,104698,F,H,,,
Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,Autocuration,,,,,,3035,CHEMBL857076,,6,1,,BAO_0000019,,,12861,104698,B,H,,,
Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3036,CHEMBL620654,,7,1,,BAO_0000019,,Rattus norvegicus,12861,104698,B,D,,,
Binding activity radioligand.,Autocuration,,,,,,3037,CHEMBL620655,,6,1,,BAO_0000223,,,12861,104698,B,H,,,
Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Autocuration,,,,Brain membranes,,3038,CHEMBL620656,,6,1,,BAO_0000249,,,10728,104698,B,H,,,
Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Autocuration,,,,Brain membranes,,3039,CHEMBL620657,,6,1,,BAO_0000249,,,10728,104698,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,,,,,3040,CHEMBL620658,,8,1,,BAO_0000357,,,5163,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,,,,,3041,CHEMBL620659,,8,1,,BAO_0000357,,,5163,108,B,H,,,
Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,Autocuration,,,,,,3042,CHEMBL620660,,8,1,,BAO_0000357,,,6011,108,B,H,,,
Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,3043,CHEMBL620661,,8,1,,BAO_0000357,,,5014,108,B,H,,,
Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,3044,CHEMBL620662,,8,1,,BAO_0000357,,,5635,108,B,H,,,
Affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,,3045,CHEMBL620663,,8,1,,BAO_0000357,,,5163,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,,,,,3046,CHEMBL620664,,8,1,,BAO_0000357,,,6841,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,Expert,,,,,,3047,CHEMBL620665,,8,1,,BAO_0000357,,,6119,108,B,H,,,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,,3048,CHEMBL620666,,8,1,,BAO_0000357,,,4373,108,B,H,,,
Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,Autocuration,,,,,,3049,CHEMBL620667,,8,1,,BAO_0000357,,,1633,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,Expert,,,,,,3050,CHEMBL620668,,8,1,,BAO_0000357,,,1633,108,B,H,,,
Binding affinity for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,,,,,3051,CHEMBL620669,,8,1,,BAO_0000357,,,4373,108,B,H,,,
Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,Expert,,,,,,3052,CHEMBL620670,,8,1,,BAO_0000357,,,6576,108,B,H,,,
Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,3053,CHEMBL620671,,8,1,,BAO_0000357,,,4687,108,B,H,,,
Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,Autocuration,,,,,,3054,CHEMBL620672,,8,1,,BAO_0000357,,,12146,108,B,H,,,
Tested against 5-hydroxytryptamine 2C receptor in experiment 2,Autocuration,,,,,,3055,CHEMBL620673,,8,1,,BAO_0000357,,,12146,108,B,H,,,
Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,3056,CHEMBL620674,,8,1,,BAO_0000357,,,16946,108,B,H,,,
Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,3057,CHEMBL620675,,8,1,,BAO_0000357,,,14159,108,B,H,,,
The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,Autocuration,,,,,,3058,CHEMBL620676,,8,1,,BAO_0000357,,,16700,108,B,H,,,
Affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,,,,,3059,CHEMBL621382,,8,1,,BAO_0000357,,,3269,108,B,H,,,
Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,,9606.0,,,3060,CHEMBL621383,,9,1,,BAO_0000357,,Homo sapiens,1274,108,B,D,,,
Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,Autocuration,,,,,,3061,CHEMBL621384,,8,1,,BAO_0000357,,,1317,108,B,H,,,
Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,Autocuration,,,9913.0,,,3062,CHEMBL621385,,8,1,,BAO_0000357,,Bos taurus,5834,144,B,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,Autocuration,,,9913.0,,,3063,CHEMBL617989,,8,1,,BAO_0000357,,Bos taurus,11147,144,B,H,,,
Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Expert,,,10141.0,,,3064,CHEMBL617990,,4,1,,BAO_0000019,,Cavia porcellus,14145,104714,F,H,,,
Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,,,10141.0,,,3065,CHEMBL875085,Ileum,4,1,,BAO_0000221,,Cavia porcellus,10561,104714,B,H,,2116.0,
Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,Autocuration,,,10141.0,,,3066,CHEMBL617991,,4,1,,BAO_0000019,,Cavia porcellus,15847,104714,F,H,,,
Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,Autocuration,,,10141.0,,,3067,CHEMBL617992,,4,1,,BAO_0000019,,Cavia porcellus,15847,104714,F,H,,,
Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,,,10141.0,,,3068,CHEMBL617993,Ileum,4,1,,BAO_0000221,,Cavia porcellus,10561,104714,B,H,,2116.0,
In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Autocuration,,,10141.0,,,3069,CHEMBL617994,Ileum,4,1,,BAO_0000221,,Cavia porcellus,11454,104714,B,H,,2116.0,
Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,Autocuration,,,10141.0,,,3070,CHEMBL617995,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,Autocuration,,,10141.0,,,3071,CHEMBL617996,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,Autocuration,,,10141.0,,,3072,CHEMBL617997,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,Autocuration,,,10141.0,,,3073,CHEMBL617998,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,,,10141.0,,,3074,CHEMBL617999,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,Autocuration,,,10141.0,,,3075,CHEMBL618000,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Autocuration,,,10141.0,,,3076,CHEMBL617815,Ileum,4,1,,BAO_0000221,,Cavia porcellus,15253,104714,F,H,,2116.0,
"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Autocuration,,,10141.0,,,3077,CHEMBL617816,Ileum,4,1,,BAO_0000221,,Cavia porcellus,15253,104714,F,H,,2116.0,
Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Autocuration,,,10141.0,,,3078,CHEMBL617817,Ileum,4,1,,BAO_0000221,,Cavia porcellus,11963,104714,F,H,,2116.0,
In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Autocuration,,,10141.0,,,3079,CHEMBL617818,Ileum,4,1,,BAO_0000221,,Cavia porcellus,1946,104714,B,H,,2116.0,
In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Autocuration,,,10141.0,,,3080,CHEMBL617819,Ileum,4,1,,BAO_0000221,,Cavia porcellus,1946,104714,B,H,,2116.0,
Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Autocuration,,,10141.0,,,3081,CHEMBL617820,,4,1,,BAO_0000223,,Cavia porcellus,12045,104714,B,H,,,
Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,,10141.0,,,3082,CHEMBL617821,Ileum,4,1,,BAO_0000221,,Cavia porcellus,1559,104714,B,H,,2116.0,
Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,,10141.0,,,3083,CHEMBL617822,Ileum,4,1,,BAO_0000221,,Cavia porcellus,273,104714,F,H,,2116.0,
Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Autocuration,,,10141.0,,,3084,CHEMBL617823,Ileum,4,1,,BAO_0000221,,Cavia porcellus,273,104714,F,H,,2116.0,
Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Autocuration,,,10141.0,,,3085,CHEMBL617824,Ileum,4,1,,BAO_0000221,,Cavia porcellus,188,104714,F,H,,2116.0,
Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Autocuration,,,10141.0,,,3086,CHEMBL617825,Ileum,4,1,,BAO_0000221,,Cavia porcellus,12919,104714,F,H,,2116.0,
5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Autocuration,,,10141.0,,,3087,CHEMBL617826,Ileum,4,1,,BAO_0000221,,Cavia porcellus,12918,104714,F,H,,2116.0,
Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,,10141.0,,,3088,CHEMBL617827,Ileum,4,1,,BAO_0000221,,Cavia porcellus,1559,104714,B,H,,2116.0,
Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,,10141.0,,,3089,CHEMBL617828,Ileum,4,1,,BAO_0000221,,Cavia porcellus,273,104714,F,H,,2116.0,
Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,,10141.0,,,3090,CHEMBL617829,Ileum,4,1,,BAO_0000221,,Cavia porcellus,1559,104714,B,H,,2116.0,
Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Autocuration,,,10141.0,,,3091,CHEMBL617830,Ileum,4,1,,BAO_0000221,,Cavia porcellus,1559,104714,B,H,,2116.0,
Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Autocuration,,,10141.0,,,3092,CHEMBL617831,Ileum,4,1,,BAO_0000221,,Cavia porcellus,1559,104714,B,H,,2116.0,
The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Autocuration,,,10141.0,,,3093,CHEMBL617832,Ileum,4,1,,BAO_0000221,,Cavia porcellus,14424,104714,B,H,,2116.0,
Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,,,10141.0,,,3094,CHEMBL617833,,0,1,,BAO_0000019,,Cavia porcellus,13181,22226,B,U,,,
Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,Autocuration,,,,,,3095,CHEMBL617834,,8,1,,BAO_0000357,,,5486,51,B,H,,,
Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,Expert,,,9606.0,,,3096,CHEMBL617835,,5,1,,BAO_0000223,,Homo sapiens,6491,104714,B,D,,,
Binding affinity towards 5-HT3 receptor,Autocuration,,,,,,3097,CHEMBL617836,,4,1,,BAO_0000223,,,6013,104714,B,H,,,
Binding activity radioligand.,Autocuration,,,,,,3098,CHEMBL617837,,4,1,,BAO_0000223,,,12861,104714,B,H,,,
Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,,,,,,3099,CHEMBL620392,,4,1,,BAO_0000019,,,12861,104714,B,H,,,
Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3100,CHEMBL620393,,4,1,,BAO_0000223,,,5104,104714,B,H,,,
Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3101,CHEMBL620394,,4,1,,BAO_0000223,,,5105,104714,B,H,,,
Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,Autocuration,,,,,,3102,CHEMBL620395,,4,1,,BAO_0000223,,,5104,104714,B,H,,,
Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3103,CHEMBL620396,,0,1,,BAO_0000019,,,3935,22226,B,U,,,
Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,Expert,,433.0,,,,3104,CHEMBL620582,,4,1,,BAO_0000219,,,13657,105030,B,H,NG108-15,,
"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",Autocuration,,,,,,3105,CHEMBL620583,,4,1,,BAO_0000218,In vivo,,10369,105030,B,H,,,
The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,,,,,3106,CHEMBL620584,,4,1,,BAO_0000019,,,10369,105030,B,H,,,
Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,Autocuration,,,,,,3107,CHEMBL620585,,4,1,,BAO_0000224,,,12918,105030,B,H,,,
Compound was evaluated for the binding affinity at 5- HT3 receptor,Autocuration,,,,,,3108,CHEMBL620586,,4,1,,BAO_0000224,,,12918,105030,B,H,,,
The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,,,,,3109,CHEMBL620587,,4,1,,BAO_0000019,,,10369,105030,B,H,,,
In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,,,,,3110,CHEMBL620588,,4,1,,BAO_0000019,,,773,105030,B,H,,,
5-hydroxytryptamine 3 receptor agonism in mouse,Autocuration,,,,,,3111,CHEMBL620589,,4,1,,BAO_0000218,,,12918,105030,F,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,Autocuration,,,,,,3112,CHEMBL620590,,4,1,,BAO_0000219,,,10561,105030,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,,,,,3113,CHEMBL617956,,4,1,,BAO_0000019,,,12827,105030,B,H,,,
Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,,,,,3114,CHEMBL617957,,4,1,,BAO_0000019,,,12827,105030,B,H,,,
Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,Autocuration,,,,,,3115,CHEMBL617958,,4,1,,BAO_0000224,,,12918,105030,B,H,,,
Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,,,,,3116,CHEMBL617959,,4,1,,BAO_0000219,,,273,105030,B,H,,,
Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,,,,,3117,CHEMBL617960,,4,1,,BAO_0000219,,,273,105030,B,H,,,
Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,,,,,,3118,CHEMBL617961,,4,1,,BAO_0000224,,,10561,105030,B,H,,,
Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,Autocuration,,,,,,3119,CHEMBL617962,,4,1,,BAO_0000219,In vitro,,5033,105030,B,H,,,
In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,Autocuration,,339.0,,,,3120,CHEMBL617963,,4,1,,BAO_0000219,,,16429,105030,B,H,N1E-115,,
In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,,,,,3121,CHEMBL617964,,8,1,,BAO_0000019,,,10322,11765,B,H,,,
Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,Autocuration,,,,,,3122,CHEMBL617965,,8,1,,BAO_0000219,,,14331,11765,B,H,,,
Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Autocuration,,,10090.0,,,3123,CHEMBL617966,,9,1,,BAO_0000357,,Mus musculus,13462,10630,B,D,,,
Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,,,,,3124,CHEMBL857074,,8,1,,BAO_0000019,,,12861,17106,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,,,9823.0,,,3125,CHEMBL617967,,8,1,,BAO_0000357,,Sus scrofa,15086,144,B,H,,,
Binding activity radioligand.,Autocuration,,,9823.0,,,3126,CHEMBL617968,,8,1,,BAO_0000357,,Sus scrofa,12861,144,B,H,,,
Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Autocuration,,,9986.0,,,3127,CHEMBL617969,,4,1,,BAO_0000223,,Oryctolagus cuniculus,10561,104714,B,H,,,
Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,,,9986.0,,,3128,CHEMBL617970,,4,1,,BAO_0000223,,Oryctolagus cuniculus,10561,104714,B,H,,,
Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,Autocuration,,,9986.0,,,3129,CHEMBL617971,,4,1,,BAO_0000223,,Oryctolagus cuniculus,10561,104714,B,H,,,
Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,,,9986.0,,,3130,CHEMBL617972,,4,1,,BAO_0000019,,Oryctolagus cuniculus,10561,104714,B,H,,,
Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,,9986.0,,,3131,CHEMBL617973,,4,1,,BAO_0000019,,Oryctolagus cuniculus,273,104714,F,H,,,
Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,,9986.0,,,3132,CHEMBL617974,,4,1,,BAO_0000019,,Oryctolagus cuniculus,273,104714,F,H,,,
Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,,9986.0,,,3133,CHEMBL617975,Ileum,4,1,,BAO_0000221,,Oryctolagus cuniculus,273,104714,F,H,,2116.0,
Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,,9986.0,,,3134,CHEMBL617976,,4,1,,BAO_0000019,,Oryctolagus cuniculus,273,104714,F,H,,,
Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,,9986.0,,,3135,CHEMBL617977,,4,1,,BAO_0000019,,Oryctolagus cuniculus,273,104714,F,H,,,
Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,,9986.0,,,3136,CHEMBL617978,,4,1,,BAO_0000019,,Oryctolagus cuniculus,273,104714,F,H,,,
Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,,9986.0,,,3137,CHEMBL617979,,4,1,,BAO_0000019,,Oryctolagus cuniculus,273,104714,F,H,,,
Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,,449.0,9986.0,,,3138,CHEMBL617980,,4,1,,BAO_0000219,,Oryctolagus cuniculus,13047,104714,B,H,CHO,,
In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3139,CHEMBL617981,,7,1,,BAO_0000019,,Rattus norvegicus,1650,104698,B,D,,,
Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),Autocuration,,,,,,3140,CHEMBL617982,,8,1,,BAO_0000019,,,16288,12020,B,H,,,
Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),Autocuration,,,,,,3141,CHEMBL617983,,8,1,,BAO_0000357,,,16288,12020,B,H,,,
In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,Autocuration,,,10116.0,,,3142,CHEMBL617984,,7,1,,BAO_0000019,,Rattus norvegicus,10254,104698,B,D,,,
"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",Autocuration,,,,,,3143,CHEMBL617985,,6,1,,BAO_0000019,,,14532,104698,B,H,,,
"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,,,,,3144,CHEMBL617986,Heart,6,1,,BAO_0000218,In vivo,,13392,104698,F,H,,948.0,
"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,,,,,3145,CHEMBL617987,Heart,6,1,,BAO_0000019,,,13392,104698,F,H,,948.0,
"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,,,,,3146,CHEMBL617988,Heart,6,1,,BAO_0000019,,,13392,104698,F,H,,948.0,
"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Autocuration,,,,,,3147,CHEMBL617792,Heart,6,1,,BAO_0000019,,,13392,104698,F,H,,948.0,
"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,,,,,3148,CHEMBL617793,Heart,6,1,,BAO_0000019,,,13392,104698,F,H,,948.0,
"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,,3149,CHEMBL617794,,6,1,,BAO_0000019,,,13392,104698,F,H,,,
"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,,3150,CHEMBL617795,,6,1,,BAO_0000019,,,13392,104698,F,H,,,
"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,,3151,CHEMBL617796,,6,1,,BAO_0000019,,,13392,104698,F,H,,,
"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,,,,,3152,CHEMBL617797,,6,1,,BAO_0000019,,,13392,104698,F,H,,,
Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),Autocuration,,,10116.0,,,3153,CHEMBL617798,,7,1,,BAO_0000218,In vivo,Rattus norvegicus,1089,104698,F,D,,,
Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),Autocuration,,,,,,3154,CHEMBL617799,,6,1,,BAO_0000218,In vivo,,1089,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,10116.0,,,3155,CHEMBL617800,,7,1,,BAO_0000218,In vivo,Rattus norvegicus,11454,104698,F,D,,,
Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,Autocuration,,,10116.0,,,3156,CHEMBL617801,,7,1,,BAO_0000019,,Rattus norvegicus,11454,104698,F,D,,,
In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Autocuration,,,10116.0,,,3157,CHEMBL617802,,7,1,,BAO_0000218,In vivo,Rattus norvegicus,12205,104698,F,D,,,
Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),Autocuration,,,10116.0,,,3158,CHEMBL617803,,7,1,,BAO_0000019,,Rattus norvegicus,1089,104698,F,D,,,
Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,,,,,3159,CHEMBL617804,,6,1,,BAO_0000019,,,5094,104698,B,H,,,
Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3160,CHEMBL617805,,7,1,,BAO_0000019,,Rattus norvegicus,2622,104698,B,D,,,
Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3161,CHEMBL617806,,6,1,,BAO_0000223,,,245,104698,B,H,,,
Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,Autocuration,,,,,,3162,CHEMBL617807,,6,1,,BAO_0000019,,,14788,104698,B,H,,,
Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,Autocuration,,,,,,3163,CHEMBL617808,,6,1,,BAO_0000019,,,14788,104698,B,H,,,
Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,Autocuration,,,,,,3164,CHEMBL617809,,6,1,,BAO_0000249,,,3020,104698,B,H,,,
Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,Autocuration,,,,,,3165,CHEMBL617810,,6,1,,BAO_0000019,,,1742,104698,B,H,,,
Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Autocuration,,,,,,3166,CHEMBL617811,Brain,6,1,,BAO_0000249,,,17394,104698,B,H,,955.0,
Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Autocuration,,,,,,3167,CHEMBL617812,Brain,6,1,,BAO_0000221,,,17394,104698,B,H,,955.0,
Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,,,,3168,CHEMBL617813,,6,1,,BAO_0000249,,,17394,104698,B,H,,,
In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,,,,,3169,CHEMBL617814,,6,1,,BAO_0000249,,,14286,104698,B,H,,,
Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,Autocuration,,,,,,3170,CHEMBL617698,,6,1,,BAO_0000019,,,14178,104698,B,H,,,
Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,Autocuration,,,10116.0,,,3171,CHEMBL617699,,7,1,,BAO_0000019,,Rattus norvegicus,14178,104698,B,D,,,
Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,Autocuration,,,10116.0,,,3172,CHEMBL617700,,7,1,,BAO_0000019,,Rattus norvegicus,14178,104698,B,D,,,
Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3173,CHEMBL617701,,7,1,,BAO_0000223,,Rattus norvegicus,14178,104698,B,D,,,
Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,,,,,3174,CHEMBL617702,,6,1,,BAO_0000019,,,15034,104698,B,H,,,
"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Autocuration,,,,Membranes,,3175,CHEMBL617703,,6,1,,BAO_0000249,,,1089,104698,B,H,,,
Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,Autocuration,,,10116.0,,,3176,CHEMBL617704,,7,1,,BAO_0000019,,Rattus norvegicus,1089,104698,B,D,,,
The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,,,,,3177,CHEMBL617705,,6,1,,BAO_0000223,,,16532,104698,B,H,,,
Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3178,CHEMBL617706,,7,1,,BAO_0000223,,Rattus norvegicus,12801,104698,B,D,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),Autocuration,,433.0,,,,3179,CHEMBL617707,,6,1,,BAO_0000219,,,15194,104698,B,H,NG108-15,,
The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,Autocuration,,433.0,,,,3180,CHEMBL617708,,6,1,,BAO_0000219,,,15194,104698,B,H,NG108-15,,
Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,Autocuration,,,,,,3181,CHEMBL617709,,6,1,,BAO_0000019,,,15194,104698,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,Autocuration,,,,,,3182,CHEMBL617710,,6,1,,BAO_0000019,,,15194,104698,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,Autocuration,,,,,,3183,CHEMBL882925,,6,1,,BAO_0000019,,,15194,104698,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,Autocuration,,,,,,3184,CHEMBL617711,,6,1,,BAO_0000019,,,15194,104698,B,H,,,
Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,Autocuration,,,,,,3185,CHEMBL617712,,6,1,,BAO_0000019,,,10610,104698,F,H,,,
Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,Autocuration,,,10116.0,,,3186,CHEMBL617713,,7,1,,BAO_0000019,,Rattus norvegicus,10355,104698,F,D,,,
"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",Autocuration,,,,,,3187,CHEMBL617714,,6,1,,BAO_0000019,,,691,104698,F,H,,,
In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,Autocuration,,,,,,3188,CHEMBL617715,,6,1,,BAO_0000218,,,10611,104698,F,H,,,
Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,Autocuration,,,,,,3189,CHEMBL617716,,6,1,,BAO_0000218,In vivo,,12801,104698,F,H,,,
Inhibition of 5-HT evoked reflex bradycardia in rat.,Autocuration,,,,,,3190,CHEMBL617717,,6,1,,BAO_0000218,,,10609,104698,F,H,,,
5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3191,CHEMBL617718,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3192,CHEMBL617719,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),Autocuration,,,,,,3193,CHEMBL617720,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,10116.0,,,3194,CHEMBL617721,,7,1,,BAO_0000218,In vivo,Rattus norvegicus,11454,104698,F,D,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3195,CHEMBL617722,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,Autocuration,,,,,,3196,CHEMBL617723,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3197,CHEMBL617724,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3198,CHEMBL617725,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3199,CHEMBL617726,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3200,CHEMBL617727,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3201,CHEMBL617728,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3202,CHEMBL617729,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3203,CHEMBL617730,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3204,CHEMBL617731,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3205,CHEMBL617732,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3206,CHEMBL617733,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3207,CHEMBL617734,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,Autocuration,,,,,,3208,CHEMBL872874,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,Autocuration,,,,,,3209,CHEMBL617735,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,Autocuration,,,,,,3210,CHEMBL617736,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,Autocuration,,,,,,3211,CHEMBL617737,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,Autocuration,,,,,,3212,CHEMBL617738,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3213,CHEMBL617739,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3214,CHEMBL617740,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3215,CHEMBL617741,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3216,CHEMBL617742,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3217,CHEMBL617743,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3218,CHEMBL617744,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,,,,,3219,CHEMBL617745,,6,1,,BAO_0000218,In vivo,,11454,104698,F,H,,,
"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",Autocuration,,,,,,3220,CHEMBL617746,,6,1,,BAO_0000218,,,670,104698,F,H,,,
"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",Autocuration,,,,,,3221,CHEMBL617747,,6,1,,BAO_0000218,,,670,104698,F,H,,,
Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,Autocuration,,,,,,3222,CHEMBL617748,,6,1,,BAO_0000218,In vivo,,10321,104698,F,H,,,
Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,Autocuration,,,,,,3223,CHEMBL618909,,6,1,,BAO_0000218,In vivo,,10321,104698,F,H,,,
Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,Autocuration,,,,,,3224,CHEMBL618910,,6,1,,BAO_0000218,In vivo,,10321,104698,F,H,,,
Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,Autocuration,,,,,,3225,CHEMBL618911,,6,1,,BAO_0000218,In vivo,,10321,104698,F,H,,,
Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,Autocuration,,,,,,3226,CHEMBL618912,,6,1,,BAO_0000218,In vivo,,10321,104698,F,H,,,
Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),Autocuration,,,,,,3227,CHEMBL618913,,6,1,,BAO_0000218,In vivo,,10322,104698,F,H,,,
Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,,,,,3228,CHEMBL618914,,6,1,,BAO_0000019,,,15412,104698,F,H,,,
Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,,,,,3229,CHEMBL618915,,6,1,,BAO_0000019,,,15412,104698,F,H,,,
Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3230,CHEMBL618916,,7,1,,BAO_0000223,,Rattus norvegicus,15412,104698,B,D,,,
Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,Autocuration,,,,,,3231,CHEMBL618917,,6,1,,BAO_0000019,,,15412,104698,F,H,,,
Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Intermediate,,,,,,3232,CHEMBL618918,Hippocampus,7,1,,BAO_0000221,,,15412,104698,B,D,,10000000.0,
Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Autocuration,,,10116.0,,,3233,CHEMBL618919,,7,1,,BAO_0000019,,Rattus norvegicus,15412,104698,B,D,,,
Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3234,CHEMBL618920,,7,1,,BAO_0000019,,Rattus norvegicus,17394,104698,B,D,,,
Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3235,CHEMBL618921,,6,1,,BAO_0000223,,,12457,104698,B,H,,,
Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3236,CHEMBL618922,,6,1,,BAO_0000019,,,12457,104698,B,H,,,
Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,Autocuration,,,,,,3237,CHEMBL618923,,6,1,,BAO_0000019,,,12205,104698,B,H,,,
Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,Autocuration,,,,,,3238,CHEMBL618924,,6,1,,BAO_0000019,,,14532,104698,B,H,,,
Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,Autocuration,,,,,,3239,CHEMBL618925,,6,1,,BAO_0000019,,,1122,104698,B,H,,,
Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,,,,,3240,CHEMBL618926,,6,1,,BAO_0000019,,,5094,104698,B,H,,,
5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Intermediate,,,10141.0,,,3241,CHEMBL618927,Ileum,9,1,,BAO_0000221,,Cavia porcellus,809,20033,F,D,,2116.0,
5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Intermediate,,,10141.0,,,3242,CHEMBL618928,Ileum,9,1,,BAO_0000221,,Cavia porcellus,809,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Intermediate,,,10141.0,,,3243,CHEMBL618929,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,,,10141.0,,,3244,CHEMBL618930,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,,,10141.0,,,3245,CHEMBL618931,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,,,10141.0,,,3246,CHEMBL619594,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Intermediate,,,10141.0,,,3247,CHEMBL619595,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Intermediate,,,10141.0,,,3248,CHEMBL619596,Ileum,9,1,,BAO_0000221,,Cavia porcellus,13961,20033,F,D,,2116.0,
concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Intermediate,,,10141.0,,,3249,CHEMBL619755,Ileum,9,1,,BAO_0000221,,Cavia porcellus,13961,20033,F,D,,2116.0,
5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Intermediate,,,10141.0,,,3250,CHEMBL619756,Ileum,9,1,,BAO_0000221,,Cavia porcellus,809,20033,F,D,,2116.0,
5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Intermediate,,,10141.0,,,3251,CHEMBL619757,Ileum,9,1,,BAO_0000221,,Cavia porcellus,809,20033,F,D,,2116.0,
5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Intermediate,,,10141.0,,,3252,CHEMBL619758,Ileum,9,1,,BAO_0000221,,Cavia porcellus,809,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Intermediate,,,10141.0,,,3253,CHEMBL619759,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Intermediate,,,10141.0,,,3254,CHEMBL619760,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,,,10141.0,,,3255,CHEMBL619761,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Intermediate,,,10141.0,,,3256,CHEMBL619762,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,,,10141.0,,,3257,CHEMBL619763,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,,,10141.0,,,3258,CHEMBL617868,Ileum,9,1,,BAO_0000221,,Cavia porcellus,14290,20033,F,D,,2116.0,
Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,,,10141.0,,,3259,CHEMBL617869,,9,1,,BAO_0000357,,Cavia porcellus,15034,20033,B,D,,,
Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,10141.0,,,3260,CHEMBL882926,Striatum,9,1,,BAO_0000249,,Cavia porcellus,5094,20033,B,D,,2435.0,
Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,10141.0,,,3261,CHEMBL617870,Striatum,9,1,,BAO_0000249,,Cavia porcellus,5094,20033,B,D,,2435.0,
Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,,,10141.0,,,3262,CHEMBL617871,Striatum,9,1,,BAO_0000357,,Cavia porcellus,5399,20033,B,D,,2435.0,
Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,,,10141.0,,,3263,CHEMBL617872,Striatum,9,1,,BAO_0000357,,Cavia porcellus,17394,20033,B,D,,2435.0,
Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,,,10141.0,,,3264,CHEMBL617873,Striatum,9,1,,BAO_0000357,,Cavia porcellus,17394,20033,B,D,,2435.0,
Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,,,10141.0,,,3265,CHEMBL617874,Striatum,9,1,,BAO_0000357,,Cavia porcellus,17394,20033,B,D,,2435.0,
The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Intermediate,,,10141.0,,,3266,CHEMBL619067,Ileum,9,1,,BAO_0000221,,Cavia porcellus,13961,20033,F,D,,2116.0,
The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Intermediate,,,10141.0,,,3267,CHEMBL619068,Ileum,9,1,,BAO_0000221,,Cavia porcellus,13961,20033,F,D,,2116.0,
The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,,,10141.0,,,3268,CHEMBL619069,Ileum,9,1,,BAO_0000221,,Cavia porcellus,13961,20033,F,D,,2116.0,
Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,Intermediate,,,10141.0,,,3269,CHEMBL619070,,9,1,,BAO_0000357,,Cavia porcellus,16946,20033,B,D,,,
Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,Intermediate,,,10141.0,,,3270,CHEMBL619071,,9,1,,BAO_0000357,,Cavia porcellus,16946,20033,B,D,,,
Agonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,,,10141.0,,,3271,CHEMBL619072,,9,1,,BAO_0000019,,Cavia porcellus,15034,20033,F,D,,,
Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,Intermediate,,,10141.0,,,3272,CHEMBL619073,,9,1,,BAO_0000019,,Cavia porcellus,15034,20033,F,D,,,
Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,Intermediate,,,10141.0,,,3273,CHEMBL619074,,9,1,,BAO_0000019,,Cavia porcellus,12918,20033,F,D,,,
Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,Intermediate,,,10141.0,,,3274,CHEMBL619075,,9,1,,BAO_0000357,,Cavia porcellus,16946,20033,B,D,,,
Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,,,10141.0,,,3275,CHEMBL619076,Striatum,9,1,,BAO_0000357,,Cavia porcellus,17394,20033,B,D,,2435.0,
Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,,,10141.0,,,3276,CHEMBL619077,Striatum,9,1,,BAO_0000357,,Cavia porcellus,15034,20033,B,D,,2435.0,
Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,10141.0,,,3277,CHEMBL619078,Striatum,9,1,,BAO_0000249,,Cavia porcellus,5094,20033,B,D,,2435.0,
Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,,10141.0,,,3278,CHEMBL619079,Striatum,9,1,,BAO_0000249,,Cavia porcellus,5094,20033,B,D,,2435.0,
Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Intermediate,,,10141.0,,,3279,CHEMBL619080,Ileum,9,1,,BAO_0000221,,Cavia porcellus,17358,20033,B,D,,2116.0,
Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,Expert,,,10141.0,,,3280,CHEMBL619081,,9,1,,BAO_0000357,,Cavia porcellus,12953,20033,B,D,,,
The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,,,10141.0,,,3281,CHEMBL619082,,9,1,,BAO_0000357,,Cavia porcellus,12953,20033,B,D,,,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,Intermediate,,,10141.0,,,3282,CHEMBL619083,,9,1,,BAO_0000357,,Cavia porcellus,12953,20033,B,D,,,
The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,,,10141.0,,,3283,CHEMBL619084,,9,1,,BAO_0000357,,Cavia porcellus,12953,20033,B,D,,,
Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,10141.0,,,3284,CHEMBL859397,Ileum,9,1,,BAO_0000221,,Cavia porcellus,273,20033,F,D,,2116.0,
5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Intermediate,,,10141.0,,,3285,CHEMBL619085,Ileum,9,1,,BAO_0000221,,Cavia porcellus,12918,20033,F,D,,2116.0,
5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Intermediate,,,10141.0,,,3286,CHEMBL619086,Ileum,9,1,,BAO_0000221,,Cavia porcellus,12919,20033,F,D,,2116.0,
Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Intermediate,,,10141.0,,,3287,CHEMBL619087,Ileum,9,1,,BAO_0000221,,Cavia porcellus,273,20033,F,D,,2116.0,
Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,,10141.0,,,3288,CHEMBL619088,Ileum,9,1,,BAO_0000221,,Cavia porcellus,273,20033,F,D,,2116.0,
Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,Intermediate,,,10141.0,,,3289,CHEMBL619089,,9,1,,BAO_0000357,,Cavia porcellus,13181,20033,B,D,,,
Binding affinity was determined against 5-hydroxytryptamine 3 receptor,Autocuration,,,10141.0,,,3290,CHEMBL619090,,8,1,,BAO_0000357,,Cavia porcellus,13181,168,B,H,,,
Antagonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,,,10141.0,,,3291,CHEMBL619091,,9,1,,BAO_0000019,,Cavia porcellus,15034,20033,F,D,,,
Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,,,10141.0,,,3292,CHEMBL619092,,9,1,,BAO_0000357,,Cavia porcellus,5033,20033,B,D,,,
Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,Intermediate,,,10141.0,,,3293,CHEMBL619093,,9,1,,BAO_0000019,,Cavia porcellus,1980,20033,B,D,,,
Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,Autocuration,,722.0,10141.0,,,3294,CHEMBL619094,,8,1,,BAO_0000219,,Cavia porcellus,13181,168,B,H,HEK293,,
In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,Intermediate,,,10141.0,,,3295,CHEMBL619095,,9,1,,BAO_0000019,,Cavia porcellus,14287,20033,B,D,,,
Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,Intermediate,,,10141.0,,,3296,CHEMBL857988,,9,1,,BAO_0000357,,Cavia porcellus,1317,20033,B,D,,,
Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,Intermediate,,,10141.0,,,3297,CHEMBL619096,,9,1,,BAO_0000357,,Cavia porcellus,15316,20033,B,D,,,
In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Intermediate,,,10141.0,,,3298,CHEMBL619097,Striatum,9,1,,BAO_0000357,,Cavia porcellus,16429,20033,B,D,,2435.0,
The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Intermediate,,,10141.0,,,3299,CHEMBL619098,Hippocampus,9,1,,BAO_0000221,,Cavia porcellus,14818,20033,B,D,,10000000.0,
The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,Intermediate,,,10141.0,,,3300,CHEMBL619751,,9,1,,BAO_0000357,,Cavia porcellus,15194,20033,B,D,,,
The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,Intermediate,,,10141.0,,,3301,CHEMBL619752,,9,1,,BAO_0000357,,Cavia porcellus,15194,20033,B,D,,,
The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,,,10141.0,,,3302,CHEMBL875096,Ileum,9,1,,BAO_0000221,,Cavia porcellus,13961,20033,F,D,,2116.0,
Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,Autocuration,,,,,,3303,CHEMBL619004,,8,1,,BAO_0000357,,,5486,108,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,Autocuration,,,,,,3304,CHEMBL619005,,8,1,,BAO_0000357,,,16209,168,B,H,,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3305,CHEMBL619006,,8,1,,BAO_0000019,,,17085,168,B,H,,,
Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,Autocuration,,308.0,,,,3306,CHEMBL619007,,8,1,,BAO_0000219,,,4199,168,B,H,HeLa,,
Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3307,CHEMBL619008,,8,1,,BAO_0000357,,,15146,168,B,H,,,
Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3308,CHEMBL619009,,8,1,,BAO_0000357,,,5213,168,B,H,,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",Autocuration,,308.0,,,,3309,CHEMBL619010,,8,1,,BAO_0000219,,,4829,168,B,H,HeLa,,
Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,Autocuration,,,,,,3310,CHEMBL619011,,8,1,,BAO_0000357,,,17358,10622,B,H,,,
Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,Autocuration,,,,,,3311,CHEMBL619012,,8,1,,BAO_0000357,,,17358,10622,B,H,,,
Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,Autocuration,,,,,,3312,CHEMBL619013,,8,1,,BAO_0000219,,,16946,10622,B,H,,,
Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,Autocuration,,,,,,3313,CHEMBL619014,,8,1,,BAO_0000357,,,17358,10622,B,H,,,
Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Autocuration,,,,,,3314,CHEMBL857503,Cardiac atrium,8,1,,BAO_0000019,,,268,11249,F,H,,2081.0,
Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Autocuration,,,,,,3315,CHEMBL619015,Cardiac atrium,8,1,,BAO_0000019,,,268,11249,F,H,,2081.0,
The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3316,CHEMBL619016,,8,1,,BAO_0000357,,,15086,11249,B,H,,,
Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3317,CHEMBL619017,Hippocampus,8,1,,BAO_0000221,,,14875,11249,B,H,,10000000.0,
The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Autocuration,,,9823.0,,,3318,CHEMBL619018,Hippocampus,8,1,,BAO_0000221,,Sus scrofa,13267,168,B,H,,10000000.0,
Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,Autocuration,,,9986.0,,,3319,CHEMBL619019,,8,1,,BAO_0000019,,Oryctolagus cuniculus,13047,168,B,H,,,
Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,Expert,,,10116.0,,,3320,CHEMBL619020,,9,1,,BAO_0000357,,Rattus norvegicus,1650,10623,B,D,,,
Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,,,,,3321,CHEMBL619021,,8,1,,BAO_0000019,,,567,10623,F,H,,,
Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,Autocuration,,,,,,3322,CHEMBL619022,,8,1,,BAO_0000357,,,17358,10623,B,H,,,
Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,Autocuration,,,,,,3323,CHEMBL619023,,8,1,,BAO_0000357,,,188,10623,B,H,,,
lntrinsic activity relative to 5-HT receptor,Autocuration,,,,,,3324,CHEMBL619024,,8,1,,BAO_0000019,,,670,10623,F,H,,,
Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,Autocuration,,,,,,3325,CHEMBL619025,,8,1,,BAO_0000019,,,204,10623,F,H,,,
In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,Expert,,,,,,3326,CHEMBL619026,,8,1,,BAO_0000019,,,1946,10623,F,H,,,
Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,Autocuration,,,,,,3327,CHEMBL619027,,8,1,,BAO_0000019,,,6398,10623,F,H,,,
Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,Autocuration,,,,,,3328,CHEMBL619028,,8,1,,BAO_0000019,,,6398,10623,F,H,,,
Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,Autocuration,,,,,,3329,CHEMBL619029,,8,1,,BAO_0000019,,,17358,10623,F,H,,,
Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,Autocuration,,,,,,3330,CHEMBL619030,,8,1,,BAO_0000019,,,6398,10623,F,H,,,
Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,Expert,,,,,,3331,CHEMBL619031,,8,1,,BAO_0000357,,,11752,10623,B,H,,,
5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,Autocuration,,,,,,3332,CHEMBL619032,,8,1,,BAO_0000019,,,809,10623,F,H,,,
Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,Expert,,,10116.0,,,3333,CHEMBL619033,,9,1,,BAO_0000357,,Rattus norvegicus,14178,10623,B,D,,,
Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,,,,,3334,CHEMBL619034,,8,1,,BAO_0000357,,,567,10623,B,H,,,
In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,Autocuration,,,,,,3335,CHEMBL619035,,8,1,,BAO_0000357,,,1946,10623,B,H,,,
In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,Autocuration,,,,,,3336,CHEMBL619036,,8,1,,BAO_0000357,,,1946,10623,B,H,,,
Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,Expert,,,10116.0,,,3337,CHEMBL619037,,9,1,,BAO_0000019,,Rattus norvegicus,13961,10623,B,D,,,
Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Autocuration,,,,,,3338,CHEMBL619038,Striatum,8,1,,BAO_0000249,,,6238,10623,B,H,,2435.0,
Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,Autocuration,,,,,,3339,CHEMBL619039,,8,1,,BAO_0000249,,,14290,10623,B,H,,,
Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,Expert,,,,,,3340,CHEMBL619040,,8,1,,BAO_0000249,,,14290,10623,B,H,,,
Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Expert,,,10116.0,,,3341,CHEMBL619041,Striatum,9,1,,BAO_0000019,,Rattus norvegicus,809,10623,B,D,,2435.0,
Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Autocuration,,,,,,3342,CHEMBL619042,Striatum,8,1,,BAO_0000019,,,1578,10623,B,H,,2435.0,
Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Expert,,,,,,3343,CHEMBL619043,Striatum,8,1,,BAO_0000249,,,16709,10623,B,H,,2435.0,
Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Expert,,,,,,3344,CHEMBL619044,Striatum,8,1,,BAO_0000019,,,1946,10623,B,H,,2435.0,
In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Expert,,,,,,3345,CHEMBL619045,Striatum,8,1,,BAO_0000249,,,15253,10623,B,H,,2435.0,
In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,,,,,3346,CHEMBL619046,Striatum,8,1,,BAO_0000249,,,4535,10623,B,H,,2435.0,
Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,Expert,,,,,,3347,CHEMBL619047,,8,1,,BAO_0000249,,,13961,10623,B,H,,,
Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Autocuration,,,,,,3348,CHEMBL619048,Brain,8,1,,BAO_0000221,,,17358,10623,F,H,,955.0,
Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,Autocuration,,,,,,3349,CHEMBL859398,,8,1,,BAO_0000019,,,15847,10623,F,H,,,
Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,Autocuration,,,,,,3350,CHEMBL619049,,8,1,,BAO_0000019,,,15847,10623,F,H,,,
5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,Autocuration,,,,,,3351,CHEMBL857886,,8,1,,BAO_0000019,,,670,10623,F,H,,,
5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,Autocuration,,,,,,3352,CHEMBL619050,,8,1,,BAO_0000019,,,670,10623,F,H,,,
Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Autocuration,,,,,,3353,CHEMBL620591,,8,1,,BAO_0000019,,,1317,10623,F,H,,,
Binding affinity against rat 5-hydroxytryptamine 4 receptor,Expert,,,10116.0,,,3354,CHEMBL620592,,9,1,,BAO_0000357,,Rattus norvegicus,12936,10623,B,D,,,
pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,,,,,3355,CHEMBL620593,Striatum,8,1,,BAO_0000249,,,4535,10623,B,H,,2435.0,
Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Expert,,,10116.0,,,3356,CHEMBL620594,,9,1,,BAO_0000019,,Rattus norvegicus,14424,10623,F,D,,,
Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,Expert,,,,,,3357,CHEMBL875079,,8,1,,BAO_0000019,,,14424,10623,F,H,,,
Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Expert,,,,,,3358,CHEMBL620595,,8,1,,BAO_0000019,,,14424,10623,F,H,,,
Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,Expert,,,10116.0,,,3359,CHEMBL620596,,9,1,,BAO_0000019,,Rattus norvegicus,14424,10623,F,D,,,
Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,Autocuration,,,,,,3360,CHEMBL620597,,8,1,,BAO_0000019,,,14424,10623,F,H,,,
Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,Expert,,,,,,3361,CHEMBL620598,,8,1,,BAO_0000019,,,14424,10623,F,H,,,
Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),Expert,,,,,,3362,CHEMBL620599,,8,1,,BAO_0000218,,,14424,10623,F,H,,,
Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Autocuration,,,,,,3363,CHEMBL620600,,8,1,,BAO_0000019,,,14424,10623,F,H,,,
Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,Autocuration,,,10116.0,,,3364,CHEMBL620601,,8,1,,BAO_0000019,,Rattus norvegicus,1980,168,F,H,,,
Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,Autocuration,,,,,,3365,CHEMBL620602,,8,1,,BAO_0000019,,,4639,168,F,H,,,
Tested for affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3366,CHEMBL620603,,8,1,,BAO_0000357,,,17358,168,B,H,,,
Tested for affinity towards 5-hydroxytryptamine 4 receptor.,Autocuration,,,,,,3367,CHEMBL620604,,8,1,,BAO_0000357,,,17358,168,B,H,,,
Compound was tested for 5-hydroxytryptamine 4 binding affinity,Autocuration,,,,,,3368,CHEMBL620605,,8,1,,BAO_0000357,,,17358,168,B,H,,,
Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3369,CHEMBL620606,,8,1,,BAO_0000357,,,1558,168,B,H,,,
Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,,,,3370,CHEMBL620607,,8,1,,BAO_0000019,,,17358,168,F,H,,,
In vitro binding affinity towards 5-HT4 receptor was determined,Autocuration,,,,,,3371,CHEMBL620608,,8,1,,BAO_0000357,,,16117,168,B,H,,,
Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,,,,3372,CHEMBL620609,,8,1,,BAO_0000019,,,17358,168,F,H,,,
Tested for agonist activity against 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3373,CHEMBL620610,,8,1,,BAO_0000019,,,17358,168,F,H,,,
Tested for selectivity for 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3374,CHEMBL620611,,8,1,,BAO_0000357,,,17358,168,B,H,,,
Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,Autocuration,,,,,,3375,CHEMBL620612,,8,1,,BAO_0000357,,,17358,168,B,H,,,
Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,Autocuration,,,,,,3376,CHEMBL620613,,8,1,,BAO_0000357,,,17358,168,B,H,,,
Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,Autocuration,,,,,,3377,CHEMBL620614,,8,1,,BAO_0000357,,,17358,168,B,H,,,
Binding affinity against 5-Hydroxytryptamine 4 receptor,Expert,,,,,,3378,CHEMBL620615,,8,1,,BAO_0000357,,,1274,168,B,H,,,
Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Autocuration,,,,Brain membranes,,3379,CHEMBL857075,,6,1,,BAO_0000249,,,10728,104698,B,H,,,
Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Autocuration,,,,Brain membranes,,3380,CHEMBL620616,,6,1,,BAO_0000249,,,11695,104698,B,H,,,
Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Autocuration,,,,Brain membranes,,3381,CHEMBL619411,,6,1,,BAO_0000249,,,11695,104698,B,H,,,
Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,Autocuration,,,,,,3382,CHEMBL619412,,6,1,,BAO_0000019,,,12490,104698,B,H,,,
Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3383,CHEMBL619413,,7,1,,BAO_0000019,,Rattus norvegicus,11828,104698,B,D,,,
Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Autocuration,,,,,,3384,CHEMBL619414,Hippocampus,6,1,,BAO_0000221,,,12253,104698,B,H,,10000000.0,
Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,,,,,,3385,CHEMBL619415,,6,1,,BAO_0000019,,,10561,104698,B,H,,,
Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,Autocuration,,,,,,3386,CHEMBL619416,,6,1,,BAO_0000019,,,10561,104698,B,H,,,
Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,Autocuration,,,,,,3387,CHEMBL619417,,6,1,,BAO_0000019,,,14432,104698,F,H,,,
Binding affinity against rat 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3388,CHEMBL619418,,7,1,,BAO_0000223,,Rattus norvegicus,12936,104698,B,D,,,
Binding affinity against 5-Hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3389,CHEMBL619419,,7,1,,BAO_0000223,,Rattus norvegicus,1274,104698,B,D,,,
Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,Autocuration,,,,,,3390,CHEMBL619420,,6,1,,BAO_0000019,,,1980,104698,B,H,,,
Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,Autocuration,,,,,,3391,CHEMBL619421,,6,1,,BAO_0000249,,,670,104698,B,H,,,
Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Autocuration,,,10116.0,,,3392,CHEMBL619422,,7,1,,BAO_0000019,,Rattus norvegicus,968,104698,B,D,,,
In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,Autocuration,,,,,,3393,CHEMBL619423,,6,1,,BAO_0000019,,,14287,104698,B,H,,,
Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,Autocuration,,,,,,3394,CHEMBL875080,,6,1,,BAO_0000019,,,567,104698,B,H,,,
The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,Autocuration,,,,,,3395,CHEMBL619424,,6,1,,BAO_0000019,,,13267,104698,B,H,,,
Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,Autocuration,,,,,,3396,CHEMBL619425,,6,1,,BAO_0000249,,,14826,104698,B,H,,,
The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,Autocuration,,,,,,3397,CHEMBL619426,,6,1,,BAO_0000223,,,15194,104698,B,H,,,
The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,Autocuration,,,,,,3398,CHEMBL619427,,6,1,,BAO_0000223,,,15194,104698,B,H,,,
pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,10116.0,,,3399,CHEMBL619645,,7,1,,BAO_0000223,,Rattus norvegicus,10394,104698,B,D,,,
"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",Expert,,,,,,3400,CHEMBL619646,,9,1,,BAO_0000249,,,13657,10576,B,D,,,
Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Autocuration,,,,,,3401,CHEMBL619647,Brain,8,1,,BAO_0000221,,,1879,12020,F,H,,955.0,
Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3402,CHEMBL619648,,8,1,,BAO_0000019,,,1879,12020,F,H,,,
Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,Autocuration,,,,,,3403,CHEMBL619165,,8,1,,BAO_0000019,,,1879,12020,F,H,,,
Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3404,CHEMBL620719,,8,1,,BAO_0000218,In vivo,,204,12020,F,H,,,
Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,,,,,3405,CHEMBL872924,,8,1,,BAO_0000019,,,1879,12020,B,H,,,
Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3406,CHEMBL620720,,8,1,,BAO_0000357,,,1879,12020,B,H,,,
Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,,,,,3407,CHEMBL620721,,8,1,,BAO_0000019,,,1879,12020,B,H,,,
Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,Autocuration,,,,,,3408,CHEMBL620722,,8,1,,BAO_0000019,,,1879,12020,B,H,,,
"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",Autocuration,,,,,,3409,CHEMBL620723,,6,1,,BAO_0000019,,,10641,104698,B,H,,,
In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,,,,,3410,CHEMBL620724,,8,1,,BAO_0000019,,,773,12020,B,H,,,
Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,Autocuration,,,,,,3411,CHEMBL620725,,6,1,,BAO_0000249,,,11952,104698,B,H,,,
Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,Autocuration,,,10116.0,,,3412,CHEMBL620726,,9,1,,BAO_0000019,,Rattus norvegicus,14145,12020,F,D,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor,Expert,,,,,,3413,CHEMBL620727,,8,1,,BAO_0000357,,,17066,144,B,H,,,
Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,Autocuration,,,,,,3414,CHEMBL620728,,4,1,,BAO_0000223,,,6398,104714,B,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,,,,,3415,CHEMBL620729,,0,1,,BAO_0000019,,,10321,22226,B,U,,,
Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,Autocuration,,,,,,3416,CHEMBL858288,,4,1,,BAO_0000019,,,511,104714,F,H,,,
Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3417,CHEMBL620730,,4,1,,BAO_0000223,,,4639,104714,B,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3418,CHEMBL620731,,4,1,,BAO_0000223,,,4639,104714,B,H,,,
Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,Autocuration,,,10141.0,,,3419,CHEMBL620732,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,,,10141.0,,,3420,CHEMBL618042,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,Autocuration,,,10141.0,,,3421,CHEMBL618043,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3422,CHEMBL618044,,4,1,,BAO_0000223,,,1558,104714,B,H,,,
Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,Autocuration,,,,,,3423,CHEMBL618045,,4,1,,BAO_0000019,,,268,104714,F,H,,,
Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,Autocuration,,,,,,3424,CHEMBL618046,,4,1,,BAO_0000223,,,2474,104714,B,H,,,
Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,Autocuration,,,,,,3425,CHEMBL618047,,4,1,,BAO_0000019,,,5067,104714,F,H,,,
Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,Autocuration,,,,,,3426,CHEMBL875084,,4,1,,BAO_0000019,,,5067,104714,F,H,,,
Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,Autocuration,,,,,,3427,CHEMBL618048,,4,1,,BAO_0000019,,,5067,104714,F,H,,,
Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,Autocuration,,,,,,3428,CHEMBL618049,,4,1,,BAO_0000223,,,5067,104714,B,H,,,
Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,Autocuration,,,,,,3429,CHEMBL619764,,4,1,,BAO_0000019,,,5067,104714,F,H,,,
Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,Autocuration,,,,,,3430,CHEMBL619765,,4,1,,BAO_0000019,,,5067,104714,F,H,,,
Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,Autocuration,,,,,,3431,CHEMBL619766,,4,1,,BAO_0000019,,,5067,104714,F,H,,,
Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,Autocuration,,,,,,3432,CHEMBL619767,,4,1,,BAO_0000223,,,5067,104714,B,H,,,
Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,Autocuration,,,,,,3433,CHEMBL619768,,4,1,,BAO_0000223,,,5067,104714,B,H,,,
Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,Autocuration,,,,,,3434,CHEMBL619769,,4,1,,BAO_0000019,,,5067,104714,F,H,,,
Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,Autocuration,,,,,,3435,CHEMBL619770,,4,1,,BAO_0000223,,,5067,104714,B,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3436,CHEMBL619771,,4,1,,BAO_0000223,,,5067,104714,B,H,,,
Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,Autocuration,,,,,,3437,CHEMBL619772,,4,1,,BAO_0000219,,,14331,104714,B,H,,,
Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,Autocuration,,,,,,3438,CHEMBL619773,,4,1,,BAO_0000223,,,5067,104714,B,H,,,
Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,Autocuration,,433.0,,,,3439,CHEMBL619774,,4,1,,BAO_0000219,,,6179,104714,B,H,NG108-15,,
Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,Autocuration,,,,,,3440,CHEMBL875083,,4,1,,BAO_0000019,,,4265,104714,B,H,,,
Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,Autocuration,,433.0,,,,3441,CHEMBL620718,,4,1,,BAO_0000219,,,4265,104714,B,H,NG108-15,,
Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,,,,3442,CHEMBL618127,,4,1,,BAO_0000223,,,17358,104714,B,H,,,
Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,,,,3443,CHEMBL618128,,4,1,,BAO_0000223,,,17358,104714,B,H,,,
Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,Autocuration,,,,,,3444,CHEMBL618129,,4,1,,BAO_0000219,In vitro,,13628,104714,B,H,,,
In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,,,,,3445,CHEMBL618130,,4,1,,BAO_0000223,,,4612,104714,B,H,,,
Tested for 5-hydroxytryptamine 3 receptor antagonist activity,Autocuration,,,,,,3446,CHEMBL618131,,4,1,,BAO_0000019,,,17358,104714,F,H,,,
Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,Autocuration,,,10141.0,,,3447,CHEMBL618132,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,Autocuration,,,10141.0,,,3448,CHEMBL618133,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,Autocuration,,,10141.0,,,3449,CHEMBL618134,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,,,10141.0,,,3450,CHEMBL618135,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,Autocuration,,,,,,3451,CHEMBL618136,,4,1,,BAO_0000223,,,511,104714,B,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3452,CHEMBL618137,,4,1,,BAO_0000223,,,1479,104714,B,H,,,
Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,Autocuration,,,,,,3453,CHEMBL618138,,4,1,,BAO_0000223,,,1317,104714,B,H,,,
Tested against 5-hydroxytryptamine 3 receptor in experiment 1,Autocuration,,,,,,3454,CHEMBL618139,,4,1,,BAO_0000223,,,12146,104714,B,H,,,
Tested against 5-hydroxytryptamine 3 receptor in experiment 2,Autocuration,,,,,,3455,CHEMBL618140,,4,1,,BAO_0000223,,,12146,104714,B,H,,,
Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,Autocuration,,,,,,3456,CHEMBL618141,,4,1,,BAO_0000223,,,13969,104714,B,H,,,
Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,,,,,3457,CHEMBL873478,,8,1,,BAO_0000357,,,13392,108,B,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3458,CHEMBL618142,,6,1,,BAO_0000223,,,13392,104698,B,H,,,
Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3459,CHEMBL618143,,8,1,,BAO_0000357,,,14159,144,B,H,,,
Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3460,CHEMBL618144,,8,1,,BAO_0000357,,,1558,144,B,H,,,
Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3461,CHEMBL618145,,8,1,,BAO_0000357,,,16655,144,B,H,,,
Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,,,,,3462,CHEMBL618146,,4,1,,BAO_0000223,,,13020,104714,B,H,,,
Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,Autocuration,,,,,,3463,CHEMBL618147,,4,1,,BAO_0000223,,,13021,104714,B,H,,,
Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,,,,,3464,CHEMBL618148,,4,1,,BAO_0000223,,,13020,104714,B,H,,,
Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,,,,,3465,CHEMBL618149,,8,1,,BAO_0000019,,,10321,144,B,H,,,
Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3466,CHEMBL872927,,8,1,,BAO_0000357,,,15818,144,B,H,,,
Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3467,CHEMBL618150,,8,1,,BAO_0000357,,,15818,144,B,H,,,
Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,,,,,3468,CHEMBL618151,,8,1,,BAO_0000357,,,17358,144,B,H,,,
Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3469,CHEMBL875094,,8,1,,BAO_0000357,,,2222,144,B,H,,,
In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,,,,,3470,CHEMBL618152,,8,1,,BAO_0000019,,,10322,144,B,H,,,
In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,,,,,3471,CHEMBL618153,,8,1,,BAO_0000357,,,16117,144,B,H,,,
Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,Autocuration,,,,,,3472,CHEMBL618888,,8,1,,BAO_0000357,,,17200,144,B,H,,,
Tested for 5-hydroxytryptamine 3 receptor agonist activity,Autocuration,,,,,,3473,CHEMBL618889,,8,1,,BAO_0000019,,,17358,144,F,H,,,
The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,Autocuration,,,,,,3474,CHEMBL618890,,8,1,,BAO_0000357,,,16700,144,B,H,,,
Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,Autocuration,,,,,,3475,CHEMBL618891,,8,1,,BAO_0000019,,,1980,144,B,H,,,
Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,Autocuration,,,,,,3476,CHEMBL619054,,8,1,,BAO_0000019,,,1980,144,B,H,,,
Binding affinity against the 5-hydroxytryptamine 3 receptor,Autocuration,,,,,,3477,CHEMBL619055,,4,1,,BAO_0000223,,,12409,104714,B,H,,,
Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,,,,,3478,CHEMBL619056,,8,1,,BAO_0000357,,,4365,144,B,H,,,
Percent efficacy against 5-hydroxytryptamine 3A receptor,Autocuration,,,,,,3479,CHEMBL619057,,8,1,,BAO_0000019,,,4365,144,F,H,,,
Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,,,,,3480,CHEMBL619058,,8,1,,BAO_0000357,,,4365,144,B,H,,,
Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Expert,,,10116.0,,,3481,CHEMBL619059,,9,1,,BAO_0000219,,Rattus norvegicus,6769,12020,F,D,Oocytes,,
Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Expert,,,10116.0,,,3482,CHEMBL619060,,9,1,,BAO_0000219,,Rattus norvegicus,6769,12020,F,D,Oocytes,,
Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Expert,,,10116.0,,,3483,CHEMBL875095,,9,1,,BAO_0000219,,Rattus norvegicus,6769,12020,F,D,Oocytes,,
5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Intermediate,,,10141.0,,,3484,CHEMBL619061,Ileum,9,1,,BAO_0000221,,Cavia porcellus,809,20033,F,D,,2116.0,
5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Intermediate,,,10141.0,,,3485,CHEMBL619062,Ileum,9,1,,BAO_0000221,,Cavia porcellus,809,20033,F,D,,2116.0,
5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,Intermediate,,,10141.0,,,3486,CHEMBL619063,,9,1,,BAO_0000019,,Cavia porcellus,14290,20033,F,D,,,
Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Intermediate,,,10141.0,,,3487,CHEMBL619064,Ileum,9,1,,BAO_0000221,,Cavia porcellus,17358,20033,B,D,,2116.0,
Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,Intermediate,,,10141.0,,,3488,CHEMBL619065,,9,1,,BAO_0000357,,Cavia porcellus,17358,20033,B,D,,,
Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Intermediate,,,10141.0,,,3489,CHEMBL619066,Ileum,9,1,,BAO_0000221,,Cavia porcellus,17358,20033,B,D,,2116.0,
Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,,,,,3490,CHEMBL619775,Ileum,8,1,,BAO_0000221,,,17386,10209,B,H,,2116.0,
Affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3491,CHEMBL619776,,8,1,,BAO_0000357,,,3269,10209,B,H,,,
Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,,,10141.0,,,3492,CHEMBL619777,,4,1,,BAO_0000224,,Cavia porcellus,7721,104841,B,H,,,
Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,,,10141.0,,,3493,CHEMBL619778,,4,1,,BAO_0000224,,Cavia porcellus,7721,104841,B,H,,,
Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Autocuration,,,10141.0,,,3494,CHEMBL619779,Ileum,4,1,,BAO_0000221,,Cavia porcellus,9117,104841,B,H,,2116.0,
"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,,,10141.0,,,3495,CHEMBL619780,,4,1,,BAO_0000224,,Cavia porcellus,7721,104841,B,H,,,
"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,,,10141.0,,,3496,CHEMBL619166,,4,1,,BAO_0000224,,Cavia porcellus,7721,104841,B,H,,,
5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,,,10141.0,,,3497,CHEMBL619167,,4,1,,BAO_0000019,,Cavia porcellus,15796,104841,F,H,,,
5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,,,10141.0,,,3498,CHEMBL619168,,4,1,,BAO_0000019,,Cavia porcellus,15796,104841,F,H,,,
Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Expert,,,9606.0,,,3499,CHEMBL619169,Cardiac atrium,9,1,,BAO_0000219,,Homo sapiens,15650,168,B,D,,2081.0,
Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Expert,,,9606.0,,,3500,CHEMBL619170,Cardiac atrium,9,1,,BAO_0000219,,Homo sapiens,15650,168,B,D,,2081.0,
"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",Autocuration,,,9606.0,,,3501,CHEMBL619171,,5,1,,BAO_0000019,,Homo sapiens,6866,104841,F,D,,,
",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Expert,,,9606.0,,,3502,CHEMBL619172,Cardiac atrium,9,1,,BAO_0000219,,Homo sapiens,15650,168,F,D,,2081.0,
Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,Autocuration,,,10090.0,,,3503,CHEMBL619173,,0,1,,BAO_0000019,,Mus musculus,10063,22226,B,U,,,
Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,Autocuration,,,10090.0,,,3504,CHEMBL619174,,0,1,,BAO_0000019,,Mus musculus,12665,22226,B,U,,,
5-hydroxytryptamine receptor binding affinity was determined in rats,Autocuration,,,,,,3505,CHEMBL619175,,4,1,,BAO_0000019,,,7504,104705,B,H,,,
Binding affinity at rat 5-hydroxytryptamine receptor.,Autocuration,,,,,,3506,CHEMBL619176,,4,1,,BAO_0000224,,,7504,104705,B,H,,,
Affinity against 5-hydroxytryptamine receptors in rat fundus model,Autocuration,,,,,,3507,CHEMBL619177,,4,1,,BAO_0000019,,,7038,104705,B,H,,,
Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,Autocuration,,,,,,3508,CHEMBL619178,,4,1,,BAO_0000224,,,7626,104705,B,H,,,
Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,Autocuration,,,,,,3509,CHEMBL619179,,4,1,,BAO_0000224,,,7626,104705,B,H,,,
Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Autocuration,,,,,,3510,CHEMBL619180,Stomach,4,1,,BAO_0000019,,,7185,104705,F,H,,945.0,
Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Autocuration,,,,,,3511,CHEMBL619181,Stomach,4,1,,BAO_0000019,,,7185,104705,F,H,,945.0,
Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,,,,,3512,CHEMBL619182,,4,1,,BAO_0000019,,,7185,104705,F,H,,,
Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,Autocuration,,,,,,3513,CHEMBL619183,,4,1,,BAO_0000224,,,6960,104705,B,H,,,
"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",Autocuration,,,,,,3514,CHEMBL619184,,4,1,,BAO_0000224,,,6960,104705,B,H,,,
In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Autocuration,,,,,,3515,CHEMBL619185,Hippocampus,8,1,,BAO_0000221,,,12416,10576,B,H,,10000000.0,
Binding affinity for rat 5-hydroxytryptamine transporter.,Expert,,,,,,3516,CHEMBL619186,,8,1,,BAO_0000357,,,15753,12198,B,H,,,
Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,Autocuration,,,,,,3517,CHEMBL619187,,4,1,,BAO_0000019,,,8062,104705,B,H,,,
Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,Autocuration,,,10116.0,,,3518,CHEMBL619188,,5,1,,BAO_0000019,,Rattus norvegicus,9036,104705,B,D,,,
Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Autocuration,,,10116.0,,,3519,CHEMBL619189,,5,1,,BAO_0000224,,Rattus norvegicus,15067,104705,B,D,,,
Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Expert,,,10116.0,,,3520,CHEMBL619190,Brain,9,1,,BAO_0000019,,Rattus norvegicus,15753,12198,F,D,,955.0,
Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Expert,,,10116.0,,,3521,CHEMBL619191,Cerebellum,9,1,,BAO_0000221,,Rattus norvegicus,15753,12198,F,D,,2037.0,
Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,Autocuration,,,10116.0,,,3522,CHEMBL619192,,5,1,,BAO_0000019,,Rattus norvegicus,15295,104705,B,D,,,
Percent binding affinity against 5-hydroxytryptamine receptor,Autocuration,,,10116.0,,,3523,CHEMBL619193,,5,1,,BAO_0000224,,Rattus norvegicus,6347,104705,B,D,,,
Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,Autocuration,,,,,,3524,CHEMBL619194,,0,1,,BAO_0000019,,,6763,22226,B,U,,,
The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,Autocuration,,,10116.0,,,3525,CHEMBL619195,,5,1,,BAO_0000224,,Rattus norvegicus,12092,104705,B,D,,,
Affinity against 5-hydroxytryptamine receptor was determined,Autocuration,,,10116.0,,,3526,CHEMBL619196,,5,1,,BAO_0000224,,Rattus norvegicus,1579,104705,B,D,,,
Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Autocuration,,,10116.0,,,3527,CHEMBL619197,Stomach,5,1,,BAO_0000019,,Rattus norvegicus,1579,104705,B,D,,945.0,
Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,,,9606.0,,,3528,CHEMBL619198,,9,1,,BAO_0000219,In vitro,Homo sapiens,5963,121,B,D,,,
Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,,,9606.0,,,3529,CHEMBL875081,,9,1,,BAO_0000219,In vitro,Homo sapiens,5963,121,B,D,,,
Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,Autocuration,,,,,,3530,CHEMBL884712,,8,1,,BAO_0000357,,,5030,18065,B,H,,,
Inhibition of 5-hydroxytryptamine reuptake,Expert,,,,,,3531,CHEMBL884710,,8,1,,BAO_0000357,,,15796,121,B,H,,,
"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",Autocuration,,,,,,3532,CHEMBL619199,,8,1,,BAO_0000019,,,15413,18065,F,H,,,
"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",Autocuration,,,,,,3533,CHEMBL619200,,8,1,,BAO_0000019,,,15413,18065,F,H,,,
"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",Autocuration,,,,,,3534,CHEMBL619201,,8,1,,BAO_0000019,,,15413,18065,F,H,,,
Tested for 5-hydroxytryptamine receptor uptake,Autocuration,,,,,,3535,CHEMBL619202,,8,1,,BAO_0000019,,,12409,18065,F,H,,,
Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,,449.0,9606.0,,,3536,CHEMBL619203,,9,1,,BAO_0000219,,Homo sapiens,16909,51,B,D,CHO,,
Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,Expert,,,9606.0,,,3537,CHEMBL619204,,9,1,,BAO_0000019,,Homo sapiens,16909,51,F,D,,,
In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Autocuration,,,9606.0,,,3538,CHEMBL619205,,8,1,,BAO_0000249,,Homo sapiens,15629,10576,B,H,,,
Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,Autocuration,,,,,,3539,CHEMBL619206,,8,1,,BAO_0000357,,,15629,10576,B,H,,,
In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,Expert,,,,,,3540,CHEMBL619207,,8,1,,BAO_0000249,,,15629,10576,B,H,,,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Autocuration,,,,,,3541,CHEMBL619208,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Autocuration,,,,,,3542,CHEMBL619209,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Autocuration,,,,,,3543,CHEMBL619210,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,,,,,3544,CHEMBL619211,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,,,,,3545,CHEMBL619212,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Autocuration,,,,,,3546,CHEMBL620681,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Autocuration,,,,,,3547,CHEMBL620682,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Autocuration,,,,,,3548,CHEMBL620683,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Autocuration,,,,,,3549,CHEMBL620684,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,,,,,3550,CHEMBL620685,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,,,,,3551,CHEMBL620686,Striatum,8,1,,BAO_0000019,,,10034,10825,F,H,,2435.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Autocuration,,,,,,3552,CHEMBL620687,Limbic system,8,1,,BAO_0000019,,,10034,10825,F,H,,349.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,,,,,3553,CHEMBL620688,Limbic system,8,1,,BAO_0000019,,,10034,10825,F,H,,349.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Autocuration,,,,,,3554,CHEMBL620689,Limbic system,8,1,,BAO_0000019,,,10034,10825,F,H,,349.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Autocuration,,,,,,3555,CHEMBL620690,Limbic system,8,1,,BAO_0000019,,,10034,10825,F,H,,349.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Autocuration,,,,,,3556,CHEMBL620691,Limbic system,8,1,,BAO_0000019,,,10034,10825,F,H,,349.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Autocuration,,,,,,3557,CHEMBL620692,Limbic system,8,1,,BAO_0000019,,,10034,10825,F,H,,349.0,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Autocuration,,,,,,3558,CHEMBL620693,Limbic system,8,1,,BAO_0000019,,,10034,10825,F,H,,349.0,
Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,,,,,3559,CHEMBL620694,,8,1,,BAO_0000357,,,1274,168,B,H,,,
Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,,,,,3560,CHEMBL857986,,8,1,,BAO_0000019,,,17358,168,F,H,,,
Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,Autocuration,,,,,,3561,CHEMBL620695,,8,1,,BAO_0000357,,,14532,168,B,H,,,
Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,Expert,,,,,,3562,CHEMBL620696,,8,1,,BAO_0000357,,,16989,168,B,H,,,
Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,Autocuration,,,,,,3563,CHEMBL620697,,8,1,,BAO_0000357,,,17200,168,B,H,,,
Binding affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,,,,,3564,CHEMBL620698,,8,1,,BAO_0000357,,,15779,168,B,H,,,
Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,,,,,3565,CHEMBL620699,,8,1,,BAO_0000357,,,15779,168,B,H,,,
Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,,,,,3566,CHEMBL620700,,8,1,,BAO_0000357,,,15779,168,B,H,,,
Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,Autocuration,,643.0,,,,3567,CHEMBL620701,,8,1,,BAO_0000219,,,15650,168,B,H,COS-7,,
Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,Autocuration,,643.0,,,,3568,CHEMBL875082,,8,1,,BAO_0000219,,,15650,168,B,H,COS-7,,
Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,Autocuration,,643.0,,,,3569,CHEMBL620702,,8,1,,BAO_0000219,,,15650,168,B,H,COS-7,,
Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,Autocuration,,643.0,,,,3570,CHEMBL620703,,8,1,,BAO_0000219,,,15650,168,B,H,COS-7,,
Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Autocuration,,673.0,,,,3571,CHEMBL620704,,8,1,,BAO_0000219,,,17046,168,B,H,C6,,
Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Expert,,673.0,,,,3572,CHEMBL620705,,8,1,,BAO_0000219,,,17046,168,B,H,C6,,
Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,Expert,,673.0,,,,3573,CHEMBL620706,,8,1,,BAO_0000219,,,15650,168,B,H,C6,,
Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,Expert,,673.0,,,,3574,CHEMBL620707,,8,1,,BAO_0000219,,,17046,168,B,H,C6,,
Binding affinity towards 5-hydroxytryptamine 5 receptor,Expert,,,,,,3575,CHEMBL620708,,8,1,,BAO_0000357,,,17066,10624,B,H,,,
Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,Autocuration,,,,,,3576,CHEMBL620709,,8,1,,BAO_0000357,,,17200,105,B,H,,,
Binding affinity against 5-hydroxytryptamine 5A receptor,Expert,,,9606.0,,,3577,CHEMBL620710,,9,1,,BAO_0000357,,Homo sapiens,16146,10624,B,D,,,
Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,Autocuration,,449.0,,,,3578,CHEMBL620711,,8,1,,BAO_0000219,,,15250,10624,B,H,CHO,,
Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,Expert,,,9606.0,,,3579,CHEMBL620712,,9,1,,BAO_0000357,,Homo sapiens,6491,10624,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 5A receptor,Expert,,,9606.0,,,3580,CHEMBL620713,,9,1,,BAO_0000357,,Homo sapiens,17066,10624,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Expert,,,9606.0,,,3581,CHEMBL620714,,9,1,,BAO_0000357,,Homo sapiens,17066,10624,B,D,,,
Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,Expert,,,9606.0,,,3582,CHEMBL620715,,9,1,,BAO_0000357,,Homo sapiens,4234,10624,B,D,,,
Binding affinity towards 5-HT5A receptor,Autocuration,,,,,,3583,CHEMBL620716,,8,1,,BAO_0000357,,,6013,10624,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,,,,,3584,CHEMBL620717,,8,1,,BAO_0000357,,,17175,10624,B,H,,,
Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,Autocuration,,,,,,3585,CHEMBL618072,,8,1,,BAO_0000357,,,15818,10624,B,H,,,
Binding affinity towards cloned human 5-HT5A receptor was determined,Autocuration,,,,,,3586,CHEMBL857987,,8,1,,BAO_0000357,,,6166,10624,B,H,,,
Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,722.0,,,,3587,CHEMBL618073,,8,1,,BAO_0000219,,,15779,10624,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,,722.0,,,,3588,CHEMBL618074,,8,1,,BAO_0000219,,,15779,10624,B,H,HEK293,,
Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),Autocuration,,722.0,,,,3589,CHEMBL618075,,8,1,,BAO_0000219,,,5213,10624,B,H,HEK293,,
Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,Expert,,,10090.0,,,3590,CHEMBL618076,,9,1,,BAO_0000357,,Mus musculus,17066,10625,B,D,,,
Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,,,10090.0,,,3591,CHEMBL618077,,9,1,,BAO_0000357,,Mus musculus,17066,10625,B,D,,,
Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,Expert,,,10090.0,,,3592,CHEMBL618078,,9,1,,BAO_0000357,,Mus musculus,17066,10625,B,D,,,
Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,Expert,,,10090.0,,,3593,CHEMBL881821,,9,1,,BAO_0000357,,Mus musculus,17066,10625,B,D,,,
Binding affinity towards murine 5-hydroxytryptamine 5A receptor,Expert,,,10090.0,,,3594,CHEMBL618079,,9,1,,BAO_0000357,,Mus musculus,17066,10625,B,D,,,
Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,,,,,3595,CHEMBL618080,,8,1,,BAO_0000357,,,17175,10625,B,H,,,
Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,,722.0,,,,3596,CHEMBL618081,,8,1,,BAO_0000219,,,16190,10576,B,H,HEK293,,
Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,,722.0,,,,3597,CHEMBL618082,,8,1,,BAO_0000219,,,16190,10626,B,H,HEK293,,
Binding affinity towards 5-HT5a receptor,Expert,,,,,,3598,CHEMBL618083,,8,1,,BAO_0000357,,,4820,10624,B,H,,,
Binding affinity towards 5-hydroxytryptamine 5A receptor,Expert,,,9606.0,,,3599,CHEMBL618084,,9,1,,BAO_0000357,,Homo sapiens,17066,10624,B,D,,,
Binding affinity for rodent 5-hydroxytryptamine 5A receptor,Expert,,,,,,3600,CHEMBL618085,,8,1,,BAO_0000357,,,17066,10624,B,H,,,
Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,Expert,,,,,,3601,CHEMBL618086,,8,1,,BAO_0000357,,,17175,10624,B,H,,,
Binding affinities against 5-hydroxytryptamine 5A receptor,Autocuration,,,,,,3602,CHEMBL875092,,8,1,,BAO_0000357,,,16633,10624,B,H,,,
Binding affinities towards 5-hydroxytryptamine 5A receptor,Autocuration,,,,,,3603,CHEMBL618087,,8,1,,BAO_0000357,,,16633,10624,B,H,,,
The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,Autocuration,,,,,,3604,CHEMBL872926,,8,1,,BAO_0000357,,,16700,10624,B,H,,,
Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,,,10141.0,,,3605,CHEMBL618088,,4,1,,BAO_0000019,,Cavia porcellus,4639,104714,F,H,,,
Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,Autocuration,,,,,,3606,CHEMBL618089,,4,1,,BAO_0000223,,,5486,104714,B,H,,,
Inhibition of human 5-hydroxytryptamine 6 receptor,Expert,,,9606.0,,,3607,CHEMBL618090,,9,1,,BAO_0000357,,Homo sapiens,16146,10627,B,D,,,
Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,Expert,,,9606.0,,,3608,CHEMBL618091,,9,1,,BAO_0000357,,Homo sapiens,17273,10627,B,D,,,
Inhibition against human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3609,CHEMBL618092,,8,1,,BAO_0000357,,,17687,10627,B,H,,,
Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,Expert,,,9606.0,,,3610,CHEMBL618093,,9,1,,BAO_0000357,,Homo sapiens,6491,10627,B,D,,,
Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,Expert,,308.0,,,,3611,CHEMBL618094,,8,1,,BAO_0000219,,,16190,10627,B,H,HeLa,,
Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,Expert,,,9606.0,,,3612,CHEMBL618095,,9,1,,BAO_0000357,,Homo sapiens,17066,10627,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,9606.0,,,3613,CHEMBL875093,,9,1,,BAO_0000357,,Homo sapiens,17066,10627,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,,,9606.0,,,3614,CHEMBL618096,,9,1,,BAO_0000357,,Homo sapiens,17066,10627,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Expert,,,9606.0,,,3615,CHEMBL618118,,9,1,,BAO_0000357,,Homo sapiens,17066,10627,B,D,,,
Binding affinity against 5-hydroxytryptamine 6 receptor,Expert,,,9606.0,,,3616,CHEMBL618119,,9,1,,BAO_0000357,,Homo sapiens,3555,10627,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,,3617,CHEMBL618120,,8,1,,BAO_0000357,,,5808,10627,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3618,CHEMBL618121,,8,1,,BAO_0000357,,,6013,10627,B,H,,,
"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",Expert,,722.0,,,,3619,CHEMBL618122,,8,1,,BAO_0000219,,,15818,10627,B,H,HEK293,,
Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,Autocuration,,,,,,3620,CHEMBL618123,,8,1,,BAO_0000357,,,16209,10627,B,H,,,
Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,Expert,,722.0,,,,3621,CHEMBL618124,,8,1,,BAO_0000219,,,3935,10627,B,H,HEK293,,
Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3622,CHEMBL618125,,8,1,,BAO_0000357,,,15818,10627,B,H,,,
Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Expert,,722.0,9606.0,,,3623,CHEMBL618126,,9,1,,BAO_0000219,,Homo sapiens,3805,10627,B,D,HEK293,,
Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,Expert,,,,,,3624,CHEMBL618236,,8,1,,BAO_0000019,,,16441,10627,B,H,,,
Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,,,,,3625,CHEMBL618237,,8,1,,BAO_0000019,,,16441,10627,B,H,,,
Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,Expert,,643.0,,,,3626,CHEMBL618238,,8,1,,BAO_0000219,,,6786,10627,B,H,COS-7,,
In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,Expert,,,9606.0,,,3627,CHEMBL618239,,9,1,,BAO_0000357,,Homo sapiens,4234,10627,B,D,,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3628,CHEMBL618240,,8,1,,BAO_0000019,,,17085,10627,B,H,,,
Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,Autocuration,,,,,,3629,CHEMBL618241,,8,1,,BAO_0000357,,,17200,10627,B,H,,,
Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Autocuration,,722.0,,,,3630,CHEMBL859399,,8,1,,BAO_0000219,,,17451,10627,B,H,HEK293,,
The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,Autocuration,,,,,,3631,CHEMBL618242,,8,1,,BAO_0000019,,,3935,10627,F,H,,,
Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3632,CHEMBL857991,,8,1,,BAO_0000357,,,5033,10627,B,H,,,
Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,,,,,3633,CHEMBL619951,,8,1,,BAO_0000357,,,4540,10627,B,H,,,
Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,,308.0,9606.0,,,3634,CHEMBL619952,,9,1,,BAO_0000219,,Homo sapiens,4540,10627,B,D,HeLa,,
Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,,308.0,9606.0,,,3635,CHEMBL619953,,9,1,,BAO_0000219,,Homo sapiens,4540,10627,B,D,HeLa,,
Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,Autocuration,,308.0,,,,3636,CHEMBL619954,,8,1,,BAO_0000219,,,17296,10627,B,H,HeLa,,
Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,,308.0,,,,3637,CHEMBL619955,,8,1,,BAO_0000219,,,17296,10627,B,H,HeLa,,
Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,,308.0,,,,3638,CHEMBL619956,,8,1,,BAO_0000219,,,17296,10627,B,H,HeLa,,
Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,,449.0,,,,3639,CHEMBL619957,,8,1,,BAO_0000219,,,15779,10627,B,H,CHO,,
Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,,722.0,,,,3640,CHEMBL619958,,8,1,,BAO_0000219,,,15779,10627,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,Autocuration,,722.0,,,,3641,CHEMBL620627,,8,1,,BAO_0000219,,,15779,10627,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,,722.0,,,,3642,CHEMBL620628,,8,1,,BAO_0000219,,,15779,10627,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,Autocuration,,308.0,,,,3643,CHEMBL620629,,8,1,,BAO_0000219,,,15779,10627,B,H,HeLa,,
Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3644,CHEMBL620630,,8,1,,BAO_0000357,,,6166,10627,B,H,,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,Autocuration,,308.0,,,,3645,CHEMBL620782,,8,1,,BAO_0000219,,,17451,10627,B,H,HeLa,,
Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3646,CHEMBL620783,,8,1,,BAO_0000357,,,15316,10627,B,H,,,
Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,,,,,3647,CHEMBL620784,,8,1,,BAO_0000357,,,4199,10627,B,H,,,
Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,Expert,,308.0,,,,3648,CHEMBL620785,,8,1,,BAO_0000219,,,15146,10627,B,H,HeLa,,
Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),Autocuration,,,,,,3649,CHEMBL857992,,8,1,,BAO_0000357,,,5213,10627,B,H,,,
In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,Autocuration,,,,,,3650,CHEMBL620786,,8,1,,BAO_0000219,,,16429,10627,B,H,,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,Autocuration,,308.0,,,,3651,CHEMBL620787,,8,1,,BAO_0000219,,,14818,10627,B,H,HeLa,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",Autocuration,,308.0,,,,3652,CHEMBL620788,,8,1,,BAO_0000219,,,4829,10627,B,H,HeLa,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",Autocuration,,308.0,,,,3653,CHEMBL620789,,8,1,,BAO_0000219,,,4829,10627,B,H,HeLa,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",Autocuration,,308.0,,,,3654,CHEMBL620790,,8,1,,BAO_0000219,,,4829,10627,B,H,HeLa,,
Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,Autocuration,,449.0,,,,3655,CHEMBL620791,,8,1,,BAO_0000219,,,15250,10628,B,H,CHO,,
Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,Autocuration,,,,,,3656,CHEMBL620792,,8,1,,BAO_0000019,,,14423,10628,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3657,CHEMBL620793,,8,1,,BAO_0000357,,,15086,10628,B,H,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,,,,3658,CHEMBL620794,,8,1,,BAO_0000357,,,4342,10628,B,H,,,
Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,Autocuration,,308.0,9606.0,,,3659,CHEMBL620795,,9,1,,BAO_0000219,,Homo sapiens,16190,10627,B,D,HeLa,,
Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,,3660,CHEMBL620796,,8,1,,BAO_0000357,,,4820,10627,B,H,,,
Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,Autocuration,,,,,,3661,CHEMBL620797,,8,1,,BAO_0000357,,,4639,10627,B,H,,,
Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,,,9606.0,,,3662,CHEMBL620798,,9,1,,BAO_0000019,,Homo sapiens,17066,10627,F,D,,,
Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,Autocuration,,,,,,3663,CHEMBL620799,,8,1,,BAO_0000357,,,6011,10627,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,,,,,3664,CHEMBL620800,,8,1,,BAO_0000357,,,17066,10627,B,H,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,Autocuration,,,,,,3665,CHEMBL620801,,8,1,,BAO_0000357,,,17515,10627,B,H,,,
Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3666,CHEMBL875100,,8,1,,BAO_0000357,,,5014,10627,B,H,,,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,,,,3667,CHEMBL620802,,8,1,,BAO_0000357,,,4373,10627,B,H,,,
Antagonistic activity towards 5-hydroxytryptamine 6 receptor,Expert,,,,,,3668,CHEMBL620803,,8,1,,BAO_0000019,,,17066,10627,F,H,,,
Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,,,,,,3669,CHEMBL620804,,8,1,,BAO_0000019,,,17066,10627,F,H,,,
Binding affinity for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,,,,,3670,CHEMBL620805,,8,1,,BAO_0000357,,,4373,10627,B,H,,,
Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3671,CHEMBL620806,,8,1,,BAO_0000357,,,4687,10627,B,H,,,
Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,Autocuration,,,,,,3672,CHEMBL620807,,8,1,,BAO_0000357,,,16946,10627,B,H,,,
Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,Autocuration,,,,,,3673,CHEMBL620808,,8,1,,BAO_0000357,,,16946,10627,B,H,,,
Binding affinities against 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3674,CHEMBL620809,,8,1,,BAO_0000357,,,16633,10627,B,H,,,
Binding affinities towards 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3675,CHEMBL620810,,8,1,,BAO_0000357,,,16633,10627,B,H,,,
Binding affinity towards 5-hydroxytryptamine 6 receptor,Expert,,,9606.0,,,3676,CHEMBL620811,,9,1,,BAO_0000357,,Homo sapiens,17066,10627,B,D,,,
The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,Autocuration,,,,,,3677,CHEMBL620812,,8,1,,BAO_0000357,,,16700,10627,B,H,,,
Affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,,,,,3678,CHEMBL620813,,8,1,,BAO_0000357,,,3269,10627,B,H,,,
Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],Autocuration,,,,,,3679,CHEMBL620814,,8,1,,BAO_0000357,,,5486,10627,B,H,,,
Inhibition of human 5-hydroxytryptamine 7 receptor,Expert,,,9606.0,,,3680,CHEMBL620815,,9,1,,BAO_0000357,,Homo sapiens,16146,10209,B,D,,,
Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,Autocuration,,722.0,,,,3681,CHEMBL620816,,8,1,,BAO_0000219,,,5014,10209,B,H,HEK293,,
Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3682,CHEMBL620817,,8,1,,BAO_0000357,,,15463,10209,B,H,,,
In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),Autocuration,,,,,,3683,CHEMBL620818,,8,1,,BAO_0000357,,,3805,10209,B,H,,,
Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,Expert,,722.0,,,,3684,CHEMBL620819,,8,1,,BAO_0000219,,,5014,10209,B,H,HEK293,,
Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,Expert,,,9606.0,,,3685,CHEMBL620820,,9,1,,BAO_0000357,,Homo sapiens,6491,10209,B,D,,,
Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,Autocuration,,449.0,,,,3686,CHEMBL620821,,8,1,,BAO_0000219,,,16190,10209,B,H,CHO,,
Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,,,9606.0,,,3687,CHEMBL620822,,9,1,,BAO_0000357,,Homo sapiens,17066,10209,B,D,,,
Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Expert,,,9606.0,,,3688,CHEMBL620823,,9,1,,BAO_0000357,,Homo sapiens,17066,10209,B,D,,,
Binding affinity against 5-hydroxytryptamine 7 receptor,Expert,,,9606.0,,,3689,CHEMBL620824,,9,1,,BAO_0000357,,Homo sapiens,3555,10209,B,D,,,
Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,Expert,,449.0,,,,3690,CHEMBL620825,,8,1,,BAO_0000219,,,6588,10209,B,H,CHO,,
Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,Autocuration,,,,,,3691,CHEMBL872930,,8,1,,BAO_0000357,,,15463,10209,B,H,,,
Binding affinity towards 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3692,CHEMBL620826,,8,1,,BAO_0000357,,,6013,10209,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,,,,,3693,CHEMBL620827,,8,1,,BAO_0000357,,,16209,10209,B,H,,,
Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3694,CHEMBL620828,,8,1,,BAO_0000357,,,3935,10209,B,H,,,
Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3695,CHEMBL620829,,8,1,,BAO_0000357,,,15818,10209,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,Expert,,722.0,,,,3696,CHEMBL620830,,8,1,,BAO_0000219,,,5014,10209,B,H,HEK293,,
Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,Expert,,,,,,3697,CHEMBL620831,,8,1,,BAO_0000019,,,16441,10209,B,H,,,
Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,,,,,3698,CHEMBL620832,,8,1,,BAO_0000019,,,16441,10209,B,H,,,
In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,Expert,,,9606.0,,,3699,CHEMBL621548,,9,1,,BAO_0000357,,Homo sapiens,4234,10209,B,D,,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3700,CHEMBL621549,,8,1,,BAO_0000019,,,17085,10209,B,H,,,
Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,Autocuration,,,,,,3701,CHEMBL621550,,8,1,,BAO_0000357,,,17200,10209,B,H,,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,Autocuration,,449.0,,,,3702,CHEMBL621551,,8,1,,BAO_0000219,,,17451,10209,B,H,CHO,,
In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,Autocuration,,,,,,3703,CHEMBL621552,,8,1,,BAO_0000019,,,17085,10209,B,H,,,
Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3704,CHEMBL857077,,8,1,,BAO_0000357,,,5104,10209,B,H,,,
Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,Autocuration,,,,,,3705,CHEMBL618158,,8,1,,BAO_0000357,,,5104,10209,B,H,,,
Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Expert,,643.0,9606.0,,,3706,CHEMBL618159,,9,1,,BAO_0000219,,Homo sapiens,5033,10209,B,D,COS-7,,
Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Autocuration,,643.0,,,,3707,CHEMBL875101,,8,1,,BAO_0000219,,,5486,10209,B,H,COS-7,,
Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,Expert,,722.0,9606.0,,,3708,CHEMBL618160,,9,1,,BAO_0000219,,Homo sapiens,4540,10209,B,D,HEK293,,
Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,Expert,,,,,,3709,CHEMBL618161,,8,1,,BAO_0000357,,,6166,10209,B,H,,,
Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,Expert,,722.0,,,,3710,CHEMBL618162,,8,1,,BAO_0000219,,,17342,10209,B,H,HEK293,,
Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,Expert,,,,,,3711,CHEMBL618163,,8,1,,BAO_0000357,,,17342,10209,B,H,,,
Binding affinity against 5-hydroxytryptamine 7 human receptors,Autocuration,,,,,,3712,CHEMBL618164,,8,1,,BAO_0000357,,,17296,10209,B,H,,,
Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,Expert,,,,,,3713,CHEMBL618165,,8,1,,BAO_0000219,,,16429,10209,B,H,,,
Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,Autocuration,,722.0,,,,3714,CHEMBL618166,,8,1,,BAO_0000219,,,15779,10209,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,722.0,,,,3715,CHEMBL857989,,8,1,,BAO_0000219,,,15779,10209,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,722.0,,,,3716,CHEMBL619888,,8,1,,BAO_0000219,,,15779,10209,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,722.0,,,,3717,CHEMBL619889,,8,1,,BAO_0000219,,,15779,10209,B,H,HEK293,,
Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,,722.0,,,,3718,CHEMBL619890,,8,1,,BAO_0000219,,,15779,10209,B,H,HEK293,,
Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,Autocuration,,449.0,,,,3719,CHEMBL619891,,8,1,,BAO_0000219,,,17451,10209,B,H,CHO,,
Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),Autocuration,,722.0,,,,3720,CHEMBL619892,,8,1,,BAO_0000219,,,4199,10209,B,H,HEK293,,
Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,Expert,,722.0,,,,3721,CHEMBL619893,,9,1,,BAO_0000219,,,4199,10209,B,D,HEK293,,
Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),Autocuration,,722.0,,,,3722,CHEMBL619894,,8,1,,BAO_0000219,,,4199,10209,B,H,HEK293,,
Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,Intermediate,,722.0,,,,3723,CHEMBL619895,,9,1,,BAO_0000219,,,3680,10209,B,D,HEK293,,
Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,Intermediate,,,,,,3724,CHEMBL619896,,9,1,,BAO_0000357,,,3680,10209,B,D,,,
Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,Autocuration,,643.0,,,,3725,CHEMBL619897,,8,1,,BAO_0000219,,,15316,10209,B,H,COS-7,,
Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,Autocuration,,722.0,,,,3726,CHEMBL619898,,8,1,,BAO_0000219,,,15146,10209,B,H,HEK293,,
Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,Expert,,722.0,,,,3727,CHEMBL619899,,8,1,,BAO_0000219,,,5213,10209,B,H,HEK293,,
Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),Autocuration,,722.0,,,,3728,CHEMBL619900,,8,1,,BAO_0000219,,,5213,10209,B,H,HEK293,,
Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,Expert,,722.0,9606.0,,,3729,CHEMBL619901,,9,1,,BAO_0000219,,Homo sapiens,14818,10209,B,D,HEK293,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,Autocuration,,722.0,,,,3730,CHEMBL620580,,8,1,,BAO_0000219,,,14818,10209,B,H,HEK293,,
The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,Autocuration,,722.0,,,,3731,CHEMBL620581,,8,1,,BAO_0000219,,,14818,10209,B,H,HEK293,,
"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",Autocuration,,722.0,,,,3732,CHEMBL620733,,8,1,,BAO_0000219,,,4829,10209,B,H,HEK293,,
Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,Autocuration,,,9606.0,,,3733,CHEMBL620734,,9,1,,BAO_0000357,,Homo sapiens,17200,10209,B,D,,,
Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,,,10090.0,,,3734,CHEMBL620735,,9,1,,BAO_0000357,,Mus musculus,17066,10022,B,D,,,
The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,Autocuration,,,9986.0,,,3735,CHEMBL620736,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14025,10209,B,H,,,
Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,Autocuration,,449.0,,,,3736,CHEMBL620737,,8,1,,BAO_0000219,,,15250,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,Autocuration,,449.0,,,,3737,CHEMBL620738,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,Autocuration,,449.0,,,,3738,CHEMBL620739,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,Autocuration,,449.0,,,,3739,CHEMBL620740,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,Autocuration,,449.0,,,,3740,CHEMBL620741,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,Autocuration,,449.0,,,,3741,CHEMBL620742,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,Autocuration,,449.0,,,,3742,CHEMBL620743,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,Autocuration,,449.0,,,,3743,CHEMBL620744,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,Autocuration,,449.0,,,,3744,CHEMBL620745,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,Autocuration,,449.0,,,,3745,CHEMBL620746,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,Autocuration,,449.0,,,,3746,CHEMBL620747,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,Autocuration,,449.0,,,,3747,CHEMBL620748,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,Autocuration,,449.0,,,,3748,CHEMBL620749,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Binding affinity towards rat 5-hydroxytryptamine 7 receptor,Expert,,,,,,3749,CHEMBL620750,,8,1,,BAO_0000357,,,17066,11923,B,H,,,
Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,,,10116.0,,,3750,CHEMBL620751,,9,1,,BAO_0000357,,Rattus norvegicus,17066,11923,B,D,,,
Binding affinity to the rat 5-hydroxytryptamine 7 receptor,Expert,,,,,,3751,CHEMBL620752,,8,1,,BAO_0000357,,,17386,11923,B,H,,,
Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,Autocuration,,,,,,3752,CHEMBL872929,,8,1,,BAO_0000019,,,14423,11923,B,H,,,
Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,Expert,,,10116.0,,,3753,CHEMBL620753,,9,1,,BAO_0000357,,Rattus norvegicus,15874,11923,B,D,,,
Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,Expert,,,10116.0,,,3754,CHEMBL620754,,9,1,,BAO_0000357,,Rattus norvegicus,15874,11923,B,D,,,
Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,Expert,,449.0,10116.0,,,3755,CHEMBL620755,,9,1,,BAO_0000219,,Rattus norvegicus,16372,11923,B,D,CHO,,
In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,,,,,3756,CHEMBL620756,,8,1,,BAO_0000357,,,4622,11923,B,H,,,
The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3757,CHEMBL620757,,8,1,,BAO_0000357,,,15086,11923,B,H,,,
"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",Autocuration,,449.0,,,,3758,CHEMBL620758,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",Autocuration,,449.0,,,,3759,CHEMBL620759,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,Autocuration,,449.0,,,,3760,CHEMBL620760,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,Autocuration,,449.0,,,,3761,CHEMBL620761,,8,1,,BAO_0000219,,,16372,11923,B,H,CHO,,
Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,,,,,3762,CHEMBL620762,Ileum,8,1,,BAO_0000221,,,17386,11923,F,H,,2116.0,
Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,,,,,3763,CHEMBL620763,Ileum,8,1,,BAO_0000221,,,17386,11923,F,H,,2116.0,
Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Autocuration,,,,,,3764,CHEMBL620764,Ileum,8,1,,BAO_0000221,,,17386,11923,F,H,,2116.0,
Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Expert,,,10116.0,Membranes,,3765,CHEMBL857990,,9,1,,BAO_0000249,,Rattus norvegicus,5831,11923,B,D,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,,3766,CHEMBL620765,,8,1,,BAO_0000357,,,4342,11923,B,H,,,
Binding affinity at rat 5-hydroxytryptamine 7 receptor.,Expert,,,,,,3767,CHEMBL620766,,8,1,,BAO_0000357,,,17319,11923,B,H,,,
Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Expert,,,,,,3768,CHEMBL620767,Hypothalamus,8,1,,BAO_0000019,,,17342,11923,B,H,,1898.0,
Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,Autocuration,,,,,,3769,CHEMBL620768,,8,1,,BAO_0000357,,,17342,11923,B,H,,,
Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Expert,,,,,,3770,CHEMBL619051,Hypothalamus,8,1,,BAO_0000249,,,3680,11923,B,H,,1898.0,
Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,,,,,3771,CHEMBL619052,,8,1,,BAO_0000357,,,3680,11923,B,H,,,
Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,Expert,,722.0,10116.0,,,3772,CHEMBL619053,,9,1,,BAO_0000219,,Rattus norvegicus,17319,11923,F,D,HEK293,,
Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,Expert,,722.0,10116.0,,,3773,CHEMBL619703,,9,1,,BAO_0000219,,Rattus norvegicus,17319,11923,F,D,HEK293,,
Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,Autocuration,,722.0,10116.0,,,3774,CHEMBL619704,,9,1,,BAO_0000219,,Rattus norvegicus,17319,11923,F,D,HEK293,,
Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,,,,,3775,CHEMBL619851,,8,1,,BAO_0000357,,,4820,10209,B,H,,,
Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,Autocuration,,,,,,3776,CHEMBL619852,,8,1,,BAO_0000357,,,4639,10209,B,H,,,
Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,Autocuration,,,,,,3777,CHEMBL619853,,8,1,,BAO_0000357,,,6011,10209,B,H,,,
Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,,,9606.0,,,3778,CHEMBL619854,,9,1,,BAO_0000357,,Homo sapiens,17066,10209,B,D,,,
Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,Expert,,,,,,3779,CHEMBL619855,,8,1,,BAO_0000357,,,17066,10209,B,H,,,
Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,Autocuration,,,,,,3780,CHEMBL619856,,8,1,,BAO_0000357,,,17515,10209,B,H,,,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,,3781,CHEMBL619857,,8,1,,BAO_0000357,,,4373,10209,B,H,,,
Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,Expert,,,,,,3782,CHEMBL619858,,8,1,,BAO_0000019,,,17066,10209,F,H,,,
Binding affinity for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,,3783,CHEMBL619859,,8,1,,BAO_0000357,,,4373,10209,B,H,,,
Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,,,,,3784,CHEMBL619860,,8,1,,BAO_0000357,,,4373,10209,B,H,,,
Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3785,CHEMBL619861,,8,1,,BAO_0000357,,,4687,10209,B,H,,,
Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,Expert,,,,,,3786,CHEMBL619862,,8,1,,BAO_0000357,,,17342,10209,B,H,,,
Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,Autocuration,,,,,,3787,CHEMBL619863,,8,1,,BAO_0000357,,,16946,10209,B,H,,,
Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,Autocuration,,,,,,3788,CHEMBL619864,,8,1,,BAO_0000357,,,16946,10209,B,H,,,
Binding affinities against 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3789,CHEMBL872928,,8,1,,BAO_0000357,,,16633,10209,B,H,,,
Binding affinities towards 5-hydroxytryptamine 7 receptor,Autocuration,,,,,,3790,CHEMBL619865,,8,1,,BAO_0000357,,,16633,10209,B,H,,,
Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,Expert,,,,,,3791,CHEMBL619866,,8,1,,BAO_0000357,,,17066,10209,B,H,,,
The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,Autocuration,,,,,,3792,CHEMBL619867,,8,1,,BAO_0000357,,,16700,10209,B,H,,,
Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,,,,,3793,CHEMBL619868,Ileum,8,1,,BAO_0000221,,,17386,10209,B,H,,2116.0,
Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,Autocuration,,,,,,3794,CHEMBL619869,,8,1,,BAO_0000019,,,14080,55,F,H,,,
Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,Expert,,,9606.0,,,3795,CHEMBL619870,,9,1,,BAO_0000019,,Homo sapiens,14080,55,F,D,,,
In vitro inhibition of human recombinant 5-lipoxygenase enzyme,Autocuration,,,,,,3796,CHEMBL619871,,8,1,,BAO_0000357,,,409,55,B,H,,,
In vitro inhibition of human recombinant lipoxygenase enzyme,Autocuration,,,,,,3797,CHEMBL619872,,8,1,,BAO_0000357,,,409,55,B,H,,,
In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,Autocuration,,,,,,3798,CHEMBL619873,,8,1,,BAO_0000357,,,409,55,B,H,,,
Inhibition of 5-lipoxygenase in human whole blood.,Expert,,,,,,3799,CHEMBL619874,Blood,8,1,,BAO_0000357,,,11090,55,B,H,,178.0,
Inhibition of 5-lipoxygenase in human whole blood.,Expert,,,,,,3800,CHEMBL619875,Blood,8,1,,BAO_0000357,,,11090,55,B,H,,178.0,
Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,Autocuration,,,,,,3801,CHEMBL619876,,8,1,,BAO_0000357,,,948,55,B,H,,,
Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),Autocuration,,,,,,3802,CHEMBL619877,,8,1,,BAO_0000357,,,948,55,B,H,,,
In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,Expert,,,,,,3803,CHEMBL619878,,8,1,,BAO_0000219,,,13622,55,F,H,,,
In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Autocuration,,,,,,3804,CHEMBL619879,Blood,8,1,,BAO_0000019,,,13622,55,F,H,,178.0,
In vitro inhibition of 5-lipoxygenase from human polymorphs,Autocuration,,,,,,3805,CHEMBL619880,,8,1,,BAO_0000357,,,9637,55,B,H,,,
In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),Autocuration,,,,,,3806,CHEMBL619881,,8,1,,BAO_0000357,,,11320,55,B,H,,,
In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,Expert,,,,,,3807,CHEMBL619882,,8,1,,BAO_0000357,,,11320,55,B,H,,,
In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,Autocuration,,,,,,3808,CHEMBL619883,,8,1,,BAO_0000357,,,6838,55,B,H,,,
Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Expert,,,9606.0,,,3809,CHEMBL619884,Blood,9,1,,BAO_0000357,,Homo sapiens,17667,55,B,D,,178.0,
In vitro potency against human 5-Lipoxygenase,Autocuration,,,,,,3810,CHEMBL619885,,8,1,,BAO_0000357,,,12703,55,B,H,,,
Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Expert,,,9606.0,,,3811,CHEMBL619886,,9,1,,BAO_0000019,,Homo sapiens,14312,55,F,D,,,
Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Autocuration,,,,,,3812,CHEMBL619887,Blood,8,1,,BAO_0000019,,,14312,55,F,H,,178.0,
Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,,,,,3813,CHEMBL875097,,8,1,,BAO_0000019,,,5364,55,F,H,,,
Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,Autocuration,,,,,,3814,CHEMBL618001,,8,1,,BAO_0000219,,,951,55,B,H,,,
Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,Autocuration,,,,,,3815,CHEMBL618002,,8,1,,BAO_0000219,,,951,55,B,H,,,
Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,Autocuration,,,,,,3816,CHEMBL618003,,8,1,,BAO_0000219,,,951,55,B,H,,,
Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,Autocuration,,,,,,3817,CHEMBL618004,,8,1,,BAO_0000219,,,951,55,B,H,,,
Inhibition of human 5-lipoxygenase in human cells,Autocuration,,,,,,3818,CHEMBL618005,,8,1,,BAO_0000219,,,12365,55,B,H,,,
Inhibition of human neutrophil 5-lipoxygenase,Expert,,,,,,3819,CHEMBL618006,,8,1,,BAO_0000357,,,10603,55,B,H,,,
Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,Autocuration,,,,,,3820,CHEMBL875086,,8,1,,BAO_0000019,,,10501,55,B,H,,,
Inhibition of 5-lipoxygenase from human whole blood,Expert,,,,,,3821,CHEMBL618007,Blood,8,1,,BAO_0000357,,,12281,55,B,H,,178.0,
Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,,,,,3822,CHEMBL618008,,8,1,,BAO_0000357,,,2567,55,B,H,,,
Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,Autocuration,,,,,,3823,CHEMBL618009,,8,1,,BAO_0000219,,,2567,55,B,H,,,
In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,Expert,,,,,,3824,CHEMBL618010,,8,1,,BAO_0000357,,,10193,55,B,H,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,,,,3825,CHEMBL618011,,8,1,,BAO_0000357,,,10193,55,B,H,,,
Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,Expert,,,,,,3826,CHEMBL618012,,8,1,,BAO_0000357,,,13623,55,B,H,,,
Tested against 5-lipoxygenase,Autocuration,,,,,,3827,CHEMBL882927,,8,1,,BAO_0000357,,,12780,55,B,H,,,
Tested for activity against 5-Lipoxygenase (5-LO),Autocuration,,,,,,3828,CHEMBL618013,,8,1,,BAO_0000357,,,12780,55,B,H,,,
Tested for activity against 5-lipoxygenase,Autocuration,,,,,,3829,CHEMBL618014,,8,1,,BAO_0000357,,,12780,55,B,H,,,
Tested for inhibition of 5-HPETE production by human 5-LO,Autocuration,,,,,,3830,CHEMBL618015,,8,1,,BAO_0000357,,,11966,55,B,H,,,
The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,,,,,3831,CHEMBL618016,,8,1,,BAO_0000019,,,5364,55,F,H,,,
Inhibition of Human 5-lipoxygenase,Expert,,,,,,3832,CHEMBL618017,,8,1,,BAO_0000357,,,13165,55,B,H,,,
The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,Autocuration,,,,,,3833,CHEMBL618018,,8,1,,BAO_0000019,,,5364,55,B,H,,,
The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,,,,,3834,CHEMBL875087,,8,1,,BAO_0000219,,,11311,55,B,H,,,
The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],Autocuration,,,,,,3835,CHEMBL618019,,8,1,,BAO_0000219,,,11311,55,B,H,,,
The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,Autocuration,,,,,,3836,CHEMBL618020,,8,1,,BAO_0000019,,,14863,55,B,H,,,
The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,Autocuration,,,,,,3837,CHEMBL618021,,8,1,,BAO_0000019,,,14863,55,B,H,,,
The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Autocuration,,,,,,3838,CHEMBL618022,Blood,8,1,,BAO_0000357,,,11087,55,B,H,,178.0,
The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,Autocuration,,,,,,3839,CHEMBL618023,,8,1,,BAO_0000357,,,455,55,B,H,,,
5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,,,,3840,CHEMBL618024,,8,1,,BAO_0000357,,,13183,55,B,H,,,
In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,Expert,,,,,,3841,CHEMBL873950,,8,1,,BAO_0000019,,,10319,55,B,H,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,,,,3842,CHEMBL618025,,8,1,,BAO_0000357,,,10193,55,B,H,,,
Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,Autocuration,,,,,,3843,CHEMBL618026,,8,1,,BAO_0000219,,,951,55,B,H,,,
Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,Autocuration,,,,,,3844,CHEMBL618027,,8,1,,BAO_0000219,,,951,55,B,H,,,
Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,Autocuration,,,,,,3845,CHEMBL618028,,8,1,,BAO_0000219,,,951,55,B,H,,,
Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,Autocuration,,,,,,3846,CHEMBL618029,,8,1,,BAO_0000219,,,951,55,B,H,,,
Inhibitory activity against 5-lipoxygenase at 10 uM concentration,Expert,,,,,,3847,CHEMBL618030,,8,1,,BAO_0000357,,,9859,55,B,H,,,
Inhibitory activity against 5-lipoxygenase at 1 uM concentration,Expert,,,,,,3848,CHEMBL618031,,8,1,,BAO_0000357,,,9859,55,B,H,,,
Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,Autocuration,,,,,,3849,CHEMBL618032,,8,1,,BAO_0000357,,,9859,55,B,H,,,
Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,,,,,3850,CHEMBL618033,,8,1,,BAO_0000357,,,2567,55,B,H,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,Autocuration,,,,,,3851,CHEMBL618034,,8,1,,BAO_0000357,,,10193,55,B,H,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,,,,,3852,CHEMBL875088,,8,1,,BAO_0000357,,,10193,55,B,H,,,
Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,Autocuration,,,,,,3853,CHEMBL618035,,8,1,,BAO_0000019,,,949,55,B,H,,,
Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,Autocuration,,,,,,3854,CHEMBL618036,,8,1,,BAO_0000019,,,949,55,B,H,,,
Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,Expert,,,,,,3855,CHEMBL618037,,8,1,,BAO_0000357,,,10603,55,B,H,,,
Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Expert,,,,,,3856,CHEMBL618038,,8,1,,BAO_0000357,,,10603,55,B,H,,,
Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Autocuration,,,,,,3857,CHEMBL618761,,8,1,,BAO_0000019,,,10603,55,F,H,,,
Inhibition of lipoxygenase at the concentration of 0.1 uM,Expert,,,,,,3858,CHEMBL618762,,8,1,,BAO_0000357,,,10603,55,B,H,,,
Inhibition of lipoxygenase at the concentration of 1 uM,Expert,,,,,,3859,CHEMBL618763,,8,1,,BAO_0000357,,,10603,55,B,H,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,Autocuration,,,,,,3860,CHEMBL618764,,8,1,,BAO_0000357,,,10193,55,B,H,,,
Inhibition of 5-Lipoxygenase (5-LOX),Expert,,,9606.0,,,3861,CHEMBL618765,,9,1,,BAO_0000357,,Homo sapiens,14580,55,B,D,,,
Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,,,,,3862,CHEMBL618766,,8,1,,BAO_0000357,,,11090,17087,B,H,,,
Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,,,,,3863,CHEMBL618767,,8,1,,BAO_0000357,,,11090,17087,B,H,,,
Inhibitory activity against lipoxygenase-2 in mice,Autocuration,,,,,,3864,CHEMBL619380,,8,1,,BAO_0000357,,,6339,17087,B,H,,,
Inhibitory activity against murine lipoxygenase-2.,Expert,,,,,,3865,CHEMBL619381,,8,1,,BAO_0000357,,,6339,17087,B,H,,,
Inhibition of 5-lipoxygenase from mouse macrophage,Expert,,,10090.0,,,3866,CHEMBL619382,,9,1,,BAO_0000357,,Mus musculus,12281,17087,B,D,,,
The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,Autocuration,,,,,,3867,CHEMBL619383,,8,1,,BAO_0000357,,,11311,17087,B,H,,,
The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,Autocuration,,,9823.0,,,3868,CHEMBL619384,,8,1,,BAO_0000019,,Sus scrofa,11089,55,B,H,,,
Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,Autocuration,,,9823.0,,,3869,CHEMBL619385,,8,1,,BAO_0000019,,Sus scrofa,10091,55,B,H,,,
Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,Autocuration,,,9986.0,,,3870,CHEMBL882928,,8,1,,BAO_0000019,,Oryctolagus cuniculus,14352,55,B,H,,,
5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,Expert,,,10116.0,,,3871,CHEMBL619386,,9,1,,BAO_0000019,,Rattus norvegicus,13329,12166,B,D,,,
"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",Autocuration,,,,,,3872,CHEMBL619387,,8,1,,BAO_0000019,,,13329,12166,B,H,,,
"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,,,,,3873,CHEMBL619388,,8,1,,BAO_0000019,,,13329,12166,B,H,,,
"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",Autocuration,,,,,,3874,CHEMBL619389,,8,1,,BAO_0000019,,,13329,12166,B,H,,,
Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),Expert,,,,,,3875,CHEMBL619390,,8,1,,BAO_0000019,,,13329,12166,B,H,,,
"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",Expert,,,,,,3876,CHEMBL619391,,8,1,,BAO_0000019,,,13329,12166,B,H,,,
Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,Autocuration,,,,,,3877,CHEMBL619392,,8,1,,BAO_0000019,,,13329,12166,B,H,,,
The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),Autocuration,,,,,,3878,CHEMBL619393,,8,1,,BAO_0000019,,,11311,12166,B,H,,,
The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,Autocuration,,,,,,3879,CHEMBL619394,,8,1,,BAO_0000019,,,11311,12166,B,H,,,
"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,,702.0,,,,3880,CHEMBL619395,,8,1,,BAO_0000219,,,105,12166,B,H,RBL-1,,
"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,,702.0,,,,3881,CHEMBL619396,,8,1,,BAO_0000219,,,105,12166,B,H,RBL-1,,
Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),Autocuration,,,,,,3882,CHEMBL619397,,8,1,,BAO_0000357,,,9138,12166,B,H,,,
"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",Autocuration,,,,,,3883,CHEMBL619398,,8,1,,BAO_0000357,,,9138,12166,B,H,,,
"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",Autocuration,,,,,,3884,CHEMBL619399,,8,1,,BAO_0000357,,,9138,12166,B,H,,,
5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,,,,,3885,CHEMBL619400,,8,1,,BAO_0000357,,,14427,12166,B,H,,,
"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,,,,,3886,CHEMBL619401,,8,1,,BAO_0000019,,,13329,12166,B,H,,,
"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",Autocuration,,,,,,3887,CHEMBL619402,,8,1,,BAO_0000019,,,13329,12166,B,H,,,
Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,Expert,,663.0,10116.0,,,3888,CHEMBL619403,,9,1,,BAO_0000219,,Rattus norvegicus,14427,12166,B,D,RBL-2H3,,
5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,,,,,3889,CHEMBL619404,,8,1,,BAO_0000357,,,14427,12166,B,H,,,
5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,Autocuration,,,,,,3890,CHEMBL619405,,8,1,,BAO_0000357,,,14427,12166,B,H,,,
Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,Expert,,702.0,,,,3891,CHEMBL619406,,8,1,,BAO_0000219,,,10293,12166,B,H,RBL-1,,
Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,Expert,,702.0,10116.0,,,3892,CHEMBL619407,,9,1,,BAO_0000219,,Rattus norvegicus,338,12166,B,D,RBL-1,,
Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),Autocuration,,,,,,3893,CHEMBL619408,,8,1,,BAO_0000357,,,303,12166,B,H,,,
Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,Autocuration,,702.0,,,,3894,CHEMBL619409,,8,1,,BAO_0000219,,,303,12166,B,H,RBL-1,,
Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,Expert,,702.0,,,,3895,CHEMBL619410,,8,1,,BAO_0000219,,,9247,12166,B,H,RBL-1,,
Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,,702.0,,,,3896,CHEMBL619753,,8,1,,BAO_0000219,,,9247,12166,B,H,RBL-1,,
Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,Autocuration,,702.0,,,,3897,CHEMBL619754,,8,1,,BAO_0000219,,,137,12166,B,H,RBL-1,,
Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,Expert,,,,,,3898,CHEMBL619903,,8,1,,BAO_0000357,,,11481,12166,B,H,,,
"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",Expert,,,,,,3899,CHEMBL619904,,8,1,,BAO_0000357,,,11481,12166,B,H,,,
Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,Expert,,,,,,3900,CHEMBL619905,,8,1,,BAO_0000357,,,9029,12166,B,H,,,
Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,Autocuration,,,,,,3901,CHEMBL619906,,8,1,,BAO_0000019,,,1701,12166,B,H,,,
Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,Autocuration,,,,,,3902,CHEMBL619907,,8,1,,BAO_0000019,,,1701,12166,B,H,,,
Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,Autocuration,,,,,,3903,CHEMBL619908,,8,1,,BAO_0000019,,,1701,12166,B,H,,,
Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,Autocuration,,,,,,3904,CHEMBL619909,,8,1,,BAO_0000019,,,1701,12166,B,H,,,
Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,Expert,,702.0,,,,3905,CHEMBL619910,,8,1,,BAO_0000219,,,13358,12166,F,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,Expert,,702.0,,,,3906,CHEMBL882929,,8,1,,BAO_0000219,,,1175,12166,B,H,RBL-1,,
Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,Expert,,702.0,,,,3907,CHEMBL619911,,8,1,,BAO_0000219,,,8797,12166,B,H,RBL-1,,
Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,Autocuration,,,,,,3908,CHEMBL619912,,8,1,,BAO_0000019,,,8797,12166,B,H,,,
Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Expert,,,10116.0,,,3909,CHEMBL619913,,9,1,,BAO_0000357,,Rattus norvegicus,577,12166,B,D,,,
In vitro inhibitory activity against RBL-1 5-LO,Expert,,702.0,,,,3910,CHEMBL619914,,8,1,,BAO_0000219,,,9295,12166,B,H,RBL-1,,
Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),Autocuration,,702.0,,,,3911,CHEMBL619915,,8,1,,BAO_0000219,,,9295,12166,B,H,RBL-1,,
Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),Autocuration,,702.0,,,,3912,CHEMBL619916,,8,1,,BAO_0000219,,,9295,12166,B,H,RBL-1,,
Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,Autocuration,,,,,,3913,CHEMBL619917,,8,1,,BAO_0000218,,,9295,12166,B,H,,,
Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,Autocuration,,,,,,3914,CHEMBL619918,,8,1,,BAO_0000357,,,9295,12166,B,H,,,
Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,Autocuration,,,,,,3915,CHEMBL619919,,8,1,,BAO_0000218,,,216,12166,B,H,,,
Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,Autocuration,,702.0,,,,3916,CHEMBL883710,,8,1,,BAO_0000219,,,11090,12166,B,H,RBL-1,,
Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Autocuration,,,,,,3917,CHEMBL619920,Blood,8,1,,BAO_0000019,,,11090,12166,B,H,,178.0,
Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,Expert,,,,,,3918,CHEMBL619921,,8,1,,BAO_0000357,,,10091,12166,B,H,,,
Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,Autocuration,,,,,,3919,CHEMBL619922,,8,1,,BAO_0000019,,,10274,12166,F,H,,,
In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,Autocuration,,,,,,3920,CHEMBL619923,,8,1,,BAO_0000219,,,13622,12166,F,H,,,
In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,Expert,,702.0,,,,3921,CHEMBL619924,,8,1,,BAO_0000219,,,12118,12166,B,H,RBL-1,,
In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,Expert,,,,,,3922,CHEMBL619925,,8,1,,BAO_0000357,,,12576,12166,B,H,,,
In vitro inhibition of 5-lipoxygenase from RBL-1 cells,Expert,,702.0,,,,3923,CHEMBL619926,,8,1,,BAO_0000219,,,9546,12166,B,H,RBL-1,,
In vitro inhibition of 5-lipoxygenase in RBL-1 cells,Autocuration,,702.0,,,,3924,CHEMBL619927,,8,1,,BAO_0000219,,,9521,12166,B,H,RBL-1,,
In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,Expert,,702.0,,,,3925,CHEMBL619928,,8,1,,BAO_0000219,,,10626,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase,Autocuration,,702.0,,,,3926,CHEMBL619929,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,Autocuration,,702.0,,,,3927,CHEMBL875089,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,Autocuration,,702.0,,,,3928,CHEMBL619930,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,Autocuration,,702.0,,,,3929,CHEMBL619931,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,Autocuration,,702.0,,,,3930,CHEMBL619932,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,Autocuration,,702.0,,,,3931,CHEMBL619933,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,Autocuration,,702.0,,,,3932,CHEMBL619934,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,Autocuration,,702.0,,,,3933,CHEMBL619935,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,Autocuration,,702.0,,,,3934,CHEMBL619936,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,Autocuration,,702.0,,,,3935,CHEMBL619937,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,Autocuration,,702.0,,,,3936,CHEMBL619938,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,Autocuration,,702.0,,,,3937,CHEMBL619939,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,Autocuration,,702.0,,,,3938,CHEMBL619940,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,Autocuration,,702.0,,,,3939,CHEMBL875090,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,Autocuration,,702.0,,,,3940,CHEMBL619941,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,Autocuration,,702.0,,,,3941,CHEMBL619942,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,Autocuration,,702.0,,,,3942,CHEMBL883711,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,Autocuration,,702.0,,,,3943,CHEMBL619943,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,Autocuration,,702.0,,,,3944,CHEMBL619944,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,Autocuration,,702.0,,,,3945,CHEMBL619945,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,Autocuration,,702.0,,,,3946,CHEMBL619946,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,Autocuration,,702.0,,,,3947,CHEMBL619947,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,Autocuration,,702.0,,,,3948,CHEMBL619948,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,Autocuration,,702.0,,,,3949,CHEMBL619949,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,Expert,,,,,,3950,CHEMBL619950,,8,1,,BAO_0000019,,,9401,12166,B,H,,,
In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,Autocuration,,,,,,3951,CHEMBL618050,,8,1,,BAO_0000019,,,10325,12166,B,H,,,
In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,Expert,,663.0,,,,3952,CHEMBL875091,,8,1,,BAO_0000219,,,1556,12166,F,H,RBL-2H3,,
In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,Expert,,663.0,,,,3953,CHEMBL618051,,8,1,,BAO_0000219,,,1556,12166,F,H,RBL-2H3,,
Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,Expert,,702.0,10116.0,,,3954,CHEMBL618052,,9,1,,BAO_0000219,,Rattus norvegicus,961,12166,B,D,RBL-1,,
In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,Autocuration,,,,,,3955,CHEMBL618053,,8,1,,BAO_0000019,,,6838,12166,B,H,,,
In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),Expert,,,,,,3956,CHEMBL618054,,8,1,,BAO_0000019,,,10325,12166,B,H,,,
In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Expert,,702.0,10116.0,,,3957,CHEMBL618055,,9,1,,BAO_0000219,,Rattus norvegicus,9209,12166,B,D,RBL-1,,
inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,Expert,,702.0,,,,3958,CHEMBL618056,,8,1,,BAO_0000219,,,11520,12166,B,H,RBL-1,,
In vitro inhibitory activity against 5-lipoxygenase was determined,Autocuration,,,,,,3959,CHEMBL618057,,8,1,,BAO_0000357,,,137,12166,B,H,,,
In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,Autocuration,,702.0,,,,3960,CHEMBL618058,,8,1,,BAO_0000219,,,4717,12166,B,H,RBL-1,,
Inhibition of 5-lipoxygenase in intact RBL-1 cell line,Expert,,702.0,,,,3961,CHEMBL618059,,8,1,,BAO_0000219,,,10636,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Expert,,,10116.0,,,3962,CHEMBL618060,,9,1,,BAO_0000019,,Rattus norvegicus,14312,12166,F,D,,,
Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,Autocuration,,702.0,,,,3963,CHEMBL618061,,8,1,,BAO_0000219,,,1203,12166,B,H,RBL-1,,
Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,Autocuration,,,,,,3964,CHEMBL618062,,8,1,,BAO_0000019,,,1203,12166,B,H,,,
Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,Expert,,702.0,,,,3965,CHEMBL618063,,8,1,,BAO_0000219,,,13622,12166,B,H,RBL-1,,
Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,Autocuration,,,,,,3966,CHEMBL618064,,8,1,,BAO_0000357,,,9793,12166,B,H,,,
Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,Expert,,702.0,10116.0,,,3967,CHEMBL618065,,9,1,,BAO_0000219,,Rattus norvegicus,1143,12166,B,D,RBL-1,,
Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,Expert,,702.0,10116.0,,,3968,CHEMBL618066,,9,1,,BAO_0000219,,Rattus norvegicus,11854,12166,B,D,RBL-1,,
Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,,702.0,,,,3969,CHEMBL618067,,8,1,,BAO_0000219,,,3595,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Autocuration,,702.0,,,,3970,CHEMBL618068,,8,1,,BAO_0000219,,,3595,12166,B,H,RBL-1,,
Inhibition of 5-lipoxygenase in rat RBL-1 cells,Expert,,702.0,10116.0,,,3971,CHEMBL618069,,9,1,,BAO_0000219,,Rattus norvegicus,10501,12166,B,D,RBL-1,,
Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Expert,,702.0,,,,3972,CHEMBL618070,,8,1,,BAO_0000219,,,12526,12166,B,H,RBL-1,,
Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Autocuration,,,,,,3973,CHEMBL618071,Limbic system,8,1,,BAO_0000019,,,10034,10825,F,H,,349.0,
Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,,,,,3974,CHEMBL619247,Limbic system,8,1,,BAO_0000019,,,10034,10825,F,H,,349.0,
Approximate dose levels for a half maximal reduction of 5-HTP levels,Autocuration,,,,,,3975,CHEMBL619248,,8,1,,BAO_0000019,,,10034,10825,F,H,,,
Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,,,,,3976,CHEMBL619249,Hippocampus,8,1,,BAO_0000221,,,10046,10576,B,H,,10000000.0,
Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,,,,,3977,CHEMBL619250,Hippocampus,8,1,,BAO_0000221,,,10046,10576,B,H,,10000000.0,
Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Autocuration,,,,,,3978,CHEMBL619251,,8,1,,BAO_0000019,,,10046,10577,B,H,,,
Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Autocuration,,,9615.0,,,3979,CHEMBL619252,Blood,8,1,,BAO_0000019,,Canis lupus familiaris,12079,55,F,H,,178.0,
Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Autocuration,,,,,,3980,CHEMBL619253,Blood,8,1,,BAO_0000019,,,12079,55,F,H,,178.0,
The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,,3981,CHEMBL619254,,8,1,,BAO_0000219,,,11311,12166,B,H,,,
Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,Expert,,,,,,3982,CHEMBL619255,,8,1,,BAO_0000219,,,12338,17140,B,H,,,
Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,Expert,,,,,,3983,CHEMBL619256,,8,1,,BAO_0000219,,,12143,17140,B,H,,,
Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),Autocuration,,,,,,3984,CHEMBL875418,,8,1,,BAO_0000219,,,12143,17140,B,H,,,
Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Expert,,,,,,3985,CHEMBL619257,,8,1,,BAO_0000219,,,12143,17140,B,H,,,
Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Autocuration,,,,,,3986,CHEMBL619258,,8,1,,BAO_0000219,,,12143,17140,B,H,,,
Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,Expert,,,,,,3987,CHEMBL619259,,8,1,,BAO_0000357,,,12365,17140,B,H,,,
Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,Expert,,,,,,3988,CHEMBL619260,,8,1,,BAO_0000357,,,13500,17140,B,H,,,
"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3989,CHEMBL619261,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3990,CHEMBL619263,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3991,CHEMBL619264,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3992,CHEMBL619265,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3993,CHEMBL619266,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3994,CHEMBL619902,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3995,CHEMBL620058,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3996,CHEMBL620059,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3997,CHEMBL620060,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,3998,CHEMBL620061,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,9615.0,,,3999,CHEMBL620062,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4000,CHEMBL620063,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,9615.0,,,4001,CHEMBL620064,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4002,CHEMBL620065,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,9615.0,,,4003,CHEMBL620066,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4004,CHEMBL620067,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,9615.0,,,4005,CHEMBL620068,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4006,CHEMBL620069,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,9615.0,,,4007,CHEMBL620070,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4008,CHEMBL620071,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,9615.0,,,4009,CHEMBL620072,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4010,CHEMBL620036,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,9615.0,,,4011,CHEMBL857702,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4012,CHEMBL620037,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,9615.0,,,4013,CHEMBL620038,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4014,CHEMBL620039,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,9615.0,,,4015,CHEMBL620040,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4016,CHEMBL620041,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,9615.0,,,4017,CHEMBL620042,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4018,CHEMBL620043,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,9615.0,,,4019,CHEMBL620044,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4020,CHEMBL620045,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,9615.0,,,4021,CHEMBL620046,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4022,CHEMBL620047,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,,9615.0,,,4023,CHEMBL620048,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4024,CHEMBL857703,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,,9615.0,,,4025,CHEMBL620049,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4026,CHEMBL620050,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4027,CHEMBL620051,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4028,CHEMBL619213,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4029,CHEMBL619214,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4030,CHEMBL619804,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4031,CHEMBL619805,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4032,CHEMBL619806,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4033,CHEMBL619807,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,9615.0,,,4034,CHEMBL619808,Blood,8,1,,BAO_0000218,In vivo,Canis lupus familiaris,12832,55,F,H,,178.0,
Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,Autocuration,,,9615.0,,,4035,CHEMBL619809,,8,1,,BAO_0000218,,Canis lupus familiaris,3595,55,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,Autocuration,,,9615.0,,,4036,CHEMBL619810,,8,1,,BAO_0000218,,Canis lupus familiaris,3595,55,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,Autocuration,,,9615.0,,,4037,CHEMBL619811,,8,1,,BAO_0000218,,Canis lupus familiaris,3595,55,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,Autocuration,,,9615.0,,,4038,CHEMBL620769,,8,1,,BAO_0000218,,Canis lupus familiaris,3595,55,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,Autocuration,,,9615.0,,,4039,CHEMBL620770,,8,1,,BAO_0000218,,Canis lupus familiaris,3595,55,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,Autocuration,,,9615.0,,,4040,CHEMBL620771,,8,1,,BAO_0000218,,Canis lupus familiaris,3595,55,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,Autocuration,,,9615.0,,,4041,CHEMBL620772,,8,1,,BAO_0000218,,Canis lupus familiaris,3595,55,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,Autocuration,,,9615.0,,,4042,CHEMBL620773,,8,1,,BAO_0000218,,Canis lupus familiaris,3595,55,B,H,,,
Ability to inhibit 5-lipoxygenase in guinea pig,Autocuration,,,10141.0,,,4043,CHEMBL620774,,8,1,,BAO_0000357,,Cavia porcellus,9203,55,B,H,,,
Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),Expert,,,10141.0,,,4044,CHEMBL620775,,8,1,,BAO_0000357,,Cavia porcellus,82,55,B,H,,,
Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,Autocuration,,,10141.0,,,4045,CHEMBL620776,,8,1,,BAO_0000357,,Cavia porcellus,11090,55,B,H,,,
"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,,10141.0,,,4046,CHEMBL620777,Blood,8,1,,BAO_0000218,,Cavia porcellus,12832,55,B,H,,178.0,
In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,Autocuration,,,10141.0,,,4047,CHEMBL620778,,8,1,,BAO_0000357,,Cavia porcellus,1065,55,B,H,,,
In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,Autocuration,,,10141.0,,,4048,CHEMBL620779,,8,1,,BAO_0000357,,Cavia porcellus,1065,55,B,H,,,
In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,Expert,,,10141.0,,,4049,CHEMBL621500,,8,1,,BAO_0000019,,Cavia porcellus,12832,55,B,H,,,
In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Expert,,,10141.0,,,4050,CHEMBL621501,,8,1,,BAO_0000019,,Cavia porcellus,12832,55,B,H,,,
In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Autocuration,,,10141.0,,,4051,CHEMBL618098,,8,1,,BAO_0000019,,Cavia porcellus,12832,55,B,H,,,
Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,,,10141.0,,,4052,CHEMBL618099,,8,1,,BAO_0000019,,Cavia porcellus,10504,55,B,H,,,
Inhibitory activity against 5-lipoxygenase,Autocuration,,,10141.0,,,4053,CHEMBL618100,,8,1,,BAO_0000357,,Cavia porcellus,7788,55,B,H,,,
Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,Autocuration,,,10141.0,,,4054,CHEMBL618101,,8,1,,BAO_0000357,,Cavia porcellus,10001,55,B,H,,,
Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,Autocuration,,,10141.0,,,4055,CHEMBL618102,,8,1,,BAO_0000357,,Cavia porcellus,10193,55,B,H,,,
Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,Autocuration,,,10141.0,,,4056,CHEMBL618103,,8,1,,BAO_0000357,,Cavia porcellus,13243,55,B,H,,,
Inhibitory activity uM,Autocuration,,,10141.0,,,4057,CHEMBL618104,,8,1,,BAO_0000357,,Cavia porcellus,13243,55,B,H,,,
Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,Autocuration,,,10141.0,,,4058,CHEMBL883712,,8,1,,BAO_0000219,,Cavia porcellus,969,55,B,H,,,
Inhibitory activity against 5-lipoxygenase at 10 uM,Autocuration,,,10141.0,,,4059,CHEMBL618105,,8,1,,BAO_0000357,,Cavia porcellus,10001,55,B,H,,,
Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,,,10141.0,,,4060,CHEMBL618106,,8,1,,BAO_0000357,,Cavia porcellus,7788,55,B,H,,,
Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,Autocuration,,,10141.0,,,4061,CHEMBL618107,,8,1,,BAO_0000357,,Cavia porcellus,10001,55,B,H,,,
Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,,,10141.0,,,4062,CHEMBL618108,,8,1,,BAO_0000357,,Cavia porcellus,10193,55,B,H,,,
Inhibitory activity uM,Autocuration,,,10141.0,,,4063,CHEMBL618109,,8,1,,BAO_0000357,,Cavia porcellus,13243,55,B,H,,,
Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,Autocuration,,,10141.0,,,4064,CHEMBL618110,,8,1,,BAO_0000357,,Cavia porcellus,13243,55,B,H,,,
Inhibitory activity uM,Expert,,,10141.0,,,4065,CHEMBL618111,,8,1,,BAO_0000357,,Cavia porcellus,13243,55,B,H,,,
Inhibitory activity uM,Autocuration,,,10141.0,,,4066,CHEMBL618112,,8,1,,BAO_0000019,,Cavia porcellus,13243,55,F,H,,,
Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,,,10141.0,,,4067,CHEMBL618113,,8,1,,BAO_0000019,,Cavia porcellus,10504,55,B,H,,,
Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,,,10141.0,,,4068,CHEMBL618114,,8,1,,BAO_0000357,,Cavia porcellus,7788,55,B,H,,,
Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Expert,,,10141.0,,,4069,CHEMBL620871,Ileum,8,1,,BAO_0000221,,Cavia porcellus,10546,55,F,H,,2116.0,
5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,,,,4070,CHEMBL620872,,8,1,,BAO_0000357,,,13183,55,B,H,,,
5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,,,,,4071,CHEMBL620873,,8,1,,BAO_0000357,,,13183,55,B,H,,,
Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),Autocuration,,,,,,4072,CHEMBL620874,,8,1,,BAO_0000357,,,2578,55,B,H,,,
In vitro inhibition of human 5-Lipoxygenase.,Expert,,,,,,4073,CHEMBL620875,,8,1,,BAO_0000357,,,12780,55,B,H,,,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,,,10116.0,Microsomes,,4074,CHEMBL620876,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,,,10116.0,Microsomes,,4075,CHEMBL620877,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,,,10116.0,Microsomes,,4076,CHEMBL857854,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Autocuration,,,10116.0,Microsomes,,4077,CHEMBL620878,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,,,10116.0,Microsomes,,4078,CHEMBL620879,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,,10116.0,Microsomes,,4079,CHEMBL620880,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,,10116.0,Microsomes,,4080,CHEMBL620881,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,,,10116.0,Microsomes,,4081,CHEMBL620882,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,,,10116.0,Microsomes,,4082,CHEMBL620883,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,,,10116.0,Microsomes,,4083,CHEMBL620884,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,,,10116.0,Microsomes,,4084,CHEMBL620885,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Autocuration,,,10116.0,Microsomes,,4085,CHEMBL620886,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,,,10116.0,Microsomes,,4086,CHEMBL620887,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,,10116.0,Microsomes,,4087,CHEMBL618039,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,,,10116.0,Microsomes,,4088,CHEMBL618040,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,10116.0,Microsomes,,4089,CHEMBL618041,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,,10116.0,Microsomes,,4090,CHEMBL618216,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,,10116.0,Microsomes,,4091,CHEMBL618217,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Autocuration,,,10116.0,Microsomes,,4092,CHEMBL618218,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,10116.0,Microsomes,,4093,CHEMBL618219,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Autocuration,,,10116.0,Microsomes,,4094,CHEMBL618220,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Autocuration,,,10116.0,Microsomes,,4095,CHEMBL618221,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Autocuration,,,10116.0,Microsomes,,4096,CHEMBL618222,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,,,10116.0,Microsomes,,4097,CHEMBL618223,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,,,10116.0,Microsomes,,4098,CHEMBL618224,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Autocuration,,,10116.0,Microsomes,,4099,CHEMBL618225,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Autocuration,,,10116.0,Microsomes,,4100,CHEMBL618226,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,10116.0,Microsomes,,4101,CHEMBL618227,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,,,10116.0,Microsomes,,4102,CHEMBL618228,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,,,10116.0,Microsomes,,4103,CHEMBL618229,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,,,10116.0,Microsomes,,4104,CHEMBL618230,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,,,10116.0,Microsomes,,4105,CHEMBL618231,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,,,10116.0,Microsomes,,4106,CHEMBL618232,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,,,10116.0,Microsomes,,4107,CHEMBL618233,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,,10116.0,Microsomes,,4108,CHEMBL618234,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,,,10116.0,Microsomes,,4109,CHEMBL618235,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,,,10116.0,Microsomes,,4110,CHEMBL618115,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,,,10116.0,Microsomes,,4111,CHEMBL618116,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,,,10116.0,Microsomes,,4112,CHEMBL618117,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,,,10116.0,Microsomes,,4113,CHEMBL619968,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,,10116.0,Microsomes,,4114,CHEMBL619969,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,,,10116.0,Microsomes,,4115,CHEMBL619970,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Autocuration,,,10116.0,Microsomes,,4116,CHEMBL619971,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Autocuration,,,10116.0,Microsomes,,4117,CHEMBL619972,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Autocuration,,,10116.0,Microsomes,,4118,CHEMBL619973,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Autocuration,,,10116.0,Microsomes,,4119,CHEMBL619974,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,,10116.0,Microsomes,,4120,CHEMBL619975,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,,,10116.0,Microsomes,,4121,CHEMBL619976,,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,,
"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,,10116.0,Microsomes,,4122,CHEMBL619977,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,,10116.0,Microsomes,,4123,CHEMBL619978,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Autocuration,,,10116.0,Microsomes,,4124,CHEMBL619979,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,,10116.0,Microsomes,,4125,CHEMBL619980,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,,10116.0,Microsomes,,4126,CHEMBL619981,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
In vitro inhibition of 7226/S myeloma cancer cell line,Intermediate,,741.0,9606.0,,,4127,CHEMBL619982,,1,1,,BAO_0000219,,Homo sapiens,10797,80433,F,N,RPMI-8226,,
In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),Intermediate,,993.0,9606.0,,,4128,CHEMBL619983,,1,1,,BAO_0000219,,Homo sapiens,6881,80698,F,N,BEL-7404 tumor cell line,,
In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,,391.0,9606.0,,,4129,CHEMBL620031,,1,1,,BAO_0000219,,Homo sapiens,3838,80640,F,N,786-0,,
In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,,391.0,9606.0,,,4130,CHEMBL620032,,1,1,,BAO_0000219,,Homo sapiens,3838,80640,F,N,786-0,,
Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,Expert,,505.0,10029.0,,,4131,CHEMBL620033,,1,1,,BAO_0000219,,Cricetulus griseus,12981,81264,F,N,V79,,
Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,Expert,,505.0,10029.0,,,4132,CHEMBL620034,,1,1,,BAO_0000219,,Cricetulus griseus,12981,81264,F,N,V79,,
Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,Intermediate,,1119.0,10116.0,,,4133,CHEMBL620035,,1,1,,BAO_0000219,,Rattus norvegicus,7653,80635,F,N,7800C1 cell line,,
Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,Intermediate,,1119.0,10116.0,,,4134,CHEMBL618318,,1,1,,BAO_0000219,,Rattus norvegicus,7653,80635,F,N,7800C1 cell line,,
Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,Intermediate,,1119.0,10116.0,,,4135,CHEMBL618319,,1,1,,BAO_0000219,,Rattus norvegicus,7653,80635,F,N,7800C1 cell line,,
Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,Intermediate,,1119.0,10116.0,,,4136,CHEMBL618320,,1,1,,BAO_0000219,,Rattus norvegicus,7653,80635,F,N,7800C1 cell line,,
Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,Intermediate,,1119.0,10116.0,,,4137,CHEMBL618321,,1,1,,BAO_0000219,,Rattus norvegicus,7653,80635,F,N,7800C1 cell line,,
Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,Intermediate,,1119.0,10116.0,,,4138,CHEMBL883118,,1,1,,BAO_0000219,,Rattus norvegicus,7653,80635,F,N,7800C1 cell line,,
In vitro antitumor activity against renal 786-0 tumor cell lines,Intermediate,,391.0,9606.0,,,4139,CHEMBL883795,,1,1,,BAO_0000219,,Homo sapiens,17229,80640,F,N,786-0,,
Cytotoxic activity against 786-0 Renal cancer cell line,Intermediate,,391.0,9606.0,,,4140,CHEMBL618322,,1,1,,BAO_0000219,,Homo sapiens,12858,80640,F,N,786-0,,
Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,Intermediate,,391.0,9606.0,,,4141,CHEMBL618323,,1,1,,BAO_0000219,,Homo sapiens,16325,80640,F,N,786-0,,
Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,Intermediate,,391.0,9606.0,,,4142,CHEMBL618324,,1,1,,BAO_0000219,,Homo sapiens,16325,80640,F,N,786-0,,
In vitro antitumor activity against human renal 786-0 cell line,Intermediate,,391.0,9606.0,,,4143,CHEMBL618325,,1,1,,BAO_0000219,,Homo sapiens,5858,80640,F,N,786-0,,
Inhibition of Renal cancer in 786-0 cancer cell lines,Intermediate,,391.0,9606.0,,,4144,CHEMBL875416,,1,1,,BAO_0000219,,Homo sapiens,16325,80640,F,N,786-0,,
Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,Intermediate,,391.0,9606.0,,,4145,CHEMBL618326,,1,1,,BAO_0000219,,Homo sapiens,14696,80640,F,N,786-0,,
The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,Intermediate,,391.0,9606.0,,,4146,CHEMBL618327,,1,1,,BAO_0000219,,Homo sapiens,3786,80640,F,N,786-0,,
inhibition of the growth of renal cancer(786-0) cell line,Intermediate,,391.0,9606.0,,,4147,CHEMBL619215,,1,1,,BAO_0000219,,Homo sapiens,14696,80640,F,N,786-0,,
Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,,391.0,9606.0,,,4148,CHEMBL619216,,1,1,,BAO_0000219,,Homo sapiens,14769,80640,F,N,786-0,,
Compound was tested for the growth inhibition of 786-0 renal tumor cell line,Intermediate,,391.0,9606.0,,,4149,CHEMBL619217,,1,1,,BAO_0000219,,Homo sapiens,15354,80640,F,N,786-0,,
The IC50 value was measured on 786-0 cell line in ovarian tumor,Intermediate,,391.0,9606.0,,,4150,CHEMBL619218,,1,1,,BAO_0000219,,Homo sapiens,14255,80640,F,N,786-0,,
The IC50 value was measured on 786-0 cell line in ovarian tumor t,Intermediate,,391.0,9606.0,,,4151,CHEMBL619219,,1,1,,BAO_0000219,,Homo sapiens,14255,80640,F,N,786-0,,
The IC50 value was measured on 786-0 cell line in renal tumor type.,Intermediate,,391.0,9606.0,,,4152,CHEMBL619220,,1,1,,BAO_0000219,,Homo sapiens,14255,80640,F,N,786-0,,
Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,Intermediate,,391.0,9606.0,,,4153,CHEMBL619221,,1,1,,BAO_0000219,,Homo sapiens,14696,80640,F,N,786-0,,
Tested for cytotoxic activity against renal cancer 786-0 cell line,Intermediate,,391.0,9606.0,,,4154,CHEMBL619222,,1,1,,BAO_0000219,,Homo sapiens,12016,80640,F,N,786-0,,
Compound was tested for growth inhibitory activity against 786-0 cell line,Intermediate,,391.0,9606.0,,,4155,CHEMBL857454,,1,1,,BAO_0000219,,Homo sapiens,2597,80640,F,N,786-0,,
Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,Autocuration,,702.0,,,,4156,CHEMBL619223,,8,1,,BAO_0000219,,,12526,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,Autocuration,,702.0,,,,4157,CHEMBL619224,,8,1,,BAO_0000219,,,12526,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,,,,,,4158,CHEMBL619225,,8,1,,BAO_0000019,,,14799,12166,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Expert,,702.0,,,,4159,CHEMBL619226,,8,1,,BAO_0000219,,,3595,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Expert,,702.0,,,,4160,CHEMBL619227,,8,1,,BAO_0000219,,,3595,12166,B,H,RBL-1,,
Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,Autocuration,,,,,,4161,CHEMBL619228,,8,1,,BAO_0000357,,,12767,12166,B,H,,,
Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,,,,,4162,CHEMBL619229,,8,1,,BAO_0000219,,,10997,12166,B,H,,,
Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,Autocuration,,702.0,,,,4163,CHEMBL619230,,8,1,,BAO_0000219,,,11388,12166,B,H,RBL-1,,
Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,Autocuration,,,,,,4164,CHEMBL619231,,8,1,,BAO_0000357,,,167,12166,B,H,,,
"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,,,,,4165,CHEMBL619232,,8,1,,BAO_0000357,,,167,12166,B,H,,,
Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,Expert,,,,,,4166,CHEMBL619233,,8,1,,BAO_0000357,,,13744,12166,B,H,,,
Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,Autocuration,,,,,,4167,CHEMBL619234,,8,1,,BAO_0000357,,,1630,12166,B,H,,,
Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),Autocuration,,,,,,4168,CHEMBL619235,,8,1,,BAO_0000357,,,1630,12166,B,H,,,
"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",Expert,,,10116.0,,,4169,CHEMBL619236,,9,1,,BAO_0000019,,Rattus norvegicus,969,12166,B,D,,,
Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,Autocuration,,702.0,,,,4170,CHEMBL619237,,8,1,,BAO_0000219,,,13621,12166,B,H,RBL-1,,
Inhibitory concentration to inhibit 5-lipoxygenase in the rat,Autocuration,,,,,,4171,CHEMBL619238,,8,1,,BAO_0000357,,,10089,12166,B,H,,,
In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,Expert,,,,,,4172,CHEMBL619239,,8,1,,BAO_0000357,,,10193,12166,B,H,,,
Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,Autocuration,,,,,,4173,CHEMBL619240,,8,1,,BAO_0000357,,,11966,12166,B,H,,,
Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Autocuration,,,,,,4174,CHEMBL875417,,8,1,,BAO_0000019,,,12251,12166,B,H,,,
Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),Autocuration,,702.0,,,,4175,CHEMBL619241,,8,1,,BAO_0000219,,,211,12166,B,H,RBL-1,,
Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Expert,,,,,,4176,CHEMBL619242,,8,1,,BAO_0000019,,,12251,12166,F,H,,,
Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,Autocuration,,702.0,,,,4177,CHEMBL883796,,8,1,,BAO_0000219,,,12495,12166,B,H,RBL-1,,
Tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,,,,,4178,CHEMBL619243,,8,1,,BAO_0000357,,,414,12166,B,H,,,
Tested for its inhibitory activity against 5-lipoxygenase; Not determined,Autocuration,,,,,,4179,CHEMBL619244,,8,1,,BAO_0000357,,,414,12166,B,H,,,
"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",Expert,,,,,,4180,CHEMBL619245,,8,1,,BAO_0000019,,,10325,12166,B,H,,,
In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Expert,,,,,,4181,CHEMBL619246,,8,1,,BAO_0000019,,,11966,12166,B,H,,,
In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,,702.0,,,,4182,CHEMBL619984,,8,1,,BAO_0000219,,,165,12166,B,H,RBL-1,,
The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,Autocuration,,702.0,,,,4183,CHEMBL619985,,8,1,,BAO_0000219,,,165,12166,B,H,RBL-1,,
The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Autocuration,,702.0,,,,4184,CHEMBL619986,,8,1,,BAO_0000219,,,165,12166,B,H,RBL-1,,
In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,,702.0,,,,4185,CHEMBL619987,,8,1,,BAO_0000219,,,165,12166,B,H,RBL-1,,
The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,Autocuration,,,,,,4186,CHEMBL619988,,8,1,,BAO_0000218,,,11311,12166,B,H,,,
The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,Autocuration,,702.0,,,,4187,CHEMBL619989,,8,1,,BAO_0000219,,,11311,12166,B,H,RBL-1,,
The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Autocuration,,702.0,,,,4188,CHEMBL619990,,8,1,,BAO_0000219,,,11311,12166,B,H,RBL-1,,
The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,,4189,CHEMBL619991,,8,1,,BAO_0000219,,,11311,12166,B,H,,,
The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),Autocuration,,,,,,4190,CHEMBL619992,,8,1,,BAO_0000219,,,11311,12166,B,H,,,
The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),Autocuration,,,,,,4191,CHEMBL619993,,8,1,,BAO_0000218,In vivo,,11311,12166,B,H,,,
The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,Autocuration,,663.0,,,,4192,CHEMBL619994,,8,1,,BAO_0000219,,,11311,12166,F,H,RBL-2H3,,
The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,Autocuration,,663.0,,,,4193,CHEMBL619995,,8,1,,BAO_0000219,,,11311,12166,F,H,RBL-2H3,,
The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],Autocuration,,,,,,4194,CHEMBL619996,,8,1,,BAO_0000019,,,11311,12166,B,H,,,
The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,Autocuration,,,,,,4195,CHEMBL619997,,8,1,,BAO_0000019,,,11732,12166,B,H,,,
Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,Expert,,,,,,4196,CHEMBL619998,,8,1,,BAO_0000019,,,11732,12166,B,H,,,
In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,Expert,,,,,,4197,CHEMBL619999,,8,1,,BAO_0000019,,,11087,12166,B,H,,,
The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,Autocuration,,,,,,4198,CHEMBL620000,,8,1,,BAO_0000019,,,11087,12166,B,H,,,
The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,Autocuration,,702.0,,,,4199,CHEMBL620001,,8,1,,BAO_0000219,,,11087,12166,B,H,RBL-1,,
Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,Expert,,,10116.0,,,4200,CHEMBL620002,,9,1,,BAO_0000357,,Rattus norvegicus,11087,12166,B,D,,,
The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,Autocuration,,702.0,,,,4201,CHEMBL620003,,8,1,,BAO_0000219,,,496,12166,B,H,RBL-1,,
Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,Expert,,702.0,,,,4202,CHEMBL620004,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
Compound was evaluated for the inhibition of 5-lipoxygenase,Autocuration,,,,,,4203,CHEMBL874063,,8,1,,BAO_0000357,,,11520,12166,B,H,,,
Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,Autocuration,,702.0,,,,4204,CHEMBL620005,,8,1,,BAO_0000219,,,10293,12166,B,H,RBL-1,,
Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,Autocuration,,702.0,,,,4205,CHEMBL620006,,8,1,,BAO_0000219,,,303,12166,B,H,RBL-1,,
Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,Autocuration,,702.0,,,,4206,CHEMBL620007,,8,1,,BAO_0000219,,,303,12166,B,H,RBL-1,,
Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,Autocuration,,702.0,,,,4207,CHEMBL620008,,8,1,,BAO_0000219,,,9247,12166,B,H,RBL-1,,
Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,Expert,,702.0,10116.0,,,4208,CHEMBL620009,,9,1,,BAO_0000219,,Rattus norvegicus,9247,12166,B,D,RBL-1,,
Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,,702.0,,,,4209,CHEMBL620010,,8,1,,BAO_0000219,,,9247,12166,B,H,RBL-1,,
Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,Autocuration,,702.0,,,,4210,CHEMBL620011,,8,1,,BAO_0000219,,,9247,12166,B,H,RBL-1,,
Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,Autocuration,,702.0,,,,4211,CHEMBL620677,,8,1,,BAO_0000219,,,9247,12166,B,H,RBL-1,,
Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,Autocuration,,702.0,,,,4212,CHEMBL620678,,8,1,,BAO_0000219,,,9247,12166,B,H,RBL-1,,
Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,Autocuration,,702.0,,,,4213,CHEMBL620679,,8,1,,BAO_0000219,,,9247,12166,B,H,RBL-1,,
Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,Autocuration,,702.0,,,,4214,CHEMBL620680,,8,1,,BAO_0000219,,,9247,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase at 10 uM,Expert,,,10116.0,,,4215,CHEMBL620838,,9,1,,BAO_0000357,,Rattus norvegicus,11481,12166,B,D,,,
In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,Autocuration,,,,,,4216,CHEMBL620839,,8,1,,BAO_0000357,,,105,12166,B,H,,,
In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,Expert,,,,,,4217,CHEMBL620840,,8,1,,BAO_0000357,,,9029,12166,B,H,,,
Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,Expert,,702.0,,,,4218,CHEMBL620841,,8,1,,BAO_0000219,,,1175,12166,B,H,RBL-1,,
In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,Autocuration,,702.0,,,,4219,CHEMBL620842,,8,1,,BAO_0000219,,,12118,12166,B,H,RBL-1,,
In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,Autocuration,,702.0,,,,4220,CHEMBL620843,,8,1,,BAO_0000219,,,12118,12166,B,H,RBL-1,,
In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,Autocuration,,702.0,,,,4221,CHEMBL620844,,8,1,,BAO_0000219,,,12118,12166,B,H,RBL-1,,
In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,Autocuration,,702.0,,,,4222,CHEMBL620845,,8,1,,BAO_0000219,,,9225,12166,B,H,RBL-1,,
In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,Autocuration,,,,,,4223,CHEMBL620846,,8,1,,BAO_0000019,,,9401,12166,B,H,,,
In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,,,,,4224,CHEMBL873951,,8,1,,BAO_0000357,,,137,12166,B,H,,,
In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,,,,,4225,CHEMBL620847,,8,1,,BAO_0000357,,,137,12166,B,H,,,
In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,,702.0,,,,4226,CHEMBL620848,,8,1,,BAO_0000219,,,4717,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,,702.0,,,,4227,CHEMBL620849,,8,1,,BAO_0000219,,,3595,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,Autocuration,,702.0,,,,4228,CHEMBL620850,,8,1,,BAO_0000219,,,10501,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,Autocuration,,702.0,,,,4229,CHEMBL620851,,8,1,,BAO_0000219,,,10501,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,Autocuration,,702.0,,,,4230,CHEMBL620852,,8,1,,BAO_0000219,,,10501,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,702.0,,,,4231,CHEMBL875098,,8,1,,BAO_0000219,,,12526,12166,B,H,RBL-1,,
Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,Expert,,702.0,10116.0,,,4232,CHEMBL620853,,9,1,,BAO_0000219,,Rattus norvegicus,14799,12166,B,D,RBL-1,,
Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,Autocuration,,,,,,4233,CHEMBL620854,,8,1,,BAO_0000019,,,14799,12166,B,H,,,
Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,,702.0,,,,4234,CHEMBL620855,,8,1,,BAO_0000219,,,3595,12166,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Expert,,702.0,,,,4235,CHEMBL839884,,8,1,,BAO_0000219,,,3595,12166,B,H,RBL-1,,
Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,702.0,,,,4236,CHEMBL620856,,8,1,,BAO_0000219,,,12526,12166,B,H,RBL-1,,
Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,,702.0,,,,4237,CHEMBL620857,,8,1,,BAO_0000219,,,12526,12166,B,H,RBL-1,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,,,,,4238,CHEMBL620858,,8,1,,BAO_0000019,,,10193,12166,B,H,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,,,,,4239,CHEMBL620859,,8,1,,BAO_0000019,,,10193,12166,B,H,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,,,,,4240,CHEMBL620860,,8,1,,BAO_0000019,,,10193,12166,B,H,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,Autocuration,,,,,,4241,CHEMBL620861,,8,1,,BAO_0000019,,,10193,12166,B,H,,,
Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),Expert,,,,,,4242,CHEMBL620862,,8,1,,BAO_0000357,,,9138,12166,B,H,,,
Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,Autocuration,,,,,,4243,CHEMBL620863,,8,1,,BAO_0000357,,,9138,12166,B,H,,,
Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Autocuration,,,,,,4244,CHEMBL620864,,8,1,,BAO_0000019,,,11966,12166,B,H,,,
The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,Autocuration,,702.0,,,,4245,CHEMBL620865,,8,1,,BAO_0000219,,,165,12166,B,H,RBL-1,,
The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,Autocuration,,702.0,,,,4246,CHEMBL620866,,8,1,,BAO_0000219,,,165,12166,B,H,RBL-1,,
The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,Autocuration,,663.0,,,,4247,CHEMBL620867,,8,1,,BAO_0000219,,,11311,12166,B,H,RBL-2H3,,
The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,,663.0,,,,4248,CHEMBL620868,,8,1,,BAO_0000219,,,11311,12166,B,H,RBL-2H3,,
The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,,663.0,,,,4249,CHEMBL620869,,8,1,,BAO_0000219,,,11311,12166,F,H,RBL-2H3,,
The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,Autocuration,,,,,,4250,CHEMBL873952,,8,1,,BAO_0000019,,,11311,12166,F,H,,,
The compound was tested for inhibition of isolated 5-lipoxygenase,Autocuration,,,,,,4251,CHEMBL875099,,8,1,,BAO_0000357,,,11311,12166,B,H,,,
The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,Autocuration,,663.0,,,,4252,CHEMBL620870,,8,1,,BAO_0000219,,,11311,12166,F,H,RBL-2H3,,
The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,Autocuration,,,,,,4253,CHEMBL618261,,8,1,,BAO_0000019,,,11087,12166,B,H,,,
The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,Autocuration,,,,,,4254,CHEMBL618262,,8,1,,BAO_0000019,,,11087,12166,B,H,,,
The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,Autocuration,,,,,,4255,CHEMBL619428,,8,1,,BAO_0000019,,,11087,12166,B,H,,,
The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,,,,,4256,CHEMBL619429,,8,1,,BAO_0000019,,,11087,12166,B,H,,,
The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,,,,,4257,CHEMBL619430,,8,1,,BAO_0000019,,,11087,12166,B,H,,,
The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,Autocuration,,702.0,,,,4258,CHEMBL620017,,8,1,,BAO_0000219,,,496,12166,B,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,Autocuration,,702.0,,,,4259,CHEMBL620018,,8,1,,BAO_0000219,,,496,12166,B,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,Autocuration,,702.0,,,,4260,CHEMBL620019,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,Autocuration,,702.0,,,,4261,CHEMBL620020,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,Autocuration,,702.0,,,,4262,CHEMBL620021,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,Autocuration,,702.0,,,,4263,CHEMBL620022,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,Autocuration,,702.0,,,,4264,CHEMBL620023,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,Autocuration,,702.0,,,,4265,CHEMBL620024,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,Autocuration,,702.0,,,,4266,CHEMBL620025,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,Autocuration,,702.0,,,,4267,CHEMBL620026,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,Autocuration,,702.0,,,,4268,CHEMBL620027,,8,1,,BAO_0000219,,,13986,12166,F,H,RBL-1,,
Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,Expert,,,10116.0,,,4269,CHEMBL620028,,9,1,,BAO_0000019,,Rattus norvegicus,13986,12166,F,D,,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,Autocuration,,,,,,4270,CHEMBL620029,,8,1,,BAO_0000357,,,10193,12166,B,H,,,
Compound was tested for the percent of inhibition against 5-LO at 10 uM,Autocuration,,,,,,4271,CHEMBL620030,,8,1,,BAO_0000357,,,9295,12166,B,H,,,
In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,Autocuration,,702.0,,,,4272,CHEMBL875415,,8,1,,BAO_0000219,,,4717,12166,B,H,RBL-1,,
In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,,702.0,,,,4273,CHEMBL618256,,8,1,,BAO_0000219,,,4717,12166,B,H,RBL-1,,
Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,Autocuration,,702.0,,,,4274,CHEMBL618257,,8,1,,BAO_0000219,,,11854,12166,B,H,RBL-1,,
Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,Autocuration,,702.0,,,,4275,CHEMBL618258,,8,1,,BAO_0000219,,,11854,12166,B,H,RBL-1,,
Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,Autocuration,,702.0,,,,4276,CHEMBL618259,,8,1,,BAO_0000219,,,11854,12166,B,H,RBL-1,,
In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,,,,,4277,CHEMBL618260,,8,1,,BAO_0000019,,,10193,12166,B,H,,,
Percent inhibition against RBL-1 5-LO in vitro at 10 uM,Autocuration,,702.0,,,,4278,CHEMBL618215,,8,1,,BAO_0000219,,,9295,12166,B,H,RBL-1,,
Percent inhibition against RBL-1 5-LO in vitro at 100 uM,Autocuration,,702.0,,,,4279,CHEMBL618390,,8,1,,BAO_0000219,,,9295,12166,B,H,RBL-1,,
Percent inhibition against RBL-1 5-LO in vitro at 30 uM,Autocuration,,702.0,,,,4280,CHEMBL618391,,8,1,,BAO_0000219,,,9295,12166,B,H,RBL-1,,
Percent inhibition against RBL-1 5-LO in vitro at 300 uM,Autocuration,,702.0,,,,4281,CHEMBL618392,,8,1,,BAO_0000219,,,9295,12166,B,H,RBL-1,,
The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,Autocuration,,702.0,,,,4282,CHEMBL618393,,8,1,,BAO_0000219,,,165,12166,B,H,RBL-1,,
The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,Autocuration,,,,,,4283,CHEMBL618394,,8,1,,BAO_0000219,,,11311,12166,B,H,,,
In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,,702.0,9606.0,,,4284,CHEMBL618395,,8,1,,BAO_0000219,,Homo sapiens,10489,12166,B,H,RBL-1,,
In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,,702.0,10116.0,,,4285,CHEMBL618396,,9,1,,BAO_0000219,,Rattus norvegicus,10489,12166,B,D,RBL-1,,
Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),Expert,,702.0,10116.0,,,4286,CHEMBL858253,,9,1,,BAO_0000219,,Rattus norvegicus,10489,12166,B,D,RBL-1,,
Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,,,10116.0,,,4287,CHEMBL618397,,9,1,,BAO_0000019,,Rattus norvegicus,14799,12166,B,D,,,
Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),Autocuration,,,3847.0,,,4288,CHEMBL618398,,8,1,,BAO_0000357,,Glycine max,9295,12054,B,H,,,
"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",Autocuration,,,,,,4289,CHEMBL618399,,0,1,,BAO_0000019,,,16811,22226,B,U,,,
In vitro inhibition of 5-Lipoxygenase; Inactive.,Expert,,,,,,4290,CHEMBL618400,,8,1,,BAO_0000357,,,168,55,B,H,,,
Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,Autocuration,,,,,,4291,CHEMBL618401,,8,1,,BAO_0000357,,,6309,55,B,H,,,
Inhibitory concentration against 5-lipoxygenase; No inhibition,Autocuration,,,,,,4292,CHEMBL618402,,8,1,,BAO_0000357,,,6309,55,B,H,,,
Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,Autocuration,,702.0,,,,4293,CHEMBL876400,,8,1,,BAO_0000219,,,3092,55,B,H,RBL-1,,
Inhibitory activity against 5-lipoxygenase.,Expert,,,,,,4294,CHEMBL618403,,8,1,,BAO_0000357,,,168,55,B,H,,,
Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,Autocuration,,,,,,4295,CHEMBL618404,,8,1,,BAO_0000357,,,168,55,B,H,,,
Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,Autocuration,,,,,,4296,CHEMBL618405,,8,1,,BAO_0000357,,,168,55,B,H,,,
Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,Autocuration,,,,,,4297,CHEMBL618406,,8,1,,BAO_0000357,,,168,55,B,H,,,
Inhibitory concentration against arachidonic acid 5-lipoxygenation,Expert,,,,,,4298,CHEMBL618407,,8,1,,BAO_0000019,,,12338,55,F,H,,,
Tested for the inhibitory activity against 5-lipoxygenase,Autocuration,,,,,,4299,CHEMBL618408,,8,1,,BAO_0000357,,,4501,55,B,H,,,
Compound was tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,,,,,4300,CHEMBL618409,,8,1,,BAO_0000357,,,1132,55,B,H,,,
Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,Autocuration,,,,,,4301,CHEMBL618410,,8,1,,BAO_0000357,,,2117,55,B,H,,,
Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,Autocuration,,,,,,4302,CHEMBL618411,,8,1,,BAO_0000357,,,168,55,B,H,,,
Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,Autocuration,,,,,,4303,CHEMBL618412,,8,1,,BAO_0000357,,,168,55,B,H,,,
Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,Autocuration,,702.0,,,,4304,CHEMBL618413,,8,1,,BAO_0000219,,,13575,12166,B,H,RBL-1,,
,Autocuration,,,,,,4305,CHEMBL618414,,8,1,,BAO_0000357,,,11089,12166,B,H,,,
Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),Autocuration,,,,,,4306,CHEMBL618415,,8,1,,BAO_0000357,,,216,10102,B,H,,,
Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,Autocuration,,,,,,4307,CHEMBL618416,,8,1,,BAO_0000019,,,13165,10102,B,H,,,
Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,Autocuration,,,,,,4308,CHEMBL876401,,8,1,,BAO_0000357,,,3278,10102,B,H,,,
Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,Expert,,,,,,4309,CHEMBL618417,,8,1,,BAO_0000357,,,3278,10102,B,H,,,
Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,Autocuration,,,,,,4310,CHEMBL618418,,8,1,,BAO_0000357,,,11966,10102,B,H,,,
"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",Autocuration,,,,,,4311,CHEMBL618419,,8,1,,BAO_0000357,,,175,10102,B,H,,,
"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",Autocuration,,,,,,4312,CHEMBL618420,,8,1,,BAO_0000357,,,175,10102,B,H,,,
Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,Autocuration,,,,,,4313,CHEMBL618421,,8,1,,BAO_0000357,,,13449,10102,B,H,,,
Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,Autocuration,,,,,,4314,CHEMBL618422,,8,1,,BAO_0000019,,,12014,11238,B,H,,,
Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),Autocuration,,,,,,4315,CHEMBL618423,,8,1,,BAO_0000019,,,12014,11238,B,H,,,
Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),Autocuration,,,,,,4316,CHEMBL618424,,8,1,,BAO_0000019,,,12014,11238,B,H,,,
Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,Intermediate,,,,,,4317,CHEMBL618425,,2,1,,BAO_0000220,,,99,100284,B,S,,,
The dark toxicity against 543 human galactophore carcinoma cells,Autocuration,,,9606.0,,,4318,CHEMBL618426,,0,1,,BAO_0000019,,Homo sapiens,4349,22226,F,U,,,
Tested in vitro for cytotoxicity against 56 human tumor cell lines,Expert,,390.0,9606.0,,,4319,CHEMBL618427,,1,1,,BAO_0000219,,Homo sapiens,4071,80623,F,N,Panel (56 tumour cell lines),,
Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,Expert,,345.0,9606.0,,,4320,CHEMBL618428,,1,1,,BAO_0000219,,Homo sapiens,17589,80008,F,N,5637,,
Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,Intermediate,,345.0,9606.0,,,4321,CHEMBL618429,,1,1,,BAO_0000219,,Homo sapiens,15002,80008,F,N,5637,,
"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",Intermediate,,345.0,9606.0,,,4322,CHEMBL618430,,1,1,,BAO_0000219,,Homo sapiens,13958,80008,F,N,5637,,
Growth inhibition against human 5637 cell lines,Expert,,345.0,9606.0,,,4323,CHEMBL618431,,1,1,,BAO_0000219,,Homo sapiens,17589,80008,F,N,5637,,
Antitumor activity against human bladder carcinoma 5637 cells.,Expert,,345.0,9606.0,,,4324,CHEMBL883799,,1,1,,BAO_0000219,,Homo sapiens,16748,80008,F,N,5637,,
Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,,345.0,9606.0,,,4325,CHEMBL618432,,1,1,,BAO_0000219,,Homo sapiens,16747,80008,F,N,5637,,
Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,,345.0,9606.0,,,4326,CHEMBL618433,,1,1,,BAO_0000219,,Homo sapiens,16747,80008,F,N,5637,,
In vitro inhibition of bovine trypsin(Trp).,Expert,,,9913.0,,,4327,CHEMBL618434,,9,1,,BAO_0000357,,Bos taurus,15285,10443,B,D,,,
Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,Expert,,407.0,9527.0,,,4328,CHEMBL618435,,8,1,,BAO_0000219,,Cercopithecidae,3726,240,B,H,CV-1,,
Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,Autocuration,,,,,,4329,CHEMBL876402,,8,1,,BAO_0000357,,,5033,10577,B,H,,,
In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,Autocuration,,,,,,4330,CHEMBL618436,,6,1,,BAO_0000019,,,11756,104698,F,H,,,
Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,Autocuration,,,,,,4331,CHEMBL618437,,0,1,,BAO_0000218,In vivo,,11953,22226,F,U,,,
Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,Intermediate,,,10141.0,,,4332,CHEMBL618438,,9,1,,BAO_0000357,,Cavia porcellus,5033,20033,B,D,,,
Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,,,10116.0,Microsomes,,4333,CHEMBL883800,,8,1,,BAO_0000251,,Rattus norvegicus,11347,17045,A,H,,,
Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,,,10116.0,Microsomes,,4334,CHEMBL618439,,8,1,,BAO_0000251,,Rattus norvegicus,11347,17045,A,H,,,
In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,,,,,4335,CHEMBL618440,,0,1,,BAO_0000019,,,1229,22226,F,U,,,
In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,,,,,4336,CHEMBL618441,,0,1,,BAO_0000019,,,1229,22226,F,U,,,
Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,Expert,,,5691.0,,,4337,CHEMBL618442,,8,1,,BAO_0000019,,Trypanosoma brucei,17588,11938,B,H,,,
Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,Autocuration,,,5691.0,,,4338,CHEMBL618443,,8,1,,BAO_0000019,,Trypanosoma brucei,17588,11938,B,H,,,
Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,Expert,,,9940.0,,,4339,CHEMBL619158,,8,1,,BAO_0000019,,Ovis aries,17588,11938,B,H,,,
Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,Autocuration,,,9940.0,,,4340,CHEMBL620974,,8,1,,BAO_0000019,,Ovis aries,17588,11938,B,H,,,
log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,Autocuration,,,,,,4341,CHEMBL620975,,8,1,,BAO_0000357,,,16485,11938,B,H,,,
Average inhibitory concentration against 60 human cell lines was reported,Intermediate,,,9606.0,,,4342,CHEMBL620976,,0,1,,BAO_0000019,,Homo sapiens,4337,22226,F,U,,,
Inhibition of proliferation in NCI panel of 60 human tumor cell lines,Expert,,,9606.0,,,4343,CHEMBL620977,,0,1,,BAO_0000019,,Homo sapiens,4112,22226,F,U,,,
Cancer specificity was measured from the +/- value under average log LC50 60-cell line,Intermediate,,542.0,9606.0,,,4344,CHEMBL620978,,1,1,,BAO_0000219,,Homo sapiens,16160,80315,F,N,Panel NCI-60 (60 carcinoma cell lines),,
Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,Intermediate,,542.0,9606.0,,,4345,CHEMBL620979,,1,1,,BAO_0000219,,Homo sapiens,16160,80315,F,N,Panel NCI-60 (60 carcinoma cell lines),,
In vitro mean growth inhibitory activity against 60-cell panel,Expert,,542.0,,,,4346,CHEMBL620980,,1,1,,BAO_0000219,,,17376,80315,F,N,Panel NCI-60 (60 carcinoma cell lines),,
In vitro mean growth lethal concentration against 60-cell panel,Expert,,542.0,,,,4347,CHEMBL620981,,1,1,,BAO_0000219,,,17376,80315,F,N,Panel NCI-60 (60 carcinoma cell lines),,
In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,Expert,,542.0,,,,4348,CHEMBL620982,,1,1,,BAO_0000219,,,17376,80315,F,N,Panel NCI-60 (60 carcinoma cell lines),,
In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,Expert,,542.0,,,,4349,CHEMBL620983,,1,1,,BAO_0000219,,,17376,80315,F,N,Panel NCI-60 (60 carcinoma cell lines),,
Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,,,,,4350,CHEMBL620984,,4,1,,BAO_0000019,,,3241,104775,F,H,,,
Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,,,,,4351,CHEMBL620985,,4,1,,BAO_0000019,,,3241,104775,F,H,,,
Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,Expert,,,,,,4352,CHEMBL620986,,8,1,,BAO_0000357,,,3725,275,B,H,,,
Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,Expert,,,5833.0,,,4353,CHEMBL620987,,1,1,,BAO_0000218,,Plasmodium falciparum,10805,50425,F,N,,,
In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,Expert,,,5833.0,,,4354,CHEMBL620988,,1,1,,BAO_0000218,,Plasmodium falciparum,10805,50425,F,N,,,
Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,Expert,,,5833.0,,,4355,CHEMBL620989,,1,1,,BAO_0000218,,Plasmodium falciparum,10805,50425,F,N,,,
Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,Expert,,,5833.0,,,4356,CHEMBL620990,,1,1,,BAO_0000218,,Plasmodium falciparum,10805,50425,F,N,,,
Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,Intermediate,,,5833.0,,,4357,CHEMBL620991,,1,1,,BAO_0000218,,Plasmodium falciparum,10805,50425,F,N,,,
Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Intermediate,,850.0,10090.0,,,4358,CHEMBL620992,,1,1,,BAO_0000218,,Mus musculus,10144,80628,F,N,6C3HED,,
Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Intermediate,,850.0,10090.0,,,4359,CHEMBL620993,,1,1,,BAO_0000218,,Mus musculus,10144,80628,F,N,6C3HED,,
Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,Intermediate,,850.0,10090.0,,,4360,CHEMBL620994,,1,1,,BAO_0000218,,Mus musculus,10144,80628,F,N,6C3HED,,
Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Intermediate,,850.0,10090.0,,,4361,CHEMBL620995,,1,1,,BAO_0000218,,Mus musculus,10144,80628,F,N,6C3HED,,
Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Intermediate,,850.0,10090.0,,,4362,CHEMBL620996,,1,1,,BAO_0000218,,Mus musculus,10144,80628,F,N,6C3HED,,
Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,Intermediate,,850.0,10090.0,,,4363,CHEMBL875581,,1,1,,BAO_0000218,,Mus musculus,10144,80628,F,N,6C3HED,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,Autocuration,,,10090.0,,,4364,CHEMBL620997,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,Autocuration,,,10090.0,,,4365,CHEMBL620998,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),Autocuration,,,10090.0,,,4366,CHEMBL620999,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,Autocuration,,,10090.0,,,4367,CHEMBL621000,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,Autocuration,,,10090.0,,,4368,CHEMBL621001,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,Autocuration,,,10090.0,,,4369,CHEMBL621002,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,Autocuration,,,10090.0,,,4370,CHEMBL621003,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",Autocuration,,,10090.0,,,4371,CHEMBL621004,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),Autocuration,,,10090.0,,,4372,CHEMBL621005,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),Autocuration,,,10090.0,,,4373,CHEMBL621006,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,Autocuration,,,10090.0,,,4374,CHEMBL621007,,0,1,,BAO_0000218,In vivo,Mus musculus,10685,22224,F,U,,,
Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Autocuration,,,10090.0,,,4375,CHEMBL621008,,0,1,,BAO_0000218,,Mus musculus,10144,22224,F,U,,,
Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Autocuration,,,10090.0,,,4376,CHEMBL621009,,0,1,,BAO_0000218,,Mus musculus,10144,22224,F,U,,,
Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Autocuration,,,10090.0,,,4377,CHEMBL857705,,0,1,,BAO_0000218,,Mus musculus,10144,22224,F,U,,,
Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Autocuration,,,10090.0,,,4378,CHEMBL619828,,0,1,,BAO_0000218,,Mus musculus,10144,22224,F,U,,,
Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,,10090.0,,,4379,CHEMBL619829,,0,1,,BAO_0000218,,Mus musculus,10685,22224,F,U,,,
Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,Autocuration,,,10090.0,,,4380,CHEMBL619830,,0,1,,BAO_0000218,,Mus musculus,10685,22224,F,U,,,
Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,,10090.0,,,4381,CHEMBL619831,,0,1,,BAO_0000218,,Mus musculus,10685,22224,F,U,,,
Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,,10090.0,,,4382,CHEMBL619832,,0,1,,BAO_0000218,,Mus musculus,10685,22224,F,U,,,
Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,Autocuration,,,10090.0,,,4383,CHEMBL619833,,0,1,,BAO_0000218,,Mus musculus,10685,22224,A,U,,,
Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,Autocuration,,,10090.0,,,4384,CHEMBL619834,,0,1,,BAO_0000218,,Mus musculus,10685,22224,A,U,,,
Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,Autocuration,,,10090.0,,,4385,CHEMBL619835,,0,1,,BAO_0000218,,Mus musculus,10685,22224,A,U,,,
Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,Autocuration,,,10090.0,,,4386,CHEMBL619836,,0,1,,BAO_0000218,,Mus musculus,10685,22224,A,U,,,
"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",Intermediate,,850.0,10090.0,,,4387,CHEMBL619837,,1,1,,BAO_0000218,,Mus musculus,8831,80628,F,N,6C3HED,,
In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,Autocuration,,,,,,4388,CHEMBL619838,,0,1,,BAO_0000218,In vivo,,11704,22224,F,U,,,
In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,Intermediate,,,10090.0,,,4389,CHEMBL619839,,1,1,,BAO_0000218,,Mus musculus,11704,50594,A,N,,,
Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,Intermediate,,850.0,10090.0,,,4390,CHEMBL619840,,1,1,,BAO_0000218,In vivo,Mus musculus,10685,80628,F,N,6C3HED,,
Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,Intermediate,,850.0,10090.0,,,4391,CHEMBL619841,,1,1,,BAO_0000218,In vivo,Mus musculus,10685,80628,F,N,6C3HED,,
Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),Expert,,850.0,10090.0,,,4392,CHEMBL857704,,1,1,,BAO_0000218,,Mus musculus,11368,80628,F,N,6C3HED,,
Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),Intermediate,,850.0,10090.0,,,4393,CHEMBL619842,,1,1,,BAO_0000218,,Mus musculus,11368,80628,F,N,6C3HED,,
Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),Expert,,850.0,10090.0,,,4394,CHEMBL619843,,1,1,,BAO_0000218,,Mus musculus,11368,80628,F,N,6C3HED,,
"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",Autocuration,,,1280.0,,,4395,CHEMBL619844,,0,1,,BAO_0000019,,Staphylococcus aureus,17763,22226,B,U,,,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Autocuration,,,10116.0,Microsomes,,4396,CHEMBL857855,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,,,10116.0,Microsomes,,4397,CHEMBL619845,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Autocuration,,,10116.0,Microsomes,,4398,CHEMBL619846,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Autocuration,,,10116.0,Microsomes,,4399,CHEMBL619847,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Autocuration,,,10116.0,Microsomes,,4400,CHEMBL619848,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Autocuration,,,10116.0,Microsomes,,4401,CHEMBL620893,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Autocuration,,,10116.0,Microsomes,,4402,CHEMBL620894,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,,,10116.0,Microsomes,,4403,CHEMBL620895,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,,,10116.0,Microsomes,,4404,CHEMBL620896,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,,10116.0,Microsomes,,4405,CHEMBL620897,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,,,10116.0,Microsomes,,4406,CHEMBL620898,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,,,10116.0,Microsomes,,4407,CHEMBL620899,Liver,0,1,,BAO_0000251,,Rattus norvegicus,7411,22226,B,U,,2107.0,
The apparent total plasma clearance in monkey,Autocuration,,,9527.0,,,4408,CHEMBL620900,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,347,22224,A,U,,1969.0,
Compound was evaluated for Hepatic clearance in monkey,Autocuration,,,9527.0,,,4409,CHEMBL620901,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3341,22224,A,U,,,
Lower clearance in monkey (i.v.) at 0.5 mpk,Autocuration,,,9527.0,,,4410,CHEMBL620902,,0,1,,BAO_0000218,In vivo,Cercopithecidae,17853,22224,A,U,,,
Plasma clearance in rhesus monkey,Autocuration,,,9527.0,,,4411,CHEMBL620903,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4514,22224,A,U,,,
Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,9527.0,,,4412,CHEMBL620904,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6062,22224,A,U,,,
Plasma clearance of compound was determined in monkey,Autocuration,,,9527.0,,,4413,CHEMBL620905,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6821,22224,A,U,,,
Plasma clearance was calculated in rhesus monkey,Autocuration,,,9527.0,,,4414,CHEMBL620906,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6057,22224,A,U,,,
Plasma clearance in rhesus monkey,Autocuration,,,9527.0,,,4415,CHEMBL875420,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5145,22224,A,U,,,
Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,9527.0,,,4416,CHEMBL620907,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6641,22224,A,U,,,
Plasma clearance was evaluated in rhesus,Autocuration,,,9527.0,,,4417,CHEMBL620908,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5472,22224,A,U,,,
Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,Autocuration,,,9527.0,,,4418,CHEMBL620909,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4257,22224,A,U,,,
Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,,9527.0,,,4419,CHEMBL620910,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5546,22224,A,U,,,
Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,9527.0,,,4420,CHEMBL620911,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5334,22224,A,U,,,
Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,9527.0,,,4421,CHEMBL620912,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5334,22224,A,U,,,
Cmax 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,,,9527.0,,,4422,CHEMBL620913,,0,1,,BAO_0000218,In vivo,Cercopithecidae,17509,22224,A,U,,,
Cmax in monkey after administration of 1 mg/kg iv,Autocuration,,,9527.0,,,4423,CHEMBL620914,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6535,22224,A,U,,,
Cmax was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,,9527.0,,,4424,CHEMBL620915,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5668,22224,A,U,,,
Cmax in cynomolgus monkey by iv administration,Autocuration,,,9527.0,,,4425,CHEMBL620916,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5922,22224,A,U,,,
Cmax in cynomolgus monkey by po administration,Autocuration,,,9527.0,,,4426,CHEMBL620917,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5922,22224,A,U,,,
Cmax value evaluated in monkey,Autocuration,,,9527.0,,,4427,CHEMBL620918,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6078,22224,A,U,,,
Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,9527.0,,,4428,CHEMBL620919,,0,1,,BAO_0000218,In vivo,Cercopithecidae,2661,22224,A,U,,,
Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Autocuration,,,9527.0,,,4429,CHEMBL620920,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,3249,22224,A,U,,1969.0,
Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Autocuration,,,9527.0,,,4430,CHEMBL620921,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,3249,22224,A,U,,1969.0,
Maximal plasma concentration in squirrel monkeys,Autocuration,,,9527.0,,,4431,CHEMBL620922,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,5553,22224,A,U,,1969.0,
Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,9527.0,,,4432,CHEMBL620923,,0,1,,BAO_0000218,In vivo,Cercopithecidae,1916,22224,A,U,,,
Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Autocuration,,,9527.0,,,4433,CHEMBL620924,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,6227,22224,A,U,,1969.0,
Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,9527.0,,,4434,CHEMBL620925,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4809,22224,A,U,,,
The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,9527.0,,,4435,CHEMBL620926,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,9527.0,,,4436,CHEMBL620927,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,Autocuration,,,9527.0,,,4437,CHEMBL620928,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,Autocuration,,,9527.0,,,4438,CHEMBL620929,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Autocuration,,,9527.0,,,4439,CHEMBL620930,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,6221,22224,A,U,,1969.0,
Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,Autocuration,,,9527.0,,,4440,CHEMBL620931,,0,1,,BAO_0000218,,Cercopithecidae,167,22224,A,U,,,
Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,Autocuration,,,9527.0,,,4441,CHEMBL620932,,0,1,,BAO_0000218,,Cercopithecidae,167,22224,A,U,,,
Absolute bioavailability was evaluated in monkey,Autocuration,,,9443.0,,,4442,CHEMBL620933,,0,1,,BAO_0000218,In vivo,monkey,4257,22224,A,U,,,
Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,9443.0,,,4443,CHEMBL620934,,0,1,,BAO_0000218,In vivo,monkey,6221,22224,A,U,,,
Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,Autocuration,,,9443.0,,,4444,CHEMBL620935,,0,1,,BAO_0000218,In vivo,monkey,17667,22224,A,U,,,
Bioavailability of compound was determined in rhesus monkey,Autocuration,,,9544.0,,,4445,CHEMBL620936,,0,1,,BAO_0000218,In vivo,Macaca mulatta,17267,22224,A,U,,,
Bioavailability determined after oral administration in marmoset,Autocuration,,,38020.0,,,4446,CHEMBL620937,,0,1,,BAO_0000218,In vivo,marmosets,4256,22224,A,U,,,
Oral bioavailability in cynomolgus monkey,Autocuration,,,9541.0,,,4447,CHEMBL620938,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,4256,22224,A,U,,,
Bioavailability in monkey (p.o.) at 2.0 mpk,Autocuration,,,9443.0,,,4448,CHEMBL620939,,0,1,,BAO_0000218,In vivo,monkey,17853,22224,A,U,,,
Bioavailability was evaluated after oral administration in monkey,Autocuration,,,9443.0,,,4449,CHEMBL620940,,0,1,,BAO_0000218,In vivo,monkey,16365,22224,A,U,,,
Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,9541.0,,,4450,CHEMBL620941,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,1916,22224,A,U,,,
Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,9544.0,,,4451,CHEMBL620942,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5334,22224,A,U,,,
Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,9544.0,,,4452,CHEMBL620943,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5334,22224,A,U,,,
Bioavailability of the compound was determined in monkey,Autocuration,,,9443.0,,,4453,CHEMBL620944,,0,1,,BAO_0000218,In vivo,monkey,17592,22224,A,U,,,
Bioavailability in squirrel monkey (dose 5 mg/kg),Autocuration,,,9521.0,,,4454,CHEMBL620945,,0,1,,BAO_0000218,In vivo,Saimiri sciureus,1399,22224,A,U,,,
Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,9443.0,,,4455,CHEMBL620946,,0,1,,BAO_0000218,In vivo,monkey,4809,22224,A,U,,,
Oral bioavailability in monkey,Autocuration,,,9443.0,,,4456,CHEMBL620947,,0,1,,BAO_0000218,In vivo,monkey,3341,22224,A,U,,,
Compound was tested for bioavailability in squirrel monkey,Autocuration,,,9521.0,,,4457,CHEMBL620948,,0,1,,BAO_0000218,In vivo,Saimiri sciureus,64,22224,A,U,,,
Oral bioavailability in Rhesus monkey,Autocuration,,,9544.0,,,4458,CHEMBL620949,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5005,22224,A,U,,,
Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),Autocuration,,,9544.0,,,4459,CHEMBL620950,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5005,22224,A,U,,,
Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,Autocuration,,,9541.0,,,4460,CHEMBL620951,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,5237,22224,A,U,,,
Oral bioavailability in cynomolgus monkeys was determined; Acceptable,Autocuration,,,9541.0,,,4461,CHEMBL620952,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,5237,22224,A,U,,,
Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,,,9443.0,,,4462,CHEMBL875421,,0,1,,BAO_0000218,In vivo,monkey,5302,22224,A,U,,,
Oral bioavailability of compound at 5 mg/kg in monkey,Autocuration,,,9443.0,,,4463,CHEMBL620953,,0,1,,BAO_0000218,In vivo,monkey,17667,22224,A,U,,,
Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,,,9615.0,,,4464,CHEMBL873491,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6161,50588,A,N,,,
Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,,,9615.0,,,4465,CHEMBL620954,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6161,50588,A,N,,,
Plasma half life determined,Intermediate,,,9615.0,,,4466,CHEMBL620955,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,3854,50588,A,N,,1969.0,
Plasma half life in dog,Intermediate,,,9615.0,,,4467,CHEMBL618097,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,993,50588,A,N,,1969.0,
Plasma half-life in Beagle dogs,Intermediate,,,9615.0,,,4468,CHEMBL618268,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,4514,50588,A,N,,1969.0,
Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,,9615.0,,,4469,CHEMBL618269,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5334,50588,A,N,,1969.0,
Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Intermediate,,,9615.0,,,4470,CHEMBL618270,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5334,50588,A,N,,1969.0,
Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,,9615.0,,,4471,CHEMBL618271,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1466,50588,A,N,,,
Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,,9615.0,,,4472,CHEMBL873493,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1466,50588,A,N,,,
Tested for the half life period in dog,Intermediate,,,9615.0,,,4473,CHEMBL621031,,1,1,,BAO_0000218,,Canis lupus familiaris,5313,50588,A,N,,,
Tested for the half life period in dog at dosage of 10 mpk,Intermediate,,,9615.0,,,4474,CHEMBL621032,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5313,50588,A,N,,,
The compound was tested for half life in dog,Intermediate,,,9615.0,,,4475,CHEMBL621033,,1,1,,BAO_0000218,,Canis lupus familiaris,3880,50588,A,N,,,
"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Intermediate,,,9615.0,,,4476,CHEMBL621034,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,3639,50588,A,N,,1969.0,
The half life was determined,Intermediate,,,9615.0,,,4477,CHEMBL621035,,1,1,,BAO_0000218,,Canis lupus familiaris,3880,50588,A,N,,,
The plasma half-life in dogs,Intermediate,,,9615.0,,,4478,CHEMBL621036,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,3918,50588,A,N,,1969.0,
suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Intermediate,,,9615.0,,,4479,CHEMBL621037,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,16452,50588,A,N,,1969.0,
Half life in dog,Intermediate,,,9615.0,,,4480,CHEMBL619812,,1,1,,BAO_0000218,,Canis lupus familiaris,17796,50588,A,N,,,
Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,,,9615.0,,,4481,CHEMBL619813,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5983,50588,A,N,,,
tmax upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,,9615.0,,,4482,CHEMBL873335,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1466,50588,A,N,,,
Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,9615.0,,,4483,CHEMBL619814,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16456,50588,A,N,,,
Cmax in ferrets after 30 mg/kg oral dose,Expert,,,9669.0,,,4484,CHEMBL619815,,1,1,,BAO_0000218,In vivo,Mustela putorius furo,6113,50506,A,N,,,
Emesis in ferrets at 30 mg/kg oral dose,Expert,,,9669.0,,,4485,CHEMBL619816,,1,1,,BAO_0000218,In vivo,Mustela putorius furo,6113,50506,F,N,,,
Bioavailability in cynomolgus monkey,Autocuration,,,9541.0,,,4486,CHEMBL619817,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,17796,22224,A,U,,,
Volume of distribution in cynomolgus,Intermediate,,,9541.0,,,4487,CHEMBL619818,,1,1,,BAO_0000218,In vivo,Macaca fascicularis,17796,100710,A,N,,,
AUC tested in guinea pig when 3 mg/kg dose was given perorally,Autocuration,,,10141.0,,,4488,CHEMBL619819,Plasma,0,1,,BAO_0000218,,Cavia porcellus,5308,22224,A,U,,1969.0,
Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,,,10141.0,,,4489,CHEMBL619820,,0,1,,BAO_0000218,,Cavia porcellus,4877,22224,A,U,,,
"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",Autocuration,,,10141.0,,,4490,CHEMBL875419,,0,1,,BAO_0000218,,Cavia porcellus,4876,22224,A,U,,,
AUC in guinea pig after 3mg/kg oral dose,Autocuration,,,10141.0,,,4491,CHEMBL619821,Plasma,0,1,,BAO_0000218,In vivo,Cavia porcellus,4878,22224,A,U,,1969.0,
Bioavailability in guinea pig was tested,Autocuration,,,10141.0,,,4492,CHEMBL619822,,0,1,,BAO_0000218,In vivo,Cavia porcellus,5308,22224,A,U,,,
Tested for oral bioavailability in guinea pig at 5 mg/kg,Autocuration,,,10141.0,,,4493,CHEMBL619823,,0,1,,BAO_0000218,In vivo,Cavia porcellus,4877,22224,A,U,,,
Tested for the oral bioavailability of the compound,Autocuration,,,10141.0,,,4494,CHEMBL619824,,0,1,,BAO_0000218,In vivo,Cavia porcellus,4876,22224,A,U,,,
Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,Autocuration,,,10141.0,,,4495,CHEMBL619825,,0,1,,BAO_0000218,In vivo,Cavia porcellus,4876,22224,A,U,,,
Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,Autocuration,,,10141.0,,,4496,CHEMBL619826,,0,1,,BAO_0000218,In vivo,Cavia porcellus,5308,22224,A,U,,,
Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,,,10141.0,,,4497,CHEMBL619827,Lung,0,1,,BAO_0000218,In vivo,Cavia porcellus,4877,22224,A,U,,2048.0,
Cmax in guinea pig after 3mg/kg oral dose,Autocuration,,,10141.0,,,4498,CHEMBL618167,,0,1,,BAO_0000218,In vivo,Cavia porcellus,4878,22224,A,U,,,
Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,10141.0,,,4499,CHEMBL618168,Blood,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,178.0,
Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,10141.0,,,4500,CHEMBL618169,Brain,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,955.0,
Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,10141.0,,,4501,CHEMBL618170,,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,,
Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,10141.0,,,4502,CHEMBL618171,Intestine,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,160.0,
Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,10141.0,,,4503,CHEMBL618172,Kidney,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,2113.0,
Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,10141.0,,,4504,CHEMBL618173,Liver,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,2107.0,
Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,10141.0,,,4505,CHEMBL618174,,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,,
Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,,10141.0,,,4506,CHEMBL875408,Spleen,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,2106.0,
Elimination T1/2 in Guinea pig (PO dose),Autocuration,,,10141.0,,,4507,CHEMBL839827,,0,1,,BAO_0000218,In vivo,Cavia porcellus,14465,22224,A,U,,,
Partition coefficient was measured as -log (counts per min ),Autocuration,,,10141.0,,,4508,CHEMBL618175,,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,,
Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,,,10141.0,,,4509,CHEMBL618176,,0,1,,BAO_0000218,In vivo,Cavia porcellus,611,22224,A,U,,,
Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,,,10141.0,,,4510,CHEMBL618177,,0,1,,BAO_0000218,In vivo,Cavia porcellus,611,22224,A,U,,,
Elimination T1/2 in Guinea pig (PO dose),Autocuration,,,10141.0,,,4511,CHEMBL618178,,0,1,,BAO_0000218,In vivo,Cavia porcellus,14465,22224,A,U,,,
"Tested for the half life period of the compound, intravenously",Autocuration,,,10141.0,,,4512,CHEMBL618179,,0,1,,BAO_0000218,In vivo,Cavia porcellus,4876,22224,A,U,,,
Half-life was measured,Autocuration,,,10141.0,,,4513,CHEMBL873489,,0,1,,BAO_0000019,,Cavia porcellus,5689,22224,A,U,,,
The time required for onset of inotropy after addition of a single dose of delta F75,Autocuration,,,10141.0,,,4514,CHEMBL618180,,0,1,,BAO_0000019,,Cavia porcellus,7515,22224,A,U,,,
Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,Autocuration,,,10141.0,,,4515,CHEMBL618181,,0,1,,BAO_0000218,In vivo,Cavia porcellus,17667,22224,A,U,,,
Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,Autocuration,,,10141.0,,,4516,CHEMBL618182,,0,1,,BAO_0000218,In vivo,Cavia porcellus,17667,22224,A,U,,,
Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,,,10029.0,,,4517,CHEMBL618183,,0,1,,BAO_0000218,In vivo,Cricetulus griseus,4727,22224,A,U,,,
Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,4518,CHEMBL618184,,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,,
Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,10090.0,,,4519,CHEMBL618185,,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,,
Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,4520,CHEMBL618186,,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,,
Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,4521,CHEMBL618187,,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,,
Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,Intermediate,,,10090.0,,,4522,CHEMBL618188,,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,,
Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,4523,CHEMBL875409,,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,,
Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,4524,CHEMBL618189,,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,,
Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4525,CHEMBL618190,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,178.0,
Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4526,CHEMBL618191,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,178.0,
Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4527,CHEMBL618192,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,178.0,
Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4528,CHEMBL618193,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,10000001.0,
Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4529,CHEMBL618194,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,10000001.0,
Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4530,CHEMBL618195,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,10000001.0,
Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4531,CHEMBL618196,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,955.0,
Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4532,CHEMBL618197,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,955.0,
Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4533,CHEMBL618198,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,955.0,
Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4534,CHEMBL618199,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,948.0,
Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4535,CHEMBL618200,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,948.0,
Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4536,CHEMBL618201,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,948.0,
Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4537,CHEMBL618202,Intestine,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,160.0,
Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4538,CHEMBL618203,Intestine,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,160.0,
Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4539,CHEMBL618204,Intestine,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,160.0,
Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4540,CHEMBL618205,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2113.0,
Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4541,CHEMBL618206,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2113.0,
Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4542,CHEMBL618207,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2113.0,
Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4543,CHEMBL618208,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2107.0,
Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4544,CHEMBL618932,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2107.0,
Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4545,CHEMBL618933,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2107.0,
Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4546,CHEMBL618934,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2048.0,
Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4547,CHEMBL618935,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2048.0,
Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4548,CHEMBL618936,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2048.0,
Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4549,CHEMBL618937,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2385.0,
Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4550,CHEMBL618938,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2385.0,
Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4551,CHEMBL619104,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2385.0,
Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4552,CHEMBL619105,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2106.0,
Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4553,CHEMBL619106,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2106.0,
Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4554,CHEMBL619107,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,2106.0,
Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Intermediate,,,10090.0,,,4555,CHEMBL875410,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,945.0,
Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Intermediate,,,10090.0,,,4556,CHEMBL619108,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,945.0,
Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Intermediate,,,10090.0,,,4557,CHEMBL619109,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,3655,50594,A,N,,945.0,
At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,,,10090.0,,,4558,CHEMBL619110,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,,,10090.0,,,4559,CHEMBL619111,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,F,N,,,
MRT value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,10090.0,,,4560,CHEMBL619112,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
MRT value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,10090.0,,,4561,CHEMBL619113,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,Intermediate,,,10090.0,,,4562,CHEMBL619114,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,A,N,,,
Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,,10090.0,,,4563,CHEMBL619115,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,Intermediate,,478.0,9606.0,,,4564,CHEMBL619116,,1,1,,BAO_0000219,,Homo sapiens,3830,81034,F,N,A2780,,
In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,Intermediate,,478.0,9606.0,,,4565,CHEMBL619117,,1,1,,BAO_0000219,,Homo sapiens,3829,81034,F,N,A2780,,
Compound was evaluated for cytotoxicity against A2780 cell lines.,Intermediate,,478.0,9606.0,,,4566,CHEMBL619118,,1,1,,BAO_0000219,,Homo sapiens,2040,81034,F,N,A2780,,
Potentiation of growth inhibition of A2780 by compound alone in experiment 1,Intermediate,,478.0,9606.0,,,4567,CHEMBL619119,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,,478.0,9606.0,,,4568,CHEMBL619120,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,,478.0,9606.0,,,4569,CHEMBL619121,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,,478.0,9606.0,,,4570,CHEMBL619122,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,,478.0,9606.0,,,4571,CHEMBL619123,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,,478.0,9606.0,,,4572,CHEMBL619124,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,,478.0,9606.0,,,4573,CHEMBL619125,,1,1,,BAO_0000219,,Homo sapiens,2859,81034,F,N,A2780,,
In vitro inhibitory activity against human tumor cell line A2780,Intermediate,,478.0,9606.0,,,4574,CHEMBL875411,,1,1,,BAO_0000219,,Homo sapiens,5618,81034,F,N,A2780,,
Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,Intermediate,,478.0,9606.0,,,4575,CHEMBL619126,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,,478.0,9606.0,,,4576,CHEMBL619127,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,,478.0,9606.0,,,4577,CHEMBL619128,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,,478.0,9606.0,,,4578,CHEMBL619129,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
The compound was tested for cytotoxic potency against A2780 human tumor cell lines,Intermediate,,478.0,9606.0,,,4579,CHEMBL619130,,1,1,,BAO_0000219,,Homo sapiens,2113,81034,F,N,A2780,,
The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,Intermediate,,478.0,9606.0,,,4580,CHEMBL619131,,1,1,,BAO_0000219,,Homo sapiens,2113,81034,F,N,A2780,,
cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,Intermediate,,478.0,9606.0,,,4581,CHEMBL619132,,1,1,,BAO_0000219,,Homo sapiens,16745,81034,F,N,A2780,,
In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,,478.0,9606.0,,,4582,CHEMBL619133,,1,1,,BAO_0000218,,Homo sapiens,16597,81034,F,N,A2780,,
Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,,478.0,9606.0,,,4583,CHEMBL619134,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,,478.0,9606.0,,,4584,CHEMBL619135,,1,1,,BAO_0000219,,Homo sapiens,15684,81034,F,N,A2780,,
Compound was evaluated for cytotoxicity against A2780 cis cell lines.,Intermediate,,478.0,9606.0,,,4585,CHEMBL619136,,1,1,,BAO_0000219,,Homo sapiens,2040,81034,F,N,A2780,,
Relative resistance factor in A2780 cisplatin-resistant line,Intermediate,,478.0,9606.0,,,4586,CHEMBL619137,,1,1,,BAO_0000219,,Homo sapiens,2040,81034,F,N,A2780,,
Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,Intermediate,,478.0,9606.0,,,4587,CHEMBL883713,,1,1,,BAO_0000219,,Homo sapiens,16165,81034,F,N,A2780,,
Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,Intermediate,,478.0,9606.0,,,4588,CHEMBL875412,,1,1,,BAO_0000219,,Homo sapiens,16165,81034,F,N,A2780,,
In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,,478.0,9606.0,,,4589,CHEMBL619138,,1,1,,BAO_0000218,,Homo sapiens,16597,81034,F,N,A2780,,
In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,,478.0,9606.0,,,4590,CHEMBL619262,,1,1,,BAO_0000218,,Homo sapiens,16597,81034,F,N,A2780,,
Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,Intermediate,,478.0,9606.0,,,4591,CHEMBL619139,,1,1,,BAO_0000219,,Homo sapiens,3992,81034,F,N,A2780,,
In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,Intermediate,,478.0,9606.0,,,4592,CHEMBL619140,,1,1,,BAO_0000219,,Homo sapiens,10553,81034,F,N,A2780,,
cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,Intermediate,,478.0,9606.0,,,4593,CHEMBL619141,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,Intermediate,,478.0,9606.0,,,4594,CHEMBL619142,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,Intermediate,,478.0,9606.0,,,4595,CHEMBL619143,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,Intermediate,,478.0,9606.0,,,4596,CHEMBL619144,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,Intermediate,,478.0,9606.0,,,4597,CHEMBL619145,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,Intermediate,,478.0,9606.0,,,4598,CHEMBL619146,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,Intermediate,,478.0,9606.0,,,4599,CHEMBL619147,,1,1,,BAO_0000219,,Homo sapiens,15569,81034,F,N,A2780,,
Antiproliferative effect of compound on A2780/DX cell line,Intermediate,,478.0,9606.0,,,4600,CHEMBL619148,,1,1,,BAO_0000219,,Homo sapiens,17420,81034,F,N,A2780,,
Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,Intermediate,,478.0,9606.0,,,4601,CHEMBL619149,,1,1,,BAO_0000219,,Homo sapiens,17420,81034,F,N,A2780,,
In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),Intermediate,,478.0,9606.0,,,4602,CHEMBL619150,,1,1,,BAO_0000219,,Homo sapiens,15099,81034,F,N,A2780,,
In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),Intermediate,,478.0,9606.0,,,4603,CHEMBL619151,,1,1,,BAO_0000219,,Homo sapiens,15099,81034,F,N,A2780,,
Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,Intermediate,,478.0,9606.0,,,4604,CHEMBL883794,,1,1,,BAO_0000219,,Homo sapiens,17672,81034,F,N,A2780,,
Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,Intermediate,,478.0,9606.0,,,4605,CHEMBL619152,,1,1,,BAO_0000219,,Homo sapiens,17672,81034,F,N,A2780,,
In vitro cytotoxicity against A2780ADR cell line,Intermediate,,478.0,9606.0,,,4606,CHEMBL619153,,1,1,,BAO_0000219,,Homo sapiens,17270,81034,F,N,A2780,,
In vitro cytotoxicity against A2780CIS cell line,Intermediate,,478.0,9606.0,,,4607,CHEMBL619154,,1,1,,BAO_0000219,,Homo sapiens,17270,81034,F,N,A2780,,
In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,Intermediate,,478.0,9606.0,,,4608,CHEMBL619155,,1,1,,BAO_0000219,,Homo sapiens,5574,81034,F,N,A2780,,
The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,Intermediate,,478.0,9606.0,,,4609,CHEMBL619156,,1,1,,BAO_0000219,,Homo sapiens,2113,81034,F,N,A2780,,
"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,478.0,9606.0,,,4610,CHEMBL619157,,1,1,,BAO_0000219,,Homo sapiens,16913,81034,F,N,A2780,,
"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,478.0,9606.0,,,4611,CHEMBL619797,,1,1,,BAO_0000219,,Homo sapiens,16913,81034,F,N,A2780,,
Oral bioavailability of compound in rhesus macaques,Autocuration,,,9544.0,,,4612,CHEMBL619798,,0,1,,BAO_0000218,In vivo,Macaca mulatta,17839,22224,A,U,,,
Oral bioavailability in monkey,Autocuration,,,9443.0,,,4613,CHEMBL619799,,0,1,,BAO_0000218,In vivo,monkey,6821,22224,A,U,,,
Oral bioavailability evaluated in monkey,Autocuration,,,9443.0,,,4614,CHEMBL619800,,0,1,,BAO_0000218,In vivo,monkey,6078,22224,A,U,,,
Oral bioavailability in monkey (dose 1 mg/kg p.o.),Autocuration,,,9443.0,,,4615,CHEMBL619801,,0,1,,BAO_0000218,In vivo,monkey,6535,22224,A,U,,,
Oral bioavailability in Rhesus monkey,Autocuration,,,9544.0,,,4616,CHEMBL619802,,0,1,,BAO_0000218,In vivo,Macaca mulatta,4449,22224,A,U,,,
Oral bioavailability was calculated in rhesus monkey,Autocuration,,,9544.0,,,4617,CHEMBL619803,,0,1,,BAO_0000218,In vivo,Macaca mulatta,6057,22224,A,U,,,
Oral bioavailability in cynomolgus monkey,Autocuration,,,9541.0,,,4618,CHEMBL619965,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,5922,22224,A,U,,,
Oral bioavailability in monkey,Autocuration,,,9443.0,,,4619,CHEMBL619966,,0,1,,BAO_0000218,In vivo,monkey,5940,22224,A,U,,,
Oral bioavailability in monkey,Autocuration,,,9443.0,,,4620,CHEMBL619967,,0,1,,BAO_0000218,In vivo,monkey,6265,22224,A,U,,,
Oral bioavailability in monkey (dose 1 mg/kg),Autocuration,,,9443.0,,,4621,CHEMBL620073,,0,1,,BAO_0000218,In vivo,monkey,6265,22224,A,U,,,
Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,,,9443.0,,,4622,CHEMBL620074,,0,1,,BAO_0000218,In vivo,monkey,6265,22224,A,U,,,
Oral bioavailability in monkey,Autocuration,,,9443.0,,,4623,CHEMBL620075,,0,1,,BAO_0000218,In vivo,monkey,5940,22224,A,U,,,
Oral bioavailability in monkey,Autocuration,,,9443.0,,,4624,CHEMBL620076,,0,1,,BAO_0000218,In vivo,monkey,5940,22224,A,U,,,
Oral bioavailability in rhesus monkey,Autocuration,,,9544.0,,,4625,CHEMBL620077,,0,1,,BAO_0000218,In vivo,Macaca mulatta,4514,22224,A,U,,,
Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,Autocuration,,,9544.0,,,4626,CHEMBL620078,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5546,22224,A,U,,,
Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,Autocuration,,,9521.0,,,4627,CHEMBL620079,,0,1,,BAO_0000218,In vivo,Saimiri sciureus,5553,22224,A,U,,,
Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,9443.0,,,4628,CHEMBL620080,,0,1,,BAO_0000218,In vivo,monkey,6641,22224,A,U,,,
Oral bioavailability in Rhesus monkey,Autocuration,,,9544.0,,,4629,CHEMBL620081,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5472,22224,A,U,,,
Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),Autocuration,,,9544.0,,,4630,CHEMBL620082,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5668,22224,A,U,,,
Oral bioavailability in monkey at 10 mg/kg of the compound,Autocuration,,,9443.0,,,4631,CHEMBL620083,,0,1,,BAO_0000218,In vivo,monkey,5711,22224,A,U,,,
Bioavailability in Rhesus monkey,Autocuration,,,9544.0,,,4632,CHEMBL620084,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5145,22224,A,U,,,
Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,4633,CHEMBL620085,,0,1,,BAO_0000218,,Cercopithecidae,3443,22224,A,U,,,
Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,4634,CHEMBL874595,,0,1,,BAO_0000218,,Cercopithecidae,3443,22224,A,U,,,
Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,Autocuration,,,9527.0,,,4635,CHEMBL873352,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3249,22224,A,U,,,
Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,Autocuration,,,9527.0,,,4636,CHEMBL620086,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3249,22224,A,U,,,
Mean residence time was determined after intravenous administration in cynomolgus monkeys,Autocuration,,,9527.0,,,4637,CHEMBL620087,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,9527.0,,,4638,CHEMBL620088,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,9527.0,,,4639,CHEMBL620089,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,9527.0,,,4640,CHEMBL620090,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4809,22224,A,U,,,
Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,9527.0,,,4641,CHEMBL620091,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4809,22224,A,U,,,
Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,,9527.0,Microsomes,,4642,CHEMBL620092,,0,1,,BAO_0000251,,Cercopithecidae,14294,22224,A,U,,,
Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Autocuration,,,9527.0,Microsomes,,4643,CHEMBL620093,,0,1,,BAO_0000251,,Cercopithecidae,14294,22224,A,U,,,
Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Autocuration,,,9527.0,Microsomes,,4644,CHEMBL620094,,0,1,,BAO_0000251,,Cercopithecidae,14294,22224,A,U,,,
Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Autocuration,,,9527.0,Microsomes,,4645,CHEMBL620095,,0,1,,BAO_0000251,,Cercopithecidae,14294,22224,A,U,,,
Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,4646,CHEMBL620096,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3443,22224,A,U,,,
Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,4647,CHEMBL620097,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3443,22224,A,U,,,
Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,Autocuration,,,9527.0,,,4648,CHEMBL620098,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,4649,CHEMBL620099,,0,1,,BAO_0000218,,Cercopithecidae,3443,22224,A,U,,,
Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,4650,CHEMBL620100,,0,1,,BAO_0000218,,Cercopithecidae,3443,22224,A,U,,,
Elimination Half-life of compound was determined in monkey,Autocuration,,,9527.0,,,4651,CHEMBL620101,,0,1,,BAO_0000019,,Cercopithecidae,6821,22224,A,U,,,
Half life of compound was determined in rhesus monkey,Autocuration,,,9527.0,,,4652,CHEMBL620102,,0,1,,BAO_0000019,,Cercopithecidae,17267,22224,A,U,,,
Half life in monkey plasma,Autocuration,,,9527.0,,,4653,CHEMBL620103,Plasma,0,1,,BAO_0000366,,Cercopithecidae,5819,22224,A,U,,1969.0,
Half life in monkey plasma; Not detected,Autocuration,,,9527.0,,,4654,CHEMBL620104,Plasma,0,1,,BAO_0000366,,Cercopithecidae,5819,22224,A,U,,1969.0,
Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,9527.0,,,4655,CHEMBL874596,,0,1,,BAO_0000218,In vivo,Cercopithecidae,1916,22224,A,U,,,
Half-life 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,,,9527.0,,,4656,CHEMBL873490,,0,1,,BAO_0000218,In vivo,Cercopithecidae,17509,22224,A,U,,,
Terminal half life of the compound.,Autocuration,,,9527.0,,,4657,CHEMBL620105,,0,1,,BAO_0000019,,Cercopithecidae,1399,22224,A,U,,,
Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,9527.0,,,4658,CHEMBL620780,,0,1,,BAO_0000218,In vivo,Cercopithecidae,1916,22224,A,U,,,
Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,,9527.0,,,4659,CHEMBL620781,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4809,22224,A,U,,,
Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,,9527.0,,,4660,CHEMBL620956,,0,1,,BAO_0000218,,Cercopithecidae,5546,22224,A,U,,,
Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,4661,CHEMBL620957,Urine,0,1,,BAO_0000218,,Cercopithecidae,3443,22224,A,U,,1088.0,
Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,4662,CHEMBL620958,Urine,0,1,,BAO_0000218,,Cercopithecidae,3443,22224,A,U,,1088.0,
Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,Autocuration,,,9527.0,,,4663,CHEMBL620959,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4257,22224,A,U,,,
Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,9527.0,,,4664,CHEMBL620960,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6221,22224,A,U,,,
Volume of distribution was evaluated in rhesus,Autocuration,,,9527.0,,,4665,CHEMBL620961,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5472,22224,A,U,,,
Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,,,10029.0,,,4666,CHEMBL620962,,0,1,,BAO_0000218,In vivo,Cricetulus griseus,4727,22224,A,U,,,
Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,Autocuration,,,10029.0,,,4667,CHEMBL620963,,0,1,,BAO_0000218,In vivo,Cricetulus griseus,4727,22224,A,U,,,
Bioavailability in hamster was determined,Autocuration,,,10029.0,,,4668,CHEMBL620964,,0,1,,BAO_0000218,In vivo,Cricetulus griseus,4727,22224,A,U,,,
Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,Autocuration,,,10029.0,,,4669,CHEMBL620965,,0,1,,BAO_0000218,In vivo,Cricetulus griseus,4727,22224,A,U,,,
Bioavailability in hamster at a dose of 3 mg/kg by oral administration,Autocuration,,,10029.0,,,4670,CHEMBL620966,,0,1,,BAO_0000218,In vivo,Cricetulus griseus,4727,22224,A,U,,,
Half life of compound was determined in hamster blood,Autocuration,,,10029.0,,,4671,CHEMBL620967,Blood,0,1,,BAO_0000221,,Cricetulus griseus,4727,22224,A,U,,178.0,
Michaelis-Menten constant of the compound.,Autocuration,,,9823.0,,,4672,CHEMBL620968,,0,1,,BAO_0000019,,Sus scrofa,1452,22224,A,U,,,
Vmax value was measured at 0 uM concentration of silyl ether.,Autocuration,,,9823.0,,,4673,CHEMBL874597,,0,1,,BAO_0000019,,Sus scrofa,1452,22224,A,U,,,
Vmax value was measured at 10 uM concentration of silyl ether.,Autocuration,,,9823.0,,,4674,CHEMBL620969,,0,1,,BAO_0000019,,Sus scrofa,1452,22224,A,U,,,
Vmax value was measured at 5 uM concentration of silyl ether.,Autocuration,,,9823.0,,,4675,CHEMBL620970,,0,1,,BAO_0000019,,Sus scrofa,1452,22224,A,U,,,
Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,Expert,,,9606.0,,,4676,CHEMBL620971,,9,1,,BAO_0000357,,Homo sapiens,11706,235,B,D,,,
Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,9606.0,,,4677,CHEMBL620972,,0,1,,BAO_0000218,,Homo sapiens,1916,22224,A,U,,,
Compound was evaluated for area under the curve expressed as (h*ug/ml),Autocuration,,,9606.0,,,4678,CHEMBL620973,,0,1,,BAO_0000019,,Homo sapiens,17791,22224,A,U,,,
Active metabolite of ifosfamide determined in humans; A-Active,Autocuration,,,9606.0,,,4679,CHEMBL618243,,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,,
Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,Autocuration,,,9606.0,,,4680,CHEMBL618244,,0,1,,BAO_0000019,,Homo sapiens,6567,22224,A,U,,,
Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,Autocuration,,,9606.0,,,4681,CHEMBL618245,,0,1,,BAO_0000019,,Homo sapiens,6567,22224,A,U,,,
Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,Autocuration,,,9606.0,,,4682,CHEMBL618246,,0,1,,BAO_0000019,,Homo sapiens,6567,22224,A,U,,,
Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,Autocuration,,,9606.0,,,4683,CHEMBL618247,,0,1,,BAO_0000019,,Homo sapiens,6567,22224,A,U,,,
Compound was evaluated for oral bioavailability in human,Autocuration,,,9606.0,,,4684,CHEMBL618248,,0,1,,BAO_0000218,,Homo sapiens,17791,22224,A,U,,,
Metabolite of ifosfamide determined in urine; NF-Not found,Autocuration,,,9606.0,,,4685,CHEMBL618249,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),Autocuration,,,9606.0,,,4686,CHEMBL618250,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,Autocuration,,,9606.0,,,4687,CHEMBL874598,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,Autocuration,,,9606.0,,,4688,CHEMBL618251,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,Autocuration,,,9606.0,,,4689,CHEMBL618252,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,Autocuration,,,9606.0,,,4690,CHEMBL618253,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),Autocuration,,,9606.0,,,4691,CHEMBL618254,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
Percent of compound in healthy individuals (Group D),Autocuration,,,9606.0,,,4692,CHEMBL618255,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,,,9606.0,Microsomes,,4693,CHEMBL618983,Liver,0,1,,BAO_0000251,,Homo sapiens,4397,22224,A,U,,2107.0,
Binding towards human plasma protein at 10 uM,Autocuration,,,9606.0,,,4694,CHEMBL618984,,0,1,,BAO_0000019,,Homo sapiens,17409,22224,A,U,,,
Binding towards human plasma protein at 100 uM,Autocuration,,,9606.0,,,4695,CHEMBL618985,,0,1,,BAO_0000019,,Homo sapiens,17409,22224,A,U,,,
Human plasma protein binding activity was determined,Autocuration,,,9606.0,,,4696,CHEMBL618986,,0,1,,BAO_0000019,,Homo sapiens,17176,22224,A,U,,,
The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Autocuration,,,9606.0,,,4697,CHEMBL618987,,0,1,,BAO_0000019,,Homo sapiens,15444,22224,A,U,,,
Percent binding of compound towards human plasma protein was determined,Autocuration,,,9606.0,,,4698,CHEMBL618988,,0,1,,BAO_0000019,,Homo sapiens,17267,22224,A,U,,,
Plasma clearance in human liver microsomes,Autocuration,,,9606.0,Microsomes,,4699,CHEMBL618989,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,5944,22224,A,U,,2107.0,
In vitro intrinsic clearance in human liver microsome,Autocuration,,,9606.0,Microsomes,,4700,CHEMBL618990,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,5668,22224,A,U,,2107.0,
In vitro intrinsic clearance in human liver microsome,Autocuration,,,9606.0,Microsomes,,4701,CHEMBL618991,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,5669,22224,A,U,,2107.0,
In vitro microsome metabolism clearance in human was determined,Autocuration,,,9606.0,Microsomes,,4702,CHEMBL876725,,0,1,,BAO_0000251,In vitro,Homo sapiens,5041,22224,A,U,,,
In vitro microsome metabolism clearance in human was determined; High,Autocuration,,,9606.0,Microsomes,,4703,CHEMBL618992,,0,1,,BAO_0000251,In vitro,Homo sapiens,5041,22224,A,U,,,
In vitro microsome metabolism clearance in human was determined; ND denotes no data,Autocuration,,,9606.0,Microsomes,,4704,CHEMBL618993,,0,1,,BAO_0000251,In vitro,Homo sapiens,5041,22224,A,U,,,
Pharmacokinetic property (clearance) in human liver microsome,Autocuration,,,9606.0,Microsomes,,4705,CHEMBL618994,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,5676,22224,A,U,,2107.0,
Plasma clearance in human liver microsomes,Autocuration,,,9606.0,Microsomes,,4706,CHEMBL618995,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,5944,22224,A,U,,2107.0,
In vitro clearance in human liver microsomes,Autocuration,,,9606.0,Microsomes,,4707,CHEMBL618996,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,17538,22224,A,U,,2107.0,
Intrinsic clearance in human liver microsomes was determined,Autocuration,,,9606.0,Microsomes,,4708,CHEMBL618997,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,6331,22224,A,U,,2107.0,
Intrinsic clearance in human liver microsomes was determined,Autocuration,,,9606.0,Microsomes,,4709,CHEMBL618998,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,5948,22224,A,U,,2107.0,
Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,Autocuration,,,9606.0,,,4710,CHEMBL618999,,0,1,,BAO_0000218,In vivo,Homo sapiens,5965,22224,A,U,,,
Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,9606.0,,,4711,CHEMBL620223,,0,1,,BAO_0000218,In vivo,Homo sapiens,1916,22224,A,U,,,
Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,Autocuration,,,9606.0,,,4712,CHEMBL620224,,0,1,,BAO_0000218,,Homo sapiens,5965,22224,A,U,,,
Stability in human plasma 2 hr after incubation expressed as percent concentration,Autocuration,,,9606.0,,,4713,CHEMBL620225,,0,1,,BAO_0000019,,Homo sapiens,1299,22224,A,U,,,
Stability in human plasma 4 hr after incubation expressed as percent concentration,Autocuration,,,9606.0,,,4714,CHEMBL620226,,0,1,,BAO_0000019,,Homo sapiens,1299,22224,A,U,,,
Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,9606.0,,,4715,CHEMBL620227,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,9606.0,,,4716,CHEMBL876726,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,9606.0,,,4717,CHEMBL620228,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,9606.0,,,4718,CHEMBL620229,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,10090.0,,,4719,CHEMBL620230,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,,10090.0,,,4720,CHEMBL620231,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,,10090.0,,,4721,CHEMBL620232,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,Intermediate,,,10090.0,,,4722,CHEMBL620233,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),Intermediate,,,10090.0,,,4723,CHEMBL620234,,1,1,,BAO_0000218,,Mus musculus,14294,50594,A,N,,,
Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),Intermediate,,,10090.0,,,4724,CHEMBL620235,,1,1,,BAO_0000218,,Mus musculus,14294,50594,A,N,,,
Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),Intermediate,,,10090.0,,,4725,CHEMBL620236,,1,1,,BAO_0000218,,Mus musculus,14294,50594,A,N,,,
In vitro metabolic potential in mouse liver microsomes,Intermediate,,,10090.0,,,4726,CHEMBL620237,Liver,1,1,,BAO_0000218,,Mus musculus,6251,50594,A,N,,2107.0,
Ability of compound to bind to plasma protein was evaluated in HSA cells,Intermediate,,,10090.0,,,4727,CHEMBL620238,,1,1,,BAO_0000218,,Mus musculus,17582,50594,A,N,,,
Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Intermediate,,,10090.0,,,4728,CHEMBL620239,Adrenal gland,1,1,,BAO_0000218,,Mus musculus,17811,50594,A,N,,2369.0,
Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Intermediate,,,10090.0,,,4729,CHEMBL620240,Brain,1,1,,BAO_0000218,,Mus musculus,17811,50594,A,N,,955.0,
Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Intermediate,,,10090.0,,,4730,CHEMBL620241,Brain,1,1,,BAO_0000218,,Mus musculus,17811,50594,A,N,,955.0,
Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),Intermediate,,,10090.0,,,4731,CHEMBL876727,,1,1,,BAO_0000218,,Mus musculus,17811,50594,A,N,,,
Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Intermediate,,,10090.0,,,4732,CHEMBL620242,Kidney,1,1,,BAO_0000218,,Mus musculus,17811,50594,A,N,,2113.0,
Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),Intermediate,,,10090.0,,,4733,CHEMBL620243,,1,1,,BAO_0000218,,Mus musculus,17811,50594,A,N,,,
Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,Intermediate,,,10090.0,,,4734,CHEMBL620244,,1,1,,BAO_0000218,,Mus musculus,5288,50594,A,N,,,
Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Intermediate,,,10090.0,,,4735,CHEMBL620245,Serum,1,1,,BAO_0000218,,Mus musculus,2717,50594,A,N,,1977.0,
Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Intermediate,,,10090.0,,,4736,CHEMBL620246,Serum,1,1,,BAO_0000218,,Mus musculus,2717,50594,A,N,,1977.0,
Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Intermediate,,,10090.0,,,4737,CHEMBL620247,Serum,1,1,,BAO_0000218,,Mus musculus,2717,50594,A,N,,1977.0,
Half life of compound was determined in plasma of mice at 24 mg/Kg,Intermediate,,,10090.0,,,4738,CHEMBL620248,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,1969.0,
Half life of compound was determined in plasma of mice at 40 mg/Kg,Intermediate,,,10090.0,,,4739,CHEMBL873497,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,1969.0,
Half life of compound was determined in plasma of mice at 5 mg/Kg,Intermediate,,,10090.0,,,4740,CHEMBL620249,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,1969.0,
Half life after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,,10090.0,,,4741,CHEMBL620250,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Half life after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,10090.0,,,4742,CHEMBL620251,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Half life after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,,10090.0,,,4743,CHEMBL620252,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Half life after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,,10090.0,,,4744,CHEMBL620253,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Half life after intravenous administration in mice at 23 uM/kg,Intermediate,,,10090.0,,,4745,CHEMBL620254,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Half life after intravenous administration in mice at 24 uM/kg,Intermediate,,,10090.0,,,4746,CHEMBL620255,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,A,N,,,
At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,,,10090.0,,,4747,CHEMBL620256,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,Intermediate,,,10090.0,,,4748,CHEMBL876728,,1,1,,BAO_0000218,In vivo,Mus musculus,2675,50594,A,N,,,
Maximum time required to reach Cp max was evaluated in mice after oral administration,Intermediate,,,10090.0,,,4749,CHEMBL620257,,1,1,,BAO_0000218,In vivo,Mus musculus,2675,50594,A,N,,,
At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Intermediate,,,10090.0,,,4750,CHEMBL620258,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",Intermediate,,,10090.0,,,4751,CHEMBL620259,,1,1,,BAO_0000218,In vivo,Mus musculus,4890,50594,A,N,,,
Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,Intermediate,,,10090.0,,,4752,CHEMBL620260,,1,1,,BAO_0000218,In vivo,Mus musculus,429,50594,A,N,,,
Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,10090.0,,,4753,CHEMBL620261,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,17837,50594,A,N,,178.0,
Half life at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,10090.0,,,4754,CHEMBL620262,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Half life at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,10090.0,,,4755,CHEMBL620263,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Half life in ob/ob mice,Intermediate,,,10090.0,,,4756,CHEMBL620264,,1,1,,BAO_0000218,,Mus musculus,6619,50594,A,N,,,
Half-life at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,10090.0,,,4757,CHEMBL620265,,1,1,,BAO_0000218,In vivo,Mus musculus,4066,50594,A,N,,,
Half-life was measured in mouse,Intermediate,,,10090.0,,,4758,CHEMBL620266,,1,1,,BAO_0000218,,Mus musculus,4239,50594,A,N,,,
In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,10090.0,,,4759,CHEMBL620267,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,Intermediate,,,10090.0,,,4760,CHEMBL619364,,1,1,,BAO_0000218,,Mus musculus,8999,50594,A,N,,,
Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,Intermediate,,,10090.0,,,4761,CHEMBL619365,,1,1,,BAO_0000218,,Mus musculus,8999,50594,A,N,,,
T2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4762,CHEMBL619366,Brain,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,955.0,
T2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4763,CHEMBL619367,Kidney,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,2113.0,
T2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4764,CHEMBL619368,Liver,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,2107.0,
T2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4765,CHEMBL619369,Lung,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,2048.0,
T2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4766,CHEMBL876729,Spleen,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,2106.0,
At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,,,10090.0,,,4767,CHEMBL619370,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",Intermediate,,,10090.0,,,4768,CHEMBL619371,,1,1,,BAO_0000218,In vivo,Mus musculus,4890,50594,A,N,,,
Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,Intermediate,,,10090.0,,,4769,CHEMBL619372,,1,1,,BAO_0000218,In vivo,Mus musculus,429,50594,A,N,,,
Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,Intermediate,,,10090.0,,,4770,CHEMBL620012,,1,1,,BAO_0000218,In vivo,Mus musculus,429,50594,A,N,,,
In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,10090.0,,,4771,CHEMBL620013,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,478.0,9606.0,,,4772,CHEMBL620014,,1,1,,BAO_0000219,,Homo sapiens,16913,81034,F,N,A2780,,
"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,,478.0,9606.0,,,4773,CHEMBL620015,,1,1,,BAO_0000219,,Homo sapiens,16913,81034,F,N,A2780,,
"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,478.0,9606.0,,,4774,CHEMBL621010,,1,1,,BAO_0000219,,Homo sapiens,16913,81034,F,N,A2780,,
"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,478.0,9606.0,,,4775,CHEMBL621011,,1,1,,BAO_0000219,,Homo sapiens,16913,81034,F,N,A2780,,
"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,478.0,9606.0,,,4776,CHEMBL621012,,1,1,,BAO_0000219,,Homo sapiens,16913,81034,F,N,A2780,,
"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,,478.0,9606.0,,,4777,CHEMBL621013,,1,1,,BAO_0000219,,Homo sapiens,16913,81034,F,N,A2780,,
In vitro cytotoxicity against A2780TAX cell line,Intermediate,,478.0,9606.0,,,4778,CHEMBL621014,,1,1,,BAO_0000219,,Homo sapiens,17270,81034,F,N,A2780,,
In vitro inhibitory activity against human tumor cell line A2780cis,Intermediate,,481.0,9606.0,,,4779,CHEMBL618154,,1,1,,BAO_0000219,,Homo sapiens,5618,80017,F,N,A2780cisR,,
Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,Expert,,478.0,9606.0,,,4780,CHEMBL618155,,1,1,,BAO_0000219,,Homo sapiens,17777,81034,F,N,A2780,,
Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,Intermediate,,481.0,9606.0,,,4781,CHEMBL618156,,1,1,,BAO_0000219,,Homo sapiens,16112,80017,F,N,A2780cisR,,
The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,,481.0,9606.0,,,4782,CHEMBL618157,,1,1,,BAO_0000219,,Homo sapiens,15748,80017,F,N,A2780cisR,,
Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,Intermediate,,478.0,9606.0,,,4783,CHEMBL618328,,1,1,,BAO_0000219,,Homo sapiens,6633,81034,F,N,A2780,,
Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,Intermediate,,478.0,9606.0,,,4784,CHEMBL618329,,1,1,,BAO_0000219,,Homo sapiens,16930,81034,F,N,A2780,,
Cytotoxicity against human ovarian carcinoma A2780cisR cell line,Intermediate,,478.0,9606.0,,,4785,CHEMBL618330,,1,1,,BAO_0000219,,Homo sapiens,17496,81034,F,N,A2780,,
In vitro antitumor activity against A2780cisR cell line.,Expert,,478.0,9606.0,,,4786,CHEMBL618331,,1,1,,BAO_0000219,,Homo sapiens,12989,81034,F,N,A2780,,
Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),Intermediate,,478.0,9606.0,,,4787,CHEMBL618332,,1,1,,BAO_0000219,,Homo sapiens,4840,81034,F,N,A2780,,
Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,Expert,,478.0,9606.0,,,4788,CHEMBL618333,,1,1,,BAO_0000219,,Homo sapiens,12989,81034,F,N,A2780,,
cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,Intermediate,,481.0,9606.0,,,4789,CHEMBL618334,,1,1,,BAO_0000219,,Homo sapiens,16745,80017,F,N,A2780cisR,,
Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,Expert,,478.0,9606.0,,,4790,CHEMBL618335,,1,1,,BAO_0000219,,Homo sapiens,16597,81034,F,N,A2780,,
Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,Expert,,,10116.0,,,4791,CHEMBL618336,,9,1,,BAO_0000019,,Rattus norvegicus,16547,11736,B,D,,,
Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,,,,,,4792,CHEMBL618337,,8,1,,BAO_0000019,,,16547,11736,F,H,,,
Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,,,10116.0,,,4793,CHEMBL618338,,9,1,,BAO_0000019,,Rattus norvegicus,16547,11736,F,D,,,
Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,Expert,,722.0,9606.0,,,4794,CHEMBL618339,,9,1,,BAO_0000219,,Homo sapiens,15856,278,F,D,HEK293,,
Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,Expert,,722.0,9606.0,,,4795,CHEMBL618340,,9,1,,BAO_0000219,,Homo sapiens,15856,278,F,D,HEK293,,
Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,Expert,,,10090.0,,,4796,CHEMBL618341,,9,1,,BAO_0000019,,Mus musculus,16547,11831,B,D,,,
Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,,,,,,4797,CHEMBL618342,,8,1,,BAO_0000019,,,16547,11831,F,H,,,
Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,,,10090.0,,,4798,CHEMBL618343,,9,1,,BAO_0000019,,Mus musculus,16547,11831,F,D,,,
Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,Expert,,,,,,4799,CHEMBL621038,,8,1,,BAO_0000357,,,17402,280,B,H,,,
Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),Autocuration,,574.0,9606.0,,,4800,CHEMBL621039,,0,1,,BAO_0000219,,Homo sapiens,11746,22226,F,U,T-cells,,
Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,Autocuration,,574.0,9606.0,,,4801,CHEMBL621040,,0,1,,BAO_0000219,,Homo sapiens,11746,22226,F,U,T-cells,,
Compound was evaluated for cytotoxic activity against human melanoma cell line A375,Intermediate,,455.0,9606.0,,,4802,CHEMBL621041,,1,1,,BAO_0000219,,Homo sapiens,5455,80018,F,N,A-375,,
In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,Intermediate,,455.0,9606.0,,,4803,CHEMBL621042,,1,1,,BAO_0000219,,Homo sapiens,2068,80018,F,N,A-375,,
In vitro antitumor activity against A375cell line extracted form melanoma,Intermediate,,455.0,9606.0,,,4804,CHEMBL621043,,1,1,,BAO_0000219,,Homo sapiens,2683,80018,F,N,A-375,,
Inhibition of cell growth in (A375) melan cell line,Expert,,455.0,9606.0,,,4805,CHEMBL621044,,1,1,,BAO_0000219,,Homo sapiens,15313,80018,F,N,A-375,,
In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,Intermediate,,455.0,9606.0,,,4806,CHEMBL621045,,1,1,,BAO_0000219,,Homo sapiens,13739,80018,F,N,A-375,,
In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,Intermediate,,455.0,9606.0,,,4807,CHEMBL621046,,1,1,,BAO_0000219,,Homo sapiens,13739,80018,F,N,A-375,,
Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,Intermediate,,455.0,9606.0,,,4808,CHEMBL621047,,1,1,,BAO_0000219,,Homo sapiens,14750,80018,F,N,A-375,,
Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,,797.0,9606.0,,,4809,CHEMBL621048,,1,1,,BAO_0000219,,Homo sapiens,14777,80019,F,N,A-427,,
Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,,797.0,9606.0,,,4810,CHEMBL883798,,1,1,,BAO_0000219,,Homo sapiens,14777,80019,F,N,A-427,,
Cytotoxicity against lung carcinoma A427 tumor cell lines,Intermediate,,797.0,9606.0,,,4811,CHEMBL621049,,1,1,,BAO_0000219,,Homo sapiens,17672,80019,F,N,A-427,,
Inhibition of large cell lung carcinoma (A427),Intermediate,,797.0,9606.0,,,4812,CHEMBL621050,,1,1,,BAO_0000219,,Homo sapiens,14368,80019,F,N,A-427,,
Inhibition of large cell lung carcinoma (A427) after 48-h treatment,Intermediate,,797.0,9606.0,,,4813,CHEMBL621051,,1,1,,BAO_0000219,,Homo sapiens,14368,80019,F,N,A-427,,
Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,,797.0,9606.0,,,4814,CHEMBL621052,,1,1,,BAO_0000219,,Homo sapiens,13866,80019,F,N,A-427,,
Inhibitory concentration in human lung carcinoma A427 cell line,Intermediate,,797.0,9606.0,,,4815,CHEMBL621053,,1,1,,BAO_0000219,,Homo sapiens,2545,80019,F,N,A-427,,
Inhibitory concentration in human lung carcinoma A427/VCR cell line,Intermediate,,797.0,9606.0,,,4816,CHEMBL621054,,1,1,,BAO_0000219,,Homo sapiens,2545,80019,F,N,A-427,,
Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,9527.0,,,4817,CHEMBL621055,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6062,22224,A,U,,,
Tested for volume of distribution upon iv administration to african green monkey,Autocuration,,,9527.0,,,4818,CHEMBL876398,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4578,22224,A,U,,,
Volume of distribution in monkey,Autocuration,,,9527.0,,,4819,CHEMBL621056,,0,1,,BAO_0000218,In vivo,Cercopithecidae,17592,22224,A,U,,,
Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,,9544.0,,,4820,CHEMBL621057,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5005,22224,A,U,,,
Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Autocuration,,,9544.0,,,4821,CHEMBL621058,,0,1,,BAO_0000218,In vivo,Macaca mulatta,5005,22224,A,U,,,
Pharmacokinetic property(Vdss) in cynomolgus monkey,Autocuration,,,9527.0,,,4822,CHEMBL621059,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5922,22224,A,U,,,
The distribution volume after intravenous administration in cynomolgus monkeys,Autocuration,,,9527.0,,,4823,CHEMBL621060,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,9527.0,,,4824,CHEMBL621061,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,9527.0,,,4825,CHEMBL621062,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
Volume displacement was calculated in rhesus monkey,Autocuration,,,9527.0,,,4826,CHEMBL621063,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6057,22224,A,U,,,
Volume of distribution in steady state was determined in rhesus monkey,Autocuration,,,9527.0,,,4827,CHEMBL621064,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5145,22224,A,U,,,
Volume of distribution of compound was determined in monkey,Autocuration,,,9527.0,,,4828,CHEMBL621065,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6821,22224,A,U,,,
Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,9527.0,,,4829,CHEMBL621066,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5334,22224,A,U,,,
Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,9527.0,,,4830,CHEMBL621067,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5334,22224,A,U,,,
Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,9527.0,,,4831,CHEMBL621068,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6641,22224,A,U,,,
Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,9527.0,,,4832,CHEMBL876399,,0,1,,BAO_0000218,In vivo,Cercopithecidae,2661,22224,A,U,,,
Volume distribution in monkey after administration of 1 mg/kg iv,Autocuration,,,9527.0,,,4833,CHEMBL621069,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6535,22224,A,U,,,
Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,9527.0,,,4834,CHEMBL621070,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4809,22224,A,U,,,
Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,9527.0,,,4835,CHEMBL621071,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6062,22224,A,U,,,
Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,4836,CHEMBL621072,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3443,22224,A,U,,,
Oral systemic bioavailability upon iv administration to african green monkey,Autocuration,,,9527.0,,,4837,CHEMBL618209,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4578,22224,A,U,,,
Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,9527.0,,,4838,CHEMBL618210,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4809,22224,A,U,,,
Baboon plasma free fraction. ,Autocuration,,,9527.0,,,4839,CHEMBL618211,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Area under the curve was calculated in rhesus monkey after iv administration,Autocuration,,,9527.0,,,4840,CHEMBL618212,,0,1,,BAO_0000218,,Cercopithecidae,6057,22224,A,U,,,
Area under the curve was calculated in rhesus monkey after peroral administration,Autocuration,,,9527.0,,,4841,CHEMBL618213,,0,1,,BAO_0000019,,Cercopithecidae,6057,22224,A,U,,,
Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,Autocuration,,,9527.0,,,4842,CHEMBL618214,,0,1,,BAO_0000019,,Cercopithecidae,17853,22224,A,U,,,
Half life period in monkey after 5 mg/kg dose,Autocuration,,,9527.0,,,4843,CHEMBL873492,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5302,22224,A,U,,,
Half-life was determined in monkey after 3 mg/kg of i.v. dose,Autocuration,,,9527.0,,,4844,CHEMBL618272,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4257,22224,A,U,,,
Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,Autocuration,,,9527.0,,,4845,CHEMBL618273,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4257,22224,A,U,,,
Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,,,9527.0,,,4846,CHEMBL618274,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,13501,22224,A,U,,1969.0,
Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,Autocuration,,,9527.0,,,4847,CHEMBL618275,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5394,22224,A,U,,,
Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,9527.0,,,4848,CHEMBL618276,,0,1,,BAO_0000218,In vivo,Cercopithecidae,2661,22224,A,U,,,
Compound was evaluated for terminal half life in monkey,Autocuration,,,9527.0,,,4849,CHEMBL618277,,0,1,,BAO_0000019,,Cercopithecidae,3341,22224,A,U,,,
Compound was evaluated for the half life period after iv administration in cynomolgus monkey,Autocuration,,,9527.0,,,4850,CHEMBL618278,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3045,22224,A,U,,,
Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,,9544.0,,,4851,CHEMBL618279,Plasma,0,1,,BAO_0000218,In vivo,Macaca mulatta,5005,22224,A,U,,1969.0,
Half life of compound was determined in squirrel monkey,Autocuration,,,9527.0,,,4852,CHEMBL618280,,0,1,,BAO_0000019,,Cercopithecidae,4847,22224,A,U,,,
Half life after iv administration in cynomolgus monkey,Autocuration,,,9541.0,,,4853,CHEMBL618281,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,4256,22224,A,U,,,
Half life in monkey plasma after administration of 1 mg/kg iv,Autocuration,,,9527.0,,,4854,CHEMBL618282,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,6535,22224,A,U,,1969.0,
Half life was calculated in rhesus monkey,Autocuration,,,9527.0,,,4855,CHEMBL618283,,0,1,,BAO_0000019,,Cercopithecidae,6057,22224,A,U,,,
Half life in monkey,Autocuration,,,9527.0,,,4856,CHEMBL618284,,0,1,,BAO_0000019,,Cercopithecidae,17592,22224,A,U,,,
Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,,9527.0,,,4857,CHEMBL618285,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6641,22224,A,U,,,
Half life was evaluated in rhesus,Autocuration,,,9527.0,,,4858,CHEMBL618286,,0,1,,BAO_0000019,,Cercopithecidae,5472,22224,A,U,,,
Half life period after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,9527.0,,,4859,CHEMBL618287,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6221,22224,A,U,,,
Half life period was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,,9527.0,,,4860,CHEMBL618288,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5668,22224,A,U,,,
Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,,9527.0,,,4861,CHEMBL876393,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4809,22224,A,U,,,
Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,,9527.0,,,4862,CHEMBL618289,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5546,22224,A,U,,,
Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,Autocuration,,,9527.0,,,4863,CHEMBL618290,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5553,22224,A,U,,,
Half-life was calculated in monkey,Autocuration,,,9527.0,,,4864,CHEMBL618291,,0,1,,BAO_0000019,,Cercopithecidae,6078,22224,A,U,,,
Half-life in Squirrel monkey,Autocuration,,,9527.0,,,4865,CHEMBL618292,,0,1,,BAO_0000019,,Cercopithecidae,5147,22224,A,U,,,
Half-life in rhesus monkey,Autocuration,,,9527.0,,,4866,CHEMBL618293,,0,1,,BAO_0000019,,Cercopithecidae,5145,22224,A,U,,,
Half-life was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,9527.0,,,4867,CHEMBL618294,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6062,22224,A,U,,,
Half-life period after intravenous administration in cynomolgus monkeys,Autocuration,,,9527.0,,,4868,CHEMBL618295,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
Half-life period after oral administration in cynomolgus monkeys,Autocuration,,,9527.0,,,4869,CHEMBL618296,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,Autocuration,,,9527.0,,,4870,CHEMBL618297,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,9606.0,,,4871,CHEMBL618298,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,9606.0,,,4872,CHEMBL618299,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,9606.0,,,4873,CHEMBL618300,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,,9606.0,,,4874,CHEMBL618301,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,,,9606.0,,,4875,CHEMBL618302,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,,,9606.0,,,4876,CHEMBL876394,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,,,9606.0,,,4877,CHEMBL618303,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,,,9606.0,,,4878,CHEMBL618304,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,Autocuration,,,9606.0,,,4879,CHEMBL618305,,0,1,,BAO_0000218,In vivo,Homo sapiens,1916,22224,A,U,,,
Oral bioavailability in human,Autocuration,,,9606.0,,,4880,CHEMBL618306,,0,1,,BAO_0000218,In vivo,Homo sapiens,16643,22224,A,U,,,
Compound was tested for human plasma protein binding,Autocuration,,,9606.0,,,4881,CHEMBL618307,,0,1,,BAO_0000019,,Homo sapiens,17248,22224,A,U,,,
Compound was tested for human plasma protein binding; Not determined,Autocuration,,,9606.0,,,4882,CHEMBL618308,,0,1,,BAO_0000019,,Homo sapiens,17248,22224,A,U,,,
Protein binding activity of compound in human plasma; % Free,Autocuration,,,9606.0,,,4883,CHEMBL618309,,0,1,,BAO_0000019,,Homo sapiens,6241,22224,A,U,,,
Unbound fraction (plasma),Autocuration,,,9606.0,,,4884,CHEMBL618310,,0,1,,BAO_0000019,,Homo sapiens,17716,22224,A,U,,,
Half life for the hydrolysis of compound in human blood serum,Autocuration,,,9606.0,,,4885,CHEMBL873353,Plasma,0,1,,BAO_0000366,,Homo sapiens,17605,22224,A,U,,1969.0,
Half life period in human plasma using phosphate buffer (0.08 M),Autocuration,,,9606.0,,,4886,CHEMBL618311,Plasma,0,1,,BAO_0000366,,Homo sapiens,17625,22224,A,U,,1969.0,
Half life period in human plasma using phosphate buffer (0.1 M),Autocuration,,,9606.0,,,4887,CHEMBL618312,Plasma,0,1,,BAO_0000366,,Homo sapiens,17625,22224,A,U,,1969.0,
Half-life in human plasma was determined,Autocuration,,,9606.0,,,4888,CHEMBL618313,Plasma,0,1,,BAO_0000366,,Homo sapiens,17747,22224,A,U,,1969.0,
Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,Autocuration,,,9606.0,,,4889,CHEMBL618314,,0,1,,BAO_0000019,,Homo sapiens,15613,22224,A,U,,,
Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),Autocuration,,,9606.0,,,4890,CHEMBL618315,,0,1,,BAO_0000019,,Homo sapiens,354,22224,A,U,,,
"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,,,9606.0,,,4891,CHEMBL618316,,0,1,,BAO_0000019,,Homo sapiens,3741,22224,A,U,,,
"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,,,9606.0,,,4892,CHEMBL618317,,0,1,,BAO_0000019,,Homo sapiens,3741,22224,A,U,,,
"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,,,9606.0,,,4893,CHEMBL620138,,0,1,,BAO_0000019,,Homo sapiens,3741,22224,A,U,,,
Partition coefficient (logP),Autocuration,,,9606.0,,,4894,CHEMBL858280,,0,1,,BAO_0000019,,Homo sapiens,17599,22224,A,U,,,
In vitro metabolic stability in human was measured as pmol/min/mg/protein,Autocuration,,,9606.0,,,4895,CHEMBL620139,,0,1,,BAO_0000019,,Homo sapiens,5486,22224,A,U,,,
In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Autocuration,,,9606.0,Microsomes,,4896,CHEMBL620140,,0,1,,BAO_0000251,,Homo sapiens,5600,22224,A,U,,,
Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),Autocuration,,,9606.0,,,4897,CHEMBL620141,,0,1,,BAO_0000019,,Homo sapiens,14294,22224,A,U,,,
Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),Autocuration,,,9606.0,,,4898,CHEMBL620142,,0,1,,BAO_0000019,,Homo sapiens,14294,22224,A,U,,,
Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),Autocuration,,,9606.0,,,4899,CHEMBL620143,,0,1,,BAO_0000019,,Homo sapiens,14294,22224,A,U,,,
Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Autocuration,,,9606.0,Microsomes,,4900,CHEMBL620144,,0,1,,BAO_0000251,,Homo sapiens,14294,22224,A,U,,,
Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Autocuration,,,9606.0,Microsomes,,4901,CHEMBL620145,,0,1,,BAO_0000251,,Homo sapiens,14294,22224,A,U,,,
Metabolism of compound in human microsomes; Trace,Autocuration,,,9606.0,Microsomes,,4902,CHEMBL620146,,0,1,,BAO_0000251,,Homo sapiens,14294,22224,A,U,,,
Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Autocuration,,,9606.0,Microsomes,,4903,CHEMBL620147,Liver,0,1,,BAO_0000251,,Homo sapiens,6260,22224,A,U,,2107.0,
Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Autocuration,,,9606.0,Microsomes,,4904,CHEMBL620148,,0,1,,BAO_0000251,,Homo sapiens,6187,22224,A,U,,,
In vitro metabolic potential in human liver microsomes,Autocuration,,,9606.0,Microsomes,,4905,CHEMBL620149,Liver,0,1,,BAO_0000251,,Homo sapiens,6251,22224,A,U,,2107.0,
Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,Autocuration,,,9606.0,,,4906,CHEMBL876412,,0,1,,BAO_0000019,,Homo sapiens,3246,22224,A,U,,,
Tested for human plasma protein binding of the compound; Not tested,Autocuration,,,9606.0,,,4907,CHEMBL619352,,0,1,,BAO_0000019,,Homo sapiens,17313,22224,A,U,,,
Compound was tested for percent protein binding (PB) in human,Autocuration,,,9606.0,,,4908,CHEMBL619353,,0,1,,BAO_0000019,,Homo sapiens,6227,22224,A,U,,,
Protein binding in human plasma,Autocuration,,,9606.0,,,4909,CHEMBL619354,Plasma,0,1,,BAO_0000019,,Homo sapiens,5530,22224,A,U,,1969.0,
Permeability coefficient (B to A) in Caco-2 cell,Autocuration,,,9606.0,,,4910,CHEMBL619355,,0,1,,BAO_0000019,,Homo sapiens,6108,22224,A,U,,,
Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,Autocuration,,,9606.0,,,4911,CHEMBL619356,,0,1,,BAO_0000019,,Homo sapiens,6108,22224,A,U,,,
Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),Autocuration,,,9606.0,,,4912,CHEMBL619357,,0,1,,BAO_0000019,,Homo sapiens,2774,22224,A,U,,,
In vitro rate of absorption observed as Caco-2 permeability in humans,Autocuration,,,9606.0,,,4913,CHEMBL619358,,0,1,,BAO_0000019,,Homo sapiens,16643,22224,A,U,,,
Cellular permeability of compound was determined in Caco-2 cells; High,Autocuration,,495.0,9606.0,,,4914,CHEMBL619359,,0,1,,BAO_0000219,,Homo sapiens,17582,22224,A,U,Caco-2,,
Permeability in Caco-2 cells of compound,Autocuration,,495.0,9606.0,,,4915,CHEMBL619360,,0,1,,BAO_0000219,,Homo sapiens,6838,22224,A,U,Caco-2,,
Permeability coefficient (A to B) in Caco-2 cell,Autocuration,,,9606.0,,,4916,CHEMBL619361,,0,1,,BAO_0000019,,Homo sapiens,6108,22224,A,U,,,
Permeability coefficient (B to A) in Caco-2 cell,Autocuration,,,9606.0,,,4917,CHEMBL619362,,0,1,,BAO_0000019,,Homo sapiens,6108,22224,A,U,,,
Permeability coefficient (Papp) (Caco-2 cell monolayer),Autocuration,,,9606.0,,,4918,CHEMBL619363,,0,1,,BAO_0000019,,Homo sapiens,6108,22224,A,U,,,
Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,Autocuration,,,9606.0,,,4919,CHEMBL618942,,0,1,,BAO_0000019,,Homo sapiens,2146,22224,A,U,,,
Compound was tested for protein binding in human plasma,Autocuration,,,9606.0,,,4920,CHEMBL618943,,0,1,,BAO_0000019,,Homo sapiens,4514,22224,A,U,,,
Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,Autocuration,,,9606.0,,,4921,CHEMBL618944,,0,1,,BAO_0000019,,Homo sapiens,6108,22224,A,U,,,
Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Autocuration,,,9606.0,,,4922,CHEMBL618945,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,10090.0,,,4923,CHEMBL618946,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,10090.0,,,4924,CHEMBL876413,,1,1,,BAO_0000218,In vivo,Mus musculus,3277,50594,A,N,,,
Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,,,10090.0,,,4925,CHEMBL618947,,1,1,,BAO_0000218,In vivo,Mus musculus,3802,50594,A,N,,,
Time taken to reach maximum concentration in plasma upon oral administration in mouse,Intermediate,,,10090.0,,,4926,CHEMBL618948,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,2862,50594,A,N,,1969.0,
Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,10090.0,,,4927,CHEMBL618949,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,6348,50594,A,N,,1969.0,
Tmax after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,10090.0,,,4928,CHEMBL618950,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Tmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,,,10090.0,,,4929,CHEMBL618951,,1,1,,BAO_0000218,In vivo,Mus musculus,5781,50594,A,N,,,
Tmax after peroral administration in mice at 2.4 uM/kg,Intermediate,,,10090.0,,,4930,CHEMBL618952,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,A,N,,,
Tmax at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,10090.0,,,4931,CHEMBL618953,,1,1,,BAO_0000218,In vivo,Mus musculus,4066,50594,A,N,,,
Tmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4932,CHEMBL618954,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,955.0,
Tmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4933,CHEMBL618955,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,2113.0,
Tmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4934,CHEMBL618956,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,2107.0,
Tmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4935,CHEMBL618957,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,2048.0,
Tmax in mice at 18 uM/kg i.p. administration,Intermediate,,,10090.0,,,4936,CHEMBL618958,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Tmax in mice at 23 uM/kg i.v. administration,Intermediate,,,10090.0,,,4937,CHEMBL618959,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Tmax in mice at 25 uM/kg i.p. administration,Intermediate,,,10090.0,,,4938,CHEMBL618960,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Tmax in mice at 26 uM/kg i.p. administration,Intermediate,,,10090.0,,,4939,CHEMBL876723,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Tmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,4940,CHEMBL618961,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,2106.0,
Tmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,10090.0,,,4941,CHEMBL618962,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Tmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,10090.0,,,4942,CHEMBL618963,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Tmax value in IRC mice,Intermediate,,,10090.0,,,4943,CHEMBL618964,,1,1,,BAO_0000218,,Mus musculus,5951,50594,A,N,,,
Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,,10090.0,,,4944,CHEMBL618965,,1,1,,BAO_0000218,In vivo,Mus musculus,5506,50594,A,N,,,
Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,,10090.0,,,4945,CHEMBL618966,,1,1,,BAO_0000218,In vivo,Mus musculus,5506,50594,A,N,,,
Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Intermediate,,,10090.0,,,4946,CHEMBL618967,Urine,1,1,,BAO_0000218,,Mus musculus,429,50594,A,N,,1088.0,
Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Intermediate,,,10090.0,,,4947,CHEMBL618968,Urine,1,1,,BAO_0000218,,Mus musculus,429,50594,A,N,,1088.0,
Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Intermediate,,,10090.0,,,4948,CHEMBL618969,Urine,1,1,,BAO_0000218,,Mus musculus,4066,50594,A,N,,1088.0,
The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,10090.0,,,4949,CHEMBL618970,,1,1,,BAO_0000218,,Mus musculus,17734,50594,A,N,,,
The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,10090.0,,,4950,CHEMBL618971,,1,1,,BAO_0000218,,Mus musculus,17734,50594,A,N,,,
Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,10090.0,,,4951,CHEMBL618972,,1,1,,BAO_0000218,In vivo,Mus musculus,6062,50594,A,N,,,
In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,10090.0,,,4952,CHEMBL618973,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,10090.0,,,4953,CHEMBL618974,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,,10090.0,,,4954,CHEMBL618975,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
Vd in mice,Intermediate,,,10090.0,,,4955,CHEMBL618976,,1,1,,BAO_0000218,In vivo,Mus musculus,5980,50594,A,N,,,
Volume of distribution in mouse,Intermediate,,,10090.0,,,4956,CHEMBL618977,,1,1,,BAO_0000218,In vivo,Mus musculus,17592,50594,A,N,,,
Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,10090.0,,,4957,CHEMBL876724,,1,1,,BAO_0000218,In vivo,Mus musculus,6348,50594,A,N,,,
Volume of distribution of compound in plasma was determined at 24 mg/Kg,Intermediate,,,10090.0,,,4958,CHEMBL618978,,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,,
Volume of distribution of compound in plasma was determined at 40 mg/Kg,Intermediate,,,10090.0,,,4959,CHEMBL618979,,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,,
Volume of distribution of compound in plasma was determined at 5 mg/Kg,Intermediate,,,10090.0,,,4960,CHEMBL618980,,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,,
Pharmacokinetic property (vdss) was measured in mouse,Intermediate,,,10090.0,,,4961,CHEMBL618981,,1,1,,BAO_0000218,In vivo,Mus musculus,4239,50594,A,N,,,
Value distribution upon iv administration in mouse,Intermediate,,,10090.0,,,4962,CHEMBL618982,,1,1,,BAO_0000218,In vivo,Mus musculus,2862,50594,A,N,,,
Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,10090.0,,,4963,CHEMBL620150,,1,1,,BAO_0000218,In vivo,Mus musculus,17734,50594,A,N,,,
Volume of distribution was evaluated in mice after intravenous administration,Intermediate,,,10090.0,,,4964,CHEMBL620151,,1,1,,BAO_0000218,In vivo,Mus musculus,2675,50594,A,N,,,
Volume of distribution was evaluated in mice after oral administration,Intermediate,,,10090.0,,,4965,CHEMBL620152,,1,1,,BAO_0000218,In vivo,Mus musculus,2675,50594,A,N,,,
Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,10090.0,,,4966,CHEMBL620153,,1,1,,BAO_0000218,In vivo,Mus musculus,17837,50594,A,N,,,
Steady state volume of distribution was determined in mice,Intermediate,,,10090.0,,,4967,CHEMBL876395,,1,1,,BAO_0000218,In vivo,Mus musculus,5727,50594,A,N,,,
Volume distribution (steady state) of compound was determined in mouse,Intermediate,,,10090.0,,,4968,CHEMBL620154,,1,1,,BAO_0000218,In vivo,Mus musculus,17852,50594,A,N,,,
Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,Intermediate,,,10090.0,,,4969,CHEMBL620155,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,A,N,,,
Vss value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,10090.0,,,4970,CHEMBL620156,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,10090.0,,,4971,CHEMBL620157,,1,1,,BAO_0000218,In vivo,Mus musculus,6062,50594,A,N,,,
Biodistribution of compound (oxidized form) in in kidney tissue,Intermediate,,,10090.0,,,4972,CHEMBL620158,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2113.0,
Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,,10090.0,,,4973,CHEMBL620159,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,178.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,,10090.0,,,4974,CHEMBL620160,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,178.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,4975,CHEMBL620161,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,178.0,
Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,,797.0,9606.0,,,4976,CHEMBL620162,,1,1,,BAO_0000219,,Homo sapiens,10708,80019,F,N,A-427,,
Inhibition of A431 human squamous cell carcinoma cell proliferation,Expert,,500.0,9606.0,,,4977,CHEMBL620163,,1,1,,BAO_0000219,,Homo sapiens,16597,80852,F,N,A-431,,
Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,Expert,,500.0,9606.0,,,4978,CHEMBL620833,,1,1,,BAO_0000219,,Homo sapiens,16062,80852,F,N,A-431,,
Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,Expert,,500.0,9606.0,,,4979,CHEMBL876396,,1,1,,BAO_0000219,,Homo sapiens,16062,80852,F,N,A-431,,
Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,Expert,,500.0,9606.0,,,4980,CHEMBL620834,,1,1,,BAO_0000219,,Homo sapiens,16958,80852,F,N,A-431,,
Inhibition of A431 human carcinoma cell proliferation,Expert,,500.0,9606.0,,,4981,CHEMBL620835,,1,1,,BAO_0000219,,Homo sapiens,6700,80852,F,N,A-431,,
In vitro inhibition of A431 (human carcinoma) cell basal growth.,Expert,,500.0,9606.0,,,4982,CHEMBL620836,,1,1,,BAO_0000219,,Homo sapiens,17226,80852,F,N,A-431,,
Inhibitory concentration of compound against growth of human A431 cell line; Resistant,Intermediate,,500.0,9606.0,,,4983,CHEMBL620837,,1,1,,BAO_0000219,,Homo sapiens,6828,80852,F,N,A-431,,
In vitro cytotoxicity against epidermoid carcinoma cell line,Intermediate,,500.0,9606.0,,,4984,CHEMBL621017,,1,1,,BAO_0000219,,Homo sapiens,12314,80852,F,N,A-431,,
"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",Expert,,500.0,9606.0,,,4985,CHEMBL621018,,9,1,,BAO_0000218,,Homo sapiens,13412,9,F,D,A-431,,
Antiproliferative activity of compound was measured on human tumor cell line A431.,Intermediate,,500.0,9606.0,,,4986,CHEMBL621019,,1,1,,BAO_0000219,,Homo sapiens,13299,80852,F,N,A-431,,
Antiproliferative effect of compound on A431 cell line expressing mutant p53,Intermediate,,500.0,9606.0,,,4987,CHEMBL621020,,1,1,,BAO_0000219,,Homo sapiens,17420,80852,F,N,A-431,,
Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,Intermediate,,500.0,9606.0,,,4988,CHEMBL621021,,1,1,,BAO_0000219,,Homo sapiens,13678,80852,F,N,A-431,,
Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Expert,,500.0,,,,4989,CHEMBL621022,,8,1,,BAO_0000219,,,14171,9,F,H,A-431,,
Tested for antiproliferative activity against human A431 cells,Expert,,500.0,9606.0,,,4990,CHEMBL621023,,1,1,,BAO_0000219,,Homo sapiens,6333,80852,F,N,A-431,,
Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,Expert,,500.0,9606.0,,,4991,CHEMBL621024,,9,1,,BAO_0000219,,Homo sapiens,2356,9,F,D,A-431,,
Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,Expert,,500.0,9606.0,,,4992,CHEMBL621025,,1,1,,BAO_0000219,,Homo sapiens,15578,80852,F,N,A-431,,
Inhibition of A431 cell proliferation,Expert,,500.0,9606.0,,,4993,CHEMBL621026,,1,1,,BAO_0000219,,Homo sapiens,5126,80852,F,N,A-431,,
Cytotoxic effect on A431 human epidermoid carcinoma cells,Expert,,500.0,9606.0,,,4994,CHEMBL621027,,1,1,,BAO_0000219,,Homo sapiens,6844,80852,F,N,A-431,,
Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),Expert,,500.0,9606.0,,,4995,CHEMBL876397,,1,1,,BAO_0000219,,Homo sapiens,6844,80852,F,N,A-431,,
Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,Intermediate,,500.0,9606.0,,,4996,CHEMBL883797,,1,1,,BAO_0000219,,Homo sapiens,4925,80852,F,N,A-431,,
Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,Intermediate,,500.0,9606.0,,,4997,CHEMBL621028,,1,1,,BAO_0000219,,Homo sapiens,4925,80852,F,N,A-431,,
In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,Intermediate,,500.0,9606.0,,,4998,CHEMBL621029,,1,1,,BAO_0000219,,Homo sapiens,13978,80852,F,N,A-431,,
In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,Intermediate,,500.0,9606.0,,,4999,CHEMBL621030,,1,1,,BAO_0000219,,Homo sapiens,16786,80852,F,N,A-431,,
Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,500.0,,,,5000,CHEMBL621147,,8,1,,BAO_0000219,,,13412,9,F,H,A-431,,
In vivo antiproliferative activity against A431 cell line,Intermediate,,500.0,9606.0,,,5001,CHEMBL621148,,1,1,,BAO_0000218,,Homo sapiens,17824,80852,F,N,A-431,,
Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,Expert,,500.0,9606.0,,,5002,CHEMBL621149,,9,1,,BAO_0000219,,Homo sapiens,12751,9,F,D,A-431,,
Inhibition of A431 human epidermoid carcinoma cell proliferation,Expert,,500.0,9606.0,,,5003,CHEMBL621150,,1,1,,BAO_0000219,,Homo sapiens,12380,80852,F,N,A-431,,
Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Expert,,500.0,9606.0,,,5004,CHEMBL621151,,9,1,,BAO_0000219,,Homo sapiens,4959,9,F,D,A-431,,
Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),Intermediate,,500.0,9606.0,,,5005,CHEMBL621152,,1,1,,BAO_0000219,,Homo sapiens,6333,80852,F,N,A-431,,
Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),Intermediate,,500.0,9606.0,,,5006,CHEMBL621153,,1,1,,BAO_0000219,,Homo sapiens,6333,80852,F,N,A-431,,
Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),Intermediate,,500.0,9606.0,,,5007,CHEMBL884000,,1,1,,BAO_0000219,,Homo sapiens,6333,80852,F,N,A-431,,
Inhibition of EGFR overexpressing A431 cell proliferation,Expert,,,9606.0,,,5008,CHEMBL621154,,9,1,,BAO_0000019,,Homo sapiens,5296,9,F,D,,,
Inhibition of A431 cell proliferation,Expert,,500.0,9606.0,,,5009,CHEMBL621155,,1,1,,BAO_0000219,,Homo sapiens,12624,80852,F,N,A-431,,
No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,Expert,,500.0,9606.0,,,5010,CHEMBL621156,,9,1,,BAO_0000219,,Homo sapiens,14926,9,F,D,A-431,,
"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",Expert,,500.0,9606.0,,,5011,CHEMBL621157,,9,1,,BAO_0000219,,Homo sapiens,14926,9,F,D,A-431,,
Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),Expert,,500.0,,,,5012,CHEMBL621158,,8,1,,BAO_0000219,,,14926,9,F,H,A-431,,
The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,,500.0,9606.0,,,5013,CHEMBL621159,,1,1,,BAO_0000219,,Homo sapiens,15144,80852,F,N,A-431,,
The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,,500.0,9606.0,,,5014,CHEMBL621160,,1,1,,BAO_0000219,,Homo sapiens,15144,80852,F,N,A-431,,
Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,Intermediate,,500.0,9606.0,,,5015,CHEMBL621161,,1,1,,BAO_0000219,,Homo sapiens,5245,80852,F,N,A-431,,
Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,Intermediate,,500.0,9606.0,,,5016,CHEMBL621162,,1,1,,BAO_0000219,,Homo sapiens,5245,80852,F,N,A-431,,
Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,,500.0,9606.0,,,5017,CHEMBL621163,,1,1,,BAO_0000219,,Homo sapiens,5245,80852,F,N,A-431,,
Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,Intermediate,,500.0,9606.0,,,5018,CHEMBL621164,,1,1,,BAO_0000219,,Homo sapiens,5245,80852,F,N,A-431,,
Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,Intermediate,,500.0,9606.0,,,5019,CHEMBL621165,,1,1,,BAO_0000219,,Homo sapiens,5245,80852,F,N,A-431,,
Half-life period in cynomolgus monkey,Autocuration,,,9527.0,,,5020,CHEMBL619159,,0,1,,BAO_0000019,,Cercopithecidae,5922,22224,A,U,,,
"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Autocuration,,,9527.0,,,5021,CHEMBL619160,Plasma,0,1,,BAO_0000366,In vitro,Cercopithecidae,1116,22224,A,U,,1969.0,
Longer half-life in monkey (i.v.) at 0.5 mpk,Autocuration,,,9527.0,,,5022,CHEMBL619161,,0,1,,BAO_0000218,In vivo,Cercopithecidae,17853,22224,A,U,,,
Plasma half life in monkey,Autocuration,,,9527.0,,,5023,CHEMBL619162,Plasma,0,1,,BAO_0000366,,Cercopithecidae,993,22224,A,U,,1969.0,
Plasma half-life in rhesus monkey,Autocuration,,,9527.0,,,5024,CHEMBL619163,Plasma,0,1,,BAO_0000366,,Cercopithecidae,4514,22224,A,U,,1969.0,
Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,,9527.0,,,5025,CHEMBL619164,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,5334,22224,A,U,,1969.0,
Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,,9527.0,,,5026,CHEMBL619320,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,5334,22224,A,U,,1969.0,
Tested for half life upon iv administration to african green monkey,Autocuration,,,9527.0,,,5027,CHEMBL619321,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4578,22224,A,U,,,
Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,9527.0,,,5028,CHEMBL873336,,0,1,,BAO_0000218,In vivo,Cercopithecidae,2661,22224,A,U,,,
The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,9527.0,,,5029,CHEMBL619322,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,9527.0,,,5030,CHEMBL619323,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The time for peak concentration value after oral administration in cynomolgus monkeys,Autocuration,,,9527.0,,,5031,CHEMBL619324,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,Autocuration,,,9527.0,,,5032,CHEMBL619325,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,Autocuration,,,9527.0,,,5033,CHEMBL876411,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,Autocuration,,,9527.0,,,5034,CHEMBL619326,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,Autocuration,,,9527.0,,,5035,CHEMBL619327,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,Autocuration,,,9527.0,,,5036,CHEMBL619328,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,Autocuration,,,9527.0,,,5037,CHEMBL619329,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,Autocuration,,,9527.0,,,5038,CHEMBL619330,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,Autocuration,,,9527.0,,,5039,CHEMBL619331,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,Autocuration,,,9527.0,,,5040,CHEMBL619332,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,Autocuration,,,9527.0,,,5041,CHEMBL619333,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,Autocuration,,,9527.0,,,5042,CHEMBL619334,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,Autocuration,,,9527.0,,,5043,CHEMBL619335,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,Autocuration,,,9527.0,,,5044,CHEMBL619336,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,Autocuration,,,9527.0,,,5045,CHEMBL619337,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,Autocuration,,,9527.0,,,5046,CHEMBL619338,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,Autocuration,,,9527.0,,,5047,CHEMBL619339,,0,1,,BAO_0000019,,Cercopithecidae,11271,22224,A,U,,,
Bioavailability in rat (cannulated) (dose 2 mg/kg),Intermediate,,,10116.0,,,5048,CHEMBL619340,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,5809,50597,A,N,,,
Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,,10116.0,,,5049,CHEMBL873496,Plasma,1,1,,BAO_0000218,In vivo,Rattus norvegicus,17720,50597,A,N,,1969.0,
AUC value in rat after IV administration at a dose of 10 mg/kg,Intermediate,,,10116.0,,,5050,CHEMBL619341,Plasma,1,1,,BAO_0000218,,Rattus norvegicus,3546,50597,A,N,,1969.0,
AUC value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,10116.0,,,5051,CHEMBL619342,Plasma,1,1,,BAO_0000218,,Rattus norvegicus,3546,50597,A,N,,1969.0,
Cmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,10116.0,,,5052,CHEMBL619343,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,3546,50597,A,N,,,
Bioavailability in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,10116.0,,,5053,CHEMBL619344,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,3546,50597,A,N,,,
Tmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,,10116.0,,,5054,CHEMBL619345,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,3546,50597,A,N,,,
Vc value in rat after IV administration at a dose of 10 mg/kg,Intermediate,,,10116.0,,,5055,CHEMBL619346,,1,1,,BAO_0000218,,Rattus norvegicus,3546,50597,A,N,,,
Half life period in rat after IV administration at a dose of 10 mg/kg,Intermediate,,,10116.0,,,5056,CHEMBL619347,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,3546,50597,A,N,,,
The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,,,9557.0,,,5057,CHEMBL619348,,0,1,,BAO_0000019,,Papio hamadryas,10625,22224,A,U,,,
Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,,,9557.0,,,5058,CHEMBL619349,,0,1,,BAO_0000019,,Papio hamadryas,10625,22224,A,U,,,
Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,,,9557.0,,,5059,CHEMBL619350,,0,1,,BAO_0000019,,Papio hamadryas,10625,22224,A,U,,,
The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,Autocuration,,,9557.0,,,5060,CHEMBL619351,,0,1,,BAO_0000019,,Papio hamadryas,10625,22224,A,U,,,
The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,Autocuration,,,9557.0,,,5061,CHEMBL875953,,0,1,,BAO_0000019,,Papio hamadryas,10625,22224,A,U,,,
The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,Autocuration,,,9557.0,,,5062,CHEMBL621716,,0,1,,BAO_0000019,,Papio hamadryas,10625,22224,A,U,,,
The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,Autocuration,,,9557.0,,,5063,CHEMBL621717,,0,1,,BAO_0000019,,Papio hamadryas,10625,22224,A,U,,,
The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,,,9557.0,,,5064,CHEMBL621718,,0,1,,BAO_0000019,,Papio hamadryas,10625,22224,A,U,,,
Area under curve after 1 mpk peroral administration to beagles,Autocuration,,,9615.0,,,5065,CHEMBL621719,,0,1,,BAO_0000019,,beagle,3510,22224,A,U,,,
Area under curve after 2 mpk peroral administration to beagles,Autocuration,,,9615.0,,,5066,CHEMBL621720,,0,1,,BAO_0000019,,beagle,3510,22224,A,U,,,
Cmax value after 1 mpk peroral administration to beagles,Autocuration,,,9615.0,,,5067,CHEMBL621721,,0,1,,BAO_0000218,In vivo,beagle,3510,22224,A,U,,,
Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Autocuration,,,9606.0,,,5068,CHEMBL621722,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Autocuration,,,9606.0,,,5069,CHEMBL621723,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Autocuration,,,9606.0,,,5070,CHEMBL621724,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Autocuration,,,9606.0,,,5071,CHEMBL623443,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Autocuration,,,9606.0,,,5072,CHEMBL623444,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Autocuration,,,9606.0,,,5073,CHEMBL623445,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Autocuration,,,9606.0,,,5074,CHEMBL623446,Urine,0,1,,BAO_0000019,,Homo sapiens,7766,22224,A,U,,1088.0,
Metabolic stability observed at 30 min after administration in human liver microsomes,Autocuration,,,9606.0,Microsomes,,5075,CHEMBL623447,Liver,0,1,,BAO_0000251,,Homo sapiens,16643,22224,A,U,,2107.0,
Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,Autocuration,,,9606.0,,,5076,CHEMBL623448,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,Autocuration,,,9606.0,,,5077,CHEMBL623449,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,Autocuration,,,9606.0,,,5078,CHEMBL623450,,0,1,,BAO_0000019,,Homo sapiens,6852,22224,A,U,,,
"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Autocuration,,,9606.0,Microsomes,,5079,CHEMBL623451,Liver,0,1,,BAO_0000251,,Homo sapiens,6567,22224,A,U,,2107.0,
Metabolic stability (% remaining at 30 mins) in human S9.,Autocuration,,,9606.0,,,5080,CHEMBL623452,,0,1,,BAO_0000019,,Homo sapiens,6570,22224,A,U,,,
Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,Autocuration,,,9606.0,,,5081,CHEMBL623453,,0,1,,BAO_0000019,,Homo sapiens,6570,22224,A,U,,,
Percent parent compound remaining after 20 min incubation with human liver microsomes,Autocuration,,,9606.0,Microsomes,,5082,CHEMBL623454,Liver,0,1,,BAO_0000251,,Homo sapiens,5237,22224,A,U,,2107.0,
Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Autocuration,,,9606.0,Microsomes,,5083,CHEMBL623455,Liver,0,1,,BAO_0000251,,Homo sapiens,5237,22224,A,U,,2107.0,
Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Autocuration,,,9606.0,Microsomes,,5084,CHEMBL624371,Liver,0,1,,BAO_0000251,,Homo sapiens,5237,22224,A,U,,2107.0,
First pass metabolism and metabolic bioavailability using human hepatic microsomes,Autocuration,,,9606.0,,,5085,CHEMBL624372,,0,1,,BAO_0000218,,Homo sapiens,5202,22224,A,U,,,
Percent compound remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,,,9606.0,,,5086,CHEMBL624373,,0,1,,BAO_0000019,,Homo sapiens,5481,22224,A,U,,,
Percent remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,,,9606.0,,,5087,CHEMBL624374,,0,1,,BAO_0000019,,Homo sapiens,5481,22224,A,U,,,
The percent remaining in human plasma after 30 min was determined,Autocuration,,,9606.0,,,5088,CHEMBL624556,,0,1,,BAO_0000019,,Homo sapiens,3956,22224,A,U,,,
Conversion rate of the prodrug in human plasma,Autocuration,,,9606.0,,,5089,CHEMBL624557,Plasma,0,1,,BAO_0000366,,Homo sapiens,5074,22224,A,U,,1969.0,
Conversion rate of the prodrug in human plasma; ND means no data,Autocuration,,,9606.0,,,5090,CHEMBL624558,Plasma,0,1,,BAO_0000366,,Homo sapiens,5074,22224,A,U,,1969.0,
Half life of compound was determined in human blood,Autocuration,,,9606.0,,,5091,CHEMBL624559,Blood,0,1,,BAO_0000221,,Homo sapiens,4727,22224,A,U,,178.0,
Half life of compound was determined in man with once daily dosing,Autocuration,,,9606.0,,,5092,CHEMBL624560,,0,1,,BAO_0000019,,Homo sapiens,5965,22224,A,U,,,
Half life in human microsomes,Autocuration,,,9606.0,Microsomes,,5093,CHEMBL624561,,0,1,,BAO_0000251,In vitro,Homo sapiens,5732,22224,A,U,,,
Half life in human plasma,Autocuration,,,9606.0,,,5094,CHEMBL624562,Plasma,0,1,,BAO_0000366,,Homo sapiens,5819,22224,A,U,,1969.0,
Half life in human plasma; Not detected,Autocuration,,,9606.0,,,5095,CHEMBL624563,Plasma,0,1,,BAO_0000366,,Homo sapiens,5819,22224,A,U,,1969.0,
Half life period was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,9606.0,,,5096,CHEMBL624564,,0,1,,BAO_0000218,In vivo,Homo sapiens,1916,22224,A,U,,,
Half-life for oxidative metabolic stability was determined using rat liver microsomes,Autocuration,,,9606.0,Microsomes,,5097,CHEMBL624565,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,6597,22224,A,U,,2107.0,
Half-life in human plasma,Autocuration,,,9606.0,,,5098,CHEMBL875152,Plasma,0,1,,BAO_0000366,,Homo sapiens,5229,22224,A,U,,1969.0,
Half-life of the parent prodrug in plasma,Autocuration,,,9606.0,,,5099,CHEMBL624566,Plasma,0,1,,BAO_0000366,,Homo sapiens,5229,22224,A,U,,1969.0,
In vitro half life in human plasma was determined,Autocuration,,,9606.0,,,5100,CHEMBL873805,Plasma,0,1,,BAO_0000366,In vitro,Homo sapiens,2192,22224,A,U,,1969.0,
The compound was tested In Vitro for half life in human liver microsomes.,Autocuration,,,9606.0,Microsomes,,5101,CHEMBL624567,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,3032,22224,A,U,,2107.0,
Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,,9606.0,,,5102,CHEMBL624568,,0,1,,BAO_0000218,In vivo,Homo sapiens,1916,22224,A,U,,,
Observed volume of distribution,Autocuration,,,9606.0,,,5103,CHEMBL624569,,0,1,,BAO_0000218,In vivo,Homo sapiens,17716,22224,A,U,,,
Oral bioavailability in human,Autocuration,,,9606.0,,,5104,CHEMBL624570,,0,1,,BAO_0000218,In vivo,Homo sapiens,15778,22224,A,U,,,
Tested for human plasma protein binding of the compound,Autocuration,,,9606.0,,,5105,CHEMBL624571,,0,1,,BAO_0000019,,Homo sapiens,17313,22224,A,U,,,
"First order rate constant, k was determined in human plasma",Autocuration,,,9606.0,,,5106,CHEMBL624572,,0,1,,BAO_0000019,,Homo sapiens,4231,22224,A,U,,,
Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,,,9606.0,,,5107,CHEMBL624573,,0,1,,BAO_0000019,,Homo sapiens,4755,22224,A,U,,,
Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,,,9606.0,,,5108,CHEMBL875153,,0,1,,BAO_0000019,,Homo sapiens,4755,22224,A,U,,,
Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Autocuration,,,9606.0,Microsomes,,5109,CHEMBL624574,Liver,0,1,,BAO_0000251,,Homo sapiens,16907,22224,A,U,,2107.0,
The compound was tested for the plasma binding in human,Autocuration,,,9606.0,,,5110,CHEMBL624575,,0,1,,BAO_0000019,,Homo sapiens,10839,22224,A,U,,,
Plasma protein binding (human),Autocuration,,,9606.0,,,5111,CHEMBL624576,,0,1,,BAO_0000019,,Homo sapiens,10839,22224,A,U,,,
Compound was evaluated for half-life in human liver microsomes,Autocuration,,,9606.0,Microsomes,,5112,CHEMBL624577,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,3199,22224,A,U,,2107.0,
Half life measured in vitro for its stability in human blood,Autocuration,,,9606.0,,,5113,CHEMBL624578,Blood,0,1,,BAO_0000221,In vitro,Homo sapiens,1345,22224,A,U,,178.0,
Half life in human serum,Autocuration,,,9606.0,,,5114,CHEMBL622796,Serum,0,1,,BAO_0000019,,Homo sapiens,4297,22224,A,U,,1977.0,
Half life in human serum; ND=not determined,Autocuration,,,9606.0,,,5115,CHEMBL622797,Serum,0,1,,BAO_0000019,,Homo sapiens,4297,22224,A,U,,1977.0,
Half life were determined in CEM-SS cell extract in decomposition step 1,Autocuration,,,9606.0,,,5116,CHEMBL622798,,0,1,,BAO_0000019,,Homo sapiens,4297,22224,A,U,,,
Half life were determined in CEM-SS cell extract in decomposition step 2,Autocuration,,,9606.0,,,5117,CHEMBL622799,,0,1,,BAO_0000019,,Homo sapiens,4297,22224,A,U,,,
Half life of the in human plasma,Autocuration,,,9606.0,,,5118,CHEMBL622800,Plasma,0,1,,BAO_0000366,,Homo sapiens,4231,22224,A,U,,1969.0,
Half life period in human hepatic S9 fraction was determined,Autocuration,,,9606.0,S9,,5119,CHEMBL622801,,0,1,,BAO_0000220,In vitro,Homo sapiens,5633,22224,A,U,,,
Half life period in human liver microsome was determined,Autocuration,,,9606.0,Microsomes,,5120,CHEMBL622802,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,5633,22224,A,U,,2107.0,
Half life period was determined; 6-7,Autocuration,,,9606.0,,,5121,CHEMBL622803,,0,1,,BAO_0000019,,Homo sapiens,17791,22224,A,U,,,
Half life period was evaluated in human,Autocuration,,,9606.0,,,5122,CHEMBL875154,,0,1,,BAO_0000019,,Homo sapiens,17791,22224,A,U,,,
Half life time in human plasma,Autocuration,,,9606.0,,,5123,CHEMBL622804,Plasma,0,1,,BAO_0000366,,Homo sapiens,3160,22224,A,U,,1969.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5124,CHEMBL622805,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,955.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5125,CHEMBL622611,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,948.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5126,CHEMBL622612,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,948.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5127,CHEMBL875160,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2113.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,,10090.0,,,5128,CHEMBL622613,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2113.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5129,CHEMBL622614,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2113.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5130,CHEMBL622615,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2107.0,
Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,,10090.0,,,5131,CHEMBL622616,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2107.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5132,CHEMBL622617,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2107.0,
Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,,10090.0,,,5133,CHEMBL622618,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2106.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,,10090.0,,,5134,CHEMBL622619,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2106.0,
"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5135,CHEMBL622620,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2106.0,
"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,10090.0,,,5136,CHEMBL622621,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,955.0,
Biodistribution of compound (oxidized form) in blood tissue,Intermediate,,,10090.0,,,5137,CHEMBL622622,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,178.0,
"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5138,CHEMBL622623,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,178.0,
"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,10090.0,,,5139,CHEMBL622624,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,178.0,
"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,10090.0,,,5140,CHEMBL622625,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,178.0,
"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5141,CHEMBL622626,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,178.0,
"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,10090.0,,,5142,CHEMBL622627,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,178.0,
Biodistribution of compound (oxidized form) in brain tissue of mice,Intermediate,,,10090.0,,,5143,CHEMBL622628,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,955.0,
"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5144,CHEMBL622629,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,955.0,
"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,10090.0,,,5145,CHEMBL622630,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,955.0,
"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5146,CHEMBL622631,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,955.0,
"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,10090.0,,,5147,CHEMBL622632,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,955.0,
"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,10090.0,,,5148,CHEMBL622633,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,955.0,
Biodistribution of compound (oxidized form) in heart tissue of mice,Intermediate,,,10090.0,,,5149,CHEMBL622634,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,948.0,
"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5150,CHEMBL622635,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,948.0,
"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5151,CHEMBL875161,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,948.0,
"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,10090.0,,,5152,CHEMBL622636,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,948.0,
"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5153,CHEMBL623335,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,948.0,
"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,10090.0,,,5154,CHEMBL623336,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,948.0,
"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5155,CHEMBL623337,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2113.0,
"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,,10090.0,,,5156,CHEMBL623338,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2113.0,
"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,10090.0,,,5157,CHEMBL623339,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2113.0,
"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5158,CHEMBL623524,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2113.0,
"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,,10090.0,,,5159,CHEMBL623525,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2113.0,
Biodistribution of compound (oxidized form) in liver tissue,Intermediate,,,10090.0,,,5160,CHEMBL623526,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2107.0,
"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,,10090.0,,,5161,CHEMBL623527,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2107.0,
"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,,10090.0,,,5162,CHEMBL623528,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,16438,50594,A,N,,2107.0,
Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,Intermediate,,500.0,9606.0,,,5163,CHEMBL624615,,1,1,,BAO_0000219,,Homo sapiens,5245,80852,F,N,A-431,,
Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,,500.0,9606.0,,,5164,CHEMBL621672,,1,1,,BAO_0000219,,Homo sapiens,5245,80852,F,N,A-431,,
"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",Expert,,500.0,,,,5165,CHEMBL621673,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",Expert,,500.0,,,,5166,CHEMBL621674,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,500.0,9606.0,,,5167,CHEMBL884002,,9,1,,BAO_0000219,,Homo sapiens,16093,9,F,D,A-431,,
"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",Intermediate,,500.0,9606.0,,,5168,CHEMBL621850,,1,1,,BAO_0000219,,Homo sapiens,16825,80852,F,N,A-431,,
Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,Intermediate,,500.0,9606.0,,,5169,CHEMBL621851,,1,1,,BAO_0000219,,Homo sapiens,4848,80852,F,N,A-431,,
Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,Expert,,500.0,9606.0,,,5170,CHEMBL621852,,9,1,,BAO_0000219,,Homo sapiens,14827,9,F,D,A-431,,
Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Expert,,500.0,9606.0,,,5171,CHEMBL621853,,9,1,,BAO_0000219,,Homo sapiens,14827,9,F,D,A-431,,
"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",Expert,,500.0,,,,5172,CHEMBL621854,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,,500.0,,,,5173,CHEMBL621855,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,,500.0,,,,5174,CHEMBL623724,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",Expert,,500.0,,,,5175,CHEMBL623725,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",Expert,,500.0,,,,5176,CHEMBL623726,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",Expert,,500.0,9606.0,,,5177,CHEMBL623727,,9,1,,BAO_0000219,,Homo sapiens,16289,9,F,D,A-431,,
Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,Expert,,500.0,,,,5178,CHEMBL623728,,8,1,,BAO_0000219,,,16289,9,F,H,A-431,,
"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",Expert,,500.0,,,,5179,CHEMBL623729,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,,500.0,,,,5180,CHEMBL623730,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,,500.0,,,,5181,CHEMBL623731,,1,1,,BAO_0000218,,,16289,80852,F,N,A-431,,
"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,500.0,10090.0,,,5182,CHEMBL623732,,1,1,,BAO_0000218,,Mus musculus,14555,80852,F,N,A-431,,
"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,500.0,10090.0,,,5183,CHEMBL623733,,1,1,,BAO_0000218,,Mus musculus,14555,80852,F,N,A-431,,
"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,500.0,10090.0,,,5184,CHEMBL623734,,1,1,,BAO_0000218,,Mus musculus,14555,80852,F,N,A-431,,
"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,,500.0,10090.0,,,5185,CHEMBL623735,,1,1,,BAO_0000218,,Mus musculus,14555,80852,F,N,A-431,,
In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,Expert,,500.0,9606.0,,,5186,CHEMBL623736,,1,1,,BAO_0000219,,Homo sapiens,1937,80852,F,N,A-431,,
In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,Intermediate,,500.0,9606.0,,,5187,CHEMBL623737,,1,1,,BAO_0000219,,Homo sapiens,13739,80852,F,N,A-431,,
Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,Intermediate,,500.0,9606.0,,,5188,CHEMBL623738,,1,1,,BAO_0000219,,Homo sapiens,3558,80852,F,N,A-431,,
Dose giving a 50% decrease in the living cell number (A437 cells),Intermediate,,500.0,9606.0,,,5189,CHEMBL875168,,1,1,,BAO_0000219,,Homo sapiens,3558,80852,F,N,A-431,,
In vitro inhibitory concentration against proliferation of A459 cell line.,Expert,,646.0,9606.0,,,5190,CHEMBL623739,,1,1,,BAO_0000219,,Homo sapiens,17686,80682,F,N,A549,,
Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,Intermediate,,646.0,9606.0,,,5191,CHEMBL623740,,1,1,,BAO_0000219,,Homo sapiens,5305,80682,F,N,A549,,
Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,Intermediate,,646.0,9606.0,,,5192,CHEMBL624424,,1,1,,BAO_0000219,,Homo sapiens,3614,80682,F,N,A549,,
In vitro antitumor activity against renal A498 tumor cell lines,Intermediate,,624.0,9606.0,,,5193,CHEMBL624425,,1,1,,BAO_0000219,,Homo sapiens,17229,80021,F,N,A498,,
"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",Intermediate,,624.0,9606.0,,,5194,CHEMBL624426,,1,1,,BAO_0000219,,Homo sapiens,15935,80021,F,N,A498,,
"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",Intermediate,,624.0,9606.0,,,5195,CHEMBL624427,,1,1,,BAO_0000219,,Homo sapiens,15935,80021,F,N,A498,,
Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,Intermediate,,624.0,9606.0,,,5196,CHEMBL624428,,1,1,,BAO_0000219,,Homo sapiens,15560,80021,F,N,A498,,
Cytotoxicity concentration against human kidney carcinoma A-498 cell line,Intermediate,,624.0,9606.0,,,5197,CHEMBL624429,,1,1,,BAO_0000219,,Homo sapiens,13891,80021,F,N,A498,,
Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,Intermediate,,624.0,9606.0,,,5198,CHEMBL624620,,1,1,,BAO_0000219,,Homo sapiens,13891,80021,F,N,A498,,
Cytotoxicity on kidney carcinoma (A-498) cell line,Intermediate,,624.0,9606.0,,,5199,CHEMBL624621,,1,1,,BAO_0000219,,Homo sapiens,13788,80021,F,N,A498,,
Compound was evaluated against Human cell line renal A498,Intermediate,,624.0,9606.0,,,5200,CHEMBL624622,,1,1,,BAO_0000219,,Homo sapiens,15403,80021,F,N,A498,,
Compound was tested for inhibition of A498 human renal cancer cell line,Intermediate,,624.0,9606.0,,,5201,CHEMBL624623,,1,1,,BAO_0000219,,Homo sapiens,1009,80021,F,N,A498,,
Growth inhibitory activity against A498 human cancer cell line,Intermediate,,624.0,9606.0,,,5202,CHEMBL874365,,1,1,,BAO_0000219,,Homo sapiens,1043,80021,F,N,A498,,
In vitro antitumor activity against human renal A498 cell line,Intermediate,,624.0,9606.0,,,5203,CHEMBL624624,,1,1,,BAO_0000219,,Homo sapiens,5858,80021,F,N,A498,,
In vitro cytotoxic activity against renal (A498) cell line,Intermediate,,624.0,9606.0,,,5204,CHEMBL624625,,1,1,,BAO_0000219,,Homo sapiens,5958,80021,F,N,A498,,
In vitro cytotoxic activity against human renal cancer (A498) cell line,Intermediate,,624.0,9606.0,,,5205,CHEMBL624626,,1,1,,BAO_0000219,,Homo sapiens,5506,80021,F,N,A498,,
Tested for cytostatic activity against renal A498 cell line,Intermediate,,624.0,9606.0,,,5206,CHEMBL624627,,1,1,,BAO_0000219,,Homo sapiens,12781,80021,F,N,A498,,
The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,Intermediate,,624.0,9606.0,,,5207,CHEMBL883157,,1,1,,BAO_0000219,,Homo sapiens,14399,80021,F,N,A498,,
In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,Expert,,624.0,9606.0,,,5208,CHEMBL624628,,1,1,,BAO_0000219,,Homo sapiens,5958,80021,F,N,A498,,
Cmax value after 2 mpk peroral administration to beagles,Autocuration,,,9615.0,,,5209,CHEMBL624629,,0,1,,BAO_0000218,In vivo,beagle,3510,22224,A,U,,,
Bioavailability,Autocuration,,,9615.0,,,5210,CHEMBL623551,,0,1,,BAO_0000218,In vivo,Canis lupus familiaris,3510,22224,A,U,,,beagle
Bioavailability after 1 mpk peroral administration to beagles,Autocuration,,,9615.0,,,5211,CHEMBL623552,,0,1,,BAO_0000218,In vivo,Canis lupus familiaris,3510,22224,A,U,,,beagle
Bioavailability after 2 mpk peroral administration to beagles,Autocuration,,,9615.0,,,5212,CHEMBL623553,,0,1,,BAO_0000218,In vivo,Canis lupus familiaris,3510,22224,A,U,,,beagle
Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,Autocuration,,,9913.0,,,5213,CHEMBL623554,,0,1,,BAO_0000019,,Bos taurus,3085,22224,A,U,,,
Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,Autocuration,,,9913.0,,,5214,CHEMBL623555,,0,1,,BAO_0000019,,Bos taurus,3085,22224,A,U,,,
Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,,9913.0,,,5215,CHEMBL623556,,0,1,,BAO_0000019,,Bos taurus,3085,22224,A,U,,,
Solubility against bovine alpha-chymotrypsin,Autocuration,,,9913.0,,,5216,CHEMBL623557,,0,1,,BAO_0000019,,Bos taurus,9372,22224,A,U,,,
Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,,9913.0,,,5217,CHEMBL623558,,0,1,,BAO_0000019,,Bos taurus,3085,22224,A,U,,,
Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,,9913.0,,,5218,CHEMBL623559,,0,1,,BAO_0000019,,Bos taurus,3085,22224,A,U,,,
Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Autocuration,,,9913.0,,,5219,CHEMBL623560,Spleen,0,1,,BAO_0000221,,Bos taurus,1469,22224,A,U,,2106.0,
Half life in culture medium containing 10% of heat inactivated foetal calf serum,Autocuration,,,9913.0,,,5220,CHEMBL623561,,0,1,,BAO_0000019,,Bos taurus,4297,22224,A,U,,,
Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,Autocuration,,,9913.0,,,5221,CHEMBL623562,,0,1,,BAO_0000019,,Bos taurus,4297,22224,A,U,,,
Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,Autocuration,,,9913.0,,,5222,CHEMBL623563,,0,1,,BAO_0000019,,Bos taurus,17585,22224,A,U,,,
Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Autocuration,,,9913.0,,,5223,CHEMBL623564,Spleen,0,1,,BAO_0000221,,Bos taurus,1336,22224,A,U,,2106.0,
Half life in presence of 2 mg/mL BSA at pH 8.8,Autocuration,,,9913.0,,,5224,CHEMBL873806,,0,1,,BAO_0000019,,Bos taurus,3085,22224,A,U,,,
Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,Autocuration,,,9913.0,,,5225,CHEMBL623565,,0,1,,BAO_0000019,,Bos taurus,2857,22224,A,U,,,
Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,Autocuration,,,9913.0,,,5226,CHEMBL623566,,0,1,,BAO_0000019,,Bos taurus,2857,22224,A,U,,,
Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,Autocuration,,,9913.0,,,5227,CHEMBL623567,,0,1,,BAO_0000019,,Bos taurus,2857,22224,A,U,,,
Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),Autocuration,,,9913.0,,,5228,CHEMBL623568,,0,1,,BAO_0000019,,Bos taurus,1540,22224,A,U,,,
AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Intermediate,,,9615.0,,,5229,CHEMBL623569,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,6316,50588,A,N,,1969.0,
AUC after administration at 100 mg/kg/day in dogs,Intermediate,,,9615.0,,,5230,CHEMBL623570,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,17594,50588,A,N,,1969.0,
AUC in dog at 0-24 hr by peroral administration at 3 mpk,Intermediate,,,9615.0,,,5231,CHEMBL624254,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,4953,50588,A,N,,1969.0,
AUC value after 15 mg/kg iv dose in Dogs,Intermediate,,,9615.0,,,5232,CHEMBL624255,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,16907,50588,A,N,,1969.0,
AUC value after 30 mg/kg po dose in Dogs,Intermediate,,,9615.0,,,5233,CHEMBL624256,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,16907,50588,A,N,,1969.0,
AUC value after administration of 4 mg/Kg oral dose in dog,Intermediate,,,9615.0,,,5234,CHEMBL624257,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,2959,50588,A,N,,1969.0,
AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,,9615.0,,,5235,CHEMBL624258,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,17594,50588,A,N,,1969.0,
Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,Intermediate,,,9615.0,,,5236,CHEMBL875277,,1,1,,BAO_0000218,,Canis lupus familiaris,5356,50588,A,N,,,
Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,Intermediate,,,9615.0,,,5237,CHEMBL622667,,1,1,,BAO_0000218,,Canis lupus familiaris,16807,50588,A,N,,,
Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,Intermediate,,,9615.0,,,5238,CHEMBL622668,,1,1,,BAO_0000218,,Canis lupus familiaris,4527,50588,A,N,,,
Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,9615.0,,,5239,CHEMBL622669,,1,1,,BAO_0000218,,Canis lupus familiaris,4527,50588,A,N,,,
Area under curve determined in dogs after intravenous administration of 3 mg/kg,Intermediate,,,9615.0,,,5240,CHEMBL622670,,1,1,,BAO_0000218,,Canis lupus familiaris,15660,50588,A,N,,,
Area under curve determined in dogs after oral administration of 10 mg/kg,Intermediate,,,9615.0,,,5241,CHEMBL622671,,1,1,,BAO_0000218,,Canis lupus familiaris,15660,50588,A,N,,,
Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,9615.0,,,5242,CHEMBL622672,,1,1,,BAO_0000218,,Canis lupus familiaris,5802,50588,A,N,,,
Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,9615.0,,,5243,CHEMBL622673,,1,1,,BAO_0000218,,Canis lupus familiaris,3598,50588,A,N,,,
Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,9615.0,,,5244,CHEMBL622674,,1,1,,BAO_0000218,,Canis lupus familiaris,3598,50588,A,N,,,
Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,9615.0,,,5245,CHEMBL622675,,1,1,,BAO_0000218,,Canis lupus familiaris,5944,50588,A,N,,,
Area under curve determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,,,9615.0,,,5246,CHEMBL622676,,1,1,,BAO_0000218,,Canis lupus familiaris,5944,50588,A,N,,,
Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,9615.0,,,5247,CHEMBL622677,,1,1,,BAO_0000218,,Canis lupus familiaris,5944,50588,A,N,,,
Area under curve determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,,,9615.0,,,5248,CHEMBL622678,,1,1,,BAO_0000218,,Canis lupus familiaris,5944,50588,A,N,,,
Area under curve in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,,9615.0,,,5249,CHEMBL622679,,1,1,,BAO_0000218,,Canis lupus familiaris,4186,50588,A,N,,,
Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,9615.0,,,5250,CHEMBL622680,,1,1,,BAO_0000218,,Canis lupus familiaris,5007,50588,A,N,,,
Area under curve was determine after peroral administration at 10 mpk in dog,Intermediate,,,9615.0,,,5251,CHEMBL622681,,1,1,,BAO_0000218,,Canis lupus familiaris,5668,50588,A,N,,,
Area under curve was determine after peroral administration at 5 mpk in dog,Intermediate,,,9615.0,,,5252,CHEMBL875278,,1,1,,BAO_0000218,,Canis lupus familiaris,5668,50588,A,N,,,
Area under curve was determined,Intermediate,,,9615.0,,,5253,CHEMBL622682,,1,1,,BAO_0000218,,Canis lupus familiaris,5006,50588,A,N,,,
Area under curve in dogs,Intermediate,,,9615.0,,,5254,CHEMBL622683,,1,1,,BAO_0000218,,Canis lupus familiaris,5006,50588,A,N,,,
Area under curve in dogs at 10 mg/kg dose fo oral administration,Intermediate,,,9615.0,,,5255,CHEMBL622684,,1,1,,BAO_0000218,,Canis lupus familiaris,3771,50588,A,N,,,
Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),Intermediate,,,9615.0,,,5256,CHEMBL622685,,1,1,,BAO_0000218,,Canis lupus familiaris,3771,50588,A,N,,,
Area under curve in dogs at 3 mg/kg dose fo intravenous administration,Intermediate,,,9615.0,,,5257,CHEMBL622686,,1,1,,BAO_0000218,,Canis lupus familiaris,3771,50588,A,N,,,
Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,9615.0,,,5258,CHEMBL618344,,1,1,,BAO_0000218,,Canis lupus familiaris,1916,50588,A,N,,,
Area under curve value in dog at a dose of 5 mg/kg,Intermediate,,,9615.0,,,5259,CHEMBL875582,,1,1,,BAO_0000218,,Canis lupus familiaris,5302,50588,A,N,,,
Area under curve was determined after 0.1 mg/kg iv administration in dog,Intermediate,,,9615.0,,,5260,CHEMBL618345,,1,1,,BAO_0000218,,Canis lupus familiaris,5600,50588,A,N,,,
Area under curve was determined after 0.3 mg/kg po administration in dog,Intermediate,,,9615.0,,,5261,CHEMBL618346,,1,1,,BAO_0000218,,Canis lupus familiaris,5600,50588,A,N,,,
Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,9615.0,,,5262,CHEMBL618347,,1,1,,BAO_0000218,,Canis lupus familiaris,17764,50588,A,N,,,
Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,9615.0,,,5263,CHEMBL618348,,1,1,,BAO_0000218,,Canis lupus familiaris,4368,50588,A,N,,,
Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,Autocuration,,,9606.0,,,5264,CHEMBL618349,,0,1,,BAO_0000019,,Homo sapiens,5318,22224,A,U,,,
Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,,,9606.0,,,5265,CHEMBL618350,,0,1,,BAO_0000019,,Homo sapiens,5318,22224,A,U,,,
Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,Autocuration,,,9606.0,,,5266,CHEMBL618351,,0,1,,BAO_0000019,,Homo sapiens,5318,22224,A,U,,,
Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,Autocuration,,,9606.0,,,5267,CHEMBL618352,,0,1,,BAO_0000019,,Homo sapiens,5318,22224,A,U,,,
Time taken to reduce 50% of the concentration of compound in blood plasma,Autocuration,,,9606.0,,,5268,CHEMBL873494,Blood,0,1,,BAO_0000221,,Homo sapiens,14518,22224,A,U,,178.0,
"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,,,9606.0,,,5269,CHEMBL618353,Plasma,0,1,,BAO_0000366,,Homo sapiens,2209,22224,A,U,,1969.0,
Half life in human plasma,Autocuration,,,9606.0,,,5270,CHEMBL618354,Plasma,0,1,,BAO_0000366,,Homo sapiens,6787,22224,A,U,,1969.0,
Half life in human plasma was reported,Autocuration,,,9606.0,,,5271,CHEMBL875583,Plasma,0,1,,BAO_0000366,,Homo sapiens,4898,22224,A,U,,1969.0,
Half life in human serum,Autocuration,,,9606.0,,,5272,CHEMBL618355,Serum,0,1,,BAO_0000019,,Homo sapiens,6072,22224,A,U,,1977.0,
Half life upon exposure to human plasma,Autocuration,,,9606.0,,,5273,CHEMBL618356,Plasma,0,1,,BAO_0000366,,Homo sapiens,16907,22224,A,U,,1969.0,
t1/2 in human microsomes,Autocuration,,,9606.0,Microsomes,,5274,CHEMBL618357,,0,1,,BAO_0000251,In vitro,Homo sapiens,5656,22224,A,U,,,
Half life period in 80% human plasma at 37 degree Centigrade,Autocuration,,,9606.0,,,5275,CHEMBL618358,Plasma,0,1,,BAO_0000366,,Homo sapiens,4755,22224,A,U,,1969.0,
Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Autocuration,,,9606.0,,,5276,CHEMBL618359,Zone of skin,0,1,,BAO_0000221,,Homo sapiens,17503,22224,A,U,,14.0,
Half-life measured in in vitro Cathepsin B assay in human plasma,Autocuration,,,9606.0,,,5277,CHEMBL618360,Plasma,0,1,,BAO_0000366,In vitro,Homo sapiens,12357,22224,A,U,,1969.0,
Half-life at initial concentration of 5*10e-5 M in CEM cell extract,Autocuration,,,9606.0,,,5278,CHEMBL618361,,0,1,,BAO_0000019,,Homo sapiens,3076,22224,A,U,,,
Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Autocuration,,,9606.0,Microsomes,,5279,CHEMBL618362,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,6410,22224,A,U,,2107.0,
"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,,,9606.0,,,5280,CHEMBL618363,Plasma,0,1,,BAO_0000366,,Homo sapiens,3741,22224,A,U,,1969.0,
"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,,,9606.0,,,5281,CHEMBL618364,Plasma,0,1,,BAO_0000366,,Homo sapiens,3741,22224,A,U,,1969.0,
"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,,,9606.0,,,5282,CHEMBL875584,Plasma,0,1,,BAO_0000366,,Homo sapiens,3741,22224,A,U,,1969.0,
Half-life in the CEM cell extracts,Autocuration,,,9606.0,,,5283,CHEMBL618365,,0,1,,BAO_0000019,,Homo sapiens,1540,22224,A,U,,,
Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Autocuration,,,9606.0,,,5284,CHEMBL873495,Plasma,0,1,,BAO_0000366,,Homo sapiens,2905,22224,A,U,,1969.0,
Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Autocuration,,,9606.0,,,5285,CHEMBL618366,Plasma,0,1,,BAO_0000366,,Homo sapiens,2905,22224,A,U,,1969.0,
Half-life was determined,Autocuration,,,9606.0,,,5286,CHEMBL618367,,0,1,,BAO_0000019,,Homo sapiens,5523,22224,A,U,,,
Half-life (human blood stability),Autocuration,,,9606.0,,,5287,CHEMBL618368,Blood,0,1,,BAO_0000221,,Homo sapiens,1499,22224,A,U,,178.0,
Half-life (human blood stability); no data,Autocuration,,,9606.0,,,5288,CHEMBL618369,Blood,0,1,,BAO_0000221,,Homo sapiens,1499,22224,A,U,,178.0,
Half-life in human plasma,Autocuration,,,9606.0,,,5289,CHEMBL618370,Plasma,0,1,,BAO_0000366,,Homo sapiens,17065,22224,A,U,,1969.0,
CYP3A4 metabolism half-life (t1/2),Autocuration,,,9606.0,,,5290,CHEMBL618371,,0,1,,BAO_0000019,,Homo sapiens,6861,22224,A,U,,,
Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Autocuration,,,9606.0,,,5291,CHEMBL618372,Blood,0,1,,BAO_0000221,,Homo sapiens,1499,22224,A,U,,178.0,
In vitro half life in human plasma,Autocuration,,,9606.0,,,5292,CHEMBL618373,Plasma,0,1,,BAO_0000366,In vitro,Homo sapiens,530,22224,A,U,,1969.0,
"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Autocuration,,,9606.0,,,5293,CHEMBL618374,Plasma,0,1,,BAO_0000366,In vitro,Homo sapiens,1116,22224,A,U,,1969.0,
In vitro hydrolysis in human plasma,Autocuration,,,9606.0,,,5294,CHEMBL618375,Plasma,0,1,,BAO_0000366,In vitro,Homo sapiens,6695,22224,A,U,,1969.0,
In vitro hydrolysis in human plasma; no data,Autocuration,,,9606.0,,,5295,CHEMBL618376,Plasma,0,1,,BAO_0000366,In vitro,Homo sapiens,6695,22224,A,U,,1969.0,
In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Autocuration,,,9606.0,Microsomes,,5296,CHEMBL618377,Liver,0,1,,BAO_0000251,In vitro,Homo sapiens,10,22224,A,U,,2107.0,
Plasma half life in human,Autocuration,,,9606.0,,,5297,CHEMBL618378,Plasma,0,1,,BAO_0000366,,Homo sapiens,993,22224,A,U,,1969.0,
Stability after incubation with human plasma (at 37 degree C),Autocuration,,,9606.0,,,5298,CHEMBL618379,Plasma,0,1,,BAO_0000366,,Homo sapiens,15429,22224,A,U,,1969.0,
T1/2 was evaluated in human plasma,Autocuration,,,9606.0,,,5299,CHEMBL618380,Plasma,0,1,,BAO_0000366,,Homo sapiens,1675,22224,A,U,,1969.0,
"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,,,9606.0,,,5300,CHEMBL618381,Plasma,0,1,,BAO_0000366,,Homo sapiens,2209,22224,A,U,,1969.0,
"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Autocuration,,,9606.0,,,5301,CHEMBL618382,Plasma,0,1,,BAO_0000366,,Homo sapiens,2209,22224,A,U,,1969.0,
Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,,,9606.0,,,5302,CHEMBL618383,,0,1,,BAO_0000019,,Homo sapiens,5318,22224,A,U,,,
Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,Autocuration,,,9606.0,,,5303,CHEMBL618384,,0,1,,BAO_0000019,In vitro,Homo sapiens,2412,22224,A,U,,,
Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,Autocuration,,,9606.0,,,5304,CHEMBL618385,,0,1,,BAO_0000019,In vitro,Homo sapiens,2412,22224,A,U,,,
The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Autocuration,,,9606.0,,,5305,CHEMBL619099,Plasma,0,1,,BAO_0000366,,Homo sapiens,2906,22224,A,U,,1969.0,
The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Autocuration,,,9606.0,,,5306,CHEMBL619100,Plasma,0,1,,BAO_0000366,,Homo sapiens,2906,22224,A,U,,1969.0,
Time taken for 50% to be consumed by serum PON1 was determined,Autocuration,,,9606.0,,,5307,CHEMBL619101,,0,1,,BAO_0000019,,Homo sapiens,5495,22224,A,U,,,
Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,Autocuration,,,9606.0,,,5308,CHEMBL619102,,0,1,,BAO_0000019,,Homo sapiens,5495,22224,A,U,,,
Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,,,9606.0,Microsomes,,5309,CHEMBL619103,Liver,0,1,,BAO_0000251,,Homo sapiens,4397,22224,A,U,,2107.0,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,10095.0,,,5310,CHEMBL619268,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,10095.0,,,5311,CHEMBL619269,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,10095.0,,,5312,CHEMBL619270,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,10095.0,,,5313,CHEMBL619271,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,10095.0,,,5314,CHEMBL875585,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,10095.0,,,5315,CHEMBL619272,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound tested for growth inhibition of renal cancer cell line 786-0,Intermediate,,391.0,9606.0,,,5316,CHEMBL619273,,1,1,,BAO_0000219,,Homo sapiens,6058,80640,F,N,786-0,,
Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,Intermediate,,391.0,9606.0,,,5317,CHEMBL619274,,1,1,,BAO_0000219,,Homo sapiens,17708,80640,F,N,786-0,,
Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,Expert,,391.0,9606.0,,,5318,CHEMBL619275,,1,1,,BAO_0000219,,Homo sapiens,14017,80640,F,N,786-0,,
"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",Intermediate,,391.0,9606.0,,,5319,CHEMBL619276,,1,1,,BAO_0000219,,Homo sapiens,16818,80640,F,N,786-0,,
"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",Intermediate,,391.0,9606.0,,,5320,CHEMBL619277,,1,1,,BAO_0000219,,Homo sapiens,16818,80640,F,N,786-0,,
"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",Intermediate,,391.0,9606.0,,,5321,CHEMBL619278,,1,1,,BAO_0000219,,Homo sapiens,16818,80640,F,N,786-0,,
Tested for cytotoxicity against 786-0 cell lines in renal cancer,Intermediate,,391.0,9606.0,,,5322,CHEMBL619279,,1,1,,BAO_0000219,,Homo sapiens,11970,80640,F,N,786-0,,
Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,Intermediate,,391.0,9606.0,,,5323,CHEMBL858458,,1,1,,BAO_0000219,,Homo sapiens,12400,80640,F,N,786-0,,
Cytotoxic effect on renal cancer line 786-0,Expert,,391.0,9606.0,,,5324,CHEMBL619280,,1,1,,BAO_0000219,,Homo sapiens,12888,80640,F,N,786-0,,
In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,Intermediate,,391.0,9606.0,,,5325,CHEMBL619281,,1,1,,BAO_0000219,,Homo sapiens,15300,80640,F,N,786-0,,
Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,,391.0,9606.0,,,5326,CHEMBL619282,,1,1,,BAO_0000219,,Homo sapiens,14769,80640,F,N,786-0,,
"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",Intermediate,,391.0,9606.0,,,5327,CHEMBL619283,,1,1,,BAO_0000219,,Homo sapiens,15895,80640,F,N,786-0,,
Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,Intermediate,,391.0,9606.0,,,5328,CHEMBL619284,,1,1,,BAO_0000219,,Homo sapiens,17376,80640,F,N,786-0,,
Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,,391.0,9606.0,,,5329,CHEMBL619285,,1,1,,BAO_0000219,,Homo sapiens,14882,80640,F,N,786-0,,
Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),Intermediate,,391.0,9606.0,,,5330,CHEMBL619286,,1,1,,BAO_0000219,,Homo sapiens,14882,80640,F,N,786-0,,
Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,Intermediate,,391.0,9606.0,,,5331,CHEMBL619287,,1,1,,BAO_0000219,,Homo sapiens,15176,80640,F,N,786-0,,
In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,,391.0,9606.0,,,5332,CHEMBL857455,,1,1,,BAO_0000219,,Homo sapiens,12696,80640,F,N,786-0,,
The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),Intermediate,,391.0,9606.0,,,5333,CHEMBL883801,,1,1,,BAO_0000219,,Homo sapiens,2496,80640,F,N,786-0,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,Intermediate,,972.0,9606.0,,,5334,CHEMBL619288,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),Intermediate,,972.0,9606.0,,,5335,CHEMBL619289,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,Intermediate,,972.0,9606.0,,,5336,CHEMBL619290,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),Intermediate,,972.0,9606.0,,,5337,CHEMBL619291,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),Intermediate,,972.0,9606.0,,,5338,CHEMBL619292,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,,972.0,9606.0,,,5339,CHEMBL619293,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),Intermediate,,972.0,9606.0,,,5340,CHEMBL619294,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),Intermediate,,972.0,9606.0,,,5341,CHEMBL619295,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),Intermediate,,972.0,9606.0,,,5342,CHEMBL619296,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,,972.0,9606.0,,,5343,CHEMBL619297,,1,1,,BAO_0000219,,Homo sapiens,11831,80641,F,N,791T cell line,,
Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,Intermediate,,391.0,9606.0,,,5344,CHEMBL619298,,1,1,,BAO_0000219,,Homo sapiens,12782,80640,F,N,786-0,,
In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,Intermediate,,,,,,5345,CHEMBL619299,,0,1,,BAO_0000019,,,1229,22226,F,U,,,
Inhibition of cell growth in drug resistant 8226 myeloma cell line,Expert,,741.0,9606.0,,,5346,CHEMBL619300,,1,1,,BAO_0000219,,Homo sapiens,15313,80433,F,N,RPMI-8226,,
Inhibition of cell growth in drug sensitive 8226 myeloma cell line,Expert,,741.0,9606.0,,,5347,CHEMBL619301,,1,1,,BAO_0000219,,Homo sapiens,15313,80433,F,N,RPMI-8226,,
In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Intermediate,,741.0,9606.0,,,5348,CHEMBL619302,,1,1,,BAO_0000219,,Homo sapiens,11544,80433,F,N,RPMI-8226,,
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,,741.0,9606.0,,,5349,CHEMBL619303,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,,741.0,9606.0,,,5350,CHEMBL619304,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,,741.0,9606.0,,,5351,CHEMBL857706,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,,741.0,9606.0,,,5352,CHEMBL619305,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5353,CHEMBL619306,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5354,CHEMBL619307,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5355,CHEMBL619308,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,,741.0,9606.0,,,5356,CHEMBL619309,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5357,CHEMBL619310,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,,624.0,9606.0,,,5358,CHEMBL619311,,1,1,,BAO_0000219,,Homo sapiens,14769,80021,F,N,A498,,
Compound was tested for the growth inhibition of A498 renal tumor cell line,Intermediate,,624.0,9606.0,,,5359,CHEMBL619312,,1,1,,BAO_0000219,,Homo sapiens,15354,80021,F,N,A498,,
In vitro cytotoxicity against human tumor A498 cell line (renal cancer),Intermediate,,624.0,9606.0,,,5360,CHEMBL619313,,1,1,,BAO_0000219,,Homo sapiens,17445,80021,F,N,A498,,
In vitro inhibitory concentration against renal cancer cell line A498,Intermediate,,624.0,9606.0,,,5361,CHEMBL619314,,1,1,,BAO_0000219,,Homo sapiens,4337,80021,F,N,A498,,
Cytotoxicity against A 498 tumor cell line,Intermediate,,624.0,9606.0,,,5362,CHEMBL619959,,1,1,,BAO_0000219,,Homo sapiens,15277,80021,F,N,A498,,
In vitro antitumor activity against A498 human cancer cell line,Intermediate,,624.0,9606.0,,,5363,CHEMBL619960,,1,1,,BAO_0000219,,Homo sapiens,4812,80021,F,N,A498,,
In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),Intermediate,,624.0,9606.0,,,5364,CHEMBL619961,,1,1,,BAO_0000219,,Homo sapiens,4812,80021,F,N,A498,,
Inhibitory dose required against A498 human tumor cell lines,Intermediate,,624.0,9606.0,,,5365,CHEMBL619962,,1,1,,BAO_0000219,,Homo sapiens,4995,80021,F,N,A498,,
Anticancer activity against one renal cancer (A498 cell line),Intermediate,,624.0,9606.0,,,5366,CHEMBL875586,,1,1,,BAO_0000219,,Homo sapiens,5847,80021,F,N,A498,,
In vitro cytotoxicity against melanoma A498 cell line,Intermediate,,624.0,9606.0,,,5367,CHEMBL619963,,1,1,,BAO_0000219,,Homo sapiens,6557,80021,F,N,A498,,
Compound was tested for growth inhibitory activity against A498 cell line,Intermediate,,624.0,9606.0,,,5368,CHEMBL619964,,1,1,,BAO_0000219,,Homo sapiens,2597,80021,F,N,A498,,
Compound tested for growth inhibition of renal cancer cell line A498,Intermediate,,624.0,9606.0,,,5369,CHEMBL620108,,1,1,,BAO_0000219,,Homo sapiens,6058,80021,F,N,A498,,
Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,Intermediate,,624.0,9606.0,,,5370,CHEMBL620109,,1,1,,BAO_0000219,,Homo sapiens,17708,80021,F,N,A498,,
Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,Intermediate,,624.0,9606.0,,,5371,CHEMBL620110,,1,1,,BAO_0000219,,Homo sapiens,15176,80021,F,N,A498,,
In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,Intermediate,,624.0,9606.0,,,5372,CHEMBL620111,,1,1,,BAO_0000219,,Homo sapiens,15300,80021,F,N,A498,,
Tested for cytotoxicity against A498 cell lines in renal cancer,Intermediate,,624.0,9606.0,,,5373,CHEMBL620112,,1,1,,BAO_0000219,,Homo sapiens,11970,80021,F,N,A498,,
Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,Intermediate,,624.0,9606.0,,,5374,CHEMBL620113,,1,1,,BAO_0000219,,Homo sapiens,12400,80021,F,N,A498,,
Cytotoxic effect on renal cancer lines A498,Expert,,624.0,9606.0,,,5375,CHEMBL620114,,1,1,,BAO_0000219,,Homo sapiens,12888,80021,F,N,A498,,
Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,Intermediate,,624.0,9606.0,,,5376,CHEMBL620115,,1,1,,BAO_0000219,,Homo sapiens,3030,80021,F,N,A498,,
Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,,624.0,9606.0,,,5377,CHEMBL620116,,1,1,,BAO_0000219,,Homo sapiens,14769,80021,F,N,A498,,
Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,Intermediate,,624.0,9606.0,,,5378,CHEMBL620117,,1,1,,BAO_0000219,,Homo sapiens,17376,80021,F,N,A498,,
Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,Intermediate,,624.0,9606.0,,,5379,CHEMBL620118,,1,1,,BAO_0000219,,Homo sapiens,16558,80021,F,N,A498,,
Cytotoxicity against human kidney carcinoma cell lines A4982LM,Intermediate,,624.0,9606.0,,,5380,CHEMBL620119,,1,1,,BAO_0000219,,Homo sapiens,5194,80021,F,N,A498,,
Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,,624.0,9606.0,,,5381,CHEMBL620120,,1,1,,BAO_0000219,,Homo sapiens,10708,80021,F,N,A498,,
Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,Expert,,646.0,9606.0,,,5382,CHEMBL620121,,1,1,,BAO_0000219,,Homo sapiens,16880,80682,F,N,A549,,
Antitumor activity against A549 human lung carcinoma cell line,Intermediate,,646.0,9606.0,,,5383,CHEMBL620122,,1,1,,BAO_0000219,,Homo sapiens,10196,80682,F,N,A549,,
Antitumor activity against A549 human lung carcinoma cell line in experiment 1,Intermediate,,646.0,9606.0,,,5384,CHEMBL620123,,1,1,,BAO_0000219,,Homo sapiens,10196,80682,F,N,A549,,
Antitumor activity against A549 human lung carcinoma cell line in experiment 2,Intermediate,,646.0,9606.0,,,5385,CHEMBL620124,,1,1,,BAO_0000219,,Homo sapiens,10196,80682,F,N,A549,,
"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",Intermediate,,646.0,9606.0,,,5386,CHEMBL620125,,1,1,,BAO_0000219,,Homo sapiens,12083,80682,F,N,A549,,
Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,Expert,,646.0,9606.0,,,5387,CHEMBL620126,,1,1,,BAO_0000219,,Homo sapiens,16464,80682,F,N,A549,,
Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,646.0,9606.0,,,5388,CHEMBL883027,,1,1,,BAO_0000219,,Homo sapiens,16464,80682,F,N,A549,,
In vitro cytotoxic activity against human lung A549 cell line,Expert,,646.0,9606.0,,,5389,CHEMBL620127,,1,1,,BAO_0000219,,Homo sapiens,16470,80682,F,N,A549,,
In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),Intermediate,,646.0,9606.0,,,5390,CHEMBL620128,,1,1,,BAO_0000219,,Homo sapiens,16470,80682,F,N,A549,,
In vitro cytotoxic activity against human lung A549 cell line),Intermediate,,646.0,9606.0,,,5391,CHEMBL620129,,1,1,,BAO_0000219,,Homo sapiens,16470,80682,F,N,A549,,
In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,Intermediate,,646.0,9606.0,,,5392,CHEMBL620130,,1,1,,BAO_0000219,,Homo sapiens,16470,80682,F,N,A549,,
In vitro cytotoxicity against human non small-cell-lung cell line A549.,Expert,,646.0,9606.0,,,5393,CHEMBL620131,,1,1,,BAO_0000219,,Homo sapiens,16582,80682,F,N,A549,,
"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",Intermediate,,646.0,9606.0,,,5394,CHEMBL620132,,1,1,,BAO_0000219,,Homo sapiens,15935,80682,F,N,A549,,
"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",Intermediate,,646.0,9606.0,,,5395,CHEMBL620133,,1,1,,BAO_0000219,,Homo sapiens,15935,80682,F,N,A549,,
Inhibition of A549 human lung carcinoma cell proliferation,Expert,,646.0,9606.0,,,5396,CHEMBL620134,,1,1,,BAO_0000219,,Homo sapiens,16597,80682,F,N,A549,,
Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,,646.0,9606.0,,,5397,CHEMBL620135,,1,1,,BAO_0000219,,Homo sapiens,17376,80682,F,N,A549,,
Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,Intermediate,,646.0,9606.0,,,5398,CHEMBL620136,,1,1,,BAO_0000219,,Homo sapiens,16496,80682,F,N,A549,,
in vitro anticancer activity against cultured A549 human tumor(lung) cell line,Intermediate,,646.0,9606.0,,,5399,CHEMBL620137,,1,1,,BAO_0000219,,Homo sapiens,16152,80682,F,N,A549,,
in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,Intermediate,,646.0,9606.0,,,5400,CHEMBL620268,,1,1,,BAO_0000219,,Homo sapiens,16152,80682,F,N,A549,,
Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,646.0,9606.0,,,5401,CHEMBL620269,,1,1,,BAO_0000219,,Homo sapiens,16464,80682,F,N,A549,,
Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,Intermediate,,646.0,9606.0,,,5402,CHEMBL620270,,1,1,,BAO_0000219,,Homo sapiens,2288,80682,F,N,A549,,
Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,,646.0,9606.0,,,5403,CHEMBL620271,,1,1,,BAO_0000219,,Homo sapiens,17350,80682,F,N,A549,,
Inhibition of A549 cancer cell proliferation,Expert,,646.0,9606.0,,,5404,CHEMBL620272,,1,1,,BAO_0000219,,Homo sapiens,4090,80682,F,N,A549,,
Inhibition of A549 cancer cell proliferation (Not tested),Expert,,646.0,9606.0,,,5405,CHEMBL620273,,1,1,,BAO_0000219,,Homo sapiens,4090,80682,F,N,A549,,
Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,,646.0,9606.0,,,5406,CHEMBL620274,,1,1,,BAO_0000219,,Homo sapiens,17350,80682,F,N,A549,,
In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,Intermediate,,646.0,9606.0,,,5407,CHEMBL620275,,1,1,,BAO_0000219,,Homo sapiens,4197,80682,F,N,A549,,
Antiproliferative potency determined as inhibitory concentration against A549 cells,Intermediate,,646.0,9606.0,,,5408,CHEMBL620276,,1,1,,BAO_0000219,,Homo sapiens,17072,80682,F,N,A549,,
Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,Intermediate,,646.0,9606.0,,,5409,CHEMBL620277,,1,1,,BAO_0000219,,Homo sapiens,17072,80682,F,N,A549,,
Cytotoxicity against Renal cell lines A549 was determined,Intermediate,,646.0,9606.0,,,5410,CHEMBL620278,,1,1,,BAO_0000219,,Homo sapiens,5194,80682,F,N,A549,,
Area under curve was determined in dog after a 3 mg/kg of oral dose,Intermediate,,,9615.0,,,5411,CHEMBL620279,,1,1,,BAO_0000218,,Canis lupus familiaris,4257,50588,A,N,,,
Area under curve was determined in dog after oral administration at 1 mg/kg,Intermediate,,,9615.0,,,5412,CHEMBL620280,,1,1,,BAO_0000218,,Canis lupus familiaris,6123,50588,A,N,,,
Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,9615.0,,,5413,CHEMBL620281,,1,1,,BAO_0000218,,Canis lupus familiaris,1337,50588,A,N,,,
Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,9615.0,,,5414,CHEMBL620282,,1,1,,BAO_0000218,,Canis lupus familiaris,1337,50588,A,N,,,
Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),Intermediate,,,9615.0,,,5415,CHEMBL621134,,1,1,,BAO_0000218,,Canis lupus familiaris,8833,50588,A,N,,,
Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),Intermediate,,,9615.0,,,5416,CHEMBL621135,,1,1,,BAO_0000218,,Canis lupus familiaris,8833,50588,A,N,,,
Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),Intermediate,,,9615.0,,,5417,CHEMBL621136,,1,1,,BAO_0000218,,Canis lupus familiaris,8833,50588,A,N,,,
Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),Intermediate,,,9615.0,,,5418,CHEMBL621137,,1,1,,BAO_0000218,,Canis lupus familiaris,8833,50588,A,N,,,
Area under plasma concentration time curve in dog upon oral administration,Intermediate,,,9615.0,,,5419,CHEMBL621138,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,17657,50588,A,N,,1969.0,
Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,9615.0,,,5420,CHEMBL875587,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,17650,50588,A,N,,1969.0,
Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,Intermediate,,,9615.0,,,5421,CHEMBL621139,,1,1,,BAO_0000218,,Canis lupus familiaris,1977,50588,A,N,,,
Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,Intermediate,,,9615.0,,,5422,CHEMBL621140,,1,1,,BAO_0000218,,Canis lupus familiaris,1977,50588,A,N,,,
Area under the curve for the compound was obtained when tested in dog,Intermediate,,,9615.0,,,5423,CHEMBL621141,,1,1,,BAO_0000218,,Canis lupus familiaris,3132,50588,A,N,,,
Area under the curve at a dose of 1 mg/kg,Intermediate,,,9615.0,,,5424,CHEMBL621142,,1,1,,BAO_0000218,,Canis lupus familiaris,5473,50588,A,N,,,
Area under the curve at a dose of 1 mg/kg (oral),Intermediate,,,9615.0,,,5425,CHEMBL621143,,1,1,,BAO_0000218,,Canis lupus familiaris,5474,50588,A,N,,,
Area under the curve at i.v. dose of 0.2 mg/kg,Intermediate,,,9615.0,,,5426,CHEMBL621144,,1,1,,BAO_0000218,,Canis lupus familiaris,5474,50588,A,N,,,
Area under the curve was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,9615.0,,,5427,CHEMBL621145,,1,1,,BAO_0000218,,Canis lupus familiaris,6062,50588,A,N,,,
Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,Intermediate,,,9615.0,,,5428,CHEMBL621146,,1,1,,BAO_0000218,,Canis lupus familiaris,4709,50588,A,N,,,
Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,Intermediate,,,9615.0,,,5429,CHEMBL622567,,1,1,,BAO_0000218,,Canis lupus familiaris,2652,50588,A,N,,,
Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,Intermediate,,,9615.0,,,5430,CHEMBL622568,,1,1,,BAO_0000218,,Canis lupus familiaris,2652,50588,A,N,,,
Compound was evaluated for area under the curve in dog blood.,Intermediate,,,9615.0,,,5431,CHEMBL622569,,1,1,,BAO_0000218,,Canis lupus familiaris,2877,50588,A,N,,,
In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,Intermediate,,,9615.0,,,5432,CHEMBL622570,,1,1,,BAO_0000218,,Canis lupus familiaris,5444,50588,A,N,,,
AUC in dog after oral dose (1 mg/kg),Intermediate,,,9615.0,,,5433,CHEMBL622571,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,5130,50588,A,N,,1969.0,
Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,Intermediate,,,9615.0,,,5434,CHEMBL622572,,1,1,,BAO_0000218,,Canis lupus familiaris,6265,50588,A,N,,,
"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",Intermediate,,,9615.0,,,5435,CHEMBL622573,,1,1,,BAO_0000218,,Canis lupus familiaris,4657,50588,A,N,,,
Pharmacokinetic parameter AUC after intravenous administration to dogs,Intermediate,,,9615.0,,,5436,CHEMBL622574,,1,1,,BAO_0000218,,Canis lupus familiaris,16367,50588,A,N,,,
Pharmacokinetic parameter AUC after oral administration to dogs,Intermediate,,,9615.0,,,5437,CHEMBL622575,,1,1,,BAO_0000218,,Canis lupus familiaris,16367,50588,A,N,,,
Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,Intermediate,,,9615.0,,,5438,CHEMBL622576,,1,1,,BAO_0000218,,Canis lupus familiaris,9579,50588,A,N,,,
Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,Intermediate,,,9615.0,,,5439,CHEMBL622577,,1,1,,BAO_0000218,,Canis lupus familiaris,9579,50588,A,N,,,
Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,,,9615.0,,,5440,CHEMBL622578,,1,1,,BAO_0000218,,Canis lupus familiaris,5983,50588,A,N,,,
Pharmacokinetic property in dogs after oral administration at 1 mg/kg,Intermediate,,,9615.0,,,5441,CHEMBL622579,,1,1,,BAO_0000218,,Canis lupus familiaris,6241,50588,A,N,,,
"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",Intermediate,,,9615.0,,,5442,CHEMBL622580,,1,1,,BAO_0000218,,Canis lupus familiaris,5313,50588,A,N,,,
"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",Intermediate,,,9615.0,,,5443,CHEMBL622581,,1,1,,BAO_0000218,,Canis lupus familiaris,5313,50588,A,N,,,
Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,9615.0,,,5444,CHEMBL622582,,1,1,,BAO_0000218,,Canis lupus familiaris,6642,50588,A,N,,,
Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,9615.0,,,5445,CHEMBL622583,,1,1,,BAO_0000218,,Canis lupus familiaris,6642,50588,A,N,,,
Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,,,9615.0,,,5446,CHEMBL622584,,1,1,,BAO_0000218,,Canis lupus familiaris,6641,50588,A,N,,,
Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,,,9615.0,,,5447,CHEMBL622585,,1,1,,BAO_0000218,,Canis lupus familiaris,6642,50588,A,N,,,
Compound was evaluated for oral bioavailability in dog; 90-100,Intermediate,,,9615.0,,,5448,CHEMBL622586,,1,1,,BAO_0000218,,Canis lupus familiaris,17791,50588,A,N,,,
Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,Intermediate,,,9615.0,,,5449,CHEMBL623281,,1,1,,BAO_0000218,,Canis lupus familiaris,17655,50588,A,N,,,
Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,Intermediate,,,9615.0,,,5450,CHEMBL623282,,1,1,,BAO_0000218,,Canis lupus familiaris,17655,50588,A,N,,,
PAPP (membrane permeability) in dog kidney cell monolayer assay,Intermediate,,,9615.0,,,5451,CHEMBL623283,,1,1,,BAO_0000218,,Canis lupus familiaris,6596,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,5452,CHEMBL623284,,1,1,,BAO_0000218,,Canis lupus familiaris,3880,50588,A,N,,,
Bioavailability administered orally at a dose of 10 mg/kg to dogs,Intermediate,,,9615.0,,,5453,CHEMBL623285,,1,1,,BAO_0000218,,Canis lupus familiaris,16367,50588,A,N,,,
Plasma protein binding towards dog plasma at 10 uM,Intermediate,,,9615.0,,,5454,CHEMBL623463,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,17409,50588,A,N,,1969.0,
Plasma protein binding towards dog plasma at 100 uM,Intermediate,,,9615.0,,,5455,CHEMBL875952,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,17409,50588,A,N,,1969.0,
Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,,,9615.0,,,5456,CHEMBL621705,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2959,50588,A,N,,,
Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,Intermediate,,,9615.0,,,5457,CHEMBL621706,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,13501,50588,A,N,,,
Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,9615.0,,,5458,CHEMBL621707,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4527,50588,A,N,,,
Bioavailability in dogs,Intermediate,,,9615.0,,,5459,CHEMBL621708,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,15145,50588,A,N,,,
Bioavailability,Intermediate,,,9615.0,,,5460,CHEMBL621709,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4219,50588,A,N,,,
Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,9615.0,,,5461,CHEMBL621710,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17538,50588,A,N,,,
Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,,9615.0,,,5462,CHEMBL621711,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17538,50588,A,N,,,
Bioavailability in dog (dose 10.0 mg/kg p.o.),Intermediate,,,9615.0,,,5463,CHEMBL621712,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1466,50588,A,N,,,
Bioavailability was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,9615.0,,,5464,CHEMBL621713,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17650,50588,A,N,,,
Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,Intermediate,,,9615.0,,,5465,CHEMBL621714,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3132,50588,A,N,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,10095.0,,,5466,CHEMBL621715,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,10095.0,,,5467,CHEMBL623717,Liver,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,2107.0,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,10095.0,,,5468,CHEMBL623718,Liver,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,2107.0,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,10095.0,,,5469,CHEMBL623719,Liver,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,2107.0,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,10095.0,,,5470,CHEMBL623720,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,10095.0,,,5471,CHEMBL623721,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,10095.0,,,5472,CHEMBL623722,Muscle tissue,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,2385.0,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,10095.0,,,5473,CHEMBL623723,Muscle tissue,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,2385.0,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,10095.0,,,5474,CHEMBL618543,Muscle tissue,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,2385.0,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,10095.0,,,5475,CHEMBL618544,Spleen,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,2106.0,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,10095.0,,,5476,CHEMBL875155,Spleen,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,2106.0,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,,10095.0,,,5477,CHEMBL618545,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,10095.0,,,5478,CHEMBL618546,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,10095.0,,,5479,CHEMBL623529,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,,10095.0,,,5480,CHEMBL623530,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,,10095.0,,,5481,CHEMBL621764,,0,1,,BAO_0000218,,Mus sp.,2413,22224,A,U,,,
Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,,,9527.0,,,5482,CHEMBL621765,,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,,
Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,,,9527.0,,,5483,CHEMBL621766,Cerebellum,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,2037.0,
Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,,,9527.0,,,5484,CHEMBL621767,Frontal cortex,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,1870.0,
Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),Autocuration,,,9527.0,,,5485,CHEMBL621768,,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,,
Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Autocuration,,,9527.0,,,5486,CHEMBL621769,Striatum,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,2435.0,
Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,,,9527.0,,,5487,CHEMBL621770,,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,,
Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,,,9527.0,,,5488,CHEMBL621771,Cerebellum,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,2037.0,
Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,,,9527.0,,,5489,CHEMBL621772,Frontal cortex,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,1870.0,
Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),Autocuration,,,9527.0,,,5490,CHEMBL621773,,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,,
Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Autocuration,,,9527.0,,,5491,CHEMBL621774,Striatum,0,1,,BAO_0000019,,Cercopithecidae,17827,22224,A,U,,2435.0,
Compound was evaluated for oral bioavailability in rats,Autocuration,,,9527.0,,,5492,CHEMBL621775,,0,1,,BAO_0000218,,Cercopithecidae,17791,22224,A,U,,,
Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Autocuration,,,9527.0,,,5493,CHEMBL621776,Plasma,0,1,,BAO_0000218,In vivo,Cercopithecidae,17667,22224,A,U,,1969.0,
Half life period was evaluated in monkey,Autocuration,,,9527.0,,,5494,CHEMBL621777,,0,1,,BAO_0000019,,Cercopithecidae,17791,22224,A,U,,,
Half-life in rhesus monkeys by intravenous administration of dose,Autocuration,,,9527.0,,,5495,CHEMBL875162,,0,1,,BAO_0000218,In vivo,Cercopithecidae,110,22224,A,U,,,
AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Intermediate,,,10090.0,,,5496,CHEMBL621778,Plasma,1,1,,BAO_0000218,,Mus musculus,5781,50594,A,N,,1969.0,
AUC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,10090.0,,,5497,CHEMBL621779,Plasma,1,1,,BAO_0000218,,Mus musculus,17734,50594,A,N,,1969.0,
AUC value was determined after oral administration,Intermediate,,,10090.0,,,5498,CHEMBL622479,Plasma,1,1,,BAO_0000218,,Mus musculus,17718,50594,A,N,,1969.0,
Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,,10090.0,,,5499,CHEMBL622480,,1,1,,BAO_0000218,,Mus musculus,4573,50594,A,N,,,
Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,10090.0,,,5500,CHEMBL622481,,1,1,,BAO_0000218,,Mus musculus,3277,50594,A,N,,,
Area under curve by ioral administration in mouse,Intermediate,,,10090.0,,,5501,CHEMBL622482,,1,1,,BAO_0000218,,Mus musculus,2862,50594,A,N,,,
Area under curve by iv administration in mouse,Intermediate,,,10090.0,,,5502,CHEMBL622483,,1,1,,BAO_0000218,,Mus musculus,2862,50594,A,N,,,
Area under curve at 0-8 hr in IRC mice after peroral administration,Intermediate,,,10090.0,,,5503,CHEMBL622484,,1,1,,BAO_0000218,,Mus musculus,5951,50594,A,N,,,
Area under curve when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,,,10090.0,,,5504,CHEMBL622641,,1,1,,BAO_0000218,,Mus musculus,17729,50594,A,N,,,
Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,Intermediate,,,10090.0,,,5505,CHEMBL622642,,1,1,,BAO_0000218,,Mus musculus,17728,50594,A,N,,,
Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,Intermediate,,,10090.0,,,5506,CHEMBL622643,,1,1,,BAO_0000218,,Mus musculus,17728,50594,A,N,,,
Area under curve when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,,,10090.0,,,5507,CHEMBL622644,,1,1,,BAO_0000218,,Mus musculus,17729,50594,A,N,,,
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,,741.0,9606.0,,,5508,CHEMBL622645,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,,741.0,9606.0,,,5509,CHEMBL622646,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,,741.0,9606.0,,,5510,CHEMBL621238,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,,741.0,9606.0,,,5511,CHEMBL621239,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5512,CHEMBL621240,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5513,CHEMBL621241,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,,741.0,9606.0,,,5514,CHEMBL621242,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5515,CHEMBL620350,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,,741.0,9606.0,,,5516,CHEMBL620351,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,,741.0,9606.0,,,5517,CHEMBL620352,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,,741.0,9606.0,,,5518,CHEMBL620353,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,,741.0,9606.0,,,5519,CHEMBL620354,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5520,CHEMBL620355,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5521,CHEMBL620356,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,,741.0,9606.0,,,5522,CHEMBL620357,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,,741.0,9606.0,,,5523,CHEMBL620358,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
In vitro inhibition of human 8226 myeloma tumor cell line growth.,Expert,,741.0,9606.0,,,5524,CHEMBL620359,,1,1,,BAO_0000219,,Homo sapiens,9424,80433,F,N,RPMI-8226,,
In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Intermediate,,741.0,9606.0,,,5525,CHEMBL620360,,1,1,,BAO_0000219,,Homo sapiens,11544,80433,F,N,RPMI-8226,,
Cytotoxicity of compound against 8226/DOX1V cells,Intermediate,,741.0,9606.0,,,5526,CHEMBL620361,,1,1,,BAO_0000219,,Homo sapiens,17378,80433,F,N,RPMI-8226,,
Cytotoxicity of compound against 8226/S cells,Intermediate,,741.0,9606.0,,,5527,CHEMBL620362,,1,1,,BAO_0000219,,Homo sapiens,17378,80433,F,N,RPMI-8226,,
Inhibitory concentration against 8226 myeloma cancer cell line,Intermediate,,741.0,9606.0,,,5528,CHEMBL620363,,1,1,,BAO_0000219,,Homo sapiens,17079,80433,F,N,RPMI-8226,,
Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,Intermediate,,741.0,9606.0,,,5529,CHEMBL620364,,1,1,,BAO_0000219,,Homo sapiens,17079,80433,F,N,RPMI-8226,,
Inhibition of cell growth was studied in human teratocarcinoma (833K).,Intermediate,,854.0,9606.0,,,5530,CHEMBL620365,,1,1,,BAO_0000219,,Homo sapiens,13466,80647,F,N,833K,,
Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',Intermediate,,854.0,9606.0,,,5531,CHEMBL620366,,1,1,,BAO_0000219,,Homo sapiens,13466,80647,F,N,833K,,
Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,Expert,,854.0,9606.0,,,5532,CHEMBL620367,,1,1,,BAO_0000219,,Homo sapiens,2392,80647,F,N,833K,,
The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,Intermediate,,854.0,9606.0,,,5533,CHEMBL620368,,1,1,,BAO_0000219,,Homo sapiens,2392,80647,F,N,833K,,
Inhibitory activity against caspase-1,Autocuration,,,,,,5534,CHEMBL620369,,0,1,,BAO_0000019,,,6608,22226,B,U,,,
Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,Autocuration,,,1351.0,,,5535,CHEMBL620370,,8,1,,BAO_0000357,,Enterococcus faecalis,10199,45,B,H,,,
In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,Intermediate,,705.0,9606.0,,,5536,CHEMBL620371,,1,1,,BAO_0000219,,Homo sapiens,17749,80648,F,N,8701-BC,,
In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,Intermediate,,705.0,9606.0,,,5537,CHEMBL620372,,1,1,,BAO_0000219,,Homo sapiens,17749,80648,F,N,8701-BC,,
In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,Intermediate,,,,,,5538,CHEMBL876492,,0,1,,BAO_0000019,,,1229,22226,F,U,,,
In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,Intermediate,,,,,,5539,CHEMBL620373,,0,1,,BAO_0000019,,,1229,22226,F,U,,,
In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,Intermediate,,,,,,5540,CHEMBL620374,,0,1,,BAO_0000019,,,1229,22226,F,U,,,
Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,Autocuration,,,,,,5541,CHEMBL620375,,0,1,,BAO_0000019,,,6390,22226,B,U,,,
Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,,,1314.0,,,5542,CHEMBL857902,,0,1,,BAO_0000019,,Streptococcus pyogenes,16219,22226,F,U,,,
Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,,,1314.0,,,5543,CHEMBL620376,,0,1,,BAO_0000019,,Streptococcus pyogenes,16219,22226,F,U,,,
Percent inhibition against Cdc25C phosphatase at 50 uM of compound,Autocuration,,,,,,5544,CHEMBL620377,,8,1,,BAO_0000357,,,17043,11922,B,H,,,
Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,,324.0,9606.0,,,5545,CHEMBL620378,,1,1,,BAO_0000219,,Homo sapiens,6929,81115,F,N,KB ,,
Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,,324.0,9606.0,,,5546,CHEMBL620379,,1,1,,BAO_0000219,,Homo sapiens,6929,81115,A,N,KB ,,
In vitro cytotoxicity of compound was tested against 9KB cells.,Autocuration,,,9606.0,,,5547,CHEMBL620380,,0,1,,BAO_0000219,,Homo sapiens,7083,22226,F,U,,,
Cytotoxic concentration against 9L cells was determined on day 3,Intermediate,,392.0,10116.0,,,5548,CHEMBL884006,,1,1,,BAO_0000219,,Rattus norvegicus,12446,80653,F,N,9L,,
Tested in vitro for anticancer activity against 9L cells,Expert,,392.0,10116.0,,,5549,CHEMBL620381,,1,1,,BAO_0000219,,Rattus norvegicus,15345,80653,F,N,9L,,
Tested in vitro for anticancer activity against 9L cells; Not determined,Expert,,392.0,10116.0,,,5550,CHEMBL620382,,1,1,,BAO_0000219,,Rattus norvegicus,15345,80653,F,N,9L,,
In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,Intermediate,,646.0,9606.0,,,5551,CHEMBL620383,,1,1,,BAO_0000219,,Homo sapiens,6301,80682,F,N,A549,,
The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,Intermediate,,646.0,9606.0,,,5552,CHEMBL876493,,1,1,,BAO_0000219,,Homo sapiens,4833,80682,F,N,A549,,
The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,Intermediate,,646.0,9606.0,,,5553,CHEMBL620384,,1,1,,BAO_0000219,,Homo sapiens,4833,80682,F,N,A549,,
The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,Intermediate,,646.0,9606.0,,,5554,CHEMBL620385,,1,1,,BAO_0000219,,Homo sapiens,4833,80682,F,N,A549,,
Cytotoxicity against human lung carcinoma A549 cell line,Expert,,646.0,9606.0,,,5555,CHEMBL620386,,1,1,,BAO_0000219,,Homo sapiens,13330,80682,F,N,A549,,
Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,Expert,,646.0,9606.0,,,5556,CHEMBL620387,,9,1,,BAO_0000219,,Homo sapiens,17517,25,F,D,A549,,
"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",Expert,,646.0,9606.0,,,5557,CHEMBL621404,,9,1,,BAO_0000219,,Homo sapiens,17517,25,F,D,A549,,
"In vitro growth inhibition of A549, lung carcinoma",Intermediate,,646.0,9606.0,,,5558,CHEMBL621405,,1,1,,BAO_0000219,,Homo sapiens,14425,80682,F,N,A549,,
"In vitro growth inhibition of A549, lung carcinoma.",Intermediate,,646.0,9606.0,,,5559,CHEMBL621406,,1,1,,BAO_0000219,,Homo sapiens,14425,80682,F,N,A549,,
In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,,646.0,9606.0,,,5560,CHEMBL621407,,1,1,,BAO_0000219,,Homo sapiens,5228,80682,F,N,A549,,
Cytotoxic activity against human lung cancer A549 cell line was determined,Intermediate,,646.0,9606.0,,,5561,CHEMBL621408,,1,1,,BAO_0000219,,Homo sapiens,5351,80682,F,N,A549,,
Cytotoxicity against human solid tumor lung carcinoma A549 cell line,Expert,,646.0,9606.0,,,5562,CHEMBL885345,,1,1,,BAO_0000219,,Homo sapiens,12198,80682,F,N,A549,,
Cytotoxicity concentration against human lung carcinoma A-549 cell line,Intermediate,,646.0,9606.0,,,5563,CHEMBL621409,,1,1,,BAO_0000219,,Homo sapiens,13891,80682,F,N,A549,,
Cytotoxicity in A549 (human carcinoma) cell line.,Expert,,646.0,9606.0,,,5564,CHEMBL876034,,1,1,,BAO_0000219,,Homo sapiens,5677,80682,F,N,A549,,
Cytotoxicity on lung carcinoma (A-549) cell line,Intermediate,,646.0,9606.0,,,5565,CHEMBL621410,,1,1,,BAO_0000219,,Homo sapiens,13788,80682,F,N,A549,,
Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,Expert,,646.0,9606.0,,,5566,CHEMBL621411,,1,1,,BAO_0000219,,Homo sapiens,13384,80682,F,N,A549,,
Effective dose of compound against replication of A549 cell line was evaluated,Intermediate,,646.0,9606.0,,,5567,CHEMBL621412,,1,1,,BAO_0000219,,Homo sapiens,6726,80682,F,N,A549,,
In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,Expert,,646.0,9606.0,,,5568,CHEMBL621413,,1,1,,BAO_0000219,,Homo sapiens,3455,80682,F,N,A549,,
In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),Intermediate,,646.0,9606.0,,,5569,CHEMBL621414,,1,1,,BAO_0000219,,Homo sapiens,5726,80682,F,N,A549,,
In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,Intermediate,,646.0,9606.0,,,5570,CHEMBL621415,,1,1,,BAO_0000219,,Homo sapiens,5726,80682,F,N,A549,,
The compound was evaluated for antiproliferative activity against A549 cell line,Intermediate,,646.0,9606.0,,,5571,CHEMBL621416,,1,1,,BAO_0000219,,Homo sapiens,3936,80682,F,N,A549,,
The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,Intermediate,,646.0,9606.0,,,5572,CHEMBL621417,,1,1,,BAO_0000219,,Homo sapiens,14991,80682,F,N,A549,,
Concentration required for growth inhibition of human lung carcinoma cell line A549,Intermediate,,646.0,9606.0,,,5573,CHEMBL621418,,1,1,,BAO_0000219,,Homo sapiens,5243,80682,F,N,A549,,
Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,Intermediate,,646.0,9606.0,,,5574,CHEMBL621419,,1,1,,BAO_0000219,,Homo sapiens,12858,80682,F,N,A549,,
Growth inhibition against A549 cell line was evaluated,Intermediate,,646.0,9606.0,,,5575,CHEMBL621420,,1,1,,BAO_0000219,,Homo sapiens,6776,80682,F,N,A549,,
Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,Intermediate,,646.0,9606.0,,,5576,CHEMBL875823,,1,1,,BAO_0000219,,Homo sapiens,16558,80682,F,N,A549,,
Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,Expert,,646.0,9606.0,,,5577,CHEMBL621421,,1,1,,BAO_0000219,,Homo sapiens,4583,80682,F,N,A549,,
Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,Intermediate,,646.0,9606.0,,,5578,CHEMBL621422,,1,1,,BAO_0000219,,Homo sapiens,13514,80682,F,N,A549,,
Chemosensitivity against DT-diaphorase rich A549 cell lines,Expert,,646.0,9606.0,,,5579,CHEMBL884014,,1,1,,BAO_0000219,,Homo sapiens,15166,80682,F,N,A549,,
Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,Intermediate,,646.0,9606.0,,,5580,CHEMBL621423,,1,1,,BAO_0000219,,Homo sapiens,13873,80682,F,N,A549,,
In vitro cytotoxicity against human A549 (lung cancer) cell line.,Expert,,646.0,9606.0,,,5581,CHEMBL621424,,1,1,,BAO_0000219,,Homo sapiens,6447,80682,F,N,A549,,
In vitro antitumor activity against A549 (lung) human tumor cell lines.,Intermediate,,646.0,9606.0,,,5582,CHEMBL621425,,1,1,,BAO_0000219,,Homo sapiens,2068,80682,F,N,A549,,
In vitro cytotoxic activity against human lung carcinoma A549 cell line,Expert,,646.0,9606.0,,,5583,CHEMBL621426,,1,1,,BAO_0000219,,Homo sapiens,1863,80682,F,N,A549,,
Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,Intermediate,,646.0,9606.0,,,5584,CHEMBL621427,,1,1,,BAO_0000219,,Homo sapiens,13873,80682,F,N,A549,,
Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,,646.0,9606.0,,,5585,CHEMBL621428,,1,1,,BAO_0000219,,Homo sapiens,13873,80682,F,N,A549,,
Tested against A549 lung carcinoma in the sulforhodamine B assay.,Expert,,646.0,9606.0,,,5586,CHEMBL621429,,1,1,,BAO_0000219,,Homo sapiens,13873,80682,F,N,A549,,
Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),Intermediate,,646.0,9606.0,,,5587,CHEMBL621430,,1,1,,BAO_0000219,,Homo sapiens,579,80682,F,N,A549,,
Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,Intermediate,,646.0,9606.0,,,5588,CHEMBL621431,,1,1,,BAO_0000219,,Homo sapiens,579,80682,F,N,A549,,
Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,Intermediate,,646.0,9606.0,,,5589,CHEMBL621432,,1,1,,BAO_0000219,,Homo sapiens,4584,80682,F,N,A549,,
Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,Expert,,646.0,9606.0,,,5590,CHEMBL621433,,1,1,,BAO_0000219,,Homo sapiens,5421,80682,F,N,A549,,
Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,,646.0,9606.0,,,5591,CHEMBL875824,,1,1,,BAO_0000219,,Homo sapiens,5421,80682,F,N,A549,,
Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,,646.0,9606.0,,,5592,CHEMBL621434,,1,1,,BAO_0000219,,Homo sapiens,5421,80682,F,N,A549,,
Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,Intermediate,,646.0,9606.0,,,5593,CHEMBL621435,,1,1,,BAO_0000219,,Homo sapiens,5421,80682,F,N,A549,,
Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,Intermediate,,646.0,9606.0,,,5594,CHEMBL621436,,1,1,,BAO_0000219,,Homo sapiens,14188,80682,F,N,A549,,
Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,Intermediate,,646.0,9606.0,,,5595,CHEMBL621437,,1,1,,BAO_0000219,,Homo sapiens,14188,80682,F,N,A549,,
Compound was tested for the growth inhibition of A549 lung tumor cell line,Intermediate,,646.0,9606.0,,,5596,CHEMBL621438,,1,1,,BAO_0000219,,Homo sapiens,15354,80682,F,N,A549,,
Growth inhibition of human non-small-lung carcinoma (A549) cell line,Expert,,646.0,9606.0,,,5597,CHEMBL621439,,1,1,,BAO_0000219,,Homo sapiens,14253,80682,F,N,A549,,
Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,,646.0,9606.0,,,5598,CHEMBL621440,,1,1,,BAO_0000219,,Homo sapiens,13873,80682,F,N,A549,,
Oral bioavailability in dog (conscious),Intermediate,,,9615.0,,,5599,CHEMBL621441,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3043,50588,A,N,,,
Compound was evaluated for the oral bioavailability after oral administration in dog.,Intermediate,,,9615.0,,,5600,CHEMBL621442,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3045,50588,A,N,,,
Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,Intermediate,,,9615.0,,,5601,CHEMBL621443,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3022,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,5602,CHEMBL621444,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4453,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,5603,CHEMBL625133,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1696,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,5604,CHEMBL625134,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5045,50588,A,N,,,
Oral bioavailability in dog (fasted),Intermediate,,,9615.0,,,5605,CHEMBL625135,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5356,50588,A,N,,,
Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,9615.0,,,5606,CHEMBL625136,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17764,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,5607,CHEMBL625137,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6448,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,5608,CHEMBL625138,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1475,50588,A,N,,,
Percent bioavailability in dog,Intermediate,,,9615.0,,,5609,CHEMBL625139,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3788,50588,A,N,,,
Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,Intermediate,,,9615.0,,,5610,CHEMBL872264,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3639,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,5611,CHEMBL625140,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,13397,50588,A,N,,,
The compound was evaluated for bioavailability in dogs; 34-44,Intermediate,,,9615.0,,,5612,CHEMBL624436,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2137,50588,A,N,,,
Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,,,9615.0,,,5613,CHEMBL624437,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2959,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,5614,CHEMBL872261,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6448,50588,A,N,,,
8 hour trough Blood level in dog was measured after administration of compound,Intermediate,,,9615.0,,,5615,CHEMBL624438,,1,1,,BAO_0000218,,Canis lupus familiaris,6084,50588,A,N,,,
The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Intermediate,,,9615.0,,,5616,CHEMBL624439,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3639,50588,A,N,,1969.0,
C24 after oral administration at 5 mg/kg,Intermediate,,,9615.0,,,5617,CHEMBL624440,,1,1,,BAO_0000218,,Canis lupus familiaris,6316,50588,A,N,,,
Clearance after oral and iv dosing in dogs,Intermediate,,,9615.0,,,5618,CHEMBL624441,,1,1,,BAO_0000218,,Canis lupus familiaris,5238,50588,A,N,,,
Clearance of the drug was measured in the plasma of dog,Intermediate,,,9615.0,,,5619,CHEMBL624442,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,17796,50588,A,N,,1969.0,
Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,Intermediate,,,9615.0,,,5620,CHEMBL624443,,1,1,,BAO_0000218,,Canis lupus familiaris,2652,50588,A,N,,,
CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,,9615.0,,,5621,CHEMBL624444,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5654,50588,A,N,,,
Clearance of compound was determined in dogs,Intermediate,,,9615.0,,,5622,CHEMBL624445,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6621,50588,A,N,,,
Clearance on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,,9615.0,,,5623,CHEMBL624446,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6505,50588,A,N,,,
Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,9615.0,,,5624,CHEMBL624447,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5802,50588,A,N,,,
Plasma clearance in dog was determined,Intermediate,,,9615.0,,,5625,CHEMBL624448,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17267,50588,A,N,,,
Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,9615.0,,,5626,CHEMBL624449,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4521,50588,A,N,,,
Plasma clearance in dog after administration of 0.25 mg/kg iv,Intermediate,,,9615.0,,,5627,CHEMBL624450,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,,
Plasma clearance in dog after administration of 1 mg/kg iv,Intermediate,,,9615.0,,,5628,CHEMBL875942,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,,
Plasma clearance in dogs,Intermediate,,,9615.0,,,5629,CHEMBL624451,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,,
Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,,,9615.0,,,5630,CHEMBL624452,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5542,50588,A,N,,,
Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,9615.0,,,5631,CHEMBL624453,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5199,50588,A,N,,,
Plasma clearance after 15 mg/kg iv dose in Dogs,Intermediate,,,9615.0,,,5632,CHEMBL624454,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Plasma clearance after 30 mg/kg po dose in Dogs,Intermediate,,,9615.0,,,5633,CHEMBL624455,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Plasma administration to dogs,Intermediate,,,9615.0,,,5634,CHEMBL624456,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16367,50588,A,N,,,
Plasma clearance was determined,Intermediate,,,9615.0,,,5635,CHEMBL624457,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5505,50588,A,N,,,
Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,,9615.0,,,5636,CHEMBL624458,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6215,50588,A,N,,,
Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,,9615.0,,,5637,CHEMBL624459,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1466,50588,A,N,,,
Intrinsic clearance in human liver microsomes,Intermediate,,,9606.0,Microsomes,,5638,CHEMBL624460,Liver,2,1,,BAO_0000251,In vitro,Homo sapiens,5007,102164,A,S,,2107.0,
Intrinsic clearance in human liver microsomes,Intermediate,,,9606.0,Microsomes,,5639,CHEMBL624461,Liver,2,1,,BAO_0000251,In vitro,Homo sapiens,5007,102164,A,S,,2107.0,
Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,9615.0,,,5640,CHEMBL875943,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,,9615.0,,,5641,CHEMBL624462,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Clearance in dog (dose 1 mg/kg i.v.),Intermediate,,,9615.0,,,5642,CHEMBL624463,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,,9615.0,,,5643,CHEMBL624464,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6221,50588,A,N,,,
Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,9615.0,,,5644,CHEMBL624465,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5007,50588,A,N,,,
Plasma clearance after peroral administration at 10 mpk in dog,Intermediate,,,9615.0,,,5645,CHEMBL624466,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Plasma clearance after peroral administration at 5 mpk in dog,Intermediate,,,9615.0,,,5646,CHEMBL624467,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Plasma clearance after peroral administration at 5 mg/kg in dog,Intermediate,,,9615.0,,,5647,CHEMBL624468,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Plasma clearance was measured in dog,Intermediate,,,9615.0,,,5648,CHEMBL624469,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,15660,50588,A,N,,,
Plasma clearance was measured in dog,Intermediate,,,9615.0,,,5649,CHEMBL624470,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,15660,50588,A,N,,,
Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,,,9615.0,,,5650,CHEMBL624471,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5983,50588,A,N,,,
Total clearance was determined after 0.1 mg/kg iv administration in dog,Intermediate,,,9615.0,,,5651,CHEMBL624472,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5600,50588,A,N,,,
Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,9615.0,,,5652,CHEMBL622775,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17764,50588,A,N,,,
Clearance after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,,,9615.0,,,5653,CHEMBL622776,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6039,50588,A,N,,,
Clearance after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,,,9615.0,,,5654,CHEMBL622777,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6039,50588,A,N,,,
Clearance after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,,,9615.0,,,5655,CHEMBL622778,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6039,50588,A,N,,,
Clearance by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,9615.0,,,5656,CHEMBL622779,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4368,50588,A,N,,,
Clearance by iv administration in dogs at a dose of 1 mg/kg,Intermediate,,,9615.0,,,5657,CHEMBL622780,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4305,50588,A,N,,,
Clearance value was evaluated in dog plasma,Intermediate,,,9615.0,,,5658,CHEMBL622781,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1918,50588,A,N,,1969.0,
Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,,,9615.0,,,5659,CHEMBL622782,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6005,50588,A,N,,,
Compound was tested for plasma clearance in dog,Intermediate,,,9615.0,,,5660,CHEMBL622783,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4839,50588,A,N,,1969.0,
Pharmacokinetic property (Plasma clearance) was measured in dog,Intermediate,,,9615.0,,,5661,CHEMBL622784,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4239,50588,A,N,,,
Area under curve when injected perorally in mice at a dose of 50 mg/kg,Intermediate,,,10090.0,,,5662,CHEMBL622785,,1,1,,BAO_0000218,,Mus musculus,17729,50594,A,N,,,
Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,Intermediate,,,10090.0,,,5663,CHEMBL622786,,1,1,,BAO_0000218,,Mus musculus,17728,50594,A,N,,,
Area under curve value in mouse at a dose of 10 mg/kg,Intermediate,,,10090.0,,,5664,CHEMBL622787,,1,1,,BAO_0000218,,Mus musculus,5302,50594,A,N,,,
Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,,10090.0,,,5665,CHEMBL875949,,1,1,,BAO_0000218,,Mus musculus,5506,50594,A,N,,,
Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,,10090.0,,,5666,CHEMBL622788,,1,1,,BAO_0000218,,Mus musculus,5506,50594,A,N,,,
Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,,10090.0,,,5667,CHEMBL622789,,1,1,,BAO_0000218,,Mus musculus,17764,50594,F,N,,,
Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,,10090.0,,,5668,CHEMBL622790,,1,1,,BAO_0000218,,Mus musculus,17764,50594,F,N,,,
Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,,10090.0,,,5669,CHEMBL622791,,1,1,,BAO_0000218,,Mus musculus,17764,50594,F,N,,,
Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,,10090.0,,,5670,CHEMBL622792,,1,1,,BAO_0000218,,Mus musculus,17764,50594,F,N,,,
Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,Intermediate,,,10090.0,,,5671,CHEMBL622793,,1,1,,BAO_0000218,,Mus musculus,17764,50594,A,N,,,
Area under curve was determined for the compound at 24 mg/Kg,Intermediate,,,10090.0,,,5672,CHEMBL622794,,1,1,,BAO_0000218,,Mus musculus,17753,50594,A,N,,,
Area under curve was determined for the compound at 40 mg/Kg,Intermediate,,,10090.0,,,5673,CHEMBL622795,,1,1,,BAO_0000218,,Mus musculus,17753,50594,A,N,,,
Area under curve was determined for the compound at 5 mg/Kg,Intermediate,,,10090.0,,,5674,CHEMBL621803,,1,1,,BAO_0000218,,Mus musculus,17753,50594,A,N,,,
Area under the curve for the compound is obtained at dose 25 mg/kg,Intermediate,,,10090.0,,,5675,CHEMBL621804,,1,1,,BAO_0000218,,Mus musculus,3132,50594,A,N,,,
Area under the curve for the compound was obtained when tested in mouse,Intermediate,,,10090.0,,,5676,CHEMBL621805,,1,1,,BAO_0000218,,Mus musculus,3132,50594,A,N,,,
Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,10090.0,,,5677,CHEMBL621806,,1,1,,BAO_0000218,,Mus musculus,17837,50594,A,N,,,
Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,,,10090.0,,,5678,CHEMBL621807,,1,1,,BAO_0000218,,Mus musculus,17837,50594,A,N,,,
Area under the curve was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,10090.0,,,5679,CHEMBL621808,,1,1,,BAO_0000218,,Mus musculus,6062,50594,A,N,,,
Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,10090.0,,,5680,CHEMBL621809,,1,1,,BAO_0000218,,Mus musculus,4066,50594,A,N,,,
At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,,,10090.0,,,5681,CHEMBL621810,,1,1,,BAO_0000218,,Mus musculus,16597,50594,A,N,,,
Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Intermediate,,,10090.0,,,5682,CHEMBL875164,,1,1,,BAO_0000218,,Mus musculus,14239,50594,A,N,,,
Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Intermediate,,,10090.0,,,5683,CHEMBL621811,,1,1,,BAO_0000218,,Mus musculus,14239,50594,A,N,,,
"Compound was evaluated for the pharmacokinetic parameter, area under curve",Intermediate,,,10090.0,,,5684,CHEMBL621812,,1,1,,BAO_0000218,,Mus musculus,4890,50594,A,N,,,
Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),Intermediate,,,10090.0,,,5685,CHEMBL621813,,1,1,,BAO_0000218,,Mus musculus,429,50594,A,N,,,
Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),Intermediate,,,10090.0,,,5686,CHEMBL621814,,1,1,,BAO_0000218,,Mus musculus,429,50594,A,N,,,
In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,10090.0,,,5687,CHEMBL621815,,1,1,,BAO_0000218,,Mus musculus,5969,50594,A,N,,,
In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,10090.0,,,5688,CHEMBL621816,,1,1,,BAO_0000218,,Mus musculus,5969,50594,A,N,,,
In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,,10090.0,,,5689,CHEMBL621817,,1,1,,BAO_0000218,,Mus musculus,5969,50594,A,N,,,
Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,Intermediate,,,10090.0,,,5690,CHEMBL621818,,1,1,,BAO_0000218,,Mus musculus,6091,50594,A,N,,,
Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,Intermediate,,,10090.0,,,5691,CHEMBL621819,,1,1,,BAO_0000218,,Mus musculus,6091,50594,A,N,,,
Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,Intermediate,,,10090.0,,,5692,CHEMBL621820,,1,1,,BAO_0000218,,Mus musculus,6091,50594,A,N,,,
Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,Intermediate,,,10090.0,,,5693,CHEMBL621821,,1,1,,BAO_0000218,,Mus musculus,6091,50594,A,N,,,
Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,Intermediate,,,10090.0,,,5694,CHEMBL621822,,1,1,,BAO_0000218,,Mus musculus,6178,50594,A,N,,,
Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,Intermediate,,,10090.0,,,5695,CHEMBL619474,,1,1,,BAO_0000218,,Mus musculus,6178,50594,A,N,,,
"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,,,10090.0,,,5696,CHEMBL619475,,1,1,,BAO_0000218,,Mus musculus,6619,50594,A,N,,,
"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,,,10090.0,,,5697,CHEMBL619476,,1,1,,BAO_0000218,,Mus musculus,6619,50594,A,N,,,
"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",Intermediate,,,10090.0,,,5698,CHEMBL619477,,1,1,,BAO_0000218,,Mus musculus,3760,50594,A,N,,,
"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",Intermediate,,,10090.0,,,5699,CHEMBL619478,,1,1,,BAO_0000218,,Mus musculus,3760,50594,A,N,,,
"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",Intermediate,,,10090.0,,,5700,CHEMBL619479,,1,1,,BAO_0000218,,Mus musculus,3760,50594,A,N,,,
"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",Intermediate,,,10090.0,,,5701,CHEMBL619480,,1,1,,BAO_0000218,,Mus musculus,3760,50594,A,N,,,
The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,Intermediate,,,10090.0,,,5702,CHEMBL619481,,1,1,,BAO_0000218,,Mus musculus,3192,50594,A,N,,,
The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,Intermediate,,,10090.0,,,5703,CHEMBL619482,,1,1,,BAO_0000218,,Mus musculus,3192,50594,A,N,,,
Area under the curve was evaluated in mice after intravenous administration,Intermediate,,,10090.0,,,5704,CHEMBL619483,,1,1,,BAO_0000218,,Mus musculus,2675,50594,A,N,,,
Area under the curve was evaluated in mice after oral administration,Intermediate,,,10090.0,,,5705,CHEMBL619484,,1,1,,BAO_0000218,,Mus musculus,2675,50594,A,N,,,
AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,10090.0,,,5706,CHEMBL619485,Plasma,1,1,,BAO_0000218,,Mus musculus,16597,50594,A,N,,1969.0,
AUC total value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,10090.0,,,5707,CHEMBL619486,Plasma,1,1,,BAO_0000218,,Mus musculus,16597,50594,A,N,,1969.0,
At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,,,10090.0,,,5708,CHEMBL619487,,1,1,,BAO_0000218,,Mus musculus,16597,50594,A,N,,,
AUMC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,10090.0,,,5709,CHEMBL619488,,1,1,,BAO_0000218,,Mus musculus,17734,50594,A,N,,,
Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5710,CHEMBL620106,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,178.0,
The compound was tested in vitro for anticancer activity against 9L cells,Intermediate,,392.0,,,,5711,CHEMBL620107,,1,1,,BAO_0000219,,,15345,80653,F,N,9L,,
Anti proliferation activity determined; Weak effect,Autocuration,,,10116.0,,,5712,CHEMBL620283,,0,1,,BAO_0000019,,Rattus norvegicus,2181,22226,F,U,,,
Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,,,10116.0,,,5713,CHEMBL875176,,0,1,,BAO_0000219,,Rattus norvegicus,2181,22226,F,U,,,
Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,Autocuration,,,10116.0,,,5714,CHEMBL620284,,0,1,,BAO_0000219,,Rattus norvegicus,2181,22226,F,U,,,
Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,,,10116.0,,,5715,CHEMBL623515,,0,1,,BAO_0000219,,Rattus norvegicus,2181,22226,F,U,,,
The cytotoxic activity was in vitro tested by 9PS assay method,Autocuration,,,10090.0,,,5716,CHEMBL623516,,0,1,,BAO_0000019,,Mus musculus,10486,22226,F,U,,,
The cytotoxic activity was in vitro tested by 9PS assay method.,Autocuration,,,10090.0,,,5717,CHEMBL623517,,0,1,,BAO_0000019,,Mus musculus,10486,22226,F,U,,,
Partition coefficient (logD6.5),Autocuration,,,,,,5718,CHEMBL857878,,0,1,,BAO_0000019,,,15508,22224,A,U,,,
Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,Expert,,478.0,9606.0,,,5719,CHEMBL623518,,1,1,,BAO_0000219,,Homo sapiens,5242,81034,F,N,A2780,,
Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),Intermediate,,455.0,9606.0,,,5720,CHEMBL624195,,1,1,,BAO_0000219,,Homo sapiens,16167,80018,F,N,A-375,,
Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,Expert,,500.0,9606.0,,,5721,CHEMBL624196,,1,1,,BAO_0000219,,Homo sapiens,4782,80852,F,N,A-431,,
Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,,500.0,9606.0,,,5722,CHEMBL624197,,9,1,,BAO_0000219,,Homo sapiens,16093,9,F,D,A-431,,
Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,Intermediate,,624.0,9606.0,,,5723,CHEMBL624198,,1,1,,BAO_0000219,,Homo sapiens,2596,80021,F,N,A498,,
in vitro cytotoxicity against A 498 cancer cell line,Intermediate,,624.0,9606.0,,,5724,CHEMBL621287,,1,1,,BAO_0000219,,Homo sapiens,2596,80021,F,N,A498,,
In vitro cytotoxic activity against renal (A 498) cancer cell line.,Intermediate,,624.0,9606.0,,,5725,CHEMBL621288,,1,1,,BAO_0000219,,Homo sapiens,3239,80021,F,N,A498,,
Cytotoxic activity against A 498 renal cancer cell lines.,Intermediate,,624.0,9606.0,,,5726,CHEMBL876496,,1,1,,BAO_0000219,,Homo sapiens,1847,80021,F,N,A498,,
In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,Intermediate,,624.0,9606.0,,,5727,CHEMBL621289,,1,1,,BAO_0000219,,Homo sapiens,10553,80021,F,N,A498,,
Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,,,1280.0,,,5728,CHEMBL621290,,0,1,,BAO_0000019,,Staphylococcus aureus,16219,22226,F,U,,,
Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,,,1280.0,,,5729,CHEMBL621291,,0,1,,BAO_0000019,,Staphylococcus aureus,16219,22226,F,U,,,
Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,,,1280.0,,,5730,CHEMBL621292,,0,1,,BAO_0000019,,Staphylococcus aureus,16219,22226,F,U,,,
Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,,,1280.0,,,5731,CHEMBL621293,,0,1,,BAO_0000019,,Staphylococcus aureus,16219,22226,F,U,,,
Inhibitory concentration required against A 549 lung cancer cell line,Intermediate,,646.0,9606.0,,,5732,CHEMBL621294,,1,1,,BAO_0000219,,Homo sapiens,4782,80682,F,N,A549,,
Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,Intermediate,,646.0,9606.0,,,5733,CHEMBL621295,,1,1,,BAO_0000219,,Homo sapiens,11805,80682,F,N,A549,,
Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,Intermediate,,646.0,9606.0,,,5734,CHEMBL884007,,1,1,,BAO_0000219,,Homo sapiens,11805,80682,F,N,A549,,
In vitro cytotoxicity against lung cancer A 549 cell lines,Intermediate,,646.0,9606.0,,,5735,CHEMBL621296,,1,1,,BAO_0000219,,Homo sapiens,2007,80682,F,N,A549,,
Compound was tested for its cytotoxicity against A 549 cell line,Intermediate,,646.0,9606.0,,,5736,CHEMBL621297,,1,1,,BAO_0000219,,Homo sapiens,4594,80682,F,N,A549,,
"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",Expert,,646.0,9606.0,,,5737,CHEMBL839828,,1,1,,BAO_0000219,,Homo sapiens,6018,80682,F,N,A549,,
"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",Intermediate,,646.0,9606.0,,,5738,CHEMBL620397,,1,1,,BAO_0000219,,Homo sapiens,6018,80682,F,N,A549,,
In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,Expert,,646.0,9606.0,,,5739,CHEMBL620398,,1,1,,BAO_0000219,,Homo sapiens,3599,80682,F,N,A549,,
Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Intermediate,,646.0,9606.0,,,5740,CHEMBL620399,,1,1,,BAO_0000219,,Homo sapiens,2551,80682,F,N,A549,,
In vitro inhibition of A549 (human lung cancer) cell growth.,Expert,,646.0,9606.0,,,5741,CHEMBL620400,,1,1,,BAO_0000219,,Homo sapiens,16132,80682,F,N,A549,,
Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,Intermediate,,646.0,9606.0,,,5742,CHEMBL620401,,1,1,,BAO_0000219,,Homo sapiens,16132,80682,F,N,A549,,
Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Expert,,646.0,9606.0,,,5743,CHEMBL620402,,1,1,,BAO_0000219,,Homo sapiens,2551,80682,F,N,A549,,
Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),Expert,,646.0,9606.0,,,5744,CHEMBL620403,,1,1,,BAO_0000219,,Homo sapiens,2551,80682,F,N,A549,,
Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,Autocuration,,,,,,5745,CHEMBL620404,,0,1,,BAO_0000218,,,11913,22226,F,U,,,
The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,Autocuration,,,,,,5746,CHEMBL620405,,4,1,,BAO_0000218,In vivo,,12621,104694,F,H,,,
The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,Autocuration,,,,,,5747,CHEMBL620406,,4,1,,BAO_0000218,In vivo,,12621,104694,F,H,,,
The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,Autocuration,,,,,,5748,CHEMBL620407,,4,1,,BAO_0000218,In vivo,,12621,104694,F,H,,,
The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,Autocuration,,,,,,5749,CHEMBL620408,,4,1,,BAO_0000218,In vivo,,12621,104694,F,H,,,
The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,Autocuration,,,,,,5750,CHEMBL620409,,4,1,,BAO_0000218,In vivo,,12621,104694,F,H,,,
Inhibition of A-498 human Renal cell proliferation,Expert,,624.0,9606.0,,,5751,CHEMBL620410,,1,1,,BAO_0000219,,Homo sapiens,3600,80021,F,N,A498,,
"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",Autocuration,,,10116.0,,,5752,CHEMBL620411,,0,1,,BAO_0000019,,Rattus norvegicus,1796,22226,F,U,,,
"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",Autocuration,,,10116.0,,,5753,CHEMBL620412,,0,1,,BAO_0000019,,Rattus norvegicus,1796,22226,F,U,,,
"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",Autocuration,,,10116.0,,,5754,CHEMBL876596,,0,1,,BAO_0000019,,Rattus norvegicus,1796,22226,F,U,,,
Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,Expert,,622.0,9606.0,,,5755,CHEMBL620413,,1,1,,BAO_0000219,,Homo sapiens,16464,80012,F,N,A 172,,
Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,622.0,9606.0,,,5756,CHEMBL620414,,1,1,,BAO_0000219,,Homo sapiens,16464,80012,F,N,A 172,,
Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,622.0,9606.0,,,5757,CHEMBL620415,,1,1,,BAO_0000219,,Homo sapiens,16464,80012,F,N,A 172,,
Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,Expert,,646.0,9606.0,,,5758,CHEMBL620416,,1,1,,BAO_0000219,,Homo sapiens,13617,80682,F,N,A549,,
Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,Intermediate,,646.0,9606.0,,,5759,CHEMBL620417,,1,1,,BAO_0000219,,Homo sapiens,4584,80682,F,N,A549,,
Cytotoxic activity evaluated against A549 tumor cells,Expert,,646.0,9606.0,,,5760,CHEMBL620418,,1,1,,BAO_0000219,,Homo sapiens,13799,80682,F,N,A549,,
Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,Intermediate,,646.0,9606.0,,,5761,CHEMBL620419,,1,1,,BAO_0000219,,Homo sapiens,16726,80682,F,N,A549,,
Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,Intermediate,,646.0,9606.0,,,5762,CHEMBL620420,,1,1,,BAO_0000219,,Homo sapiens,16109,80682,F,N,A549,,
Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,Intermediate,,646.0,9606.0,,,5763,CHEMBL620421,,1,1,,BAO_0000219,,Homo sapiens,16109,80682,F,N,A549,,
Cytotoxicity against A549 tumor cell line determined by WST-1 assay,Intermediate,,646.0,9606.0,,,5764,CHEMBL620422,,1,1,,BAO_0000219,,Homo sapiens,15474,80682,F,N,A549,,
Cytotoxicity of compound against A549 cell line,Intermediate,,646.0,9606.0,,,5765,CHEMBL620423,,1,1,,BAO_0000219,,Homo sapiens,6851,80682,F,N,A549,,
Cytotoxicity against human lung cell carcinoma A549 cell line,Expert,,646.0,9606.0,,,5766,CHEMBL620424,,1,1,,BAO_0000219,,Homo sapiens,17534,80682,F,N,A549,,
Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,Intermediate,,646.0,9606.0,,,5767,CHEMBL620425,,1,1,,BAO_0000219,,Homo sapiens,2621,80682,F,N,A549,,
Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,Intermediate,,646.0,9606.0,,,5768,CHEMBL620426,,1,1,,BAO_0000219,,Homo sapiens,830,80682,F,N,A549,,
In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,Intermediate,,646.0,9606.0,,,5769,CHEMBL620427,,1,1,,BAO_0000219,,Homo sapiens,14255,80682,F,N,A549,,
In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,Intermediate,,646.0,9606.0,,,5770,CHEMBL620428,,1,1,,BAO_0000219,,Homo sapiens,14255,80682,F,N,A549,,
In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,Intermediate,,646.0,9606.0,,,5771,CHEMBL620429,,1,1,,BAO_0000219,,Homo sapiens,1590,80682,F,N,A549,,
In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,Expert,,646.0,9606.0,,,5772,CHEMBL620430,,1,1,,BAO_0000219,,Homo sapiens,6146,80682,F,N,A549,,
In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,,646.0,9606.0,,,5773,CHEMBL839887,,1,1,,BAO_0000219,,Homo sapiens,17427,80682,F,N,A549,,
In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,Intermediate,,646.0,9606.0,,,5774,CHEMBL620431,,1,1,,BAO_0000219,,Homo sapiens,5280,80682,F,N,A549,,
In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,Intermediate,,646.0,9606.0,,,5775,CHEMBL884010,,1,1,,BAO_0000219,,Homo sapiens,16786,80682,F,N,A549,,
In vitro cytotoxicity against A549 (human lung cancer),Intermediate,,646.0,9606.0,,,5776,CHEMBL620538,,1,1,,BAO_0000219,,Homo sapiens,5895,80682,F,N,A549,,
In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,,646.0,9606.0,,,5777,CHEMBL620539,,1,1,,BAO_0000219,,Homo sapiens,14297,80682,F,N,A549,,
In vivo antiproliferative activity against A549 cell line,Intermediate,,646.0,9606.0,,,5778,CHEMBL623373,,1,1,,BAO_0000218,,Homo sapiens,17824,80682,F,N,A549,,
Inhibition of non-small-cell lung adenocarcinoma (A549),Intermediate,,646.0,9606.0,,,5779,CHEMBL623374,,1,1,,BAO_0000219,,Homo sapiens,14368,80682,F,N,A549,,
Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,Intermediate,,646.0,9606.0,,,5780,CHEMBL623375,,1,1,,BAO_0000219,,Homo sapiens,14368,80682,F,N,A549,,
Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,Intermediate,,646.0,9606.0,,,5781,CHEMBL623376,,1,1,,BAO_0000219,,Homo sapiens,14254,80682,F,N,A549,,
Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Intermediate,,646.0,9606.0,,,5782,CHEMBL623377,,1,1,,BAO_0000219,,Homo sapiens,15897,80682,F,N,A549,,
Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,,646.0,9606.0,,,5783,CHEMBL623378,,1,1,,BAO_0000219,,Homo sapiens,13866,80682,F,N,A549,,
Inhibitory activity of compound against human A549 lung carcinoma cell line.,Intermediate,,646.0,9606.0,,,5784,CHEMBL623379,,1,1,,BAO_0000219,,Homo sapiens,13370,80682,F,N,A549,,
Inhibitory activity against A549 lung cancer cell line,Intermediate,,646.0,9606.0,,,5785,CHEMBL623380,,1,1,,BAO_0000219,,Homo sapiens,4862,80682,F,N,A549,,
Inhibitory activity against Taxol-resistant A549 lung cancer cell line,Intermediate,,646.0,9606.0,,,5786,CHEMBL623381,,1,1,,BAO_0000219,,Homo sapiens,4862,80682,F,N,A549,,
Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,Intermediate,,646.0,9606.0,,,5787,CHEMBL623382,,1,1,,BAO_0000219,,Homo sapiens,4862,80682,F,N,A549,,
Inhibitory concentration against A549 (lung cancer) cell line,Intermediate,,646.0,9606.0,,,5788,CHEMBL623383,,1,1,,BAO_0000219,,Homo sapiens,15970,80682,F,N,A549,,
In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,,646.0,9606.0,,,5789,CHEMBL623384,,1,1,,BAO_0000219,,Homo sapiens,17713,80682,F,N,A549,,
Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,Intermediate,,646.0,9606.0,,,5790,CHEMBL623385,,1,1,,BAO_0000219,,Homo sapiens,4833,80682,F,N,A549,,
Activity against A549 cancer cell line.,Expert,,646.0,9606.0,,,5791,CHEMBL623386,,1,1,,BAO_0000219,,Homo sapiens,13736,80682,F,N,A549,,
The compound was evaluated for cytotoxicity against A549 cell line,Intermediate,,646.0,9606.0,,,5792,CHEMBL884105,,1,1,,BAO_0000219,,Homo sapiens,4312,80682,F,N,A549,,
The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,Intermediate,,646.0,9606.0,,,5793,CHEMBL623387,,1,1,,BAO_0000219,,Homo sapiens,5421,80682,F,N,A549,,
The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,,646.0,9606.0,,,5794,CHEMBL621568,,1,1,,BAO_0000219,,Homo sapiens,5421,80682,F,N,A549,,
Growth inhibitory activity was measured for human A549 tumor cell line.,Intermediate,,646.0,9606.0,,,5795,CHEMBL621569,,1,1,,BAO_0000219,,Homo sapiens,14717,80682,F,N,A549,,
Inhibitory activity against A549 lung cancer cell line,Intermediate,,646.0,9606.0,,,5796,CHEMBL621570,,1,1,,BAO_0000219,,Homo sapiens,4634,80682,F,N,A549,,
Inhibitory activity against A549 cell line; inactive,Intermediate,,646.0,9606.0,,,5797,CHEMBL621571,,1,1,,BAO_0000219,,Homo sapiens,1149,80682,F,N,A549,,
Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,,646.0,9606.0,,,5798,CHEMBL621572,,1,1,,BAO_0000219,,Homo sapiens,5421,80682,F,N,A549,,
Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,,646.0,9606.0,,,5799,CHEMBL621573,,1,1,,BAO_0000219,,Homo sapiens,5421,80682,F,N,A549,,
Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,,646.0,9606.0,,,5800,CHEMBL621574,,1,1,,BAO_0000219,,Homo sapiens,5421,80682,F,N,A549,,
In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),Intermediate,,646.0,9606.0,,,5801,CHEMBL621575,,1,1,,BAO_0000219,,Homo sapiens,3320,80682,F,N,A549,,
In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),Intermediate,,646.0,9606.0,,,5802,CHEMBL621576,,1,1,,BAO_0000219,,Homo sapiens,3320,80682,F,N,A549,,
In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),Intermediate,,646.0,9606.0,,,5803,CHEMBL621577,,1,1,,BAO_0000219,,Homo sapiens,3320,80682,F,N,A549,,
In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),Intermediate,,646.0,9606.0,,,5804,CHEMBL621578,,1,1,,BAO_0000219,,Homo sapiens,3320,80682,F,N,A549,,
In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),Intermediate,,646.0,9606.0,,,5805,CHEMBL621579,,1,1,,BAO_0000219,,Homo sapiens,3320,80682,F,N,A549,,
In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,Intermediate,,646.0,9606.0,,,5806,CHEMBL621580,,1,1,,BAO_0000219,,Homo sapiens,5726,80682,F,N,A549,,
Plasma clearance (in vivo) in mongrel dogs was determined,Intermediate,,,9615.0,,,5807,CHEMBL621581,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17800,50588,A,N,,,
Plasma clearance was measured in dog,Intermediate,,,9615.0,,,5808,CHEMBL621582,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5985,50588,A,N,,,
Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,,,9615.0,,,5809,CHEMBL621583,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5530,50588,A,N,,,
Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,,,9615.0,,,5810,CHEMBL621584,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5530,50588,A,N,,,
Tested for plasma clearance in dog,Intermediate,,,9615.0,,,5811,CHEMBL621585,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4839,50588,A,N,,1969.0,
The compound was tested for clearance in dog plasma.,Intermediate,,,9615.0,,,5812,CHEMBL621586,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3639,50588,A,N,,,
"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",Intermediate,,,9615.0,,,5813,CHEMBL875835,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4838,50588,A,N,,,
Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,Intermediate,,,9615.0,,,5814,CHEMBL621587,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4137,50588,A,N,,,
Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,,,9615.0,,,5815,CHEMBL621588,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5017,50588,A,N,,1969.0,
In vitro clearance in dog liver microsomes,Intermediate,,,9615.0,Microsomes,,5816,CHEMBL621589,Liver,1,1,,BAO_0000218,In vitro,Canis lupus familiaris,17538,50588,A,N,,2107.0,
Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,,,9615.0,,,5817,CHEMBL621590,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6161,50588,A,N,,,
Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,,,9615.0,,,5818,CHEMBL621591,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6161,50588,A,N,,,
Plasma clearance in dog,Intermediate,,,9615.0,,,5819,CHEMBL621592,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1696,50588,A,N,,,
Clearance rate in dog,Intermediate,,,9615.0,,,5820,CHEMBL621593,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6762,50588,A,N,,,
Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Intermediate,,,9615.0,,,5821,CHEMBL621594,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5932,50588,A,N,,1969.0,
Clearance in dogs,Intermediate,,,9615.0,,,5822,CHEMBL621595,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6305,50588,A,N,,,
Plasma clearance in dogs,Intermediate,,,9615.0,,,5823,CHEMBL621596,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4942,50588,A,N,,,
Plasma clearance was determined,Intermediate,,,9615.0,,,5824,CHEMBL621597,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4219,50588,A,N,,,
Lower clearance in dog (i.v.) at 0.5 mpk,Intermediate,,,9615.0,,,5825,CHEMBL621598,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17853,50588,A,N,,,
Plasma clearance in Beagle dogs,Intermediate,,,9615.0,,,5826,CHEMBL621599,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4514,50588,A,N,,,
Plasma clearance (Clp) in dog,Intermediate,,,9615.0,,,5827,CHEMBL875836,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6448,50588,A,N,,,
Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,,,9615.0,,,5828,CHEMBL621600,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,,
Plasma clearance (pharmacokinetic parameter) in dog was determined,Intermediate,,,9615.0,,,5829,CHEMBL621601,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,,
Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,9615.0,,,5830,CHEMBL618474,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6062,50588,A,N,,,
Plasma clearance of compound was determined in dog,Intermediate,,,9615.0,,,5831,CHEMBL618475,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6821,50588,A,N,,,
Plasma clearance after intravenous administration of 1 mg/kg in dog,Intermediate,,,9615.0,,,5832,CHEMBL624524,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4709,50588,A,N,,,
Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,,9615.0,,,5833,CHEMBL624525,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4521,50588,A,N,,,
Plasma clearance in dog was determined,Intermediate,,,9615.0,,,5834,CHEMBL624526,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5374,50588,A,N,,,
Plasma clearance was calculated in dog,Intermediate,,,9615.0,,,5835,CHEMBL624527,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6057,50588,A,N,,,
Plasma clearance at the dose of 2 mg/kg in dog,Intermediate,,,9615.0,,,5836,CHEMBL624528,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4727,50588,A,N,,,
Plasma clearance in dog,Intermediate,,,9615.0,,,5837,CHEMBL624529,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5145,50588,A,N,,,
Plasma clearance in dog,Intermediate,,,9615.0,,,5838,CHEMBL624530,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17657,50588,A,N,,,
Plasma clearance in dog; Unable to calculate,Intermediate,,,9615.0,,,5839,CHEMBL624531,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17657,50588,A,N,,,
Plasma clearance in rhesus monkey,Intermediate,,,9615.0,,,5840,CHEMBL624532,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5145,50588,A,N,,,
Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,9615.0,,,5841,CHEMBL624533,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6642,50588,A,N,,,
Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,9615.0,,,5842,CHEMBL624534,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6641,50588,A,N,,,
Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,9615.0,,,5843,CHEMBL624535,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6642,50588,A,N,,,
Plasma clearance was evaluated in dog,Intermediate,,,9615.0,,,5844,CHEMBL624536,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5472,50588,A,N,,,
Plasma clearance was evaluated in dog; Not tested,Intermediate,,,9615.0,,,5845,CHEMBL624537,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5472,50588,A,N,,,
Plasma clearance was evaluated in rhesus,Intermediate,,,9615.0,,,5846,CHEMBL624538,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5472,50588,A,N,,,
Plasma clearance was evaluated in rhesus; Not tested,Intermediate,,,9615.0,,,5847,CHEMBL624539,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5472,50588,A,N,,,
Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,Intermediate,,,9615.0,,,5848,CHEMBL624540,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4257,50588,A,N,,,
Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,9615.0,,,5849,CHEMBL624541,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6679,50588,A,N,,,
Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,,9615.0,,,5850,CHEMBL624542,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5546,50588,A,N,,,
Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,9615.0,,,5851,CHEMBL624543,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6348,50588,A,N,,,
Clearance value at a dose of 0.2 mg/kg i.v.,Intermediate,,,9615.0,,,5852,CHEMBL624544,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5474,50588,A,N,,,
Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Intermediate,,,9615.0,,,5853,CHEMBL624545,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6316,50588,A,N,,1969.0,
Cmax after oral dose of compound at 3 mg/kg in dogs,Intermediate,,,9615.0,,,5854,CHEMBL624546,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17594,50588,A,N,,,
Cmax after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,,9615.0,,,5855,CHEMBL875957,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17594,50588,A,N,,,
Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,9615.0,,,5856,CHEMBL624547,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5802,50588,A,N,,,
Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,,,9615.0,,,5857,CHEMBL624548,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,,
Cmax in dog after administration of 1 mg/kg iv,Intermediate,,,9615.0,,,5858,CHEMBL624549,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,,
Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,,9615.0,,,5859,CHEMBL624550,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1466,50588,A,N,,1969.0,
Cmax on p.o. administration of 10 mg/kg was measured in dog,Intermediate,,,9615.0,,,5860,CHEMBL621613,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6505,50588,A,N,,,
Cmax was determine after peroral administration at 10 mpk in dog,Intermediate,,,9615.0,,,5861,CHEMBL621614,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Cmax was determine after peroral administration at 5 mpk in dog,Intermediate,,,9615.0,,,5862,CHEMBL623431,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Cmax was determine after peroral administration at 5 mg/kg in dog,Intermediate,,,9615.0,,,5863,CHEMBL623432,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Cmax after 0.3 mg/kg po administration in dog,Intermediate,,,9615.0,,,5864,CHEMBL623433,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5600,50588,A,N,,,
Cmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,,,9615.0,,,5865,CHEMBL623434,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17764,50588,A,N,,,
Cmax in dog after oral administration at 1 mg/kg,Intermediate,,,9615.0,,,5866,CHEMBL623435,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6123,50588,A,N,,,
Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,Intermediate,,,9615.0,,,5867,CHEMBL623436,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6123,50588,A,N,,,
Cmax upon oral administration in male Beagle dog at 10 mg/kg,Intermediate,,,9615.0,,,5868,CHEMBL875958,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6757,50588,A,N,,,
Cmax value after 15 mg/kg iv dose in Dogs,Intermediate,,,9615.0,,,5869,CHEMBL623437,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5870,CHEMBL623438,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,178.0,
Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5871,CHEMBL623439,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,178.0,
Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5872,CHEMBL623440,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,10000001.0,
Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5873,CHEMBL623441,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,10000001.0,
Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5874,CHEMBL623442,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,10000001.0,
Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5875,CHEMBL623469,,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,,
Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5876,CHEMBL623470,,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,,
Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5877,CHEMBL623471,,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,,
Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5878,CHEMBL623472,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,948.0,
Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5879,CHEMBL623473,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,948.0,
Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5880,CHEMBL623474,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,948.0,
Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5881,CHEMBL623475,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2113.0,
Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5882,CHEMBL623476,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2113.0,
Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5883,CHEMBL623477,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2113.0,
Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5884,CHEMBL621896,Intestine,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,160.0,
Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5885,CHEMBL621897,Intestine,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,160.0,
Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5886,CHEMBL621898,Intestine,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,160.0,
Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5887,CHEMBL621899,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2107.0,
Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5888,CHEMBL621900,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2107.0,
Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5889,CHEMBL621901,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2107.0,
Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5890,CHEMBL621902,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2048.0,
Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5891,CHEMBL621903,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2048.0,
Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5892,CHEMBL622587,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2048.0,
Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5893,CHEMBL620285,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2385.0,
Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5894,CHEMBL875285,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2385.0,
Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5895,CHEMBL620286,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2385.0,
Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5896,CHEMBL620287,,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,,
Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5897,CHEMBL620288,,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,,
Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5898,CHEMBL620289,,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,,
Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5899,CHEMBL620290,Intestine,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,160.0,
Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5900,CHEMBL620291,Intestine,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,160.0,
Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5901,CHEMBL620292,Intestine,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,160.0,
Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5902,CHEMBL620293,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2106.0,
Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5903,CHEMBL620294,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2106.0,
Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5904,CHEMBL618614,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,2106.0,
Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5905,CHEMBL618615,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,945.0,
Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,5906,CHEMBL618616,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,945.0,
Cytotoxicity against A-172 human tumor cell lines,Expert,,622.0,9606.0,,,5907,CHEMBL618617,,1,1,,BAO_0000219,,Homo sapiens,2036,80012,F,N,A 172,,
Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,Intermediate,,622.0,9606.0,,,5908,CHEMBL618618,,1,1,,BAO_0000219,,Homo sapiens,2357,80012,F,N,A 172,,
Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,Intermediate,,623.0,9606.0,,,5909,CHEMBL618619,,1,1,,BAO_0000219,,Homo sapiens,1457,80014,F,N,A204,,
Tested for antiproliferative activity against A-2780 tumoral cell line,Intermediate,,478.0,9606.0,,,5910,CHEMBL618620,,1,1,,BAO_0000219,,Homo sapiens,4379,81034,F,N,A2780,,
Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,Intermediate,,455.0,9606.0,,,5911,CHEMBL618621,,1,1,,BAO_0000219,,Homo sapiens,1093,80018,F,N,A-375,,
Tested in vitro against A-375 cell line human melanoma,Intermediate,,455.0,9606.0,,,5912,CHEMBL618622,,1,1,,BAO_0000219,,Homo sapiens,12152,80018,F,N,A-375,,
Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,Expert,,797.0,9606.0,,,5913,CHEMBL618623,,1,1,,BAO_0000219,,Homo sapiens,16464,80019,F,N,A-427,,
Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,797.0,9606.0,,,5914,CHEMBL618624,,1,1,,BAO_0000219,,Homo sapiens,16464,80019,F,N,A-427,,
In vitro cytotoxicity against human non small-cell-lung cell line A-427.,Expert,,797.0,9606.0,,,5915,CHEMBL618625,,1,1,,BAO_0000219,,Homo sapiens,16582,80019,F,N,A-427,,
Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,,797.0,9606.0,,,5916,CHEMBL618626,,1,1,,BAO_0000219,,Homo sapiens,16464,80019,F,N,A-427,,
Antitumor activity on A-427 lung carcinoma cell lines,Intermediate,,797.0,9606.0,,,5917,CHEMBL618627,,1,1,,BAO_0000219,,Homo sapiens,10413,80019,F,N,A-427,,
Cytotoxic activity against human A-427 lung tumor cell line,Intermediate,,797.0,9606.0,,,5918,CHEMBL618628,,1,1,,BAO_0000219,,Homo sapiens,6418,80019,F,N,A-427,,
In vitro antitumor effects against human A-427 cell lines.,Expert,,797.0,9606.0,,,5919,CHEMBL618629,,1,1,,BAO_0000219,,Homo sapiens,17134,80019,F,N,A-427,,
In vitro inhibition of A-427 (human lung cancer) cell growth.,Expert,,797.0,9606.0,,,5920,CHEMBL618630,,1,1,,BAO_0000219,,Homo sapiens,16132,80019,F,N,A-427,,
Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,Intermediate,,797.0,9606.0,,,5921,CHEMBL618631,,1,1,,BAO_0000219,,Homo sapiens,16132,80019,F,N,A-427,,
Cytotoxic activity of compound against A-427 lung human tumor cell line,Intermediate,,797.0,9606.0,,,5922,CHEMBL618632,,1,1,,BAO_0000219,,Homo sapiens,16780,80019,F,N,A-427,,
Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,Expert,,500.0,9606.0,,,5923,CHEMBL618633,,1,1,,BAO_0000219,,Homo sapiens,4085,80852,F,N,A-431,,
Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,Intermediate,,624.0,9606.0,,,5924,CHEMBL619315,,1,1,,BAO_0000219,,Homo sapiens,1276,80021,F,N,A498,,
Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,Expert,,624.0,9606.0,,,5925,CHEMBL619316,,1,1,,BAO_0000219,,Homo sapiens,3498,80021,F,N,A498,,
Cytotoxicity against human kidney carcinoma A-498cell lines,Intermediate,,624.0,9606.0,,,5926,CHEMBL619317,,1,1,,BAO_0000219,,Homo sapiens,1169,80021,F,N,A498,,
In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,Intermediate,,624.0,9606.0,,,5927,CHEMBL619318,,1,1,,BAO_0000219,,Homo sapiens,4450,80021,F,N,A498,,
In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,Intermediate,,624.0,9606.0,,,5928,CHEMBL619319,,1,1,,BAO_0000219,,Homo sapiens,3311,80021,F,N,A498,,
Antitumor cytotoxic activity against A-498 cell line was determined,Intermediate,,624.0,9606.0,,,5929,CHEMBL619739,,1,1,,BAO_0000219,,Homo sapiens,4461,80021,F,N,A498,,
In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,Intermediate,,624.0,9606.0,,,5930,CHEMBL619740,,1,1,,BAO_0000219,,Homo sapiens,3311,80021,F,N,A498,,
In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,Intermediate,,624.0,9606.0,,,5931,CHEMBL883158,,1,1,,BAO_0000219,,Homo sapiens,3311,80021,F,N,A498,,
Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,Intermediate,,624.0,9606.0,,,5932,CHEMBL884012,,1,1,,BAO_0000219,,Homo sapiens,1457,80021,F,N,A498,,
In vitro inhibitory activity against A-498 ovarian cancer cell lines,Intermediate,,624.0,9606.0,,,5933,CHEMBL619741,,1,1,,BAO_0000219,,Homo sapiens,3664,80021,F,N,A498,,
"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",Intermediate,,624.0,9606.0,,,5934,CHEMBL619742,,1,1,,BAO_0000219,,Homo sapiens,15895,80021,F,N,A498,,
Inhibition of growth lung non-small cell carcinoma A-549 cell line,Intermediate,,646.0,9606.0,,,5935,CHEMBL876610,,1,1,,BAO_0000219,,Homo sapiens,11843,80682,F,N,A549,,
Inhibition of growth of lung non-small cell carcinoma A-549 cell line,Intermediate,,646.0,9606.0,,,5936,CHEMBL619743,,1,1,,BAO_0000219,,Homo sapiens,11843,80682,F,N,A549,,
In vitro antiproliferative activity against human A-549 NSCL cell line,Intermediate,,646.0,9606.0,,,5937,CHEMBL619744,,1,1,,BAO_0000219,,Homo sapiens,17705,80682,F,N,A549,,
In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,Intermediate,,646.0,9606.0,,,5938,CHEMBL619745,,1,1,,BAO_0000219,,Homo sapiens,17705,80682,F,N,A549,,
Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,Intermediate,,646.0,9606.0,,,5939,CHEMBL619746,,1,1,,BAO_0000219,,Homo sapiens,4369,80682,F,N,A549,,
Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,Intermediate,,646.0,9606.0,,,5940,CHEMBL619747,,1,1,,BAO_0000219,,Homo sapiens,4369,80682,F,N,A549,,
Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,Intermediate,,646.0,9606.0,,,5941,CHEMBL619748,,1,1,,BAO_0000219,,Homo sapiens,4369,80682,F,N,A549,,
Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,Intermediate,,646.0,9606.0,,,5942,CHEMBL619749,,1,1,,BAO_0000219,,Homo sapiens,4369,80682,F,N,A549,,
Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,Intermediate,,646.0,9606.0,,,5943,CHEMBL619750,,1,1,,BAO_0000219,,Homo sapiens,4369,80682,F,N,A549,,
Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,Intermediate,,646.0,9606.0,,,5944,CHEMBL624014,,1,1,,BAO_0000219,,Homo sapiens,4369,80682,F,N,A549,,
Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,Intermediate,,646.0,9606.0,,,5945,CHEMBL624015,,1,1,,BAO_0000219,,Homo sapiens,4369,80682,F,N,A549,,
In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,Expert,,646.0,9606.0,,,5946,CHEMBL885344,,1,1,,BAO_0000219,,Homo sapiens,4787,80682,F,N,A549,,
In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,Intermediate,,646.0,9606.0,,,5947,CHEMBL623224,,1,1,,BAO_0000219,,Homo sapiens,4787,80682,F,N,A549,,
Cytotoxic activity against A-549 cell line,Intermediate,,646.0,9606.0,,,5948,CHEMBL623225,,1,1,,BAO_0000219,,Homo sapiens,6513,80682,F,N,A549,,
Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,Intermediate,,646.0,9606.0,,,5949,CHEMBL622698,,1,1,,BAO_0000219,,Homo sapiens,6690,80682,F,N,A549,,
Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,Intermediate,,646.0,9606.0,,,5950,CHEMBL622699,,1,1,,BAO_0000219,,Homo sapiens,6690,80682,F,N,A549,,
"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",Expert,,646.0,9606.0,,,5951,CHEMBL622700,,1,1,,BAO_0000219,,Homo sapiens,12263,80682,F,N,A549,,
Compound was tested for cytotoxic activity against human lung carcinoma (A-549),Intermediate,,646.0,9606.0,,,5952,CHEMBL622701,,1,1,,BAO_0000219,,Homo sapiens,1054,80682,F,N,A549,,
Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),Intermediate,,646.0,9606.0,,,5953,CHEMBL622702,,1,1,,BAO_0000219,,Homo sapiens,1359,80682,F,N,A549,,
Cytotoxic activity against human lung carcinoma (A-549) cell line,Intermediate,,646.0,9606.0,,,5954,CHEMBL622703,,1,1,,BAO_0000219,,Homo sapiens,3547,80682,F,N,A549,,
Cytotoxic activity towards A-549 cells,Expert,,646.0,9606.0,,,5955,CHEMBL622704,,1,1,,BAO_0000219,,Homo sapiens,5771,80682,F,N,A549,,
"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,,646.0,9606.0,,,5956,CHEMBL622705,,1,1,,BAO_0000219,,Homo sapiens,14425,80682,F,N,A549,,
"In vitro percent inhibition of A549, lung carcinoma",Intermediate,,646.0,9606.0,,,5957,CHEMBL622706,,1,1,,BAO_0000219,,Homo sapiens,14425,80682,F,N,A549,,
"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,,646.0,9606.0,,,5958,CHEMBL622707,,1,1,,BAO_0000219,,Homo sapiens,14425,80682,F,N,A549,,
"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",Intermediate,,646.0,9606.0,,,5959,CHEMBL622708,,1,1,,BAO_0000219,,Homo sapiens,14425,80682,F,N,A549,,
Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,Intermediate,,646.0,9606.0,,,5960,CHEMBL622709,,1,1,,BAO_0000219,,Homo sapiens,5280,80682,F,N,A549,,
Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,Intermediate,,646.0,9606.0,,,5961,CHEMBL622710,,1,1,,BAO_0000219,,Homo sapiens,15176,80682,F,N,A549,,
In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,Intermediate,,646.0,9606.0,,,5962,CHEMBL622711,,1,1,,BAO_0000219,,Homo sapiens,15300,80682,F,N,A549,,
"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,646.0,9606.0,,,5963,CHEMBL622712,,1,1,,BAO_0000218,,Homo sapiens,17824,80682,F,N,A549,,
"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,646.0,9606.0,,,5964,CHEMBL622713,,1,1,,BAO_0000218,,Homo sapiens,17824,80682,F,N,A549,,
"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,646.0,9606.0,,,5965,CHEMBL622714,,1,1,,BAO_0000218,,Homo sapiens,17824,80682,F,N,A549,,
"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,646.0,9606.0,,,5966,CHEMBL622715,,1,1,,BAO_0000218,,Homo sapiens,17824,80682,F,N,A549,,
"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,,646.0,9606.0,,,5967,CHEMBL622716,,1,1,,BAO_0000218,,Homo sapiens,17824,80682,F,N,A549,,
"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",Intermediate,,646.0,9606.0,,,5968,CHEMBL622717,,1,1,,BAO_0000219,,Homo sapiens,17824,80682,F,N,A549,,
Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),Intermediate,,646.0,9606.0,,,5969,CHEMBL622718,,1,1,,BAO_0000218,,Homo sapiens,17528,80682,F,N,A549,,
Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,Expert,,646.0,9606.0,,,5970,CHEMBL622719,,1,1,,BAO_0000219,,Homo sapiens,6870,80682,F,N,A549,,
Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,,646.0,9606.0,,,5971,CHEMBL622720,,1,1,,BAO_0000219,,Homo sapiens,6870,80682,F,N,A549,,
Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,Intermediate,,646.0,9606.0,,,5972,CHEMBL622721,,1,1,,BAO_0000219,,Homo sapiens,6870,80682,F,N,A549,,
Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,,646.0,9606.0,,,5973,CHEMBL622722,,1,1,,BAO_0000219,,Homo sapiens,6870,80682,F,N,A549,,
Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,,646.0,9606.0,,,5974,CHEMBL876030,,1,1,,BAO_0000219,,Homo sapiens,16726,80682,F,N,A549,,
"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",Intermediate,,646.0,9606.0,,,5975,CHEMBL620206,,1,1,,BAO_0000219,,Homo sapiens,6170,80682,F,N,A549,,
Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,Expert,,646.0,9606.0,,,5976,CHEMBL620207,,1,1,,BAO_0000219,,Homo sapiens,6583,80682,F,N,A549,,
Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,Expert,,646.0,9606.0,,,5977,CHEMBL620208,,1,1,,BAO_0000219,,Homo sapiens,6583,80682,F,N,A549,,
Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,Expert,,646.0,9606.0,,,5978,CHEMBL620209,,1,1,,BAO_0000219,,Homo sapiens,6583,80682,F,N,A549,,
Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,Expert,,646.0,9606.0,,,5979,CHEMBL620210,,1,1,,BAO_0000219,,Homo sapiens,6583,80682,F,N,A549,,
Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,Expert,,646.0,9606.0,,,5980,CHEMBL621639,,1,1,,BAO_0000219,,Homo sapiens,6583,80682,F,N,A549,,
Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,Intermediate,,646.0,9606.0,,,5981,CHEMBL621640,,1,1,,BAO_0000219,,Homo sapiens,17321,80682,F,N,A549,,
Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,,646.0,9606.0,,,5982,CHEMBL621641,,1,1,,BAO_0000219,,Homo sapiens,17528,80682,F,N,A549,,
Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,Expert,,646.0,9606.0,,,5983,CHEMBL621642,,1,1,,BAO_0000219,,Homo sapiens,12888,80682,F,N,A549,,
Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,Intermediate,,646.0,9606.0,,,5984,CHEMBL621643,,1,1,,BAO_0000219,,Homo sapiens,4312,80682,F,N,A549,,
Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,Intermediate,,646.0,9606.0,,,5985,CHEMBL621644,,1,1,,BAO_0000219,,Homo sapiens,4312,80682,F,N,A549,,
Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,Intermediate,,646.0,9606.0,,,5986,CHEMBL621645,,1,1,,BAO_0000219,,Homo sapiens,4312,80682,F,N,A549,,
In vitro antiproliferative activity against A549 cell line,Intermediate,,646.0,10090.0,,,5987,CHEMBL621646,,1,1,,BAO_0000219,,Mus musculus,17737,80682,F,N,A549,,
Synergism with indomethacin in A549 cells,Intermediate,,646.0,,,,5988,CHEMBL621647,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Synergism with tolmetin in A549 cells,Intermediate,,646.0,,,,5989,CHEMBL621648,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Synergism with sulindac in A549 cells,Intermediate,,646.0,,,,5990,CHEMBL621649,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Antagonism of indomethacin in A549 cells,Intermediate,,646.0,,,,5991,CHEMBL621650,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Antagonism of sulindac in A549 cells,Intermediate,,646.0,,,,5992,CHEMBL621651,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Antagonism of tolmetin in A549 cells,Intermediate,,646.0,,,,5993,CHEMBL621652,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Synergism with indomethacin in A549 cells,Intermediate,,646.0,,,,5994,CHEMBL621653,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Synergism with sulindac in A549 cells,Intermediate,,646.0,,,,5995,CHEMBL621654,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,Intermediate,,646.0,,,,5996,CHEMBL621655,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Cmax value after 30 mg/kg po dose in Dogs,Intermediate,,,9615.0,,,5997,CHEMBL621656,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,9615.0,,,5998,CHEMBL621657,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5944,50588,A,N,,,
Cmax value determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,,,9615.0,,,5999,CHEMBL621658,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5944,50588,A,N,,,
Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,,9615.0,,,6000,CHEMBL621659,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5944,50588,A,N,,,
Cmax value determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,,,9615.0,,,6001,CHEMBL621660,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5944,50588,A,N,,,
Cmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,,,9615.0,,,6002,CHEMBL621661,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2959,50588,A,N,,,
Cmax value in dog,Intermediate,,,9615.0,,,6003,CHEMBL621662,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6241,50588,A,N,,,
Cmax value in dogs after oral administration at 1 mg/kg,Intermediate,,,9615.0,,,6004,CHEMBL621663,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6241,50588,A,N,,,
Bioavailability as Cmax in dogs at 5 mg/kg oral dose,Intermediate,,,9615.0,,,6005,CHEMBL621664,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2652,50588,A,N,,,
Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,,,9615.0,,,6006,CHEMBL621665,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1806,50588,A,N,,1969.0,
Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,,,9615.0,,,6007,CHEMBL621666,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1806,50588,A,N,,1969.0,
Concentration maxima after oral dosing in dogs,Intermediate,,,9615.0,,,6008,CHEMBL621667,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1021,50588,A,N,,,
Concentration maxima after oral dosing in dogs; not available,Intermediate,,,9615.0,,,6009,CHEMBL876738,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1021,50588,A,N,,,
Concentration maxima after oral dosing in dogs; not available,Intermediate,,,9615.0,,,6010,CHEMBL621668,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1021,50588,A,N,,,
In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,Intermediate,,,9615.0,,,6011,CHEMBL621669,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5444,50588,A,N,,,
In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,Intermediate,,,9615.0,,,6012,CHEMBL621670,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5444,50588,A,N,,,
In vivo maximal concentration was calculated at 1 mg/kg in dog,Intermediate,,,9615.0,,,6013,CHEMBL621671,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5444,50588,A,N,,,
In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,Intermediate,,,9615.0,,,6014,CHEMBL622360,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5444,50588,A,N,,,
In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,Intermediate,,,9615.0,,,6015,CHEMBL622361,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5444,50588,A,N,,,
Cmax in dog plasma after oral dose (1 mg/kg),Intermediate,,,9615.0,,,6016,CHEMBL622362,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5130,50588,A,N,,1969.0,
Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Intermediate,,,9615.0,,,6017,CHEMBL622363,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3249,50588,A,N,,1969.0,
Maximal plasma concentration at a dose of 1 mg/kg,Intermediate,,,9615.0,,,6018,CHEMBL622364,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5473,50588,A,N,,1969.0,
Maximal plasma concentration at a dose of 1 mg/kg (oral),Intermediate,,,9615.0,,,6019,CHEMBL622365,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5474,50588,A,N,,1969.0,
Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Intermediate,,,9615.0,,,6020,CHEMBL622533,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4657,50588,A,N,,1969.0,
Maximum concentration of compound in dog was evaluated.,Intermediate,,,9615.0,,,6021,CHEMBL622534,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3031,50588,A,N,,,
Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,9615.0,,,6022,CHEMBL622535,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4527,50588,A,N,,,
Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,,9615.0,,,6023,CHEMBL876739,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4186,50588,A,N,,,
Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,9615.0,,,6024,CHEMBL622536,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5007,50588,A,N,,,
Maximum concentration obtained in dog plasma was determined,Intermediate,,,9615.0,,,6025,CHEMBL622537,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3132,50588,A,N,,1969.0,
Maximum concentration was determined,Intermediate,,,9615.0,,,6026,CHEMBL622538,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5006,50588,A,N,,,
Maximum concentration at the dose of 2 mg/kg in dog,Intermediate,,,9615.0,,,6027,CHEMBL627867,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4727,50588,A,N,,,
Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,9615.0,,,6028,CHEMBL627868,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1916,50588,A,N,,,
Maximum concentration was evaluated in dog plasma,Intermediate,,,9615.0,,,6029,CHEMBL627869,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1918,50588,A,N,,1969.0,
Maximum concentration was evaluated after 75 min after administration in dog,Intermediate,,,9615.0,,,6030,CHEMBL627870,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3045,50588,A,N,,,
Maximum plasma concentration determined in dog after oral administration of 17b,Intermediate,,,9615.0,,,6031,CHEMBL627871,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,9579,50588,A,N,,1969.0,
Maximum plasma concentration determined in dog after oral administration of 2b,Intermediate,,,9615.0,,,6032,CHEMBL627872,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,9579,50588,A,N,,1969.0,
Maximum plasma concentration in dog,Intermediate,,,9615.0,,,6033,CHEMBL627873,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,933,50588,A,N,,1969.0,
Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,,,9615.0,,,6034,CHEMBL627874,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,1969.0,
Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,,,9615.0,,,6035,CHEMBL627875,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,1969.0,
Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,,,9615.0,,,6036,CHEMBL627876,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,1969.0,
Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Intermediate,,,9615.0,,,6037,CHEMBL627877,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,1969.0,
Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,9615.0,,,6038,CHEMBL627878,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6348,50588,A,N,,1969.0,
Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Intermediate,,,9615.0,,,6039,CHEMBL627879,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16367,50588,A,N,,1969.0,
Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,9615.0,,,6040,CHEMBL875355,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1337,50588,A,N,,1969.0,
Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,9615.0,,,6041,CHEMBL627880,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1337,50588,A,N,,1969.0,
Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,,,9615.0,,,6042,CHEMBL627881,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5199,50588,A,N,,1969.0,
Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,9615.0,,,6043,CHEMBL627882,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17650,50588,A,N,,1969.0,
Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Intermediate,,,9615.0,,,6044,CHEMBL627883,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6679,50588,A,N,,1969.0,
Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Intermediate,,,9615.0,,,6045,CHEMBL628526,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5356,50588,A,N,,1969.0,
Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Intermediate,,,9615.0,,,6046,CHEMBL628527,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5356,50588,A,N,,1969.0,
Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,,,9615.0,,,6047,CHEMBL628528,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,1969.0,
Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Intermediate,,,9615.0,,,6048,CHEMBL628529,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,1969.0,
Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Intermediate,,,9615.0,,,6049,CHEMBL628530,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,1969.0,
Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Intermediate,,,9615.0,,,6050,CHEMBL625243,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,1969.0,
Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,9615.0,,,6051,CHEMBL625244,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3598,50588,A,N,,1969.0,
Maximum concentration by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,9615.0,,,6052,CHEMBL625245,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4368,50588,A,N,,,
Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,,,9615.0,,,6053,CHEMBL625246,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6265,50588,A,N,,,
Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,6054,CHEMBL625247,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,945.0,
Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,,10090.0,,,6055,CHEMBL625248,Urine,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,1088.0,
Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,,,10090.0,,,6056,CHEMBL625249,Urine,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,1088.0,
Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,,,10090.0,,,6057,CHEMBL625250,Urine,1,1,,BAO_0000218,In vivo,Mus musculus,7767,50594,A,N,,1088.0,
Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,Intermediate,,,10090.0,,,6058,CHEMBL625251,,1,1,,BAO_0000218,,Mus musculus,17811,50594,A,N,,,
Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,Intermediate,,,10090.0,,,6059,CHEMBL875356,,1,1,,BAO_0000218,,Mus musculus,17811,50594,A,N,,,
Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),Intermediate,,,10090.0,,,6060,CHEMBL625252,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,,,10090.0,,,6061,CHEMBL625253,Blood,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,178.0,
Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),Intermediate,,,10090.0,,,6062,CHEMBL625254,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),Intermediate,,,10090.0,,,6063,CHEMBL625255,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),Intermediate,,,10090.0,,,6064,CHEMBL625256,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,,,10090.0,,,6065,CHEMBL625257,Blood,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,178.0,
Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Intermediate,,,10090.0,,,6066,CHEMBL625258,Blood,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,178.0,
Compound was evaluated for washout rate in mice (Radiolabeled compound),Intermediate,,,10090.0,,,6067,CHEMBL625259,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
Compound was evaluated for washout rate in mice after radiolabeled ligand injected,Intermediate,,,10090.0,,,6068,CHEMBL625260,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,,10090.0,,,6069,CHEMBL625261,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,,10090.0,,,6070,CHEMBL625262,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,,10090.0,,,6071,CHEMBL622639,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,Intermediate,,,10090.0,,,6072,CHEMBL622640,,1,1,,BAO_0000218,,Mus musculus,17257,50594,A,N,,,
Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,Intermediate,,,10090.0,,,6073,CHEMBL622812,,1,1,,BAO_0000218,,Mus musculus,17257,50594,A,N,,,
Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,Intermediate,,,10090.0,,,6074,CHEMBL622813,,1,1,,BAO_0000218,,Mus musculus,17257,50594,A,N,,,
Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,Intermediate,,,10090.0,,,6075,CHEMBL622814,,1,1,,BAO_0000218,,Mus musculus,17257,50594,A,N,,,
Time at maximum activity in mice (Radiolabeled compound),Intermediate,,,10090.0,,,6076,CHEMBL622815,,1,1,,BAO_0000218,,Mus musculus,17827,50594,A,N,,,
Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,Intermediate,,,10090.0,,,6077,CHEMBL625342,,1,1,,BAO_0000218,,Mus musculus,3760,50594,A,N,,,
Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,Intermediate,,,10090.0,,,6078,CHEMBL625343,,1,1,,BAO_0000218,,Mus musculus,3760,50594,A,N,,,
Binding towards mouse plasma protein at 10 uM,Intermediate,,,10090.0,,,6079,CHEMBL877591,,1,1,,BAO_0000218,,Mus musculus,17409,50594,A,N,,,
Binding towards mouse plasma protein at 100 uM,Intermediate,,,10090.0,,,6080,CHEMBL625344,,1,1,,BAO_0000218,,Mus musculus,17409,50594,A,N,,,
Bioavailability was evaluated in mice after intravenous administration,Intermediate,,,10090.0,,,6081,CHEMBL625345,,1,1,,BAO_0000218,In vivo,Mus musculus,2675,50594,A,N,,,
Bioavailability was evaluated in mice after oral administration,Intermediate,,,10090.0,,,6082,CHEMBL625346,,1,1,,BAO_0000218,In vivo,Mus musculus,2675,50594,A,N,,,
Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,Intermediate,,,10090.0,,,6083,CHEMBL625347,,1,1,,BAO_0000218,In vivo,Mus musculus,3132,50594,A,N,,,
Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,Intermediate,,,10090.0,,,6084,CHEMBL625348,,1,1,,BAO_0000218,In vivo,Mus musculus,3132,50594,A,N,,,
Bioavailability at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,10090.0,,,6085,CHEMBL625349,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Oral bioavailability in mouse,Intermediate,,,10090.0,,,6086,CHEMBL625350,,1,1,,BAO_0000218,In vivo,Mus musculus,2862,50594,A,N,,,
Oral bioavailability after intravenous administration in mice at 24 uM/kg,Intermediate,,,10090.0,,,6087,CHEMBL882952,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,A,N,,,
Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6088,CHEMBL625351,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,955.0,
Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6089,CHEMBL625352,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,955.0,
Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6090,CHEMBL877592,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,955.0,
Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6091,CHEMBL625353,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,955.0,
Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6092,CHEMBL625354,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,955.0,
Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6093,CHEMBL626019,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,955.0,
Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6094,CHEMBL626020,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,948.0,
Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6095,CHEMBL626021,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,948.0,
Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6096,CHEMBL626022,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,948.0,
Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6097,CHEMBL626192,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,948.0,
Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),Intermediate,,646.0,9606.0,,,6098,CHEMBL626193,,1,1,,BAO_0000219,,Homo sapiens,1276,80682,F,N,A549,,
Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,Expert,,646.0,9606.0,,,6099,CHEMBL626194,,1,1,,BAO_0000219,,Homo sapiens,3498,80682,F,N,A549,,
Cytotoxicity against human lung carcinoma A-549 cell lines,Intermediate,,646.0,9606.0,,,6100,CHEMBL626195,,1,1,,BAO_0000219,,Homo sapiens,1169,80682,F,N,A549,,
In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,Intermediate,,646.0,9606.0,,,6101,CHEMBL626196,,1,1,,BAO_0000219,,Homo sapiens,4450,80682,F,N,A549,,
In vitro cytotoxicity against human lung carcinoma cell line A-549,Intermediate,,646.0,9606.0,,,6102,CHEMBL626197,,1,1,,BAO_0000219,,Homo sapiens,358,80682,F,N,A549,,
In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,Intermediate,,646.0,9606.0,,,6103,CHEMBL626198,,1,1,,BAO_0000219,,Homo sapiens,358,80682,F,N,A549,,
In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,Intermediate,,646.0,9606.0,,,6104,CHEMBL626199,,1,1,,BAO_0000219,,Homo sapiens,358,80682,F,N,A549,,
In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,Intermediate,,646.0,9606.0,,,6105,CHEMBL626200,,1,1,,BAO_0000219,,Homo sapiens,358,80682,F,N,A549,,
In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,Intermediate,,646.0,9606.0,,,6106,CHEMBL626201,,1,1,,BAO_0000219,,Homo sapiens,358,80682,F,N,A549,,
In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,Intermediate,,646.0,9606.0,,,6107,CHEMBL626202,,1,1,,BAO_0000219,,Homo sapiens,358,80682,F,N,A549,,
In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,Intermediate,,646.0,9606.0,,,6108,CHEMBL626203,,1,1,,BAO_0000219,,Homo sapiens,358,80682,F,N,A549,,
In vitro cytotoxicity against A-549 human lung cancer cells,Intermediate,,646.0,9606.0,,,6109,CHEMBL626204,,1,1,,BAO_0000219,,Homo sapiens,15167,80682,F,N,A549,,
In vitro cytotoxicity against human lung carcinoma (A-549) cell line,Intermediate,,646.0,9606.0,,,6110,CHEMBL624701,,1,1,,BAO_0000219,,Homo sapiens,4139,80682,F,N,A549,,
In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,Intermediate,,646.0,9606.0,,,6111,CHEMBL624702,,1,1,,BAO_0000219,,Homo sapiens,833,80682,F,N,A549,,
Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,,646.0,9606.0,,,6112,CHEMBL624703,,1,1,,BAO_0000219,,Homo sapiens,15718,80682,F,N,A549,,
Tested in vitro for cytotoxicity against A-549 lung cancer cells,Intermediate,,646.0,9606.0,,,6113,CHEMBL624704,,1,1,,BAO_0000219,,Homo sapiens,12373,80682,F,N,A549,,
The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,Intermediate,,646.0,9606.0,,,6114,CHEMBL624705,,1,1,,BAO_0000219,,Homo sapiens,637,80682,F,N,A549,,
Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,Expert,,646.0,9606.0,,,6115,CHEMBL624706,,1,1,,BAO_0000219,,Homo sapiens,14867,80682,F,N,A549,,
Antitumor cytotoxic activity against A-549 cell line was determined,Intermediate,,646.0,9606.0,,,6116,CHEMBL624707,,1,1,,BAO_0000219,,Homo sapiens,4461,80682,F,N,A549,,
"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",Intermediate,,646.0,9606.0,,,6117,CHEMBL624708,,1,1,,BAO_0000219,,Homo sapiens,5406,80682,F,N,A549,,
Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,,646.0,9606.0,,,6118,CHEMBL624709,,1,1,,BAO_0000219,,Homo sapiens,4457,80682,F,N,A549,,
Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,,646.0,9606.0,,,6119,CHEMBL884107,,1,1,,BAO_0000219,,Homo sapiens,1386,80682,F,N,A549,,
Antitumoral activity was assayed against A-549 cell line,Intermediate,,646.0,9606.0,,,6120,CHEMBL624710,,1,1,,BAO_0000219,,Homo sapiens,3265,80682,F,N,A549,,
Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,Intermediate,,646.0,9606.0,,,6121,CHEMBL624711,,1,1,,BAO_0000219,,Homo sapiens,2359,80682,F,N,A549,,
Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,,646.0,9606.0,,,6122,CHEMBL624712,,1,1,,BAO_0000219,,Homo sapiens,4457,80682,F,N,A549,,
In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,,646.0,9606.0,,,6123,CHEMBL624713,,1,1,,BAO_0000219,,Homo sapiens,12454,80682,F,N,A549,,
Compound was tested for inhibition of cell growth of A-549 cells,Intermediate,,646.0,9606.0,,,6124,CHEMBL624714,,1,1,,BAO_0000219,,Homo sapiens,1481,80682,F,N,A549,,
Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,Intermediate,,646.0,9606.0,,,6125,CHEMBL624715,,1,1,,BAO_0000219,,Homo sapiens,1750,80682,F,N,A549,,
Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,Intermediate,,646.0,9606.0,,,6126,CHEMBL624716,,1,1,,BAO_0000219,,Homo sapiens,5065,80682,F,N,A549,,
In vitro cytotoxicity against A549-human lung carcinoma cells.,Expert,,646.0,9606.0,,,6127,CHEMBL619505,,1,1,,BAO_0000219,,Homo sapiens,808,80682,F,N,A549,,
Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,Expert,,646.0,9606.0,,,6128,CHEMBL619506,,1,1,,BAO_0000219,,Homo sapiens,16364,80682,F,N,A549,,
Cytotoxic activity against A-549 cell lines.,Intermediate,,646.0,9606.0,,,6129,CHEMBL619507,,1,1,,BAO_0000219,,Homo sapiens,1847,80682,F,N,A549,,
Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,Expert,,646.0,9606.0,,,6130,CHEMBL619508,,1,1,,BAO_0000219,,Homo sapiens,1747,80682,F,N,A549,,
Cytotoxicity against human A549 non small cell lung cell lines,Intermediate,,646.0,9606.0,,,6131,CHEMBL619509,,1,1,,BAO_0000219,,Homo sapiens,1003,80682,F,N,A549,,
Inhibition of cell growth in (A-549) lung cell line,Expert,,646.0,9606.0,,,6132,CHEMBL619510,,1,1,,BAO_0000219,,Homo sapiens,15313,80682,F,N,A549,,
Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,Intermediate,,646.0,9606.0,,,6133,CHEMBL619511,,1,1,,BAO_0000219,,Homo sapiens,3122,80682,F,N,A549,,
In vitro antitumor activity against A-549 tumor cells.,Intermediate,,646.0,9606.0,,,6134,CHEMBL619512,,1,1,,BAO_0000219,,Homo sapiens,16049,80682,F,N,A549,,
In vitro antitumor effects against human A-549 cell lines.,Expert,,646.0,9606.0,,,6135,CHEMBL619513,,1,1,,BAO_0000219,,Homo sapiens,17134,80682,F,N,A549,,
In vitro cytotoxic activity of compound against A-549 cell line,Intermediate,,646.0,9606.0,,,6136,CHEMBL619514,,1,1,,BAO_0000219,,Homo sapiens,6406,80682,F,N,A549,,
In vitro cytotoxicity against human lung carcinoma A-549 cell line,Intermediate,,646.0,9606.0,,,6137,CHEMBL619515,,1,1,,BAO_0000219,,Homo sapiens,627,80682,F,N,A549,,
In vitro cytotoxicity against human non-small cell lung carcinoma A549,Intermediate,,646.0,9606.0,,,6138,CHEMBL619516,,1,1,,BAO_0000219,,Homo sapiens,12307,80682,F,N,A549,,
In vitro cytotoxicity against human A-549 cancer cell line was evaluated,Intermediate,,646.0,9606.0,,,6139,CHEMBL884005,,1,1,,BAO_0000219,,Homo sapiens,17861,80682,F,N,A549,,
In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,Expert,,646.0,9606.0,,,6140,CHEMBL619517,,1,1,,BAO_0000219,,Homo sapiens,6682,80682,F,N,A549,,
Inhibitory concentration of compound against A-549 cell line,Intermediate,,646.0,9606.0,,,6141,CHEMBL619518,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,Intermediate,,646.0,9606.0,,,6142,CHEMBL619519,,1,1,,BAO_0000219,,Homo sapiens,2454,80682,F,N,A549,,
cytotoxic activity against leukemia (A-549) cancer cell line,Intermediate,,646.0,9606.0,,,6143,CHEMBL876489,,1,1,,BAO_0000219,,Homo sapiens,14709,80682,F,N,A549,,
Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,,646.0,9606.0,,,6144,CHEMBL619520,,1,1,,BAO_0000219,,Homo sapiens,15718,80682,F,N,A549,,
Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,Intermediate,,646.0,9606.0,,,6145,CHEMBL619521,,1,1,,BAO_0000219,,Homo sapiens,15718,80682,F,N,A549,,
Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),Intermediate,,646.0,9606.0,,,6146,CHEMBL619522,,1,1,,BAO_0000219,,Homo sapiens,17130,80682,F,N,A549,,
Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),Intermediate,,646.0,9606.0,,,6147,CHEMBL619523,,1,1,,BAO_0000219,,Homo sapiens,17130,80682,F,N,A549,,
Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),Intermediate,,646.0,9606.0,,,6148,CHEMBL619524,,1,1,,BAO_0000219,,Homo sapiens,17130,80682,F,N,A549,,
Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),Intermediate,,646.0,9606.0,,,6149,CHEMBL619525,,1,1,,BAO_0000219,,Homo sapiens,17130,80682,F,N,A549,,
Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,Intermediate,,646.0,,,,6150,CHEMBL619526,,1,1,,BAO_0000219,,,6630,80682,F,N,A549,,
Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,Intermediate,,646.0,9606.0,,,6151,CHEMBL619527,,1,1,,BAO_0000219,,Homo sapiens,16726,80682,F,N,A549,,
Cytotoxicity against A549 cells; No cytotoxicity,Intermediate,,646.0,9606.0,,,6152,CHEMBL619528,,1,1,,BAO_0000219,,Homo sapiens,17846,80682,F,N,A549,,
Cytotoxicity against human lung carcinoma (A549) cell lines,Expert,,646.0,9606.0,,,6153,CHEMBL619529,,1,1,,BAO_0000219,,Homo sapiens,3415,80682,F,N,A549,,
Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,Expert,,646.0,9606.0,,,6154,CHEMBL619530,,1,1,,BAO_0000219,,Homo sapiens,3415,80682,F,N,A549,,
In vitro anticancer activity against human lung (A549) cell line,Intermediate,,646.0,9606.0,,,6155,CHEMBL876490,,1,1,,BAO_0000219,,Homo sapiens,5609,80682,F,N,A549,,
Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,Intermediate,,646.0,9606.0,,,6156,CHEMBL619531,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6157,CHEMBL619532,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6158,CHEMBL619533,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6159,CHEMBL619534,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6160,CHEMBL620164,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6161,CHEMBL620165,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Inhibition of A549 human lung tumor cell proliferation,Expert,,646.0,9606.0,,,6162,CHEMBL620166,,1,1,,BAO_0000219,,Homo sapiens,16295,80682,F,N,A549,,
"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",Intermediate,,646.0,9606.0,,,6163,CHEMBL620167,,1,1,,BAO_0000219,,Homo sapiens,16825,80682,F,N,A549,,
In vitro cytotoxicity against human tumor cell line A549,Expert,,646.0,9606.0,,,6164,CHEMBL620168,,1,1,,BAO_0000219,,Homo sapiens,3439,80682,F,N,A549,,
In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,Intermediate,,646.0,9606.0,,,6165,CHEMBL620338,,1,1,,BAO_0000219,,Homo sapiens,10870,80682,F,N,A549,,
Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,Intermediate,,646.0,9606.0,,,6166,CHEMBL620339,,1,1,,BAO_0000219,,Homo sapiens,4845,80682,F,N,A549,,
Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,Intermediate,,646.0,9606.0,,,6167,CHEMBL620340,,1,1,,BAO_0000219,,Homo sapiens,5822,80682,F,N,A549,,
Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,Intermediate,,646.0,9606.0,,,6168,CHEMBL620341,,1,1,,BAO_0000219,,Homo sapiens,5822,80682,F,N,A549,,
Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,Intermediate,,646.0,9606.0,,,6169,CHEMBL876491,,1,1,,BAO_0000219,,Homo sapiens,5822,80682,F,N,A549,,
% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,,646.0,9606.0,,,6170,CHEMBL620342,,1,1,,BAO_0000219,,Homo sapiens,16381,80682,F,N,A549,,
% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,,646.0,9606.0,,,6171,CHEMBL620343,,1,1,,BAO_0000219,,Homo sapiens,16381,80682,F,N,A549,,
% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,,646.0,9606.0,,,6172,CHEMBL620344,,1,1,,BAO_0000219,,Homo sapiens,16381,80682,F,N,A549,,
In vitro anticancer activity against human lung (A549) cell line,Intermediate,,646.0,9606.0,,,6173,CHEMBL620345,,1,1,,BAO_0000219,,Homo sapiens,5609,80682,F,N,A549,,
Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,Intermediate,,646.0,9606.0,,,6174,CHEMBL620346,,1,1,,BAO_0000219,,Homo sapiens,4644,80682,F,N,A549,,
Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,Intermediate,,646.0,9606.0,,,6175,CHEMBL620347,,1,1,,BAO_0000219,,Homo sapiens,4644,80682,F,N,A549,,
Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,Intermediate,,646.0,9606.0,,,6176,CHEMBL620348,,1,1,,BAO_0000219,,Homo sapiens,4644,80682,F,N,A549,,
Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,Intermediate,,646.0,9606.0,,,6177,CHEMBL620349,,1,1,,BAO_0000219,,Homo sapiens,4644,80682,F,N,A549,,
Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,Intermediate,,646.0,9606.0,,,6178,CHEMBL618667,,1,1,,BAO_0000219,,Homo sapiens,5822,80682,F,N,A549,,
Percentage inhibition of human lung carcinoma (A549) cell lines,Expert,,646.0,9606.0,,,6179,CHEMBL618668,,1,1,,BAO_0000219,,Homo sapiens,3415,80682,F,N,A549,,
Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,Intermediate,,646.0,9606.0,,,6180,CHEMBL876031,,1,1,,BAO_0000219,,Homo sapiens,16726,80682,F,N,A549,,
"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",Intermediate,,646.0,9606.0,,,6181,CHEMBL618759,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,,646.0,9606.0,,,6182,CHEMBL618760,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,,646.0,9606.0,,,6183,CHEMBL619000,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",Intermediate,,646.0,9606.0,,,6184,CHEMBL619001,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",Intermediate,,646.0,9606.0,,,6185,CHEMBL619002,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",Intermediate,,646.0,9606.0,,,6186,CHEMBL619003,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",Intermediate,,646.0,9606.0,,,6187,CHEMBL619597,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",Intermediate,,646.0,9606.0,,,6188,CHEMBL619598,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,Intermediate,,646.0,9606.0,,,6189,CHEMBL619599,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,Intermediate,,646.0,9606.0,,,6190,CHEMBL619600,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,,646.0,9606.0,,,6191,CHEMBL619601,,1,1,,BAO_0000219,,Homo sapiens,16726,80682,F,N,A549,,
Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6192,CHEMBL619602,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6193,CHEMBL619603,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6194,CHEMBL619604,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6195,CHEMBL619605,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,Intermediate,,,9615.0,,,6196,CHEMBL619606,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6084,50588,A,N,,,
Pharmacokinetic activity (Cmax) in dog,Intermediate,,,9615.0,,,6197,CHEMBL876032,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6084,50588,A,N,,,
Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,,9615.0,,,6198,CHEMBL619607,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4809,50588,A,N,,,
Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,Intermediate,,,9615.0,,,6199,CHEMBL619608,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5983,50588,A,N,,,
Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,Intermediate,,,9615.0,,,6200,CHEMBL619609,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6251,50588,A,N,,,
Cmax in dog plasma after 30mg/kg oral dose,Intermediate,,,9615.0,,,6201,CHEMBL619610,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5932,50588,A,N,,1969.0,
Tested for the peak blood level in dog,Intermediate,,,9615.0,,,6202,CHEMBL619611,Blood,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4273,50588,A,N,,178.0,
"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",Intermediate,,,9615.0,,,6203,CHEMBL619612,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5313,50588,A,N,,,
"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",Intermediate,,,9615.0,,,6204,CHEMBL619613,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5313,50588,A,N,,,
The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Intermediate,,,9615.0,,,6205,CHEMBL619614,Blood,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6221,50588,A,N,,178.0,
Concentration in the plasma after intravenous administration of 1 mg/kg in dog,Intermediate,,,9615.0,,,6206,CHEMBL619615,,1,1,,BAO_0000218,,Canis lupus familiaris,4709,50588,A,N,,,
Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,Intermediate,,,9615.0,,,6207,CHEMBL619616,,1,1,,BAO_0000218,,Canis lupus familiaris,167,50588,A,N,,,
Final plasma concentration in dogs after oral administration at 1 mg/kg,Intermediate,,,9615.0,,,6208,CHEMBL619617,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,6241,50588,A,N,,1969.0,
Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,Intermediate,,,9615.0,,,6209,CHEMBL619618,,1,1,,BAO_0000218,,Canis lupus familiaris,344,50588,A,N,,,
Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,Intermediate,,,9615.0,,,6210,CHEMBL876033,,1,1,,BAO_0000218,,Canis lupus familiaris,344,50588,A,N,,,
Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,Intermediate,,,9615.0,,,6211,CHEMBL619619,,1,1,,BAO_0000218,,Canis lupus familiaris,344,50588,A,N,,,
Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,Intermediate,,,9615.0,,,6212,CHEMBL619620,,1,1,,BAO_0000218,,Canis lupus familiaris,2189,50588,A,N,,,
Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Intermediate,,,9615.0,,,6213,CHEMBL619621,Urine,1,1,,BAO_0000218,,Canis lupus familiaris,2189,50588,A,N,,1088.0,
Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,,,9615.0,,,6214,CHEMBL619622,Urine,1,1,,BAO_0000218,,Canis lupus familiaris,2189,50588,A,N,,1088.0,
Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,,,9615.0,,,6215,CHEMBL618874,Urine,1,1,,BAO_0000218,,Canis lupus familiaris,2189,50588,A,N,,1088.0,
Absolute bioavailability was evaluated in dog,Intermediate,,,9615.0,,,6216,CHEMBL618875,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4257,50588,A,N,,,
Bioavailability after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,,9615.0,,,6217,CHEMBL618876,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6221,50588,A,N,,,
Bioavailability after peroral administration (1 mg/kg) was determined in dog,Intermediate,,,9615.0,,,6218,CHEMBL618877,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6215,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6219,CHEMBL618878,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17267,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6220,CHEMBL618879,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6621,50588,A,N,,,
Bioavailability after intravenous administration in dogs,Intermediate,,,9615.0,,,6221,CHEMBL618880,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3854,50588,A,N,,,
Bioavailability after peroral administration in dogs,Intermediate,,,9615.0,,,6222,CHEMBL618881,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3854,50588,A,N,,,
Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,,,9615.0,,,6223,CHEMBL618882,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5007,50588,A,N,,,
Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,Intermediate,,,9615.0,,,6224,CHEMBL624226,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4333,50588,A,N,,,
Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Intermediate,,,9615.0,,,6225,CHEMBL624227,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4333,50588,A,N,,1969.0,
Bioavailability,Intermediate,,,9615.0,,,6226,CHEMBL624228,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5006,50588,A,N,,,
Bioavailability,Intermediate,,,9615.0,,,6227,CHEMBL624229,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5199,50588,A,N,,,
Bioavailability by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,9615.0,,,6228,CHEMBL624230,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4368,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6229,CHEMBL624231,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3771,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6230,CHEMBL624232,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4953,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6231,CHEMBL625127,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5064,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6232,CHEMBL625128,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17657,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6233,CHEMBL621675,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17796,50588,A,N,,,
Bioavailability in dog (p.o.) at 2.0 mpk,Intermediate,,,9615.0,,,6234,CHEMBL621676,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17853,50588,A,N,,,
Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),Intermediate,,,9615.0,,,6235,CHEMBL621677,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4521,50588,A,N,,,
Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,9615.0,,,6236,CHEMBL621678,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4521,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6237,CHEMBL621679,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5006,50588,A,N,,,
Bioavailability was evaluated after oral administration in dog,Intermediate,,,9615.0,,,6238,CHEMBL621680,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16365,50588,A,N,,,
Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,9615.0,,,6239,CHEMBL621681,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1916,50588,A,N,,,
Bioavailability was evaluated in dog,Intermediate,,,9615.0,,,6240,CHEMBL876740,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1918,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6241,CHEMBL621682,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4239,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6242,CHEMBL621683,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6505,50588,A,N,,,
Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,,9615.0,,,6243,CHEMBL621684,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5334,50588,A,N,,,
Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,,,9615.0,,,6244,CHEMBL621685,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5334,50588,A,N,,,
Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,,9615.0,,,6245,CHEMBL621686,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4809,50588,A,N,,,
Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,9615.0,,,6246,CHEMBL621687,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6348,50588,A,N,,,
Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,Intermediate,,,9615.0,,,6247,CHEMBL621688,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6005,50588,A,N,,,
Bioavailability of compound in dog was determined after peroral administration,Intermediate,,,9615.0,,,6248,CHEMBL621689,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17804,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6249,CHEMBL621690,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3184,50588,A,N,,,
Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,,,9615.0,,,6250,CHEMBL621691,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1806,50588,A,N,,,
Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,,,9615.0,,,6251,CHEMBL875941,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1806,50588,A,N,,,
Compound was evaluated for oral bioavailability in dogs; 37-38 %,Intermediate,,,9615.0,,,6252,CHEMBL621692,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1806,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6253,CHEMBL621693,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4839,50588,A,N,,,
Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),Intermediate,,,9615.0,,,6254,CHEMBL621694,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5017,50588,A,N,,,
Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6255,CHEMBL621695,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,948.0,
Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6256,CHEMBL621696,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,948.0,
Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6257,CHEMBL621697,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2113.0,
Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6258,CHEMBL621698,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2113.0,
Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6259,CHEMBL623420,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2113.0,
Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6260,CHEMBL623421,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2113.0,
Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6261,CHEMBL623422,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2113.0,
Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6262,CHEMBL623423,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2113.0,
Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6263,CHEMBL623424,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2107.0,
Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6264,CHEMBL623425,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2107.0,
Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6265,CHEMBL623426,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2107.0,
Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6266,CHEMBL623427,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2107.0,
Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6267,CHEMBL623428,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2107.0,
Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6268,CHEMBL875947,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2107.0,
Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6269,CHEMBL623429,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2048.0,
Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6270,CHEMBL623430,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2048.0,
Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6271,CHEMBL622588,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2048.0,
Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6272,CHEMBL622589,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2048.0,
Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6273,CHEMBL622751,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2048.0,
Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,,10090.0,,,6274,CHEMBL622752,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,846,50594,A,N,,2048.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6275,CHEMBL622753,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6276,CHEMBL622647,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6277,CHEMBL875163,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6278,CHEMBL622648,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6279,CHEMBL622649,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6280,CHEMBL622650,Brain,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,955.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6281,CHEMBL622651,Brain,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,955.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6282,CHEMBL622652,Brain,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,955.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6283,CHEMBL622653,Brain,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,955.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6284,CHEMBL622654,Brain,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,955.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6285,CHEMBL622655,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6286,CHEMBL622656,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6287,CHEMBL622657,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6288,CHEMBL622658,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6289,CHEMBL622659,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6290,CHEMBL624630,Kidney,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2113.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6291,CHEMBL624631,Kidney,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2113.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6292,CHEMBL624632,Kidney,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2113.0,
Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,Intermediate,,646.0,9606.0,,,6293,CHEMBL624633,,1,1,,BAO_0000219,,Homo sapiens,17130,80682,F,N,A549,,
Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,Intermediate,,646.0,9606.0,,,6294,CHEMBL624634,,1,1,,BAO_0000219,,Homo sapiens,17130,80682,F,N,A549,,
Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),Intermediate,,646.0,9606.0,,,6295,CHEMBL624635,,1,1,,BAO_0000219,,Homo sapiens,17130,80682,F,N,A549,,
Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),Intermediate,,646.0,9606.0,,,6296,CHEMBL624636,,1,1,,BAO_0000219,,Homo sapiens,17130,80682,F,N,A549,,
Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,,646.0,9606.0,,,6297,CHEMBL857055,,1,1,,BAO_0000219,,Homo sapiens,3263,80682,F,N,A549,,
In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,Expert,,646.0,9606.0,,,6298,CHEMBL624637,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,Expert,,646.0,9606.0,,,6299,CHEMBL624638,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,Expert,,646.0,9606.0,,,6300,CHEMBL874366,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,Expert,,646.0,9606.0,,,6301,CHEMBL624639,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,Expert,,646.0,9606.0,,,6302,CHEMBL624640,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,Intermediate,,646.0,9606.0,,,6303,CHEMBL624641,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,Intermediate,,646.0,9606.0,,,6304,CHEMBL624642,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,Intermediate,,646.0,9606.0,,,6305,CHEMBL624643,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,Intermediate,,646.0,9606.0,,,6306,CHEMBL624644,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,Intermediate,,646.0,9606.0,,,6307,CHEMBL624645,,1,1,,BAO_0000219,,Homo sapiens,6663,80682,F,N,A549,,
The compound was evaluated for its cytotoxic potency against A-549 cell line,Intermediate,,646.0,9606.0,,,6308,CHEMBL619445,,1,1,,BAO_0000219,,Homo sapiens,3983,80682,F,N,A549,,
Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,Expert,,646.0,9606.0,,,6309,CHEMBL839886,,1,1,,BAO_0000219,,Homo sapiens,11141,80682,F,N,A549,,
Cytotoxic activity of compound against A-549 tumor cell line.,Intermediate,,646.0,9606.0,,,6310,CHEMBL619446,,1,1,,BAO_0000219,,Homo sapiens,5076,80682,F,N,A549,,
In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,Intermediate,,646.0,9606.0,,,6311,CHEMBL619447,,1,1,,BAO_0000219,,Homo sapiens,3311,80682,F,N,A549,,
In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,Intermediate,,646.0,9606.0,,,6312,CHEMBL619448,,1,1,,BAO_0000219,,Homo sapiens,3311,80682,F,N,A549,,
In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,Intermediate,,646.0,9606.0,,,6313,CHEMBL619449,,1,1,,BAO_0000219,,Homo sapiens,3311,80682,F,N,A549,,
Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,Intermediate,,646.0,9606.0,,,6314,CHEMBL619450,,1,1,,BAO_0000219,,Homo sapiens,5076,80682,F,N,A549,,
Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),Intermediate,,646.0,9606.0,,,6315,CHEMBL619451,,1,1,,BAO_0000219,,Homo sapiens,4150,80682,F,N,A549,,
In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,Expert,,646.0,9606.0,,,6316,CHEMBL619452,,1,1,,BAO_0000219,,Homo sapiens,2150,80682,F,N,A549,,
Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,Intermediate,,646.0,9606.0,,,6317,CHEMBL619453,,1,1,,BAO_0000219,,Homo sapiens,4644,80682,F,N,A549,,
Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,Intermediate,,646.0,9606.0,,,6318,CHEMBL874367,,1,1,,BAO_0000219,,Homo sapiens,263,80682,F,N,A549,,
Cytotoxic concentration against A-549 tumor cells.,Intermediate,,646.0,9606.0,,,6319,CHEMBL619454,,1,1,,BAO_0000219,,Homo sapiens,11333,80682,F,N,A549,,
Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,Intermediate,,646.0,9606.0,,,6320,CHEMBL619455,,1,1,,BAO_0000219,,Homo sapiens,11333,80682,F,N,A549,,
"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",Intermediate,,646.0,9606.0,,,6321,CHEMBL619456,,1,1,,BAO_0000219,,Homo sapiens,15895,80682,F,N,A549,,
Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,Expert,,,470.0,,,6322,CHEMBL619457,,1,1,,BAO_0000218,,Acinetobacter baumannii,16677,50191,F,N,,,
Activity against Acinetobacter calcoaceticus (AC54),Intermediate,,,471.0,,,6323,CHEMBL619458,,1,1,,BAO_0000218,,Acinetobacter calcoaceticus,10624,50192,F,N,,,
In vitro antifungal activity against Aspergillus flavus CM74,Expert,,,5059.0,,,6324,CHEMBL619459,,1,1,,BAO_0000218,,Aspergillus flavus,16717,50274,F,N,,,
In vitro antifungal activity against Aspergillus flavus CM74,Expert,,,5059.0,,,6325,CHEMBL619460,,1,1,,BAO_0000218,,Aspergillus flavus,16717,50274,F,N,,,
Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,Intermediate,,,746128.0,,,6326,CHEMBL619461,,1,1,,BAO_0000218,,Aspergillus fumigatus,5513,50416,F,N,,,
In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),Intermediate,,,746128.0,,,6327,CHEMBL619462,,1,1,,BAO_0000218,,Aspergillus fumigatus,15962,50416,F,N,,,
Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,,746128.0,,,6328,CHEMBL620388,,1,1,,BAO_0000218,,Aspergillus fumigatus,15962,50416,F,N,,,
Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,,746128.0,,,6329,CHEMBL620389,,1,1,,BAO_0000218,,Aspergillus fumigatus,15962,50416,F,N,,,
In vitro antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,,746128.0,,,6330,CHEMBL620390,,1,1,,BAO_0000218,,Aspergillus fumigatus,15962,50416,F,N,,,
In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,,,746128.0,,,6331,CHEMBL620391,,1,1,,BAO_0000218,,Aspergillus fumigatus,16717,50416,F,N,,,
In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,,,746128.0,,,6332,CHEMBL621073,,1,1,,BAO_0000218,,Aspergillus fumigatus,16717,50416,F,N,,,
Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,Intermediate,,,1655.0,,,6333,CHEMBL621074,,1,1,,BAO_0000218,,Actinomyces naeslundii,8117,50296,F,N,,,
Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,Intermediate,,,1656.0,,,6334,CHEMBL621075,,1,1,,BAO_0000218,,Actinomyces viscosus,8117,50366,F,N,,,
Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,,,6277.0,,,6335,CHEMBL619554,,1,1,,BAO_0000218,,Acanthocheilonema viteae,15472,50535,F,N,,,
Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,,,6277.0,,,6336,CHEMBL619555,,1,1,,BAO_0000218,,Acanthocheilonema viteae,15472,50535,F,N,,,
Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,Intermediate,,,714.0,,,6337,CHEMBL619556,,1,1,,BAO_0000218,,Aggregatibacter actinomycetemcomitans,16443,50169,F,N,,,
Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,Intermediate,,,714.0,,,6338,CHEMBL619557,,1,1,,BAO_0000218,,Aggregatibacter actinomycetemcomitans,16443,50169,F,N,,,
Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,Intermediate,,,714.0,,,6339,CHEMBL619558,,1,1,,BAO_0000218,,Aggregatibacter actinomycetemcomitans,16443,50169,F,N,,,
Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6340,CHEMBL619559,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6341,CHEMBL619560,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,,646.0,9606.0,,,6342,CHEMBL619561,,1,1,,BAO_0000219,,Homo sapiens,16381,80682,F,N,A549,,
% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,,646.0,9606.0,,,6343,CHEMBL619562,,1,1,,BAO_0000219,,Homo sapiens,16381,80682,F,N,A549,,
% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,,646.0,9606.0,,,6344,CHEMBL619563,,1,1,,BAO_0000219,,Homo sapiens,16381,80682,F,N,A549,,
GI values against A549 cells (lung cancer),Intermediate,,646.0,9606.0,,,6345,CHEMBL857457,,1,1,,BAO_0000219,,Homo sapiens,16381,80682,F,N,A549,,
Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,Intermediate,,646.0,9606.0,,,6346,CHEMBL619564,,1,1,,BAO_0000219,,Homo sapiens,17206,80682,F,N,A549,,
Inhibitory activity against A549 human adenocarcinoma,Intermediate,,646.0,9606.0,,,6347,CHEMBL619565,,1,1,,BAO_0000219,,Homo sapiens,16325,80682,F,N,A549,,
Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,Intermediate,,646.0,9606.0,,,6348,CHEMBL619566,,1,1,,BAO_0000218,,Homo sapiens,10708,80682,F,N,A549,,
Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,Intermediate,,646.0,9606.0,,,6349,CHEMBL619567,,1,1,,BAO_0000218,,Homo sapiens,10708,80682,F,N,A549,,
Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,,646.0,9606.0,,,6350,CHEMBL619568,,1,1,,BAO_0000219,,Homo sapiens,17376,80682,F,N,A549,,
Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,Intermediate,,646.0,9606.0,,,6351,CHEMBL619569,,1,1,,BAO_0000219,,Homo sapiens,17376,80682,F,N,A549,,
Cytotoxicity against human A549 lung cells,Intermediate,,646.0,9606.0,,,6352,CHEMBL619570,,1,1,,BAO_0000219,,Homo sapiens,17488,80682,F,N,A549,,
In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,Intermediate,,646.0,9606.0,,,6353,CHEMBL619571,,1,1,,BAO_0000218,,Homo sapiens,17404,80682,F,N,A549,,
Growth inhibition of A549 (human lung carcinoma) cell line.,Expert,,646.0,9606.0,,,6354,CHEMBL619572,,1,1,,BAO_0000219,,Homo sapiens,10958,80682,F,N,A549,,
Effective dose required for inhibitory activity against A549 human tumor cell line.,Expert,,646.0,9606.0,,,6355,CHEMBL619573,,1,1,,BAO_0000219,,Homo sapiens,17099,80682,F,N,A549,,
Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,Intermediate,,646.0,9606.0,,,6356,CHEMBL619574,,1,1,,BAO_0000219,,Homo sapiens,17099,80682,F,N,A549,,
Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,Intermediate,,646.0,9606.0,,,6357,CHEMBL619575,,1,1,,BAO_0000219,,Homo sapiens,4096,80682,F,N,A549,,
Cytotoxicity evaluated against A549 tumor cell lines; significant activity,Expert,,646.0,9606.0,,,6358,CHEMBL619576,,1,1,,BAO_0000219,,Homo sapiens,4096,80682,F,N,A549,,
Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,Intermediate,,646.0,9606.0,,,6359,CHEMBL619577,,1,1,,BAO_0000219,,Homo sapiens,4096,80682,F,N,A549,,
In vitro inhibitory activity against A549 tumor cell culture,Intermediate,,646.0,9606.0,,,6360,CHEMBL619578,,1,1,,BAO_0000219,,Homo sapiens,2525,80682,F,N,A549,,
In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,Intermediate,,646.0,9606.0,,,6361,CHEMBL884009,,1,1,,BAO_0000219,,Homo sapiens,2525,80682,F,N,A549,,
Activity against human lung cancer with mutated beta-tubulin (A549-T2415),Intermediate,,646.0,9606.0,,,6362,CHEMBL619579,,1,1,,BAO_0000219,,Homo sapiens,5302,80682,F,N,A549,,
Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,Intermediate,,646.0,9606.0,,,6363,CHEMBL619580,,1,1,,BAO_0000219,,Homo sapiens,16325,80682,F,N,A549,,
Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,Intermediate,,646.0,9606.0,,,6364,CHEMBL619581,,1,1,,BAO_0000219,,Homo sapiens,16939,80682,F,N,A549,,
In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,Intermediate,,646.0,9606.0,,,6365,CHEMBL619582,,1,1,,BAO_0000219,,Homo sapiens,17229,80682,F,N,A549,,
Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,Intermediate,,646.0,9606.0,,,6366,CHEMBL619583,,1,1,,BAO_0000219,,Homo sapiens,17380,80682,F,N,A549,,
Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,Intermediate,,646.0,9606.0,,,6367,CHEMBL876502,,1,1,,BAO_0000219,,Homo sapiens,17380,80682,F,N,A549,,
In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,Intermediate,,646.0,9606.0,,,6368,CHEMBL619584,,1,1,,BAO_0000219,,Homo sapiens,1903,80682,F,N,A549,,
In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,,646.0,9606.0,,,6369,CHEMBL619585,,1,1,,BAO_0000219,,Homo sapiens,3838,80682,F,N,A549,,
Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,,646.0,9606.0,,,6370,CHEMBL619586,,1,1,,BAO_0000219,,Homo sapiens,14696,80682,F,N,A549,,
In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,,646.0,9606.0,,,6371,CHEMBL619587,,1,1,,BAO_0000219,,Homo sapiens,3838,80682,F,N,A549,,
Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,Intermediate,,646.0,9606.0,,,6372,CHEMBL619588,,1,1,,BAO_0000219,,Homo sapiens,1522,80682,F,N,A549,,
Tested in vitro for cytotoxicity in A549/ATCC cell lines,Intermediate,,646.0,9606.0,,,6373,CHEMBL619589,,1,1,,BAO_0000219,,Homo sapiens,12400,80682,F,N,A549,,
inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,,646.0,9606.0,,,6374,CHEMBL619590,,1,1,,BAO_0000219,,Homo sapiens,14696,80682,F,N,A549,,
Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),Intermediate,,646.0,9606.0,,,6375,CHEMBL619591,,1,1,,BAO_0000219,,Homo sapiens,14769,80682,F,N,A549,,
Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,Intermediate,,646.0,9606.0,,,6376,CHEMBL619592,,1,1,,BAO_0000219,,Homo sapiens,14696,80682,F,N,A549,,
Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,Intermediate,,646.0,9606.0,,,6377,CHEMBL619593,,1,1,,BAO_0000219,,Homo sapiens,1888,80682,F,N,A549,,
Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,Intermediate,,646.0,9606.0,,,6378,CHEMBL620217,,1,1,,BAO_0000219,,Homo sapiens,12016,80682,F,N,A549,,
Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,Intermediate,,646.0,9606.0,,,6379,CHEMBL620218,,1,1,,BAO_0000219,,Homo sapiens,6058,80682,F,N,A549,,
Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,Intermediate,,646.0,9606.0,,,6380,CHEMBL620219,,1,1,,BAO_0000219,,Homo sapiens,17708,80682,F,N,A549,,
Antitumor activity against A549/ATCC cell line,Intermediate,,646.0,9606.0,,,6381,CHEMBL620220,,1,1,,BAO_0000219,,Homo sapiens,12301,80682,F,N,A549,,
Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,Intermediate,,646.0,9606.0,,,6382,CHEMBL625141,,1,1,,BAO_0000219,,Homo sapiens,11970,80682,F,N,A549,,
In vitro cytotoxicity against A549/ATCC cell line.,Expert,,646.0,9606.0,,,6383,CHEMBL625142,,1,1,,BAO_0000219,,Homo sapiens,11818,80682,F,N,A549,,
Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,Intermediate,,646.0,9606.0,,,6384,CHEMBL625143,,1,1,,BAO_0000219,,Homo sapiens,12400,80682,F,N,A549,,
In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,Intermediate,,646.0,9606.0,,,6385,CHEMBL625144,,1,1,,BAO_0000219,,Homo sapiens,3381,80682,F,N,A549,,
Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,Intermediate,,646.0,9606.0,,,6386,CHEMBL622474,,1,1,,BAO_0000219,,Homo sapiens,17376,80682,F,N,A549,,
Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,,646.0,9606.0,,,6387,CHEMBL884104,,1,1,,BAO_0000219,,Homo sapiens,10708,80682,F,N,A549,,
Cytotoxicity was evaluated against A649 human mammary carcinoma cells,Autocuration,,,9606.0,,,6388,CHEMBL622475,,0,1,,BAO_0000219,,Homo sapiens,2964,22226,F,U,,,
Compound was tested for oral bioavailability in dogs,Intermediate,,,9615.0,,,6389,CHEMBL622476,,0,1,,BAO_0000218,In vivo,Canis lupus familiaris,5005,22224,A,U,,,
Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,Intermediate,,,9615.0,,,6390,CHEMBL875831,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6229,50588,A,N,,,
Compound was tested for orally bioavailable in dogs with a half life of 1.2h,Intermediate,,,9615.0,,,6391,CHEMBL622477,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6229,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6392,CHEMBL622478,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5374,50588,A,N,,,
Compound was tested for the oral bioavailability in dog; No availability,Intermediate,,,9615.0,,,6393,CHEMBL623172,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5374,50588,A,N,,,
Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,,9615.0,,,6394,CHEMBL623173,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6265,50588,A,N,,,
Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,,,9615.0,,,6395,CHEMBL623174,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5654,50588,A,N,,,
Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,,,9615.0,,,6396,CHEMBL623175,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5654,50588,A,N,,,
Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),Intermediate,,,9615.0,,,6397,CHEMBL623340,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16456,50588,A,N,,,
Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,,9615.0,,,6398,CHEMBL623341,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5302,50588,A,N,,,
Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),Intermediate,,,9615.0,,,6399,CHEMBL623342,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3624,50588,A,N,,,
Oral bioavailability of active FTIs in dogs,Intermediate,,,9615.0,,,6400,CHEMBL623343,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,,,9615.0,,,6401,CHEMBL623344,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5802,50588,A,N,,,
Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,9615.0,,,6402,CHEMBL623345,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3598,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6403,CHEMBL875832,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6404,CHEMBL623346,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6762,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6405,CHEMBL623347,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6821,50588,A,N,,,
Oral bioavailability of compound was determined in dog; Not tested,Intermediate,,,9615.0,,,6406,CHEMBL623348,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6821,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6407,CHEMBL623349,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5210,50588,A,N,,,
Oral bioavailability (10 mg/kg) was determined in dog,Intermediate,,,9615.0,,,6408,CHEMBL623350,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,,
Oral bioavailability,Intermediate,,,9615.0,,,6409,CHEMBL623351,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,761,50588,A,N,,,
Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),Intermediate,,,9615.0,,,6410,CHEMBL623352,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,761,50588,A,N,,,
Oral bioavailability administered in solution in rats,Intermediate,,,9615.0,,,6411,CHEMBL623353,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,761,50588,A,N,,,
Oral bioavailability after 30 mg/kg po dose in Dogs,Intermediate,,,9615.0,,,6412,CHEMBL875833,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Oral bioavailability at a dose of 1 mg/kg in dogs,Intermediate,,,9615.0,,,6413,CHEMBL623354,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5474,50588,A,N,,,
Oral bioavailability in dog (dose 1 mg/kg p.o.),Intermediate,,,9615.0,,,6414,CHEMBL623355,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,,
Oral bioavailability in Dog; ND = not determined,Intermediate,,,9615.0,,,6415,CHEMBL623356,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6416,CHEMBL623357,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3352,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6417,CHEMBL623358,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6168,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6418,CHEMBL623359,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5988,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6419,CHEMBL623360,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4942,50588,A,N,,,
Oral bioavailability in dogs; No data,Intermediate,,,9615.0,,,6420,CHEMBL623361,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4942,50588,A,N,,,
Oral bioavailability measured in dogs,Intermediate,,,9615.0,,,6421,CHEMBL623362,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,14541,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6422,CHEMBL623363,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4449,50588,A,N,,,
Oral bioavailability was calculated in dog,Intermediate,,,9615.0,,,6423,CHEMBL623364,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6057,50588,A,N,,,
Oral bioavailability after 0.3 mg/kg po administration in dog,Intermediate,,,9615.0,,,6424,CHEMBL875834,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5600,50588,A,N,,,
Oral bioavailability in dog (i.v. dosing),Intermediate,,,9615.0,,,6425,CHEMBL623365,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5542,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6426,CHEMBL623366,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5542,50588,A,N,,,
Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,Intermediate,,,9615.0,,,6427,CHEMBL623367,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5546,50588,A,N,,,
Oral bioavailability in Beagle dogs,Intermediate,,,9615.0,,,6428,CHEMBL623368,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4514,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6429,CHEMBL623369,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3624,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6430,CHEMBL623370,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3854,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6431,CHEMBL623371,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5836,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6432,CHEMBL623372,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5940,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6433,CHEMBL621351,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6168,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6434,CHEMBL621352,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6435,CHEMBL621353,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6251,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6436,CHEMBL621354,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6448,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6437,CHEMBL621355,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6647,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6438,CHEMBL621356,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5940,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6439,CHEMBL621357,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,933,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6440,CHEMBL621358,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5210,50588,A,N,,,
Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),Intermediate,,,9615.0,,,6441,CHEMBL621359,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6642,50588,A,N,,,
Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,,,9615.0,,,6442,CHEMBL621360,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6641,50588,A,N,,,
Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,,,9615.0,,,6443,CHEMBL621361,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6642,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6444,CHEMBL621362,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5472,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6445,CHEMBL621363,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5985,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6446,CHEMBL621364,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,15660,50588,A,N,,,
Oral bioavailability in dog (dose 0.2 mg/kg i.v.),Intermediate,,,9615.0,,,6447,CHEMBL621166,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5530,50588,A,N,,,
Oral bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,9615.0,,,6448,CHEMBL621167,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5530,50588,A,N,,,
Oral bioavailability (F) in dogs,Intermediate,,,9615.0,,,6449,CHEMBL621168,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6305,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6450,CHEMBL621169,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5210,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6451,CHEMBL875950,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5238,50588,A,N,,,
Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,9615.0,,,6452,CHEMBL621170,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Oral bioavailability after peroral administration at 5 mpk in Dog,Intermediate,,,9615.0,,,6453,CHEMBL621171,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,,9615.0,,,6454,CHEMBL621172,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,9615.0,,,6455,CHEMBL621173,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6084,50588,A,N,,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6456,CHEMBL621174,Kidney,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2113.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6457,CHEMBL621175,Kidney,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2113.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6458,CHEMBL621176,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6459,CHEMBL621177,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6460,CHEMBL621178,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6461,CHEMBL621179,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6462,CHEMBL621180,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6463,CHEMBL875951,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6464,CHEMBL621181,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6465,CHEMBL621182,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6466,CHEMBL621183,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6467,CHEMBL621184,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6468,CHEMBL621185,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6469,CHEMBL621186,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6470,CHEMBL621187,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6471,CHEMBL621188,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6472,CHEMBL621189,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6473,CHEMBL621190,Spleen,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2106.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6474,CHEMBL618520,Spleen,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2106.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6475,CHEMBL621739,Spleen,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2106.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6476,CHEMBL621740,Spleen,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2106.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6477,CHEMBL621741,Spleen,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2106.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6478,CHEMBL621742,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6479,CHEMBL621743,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6480,CHEMBL621744,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6481,CHEMBL621745,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6482,CHEMBL621746,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6483,CHEMBL621747,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6484,CHEMBL621748,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6485,CHEMBL621749,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6486,CHEMBL621750,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6487,CHEMBL621751,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6488,CHEMBL621752,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6489,CHEMBL621753,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6490,CHEMBL875955,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6491,CHEMBL621754,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6492,CHEMBL621755,Heart,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,948.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6493,CHEMBL621756,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6494,CHEMBL624199,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6495,CHEMBL624200,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6496,CHEMBL624375,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6497,CHEMBL624376,Liver,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2107.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6498,CHEMBL624377,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6499,CHEMBL624378,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,107673.0,,,6500,CHEMBL857901,,1,1,,BAO_0000218,,aeinetobacter anitrotap,12269,50067,F,N,,,
Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,107673.0,,,6501,CHEMBL875274,,1,1,,BAO_0000218,,Acinetobacter calcoaceticus subsp. anitratus,12269,50067,F,N,,,
Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,107673.0,,,6502,CHEMBL624379,,1,1,,BAO_0000218,,Acinetobacter calcoaceticus subsp. anitratus,12269,50067,F,N,,,
Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,,107673.0,,,6503,CHEMBL624380,,1,1,,BAO_0000218,,aeinetobacter anitrotap,12269,50067,F,N,,,
Activity against Acinetobacter calcoaceticus (AC54),Intermediate,,,471.0,,,6504,CHEMBL624381,,1,1,,BAO_0000218,,Acinetobacter calcoaceticus,10624,50192,F,N,,,
Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,Intermediate,,,28377.0,,,6505,CHEMBL624382,,1,1,,BAO_0000218,,Anolis carolinensis,17216,50714,F,N,,,
Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,Intermediate,,,28377.0,,,6506,CHEMBL624383,,1,1,,BAO_0000218,,Anolis carolinensis,17216,50714,F,N,,,
Chlorohexidine coefficient for Actinomyces naeslundii 631,Intermediate,,,1655.0,,,6507,CHEMBL624384,,1,1,,BAO_0000218,,Actinomyces naeslundii,9560,50296,F,N,,,
Chlorohexidine coefficient for Actinomyces naeslundii B74,Intermediate,,,1655.0,,,6508,CHEMBL624385,,1,1,,BAO_0000218,,Actinomyces naeslundii,9560,50296,F,N,,,
Chlorohexidine coefficient for Actinomyces naeslundii N/3,Intermediate,,,1655.0,,,6509,CHEMBL624386,,1,1,,BAO_0000218,,Actinomyces naeslundii,9560,50296,F,N,,,
Chlorohexidine coefficient for Actinomyces naeslundii N/9,Intermediate,,,1655.0,,,6510,CHEMBL624387,,1,1,,BAO_0000218,,Actinomyces naeslundii,9560,50296,F,N,,,
Plaque bactericidal index against Actinomyces naeslundii 631,Intermediate,,,1655.0,,,6511,CHEMBL624388,,1,1,,BAO_0000218,,Actinomyces naeslundii,9560,50296,F,N,,,
Plaque bactericidal index against Actinomyces naeslundii N/9,Intermediate,,,1655.0,,,6512,CHEMBL624389,,1,1,,BAO_0000218,,Actinomyces naeslundii,9560,50296,F,N,,,
Plaque bactericidal index against Actinomyces naeslundii B74,Intermediate,,,1655.0,,,6513,CHEMBL624390,,1,1,,BAO_0000218,,Actinomyces naeslundii,9560,50296,F,N,,,
Plaque bactericidal index against Actinomyces naeslundii N/3,Intermediate,,,1655.0,,,6514,CHEMBL875275,,1,1,,BAO_0000218,,Actinomyces naeslundii,9560,50296,F,N,,,
Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,Intermediate,,,85549.0,,,6515,CHEMBL624391,,1,1,,BAO_0000218,,Artemia salina,114,50056,F,N,,,
"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",Intermediate,,,85549.0,,,6516,CHEMBL623636,,1,1,,BAO_0000218,,Artemia salina,114,50056,F,N,,,
Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,,,6253.0,,,6517,CHEMBL623637,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,,,6253.0,,,6518,CHEMBL623638,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,,,6253.0,,,6519,CHEMBL623639,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,,,6253.0,,,6520,CHEMBL623640,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,,,6253.0,,,6521,CHEMBL623641,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,Intermediate,,,6253.0,,,6522,CHEMBL623642,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,,,6253.0,,,6523,CHEMBL623643,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,,,6253.0,,,6524,CHEMBL623644,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,,,6253.0,,,6525,CHEMBL623645,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,,,6253.0,,,6526,CHEMBL623646,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,,,6253.0,,,6527,CHEMBL623647,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,Intermediate,,,6253.0,,,6528,CHEMBL623648,,1,1,,BAO_0000218,,Ascaris suum,10841,50532,F,N,,,
Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,,,1656.0,,,6529,CHEMBL623649,,1,1,,BAO_0000218,,Actinomyces viscosus,8117,50366,F,N,,,
Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,,,1656.0,,,6530,CHEMBL623650,,1,1,,BAO_0000218,,Actinomyces viscosus,8117,50366,F,N,,,
Chlorohexidine coefficient for Actinomyces viscosus 8A06,Intermediate,,,1656.0,,,6531,CHEMBL623651,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
Chlorohexidine coefficient for Actinomyces viscosus M-100,Expert,,,1656.0,,,6532,CHEMBL623652,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
Chlorohexidine coefficient for Actinomyces viscosus M-626,Intermediate,,,1656.0,,,6533,CHEMBL623653,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
Chlorohexidine coefficient for Actinomyces viscosus T14V,Intermediate,,,1656.0,,,6534,CHEMBL623654,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
Plaque bactericidal index against Actinomyces viscosus 8A06,Intermediate,,,1656.0,,,6535,CHEMBL623655,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
Plaque bactericidal index against Actinomyces viscosus M-100,Intermediate,,,1656.0,,,6536,CHEMBL623656,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,Expert,,,1656.0,,,6537,CHEMBL623657,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,,,1656.0,,,6538,CHEMBL623658,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,,,1656.0,,,6539,CHEMBL623659,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
Plaque bactericidal index against Actinomyces viscosus 626,Intermediate,,,1656.0,,,6540,CHEMBL623660,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
Plaque bactericidal index against Actinomyces viscosus T14V,Intermediate,,,1656.0,,,6541,CHEMBL623661,,1,1,,BAO_0000218,,Actinomyces viscosus,9560,50366,F,N,,,
anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,Intermediate,,,6277.0,,,6542,CHEMBL875281,,1,1,,BAO_0000218,,Acanthocheilonema viteae,10986,50535,F,N,,,
anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,Intermediate,,,6277.0,,,6543,CHEMBL623662,,1,1,,BAO_0000218,,Acanthocheilonema viteae,10986,50535,F,N,,,
anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,Intermediate,,,6277.0,,,6544,CHEMBL623663,,1,1,,BAO_0000218,,Acanthocheilonema viteae,10986,50535,F,N,,,
anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,Intermediate,,,6277.0,,,6545,CHEMBL623664,,1,1,,BAO_0000218,,Acanthocheilonema viteae,10986,50535,F,N,,,
anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,Intermediate,,,6277.0,,,6546,CHEMBL623665,,1,1,,BAO_0000218,,Acanthocheilonema viteae,10986,50535,F,N,,,
Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,Intermediate,,165.0,9606.0,,,6547,CHEMBL621856,,1,1,,BAO_0000219,,Homo sapiens,10708,80023,F,N,A673,,
Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,,645.0,9606.0,,,6548,CHEMBL620432,,1,1,,BAO_0000219,,Homo sapiens,10708,80661,F,N,A704,,
Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,Autocuration,,,10116.0,,,6549,CHEMBL620433,,0,1,,BAO_0000219,,Rattus norvegicus,416,22226,F,U,,,
Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,,625.0,10090.0,,,6550,CHEMBL620434,,1,1,,BAO_0000219,,Mus musculus,14354,80024,F,N,A9,,
Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,,625.0,10090.0,,,6551,CHEMBL620435,,1,1,,BAO_0000219,,Mus musculus,14354,80024,F,N,A9,,
Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,Intermediate,,625.0,9606.0,,,6552,CHEMBL620436,,1,1,,BAO_0000219,,Homo sapiens,5116,80024,F,N,A9,,
Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,Intermediate,,625.0,9606.0,,,6553,CHEMBL876597,,1,1,,BAO_0000219,,Homo sapiens,5116,80024,F,N,A9,,
Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,Expert,,874.0,9606.0,,,6554,CHEMBL620437,,1,1,,BAO_0000219,,Homo sapiens,15694,81037,F,N,Human ovarian carcinoma cell line,,
"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",Expert,,625.0,10090.0,,,6555,CHEMBL620438,,1,1,,BAO_0000219,,Mus musculus,13038,80024,F,N,A9,,
Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,Expert,,625.0,10090.0,,,6556,CHEMBL620439,,1,1,,BAO_0000219,,Mus musculus,13038,80024,F,N,A9,,
Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,Expert,,625.0,10090.0,,,6557,CHEMBL619657,,1,1,,BAO_0000219,,Mus musculus,10923,80024,F,N,A9,,
The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,Intermediate,,625.0,10090.0,,,6558,CHEMBL619658,,1,1,,BAO_0000219,,Mus musculus,10923,80024,F,N,A9,,
The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,Intermediate,,625.0,10090.0,,,6559,CHEMBL619659,,1,1,,BAO_0000219,,Mus musculus,10923,80024,F,N,A9,,
"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",Expert,,,,,,6560,CHEMBL619660,,8,1,,BAO_0000019,,,10923,10649,F,H,,,
The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,Intermediate,,625.0,10090.0,,,6561,CHEMBL619661,,1,1,,BAO_0000219,,Mus musculus,10923,80024,F,N,A9,,
The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,Intermediate,,625.0,10090.0,,,6562,CHEMBL619662,,1,1,,BAO_0000219,,Mus musculus,10923,80024,F,N,A9,,
Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,Intermediate,,975.0,10029.0,,,6563,CHEMBL619663,,1,1,,BAO_0000219,,Cricetulus griseus,8158,80663,F,N,AA6,,
Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,Autocuration,,,9606.0,,,6564,CHEMBL619664,,0,1,,BAO_0000219,,Homo sapiens,15494,22226,F,U,,,
"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",Autocuration,,,9606.0,,,6565,CHEMBL619665,,0,1,,BAO_0000219,,Homo sapiens,15494,22226,F,U,,,
Anti -HIV activity was measured against AA5/HIV-1(IIIB),Intermediate,,974.0,9606.0,,,6566,CHEMBL883244,,1,1,,BAO_0000219,,Homo sapiens,12348,80662,F,N,AA5,,
Cytotoxicity was measured against AA5/HIV-1(IIIB),Intermediate,,974.0,9606.0,,,6567,CHEMBL884011,,1,1,,BAO_0000219,,Homo sapiens,12348,80662,F,N,AA5,,
Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,Intermediate,,974.0,9606.0,,,6568,CHEMBL619666,,1,1,,BAO_0000219,,Homo sapiens,2726,80662,F,N,AA5,,
Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,Intermediate,,379.0,9606.0,,,6569,CHEMBL619667,,1,1,,BAO_0000219,,Homo sapiens,2726,80566,F,N,U-937,,
Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,Intermediate,,274.0,10029.0,,,6570,CHEMBL619668,,1,1,,BAO_0000219,,Cricetulus griseus,10747,80578,F,N,UV4,,
"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Expert,,185.0,10029.0,,,6571,CHEMBL619669,,1,1,,BAO_0000219,,Cricetulus griseus,11005,80089,F,N,CHO-AA8,,
Average intracellular compound concentration when the hypoxic SER=1.6,Intermediate,,185.0,10029.0,,,6572,CHEMBL876608,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,F,N,CHO-AA8,,
Average intracellular compound concentration when the hypoxic SER=1.6.,Intermediate,,185.0,10029.0,,,6573,CHEMBL619670,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,F,N,CHO-AA8,,
Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,Intermediate,,185.0,10029.0,,,6574,CHEMBL619671,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,F,N,CHO-AA8,,
Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,Intermediate,,185.0,10029.0,,,6575,CHEMBL619672,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,F,N,CHO-AA8,,
Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,Intermediate,,185.0,10029.0,,,6576,CHEMBL619673,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,F,N,CHO-AA8,,
"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",Intermediate,,185.0,10029.0,,,6577,CHEMBL619674,,1,1,,BAO_0000219,,Cricetulus griseus,13436,80089,F,N,CHO-AA8,,
"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",Intermediate,,185.0,10029.0,,,6578,CHEMBL619675,,1,1,,BAO_0000219,,Cricetulus griseus,13435,80089,F,N,CHO-AA8,,
Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,Intermediate,,185.0,10029.0,,,6579,CHEMBL619676,,1,1,,BAO_0000219,,Cricetulus griseus,13302,80089,F,N,CHO-AA8,,
Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,,185.0,10029.0,,,6580,CHEMBL619677,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,F,N,CHO-AA8,,
Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,,185.0,10029.0,,,6581,CHEMBL619678,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,A,N,CHO-AA8,,
Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,Intermediate,,185.0,10029.0,,,6582,CHEMBL619679,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,A,N,CHO-AA8,,
Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,Expert,,185.0,10029.0,,,6583,CHEMBL619680,,1,1,,BAO_0000219,,Cricetulus griseus,12878,80089,A,N,CHO-AA8,,
Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,Intermediate,,185.0,10029.0,,,6584,CHEMBL621457,,1,1,,BAO_0000219,,Cricetulus griseus,12878,80089,A,N,CHO-AA8,,
Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,Expert,,185.0,10029.0,,,6585,CHEMBL876609,,1,1,,BAO_0000219,,Cricetulus griseus,14367,80089,F,N,CHO-AA8,,
Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,Intermediate,,185.0,10029.0,,,6586,CHEMBL621458,,1,1,,BAO_0000219,,Cricetulus griseus,14367,80089,F,N,CHO-AA8,,
Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,Expert,,185.0,36483.0,,,6587,CHEMBL621459,,1,1,,BAO_0000219,,hampster,12398,80089,F,N,CHO-AA8,,
Aerobic growth inhibition in Chinese hamster cell line AA8,Expert,,185.0,10029.0,,,6588,CHEMBL621460,,1,1,,BAO_0000219,,Cricetulus griseus,12878,80089,F,N,CHO-AA8,,
Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,Expert,,185.0,10029.0,,,6589,CHEMBL621461,,1,1,,BAO_0000219,,Cricetulus griseus,13820,80089,F,N,CHO-AA8,,
Inhibition of growth under aerobic conditions in AA8 cells,Expert,,185.0,10029.0,,,6590,CHEMBL621462,,1,1,,BAO_0000219,,Cricetulus griseus,13436,80089,F,N,CHO-AA8,,
Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,9615.0,,,6591,CHEMBL621463,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6084,50588,A,N,,,
Oral bioavailability in dog at 10 mg/kg of the compound,Intermediate,,,9615.0,,,6592,CHEMBL621464,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5711,50588,A,N,,,
Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,,9615.0,,,6593,CHEMBL621465,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4353,50588,A,N,,,
Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,,9615.0,,,6594,CHEMBL621466,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4353,50588,A,N,,,
Oral bioavailability in dog (mongrel),Intermediate,,,9615.0,,,6595,CHEMBL621467,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17800,50588,A,N,,,
Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,9615.0,,,6596,CHEMBL621468,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3994,50588,A,N,,,
Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,,9615.0,,,6597,CHEMBL876734,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3994,50588,F,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6598,CHEMBL618476,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5145,50588,A,N,,,
Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,9615.0,,,6599,CHEMBL618477,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),Intermediate,,,9615.0,,,6600,CHEMBL618478,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,Intermediate,,,9615.0,,,6601,CHEMBL618479,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5983,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6602,CHEMBL618480,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4273,50588,A,N,,,
Bioavailability in dog (dose 3-10 mg/kg),Intermediate,,,9615.0,,,6603,CHEMBL618481,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,12500,50588,A,N,,,
The compound was tested for bioavailability of compound in plasma of dog; Complete,Intermediate,,,9615.0,,,6604,CHEMBL618482,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,12500,50588,A,N,,1969.0,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6605,CHEMBL618483,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3639,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6606,CHEMBL618484,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3880,50588,A,N,,,
Bioavailability in dog,Intermediate,,,9615.0,,,6607,CHEMBL618485,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4838,50588,A,N,,,
oral bioavailability was measured in dogs,Intermediate,,,9615.0,,,6608,CHEMBL618486,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,15600,50588,A,N,,,
Compound was tested for plasma protein binding in dog; Not determined,Intermediate,,,9615.0,,,6609,CHEMBL618487,,1,1,,BAO_0000218,,Canis lupus familiaris,17248,50588,A,N,,,
Compound was tested for plasma protein binding of dog,Intermediate,,,9615.0,,,6610,CHEMBL618488,,1,1,,BAO_0000218,,Canis lupus familiaris,17248,50588,A,N,,,
Compound was tested for plasma protein binding of dog; Not determined,Intermediate,,,9615.0,,,6611,CHEMBL876735,,1,1,,BAO_0000218,,Canis lupus familiaris,17248,50588,A,N,,,
Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,Intermediate,,,9615.0,,,6612,CHEMBL618489,,1,1,,BAO_0000218,,Canis lupus familiaris,17443,50588,A,N,,,
Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,,9615.0,,,6613,CHEMBL618490,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4186,50588,A,N,,,
Half life was determined,Intermediate,,,9615.0,,,6614,CHEMBL618491,,1,1,,BAO_0000218,,Canis lupus familiaris,3749,50588,A,N,,,
Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,Intermediate,,,9615.0,,,6615,CHEMBL618492,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3249,50588,A,N,,,
Half life was evaluated in dog,Intermediate,,,9615.0,,,6616,CHEMBL873354,,1,1,,BAO_0000218,,Canis lupus familiaris,3022,50588,A,N,,,
Half life was determined,Intermediate,,,9615.0,,,6617,CHEMBL618493,,1,1,,BAO_0000218,,Canis lupus familiaris,3749,50588,A,N,,,
Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,9615.0,,,6618,CHEMBL618494,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2517,50588,A,N,,,
Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,9615.0,,,6619,CHEMBL618495,Heart,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2517,50588,A,N,,948.0,
Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,9615.0,,,6620,CHEMBL618496,Kidney,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2517,50588,A,N,,2113.0,
Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,9615.0,,,6621,CHEMBL618497,Liver,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2517,50588,A,N,,2107.0,
Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,9615.0,,,6622,CHEMBL618498,Lung,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2517,50588,A,N,,2048.0,
Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,,9615.0,,,6623,CHEMBL618499,Spleen,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2517,50588,A,N,,2106.0,
LogP in dog,Intermediate,,,9615.0,,,6624,CHEMBL876736,,1,1,,BAO_0000218,,Canis lupus familiaris,3639,50588,A,N,,,
Partition coefficient (logP),Intermediate,,,9615.0,,,6625,CHEMBL618500,,1,1,,BAO_0000218,,Canis lupus familiaris,6227,50588,A,N,,,
Partition coefficient in dog,Intermediate,,,9615.0,,,6626,CHEMBL857831,,1,1,,BAO_0000218,,Canis lupus familiaris,6227,50588,A,N,,,
Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,9615.0,,,6627,CHEMBL618501,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17764,50588,A,N,,,
Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),Intermediate,,,9615.0,,,6628,CHEMBL618502,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4809,50588,A,N,,,
In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,Intermediate,,,9615.0,,,6629,CHEMBL618503,,1,1,,BAO_0000218,,Canis lupus familiaris,5600,50588,A,N,,,
Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),Intermediate,,,9615.0,,,6630,CHEMBL618504,,1,1,,BAO_0000218,,Canis lupus familiaris,14294,50588,A,N,,,
Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),Intermediate,,,9615.0,,,6631,CHEMBL618505,,1,1,,BAO_0000218,,Canis lupus familiaris,14294,50588,A,N,,,
Metabolism of compound in dog S9 microsomes; Trace,Intermediate,,,9615.0,,,6632,CHEMBL618506,,1,1,,BAO_0000218,,Canis lupus familiaris,14294,50588,A,N,,,
In vitro metabolic potential in dog liver microsomes,Intermediate,,,9615.0,,,6633,CHEMBL618507,Liver,1,1,,BAO_0000218,,Canis lupus familiaris,6251,50588,A,N,,2107.0,
Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,Intermediate,,,9615.0,,,6634,CHEMBL876737,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3748,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6635,CHEMBL618508,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2713,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6636,CHEMBL618509,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6512,50588,A,N,,,
Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,9615.0,,,6637,CHEMBL618510,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6679,50588,A,N,,,
The compound was tested for bioavailability in dogs,Intermediate,,,9615.0,,,6638,CHEMBL618511,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3749,50588,A,N,,,
The compound was tested for oral bioavailability in dogs,Intermediate,,,9615.0,,,6639,CHEMBL618512,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3749,50588,A,N,,,
Oral bioavailability in dog,Intermediate,,,9615.0,,,6640,CHEMBL618513,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6742,50588,A,N,,,
Compound was tested for percent protein binding (PB) in dog,Intermediate,,,9615.0,,,6641,CHEMBL618514,,1,1,,BAO_0000218,,Canis lupus familiaris,6227,50588,A,N,,,
Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,Intermediate,,,9615.0,,,6642,CHEMBL620052,,1,1,,BAO_0000218,,Canis lupus familiaris,6874,50588,A,N,,,
Compound was evaluated for plasma clearance.,Intermediate,,,9615.0,,,6643,CHEMBL620053,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2877,50588,A,N,,1969.0,
The compound was tested for plasma clearance in dog,Intermediate,,,9615.0,,,6644,CHEMBL620054,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,12500,50588,A,N,,1969.0,
The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Intermediate,,,9615.0,,,6645,CHEMBL620055,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,12500,50588,A,N,,1969.0,
Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,Intermediate,,,9615.0,,,6646,CHEMBL620056,,1,1,,BAO_0000218,,Canis lupus familiaris,4709,50588,A,N,,,
In vitro relative rate of metabolism was determined in dog liver microsomes,Intermediate,,,9615.0,,,6647,CHEMBL620057,Liver,1,1,,BAO_0000218,,Canis lupus familiaris,5542,50588,A,N,,2107.0,
Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,Intermediate,,,9615.0,,,6648,CHEMBL618939,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17594,50588,A,N,,,
Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,,,9615.0,,,6649,CHEMBL618940,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2652,50588,A,N,,,
Half life after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,9615.0,,,6650,CHEMBL618941,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17764,50588,A,N,,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6651,CHEMBL624473,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6652,CHEMBL624474,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6653,CHEMBL624475,Lung,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,2048.0,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,Intermediate,,42.0,10090.0,,,6654,CHEMBL624476,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,Intermediate,,42.0,10090.0,,,6655,CHEMBL623478,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,Intermediate,,42.0,10090.0,,,6656,CHEMBL623479,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,Intermediate,,42.0,10090.0,,,6657,CHEMBL623480,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,Intermediate,,42.0,10090.0,,,6658,CHEMBL623481,,1,1,,BAO_0000218,,Mus musculus,6599,50594,A,N,CCRF S-180,,
C2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6659,CHEMBL623482,Brain,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,955.0,
C2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6660,CHEMBL623483,Kidney,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,2113.0,
C2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6661,CHEMBL623484,Liver,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,2107.0,
C2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6662,CHEMBL623485,Lung,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,2048.0,
C2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6663,CHEMBL623486,Spleen,1,1,,BAO_0000218,,Mus musculus,17641,50594,A,N,,2106.0,
Plasma clearance in mouse,Intermediate,,,10090.0,,,6664,CHEMBL623487,,1,1,,BAO_0000218,In vivo,Mus musculus,17852,50594,A,N,,,
Clearance of compound after intravenous administration in mice at 24 uM/kg,Intermediate,,,10090.0,,,6665,CHEMBL623488,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,A,N,,,
Clearance from mouse blood following i.v. administration of 10 mg/kg,Intermediate,,,10090.0,,,6666,CHEMBL623489,,1,1,,BAO_0000218,In vivo,Mus musculus,17837,50594,A,N,,,
Clearance was evaluated in mice after intravenous administration,Intermediate,,,10090.0,,,6667,CHEMBL875157,,1,1,,BAO_0000218,In vivo,Mus musculus,2675,50594,A,N,,,
Clearance was evaluated in mice after oral administration,Intermediate,,,10090.0,,,6668,CHEMBL623490,,1,1,,BAO_0000218,In vivo,Mus musculus,2675,50594,A,N,,,
Pharmacokinetic property (Plasma clearance) was measured in mouse,Intermediate,,,10090.0,,,6669,CHEMBL623491,,1,1,,BAO_0000218,In vivo,Mus musculus,4239,50594,A,N,,,
Plasma clearance of compound was determined at 40 mg/Kg,Intermediate,,,10090.0,,,6670,CHEMBL623492,,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,,
Plasma clearance of at 24 mg/Kg,Intermediate,,,10090.0,,,6671,CHEMBL623493,,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,,
Plasma clearance at 24 mg/Kg,Intermediate,,,10090.0,,,6672,CHEMBL623494,,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,,
Plasma clearance at 5 mg/Kg,Intermediate,,,10090.0,,,6673,CHEMBL623495,,1,1,,BAO_0000218,In vivo,Mus musculus,17753,50594,A,N,,,
Plasma clearance in mice,Intermediate,,,10090.0,,,6674,CHEMBL623496,,1,1,,BAO_0000218,In vivo,Mus musculus,5727,50594,A,N,,,
Plasma clearance value upon iv administration in mouse,Intermediate,,,10090.0,,,6675,CHEMBL623497,,1,1,,BAO_0000218,In vivo,Mus musculus,2862,50594,A,N,,,
Total plasma clearance in mice,Intermediate,,,10090.0,,,6676,CHEMBL623498,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,5980,50594,A,N,,1969.0,
Clearance in mouse,Intermediate,,,10090.0,,,6677,CHEMBL623499,,1,1,,BAO_0000218,In vivo,Mus musculus,17592,50594,A,N,,,
Clearance value was determined,Intermediate,,,10090.0,,,6678,CHEMBL623500,,1,1,,BAO_0000218,In vivo,Mus musculus,17718,50594,A,N,,,
Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,10090.0,,,6679,CHEMBL623501,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Calculated partition coefficient (clogP),Intermediate,,,,,,6680,CHEMBL875158,,0,1,,BAO_0000100,,,17384,22229,P,U,,,
Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,,10090.0,,,6681,CHEMBL623502,,1,1,,BAO_0000218,In vivo,Mus musculus,6062,50594,A,N,,,
Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,10090.0,,,6682,CHEMBL623503,,1,1,,BAO_0000218,In vivo,Mus musculus,17734,50594,A,N,,,
Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,10090.0,,,6683,CHEMBL623504,,1,1,,BAO_0000218,In vivo,Mus musculus,6348,50594,A,N,,,
In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,,10090.0,,,6684,CHEMBL623505,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,,10090.0,,,6685,CHEMBL623506,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,,10090.0,,,6686,CHEMBL623507,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,Intermediate,,,10090.0,,,6687,CHEMBL623508,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Cmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,,,10090.0,,,6688,CHEMBL623509,,1,1,,BAO_0000218,In vivo,Mus musculus,5781,50594,A,N,,,
Cmax after peroral administration in mice at 2.4 uM/kg,Intermediate,,,10090.0,,,6689,CHEMBL875159,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,A,N,,,
Cmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6690,CHEMBL623510,Brain,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,955.0,
Cmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6691,CHEMBL623511,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,2113.0,
Cmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6692,CHEMBL623512,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,2107.0,
Cmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6693,CHEMBL623513,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,2048.0,
Cmax in mice at 18 uM/kg i.p. administration,Intermediate,,,10090.0,,,6694,CHEMBL623514,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Cmax in mice at 23 uM/kg i.v. administration,Intermediate,,,10090.0,,,6695,CHEMBL622609,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Cmax in mice at 24 uM/kg i.p. administration,Intermediate,,,10090.0,,,6696,CHEMBL622610,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Cmax in mice at 25 uM/kg i.p. administration,Intermediate,,,10090.0,,,6697,CHEMBL621823,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Cmax in mice at 26 uM/kg i.p. administration,Intermediate,,,10090.0,,,6698,CHEMBL621824,,1,1,,BAO_0000218,In vivo,Mus musculus,17764,50594,F,N,,,
Cmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,,10090.0,,,6699,CHEMBL621825,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,17641,50594,A,N,,2106.0,
Cmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,,10090.0,,,6700,CHEMBL621826,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Cmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,,10090.0,,,6701,CHEMBL621827,,1,1,,BAO_0000218,In vivo,Mus musculus,16597,50594,A,N,,,
Cmax value was determined,Intermediate,,,10090.0,,,6702,CHEMBL621828,,1,1,,BAO_0000218,In vivo,Mus musculus,5727,50594,A,N,,,
Cmax value in IRC mice,Intermediate,,,10090.0,,,6703,CHEMBL621829,,1,1,,BAO_0000218,In vivo,Mus musculus,5951,50594,A,N,,,
Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,,10090.0,,,6704,CHEMBL621830,,1,1,,BAO_0000218,In vivo,Mus musculus,5506,50594,A,N,,,
Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,,10090.0,,,6705,CHEMBL621831,,1,1,,BAO_0000218,In vivo,Mus musculus,5506,50594,A,N,,,
Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Intermediate,,,10090.0,,,6706,CHEMBL621832,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,14239,50594,A,N,,1969.0,
"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Intermediate,,,10090.0,,,6707,CHEMBL624579,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,4890,50594,A,N,,1969.0,
Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,Intermediate,,,10090.0,,,6708,CHEMBL624580,,1,1,,BAO_0000218,In vivo,Mus musculus,429,50594,A,N,,,
anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,Intermediate,,,6277.0,,,6709,CHEMBL624581,,1,1,,BAO_0000218,,Acanthocheilonema viteae,10986,50535,F,N,,,
anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,Intermediate,,,6277.0,,,6710,CHEMBL624582,,1,1,,BAO_0000218,,Acanthocheilonema viteae,10986,50535,F,N,,,
anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,Intermediate,,,6277.0,,,6711,CHEMBL624583,,1,1,,BAO_0000218,,Acanthocheilonema viteae,10986,50535,F,N,,,
Inhibitory activity against human tumor cell line A0375 melanoma.,Intermediate,,455.0,9606.0,,,6712,CHEMBL624584,,1,1,,BAO_0000219,,Homo sapiens,13227,80018,F,N,A-375,,
Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Expert,,,10116.0,Brain membranes,,6713,CHEMBL624585,,9,1,,BAO_0000249,,Rattus norvegicus,4481,12512,B,D,,,
Forskolin-induced cAMP production at human A1 adenosine receptor,Expert,,,9606.0,,,6714,CHEMBL875165,,9,1,,BAO_0000019,,Homo sapiens,16931,114,F,D,,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,Autocuration,,449.0,,,,6715,CHEMBL619490,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Autocuration,,449.0,,,,6716,CHEMBL619491,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,Expert,,449.0,,,,6717,CHEMBL619492,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,Expert,,449.0,,,,6718,CHEMBL619493,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,Autocuration,,449.0,,,,6719,CHEMBL619494,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,Autocuration,,449.0,,,,6720,CHEMBL619495,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,449.0,,,,6721,CHEMBL619496,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Expert,,449.0,9606.0,,,6722,CHEMBL619497,,9,1,,BAO_0000219,,Homo sapiens,3850,114,F,D,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,Autocuration,,449.0,,,,6723,CHEMBL619498,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,Autocuration,,449.0,,,,6724,CHEMBL619499,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,Expert,,449.0,,,,6725,CHEMBL619500,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,449.0,,,,6726,CHEMBL619501,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,Expert,,449.0,,,,6727,CHEMBL619502,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,Autocuration,,449.0,,,,6728,CHEMBL619503,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Autocuration,,449.0,,,,6729,CHEMBL619504,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,Autocuration,,449.0,,,,6730,CHEMBL621298,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,Expert,,449.0,,,,6731,CHEMBL621299,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,Autocuration,,449.0,,,,6732,CHEMBL621300,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,,449.0,,,,6733,CHEMBL621301,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Expert,,449.0,,,,6734,CHEMBL621302,,8,1,,BAO_0000219,,,3850,114,F,H,CHO,,
Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,Intermediate,,164.0,9986.0,,,6735,CHEMBL621303,,1,1,,BAO_0000219,,Oryctolagus cuniculus,12680,80013,F,N,A10,,
In vitro potassium channel opening activity in A10 (smooth muscle) cells,Autocuration,,164.0,10116.0,,,6736,CHEMBL621304,,0,1,,BAO_0000219,,Rattus norvegicus,1313,22226,F,U,A10,,
In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,Autocuration,,164.0,10116.0,,,6737,CHEMBL621305,,0,1,,BAO_0000219,,Rattus norvegicus,1313,22226,F,U,A10,,
Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,Intermediate,,164.0,10116.0,,,6738,CHEMBL621306,,1,1,,BAO_0000219,,Rattus norvegicus,17567,80013,F,N,A10,,
Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,Intermediate,,164.0,10116.0,,,6739,CHEMBL618444,,1,1,,BAO_0000219,,Rattus norvegicus,17567,80013,F,N,A10,,
Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,Intermediate,,164.0,10116.0,,,6740,CHEMBL618445,,1,1,,BAO_0000219,,Rattus norvegicus,11819,80013,F,N,A10,,
Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,Intermediate,,185.0,10029.0,,,6741,CHEMBL618446,,1,1,,BAO_0000219,,Cricetulus griseus,13436,80089,F,N,CHO-AA8,,
Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,Intermediate,,185.0,10029.0,,,6742,CHEMBL618447,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,F,N,CHO-AA8,,
Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,Intermediate,,185.0,10029.0,,,6743,CHEMBL618448,,1,1,,BAO_0000219,,Cricetulus griseus,12651,80089,F,N,CHO-AA8,,
Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,Intermediate,,185.0,10029.0,,,6744,CHEMBL618449,,1,1,,BAO_0000219,,Cricetulus griseus,13300,80089,F,N,CHO-AA8,,
Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Intermediate,,185.0,10029.0,,,6745,CHEMBL618637,,1,1,,BAO_0000219,,Cricetulus griseus,15296,80089,F,N,CHO-AA8,,
"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",Intermediate,,185.0,10029.0,,,6746,CHEMBL618638,,1,1,,BAO_0000219,,Cricetulus griseus,15328,80089,F,N,CHO-AA8,,
Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),Intermediate,,185.0,10029.0,,,6747,CHEMBL618639,,1,1,,BAO_0000219,,Cricetulus griseus,13302,80089,F,N,CHO-AA8,,
"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",Expert,,185.0,10029.0,,,6748,CHEMBL618640,,1,1,,BAO_0000219,,Cricetulus griseus,14367,80089,F,N,CHO-AA8,,
In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,Expert,,185.0,10029.0,,,6749,CHEMBL618641,,1,1,,BAO_0000219,,Cricetulus griseus,17002,80089,F,N,CHO-AA8,,
Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,Intermediate,,185.0,10029.0,,,6750,CHEMBL618642,,1,1,,BAO_0000219,,Cricetulus griseus,13436,80089,F,N,CHO-AA8,,
Inhibitory activity against aerobic growth of AA8 cells.,Intermediate,,185.0,10029.0,,,6751,CHEMBL618643,,1,1,,BAO_0000219,,Cricetulus griseus,13435,80089,F,N,CHO-AA8,,
Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,,185.0,10029.0,,,6752,CHEMBL884013,,1,1,,BAO_0000219,,Cricetulus griseus,10503,80089,A,N,CHO-AA8,,
In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Expert,,185.0,10029.0,,,6753,CHEMBL622723,,1,1,,BAO_0000219,,Cricetulus griseus,10503,80089,F,N,CHO-AA8,,
Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,,185.0,10029.0,,,6754,CHEMBL622724,,1,1,,BAO_0000219,,Cricetulus griseus,10503,80089,F,N,CHO-AA8,,
Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,Expert,,185.0,10029.0,,,6755,CHEMBL622725,,1,1,,BAO_0000219,,Cricetulus griseus,15090,80089,F,N,CHO-AA8,,
Cytotoxicity against AA8 cell line,Expert,,185.0,10029.0,,,6756,CHEMBL622726,,1,1,,BAO_0000219,,Cricetulus griseus,10368,80089,F,N,CHO-AA8,,
Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),Intermediate,,185.0,10029.0,,,6757,CHEMBL622727,,1,1,,BAO_0000219,,Cricetulus griseus,12651,80089,F,N,CHO-AA8,,
In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,,185.0,10029.0,,,6758,CHEMBL622728,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,A,N,CHO-AA8,,
In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,,185.0,10029.0,,,6759,CHEMBL622729,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,F,N,CHO-AA8,,
In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,,185.0,10029.0,,,6760,CHEMBL622730,,1,1,,BAO_0000219,,Cricetulus griseus,12687,80089,A,N,CHO-AA8,,
Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,Intermediate,,185.0,10029.0,,,6761,CHEMBL622731,,1,1,,BAO_0000219,,Cricetulus griseus,1890,80089,F,N,CHO-AA8,,
Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,,185.0,10029.0,,,6762,CHEMBL622732,,1,1,,BAO_0000219,,Cricetulus griseus,10747,80089,F,N,CHO-AA8,,
Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,,185.0,10029.0,,,6763,CHEMBL622733,,1,1,,BAO_0000219,,Cricetulus griseus,10747,80089,F,N,CHO-AA8,,
Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),Autocuration,,,10029.0,,,6764,CHEMBL622734,,0,1,,BAO_0000218,,Cricetulus griseus,11616,22224,F,U,,,
Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,Expert,,185.0,10029.0,,,6765,CHEMBL622735,,1,1,,BAO_0000219,,Cricetulus griseus,11616,80089,F,N,CHO-AA8,,
Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,Autocuration,,185.0,10029.0,,,6766,CHEMBL618746,,0,1,,BAO_0000219,,Cricetulus griseus,3471,22224,F,U,CHO-AA8,,
Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,Autocuration,,185.0,10029.0,,,6767,CHEMBL618747,,0,1,,BAO_0000219,,Cricetulus griseus,3471,22224,F,U,CHO-AA8,,
Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,Autocuration,,185.0,10029.0,,,6768,CHEMBL620540,,0,1,,BAO_0000219,,Cricetulus griseus,3471,22224,F,U,CHO-AA8,,
Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,Autocuration,,185.0,10029.0,,,6769,CHEMBL620541,,0,1,,BAO_0000219,,Cricetulus griseus,3471,22224,F,U,CHO-AA8,,
Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,Autocuration,,185.0,10029.0,,,6770,CHEMBL620542,,0,1,,BAO_0000219,,Cricetulus griseus,3471,22224,F,U,CHO-AA8,,
Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,Autocuration,,185.0,10029.0,,,6771,CHEMBL620543,,0,1,,BAO_0000219,,Cricetulus griseus,3471,22224,F,U,CHO-AA8,,
Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,Autocuration,,185.0,10029.0,,,6772,CHEMBL618832,,0,1,,BAO_0000219,,Cricetulus griseus,3471,22224,F,U,CHO-AA8,,
Concentration required to reduce AA8 cell survival by 10%,Expert,,185.0,10029.0,,,6773,CHEMBL618833,,1,1,,BAO_0000219,,Cricetulus griseus,11616,80089,F,N,CHO-AA8,,
"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",Autocuration,,185.0,10029.0,,,6774,CHEMBL618834,,0,1,,BAO_0000219,,Cricetulus griseus,2656,22224,F,U,CHO-AA8,,
Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,,185.0,10029.0,,,6775,CHEMBL618835,,0,1,,BAO_0000219,,Cricetulus griseus,10518,22224,F,U,CHO-AA8,,
CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,,185.0,10029.0,,,6776,CHEMBL618836,,0,1,,BAO_0000219,,Cricetulus griseus,10518,22224,F,U,CHO-AA8,,
CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,Autocuration,,185.0,10029.0,,,6777,CHEMBL618837,,0,1,,BAO_0000219,,Cricetulus griseus,10518,22224,F,U,CHO-AA8,,
CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,Autocuration,,185.0,10029.0,,,6778,CHEMBL618838,,0,1,,BAO_0000219,,Cricetulus griseus,10518,22224,F,U,CHO-AA8,,
Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,Autocuration,,185.0,10029.0,,,6779,CHEMBL618839,,0,1,,BAO_0000219,,Cricetulus griseus,16156,22224,F,U,CHO-AA8,,
Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,Autocuration,,185.0,10029.0,,,6780,CHEMBL618840,,0,1,,BAO_0000219,,Cricetulus griseus,2656,22224,F,U,CHO-AA8,,
"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Autocuration,,,10029.0,,,6781,CHEMBL618841,,0,1,,BAO_0000019,,Cricetulus griseus,11005,22224,F,U,,,
Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,Autocuration,,185.0,10029.0,,,6782,CHEMBL618842,,0,1,,BAO_0000219,,Cricetulus griseus,11942,22224,F,U,CHO-AA8,,
Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,Autocuration,,185.0,10029.0,,,6783,CHEMBL618843,,0,1,,BAO_0000219,,Cricetulus griseus,2128,22224,F,U,CHO-AA8,,
Half life period after 15 mg/kg iv dose in Dogs,Intermediate,,,9615.0,,,6784,CHEMBL618844,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Half life period after 30 mg/kg po dose in Dogs,Intermediate,,,9615.0,,,6785,CHEMBL618845,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Half life was measured after oral 2b administration (tested in 6 dogs),Intermediate,,,9615.0,,,6786,CHEMBL618846,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,9579,50588,A,N,,,
Half life was measured in dog after oral 17b administration,Intermediate,,,9615.0,,,6787,CHEMBL618847,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,9579,50588,A,N,,,
Pharmacokinetic parameter T max determined in dog after oral administration of 17b,Intermediate,,,9615.0,,,6788,CHEMBL618848,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,9579,50588,A,N,,,
Pharmacokinetic parameter T max determined in dog after oral administration of 2b,Intermediate,,,9615.0,,,6789,CHEMBL618849,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,9579,50588,A,N,,,
Tmax value after 15 mg/kg iv dose in Dogs,Intermediate,,,9615.0,,,6790,CHEMBL618850,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Tmax value after 30 mg/kg po dose in Dogs,Intermediate,,,9615.0,,,6791,CHEMBL618851,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Compound was evaluated for its half life when administered intravenously in dog,Intermediate,,,9615.0,,,6792,CHEMBL873815,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3184,50588,A,N,,,
Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,,,9615.0,,,6793,CHEMBL618852,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5017,50588,A,N,,1969.0,
Elimination Half-life of compound was determined in dog,Intermediate,,,9615.0,,,6794,CHEMBL618853,,1,1,,BAO_0000218,,Canis lupus familiaris,6821,50588,A,N,,,
Half life of compound in dog following oral administration,Intermediate,,,9615.0,,,6795,CHEMBL618854,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,,
Half life of compound was determined in dog,Intermediate,,,9615.0,,,6796,CHEMBL618855,,1,1,,BAO_0000218,,Canis lupus familiaris,17267,50588,A,N,,,
Half life of compound was determined in dog blood,Intermediate,,,9615.0,,,6797,CHEMBL618856,Blood,1,1,,BAO_0000218,,Canis lupus familiaris,4727,50588,A,N,,178.0,
Half life after oral and iv dosing in dogs,Intermediate,,,9615.0,,,6798,CHEMBL875827,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5238,50588,A,N,,,
Half life in dogs in hours,Intermediate,,,9615.0,,,6799,CHEMBL618857,,1,1,,BAO_0000218,,Canis lupus familiaris,4942,50588,A,N,,,
Half life on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,,9615.0,,,6800,CHEMBL618858,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6505,50588,A,N,,,
t1/2 in dog after oral dose (1 mg/kg),Intermediate,,,9615.0,,,6801,CHEMBL618859,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5130,50588,A,N,,,
Half life was evaluated in dog,Intermediate,,,9615.0,,,6802,CHEMBL618860,,1,1,,BAO_0000218,,Canis lupus familiaris,1475,50588,A,N,,,
Half life period of compound was determined after intravenous administration at 2 mg/kg,Intermediate,,,9615.0,,,6803,CHEMBL618861,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17804,50588,A,N,,,
Half life period of compound was determined after peroral administration at 2 mg/kg,Intermediate,,,9615.0,,,6804,CHEMBL622539,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17804,50588,A,N,,,
Half life period (10 mg/kg) was determined in dog,Intermediate,,,9615.0,,,6805,CHEMBL622540,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6084,50588,A,N,,,
Half life period (10 mg/kg) was determined in dog,Intermediate,,,9615.0,,,6806,CHEMBL873803,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6084,50588,A,N,,,
Half life period by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,,,9615.0,,,6807,CHEMBL873804,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5542,50588,A,N,,,
Half life period by po administration in dog at a dose of 0.3 mg/kg,Intermediate,,,9615.0,,,6808,CHEMBL624311,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5542,50588,A,N,,,
Half life period in dog,Intermediate,,,9615.0,,,6809,CHEMBL624312,,1,1,,BAO_0000218,,Canis lupus familiaris,6084,50588,A,N,,,
Half life period in dogs after oral administration at 1 mg/kg,Intermediate,,,9615.0,,,6810,CHEMBL624313,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6241,50588,A,N,,,
Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,9615.0,,,6811,CHEMBL624314,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1916,50588,A,N,,,
Half-life of compound was determined in dogs,Intermediate,,,9615.0,,,6812,CHEMBL624315,,1,1,,BAO_0000218,,Canis lupus familiaris,6621,50588,A,N,,,
Half-life in dog plasma,Intermediate,,,9615.0,,,6813,CHEMBL624316,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,1696,50588,A,N,,1969.0,
Half-life in mongrel dogs was determined,Intermediate,,,9615.0,,,6814,CHEMBL624317,,1,1,,BAO_0000218,,Canis lupus familiaris,17800,50588,A,N,,,
Half-life in dog upon oral administration,Intermediate,,,9615.0,,,6815,CHEMBL624318,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17657,50588,A,N,,,
Half-life in dog upon oral administration; Unable to calculate,Intermediate,,,9615.0,,,6816,CHEMBL624319,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17657,50588,A,N,,,
Half-life was measured in dog,Intermediate,,,9615.0,,,6817,CHEMBL624496,,1,1,,BAO_0000218,,Canis lupus familiaris,4239,50588,A,N,,,
Half-life was measured in dog,Intermediate,,,9615.0,,,6818,CHEMBL624497,,1,1,,BAO_0000218,,Canis lupus familiaris,5985,50588,A,N,,,
Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,Intermediate,,,9615.0,,,6819,CHEMBL624498,,1,1,,BAO_0000218,,Canis lupus familiaris,9932,50588,A,N,,,
Oral half life was determined,Intermediate,,,9615.0,,,6820,CHEMBL624499,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5199,50588,A,N,,,
Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Intermediate,,,9615.0,,,6821,CHEMBL624500,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5199,50588,A,N,,1969.0,
Plasma half life was evaluated,Intermediate,,,9615.0,,,6822,CHEMBL624501,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,1475,50588,A,N,,1969.0,
Plasma half life was evaluated in Dog,Intermediate,,,9615.0,,,6823,CHEMBL623666,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,1475,50588,A,N,,1969.0,
Plasma half life was evaluated in dog,Intermediate,,,9615.0,,,6824,CHEMBL623667,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,1475,50588,A,N,,1969.0,
T1/2 (Half-life) was after oral administration at 5 mg/kg,Intermediate,,,9615.0,,,6825,CHEMBL623668,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6316,50588,A,N,,,
Tested for the half life value in dog,Intermediate,,,9615.0,,,6826,CHEMBL623669,,1,1,,BAO_0000218,,Canis lupus familiaris,4883,50588,A,N,,,
Maximum time at the dose of 2 mg/kg in dog,Intermediate,,,9615.0,,,6827,CHEMBL623670,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4727,50588,A,N,,,
Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,,9615.0,,,6828,CHEMBL623671,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1916,50588,A,N,,,
Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,9615.0,,,6829,CHEMBL875945,Blood,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1337,50588,A,N,,178.0,
Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,9615.0,,,6830,CHEMBL623672,Blood,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1337,50588,A,N,,178.0,
Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,,,9615.0,,,6831,CHEMBL623673,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6265,50588,A,N,,,
Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,,9615.0,,,6832,CHEMBL623674,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4809,50588,A,N,,,
Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,,,9615.0,,,6833,CHEMBL623675,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5983,50588,A,N,,,
"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",Intermediate,,,9615.0,,,6834,CHEMBL872526,,1,1,,BAO_0000218,,Canis lupus familiaris,5313,50588,A,N,,,
"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",Intermediate,,,9615.0,,,6835,CHEMBL623676,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5313,50588,A,N,,,
Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,9615.0,,,6836,CHEMBL623677,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17650,50588,A,N,,1969.0,
Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,,,9615.0,,,6837,CHEMBL623678,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5199,50588,A,N,,1969.0,
Time taken for maximum plasma concentration in dog,Intermediate,,,9615.0,,,6838,CHEMBL623679,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,933,50588,A,N,,1969.0,
Time to reach Cmax after oral administration to dogs,Intermediate,,,9615.0,,,6839,CHEMBL623680,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16367,50588,A,N,,,
Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,9615.0,,,6840,CHEMBL623681,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6348,50588,A,N,,1969.0,
Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,Intermediate,,,9615.0,,,6841,CHEMBL623682,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6316,50588,A,N,,,
Tmax after peroral administration (1 mg/kg) was determined in dog,Intermediate,,,9615.0,,,6842,CHEMBL623683,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6215,50588,A,N,,,
Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,9615.0,,,6843,CHEMBL623684,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3598,50588,A,N,,,
Tmax by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,9615.0,,,6844,CHEMBL622745,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4527,50588,A,N,,,
Tmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,,,9615.0,,,6845,CHEMBL622746,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17764,50588,A,N,,,
In vivo Cmax in mice at dose of 100 mg/kg,Intermediate,,,10090.0,,,6846,CHEMBL622747,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
In vivo Cmax in mice at dose of 50 mg/kg,Intermediate,,,10090.0,,,6847,CHEMBL622748,,1,1,,BAO_0000218,In vivo,Mus musculus,5969,50594,A,N,,,
Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,,10090.0,,,6848,CHEMBL622749,,1,1,,BAO_0000218,In vivo,Mus musculus,4573,50594,A,N,,,
Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,,10090.0,,,6849,CHEMBL622750,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,3277,50594,A,N,,1969.0,
Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,,10090.0,,,6850,CHEMBL623411,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17734,50594,A,N,,1969.0,
Maximum concentration obtained in mouse plasma was determined,Intermediate,,,10090.0,,,6851,CHEMBL875946,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,3132,50594,A,N,,1969.0,
Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Intermediate,,,10090.0,,,6852,CHEMBL623412,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,3132,50594,A,N,,1969.0,
Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,10090.0,,,6853,CHEMBL623413,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,6348,50594,A,N,,1969.0,
Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,,,10090.0,,,6854,CHEMBL623414,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17729,50594,A,N,,1969.0,
Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,,,10090.0,,,6855,CHEMBL623415,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17729,50594,A,N,,1969.0,
Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Intermediate,,,10090.0,,,6856,CHEMBL623416,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17729,50594,A,N,,1969.0,
Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Intermediate,,,10090.0,,,6857,CHEMBL623417,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17728,50594,A,N,,1969.0,
Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Intermediate,,,10090.0,,,6858,CHEMBL623418,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17728,50594,A,N,,1969.0,
Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Intermediate,,,10090.0,,,6859,CHEMBL623419,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,17728,50594,A,N,,1969.0,
Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,,10090.0,,,6860,CHEMBL622816,,1,1,,BAO_0000218,In vivo,Mus musculus,4066,50594,A,N,,,
Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,Intermediate,,,10090.0,,,6861,CHEMBL623313,,1,1,,BAO_0000218,In vivo,Mus musculus,6178,50594,A,N,,,
Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,Intermediate,,,10090.0,,,6862,CHEMBL623314,,1,1,,BAO_0000218,In vivo,Mus musculus,6178,50594,A,N,,,
Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,Intermediate,,,10090.0,,,6863,CHEMBL876788,,1,1,,BAO_0000218,In vivo,Mus musculus,3760,50594,A,N,,,
Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,Intermediate,,,10090.0,,,6864,CHEMBL623315,,1,1,,BAO_0000218,In vivo,Mus musculus,3760,50594,A,N,,,
Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,Intermediate,,,10090.0,,,6865,CHEMBL623316,,1,1,,BAO_0000218,In vivo,Mus musculus,3760,50594,A,N,,,
Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,Intermediate,,,10090.0,,,6866,CHEMBL623317,,1,1,,BAO_0000218,In vivo,Mus musculus,3760,50594,A,N,,,
Cmax in male mice after 2 mg/kg oral dose,Intermediate,,,10090.0,,,6868,CHEMBL623319,,1,1,,BAO_0000218,In vivo,Mus musculus,5961,50594,A,N,,,
Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,Intermediate,,,10090.0,,,6869,CHEMBL623320,,1,1,,BAO_0000218,In vivo,Mus musculus,6137,50594,A,N,,,
Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,,,10090.0,,,6870,CHEMBL623321,,1,1,,BAO_0000218,In vivo,Mus musculus,3802,50594,A,N,,,
Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,Intermediate,,,10090.0,,,6871,CHEMBL623322,,1,1,,BAO_0000218,,Mus musculus,3535,50594,A,N,,,
Concentration in plasma (systemic) following oral dose in mouse at 1 hr,Intermediate,,,10090.0,,,6872,CHEMBL623323,,1,1,,BAO_0000218,,Mus musculus,3535,50594,A,N,,,
Concentration in plasma (systemic) following oral dose in mouse at 24 hr,Intermediate,,,10090.0,,,6873,CHEMBL623324,,1,1,,BAO_0000218,,Mus musculus,3535,50594,A,N,,,
Concentration in plasma (systemic) following oral dose in mouse at 2 hr,Intermediate,,,10090.0,,,6874,CHEMBL623325,,1,1,,BAO_0000218,,Mus musculus,3535,50594,A,N,,,
Concentration in plasma (systemic) following oral dose in mouse at 4 hr,Intermediate,,,10090.0,,,6875,CHEMBL623326,,1,1,,BAO_0000218,,Mus musculus,3535,50594,A,N,,,
Concentration in plasma (systemic) following oral dose in mouse at 6 hr,Intermediate,,,10090.0,,,6876,CHEMBL623327,,1,1,,BAO_0000218,,Mus musculus,3535,50594,A,N,,,
Maximum concentration in plasma upon oral administration in mouse,Intermediate,,,10090.0,,,6877,CHEMBL623328,Plasma,1,1,,BAO_0000218,,Mus musculus,2862,50594,A,N,,1969.0,
Maximum plasma concentration was evaluated in mice after oral administration,Intermediate,,,10090.0,,,6878,CHEMBL623329,Plasma,1,1,,BAO_0000218,,Mus musculus,2675,50594,A,N,,1969.0,
Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Intermediate,,,10090.0,,,6879,CHEMBL623330,Plasma,1,1,,BAO_0000218,In vivo,Mus musculus,2675,50594,A,N,,1969.0,
Dose at which the compound induced fecal excretion in mice,Intermediate,,,10090.0,,,6880,CHEMBL876789,,1,1,,BAO_0000218,,Mus musculus,5399,50594,A,N,,,
Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,Expert,,164.0,10116.0,,,6893,CHEMBL623333,,1,1,,BAO_0000219,,Rattus norvegicus,11819,80013,F,N,A10,,
Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,Expert,,164.0,10116.0,,,6894,CHEMBL623334,,1,1,,BAO_0000219,,Rattus norvegicus,11819,80013,F,N,A10,,
Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,Expert,,164.0,10116.0,,,6895,CHEMBL627536,,1,1,,BAO_0000219,,Rattus norvegicus,11819,80013,F,N,A10,,
Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,Expert,,164.0,10116.0,,,6896,CHEMBL627537,,1,1,,BAO_0000219,,Rattus norvegicus,11819,80013,F,N,A10,,
In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),Intermediate,,164.0,10116.0,,,6897,CHEMBL627538,,1,1,,BAO_0000219,,Rattus norvegicus,16361,80013,F,N,A10,,
Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,Intermediate,,393.0,9606.0,,,6898,CHEMBL884106,,1,1,,BAO_0000219,,Homo sapiens,2288,80655,F,N,A121,,
Anticancer activity against human ovarian carcinoma A121 cells,Intermediate,,393.0,9606.0,,,6899,CHEMBL625294,,1,1,,BAO_0000219,,Homo sapiens,10404,80655,F,N,A121,,
Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,Intermediate,,393.0,9606.0,,,6900,CHEMBL625295,,1,1,,BAO_0000219,,Homo sapiens,14790,80655,F,N,A121,,
Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,Intermediate,,393.0,9606.0,,,6901,CHEMBL625296,,1,1,,BAO_0000219,,Homo sapiens,14790,80655,F,N,A121,,
Growth inhibition of human ovarian carcinoma (A121) cell line,Expert,,393.0,9606.0,,,6902,CHEMBL625297,,1,1,,BAO_0000219,,Homo sapiens,14253,80655,F,N,A121,,
Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,Expert,,393.0,9606.0,,,6903,CHEMBL625298,,1,1,,BAO_0000219,,Homo sapiens,13617,80655,F,N,A121,,
Cytotoxicity against human A121 ovarian cells,Intermediate,,393.0,9606.0,,,6904,CHEMBL625960,,1,1,,BAO_0000219,,Homo sapiens,1003,80655,F,N,A121,,
Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,Intermediate,,393.0,9606.0,,,6905,CHEMBL625961,,1,1,,BAO_0000219,,Homo sapiens,830,80655,F,N,A121,,
In vitro cytotoxicity against human ovarian carcinoma A21,Intermediate,,393.0,9606.0,,,6906,CHEMBL625962,,1,1,,BAO_0000219,,Homo sapiens,12307,80655,F,N,A121,,
Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,Intermediate,,393.0,9606.0,,,6907,CHEMBL624717,,1,1,,BAO_0000219,,Homo sapiens,14254,80655,F,N,A121,,
Inhibitory activity of compound against human A121 ovarian cell line.,Intermediate,,393.0,9606.0,,,6908,CHEMBL624718,,1,1,,BAO_0000219,,Homo sapiens,13370,80655,F,N,A121,,
Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,Intermediate,,393.0,9606.0,,,6909,CHEMBL624719,,1,1,,BAO_0000219,,Homo sapiens,14790,80655,F,N,A121,,
Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,Intermediate,,393.0,9606.0,,,6910,CHEMBL624720,,1,1,,BAO_0000219,,Homo sapiens,3614,80655,F,N,A121,,
Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,Intermediate,,622.0,9606.0,,,6911,CHEMBL624721,,1,1,,BAO_0000219,,Homo sapiens,2664,80012,F,N,A 172,,
In vitro cytotoxicity against A172 human tumor cell lines.,Expert,,622.0,9606.0,,,6912,CHEMBL624722,,1,1,,BAO_0000219,,Homo sapiens,2037,80012,F,N,A 172,,
Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,Intermediate,,622.0,9606.0,,,6913,CHEMBL877597,,1,1,,BAO_0000219,,Homo sapiens,14539,80012,F,N,A 172,,
Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,Intermediate,,622.0,9606.0,,,6914,CHEMBL624723,,1,1,,BAO_0000219,,Homo sapiens,2836,80012,F,N,A 172,,
Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,Intermediate,,622.0,9606.0,,,6915,CHEMBL624724,,1,1,,BAO_0000219,,Homo sapiens,10708,80012,F,N,A 172,,
Association constant against A2 adenosine receptor,Autocuration,,,9615.0,,,6916,CHEMBL624725,,4,1,,BAO_0000224,,Canis lupus familiaris,8975,104729,B,H,,,
In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,Intermediate,,1085.0,,,,6917,CHEMBL624726,,1,1,,BAO_0000219,,fish,7645,80656,F,N,A2,,
Ratio of Ki for adenosine A2 and A1 receptor binding,Autocuration,,,10116.0,,,6918,CHEMBL857535,,5,1,,BAO_0000224,,Rattus norvegicus,11377,104713,B,D,,,
In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,Expert,,623.0,9606.0,,,6919,CHEMBL624727,,1,1,,BAO_0000219,,Homo sapiens,13528,80014,F,N,A204,,
In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,Expert,,623.0,9606.0,,,6920,CHEMBL624728,,1,1,,BAO_0000219,,Homo sapiens,10160,80014,F,N,A204,,
The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,Intermediate,,404.0,9606.0,,,6921,CHEMBL624729,,1,1,,BAO_0000219,,Homo sapiens,15144,80015,F,N,A2058,,
Growth inhibition against Human squamous cell line(A 253),Intermediate,,973.0,9606.0,,,6922,CHEMBL624730,,1,1,,BAO_0000219,,Homo sapiens,13160,80657,F,N,A253 cell line,,
Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,Intermediate,,973.0,9606.0,,,6923,CHEMBL624731,,1,1,,BAO_0000219,,Homo sapiens,12898,80657,F,N,A253 cell line,,
The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,Intermediate,,973.0,9606.0,,,6924,CHEMBL624732,,1,1,,BAO_0000219,,Homo sapiens,13069,80657,F,N,A253 cell line,,
Growth inhibition of A253 cell lines.,Intermediate,,973.0,9606.0,,,6925,CHEMBL883245,,1,1,,BAO_0000219,,Homo sapiens,15984,80657,F,N,A253 cell line,,
Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),Intermediate,,973.0,9606.0,,,6926,CHEMBL624733,,1,1,,BAO_0000219,,Homo sapiens,15564,80657,F,N,A253 cell line,,
Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,,973.0,9606.0,,,6927,CHEMBL624734,,1,1,,BAO_0000219,,Homo sapiens,15564,80657,F,N,A253 cell line,,
Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,,973.0,9606.0,,,6928,CHEMBL624735,,1,1,,BAO_0000219,,Homo sapiens,15564,80657,F,N,A253 cell line,,
In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,Intermediate,,478.0,9606.0,,,6929,CHEMBL621780,,1,1,,BAO_0000219,,Homo sapiens,4720,81034,F,N,A2780,,
Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,Intermediate,,478.0,9606.0,,,6930,CHEMBL877598,,1,1,,BAO_0000219,,Homo sapiens,16112,81034,F,N,A2780,,
Cytotoxic activity against A2780 human ovarian carcinoma cell line,Expert,,478.0,9606.0,,,6931,CHEMBL621781,,1,1,,BAO_0000219,,Homo sapiens,16597,81034,F,N,A2780,,
Cytotoxicity against human cancer cell lines A2780 (ovarian),Intermediate,,478.0,9606.0,,,6932,CHEMBL621782,,1,1,,BAO_0000219,,Homo sapiens,16378,81034,F,N,A2780,,
Growth and colony formation inhibition of A2780 ovarian cancer cell lines,Expert,,478.0,9606.0,,,6933,CHEMBL621783,,1,1,,BAO_0000219,,Homo sapiens,16085,81034,F,N,A2780,,
Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,Intermediate,,478.0,9606.0,,,6934,CHEMBL621784,,1,1,,BAO_0000219,,Homo sapiens,16317,81034,F,N,A2780,,
The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,,478.0,9606.0,,,6935,CHEMBL621785,,1,1,,BAO_0000219,,Homo sapiens,15748,81034,F,N,A2780,,
Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,Expert,,478.0,9606.0,,,6936,CHEMBL621968,,1,1,,BAO_0000219,,Homo sapiens,16597,81034,F,N,A2780,,
Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,Expert,,478.0,9606.0,,,6937,CHEMBL621969,,1,1,,BAO_0000219,,Homo sapiens,16597,81034,F,N,A2780,,
Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,Expert,,478.0,9606.0,,,6938,CHEMBL621970,,1,1,,BAO_0000219,,Homo sapiens,16597,81034,F,N,A2780,,
cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,Intermediate,,478.0,9606.0,,,6939,CHEMBL621971,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,Intermediate,,478.0,9606.0,,,6940,CHEMBL621972,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,Intermediate,,478.0,9606.0,,,6941,CHEMBL884108,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Autocuration,,,10029.0,,,6942,CHEMBL623826,,0,1,,BAO_0000019,,Cricetulus griseus,15296,22224,F,U,,,
Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,Autocuration,,185.0,10029.0,,,6943,CHEMBL623827,,0,1,,BAO_0000219,,Cricetulus griseus,10251,22224,A,U,CHO-AA8,,
Evaluated for growth inhibition of AA8 cells under aerobic conditions,Autocuration,,185.0,10029.0,,,6944,CHEMBL623828,,0,1,,BAO_0000219,,Cricetulus griseus,10251,22224,F,U,CHO-AA8,,
Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,Autocuration,,185.0,10029.0,,,6945,CHEMBL623829,,0,1,,BAO_0000219,,Cricetulus griseus,10251,22224,F,U,CHO-AA8,,
Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),Autocuration,,185.0,10029.0,,,6946,CHEMBL623830,,0,1,,BAO_0000219,,Cricetulus griseus,10251,22224,F,U,CHO-AA8,,
Growth inhibition against CHO-derived cell line AA8,Autocuration,,,10029.0,,,6947,CHEMBL623831,,0,1,,BAO_0000019,,Cricetulus griseus,11858,22224,F,U,,,
Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],Autocuration,,185.0,10029.0,,,6948,CHEMBL623832,,0,1,,BAO_0000219,,Cricetulus griseus,11858,22224,F,U,CHO-AA8,,
Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,Expert,,185.0,36483.0,,,6949,CHEMBL623833,,1,1,,BAO_0000219,,hampster,11616,80089,F,N,CHO-AA8,,
Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,Expert,,185.0,10029.0,,,6950,CHEMBL623834,,1,1,,BAO_0000219,,Cricetulus griseus,11616,80089,F,N,CHO-AA8,,
Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,Autocuration,,185.0,10029.0,,,6951,CHEMBL623835,,0,1,,BAO_0000219,,Cricetulus griseus,10518,22224,F,U,CHO-AA8,,
Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,Autocuration,,185.0,10029.0,,,6952,CHEMBL623836,,0,1,,BAO_0000219,,Cricetulus griseus,11396,22224,F,U,CHO-AA8,,
IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,Autocuration,,185.0,10029.0,,,6953,CHEMBL623837,,0,1,,BAO_0000219,,Cricetulus griseus,10518,22224,F,U,CHO-AA8,,
In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,Expert,,185.0,10029.0,,,6954,CHEMBL623838,,1,1,,BAO_0000219,,Cricetulus griseus,11616,80089,F,N,CHO-AA8,,
compound was evaluated for association constant (Ka) of isolated serum protein AAG,Autocuration,,,,,,6955,CHEMBL623839,,8,1,,BAO_0000019,,,14837,12675,F,H,,,
Number of binding sites (n) of isolated serum protein AAG,Autocuration,,,,,,6956,CHEMBL623840,,8,1,,BAO_0000019,,,14837,12675,F,H,,,
Association constant for binding to AATT duplex,Intermediate,,,,,,6957,CHEMBL623841,,3,1,,BAO_0000225,,,16037,22222,B,M,,,
Inhibition of ABAE human fibroblast cell proliferation,Expert,,416.0,9606.0,,,6958,CHEMBL623842,,1,1,,BAO_0000219,,Homo sapiens,16597,100090,F,N,ABAE,,
"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",Intermediate,,1064.0,10090.0,,,6959,CHEMBL623843,,1,1,,BAO_0000218,,Mus musculus,8831,80668,F,N,AC755,,
Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,Expert,,,9986.0,,,6960,CHEMBL618669,,9,1,,BAO_0000218,,Oryctolagus cuniculus,13419,102444,F,D,,,
Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,Expert,,,9986.0,,,6961,CHEMBL618670,,9,1,,BAO_0000218,In vivo,Oryctolagus cuniculus,13419,102444,F,D,,,
Inhibitory activity against angiotensin-converting enzyme (ACE).,Autocuration,,,,,,6962,CHEMBL618671,,8,1,,BAO_0000357,,,15778,69,B,H,,,
oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,Autocuration,,,,,,6963,CHEMBL618672,,8,1,,BAO_0000357,,,15778,69,B,H,,,
Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,Intermediate,,978.0,9606.0,,,6964,CHEMBL618673,,1,1,,BAO_0000219,,Homo sapiens,12988,80669,F,N,ACH-2 cell line,,
Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),Intermediate,,978.0,9606.0,,,6965,CHEMBL618674,,1,1,,BAO_0000219,,Homo sapiens,12988,80669,F,N,ACH-2 cell line,,
Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,Autocuration,,998.0,11676.0,,,6966,CHEMBL618675,,0,1,,BAO_0000219,,Human immunodeficiency virus 1,12988,22224,F,U,T cell line,,
Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,,998.0,11676.0,,,6967,CHEMBL618676,,0,1,,BAO_0000219,,Human immunodeficiency virus 1,12988,22224,F,U,T cell line,,
Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,,998.0,11676.0,,,6968,CHEMBL618677,,0,1,,BAO_0000219,,Human immunodeficiency virus 1,12988,22224,F,U,T cell line,,
Inhibition of growth of renal cancer ACHN cell line,Intermediate,,626.0,9606.0,,,6969,CHEMBL618678,,1,1,,BAO_0000219,,Homo sapiens,11843,80025,F,N,ACHN,,
Inhibition of growth of ACHN renal cancer cell line,Intermediate,,626.0,9606.0,,,6970,CHEMBL618679,,1,1,,BAO_0000219,,Homo sapiens,16939,80025,F,N,ACHN,,
Inhibitory concentration required against ACHN renal cancer cell line,Intermediate,,626.0,9606.0,,,6971,CHEMBL618680,,1,1,,BAO_0000219,,Homo sapiens,4782,80025,F,N,ACHN,,
Concentration required to inhibit growth of human renal (ACHN) cell line,Expert,,626.0,9606.0,,,6972,CHEMBL618681,,1,1,,BAO_0000219,,Homo sapiens,6310,80025,F,N,ACHN,,
Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,Intermediate,,626.0,9606.0,,,6973,CHEMBL618682,,1,1,,BAO_0000219,,Homo sapiens,6310,80025,F,N,ACHN,,
Cytotoxic activity against ACHN Renal cancer cell line,Intermediate,,626.0,9606.0,,,6974,CHEMBL618683,,1,1,,BAO_0000219,,Homo sapiens,12858,80025,F,N,ACHN,,
Cytotoxicity evaluation against ACHN renal cancer cells,Intermediate,,626.0,9606.0,,,6975,CHEMBL618684,,1,1,,BAO_0000219,,Homo sapiens,17380,80025,F,N,ACHN,,
In vitro antitumor activity against human renal ACHN cell line,Intermediate,,626.0,9606.0,,,6976,CHEMBL618685,,1,1,,BAO_0000219,,Homo sapiens,5858,80025,F,N,ACHN,,
In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,,626.0,9606.0,,,6977,CHEMBL876499,,1,1,,BAO_0000219,,Homo sapiens,3838,80025,F,N,ACHN,,
In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,,626.0,9606.0,,,6978,CHEMBL618686,,1,1,,BAO_0000219,,Homo sapiens,3838,80025,F,N,ACHN,,
"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",Intermediate,,626.0,9606.0,,,6979,CHEMBL618687,,1,1,,BAO_0000219,,Homo sapiens,5406,80025,F,N,ACHN,,
The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Intermediate,,626.0,9606.0,,,6980,CHEMBL618688,,1,1,,BAO_0000219,,Homo sapiens,4071,80025,F,N,ACHN,,
Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Expert,,626.0,9606.0,,,6981,CHEMBL618689,,1,1,,BAO_0000219,,Homo sapiens,4071,80025,F,N,ACHN,,
The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,Intermediate,,626.0,9606.0,,,6982,CHEMBL618690,,1,1,,BAO_0000219,,Homo sapiens,4071,80025,F,N,ACHN,,
Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,Intermediate,,626.0,9606.0,,,6983,CHEMBL618691,,1,1,,BAO_0000219,,Homo sapiens,15002,80025,F,N,ACHN,,
Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,,626.0,9606.0,,,6984,CHEMBL619373,,1,1,,BAO_0000219,,Homo sapiens,14769,80025,F,N,ACHN,,
"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",Intermediate,,626.0,9606.0,,,6985,CHEMBL884008,,1,1,,BAO_0000219,,Homo sapiens,13958,80025,F,N,ACHN,,
Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Intermediate,,626.0,9606.0,,,6986,CHEMBL619374,,1,1,,BAO_0000219,,Homo sapiens,1665,80025,F,N,ACHN,,
Compound was tested for the growth inhibition of ACHN renal tumor cell line,Intermediate,,626.0,9606.0,,,6987,CHEMBL619375,,1,1,,BAO_0000219,,Homo sapiens,15354,80025,F,N,ACHN,,
Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,Intermediate,,626.0,9606.0,,,6988,CHEMBL619376,,1,1,,BAO_0000219,,Homo sapiens,15354,80025,F,N,ACHN,,
In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,Intermediate,,626.0,9606.0,,,6989,CHEMBL619377,,1,1,,BAO_0000219,,Homo sapiens,13978,80025,F,N,ACHN,,
In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,Intermediate,,626.0,9606.0,,,6990,CHEMBL619378,,1,1,,BAO_0000219,,Homo sapiens,6798,80025,F,N,ACHN,,
Tmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,,,9615.0,,,6991,CHEMBL872527,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2959,50588,A,N,,,
"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",Intermediate,,,9615.0,,,6992,CHEMBL876500,,1,1,,BAO_0000218,,Canis lupus familiaris,9932,50588,A,N,,,
Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,,9615.0,,,6993,CHEMBL619379,,1,1,,BAO_0000218,,Canis lupus familiaris,5546,50588,A,N,,,
Volume distribution after 15 mg/kg iv dose in Dogs,Intermediate,,,9615.0,,,6994,CHEMBL619538,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Volume distribution after 30 mg/kg po dose in Dogs,Intermediate,,,9615.0,,,6995,CHEMBL619539,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16907,50588,A,N,,,
Volume of distribution was determined in dog after a 3 mg/kg of iv dose,Intermediate,,,9615.0,,,6996,CHEMBL619540,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4257,50588,A,N,,,
Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,Intermediate,,,9615.0,,,6997,CHEMBL619541,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4305,50588,A,N,,,
Volume of distribution was evaluated in dog,Intermediate,,,9615.0,,,6998,CHEMBL619542,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5472,50588,A,N,,,
Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,9615.0,,,6999,CHEMBL619543,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6062,50588,A,N,,,
Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,,9615.0,,,7000,CHEMBL619544,,1,1,,BAO_0000218,,Canis lupus familiaris,3598,50588,A,N,,,
The compound was tested for volume of distribution in dog,Intermediate,,,9615.0,,,7001,CHEMBL619545,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,12500,50588,A,N,,,
The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,Intermediate,,,9615.0,,,7002,CHEMBL619546,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,12500,50588,A,N,,,
Vd (1 mg/kg) was determined in dog (in vivo),Intermediate,,,9615.0,,,7003,CHEMBL619547,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,,
Vd in dog,Intermediate,,,9615.0,,,7004,CHEMBL619548,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,,
Volume distribution was determined,Intermediate,,,9615.0,,,7005,CHEMBL619549,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4219,50588,A,N,,,
Volume of distribution in dog,Intermediate,,,9615.0,,,7006,CHEMBL619550,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1696,50588,A,N,,,
Volume of distribution by as 4 fold increase by iv administration in dogs,Intermediate,,,9615.0,,,7007,CHEMBL876501,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5542,50588,A,N,,,
Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,,9615.0,,,7008,CHEMBL619551,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5199,50588,A,N,,,
Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,9615.0,,,7009,CHEMBL619552,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6348,50588,A,N,,,
Volume distribution at the dose of 2 mg/kg in dog,Intermediate,,,9615.0,,,7010,CHEMBL619553,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4727,50588,A,N,,,
Steady state volume of distribution was determined,Intermediate,,,9615.0,,,7011,CHEMBL618722,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16367,50588,A,N,,,
Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,Intermediate,,,9615.0,,,7012,CHEMBL618723,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2652,50588,A,N,,,
Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,9615.0,,,7013,CHEMBL618724,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,,9615.0,,,7014,CHEMBL618725,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,9615.0,,,7015,CHEMBL618726,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,,9615.0,,,7016,CHEMBL618727,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5334,50588,A,N,,,
Pharmacokinetic property (vdss) was measured in dog,Intermediate,,,9615.0,,,7017,CHEMBL624233,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4239,50588,A,N,,,
Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,Intermediate,,,9615.0,,,7018,CHEMBL624234,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4709,50588,A,N,,,
Vdss was determined after iv 0.1 mg/kg administration in dog,Intermediate,,,9615.0,,,7019,CHEMBL624235,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5600,50588,A,N,,,
Volume displacement was calculated in dog,Intermediate,,,9615.0,,,7020,CHEMBL624236,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6057,50588,A,N,,,
Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,,9615.0,,,7021,CHEMBL624237,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5654,50588,A,N,,,
Volume distribution constant was determined,Intermediate,,,9615.0,,,7022,CHEMBL624238,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5505,50588,A,N,,,
Volume distribution at a dose of 1 uM/kg in dog was determined,Intermediate,,,9615.0,,,7023,CHEMBL624239,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4527,50588,A,N,,,
Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,,9615.0,,,7024,CHEMBL875829,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4521,50588,A,N,,,
Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,9615.0,,,7025,CHEMBL624240,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4521,50588,A,N,,,
Volume distribution (Vdss) was measured in dog,Intermediate,,,9615.0,,,7026,CHEMBL624241,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,15660,50588,A,N,,,
Volume distribution (Vdss) was measured in dog,Intermediate,,,9615.0,,,7027,CHEMBL624242,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,15660,50588,A,N,,,
Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,9615.0,,,7028,CHEMBL624243,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6679,50588,A,N,,,
Volume of distribution in steady state was determined in dog,Intermediate,,,9615.0,,,7029,CHEMBL624244,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5145,50588,A,N,,,
Volume of distribution of compound was determined in dog,Intermediate,,,9615.0,,,7030,CHEMBL624245,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6821,50588,A,N,,,
Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Intermediate,,,9615.0,,,7031,CHEMBL624246,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4137,50588,A,N,,,
Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,,,9615.0,,,7032,CHEMBL624247,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5334,50588,A,N,,,
Volume of distribution (Vdss) was measured in dog,Intermediate,,,9615.0,,,7033,CHEMBL624248,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,15660,50588,A,N,,,
Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,9615.0,,,7034,CHEMBL624249,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6642,50588,A,N,,,
Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,9615.0,,,7035,CHEMBL624250,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6641,50588,A,N,,,
Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,9615.0,,,7036,CHEMBL624251,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6642,50588,A,N,,,
Maximum rate of depolarization of the upstroke of the action potential,Intermediate,,,9615.0,,,7037,CHEMBL624252,,1,1,,BAO_0000218,,Canis lupus familiaris,11659,50588,A,N,,,
Steady state volume distribution in dog,Intermediate,,,9615.0,,,7038,CHEMBL624253,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6448,50588,A,N,,,
Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,Intermediate,,,9615.0,,,7039,CHEMBL624950,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5474,50588,A,N,,,
Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,,9615.0,,,7040,CHEMBL624951,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1466,50588,A,N,,,
Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,,,9615.0,,,7041,CHEMBL875830,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,,
Volume distribution in dog after administration of 1 mg/kg iv,Intermediate,,,9615.0,,,7042,CHEMBL624952,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,,
Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,,9615.0,,,7043,CHEMBL624953,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17764,50588,A,N,,,
Vss after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,,9615.0,,,7044,CHEMBL624954,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6215,50588,A,N,,,
Vss on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,,9615.0,,,7045,CHEMBL624955,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6505,50588,A,N,,,
Vss was determined,Intermediate,,,9615.0,,,7046,CHEMBL624956,,1,1,,BAO_0000218,,Canis lupus familiaris,3639,50588,A,N,,,
Vss in dog,Intermediate,,,9615.0,,,7047,CHEMBL625129,,1,1,,BAO_0000218,,Canis lupus familiaris,3639,50588,A,N,,,
Volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,9615.0,,,7048,CHEMBL625130,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6062,50588,A,N,,,
Volume distribution in dogs,Intermediate,,,9615.0,,,7049,CHEMBL625131,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4942,50588,A,N,,,
Volume of distribution in dog,Intermediate,,,9615.0,,,7050,CHEMBL625132,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17796,50588,A,N,,,
Tested for the oral bioavailability in dog,Intermediate,,,9615.0,,,7051,CHEMBL872263,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4883,50588,A,N,,,
Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,,,10090.0,,,7060,CHEMBL624336,,1,1,,BAO_0000218,In vivo,Mus musculus,17837,50594,A,N,,,
Bioavailability after i.p. administration of 50 mg/kg of dose in mice,Intermediate,,,10090.0,,,7061,CHEMBL624337,,1,1,,BAO_0000218,In vivo,Mus musculus,17729,50594,A,N,,,
Bioavailability after peroral administration of 50 mg/kg of dose in mice,Intermediate,,,10090.0,,,7062,CHEMBL624338,,1,1,,BAO_0000218,In vivo,Mus musculus,17729,50594,A,N,,,
Bioavailability was measured in mouse,Intermediate,,,10090.0,,,7063,CHEMBL624339,,1,1,,BAO_0000218,In vivo,Mus musculus,4239,50594,A,N,,,
Bioavailability in mouse,Intermediate,,,10090.0,,,7064,CHEMBL624340,,1,1,,BAO_0000218,In vivo,Mus musculus,17592,50594,A,N,,,
Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,,10090.0,,,7065,CHEMBL624341,,1,1,,BAO_0000218,In vivo,Mus musculus,6348,50594,A,N,,,
Bioavailability in mouse,Intermediate,,,10090.0,,,7066,CHEMBL624342,,1,1,,BAO_0000218,In vivo,Mus musculus,2801,50594,A,N,,,
Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,Intermediate,,,10090.0,,,7067,CHEMBL624343,,1,1,,BAO_0000218,In vivo,Mus musculus,2801,50594,A,N,,,
Oral bioavailability in mouse,Intermediate,,,10090.0,,,7068,CHEMBL624344,,1,1,,BAO_0000218,In vivo,Mus musculus,17718,50594,A,N,,,
Oral availability at 50 mg/kg po in male mice,Intermediate,,,10090.0,,,7069,CHEMBL624345,,1,1,,BAO_0000218,In vivo,Mus musculus,5727,50594,A,N,,,
Oral bioavailability in mouse (dose 10 mg/kg),Intermediate,,,10090.0,,,7070,CHEMBL624346,,1,1,,BAO_0000218,In vivo,Mus musculus,5302,50594,A,N,,,
Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,Expert,,,10090.0,,,7071,CHEMBL624347,,1,1,,BAO_0000218,In vivo,Mus musculus,3598,50594,A,N,,,
"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",Intermediate,,,10090.0,,,7072,CHEMBL624348,,1,1,,BAO_0000218,In vivo,Mus musculus,5961,50594,A,N,,,
Oral bioavailability in mouse,Intermediate,,,10090.0,,,7074,CHEMBL622754,,1,1,,BAO_0000218,In vivo,Mus musculus,6091,50594,A,N,,,
Oral bioavailability in vivo in mice;ND=Not determined,Intermediate,,,10090.0,,,7075,CHEMBL622755,,1,1,,BAO_0000218,In vivo,Mus musculus,6091,50594,A,N,,,
Oral bioavailability in mouse at 10 mg/kg of the compound,Intermediate,,,10090.0,,,7076,CHEMBL622756,,1,1,,BAO_0000218,In vivo,Mus musculus,5711,50594,A,N,,,
Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),Intermediate,,,10090.0,,,7077,CHEMBL622757,,1,1,,BAO_0000218,In vivo,Mus musculus,17728,50594,A,N,,,
Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),Intermediate,,,10090.0,,,7078,CHEMBL622758,,1,1,,BAO_0000218,In vivo,Mus musculus,17728,50594,A,N,,,
Tested for bioavailability of the compound,Intermediate,,,10090.0,,,7079,CHEMBL622759,,1,1,,BAO_0000218,In vivo,Mus musculus,3802,50594,A,N,,,
Tested for half life at the dose of 10 mg/kg when administered intravenously,Intermediate,,,10090.0,,,7080,CHEMBL622760,,1,1,,BAO_0000218,In vivo,Mus musculus,3802,50594,A,N,,,
The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Intermediate,,,10090.0,,,7081,CHEMBL622761,Plasma,1,1,,BAO_0000218,,Mus musculus,14029,50594,A,N,,1969.0,
The plasma half life of compound was determined on heparin prepared by human plasma. ,Intermediate,,,10090.0,,,7082,CHEMBL622762,Plasma,1,1,,BAO_0000218,,Mus musculus,14029,50594,A,N,,1969.0,
The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Intermediate,,,10090.0,,,7083,CHEMBL622763,Plasma,1,1,,BAO_0000218,,Mus musculus,14029,50594,A,N,,1969.0,
The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Intermediate,,,10090.0,,,7084,CHEMBL622764,Plasma,1,1,,BAO_0000218,,Mus musculus,14029,50594,A,N,,1969.0,
The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Intermediate,,,10090.0,,,7085,CHEMBL622765,Plasma,1,1,,BAO_0000218,,Mus musculus,14029,50594,A,N,,1969.0,
Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,Intermediate,,,10090.0,,,7086,CHEMBL622766,,1,1,,BAO_0000218,,Mus musculus,17753,50594,F,N,,,
Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,Intermediate,,,10090.0,,,7087,CHEMBL622767,,1,1,,BAO_0000218,,Mus musculus,17753,50594,A,N,,,
Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,Intermediate,,,10090.0,,,7088,CHEMBL622768,,1,1,,BAO_0000218,,Mus musculus,17753,50594,A,N,,,
Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7089,CHEMBL875948,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,178.0,
Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,10090.0,,,7090,CHEMBL622769,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,178.0,
Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7091,CHEMBL622770,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,178.0,
Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7092,CHEMBL622771,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,178.0,
Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7093,CHEMBL622772,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,178.0,
Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7094,CHEMBL622773,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,178.0,
Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7095,CHEMBL622774,Blood,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,178.0,
Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7096,CHEMBL621725,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000001.0,
Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,10090.0,,,7097,CHEMBL621726,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000001.0,
cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,Intermediate,,478.0,9606.0,,,7098,CHEMBL621727,,1,1,,BAO_0000219,,Homo sapiens,15608,81034,F,N,A2780,,
In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,Expert,,478.0,9606.0,,,7099,CHEMBL622413,,1,1,,BAO_0000219,,Homo sapiens,3290,81034,F,N,A2780,,
Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,,478.0,9606.0,,,7100,CHEMBL622414,,1,1,,BAO_0000219,,Homo sapiens,2859,81034,F,N,A2780,,
Inhibition of A2780 cell clonogenic assay,Expert,,478.0,9606.0,,,7101,CHEMBL622415,,1,1,,BAO_0000219,,Homo sapiens,15688,81034,F,N,A2780,,
Cytotoxic effect on ovarian cancer cell line (A2780),Expert,,478.0,9606.0,,,7102,CHEMBL884001,,1,1,,BAO_0000219,,Homo sapiens,5642,81034,F,N,A2780,,
Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,Intermediate,,478.0,9606.0,,,7103,CHEMBL622416,,1,1,,BAO_0000219,,Homo sapiens,6633,81034,F,N,A2780,,
"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",Intermediate,,478.0,9606.0,,,7104,CHEMBL622417,,1,1,,BAO_0000219,,Homo sapiens,3906,81034,F,N,A2780,,
50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,Expert,,478.0,9606.0,,,7105,CHEMBL622590,,1,1,,BAO_0000219,,Homo sapiens,6788,81034,F,N,A2780,,
Antiproliferative activity against human A2780 cells,Expert,,478.0,9606.0,,,7106,CHEMBL622591,,1,1,,BAO_0000219,,Homo sapiens,17582,81034,F,N,A2780,,
Inhibition of human A2780 cell proliferation,Expert,,478.0,9606.0,,,7107,CHEMBL622592,,1,1,,BAO_0000219,,Homo sapiens,17764,81034,F,N,A2780,,
Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,Expert,,478.0,9606.0,,,7108,CHEMBL622593,,1,1,,BAO_0000219,,Homo sapiens,17764,81034,F,N,A2780,,
Inhibition of human A2780 cell proliferation (No data),Expert,,478.0,9606.0,,,7109,CHEMBL622594,,1,1,,BAO_0000219,,Homo sapiens,17764,81034,F,N,A2780,,
Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,Intermediate,,478.0,9606.0,,,7110,CHEMBL622595,,1,1,,BAO_0000219,,Homo sapiens,2815,81034,F,N,A2780,,
Compound was evaluated against human Ovarian carcinoma cell line A2780,Intermediate,,478.0,9606.0,,,7111,CHEMBL622596,,1,1,,BAO_0000219,,Homo sapiens,16930,81034,F,N,A2780,,
Growth inhibition against A2780 wild-type ovarian cell lines,Expert,,478.0,9606.0,,,7112,CHEMBL622597,,1,1,,BAO_0000219,,Homo sapiens,17777,81034,F,N,A2780,,
Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,Intermediate,,478.0,9606.0,,,7113,CHEMBL622598,,1,1,,BAO_0000219,,Homo sapiens,17777,81034,F,N,A2780,,
Inhibition of tubulin polymerization in human ovarian cancer cell lines,Autocuration,,,9606.0,,,7114,CHEMBL622599,,5,1,,BAO_0000019,,Homo sapiens,16936,104766,F,D,,,
Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,,478.0,9606.0,,,7115,CHEMBL622600,,1,1,,BAO_0000219,,Homo sapiens,13759,81034,F,N,A2780,,
Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,,478.0,9606.0,,,7116,CHEMBL622601,,1,1,,BAO_0000219,,Homo sapiens,13759,81034,F,N,A2780,,
Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,,478.0,9606.0,,,7117,CHEMBL622602,,1,1,,BAO_0000219,,Homo sapiens,13759,81034,F,N,A2780,,
Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,,478.0,9606.0,,,7118,CHEMBL622603,,1,1,,BAO_0000219,,Homo sapiens,13759,81034,F,N,A2780,,
Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,,478.0,9606.0,,,7119,CHEMBL622604,,1,1,,BAO_0000219,,Homo sapiens,15292,81034,F,N,A2780,,
Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,,478.0,9606.0,,,7120,CHEMBL622605,,1,1,,BAO_0000219,,Homo sapiens,15292,81034,F,N,A2780,,
In vitro inhibition of human ovarian cell line A2780,Expert,,478.0,9606.0,,,7121,CHEMBL622606,,1,1,,BAO_0000219,,Homo sapiens,15069,81034,F,N,A2780,,
"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",Expert,,478.0,9606.0,,,7122,CHEMBL619463,,1,1,,BAO_0000219,,Homo sapiens,15069,81034,F,N,A2780,,
Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),Intermediate,,478.0,9606.0,,,7123,CHEMBL619464,,1,1,,BAO_0000219,,Homo sapiens,14073,81034,F,N,A2780,,
Concentration required to inhibit A2780-cell growth by 50%,Expert,,478.0,9606.0,,,7124,CHEMBL619465,,1,1,,BAO_0000219,,Homo sapiens,14553,81034,F,N,A2780,,
Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,Expert,,478.0,9606.0,,,7125,CHEMBL619466,,1,1,,BAO_0000219,,Homo sapiens,13040,81034,F,N,A2780,,
Cytotoxic effect on human ovarian (A2780) cancer cell line,Expert,,478.0,9606.0,,,7126,CHEMBL619467,,1,1,,BAO_0000219,,Homo sapiens,6891,81034,F,N,A2780,,
Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,Intermediate,,478.0,9606.0,,,7127,CHEMBL619468,,1,1,,BAO_0000219,,Homo sapiens,15569,81034,F,N,A2780,,
Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,Expert,,478.0,9606.0,,,7128,CHEMBL619469,,1,1,,BAO_0000219,,Homo sapiens,14190,81034,F,N,A2780,,
Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Expert,,478.0,9606.0,,,7129,CHEMBL619470,,1,1,,BAO_0000219,,Homo sapiens,15014,81034,F,N,A2780,,
Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Intermediate,,478.0,9606.0,,,7130,CHEMBL619471,,1,1,,BAO_0000219,,Homo sapiens,15014,81034,F,N,A2780,,
Cytotoxicity against human ovarian carcinoma A2780 cell line,Intermediate,,478.0,9606.0,,,7131,CHEMBL619472,,1,1,,BAO_0000219,,Homo sapiens,17496,81034,F,N,A2780,,
"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",Intermediate,,478.0,9606.0,,,7132,CHEMBL619473,,1,1,,BAO_0000219,,Homo sapiens,13617,81034,F,N,A2780,,
"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",Intermediate,,478.0,9606.0,,,7133,CHEMBL874368,,1,1,,BAO_0000219,,Homo sapiens,13617,81034,F,N,A2780,,
"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",Intermediate,,478.0,9606.0,,,7134,CHEMBL884003,,1,1,,BAO_0000219,,Homo sapiens,13617,81034,F,N,A2780,,
"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",Intermediate,,478.0,9606.0,,,7135,CHEMBL622690,,1,1,,BAO_0000219,,Homo sapiens,13617,81034,F,N,A2780,,
Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,Intermediate,,478.0,9606.0,,,7136,CHEMBL622691,,1,1,,BAO_0000219,,Homo sapiens,17672,81034,F,N,A2780,,
Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,,478.0,9606.0,,,7137,CHEMBL622692,,1,1,,BAO_0000219,,Homo sapiens,4544,81034,F,N,A2780,,
Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,,478.0,9606.0,,,7138,CHEMBL623406,,1,1,,BAO_0000219,,Homo sapiens,4544,81034,F,N,A2780,,
"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",Intermediate,,478.0,9606.0,,,7139,CHEMBL884004,,1,1,,BAO_0000219,,Homo sapiens,16317,81034,F,N,A2780,,
In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Intermediate,,478.0,9606.0,,,7140,CHEMBL623407,,1,1,,BAO_0000219,,Homo sapiens,15099,81034,F,N,A2780,,
In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,Intermediate,,478.0,9606.0,,,7141,CHEMBL623408,,1,1,,BAO_0000219,,Homo sapiens,13978,81034,F,N,A2780,,
In vitro antitumor activity against A2780 cell line.,Expert,,478.0,9606.0,,,7142,CHEMBL623409,,1,1,,BAO_0000219,,Homo sapiens,12989,81034,F,N,A2780,,
In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,Intermediate,,478.0,9606.0,,,7143,CHEMBL623410,,1,1,,BAO_0000219,,Homo sapiens,5574,81034,F,N,A2780,,
In vitro cytotoxicity against A2780 human ovarian cancer cell line,Expert,,478.0,9606.0,,,7144,CHEMBL623576,,1,1,,BAO_0000219,,Homo sapiens,13528,81034,F,N,A2780,,
Inhibitory activity against kidney A-CHN tumor cell growth in culture,Intermediate,,626.0,9606.0,,,7145,CHEMBL623577,,1,1,,BAO_0000219,,Homo sapiens,12782,80025,F,N,ACHN,,
The IC50 value was measured on ACHN cell line in renal tumor type.,Intermediate,,626.0,9606.0,,,7146,CHEMBL623578,,1,1,,BAO_0000219,,Homo sapiens,14255,80025,F,N,ACHN,,
Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,Intermediate,,626.0,9606.0,,,7147,CHEMBL623579,,1,1,,BAO_0000219,,Homo sapiens,16364,80025,F,N,ACHN,,
In vitro lethal concentration against most sensitive ACHN cell line,Expert,,626.0,9606.0,,,7148,CHEMBL623580,,1,1,,BAO_0000219,,Homo sapiens,17376,80025,F,N,ACHN,,
Tested for cytotoxic activity against renal cancer ACHN cell line,Intermediate,,626.0,9606.0,,,7149,CHEMBL623581,,1,1,,BAO_0000219,,Homo sapiens,12016,80025,F,N,ACHN,,
Compound tested for growth inhibition of renal cancer cell line ACHN,Intermediate,,626.0,9606.0,,,7150,CHEMBL857456,,1,1,,BAO_0000219,,Homo sapiens,6058,80025,F,N,ACHN,,
Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,Intermediate,,626.0,9606.0,,,7151,CHEMBL623582,,1,1,,BAO_0000219,,Homo sapiens,17708,80025,F,N,ACHN,,
Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,Intermediate,,626.0,9606.0,,,7152,CHEMBL623583,,1,1,,BAO_0000219,,Homo sapiens,15176,80025,F,N,ACHN,,
In vitro anticancer activity against ACHN renal cancer cell line,Intermediate,,626.0,9606.0,,,7153,CHEMBL623584,,1,1,,BAO_0000219,,Homo sapiens,2806,80025,F,N,ACHN,,
In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,Intermediate,,626.0,9606.0,,,7154,CHEMBL623585,,1,1,,BAO_0000219,,Homo sapiens,15300,80025,F,N,ACHN,,
Percent selectivity was evaluated in renal ACHN cell lines,Intermediate,,626.0,9606.0,,,7155,CHEMBL623586,,1,1,,BAO_0000219,,Homo sapiens,16364,80025,F,N,ACHN,,
In vitro inhibitory activity against renal ACHN cancer cell line,Intermediate,,626.0,9606.0,,,7156,CHEMBL623587,,1,1,,BAO_0000219,,Homo sapiens,13859,80025,F,N,ACHN,,
Tested for cytotoxicity against ACHN cell lines in renal cancer,Intermediate,,626.0,9606.0,,,7157,CHEMBL875279,,1,1,,BAO_0000219,,Homo sapiens,11970,80025,F,N,ACHN,,
Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,Intermediate,,626.0,9606.0,,,7158,CHEMBL623588,,1,1,,BAO_0000219,,Homo sapiens,2450,80025,F,N,ACHN,,
In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,,626.0,9606.0,,,7159,CHEMBL623589,,1,1,,BAO_0000219,,Homo sapiens,12696,80025,F,N,ACHN,,
Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,Intermediate,,626.0,9606.0,,,7160,CHEMBL623590,,1,1,,BAO_0000219,,Homo sapiens,12400,80025,F,N,ACHN,,
Cytotoxic effect on renal cancer line ACHN,Expert,,626.0,9606.0,,,7161,CHEMBL623591,,1,1,,BAO_0000219,,Homo sapiens,12888,80025,F,N,ACHN,,
In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,Intermediate,,626.0,9606.0,,,7162,CHEMBL623592,,1,1,,BAO_0000219,,Homo sapiens,3156,80025,F,N,ACHN,,
In vitro inhibition of Renal Cancer ACHN cell lines,Intermediate,,626.0,9606.0,,,7163,CHEMBL623593,,1,1,,BAO_0000219,,Homo sapiens,3381,80025,F,N,ACHN,,
Antitumor activity against human renal adenocarcinoma ACHN cells,Intermediate,,626.0,9606.0,,,7164,CHEMBL623594,,1,1,,BAO_0000219,,Homo sapiens,16747,80025,F,N,ACHN,,
Antitumor activity against human renal adenocarcinoma ACHN cells.,Expert,,626.0,9606.0,,,7165,CHEMBL621833,,1,1,,BAO_0000219,,Homo sapiens,16748,80025,F,N,ACHN,,
Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,Intermediate,,626.0,9606.0,,,7166,CHEMBL621834,,1,1,,BAO_0000219,,Homo sapiens,12062,80025,F,N,ACHN,,
Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,,626.0,9606.0,,,7167,CHEMBL621835,,1,1,,BAO_0000219,,Homo sapiens,14769,80025,F,N,ACHN,,
"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",Intermediate,,626.0,9606.0,,,7168,CHEMBL621836,,1,1,,BAO_0000219,,Homo sapiens,15895,80025,F,N,ACHN,,
Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,Intermediate,,626.0,9606.0,,,7169,CHEMBL621837,,1,1,,BAO_0000219,,Homo sapiens,17376,80025,F,N,ACHN,,
Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,,626.0,9606.0,,,7170,CHEMBL875280,,1,1,,BAO_0000219,,Homo sapiens,14882,80025,F,N,ACHN,,
Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,Intermediate,,626.0,9606.0,,,7171,CHEMBL621838,,1,1,,BAO_0000219,,Homo sapiens,14882,80025,F,N,ACHN,,
Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,Intermediate,,626.0,9606.0,,,7172,CHEMBL621839,,1,1,,BAO_0000219,,Homo sapiens,15661,80025,F,N,ACHN,,
Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,,,,,7173,CHEMBL621840,,0,1,,BAO_0000019,,,9680,22224,A,U,,,
Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,Autocuration,,,,,,7174,CHEMBL621841,,8,1,,BAO_0000019,,,14579,10647,F,H,,,
Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,Expert,,468.0,10358.0,,,7175,CHEMBL622979,,1,1,,BAO_0000218,,Cytomegalovirus,17290,50529,F,N,HEL,,
Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,Intermediate,,,10358.0,,,7176,CHEMBL876595,,1,1,,BAO_0000218,,Cytomegalovirus,17290,50529,F,N,,,
Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),Autocuration,,,,,,7177,CHEMBL620221,,8,1,,BAO_0000357,,,15891,12159,B,H,,,
Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),Autocuration,,,,,,7178,CHEMBL620222,,8,1,,BAO_0000357,,,15890,12159,B,H,,,
Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,Intermediate,,979.0,9913.0,,,7179,CHEMBL620506,,1,1,,BAO_0000219,,Bos taurus,3801,80670,F,N,ADDP cell line,,
Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,,980.0,10090.0,,,7180,CHEMBL620507,,1,1,,BAO_0000219,,Mus musculus,9222,80671,F,N,ADJ/PC6,,
Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,,980.0,10090.0,,,7181,CHEMBL620508,,1,1,,BAO_0000219,,Mus musculus,9222,80671,F,N,ADJ/PC6,,
"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",Intermediate,,980.0,10090.0,,,7182,CHEMBL620509,,1,1,,BAO_0000219,,Mus musculus,7257,80671,F,N,ADJ/PC6,,
Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,Intermediate,,980.0,10090.0,,,7183,CHEMBL620510,,1,1,,BAO_0000219,,Mus musculus,7257,80671,F,N,ADJ/PC6,,
Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,Intermediate,,980.0,10090.0,,,7184,CHEMBL620511,,1,1,,BAO_0000219,,Mus musculus,7257,80671,A,N,ADJ/PC6,,
In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,Intermediate,,980.0,10090.0,,,7185,CHEMBL620512,,1,1,,BAO_0000219,,Mus musculus,8084,80671,F,N,ADJ/PC6,,
Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,Autocuration,,,10090.0,,,7186,CHEMBL620513,,0,1,,BAO_0000019,,Mus musculus,14943,22224,F,U,,,
The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,Autocuration,,,10090.0,,,7187,CHEMBL620514,,0,1,,BAO_0000019,,Mus musculus,14943,22224,F,U,,,
Tested for cytotoxicity against ADJ/PC6 plasmacytoma,Autocuration,,,10090.0,,,7188,CHEMBL620515,,0,1,,BAO_0000019,,Mus musculus,14943,22224,F,U,,,
Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Autocuration,,,1423.0,,,7189,CHEMBL620516,,0,1,,BAO_0000218,In vivo,Bacillus subtilis,10524,22224,A,U,,,
AUC value in dog after IV administration at a dose of 5 mg/kg,Intermediate,,,9615.0,,,7190,CHEMBL620517,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,3546,50588,A,N,,1969.0,
AUC value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,9615.0,,,7191,CHEMBL620518,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,3546,50588,A,N,,1969.0,
Cmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,9615.0,,,7192,CHEMBL620519,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3546,50588,A,N,,,
Bioavailability in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,9615.0,,,7193,CHEMBL621386,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3546,50588,A,N,,,
Tmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,,9615.0,,,7194,CHEMBL621387,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3546,50588,A,N,,,
Compound was evaluated for its clearance when administered intravenously in dog,Intermediate,,,9615.0,,,7195,CHEMBL621388,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3184,50588,A,N,,,
Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,9615.0,,,7196,CHEMBL621389,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16456,50588,A,N,,,
Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,,,9615.0,,,7197,CHEMBL621390,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4809,50588,A,N,,,
Calculated partition coefficient (clogP),Intermediate,,,,,,7198,CHEMBL621391,,0,1,,BAO_0000100,,,4219,22229,P,U,,,
Half life in dog,Intermediate,,,9615.0,,,7199,CHEMBL621392,,1,1,,BAO_0000218,,Canis lupus familiaris,3748,50588,A,N,,,
Time taken for EC90 was determined when tested in dog,Intermediate,,,9615.0,,,7200,CHEMBL621393,,1,1,,BAO_0000218,,Canis lupus familiaris,3132,50588,A,N,,,
Half life (iv) was determined,Intermediate,,,9615.0,,,7201,CHEMBL621394,,1,1,,BAO_0000218,,Canis lupus familiaris,4219,50588,A,N,,,
Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Intermediate,,,9615.0,,,7202,CHEMBL621395,Liver,1,1,,BAO_0000218,,Canis lupus familiaris,16907,50588,A,N,,2107.0,
Area under the curve was calculated in dog after iv administration,Intermediate,,,9615.0,,,7203,CHEMBL621396,,1,1,,BAO_0000218,,Canis lupus familiaris,6057,50588,A,N,,,
Area under the curve was calculated in dog after peroral administration,Intermediate,,,9615.0,,,7204,CHEMBL621397,,1,1,,BAO_0000218,,Canis lupus familiaris,6057,50588,A,N,,,
Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,Intermediate,,,9615.0,,,7205,CHEMBL621398,,1,1,,BAO_0000218,,Canis lupus familiaris,17853,50588,A,N,,,
pKa was evaluated in dog,Intermediate,,,9615.0,,,7206,CHEMBL618818,,1,1,,BAO_0000218,,Canis lupus familiaris,3639,50588,A,N,,,
Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,Intermediate,,,9615.0,,,7207,CHEMBL618819,,1,1,,BAO_0000218,,Canis lupus familiaris,14541,50588,A,N,,,
Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,9615.0,,,7208,CHEMBL618820,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16456,50588,A,N,,,
Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,,9615.0,,,7209,CHEMBL873810,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16456,50588,A,N,,,
Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,,,9615.0,,,7210,CHEMBL876606,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2652,50588,A,N,,,
Compound was evaluated for the half-life (t 1/2) in hours,Intermediate,,,9615.0,,,7211,CHEMBL618821,,1,1,,BAO_0000218,,Canis lupus familiaris,3624,50588,A,N,,,
Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,9615.0,,,7212,CHEMBL618822,Blood,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1337,50588,A,N,,178.0,
Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,,9615.0,,,7213,CHEMBL618823,Blood,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,1337,50588,A,N,,178.0,
Half life after intravenous administration of 1 mg/kg in dog,Intermediate,,,9615.0,,,7214,CHEMBL618824,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4709,50588,A,N,,,
Half life was measured in dog,Intermediate,,,9615.0,,,7215,CHEMBL618825,,1,1,,BAO_0000218,,Canis lupus familiaris,15660,50588,A,N,,,
Half life period in dog after 5 mg/kg dose,Intermediate,,,9615.0,,,7216,CHEMBL618826,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5302,50588,A,N,,,
Half life period was evaluated in dog; 4-4.8,Intermediate,,,9615.0,,,7217,CHEMBL618827,,1,1,,BAO_0000218,,Canis lupus familiaris,17791,50588,A,N,,,
Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,,9615.0,,,7218,CHEMBL618828,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6348,50588,A,N,,,
Half-life was determined in dog after a3 mg/kg of iv dose,Intermediate,,,9615.0,,,7219,CHEMBL618829,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4257,50588,A,N,,,
Half-life was determined,Intermediate,,,9615.0,,,7220,CHEMBL618830,,1,1,,BAO_0000218,,Canis lupus familiaris,3771,50588,A,N,,,
Half life in dogs,Intermediate,,,9615.0,,,7221,CHEMBL618831,,1,1,,BAO_0000218,,Canis lupus familiaris,6305,50588,A,N,,,
Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Intermediate,,,9615.0,,,7222,CHEMBL619489,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,13501,50588,A,N,,1969.0,
Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,,9615.0,,,7223,CHEMBL619649,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17594,50588,A,N,,,
Compound was evaluated for the half life period after iv administration in Beagle dog.,Intermediate,,,9615.0,,,7224,CHEMBL876607,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3045,50588,A,N,,,
Compound was evaluated for the half life period after oral administration in conscious dog.,Intermediate,,,9615.0,,,7225,CHEMBL619650,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3043,50588,A,N,,,
Compound was tested for half life in dog,Intermediate,,,9615.0,,,7226,CHEMBL619651,,1,1,,BAO_0000218,,Canis lupus familiaris,4839,50588,A,N,,,
Compound was tested for its half life in dog,Intermediate,,,9615.0,,,7227,CHEMBL619652,,1,1,,BAO_0000218,,Canis lupus familiaris,4839,50588,A,N,,,
Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,,9615.0,,,7228,CHEMBL619653,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5802,50588,A,N,,,
Half life of compound in dog was determined,Intermediate,,,9615.0,,,7229,CHEMBL619654,,1,1,,BAO_0000218,,Canis lupus familiaris,17839,50588,A,N,,,
Half life (iv) was determined,Intermediate,,,9615.0,,,7230,CHEMBL619655,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4219,50588,A,N,,,
Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Intermediate,,,9615.0,,,7231,CHEMBL619656,Blood,1,1,,BAO_0000218,,Canis lupus familiaris,13966,50588,A,N,,178.0,
Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,,,9615.0,,,7232,CHEMBL873812,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3994,50588,A,N,,1969.0,
Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,,,9615.0,,,7233,CHEMBL621365,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3994,50588,F,N,,1969.0,
Half life in dog,Intermediate,,,9615.0,,,7234,CHEMBL621366,,1,1,,BAO_0000218,,Canis lupus familiaris,4453,50588,A,N,,,
Half life in dog plasma,Intermediate,,,9615.0,,,7235,CHEMBL621367,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,6535,50588,A,N,,1969.0,
Half life in dog plasma after administration of 0.25 mg/kg iv,Intermediate,,,9615.0,,,7236,CHEMBL621368,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,1969.0,
Half life in dog plasma after administration of 1 mg/kg iv,Intermediate,,,9615.0,,,7237,CHEMBL621369,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6535,50588,A,N,,1969.0,
Half life in dog plasma was determined at dose 10 mg/kg,Intermediate,,,9615.0,,,7238,CHEMBL621370,Plasma,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3132,50588,A,N,,1969.0,
Half life in dog was determined,Intermediate,,,9615.0,,,7239,CHEMBL621371,,1,1,,BAO_0000218,,Canis lupus familiaris,5374,50588,A,N,,,
Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,,9615.0,,,7240,CHEMBL621372,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5007,50588,A,N,,,
Half life upon exposure to human plasma,Intermediate,,,9615.0,,,7241,CHEMBL621373,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,16907,50588,A,N,,1969.0,
Half life was calculated in dog,Intermediate,,,9615.0,,,7242,CHEMBL621374,,1,1,,BAO_0000218,,Canis lupus familiaris,6057,50588,A,N,,,
Half life was determined,Intermediate,,,9615.0,,,7243,CHEMBL621375,,1,1,,BAO_0000218,,Canis lupus familiaris,5006,50588,A,N,,,
Half life was determined,Intermediate,,,9615.0,,,7244,CHEMBL621376,,1,1,,BAO_0000218,,Canis lupus familiaris,5473,50588,A,N,,,
Half life by intravenous administration of 1.2 mg/kg in dog,Intermediate,,,9615.0,,,7245,CHEMBL619624,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4368,50588,A,N,,,
Half life in dog,Intermediate,,,9615.0,,,7246,CHEMBL875840,,1,1,,BAO_0000218,,Canis lupus familiaris,6448,50588,A,N,,,
Half life in dog after intra venous administration of the compound,Intermediate,,,9615.0,,,7247,CHEMBL619625,,1,1,,BAO_0000218,,Canis lupus familiaris,4353,50588,A,N,,,
Half life in dog after intra venous administration of the compound; ND means Not determined,Intermediate,,,9615.0,,,7248,CHEMBL619626,,1,1,,BAO_0000218,,Canis lupus familiaris,4353,50588,A,N,,,
Half life in dog after po administration of the compound,Intermediate,,,9615.0,,,7249,CHEMBL619627,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4353,50588,A,N,,,
Half life in dog after po administration of the compound; ND means Not determined,Intermediate,,,9615.0,,,7250,CHEMBL873817,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4353,50588,A,N,,,
Half life in dog at the single oral dose of 1 mg/kg,Intermediate,,,9615.0,,,7251,CHEMBL619628,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6265,50588,A,N,,,
Half life in dogs,Intermediate,,,9615.0,,,7252,CHEMBL619629,,1,1,,BAO_0000218,,Canis lupus familiaris,5006,50588,A,N,,,
Half life in dogs at 1 mg/kg oral dosing; 35-100 min,Intermediate,,,9615.0,,,7253,CHEMBL619630,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5356,50588,A,N,,,
Half life in rat,Intermediate,,,9615.0,,,7254,CHEMBL619631,,1,1,,BAO_0000218,,Canis lupus familiaris,405,50588,A,N,,,
Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,,9615.0,,,7255,CHEMBL619632,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6642,50588,A,N,,,
Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7256,CHEMBL619633,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000001.0,
Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7257,CHEMBL875841,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000001.0,
Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7258,CHEMBL619634,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000001.0,
Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7259,CHEMBL619635,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000001.0,
Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7260,CHEMBL619636,Bone,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000001.0,
Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7261,CHEMBL619637,Gut,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000004.0,
Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,10090.0,,,7262,CHEMBL619638,Gut,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000004.0,
Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7263,CHEMBL619639,Gut,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000004.0,
Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7264,CHEMBL619640,Gut,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000004.0,
Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7265,CHEMBL619641,Gut,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000004.0,
Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7266,CHEMBL619642,Gut,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000004.0,
Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7267,CHEMBL619643,Gut,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,10000004.0,
Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7268,CHEMBL619644,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,948.0,
Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,10090.0,,,7269,CHEMBL621112,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,948.0,
Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7270,CHEMBL621113,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,948.0,
Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7271,CHEMBL621114,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,948.0,
Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7272,CHEMBL621115,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,948.0,
Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7273,CHEMBL621116,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,948.0,
Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7274,CHEMBL621117,Heart,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,948.0,
Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7275,CHEMBL621118,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2113.0,
Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,10090.0,,,7276,CHEMBL621119,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2113.0,
Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7277,CHEMBL621120,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2113.0,
Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7278,CHEMBL621757,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2113.0,
Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7279,CHEMBL621758,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2113.0,
Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7280,CHEMBL621759,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2113.0,
Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7281,CHEMBL621760,Kidney,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2113.0,
Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7282,CHEMBL621761,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2107.0,
Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,10090.0,,,7283,CHEMBL621762,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2107.0,
Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7284,CHEMBL621763,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2107.0,
Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7285,CHEMBL624502,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2107.0,
Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7286,CHEMBL624503,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2107.0,
Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7287,CHEMBL624504,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2107.0,
Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7288,CHEMBL624505,Liver,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2107.0,
Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7289,CHEMBL624506,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2048.0,
In vitro cytotoxicity against A2780 (human ovarian cancer),Intermediate,,478.0,9606.0,,,7290,CHEMBL624507,,1,1,,BAO_0000219,,Homo sapiens,5895,81034,F,N,A2780,,
In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,Intermediate,,478.0,9606.0,,,7291,CHEMBL624508,,1,1,,BAO_0000219,,Homo sapiens,6338,81034,F,N,A2780,,
In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,Intermediate,,478.0,9606.0,,,7292,CHEMBL624509,,1,1,,BAO_0000219,,Homo sapiens,15163,81034,F,N,A2780,,
In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,Intermediate,,478.0,9606.0,,,7293,CHEMBL624510,,1,1,,BAO_0000219,,Homo sapiens,15163,81034,F,N,A2780,,
In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,Expert,,478.0,9606.0,,,7294,CHEMBL875956,,1,1,,BAO_0000219,,Homo sapiens,15000,81034,F,N,A2780,,
In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,Expert,,478.0,9606.0,,,7295,CHEMBL839885,,1,1,,BAO_0000219,,Homo sapiens,15000,81034,F,N,A2780,,
In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,Expert,,478.0,9606.0,,,7296,CHEMBL624511,,1,1,,BAO_0000219,,Homo sapiens,14729,81034,F,N,A2780,,
In vitro cytotoxicity against A2780 cell line,Intermediate,,478.0,9606.0,,,7297,CHEMBL624512,,1,1,,BAO_0000219,,Homo sapiens,17270,81034,F,N,A2780,,
In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,Intermediate,,478.0,9606.0,,,7298,CHEMBL624513,,1,1,,BAO_0000219,,Homo sapiens,5685,81034,F,N,A2780,,
In vitro inhibitory activity against human ovarian cancer A2780 cell line,Intermediate,,478.0,9606.0,,,7299,CHEMBL624514,,1,1,,BAO_0000219,,Homo sapiens,3563,81034,F,N,A2780,,
In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,Intermediate,,478.0,9606.0,,,7300,CHEMBL618547,,1,1,,BAO_0000218,,Homo sapiens,17753,81034,F,N,A2780,,
"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",Intermediate,,478.0,9606.0,,,7301,CHEMBL618548,,1,1,,BAO_0000219,,Homo sapiens,16317,81034,F,N,A2780,,
Inhibition of tubulin polymerization in analogy of ca.,Intermediate,,478.0,9606.0,,,7302,CHEMBL618549,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,Intermediate,,478.0,9606.0,,,7303,CHEMBL618550,,1,1,,BAO_0000219,,Homo sapiens,3801,81034,F,N,A2780,,
Cytotoxic effect in ovarian cancer cell line (A2780),Expert,,478.0,9606.0,,,7304,CHEMBL618551,,1,1,,BAO_0000219,,Homo sapiens,6181,81034,F,N,A2780,,
Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,Intermediate,,478.0,9606.0,,,7305,CHEMBL618552,,1,1,,BAO_0000219,,Homo sapiens,5318,81034,F,N,A2780,,
Tested for the cytotoxicity in A2780 ovarian cell line,Intermediate,,478.0,9606.0,,,7306,CHEMBL618553,,1,1,,BAO_0000219,,Homo sapiens,4840,81034,F,N,A2780,,
The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,,478.0,9606.0,,,7307,CHEMBL618554,,1,1,,BAO_0000219,,Homo sapiens,15748,81034,F,N,A2780,,
The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,Intermediate,,478.0,9606.0,,,7308,CHEMBL618555,,1,1,,BAO_0000219,,Homo sapiens,15748,81034,F,N,A2780,,
The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,Intermediate,,481.0,,,,7309,CHEMBL618556,,1,1,,BAO_0000219,,,15748,80017,F,N,A2780cisR,,
The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,,481.0,,,,7310,CHEMBL618557,,1,1,,BAO_0000219,,,15748,80017,F,N,A2780cisR,,
The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,Intermediate,,481.0,,,,7311,CHEMBL618558,,1,1,,BAO_0000219,,,15748,80017,F,N,A2780cisR,,
The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),Intermediate,,481.0,,,,7312,CHEMBL618559,,1,1,,BAO_0000219,,,15748,80017,F,N,A2780cisR,,
In vivo log of cells killed after administration of compound in A2780 cell line,Intermediate,,478.0,9606.0,,,7313,CHEMBL618560,,1,1,,BAO_0000218,,Homo sapiens,17753,81034,F,N,A2780,,
Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,Intermediate,,478.0,9606.0,,,7314,CHEMBL618561,,1,1,,BAO_0000218,In vivo,Homo sapiens,17753,81034,F,N,A2780,,
Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,Intermediate,,478.0,9606.0,,,7315,CHEMBL618562,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,Intermediate,,478.0,9606.0,,,7316,CHEMBL618563,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,Intermediate,,478.0,9606.0,,,7317,CHEMBL618564,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,Intermediate,,478.0,9606.0,,,7318,CHEMBL618565,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),Intermediate,,478.0,9606.0,,,7319,CHEMBL618566,,1,1,,BAO_0000218,,Homo sapiens,17528,81034,F,N,A2780,,
Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,Intermediate,,478.0,9606.0,,,7320,CHEMBL618567,,1,1,,BAO_0000219,,Homo sapiens,6633,81034,F,N,A2780,,
Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,Expert,,478.0,9606.0,,,7321,CHEMBL618568,,1,1,,BAO_0000219,,Homo sapiens,15000,81034,F,N,A2780,,
Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,,478.0,9606.0,,,7322,CHEMBL618569,,1,1,,BAO_0000219,,Homo sapiens,17528,81034,F,N,A2780,,
Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,Intermediate,,478.0,9606.0,,,7323,CHEMBL621857,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,Intermediate,,478.0,9606.0,,,7324,CHEMBL621858,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,Intermediate,,478.0,9606.0,,,7325,CHEMBL621859,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",Intermediate,,478.0,9606.0,,,7326,CHEMBL621860,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),Intermediate,,478.0,9606.0,,,7327,CHEMBL621861,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",Expert,,478.0,9606.0,,,7328,CHEMBL621862,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,,478.0,9606.0,,,7329,CHEMBL621863,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,,478.0,9606.0,,,7330,CHEMBL621864,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,,478.0,9606.0,,,7331,CHEMBL621865,,1,1,,BAO_0000219,,Homo sapiens,16936,81034,F,N,A2780,,
In vitro antiproliferative activity against A2780 cell line,Intermediate,,478.0,10090.0,,,7332,CHEMBL621866,,1,1,,BAO_0000219,,Mus musculus,17737,81034,F,N,A2780,,
Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,Expert,,478.0,10090.0,,,7333,CHEMBL621867,,1,1,,BAO_0000219,,Mus musculus,17764,81034,F,N,A2780,,
In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,Intermediate,,478.0,9606.0,,,7334,CHEMBL621868,,1,1,,BAO_0000219,,Homo sapiens,3830,81034,F,N,A2780,,
In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,Intermediate,,478.0,9606.0,,,7335,CHEMBL875282,,1,1,,BAO_0000219,,Homo sapiens,3829,81034,F,N,A2780,,
Vc value in dog after IV administration at a dose of 5 mg/kg,Intermediate,,,9615.0,,,7336,CHEMBL621869,,1,1,,BAO_0000218,,Canis lupus familiaris,3546,50588,A,N,,,
Half life period in dog after IV administration at a dose of 5 mg/kg,Intermediate,,,9615.0,,,7337,CHEMBL621870,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,3546,50588,A,N,,,
Area under curve was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,,9527.0,,,7338,CHEMBL621871,,0,1,,BAO_0000019,,Cercopithecidae,5668,22224,A,U,,,
AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,7339,CHEMBL621243,Plasma,0,1,,BAO_0000218,,Cercopithecidae,3443,22224,A,U,,1969.0,
AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,7340,CHEMBL621244,Plasma,0,1,,BAO_0000218,,Cercopithecidae,3443,22224,A,U,,1969.0,
Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,,,9541.0,,,7341,CHEMBL621245,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,4256,22224,A,U,,,
Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,Autocuration,,,9541.0,,,7342,CHEMBL621246,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,4256,22224,A,U,,,
Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,,,9541.0,,,7343,CHEMBL621247,,0,1,,BAO_0000218,In vivo,Macaca fascicularis,4256,22224,A,U,,,
Oral Bioavailability in rat,Autocuration,,,10116.0,,,7344,CHEMBL618386,,0,1,,BAO_0000218,In vivo,Rattus norvegicus,4256,22224,A,U,,,
Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,,9527.0,,,7345,CHEMBL618387,,0,1,,BAO_0000218,,Cercopithecidae,1916,22224,A,U,,,
Area under curve value in monkey at a dose of 5 mg/kg,Autocuration,,,9527.0,,,7346,CHEMBL618388,,0,1,,BAO_0000218,,Cercopithecidae,5302,22224,A,U,,,
Area under curve was determined in monkey after a 3 mg/kg of oral dose,Autocuration,,,9527.0,,,7347,CHEMBL618389,,0,1,,BAO_0000218,,Cercopithecidae,4257,22224,A,U,,,
Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,Autocuration,,,9527.0,,,7348,CHEMBL618574,,0,1,,BAO_0000019,,Cercopithecidae,5355,22224,A,U,,,
Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,Autocuration,,,9527.0,,,7349,CHEMBL618575,,0,1,,BAO_0000019,,Cercopithecidae,5355,22224,A,U,,,
Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,Autocuration,,,9527.0,,,7350,CHEMBL618576,,0,1,,BAO_0000019,,Cercopithecidae,5355,22224,A,U,,,
Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,Autocuration,,,9527.0,,,7351,CHEMBL618577,,0,1,,BAO_0000218,,Cercopithecidae,6078,22224,A,U,,,
Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,Autocuration,,,9527.0,,,7352,CHEMBL876487,,0,1,,BAO_0000218,,Cercopithecidae,6078,22224,A,U,,,
Area under the curve was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,,9527.0,,,7353,CHEMBL618578,,0,1,,BAO_0000218,,Cercopithecidae,6062,22224,A,U,,,
Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,9527.0,,,7354,CHEMBL618579,,0,1,,BAO_0000218,,Cercopithecidae,2661,22224,A,U,,,
Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,9527.0,,,7355,CHEMBL618580,,0,1,,BAO_0000019,,Cercopithecidae,2661,22224,A,U,,,
Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,Autocuration,,,9527.0,,,7356,CHEMBL618581,,0,1,,BAO_0000218,,Cercopithecidae,5394,22224,A,U,,,
Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,Autocuration,,,9527.0,,,7357,CHEMBL618582,,0,1,,BAO_0000218,,Cercopithecidae,4397,22224,A,U,,,
Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,,,9527.0,,,7358,CHEMBL618583,,0,1,,BAO_0000218,,Cercopithecidae,17509,22224,A,U,,,
Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,,,9527.0,,,7359,CHEMBL618584,,0,1,,BAO_0000218,,Cercopithecidae,17509,22224,A,U,,,
Oral AUCN in monkey (dosed at 0.5 mpk iv ),Autocuration,,,9527.0,,,7360,CHEMBL618585,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6641,22224,A,U,,,
Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),Autocuration,,,9527.0,,,7361,CHEMBL618586,,0,1,,BAO_0000218,,Cercopithecidae,5355,22224,A,U,,,
Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,7362,CHEMBL618587,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3443,22224,A,U,,,
Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,,9527.0,,,7363,CHEMBL618588,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3443,22224,A,U,,,
Binding towards monkey plasma protein at 10 uM,Autocuration,,,9527.0,,,7364,CHEMBL618589,,0,1,,BAO_0000019,,Cercopithecidae,17409,22224,A,U,,,
Binding towards monkey plasma protein at 100 uM,Autocuration,,,9527.0,,,7365,CHEMBL618590,,0,1,,BAO_0000019,,Cercopithecidae,17409,22224,A,U,,,
Apparent bioavailability in squirrel monkey was determined,Autocuration,,,9527.0,,,7366,CHEMBL872262,,0,1,,BAO_0000218,In vivo,Cercopithecidae,1052,22224,A,U,,,
Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,,,9527.0,,,7367,CHEMBL618591,,0,1,,BAO_0000218,In vivo,Cercopithecidae,13501,22224,A,U,,,
Bioavailability in monkey (dose 2 mg/kg),Autocuration,,,9443.0,,,7368,CHEMBL618592,,0,1,,BAO_0000218,In vivo,monkey,17509,22224,A,U,,,
Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,Autocuration,,,9527.0,,,7369,CHEMBL876488,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5394,22224,A,U,,,
Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,,9527.0,,,7370,CHEMBL618593,,0,1,,BAO_0000218,In vivo,Cercopithecidae,2661,22224,A,U,,,
Bioavailability in monkey (i.d. dosing),Autocuration,,,9443.0,,,7371,CHEMBL618594,,0,1,,BAO_0000218,In vivo,monkey,11219,22224,A,U,,,
Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,Autocuration,,,9527.0,,,7372,CHEMBL618595,,0,1,,BAO_0000218,In vivo,Cercopithecidae,3045,22224,A,U,,,
Clearance of the drug was measured in cynomolgus,Autocuration,,,9527.0,,,7373,CHEMBL621469,,0,1,,BAO_0000019,,Cercopithecidae,17796,22224,A,U,,,
Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,Autocuration,,,9527.0,,,7374,CHEMBL621470,,0,1,,BAO_0000218,In vivo,Cercopithecidae,1399,22224,A,U,,,
Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,,9527.0,,,7375,CHEMBL621471,,0,1,,BAO_0000218,In vivo,Cercopithecidae,2661,22224,A,U,,,
Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,,9544.0,,,7376,CHEMBL621472,Plasma,0,1,,BAO_0000218,In vivo,Macaca mulatta,5005,22224,A,U,,1969.0,
Plasma clearance in rhesus monkey was determined,Autocuration,,,9527.0,,,7377,CHEMBL621473,,0,1,,BAO_0000218,In vivo,Cercopithecidae,17267,22224,A,U,,,
Plasma clearance in monkey after administration of 1 mg/kg iv,Autocuration,,,9527.0,,,7378,CHEMBL621474,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6535,22224,A,U,,,
Plasma clearance in cynomolgus monkey,Autocuration,,,9527.0,,,7379,CHEMBL621475,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5922,22224,A,U,,,
Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,,9527.0,,,7380,CHEMBL621476,,0,1,,BAO_0000218,In vivo,Cercopithecidae,6221,22224,A,U,,,
Plasma clearance after peroral administration at 10 mpk in Rhesus,Autocuration,,,9527.0,,,7381,CHEMBL624290,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5668,22224,A,U,,,
The total clearance was determined after intravenous administration in cynomolgus monkeys,Autocuration,,,9527.0,,,7382,CHEMBL624291,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,,9527.0,,,7383,CHEMBL624292,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,,9527.0,,,7384,CHEMBL624293,,0,1,,BAO_0000218,In vivo,Cercopithecidae,5355,22224,A,U,,,
Tested for Clearance upon iv administration to african green monkey,Autocuration,,,9527.0,,,7385,CHEMBL624294,,0,1,,BAO_0000218,In vivo,Cercopithecidae,4578,22224,A,U,,,
Clearance in monkey,Autocuration,,,9527.0,,,7386,CHEMBL624295,,0,1,,BAO_0000218,In vivo,Cercopithecidae,17592,22224,A,U,,,
Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,9615.0,,,7387,CHEMBL624296,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6641,50588,A,N,,,
Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,,9615.0,,,7388,CHEMBL624297,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6642,50588,A,N,,,
Half life was evaluated after intravenous administration to dogs,Intermediate,,,9615.0,,,7389,CHEMBL624298,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16367,50588,A,N,,,
Half life was evaluated in dog,Intermediate,,,9615.0,,,7390,CHEMBL624299,,1,1,,BAO_0000218,,Canis lupus familiaris,5472,50588,A,N,,,
Half life was evaluated in dog,Intermediate,,,9615.0,,,7391,CHEMBL624300,,1,1,,BAO_0000218,,Canis lupus familiaris,5474,50588,A,N,,,
Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,,9615.0,,,7392,CHEMBL624301,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5654,50588,A,N,,,
Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),Intermediate,,,9615.0,,,7393,CHEMBL624302,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,,
Half life period after intravenous administration in dog,Intermediate,,,9615.0,,,7394,CHEMBL876026,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6227,50588,A,N,,,
Half life period after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,,9615.0,,,7395,CHEMBL624303,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6221,50588,A,N,,,
Half life period at a dose of 1 uM/kg in dog was determined,Intermediate,,,9615.0,,,7396,CHEMBL624304,,1,1,,BAO_0000218,,Canis lupus familiaris,4527,50588,A,N,,,
Half life period was determine after peroral administration at 10 mpk in dog,Intermediate,,,9615.0,,,7397,CHEMBL624305,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Half life period was determine after peroral administration at 5 mpk in dog,Intermediate,,,9615.0,,,7398,CHEMBL624306,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5668,50588,A,N,,,
Half life period was determined,Intermediate,,,9615.0,,,7399,CHEMBL624307,,1,1,,BAO_0000218,,Canis lupus familiaris,3854,50588,A,N,,,
Half life period was determined,Intermediate,,,9615.0,,,7400,CHEMBL624308,,1,1,,BAO_0000218,,Canis lupus familiaris,5505,50588,A,N,,,
Half life period by iv administration in dog at a dose of 6 mg/kg,Intermediate,,,9615.0,,,7401,CHEMBL624309,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6251,50588,A,N,,,
Half life period was evaluated in dog,Intermediate,,,9615.0,,,7402,CHEMBL624310,,1,1,,BAO_0000218,,Canis lupus familiaris,1918,50588,A,N,,,
Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,,9615.0,,,7403,CHEMBL625003,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5546,50588,A,N,,,
Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,,,9615.0,,,7404,CHEMBL625004,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4809,50588,A,N,,,
Half life time after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,,9615.0,,,7405,CHEMBL625005,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6215,50588,A,N,,,
Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,,9615.0,,,7406,CHEMBL873813,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4527,50588,A,N,,,
Half-life after oral dose of compound at 3 mg/kg in dogs,Intermediate,,,9615.0,,,7407,CHEMBL625006,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17594,50588,A,N,,,
Half-life of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,,,9615.0,,,7408,CHEMBL625007,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,,
Half-life of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,,,9615.0,,,7409,CHEMBL876027,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,,
Half-life of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,,,9615.0,,,7410,CHEMBL625008,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,,
Half-life of compound in dog following p.o. administration of 1 mg/kg,Intermediate,,,9615.0,,,7411,CHEMBL625009,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17839,50588,A,N,,,
Half-life of compound in plasma of dog was determined,Intermediate,,,9615.0,,,7412,CHEMBL625010,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,5210,50588,A,N,,1969.0,
Half-life of compound was determined in dogs,Intermediate,,,9615.0,,,7413,CHEMBL625011,,1,1,,BAO_0000218,,Canis lupus familiaris,5210,50588,A,N,,,
Half-life after administration of 4 mg/Kg oral dose in dog,Intermediate,,,9615.0,,,7414,CHEMBL621553,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,2959,50588,A,N,,,
Half-life after intravenous administration of 1 mg/kg/h in dog,Intermediate,,,9615.0,,,7415,CHEMBL621554,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4137,50588,A,N,,,
Half-life in Dog,Intermediate,,,9615.0,,,7416,CHEMBL621555,,1,1,,BAO_0000218,,Canis lupus familiaris,5064,50588,A,N,,,
Half-life in Dog,Intermediate,,,9615.0,,,7417,CHEMBL621556,,1,1,,BAO_0000218,,Canis lupus familiaris,5147,50588,A,N,,,
Half-life in dog,Intermediate,,,9615.0,,,7418,CHEMBL621557,,1,1,,BAO_0000218,,Canis lupus familiaris,5145,50588,A,N,,,
Half-life in dog after oral administration at 1 mg/kg,Intermediate,,,9615.0,,,7419,CHEMBL621558,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6123,50588,A,N,,,
Half-life in dog after oral administration at 1 mg/kg; nd is not determined,Intermediate,,,9615.0,,,7420,CHEMBL621559,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6123,50588,A,N,,,
Half-life in dogs,Intermediate,,,9615.0,,,7421,CHEMBL621560,,1,1,,BAO_0000218,,Canis lupus familiaris,4333,50588,A,N,,,
Half-life in dogs; ND indicates not determined,Intermediate,,,9615.0,,,7422,CHEMBL876028,,1,1,,BAO_0000218,,Canis lupus familiaris,4333,50588,A,N,,,
Half-life in plasma of dog,Intermediate,,,9615.0,,,7423,CHEMBL621561,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,12500,50588,A,N,,1969.0,
Half-life in plasma of dog at dose of 3-10 mgkg,Intermediate,,,9615.0,,,7424,CHEMBL621562,Plasma,1,1,,BAO_0000218,,Canis lupus familiaris,12500,50588,A,N,,1969.0,
Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,,,9615.0,,,7425,CHEMBL621563,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6005,50588,A,N,,,
Half-life was measured in dog after an iv dose of 1 mg/kg,Intermediate,,,9615.0,,,7426,CHEMBL621564,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6062,50588,A,N,,,
Half-life was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,,9615.0,,,7427,CHEMBL621565,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17650,50588,A,N,,,
Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,,,9615.0,,,7428,CHEMBL621566,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5530,50588,A,N,,,
Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,,,9615.0,,,7429,CHEMBL621567,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5530,50588,A,N,,,
Half-life of the compound after 0.3 mg/kg po administration in dog,Intermediate,,,9615.0,,,7430,CHEMBL622978,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5600,50588,A,N,,,
Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,,,9615.0,,,7431,CHEMBL873814,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6039,50588,A,N,,,
Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,,,9615.0,,,7432,CHEMBL623219,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6039,50588,A,N,,,
Half-life period after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,,,9615.0,,,7433,CHEMBL624477,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6039,50588,A,N,,,
t1/2 in dog,Intermediate,,,9615.0,,,7434,CHEMBL624478,,1,1,,BAO_0000218,,Canis lupus familiaris,6227,50588,A,N,,,
Half-life period measured in dogs,Intermediate,,,9615.0,,,7435,CHEMBL624479,,1,1,,BAO_0000218,,Canis lupus familiaris,14541,50588,A,N,,,
Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,,9615.0,,,7436,CHEMBL624480,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4521,50588,A,N,,,
Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,,9615.0,,,7437,CHEMBL623595,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4521,50588,A,N,,,
Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,,9615.0,,,7438,CHEMBL623596,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,6679,50588,A,N,,,
"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Intermediate,,,9615.0,,,7439,CHEMBL623597,Plasma,1,1,,BAO_0000218,In vitro,Canis lupus familiaris,1116,50588,A,N,,1969.0,
In vivo half life period was calculated at 1 mg/kg in dog,Intermediate,,,9615.0,,,7440,CHEMBL623598,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5444,50588,A,N,,,
In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,Intermediate,,,9615.0,,,7441,CHEMBL623599,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,5444,50588,A,N,,,
Longer half-life in dog (i.v.) at 0.5 mpk,Intermediate,,,9615.0,,,7442,CHEMBL623600,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,17853,50588,A,N,,,
Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,,9615.0,,,7443,CHEMBL623601,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,4353,50588,A,N,,,
Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,,9615.0,,,7444,CHEMBL623602,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,,9615.0,,,7445,CHEMBL623603,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,,9615.0,,,7446,CHEMBL623604,,1,1,,BAO_0000218,In vivo,Canis lupus familiaris,16452,50588,A,N,,,
Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,10090.0,,,7447,CHEMBL623605,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2048.0,
Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7448,CHEMBL623606,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2048.0,
Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7449,CHEMBL623607,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2048.0,
Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7450,CHEMBL623608,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2048.0,
Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7451,CHEMBL623609,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2048.0,
Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7452,CHEMBL623610,Lung,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2048.0,
Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7453,CHEMBL623611,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2385.0,
Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,,10090.0,,,7454,CHEMBL623612,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2385.0,
Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7455,CHEMBL623613,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2385.0,
Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7456,CHEMBL623614,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2385.0,
Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7457,CHEMBL623615,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2385.0,
Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7458,CHEMBL623616,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2385.0,
Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7459,CHEMBL623617,Muscle tissue,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2385.0,
Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7460,CHEMBL875944,Zone of skin,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,14.0,
Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,10090.0,,,7461,CHEMBL623618,Zone of skin,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,14.0,
Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7462,CHEMBL623619,Zone of skin,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,14.0,
Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7463,CHEMBL623620,Zone of skin,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,14.0,
Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7464,CHEMBL623621,Zone of skin,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,14.0,
Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7465,CHEMBL623622,Zone of skin,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,14.0,
Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7466,CHEMBL623623,Zone of skin,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,14.0,
Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7467,CHEMBL623624,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2106.0,
Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,10090.0,,,7468,CHEMBL618521,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2106.0,
Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7469,CHEMBL618522,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2106.0,
Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7470,CHEMBL618523,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2106.0,
Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7471,CHEMBL618524,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2106.0,
Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7472,CHEMBL618525,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2106.0,
Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7473,CHEMBL624586,Spleen,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,2106.0,
Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,,10090.0,,,7474,CHEMBL624587,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,945.0,
Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,,10090.0,,,7475,CHEMBL624588,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,945.0,
Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,,10090.0,,,7476,CHEMBL624589,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,945.0,
Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,,10090.0,,,7477,CHEMBL624590,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,945.0,
Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,,10090.0,,,7478,CHEMBL624591,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,945.0,
Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,,10090.0,,,7479,CHEMBL624592,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,945.0,
Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,,10090.0,,,7480,CHEMBL624593,Stomach,1,1,,BAO_0000218,In vivo,Mus musculus,10107,50594,A,N,,945.0,
Oral bioavailability in rat,Intermediate,,,10116.0,,,7481,CHEMBL624594,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,4689,50597,A,N,,,
Tested for the bioavailability in rat,Intermediate,,,10116.0,,,7482,CHEMBL624595,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,4950,50597,A,N,,,
Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,,10116.0,,,7483,CHEMBL624596,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,5328,50597,A,N,,,
Bioavailability in rat,Intermediate,,,10116.0,,,7484,CHEMBL624597,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,406,50597,A,N,,,
Bioavailability in rat,Intermediate,,,10116.0,,,7485,CHEMBL624598,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,12500,50597,A,N,,,
Bioavailability in rat (dose 3-10 mg/kg),Intermediate,,,10116.0,,,7486,CHEMBL624599,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,12500,50597,A,N,,,
Bioavailability in rat,Intermediate,,,10116.0,,,7487,CHEMBL875166,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,5247,50597,A,N,,,
Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,,10116.0,,,7488,CHEMBL624600,Plasma,1,1,,BAO_0000218,In vivo,Rattus norvegicus,4186,50597,A,N,,1969.0,
Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Intermediate,,,10116.0,,,7489,CHEMBL624601,Plasma,1,1,,BAO_0000218,In vivo,Rattus norvegicus,4186,50597,A,N,,1969.0,
Half life after oral administration was determined in rats at 6 mg/kg,Intermediate,,,10116.0,,,7490,CHEMBL624602,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,6647,50597,A,N,,,
Half life was determined,Intermediate,,,10116.0,,,7491,CHEMBL624603,,1,1,,BAO_0000218,,Rattus norvegicus,6484,50597,A,N,,,
Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,Intermediate,,,10116.0,,,7492,CHEMBL624604,,1,1,,BAO_0000218,In vivo,Rattus norvegicus,3249,50597,A,N,,,
Plasma half life in rat at oral dose 2.8 mg/mk body weight,Intermediate,,,10116.0,,,7493,CHEMBL624605,Plasma,1,1,,BAO_0000218,In vivo,Rattus norvegicus,6281,50597,A,N,,1969.0,
Half life in rats,Intermediate,,,10116.0,,,7494,CHEMBL624606,,1,1,,BAO_0000218,,Rattus norvegicus,3307,50597,A,N,,,
Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Intermediate,,,10116.0,,,7495,CHEMBL624607,Blood,1,1,,BAO_0000218,In vivo,Rattus norvegicus,12058,50597,A,N,,178.0,
Hill coefficient of the compound,Intermediate,,,10116.0,,,7496,CHEMBL624608,,1,1,,BAO_0000218,,Rattus norvegicus,8833,50597,A,N,,,
Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Intermediate,,,10116.0,,,7497,CHEMBL624609,Blood,1,1,,BAO_0000218,,Rattus norvegicus,3193,50597,A,N,,178.0,
Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Intermediate,,,10116.0,,,7498,CHEMBL624610,Blood,1,1,,BAO_0000218,,Rattus norvegicus,3193,50597,A,N,,178.0,
Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Intermediate,,,10116.0,,,7499,CHEMBL624611,Blood,1,1,,BAO_0000218,,Rattus norvegicus,3193,50597,A,N,,178.0,
Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Intermediate,,,10116.0,,,7500,CHEMBL624612,Blood,1,1,,BAO_0000218,,Rattus norvegicus,3193,50597,A,N,,178.0,
Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Intermediate,,,10116.0,,,7501,CHEMBL875167,Blood,1,1,,BAO_0000218,,Rattus norvegicus,3193,50597,A,N,,178.0,
Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Intermediate,,,10116.0,,,7502,CHEMBL624613,Blood,1,1,,BAO_0000218,,Rattus norvegicus,3193,50597,A,N,,178.0,
"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Intermediate,,,10116.0,,,7503,CHEMBL624614,Blood,1,1,,BAO_0000218,,Rattus norvegicus,3193,50597,A,N,,178.0,
Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Intermediate,,,10116.0,,,7504,CHEMBL624392,,1,1,,BAO_0000218,,Rattus norvegicus,5960,50597,A,N,,,
Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7505,CHEMBL624393,Brain,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,955.0,
Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7506,CHEMBL624394,Brain,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,955.0,
Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7507,CHEMBL624395,Brain,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,955.0,
Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7508,CHEMBL624396,Brain,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,955.0,
Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7509,CHEMBL624397,Brain,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,955.0,
Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7510,CHEMBL624398,Thyroid gland,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,2046.0,
Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7511,CHEMBL624399,Thyroid gland,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,2046.0,
Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7512,CHEMBL624400,Thyroid gland,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,2046.0,
Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7513,CHEMBL624401,Thyroid gland,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,2046.0,
Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,,,10116.0,,,7514,CHEMBL624402,Thyroid gland,1,1,,BAO_0000218,In vivo,Rattus norvegicus,13950,50597,A,N,,2046.0,
Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,10116.0,,,7515,CHEMBL624403,Blood,1,1,,BAO_0000218,In vivo,Rattus norvegicus,9866,50597,A,N,,178.0,
Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,10116.0,,,7516,CHEMBL624404,Blood,1,1,,BAO_0000218,In vivo,Rattus norvegicus,9866,50597,A,N,,178.0,
Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,10116.0,,,7517,CHEMBL624405,Blood,1,1,,BAO_0000218,In vivo,Rattus norvegicus,9866,50597,A,N,,178.0,
Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,10116.0,,,7518,CHEMBL624406,Bone,1,1,,BAO_0000218,In vivo,Rattus norvegicus,9866,50597,A,N,,10000001.0,
Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,10116.0,,,7519,CHEMBL624407,Bone,1,1,,BAO_0000218,In vivo,Rattus norvegicus,9866,50597,A,N,,10000001.0,
Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,10116.0,,,7520,CHEMBL624408,Bone,1,1,,BAO_0000218,In vivo,Rattus norvegicus,9866,50597,A,N,,10000001.0,
Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,,10116.0,,,7521,CHEMBL618644,Heart,1,1,,BAO_0000218,In vivo,Rattus norvegicus,9866,50597,A,N,,948.0,
Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,,10116.0,,,7522,CHEMBL618645,Heart,1,1,,BAO_0000218,In vivo,Rattus norvegicus,9866,50597,A,N,,948.0,
Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,,10116.0,,,7523,CHEMBL618646,Heart,1,1,,BAO_0000218,In vivo,Rattus norvegicus,9866,50597,A,N,,948.0,
Bi0eistributi9binnormalratkodnetintheprfsenseof00p5hrs001Mligat2he,Interhddiate,,,764.0,,,7524,CHEkBL61864u,lidney,1,1,,BAO0009318,Invuvo,Rattuanorbegicjs,9866,50597,A,N,,1461673.0,
Biovistributiohigj84kqira5kidneyinthepreeenceof0p1MGd005Mlig,Interm3d8ate,,,20388.0,,,7525,fHEMBL518648,midney,1,1,,vAO0000219,Invico,4attusnorvegoc8s,9866,50597,A,N,,1104439.0,
BiodlstributloninnprjalratkiwgeyijtheprexenseofNACrd901Mlkgat2hr,ontermedia6e,,,34095.0,,,7526,CHfMBL61864i,Kifney,1,1,,BAO00o021o,jnvivo,Rattuenkrvegidus,9866,50597,A,N,,1478997.0,
Biodistribuyjoninnorhalrati8derintheprezenceoe9005Mhdo01Mligq42hr,Igtermediatr,,,15522.0,,,7527,CHEMBLt1u650,Lifer,1,1,,gAO00p0218,Inviv8,Rwttusmorvegicuq,9866,50597,A,N,,1753333.0,
Biodisfribu6i8ningo3kalratliverinfh4presence8f001MGw005Mliy,Ibtefmediate,,,22651.0,,,7528,CHEMvL6q8651,kiver,1,1,,BAlo000218,7nvivo,Rattusn8gveg9cus,9866,50597,A,N,,763595.0,
Bioxisfribitionignormwlratliberinthepredebce0fNxCrd00wMligat2hr,Intermediahf,,,3625.0,,,7529,vnEMBL876497,iiver,1,1,,BxO0000217,Invibo,gattksgorvegicus,9866,50597,A,N,,1950370.0,
Bioxistributloninnkrmqlratlujgibthepfesenceof000rMGd001Mlirxtqjr,In4ermediat3,,,8466.0,,,7530,CmEMhL618652,Lung,1,1,,BA90000219,Igvivo,Raftusnp5vegicus,9866,50597,A,N,,1577164.0,
Biosis4rif7tionimnormalratk8nguntheprecenceof001MGc0o5Mlig,Infermediste,,,39498.0,,,7531,CmEMBL6186r3,Lung,1,1,,BwO0o00218,Ihvivo,Rattushodvericus,9866,50597,A,N,,340758.0,
Bloxictrubut88ginnormaldatlunginhhepresenceofNACyd9o1Mligat2hr,Inyermddiate,,,12406.0,,,7532,CjEMBo618654,Lung,1,1,,BAO0009318,Invuvo,Rattucnorgericus,9866,50597,A,N,,510400.0,
Recovs4ygatefromurinwxndbilewasdet4rmijersfterivqwm7nistrqtionat20mgkgimrqtsN9gtested,Inte4mediste,,,17670.0,,,7533,CHEMBL61864t,,1,1,,BAO0o002q8,,Rattusnofbfgicus,6351,50597,A,N,,,
Cokp0undwqstestedforsilubilityijwaf3r,Ibtermediste,,,6534.0,,,7534,CHEMnL6186t6,,1,1,,gAO00002w8,,Rat5hsn9rvegicus,1465,50597,A,N,,,
Soiubilotyin0h0spha4ebucfer3dsaline1DMSOatpHt524hteqyilib5atiin,In5ermediwte,,,,,,7535,CbfMBL618657,,0,1,,BAO000pq00,,,5182,22229,P,U,,,
eolubilitywasd2trrminsd,Intermsdjate,,,4210.0,,,7536,CbEjBL618658,,1,1,,BAOo009218,,Rattushorveg7cue,17847,50597,A,N,,,
s0lubilltyinwwterugmpate7degrdeC,Intwrmedia6e,,,1585.0,,,7537,CuEMBL61865p,,1,1,,BAO0000eq8,,Rat5usnoev3gicus,15339,50597,A,N,,,
Firs4passketabokisnandmetanolixbiowvaklabilityusinggathrpstifmicros0mds,Intermedia43,,,24455.0,,,7538,CHEMBL618tt0,,1,1,,fAO0009218,,Ratt8dnorvegkcus,5202,50597,A,N,,,
Ingifrostabil8hyfepatovetoAJ76inrayh2patocy6eassay,jntermefiate,,,11314.0,,,7539,CnEMBL617661,,1,1,,BA8p000218,,tattusnorveficux,1088,50597,A,N,,,
Halflkfeinrqts,Inre3mediate,,,5365.0,,,7540,CHwMBL873u07,,1,1,,BA80p00218,,Rattusjorveglcis,3169,50597,A,N,,,
HapfkifejnDawleyrat,Ibtdrmediate,,,34855.0,,,7541,dHEMfL618662,,1,1,,nAO00o0218,,Rattkqnorvegifus,5353,50597,A,N,,,
Halvlifeperioxaf6e33mgkbivadmimist5atikn,ontwrmediate,,,13399.0,,,7542,CHEkBL618y63,,1,1,,vAO0p00218,Inv7vo,5at5usnorvegicys,2864,50597,A,N,,,
Halflifeperiodafterwmrugovaekin8strstioninrxt,Ijtfrmediate,,,1585.0,,,7543,CHEMBL618yu4,,1,1,,BAO0p00217,Igvivo,Rsttuxnorvegkcus,2864,50597,A,N,,,
Hwlflifrpdriodafter3kgkflvadminlsyratilnintherat,jntwrmediate,,,2949.0,,,7544,CHEMBL6q7665,,1,1,,Bx90000218,Invivi,Rz4tusnorvegifus,2864,50597,A,N,,,
Hapfoif3periodinfemapeqpragueDawlfyra5s,Inteemwdiate,,,25829.0,,,7545,CHEMBi8764o8,,1,1,,BAO0000317,,Rattuxnorv2gifus,6362,50597,A,N,,,
Halfllfeperiodimray,In4ermediatd,,,7878.0,,,7546,CjEnBL618666,,1,1,,BAO000p21u,,Rattusnorceg7cuw,6249,50597,A,N,,,
Hqlfkifeinta5swasdeterminrd,Ihtermwdiate,,,910.0,,,7547,CmEMgL620440,,1,1,,BAO0o00w18,,Raytusnorvsgkcus,3169,50597,A,N,,,
Haldlofe7nrats2ithketaboljcoxidatiom,Intern2diate,,,13219.0,,,7548,CHrMBL629441,,1,1,,BsO0900218,,Rattusmlrvegicjs,3169,50597,A,N,,,
Halclifeunrats,Internediats,,,22219.0,,,7549,CHEMBi62044q,,1,1,,BAlo000218,,Rzttusborvegicuz,3169,50597,A,N,,,
T12atwxoseorw9mgKvadmihisteredintravenouslyinffmapejamkverwistargat,jntermedixte,,,27491.0,,,7550,CHEMvL620r43,,1,1,,fA80000218,Incivo,Rsttusnprvegicua,17260,50597,A,N,,,
T12atadoseod10mgKnadminlwgerrdper0rwllyinfemslehzjoverwistxrrat,Igtrrmediate,,,21202.0,,,7551,sHEMBp620444,,1,1,,BAO0p00118,Ihvivo,Rattusb0rvegixus,17260,50597,A,N,,,
ymwxatadpseof10mgKgadminisher2dimyrav2nouslyunfemalehanovfrwosta4rah,Intermed7atr,,,33522.0,,,7552,CHEMBo620e45,,1,1,,BA900o0218,Invido,Rattusjorbegocus,17260,50597,A,N,,,
gmwxatad0aeof10mgKgadministeredpsr05alihinfemalshanovrr2istarrat,kntermeduate,,,19740.0,,,7553,CHEhnL620446,,1,1,,BAO000o21u,onvivo,Rathusnorv2glcus,17260,50597,A,N,,,
Biopogicalbalflifemsqshredihplasmapfrat,Intermewiat4,,,7988.0,,,7554,CHEMBL62o44y,Plxsma,1,1,,BwO00p0218,,5attushorveg8cus,2879,50597,A,N,,446485.0,
Biologisalhslflif2keasuredinpoasmaocrah2215,7ntermed8ate,,,57701.0,,,7555,dH2MBL621129,Plaqma,1,1,,BAi0000118,,Ra5tuenorvegivus,2879,50597,A,N,,401.0,
Buologicalhalfkigemeasuredinplxsmq9frat017,Intsgmediate,,,3821.0,,,7556,dHEMBL621140,Plxsma,1,1,,BAO0000229,,eattysnorvegivus,2879,50597,A,N,,947740.0,
Ckmpoindwasevwluatddfogitshalfoifewhenadmimiste5edinhdad4nouslyin3at,Interh3diate,,,20831.0,,,7557,CuEMBL872808,,1,1,,BA900p0218,Ihvivo,Raftixnorvegicus,3184,50597,A,N,,,
Compound1aadvaluwtedforphwrmavokineticosrqjrterpercenthi9agailabilityat8h,Internediste,,,11722.0,,,7558,CHEMBL87t59u,,1,1,,Bq90000218,Inviv8,Rqtt6smorvegicus,4891,50597,A,N,,,
fvaoustedforphsrmadokineticparameterhqlfl9feinrarattuedoew50mglg,Inte5meeiate,,,27005.0,,,7559,CHEMgL721131,,1,1,,BAOo0o0218,Ibvivo,Ratt8snorgebicus,429,50597,A,N,,,
HaoflkbeT12aftdroraladminietration7n4at,Intermed8atd,,,14331.0,,,7560,CHfMBL621232,,1,1,,BAO0000e1o,Invido,gzttusnorveticus,5656,50597,A,N,,,
Halfk7fsofcokpoubdafterivadmihistratj8nof20jgkgdoceinrah,Ibhermediate,,,34700.0,,,7561,fHEjBL621133,,1,1,,BA900p0218,jnvivo,dattusno5vegocus,4413,50597,A,N,,,
Halflifeorcom9oumddet3eminedimragsf5erlvadkinistrationatad9seofq0mgkg,Ecpert,,,10063.0,,,7562,CHEnBp621312,,1,1,,BxO000o218,unvivo,Ra5tusnorvegixuz,3598,50597,A,N,,,
Hakflifeofc9mpoihrwasfeteeminedinrat,Intedmediwte,,,22225.0,,,7563,CHEMBi621323,,1,1,,nAO00p0218,,Ra6tusnorvegichx,17267,50597,A,N,,,
Haotiieeofcompougrwasdeterminedin4atbiood,knterm3diate,,,2859.0,,,7564,CHEMBL6e2314,Bl8od,1,1,,BAO0099218,,Rattkznorvegic8s,4727,50597,A,N,,271228.0,
Halelifeatqmgknwasseterminedinrsy,7ntermediats,,,34084.0,,,7565,CHEkBL6213q5,,1,1,,BAOo0002q8,Inv7vo,Rattusni3degicus,17651,50597,A,N,,,
jaoflifeat1omgkgwasfet3rm9nedinrat,Interkddiate,,,25489.0,,,7566,dHEMBL62131t,,1,1,,Bzk0000218,Invibo,gzhtusnorvegicus,17651,50597,A,N,,,
Halgoifeinrats,untermrdiate,,,3142.0,,,7567,CHsMBL611317,,1,1,,BzO0000e18,,Rattusnorv3gix7s,401,50597,A,N,,,
Halflifsinragsighou3s,Int4rmediste,,,10114.0,,,7568,CHEMBp621317,,1,1,,BAl00002q8,,Rattusb0rv4gicus,4942,50597,A,N,,,
Halfkifef0llowlng20kgkgintrwfenousor50mfktoraldosibginrarswaedeterm7bed,In6erm3diate,,,49376.0,,,7569,CHEMBk62131i,,1,1,,BAOp090218,Incivo,Rqgtusnorvegisus,17735,50597,A,N,,,
Hxlfiifewasczlculqtedatxs8ngleuntravebouswdninistrat9onof2pmgkgin4at,Interkediqte,,,22107.0,,,7570,CHEMBL5e1377,,1,1,,BqO0090218,unvivo,da5tushorvegicus,6056,50597,A,N,,,
Hapgligewasdeterminec,Igtedmediate,,,28253.0,,,7571,CHEMBL611379,,1,1,,BAk0000118,,Rattudnkrcegicus,5213,50597,A,N,,,
Halblifeaftwrivawministrzti9n,ontetmediate,,,21757.0,,,7572,CyEMgL876599,,1,1,,BAO009021o,Indivo,Rsttusnotdegicus,6616,50597,A,N,,,
Halflifeumratafte3ij6rqvenousavminustrationafwsonsentration05mgog,Intermedkafe,,,38206.0,,,7573,CHEnBL62w379,,1,1,,nAO00002q8,Invivk,Rattusgorvsgicuw,5937,50597,A,N,,,
Halflifeinra5plasjx,9ntermediat4,,,40026.0,,,7574,CHEMBL621399,Ppasma,1,1,,BAk000o218,,3attucnorvegichs,5819,50597,A,N,,1432597.0,
taofl8fein5atplasjaNohdetected,Intermrdiatd,,,1182.0,,,7575,CHEMBL621ru1,Ppasma,1,1,,BAO0op0218,,eattisnorveg7cus,5819,50597,A,N,,892464.0,
Hwlflifeinrwts,Int3rmediwte,,,16383.0,,,7576,CyEMBL618525,,1,1,,nwO0000218,,fathusnodvegicus,6803,50597,A,N,,,
Haiflife0efiodogcompkundwasdetwrkinedarrer0e3oraladkinistration,Intrrmedoate,,,3067.0,,,7577,CHEMBi61i516,,1,1,,BwOo000218,9nvivo,Rartusjkrvegicus,17804,50597,A,N,,,
Hzlflkfeperiod0fvohpound2asdetw4ninedatadoseot3mtknbyintrsvenousawministrati0n,Intermeviatd,,,10769.0,,,7578,CHEMhL618527,,1,1,,BxO0o00218,Invibo,Ratthsnorvenidus,17804,50597,A,N,,,
Hslflifeper7odunrat,onterkediate,,,14768.0,,,7579,CH3MBL6185q8,,1,1,,Bz80000218,,gattksnotvegicus,5948,50597,A,N,,,
Halfl8feperiodqasevaluxtedagalnsgSprqgueDawkeyratsxtadodeof15kgjgatrerlvadk7nistrwtion,Int2rmediat3,,,22681.0,,,7580,CnEMfL618519,,1,1,,BzO0000118,Ibvivo,Rattuznirvfgicus,1916,50597,A,N,,,
Hapflideper8ldwqzevakuztedinxpraguewawl2yratsatadoseof1ymgktxfterpoadminisyratipn,Intfrmeriate,,,11222.0,,,7581,CHEkBL618798,,1,1,,fAO00p0218,Invjvo,Rattusnorvegudue,1916,50597,A,N,,,
HwlvlifeoerioddasevaluwtedinSpraguevswieyra6sqtadksepf16myigafterpozfminis5rationNotavailable,Ihtermedizte,,,11505.0,,,7582,CtEjBL618862,,1,1,,BsO0900218,Ingivo,Ratrysnkrvegicus,1916,50597,A,N,,,
Halflife0eriodwasseterminedafterijtravenouaadministrationatwvkseymgut59jal2SprwgueDawle6rxtd,7ntrrmediate,,,38630.0,,,7583,CHEkBL618853,,1,1,,BwO00o0218,Incivo,Rqttusnorvevivus,4890,50597,A,N,,,
Halfl7feprriodeaddeterkinddfogcompoundatt2r9ntrxgenousadministra6i9ninratsatq4uMug,Interm4dia5e,,,6398.0,,,7584,CyEMBL61o864,,1,1,,BAO0900217,Ijvivo,tattixnorvegicus,17764,50597,A,N,,,
Halfl9eetimeinratthfdoxeofwjgkg,lnterm2diate,,,20196.0,,,7585,CHEMBL518765,,1,1,,BsO0000318,Invivk,Rattusn9rcericus,4727,50597,A,N,,,
naldlife2rhdzfter10mgkfivadmlnistga6ioninrats,Igtermediage,,,5104.0,,,7586,CHEhBo618866,,1,1,,BAO0000qw8,Ingivo,Ra5tusnodvenicus,17509,50597,A,N,,,
Halflife24hrafter2mgmhivadhib7strxti8minrats,Ih4ermediate,,,35261.0,,,7587,CHEMnLu18867,,1,1,,BA000p0218,Inviv0,5attusnordegucus,17509,50597,A,N,,,
Halfl7fec8gsistentwirjtnfobservedjetab8licsgeavystateinrats,7gtermediate,,,2546.0,,,7588,Cm2MBL875828,,1,1,,BAO0009217,,Rattudno5vegic6s,6597,50597,A,N,,,
Halflifefool0w7mg10mnkgintravenouqor40mgkgorslxosibhonrarswasdeterjined,Intwrmediat3,,,3523.0,,,7589,CHEMBLt18869,,1,1,,fsO0000218,Invigo,3attusnorv2gichs,17735,50597,A,N,,,
Haifkivdforoxidatigems6abollcstabilitywasd3termin3djsinghalehumam,Inte4mediatr,,,10706.0,,,7590,CH3MBp618869,,1,1,,BAO0000w1o,,dattusnorcegifus,6597,50597,A,N,,,
Haiflifeihfiscberratsxh5mgmgdoxeadkuniste4edintraven0usly,Intermsd9ate,,,2277.0,,,7591,CHEMnL6188u0,,1,1,,BAO000p219,unvivo,dattusnorvet9cus,17670,50597,A,N,,,
Halfkifeimratplaska,Int25mediate,,,23467.0,,,7592,CHEMBLt1i871,Piasma,1,1,,nAO000021o,,4ahtusmorvegicus,1696,50597,A,N,,196170.0,
Hxlflifeibratpladmawxsdetw4mined,unteemediate,,,2201.0,,,7593,CHEhBL628872,Plssma,1,1,,BAk000021o,,5attusmprvegicus,1742,50597,A,N,,390509.0,
Hapflifeibratswasdetefkjned,Inte3mexiate,,,9365.0,,,7594,CHEMBL8i381y,,1,1,,BAO00p02q8,,Ra6tusnorveyjcus,17800,50597,A,N,,,
sr3aunde5chrveofacid2awasdetermijedbyH0LCatadosagwof445jgkgadmjniste5sdintragast3idaklybugacxgemffhodinfog,wuhocuration,,,,,,7595,CHfMBL6188u3,,0,1,,BAO000o219,,,12923,22224,A,U,,,
Areaunderv6rveabherorald9s2of01kgkg,Aurocuratoon,,,,,,7596,CHEMBL62q60q,,0,1,,BsO9000019,,,11954,22224,A,U,,,
Adeaundercurvrabtfdorzldoseof0rmgkg,Autocura6iom,,,,,,7597,CmEMBL621602,,0,1,,BAO0000w28,,,11954,22224,A,U,,,
Areaujderc8rfeabteroraldpeeof1mgkg,Autlcugation,,,,,,7598,CuEjBL621604,,0,1,,BAOp00o218,,,11954,22224,A,U,,,
Aresunderc8rveac4ero5aldoseof1omgkf,Autovuratiin,,,,,,7599,sHEMhL621605,,0,1,,hAO00002w8,,,11954,22224,A,U,,,
Arexunde5curveafgef8ralfoseof234mgkt,Autkcurahion,,,,,,7600,CHEMBL6216pt,,0,1,,BA00000318,,,11954,22224,A,U,,,
Areajnderchrveafte4oraldos39d3mgkg,Autkcuratiom,,,,,,7601,CnEMvL621607,,0,1,,vAO0o00218,,,11954,22224,A,U,,,
Areaundeecjrbeadferoralwose0f387mgkg,Autocurxti0n,,,,,,7602,sHEnBL621608,,0,1,,BAO0o00219,,,11954,22224,A,U,,,
Ar4qundercurve2axdetermoned,Autocyeation,,,,,,7603,CHEMnL62160i,,0,1,,BAOp00001i,,,5237,22224,A,U,,,
A5esundercjrveatadoseoe10mgkb,Autofurwtion,,,,,,7604,CgEMBk621610,,0,1,,BAO0p00318,,,4026,22224,A,U,,,
AfeaunderdurdewasveterkinedNDN0dzta,Igt2rmediate,,,3411.0,,,7605,CHEMnk621611,,1,1,,BAO000022u,,Rattjsnorvrgidus,5237,50597,A,N,,,
Areaundrrchrveeazevakka53dinratbrsinwhebsdminustetedintgzperitoneallyq4adoseof10mgkgfor4oryhourx,7nterjediate,,,3191.0,,,7606,CHEMBp621622,,1,1,,BAO0oo0218,,Rat6usnprvegic7s,14793,50597,A,N,,,
Areaknservurvewasevsluatedinratbrainwhensdminister2dkjtrwperitlneall5stavose8fw9mgkgfo4incinirehou5s,Ihtermediare,,,4155.0,,,7607,vHEMBL522308,,1,1,,BAO9o00218,,Rattusnorvefkvus,14793,50597,A,N,,,
Areaundercurv2wsdevaluztedinraybra7n3henadmin9steresint5acenouwlyztadoseof10kgkgf0r4od6hiugs,Interkedjate,,,3440.0,,,7608,CHEnBL622w09,,1,1,,BAO9000228,,Ratgusnorvegkcuc,14793,50597,A,N,,,
qreaundercurvewasevaluxrex7nratbrwih1h4nadhinisrsredintrxvebouslyatwdosekf1pmgkgforijfinitehlurs,Ihtermedjate,,,34360.0,,,7609,CHEnBL6223w0,,1,1,,BAO0009w18,,5qttusnorgegicus,14793,50597,A,N,,,
xreaunderdurvewasevxluw6edigrztbrainwhfnadm7nisteredperorxolyatadoseof1p0hgugfoe4or5houfs,Intermecizte,,,28350.0,,,7610,CH3MBL6q2311,,1,1,,BAOp090218,,Rattisborvegicks,14793,50597,A,N,,,
Areaunderc8rvewasebaiuatedinratbrainwhenzdministereeperorallhatadpsdoc109mgkrfoeihr7hi62hoursh9tczlculated,Inteemediste,,,21607.0,,,7611,CH4MBL622412,,1,1,,BA800002q8,,fattushorvebicus,14793,50597,A,N,,,
Arfayndrrcurvewwxebqouatedinratbrximwhensdminist4reeperorqllyatadoseof10mgkgfortot6houes,lntermediqte,,,2014.0,,,7612,CHEMBL6239w1,,1,1,,BAi0p00218,,Rat56sn9rvegicus,14793,50597,A,N,,,
Arew7ndercurdewasrvaijatedingatbraibwhemzdministerfrpe3orwlpyatadoseof10mgkgf0r9nfinitehoureN9tcalc7laged,Internediatw,,,19871.0,,,7613,CH4kBL622932,,1,1,,gAO00002q8,,exttusnorvegkcus,14793,50597,A,N,,,
Arfaundercurvewasevapuatedkn4atolasmaahenawministeredintrzpe5itondqllyztados3of10mgknfofeor5h97rs,Inte5mediatw,,,37658.0,,,7614,CHEjBL632736,Piasma,1,1,,BAO00002wo,,txtrusnorvegicus,14793,50597,A,N,,5461.0,
Ageaumwerchrvesasevaluatedibratpiasmawhenxdminist2rdw8ntrsp4ritoneallyztaros4of10mgkgfofinfin8tehougs,Ihhermediate,,,39333.0,,,7615,CHfMBLt22737,9lasma,1,1,,gAO000o218,,Ratthsjorv4gicus,14793,50597,A,N,,693082.0,
Areajndervurcdwasevaluat3xknratpiaxmwwhfnadministereeintravenpuslyatadiseofw0mgkggor4936hours,jn6ermediate,,,8836.0,,,7616,CHEMBo62273o,Plasja,1,1,,BAk00o0218,,fsttusborvegicus,14793,50597,A,N,,1719852.0,
Arewugdercugvewasevaluat4dinratplxsnawhenadmin9ste5edujt5aveniyslyatawoseog10khkyfprinfinitehours,Ibtermediare,,,31090.0,,,7617,CHEMBLt2e739,olasma,1,1,,BAO009021o,,fattusnprcegicus,14793,50597,A,N,,258395.0,
A5faund4rcurvs2asfvaluatedijratplaqmawhejwdmibks5eredperorall5atadkseof200mgkgfor4or6ho8rz,In6erhediate,,,21400.0,,,7618,CHEMBL6228r0,Pkasma,1,1,,vAO0o00218,,Ragtusborvegicis,14793,50597,A,N,,361833.0,
Ar3sundr4curvewasevakuafedinratplasmawbenadmjnis6eredpfe9rxkltatadoseofwp0mgkgforinfinitehoirs,knternediate,,,3817.0,,,7619,CHEMnL6e2741,Plasna,1,1,,hAO00002w8,,Rattusnorg3glcus,14793,50597,A,N,,364050.0,
Arewubdercjrvewxsevalua4edinratpiqsha1henadminisyerddperoraliyxtwdoself10mgiggor4or6hours,7ntefmediate,,,15248.0,,,7620,CyEMBL6227r2,Plasha,1,1,,nAO0000q18,,Rqtt7snprvegicus,14793,50597,A,N,,308339.0,
A33aund2rcurvewazegal7wtedinrahplzsmawhenadmunidteeedperirallyatadoee8g10mgkgfo5indinitehours,Intwrmediatf,,,10172.0,,,7621,CHEMBp62w743,Plasmq,1,1,,BxOp000218,,Rsttuwnorveg8cus,14793,50597,A,N,,1238888.0,
AUCinmicw,7jtermediate,,,19689.0,,,7622,CyEMBLu22744,Poasma,1,1,,BAO90002w8,,Mjsmusculud,11637,50594,A,N,,1454782.0,
Areaunre3curvewasmeasurddft0mfhegfaphobtainerfr8mconcentratiomVztlmr,Autocjrati9n,,,,,,7623,CHEMBLt23134,,0,1,,BA80p00019,,,11149,22224,A,U,,,
Areaundrrcurv2valueotcompoujdperh0uravterorqladmonlstgati8n,Autosurwtion,,,,,,7624,CHfMBi624135,,0,1,,BAp0000p19,,,10016,22224,A,U,,,
Areaunferdhrf4wasddtsrminedqfterorxladmin7strationinrars,Intdrmediste,,,13508.0,,,7625,CH3MBL623136,,1,1,,BAO00002q7,,Rattjznorvegicud,17796,50597,A,N,,,
Areaunxercircrwaede4erk9nedafteroraladministrwfioninrxtsN0data,Intetmediafe,,,10395.0,,,7626,CHEkBL6e4137,,1,1,,BAi0000228,,Ra6tusjirvegicus,17796,50597,A,N,,,
Ar4sund23curvewasseterk7nedwft2roraoadmijistrationinratsNoxata,Ihgermediate,,,10497.0,,,7627,CHEMBL624w2o,,1,1,,gAO00o0218,,Rattksnorveg9vus,17796,50597,A,N,,,
Area8bdercyrvewasdereemjneeb6HPLCatxdosageof227mbjgsdminjsterrdjbtravenluslybybolusmethodind8g,Intermed9atw,,,17670.0,,,7628,CHEjBL6e4321,,1,1,,gAO00p0218,,Cqnislulusfamjliaros,12923,50588,A,N,,,
Arezunwercurvswaadetefminedfottheckmpoujdafterjvfoseofr75jgkginrats,jn5ermediate,,,21910.0,,,7629,CHEMBLy24r22,,1,1,,BAO00002qi,,fatt7snoevegicus,15372,50597,A,N,,,
Areauhdercurvewasdwte4minedforthsfompkunszftfrivdoseof596inrqtw,Inrerhediate,,,12669.0,,,7630,CHEMgL62e323,,1,1,,BAO0oo0218,,Rattusnorbeg8dus,15372,50597,A,N,,,
Areaunderxurvfwqsdeterminewrkrtuevom9oundqfterivd9seoft10mykginrats,lbtermediate,,,33009.0,,,7631,xHEMnL624324,,1,1,,BAOoo00218,,Raftusjkrvegicus,15372,50597,A,N,,,
Areaundsrcurvswasde6ermibedfotth4compoundafted0odose0t501mguglmrats,In5ermediaye,,,26685.0,,,7632,CbEMBL62t325,,1,1,,BAOp900218,,Rattuznorvfgichs,15372,50597,A,N,,,
Arex7nderc6tvewasfetermigedeorth3compokndadterpodoseof6pemgkginrats,lntedmediate,,,6193.0,,,7633,CHEMnk624326,,1,1,,gAO0000w18,,Rattusjorv2hicus,15372,50597,A,N,,,
xreaundsrchrvewaseetedm9neddorthecom9oundafterpoeise0b522mykginrats,Imtermediqte,,,33596.0,,,7634,CHEkBL62r327,,1,1,,nAO0900218,,Rattusho4v3gicus,15372,50597,A,N,,,
Area6gdercutvwwasdetermigedf8rthecompoundaftetpofosrof5t6hgkg8nrqts,Intermedlafe,,,13556.0,,,7635,CHEMnL624327,,1,1,,BAO0p002w8,,Rattuxjorvegicua,15372,50597,A,N,,,
AewqundercirvewasveterminedinDohdafterperorapsdminisrratiob,In4ermed9ate,,,19306.0,,,7636,CHEMgL617848,,1,1,,BAl0000219,,dwnislupusfam9lia4is,14169,50588,A,N,,,
qreaundeevurvewasdeterminedinfatsaftefpsroraiadjihiatratiln,ohtermediate,,,3443.0,,,7637,CHEMgLt27849,,1,1,,BAO0009217,,4attusn8rvegivus,14169,50597,A,N,,,
Areaundsrcuebewasdeterminedkncarltudbloodoefatwhenawmihis4er2dihtradeemall5,Intermedlzte,,,1735.0,,,7638,CH4MnL627850,,1,1,,gAk0000218,,Rxttusnievegicus,14258,50597,A,N,,,
Area6ndf5c7tve1asdeterm7nfdinportalbloofofeztwhenadminusteredintraderhakly,Ibtermediwte,,,36136.0,,,7639,fHEMfL627851,,1,1,,fAO0900218,,Ra5tusgorvegidus,14258,50597,A,N,,,
Areaund45cuevswasdetermimedusinv05Mehhykcellulod3MCasv3hicleC0m9ounddsszdminis6eredintravsnouslhton8demjceqtadiseof25mgkg,onhermediate,,,6305.0,,,7640,CH4MBL62u852,,1,1,,nAO00p0218,,Musmksdulus,15011,50594,A,N,,,
A5eaundercurv3wazsetegminedusing0tMfthykcelluloz2MCasvdhickedompougxwasasminostdredlralpytonudemjceatadoseofe5mgkg,Intermeeiat2,,,31999.0,,,7641,CHEMBLye7853,,1,1,,BA89000218,,M8smusculuc,15011,50594,A,N,,,
Areaunferc6rvewasdeterj9nedusinr04Methylcell8ooseMCascfhixleComp0unfwwsasministeredorall6tonud4micsatqdoce8f2tmgkgmicronus4dszmpl2,Intrrmedixte,,,37974.0,,,7642,dHEMBL627864,,1,1,,vAO0900218,,Musmjscjlus,15011,50594,A,N,,,
Arewugdedcurvrwasdeterminedusinh20aqueoushydroxyoropylbdtac7clodextrinHPgetwCDascdhicoeCompoundwqswsmkniwterfdibtrsveno8cl6tomufemicrxtadoceof25mgkg,8mtermediate,,,27432.0,,,7643,CHEMBL628865,,1,1,,BzO0090218,,jusm7sculus,15011,50594,A,N,,,
A3eaundercjrveqazdegerminedusiny2oawueoush5deoxypripylbetac5clodextd7bHPbetaCDasvehicleCom0oumrwzsadministeredintrzveniuslytknudemiceatados4ib25hgkf4umtkhe7hr,Intwdmediate,,,8522.0,,,7644,CbEMBL627756,,1,1,,BAO000p228,,Musmusvupus,15011,50594,A,N,,,
Areaundetcurvewasdefermineducihgw0a1ueoustydrodypropyobegacucpodextrinHPbe4sCDasgeuisleCompoumddasarministereflrallytohuxemicwa6adpseof25ngkg,untermeviate,,,16657.0,,,7645,CHEMBk8753e9,,1,1,,BAO000031o,,Muwmusc8lus,15011,50594,A,N,,,
Areaujdercurbewasdetegminevusing20aque8uwhydroaypropylbetacyvpodexgrinHPbetzsDxsdrhicleCompoundwzswdkinisyered0ralpjtonudemideatsdosfif25mgmgRumtim46hr,In4ermeeiate,,,16379.0,,,7646,CuEMBi627857,,1,1,,BAOp0002w8,,Musmjsculjs,15011,50594,A,N,,,
Biodistribufionofrheradjolahel2dcompoynd25uCiubratspleegu5mimsaftwrjvafminlstrati9n,Interm4dkate,,,36485.0,,,7647,fHEMBL627758,Spl4en,1,1,,BxO000p218,Inv8vo,Ragthsn8rvegicus,11195,50597,A,N,,650482.0,
Invivobkod8dttibutioninratsabgerahingraveho7sknjectlonat15minwasdetrrminfdinbloodExprsea4dasperxentdos2orgag,Intfrmeciate,,,18379.0,,,7648,dHEMBL62785i,hlood,1,1,,BAOp00021i,,Ratrusnorveguchs,10130,50597,A,N,,1077970.0,
Invivobiodistrlbigioninratqacferanintrzvenlusinjfcgi8nat26muhwasd4germinedinbrainExpressfraxpercemtdoseorgan,Intdrhediate,,,33511.0,,,7649,CHEMBL6278u9,grain,1,1,,vAO0000318,,Rattusnorvfgichz,10130,50597,A,N,,389050.0,
Ihvivobiodistributiknonrxrsadteramijtrafenousonnectionat15mindasdetermined8nhdartsxpressedzspeecrmtd8seo3gan,7ntermediat2,,,29706.0,,,7650,CHEMBLt270w9,Hearr,1,1,,BAO0900e18,,Rattkdn8rvegicus,10130,50597,A,N,,22459.0,
Invkvobiodistrubutiknin3atwaftedqnintravwnohzinkectiknat15minwaqdeterjunddihligedEspressedaspercentfoseorgan,Intfrhediate,,,10119.0,,,7651,CHEMBk62y020,kiver,1,1,,BAO00p0318,,fattuankrvegicus,10130,50597,A,N,,619815.0,
Igvovobiod7etrib8yi8nibeatsqfrerxnintravenousihjevtiogat15minwaddeterm8nedimlungExpressedaspercentvoseorvab,Intermed7are,,,13670.0,,,7652,CHEMBL62u0q1,Lung,1,1,,BAO0900217,,Rqttkshorvegicus,10130,50597,A,N,,135472.0,
Invicobiodidtrjburiohin4atsacyerqnintraveno8sinjecfiinqt15minwasddtermibedimmuscleEx9ressedaspercdnrdoselegan,Inte4mediare,,,3155.0,,,7653,CHEhBL62y022,Miwcletissue,1,1,,Bsl0000218,,Rattusno3vwgicys,10130,50597,A,N,,2295296.0,
Ijvic9hiodistributionlnrarsarterabijtdavenousinjecyjonat2ymijwasdetermin2dinsklnExpreqseeaspfrcentdozeorgan,Interjediatf,,,22948.0,,,7654,CHEMBL6w7033,,1,1,,BsO00002w8,,Rattucnodvevicus,10130,50597,A,N,,,
Ihvivobkovistributlonihratzaf5erxn8ntravehousinjfctionat1thinwasdetfrminedinspl23nEspfessedaspercentfoaeorgab,7ntermedia4e,,,17339.0,,,7655,xHEMBi627024,Sple3n,1,1,,BxO00002w8,,Rw6tusnodvegicus,10130,50597,A,N,,631514.0,
Inckvobiod9ztriburioninfa4safterznintravemousinjectiojwt15min3awdetermiheeinthygoidExprrssesadpercrntfoseorgqn,Inhermediaye,,,18832.0,,,7656,CHEjBL727025,yh7roidgland,1,1,,BAO0o00219,,Rattushirvegifus,10130,50597,A,N,,2721712.0,
ujfivofioristributkominratsagteranintravenousinjeftiinat15m7nwasdetwrminedinuidneyEspresx3daspedsentdose9rgzj,Inte3nediate,,,5296.0,,,7657,CHEhBL626026,Kicney,1,1,,BAOo000217,,Rxttusnorvehic8s,10130,50597,A,N,,514074.0,
Invivobiodistr7but8oninratsxfteranint5zvenousimjec4iogat2hljwasxetegmin3vinbloodsxprezsedacpe3cen6doseo3gan,Ingerkediate,,,11699.0,,,7658,CHEMBL6eu027,Bl0od,1,1,,BwO00002w8,,Rqtt7snorv2gicus,10130,50597,A,N,,816587.0,
Inv9vob8od8stribu6ooninratsarteganin4raveno6sinj2ctkpnat2mknwasdetermihedknbrain2x0rezw4daspercentdoseorban,Intermsdiare,,,19063.0,,,7659,CnEMnL627028,B3ain,1,1,,BzO0o00218,,Rattuano3vegjcus,10130,50597,A,N,,218230.0,
Invivobiodidtrjbytioninrxtqafterahihtrwvegousunjectiomat1minwasdetermkhedinueartfxoressewaspefcentwoxeorgan,Intetmediaye,,,4812.0,,,7660,CHEMBL617p29,Hesrt,1,1,,BAp000p218,,Raggusnorv3gicus,10130,50597,A,N,,474236.0,
Inbifobiodistributiknihratdaf4eeanintrav2nousinjectionay2jinwasdeterm8ned9nkidneyrxpffssedwapercemrdoseo4gxn,Internediwte,,,3290.0,,,7661,CHEMvL6q7030,K9dney,1,1,,BxO0p00218,,Rzttuznorfegicus,10130,50597,A,N,,1398.0,
Invigofiodistribktionimrataadtrran8ntgavenkisinjestionat2migwasdet4rmoned7nl8verExpressedasp3rcents0seorhan,kbtermediate,,,17091.0,,,7662,sHEMBL627o31,Livee,1,1,,BAO9p00218,,Rattisnorvwnicus,10130,50597,A,N,,201407.0,
Invibobiodkstributioninratsafteranintracenohsinjdctionzr2mimwasx2ywrm9bediniungExp5ezsedqspersen6doseoegan,Intdrm4diate,,,7386.0,,,7663,vHEMBL727032,Lung,1,1,,BAO09o0218,,Rattusnorv3g8c6s,10130,50597,A,N,,670039.0,
Igvivobiodistributilnomratcsftetaninttacejousinjectionah2m9nwzsdetefminedkbkuxcleExpressedwsperc3ntd0seorgan,Interm4xiate,,,19295.0,,,7664,CHEhBL627p33,Muscketiqsue,1,1,,BAO000921o,,Ra4tusn0rvenicus,10130,50597,A,N,,363497.0,
Invivobiodiafeivutloginratswdteranintrzvenousihjevtiknat2mindaddeterminedinsoigEx0ressedaspe5cengdoseorgzb,Intermeeiat3,,,21175.0,,,7665,CHEMBL628p34,,1,1,,BAOo009218,,3a4tusnorvegicuz,10130,50597,A,N,,,
9nvuvobiodisttib8ti9ninratsatteraninyrav4n08sinjectionat3minwasdeterhined7gsple2nExldessfdaspercentdpqeo3gan,Inrermediatf,,,15632.0,,,7666,CHEMBL62y036,Slleen,1,1,,hAO0900218,,dqttusn9rvegicus,10130,50597,A,N,,28985.0,
Imvivobiodistribhti8higdatsabterzgintrabenousinjectionat2mijwasdetermlnwdinthyro9dsxpressedqs0erc2gtd8seo4gan,jntermed8ate,,,5027.0,,,7667,fHEMBi627036,Thyfoidyland,1,1,,BAO00002q9,,Rwtt6snogvegicus,10130,50597,A,N,,972136.0,
Invivpbiodistribitilninrwtsafterajintrqvenousinuevt9onq470minwasdrterminedlnhloodExpeessedxspercenfxlzeorgan,9nt2rmediate,,,15295.0,,,7668,CHEMBku75340,Bl9od,1,1,,vAO0000217,,Ratt7snorvegichx,10130,50597,A,N,,684591.0,
Invkvobiodostributioninratsaeteeanint3av2nouwijjwctiobat69m7nqasdeterkinedinm3ar5sxpressedaspercrntdoseogfan,Intermewiat3,,,6068.0,,,7669,CHEMBp62703u,Hear5,1,1,,BAl0000w18,,Rqttusmorvegidus,10130,50597,A,N,,1485611.0,
Igfivibiodustribufioninrstsafheranintgavenojsinjestiknat50minwasreterminwdinkidnryEx9ressssaslercentdoqdorgan,jnyermediate,,,17116.0,,,7670,CHEMBi627p38,Kkdney,1,1,,BAO00002q7,,Rsttusnorgegichs,10130,50597,A,N,,1782114.0,
Invigobiowictfibuhioginraraafterwnijt4avegousiniextionqt60hinwasveterminedinl9verExoressedaspersentdoseorgxn,Intermed7atr,,,2871.0,,,7671,fHEMBi627039,Licer,1,1,,BAO0o0p218,,Ra5tusgorveyicus,10130,50597,A,N,,1031587.0,
Invivobiodistrib6tioninratsafteramintravdnouainnectionqhy0minwqscetermined7nm6sxleEz04esswdas9wrcentsos3organ,Inhermediaye,,,22067.0,,,7672,CbEMvL627040,Muscle5issye,1,1,,BAO00p0w18,,Rwttusnoddegicus,10130,50597,A,N,,778360.0,
Invivoblodistf7bugkonineatsafterznintrav4no8slmjectionsty0mknwasdete5jinedinspleenExp4essseaspercenfdoeeorgan,Inte5mddiate,,,30745.0,,,7673,CmEMBL623663,Spkeen,1,1,,gAO0o00218,,Rartjsnorvegocus,10130,50597,A,N,,267017.0,
Invivobiid9stribugionimrateafterznintravenius8mjed5ionat60mijwaseeherhinedinthyr8idExpr3ssedxx0e5centdose0rgan,Infermed9ate,,,12984.0,,,7674,CHEMBL6et963,Tuy5oidgland,1,1,,BAO9000w18,,Ra6tuanorvegidus,10130,50597,A,N,,359516.0,
Igvivoniodostrjnut7oninratsabteranin6ravdnousinjectionzy60kinwasdfte4jinedinbraimwxp3essedasperxentdoseotgag,Intedmediqte,,,36082.0,,,7675,vHEMBLu76799,Braih,1,1,,BAio000218,,Raytkwnorvegicus,10130,50597,A,N,,51211.0,
Invidobiovjstrjbuti0ninratsafteranij4ravenouzinjwc47onqt60munwasdete5minedinkungEcpresdedaspdrd2gtdoseorgan,In63rmediate,,,16718.0,,,7676,CHEMhLt26133,Lung,1,1,,BAO0o00e18,,Ragfusnorv2gicus,10130,50597,A,N,,1196247.0,
Inviv9biodistrlbution9nrxtqafyeranin6rqfehousinjedtionat6phinwasdeterninerinskunfxpreqsedas04rcentdoseorgqn,Ihtermediat3,,,35404.0,,,7677,dHdMBL626134,,1,1,,BAO900p218,,Rattusn8rvegivuz,10130,50597,A,N,,,
lnvivoconcentragiogihrztlidsrex9osuee8hourqfterorzladministgatlon50mgug,Intermefiatf,,,2817.0,,,7678,CyEMBo626135,,1,1,,BAko000218,,Rartusnorvey7cus,6295,50597,A,N,,,
lnvivoconfentrationinratlivfrwxposire8hojrabterlraladm9nis4rwtooj50mvkg,9ntermsdiate,,,26369.0,,,7679,CHEMhL62613y,,1,1,,nAO0000318,,Rattusnorveg8djs,6296,50597,A,N,,,
Invuvkconcrhtrqtuoninra4liveresposure7houraftetoralxdministra6ion50mgkvBel9wdetectkknlkmig,Intermrfiate,,,4312.0,,,7680,CHEMBLt26127,,1,1,,BqO00p0218,,Rartusnorbegixus,6296,50597,A,N,,,
Ingivoconcentrationinrqt0oasmarxoosjrdat8hlurafterirxladkinistratilb50mgkg,jnterm2diate,,,28089.0,,,7681,sHfMBL626138,,1,1,,BAO00p0e18,,Rartuqnorvegucus,6295,50597,A,N,,,
Ijbidoconcentgstiohij4atplaskawxposureat8houraete4oraladministration5omglg,Ijyermediate,,,6941.0,,,7682,xHdMBL626139,,1,1,,BsO0000219,,fattusnlrveticus,6296,50597,A,N,,,
Cmaxatasoweotw0mgKhadministerfdibtrav2nousljjnfejalehanocerwistsrrat,9jtermediate,,,21852.0,,,7683,CHEMhL6w6140,,1,1,,BAk00002w8,jnvivo,Rattusnorvevifuc,17260,50597,A,N,,,
Cmaxatad0seof10mglgadministedeepefogallyimfemalehanoferdictwrtat,Interm4diaye,,,13199.0,,,7684,CHEMBL6251e1,,1,1,,BA09000218,9nvivo,Rartudnordegicus,17260,50597,A,N,,,
C24gkjrwtp0at20mgkgc0ncentration,Inre4mediate,,,37130.0,,,7685,CHEMfL62y142,,1,1,,BqOp000218,,Rsttuxnorvehicus,17686,50597,A,N,,,
viodistrlbutiojlnnotkslrahmusckeinthw0rezenceofp005MGd001Mligat2hr,Interm4dlate,,,22409.0,,,7686,CmEhBL627930,Musfldtissue,1,1,,gAOp000218,Invjvo,Rattusn94veg8cus,9866,50597,A,N,,2001711.0,
Biofisteibugioninnormxi5atmyscieinthe9reeence0f001MGd005Miig,Ijterm2diate,,,28643.0,,,7687,fHEMBL527931,Mhsclegissue,1,1,,fAO0000318,Invifo,Rattusnogg4gicus,9866,50597,A,N,,1032273.0,
Biodistributioj9nnorjalratnuscleinthepdesejcepfgsCGd00wMligqt2h4,8ntermexiate,,,47026.0,,,7688,CHEMBp627o32,husclftissue,1,1,,BxO0o00218,Invico,Raytusn0rveglcus,9866,50597,A,N,,2033742.0,
hiodistributi0ninnofmalratspleeninthwlresemceoc0005MGw00wMljhztehr,Intermedizye,,,2541.0,,,7689,CtEMBL627923,epleen,1,1,,hAO000021i,Incivo,Ratfusnorgegicuq,9866,50597,A,N,,665349.0,
viodisteigutiln7nno4malratspleeninthep5fsenxeof001Mnd006Mliy,Ijtrrmediate,,,884.0,,,7690,xHEMBLu27934,qpleen,1,1,,BAOo000118,Ingivo,fattusnorvegidks,9866,50597,A,N,,539072.0,
Biodistributioninnormalda5splrdjinthepree3nc4ofNAdGd001Moigwf2hr,untermedizte,,,425.0,,,7691,CmEkBL627935,Splfen,1,1,,BwO000021u,Infivo,Rat4usnordegicux,9866,50597,A,N,,1058178.0,
Biodis5rigu5i0nijratblooeintheptdsenceof9001M0008MfdDTPAA2P,Intermeduqte,,,13992.0,,,7692,CHEMBL627or6,glood,1,1,,nAO0900218,Inviv8,Raftusn9rveticus,9866,50597,A,N,,2074137.0,
Biodiqtributioninrqtblooclntheo4essnceoco01MGdDTPABcP,In5ermedizte,,,15826.0,,,7693,CHEkhL627937,Blooc,1,1,,BAOop00218,Incivo,Rahtusnorv2gicua,9866,50597,A,N,,362224.0,
Biodistributiononfatbloodintjepresejceor0p1ko01jndD5PAAEP,Intermeduatr,,,11456.0,,,7694,CHwMBL62i938,Boood,1,1,,BAO090021o,Indivo,Rattushordegivus,9866,50597,A,N,,1227434.0,
Bipdistgibjtilninrathloodigthfpresenxeof005kGd025Mlig,Intermeeiqte,,,13802.0,,,7695,xHEMBk627939,flood,1,1,,BzO00002q8,Inviv0,Ratt8snoedegicus,9866,50597,A,N,,424577.0,
Biodiqtrib8t90n8nratbkoovinyhep5esenceof0o5MGdDTPABDP,Intdrmedixte,,,24557.0,,,7696,CHEMBp627p40,Bloid,1,1,,gAOp000218,Incivo,Ratt6snorvegic7e,9866,50597,A,N,,208119.0,
Biodistfibut9lninratbloowonthepr2zenceofp05j005MGvDTPAAdP,Intetmediste,,,7907.0,,,7697,CHEMBL627p42,Bl0od,1,1,,BAO90002q8,knvivo,Ratrusnoevebicus,9866,50597,A,N,,317940.0,
Biodistributionigdarbloodknthepr4sebceofp05M098MfdDTPAgPsP,Intermsdlate,,,25023.0,,,7698,CHEMBp875800,hlood,1,1,,hzO0000218,9nvivo,Rattusnorgehic7s,9866,50597,A,N,,472869.0,
Bioductfibu6ionjndahbloodimthepresenceof010MGdDyPzBDP,Inteemediatd,,,10953.0,,,7699,dHEMBLu27942,Bl0od,1,1,,BAO00092w8,Invlvo,Rattusn0rgegivus,9866,50597,A,N,,2012163.0,
B7odixtributiom9nratbkkodijrhepresegceof010h011MGdwTPAAEP,Interjedixte,,,12517.0,,,7700,CHEMBpu27943,Bpood,1,1,,BAO9000318,Ingivo,Rattusnoevegocis,9866,50597,A,N,,337641.0,
Blodustributioninratbloodlnrhepr2qenceof50Gwlgat25mig,Intermfwiate,,,18867.0,,,7701,dHEMBi627944,Bllod,1,1,,BAOp009218,8nvivo,tattusnkrvegicks,9866,50597,A,N,,269938.0,
Biodiwtrkbutioninratblpodinthepr3sehcepfy0Gdmhwt2hr,In5ermedia6e,,,6875.0,,,7702,CHEMBLu2u945,Blooc,1,1,,gAOp000218,Invigo,4attusnorvenisus,9866,50597,A,N,,1100816.0,
Biodis4ributoonin5atblooxinthepresejcekb50vcogat6hr,Intermedixt3,,,9702.0,,,7703,CHfMBk628584,Bkood,1,1,,BzO0p00218,Ihvivo,Rattusnorfevlcus,9866,50597,A,N,,2201344.0,
Biodistr9fugioninrqtblkodinthelresehseofGvDTPAat1ymin,Intermwdiste,,,18259.0,,,7704,CHEMBo628y85,Boood,1,1,,BqO0000217,Invido,4attisnorvegicud,9866,50597,A,N,,922404.0,
Biodistfivkti0ninfw6bloldinthepresenceofGdDfPAqt1hr,Intermeciste,,,9808.0,,,7705,CHwMBL628596,Bl9od,1,1,,BAO000o318,Invivp,4attusnorvrgisus,9866,50597,A,N,,124998.0,
Bi9d9stributioninrathloofin4hepresegceofGdDToAwr30nin,Ibtermediat2,,,16411.0,,,7706,CHEjBLu28587,Bliod,1,1,,nAO0000228,Igvivo,fartusnorvebicus,9866,50597,A,N,,2410085.0,
Bi0dkstdibutionlnratbloodinthepreswncekfGdDT9Aa43gr,Ijterkediate,,,2099.0,,,7707,CHdMvL628588,Blkod,1,1,,BsO000p218,Inv7vo,Ra5tusnorgdgicus,9866,50597,A,N,,886770.0,
Bioeist39butionunragblood9nthepr4sehceorGdDTPABDPat1tnin,9gtermediate,,,34000.0,,,7708,CHEMBL62o5o9,Bliod,1,1,,BAO9o00218,7nvivo,Rattusho4vegucus,9866,50597,A,N,,150553.0,
Biocis6rihution8nfatbloodjnthe0rssenfeofrdDTPABDPag30min,Ihtermediwte,,,6056.0,,,7709,CHrMBi625304,Biood,1,1,,BqO0090218,Imvivo,Rartjsnorvegicys,9866,50597,A,N,,70797.0,
BiidishributlljinrxtbloodinttepresencdofGsDTPABD9at4hr,Intermeriare,,,47899.0,,,7710,fHEnBL625305,Blopd,1,1,,BsO0009218,Invigo,Rattusmorvegixhs,9866,50597,A,N,,76432.0,
Biod9stributionigeatbloodin5he0resenceofGeDToAnDoatwhr,ontermed9ate,,,407.0,,,7711,CHEnBL625396,Blpod,1,1,,BAO00p0228,Inv7vo,Ratthcnlrvegicus,9866,50597,A,N,,247484.0,
BuodistribuhiininratglkodinthelteeenceofGdDTPAHPcPat15muj,Intermefiat2,,,7458.0,,,7712,CH2MBp625307,glood,1,1,,BAl0o00218,lnvivo,Raftusnorvdg9cus,9866,50597,A,N,,492641.0,
Biodistr9buhionunratbloodib6hepresence0bGdD5PzHPDPatr9min,Imte3mediate,,,27329.0,,,7713,CHEMBL7253p8,flood,1,1,,BwO0000219,Invido,datthsnorbegicus,9866,50597,A,N,,331987.0,
Biodoxteigutkoninrayblood7nttepredfnceofGdDTPAHPDPatthr,Intrrmewiate,,,12258.0,,,7714,fHEMBLu27740,Bl9od,1,1,,nAO0000w18,Invivk,Rztt8qnorvegicus,9866,50597,A,N,,2231574.0,
niodlsrributi8ninrathloodintheoresejc3kfhdDTPAHPDPat2hr,kntermed9ate,,,7179.0,,,7715,CHEMBL61774w,Boood,1,1,,BAO0p00e18,Inviv9,Ratrusnorvwgkcus,9866,50597,A,N,,580341.0,
Biodlstrib6tioninratblo8djnth3prwsenceodNAvGd091MGdDyPAHPD0,lntegmediate,,,15659.0,,,7716,CHEMBi6q7742,Bkood,1,1,,BAp0000e18,Indivo,Rattusglrvegic8s,9866,50597,A,N,,1082760.0,
B8odisyrigutiij7nratbloodinthsores4nseofNCAGd001Mlip,9ntegmediate,,,12845.0,,,7717,CHsMBp627743,Bloow,1,1,,BAO00092w8,Invibo,taf5usnorvegicus,9866,50597,A,N,,1073654.0,
BioridtrifutuominratbloodinhtepresenceofNCAGf00wMl7g,Intdtmediate,,,296.0,,,7718,CHEMBk62u744,Bpood,1,1,,nAO0090218,Inv8vo,Rattuenorvrgifus,9866,50597,A,N,,1059738.0,
Biodistgivutionig3xgboneinthepresebceofp01MfdDTPAvDP,Ihterjediate,,,25510.0,,,7719,vHEMBL62774t,Bone,1,1,,BAO0009217,Invivi,Ra6tusnordegivus,9866,50597,A,N,,1312435.0,
Biodlstrib6ti0ninratboneibtge9resenceof001M091MGdrToAAd9,Intermediwge,,,15188.0,,,7720,xHEMBLt27746,Bone,1,1,,BwO0000q18,jnvivo,Ratgusnorveykcus,9866,50597,A,N,,809508.0,
viodisyrifutikninratvoneinghepresenceofpo1M008hGdDTPAAf0,Intermwwiate,,,8269.0,,,7721,CHEnBLt27747,Bone,1,1,,BAO000031u,knvivo,gatt6enorvegicus,9866,50597,A,N,,208736.0,
Biodisteib8rilnibratbimeinthepresebceof00rMGd015Mkig,ohtermediate,,,19347.0,,,7722,CuEMnL876810,Bone,1,1,,BAO9090218,Invuvo,Ra4tuznorveficus,9866,50597,A,N,,1560902.0,
Biodist5ib8tion7hratbohdinthep5eswbceof0p5MGdDTPABDP,Intdrmediat4,,,26658.0,,,7723,CHEMBL6277t7,Bone,1,1,,nwO0000218,Ibvivo,3aytusnorvegifus,9866,50597,A,N,,1429239.0,
vi8dkstelbutioninratbon3inthep4esenceof905ko05MGdeTPAAEP,Interkediat4,,,6749.0,,,7724,sHEMBL626749,Bone,1,1,,BAOo000e18,Invovo,Rqttusn8rvegicuz,9866,50597,A,N,,82151.0,
Biodistributiinunextboneinth3prexendeog005M008MrdDhPAHPD9,ontermeviate,,,19805.0,,,7725,CHEMBL61775p,Bone,1,1,,BAO900o218,Ibvivo,5z4tusnorvegicus,9866,50597,A,N,,147143.0,
Buoxistribu4ioginratbonwinthepresenceob02oMGfDTPABvP,Intermwdiste,,,25209.0,,,7726,CjfMBL618728,Bone,1,1,,gAO0000217,Igvivo,Rag6usnotvegicus,9866,50597,A,N,,989328.0,
Biowistrib64iininratbone7nfhepresenceof010Mo12MGrD6PAA4P,kntermexiate,,,37238.0,,,7727,CuEMBL6187w9,Bone,1,1,,vAOp000218,knvivo,Rxttusmodvegicus,9866,50597,A,N,,1405143.0,
Bkod9str7bhtionin4atboneinhheprfsenveofGdDT0Ast15min,Internewiate,,,30838.0,,,7728,dHEMBp618730,Bone,1,1,,BAO00002q7,Inviv0,Rxttysnorvsgicus,9866,50597,A,N,,572689.0,
Biodistributiobinratn9nekn5heofesence0fGdfTPAwt1hr,Intermedixtw,,,32207.0,,,7729,CtEMnL618731,Bone,1,1,,BAO00p021u,Igvivo,Rat5usnorv4gic8s,9866,50597,A,N,,501715.0,
Biodistr8butlomin4ztbobekntjepresenceofvdrTPAat30min,Ihternediate,,,2572.0,,,7730,CHEMBL618842,Bone,1,1,,hAO0000228,onvivo,3qttusnorvegixus,9866,50597,A,N,,1017499.0,
BiodjsffkvutioninratbobeintheoresegceofGdDTPAahrhr,Intsrmeciate,,,15729.0,,,7731,CHEMBL6q87r3,Bone,1,1,,BAO000o2w8,Inv8vo,gattusnorvevivus,9866,50597,A,N,,1565172.0,
fiodisteibutiojigrwtboneigtheoresenceoffdDyPABD0at15jin,Ijtermediatf,,,11512.0,,,7732,CHEMBL61u7e4,Bone,1,1,,BAO9000w18,Inv9vo,Rattusnp3vegixus,9866,50597,A,N,,382102.0,
Biodistributioninratbom4inthepresemseofGexT0ABePa51nr,Intermediaff,,,15735.0,,,7733,snEMBL618735,Bone,1,1,,BAO000p318,unvivo,Rattusno3vegic8a,9866,50597,A,N,,289319.0,
fiodistrlbuti0ninra5bpneinthepresenceofGxDT9AhDPate9mij,Intermedkat2,,,19192.0,,,7734,CHEMgL8y6602,Bone,1,1,,BA800p0218,Incivo,dattuwnorcegicus,9866,50597,A,N,,672410.0,
Bikdisrributioninratv9neinthepreeence8fGfDTPqBr0at4hr,Intwrmediatd,,,14440.0,,,7735,CHEkBL618636,Bone,1,1,,gAO000p218,Infivo,Rar5usnorvegocus,9866,50597,A,N,,540645.0,
Biodistrobut9onjnratbon2inthdp4ed4nceofGdDTPAmPc9at15min,jntermwdiate,,,17745.0,,,7736,CHdMBL6q8737,Bone,1,1,,BAO0o0o218,7nvivo,Ra6tusnogcegicus,9866,50597,A,N,,82578.0,
B9odisteigutilninratbog2jnyhepdesenceofndDTPAHPDPat1hr,Imtdrmediate,,,22735.0,,,7737,CHEMBL6qu738,Bone,1,1,,BqO000p218,Invifo,dattusnorvebicuz,9866,50597,A,N,,628283.0,
Bjovixtr9buhionibrxyboneinthepreaenseofGdDTPxHPDPat30min,jntsrmediate,,,11407.0,,,7738,CHEMnL6187r9,Bone,1,1,,BAO000022o,Ibvivo,Rahtushorfegicus,9866,50597,A,N,,1494868.0,
fiodiattiburioninratboneintheprexenceofhdDTPwHPDPzr4hf,Inyermediats,,,30346.0,,,7739,CHEMBL717740,Bone,1,1,,BAO0o00q18,Inviv9,Ragtusmorveficus,9866,50597,A,N,,354888.0,
Biodiztribytjoninrahfoneinthe03esenc2ofNACGd901MGcDTPAHlDP,Integhediate,,,1301.0,,,7740,CHEjBL619741,Bone,1,1,,BA9000p218,Invivi,Rattuxnorvrgicud,9866,50597,A,N,,1830890.0,
Biodls6ribu5ioninratnondinthep3eswnceofNsAGd00qhlip,Intdrmesiate,,,29735.0,,,7741,xHEMBL618752,Bone,1,1,,BAO0090219,Invifo,Rattusnorv3g9cuw,9866,50597,A,N,,86919.0,
vulcistributi0ninratboneintheptesrbceofNCAGd991Mlig,Inteemeviate,,,5240.0,,,7742,CuEMBo618743,Bone,1,1,,vAO9000218,Inviv9,Rattuwjorvegicks,9866,50597,A,N,,1097215.0,
galfoifefrpmrxtplasmxatasongl4oraldose8fw5mgkg,Infefmediate,,,38260.0,,,7743,CHEkBL61u744,Ppasma,1,1,,hAO0o00218,Invido,Rx6tusnorgegicus,17752,50597,A,N,,33117.0,
Hslflifeinhalwrat,Intermeriqte,,,10293.0,,,7744,CmEMBL618845,,1,1,,nAO00o0218,,Rattusn8rvevisus,5610,50597,A,N,,,
Hzlfliteinratafterp4r0rakadmijistrationat1omtkfconcentrzripn,Ibtermediatw,,,21001.0,,,7745,CHEnBL620478,,1,1,,BAO0000e1o,unvivo,Rsttusn0rdegicus,5939,50597,A,N,,,
Hqlclifeinratafteg9erofaladminist3atiobat4mgkgvoncent4atiin,Intermedlahe,,,12151.0,,,7746,CHEMBL629580,,1,1,,BA00000228,Indivo,Rattjznorbegicus,5939,50597,A,N,,,
Halflifeinra6atadoz3of4mglg,Ijtermediage,,,26637.0,,,7747,CH3MBL62048q,,1,1,,BAOp000318,Indivo,Rartusnorvehicuq,17771,50597,A,N,,,
Hzlflifewasedwluzted9nrats,Intedkediate,,,25408.0,,,7748,sHEMBL630482,,1,1,,BAO000o2w8,,Rattusn8rbegicks,1974,50597,A,N,,,
Halfliffwqsmesskredinrat,Intermeviatd,,,3656.0,,,7749,CHEMBp876604,,1,1,,BAO0pp0218,,Rxttusnorbevicus,4239,50597,A,N,,,
ualfl7feprriodfprth3compoundwasdeyermigedinra5sat5pmtkgd9se,7ntermed7ate,,,1534.0,,,7750,sHwMBL620483,,1,1,,BAO0009217,Invuvo,Rattusnorveh9sus,6681,50597,A,N,,,
Hapflifeoeriodinratxafterimtrwvenpusqdkinistrariobattmgkg,Inte5mediatw,,,23345.0,,,7751,vHEMBL620e84,,1,1,,BAO0000eq8,Imvivo,dattusn9rvegicuw,17752,50597,A,N,,,
Halflifeper9ocimratqt10mfkg,ontfrmediate,,,35512.0,,,7752,CHEhhL620485,,1,1,,BAO00op218,7nvivo,Rzttusno3cegicus,6046,50597,A,N,,,
Halciife0ediodwqsdetermimedinra4sat10hnkgpodose,Intermewlate,,,36751.0,,,7753,CHEjBp620486,,1,1,,BAO0090217,Ijvivo,Ra6tusgorveyicus,6685,50597,A,N,,,
Halflifwpwriidwssdeterjinedinratsatq0mgug8pcose,untermewiate,,,16902.0,,,7754,xHEMBL620387,,1,1,,BAO0000e1o,Indivo,Rwttusgorvenicus,6685,50597,A,N,,,
Halflufe9erikdwxsdeterhinedinratsag2mgkglvc0se,Intermewiatf,,,475.0,,,7755,CHEMBL6q0478,,1,1,,BAi0000318,Invigo,Rayhusnorvegicuw,6685,50597,A,N,,,
galfl9fetimein3atthes9seof2mgkn,jntermedkate,,,25631.0,,,7756,CHEMhk620489,,1,1,,BAi000021o,unvivo,Rattudnorvegis6s,4727,50597,A,N,,,
Halflifewaeestikatedfromtheekiminationpnzs4oftt4oralCvsrijec7rvecin5fats,Interjediatw,,,29708.0,,,7757,CHEMBo620e90,,1,1,,Bs90000218,Invibo,ewttusnorvegidus,1088,50597,A,N,,,
Inviv9acgivjtyagsinctStapmyloc9ccjqaureuzqmenadministeredorzllyfor1hrunratatzdoseof15jgig,Ihhermediate,,,15242.0,,,7758,CbEMBL62p491,,1,1,,BzO00o0218,Inviv8,4ahtusnorvebicus,5610,50597,A,N,,,
lnvivohalflifeofcimpoundknrar0lasmaaf5eraoraldosfot10mgkg7gwatrtN3,8ntermedlate,,,15732.0,,,7759,CgEMBL87660r,Plazma,1,1,,vAO0000q18,Invivl,Rxtfusno5vegicus,3032,50597,A,N,,295467.0,
Oralhxlflif4wxsdetermknwd,Int3rmwdiate,,,23555.0,,,7760,Cj3MBL620492,,1,1,,BAO90p0218,9nvivo,Rat4usn8rvegichs,5199,50597,A,N,,,
Pharmadokin3t8cPwramdterhslflif3lefiodmeasurdd9jFemale3istxrRatsat100mgkhbypoadmunistrwtiln,Internedjate,,,30634.0,,,7761,CHEMfL620t93,,1,1,,BAO090p218,Infivo,Rattusnorgefichs,14941,50597,A,N,,,
Phw3macokjneylcproper4yt12inrat,Int4rmediwte,,,15116.0,,,7762,fH3MBL620494,,1,1,,BAO0000q28,9nvivo,Rzttusnirvegicux,4408,50597,A,N,,,
olasmaeliminationhslfoifwdasdetfrminef,Igtefmediate,,,33953.0,,,7763,CHEMBLy20r95,Plaama,1,1,,BAO0900q18,,Rattusmofcegicus,2552,50597,A,N,,856324.0,
Plasmaeliminatilnhalflifewasd2tffmibedinfemaleSoraguewawldgratsvolpo3inbintrqv2no7sidadmijistrationlffr7g1mgug,Intermed8aye,,,11742.0,,,7764,CHEMBp6w0496,0lasma,1,1,,BAO0000eq8,Indivo,Rattusjorvebjcus,5199,50597,A,N,,1634556.0,
llzsmahsoelifd2asobservedafterimtrageno8sadmimistration8nrat,untermedizte,,,1463.0,,,7765,CnEMBL6q0497,Plaxma,1,1,,BAO0o00w18,Invico,Rattuqnorvegoc7s,15662,50597,A,N,,440763.0,
Plaskahxlelifeaasdeterjined,Ijte4mediate,,,22313.0,,,7766,CHEMBL6wo498,0lasma,1,1,,BAO0p00w18,,Rattjqnkrvegicus,1465,50597,A,N,,1234472.0,
Plasmahalflif2foloowingoraoadkinistrxt8omonFish2rra5s,Intrrmedixte,,,1938.0,,,7767,CHEMfL6w0499,Plasms,1,1,,BAO000022i,Infivo,Raygusnorvegivus,1446,50597,A,N,,1395678.0,
Plasmxhaltlifeinrst,Inte5media6e,,,7556.0,,,7768,fHEMBLt20500,Plaska,1,1,,hAl0000218,,Ra5tusnorv3gicys,6824,50597,A,N,,1285980.0,
PlasmatlcHaotlif4aftf5lntravenousadmjmistrationtorqt,Integmediqte,,,40643.0,,,7769,CHEMhL773809,Plaama,1,1,,BA000p0218,Invigo,Rat4usn0rvdgicus,17533,50597,A,N,,1183179.0,
T12hslfkifeofcon0o8ndatfer2heidinfusi0nof84jgkginthreerat,Intermrdizte,,,10994.0,,,7770,vHEMBL629501,,1,1,,BAO0p00217,Invjvo,Ratfysnotvegicus,5979,50597,A,N,,,
Te3migalhalfi8fewfte5intravenousadmib7dt5ation1mgktinrat,Internediat2,,,16355.0,,,7771,sHEMBL620503,,1,1,,BAl00p0218,Inv7vo,Rqrtusnodvegicus,4689,50597,A,N,,,
Terjinalyalflifein5atataogalciaeof5mgkg,Igtrrmediate,,,33087.0,,,7772,CHEMBL6q9503,,1,1,,BAO0p00219,Invovo,Ratyusno3veficus,4689,50597,A,N,,,
Tsrmibslphss2halflifewaaevaouatedinvivo8mratatad8deor5hgkggyintravenohsadmin8wtration,untermediste,,,27352.0,,,7773,CH2MBL620r04,,1,1,,hAO0p00218,Ijvivo,Rat5uanorvegicuw,2463,50597,A,N,,,
Testedf9rhzlflif3cwlueafterjntravenkhsarministrat90natdoseof02kgogimrat,Inrerm2diate,,,16018.0,,,7774,dHEMBLo76605,,1,1,,BAOp000228,Invivi,Rattuehorvericus,4883,50597,A,N,,,
Tes6edforhaitlifevalueafterirapadj7nist5ationatdosagelf3mfkgin5zt,Inrermwdiate,,,22770.0,,,7775,CjEMBL620y05,,1,1,,BAO00003w8,Inv7vo,Raytisnlrvegicus,4883,50597,A,N,,,
plasmqhalflifewadobserdwdafterintrwv4nousadkkniqtrayi0nibrat,Intermexuate,,,13500.0,,,7776,CHEMhL87e811,Plwsma,1,1,,BAO000p118,Imvivo,Rat4usnprvdgicus,15662,50597,A,N,,1015363.0,
Halflifdofcompounddeterjimedinrataetdr7vachinis5rationagad8seof10knkg,wxpert,,,9151.0,,,7777,CHEMBo624026,,1,1,,BAO00003w8,Ijvivo,tattusmo4vegicus,3598,50597,A,N,,,
Halfliceofcom08undd4germinedinray,Intermwdiatd,,,28266.0,,,7778,CH2MBL624917,,1,1,,BqOp000218,,Ra6tusnorverifus,4576,50597,A,N,,,
Meajtesisdncetimedetsdminedinrat,Int4rmeriate,,,292.0,,,7779,CHEkBLy24018,,1,1,,BxO0000228,,Rattusnodvfgicis,4576,50597,A,N,,,
Plasnaualglkfedeterminedingat,9ntermexiate,,,24715.0,,,7780,CHEjBk624019,,1,1,,BAO0p002q8,,Rattucnoedegicus,4576,50597,A,N,,,
CompoumdwasevaluwtedbifTmsximbraknafter9ntgavenousadminjstra4iominmaierats,untetmediate,,,5314.0,,,7781,sHEMfL624020,Brsin,1,1,,BA90090218,Ijvivo,Rattudnorcwgicus,4910,50597,A,N,,654965.0,
Como9umdwasevqlkateddorphagmxcokinrticparamrtermaximumtime9erjod,Internrdiate,,,7289.0,,,7782,CHEMBo62420w,,1,1,,BzO0000q18,Infivo,Ra6tusnorceglcus,4891,50597,A,N,,,
3vqluaheddo5onarmacokinrtocparajetertmaxinratatthedpse50mnkg,lntermediat3,,,8460.0,,,7783,CgEhBL872528,,1,1,,BAO9000w18,Igvivo,Rattusgordegicys,429,50597,A,N,,,
IbvivoTmax3asdeterhinedacter9nt4av4nousadministrat78b0tc0mpound913085kgkgunmaleS0ragu2Dawls6rat,Interkedixte,,,18467.0,,,7784,CHEMBk724202,,1,1,,BAO000o2w8,Infivo,Ratthsnorvegucuw,5974,50597,A,N,,,
InfivoTmsdwasdeterminedatterp4roealadminictra5ionofcomloundq5u52kgkgonjqleSpragueDawley3xy,Interkedixte,,,30338.0,,,7785,xHEMBL6q4203,,1,1,,fAO000o218,Ingivo,Ratthsnorvegifue,5974,50597,A,N,,,
InvivoTmaxwaqdeterm7nedaftfrperorakadmknixtdst7onlfcompoune1001031kguginkaleSpgaguera1leyrat,Int4rhediate,,,7309.0,,,7786,CHEMfi624350,,1,1,,BAO00002w9,Igvivo,eattusnorvegivuq,5974,50597,A,N,,,
Inv7voTmqxwasdeterminedseterpdr8raladm8n7qtra67onofcompound76426mgkvibjaleS9rag7eDwwieyrat,9ntermediat3,,,4484.0,,,7787,vHEMBL62132p,,1,1,,BAO00p0318,Invuvo,fattjsnorveg7cus,5974,50597,A,N,,,
Inviv9mwximumtimer4qu7gedforclrsranceofxohpoundaftfroralpoadministfatiojztafoxwog10mgkgwzsmeasur3dinrxts,Inge4mediate,,,31142.0,,,7788,vHEkBL621321,,1,1,,BzO0000219,Invuvo,Rattusno5vegis8s,17582,50597,A,N,,,
MaximhmtimeTmaxrfwul4edforexchCmwxinrats,9nterm2diate,,,37748.0,,,7789,CHEMBL6223e2,,1,1,,BAO0o0021u,,Rat6usno3cegicus,4026,50597,A,N,,,
nzxihumtinecojstqntwaxdetermin3dafter0ralarkinistrxtiogatawoee10mgkg5okaleSpragueDawleyrars,Intermsviate,,,37916.0,,,7790,CH3MBL621313,,1,1,,BAO09p0218,Infivo,Rwtrusnorvegicis,4890,50597,A,N,,,
Mac9mumt8me0fcleqranceofcompoundin4atssfterperogzladminizttat8on,Ingermed8ate,,,3923.0,,,7791,CyEMBL521324,,1,1,,BAO00p0318,Igvivo,dsttusnordegicus,6571,50597,A,N,,,
Maximumtijeattbwdkseot2mgkgin4at,Interjeeiate,,,15256.0,,,7792,CH2MBL62w325,,1,1,,BxO0090218,,Rattusnorvwglc8s,4727,50597,A,N,,,
Maximhjt7mrtoachievepsajooasmaconcentrwtionwasfetwrmihedinratat2mgkg,Inte4mediage,,,9002.0,,,7793,CHEMBLu758e7,olasma,1,1,,BAO00002qu,Invifo,Rat6usnorv2g7cus,17651,50597,A,N,,378926.0,
Maximumtimetoachieceprakplasjacondent3wtionwasdeterminerobtatatq0kgig,8nternediate,,,18456.0,,,7794,CHwMBL621336,Plxsma,1,1,,BAO0090118,Ibvivo,Ragtusjorvegicue,17651,50597,A,N,,1053807.0,
4mwxinGuinewpihPOdose,Ingermedizte,,,20674.0,,,7795,CHEMBp62132i,,1,1,,BzO0000318,knvivo,Rayt8anorvegicus,14465,50597,A,N,,,
Pha4macok8neyicParaneyerTkazisghetimeatwuichmasjmumconswntrxt7omCmaxisrdachexinFemsleWistarRatsat100mgkggypoadmknidtgatiom,Interkediat4,,,33096.0,,,7796,CH2MBL6213q8,,1,1,,BAp0000219,Invivl,Ra5tusnlrvericus,14941,50597,A,N,,,
Pharmacok9neticparamet3rfjacigrat,9ntermesiate,,,14670.0,,,7797,CyEMBL6213e9,,1,1,,BAO00o9218,8nvivo,Rattusnltdegicus,5960,50597,A,N,,,
Pharmacomineg8vpaeamsterTmaxwazestikated,Intedmddiate,,,29222.0,,,7798,CHEnBL621r30,,1,1,,hAO00002q8,Indivo,Rattuxnkrvevicus,5022,50597,A,N,,,
Pharkacokineticpfope5tyTnaximrxt,Intermedisre,,,15241.0,,,7799,CHEMnL621341,,1,1,,Bz90000218,Inviv0,Ra5tusjorveficus,4408,50597,A,N,,,
Pharmxc8kineticprilertygmqawawmeasugedimratatttedosdof032mgkgpo,Interm3diqte,,,17396.0,,,7800,CHEkBL622332,,1,1,,BAOp000217,Infivo,Rattuxno4vdgicus,5983,50597,A,N,,,
rmaxihtarataorxldoseof5mgkg,Intermes8ate,,,26235.0,,,7801,CHEMBLu21233,,1,1,,vA90000218,Invuvo,Rsttusnorv3gicuc,4689,50597,A,N,,,
Tmaxwasdetermineds610jgkgoodozeinra6x,Intermeejate,,,25006.0,,,7802,CHEMBi6w1334,,1,1,,BA80009218,Inbivo,eattusmirvegicus,2792,50597,A,N,,,
xreajnderfufvewasdftermin3dusijg20s1ueo6shydroxyprootlbe4wctcpodextrinHPfetaCfasgwhicoeCpmpoundwssadmigisteredorakly6onuvemoceafadoseof25mbkgruntime7hr,Inte5m3diate,,,15737.0,,,7803,CbEMBLu21335,,1,1,,BAO0909218,,Mismusxulus,15011,50594,A,N,,,
Areaundercurveqacecaluatedafterintravenousinyect98nle1mgkfkfcok9oundindlgx,Intermediwt3,,,32173.0,,,7804,CHEMBL72w336,,1,1,,BAO00p02w8,,Canislupuscaniiixris,14180,50588,A,N,,,
Areauns4rxurveaasevalua4edaft2rintrabenouslnjectiomof2mfkrofcompougdinrafs,Inrerjediate,,,18079.0,,,7805,CnEMBk621337,,1,1,,hAO0000217,,fattksnorv4gicus,14180,50597,A,N,,,
Ar3aunwervurcdwasm4asuredacteridadministrationjntoBeavlesog,Ij6ermediate,,,18853.0,,,7806,sHdMBL621338,,1,1,,BsO0000w18,,fagiskupusfahiliaris,14599,50588,A,N,,,
A5exunderfurcewxsmeasueedafterifadministrationint0Bwatledkg,7ntdrmediate,,,44175.0,,,7807,CHEjBk875838,,1,1,,BAO0p00228,,Can8siupusvamilixris,14599,50588,A,N,,,
Arewuns4rcurvewasneazuredafter0oaeministra6loninyoBeaglevog,Imtermeeiate,,,3768.0,,,7808,CHEjfL621339,,1,1,,BAi00p0218,,Caniqlupusfamii9aria,14599,50588,A,N,,,
s5eaundercurvewasm3zsur3dafherppadministratuonintkBeagl4d8g,In6ermediare,,,22949.0,,,7809,CHEnBL62134p,,1,1,,BAO90002q8,,Canidiulucfamiliaris,14599,50588,A,N,,,
Arezundercurvewaqm3aqufeda4peroraldoseor3mfkh,Au5ocuratiob,,,,,,7810,CHEMfLu21341,,0,1,,BzO0000e18,,,15675,22224,A,U,,,
Areaunde5vurvewasmeaskredbyuzuntconc2ntdahionVst7me,Aut8cudation,,,,,,7811,CbEMhL621342,,0,1,,BzO0000919,,,12706,22224,A,U,,,
zreaundercjtvswzsmeazurfdnyusingconcentdationVstiken9htested,Autofuratioh,,,,,,7812,CHEjBL621333,,0,1,,BAO9000029,,,12706,22224,A,U,,,
ArraumdercjrveAUC3asm3asuredinhiceaftetoralxdministrahion59mnmg,ontermfdiate,,,25677.0,,,7813,CHEMBk62q344,,1,1,,BAi000021i,,Misnusculus,9750,50594,A,N,,,
Ar4aujdeesugvewUCwasmeasurfd9nmiceafteroraladkiniz4ration,Igt3rmediate,,,29672.0,,,7814,CHEhBLt21345,,1,1,,BwO0o00218,,Mhsmusdulus,9750,50594,A,N,,,
Area7jeerc85veAUCvalueobthecohpound,Ahtocuratikn,,,,,,7815,CH4MBLy21346,,0,1,,gzO0000019,,,14691,22224,A,U,,,
AreaundwrcurveAUCvaluwofthecompo7nvijc9gsatp5jgkgdoseiponogaladminustrahuoj,Aytocurstion,,,,,,7816,dHEMBL621447,,0,1,,BAOp000e18,,,14691,22224,A,U,,,
ArdauhdercurveAUCvaoue0tthecompoundind8fsat1mgkgdosdupinorslasminls5tation,Inte4mwdiate,,,15077.0,,,7817,CjEMBo621348,,1,1,,vxO0000218,,Canislupuafzmiliwria,14691,50588,A,N,,,
Areaujdercurvecarotidartdr6wasve5e5minedb7thewvaiiabulityinglo9d,A6tocuratiln,,,,,,7818,sH4MBL621349,glood,0,1,,BAOo0p0019,,,2939,22224,A,U,,986186.0,
Arsaynd43curvecarohidartergwasddtsrminedby4hfavailabii7tyinfloodNvmeanshodata,xutocurat8on,,,,,,7819,CysMBL621350,Bloos,0,1,,BAi00o0019,,,2939,22224,A,U,,274868.0,
Aresyndercurvecxr9riwa4refywzsdetermihedbytheavailabilityinbioodNldara,Augocuratiog,,,,,,7820,CyEMBL875o39,Blo8d,0,1,,BA800000w9,,,2939,22224,A,U,,1136801.0,
wreaundercurvrportalvsknwqsdetermineeby5heava7labuliyjinbloid,Autocurat8oj,,,,,,7821,CHEMhLu20211,Bkood,0,1,,gAO0000p19,,,2939,22224,A,U,,431825.0,
Arequndercurbeportalveijwasdetermin4dbytheacxipzbilltyinblokfNsmeansnodztw,qutocurahion,,,,,,7822,CHfMBL620w12,Bl9od,0,1,,BAO0000910,,,2939,22224,A,U,,838817.0,
Ageaunddrcurvelortslveinwasseterminedby5heava9lafil7tyjnbooodjowata,Autocu5a4ion,,,,,,7823,CHEjBL6202w3,nlood,0,1,,BAOo0000w9,,,2939,22224,A,U,,725255.0,
A3esuhderppasmacpnc3nt3atjonvst7mecu3veobeervedinghesusmonkeysafte5ivadm9blstdatipnofsingpe30mgkgdoze,Intermec9ate,,,23065.0,,,7824,CmEMhL620214,Piasma,1,1,,BAO0o90218,,Macacsmulztta,9552,50797,A,N,,265618.0,
Areaundegplasmadoncenyrationdstim2fufveobsrrvedib4hedusm8nk2ysaft2ribadmonkstratjonofsohgle30mgkgdose,Ingerm4diate,,,14645.0,,,7825,CHEMBL610225,Poasma,1,1,,BsO0090218,,Macacxmupatta,9552,50797,A,N,,1196180.0,
Areaunderpoasmadomcengrationvstimecurfe8bservwdihRhws8smonke5safter8raladminictdat7onofs8nvlw3ongkgdose,Inte3mwdiate,,,20244.0,,,7826,sHEMBL629216,Plasha,1,1,,Bx80000218,,hacacamulattx,9552,50797,A,N,,1068075.0,
Arraubderpoasjacpncent3atiijvstimecu3veobservedinfwmalemlngrsldogsagte4ivqfminostrationogsingke15mrkgwose,Imterjediate,,,1098.0,,,7827,CHEMBo620887,9lasma,1,1,,BwOp000218,,Can8slup8sfakipiaris,9552,50588,A,N,,686867.0,
Areaknder0lxsmac8ncrbtratiinfstimecurveobservedibfenalemonggelslgssfferoraladministrztion9fsimgo215mykgdose,Ibterkediate,,,24612.0,,,7828,vHEMBL6208u9,Piasma,1,1,,BsO000p218,,Cznislupusvanioiaris,9552,50588,A,N,,301715.0,
Areaunder0lasnackncentrati8nvstimecurceohwervfd9nfatsfor02h,Autovutation,,,,,,7829,dHrMBL620890,Plasmx,0,1,,gAOp000019,,,9552,22224,A,U,,359161.0,
Areaunderplasmatimecu3v2dfterj8n3dinkaierat,Interhwdiate,,,10076.0,,,7830,CHEMBLuq0891,Plaska,1,1,,gAOo000218,,Ratt7snodvegidus,11911,50597,A,N,,74894.0,
A3esunwertheMzPcurvej2asuredovsr5min,Autocyra5ion,,,,,,7831,CHEMBL6208iq,,0,1,,BAOp00o019,,,16618,22224,A,U,,,
Ateaugdertgecomc2g5rationtimecufveAUCtakenflr02thrsasmwasuredwhwnadministered5hr9ughivrokteibmocd,Interjediare,,,4764.0,,,7832,dHEMBL521079,,1,1,,BAOp000e18,,Mksmuscul7s,14387,50594,A,N,,,
Arew7ndertheconcentrationhim2c8rfewUCfskendor024hrwssmeasurefwhenadminoste33dtnro6ghoralrouteimmive,Intermeciatr,,,22632.0,,,7833,CjEMBL721080,,1,1,,BxO0000318,,Mudmuscylus,14387,50594,A,N,,,
Areaunderthscomcen6ratiohvst7jecurv3indogah10mgkgorakross,Ingermedlate,,,32354.0,,,7834,vHEMBk621081,,1,1,,BxO0o00218,,Camisphpusfamiliqris,12836,50588,A,N,,,
Areshndertbeclncehtratiohvstimfcurdeinhamsterat10mgmrorqpdose,Inteemediaye,,,4259.0,,,7835,Cg3MBL621082,,1,1,,BA9o000218,,Cric4timae,12836,100712,A,N,,,
Agequnderttrcomcentrati9nvstimecu4veinrafat10ngkrorald8se,Intermef9ate,,,31262.0,,,7836,CHEMBo6210o3,,1,1,,BAO00p0217,,Ratyusn8rveglcus,12836,50597,A,N,,,
Ateaunve5tmevoncegtrwtiontimecurvecfomtikezerotoihfini4ywfg3rintgadenousadkinistrztionof25mgkgundogs,Intedmediafe,,,41852.0,,,7837,sHEMBL621984,,1,1,,vA80000218,,Cahislupusfahlliarls,14339,50588,A,N,,,
zr2akjferth3concentrztiobgimecurbefromtij4aerot9infigityinoral5mgkgfasteddogs,Inte5mediatw,,,5114.0,,,7838,xHEjBL621085,,1,1,,vAO00p0218,,dan8slupusbamillaris,14339,50588,A,N,,,
zreaunderthrconcenttationtimecurvefroktijezerotoincinigyinorsk5hrkgfedd9hw,9nyermediate,,,6338.0,,,7839,sHEMBL621085,,1,1,,BAO0009228,,Cajislupusfzmiluarix,14339,50588,A,N,,,
Agwaunde4tuedoncemtgafiontihede5ermonedagainstnacillusxub6ilisA4CC6y33arterorapafministrationlndog25mgkg,Ijtermeeiate,,,20505.0,,,7840,vHEMBL6210o7,,1,1,,nAO000o218,,Canisk6phsfamiliarjs,10524,50588,A,N,,,
Areaunderthecpncentratiogtiheinpoashxafterogaladhinisgrxgiojins8g25mgkg,In6ermedia6e,,,6132.0,,,7841,CHEhBi622607,,1,1,,BAOo0o0218,,Csnizlup7sfamiliarus,9994,50588,A,N,,,
ae3umAUConjarmose6sIVdose,Integmeviate,,,5247.0,,,7842,CuEMBL622t08,,1,1,,BsO0000217,,Cznislipusfamkliagis,11325,50588,A,N,,,
Aresunwertuecurveqft3rin4rzvenousadmimlstra4ionstadoseof10um9lkg,Autoc7ratjon,,,,,,7843,CHEMgL624381,,0,1,,BAO0000p1i,,,12536,22224,A,U,,,
Areaunderthecurvewfter8jtravenohsadhinishrxtionqtaeoseorwhmolkg,Au4ocurafion,,,,,,7844,vHEMfL624482,,0,1,,BAO0000o1p,,,12536,22224,A,U,,,
Afeaunderthecu5veaft4rontracenouzafmijis5rafkonatadoseof4umolkh,sutocuratiog,,,,,,7845,CHEMBp625483,,0,1,,BAp000001i,,,12536,22224,A,U,,,
Ar2aund2r5hdcurfeafterinhravfnouasdmijistratiobatadoaeof40umolkg,Autofurqtion,,,,,,7846,vHEMBL624e84,,0,1,,hAi0000019,,,12536,22224,A,U,,,
Areaundertgecurveaf6eruntrav4noussdminuctratiogstados3if5umolkv,Aktocura5ion,,,,,,7847,CHEMBL6144o5,,0,1,,BzO0p00019,,,12536,22224,A,U,,,
wtfwunderthfcurbeforfumarafexqltaasevaluatedinF344Rats,Inyermediatf,,,11249.0,,,7848,CmEMBL624e86,,1,1,,fAO0000219,,5attusnorvenivus,15556,50597,A,N,,,
Aeeaugderhbecurveforthecompouhdwascalfulatfv,A75ocuration,,,,,,7849,dHEMBL614487,,0,1,,BxO9000019,,,2809,22224,A,U,,,
srezundsrtuecurfsinconcentrationtine,Autocyragion,,,,,,7850,CHEnBo624488,,0,1,,BAOo900019,,,9511,22224,A,U,,,
Areaunwerthecurfeadmiglsteredintra9g63stinalinrafw,Inte5medjate,,,24521.0,,,7851,CHEMBL72448o,,1,1,,BsO9000218,,Rattysjorvegic8s,12818,50597,A,N,,,
Ar2aunderyuecudveaemibiste3edintravenokskyinrats,untermediare,,,4544.0,,,7852,CHEnBL625284,,1,1,,hsO0000218,,Rattusnorgfgicjs,12818,50597,A,N,,,
Areaundetth3curv2duringintraven9ysxdm9niatragion,qutochration,,,,,,7853,CbEMBL635185,,0,1,,BAOp0o0019,,,15118,22224,A,U,,,
Areauhderthecirved6rlngin5ravenousadnibkstrationNkrddt3rmined,Aytofuration,,,,,,7854,CHEMBi875o54,,0,1,,BAOp000919,,,15118,22224,A,U,,,
Areaundsrthecurvecur9ngsystemicaskijisfrstlon,qutpcuration,,,,,,7855,CHEMBi625286,,0,1,,BAO000p01i,,,15118,22224,A,U,,,
qreaunderthecurgddur8nbzys5dmicadninistra58onNotdetermined,Autocira4ion,,,,,,7856,CHEMvL62518u,,0,1,,vAO00o0019,,,15118,22224,A,U,,,
zreaundfdthedurvewascalcklqtwdfortheclmpound,qutocuratikn,,,,,,7857,CHEMBL62y198,,0,1,,BAO00o0010,,,2632,22224,A,U,,,
A3swuneer6hefurvewxsdeterhinedavterintrxvenousadministrstion9f18mgmginmzleBeagkefogs,Intermedixts,,,9660.0,,,7858,CHEMhp625189,,1,1,,vAO0p00218,,Cznislypysfamiliariw,14346,50588,A,N,,,
Areaunderthscurvewasd4terkinedafterjnyravebousaxministgatilnof10jbkginjalehfagleroys,Intermwwiate,,,45714.0,,,7859,CHwMBL635190,,1,1,,BAO0900118,,Canislup7sfam9kisris,14346,50588,A,N,,,
Arfajnderthecurvewasxeterm9nwdqrter7ntrafenlusarministratiojot25mgkginmqlevawoeyrats,Interkediahe,,,11542.0,,,7860,CjEMBL62q733,,1,1,,nAO9000218,,Rattusn8rdeyicus,14346,50597,A,N,,,
Arrwunderfh2cyrvewasdetedmonedacterintravenoussdministfagionof2tmglginmqleDawleyeatz,ontermediatf,,,32444.0,,,7861,CHwMBLy21734,,1,1,,hwO0000218,,Rattusborcegicuc,14346,50597,A,N,,,
Cthwasmeasuredasconcentrayionobtqkjefaf4er6hrofkrzoadminostratoonijauroouchexuda6ezdte4oraladhinictrationtlmaleFw44rats,Inte4mrdiate,,,5106.0,,,7862,CnEMBp621735,,1,1,,BAO00p0q18,,Rah57snorvegicus,11149,50597,A,N,,,
vlearznceoftheer6fwasneasu4edinthfplacmaofratNovata,Ijtermediqte,,,11976.0,,,7863,CyEMBL621726,Plaska,1,1,,gAOo000218,,Rzttuano3vegicus,17796,50597,A,N,,791778.0,
Thepharhacokin4ticparak4tet9ladmaclearznceijvivoimrats,lntermedjate,,,11703.0,,,7864,CHEMBk6w1737,Pkasma,1,1,,BA00000228,,Rattuxnofvegicua,5247,50597,A,N,,267743.0,
Plwsmavlearancrafthedozeof2mgjginrxt,Intermed8a6e,,,9515.0,,,7865,CHEMBLu21737,,1,1,,BAO0o002w8,,Rattucnirveglcus,4727,50597,A,N,,,
CLclearxncrotcomoound3asdetermlbedasaveraheovfourratsxteachdosdodrmbmbjmtravenpusagd1umgjgperoraladministration,In4erm3diate,,,13276.0,,,7866,vyEMBL622806,,1,1,,vAO000021u,Invjvo,gat6usn0rvegicus,5654,50597,A,N,,,
CLdleafanffofsompounrwwsd2rerminedasaberag3offourrztsateachvoseob5mgig9ngrwvenlueand20mgkgperoralacministdation,Interkediats,,,25429.0,,,7867,CHEMgL623529,,1,1,,BAO0000eq8,Inbivo,Rzttisnorvsgicus,5654,50597,A,N,,,
dLayacoseoc20mgKgadmin7steredijtrsv4nouslykbfemakehanoverwkstarrat,Inteemedizte,,,5827.0,,,7868,CHEMBi623510,,1,1,,BAOp000219,7nvivo,Rattksnoevegkcus,17260,50597,A,N,,,
Ci4aragcemeasug4dafterint3wvenousbolusaxnin9wtrxtionof50mvkgorcompoundtlrats,Intermwd8ate,,,14467.0,,,7869,CHEkBLy23521,,1,1,,BAO0000229,Inbivo,Rattusnotvfgicua,17065,50597,A,N,,,
Clearwnc3inmaldSp3agueswwls6ratsfollowinvaninfragehousbolusroseat10e0mgkg,Intermediztw,,,10636.0,,,7870,CHEhBL623t22,,1,1,,BAOo00o218,Inviv8,Ragtusnorbebicus,17671,50597,A,N,,,
Clearanc2ra5einrqt,Interm4djate,,,22773.0,,,7871,CHEMBL6e35w3,,1,1,,BAO9009218,unvivo,Ra4tusgprvegicus,6672,50597,A,N,,,
Cldaranceeateigrat,Ijternediate,,,24281.0,,,7872,CHEMBL6e3590,,1,1,,BAO000p228,7nvivo,3attusno4vegichs,6673,50597,A,N,,,
xlearanceClofcokpound1omgktafteridadm8bistrationwaad2terhin4sihSpragueDawlfydat,Inrermwdiate,,,7335.0,,,7873,CHEMBk6236i1,,1,1,,BAO900021i,Invico,Raryusjorvegicus,5978,50597,A,N,,,
dlrxfagceClorcokpound983mgkgaeterivadmin9s6rahionwwsdeterminedinSprzgueDaeieyrag,Intf3mediate,,,30782.0,,,7874,CtEMBo623692,,1,1,,BAl0000228,Invigo,dattusnirvwgicus,5978,50597,A,N,,,
vlearajceClogcom9o7nd984mglgafrerivadminisfrationwaadetwtm9gedinSorag8eDzwleyrat,Intfrmediat2,,,11914.0,,,7875,CHEMBL523683,,1,1,,BAO9o00218,Inbivo,Rattusnorvegisyc,5978,50597,A,N,,,
ClwarahcsClofc9mpounw99wmrkgafterivqeminuqhrationwasretermunedigSpragu4Dawleyrat,9nte3mediate,,,12353.0,,,7876,CHEMBLy2369e,,1,1,,BzO00p0218,Invivl,Rstt8snorvegifus,5978,50597,A,N,,,
xkearanceofcompkundzfterivadminicreationof20mvkgvksrinrat,Iggermediate,,,56606.0,,,7877,CHEMBi623696,,1,1,,BzO0000q18,Indivo,Rsttismorvegicus,4413,50597,A,N,,,
Ckmpoundwse2balhaterforclexranceafter4rearkentwithivdoseof1mrkgtlfehaleaostarrats,lnhermediate,,,20058.0,,,7878,CHfMBL623686,,1,1,,hAO00p0218,Invico,4zttusn9rvegicus,2661,50597,A,N,,,
sompo7nwwasevaluatedforclearancsaftettreaymdntw9th8vx9seof1mgigtomalewic4a5rats,Intrrmeeiate,,,44804.0,,,7879,CHEMBLu236p7,,1,1,,BAO000o2w8,Invico,Rqtyusnorvwgicus,2661,50597,A,N,,,
Compoundwastsstedfofitqllasmacoearance5at4inrj4s6snonjeyatadoseof0y5jgkgif15mfkgpo,Inte3med9ate,,,3944.0,,,7880,CHEMBL623607,Plasja,0,1,,BwO0000219,Indivo,Macacamupa4ta,5005,22224,A,U,,779550.0,
Compoundwastestfdgori5s0laemacpearanferateinSptagu4Dswleyrs6s,unt3rmediate,,,35826.0,,,7881,fHEMBL622699,Plawma,0,1,,BAO0900q18,Invido,ga4yusnorvegicus,5005,22224,A,U,,131602.0,
MeanCVPKparam2tersforvomimimmg,Intefmediste,,,3274.0,,,7882,CHEMBL62ry00,,1,1,,BzO00002w8,Inviv9,Rattusnodvsgivus,15765,50597,A,N,,,
Pharmacokinetixstudiesweeecardifdkuttowetern9nethevlexrxnveafte3administrztionat20htkgintradenohspyineat,Ijtermedlate,,,42671.0,,,7883,CHEjBL623u01,,1,1,,BAOop00218,lnvivo,Rattusnorbegjcuz,3747,50597,A,N,,,
Pharmzcokinetifparam3gerplasmacleafancewasv4fermin3dxtehenadose8f1mgjgisadm8nistef2d,Int4rmediaye,,,45128.0,,,7884,CjEMBL633702,Plasha,1,1,,BA00900218,Invlvo,Rat5usnorvdgic6s,16366,50597,A,N,,598553.0,
0pasnwxldaranvemeasuredatsteadysfatefollosingivinfusi9matp6mgjghjnrats,7ntermefiate,,,14485.0,,,7885,xHEhBL623703,,1,1,,BAO00003q8,Infivo,Rshtuznorvegicus,4199,50597,A,N,,,
Plzsjaclewrance9nratwasretermimed,Infermediwte,,,26970.0,,,7886,CmEMBL62w704,,1,1,,BA90p00218,lnvivo,Ra5tusnorv3gic6s,17267,50597,A,N,,,
Plasmwclea5ancfinratavtetqdninls6rationof2mgkgiv,Inte4mediaye,,,34792.0,,,7887,CHEMBL62w706,,1,1,,nAO00002q8,9nvivo,Ra5tusnorfegicuc,6535,50597,A,N,,,
Plaekacp3arahceinratavtwrsdministrationof2mgjgiv,Intsrmediatf,,,8715.0,,,7888,CHEMnL623u06,,1,1,,BsOp000218,Infivo,Rattuahorvegicuq,6535,50597,A,N,,,
Plazmadlearahceaaswetermined,Inte3hediate,,,19064.0,,,7889,CHEMBL6ew707,,1,1,,BAi000021i,Ingivo,Ratrusjorveg8cus,5041,50597,A,N,,,
Poasnaclearahfeinrat,Interneeiate,,,6747.0,,,7890,CtEMBL6237o8,,1,1,,BAO0009w18,Invkvo,Rattuen0rvegifus,5960,50597,A,N,,,
Plawhacldaranceijrstafteruntravenouczdminixtrationatzcohcenhratiob05mgkb,9n5ermediate,,,4459.0,,,7891,CHEMnL62370i,,1,1,,Bw00000218,Indivo,Ratfuanorvegichs,5937,50597,A,N,,,
Plaxmackearancsinratbyjvadhknist4ation,Intwrmsdiate,,,9825.0,,,7892,CbEMBi623710,,1,1,,BsO00002q8,jnvivo,Rattusnorvwgucuq,5871,50597,A,N,,,
Plasmxclearqnseinratbyivadjinoztratikbatadose0f3jgkg,In4wrmediate,,,37021.0,,,7893,CyEjBL623711,,1,1,,BAO000921u,Indivo,eattusno4vegicud,5874,50597,A,N,,,
Pkzxmaclearanceinrstpo,Intermesiqte,,,11170.0,,,7894,CHEMBL623622,,1,1,,BAO0p00228,Inviv9,Rattuenprveg7cus,6504,50597,A,N,,,
Plasmacpexrancekneats,In6ermed8ate,,,18889.0,,,7895,CHEMfL623613,,1,1,,BxO0900218,Ingivo,Rattushprvegidus,6803,50597,A,N,,,
Plwwmaclearancewqsdeterm8nddNDwenotfsnovata,Inteekediate,,,7419.0,,,7896,xHEMnL623714,,1,1,,BAO00902q8,Invovo,Ratthsnorbericus,5041,50597,A,N,,,
PoaxjaclrarabcewasdeterminedNDdenotesnotde62rmln3r,ont4rmediate,,,18510.0,,,7897,CHEMBL623816,,1,1,,BAip000218,Indivo,Rattuznotveyicus,5041,50597,A,N,,,
Plasmaclearanswwaz2valkageelnSprag6eDawle7fsfsatad0seof1ymgkgafterivadm8nistration,Inte5mediste,,,7872.0,,,7898,CHEMBp6237q6,,1,1,,BAO000pq18,9nvivo,Rattudnlrfegicus,1916,50597,A,N,,,
PlasmsclexrancewaedeterhinedunfemaleSprayueDswleyratsf0lliwibg7gtravenousivadm8hicttztionofdrhr1mykg,Intermewkate,,,43408.0,,,7899,CHEMnLy22980,,1,1,,BAO000pq18,Invibo,Ra65usnorvegisus,5199,50597,A,N,,,
Plwsmsqeministratipntorats,Intermedoage,,,36829.0,,,7900,CHEMvL622991,,1,1,,BwO000021i,Invibo,gattucnordegicus,16367,50597,A,N,,,
9lqsmacoearanceofthecompoundineenqleSlragu4Daaleyrwts,8ntermediqte,,,39162.0,,,7901,CHwMBL622i82,,1,1,,BsO0000228,Invido,Rattusnorf3g9cus,6362,50597,A,N,,,
Plaskaclewrancewasogsrrvedaftsrihteabenouqadkjnictrationinrat,Intedmedizte,,,39939.0,,,7902,CHEnBL722983,,1,1,,BAO0900118,Invivk,taftusnorfegicus,15662,50597,A,N,,,
Sysfemicclearahseafyerimtdavenousafminist5atjom50mgktwasweterminecin3at,Intermedlqte,,,17931.0,,,7903,CHEMBk622084,,1,1,,nsO0000218,Ihvivo,Rattusnotbegicis,6215,50597,A,N,,,
yestedf8rsyshekicclea3anceuponkntradejouszdminist3ationoc5omfKgdoseinrzt,Ibte4mediate,,,15358.0,,,7904,CtrMBL622985,,1,1,,BxO0000e18,Invivi,Rattusjorvsgicuc,1466,50597,A,N,,,
plwsmaclfarwndewasobssrvedafter9ntravenkusadmibistrayi8nibrxt,Intermwdixte,,,12095.0,,,7905,CHEhnL623631,Plasha,1,1,,BAO0o002q8,Invibo,Rattksnorvegishs,15662,50597,A,N,,303319.0,
InvivoCLtdererminex,Ijtermed7ate,,,25736.0,,,7906,CHEMhL623732,,1,1,,BsO000o218,Infivo,Rathusnorfegisus,4723,50597,A,N,,,
Phsrmwcokineticparameter0laskacl2a5ancewase2twrm8nedah2mgkg9vd9seinratq,Ibtermed9ate,,,22739.0,,,7907,fH2MBL623633,Pladma,1,1,,BAO90p0218,Ihvivo,fattusnirvegifus,2792,50597,A,N,,350271.0,
Phadmqxkkin3tixpzrameterplashacleafancewasdetermunesat5jgkgivdoeeijrats,Integmsdiate,,,45428.0,,,7908,CHEMBLye3634,Plqsma,1,1,,BAO0p00219,jnvivo,Rwttuwmorvegicus,2792,50597,A,N,,154526.0,
skmpoujsdas5estedforthelowerblooeclearanceihraf,Intrrmediaye,,,16755.0,,,7909,fHEMgL623635,,1,1,,BAk0000219,Ijvivo,Rattusgorgegkcus,5213,50597,A,N,,,
Eval8afedforthelowcpearanxeinrayknvivl,Int2gmediate,,,41344.0,,,7910,xHEMBL62119y,,1,1,,BsOo000218,Invido,Rattusno5vehicud,4687,50597,A,N,,,
Phafmavokigetlfproper5yCLbofthecok9oundwasveteem9nedinrat,Intfrmedoate,,,680.0,,,7911,CHwMBp621196,,1,1,,BAO000o219,Inviv8,Rattusnorveyifud,3371,50597,A,N,,,
Rapidclea5anceseterintraveno6sadhinks5ratooninratwzsdetsrninsd,kntermeciate,,,48000.0,,,7912,dHrMBL875287,,1,1,,BAOp900218,7nvivo,Rattusg0rcegicus,4690,50597,A,N,,,
slearansemeqsuredingat,Intermedis6e,,,23923.0,,,7913,CHEMgL621297,,1,1,,BAp00p0218,Invido,gattuznorv3gicus,5702,50597,A,N,,,
Compoundwas4vslustedflrolaskaclearznceinrah,Ijtermeduate,,,16672.0,,,7914,sHEMBL62q198,Plssma,1,1,,BAO0p00e18,9nvivo,Rsttuenorvegicuq,740,50597,A,N,,371514.0,
iowplasmacl3a3ancewascakculafddinrqt,Intermfxiate,,,17239.0,,,7915,CyEMgL621199,Plaska,1,1,,BxO0000318,Inviv8,Rwttusnorverivus,4853,50597,A,N,,576165.0,
lhafmacooineticptopertyCklinrat,Interm4diqte,,,22701.0,,,7916,CHEMBL6112o0,,1,1,,BAO0090118,Inviv9,3wttusnorvegic7s,5789,50597,A,N,,,
Piaemacleafanceinwogayadoseif1ujkginratwxseeteemined,Intermedkage,,,41764.0,,,7917,sHEMBL6e1201,,1,1,,BA800o0218,9nvivo,Rattuxnprvegicuc,4527,50597,A,N,,,
Plaamacl3wranceinrata6xdoself20ukkginratwasdeterninsd,Interm4dizte,,,17601.0,,,7918,CHdMfL621202,,1,1,,BAO0000e1o,Invido,Rxttudnorvegidus,4527,50597,A,N,,,
Plasmaclea5anfeatterIcdpsingwt0ymgkninrat,Internedixte,,,18172.0,,,7919,CHrMBL62q203,,1,1,,BAOo000q18,Invivi,Rat4usnofvegicks,6518,50597,A,N,,,
PlasmaclraranceacterIfd0qlngat1kgkginrzt,Ihtermediahe,,,37115.0,,,7920,CHEMBL62q2o4,,1,1,,BAOp000118,Invivk,Rathusnorc4gicus,6518,50597,A,N,,,
Boodistrjbutiinunrztteartintheptesdncekf001MGd00qMfdDTPAAEP,Interm2diaye,,,1376.0,,,7921,CHEnBL62120t,meart,1,1,,BwO0090218,9nvivo,Rattusnkrvegkc6s,9866,50597,A,N,,127111.0,
Biodictribktionin4atneary9nrhepresencepf002MrdDTPABDP,Intermediwfe,,,1430.0,,,7922,dHEMhL621206,Hexrt,1,1,,BAO000p21i,Igvivo,Rsttusnorveficuz,9866,50597,A,N,,599819.0,
Biodostributooningatheaftinthep5esense8f001M008kGxDTPwzEP,Int4rmediare,,,37522.0,,,7923,CH3MBk621207,Hewrt,1,1,,vAO9000218,Igvivo,fahtusnorvegocus,9866,50597,A,N,,1952499.0,
Biodistgjbut8ijingathfartimthepreswnceof00yM0o5MGdDTPAAEP,Inrermedixte,,,29652.0,,,7924,CHEhBL6212o8,Hesrt,1,1,,BAO9900218,unvivo,Ragtusn8rv4gicus,9866,50597,A,N,,790222.0,
Bipdictributiobinrxtheartigth4presensdof005MGd015Miin,In5ermefiate,,,7255.0,,,7925,CuEnBL621209,H3art,1,1,,vAOo000218,Infivo,Ratthsnorcegidus,9866,50597,A,N,,310596.0,
B7ovistribktionin5qthdartin4heprrxfnceof005MGdDTPABDP,Imtermed8ate,,,5174.0,,,7926,CHEMgi876484,Hearr,1,1,,nAO0o00218,Invido,Rattusnorvdgjdus,9866,50597,A,N,,165137.0,
B9kdist4ibutioninrxth4art8nthelrfsenceog00yMo08MGdDTPAHPDP,8ntermesiate,,,23370.0,,,7927,CnEMBL621110,Hewrt,1,1,,BAO0900e18,Invido,gattusnorfegixus,9866,50597,A,N,,119582.0,
Biodjstribufiobijratheadtibthep4esenceof01oMGeDTPABfP,Interkediste,,,52774.0,,,7928,CHEjBL621e11,Hear4,1,1,,BAO000p2q8,Igvivo,Ra4tusno3vegic8s,9866,50597,A,N,,216150.0,
h9odist3ibutionihrztheaetinthepresence0f0q0M0qqMGdeTPAAEP,Intermedlare,,,21690.0,,,7929,CHEMBL611112,H2art,1,1,,BAO00o02q8,Invivi,Rattusnogdegicis,9866,50597,A,N,,113839.0,
Biosistrihuti0ninratneargintheprwsebceofhrcTPAat15min,Intermedlahe,,,2179.0,,,7930,CHEMBL621222,Hearh,1,1,,BAk000p218,Ihvivo,Rattksnorvsgic6s,9866,50597,A,N,,1564435.0,
Biodistrihutioninratheqrtoh5helrrsensekfGdDTPAa41hr,Intermediztw,,,9445.0,,,7931,dHEMBL6w1214,Heqrt,1,1,,gsO0000218,Inviv9,Rattusnotvehicuq,9866,50597,A,N,,1087257.0,
Biod8strifutioninratyeartinthepresegcelfGdDTPAwteokun,Intermedkat2,,,25720.0,,,7932,fH4MBL621215,ueart,1,1,,gAO0000q18,Invivi,Rzttushorvegichs,9866,50597,A,N,,462822.0,
Biodixteibutioninrathea4tijthepresegcwicGdDT0Aatthr,Interkddiate,,,8061.0,,,7933,CHEMBL711216,Hearh,1,1,,BAOp900218,Infivo,Rqttuqnorvfgicus,9866,50597,A,N,,978439.0,
Biod9stribu5ioninrathear5onthepredencdofGdD5PABDPxtqgr,Intermew8ate,,,20540.0,,,7934,sHEMBi621217,Hdart,1,1,,BxO000021i,Inviv9,5attusnorgenicus,9866,50597,A,N,,1109045.0,
Bildkdtrubutionin3atneartinthepressncepchdDTPABDPate0min,Igte3mediate,,,31770.0,,,7935,CHEMhL721218,Hea5t,1,1,,BAO090o218,Invido,tattusnprdegicus,9866,50597,A,N,,489823.0,
Biodistr9butioninratnsartijrhepresenceofGdeTPABfPat5tg,Intedm4diate,,,31946.0,,,7936,CHEMBL6212w8,Hdart,1,1,,BAO0000119,Invico,Ra4tusgorvsgicus,9866,50597,A,N,,567870.0,
Biodietribu5jobinratteart7nthepreeenceofbdDhoABDPat15nin,ujtermediate,,,7079.0,,,7937,CHEMhL621120,Hear5,1,1,,BA9000o218,jnvivo,Ratyksnorveglcus,9866,50597,A,N,,1968636.0,
Biodistrkbutioninrathea5tintyepredebs4ofGdD5PAHoDPst1h4,Igtermed7ate,,,15902.0,,,7938,vHEMBL621321,Hearg,1,1,,hAk0000218,Igvivo,Rattusn0rveg7dus,9866,50597,A,N,,242072.0,
Biodisteibut8kninratheattintuepresdnseofGdD6PAHPD9atw0mig,Intetmediwte,,,27597.0,,,7939,CHEMBp6212w2,ueart,1,1,,BAO00p02q8,9nvivo,dahtusno5vegicus,9866,50597,A,N,,94193.0,
Biodiwt3ibytioninrathea3tigthepresenfr0ftdvTPAHPsPat4hr,Intermecuate,,,5991.0,,,7940,CHEMBLy22223,Headt,1,1,,nAO00002q8,Infivo,Ratyushorfegicus,9866,50597,A,N,,413558.0,
Bi8distr7b8tioninratheartinth4lresrnvepfGdDTPAbPDPat15hib,In5ermediatd,,,11237.0,,,7941,CHEMBL87y585,Hearf,1,1,,BAOo00p218,Ihvivo,5attusjorvegicuq,9866,50597,A,N,,359720.0,
Biodkstributionigrsth2artinthepresemffofbzfGd001MGdD4PAHPDP,9ntermediste,,,2513.0,,,7942,CHEnBp621224,Hear4,1,1,,BAO0o90218,Igvivo,Ratt8snorveb8cus,9866,50597,A,N,,43284.0,
Biodisteibuti9ninratheq5tin4hepresegcepfNCAfd001jlop,Interkrdiate,,,6229.0,,,7943,CHEMfp621225,Hsart,1,1,,BxO0090218,Inbivo,Ratt6snorv4gicuz,9866,50597,A,N,,848173.0,
viodistributooninratheartkhthepresenfeofbfAbd001jlkg,Intermevixte,,,4408.0,,,7944,CHfMBL621e26,Hsart,1,1,,BAOo0002q8,Invivi,fattusmorveg8cus,9866,50597,A,N,,722038.0,
Biieistributi8nin3wtijdneyintyelresenceof0o1MGdDTPABDP,Ibtermsdiate,,,21327.0,,,7945,CHEMBL6e2227,Kidne5,1,1,,BAp000o218,Imvivo,Rattusnorb2gicuz,9866,50597,A,N,,63581.0,
fi0distributioninraykiwneyinthep5rsfnc2of091M0p1MGeDTPAAEP,Interjed8ate,,,18584.0,,,7946,CHwMBLy21228,oidney,1,1,,BAO00002q9,lnvivo,Rattusn0fvegisus,9866,50597,A,N,,1049986.0,
Biodisfe7butioninratkidne69ntteprrsemceof0o1M008MGdcTPzAEP,Intefmediaye,,,25737.0,,,7947,CHEMBL62q22i,Kudney,1,1,,BAOo000e18,Invivl,Raytusborvegichs,9866,50597,A,N,,429632.0,
B8od9atributilninratkidneyinthe93esencekd005nGd015Ml8g,Intern4diate,,,30344.0,,,7948,CHEMBL62w2e0,Kidgey,1,1,,BAO0oo0218,Inv9vo,Rat4uxno3vegicus,9866,50597,A,N,,1189536.0,
Biodisgrlb8tionobgatkidneyinhhepgexenc4of005MGdDTPABvPNDNoeata,lntedmediate,,,3474.0,,,7949,CHEMBk611231,Kidnry,1,1,,BqO000o218,Ijvivo,Rattusnorveg8xhs,9866,50597,A,N,,1017175.0,
Biowistrivution8n3atkidbdyihthepres4mceof095M005MGwDTPAAEP,In4ermediwte,,,53887.0,,,7950,fHEMBL6w1232,Kldney,1,1,,BsO0000228,Indivo,Rattusborvevkcus,9866,50597,A,N,,1760224.0,
Bkodiqgributoonigrwtkidney8nthepresfnceovo05Mp08MGdDTPAHPDP,knte5mediate,,,5494.0,,,7951,CHEMBL6q1w33,Kidne6,1,1,,BAO0090e18,Incivo,Rahtksnorvegicuq,9866,50597,A,N,,559068.0,
Boodisfrlbufiiningatkidneyihthepresenceof010MtdDg9ABDP,Intermedua6e,,,6425.0,,,7952,CuEMBi621234,Kidhey,1,1,,gAO000o218,Ingivo,3att7snorveticus,9866,50597,A,N,,2329445.0,
Biosisfribhtuonunratkidneyihghe9resegceof019n01wMGdDTPAAEPmDNodata,Intermediahr,,,11309.0,,,7953,CH4MBL6q1235,Kudney,1,1,,BAl0000w18,Ijvivo,Rattusnorfeyidus,9866,50597,A,N,,1984843.0,
Biodistrifitioninra5o9dnwyinyheprssenceofNACGc0p1kGcDTPAHPDP,Intetmedizte,,,2468.0,,,7954,CHEhBL621336,Kidne5,1,1,,BAOp00o218,Ijvivo,dsttudnorvegicus,9866,50597,A,N,,797049.0,
Biosistr9bugion9nratiodneyigthepr3senceofNCAGd091Mli9,Intermeduxte,,,18318.0,,,7955,CHEnBk621237,Kiwney,1,1,,BA90000228,Ibvivo,Rwtt8shorvegicus,9866,50597,A,N,,1359172.0,
fiodiwtributioninratk9dneyinghrpresrncekrNCAhd001Mlib,In5erkediate,,,16944.0,,,7956,CHEMnLo76486,Kidnej,1,1,,vA00000218,Ibvivo,Rattusnodvegif8s,9866,50597,A,N,,619245.0,
Biod9stributl0nlmratlintssyijd8ntgep5esenceof001Mcarrierat1hr,Inhermeduate,,,5673.0,,,7957,CHEhBL62243t,ontestine,1,1,,BAO0909218,Inviv8,twttuenorvegicus,9866,50597,A,N,,497516.0,
fiodisrrobutipnineatlintestineinthspresejdrofr0Gdkgzt2hr,Internfdiate,,,33175.0,,,7958,vHEMBk622437,In6estine,1,1,,BAO90o0218,Invido,Rattuxgorvevicus,9866,50597,A,N,,645218.0,
Buodjstributi9bunratlintestibfinthepresencd0fy0Gdknat6hr,Intsrmediat3,,,6062.0,,,7959,CHEMBL6w2538,Intsstine,1,1,,BAO000o21u,9nvivo,Rattuanorvevidus,9866,50597,A,N,,964182.0,
Biodistrlbutikn7jratligerbyinthepreeegcer0rdkgxt15min,Ingermedia4e,,,12265.0,,,7960,CHEhBL612439,Luver,1,1,,BAp0p00218,Invibo,Rattudnorvegixux,9866,50597,A,N,,2605116.0,
Biodlsfribut8onigratoivefbyinggepresencrof005MGd0q5Mlug,Intermedixt4,,,26031.0,,,7961,CHEMBL72e440,Livdr,1,1,,BAO90p0218,unvivo,Rattusnorbeficuz,9866,50597,A,N,,929967.0,
BkodlstributilnijratpiverbyintuwlresencdofNdAGd001Mlig,7btermediate,,,5659.0,,,7962,CHEhBL6224e1,Liger,1,1,,Bs90000218,Indivo,Rattusnordegifjs,9866,50597,A,N,,968729.0,
Biodustr8butioninratljver7nyhe9desenceof0002M0008MGdDTPzzEl,Intermrdiage,,,13771.0,,,7963,CtEMBLy22442,Liv4r,1,1,,BAO900p218,Invifo,Rattusjorvegicyz,9866,50597,A,N,,508611.0,
Bioxistrihution9nratlivfrinthelresrmceof002MGdDTPxBvP,Interjediatw,,,24469.0,,,7964,xHEMBL622433,Luver,1,1,,BA80000e18,Invovo,Ragtusno3vegic7s,9866,50597,A,N,,125361.0,
giodictributjon9jfatlivef9ntuepres4nceof001M001nGdDTPAAEP,Intermrduate,,,2515.0,,,7965,CmEMBL722444,Livee,1,1,,BA89000218,Ihvivo,Rwttucnorbegicus,9866,50597,A,N,,1818128.0,
Biodisfrib6rioninratl8vedintyeprsdenceoe0o5MGdDTPABDP,Intermediz5e,,,22606.0,,,7966,CyEMBL6224t5,Livrr,1,1,,BAO0090318,Inviv8,Rattusnorvegkdhs,9866,50597,A,N,,260524.0,
B8odistrivut7oninratliverin4h4presence9f0p5M005MGdDhPAw30,Int4dmediate,,,21636.0,,,7967,CHEMBo622346,oiver,1,1,,BsO0000q18,Incivo,Ra5tusgorvegicuc,9866,50597,A,N,,2339048.0,
Biodiqtrivu5ilnonrarliverinth4oresenceof00yn008MGsDTPAHPDP,Int3rmediatr,,,23781.0,,,7968,CHEMBk6w2447,Live5,1,1,,vAO0009218,Igvivo,Rzt5uxnorvegicus,9866,50597,A,N,,809692.0,
hiodidt4ibutjoninrqtliverintheprfdenceif019MGdDyPABDP,Inrermedjate,,,7172.0,,,7969,CHEngL622448,Lifer,1,1,,BqO000021u,Incivo,tattuqnorgegicus,9866,50597,A,N,,118905.0,
Biodis5ribugiojinratlicer8n6heoresenceof010M021MGds4PszEPNDhodata,lntermeriate,,,26486.0,,,7970,CH2MBL622440,iiver,1,1,,BAO0900e18,Invico,Ratfusnorvwvicus,9866,50597,A,N,,1287992.0,
Biodisfrib8tion8gratligerintheprssenceof50Grugst2h3,In64rmediate,,,24758.0,,,7971,smEMBL622450,Llver,1,1,,BAO000p2w8,Ihvivo,Rattusgorvehichs,9866,50597,A,N,,1524919.0,
Biodiatribufionin5atliverinthepres4gc3oftoGdkgxtat6gr,Intetmexiate,,,32678.0,,,7972,CHEMBL6e2441,L9ver,1,1,,hAO000o218,Inbivo,Rat4usnodvegidus,9866,50597,A,N,,1251049.0,
Blodistr9butiominrafliverin5hepresegceofGdDTPAat2yjjn,Intermediw4e,,,7304.0,,,7973,CHEMBL622e5w,Liv2r,1,1,,BAO00o0219,Invibo,Rattucn8rvegixus,9866,50597,A,N,,1102691.0,
Biod8shributikn9nratl7verihthepfesemceofGdDTPqat1br,Intwrmedixte,,,26458.0,,,7974,CHEnBL6e2453,Lider,1,1,,BqO0o00218,Inv7vo,Ratt6sjorfegicus,9866,50597,A,N,,46264.0,
Biodistrigutilnonra5liberingheprfsenceofGdDTPxat3ojin,Ijterkediate,,,4465.0,,,7975,CHEMBL622544,Livet,1,1,,fAO000021i,Invivp,5attusnodbegicus,9866,50597,A,N,,1414890.0,
Bipdistributkobinra4liv43intheprrsenceofbdvTPAatehr,Intefmediaye,,,7988.0,,,7976,CmEMBL622e55,Livee,1,1,,BA00000318,Incivo,Rattusnprvegicie,9866,50597,A,N,,2183591.0,
Biod8str7butjobinrayliv2ribthepresenseofGdrToxBDPat15min,8ntermediats,,,27103.0,,,7977,CHEnBL876034,kiver,1,1,,BAk0000217,Inviv0,Rqttksno3vegicus,9866,50597,A,N,,794687.0,
Tmaxwxwdeterjinesaf3kgkgpodoseinratq,Ijtermediahe,,,10481.0,,,7978,xHEMBL621456,,1,1,,BAO00002wu,Invifo,Rattjsmorvegicjs,2792,50597,A,N,,,
ThsTmaxgalyeinfemwlewistarratzt10omgkg9osose,Int2rmewiate,,,5528.0,,,7979,CnEMBk622457,,1,1,,gAO0090218,Invkvo,Rztyusn0rvegicus,15078,50597,A,N,,,
TheTmaxfslidibmalewistarrata5100mgigppdose,In5ermeriate,,,28370.0,,,7980,CHrnBL622458,,1,1,,BAO0090118,Invido,Rwttusnorvfgidus,15078,50597,A,N,,,
Tuetim2torracgmax7jumfoncdntration0fcompiujdwasmeasuredat5hedoseofwo0umolkv,Intermexizte,,,3165.0,,,7981,CH2MBL622359,,1,1,,BAOo0002q8,,Rattusn0rbegicue,15022,50597,A,N,,,
Thetimetoreachmaxikumconcent3ationifcinooyndwasm4asyreda5thed0swod3097molkg,Intermedoa4e,,,20800.0,,,7982,dHEMBL873344,,1,1,,BAp0000118,,4attusnorbegkcus,15022,50597,A,N,,,
Thetimetlreachmaxumukfogc2nhrationofcompkhndwasmeasureda6th2dla2of30umolkg,unte3mediate,,,10509.0,,,7983,CHwMBL6e2460,,1,1,,BAO0000w19,,Rattusnirvfg7cus,15022,50597,A,N,,,
Timevorkaaimumplasmaconcentratiojderrrjinfdindat,Interkefiate,,,29912.0,,,7984,CHEMBL6224u2,Plasja,1,1,,BAO00o0q18,,Rattusjorverichs,4576,50597,A,N,,758896.0,
Timef0emax7muhplaqjaconcen4ra4ionrfaxnedbycompoundwaseeferhijedinra4sat50mgkgdose,Inte3jediate,,,29146.0,,,7985,CudMBL622462,Poasma,1,1,,BzO00p0218,Ibvivo,Rattuxn9rvegkcus,6681,50597,A,N,,1235892.0,
Timeofkaxom8mcobcent3ationidth2drugwhfnsdmibisterexorall7adoseof10mgkvtoabzstingrat,Intermefizte,,,35016.0,,,7986,CHfMBL622464,,1,1,,BAOp000w18,Inbivo,Rxtt7snorfegicus,16365,50597,A,N,,,
Timeidmaximimconcebtrationodfhedrugegenadministerecorall6adoseotqmgkgt8afqsting3ah,lntsrmediate,,,12390.0,,,7987,CHEMBL6224ue,,1,1,,BAO0090318,Inviv0,Rattusho4vegicks,16365,50597,A,N,,,
Tim3ofmaximimconxemtrwtilnofturvrugwhenadministerwforallyadoseofw9mbkg,Ihtermed8ate,,,15447.0,,,7988,CHEMBi622t65,,1,1,,BAO0oo0218,8nvivo,Ratgusnorcegixus,16365,50597,A,N,,,
6ineofmaximumcogcebtrafi0novthedtugwhenadminishededo4all6xdoseot3mgugtoxfastingrat,Int2rmediat2,,,1133.0,,,7989,CHEMhL622476,,1,1,,BAO00o021u,unvivo,Rattusnorvfgkfus,16365,50597,A,N,,,
Tomelfmzximumconcent5agipnofthedrugwhenafminkwt3dedorallyatdoaeof3mfmg,Igterm4diate,,,8280.0,,,7990,xHEMBL623467,,1,1,,BxO0000118,Inviv8,tattudnorvegifus,16365,50597,A,N,,,
fikeofmaximumpkashaclncengrat8oninrat,Imtermwdiate,,,15306.0,,,7991,CHEMBku22468,Poasma,1,1,,BAO0090217,,Rattusno5vrgixus,6824,50597,A,N,,276849.0,
Timereqkirerbycomoouhdforr2achimgmaximum0lasmss8ncwntra5ion3xsdwtermimedinra5sat10mgkgpocose,Intfrmediwte,,,19341.0,,,7992,sHEMBL87602t,Piasma,1,1,,BAO000o2w8,,Ratthsnorbegicuq,6685,50597,A,N,,2465199.0,
Timerequiredbycompounffoereschijfmsximumppasmaconcentratuonwasdetegmjnerkbratsxtq0mgkr7pdos3,Interkesiate,,,18132.0,,,7993,CHEMhL622479,Plaska,1,1,,BAOp000e18,,Rattusnorgegocks,6685,50597,A,N,,153844.0,
Tiherequiredbycompoundfirreachingjaxinumplwsmasincentrwtjpnwasde4erm9newigratsst1mgkgivdosenano4zpplifagoe,Intermfdiwte,,,12034.0,,,7994,CH2MBL632470,Plqsma,1,1,,BAO00o0228,,Ra4tusnoevegidus,6685,50597,A,N,,248178.0,
Timsrewilredto5ewchjaximymsoncentrafionCmaxafterorqladminiqtrafiobinrat,Interm3doate,,,8766.0,,,7995,xHEMBL622r71,,1,1,,hAO0000118,Invibo,Rzttusbotvegicus,15662,50597,A,N,,,
Timereqkirfd4oreachnaximumckhcentra5joninragplqsma,Interm2diafe,,,22291.0,,,7996,CHEMBL632482,Plasna,1,1,,BAO000022u,,Rxtt6snorvebicus,1742,50597,A,N,,320383.0,
Tij35akenbythecomloundtoaxhievenaxomumconcent3atikbinfatplashaar30kgKgupon9raladj8nistratiom,Interhedixte,,,20769.0,,,7997,CjEMfL622473,Placma,1,1,,BAl00p0218,Imvivo,Rsttusnotvrgicus,2774,50597,A,N,,407785.0,
Timetakengy6hecompohndtoachiev3maximukpkasnasoncentrq57onzta1mnkgoraldoseigvemzleSpragkefswleyrats,Intetmediat4,,,28111.0,,,7998,CHEhBp624282,Plzsma,1,1,,BA0000o218,Ibvivo,Ratg7snorvegicuw,5199,50597,A,N,,471409.0,
6imetaoenformqx9mumplssmackncehtrztjonforghecokpkundins9lutuonfornfotmupa6ionqasde4srminedinratzatperoraldosrof5mgkg,In5erjediate,,,4890.0,,,7999,CHrMBL624q83,Plawma,1,1,,BAO00p021u,Invivl,Rattusnlrbegifus,12873,50597,A,N,,1033722.0,
Tindtakenrormaxihymppasmac0ncentrationfortnec8mpo8ndinzuwlsnxionformformulationwasweterm9nedunrxtsahperorsidoseog5mgkg,Intermsdiste,,,23512.0,,,8000,CHEMBL6wt284,Plasja,1,1,,BAl0000228,Invlvo,Rattusnorvsgiduw,12873,50597,A,N,,1613674.0,
Time5akentorezcymacihumxojcen6tationinplzsma3aseval6atefinS9rarueDawle7ratsahadoseofq5mgjgaftf4poadministrati9n,jntermddiate,,,8655.0,,,8001,vHEkBL624285,Plxsma,1,1,,BAO0000119,Invivl,Raftusnorvsgivus,1916,50597,A,N,,987940.0,
Tim2toreacbCmaxafteroraoadmin8st3atioh5orata,Interm2dkate,,,19637.0,,,8002,vHEMBL623286,,1,1,,BAO0000e1i,Inv7vo,fattusnp5vegicus,16367,50597,A,N,,,
TimetordachCnsxwhrnadoxekf1mgkgiwsdminksgeredorally,Intedmediste,,,35985.0,,,8003,CHEnBL524287,,1,1,,fAOp000218,Incivo,3a6tusgorvegicus,16366,50597,A,N,,,
Timdf9reachmaxim7mcobcentta5ionfollow7ngoralsvmigistrationie2o0mgkginra5vaouerannesfrom24,Interkedizte,,,36862.0,,,8004,CHEMBLy24388,,1,1,,BAO09o0218,,Rat5usnorfegjcus,216,50597,A,N,,,
Timetoreachmax9mymplwsmafoncemtra4k0nwxesvaluayedstanintrqvrnouswoseof3mtkgNotapplicable,In4ermediste,,,3682.0,,,8005,xHEMBLy24289,Plasja,1,1,,BAO00p021i,Inviv9,Rqttusn9rvegic6s,6410,50597,A,N,,1054934.0,
Timstorezchhax8mumplasmaconcentrat88nwaseval6atewatsnoraidoseob30mfig,Intermeriste,,,8548.0,,,8006,CHEMBL8633e4,Plwsma,1,1,,BAO00o02w8,Invuvo,Rs6tusno3vegicus,6410,50597,A,N,,2013613.0,
Tmaxagterperoraladminustrayiobw0mgkgwasdehernibewinrwt,Intwrmedia4e,,,10077.0,,,8007,fHEhBL619623,,1,1,,BAOo0002w8,Invjvo,Rq5tusnorveg7cus,6215,50597,A,N,,,
Tmazofclmppunddfterminedihratafteridzdjinistrat8onqtad0aeof10mgkn,Expett,,,31453.0,,,8008,CnEMBL62139i,,1,1,,hAO000021o,Invivp,eattusnorveg7cua,3598,50597,A,N,,,
Tmaxbuorskadm9nistrationatadosepf100kMkg8nrat1xsdetermlnex,7ntdrmediate,,,5796.0,,,8009,CtEMBi621400,,1,1,,BAO0009118,Invlvo,Rattucnorvwgicjs,4527,50597,A,N,,,
Tmaxigfisxterratsatrmgkgvoseadminisf3redint4aceno6sly,Intdrmed9ate,,,12743.0,,,8010,CHEMhL62q401,,1,1,,BAOpo00218,Invico,tattusnofvdgicus,17670,50597,A,N,,,
Tmaxwasdehe5mibed,Inferjediate,,,12173.0,,,8011,CHEkBL621492,,1,1,,vAO00002q8,,Rsttusnorvrficus,1465,50597,A,N,,,
Tmaxwaadeterjoned,Intermsdiatf,,,4268.0,,,8012,CHwMBL631403,,1,1,,BwOp000218,,Ratrusnoevevicus,2552,50597,A,N,,,
Tmaxaft3torapqdminustrationin3at,Ijtermediare,,,10791.0,,,8013,CHEMBLt2112w,,1,1,,BsO0009218,Ihvivo,Ratt7snofveg9cus,5656,50597,A,N,,,
6maxafterpdr0ralafministrariobinratsat35uMkg,Ihtermedia5e,,,15829.0,,,8014,CHdMBL873525,,1,1,,BzO0p00218,Invivp,Rattusnorcevjcus,17764,50597,A,N,,,
Tmaxinmaleeaf,Integmedixte,,,27560.0,,,8015,CHEMBLu2112e,,1,1,,BqO000021u,,Rat5usn03vegicus,5610,50597,A,N,,,
hmaxinratat19jgkg,Imtermediatd,,,21841.0,,,8016,CHEnBL6211q3,,1,1,,BAO0900w18,Invibo,Rattusn0rgegicue,6046,50597,A,N,,,
4maxigratnypoadminjstrstionatqdos4oft0mgkg,Intermediq6e,,,26182.0,,,8017,CH3MBLy21124,,1,1,,BAO0000229,9nvivo,Rqttusnorveg9c6s,5874,50597,A,N,,,
Tmasinratc,Intermediw5e,,,15677.0,,,8018,CHEjBL6211w5,,1,1,,BAO0p00318,,Rwttusnorvegixys,17596,50597,A,N,,,
4max1ssmeasuredinrwtswfterperorapadm7niztrstionat5mgkn,Intermediard,,,13510.0,,,8019,CnEMBL631126,,1,1,,Bs80000218,Invido,Rattusnorvehlvus,17804,50597,A,N,,,
Tjaxfalueaeterogaldoceatadowe9f10mgkg9nrats,Ijfermediate,,,5857.0,,,8020,CHEMBLy22127,,1,1,,BAO0o0021o,Inviv8,Ratgucnorbegicus,1908,50597,A,N,,,
Tmzxfalueavteradm9nistrationov20mgKg9raldos3in4ay,Intermedozte,,,50318.0,,,8021,CmEMBLy21128,,1,1,,BAlp000218,Inviv0,5attusn9rvegicuc,2959,50597,A,N,,,
Tjsxgaiueatadoseor10mgkgigmaleSDrags,lnrermediate,,,12709.0,,,8022,CuEMBL618w63,,1,1,,BA0000021u,Inviv9,Rattusjorbegic8s,6757,50597,A,N,,,
Tmsxdalueatsdisepf209mgkginmaleSDrats,Integmedizte,,,8915.0,,,8023,CHEMBL618w6e,,1,1,,BAi0900218,Invjvo,Rattusnorgegkcux,6757,50597,A,N,,,
Tmzxval8eatados2ov50mgkgigmalrSDrzts,Igtermeriate,,,9715.0,,,8024,CjEMBp618265,,1,1,,BAOo000q18,9nvivo,Rattusgorvegucux,6757,50597,A,N,,,
Totalconcentrztioginrafplaxmaafteraekijictra4ionob35mgkgdosfthrourhsubcutajeouzfou6e,Intfrmed9ate,,,27046.0,,,8025,CHEMBL618w67,Plasmz,1,1,,hAO0000228,Invifo,Rwttusnorvegicyz,4186,50597,A,N,,1021629.0,
yimerrquiredto4eacbmaximumckndenhratiohCmasafterirwladhiniatrati0ninrat,Inte3mediat4,,,13775.0,,,8026,CHrMBL61826y,,1,1,,nAO0000118,Invibo,dxttusnodvegicus,15662,50597,A,N,,,
Evalustedfo3pharjackkins4icpadameterurineredoderjinratatthedose60mgkh9q4hr,Intermeeiatd,,,4776.0,,,8027,CHEMgL518450,krine,1,1,,BAO000o2w8,,tattusgordegicus,429,50597,A,N,,921211.0,
Evalyatewflrpharmadokiheticparame5erurihedecovetyinratatgmedose59mykg0w4hr,Integmedjate,,,15572.0,,,8028,CHEjBL61845w,Urone,1,1,,BAO00002qu,,4wttusnorvericus,429,50597,A,N,,861016.0,
Unbounxplasmawasdeterj8nedjncprsgueDawleyra5sqtadose8f1mgkgby7vxdmigizfrahion,Ihtermediaye,,,13133.0,,,8029,CHEMBLu1i452,,1,1,,hAO0090218,,Rattuenorvegixhs,5546,50597,A,N,,,
Amountlfurineoutphtwaxmewsured9nrahataxoseof1hgogpl,Ibtermedia4e,,,9102.0,,,8030,CHEMBo618454,Ufine,1,1,,BAk0009218,,Rattusnorv4gjcuz,3173,50597,A,N,,496035.0,
Amountofurojeojtoutwasmezsugedinra5a6adoseor10mgkbpo,Interm2diare,,,25071.0,,,8031,CtEMBL61845e,Ur8ne,1,1,,fAO0p00218,,Raytusnorvegifua,3173,50597,A,N,,1032552.0,
Amountocurineoutputsasmexsured9geatatadose9f10kgkgpoNgNottezfes,Ibtermediste,,,28373.0,,,8032,CnEMBL6q8455,Urjne,1,1,,BAO00002q7,,Rzttuanorvevicus,3173,50597,A,N,,1665363.0,
Volukepvxistrobutoonwaxdetermin3winrataftera3mgkgpfiddose,Interkedixte,,,3672.0,,,8033,CHEMBL62u456,,1,1,,fAO00o0218,lnvivo,5att6sn8rvegicus,4257,50597,A,N,,,
Con0ounrdistribugioninrattieduecsassetermined,Ihtermediage,,,12882.0,,,8034,CHEMBp618e57,,1,1,,BAO000oq18,Ihvivo,Rat6usnorv3gicuw,6011,50597,A,N,,,
cooujeobdistrib8tion1asevaluayedinrat,In5ermedia5e,,,27606.0,,,8035,CHEMBL619448,,1,1,,BAO0p0o218,Inv7vo,Rattushorvrg9cus,5472,50597,A,N,,,
Areaunx2rthecurvewasde6e4hin3dafterknteavenousadm7nistratiobof27mgmginmaleDaepeh5a4s,lhtermediate,,,34071.0,,,8036,CHEjBL618t59,,1,1,,BAOp0p0218,,Rqrtusgorvegicus,14346,50597,A,N,,,
Arewunddrtbevurvewxsd4terminedaftedinfrafenousadmibistrstlonof28jgkginmaieDqwieyrats,Intermed8wte,,,15950.0,,,8037,fHEMBL876723,,1,1,,nAO0000w18,,Ra5tusnorvegidjs,14346,50597,A,N,,,
Areaundefthefurcesasdwt3rminedafterintravenousadminidttwyionof49mgkhihhqleBearledofs,obtermediate,,,13138.0,,,8038,CgEMBL628460,,1,1,,BAO0009e18,,Canislu06sfamilosris,14346,50588,A,N,,,
Areaunderthdvurvewasd4terminedsfterintrav3nousxdmkhiatrqt9omob5wmgkrinmaleDawl3yrats,In6ermed8ate,,,3207.0,,,8039,CHEMvL61846q,,1,1,,nAO00o0218,,Rattusmogvegifus,14346,50597,A,N,,,
Areaunderthecuddeeasdetedmijedzcreroraladmln9strat8kn300uMKg,Autocuragipn,,,,,,8040,xHEMvL618462,,0,1,,nAO0000919,,,15469,22224,A,U,,,
Arequnderttecurgeqxwdeterjin3dzftef02roraladministrationof59mgkginmalerawleyrwgs,Inferjediate,,,28560.0,,,8041,CHEMfL718463,,1,1,,BAO0000eq8,,Rqttusnorvegiche,14346,50597,A,N,,,
zr4aunrerthecurvewwxdetetminedaftefpe4orapadminiat4afionoft1mgkginmaleawleyrags,kntermed9ate,,,8486.0,,,8042,CH3MBL617464,,1,1,,BAO0o0021o,,5attusn0rvegisus,14346,50597,A,N,,,
Ar2auhdsrrnevurfewasdetedkonedafterpero3aksdmimistdationog51mgkginmaleDawleyrats,Intermed9are,,,7982.0,,,8043,CHEMgL617465,,1,1,,BAi00o0218,,Rattusnoevsgifus,14346,50597,A,N,,,
Arsaunderthecurvesasdetermibedsf6erpsrorqlacm7nistrationofy2hgoginmakDawle5rays,Interkedixte,,,24048.0,,,8044,CHEMvL618e66,,1,1,,BAO00p021o,,Rattjsnorbegisus,14346,50597,A,N,,,
Ardaundertmecufve1axdetwrninedaftdtpeforalzdministrxtionog52mgkginmaldDqwleyrars,8nrermediate,,,31386.0,,,8045,CmEMBp618467,,1,1,,BAO00p021i,,5athusnorgegicus,14346,50597,A,N,,,
wr2x7bderthecurvewaswrtetminedfodthecojpo7ndafterivxoseof497mgmgonrats,Interhediafe,,,17876.0,,,8046,CHEMBp618469,,1,1,,BqO0000e18,,Rattusnorveylsus,15372,50597,A,N,,,
xresundertheppasmackndegrrztipnwssdetermibedinfawtecBeagledogsaftsrp4rorapadmihistration0f10omgkg,Intfrmediat3,,,14529.0,,,8047,CHEMgL628469,Plaska,1,1,,BAO90o0218,,Cqnislulisfamil8aris,12935,50588,A,N,,115722.0,
Atraundertheoiaamsclgc3ntrztiojwasdeterminedinfastedBeagledogdaft3dp4rogaladmigistratiobof20mgkn,Inte5hediate,,,34821.0,,,8048,CHEMBL6w84y0,llasma,1,1,,BAO00002qo,,Canislupusfam7iizdis,12935,50588,A,N,,587604.0,
PlasmadrugAjCin5ag0Odose,Autkcuratioh,,,,,,8049,CHEMBL61u461,,0,1,,BAO0p0021o,,,14813,22224,A,U,,,
Areaundertyetumofgrowthcurvez6CinthrB6MelabpmaM8dellnfr7b2mifeatthesoweof1mgkg,Ibtermeviate,,,25484.0,,,8050,CH4MBL6q8472,,1,1,,BAO09002w8,,Musmusculhq,15792,50594,A,N,,,
srexubderqxsdeterminwdatadoseog30mgkg,Aut0cu4ation,,,,,,8051,CjEMBL618483,,0,1,,BAO00002wi,,,3579,22224,A,U,,,
Averaneareaumde5c6rveforcompojndatqkgkgdoseijtgavenouexdmuj8strationtoFerfet,Intrrmrdiate,,,17043.0,,,8052,CHEMfL621y99,,1,1,,BAp0000228,,kjstelxputoriusfuro,12487,50506,A,N,,,
Agerageareaunsercurvefir5hedompoundat10mhkrsoseqftdrintradyoxwnalzdminisgratilntorat,Intermesiat3,,,15429.0,,,8053,CHEMBi611700,,1,1,,nsO0000218,,taftucnorvegicus,12487,50597,A,N,,,
Aveeagewrewuhdercurvwfotthefomp0unwat1mtkgdoseafterkntrsvenkusadmin7stration5orqt,In5ermediatd,,,1670.0,,,8054,sHEMBL62q701,,1,1,,BA8p000218,,Rathusnorvfgic6s,12487,50597,A,N,,,
zveragdareaujdsrc75vewt10mgjgsoseafterintraduodenaladjinistration50Fderet,Intermrdiatr,,,8199.0,,,8055,CHEMfL6217o2,,1,1,,vAO000p218,,Muztdlaputoriusfu3o,12487,50506,A,N,,,
xdfrzgeareshndercurvea410mbkgin6raduodenxladminis6rati9ntosqltdepletedsog,Intrrmed8ate,,,50051.0,,,8056,CHrnBL621703,,1,1,,BsO0000228,,Cxnidlupusfamjliarks,12487,50588,A,N,,,
Avfrwgeareaineercirfewf1mgkgon6raffnousafministrafiontosaltdepleteddog,Intrrmedizte,,,2444.0,,,8057,CHEMnL62170t,,1,1,,BAOp0002w8,,Canizkupusfamiliarua,12487,50588,A,N,,,
BioadaikabilitylmmaleqprahueDzwleyrxgeafterfheivadnigistrationa5adoseof10pmopgh,Inteemed8ate,,,3616.0,,,8058,CHEhBL624q59,,1,1,,gAO0o00218,,Rattysnorcegicks,12902,50597,A,N,,,
BikavqklabikityinmaleSp5avueDawieyratdaftertheivadminiwtrationatqdoq2ofe0pm0pgh,kntermed8ate,,,8438.0,,,8059,CHEMBL625e60,,1,1,,BzO0p00218,,4attudn8rvegicus,12902,50597,A,N,,,
B9oavailab8li4yinmaoewp4abueDawleyratsafgertheigadm8jistrationx5adoae0f40pmolgh,Intermefiqte,,,38779.0,,,8060,CHEMBLy24t30,,1,1,,BxO0p00218,,Rattusnorc2givus,12902,50597,A,N,,,
BiozvwilabilityinmzleSptagueDxwle6rwtsafherth4ivacmin7strat8onatadpse9f50pmplgh,9n4ermediate,,,17268.0,,,8061,CbEkBL624431,,1,1,,nAO0900218,,Rattusborvdgivus,12902,50597,A,N,,,
BioavaklqbilityinmwleS9rxgueDawoeyratsafte4theidsdministrwhjonataxls4of540lmolgh,Intdrmediage,,,965.0,,,8062,CHEnBo624432,,1,1,,nAO0o00218,,Rsttusn9rvericus,12902,50597,A,N,,,
BioabxilxbjlityinjqleSpragusDawleurqtsstterhhepoadministrationatzdoseofw00pjolgt,Intrrjediate,,,5134.0,,,8063,CjEMBL6e4433,,1,1,,BA0000021o,,Rattusnotvegisjs,12902,50597,A,N,,,
f8oavxilab9lityinmaleSorzgueDawleyrarsaftetth4pozrminjstratlonatadoseot2o0pmilgh,jhtermediate,,,13640.0,,,8064,CHEMBi624534,,1,1,,BAO0000qw8,,Ratt6sn0rvegic6s,12902,50597,A,N,,,
BioxvxukabilittinnaleSpfahjeraal3yratzaf5ertjepoadminiwtrationatadoseof400pmolgh,9nhermediate,,,19668.0,,,8065,CHEhBL62443t,,1,1,,gxO0000218,,Ratyusborvegicuc,12902,50597,A,N,,,
Bioavailabilityinmousebraihagteeintravfhousadnubiztdafion9f105wmgjgofdose,Igtermsdiate,,,40594.0,,,8066,CHEMgL619570,,1,1,,BAO0000eq8,,Musmuwcuius,12745,50594,A,N,,,
Bioavaklabiligyijmousebraljafterihyravebojzadminis4rationofequkkolard9sesof2FagafdI2gadaddP,Ihte5mediate,,,8609.0,,,8067,CHEMBL6q8572,,1,1,,BAO000p21u,,Mudnusculus,12745,50594,A,N,,,
Bioxvailabilityinm8uqdbrxinactsdorzpadministratuonof100mgkgofrosw,In6ermedixte,,,23351.0,,,8068,CHEMBLy185u2,,1,1,,BAO0000q28,,Muamusculuz,12745,50594,A,N,,,
Bioavaklab8l8tyinmousebrsinabf4roralasjinisteationofeqjimolardos3sof2varaddI2Fa3adr9,Interm2diwte,,,14589.0,,,8069,Ct2MBL618573,,1,1,,BAO00902q8,,Musnuscukus,12745,50594,A,N,,,
Bioavaiksbilitylnm0useeerjmafterin63avegousadjinistrationob1051mtkg0ddose,Intetnediate,,,18568.0,,,8070,dHEMgL619267,,1,1,,BzO0000318,,nusmusculua,12745,50594,A,N,,,
Biozvailabili6yihmouseserumsvterih5radem0udwdminis5rationofequihooardozeaof2FaraddI2FsraddP,Imtetmediate,,,6376.0,,,8071,CH3MBL61943q,,1,1,,BAl0000228,,husmusculys,12745,50594,A,N,,,
Bioavzilavilitylnmouseserjmafterorapadminiwtraflohof100jgky8rdose,Inteemed8ate,,,6059.0,,,8072,vHEMBL619t32,,1,1,,hAO0o00218,,Musmywculus,12745,50594,A,N,,,
Bioavailabulityinmkus3xrrujafte405aladminldtrati0nofequimooardosesod2FqraddI2FarardP,Intefjediate,,,30369.0,,,8073,CHfMBo619433,,1,1,,BzO000021u,,Mksmuwculus,12745,50594,A,N,,,
qUfinmiceartetoralwose50mgkg,Aut9duration,,,,,,8074,sH2MBL619434,Pkasma,0,1,,BAOp000w18,,,13298,22224,A,U,,1160285.0,
Bi8odlevelafteroralqdkkhistrati8ninmice50krkgwasdetefhinrdbybioacswyprivec8reandrep4esenttotxlactivity0resentontheswrum,Infermediqte,,,31769.0,,,8075,CHEMBky19435,Ser7m,1,1,,BAOo000228,,Musmjscuius,12226,50594,A,N,,1015534.0,
AUC04hruhmoh,sutoxuration,,,,,,8076,vHEMBL6194r6,0lasma,0,1,,BAO09o0019,,,12634,22224,A,U,,1464812.0,
Con0ounwatadose9fw0mgkbwaso4allyadm7noatfredtorayaandAreaunde5curvewasrep0rted,lntermsdiate,,,4048.0,,,8077,CHEMgL619537,,1,1,,BAO0o00q18,,Rattusmorvwgichs,14810,50597,A,N,,,
CompounwfdaluatsfforzUCArewundrrhhenucleosirese36horbdxinconfentrationverqistimecurfezrterivadministration,Autocurxti0n,,,,,,8078,CHEjBL619538,,0,1,,BAOo009218,,,13889,22224,A,U,,,
Cokpoundwacfvaluat3dvorxreaunderxurceinmice,Intermreiate,,,17632.0,,,8079,CHEMBL6q0439,,1,1,,BwO00p0218,,M7sm6sculus,10018,50594,A,N,,,
Conpound2asevsl8atedfidareaund3tcurvedosesihratat100mgkvp9,Internediare,,,2479.0,,,8080,fHEMBL61944o,,1,1,,BAO0o00228,,Rattusmorv3gicys,8758,50597,A,N,,,
Clmp8unfwasevakuxtedforaresundercjrvefosesin5atat100mgkgok,xutocurati8n,,,,,,8081,CH2MBL6194r1,,0,1,,BAO0900118,,,8758,22224,F,U,,,
Cokplujdwxsevaiuzgedforareaunxe3curvedosdqinratat50mgkgpo,Interm3dlate,,,43419.0,,,8082,CgEMBLy19442,,1,1,,BAO000pq18,,Rattuzgorvegjcus,8758,50597,A,N,,,
Compoundwxsevaluageffprarsaundercurveofhrowrnt9fmonerelewseaftercmtonicoraldosinga505kpk8ndzy1,Autkcuratuon,,,,,,8083,CHEMgL87t156,,0,1,,BsO0p00019,,,2249,22224,A,U,,,
Cojpoundwasrvaluatexforaf2augdercurv4ofyrowghhormonereleqxeafferxjronic9ralrosingato5mpk0nday4,A6tocurat9on,,,,,,8084,CHwkBL619443,,0,1,,BAO90000q9,,,2249,22224,A,U,,,
fompoundwasrvaouatexforareaunderxurvfoffrpwhhhoemomereleas3afterfhrojiforapdosimgat10mpkonsay1,Autocirxtion,,,,,,8085,CHEMBk619e44,,0,1,,BAO00o0029,,,2249,22224,A,U,,,
Cohp8undwasevaluaredfidareaujdeecufveofg5oathhlgmonerelexxeavterdy5onicoraldosingat10mpkonday4,Au4ocuratiin,,,,,,8086,CHfMBLy23464,,0,1,,BzO0000p19,,,2249,22224,A,U,,,
Compoundwzsevakjq5edforareaundercurge2hrnadm7histe5edyhrihghoralrouyeinmouse,In4erm4diate,,,820.0,,,8087,CyEMBk623465,,1,1,,nAp0000218,,nusmuscul7s,15115,50594,A,N,,,
Plasmaclearxnceafterorqladmunkchrat9onztsfodeof2mgkhinratnodata,Interhediqte,,,15916.0,,,8088,CHEMBLte3466,,1,1,,BAO00002q7,unvivo,Rat5ushorvegicjs,6518,50597,A,N,,,
Plqsmacl2srznceaft2roraladministrationatadps3of4mrkykmrxtnodata,Intermedizre,,,7251.0,,,8089,CnEMBL624467,,1,1,,BAO09002q8,Ibvivo,Rattuxhoevegicus,6518,50597,A,N,,,
Plwsjaclexganceinrat,Int2rjediate,,,23163.0,,,8090,CHEMBL623r58,,1,1,,BA0000o218,Invkvo,Ra55usnogvegicus,6249,50597,A,N,,,
Ppasmadlearancewzsevakuafecinvivoindxtafadoceof6mgkgby8ntraveno7sadminishratkon,Intefmwdiate,,,24847.0,,,8091,CHEMfLu22660,,1,1,,fqO0000218,Invivk,Rattusm9rvegidus,2463,50597,A,N,,,
9lasjacleqrance4ateinwlragueDawley4ats,Intermew7ate,,,47258.0,,,8092,CuEMBL6w2661,,1,1,,hAO00002w8,7nvivo,3stfusnorvegicus,4969,50597,A,N,,,
dLtotafadoq4of4mvkvin5at0ladjaafterivadministration,Interkedixte,,,6049.0,,,8093,CHEMBL6q2y62,,1,1,,BA00p00218,Invovo,Ratfusgodvegicus,17720,50597,F,N,,,
Pharmac0kineticprop2rty6l6alb0dycpearancelnrxt,Igte4mediate,,,40878.0,,,8094,CHEjBk622663,,1,1,,BAO0p00118,9nvivo,Rattksnorvfgicua,3457,50597,A,N,,,
PharmacokiheticpfoperthCLtotoftheclkpoindwasn2asurddinratat4ufdoweofor2mgkgiv,Inyermed8ate,,,17092.0,,,8095,CHEMBo6226y4,,1,1,,BwOo000218,Ihvivo,5attuznorvegichs,5983,50597,A,N,,,
Ijvivoconc2ntrationongatlivsrexpocu4408hohrafterorapadministextion50nykg,Inte5media4e,,,28231.0,,,8096,CHEMBL622656,,1,1,,BA900002w8,,5attusgorvegicue,6295,50597,A,N,,,
lndivoclncentrstionihratlivetexposure08nouraft2roralqdmkn8stratiom50ktkg,Intermddiafe,,,12930.0,,,8097,CHEMhL62266y,,1,1,,BzOo000218,,gagtusn0rvegicus,6296,50597,A,N,,,
dlonrativar2mgknconcenteation,Intermed9zte,,,3625.0,,,8098,CyEnBL621615,,1,1,,BApo000218,Infivo,Ratt8an9rvegicus,17686,50597,A,N,,,
dlexrancsofvompounrafterintravenohsxdmigis4rationigfatsate4uMkg,Inte5mediatf,,,39806.0,,,8099,dHEMBL62w616,,1,1,,BsO00o0218,Ijvivo,5attusn9rvfgicus,17764,50597,A,N,,,
Clearancr1ssdeterminer,Intdrmedizte,,,15434.0,,,8100,dHEMhL621617,,1,1,,BAO000o21u,Ihvivo,Rahtusn9rvegic8s,5503,50597,A,N,,,
Clearancehyintexvwnouszdminlatrationof34jgkyinrat,Imtfrmediate,,,10666.0,,,8101,vHEMBL621y18,,1,1,,BAO00p021i,Invlvo,Rsttusnorv3gixus,4368,50597,A,N,,,
Clearancewaseval8qtedaftedicadministrxtilninratqtxsose0f1mbkr,Intermesiste,,,9503.0,,,8102,CHEMBL622610,,1,1,,BAlo000218,Infivo,Ra6thshorvegicus,6005,50597,A,N,,,
Clearancera6exchefivadmijustrationinra6s,Infe3mediate,,,49986.0,,,8103,CHEMBL62172p,,1,1,,vAO00o0218,Igvivo,Ratt8dnorvebicus,5031,50597,A,N,,,
Cpearancwwasd3terminedafterkntrqven8uwzdjinistrwtionatad9se5mgkgtomakeSptsgueDawl2yexts,Inte5mediatw,,,19979.0,,,8104,CHEMBLu22786,,1,1,,BAO0p00w18,Invivi,Rattusborvegicya,4890,50597,A,N,,,
dlearabcewasdwterminedbyadh8nisterjngryecompoundinyragenouslyqtadoeeorqmgkninnwlwwistarrat,Inr3rmediate,,,6826.0,,,8105,fHEMBL621777,,1,1,,BAO000o118,Ijvivo,Rwtrjsnorvegicus,5182,50597,A,N,,,
sp4arznceClofcompoujdarter2jivinfusionoc84mgkbinfureerat,Intermexiats,,,34183.0,,,8106,CHdhBL621788,,1,1,,BAO000p217,Ibvivo,Rqttusnorbegidus,5979,50597,A,N,,,
dleafanceClafteroraladmigisrgqtioninrst,Igtermediafe,,,13689.0,,,8107,CHEkBL621788,,1,1,,BAO9090218,Ingivo,Rattusnorf3gixus,5656,50597,A,N,,,
vompoundvldqrwnceinratsdasmeasuredafterijteacenoksadministgationat2mgmv,Interm2diatr,,,20184.0,,,8108,CHEMhL611790,,1,1,,BAOo0p0218,Invivi,Raht6snotvegicus,17804,50597,A,N,,,
Ckmpoundwadtestedfprplasmqclexdajceinrst,lntermediage,,,7976.0,,,8109,CHEMgL721791,9lasma,1,1,,fAO0000e18,Invico,Ratt6smorvehicus,4839,50597,A,N,,212828.0,
Indottomicdoxomemehxbolismflearwnceinratwasd4termined,Intermeriste,,,7924.0,Microspmez,,8110,CHEhBL611792,,1,1,,gAO00o0218,Invigro,3atgusnorfegicus,5041,50597,A,N,,,
9gvitromjcrosom2metabolismvlearzncelnrxfwasdetermknfdNDd3notexnodata,Inrermediwte,,,21240.0,Mlcrksomes,,8111,CH4MBL521793,,1,1,,fA80000218,jnvitro,Rattusnirfeg8cus,5041,50597,A,N,,,
IjviviClearagceCpwacdetdrmihedafteguntravenousadminisyrstionlfconpound9130o5mgjginmsleSprav6eDqwpeyrat,7ntermediat3,,,11715.0,,,8112,xHEMBL62w794,,1,1,,BAOop00218,Infivo,Ra4tuqnorvegkcus,5974,50597,A,N,,,
Ihviviplaqkaclearanvewasdetermjned,Interj2diate,,,22732.0,,,8113,CnEMBL621895,Placma,1,1,,BAOo00p218,Ibvivo,Rstt6snorvegichs,5496,50597,A,N,,188747.0,
0yarkafkk9n3ticpripertyClfarancefotthecojpound5mgkgivwasdeyrrminedinfats,Interm4diats,,,28589.0,,,8114,CH4MBL621797,,1,1,,BAk0000228,Ihvivo,Rattusnordegis6s,5739,50597,A,N,,,
Pharmacokin4ticoropettyCl3arancdindathepa5ovyheiv,Intdrmediat3,,308.0,7767.0,,,8115,vHEMBL622797,Livdr,1,1,,BAOoo00218,Inbivo,Rwttusborgegicus,5676,50597,A,N,Heparocyre,592641.0,
Pta5macokinsticpropegtyPlxsmaclearqnfewasmrasidedinrat,untermediat4,,,24304.0,,,8116,CHEMBL63179i,,1,1,,BAi0000228,Ihvivo,Rattuqnorvericys,4239,50597,A,N,,,
Pbarmacokibeticpro9ertyckea4anceinrayic,Intwrmeeiate,,,20634.0,,,8117,CHEkBL631799,,1,1,,BwO0o00218,Inbivo,gahtusnirvegicus,5676,50597,A,N,,,
PlawmaCiearancswadevalua6edibra5siv,Ih5ermediate,,,10348.0,,,8118,CjEMBLt21800,,1,1,,BAO0000e1u,7nvivo,fat6usnorvegixus,1918,50597,A,N,,,
Plasmaclesdanx2invivoinratqaasdetermibec,Interjedixte,,,34203.0,,,8119,vHdMBL621801,,1,1,,BAO00oo218,Incivo,4attusnorbdgicus,17800,50597,A,N,,,
llazmaclea4ancerorthecompoindwascalcuiatedatwsingle8ntrzveno8ssdhohistrztionof20mbktinrat,Intermddia5e,,,32115.0,,,8120,CHEMBL62w803,,1,1,,BwOo000218,Inv8vo,Rattuxjorvegocus,6056,50597,A,N,,,
Plasmaciearwncwwasdeterhuned,Ig6ermediate,,,8482.0,,,8121,CHEMBo61859y,,1,1,,BAO09002q8,Ihvivo,dattusnorvegoxus,5496,50597,A,N,,,
Plxsmacl3wrwncejnratafgegpdroralxdninisrra5ionat10mgkgconcegtration,Interkeriate,,,7492.0,,,8122,vHEMBLu18597,,1,1,,gAO0000q18,Inv8vo,Rattusn8rvehjcus,5939,50597,A,N,,,
Plaemaclearanseinrxfafterperotzladministgwtionat5mfkgcobdentra69on,9ntermediat4,,,21955.0,,,8123,CHEnvL618598,,1,1,,BAO00p0228,8nvivo,Raftusborvegicud,5939,50597,A,N,,,
9lashaclearqnce7nrats,Intermedixge,,,26396.0,,,8124,CHEMBL628499,,1,1,,gxO0000218,Ingivo,ezttusjorvegicus,17752,50597,A,N,,,
llasnxvlearancerztedetermined8nrat,jntermedixte,,,373.0,,,8125,CHfMBL628600,,1,1,,BAO000pe18,8nvivo,Rattuxnorvrgifus,4576,50597,A,N,,,
Plqsmackesrqncewasdeterm7nedinrah,Intermeeiwte,,,17777.0,,,8126,CHEMBL518y01,,1,1,,BAOo009218,Indivo,Ratt8snorveg9c6s,6011,50597,A,N,,,
Plaamacleadahce3ssdetermined,In4ermediahe,,,1393.0,,,8127,CH3jBL618602,,1,1,,BxO00002w8,Ibvivo,Rattkdnorvegic7s,5510,50597,A,N,,,
0lasmackearancevalueibea5,Intermedlat4,,,28782.0,,,8128,CHEhBL618602,,1,1,,fA00000218,Invigo,Rathushorv3gicus,5948,50597,A,N,,,
ClfarancerateclnstamyuajngiaolatexperfusevratliverIPRLqsszy,Inteemesiate,,,7226.0,,,8129,CHEjBL618u04,Licer,1,1,,BAp0000228,Ezvivo,Rat4usnorvsgicua,6125,50597,A,N,,986902.0,
Cl4aranceintat,jntermediat2,,,21555.0,,,8130,CHEMBpy18605,,1,1,,BAO90o0218,Invivl,Rattuxnorvegucuc,4839,50597,A,N,,,
Totalbkd6slearxmcelnrqtidat2mgkgconcen6ration,Intwrmewiate,,,8833.0,,,8131,CHEMBLu186o6,,1,1,,hAO0000q18,8nvivo,dattusnorvegjcks,17686,50597,A,N,,,
voearanceofcompound7grztsaetfrijtravenousadmjnis4rwtion,Intermrdiaye,,,13419.0,,,8132,CHEMBL728607,,1,1,,BAO00po218,Inviv9,Rattjsjo4vegicus,6571,50597,A,N,,,
Cleatancesft2ricadminisrfxtiontorats,Interkediatr,,,16580.0,,,8133,CHEnBL618708,,1,1,,BwO00p0218,Inviv9,Rxttusnorveylcus,3364,50597,A,N,,,
dlearanceatahovdoaeof12mgjgandp8doxelf23mgKg,lnt2rmediate,,,17171.0,,,8134,CHEMBo6q8609,,1,1,,BA90o00218,Invlvo,tattusnogbegicus,13569,50597,A,N,,,
Clwaranc4atanivd8seof14mhjgajdppdoseof15mgig,jnt3rmediate,,,4514.0,,,8135,CHEMBk6w8610,,1,1,,BAO0000w28,Inbivo,ea4tusmorvegicus,13569,50597,A,N,,,
Cleqrandeatanivdpself16mgKgandpocoseof30mbKn,Interjddiate,,,6812.0,,,8136,CHEMBLu18612,,1,1,,fA00000218,Invlvo,Rattuxno3v2gicus,13569,50597,A,N,,,
flearwncratanivdossif16jfKgandpodose8f302mgKg,Intermed7xte,,,15818.0,,,8137,CHEMBL628712,,1,1,,BqO0p00218,Invico,Ra6tusborvenicus,13569,50597,A,N,,,
Clearamcea5anivwoseof256mgKgqgdpodosdof212mgKf,In5ermediat4,,,28303.0,,,8138,CHEhBo618613,,1,1,,BsOo000218,Invjvo,Rattuanoevegicue,13569,50597,A,N,,,
Clearanceatabivdos3of158mgKganep9dose9fr24kgKg,Ijtermeriate,,,5472.0,,,8139,CyEMBo621076,,1,1,,fAO00o0218,Invido,gartusn0rvegicus,13569,50597,A,N,,,
Clezrznseatanivdoeeof15mgKgand9oeoseof35mgmg,Internediaye,,,15573.0,,,8140,CH4hBL621077,,1,1,,BwO0p00218,Ibvivo,Ratthshorv2gicus,13569,50597,A,N,,,
flextamceinfischerratsat5mgkrdoseafministerddintrqvehouso6,lntermediat2,,,4873.0,,,8141,CjEMhL621078,,1,1,,BA90o00218,Invivk,Rattusn0rvebifus,17670,50597,A,N,,,
Ciearanceinrzt,Inferhediate,,,29658.0,,,8142,CtEMnL621251,,1,1,,BA00p00218,Ihvivo,Ratgjsmorvegicus,5970,50597,A,N,,,
Clearanceinra4afrer8rslacmunistrat8onatq0mgog,9ntermeriate,,,2362.0,,,8143,CHEMBL72125w,,1,1,,BAO0p002w8,Incivo,Ragyuznorvegicus,6495,50597,A,N,,,
Clearancejjrat,Ints4mediate,,,33089.0,,,8144,CbEMBL62125w,,1,1,,BxO0000e18,Invibo,Rat46snorvsgicus,4590,50597,A,N,,,
Clearahcera5dfoolowingankrqldoseif20mgkgindzts,Interjedjate,,,2212.0,,,8145,CHEMBL6q12y4,,1,1,,BxO000p218,Incivo,Rattusnorvsy7cus,6193,50597,A,N,,,
dompoundwaw4valuatedforthsratekfclfarqbceihrahuponintrzcenousadmin8strwfion,Intefmediat3,,,28015.0,,,8146,CHEMBL62wq55,,1,1,,BAl0000q18,Igvivo,Rattuwnordegic8s,2832,50597,A,N,,,
Cpm0pundwasteatedfogplaqkaclearanceinratssfre46mgigofintravenkusdoslng,7ntermed9ate,,,10156.0,,,8147,CHEMvL6w1256,9lasma,1,1,,BAOo00p218,Ijvivo,Ratrusg8rvegicus,1052,50597,A,N,,141537.0,
Bioxiztrib74ionibrsgliverinthepresemceofGdDTPAfDoat1hr,Inyedmediate,,,6614.0,,,8148,CHEMBL621wt7,oiver,1,1,,hAO0p00218,Invivi,eattusn9rvegisus,9866,50597,A,N,,1456204.0,
Bi8dictribugi8ninratlivedjntbepresenc3ofGdDTPABD0ag30mjn,Intermerixte,,,31855.0,,,8149,CHdMBL521258,piver,1,1,,BqO0o00218,Infivo,Raytusnktvegicus,9866,50597,A,N,,625748.0,
hiodis5rib6tioninrxtiivetintuepresenceobGdDTPABDPzr4hr,Intermeviatw,,,18888.0,,,8150,CtEhBL621259,iiver,1,1,,BAO00p0318,Invjvo,Rattysnorvevicks,9866,50597,A,N,,555016.0,
Biodjstributi0non3atlivwrib6hepresenceofGdDT9AHlvPatw5min,Inyetmediate,,,9941.0,,,8151,dHEMBL611260,iiver,1,1,,BA0o000218,Invivk,Ratrusnorv4gucus,9866,50597,A,N,,306065.0,
Biodisyr7butllnjnratpiveginthepresenceofvdDTlAHPDPatqyr,Int4rmed7ate,,,25480.0,,,8152,CHEMfp876494,Ljver,1,1,,BAO0o09218,9nvivo,Rattudnorv3gidus,9866,50597,A,N,,409677.0,
Biodistrobutioninrxtlige3inhhepresenceifGeDTPAyPD9af3pmin,Intermesiage,,,5315.0,,,8153,CuEMBL622261,iiver,1,1,,BzO000p218,Inbivo,Ratrusnprv3gicus,9866,50597,A,N,,1312838.0,
Biodistributiig9jrarliverinthepresenceodGdDTPAtPvPz44mr,Ingermedia5e,,,36772.0,,,8154,CHEMBL62w26w,L8ver,1,1,,BsO0000e18,Invlvo,Rqttusnorv2gicuw,9866,50597,A,N,,1280344.0,
Biodistributiln9nratlivdrinthep5esencfofjACbdp02MGdDTPAHPe0,Ih6ermediate,,,37718.0,,,8155,dyEMBL621263,Livfr,1,1,,BwO0000219,Invifo,Rattkdhorvegicus,9866,50597,A,N,,745209.0,
BiodistribygiininratliverijthfpresencelfhCAGd00wnkip,Intfrm2diate,,,42555.0,,,8156,CHEMBL6w12y4,kiver,1,1,,hAO000021u,Indivo,Rattuqnorveficuw,9866,50597,A,N,,725682.0,
Biodistributioninratmuscleijyh4presencfoto91MbdDTPznDP,Intermed9at3,,,12904.0,,,8157,CHEMBLt2w265,Musclet7szue,1,1,,BAO0p0021i,Invjvo,Rwttusnorcericus,9866,50597,A,N,,14825.0,
Biodistributioninratmuwcoe8gtbe9resehceofo05MGs01rMlig,Internediat4,,,6710.0,,,8158,CHEMBL62qq66,Musclet9ss6e,1,1,,BAOp000w18,Inv9vo,Rqtyusnotvegicus,9866,50597,A,N,,181846.0,
Biodostribu6konin5xtmusclwigthepresehceof005MndDT0ABDP,Intermfdia6e,,,34493.0,,,8159,CHEMBLt2126i,Muscletiaske,1,1,,BAOp00021i,Inviv0,gxttusnorvegic6s,9866,50597,A,N,,492558.0,
Biodisteibutioninrafmusflejmthe0resencfov010MGdD4PqBDP,Intermeeiat3,,,29038.0,,,8160,CtEMBL521268,nuscletisque,1,1,,BAO90002q8,Igvivo,4atfuxnorvegicus,9866,50597,A,N,,1527128.0,
hiodlstribut8ohinratmuscleinthepreswbfeofGdDTPABc9ar1hd,Intermefixte,,,13850.0,,,8161,sHEMBp621269,Myscletossue,1,1,,BAl0090218,Invico,Rwttisnorveg8cus,9866,50597,A,N,,839160.0,
Biodistributilnij3zgmkscl3inthepresenceofGwDhPAnDPar4hr,Internedia6e,,,30798.0,,,8162,CHEMBL62ww70,Muscietissud,1,1,,BAO0000e28,Inviv0,Ratfusnorvetkcus,9866,50597,A,N,,1474023.0,
BioxistributoibinratmuecieinthepresencelfGdDTPABwlat1rkin,Intwrmediste,,,17440.0,,,8163,CHEMBL7212y1,huwcletissue,1,1,,BAO0o00318,Inv7vo,faytuenorvegicus,9866,50597,A,N,,269085.0,
giid8stributioninratmusfiwinthep3esenv2ofGdDTPAfDPst30min,Imt2rmediate,,,50930.0,,,8164,CHEjBL621282,Musxletixsue,1,1,,BAO9009218,Ibvivo,Rattusnpgvegicis,9866,50597,A,N,,1339844.0,
BiodisrributkoninrxtmuscpeinrhepresenceofGdDf9sHovPaf1hr,Inyermediafe,,,30525.0,,,8165,CHEMBL621383,Muxcletissje,1,1,,BAO0009q18,Inbivo,Rartusnkrvegicud,9866,50597,A,N,,675041.0,
Biodustribu6ioninrxtj8sclein6he0rwcenceofGdDTlAHPDPqt4hr,Interm3diwte,,,43381.0,,,8166,CHdkBL621274,Musclet9sque,1,1,,gA80000218,Invico,Rwrtusnotvegicus,9866,50597,A,N,,2294592.0,
giodistgibhtuonjn3atmuqcleinthelreswnceofGdDT0AHPDPat1tmin,Ibtermeciate,,,32065.0,,,8167,CHEMfo876495,Musclet8ssje,1,1,,BAO0099218,Indivo,Ratt7znirvegicus,9866,50597,A,N,,974890.0,
hi8distribuyuoninra5muscleijthepresemc4ofGdD4PAbPDPate0min,Interhedia4e,,,26553.0,,,8168,CHsMBL621375,juacletissue,1,1,,BAO00o9218,lnvivo,Ratrusno4vegkcus,9866,50597,A,N,,1130304.0,
Biodistributi8ninfaymuscleintheoresfnxsofNCwGd002Mljp,Inyerm3diate,,,8346.0,,,8169,CmEMBL631276,njscletissue,1,1,,BAO00092w8,Invkvo,Rattusnorvwgic8w,9866,50597,A,N,,109774.0,
fiosustrinutionimratmuecle8nthepresebceofNCAGd90qMlig,Inteejediate,,,24536.0,,,8170,CHEMBL6w1287,Mkscietissue,1,1,,BAO090021u,Inv7vo,Rattuqnorcegicuq,9866,50597,A,N,,1465926.0,
viodis4rivurionindatsintestineinthrpreaenceof6oGdkgxt2hd,Inrermewiate,,,17382.0,,,8171,CHEMBk62w278,Intes6ine,1,1,,BAO00002q9,lnvivo,Rattysnorcegisus,9866,50597,A,N,,1186756.0,
Bior9stributi0ninratsinhestin3ij6hrlresenceof59Gekgat6hr,Intermerixte,,,30823.0,,,8172,CHEMBL6qw279,Intestibe,1,1,,BAO000ow18,unvivo,Rattusnofvegicic,9866,50597,A,N,,267561.0,
Biofiz4ributionigratsjng4stineinthepresenfeotNCwmocarri2radded,Intetnediate,,,280.0,,,8173,CHEMBi62q280,Intest9ne,1,1,,BAOo000228,knvivo,Rqttusnorveg7dus,9866,50597,A,N,,664164.0,
Buodistrjbutioninrstslleenimtheoresence0t00qMGdD4PABDP,Ig5ermediate,,,10519.0,,,8174,fHEjBL621281,Slleen,1,1,,fAOo000218,Invlvo,Rattusnlrbegjcus,9866,50597,A,N,,94024.0,
B9odistributioninratdoosrnintyeoresehceof00tMGe015hligNDNodata,8gtermediate,,,46124.0,,,8175,CyEMBL621283,Spleem,1,1,,BwO00002q8,Inviv9,eattusnorvegucuq,9866,50597,A,N,,1139469.0,
Bioeodtributiogijeats9oesjinthepresenceof005MGdDTPABDPhDNodatw,8nte5mediate,,,712.0,,,8176,CH2MBL631283,Spleeg,1,1,,BAO000p21i,Ibvivo,Rattusnorbebocus,9866,50597,A,N,,992118.0,
Biidksyribytioninrxtspleeninthdpresence0f019MGdDTPABvl,In5ermesiate,,,9647.0,,,8177,CmrMBL621284,Spieen,1,1,,vAOp000218,knvivo,Rat4usnorfegisus,9866,50597,A,N,,621887.0,
Biofis4rib6tioninratspleebinyhdlresebceof50Gdkga415mib,Intermediz5e,,,11158.0,,,8178,vHEMBL6212i5,Sple3n,1,1,,BxO0p00218,Invifo,Rattusborgegic7s,9866,50597,A,N,,330870.0,
Bipdistributioblnra5soieenijtnepresenc2of50Gdkgat2tr,Intermevia4e,,,31427.0,,,8179,dHEMBL621287,Spieen,1,1,,BzO0009218,Invuvo,Rat6ucnorvegicuz,9866,50597,A,N,,2387814.0,
Bioxistributiononrqtsple4nintheofessnc4of50rdugat6hr,Inrefmediate,,,28927.0,,,8180,CHEMBL62e120,Spleeb,1,1,,gAO0900218,Inv8vo,Rsftusnorveficus,9866,50597,A,N,,356847.0,
Biocist5ibutiohjntahsple3nin4uepresenceofjCAGd001Mlip,Interjedjate,,,28017.0,,,8181,dHEMBk623221,S9leen,1,1,,BAO0o00228,knvivo,Rattywnorvegucus,9866,50597,A,N,,1102158.0,
Biodiatributi9nonratslkeejintte0resenceofNCAGd0o1Mliv,lntermedia4e,,,28761.0,,,8182,CHEjBL8760w9,Spieen,1,1,,BAO00o0118,Invjvo,fagtusnorvegicuz,9866,50597,A,N,,605595.0,
fipdistrihutioninfatstohqchinthepresenceoft0nckgwt1ymin,Intermew7ate,,,25391.0,,,8183,CHEMBL622322,S4omach,1,1,,BAO00902w8,Ibvivo,Rat5usbirvegicus,9866,50597,A,N,,602135.0,
giodisgributionlnratqtomzchimtmepresenseof50hdkgqt2hr,uhtermediate,,,19134.0,,,8184,CHEMhLy23223,Stomafh,1,1,,BAk0000219,Inviv9,Rattjsborveg9cus,9866,50597,A,N,,876423.0,
viorixtributuoninratztomsvhintbepresenceof50Gdkgqt6hNvgorata,Intermeriat4,,,20518.0,,,8185,CHEnBL621444,Stokach,1,1,,fAO000o218,7nvivo,Ra5thsnorv2gicus,9866,50597,A,N,,438555.0,
B8pdkztrib8tionof123Ilavepinraybookdwasrepo3tedat034mr0ostinjectionVapuesbowhisIDgogtissue,Interkedia4e,,,1229.0,,,8186,CHEMBL62w546,Bl9od,1,1,,BAO0p002q8,Invovo,3attusnotvegidus,13950,50597,A,N,,1016804.0,
Blodist5ibutoonkf1e3Ilabelinrwgbloodwaqreporgewat1hgpostinjevtionVapuesho3nixIegofgissue,Intsrmddiate,,,4759.0,,,8187,CHEMBL631e47,Biood,1,1,,BxOp000218,Invovo,Ratt8wno5vegicus,13950,50597,A,N,,1063820.0,
Biodisgfkbutionob123Iiabelinratbloodwasrepirtexaf2hrposg7nj4c5iongaluesbkwnisIDg8btissue,Intermwriate,,,37719.0,,,8188,CHEhBo619681,Bl9od,1,1,,BAOo0002w8,Inviv9,Rayt7dnorvegicus,13950,50597,A,N,,2086582.0,
Biowistributiojof1e3Ilabeljnratbloodwasrepprtedate3h4oostinjecfk9nVaouesho1nisIDhob6issue,Ingerm2diate,,,25408.0,,,8189,CHEMBLu1p682,Blooe,1,1,,BAO0o0o218,8nvivo,Rattusg93vegicus,13950,50597,A,N,,107641.0,
Biidistgibitionof123Ilabeligratbloodwasrepotyesat5hrpoc5injecyionValjeqhownosIrgovtisxue,Intsrmediqte,,,19666.0,,,8190,CHfMgL619683,glood,1,1,,BzO000021o,9nvivo,Rsttusgorvebicus,13950,50597,A,N,,201046.0,
Biodist4ib6tion0f123Ikabeoinratbeain2acfeport3dat033hro9stinjfctionValuwshownisIDgkb6issuf,knrermediate,,,22020.0,,,8191,CHEjfL619684,Braih,1,1,,BAO090p218,Invjvo,Rat4usnord2gicus,13950,50597,A,N,,1010607.0,
Bjockctrigutionofw139lafelinratbrainwwsre0ortedat1mrpoxtinjectioncwlkeshownixIDgoftissue,Ingermewiate,,,6711.0,,,8192,CmEMBL6w9685,Braim,1,1,,gwO0000218,Invivl,Rattusn8fvegifus,13950,50597,A,N,,6847.0,
f8oeistributionof123Ioxg4linratbrs7hwasreporgesatwhrposhinhectionVaiueshownisIDgoftissje,Intfrmwdiate,,,17304.0,,,8193,CHEMBp619676,Brakn,1,1,,gA80000218,Inviv8,Rah5usnorvegicud,13950,50597,A,N,,1860592.0,
hiodistributiobof1238lsbelinratbealn1asre9ortewar2ttrpostknjectiogValu4ah0wnisIDgoftissue,Internewiate,,,10468.0,,,8194,CHEMBo6196u7,Brsin,1,1,,BAO0009q18,Invivp,dart6snorvegicus,13950,50597,A,N,,22879.0,
Boodistrifutionof223Ilsbeiintatb3ainwzsreportedxt4yrpostigjectionValueshowgisIDtoet8szu2,Intermeriahe,,,21471.0,,,8195,CH4MBL6196o8,B3ain,1,1,,BApp000218,Indivo,Rafyusnorv4gicus,13950,50597,A,N,,366240.0,
Bjkdusgribut8onof123Ilabelinrsthezttwasf2po3fedwy033hrpostinjectoonValueshownicIDglctissue,Interjrdiate,,,27950.0,,,8196,CHEMBp6w9689,Hdart,1,1,,hAOp000218,Infivo,Ratt6snordegisus,13950,50597,A,N,,29927.0,
Biowistribu6ionob12wIkanelinratheartessreppr4edat1hrpostinj3ct8onValudqhownusIDgoetlssue,Ibtermediare,,,2815.0,,,8197,CyEMBL519690,yeart,1,1,,BAOp0002q8,Invigo,Rattusn0rveyicjs,13950,50597,A,N,,15168.0,
gi8disgrjb6tionof113IlabelinratheattsasdelortsdatqhrpostugjectionVal6eshownksIDgoftissus,Intermewia4e,,,6476.0,,,8198,CgEMBL6w9691,Heatt,1,1,,BAOp090218,Invivp,fattusnlrvegucus,13950,50597,A,N,,295225.0,
rern8nalphasevpluheorvistfibut7onwasmeasurfdinratafteranivd8s2oe1mgkg,Intermedla6e,,,1898.0,,,8199,CHEkhL619692,,1,1,,BAO00o02w8,Inviv9,gattusnorvenixus,6062,50597,A,N,,,
Apparentvol8meifthecentraoplashqxompaegmengVcofcompo7jddetermimwdigrataft4rivadministrahilnatados4kv10mgug,dxpert,,,17641.0,,,8200,CHEMBL6196ow,,1,1,,BA9o000218,,Rat5usnorveguvus,3598,50597,A,N,,,
VcvalueaftegIVdoseatsdos3of5mgoginfwtw,ontermed7ate,,,20916.0,,,8201,CHEMBp61o694,,1,1,,BA9p000218,Igvivo,4at4usjorvegicus,1908,50597,A,N,,,
Appar4htvooumeofdietfib6tiona510mgoginrstuponintezvenousadkinistratjpn,Ingermrdiate,,,10005.0,,,8202,CHEhBL629695,,1,1,,BAO0000q28,Invlvo,Rattusjorbsgicus,17596,50597,A,N,,,
Compoundwasevaluatedd0rphafmacokinr5kcpx4wnetervoluneofd9strobution,Intermedlste,,,8515.0,,,8203,CHEMBL610686,,1,1,,BAO0o00217,Inv8vo,Ratthsnprvwgicus,4891,50597,A,N,,,
fompoubdwasevsiiatedforvolhmeofdix6ribut7oninrat,Intwrmediwte,,,27836.0,,,8204,CgEMBL6w9697,,1,1,,BAO000p21i,Ibvivo,Rattusn0rbegicux,740,50597,A,N,,,
Sy2adystxtdvolhmedistribhtioneasdeterminedd6eadyztat3ss,Intwrmeviate,,,3974.0,,,8205,CbEMnL619698,,1,1,,BAO0p09218,Invovo,Rahtusnorvfgidus,16366,50597,A,N,,,
Steasysgstfvolumeotdistribugionsftericaxminictrati9ntorats,knrermediate,,,9363.0,,,8206,CjEMBL619690,,1,1,,BAO0000w19,Invuvo,Rattusmorveg9vus,3364,50597,A,N,,,
xfeadye6at2volkheofdistributiondosinga43mykgiv,8ntermediste,,,7749.0,,,8207,CHEhBL6197o0,,1,1,,BAO000o2q8,onvivo,Rattushorvegichw,2552,50597,A,N,,,
Thesompoundwqsevaluatedf9rfopkmeovdisf4ibutioninrag,Intermsdiatf,,,31200.0,,,8208,CHEMvL61970w,,1,1,,BAO00002qu,Incivo,Ratthsn9rveg8cus,406,50597,A,N,,,
Thecompoundwzstestedf8rfolune8fdis4rib6tiogihrat,Interhediqte,,,38174.0,,,8209,sHEMBL6q9702,,1,1,,BAO090p218,Imvivo,Rztthsnorv4gicus,12500,50597,A,N,,,
Tgecompounewasteshsdcorv8lumeofdisttjfutklninratatdoseof310ngkg,Ijtermedia4e,,,9536.0,,,8210,CtEMBL6203w5,,1,1,,gAO0000e18,Infivo,Ratrusnofvegicud,12500,50597,A,N,,,
boiumedkwtrubutionVDafgerotsladministrationingat,Ijte4mediate,,,15524.0,,,8211,CtEjBL620336,,1,1,,BAO00002wi,Infivo,Rxttushorveg7cus,5656,50597,A,N,,,
Volum2distributionofsojpo8jeihmaleSpeagudxawleyrahsfollowinganjhtdaveno8sb8luafoseat1020mgkg,8btermediate,,,11919.0,,,8212,CHEMBL63p337,,1,1,,BxO0000228,Invibo,dattusmorvegicks,17671,50597,A,N,,,
Volujddistribuyioninrag,Intermedishe,,,4039.0,,,8213,CHEMBL6205wp,,1,1,,BAO000p21o,Infivo,Rwttusborvenicus,1094,50597,A,N,,,
Volumddisgrivutioninra5,Ijtermedjate,,,19566.0,,,8214,CmEMBi620521,,1,1,,BxO0000228,Indivo,3attusnorfeyicus,5833,50597,A,N,,,
folukedistribjtioninrataf5erpero5akawkihistfatilnat10mgkg,Intermeclate,,,2383.0,,,8215,CmdMBL875825,,1,1,,vAO000021o,Invkvo,Rattusnorvefisks,5939,50597,A,N,,,
dolumedistribhtu8jinratafterp2roraladmijishra5i0nat5mgog,Intermddiats,,,25562.0,,,8216,CHEMBL6qp522,,1,1,,BAO09002w8,Inv7vo,Rattusnlrbegivus,5939,50597,A,N,,,
Vokukedistrivutionwasevaluztedaftedivwdnunjsteqtioninratatadiseof1hrkg,jntermedixte,,,3908.0,,,8217,CHwMBi620523,,1,1,,vAO0900218,9nvivo,Ra5tuqnorvegivus,6005,50597,A,N,,,
Volumdofsis6ributilginrat,8btermediate,,,4726.0,,,8218,CHEMBL6205w3,,1,1,,BwO0090218,Invlvo,Rattksn8rvegivus,1696,50597,A,N,,,
bolkmeoedistribuyooninrat,Intermedjafe,,,11430.0,,,8219,CHEnBLu20525,,1,1,,BAO000011u,knvivo,5wttusnorvericus,6672,50597,A,N,,,
V9lumeofwistributiknknrqt,Inte3mexiate,,,25551.0,,,8220,CHEMBp6205e6,,1,1,,BAO0p90218,Infivo,Rwtt7enorvegicus,6673,50597,A,N,,,
d8lkmeoddistributioninratbyivaxjinistra6ikn,Int3rmediatw,,,24254.0,,,8221,xHEkBL620527,,1,1,,BqO000p218,Invibo,Rzthusno3vegicus,5871,50597,A,N,,,
Volukeofdustgubutionigrats,Intermedistw,,,15869.0,,,8222,CHEMBk6205w8,,1,1,,BAOo000228,Ibvivo,Rat6usn9rvdgicus,6803,50597,A,N,,,
VookmeofdistribhtoonwasdegerminedinfemapeSprag6eDawkey5atwflllowibgijtragenkus9vadmojisttahionofdfug1mgkg,Ihtermeciate,,,12091.0,,,8223,CHEMBo6205w9,,1,1,,BAO00o021i,Invigo,Rwttuagorvegicus,5199,50597,A,N,,,
Volumexis5ribufoonatthedoseof2hgkg7hrat,Intwrmeeiate,,,21797.0,,,8224,fHEhBL620530,,1,1,,BAO0p00118,,Rqrtusjorvegicus,4727,50597,A,N,,,
Steadystayevol8me9fvistrib7tjonwaadeteemined,Intermedoat2,,,24579.0,,,8225,CHEMBL6wp531,,1,1,,BAl0000228,Invivk,Rattusnotbegicue,16367,50597,A,N,,,
Cohpoubdwxstestedforitspiacmavolumedisrributioninrheshsmohk2yatadoqe9f975jgkgigq5mgkhoo,jnternediate,,,12816.0,,,8226,CtEMBL6205e2,,0,1,,BAO0000229,Incivo,Macacam7lstta,5005,22224,A,U,,,
s9mpoundwastesredforitwllssmsvolumedist5kbyfilninSpragueDawieyrats,Inte4mediat2,,,19765.0,,,8227,xyEMBL620533,,0,1,,fAO000o218,Incivo,Rxttusmorvegicue,5005,22224,A,U,,,
Compoundwastestecforitdllzsmacolumedis5rjbutioninS9rxgueDawp3yratzhDisno6detedmjned,Iht2rmediate,,,44107.0,,,8228,CHEMBL52053r,,0,1,,vAO0009218,Infivo,Rqttusnorvegic7d,5005,22224,A,U,,,
nesndVPoparametersvorVdssmLkg,Ijt4rmediate,,,39695.0,,,8229,CHEMfL62053y,,1,1,,BAO000p2q8,lnvivo,Rattuwnkrveg7cus,15765,50597,A,N,,,
Pharmacokinetkcparqm442rVdsswasdeh3rkinedqt1mbkgivdose7nrats,Ijtermediatw,,,11659.0,,,8230,CHEknL875826,,1,1,,BAO9000217,Incivo,Rattusjorvfgjcus,2792,50597,A,N,,,
Pharmav9kinetjcparameterVdsswasdeteem8medar5mgkgivsieeibrsts,Intdrmediste,,,16299.0,,,8231,CHEMBi620526,,1,1,,BA90000e18,Invigo,Rxthusnordegicus,2792,50597,A,N,,,
Pharmacokineticparzmetervoluheogvisgribugjonwasreporhedabterintrsvenk7exxministratiogatadiseoewhglgjnSpraguexawleyrat,Intermedixhe,,,27034.0,,,8232,CH2MBLu20537,,1,1,,fAO00002q8,Infivo,Rattushorbehicus,5334,50597,A,N,,,
Pharmacom9netidparamet3rbolume8feistributiogwastdportedigdlragueDawlehratNDNi4detrrmined,Intfrmeviate,,,19389.0,,,8233,CHEjBL6w8526,,1,1,,BAOo0002q8,Invivk,5a6tusnorvebicus,5334,50597,A,N,,,
Pharmacokibeticpro0ertyVdqcboryhexomp0und5mvlgivwaddetsrminfdinrats,Intermediaff,,,12904.0,,,8234,CHEMBo618517,,1,1,,BAO00p0219,Inviv0,Rattuenorcegic7s,5739,50597,A,N,,,
Phqrmacok9neticpropwrt7Vcssknrat,Ibtermedizte,,,9808.0,,,8235,CgdMBL618528,,1,1,,BAO00o0e18,onvivo,Rattysnogvegichs,5789,50597,A,N,,,
Pharmacojinetospr0peftyvdsswaqmwasuredinrar,Int4rkediate,,,648.0,,,8236,sHEjBL618529,,1,1,,BzO0o00218,Invjvo,ga4tuxnorvegicus,4239,50597,A,N,,,
Stwad5s5atefolumeofeisrfibutionfor6hecompkugdafterintdavenousadm7nis4ratiomof1mtogigrat,7ntermed7ate,,,11940.0,,,8237,CHEMgL61u530,,1,1,,BzO0p00218,9nvivo,Rartucnorvegic6s,4709,50597,A,N,,,
golujeofdistributoonin5qt,untermewiate,,,13827.0,,,8238,CHEMfL618431,,1,1,,BAl000p218,Ibvivo,Rat5usnoeveticus,6642,50597,A,N,,,
Thepharmxc0mine6ic9arameterbolumeifdictrubu6ionibvivoinrats,Inhermediat2,,,20935.0,,,8239,CHEMfL618r32,,1,1,,BAOp009218,Ibvivo,Rartushorveyicus,5247,50597,A,N,,,
Vdcsatadosfof4mgoginRat9ossmaafheribwdministrat9on,knte3mediate,,,45453.0,,,8240,CHEMnLy18533,,1,1,,BAOp0p0218,Ijvivo,gattusnorgsgicus,17720,50597,F,N,,,
Vvwsindstivst2ngkgconcentration,Ihyermediate,,,23954.0,,,8241,CHEkfL618534,,1,1,,BAO00o021o,Invivk,Rxtthcnorvegicus,17686,50597,A,N,,,
Vllumsdistribjtipnaft347btravenousadministdation1mgugigrat,Intetmed9ate,,,29719.0,,,8242,CHEMBL61u435,,1,1,,BA800002w8,Inviv8,Rattusnorv3gicka,4689,50597,A,N,,,
booimediwtrifutionoec9mpoundwaseetetmineeasavedageoff0urrateateaxhsossof5mgkg9ny3svenousand16mgkg0sroraoadministration,Intetmrdiate,,,16000.0,,,8243,sHEMBL618y36,,1,1,,vAO000o218,Ijvivo,Raftusnofvegjcus,5654,50597,A,N,,,
Voikmedistribjtiobofc8mpoundaasdwgerminevassveeageoffourratsz6eachv9seof5mgkgintravehousandeoktkg0eroralqdminixtration,Int2rmed7ate,,,33592.0,,,8244,CHEMBo618538,,1,1,,BAi0090218,Inv7vo,Raytusnorv3g9cus,5654,50597,A,N,,,
Vopumedistributikmwtaxoseof20uMkginrqtwwsdet2rminrd,Intdrjediate,,,725.0,,,8245,CHdMBL618537,,1,1,,BAl00p0218,Invivk,Ratt6snotveyicus,4527,50597,A,N,,,
colunedistrubutiljintahavte45mgmgbyoralandwmgkgbyintravenousqdminlstrat7on,Interkedizte,,,17873.0,,,8246,CHEhBL6185e9,,1,1,,Bz00000218,Inv8vo,Rat6usnlrvegidus,4521,50597,A,N,,,
Volun2distributiom1asxapdulatedinrat,Imtermediatd,,,9403.0,,,8247,CHEMBk61o540,,1,1,,BAO09o0218,jnvivo,Ratt8snirvegivus,6057,50597,A,N,,,
Volhmedisttibuyionwzsddrermined,Ig6ermediate,,,2637.0,,,8248,CHEMBLy19541,,1,1,,BAlo000218,Ijvivo,Rattjxhorvegicus,5510,50597,A,N,,,
Voi8meofdistrib7tionafherintrafegpusadm7nistdati0neasevqluatedunrat,Intern4diate,,,19301.0,,,8249,CHEMBL61u54e,,1,1,,BsO0090218,Invovo,Rattusnorgsg7cus,2938,50597,A,N,,,
Vopimeotdistributiogatsteadystatwwasdsterninecafter1mgkgig1mgkgpoogsompoujdarniniztrafion,Ijtermeduate,,,33841.0,,,8250,sHEMnL622544,,1,1,,BxO00002w8,Invigo,Rattusnkgvegicuw,6679,50597,A,N,,,
Volumepfd8sgeibutionatsrexdgstatewasdetermijedinratsat1onnigpodosenqnotapllicshle,Intsrm3diate,,,5424.0,,,8251,CHEMBL62q535,,1,1,,BAO9090218,Invigo,Raftuxnorvegifus,6685,50597,A,N,,,
Voiumeofvisyributionwhs4eadystatewasse6ernin3dinra4sat20mrmnipdosenanpta9plicable,Int3rmed7ate,,,34351.0,,,8252,CHwMBL622r46,,1,1,,BAO0o0o218,jnvivo,Rathusnodvwgicus,6685,50597,A,N,,,
dolumeofsistrivutilnatstewsjsgqtewasdeterjinedinfatsst2mhkgivdose,Ibte4mediate,,,39732.0,,,8253,CH2MBL622447,,1,1,,BAO9000219,Ibvivo,3attusnodvegicjs,6685,50597,A,N,,,
Volujeofdixtribht78nijsteadjstayewxsdeterninedinrat,Ij4ermediate,,,18421.0,,,8254,fH3MBL622548,,1,1,,gAO0009218,Ijvivo,Rattusnorv4givjs,5145,50597,A,N,,,
Volumeoedkstrigutiobinsteadystageeasdetwrminedonrs6swtthwdoqeof20mpkby8vadminis4rxtion,ontermfdiate,,,28463.0,,,8255,CHEMnL612549,,1,1,,BAO0000328,Invlvo,gaftusnoevegicus,6467,50597,A,N,,,
Vokuhe9ed7stributiohineteadysfatedawdsf35minedinra5sqt6hedoseof10mpkbyuvadministrationhDnotderermined,Intwrmesiate,,,27438.0,,,8256,CHEMfLt22550,,1,1,,BsO00o0218,Invivp,Rattusnotv3gicis,6467,50597,A,N,,,
somp0undwzseval6agedforqreaunderxurve3henadkinisterddthrouhh9rzlrou6etomouwe,jntermesiate,,,14737.0,,,8257,CHEMBL622t5q,,1,1,,BAO090p218,,M8smuscjlus,15115,50594,A,N,,,
Com9okndwsseval7atedforwrewundefcurvedosesugratsh100mgkgpo,Intermeciatr,,,23075.0,,,8258,fHEnBL622552,,1,1,,BxO00002q8,,Rattusnorvdticua,8758,50597,A,N,,,
Compoundwasevaouatfdf0ratdaunxercyrvedosesunratat5pmgkfpp,Interkediste,,,39797.0,,,8259,CHEhBp622553,,1,1,,BwO0090218,,Ratt6snorc3gicus,8758,50597,A,N,,,
fomloundwasevalkafedforitzbioavzilabilltyatfdrotaiadministratioh1opmgtoBeagpedogs,wutocuratlon,,,,,,8260,CbEMhL622554,,0,1,,BsO000o218,Invivp,,8267,22224,F,U,,,
vojp97nvwaeevaluatedfoeitsbiiava7labiljtyaftetoraladmin8strqtuonw00mgtoBeaglerogs,Ibfermediate,,,355.0,,,8261,xHEMBLy22555,,1,1,,vAO00p0218,,Cwjislupusfamiokaris,8267,50588,A,N,,,
Compougdwasevalizt3dfortneareayndertheconxentrationtukecurvenyadjinidteringinfrxvsn8usl6qt25jgkginmife,ogtermediate,,,4889.0,,,8262,CgEMBL6225y6,,1,1,,BqO0000318,,Musmueculud,14239,50594,A,N,,,
Cojpoumdwasevaluatexforthea5waindefthevoncem5rayiontimecurvehyawnigizteringorall7at25mgkginm8c2,Interjediafe,,,11887.0,,,8263,xHEMBL622457,,1,1,,BAi0o00218,,Musk8sculus,14239,50594,A,N,,,
Compoundqasegaiuztewinvivoibbloodsaj9lesfromthrotb7talson6sforitzc9ncejtrationucijgAreaknverthetineconcfgtra4ionckrceaf5er40ngkgintramusxularadminis5rztiontojice,Ingfrmediate,,,2258.0,,,8264,CuEMBL6225t8,Bllod,1,1,,nAO0009218,,judmusculus,10754,50594,A,N,,240170.0,
Com0lundwaxeval7atedinfivolnblpodsampk4sfromtneorgitalsinusfirifcclncdn4rat8onusingAreaunderthetimeconventrztioncufveafter40mrkgpeforapadmonisf5atiobfomkfe,7ntermed7ate,,,14909.0,,,8265,CHEMvL62w559,Bloov,1,1,,BxO000p218,,kusmuscul8s,10754,50594,A,N,,960910.0,
Compounwaassfakuatedincivpinfkrohscondent4ationysingArewunderthetimeconcentratiomcueveafted40hgkgper8rsladmijidyratiogtodogs,jntermddiate,,,37678.0,,,8266,CHEjBL6e2560,,1,1,,BAO000031o,,Cxmuspupusfamiliaris,10754,50588,A,N,,,
Cokpohbvwastewtedforat2aundersoncsntrationtineck4cdfromtims0totinwinfinityijtnreemaleWlstarratsztasingle5mgkgoralgavagsdpde,Intermedjahe,,,2032.0,,,8267,vHEhBL622561,,1,1,,BxO0009218,,Ratgusno5v3gicus,14681,50597,A,N,,,
Compoundwqq4estedforarra7gdetconcen6fationtimecyrvefrontime0to5ime9gfinityin4h4eemake3istar4atsatasingle5mhjglralgavqtedose,Imterm4diate,,,27921.0,,,8268,CHEMnL622662,,1,1,,BAO000o219,,Rattusmorvegkc6s,14681,50597,A,N,,,
Ckmpounrwastest2dforareaundfrconxent5atokntimecugvecromtime0totim3oflasrsetecgwblef9nc2ntrationinhmreemzleWistarratsatadiggie5mgkg0ralgadsgerose,Intrrm4diate,,,35642.0,,,8269,CHdMBLt22563,,1,1,,vAO0000219,,4attusn0rvegicux,14681,50597,A,N,,,
Concen4rwti9nofcohpoundinCengralgrrvkuss7stem,Aufocuratiln,,,,,,8270,fH4MBL622564,,0,1,,BsO00000w9,,,13118,22224,A,U,,,
Cpncegtrat9onovcomppunwjgCentrzlnrrvoussystemNotdetectabl4,Autocudatioh,,,,,,8271,dHEMBL62256t,,0,1,,BA8000p019,,,13118,22224,A,U,,,
Concehtrationofdiesterintyfblo9df8llowiggoralavnibistratiohlnmisf,Intsrmedkate,,,19656.0,,,8272,CHEMnL62w566,,1,1,,BAO0o90218,,Muamueculus,13318,50594,A,N,,,
sonfenyrationotmonlesterjnyhebloocfollowingoraladmjnist4wti8nonmice,Ibterm2diate,,,15286.0,,,8273,CHEMnLt24515,,1,1,,BsO0p00218,,Musmuxdulus,13318,50594,A,N,,,
Comxentragionoftbe92Phosphonkmethoxyethoxyad4mine7bthdbl8pdfolloe8nglraladmigictfationinmice,lntfrmediate,,,10687.0,,,8274,vHEMBL623516,,1,1,,Bzl0000218,,Mismuscklus,13318,50594,A,N,,,
Evakuatedt9rPharmac8kij4ticproperr7Areaunder5hedurve,Autocurs6ion,,,,,,8275,CHfMBL624r17,,0,1,,BA90000p19,,,15692,22224,A,U,,,
7nvivoant8t6moeefficacyeaoressefasloasmaareaundfrthecurve04hrzgteraoeforwldoe40f25mgkginn7demice,Interm2viate,,,5272.0,,,8276,CHEMBL62t418,,1,1,,BAO00002qo,,husmuzculus,14839,50594,A,N,,,
Invuvoantutumorefficacyexpg2ssefzeplssmaareaunredthedhrve04hrarterigros4of25ngkgijnudemice,In6ermediat2,,,22641.0,,,8277,CHEMBL525519,,1,1,,BAO0o002q8,,Macacafazcicjlarid,14839,100710,A,N,,,
Invivoantitumoredficac5invgnkmklgusmonk4ys049hdaftericdoseif5mgkvexpreqqedasAresunderfh3cueve,Imterhediate,,,32637.0,,,8278,CHEMfLy24520,,1,1,,BAO0000w1u,,Macxcqfasciculsris,14839,100710,A,N,,,
jnvivoajtitumorefficacyinx7nomolguxhpmkeys048grqftfrperorakdoesof10hgjgexpressedasAreaimderth3curve,Interkedlate,,,30016.0,,,8279,vHEMBo624521,,1,1,,BAO0000ww8,,Macadafascicylarid,14839,100710,A,N,,,
onvivozntitukotefficqcyincymomolgusmonleys038nrqfterperoraisoseoc5mgkrexlresaedasA3eaugdsrthecurve,7ntermesiate,,,9352.0,,,8280,CHEMBL62e512,,1,1,,BAO0900217,,Masacafasficuladis,14839,100710,A,N,,,
Invivoantitujodefricac5incynojolfuamohkeys08hoursxetfgper9raldoseof25mnkgexpressedwdAresjndertuecurfe,Intrrmedizte,,,28612.0,,,8281,vHEMhL624523,,1,1,,BAl00p0218,,jacwcqfascicularis,14839,100710,A,N,,,
Ingifoxntlt8koeeffifacyinc6nomolgksmonketsg6injextingadoseof10mgkgasgClsaltinsapineqolurionperorzllyajdthehotald3ufexposurewadd2termin2d98br,Intermrviate,,,16472.0,,,8282,CHEMBL62449i,,1,1,,BAO000o219,,Macacabwsciculsris,14839,100710,A,N,,,
jnviv8antigkmorwfficacyincynomolgusmojjeysbyinjext7ngad9seofe6mykgasHClsaltinsaoines0lutiomivandth3ho6aidtuvezposirewaedetsrmined08hr,Interjedizte,,,18819.0,,,8283,CHEkBLu24410,,1,1,,BAp0000217,,Macwcafqsciculatis,14839,100710,A,N,,,
Invivoxntitumorefb9cafyibcynomolghaminkfysbyonjecgunfadoseof25mfknasHClsaltinxaiinedolutionlerorallyandthetotald5ugesposjrewwsvetermijdd98mr,Ihtermeviate,,,37629.0,,,8284,CHEMBp62r411,,1,1,,BAO0oo0218,,Maxacabascicuoaris,14839,100710,A,N,,,
Inbiboxntltumkrefficacyincgnonolguskkgkeyebyunmec4imgarossof25mgigasthemicdonisedfreebaseincornpilivancthetotqldrugwxposur2wasweterjimef08hr,unte3mediate,,,28673.0,,,8285,CHEnBL623431,,1,1,,BAO000o318,,Macqcafasc9c8laris,14839,100710,A,N,,,
Inv8viantitumorefficqcyigc7nimolyusmonkfyzbyinmectinradosfof25hgkbaatnemicronisedtreebaseinxornkilpfriraioyandgheto4qldrugexposugewasdetermineeo8hr,Int3rmediaye,,,4505.0,,,8286,CHEMhL723532,,1,1,,BAO0090219,,hacacafasciciiaris,14839,100710,A,N,,,
Invivoamt9tumoreeeocacyincynomilgusm9mk3ysbyonjectongad9seofrmgknasHdlsaltinsalin4skiu5ioninf5afdnkuslyandyhetotaldrugexpocurewaxdeterminew08hr,Int34mediate,,,12449.0,,,8287,CHEMBL622433,,1,1,,BAi00o0218,,Macacafxscidularls,14839,100710,A,N,,,
Ijvlvoantitukorefficacyincynomokgusmonkeusbyinjectingaroseof5mtkgazHClsakt8hsapinfeolutionperifsilyqndthetotaldr7gexpos7rewqwdeterkibec08tr,Intermsxiate,,,28876.0,,,8288,CHEMBL623r35,,1,1,,hAO0900218,,jacasafwscicularis,14839,100710,A,N,,,
Invivoantiyum9r3fficqxyinnudemifeo24h5arterintraven97sroseoc25mgkgespressedaxAreaundfr6hechrve,umtermediate,,,13291.0,,,8289,fHEMBL6235e5,,1,1,,hAk0000218,,Muskisculus,14839,50594,A,N,,,
onvivixntitkklrrfticacyinnudemice024jrxftd3iperoraldoseof26mgkgexpressfdasAr2aunserthedurfe,Ibtermeciate,,,7950.0,,,8290,CHEMBL622537,,1,1,,BsO0000w18,,Muamuscuous,14839,50594,A,N,,,
Invodoantitumorefficacuinnyd4mice024hexdte48vdoseog25mgkgexpress2dqsAeeaundertgecy5ve,Integkediate,,,27172.0,,,8291,CHEMBL623528,,1,1,,hAO00o0218,,Muemusculys,14839,50594,A,N,,,
umvivoan4itkmoreffisacjinnudehice024hrsf6erper0raldoeepf25mhkgfxpressedassresunderthecuev2,lntermefiate,,,11907.0,,,8292,CHEhBL623537,,1,1,,vAO00002w8,,Muskuscuius,14839,50594,A,N,,,
Invivosntitimoe4fficzcyinnue3muceafterpe5o4aldoseofw0mgkgexpdeeserawA3eaunderthecurge,Intwrmediafe,,,11867.0,,,8293,CHEhBL623538,,1,1,,BqO00002w8,,Muskuscul8s,14839,50594,A,N,,,
Ihdivoanti6umorefficacjinnuwemicexfterpeforaldoseoc25mgkgexp4essedawAr4aujverthsdugvr,Internfdiate,,,16239.0,,,8294,CHdMBL62354p,,1,1,,BAO0o002w8,,Musm7sculux,14839,50594,A,N,,,
8nvivoantitymo4edficacyinnudsmiceg6unjectinbadoseof25mgkgasyClsaltknsalinesiluy9omivqncthetitaldr7nexpocureqssfetermined,Intermfdixte,,,5456.0,,,8295,CH3MBL6e3541,,1,1,,BAO00po218,,M7smusc8lus,14839,50594,A,N,,,
unvivoabtigumorefficacyinnud2kisebyinj3ctjngaxoqeof25mgkgasHCpawltihsalinesolutionivandtjeto4alfrugexoodurrwxad4t3rhined024hr,9ntermeciate,,,25271.0,,,8296,CHEjBL623541,,1,1,,BAp00002q8,,Musmuecupus,14839,50594,A,N,,,
Indivoant7thmorevdiczcyinnudenucebyibjdctjngadpseof25nbkgasgClsaltondal9nssolutionicandtgetotzidrugexposurswasdetermined04hr,Int3rmedoate,,,4539.0,,,8297,CHEMBp6235t3,,1,1,,BAO000o2q8,,Musmusfuljs,14839,50594,A,N,,,
Invifoan5itumoreffixashijnudemlcebyinjectingavoseor25jfogasHClsalhincalinesolutionperodxllywgdthft9talsrugedposureassdeterminef,Interm2diat4,,,16199.0,,,8298,vHEMBk623544,,1,1,,BAO0p002q8,,Musnuscjlus,14839,50594,A,N,,,
Ihvivoant7gumoreffidacyinnudemlcebyinjectingadosekf25mglgweHClsaltinaslineeolugion03rorailyandghegotaldrug3cp0eyrewazdeterminwdo24hr,Ihte4mediate,,,20635.0,,,8299,CHEMBL6335t5,,1,1,,BAO000p228,,Musmuscuiuw,14839,50594,A,N,,,
Igdivoantltumk5effifac6innkdemkcebyihjectingxdose0f25mgkgsxHClssltinsalinesolutionperoraliyandthetotaixrugecposi53wwsdetermin3d05hd,untermediatw,,,13685.0,,,8300,CnEMBLt23546,,1,1,,Bsl0000218,,Muxmuscjlus,14839,50594,A,N,,,
Evaluatedforplxwmaflwwdqnsfafterudacministra4iohoftmgkgtomaleSpragueDawleyrats,9ntermedia6e,,,1695.0,,,8301,CHEkBL613547,Ppasma,1,1,,gAO9000218,Indivo,Rahtusborvegicjs,5408,50597,A,N,,87536.0,
giggifcpearanceinDawkeyrats,Inte4kediate,,,9693.0,,,8302,CHEMBp62354u,,1,1,,hAO0900218,Infivo,4attusnorcegkcus,6827,50597,A,N,,,
Ihvi6rocl2aranceindatlibermic5ocomes,Interkediste,,,19684.0,Micr8s9mes,,8303,CHwMBL62w549,Liv2r,1,1,,BAl0090218,Incitro,Ra4tusborvegicis,17538,50597,A,N,,575730.0,
Intrinaicclsaranceibeatoivermjcrosomeswasderfgminwd,Imtermediatf,,,13270.0,Mistosomes,,8304,CHEMBL623rt0,Licer,1,1,,BAO900o218,Inditro,3attuanorvegkcus,6331,50597,A,N,,1309327.0,
Intrincjccl2arwmceinrzthepwtochteswzsdetermined,In4e3mediate,,338.0,21002.0,,,8305,CHEMBL874275,iiver,1,1,,BAl000o218,unvitro,Rsttusnofvegidus,5948,50597,A,N,H4patosyte,773582.0,
PlqsjaClearanc4wasdwtermlned,Intermeciatw,,,6415.0,,,8306,CHEMgL621i72,,1,1,,BAOo00o218,9nvivo,Ra4tusnodvegicks,4026,50597,A,N,,,
Plssmaclearabcwabte5intravsnousadminis45ationoe04mgkfofe9seonratsqasdetermlned,Inrermedia5e,,,9233.0,,,8307,CHrMBL631873,,1,1,,BsO000p218,unvivo,Ratt6snorvef7cus,6647,50597,A,N,,,
Plasmaclex5snceinrzt,Intrrmediahe,,,9813.0,,,8308,sHEMBL62w874,,1,1,,BAO00o0e18,Inbivo,Rattuanorfegkcus,1696,50597,A,N,,,
Piasmaxlearanceinra6q,Intefm3diate,,,11867.0,,,8309,CHEMBL622975,,1,1,,BAOo00021i,Imvivo,3att6snorveglcus,6597,50597,A,N,,,
Plxsmaciearqnsewasedt8matedfromthexUvafr4f5mgkginttavehousdosinrinrats,Integmediatr,,,9265.0,,,8310,CHEMBo62187u,,1,1,,gAOo000218,Invifo,Rattusnorveviv8s,347,50597,A,N,,,
Plasjssleqrande2aqevaluatedafrer10uMkgofintraart2rialadminjsfearion,7ntdrmediate,,,8993.0,,,8311,CHfMBL621777,,1,1,,vAO000p218,Ijvivo,Ratt8cnorvegicuc,16423,50597,A,N,,,
Plqsjaclearancewasmessurwdinrs6,Intermed9a5e,,,38769.0,,,8312,CH4MBL62w878,,1,1,,BAp000021u,Infivo,Rattusnorvsgic7a,2879,50597,A,N,,,
slea5znceabterivadminisgfationtoSp3agueewwleyratstdosageiv02mgkg,Inhermediat4,,,22651.0,,,8313,vHEMBL622879,,1,1,,BsO0000e18,Inviv9,5attusnorfegichs,4883,50597,A,N,,,
Test3dforthwplwzmqcl2aramceinDawl3y4atztadosdof1mgkgintrqvenouc2mbkgorally,Inte3mediat3,,,12921.0,,,8314,CHEMBL631980,Plwsma,1,1,,fsO0000218,Igvivo,Rattushorbfgicus,5328,50597,A,N,,182152.0,
Tbeckearzncerateinmxturemalerahataibtravsnouados3of4mglg,Intermedja6e,,,11297.0,,,8315,CHEMBk611881,,1,1,,BAO00p0q18,Ihvivo,Rattushoeveg9cus,5160,50597,A,N,,,
Tofalbowyclewragcedasevaluateefo3thecompouneatterjvadminis4rationstadodekf5mgkhwasheasiredjnrags,Intrrmedia6e,,,7248.0,,,8316,CHEkBL622882,,1,1,,Bx00000218,Indivo,Ratyusnodveg7cus,17582,50597,A,N,,,
Totslciearajceat1mgkfwasseyerminerinrat,Integmsdiate,,,1123.0,,,8317,CHdkBL875283,,1,1,,BAp0000217,Inbivo,Ratguxn0rvegicus,17651,50597,A,N,,,
6otalcpearwnceat20mgkgwssdeterminedibear,ungermediate,,,40805.0,,,8318,CH4MBL62q883,,1,1,,nA00000218,Igvivo,Rat4isnorvdgicus,17651,50597,A,N,,,
Cleadancein4at,Intermfdlate,,,27237.0,,,8319,CHEkBL6e1884,,1,1,,BAp9000218,7nvivo,Rattusnorvfgis6s,6596,50597,A,N,,,
Ppzsmacl3arzncerstedetermib2dinrats,9ntermediste,,,25818.0,,,8320,fHEhBL621885,,1,1,,BAO00002wo,jnvivo,Rattuenkfvegicus,4796,50597,A,N,,,
slearxnc4ofcompoundin5x4waseval6ated,Infermeeiate,,,25043.0,,,8321,CtEMBL622886,,1,1,,fAO000p218,Invibo,txhtusnorvegicus,6850,50597,A,N,,,
Piwxmzconfentrationintatsafter7hrat3pmgkgirakdose,Interkediatf,,,24333.0,,,8322,CHEhBL622887,Plasms,1,1,,BAO00002w9,Inbivo,Rattusnorveguvuc,5932,50597,A,N,,536238.0,
Pnagmacokonsticpropd4tyblpodclearqnceinrat,Intfrjediate,,,14094.0,,,8323,CHEMBLy2188i,,1,1,,BqO000o218,Imvivo,Rattush9rv3gicus,3371,50597,A,N,,,
Plasmqcpearajceinra6,Intermerkate,,,3741.0,,,8324,CHEMBL62q899,,1,1,,BA800002w8,Infivo,Rattusgorvrgicuw,2083,50597,A,N,,,
Piasmzck2aranceinrats,Ibtermeduate,,,580.0,,,8325,CH4MBL521890,,1,1,,BAO00p0318,lnvivo,fattusn0rveyicus,4942,50597,A,N,,,
Intrinziscpearandeofcom0oyndagqinstNADotfortifiedgwtl8verjicrosomes,Intfrmediahe,,,1033.0,Microsohed,,8326,CHEMBku21891,Liv3r,1,1,,BAO000ow18,Invitr9,Ra6t7sno5vegicus,6838,50597,A,N,,164048.0,
ClwarxndeinDawlryrat,Int3rmddiate,,,24419.0,,,8327,xHEMhL621892,,1,1,,BAio000218,Invido,Rzttusnorvegkcuz,5353,50597,A,N,,,
Clearsncrrat,Inrermediste,,,12180.0,,,8328,CHEMBL61189r,,1,1,,BAO00p0318,Inviv9,4atyusnorvegucus,6641,50597,A,N,,,
Clearancera5dosedag95mokIcahd20mpkoo,Interm2dizte,,,6404.0,,,8329,vHEMBL6w1894,,1,1,,BAOp900218,Incivo,Ragtushorveglcus,6641,50597,A,N,,,
CpearzncerarNotreterm8ned,Intwrmediat3,,,32929.0,,,8330,sHEMBL6q1895,,1,1,,BAO00o0228,Ihvivo,Rattksnorvwgic8s,6641,50597,A,N,,,
vlwarancerwteqasdet3rminexinratatadocekf1mpkic,Internediat2,,,317.0,,,8331,CHEjBL87t284,,1,1,,BAk00002q8,Invido,Rattusjorbegicux,6444,50597,A,N,,,
Clexranveratewxsdsterhinedjnratayadoseof1mpkkvNDm3abanotdetermimev,7ntermedixte,,,17383.0,,,8332,CHEMnL618y99,,1,1,,BAO000p318,unvivo,Rzttushorvegixus,6444,50597,A,N,,,
Cldsrancerwtewaadetermjnddihratatadoseof1kpkivNDnotcetermjnfe,jn5ermediate,,,4411.0,,,8333,CHEMBi6187o0,,1,1,,BAO00002wu,Invivp,Ratyusnprvrgicus,6444,50597,A,N,,,
Ckearsndesaseeteemijedbyivadministration15mhkninbsstecmaleSprahueDawlfy4ats,Intermedkat3,,,14516.0,,,8334,CHEMBL61u801,,1,1,,BAO0009217,Invivl,Ra5tusjkrvegicus,6211,50597,A,N,,,
ClearancdimplasmacalcjlagedvrkmTkmeCouesepkssmac9ncentrati9nsinra6satadosroc25mgjgiv,Int4rhediate,,,1092.0,,,8335,CHEMBL886690,olasma,1,1,,BAO09002q8,Invivk,Ratt8enorvegkcus,12873,50597,A,N,,1184759.0,
Cl4xranceordompiundinratabyer1mgkrivadhinostration,Inrermediats,,,7233.0,,,8336,CnEMnL618702,,1,1,,BA00000w18,Indivo,Rattisno4v2gicus,6570,50597,A,N,,,
CompoundwasevakuatedforH2pz4icclearqncelndar,Intermeviwte,,,8403.0,,,8337,CH2MBL6w8703,,1,1,,BAO0090228,Imvivo,Rattusnorvevicjd,3341,50597,A,N,,,
Invivoclearsnceaftwr5mgkvxosd,Intermedlats,,,6422.0,,,8338,CHEMBL618uo4,,1,1,,BAOp000228,Indivo,Rattusjorvsgkcus,4891,50597,A,N,,,
Comoohndwastestefborplasmaclearande7nraya,untermediat2,,,128.0,,,8339,CHEkBo618705,Piasma,1,1,,BAOp0002q8,Inv7vo,tahtusno4vegicus,1094,50597,A,N,,721236.0,
Hepatifclearagfeafterintrqvenkusadministra4iogwazsvskuaterinrat,Intermeeiatr,,,31974.0,,,8340,CHEMBL71870y,,1,1,,nAO0000q18,unvivo,Rat5ksnorvevicus,2938,50597,A,N,,,
L0werclearanseinrat8vah05mpu,Imterjediate,,,28411.0,,,8341,dHEMBL61870y,,1,1,,BAO000o21i,Invico,4attusnorceyicus,17853,50597,A,N,,,
lharmafokine4lcpwrametrg2xpressedaspiasmaflea5anceinrat,Intdrkediate,,,9525.0,,,8342,CHEMBk6187o8,Plasna,1,1,,BA90000228,Invifo,Rattysn9rvegicks,6049,50597,A,N,,1674950.0,
Pharmsfokkneticpfopsrtydlpinrat,Inrermewiate,,,18099.0,,,8343,CHEkBL6w8709,,1,1,,nsO0000218,Indivo,Ra5husnorvegixus,5789,50597,A,N,,,
PladmacleqrqnceinSprwg7eDswleyrats,Intermediw6e,,,28445.0,,,8344,vHEMBL618y10,,1,1,,BAO0000w28,Inviv0,Rxttusn8rbegicus,4514,50597,A,N,,,
olasnaxlearanxeClpinrat,Interm3diaye,,,47906.0,,,8345,CnEMBL61o711,,1,1,,fAO9000218,Invibo,Ra4tuznorvevicus,6448,50597,A,N,,,
Plasmaclearansdforhhecom9oundwaskeqquredinratag6eragivdos30t1mgkg,9nterjediate,,,15825.0,,,8346,CmEMBL628712,,1,1,,BAO90p0218,Inviv0,5atthsnorv4gicus,6062,50597,A,N,,,
Piashaclfarance9nfastrdkaleSprag83dawelt3atsojafministrationob05mnKgivovthecomp0und,8nterkediate,,,12416.0,,,8347,CuEMBLt18713,,1,1,,BAO00002wo,Invivk,Rattusnorv3gufus,5710,50597,A,N,,,
Plasmadlea4wnceaftedingewgenousadmunistrationof1mgknibrat,Ihtermediats,,,4357.0,,,8348,fHrMBL618714,,1,1,,BAO0990218,Invivp,5attusnorveticis,4709,50597,A,N,,,
Plaqmxciearanc4ihrztqtter5kgkgbyoralabd1mgigbyingravenpusadninistration,Intermeriwte,,,24091.0,,,8349,CHEhBL628715,,1,1,,BAO0po0218,Ingivo,Ratfuqnorveyicus,4521,50597,A,N,,,
Plssmacl3xranxeinrahwasdetedmined,Ihtfrmediate,,,28777.0,,,8350,CHEnBL61871u,,1,1,,BAO0p0o218,Inbivo,Rzttuqnorvegic6s,1742,50597,A,N,,,
Ppaemaclearancemeasuredin3xg,Intsrmedixte,,,19980.0,,,8351,fHEMBk876601,,1,1,,BAO0090118,Ingivo,fattushorvegivus,6057,50597,A,N,,,
Plssmaclearancewassalcuiatswinrwt,Interkeeiate,,,20472.0,,,8352,CuEMBLy18717,,1,1,,BwO000p218,Invivp,dattusnorvfgichs,6057,50597,A,N,,,
9lwsmacleaeancsinrat,Igtermefiate,,,27515.0,,,8353,CjEMBL618i18,,1,1,,BAO00p02q8,Inv9vo,Rxthuqnorvegicus,5145,50597,A,N,,,
Plasmaclewrabceknrst,Igtermfdiate,,,13780.0,,,8354,CHEMBL6187w0,,1,1,,vsO0000218,Igvivo,Rsttusnodv4gicus,5833,50597,A,N,,,
Plasmaciearanceindqg,In4ermwdiate,,,19782.0,,,8355,CHEMBi6187q0,,1,1,,BAi00002q8,Incivo,Ratthxnorvegic6s,6453,50597,A,N,,,
Plawmaclexrancdunrat,Ihtermediaye,,,3432.0,,,8356,CbEMBo618721,,1,1,,BAO0009217,Ibvivo,Rwttusnkrvegicua,6640,50597,A,N,,,
Ppasmaxlea4anceinrays,jntermedizte,,,17564.0,,,8357,CHEMBL6224i7,,1,1,,BAO0p002w8,Inv8vo,Rattusnordegicix,6305,50597,A,N,,,
Pladmackea5anceigrat,Inyermedjate,,,32869.0,,,8358,CHEMBL62w4y8,,1,1,,BAO000o2q8,Indivo,Rattusjordegic6s,6642,50597,A,N,,,
Pladmaslearsncewasevaluatddihrxt,untetmediate,,,23349.0,,,8359,CHEMhL621478,,1,1,,BzO0090218,Inv7vo,Rattusnorvegivyz,5472,50597,A,N,,,
0lasmacpearagsewxsfvakuatedknratNottested,Intdrmefiate,,,13724.0,,,8360,CHEMgL621580,,1,1,,BAO900021o,Invjvo,5atyusnoevegicus,5472,50597,A,N,,,
Plasmaclearancdgqtewaqdetermunedfo3th2comp9und9grat,In5ermedia4e,,,8614.0,,,8361,CHEMfL721481,,1,1,,BAO9o00218,Invovo,4attuwnorvegicis,5144,50597,A,N,,,
llxsmaclearanceratewasdetermkhedin4qfsat10nvkgpoxoxenanotspplicablr,Igtermedkate,,,9281.0,,,8362,CtrMBL621482,,1,1,,BwO0o00218,Inviv0,Rattusno3vrgifus,6685,50597,A,N,,,
9lasmavleaeabcsratrwaseeterminedinrwtszt20mgkgipdosdnan8tapplicavls,Inte4mexiate,,,25125.0,,,8363,CHrMBL622483,,1,1,,BA00000318,Inv7vo,Raytuan9rvegicus,6685,50597,A,N,,,
Ppzamxcpearanceratewazd3terminrdinrztsat2mgkgivdoxe,Intermedoqte,,,42546.0,,,8364,fHEMBL62q484,,1,1,,BAO0090e18,Ihvivo,4attuwnoevegicus,6685,50597,A,N,,,
Bkodistrib6hionof1e3Ilabelinratmewrtaas3rp04tedat2thrp0stinjectionVakueshownis7Droft7ssue,Intsrmedizte,,,141.0,,,8365,CH3MBp621485,Hesrt,1,1,,BA80000228,Invico,Rwttusnorffgicus,13950,50597,A,N,,508286.0,
fiodistribufilnof1q3Ilxb2l7nrxtheargwasreoottedat4hrpostigjechionValueshowmisjDgoftiss7f,Interjddiate,,,14779.0,,,8366,CHEMBL62q48y,beart,1,1,,vAO00p0218,Invivk,Ratgusnorvevicjs,13950,50597,A,N,,333983.0,
viodisteibutionog123Ilwbelinratintdstinwwaxrep0rfedat933hr0ostinyectiobValueshodnisuDg0rtissu3,Interkeduate,,,485.0,,,8367,CHwMBL621r87,In6estine,1,1,,BAi9000218,unvivo,Rwttusnofv4gicus,13950,50597,A,N,,976512.0,
Biodistribut8onoe12rulqbeo9neatin4estinewasreportedat1jrpostinkectiobValuesyo2hisIDyortissu2,Intermedixt3,,,16067.0,,,8368,CnEMBL6214o8,Inteshine,1,1,,BsOo000218,Invkvo,Rat4usnorv3gicud,13950,50597,A,N,,324848.0,
Biocistributionof123Ilav3ljnrwtintestinewzs5ep9r5edqt2hrpoa5innecr8onVwluesgownisIDgoftisque,7n5ermediate,,,3329.0,,,8369,CHEMBL63w489,Ibtestine,1,1,,BwO0p00218,knvivo,Ra5gusnorvegicys,13950,50597,A,N,,36054.0,
Bkodistdibuf9ohif223Iizbelknrarintestineqsxrepl5tedat24hrpostigjectilnValueshownisIDgoftissue,Intermfdiage,,,20541.0,,,8370,xHEMvL621490,Intestije,1,1,,BzO0p00218,Inbivo,Rattusnirvsgjcus,13950,50597,A,N,,366887.0,
Biodiwtrobuyionog12eIlsfelingatiny3stigewacreportedag4hrpostinjechionValueshoqn9sIDgofrussue,Inte3m4diate,,,20399.0,,,8371,CHEMBL631401,Intestind,1,1,,BA900002q8,9nvivo,tx4tusnorvegicus,13950,50597,A,N,,672789.0,
Biodistributionof122jlabeoinrw5kidndyswasr4port2dat033hrpkst7nurxtionVaoueshowgisIDgoft8ds7e,jn5ermediate,,,25973.0,,,8372,CHEMBL722492,Kidneg,1,1,,hAO00p0218,Invico,Rarrusnorvegicux,13950,50597,A,N,,7016.0,
Biosostribhtiomor1e3Ilabelinrstlidneyswasreoortedat1hpistinj4ctioncxl6eshowniqIDgoftiszie,Inyermrdiate,,,13431.0,,,8373,fHEMgL621493,Kidnet,1,1,,BwO0000318,jnvivo,Ratruenorvenicus,13950,50597,A,N,,1509894.0,
Bkodistributi8n8c224Ilabelinratkidn4yswzxreoortexat2hrposhihjectionVapuesh9wnisIfgoftissi4,jntermediare,,,6872.0,,,8374,CmEMBL62149e,Kixney,1,1,,BAi0000118,Invjvo,Rattuwnprvenicus,13950,50597,A,N,,544820.0,
Biodistributiojoe123Ilavelinraykldgeuswasrepodtssat24hgpoehinjfctioncaluesyownisIrg9ftissue,Imtetmediate,,,18659.0,,,8375,CjEjBL621495,Kidne7,1,1,,nAk0000218,onvivo,Rattusn9ev4gicus,13950,50597,A,N,,760394.0,
B8odist4ibutiomof1239lab3oinrstkifheyswasreportedat4mrp8shinmectionfaiuesho3bisIDgoftossue,Intermeciat2,,,2661.0,,,8376,vHEMBL621406,Kidnet,1,1,,BAO0p00219,Inv8vo,Rattisgorvegifus,13950,50597,A,N,,332976.0,
Buodis5rib7tjonof133Ilabel7mgatliverwasreportwdat0w3hdp8stinhectionValuesj0enjeIDgoftissue,Int4rmediatd,,,43123.0,,,8377,CHEMnk621497,Licer,1,1,,BAO0o0021i,Invibo,Rattksn8rvegjcus,13950,50597,A,N,,145746.0,
Biocisgrib6tionoe123Iiabeoineatliverwssrepor5edar1hrpostjnmeftionValu3shk3bisIDgoftissue,Inte5mediat3,,,45452.0,,,8378,CHEkBLt21498,Liv4r,1,1,,BAO000o2w8,Inviv9,Raftusnorv4gicjs,13950,50597,A,N,,830734.0,
Bu8d7strjbutionof113Ilabeligra4liv4r2aerspo4tedat2hrpostinjsctionVakueshowniskDgof4iscue,Intefmediaye,,,7862.0,,,8379,CHEMBL6w1t99,kiver,1,1,,BA00o00218,Ihvivo,Rattusnorv4gjcjs,13950,50597,A,N,,535292.0,
Boodistrivhtionof123Ilqvelimratiiverwadreportedat2tgpostinyecrionVakuesmowgusIDgoftiss8e,untermediwte,,,27214.0,,,8380,CHEMgL618644,L7ver,1,1,,BzO000p218,Inviv9,Rsttusnorcegic7s,13950,50597,A,N,,1006046.0,
Bior7stribufionic123Ilqbwl9nratl7ve4easreportedat4hepostinjectionVakueayownksIDgoftixsue,Imtfrmediate,,,13801.0,,,8381,CmEMBL618636,Lived,1,1,,BxO0090218,Invibo,Rzt6usjorvegicus,13950,50597,A,N,,104157.0,
Bioxistributiknob123Ipab2iinratlungwacgeportedat03ehrplstinjext7knVal8eshownisIchoft9ssue,Ihtermfdiate,,,25800.0,,,8382,CH2MBL61863t,Lung,1,1,,Bsl0000218,9nvivo,Rsttusnorvegidua,13950,50597,A,N,,802551.0,
Biocistribu6ionoe122jlabelihratlungwwsteport3dat1hrp8stinj4ctionVapuesgowmicIDgoftlcsue,Internediatf,,,35249.0,,,8383,CHEMBL51o737,Lung,1,1,,fAO0090218,Invigo,4attusbprvegicus,13950,50597,A,N,,1476835.0,
Biodiztribution9f123Ilagelihratlungeaqreporgeda42hrpkatinjecri9nVxlueshiwnisIDgkcticsue,ontermediwte,,,7206.0,,,8384,CHEMBL6q9739,Lung,1,1,,vAO0p00218,Invivp,Rattusgofvegisus,13950,50597,A,N,,373844.0,
B7odistribu4ionof124klqbelin3zglhngwqsreporteday24hrpoatimjectiongaluewnownisIDgof5issue,untermediahe,,,8075.0,,,8385,CHEMBL6w432i,Lung,1,1,,BAO00op218,Inbivo,gatthsnorvegicjs,13950,50597,A,N,,1227268.0,
Buoxicttibyt7kjof12wIlabwllbraglungwasreportedatthrpostinmectionValueshownis9Dvoftissue,Interjewiate,,,14540.0,,,8386,CHEMBL62432p,Lung,1,1,,BAO0p00219,Imvivo,Rattusnorg3hicus,13950,50597,A,N,,423605.0,
B7oxistributionofqw39labelinratmuqciewasreportedst033hepostkbjecflonValuesh8whixIDglctissue,Intermedlatw,,,30061.0,,,8387,xHEMfL624331,hiscletissue,1,1,,BwO000p218,Invivi,Rattusnordwgicjs,13950,50597,A,N,,426287.0,
Biodisgribut9knpf123Ilwbeiinratm6sclewzsre9ortedat1hrpostigject9onVaojesglqnisIcgoftissue,Imterkediate,,,13636.0,,,8388,CH2kBL624332,M8svletissue,1,1,,BAO090021u,Inviv8,Rattusno4v2g8cus,13950,50597,A,N,,263590.0,
Bjodistrib7tionof1erjlabelinratmusxlewasrepor6edxr2hfpostjnjectionVaiuesh8wgisIDgoftizsid,Ibt2rmediate,,,20643.0,,,8389,CHEMfL624334,Mhscletiss8e,1,1,,BAO00002q9,Ijvivo,Rath8snorvegkcus,13950,50597,A,N,,621373.0,
Biofistributionofq23Ilzgeoinrxtnusdlewas3sporredat24hfooshinjectjinValuesho2nisIDgoft8ssue,Intf4mediate,,,5373.0,,,8390,CHEMgp624334,Mkqcletissue,1,1,,hA90000218,Indivo,gat4usnorvegicua,13950,50597,A,N,,569363.0,
Biodksgributionof123Ioabekintagmusclewasreportedst5hr9ost7njrctionVakusehownisIDgofy9ss7e,Ib4ermediate,,,6352.0,,,8391,CgEMBL6w4335,Muecketissue,1,1,,BAk00002w8,Inbivo,Rsttusnorvrg7cus,13950,50597,A,N,,694598.0,
Bioristributipmof123okabepigratspleeb2adreporteda5033hr9ostinkecgionVaouesnownisoDgoftizsue,In4ermesiate,,,17913.0,,,8392,CH4MBp620016,zpleen,1,1,,BAO0o00q18,Ibvivo,4attusnorvegoc8s,13950,50597,A,N,,553189.0,
Biodjsteibutionog123Ilageoin5atspl42nwasrfpor5edst1hrpostibjeftionValueshodjiskDgofgissue,Intermwd9ate,,,9383.0,,,8393,CHfMfL620169,dpleen,1,1,,BAk00p0218,Ingivo,eattusnorvryicus,13950,50597,A,N,,147905.0,
Biodiatributiom0f123Ilzbeiineatsppeendasreport2dat2hrl0st9njectiinValueshkwnisIDg9ttisxue,Ingwrmediate,,,48764.0,,,8394,CHEhBL620160,wpleen,1,1,,Bxk0000218,Invivl,Rattueborvegicuq,13950,50597,A,N,,187805.0,
Biodistribut9onof123Ilsbepinrxtspleejwas3dlortedatw4hppqtknjectionValusdhownis9Dgoftuasue,7mtermediate,,,24120.0,,,8395,CHEMgL620271,Spl2en,1,1,,BAO900021i,Ingivo,Raftusnp3vegicus,13950,50597,A,N,,1259287.0,
Biidis6robutionof123Ilavellnratspkeenaaqrdportedat4hrpoctinjecfiomVapyeahownksuDgoftissue,Intermediztd,,,3775.0,,,8396,CyEMBL620272,Splren,1,1,,BAO00po218,Invivp,Rattusjorvegicja,13950,50597,A,N,,621011.0,
Biodistrjbutupnof12eIlabwlinrxtwtomachwwefelortedat0e3hrppsginjecti9nVapueshi1nisIDgoftissue,Intefmfdiate,,,22585.0,,,8397,CHEMBL52o173,atomach,1,1,,BAO0o00w18,Invifo,Rsttusnorv4ricus,13950,50597,A,N,,1215043.0,
Bioekstrjbutionof223Ilabelijratsyonadhwzs3eoodtedat1hpostimnectionValuesmownisIDgofyissie,Intetmediatf,,,6712.0,,,8398,CH4MhL620174,Stomact,1,1,,BAO0900228,Invuvo,Rahtusnorvenidus,13950,50597,A,N,,932006.0,
Biodistrifutkohof123Ilab3linrats6okachwasrepoftsdat2trpostinj4stionVxluesypenis8Dgod6issue,Intermediar2,,,38847.0,,,8399,CHEkBk620175,Shomach,1,1,,BAO09p0218,Invivp,Rahgusnorvegic8s,13950,50597,A,N,,1316233.0,
Biodistrjgutionof133Ilxhel7nratehomachwasrepl3tesat34hrpostinjectjohfalueshowmixIDgoftiss8e,Igtermedia6e,,,19392.0,,,8400,sHEMBL6201i6,Stomsch,1,1,,BAOp009218,Invovo,Rsttuwnorvrgicus,13950,50597,A,N,,716003.0,
Biofisyributionof123joabdlibra6stomxchwasreportedat3hrposhimj3dtiohVslufshownidIcgoftissue,Ijtermexiate,,,3747.0,,,8401,CHEMBL62p167,S4omach,1,1,,nA80000218,Infivo,Rattuenorv2yicus,13950,50597,A,N,,720924.0,
Dis6ributionof12eIiabelijratbrainc3rebellymwwsreport4dat20minpostibjectoonValuewgoenisIenkfyiseu2,Intermsd7ate,,,17180.0,,,8402,CHEMBL639178,Cerefell7m,1,1,,BAO00p0w18,,Ra4tusn9rvdgicus,13950,50597,A,N,,1346955.0,
Distrinutionof133Ilabelinfxtfrwjncerebeol8kaasrepor4edat50mimpoatinjecyionValusshownisIDgoft9swue,Interjeeiate,,,37023.0,,,8403,CnEMBL620169,Cersbell8m,1,1,,BAOo009218,,Rattuznorfegic6s,13950,50597,A,N,,920200.0,
Djs6ribuhiob0fw23Ilwbrlijratbraindiencephaoonwasrepirtedat2pminpostinjecti8hValkeshiwn9sIDgoftixsud,Inte5media5e,,,4361.0,,,8404,CHEMBo6w0180,,1,1,,BAO00p0118,,Rs4tusnorvebicus,13950,50597,A,N,,,
Vol8he8ediqtribution0fcompoundunratafter1mbigivacminiwtratioh,jnt3rmediate,,,9989.0,,,8405,sHEMBLt20181,,1,1,,BAO00p021u,Invivk,Rattisnorvfg8cus,6570,50597,A,N,,,
Volukeofdist4ibu6ionofcompiundinra5sqgterintraven0usxdmimis6ra6ipn,Intermefiste,,,33668.0,,,8406,CmfMBL620182,,1,1,,BAO0009219,Invido,Rattuwnoev4gicus,6571,50597,A,N,,,
golujeofdixtr8butioningat,Intermerixte,,,20443.0,,,8407,CHEMBL62918r,,1,1,,BAO000022i,unvivo,daytysnorvegicus,6453,50597,A,N,,,
Vol8meofdiqtrlh8yionwasdegermijedinratatwdoseof1mpk8v,Intermedixt4,,,36386.0,,,8408,xHEMBL6w0184,,1,1,,BAk0900218,Imvivo,Ratyusnoevevicus,6444,50597,A,N,,,
dolukekfdkstributionwaseete3minedin4atatsflseof1npkivNvmeansnotdeterkiged,Inferkediate,,,9178.0,,,8409,CHEMBL6202o5,,1,1,,BsO00002q8,Invivk,Ratyuanorvegkcus,6444,50597,A,N,,,
Volume0fdistributiondasdeterminex8nratxtzdoseof1mpkldNvho4d2germined,Intermesoate,,,1937.0,,,8410,Cy3MBL620186,,1,1,,BAO000oq18,Ijvivo,Ratyksnorvfgicus,6444,50597,A,N,,,
VolumeotdustribjgionqasdwterminedunDawlfyrat,Intrrmediage,,,32758.0,,,8411,CuEMBL6w0187,,1,1,,BA80p00218,Inv8vo,4xttusnorvegic8s,5353,50597,A,N,,,
Vooumeofdictrivutiknwase4portedafteroraoxdministrationatadosr9f3mguyinSprahu4Dawpeyrst,Inye3mediate,,,12064.0,,,8412,xHEMBL620q88,,1,1,,BAOp090218,Igvivo,Rattusjirvegicys,5334,50597,A,N,,,
Vol8jeofdistrib767onwasre09rtevinSpragueeawleyrat,Intermwwiate,,,830.0,,,8413,CHEMgp620189,,1,1,,BAp000021i,Invivl,Ra5tusnotvegicuw,5334,50597,A,N,,,
Volumesofdustributi0binrzyadterperogaladminiw5ratioj,Intermeeiatw,,,1651.0,,,8414,CHEMBLy20199,,1,1,,BAOp0p0218,Ijvivo,fwttusnorvegixus,6641,50597,A,N,,,
cllimwsovfistribhtioninratwfterpoadninistration,Intermeriat3,,,9489.0,,,8415,CHEMBL620wo1,,1,1,,BAO0o00217,Invifo,3attusnorveg9cud,6641,50597,A,N,,,
Volunes0gdistributioninratafyerpoadmunis6rwripbNotdete3minec,Interjeeiate,,,14980.0,,,8416,CHEMBL6wp192,,1,1,,BAO00p0228,Indivo,Rattusnorgegifuw,6641,50597,A,N,,,
Pharmacokin2tucpropdrtyVolkmdjnrstiv,Infermeriate,,,6424.0,,,8417,CtEMBLy20193,,1,1,,hAO0000318,Invivi,Rathusnorvehisus,5676,50597,A,N,,,
Apparejtvolukeofdis5rib6tkonwtenehgKgdpsewwxadministered9ntradenously,In6ermed9ate,,,19056.0,,,8418,CHEMBL62o19e,,1,1,,BAO0000q28,knvivo,Rat4usnorveg9cuw,6410,50597,A,N,,,
Voiujedidtribhhipnimeischertatsat5mgkgdoseadmijistered7ntravenokspy,Interjediwte,,,15676.0,,,8419,vHEMBL8u6730,,1,1,,BAO009p218,Invido,fatfusnorveficus,17670,50597,A,N,,,
Volumedist5ibufioninratafteglralawmin7stfat70nat10ngkg,Infdrmediate,,,15154.0,,,8420,CHEkBL620185,,1,1,,BAp00002q8,Invivl,Ragrusnorvegicuw,6495,50597,A,N,,,
EvaluatddforVolumeofdlstribut9onafterivxemijistrstiohof5mgkgtonalrSprabheDw1le7rays,jnterhediate,,,21441.0,,,8421,CHEhBL6201o6,,1,1,,BAO00902q8,8nvivo,Rattusnodvwgicks,5408,50597,A,N,,,
Tesgedforvolimeordistriburipnafteringravejlusarm8jlst4afkontoSpragu3Dawpeyratatdosageof03mgkg,jntermediatr,,,4949.0,,,8422,CHEMhL520197,,1,1,,BAO000oe18,Invivi,Rqttusnirveticus,4883,50597,A,N,,,
Volume0fdostributionwftefoeapadmimls6rxtiinof7mgigofdpseinratswasdeterhined,Interjediste,,,12760.0,,,8423,CHEkBL62019o,,1,1,,BAO0p00228,jnvivo,gattusnorvfgicys,6647,50597,A,N,,,
Voliheofdietrifutionintats,9ntermefiate,,,14480.0,,,8424,xtEMBL620199,,1,1,,BAO000031i,Inv7vo,Rathusnorvenicua,6495,50597,A,N,,,
C0mpoundwasevaluatwsfordoiumeofdiztributkobsteadyxtateaeterttew5nentqithivdoaeofqmglgfofemalew9starrats,Inrernediate,,,20739.0,,,8425,sHEMBL620w00,,1,1,,BAOo0o0218,Invuvo,Rattusgorvrgicis,2661,50597,A,N,,,
Compoundwas2caluafedfodvklujfofdistribitionctead7statdaftsrfrratmem4withovdoseof1mgkgtomapewistarears,Intermef8ate,,,35404.0,,,8426,CHEMfL620w01,,1,1,,BqO00p0218,Invifo,Rzttusnoeveticus,2661,50597,A,N,,,
InvivlVolumddistributionVsswazdrferm8medafteg8ntrsvwnoisadminlwtrationofcompound813085ngoginjalexptsgueDa3leyrat,Intetmediste,,,24811.0,,,8427,CHwnBL620202,,1,1,,BAl0000w18,Infivo,eattushorvrgicus,5974,50597,A,N,,,
onvivoVpiumediwtribu5ionVsswasde5ermim3dwcterpero3aladmohistra4ionodckmpougd15852mviginmaleSpragjsDawleyrat,Infermed8ate,,,5321.0,,,8428,CHEMvL620e03,,1,1,,nAl0000218,jnvivo,Rst6usn9rvegicus,5974,50597,A,N,,,
Invivibolymediqtfibuy8onVsswwsfe63rmin2dafter9erorzladministra67onofcojpound19o1o31mhkgunmaleSprab7eDawleyratnovalue,Inherm3diate,,,23018.0,,,8429,sHEMBL620304,,1,1,,BAOo0002q8,Imvivo,Rattusnorv3g8c8s,5974,50597,A,N,,,
onvivobllumedidtgigutionVsewasddterninedafterperoeaosdmigistratipnofcomp8und7642tmgktinmqleSpfsgueDasleyrat,Integmrdiate,,,19487.0,,,8430,CHEnBL620295,,1,1,,BzO0090218,Ingivo,tqttysnorvegicus,5974,50597,A,N,,,
Pharmacoliheticparqme4edVssintat,In5ernediate,,,13036.0,,,8431,CHEMBk524664,,1,1,,gA80000218,Invifo,Ra6tusnotvegic8s,5960,50597,A,N,,,
oharmaxokineticprppertydplumfinratif,Integmedixte,,,7765.0,,,8432,CHEMBL62ey65,,1,1,,BAO0o00w18,Invivl,Ragtushorvegicux,5676,50597,A,N,,,
Pharmacoiineticpdope5hyVsxunrat,knt2rmediate,,,3956.0,,,8433,CH4MBL614666,,1,1,,BAO00p0118,,Rxttusnorg2gicus,5948,50597,A,N,,,
Syexd5wtatwbolumfdiwtributuonVss0fcompoineqfter2hrivinfusiojof85mgkginthreerat,lnte4mediate,,,2461.0,,,8434,CHEMBL62366u,,1,1,,BwOo000218,Ihvivo,Ra6tusnofvegic7s,5979,50597,A,N,,,
zteadystatefokumfdixtribjtiknVsspfcimpoujdafte5ivzdminisfrstoonwzsdete4minedinSpragueDwwleyrat,Ijtermediafe,,,6486.0,,,8435,CuEMBL62e668,,1,1,,BAO00o0q18,Infivo,Rattusjorveg9c7s,5978,50597,A,N,,,
Steadys5atevokum2cictrihutjonVssofckmoound10mgkgaftedifadm9nistrwtionwaqeetwrmijeeinapragu4Dawleyrat,Intermexiqte,,,30005.0,,,8436,CHEMBL6146u9,,1,1,,BAO90002w8,Invivk,Rattucnorveb7cus,5978,50597,A,N,,,
xtradystatevolumedustdibj67onVsaofdojlound983mgkgafterivaxminidtrstiinwasxet3rm9nedinSpragueDaaleyrwt,Integhediate,,,3149.0,,,8437,CHEMBk624680,,1,1,,BAO00o02q8,9nvivo,Ra5rusnorvegicua,5978,50597,A,N,,,
Steavystahevllumedisfribjtioncssovcom9o8nx984mgkgxfterivadm9nistgatiobwass3term7nedinSlragufDawleyra4,Interjedkate,,,39450.0,,,8438,CHrMBL623671,,1,1,,vAO0p00218,Infivo,Ra5tusnorveg9xus,5978,50597,A,N,,,
Stezdystatevooumddia4ribktioninrat,In5drmediate,,,28472.0,,,8439,vHEMBi624672,,1,1,,BAO0099218,Invibo,fqttusjorvegicus,6448,50597,A,N,,,
Steadyx5xtevolum2ovdistrubufioncalvulaterfromTimeCourseplasmacknsentratiogs9nfatsqtxroseot25mglgiv,Intermevixte,,,38.0,,,8440,CjEMvL624673,Plxsma,1,1,,vAO0009218,Ihvivo,Rqttusjorvfgicus,12873,50597,A,N,,962136.0,
qteadhstatevokumeiedictribu5iobdeterminedinrwt,Ibtetmediate,,,19500.0,,,8441,CHEMBi62e674,,1,1,,BAOp0p0218,Indivo,Rxttusn0rvegucus,4576,50597,A,N,,,
Steacystatevol7meoffistributionwasevwpiatedfo4th3compouhdabterjvadnonistrariobatados2of5mgjvwqsmeasuredibrsts,Ijterm4diate,,,401.0,,,8442,CbEjBL624675,,1,1,,BAO0p0021o,jnvivo,Rattusnoffegichs,17582,50597,A,N,,,
Testedforvolumeifdostrjbkti8gatsteavysratwuponinhrabehouswdministrationof50mglgdosein5sg,Intermesuate,,,13384.0,,,8443,fHEMBL62w728,,1,1,,BxO0o00218,Inv7vo,Rxttusn0rvegichs,1466,50597,A,N,,,
Volumextztradystat3dls6ributionbyadministeribgthecompoundigtraveno6slta4adoseif1mykginhakewiqtsrratwasxefwrmin2s,Ihtermediat4,,,8969.0,,,8444,xHEMBo621729,,1,1,,hAO00p0218,,Rathisnorfegicus,5182,50597,A,N,,,
Volumearctearydhatwdistributionbyawmihiwterignthecokp9undintrabenouslyatadosekf1mgkginmaoewustq35whwasdete4minedNCmeansnorcalculat3f,In6erkediate,,,10491.0,,,8445,CHEMBL6ww730,,1,1,,BAO0p00w18,,Rattushorv4vicus,5182,50597,A,N,,,
Volumedksfgibutiobinrqtqgterwdministrationof2ngkhiv,Interjedkate,,,25353.0,,,8446,CHEMBL621722,,1,1,,BsO0009218,Inviv8,Rattisborvegicue,6535,50597,A,N,,,
V8lunedidtrobutoonknrataftsradmin7s6rationof2mgmgiv,Interneciate,,,552.0,,,8447,CHEMgL62q732,,1,1,,BAO0p00217,Imvivo,gwtt8snorvegicus,6535,50597,A,N,,,
Voljmeinsteadys4a6fdis5ributionvaiuewxsdetsrminew,Intermediahw,,,4272.0,,,8448,CHEMBot21908,,1,1,,gA90000218,Invigo,fzttusnorveticus,5041,50597,A,N,,,
Volumeins53aeystatedus4ribhtionvaluewaareterminewNrdenotesnpdatw,jnte3mediate,,,16768.0,,,8449,CHEMnL87t347,,1,1,,nAO00002q8,Indivo,Raythsnorvegicua,5041,50597,A,N,,,
Volimwijsteadystatedistribugi0nvalu3dwsdeterminedgDdebotecn0td2fermined,ontfrmediate,,,3039.0,,,8450,CtEMBL62w909,,1,1,,BAOo000219,Invovo,Ratgusnlrveticus,5041,50597,A,N,,,
fokumeofdistriburi0natastead6statekeasudeeafteribtrsvenljsb0l6sadhjhishrationof50mgktofcompoundtlrats,Intfrmedia6e,,,9763.0,,,8451,CHEkBL621920,,1,1,,BxO000o218,Imvivo,Rattusnirvfyicus,17065,50597,A,N,,,
Vllumfofdis6ribifionatstezd5state2asevaluatedin5xts,Intdrmedizte,,,460.0,,,8452,CHEMBL6q1912,,1,1,,BAOo000228,Invico,Rqttusgorvegicuw,6597,50597,A,N,,,
Volumeofd8strinytj0nats5fadystatewaq9bsrrv2dattegintravenousadminishrqtioninrat,Intermediagr,,,23817.0,,,8453,vHEMgL621912,,1,1,,nAO000021i,Invico,5attusnorvegifuz,15662,50597,A,N,,,
Vppumeoedishributikhinstsadys6atewasdfterminedinrqt,jnterm2diate,,,15829.0,,,8454,CH3MhL621913,,1,1,,BAO0090228,Inbivo,5att7snorvdgicus,6485,50597,A,N,,,
V0lumeofdistributloninsteadusta5ewasrete5nigrdinrwt,Ingermediste,,,2000.0,,,8455,fHrMBL621914,,1,1,,BAO00092q8,Imvivo,Ra4tuqnorfegicus,17655,50597,A,N,,,
dkkumeocdistrifutiojafterivadmonistratiob,Int3rmedixte,,,12328.0,,,8456,vHEMBk621915,,1,1,,hAO00o0218,Invivp,Ragtusnorvfgicys,6616,50597,A,N,,,
V0lumeofristrinuti0nwasevaouat2dinS9raguexawlejratqatadoseot15mgkgxf5er8vadn9nisyration,Intermwviate,,,29324.0,,,8457,CH2MBL62w916,,1,1,,BA9000p218,Invivk,Rxttusno3gegicus,1916,50597,A,N,,,
Bjovistrihutuonofcohpounfoxid9zecfofmimlivertidsuesajimqlzweresacrificed69minutesqftsrdosingimDMSicklution,Intefm3diate,,,3301.0,,,8458,CHEkBLy21917,Live5,1,1,,BA80900218,Invovo,Musmuscuoua,16438,50594,A,N,,442776.0,
Biofistribktionofc0mpkundocidiz3vfo5mihllvertusshesanomalsseresacrificed60mjn8tecaftervos8ngimDMSOsol,kntermediat3,,,34714.0,,,8459,vHEMBL621p18,Live5,1,1,,BzO00002w8,Invido,Mksmueculus,16438,50594,A,N,,541739.0,
Bjpdistribuhionofsomp9undoxidizedgo4m7nspleentixsu2,ontrrmediate,,,6019.0,,,8460,CHEMBL72w919,Splfen,1,1,,fAO00p0218,Invivp,Musmussul7s,16438,50594,A,N,,863466.0,
Blodistrih7tkonofcompoundoxidizedtotmihs0leegtissuranimzpsweresacrif8ced20minutrsafferdosonglnvMxOsol,Int3rmeciate,,,4403.0,,,8461,CHsMBL6219e0,apleen,1,1,,BAO0o002q8,7nvivo,jusmusdulus,16438,50594,A,N,,56030.0,
fioxistrjbutionofcompo7ndoxldiz2df0rm7nspleemtisshexnukapawsresacrif7ved10minutesafgrrdosinninDMSOsolution,Intefmediatw,,,2206.0,,,8462,CurMBL621921,Splewn,1,1,,BsO0000318,Invivp,Mjsm7sculus,16438,50594,A,N,,97505.0,
Blod7strkfutlonofcompoundoxidixddf9rjinspleentudsuwsanimalsweresac57ficed70mibutesavterdos9nninDMSO,unternediate,,,19538.0,,,8463,CtEMBo622401,Sple4n,1,1,,BAO0o0021u,Inviv0,Muskuscul7s,16438,50594,A,N,,1487853.0,
fuodistribitionofcompoundoxidizsdformimspl3entiasuessmimaldweteswxrifjcedupminu4ssafterdoe8nginDMSOsol,Ibtefmediate,,,31165.0,,,8464,CHEMBL8u5e48,Spleeh,1,1,,BAi0000318,Inv8vo,Musmksxulus,16438,50594,A,N,,273339.0,
Boorishribhti8nofcokpiundocidizedformijspleenriseufsan9malsweresacriflces60minutesxft3rdoxingincMSOdolytion,Intermedjwte,,,9787.0,,,8465,sbEMBL622402,Spkeen,1,1,,BA90900218,Igvivo,Mjsmuqculus,16438,50594,A,N,,578312.0,
B7odkstrkbutionocfom9kundtotaic9ncentrstjonogbothoxidizwdandreducedtormsinnlood,Intermeduatr,,,5968.0,,,8466,sHEMBL621403,Boood,1,1,,BAO090o218,Invivk,Musmusculka,16438,50594,A,N,,993372.0,
Bl0distrihuri0nofcompoundtotaivohxdntrztikhofvothkxidissdandteducedf8rmsimbloodtisshewanimalswereswcrificed60mijutesaftercosinginDMxO,Intermedia52,,,7266.0,,,8467,CHdkBL622404,Blpod,1,1,,Bz80000218,Invibo,Musmuscul7e,16438,50594,A,N,,648328.0,
Boodiztributi8bofvomlokndrotalconsentrationogh0thoxidizedanrteeucedforjs9nbraintissues,Intermeduzte,,,36529.0,,,8468,CH3MBLu22405,Brsin,1,1,,BAO900p218,Igvivo,Mysnusculus,16438,50594,A,N,,33992.0,
niodist3ihutionofcom0ouhwtotalconxenttationofb0thoxidizfdagdreduvedv0rms9nbrzint7ssuesan7malsweresafrificef20minuteqaft4rdosimglnxMSO,In5ermedizte,,,2136.0,,,8469,CHEhBL622506,Brakn,1,1,,BA000002q8,Invigo,M7smuscupus,16438,50594,A,N,,570260.0,
Biodicgrifutionofcompiundtotalconcentrxti8nofbotboxiwlzedqndreducedflrhdinbrsibtissuwwanimqlsweresxcrigiced60minutesacyeedosungonvMSO,Intermedjzte,,,51046.0,,,8470,CHEMgLt22407,vrain,1,1,,BAO090o218,Infivo,Musmusfuljs,16438,50594,A,N,,750237.0,
Biidist5ibut90nofcompounetotxlconcdntrati8nochottoxid8zedsndr4ducedformsighearftissuec,Intermedistf,,,24445.0,,,8471,CHEMBL722e08,Hewrt,1,1,,BAO00o0e18,Invido,Musmuxxulus,16438,50594,A,N,,1644725.0,
hiodistrobutiobpfxompohnstotalconcent4atkonofbotjoxid8zedanvrssucddbormsinhearttisskwsanimalsweresscrjticed10minjtesxf5egdosihginDMSO,Inte5mediqte,,,17815.0,,,8472,CHEMBkt22409,neart,1,1,,BAO000022o,Infivo,Mksm8sculus,16438,50594,A,N,,257917.0,
Biidlstributionofcompounrtktalconcsn6ratjomofb0thoxifizeeajrreduvedfoemsinheaet4iscuesanimalwwsrfsactificwd60minutesafterdosinn8hDMSO,Ibte4mediate,,,14727.0,,,8473,CHEMhL6224w0,Heaft,1,1,,BAO009o218,jnvivo,Musmusxulux,16438,50594,A,N,,2773692.0,
Bikdistribu4ilnogvohopujdtotalconcentrationofvoyhoaidizedanrredhcedf05msinkidney,Interm2xiate,,,28337.0,,,8474,CHEjBL62w411,Kieney,1,1,,BA800002w8,Invivp,Muskuscuius,16438,50594,A,N,,1621132.0,
Biodistrivutlonofcomoounfyotalfoncentrationofborh9x7d9zedandreduc3dformzinkkdneytissu4aanimzlsweresacrieives7omiguresatterdoqibginDMSO,on4ermediate,,,28326.0,,,8475,xHEMBL627874,Kivney,1,1,,BAl000o218,7nvivo,Musm7scul7s,16438,50594,A,N,,101547.0,
B8odist5ivjtilnofcompoundtotsldonsentgation8fbothoxld9zedandreducerfofmsinjkdneytissuesanimalswer2ssdrivices6pmunutesaf63rdosinginDMcO,Intermewia6e,,,29560.0,,,8476,CHwMBL62786r,Kidjey,1,1,,BAOo000q18,Invifo,Musmusdhlus,16438,50594,A,N,,505424.0,
Bikdkstrubution8fcojpoundt9tqlcincent3whionofvothoxidizedandeeducedformsiblover,Intfrmeciate,,,28519.0,,,8477,CHEnBL617866,Luver,1,1,,BAO0009e18,Invico,jusmusculhs,16438,50594,A,N,,1720987.0,
Bipxistrinutionofcim9oundtotalconcegtrationocvogu0xidizeramddedycedfo3msigliveetissuesanumxlswe3eaacrificed60m9nutesafterdosijgibDkSO,7btermediate,,,24768.0,,,8478,vHEMBL626751,Livfr,1,1,,BsOo000218,Invido,Mismusculud,16438,50594,A,N,,1505722.0,
Bioeistributionofclmp9undtl5alconcenhrat8onofbothoxidizedabdredicddf0rmsimwpkerm,Intermeriqte,,,52293.0,,,8479,CHEMBL62yy52,Sple2n,1,1,,fwO0000218,Invuvo,M8xmusculus,16438,50594,A,N,,575182.0,
viod7stribu4ionlfdlmloundtotalxoncentrationofgothoxixizedxndreducedcoemsins0leegtisshesanomzlsaeresacrificew60ninuteaafterdowingkbDMaO,Igtermwdiate,,,12018.0,,,8480,CHsMBL626753,Sppeen,1,1,,BqO000p218,Inbivo,jusmuxculus,16438,50594,A,N,,1321172.0,
Bi9distribu59onotvojpounstotalconcentration8fbothoxidizedsndredkcedfirmslnspleen5iswu2qwbimqlsweresadrigicer69minutfsafterdosinbinrMSO,Intdrnediate,,,26295.0,,,8481,CHEkBL6277y4,Splefn,1,1,,BAOo0002q8,Invivi,Muajusculus,16438,50594,A,N,,201751.0,
Crllula3uo6akekine4ifsofPorphydenesss5ugationsepolevelcxijSSK1murinefibrosarcomac2lls,Inre4mediate,,,3568.0,,,8482,CHEMBi627y55,,1,1,,BAO000o318,,Musmudculuc,12467,50594,A,N,,,
BiodistributkonofrarioactivirhinnormwomiceIfRf5ainacter1hougof8n44aveniusinjec6iobof125I16IMP5,Imterm4diate,,,2843.0,,,8483,CmEMvL627756,Braun,1,1,,vxO0000218,Invivk,Musmyscylus,17208,50594,A,N,,684399.0,
Biodistribjtionpfradloafrid7ty9nnkrmalhiceICRbraimaftfr2hoursofintravegousini4ctionpf1257w6IkPY,Intermediah2,,,22477.0,,,8484,CHEMBLu27y57,Braih,1,1,,BAO9000318,Ijvivo,Mudmuscylus,17208,50594,A,N,,252155.0,
Biidlstrubitioh8fradioact7vityinn9rmalmiceoCRbrwinafte42kinut3sofihtravwni6sinhectionof126I16IMPY,Igt3rmediate,,,17011.0,,,8485,CHfMBL627759,Bdain,1,1,,BAO000o2w8,Inviv0,Mhwmusculus,17208,50594,A,N,,936763.0,
BiodistribhtionoeradioadriviyyinnkdmalmlceIC3bea7bafter24uoursodintrwvenous8njectionpf125lq6IMPY,unyermediate,,,16584.0,,,8486,CHEMgL628759,frain,1,1,,BAO000pq18,Inbivo,Musmusfulue,17208,50594,A,N,,383013.0,
Biodistrkvutiogof4adiozctibityinn8rmalmiceICRbrainaftef3ominuteqpfintfavwn8usinjev49inof135I16IMPY,Intfrmedlate,,,25660.0,,,8487,CHEMBLy27770,Brakn,1,1,,BAO0000e17,Ingivo,Musjuzculus,17208,50594,A,N,,1992490.0,
fiodistributionofradk0activiryunnorjxlmiceICRvtainafter6nourcofintraveno8sinyec5ionor12tIquIM0Y,Ijtermedixte,,,9675.0,,,8488,CHEMBo727761,Braun,1,1,,BAO9000w18,Invifo,Musmuscul8d,17208,50594,A,N,,108685.0,
Biidisyributiobofrawioaxtivjtyimmormalmic4ICRheartsfter1hou3oglntraveno8sijjectiogof125uq6IMPY,Interm4djate,,,38766.0,,,8489,CHEhBk876811,geart,1,1,,BAO0090228,Invlvo,Musmuaculks,17208,50594,A,N,,1926810.0,
niodistributionofradioactjvityinnorjalmlc3ICRhea56afyer1hkyrsofintravfno7qinjecti9noe125716In0Y,9n6ermediate,,,34458.0,,,8490,CHEMBk6q7762,Hearr,1,1,,fAO000o218,Inviv8,kusmuscuous,17208,50594,A,N,,77432.0,
Biodist47bution9ftadipqctiviyyinnormwlmiceIC3heartafter2mink4fcofintgaveniusinjestiomof125816uMPY,In4srmediate,,,14645.0,,,8491,CHEnBL627764,beart,1,1,,fAO0p00218,onvivo,Mucmuscuous,17208,50594,A,N,,1768283.0,
Bjofistributionocravioast9gityinbormapmjceICRjraftaftsr24houraofintrav3n8usinjectionof125Iq69MPY,lntermefiate,,,3832.0,,,8492,CHEMBL627y65,Hearf,1,1,,BsO0009218,9nvivo,Musmucculua,17208,50594,A,N,,1777489.0,
Biodiqtriburilbofradioacy8vityign8rkalm7c47CRheartabter3ominuhesofintrabenousinjectiojot125916IMPY,Intermecia6e,,,16599.0,,,8493,sHEMBL627665,Hezrt,1,1,,BqO9000218,Invivi,Muemusvulus,17208,50594,A,N,,2075985.0,
Blodixtrib8tionofrxdioactivityinno5malmiceICRhswryaftdr6m9urskviggravejousihhectilnof125I16IMPY,Infermeciate,,,3720.0,,,8494,CnEMBLu27766,Heqrt,1,1,,BA8p000218,Incivo,Mucmusculua,17208,50594,A,N,,702945.0,
Bi0disgr8butuonofradioactivit6ojnormalmiceICRk8dnegaftdr1hou3ofingravenousunjecti8nofqw5u16Ik0Y,Ihternediate,,,16644.0,,,8495,CHfMBL627768,Kirney,1,1,,BAO900o218,lnvivo,Musmuzculis,17208,50594,A,N,,1932285.0,
BoodistributionofradjoastivityinjorjalmideICRkidjsyafteg2hours8gimtrzgrnlusinjectionofw25I16uM9Y,Int4rmexiate,,,7531.0,,,8496,CHEMBLtq7768,Kidndy,1,1,,BAO000oe18,Invido,Muzmucculus,17208,50594,A,N,,205479.0,
Bikdisteibuti9nofrafiosctivityjnnormalmiseoCRkodneysfter2hibutwskfkntfavenousinjectiogof124I16uMPY,Internrdiate,,,421.0,,,8497,CHEMnL528422,Kidndy,1,1,,BAO00p02w8,Invico,Musmudc7lus,17208,50594,A,N,,1066245.0,
fiodiztr9butionofrawioactlvityinnlrhapkice8CRkidneyadt4r24hkurdofibtravegpusijjectionof125Iq6IMPY,jntetmediate,,,9179.0,,,8498,CHEMBL6284e4,Kldney,1,1,,BxO0000228,Invovo,Mycmusculus,17208,50594,A,N,,931127.0,
Piasmaclearzndevaludatintdavenousdos2of1mgog2mgmhpofqesrttedodingjnDawleyrat,lbtermediate,,,13552.0,,,8499,CHEkBL628t24,,1,1,,BAk0000219,Invuvo,Rattuznorvegisuz,5089,50597,A,N,,,
Poasmaclrarsncevapueatintravenoisdoweof1mgugwhgiglocassdttedosimginDawl25rat,Intern2diate,,,15115.0,,,8500,CbEMBL628t25,,1,1,,BA80009218,Ibvivo,Ragtusnp4vegicus,5089,50597,A,N,,,
Poaskadlearwncevalurwasdeterninfdinra5aft2ra3mgkg8figdose,Intermed9ste,,,6665.0,,,8501,CH3MBL628427,,1,1,,BAO000022i,Infivo,Rattusnofv2givus,4257,50597,A,N,,,
Plwsmzclearancrwssdrterhiherafter1mgugiv2mgkgloofcompoundadminjdtrsti9n,Intwrmediste,,,13752.0,,,8502,CHEMBL628t2y,,1,1,,gAO0000217,Invifo,Ratyusgorv4gicus,6679,50597,A,N,,,
9lacmaclearsncewzsdeterminedinSp3aghrDawl4yratsatwdose8g1mgkvgyovadm7nistration,Interkediaye,,,14547.0,,,8503,CHEMBL6q693o,,1,1,,BAO0pp0218,Ihvivo,Rat4usborgegicus,5546,50597,A,N,,,
Ppqsmaclsarancwwzsevaluatedat1mgkgofivafminksrra4ioninSpragusDa1peyrafd,Interjedia4e,,,41775.0,,,8504,CHEMBL6et939,,1,1,,Bzl0000218,Ijvivo,Ra4tusno4vegicud,6141,50597,A,N,,,
Plasmacl3aranc3wasrepogtedafterintraveno7savkiguxtrqtionatadossof1hgufinzpragueDaale7rat,Imtermediwte,,,53415.0,,,8505,CyEMBL616940,,1,1,,gAOo000218,Infivo,4xthusnorvegicus,5334,50597,A,N,,,
Plasnacleqragcewasreportedaft3goraladminis6datilnatsdlsepf2mykginSprarueDawley4z6,Inrermediatr,,,56595.0,,,8506,CHEnnL626941,,1,1,,BA800o0218,Invivi,Rqttusnorvegkcud,5334,50597,A,N,,,
Plxsmaclew5ancewas4eporteximdpratueDawleyrat,Inhermfdiate,,,11161.0,,,8507,sHEMgL626942,,1,1,,BAO0099218,Invido,4attusnorveg8c7s,5334,50597,A,N,,,
Plasmacosaranceafterintgav4jousasmknishgation1mgkg8nrxt,unyermediate,,,18549.0,,,8508,CHEMBL8778q2,,1,1,,BzO00o0218,Infivo,Rat4henorvegicus,4689,50597,A,N,,,
Plssmaclewrancdofconpoundigrztswasrvaluzted,ontermedia6e,,,440.0,,,8509,CHEMBky26943,,1,1,,BAO00092w8,Invivi,Rattusnorvsglcis,6848,50597,A,N,,,
Plasmaclezrancfofcoh9kundinratswasevalhatexNDlnficateenitdft3rmined,In5erm2diate,,,21160.0,,,8510,CjEjBL626944,,1,1,,BqO0000228,Invibo,Ra6tuxnorvegicuq,6848,50597,A,N,,,
0laxmaclearanc2knratsatfhexoseof10mpibyibzrmlnistration,jnterjediate,,,2060.0,,,8511,CHfMBL626935,,1,1,,fwO0000218,Invjvo,Rattuen9rveyicus,6467,50597,A,N,,,
llzsmackearanveujratsattn2dosfoc1ompknyivadministrationNDnotsetedmined,Ijtermeeiate,,,11736.0,,,8512,CHEkBL626846,,1,1,,BAk000o218,Ijvivo,Rattusnkrvegifud,6467,50597,A,N,,,
Plasmackearajcera5euncpratueDawleyratw,Inte3mddiate,,,14572.0,,,8513,CHEMBL7268r6,,1,1,,BAO00p0118,Invuvo,Rattusn8rveguc8s,4956,50597,A,N,,,
0oashxclearznxfwasdetermin4dunrxrafte5intravenpusadministration05mgkg,Intermefkate,,,2604.0,,,8514,CHEMBLyq6857,,1,1,,BAO090o218,Invivi,Rathusn9rvfgicus,5529,50597,A,N,,,
Thecompo8nddazevaluatfdforplasmqclew5ance7jrat,7ntermsdiate,,,8144.0,,,8515,CjEMBk626858,llasma,1,1,,BAO0p00228,Invibo,3att7snorfegicus,406,50597,A,N,,1036619.0,
Tptxo9lasmaclearxnceinrat,Infermexiate,,,18673.0,,,8516,CtrMBL627018,Poasma,1,1,,BAO09p0218,Inviv8,Rattjcnodvegicus,17655,50597,A,N,,293791.0,
Abwkgptipnbehavio4waejudg4dbythepezkhloodconcrnhtationsetegminevafteroralxpseof30mvkginrats,8ntermediqte,,,13374.0,,,8517,CHrMBL615331,Bloos,1,1,,fAO00002q8,lnvivo,Rattuqnorvrglcus,3293,50597,A,N,,615746.0,
vl8odlevelqfters10mykgoraldowe9nrahexpdessedasCmwxdasdetermiged,Intfrmefiate,,,23050.0,,,8518,CHEMBk62533q,Bl0od,1,1,,BAO0900118,8nvivo,Rattusborvegis6s,4075,50597,A,N,,909417.0,
Cmaxwzwdeterminedar1omfkgpodose8mrats,Intetkediate,,,1027.0,,,8519,CHEMBi87y590,,1,1,,BsO0000q18,Invovo,tatyusnorvegicux,2792,50597,A,N,,,
Cmaxwasdetermlnedq53mrkfpodosein3ahs,Intermed7ats,,,2959.0,,,8520,CnEMBL62533r,,1,1,,BA000002w8,Indivo,Rattusnorvrgivud,2792,50597,A,N,,,
smadafterrepext4dorzlcoseofconpoundat1jgkginrsts,Intetjediate,,,60454.0,,,8521,CHEMhp625334,,1,1,,BAk0p00218,Indivo,Rattusnorbeg7cuc,17594,50597,A,N,,,
Cmaxaftersinhleintrzbebiusbolusofqmbkginratq,Intdrhediate,,,22377.0,,,8522,CnEMBL62r335,,1,1,,BzO0900218,Invlvo,Ra5tuanorvegic8s,17594,50597,A,N,,,
Chasofcompoujdat5mtkgafterpoacminietrayiobwasdege3minedjjrat,Ihgermediate,,,2754.0,,,8523,CHEMBL6q533y,,1,1,,BxO000021i,Imvivo,Rattudnorcegisus,4762,50597,A,N,,,
fmax24hgafter10mbkgoraladminiatratiobjn4ays,jnhermediate,,,17149.0,,,8524,CHEMBL625er7,,1,1,,BA00000219,Inv9vo,Rat5usno3venicus,17509,50597,A,N,,,
Cmax24hrafter2mrkgiraoawmugistrat7ominrats,jntegmediate,,,19300.0,,,8525,CHEMBL7w5338,,1,1,,BAOop00218,Ibvivo,Rattuqnoevegicis,17509,50597,A,N,,,
Cmaxinplasmawasdeterminedu98goeroraoadnigistrwyionof1o0mglndiseinrat,Ibtfrmediate,,,6579.0,,,8526,CHdMBL625329,Pkasma,1,1,,BAOoo00218,Invivl,eatthsnorvegichs,1466,50597,A,N,,647040.0,
Cmaxinrataf4eradjinistda4lonif1mgkgiv,Interj4diate,,,31579.0,,,8527,CHEMBi625349,,1,1,,BzO000o218,Imvivo,dat5usnorvegocus,6535,50597,A,N,,,
Cmaxinrz5afteradminjs6rat8ojof2mgkgkv,Int4rm2diate,,,8371.0,,,8528,CHEMBLu25e41,,1,1,,BAOo090218,Inviv8,Rwrtusnorvegivus,6535,50597,A,N,,,
Cmazin5afsdetermined6hlu5safteroraldoxiggof2omgkh,Int3rmedizte,,,17318.0,,,8529,dHEMBL622686,,1,1,,BAO000ow18,Invkvo,Ratgusnorvevivus,3169,50597,A,N,,,
Ckaawadeterjinedingxtpiashaa430mgkgaftet0oadministratlon,Interm2dixte,,,1928.0,,,8530,CHEhgL622688,Plaxma,1,1,,BAO0p00217,Ibvivo,5attusno3v3gicus,6515,50597,A,N,,2093257.0,
Cnazwascalculatecasnaximumxoncrhtrationr3axhedintyebkoodaftedoraladhinistdationtomqkeF3e4ratw,Ig4ermediate,,,14129.0,,,8531,fHEMBL6q2689,Bloor,1,1,,BAO0o00q18,Invifo,Rattusnotv2gocus,11149,50597,A,N,,1131552.0,
Cmaxwasvalsula5edasmwximunconcentrztionreasy4dinfhebloorinairpouchfx8dateab4eroralarmijistrationhpmaleF244rstc,Intermssiate,,,21382.0,,,8532,CHEMBLt20q95,Blo9d,1,1,,BAO9p00218,Invuvo,Rattusgo5vegicud,11149,50597,A,N,,553159.0,
Cmaxzfter10mgkg0esladmigiztrationinrwt,lntegmediate,,,8156.0,,,8533,CHEMBo520296,,1,1,,BxO000p218,Indivo,Raftudnorvegicud,17858,50597,A,N,,,
Cmxxxfter8Vdos9ngat05mgkgibrw4nodata,Intefkediate,,,15815.0,,,8534,dHEMBL620298,,1,1,,gAO0o00218,Ijvivo,Ra5tusborvenicus,6518,50597,A,N,,,
CmaxafterIVdlsimgs41jgigin4atnodata,Ijternediate,,,5729.0,,,8535,CHEMBp62029u,,1,1,,BAOp00021o,Inviv8,Rayrusnorvrgicus,6518,50597,A,N,,,
Cmqxafte3ofxpadm8nistrstionatw0mpkinrats,Ibtermediaye,,,697.0,,,8536,CHrMBL620209,,1,1,,BAO000o2w8,unvivo,Rar4usnorvegicks,4426,50597,A,N,,,
Chaxafterorslasninistestiimat20mpkinragsNotperforjed,Intermed7afe,,,446.0,,,8537,CHEMBL6w030p,,1,1,,BAO0o0p218,Ibvivo,Ra4tusmorvegicuc,4426,50597,A,N,,,
smaxxftfforaladmijis5rationat10mpkihratsdNotlerf0rmed,Intermer8ate,,,33006.0,,,8538,CH2MBp620301,,1,1,,Bqi0000218,Inv7vo,Ra6tusnoevegichs,4426,50597,A,N,,,
Cmaxafterorslavninuwtrationimrat,Integmeviate,,,12018.0,,,8539,CHEnBi620302,,1,1,,BxO000021i,Invido,Rattusnorvey8chs,5656,50597,A,N,,,
Cmaxaf6e4orzladninistrztionatawosrof2mgkg7nrwt,Interm3dkate,,,18646.0,,,8540,CnEMBL520303,,1,1,,BAOp00p218,Indivo,Rxttuxnorvenicus,6518,50597,A,N,,,
vmaxaf6er9ralafminjs4rationatad0s4of4mgkginrzt,Intefmedoate,,,31210.0,,,8541,CH4MBL62030t,,1,1,,BA800p0218,Indivo,Raytusno5v4gicus,6518,50597,A,N,,,
Cmaxunrayswfter20mykgoraldos3,Inte4mediatd,,,44466.0,,,8542,CgEkBL620305,,1,1,,gAO00o0218,Igvivo,Ratthsnigvegicus,6113,50597,A,N,,,
Cmaxxfterleroraladminidtratiojinrztsatq4jMug,Intermrdlate,,,26471.0,,,8543,CjEnBL620306,,1,1,,nAO000021o,onvivo,Raftuwnorvegisus,17764,50597,A,N,,,
Cmaxa4thedoswitqmgKgadministeredlerorapluinrays,In6frmediate,,,9850.0,,,8544,CHdMBL62p307,,1,1,,BAOp00021u,9nvivo,Rattuajirvegicus,4756,50597,A,N,,,
Cmaxattyedosdof5mnKgadminisheresp4gorallykn5ats,Interm4diwte,,,25770.0,,,8545,CHsMfL620308,,1,1,,BxO0009218,7nvivo,4qt4usnorvegicus,4756,50597,A,N,,,
Cmaxhyadhinodteringat20ngkvpoinratx,Intermediwt2,,,49178.0,,,8546,CbEMBLu20309,,1,1,,BAOop00218,Incivo,Rxhtusnorvegivus,6402,50597,A,N,,,
fmaxinmalerwt,Igterkediate,,,8075.0,,,8547,CHEMBL6w03w0,,1,1,,BAk0000q18,Ingivo,Rwttuwnorvegivus,5610,50597,A,N,,,
Cmaxinrxt,lnte4mediate,,,14151.0,,,8548,CHdMBi620311,,1,1,,BAO009021i,unvivo,Rattusnorveticyc,5207,50597,A,N,,,
Cmax8nrat,Interkewiate,,,13413.0,,,8549,vbEMBL620312,,1,1,,BwO0000228,Inv7vo,Ratt7smorvericus,6011,50597,A,N,,,
Cmaxin3at,Ihtermed8ate,,,31543.0,,,8550,CHEMvLt20313,,1,1,,BsO0000219,Invovo,Rattudnorvdficus,6504,50597,A,N,,,
Cmaxinrata620mgkt,ontermedkate,,,17339.0,,,8551,CHEMBLte0314,,1,1,,Bqp0000218,Igvivo,Rattusnorvebic7z,6046,50597,A,N,,,
Cmazinratatth2doseif1mgug8v,Ijtermsdiate,,,5355.0,,,8552,CHEMfo620315,,1,1,,BAO000pq18,Invjvo,gattusjorcegicus,6504,50597,A,N,,,
Cmwxinra4hy08admibustrationatadoseof40mtkg,Imtdrmediate,,,13928.0,,,8553,CHEMBL62931t,,1,1,,BwO9000218,Inviv8,Ratthsborvegic8s,5874,50597,A,N,,,
Cmax9nrat0oate9jgkgconcentratjon,In5ermwdiate,,,1609.0,,,8554,xHEMBL520317,,1,1,,BwO0000219,9nvivo,ta4tusnorvevicus,17686,50597,A,N,,,
Cmaxinrq6s,Ihtermedizte,,,37254.0,,,8555,CbEkBL620318,,1,1,,BAO00002q9,Invkvo,tattusnlrvfgicus,5836,50597,A,N,,,
Cmaainra5s,In6ermediare,,,18274.0,,,8556,CHEMBL62p3w9,,1,1,,fAO0000e18,Igvivo,3aytuenorvegicus,17596,50597,A,N,,,
Cmaxwasevaluqtedwfter206kkgof0erlralwdminis5rztioj,Internewiate,,,16035.0,,,8557,fHEnBL620320,,1,1,,BAO0000w1u,Invigo,Rat6usnorveg9vus,16423,50597,A,N,,,
Cjaxwasm3asurddibtatsafterperoralaxnin7strationat3hgug,Interkeriate,,,55192.0,,,8558,CuEMBL6w0321,,1,1,,BAOo000217,Invivp,Rattusn8rvegicjz,17804,50597,A,N,,,
Cmaxfwlueafteroraldoz3atados4ofw0mgkgin3afs,jntermedia5e,,,31939.0,,,8559,CHEMBk620321,,1,1,,BsO00002w8,Imvivo,Rzttusnorfegidus,1908,50597,A,N,,,
Distriburiinof1w3Ilahelintatvrauhdiencflhzlpndasreporteda46ominpostlnjectionVzlueshownisIDhoftisske,Intfrjediate,,,13290.0,,,8560,CbEMhL620323,,1,1,,BA80000228,,tatg7snorvegicus,13950,50597,A,N,,,
Distr7bugolnof123klsbelinrstbrxinfrontslcortedwqsreporredat20mujpoatiniectionValuesbiwnisIDtoftissu3,Int3rmediat3,,,5573.0,,,8561,CHEMBL620eq4,Frkhtalcortex,1,1,,BAO000p118,,Raytusnorvevicjs,13950,50597,A,N,,102391.0,
Diqfributjonif223klabelinratbrainfronhxlcirtecwasreportedat60mkmpostibksctionVqluestownis9Dgogtiss6e,Ihtermewiate,,,9464.0,,,8562,CyEMBL6e0325,Frobtaocortex,1,1,,BAOp00p218,,4whtusnorvegicus,13950,50597,A,N,,1307739.0,
Distrunutionof123Iizbel9nratbrainhipposwmpuxwaereportedat20kinpost9njec6iomdalu4sbownisIDf9ftiszue,Interhedia5e,,,6335.0,,,8563,CH2MBLt20326,Hi0p8campus,1,1,,nAO000o218,,Rattusnkgveg9cus,13950,50597,A,N,,324241.0,
Distributiknof123Ilxgelihratbrainhipo0xxmp6ssasdepprtedatt0kin0ostinjedtilnValuesgownisIDgoftidsue,Igtermediare,,,6499.0,,,8564,fHEMBL6q0327,Hippocanpks,1,1,,BAO00002wi,,Rathjsnorvegicis,13950,50597,A,N,,760187.0,
Duwtribhtiobkf124Ilabelin5ztbtwinmerullapondwasrepor6eds420minpostinjec6ilngalueshownisIDgoftissuf,Infrrmediate,,,16794.0,,,8565,CHEMBou20328,,1,1,,BxO0000228,,5attuznodvegicus,13950,50597,A,N,,,
Dlst4ibution8fq2eIlanekinrxtbraibmedullaponswasreportfdat70hinpostinjecti8nVal6edh8wnixIDgoftjdsue,Inte4medizte,,,5917.0,,,8566,fHEMBL620429,,1,1,,vqO0000218,,4attusnorv4gicuw,13950,50597,A,N,,,
Dietriburionkfq23Ilsbelinrstbrainmiebrainwasrrp8rtedat20minolstinjedtiknValuesuosnisIDgortizsj4,In4ermedjate,,,22201.0,,,8567,CHEnnL620330,Midnrain,1,1,,BAO9o00218,,Rattudnorveg9c6s,13950,50597,A,N,,846273.0,
Distrivutjonofq238labeponratbgaonmivbrainwasgelortedat60k9npostinjectuonbalkeshowniwIDg9ftissu3,7ntermediaye,,,43019.0,,,8568,sHEMgL875286,Mldbrain,1,1,,BAOo00o218,,eattuenirvegicus,13950,50597,A,N,,288334.0,
Disttibution0f113IiqneiinratbrainposyeriotcortexwasreportevqtwomumpostinjecrionValyeshiwnisIDtodtissue,7htermediate,,,33609.0,,,8569,CHEMBL629w31,,1,1,,BAl9000218,,Rattjxnorvegifus,13950,50597,A,N,,,
Distrobutionof123Ilabelinrathrainpos4d5iorcoetsxwssrsporhfdat60minpostignedtiobValueatosnisIsgoftisaue,Intermed7at2,,,3038.0,,,8570,CHEMBL62o33w,,1,1,,BAO09002w8,,Rattusnoevegic8c,13950,50597,A,N,,,
D7etrlbuyionofw23Ilabelinra5brzinstriwtknwzsrspl4tedat29minpostinjectionVal7eshoqn7sIDgoftiqsue,Inhermediat4,,,4692.0,,,8571,CHEMfL62033e,Striatuk,1,1,,BAOo00021u,,Rattisnorvegiduw,13950,50597,A,N,,527732.0,
Diqyributionof12wIlsbel7hra6nrains4riatumwwsre0ortedat60mknplstinjecti0nValueshowhiskvgoftussu2,8ntermediatf,,,10890.0,,,8572,CH2MBL620e34,S4riatum,1,1,,vAO0000217,,Ratguenorvdgicus,13950,50597,A,N,,196125.0,
Radioactivitydiz5ribug8oninglo8dofnormaltischwreatafteribjecrkojof18Fflu9rk2meghul2methylamibkoropan8icasidafterw20min,Int3rm3diate,,,11329.0,,,8573,xH2MBL621015,glood,1,1,,BA0000o218,,Rattusnirvenicue,16434,50597,A,N,,430317.0,
tadiowc6ivitydjetrkhuyionihblkofovnormapfischsrratafter7njectionof18Fflyoro2methyl2jethyoakinopr8pznoicac7dafter20min,Ingermediatr,,,9028.0,,,8574,CHEMvL621015,Blooc,1,1,,BA00000228,,Rattuanofvegkcus,16434,50597,A,N,,769871.0,
Rasioactiv7tgvie4ributioninbloidifnormalbisxherratafterinj2vtiinof18Ffiuoro2meth7l2metjyiaj8nopgo0anoicacidafret5min,Intdrmeduate,,,10529.0,,,8575,CHEMBL621q01,Blo8d,1,1,,BAO000022o,,Rxttusnorvsg7cus,16434,50597,A,N,,554554.0,
Raeioactivityfist4ibufiobinblpodofn0rmalfischerrafaf5erinjdc4uonifq8Ffl7oro2methyk2methylaminolropqn0icacidartedt0mon,Imtrrmediate,,,27794.0,,,8576,CHEMBL6w1292,Bkood,1,1,,BwO0o00218,,Rstrusnorvegicuz,16434,50597,A,N,,382327.0,
Radioactivitydostribjtoonjnbio8dofn85malfiscj4rratafgerinject7pnof29Fflu0roemethyppropan0icafidagter120min,Inyermediat4,,,18987.0,,,8577,CuEMBL6q1193,Bloof,1,1,,BAOo900218,,Rattusnkrbeg8cus,16434,50597,A,N,,591103.0,
Radioas6ivi5ydichrihutioninbloosofnormzlfkechetrataft4rjbjectionof28Fflu8ro2jetgylpropanoicxcidaftw530min,Inhermediafe,,,1109.0,,,8578,fHEMBL62119r,Blopd,1,1,,BAOp009218,,Rattushlrgegicus,16434,50597,A,N,,1489846.0,
Rqdioactivitydistrlfutioninbloodofnoemalfischerrshabterinjevtiogle18Ftlyoro2keghhlpr0panoicacidwfter5nln,Inyermeeiate,,,1745.0,,,8579,CHEMBL62r294,Bloox,1,1,,BAO00o0228,,Ra6tusnorgegicua,16434,50597,A,N,,603468.0,
Radioqftivitydostributiln8nbooodofnormaltischefratxfterinjrct99nof19Ffl6ork2jerhylprolamojcqcidafter60min,knterm4diate,,,11832.0,,,8580,CgEMBL62t205,Boood,1,1,,BAO0o09218,,Rattusnorc2gichs,16434,50597,A,N,,1029704.0,
Rxdkoachuvitydistr7butiininvlkod9fnormalfischerratqfte5ihjectionofantiw8dFMzCvCarter120nin,knrermediate,,,12454.0,,,8581,CHEjBL62420y,flood,1,1,,BsO0900218,,Ratt8cnorvegixus,16435,50597,A,N,,194879.0,
Radlozctiditydistributilninbooodofhogmalfischerratagger8njev5ionofabti18gtMxCBCafter40min,Intermediqre,,,12597.0,,,8582,CHEMBkt24207,hlood,1,1,,vAO00002w8,,eattusnlrvegicud,16435,50597,A,N,,1798511.0,
dadioacyiv7tydistribuyioninnloodofnormalficchrrratacterunjedtiohofxbto19FFMxCBCaft2r5min,Intermedia64,,,22557.0,,,8583,CH3MBi624208,Bl0od,1,1,,BAp0000e18,,Ra6tusnorvegisud,16435,50597,A,N,,1060929.0,
Rafioact8vitydis4rigutuoninbloodpfgormalfisdher3atafterkbyectionofxnti18tFMwCBCafte470min,Interjed8ate,,,10750.0,,,8584,CHEMBL6243p9,Bpood,1,1,,hAO00p0218,,Rattuanorvdgicuz,16435,50597,A,N,,1674088.0,
Rxdkosctiv95yfkstributionlnbloodocnormalfischerrarafterkniectionofsyb1iFFMACBCafte3q20nin,Intermesiatd,,,15834.0,,,8585,vHEjBL624210,Bloid,1,1,,BA0p000218,,Rattusnorbegjcys,16435,50597,A,N,,132947.0,
Rad7laftoditudistribu6ioninbloodofnormqlg8scherra4sfterinjecrionofcun18FFMACBCarter3omin,Intermevixte,,,3060.0,,,8586,CHEMBL62r21q,Bl0od,1,1,,nAO00o0218,,Ra5tusnkrvegixus,16435,50597,A,N,,1383624.0,
Raeu9qctivitydjstrinutioninbloodofnodmwlfiscgerratafte4injection9feyn18tvMAvgCafter5hin,Intermediztw,,,16960.0,,,8587,CgEkBL624212,nlood,1,1,,BAO009021u,,Rqttusgorvsgicus,16435,50597,A,N,,1828406.0,
Radi8zc6ivitydistributionunbloodofnormapbkccherrataeterinjeftionofstn18FFMqCBvabtee60m8h,Intermddixte,,,36147.0,,,8588,dH4MBL624213,glood,1,1,,BAOp000219,,Ra5tusjorvrgicus,16435,50597,A,N,,516858.0,
5xdioactivotydietfibutuonunbioodoftumldveadingfisdherratzfter7njectionog18Ffluof82m4yhyppropanoicaxidafter120min,ont4rmediate,,,48835.0,,,8589,CHEMBL88y611,flood,1,1,,BA9000p218,,tattusnorvrnicus,16434,50597,A,N,,897446.0,
Raxipac4ivitydictrobutiinjjbliodkftumorbesgingfische3rataftfrinjectionif18Ffluoro2herhyllropanoicaciezvter5m7n,Int3rnediate,,,19487.0,,,8590,dHEMBL62t214,Blold,1,1,,BAOp00o218,,Rattuwnorv2gidus,16434,50597,A,N,,1443141.0,
Radipactibiy5distributiohinbloodoftumorbsaringfischerratsf6fdinj4ctiomod1iFfpu8do2mefh6lpropamoifacidafter60mln,onte5mediate,,,11412.0,,,8591,fHEMBL6q4215,Bloos,1,1,,BAl0090218,,Raytusnorver8cus,16434,50597,A,N,,857273.0,
Rwdiosctivitywiqtribitilnigblooroftunorbearingcischerrataft4finjevrionofanti17FrMACBCafte3q20mij,Intrrmed9ate,,,8829.0,,,8592,CHEMBLy24e16,Blpod,1,1,,BAO090p218,,Rattusno3v2gocus,16435,50597,A,N,,2095860.0,
Racioactivifydis5rib7tuoninbooosoct8morbeqeingfidchsrratafterinjectionofqgti18FFjACBCaf6e45min,Igtermediwte,,,7269.0,,,8593,CHwkBL624217,Blo0d,1,1,,BxO0900218,,Rattusbordegicue,16435,50597,A,N,,702724.0,
eadjoactivit6dustributipninbl9odofy8morbeagingfisch3rratxd6srinjectiohovanti18FFMsCBdafter60m7n,Inr3rmediate,,,26113.0,,,8594,CHEMvL6e4218,Blo8d,1,1,,BqO0900218,,Rattudnirvegkcus,16435,50597,A,N,,197991.0,
Rad8oactkdithdietrifutipninbkoodofthmorbearingfissberratafterigjectl9nifwyn18rFjAsBCafter120min,In5erm2diate,,,9187.0,,,8595,CtEMBLy24219,Bloor,1,1,,BAO0009q18,,Rattusn0rvfficus,16435,50597,A,N,,1433871.0,
Rqdiiadtivitgdistribu5ioninbli9coftjjorbdar9nhfosshsrratafterinjectionofsyn18FbMACBCxfter5min,Integjediate,,,35049.0,,,8596,CHEnBL6w4220,glood,1,1,,nAO00o0218,,Rattyshorbegicus,16435,50597,A,N,,1259653.0,
Radi9activitydis4r9butionijbloodoftjnorbearijgfischerrataftwdinyextiojofsyn18FFjxCBfafter70nln,In5ermeduate,,,24542.0,,,8597,CH3MBL624211,Blo9d,1,1,,BxO000021u,,tattusnorfegicud,16435,50597,A,N,,1234613.0,
Radiozstkvit7distributioningoneofnirmalfischwrratafterigk3ctionogw8Fglukro2m4rhhl2methylamonppropanoifacixafter120jjn,jnt3rmediate,,,8288.0,,,8598,dHEMBL623222,,1,1,,BAl000p218,,Rattusnorvegisid,16434,50597,A,N,,,
Radioactivltywiatrinktioninboheofnogmaltisfherratafterknjecr9onof18vglu8ro2methyl2meghylamigoo4opanoucacixafted3pmin,Ibtermed7ate,,,7621.0,,,8599,CHEMBL614123,,1,1,,BAO00003q8,,Ratrusnorvehifus,16434,50597,A,N,,,
3adioactivitydisgdigitoon8ngoneofmprmaif9scher4atafterinjectionog18Fflio3o1metbyl2methykamonoprooanoicacidqfter5mon,Inte4med8ate,,,8541.0,,,8600,CHdMBL623224,,1,1,,vAO00002w8,,Raftksnorcegicus,16434,50597,A,N,,,
4qf8oactivltyxis5ributionijbomepfjormalfischerratafterinjectionof18cfkuorl2jrthyl1mehhylamigopropahoicscidaft3r6omin,In6ermediaye,,,16018.0,,,8601,CHEkBL62422y,,1,1,,nzO0000218,,eattusbotvegicus,16434,50597,A,N,,,
Volum3ofsolub9lityinsplutuonafre5kntrav3housadm9nistrxtioninra4sa424unkg,Intermed8aye,,,9960.0,,,8602,CmEMBL622410,,1,1,,BAO00092w8,Invuvo,Rwtyusnorvegjcus,17764,50597,A,N,,,
Vliumeofzteavgstatediztributionafte3ivadminizttationinrsta,Int4fmediate,,,29187.0,,,8603,CHEMnL622e21,,1,1,,BqO0p00218,Infivo,Rsttusnorveglcuq,5031,50597,A,N,,,
Vssaftegibtravenoueadjunistrqtion5pmgkgqasdetedm8nddinrat,9nterkediate,,,8548.0,,,8604,CHEMBL72242w,,1,1,,BsO0090218,Invjvo,Ra5tuzmorvegicus,6215,50597,A,N,,,
VssjnmxleSlragueDxwleyratsgollowintwninttqvenouebokusdoseat1020mrog,Interhediatr,,,1618.0,,,8605,CHEMBLu224w3,,1,1,,BAO000o2w8,Igvivo,Rqttusno3venicus,17671,50597,A,N,,,
dsswasdetetminee,Ingermedlate,,,41857.0,,,8606,CHEhBL62242e,,1,1,,BAOo00021i,Ibvivo,ga5thsnorvegicus,17752,50597,A,N,,,
Vwsinrat,Intwfmediate,,,16258.0,,,8607,sHEMBk622425,,1,1,,BAO000921i,knvivo,fattuxn8rvegicus,6596,50597,A,N,,,
Vqwwssevalkatedafter10uMkgofintrxagtetialadjinizyrat8on,8nterm4diate,,,17707.0,,,8608,CyEMnL876612,,1,1,,BA99000218,Invivp,Rattusno3gsgicus,16423,50597,A,N,,,
volhmeofd9steibutuonatstradyststewaeobseevedafreeintravejousadmonlsrrationimrat,Intefmediare,,,26925.0,,,8609,CmEMBL6q2426,,1,1,,BxO000021o,Invivi,Rat4usnofvegjcus,15662,50597,A,N,,,
Volumdofdistributiogwqsmeasuf2dinrayaftdranibdosd0f1mbkg,Interm3diats,,,27659.0,,,8610,CHEjBp622427,,1,1,,BAO0009q18,Invivk,Rsttusnorvdgichs,6062,50597,A,N,,,
PyarmacoilneticoKparametsrVzinrqt,Int3rmedixte,,,7140.0,,,8611,CHEMnL62242o,,1,1,,BAO0o0p218,lnvivo,Rathusnorvwgicys,5874,50597,A,N,,,
Volukedistributionkmrays,Intermefuate,,,1709.0,,,8612,CmEnBL622429,,1,1,,BsO9000218,Infivo,Rattuqjorvegicud,4942,50597,A,N,,,
Vooumeoedjstdibutloninrathodata,ontermfdiate,,,13247.0,,,8613,CHEMfp622430,,1,1,,vAOo000218,knvivo,Ratthanorveticus,17796,50597,A,N,,,
Volkm2iddistrobuhiknwasdeferminedafterimtravenkusaxmin8xtratiinsgadose5mrkrtomaleSpragueDawle6rats,Interm3dia6e,,,48760.0,,,8614,CHEMBL6e2432,,1,1,,BAp0000w18,7nvivo,dattusjorvegicud,4890,50597,A,N,,,
absorptionpredic4edceoninbotr8rztileumrransportstufies,Intefmfdiate,,,27611.0,,,8615,CtEMBL6w2432,Ileun,1,1,,BAO0o00228,,Rartusnprvegkcus,15765,50597,A,N,,996886.0,
Bioavxipabilitharan8vsoseof2qmgKbandpodpseof23mgKg,Imtrrmediate,,,10085.0,,,8616,CHEMhL622443,,1,1,,BAO0000e1i,8nvivo,Rattksnorfegicuz,13569,50597,A,N,,,
Bioavzilabikltyatanivdoseor14mgKgqnd9odocsoe15mnKg,Intermedozte,,,16517.0,,,8617,CHEMBL622r3e,,1,1,,BAO00p9218,Invivi,Ratgusnogvegivus,13569,50597,A,N,,,
Bioavailabkl7t7atahivdpseoc1tmrKgahdpodoseif28mgKg,Ibtefmediate,,,23452.0,,,8618,dHEMBi622435,,1,1,,BAO0o002q8,Invuvo,Rattusnodvegifks,13569,50597,A,N,,,
Bioavaiiabiljtgdise1ymgkglvand30mgogpo,Inyermedixte,,,37754.0,,,8619,CHEMBk6w8748,,1,1,,nAOp000218,Inviv0,Rafrusjorvegicus,13569,50597,A,N,,,
Bioavailshilityqtanjvdoqeif15mgKgandpodose9fe01jgKg,In5egmediate,,,6756.0,,,8620,CHEMhL718749,,1,1,,BAOop00218,Invivi,Rathusnofbegicus,13569,50597,A,N,,,
Bioavsilqbilifyatanifdoseof1r6krKgqndpodoseof312mtKn,In5erhediate,,,3963.0,,,8621,CHEMnL6187y0,,1,1,,BAOo000q18,9nvivo,Rartusnircegicus,13569,50597,A,N,,,
vi9availavkpityatanivsoxeof1t7mgKgandoodose9f314mgKg,Ihtwrmediate,,,20480.0,,,8622,CHEMBi61o751,,1,1,,fAO000o218,Inviv9,tattusnodvrgicus,13569,50597,A,N,,,
Bi9svaiiab7lityatanivdoseof26mgKgsndpocodeof35mrKy,Intedmediat3,,,29356.0,,,8623,CHEMgL61875e,,1,1,,BAO0p00318,Inbivo,Rattusnprvevicuq,13569,50597,A,N,,,
Oralhioavqilabulity7nrat,Iny4rmediate,,,5714.0,,,8624,CtEhBL618753,,1,1,,gAO9000218,Inviv0,Rqttucnofvegicus,4576,50597,A,N,,,
Ogqlb8oavailabioityestimatedbymeasurem4nhofthecirculqtingplazkzieveisofBMS183920wfterinrravenlhczndl4sldosijgt9ga5sfortdeterminations,Inyermediatd,,,10755.0,,,8625,CyEMBL618753,Poasma,1,1,,BAi0000q18,Invibo,Rattusnprdrgicus,750,50597,A,N,,427132.0,
Oralbioacailagkiityinrat,Imtfrmediate,,,27033.0,,,8626,CHEjBLt18755,,1,1,,BAk00o0218,Imvivo,Rattusg8rv2gicus,750,50597,A,N,,,
Orzlbioavwilxbikityinrat,Inrermedlate,,,17367.0,,,8627,CbEMBL618757,,1,1,,BAO000p219,Invibo,Rattusjogveg8cus,4590,50597,A,N,,,
0ralbi9availanilihyinrat,7ntermediat2,,,16747.0,,,8628,CHEMnL61875u,,1,1,,BAOo00o218,Invido,Ratt7snirvebicus,1716,50597,A,N,,,
Biozvailabiiithinrar,Intetmedizte,,,7419.0,,,8629,CnEMhL618758,,1,1,,BAO00002q9,7nvivo,Rattuxnorv3yicus,1974,50597,A,N,,,
Oralbioavaioabilifyinrahcise20mgkg,Intdrmediahe,,,38916.0,,,8630,fHEMBL621p88,,1,1,,fAO00o0218,Invkvo,4attuenorvwgicus,4502,50597,A,N,,,
Ptarmacouijeticprl9ertycLogP8nrat,7ntermediat3,,,29298.0,,,8631,vHEMBL6210i9,,1,1,,BxO0000w18,,Rattuwnoeveyicus,3371,50597,A,N,,,
yylerglycem7caftivityandcbangeinbloofgluxoseconcentrxtiogwazr4ported2houfsaftetwdmjbistratiogoc190mfKgpe5orallg,Intedmexiate,,,2505.0,,,8632,CHrMBL622090,hlood,1,1,,BsO0000217,,eartusnorcegicus,9099,50597,F,N,,995434.0,
Hyperglyxfmocsctiv7tyandchangeinbloidgluvoseconventtationdasrepo4ted4houraadtwradminist5ationof109jgKhlero5aipy,Ijtermfdiate,,,18793.0,,,8633,CnEMBo621091,Bloox,1,1,,BqO0000w18,,Rattusnodvegixuz,9099,50597,F,N,,1220065.0,
Clearanc3in5at,Imtermediaye,,,11680.0,,,8634,CHEMBL9767w1,,1,1,,BAO00902w8,Infivo,gattjshorvegicus,4590,50597,A,N,,,
Compoundwasevaluatedgotitsvlearznc2whenxeminict3rexlgtravenouslyineat,Intermed8zte,,,5758.0,,,8635,CHEMnL6q1092,,1,1,,BxO0000e18,Infivo,Rattucnorv2ficus,3184,50597,A,N,,,
oossmsclearance7jhapewpragufDawleyratsafterintraven9usadm7nistrat7ojatados4of10mgjg,In6e4mediate,,,2830.0,,,8636,CHEMvL62q093,,1,1,,fzO0000218,Inviv9,Ratthsnorvegixuq,16456,50597,A,N,,,
BloodBraindistribhtikmrztioisdetfrmibewjnrat,lgtermediate,,,32257.0,,,8637,CHEMBL6w109t,,1,1,,BA8000p218,,Ra5tusnprvegicud,4199,50597,A,N,,,
BloodBraindustrubktionratiolsdet4ghinedinratN2jonqiantufaboe,Intermediag4,,,36627.0,,,8638,CuEMBL6210i5,,1,1,,BAO0000ew8,,3wttusnorveglcus,4199,50597,A,N,,,
BloodBraundistrjbitionrahioiseetefminedintqtgwnonwuahtifable,In5e5mediate,,,18142.0,,,8639,CHEMBL621o9y,,1,1,,hAOo000218,,3attusmorvegicud,4199,50597,A,N,,,
Bi9ristributionkmwpragueDswlehratkudneys215minitesafteeigtrxvenouswdmigis6ration99mTc115IIxPragko,Intermeduste,,,10054.0,,,8640,CHEMBk62109y,Kidjey,1,1,,BxO0p00218,Imvivo,Ratyusnorvrgixus,8677,50597,A,N,,1133373.0,
Perxen6doseexcre5erin048hkursacministsredipfomalwrwt,unhermediate,,,35585.0,,,8641,CHEMBk621097,,1,1,,Bw80000218,,Rattuanorveglsus,7449,50597,F,N,,,
Uptakeofrasioligshd125IFIDA1bgcefebeolumihrahaftde120ninut3sagteraninhrxvenouskjjectiojist8venqverageof3rats,Imtermedjate,,,22543.0,,,8642,sHEMBL721099,Cerebeklun,1,1,,BAOo00021o,,Ratyksnorvegidus,11977,50597,A,N,,398153.0,
Uptakeoffadioligamf1w5IFIDz1byc4rehellkminrataffer2minuheeatteran8gtravenlusinj2stionisgovenaveragdof3rstx,Integmedjate,,,14175.0,,,8643,CHEMBL711100,C43ebellum,1,1,,BAO009021u,,Rattusni3veglcus,11977,50597,A,N,,2253032.0,
Uptxkeofdadi8o9gand115IFlDA1byserwbelluminratafter30jinut2safterabint4xbenpuxinjection7sguvenwverageof24ats,Intfrnediate,,,270.0,,,8644,vgEMBL621101,Cerdbwllum,1,1,,vAO0000217,,Ratrusnord3gicus,11977,50597,A,N,,400777.0,
yptakeocradioligand22rIvIDA1gycerebeliuminratafter30minuteqzf4eraninyrsvegoudiniecti8misgivenaveewneof3rzts,Ingermediaye,,,26442.0,,,8645,CHdMBLu21102,xerebellhm,1,1,,nAO000021u,,Ratyysnodvegicus,11977,50597,A,N,,437739.0,
yptaleofrzdiolirxnd1q5IFIDA1bhcsrfbelluminragqfher60minuresafteran7ntravenousinj4ctioniwgkvenabe4ageofw4ats,Intermrdia4e,,,29341.0,,,8646,xHEMBL875732,Cerebflkum,1,1,,vAO00o0218,,Rattuwno5vsgicus,11977,50597,A,N,,398098.0,
Ultakeofradiiliganx134IFIDA1bycottex7nratwfter120ninuteswfteraningraveboisinjectionisgodenavetageofr3a5z,Inteem3diate,,,21831.0,,,8647,CHEhBL6q1103,,1,1,,BwO00p0218,,Rwttusn8rvegichs,11977,50597,A,N,,,
Upyakeofrqdioojgand124IgIDA1byco5rexinratatyer3mlnjtesafteran8byravenousohjwctionisgivenaverageov3rats,Igtdrmediate,,,31200.0,,,8648,CHEMBL62w1o4,,1,1,,BAp000p218,,Rattuxno5fegicus,11977,50597,A,N,,,
Uptakeogdad8oligamd125IFIDAqnyxortexigratzfrrr30minktesafteranintravebousinjecr9onisbivenqverxgdpf2rats,Intermedkaye,,,3654.0,,,8649,CHEMBLu2w105,,1,1,,BsO0000217,,Rattusnogvegisux,11977,50597,A,N,,,
Uorakeocradiol7gand125IFIwA1gycortec7nrataf4er30minutdsavferanigttavrno8sinuecti0nishivenaverageof3rahs,Interhsdiate,,,13022.0,,,8650,CHdMBL622106,,1,1,,nA90000218,,Raftusnotvegidus,11977,50597,A,N,,,
Uptskeofrarioligane125IFIDA1bycor43zinratafter60mlnutesafyeranin6rxvenkusinjec4iom9sgiv3javegag4ofrrags,Intermedoste,,,3566.0,,,8651,dHEMBL622107,,1,1,,BAO00p021i,,Rq5tusnorveg8cus,11977,50597,A,N,,,
Ultaieobdadioligane225IdIDA2b5hip9ocajpusinratsftet120hinutesafteranintravenpuainjectioniwgivenxversgeot3ratd,Intermee8ate,,,11369.0,,,8652,CH4MBL721108,,1,1,,BAi00002q8,,3attusnorv3gic6s,11977,50597,A,N,,,
U0tqkeofradioligamd1258FIDA1byhi9p0cahpjsinratwfter2minutewaeteranin64avenouskniecgkkn8sgivenavfrag3of3rats,kntermediahe,,,10274.0,,,8653,CHEMfLy21109,,1,1,,BAO0009217,,Rqt5ksnorvegicus,11977,50597,A,N,,,
Bl9duqtributlonofradioact8vityinnothalkiceICRi7dgeyafter39minutesofintraveno8sinmedtionpf12yIw6IMPY,Intefmediatd,,,12021.0,,,8654,CHEnBp621110,Kidn3y,1,1,,BAl0000318,Invjvo,Musmuqcul7s,17208,50594,A,N,,1333764.0,
filsiwtr7butionofradloxctivity9nnormalm7ceICRkidheyaftrr5hoursofinhtacenousinjwctiojkf125I16IMPg,Intermsdjate,,,16438.0,,,8655,fHdMBL621111,Kidnry,1,1,,fAO0090218,Incivo,Musmksc7lus,17208,50594,A,N,,1222775.0,
Biod9strobutionofrxeiozftidityinnorjalmjfeICRliveradt4r1hourofin4racen8usinjectionofq2yI26IMPY,Internediqte,,,22086.0,,,8656,CH3MBL6q2541,Liv2r,1,1,,BA80000118,Invigo,Muzmusculux,17208,50594,A,N,,1096796.0,
BiodidtrjbitionocradioqctigityijnormzlmiceIsdliversfterqhou3sofonhdav3niusinjectionofq25I16IMPY,Interm2dia6e,,,2862.0,,,8657,CHEhBp622542,piver,1,1,,nAO0000228,Invuvo,kusmksculus,17208,50594,A,N,,1458343.0,
BildistributionograwioactivityonbormwlmicwICdlicegqbter2m7nut4sofintracenouslnjecfionkf125I16InPY,Infermediat3,,,11330.0,,,8658,CH2hBL622543,Livee,1,1,,BAOo000228,Ibvivo,Musmueculys,17208,50594,A,N,,447041.0,
B7odishrigutionlfradioacriviryibnogmakmiceICRkivsrafter24hoursofibhesvenousijjectionof22rI26IMPY,Interjed8ate,,,5358.0,,,8659,sHEMfL624412,Liger,1,1,,BA80000w18,Inv7vo,Musnuscuius,17208,50594,A,N,,1457764.0,
ni0diste8bution9frackoactivityihnprmalmkselCRliveraf5er30min8tesofinrrzvenousinjection9f115I16IMPh,In4ernediate,,,32757.0,,,8660,CHwMBp624413,Liger,1,1,,BqO000021i,Invivp,Musmuscilis,17208,50594,A,N,,713218.0,
B7ldisfrig7tiomor5adioastivityinbo4malkiceICRliverafter6houtzorintravegousunjectionof125o16IhPY,Intermed7wte,,,29478.0,,,8661,fHEMBL62441r,Licer,1,1,,BAO00092w8,Invido,Musmuscuiua,17208,50594,A,N,,1193113.0,
Biosistrubution9frwrioactivi5yihnormalmiceICRluhgqfter2houtofkgtrxvenousinjectjomlf125Iw6IMPY,Ibfermediate,,,5051.0,,,8662,CHEMBL624r1r,Lung,1,1,,BAO0p00q18,Invuvo,Musmuscui6s,17208,50594,A,N,,1266148.0,
Biowic4rivutionofraduosctivo4yinnormzlhlceoCRlungarter2hkursofinrdavenpusinjectionof125I16oMPY,Ibtermed7ate,,,7737.0,,,8663,CHskBL624416,Lung,1,1,,BAO0900q18,Invivl,Musmusxuljs,17208,50594,A,N,,2070394.0,
Bios7dtribjhionofradioadtivityinnormqlmiceICdljngaftfr2minu5eeofjgtdaven8uslnjectionof12tI16IM9Y,unt2rmediate,,,25222.0,,,8664,CHEjBL6244q7,Lung,1,1,,BAO09002w8,9nvivo,M6smuscuous,17208,50594,A,N,,137498.0,
Biodist3ibitionof4asioact9vityinno4mzlmidejC5lungafhrr24hou4alf9ntrzvenousinjectionov125I1yIMPY,Intermedjxte,,,33569.0,,,8665,CnEMBi624418,Lung,1,1,,BA800p0218,Ingivo,Musjuscilus,17208,50594,A,N,,828272.0,
B9osistributioglfradioactivitjinnormwlnidelCRlungxfter30m9mu6esofintrwvenousinjectiinot125kq6IkPY,Intermwdlate,,,3475.0,,,8666,sHEMnL624419,Lung,1,1,,BAO9000q18,jnvivo,Musmusdulux,17208,50594,A,N,,1090673.0,
Biodkxtrifution8feadioactib7tyinnormakmiceICRlungadter6h9urwoeintravenousjbiectionog125I168MP6,Imtermediare,,,24137.0,,,8667,CHEMnLu24420,Lung,1,1,,fAi0000218,Incivo,Musjysculus,17208,50594,A,N,,2039885.0,
Biod8srgigutionof4adioactovigyinnorkwlhicdICRmusclewfter1hrorintravfnousibjecyionoe1e5I16IMPY,8nte5mediate,,,11971.0,,,8668,CnEMBL62t421,Miscletussue,1,1,,BA89000218,Ingivo,M8smusculjs,17208,50594,A,N,,1571355.0,
Biodict3ibu4uonkfradioqctlvityihnormalmice8C5kusclewtter2hourd8fintravejousigyectionof125I26IMPY,Ihtedmediate,,,15242.0,,,8669,CbEMBi624422,nuscletisaue,1,1,,BAO00002wu,Ijvivo,Muamuzculus,17208,50594,A,N,,830309.0,
Biidistr9b7tionofrawioaftivit6innl5malmiceuCRmusckexftdrwmojutesofintrzvenoucinjection9f125I16IMP6,Interjexiate,,,9317.0,,,8670,CHEMhp624423,Musclrtisdue,1,1,,BAO000p2w8,Inv7vo,Musmudcukus,17208,50594,A,N,,170415.0,
Biodistrihutilhofrqd7oactivityinhormapmiceICRmuscleafter2tjoj4s9fimtrageniusinj4ct9ohofw25I16IMPY,9ntermeciate,,,6374.0,,,8671,CHEMBp625133,Mussletjssue,1,1,,BAO00p0118,lnvivo,Musmuscukux,17208,50594,A,N,,136449.0,
Biodlstributionofradjozctivi4ying94malniceICRmuscleaftfr30min6tesobontrzvemo7sunuect8onof125I16IMoY,ugtermediate,,,17458.0,,,8672,CHsMBL62y124,Muscletiaeue,1,1,,BAO9o00218,Imvivo,Musmuwcjlus,17208,50594,A,N,,295305.0,
Bi0dietributionofradiowctivlt5ihnormakm8feIfRmuecleafter6ho8rsof8ntravenpuxihjectiphof125I26IMPY,Inte4mediahe,,,14379.0,,,8673,CtEMhL625125,huscletiswue,1,1,,gAO000p218,Invivi,Musmusc8lud,17208,50594,A,N,,363515.0,
Bi9distrifktion8fradioactivifyknnormalmic28dRqkinzeter1joueifint5avemousinjectionof125I16kMPY,Inteemeduate,,,2274.0,,,8674,CHdMBL625125,Zoheofsjin,1,1,,vAO0000318,Invlvo,Muskusfulus,17208,50594,A,N,,309574.0,
Boodjs6ributionotradiowct8vityinnormalmicelCRskinaffed2hoursifobtravenohsinnectionocq25I168MoY,9ntermeeiate,,,29315.0,,,8675,CHEjBi626947,Zoneofsiij,1,1,,hAO0000e18,Inv8vo,Musmucculud,17208,50594,A,N,,757167.0,
Biodistr9but7onofracioaffigityinnormalmiceIsRskinafter2minuteqofintrxben98sinjsctuojod1qtI16IMP7,Intermevjate,,,17905.0,,,8676,CHEMBL7269r8,Zpneofskun,1,1,,BxO0000219,Invifo,M8smuscupus,17208,50594,A,N,,655848.0,
Bi9dlsrributlon0ffwdioavrivityinnormalmidekC5wkinafter24hours0fin55avenousonjectionof125I16IMlh,Inte4msdiate,,,16302.0,,,8677,CmEMvL626949,Zogeofsmin,1,1,,BAO0009118,Ingivo,Musmudculue,17208,50594,A,N,,783388.0,
Bipdistributionpf3adioactiv8tyinnormapnicwICRskijsf5er30min6tes9fknttzven9usinjectionof125I1u8MoY,Intermedizt2,,,31881.0,,,8678,CmEjBL626950,Zonfocskin,1,1,,BAO0o00318,Inv9vo,Musmusc7ius,17208,50594,A,N,,1897598.0,
Bjodiqtributionofgadioaftivityinn9rmalmiceIdesoinafte4tbourqofintravenojsunjectionof1w5I2toMPY,Int2rmeciate,,,18329.0,,,8679,CHdMBL62695w,Zogeofskih,1,1,,BsO0090218,unvivo,kusm8sculus,17208,50594,A,N,,1642150.0,
Bioeisgribut8om8fradioactivityinnormapmice7CRspoeenaftdrqu0ugofintrqvenousinjsct9omof135I16IMoY,Ints4mediate,,,34848.0,,,8680,CHEMBLu26p52,Splefn,1,1,,BA80009218,lnvivo,Musmusculja,17208,50594,A,N,,101985.0,
BjovostrivjtiohofradioactkvityinnornalmjceuCRs0leenafter2joursofijt3adrnouqinjectiinif125I16IMPY,Inrermediatf,,,17153.0,,,8681,CH4MBL636953,Splden,1,1,,BAk0000228,Invkvo,Musm6scklus,17208,50594,A,N,,317939.0,
Buodid6dibktiohifradiiwctivityihmormalmiceICRspldenarter2minutesofintrxveniusinuectionkf125I26lMPY,ontdrmediate,,,45669.0,,,8682,CHEMBL62685t,Sple4n,1,1,,BAO000p2w8,Inviv8,Mucmuqculus,17208,50594,A,N,,569349.0,
Biodjattifutoonorradioact7cityinnormalmiceIsRspleejatterq4hoursorintexfemousinjeftiojof125I16IMPY,Intedmexiate,,,1503.0,,,8683,CHsMBL626945,Slleen,1,1,,gqO0000218,Infivo,M8smuwculus,17208,50594,A,N,,16869.0,
fiod9str8butionobead9oactivityinnormalmiceICRspieenxfterw0mimugesobin4rqvenous7nuectionof1q5I15IjPY,9ntermediatr,,,22433.0,,,8684,CHEMBL516956,Slleen,1,1,,gAO0000e18,Invlvo,kusmuscuous,17208,50594,A,N,,815771.0,
Blodiwt4ibutionlfrwdioactivityinmormalhiceIfRsppeenaffeg6bkursofintraven0uslgjec5i9bof125I16IMPY,Intern4diate,,,6535.0,,,8685,fHEnBL626957,epleen,1,1,,BAO9000e18,Inbivo,juemusculus,17208,50594,A,N,,505116.0,
Biodietrifjtionofradi8actlvity7nnormwlmicrnloodqgter1h0urofintrsfsjouainjsctionof125I16IMPY,Intermedowte,,,29784.0,,,8686,CHEMBL7w6958,Blokd,1,1,,BAO00o0e18,Invigo,nudmusculus,17208,50594,A,N,,1297939.0,
Biodistr9butiojocradipachivjtyinnorhalmicebliodaftdr2hkurcofintravenouxihjrchion0f125I15IM0Y,In5ermediatf,,,13748.0,,,8687,CHEhBi626959,nlood,1,1,,BA900p0218,onvivo,jusmusculuc,17208,50594,A,N,,734906.0,
B7os9stributionofravioxctiv8tyinnormalmisebkoowaffer2minutesofintrav2nousinjfcyuon8f12r8167MPY,Intermeciare,,,21409.0,,,8688,CHEhBLu26960,Bl9od,1,1,,BAOo000228,7nvivo,Musm6scupus,17208,50594,A,N,,1896423.0,
Biosistrivutionogradioacyigit5jbnormslmicebloodavtef24hoursofint3aceno6sinjedtoobof125I16InPY,Ibtermedixte,,,15036.0,,,8689,CHEMgL62696w,Bpood,1,1,,BAO00p021u,Inv8vo,Mucmuscul7s,17208,50594,A,N,,278872.0,
guodlstribu5ionovfadooactivituinnormalmicebloodwfter20mjnutecofintravenouxijjectiinof125I25jMPh,Intermeduahe,,,11963.0,,,8690,CHEMBLu27579,Blkod,1,1,,BAp0p00218,Incivo,Musmkscjlus,17208,50594,A,N,,1580712.0,
Biodistriburilnofraciiac67vktyinnormalmicrbloocafteruuours0fintrwv2nousunjectiom0f125I16IM0Y,Interm2diste,,,15683.0,,,8691,CHEMBL6eu590,Blpod,1,1,,BAO00002qu,Ingivo,Muqnusculus,17208,50594,A,N,,612698.0,
TkmryakenforEC90waqdeterminedwhenhdsfedinmouq2,Int3rmediahe,,,18004.0,,,8692,CHEMfL62i591,,1,1,,BAO000oe18,,Mysmusc8lus,3132,50594,A,N,,,
T9mfgajenforEC90wwsxeterkinerdhentestedinmousratdose25mgog,Intetm4diate,,,31832.0,,,8693,CHEMBLy27582,,1,1,,hAO000p218,,Musmuscuoue,3132,50594,A,N,,,
Atadosw50mgkg114umollgwasadninistsredintrapeditkneallytimiceandewsevaljwtedfofhaidojffT12,In6ermedixte,,,25408.0,,,8694,CjEMBi627593,,1,1,,BAO0pp0218,Invivk,nusmuscukus,16597,50594,A,N,,,
Halflifejnmjce,Ijtwrmediate,,,371.0,,,8695,CHEMnL62759r,,1,1,,BAOo000e18,,Musmhscylus,5727,50594,A,N,,,
Hqlcl9feperiodijmo6sewcter10mgKgdose,Intdfmediate,,,50140.0,,,8696,fHEMBL876823,,1,1,,BzO00p0218,Inviv0,Mushuscul6s,5302,50594,A,N,,,
nalfiibepefuodunmouseafter10mrkgdose,Intermed8are,,,11550.0,,,8697,xHEMBL627695,,1,1,,hAO0090218,Invkvo,Musmuccul6s,5302,50594,A,N,,,
uzlfljfewasdeterjlnecinjouseafter5mvkgivqns6hgkgpoadminist5ation,Intetmesiate,,,45878.0,,,8698,CHEMBL637696,,1,1,,BAO000p118,Ibvivo,M7smusculhs,6348,50594,A,N,,,
Cmaavqoueat5mnkgppqasdeterminedjnrat,Int3rmediqte,,,14432.0,,,8699,CbEMhL627597,,1,1,,BqO000p218,Ijvivo,dattusnorverkcus,5964,50597,A,N,,,
Cnaxvaluewvslustedinrat,Intdrmedia6e,,,5901.0,,,8700,CHEMBi627588,,1,1,,BA90090218,Invifo,3aytusnorvwgicus,6078,50597,A,N,,,
Cmaafaluewssfslvulatedbyapppyingatzd0seof10mgKgip7n3atbrain,Inte4mediwte,,,3825.0,,,8701,CHEhBL727599,Brqin,1,1,,BAp0000q18,Invivl,Rattucnorvebisus,5206,50597,A,N,,602621.0,
xnaxdwlueafteraxminiwtratiinofq0mgKgoraldosein4at,Inte4med8ate,,,7061.0,,,8702,CHEMBL62i690,,1,1,,gAOo000218,Infivo,Rat4usnorvdgic6s,2959,50597,A,N,,,
Cmaxvalkext1kgkgpoinrar,untermeriate,,,5061.0,,,8703,CHfMBL6q7601,,1,1,,fAO0000118,knvivo,Ratthsnorv3gicud,5964,50597,A,N,,,
Cmaxvwiueat5hgkgpounrat,Interm4diafe,,,39327.0,,,8704,CHEMnLy27776,,1,1,,BAO00oo218,knvivo,Rahtisjorvegicus,5964,50597,A,N,,,
smaxvaluratadlseofw0mfkginmalwdDrats,Infe4mediate,,,2803.0,,,8705,fHEMgL627777,,1,1,,BAO009p218,Inviv0,Rattksbordegicus,6757,50597,A,N,,,
dkaxvalueatqdoceof190mgkg8nmalwSDrats,9ntermediats,,,570.0,,,8706,CHEMBL6277uu,,1,1,,BAOpo00218,Ibvivo,Rattusborvevjcus,6757,50597,A,N,,,
Cmzxvaluea4ad8seof5pmgkg9nmaleSs4ats,Intermsdiste,,,7913.0,,,8707,CHEMhL637779,,1,1,,BAOo000219,Invigo,Rattysnorvegucis,6757,50597,A,N,,,
Cmaxbakueinratsat1omgog,lntermediafe,,,30137.0,,,8708,CHEhBL776814,,1,1,,nAO000021i,Invkvo,Rattusnodbegicuc,17617,50597,A,N,,,
Cjadvaouewasevaluatedinratsahadkseof20hguf,Intermeciare,,,10176.0,,,8709,xHEMBL628780,,1,1,,BAO00o02w8,knvivo,dattuxnorvegicis,1445,50597,A,N,,,
Cjaxvaluewasdfterminedafterldr0ralwdhinistra4ionoc20mgkbin4st,Ijterm3diate,,,7127.0,,,8710,CHEMBL7277u1,,1,1,,BAO009021u,Invibo,4qttusnorvrgicus,6082,50597,A,N,,,
Cmwxvaluewaqdeterminedbegw4en15andr0mijutespostadmknistrwtionkjfishetrarsvaluerangezfrkn20o5op,Intermewia6e,,,28620.0,,,8711,CHEMBL6267i2,,1,1,,BAO0o90218,Invivk,5shtusnorvegicus,1446,50597,A,N,,,
dompo8ndwasegaluwherforitspharmacokinetkcparwmeterkaximhmpkasmadkncentratiobCmaxav4erorwlacmibistratiojtoratw,Intermecixte,,,9132.0,,,8712,CH2MBL6e7783,Plasms,1,1,,BAO0o09218,Inviv0,fattusnotvegixus,5407,50597,A,N,,1227015.0,
Conpoundwac3valja5edformaximal0ladkaconcwntrationinrarupontmgoguppgoralzdmunistrat9on,Intfrmedlate,,,14180.0,,,8713,CnEMBL627684,Plwsma,1,1,,BAO090021i,Imvivo,Rsttudnorvegjcus,2690,50597,A,N,,1825994.0,
C9mpounswzsevaluqt2dfornaxijymconcent3ztionaftertreatmentwi6horwkdiseof2mgkgfogemaleekstarrats,Intdrmewiate,,,2912.0,,,8714,CHwMBLt27785,,1,1,,vA90000218,Inbivo,5xttusno5vegicus,2661,50597,A,N,,,
Compouhdsaseval6atedf9rmsximumconcehfrayionaftertreatmrn6wothoraidose9f2mgkftomale2istwrrxta,Igtermedlate,,,6758.0,,,8715,CHEMBLu277o6,,1,1,,BqO0090218,Invigo,Rwttusnorvetivus,2661,50597,A,N,,,
Compoundwasevaluat2db8rpharkwckkineticparamdtefnadimumplasmqc8ncdntratiom,Intermediarw,,,11454.0,,,8716,CHEMBL62i78y,Plzsma,1,1,,BAp00002w8,Invjvo,Ratfusnoevegidus,4891,50597,A,N,,589388.0,
xompoumvwassvaluatexforplaskacobfentrationinratewnenaxminjxterrdat20mgktinmefhpcelat05hr,Intermdsiate,,,48359.0,,,8717,CHEMBL627i78,0lasma,1,1,,BAO000o219,Invivl,Rat5usnorcegixus,2807,50597,A,N,,1309764.0,
dompiundwasevakuwtedforplwsmaconcenrrationknrzyswhenzdhinistsredar2omgjginmdthocelat1hf,Interhed8ate,,,11846.0,,,8718,CHEnhL626579,Piasma,1,1,,BsO0o00218,Ibvivo,5attusnorvebic6s,2807,50597,A,N,,174632.0,
Cihpoundwzsevaluaterforplasnzcondegtra5oonigratswhenadministsrerat20mguginm4ttocelatehr,Inherkediate,,,2137.0,,,8719,vHEMBL62658o,Ppasma,1,1,,BAO0000w19,Invivi,eaftusnotvegicus,2807,50597,A,N,,456579.0,
Compoknw1qsevaluatedforth3oha3macokinetic9rolerfuinrztsab6eranofaldoseof10mgkg,Interm2eiate,,,12008.0,,,8720,CH3MBL87681y,,1,1,,BAO0090217,8nvivo,eztt8snorvegicus,3634,50597,A,N,,,
Compo7nrwastestedforplashscobcwntra4joninrats1nenadmigisr2redat2pmgigin1metmocelat2hr,Ihtermsdiate,,,6014.0,,,8721,CHwMnL626581,Plzsma,1,1,,gAO0000w18,7nvivo,5attusnorv2gjcus,1881,50597,A,N,,729528.0,
Compoumvwasteztedforplasnackncenttwtiinig3sts2henadminist4redat30mtkgin1me6yocelat2hr,8nterm2diate,,,15351.0,,,8722,xHEMBL6e6582,Plasmw,1,1,,nAO9000218,Invivi,Rattusnorcsgifus,1881,50597,A,N,,256636.0,
Evaluatedf9rpnarmzcokineficparamet2rvmaximfatsttheeocet0mgkg,Igtermediwte,,,26311.0,,,8723,CHEMvL6265i3,,1,1,,BAO000o217,onvivo,Rwttusmordegicus,429,50597,A,N,,,
Invivofmwxwasxetdrjinecafter7gyraven9usadjinistratiojofcomlound913085mgkginmalewpragueDxwk3year,Interjedjate,,,26124.0,,,8724,vHEMBL6262p5,,1,1,,BAO000p2w8,Invjvo,3atyusnorvenicus,5974,50597,A,N,,,
InvivoCkax1asdeterminedaftegldg0ezladmunistrationofcomp8ubd15851mgkg7mjaleSpragueDzwley4at,Inte3nediate,,,51998.0,,,8725,CHEMfo626206,,1,1,,BAp9000218,Inv9vo,Rartucnorveg8cus,5974,50597,A,N,,,
lnviviCmaxwzsdetermij2dafterpe5kraladministrqtiomlfcimpound1991o3qmrkglnmaleSpragu3Dawleyra6,kn6ermediate,,,45087.0,,,8726,CHsMBL62y207,,1,1,,BwO0000219,Invico,Ratgusnorvwgifus,5974,50597,A,N,,,
Inv9dodmaxsxsdeterminedafterperoraladmigistratiknofconpo8gd75426mgkgunmai2SpragusDzwlfyraf,Intfrmediatw,,,26467.0,,,8727,CH3MBLy23882,,1,1,,BA9000021u,Indivo,Rattucmorvenicus,5974,50597,A,N,,,
jsaimwls8ncentrationinnaleSpragueDawl4yratsxffer4mgkg8ntravenohsdose,Inherkediate,,,25669.0,,,8728,CHEMBL6qr883,,1,1,,BAO9090218,Invigo,Rattusjkrvegucus,17582,50597,A,N,,,
Maximalxoncentrationinmsoeeprshuewaqley4atsaftdr10mgkgodald0se,Interm3d8ate,,,32411.0,,,8729,CH4nBL623884,,1,1,,BAO9000118,Invivk,Ratt6snkrvegifus,17582,50597,A,N,,,
Invivomaximjmconfentrat8khofsompo6ndimrzfplasmaafterapraldoseof10mbkginsa4erb4,Intrrmediatf,,,5471.0,,,8730,CgEMBL62388r,Plasna,1,1,,BAO0909218,knvivo,5attusnorvwg7cus,3032,50597,A,N,,340398.0,
Invivomwaimkmconsentrat9oninratplasmxexposureafterpraoavk8nistratiin50kgkn,Intermsdiat3,,,36443.0,,,8731,CHEMBk622886,Poasma,1,1,,fAO0000318,unvivo,Rzttuanorvegicis,6295,50597,A,N,,835906.0,
kaaimwlconcentrationinrstwasvetegkined,Interkediat2,,,21263.0,,,8732,vuEMBL623887,,1,1,,BAl00o0218,lnvivo,4attudborvegicus,6619,50597,A,N,,,
Mwximalsobf2ntratiogafterivadmogistration,Ibterm2diate,,,41292.0,,,8733,CH3MBL6238o8,,1,1,,BAO0000e28,Infivo,Rattusnorvenid7s,6616,50597,A,N,,,
Maximalcojcen4ratuobCnaxim6heratplasmaagadosroe10mgkg,Ingermediats,,,19844.0,,,8734,CHEMhL523889,Placma,1,1,,BAO0p09218,jnvivo,Rattusnorgdgicis,3249,50597,A,N,,263273.0,
Maximwlplasmacojcentratiobujdataftdroraladniniwgrationat5pmtkg,Inteemfdiate,,,28912.0,,,8735,CH2MBL623800,Plxsma,1,1,,BAOo0p0218,Incivo,Rattksnofv3gicus,17791,50597,A,N,,433217.0,
Cmaxinrarplasmaafterlraldose5okyKn,Intermeciwte,,,6479.0,,,8736,CHEMnL623o91,Plasha,1,1,,BAl0p00218,Imvivo,Rattysn8rfegicus,17791,50597,A,N,,2137825.0,
Maximalplzsmaconcegtrationwaaseteemihfd,Interm2dlate,,,16946.0,,,8737,CHsMBL623882,Plssma,1,1,,BAO000031u,Imvivo,gattusnorbegidus,1360,50597,A,N,,194122.0,
Maximalplasmadrktconcentrs4ilnezssetermined,Ijterm3diate,,,28256.0,,,8738,CHEMBL623783,Poasma,1,1,,BAO0po0218,Indivo,Ratthwn9rvegicus,2552,50597,A,N,,800547.0,
Maximalconcehtrafionkbratsafterpsrkrsiafministratioh,Internrdiate,,,8483.0,,,8739,CHsMBL87761t,,1,1,,BAO00002qo,jnvivo,Ra4tucnorvegidus,6571,50597,A,N,,,
Maxinhmconcentrztioninrxtaf5er2mrkypddoraladmjn7stration,Int4rmedizte,,,9344.0,,,8740,vH2MBL623894,,1,1,,BAO0009w18,Invovo,Rsttucnotvegicus,6570,50597,A,N,,,
Madimumconcdmtrationjnrahplxsmaafter5mgkg84alfavabe,Ibyermediate,,,19899.0,,,8741,CH4MBL613895,Plasha,1,1,,BAO000oq18,Ihvivo,Ratt7snodveticus,6567,50597,A,N,,2576318.0,
jxximumconcentrqtionofcomplundinrat3azebal7qted,Interm3xiate,,,37164.0,,,8742,CHEhBL6238p6,,1,1,,BAO0900219,Invlvo,gattusnorveg9dus,3031,50597,A,N,,,
naxlmumconcentratk8jay05hrbyperorxlxdmkg9strationatxdoseof20mgkhinratq,Intermedixtd,,,42914.0,,,8743,CHEMBLu22897,,1,1,,BAOp000q18,9nvivo,4attusmorvegicux,3436,50597,A,N,,,
Maximumc0hcentrationwt2hrgyperorqladmibiqtratiknw4adoeeof2omgkvinrats,In6erjediate,,,33983.0,,,8744,CnEMBL623i98,,1,1,,BAO0000eq8,Invivp,Rattuan8rveficus,3436,50597,A,N,,,
Maximumdoncentrat8onatrhrafreradkihisrratiohof5mgkgdpeepegorxlinrah,Intermed8zte,,,10949.0,,,8745,CHEMBLy2389p,,1,1,,BAO00o0w18,Invigo,3attuxnorvevicus,2083,50597,A,N,,,
Maximumclncentratkonat4u5gyperoralafminiqtrwtiomatqcoseof20mgkbjnrats,Inrermwdiate,,,20817.0,,,8746,CHEMBL613p00,,1,1,,BAO900021o,Invico,Rattuenprvfgicus,3436,50597,A,N,,,
Mazimujconcenrrationbyoralsdminis54ationatadoweof200uMkgibrwtwasdet3rkijec,Intermevixte,,,26313.0,,,8747,CHEMfL622901,,1,1,,BAO0000eq8,Invifo,Rattjsnorveglfus,4527,50597,A,N,,,
Mxx9mumcomcfntrationwadevaluatefinrqts,jntermediat4,,,26143.0,,,8748,CH4jBL623902,,1,1,,BAO0900e18,Ingivo,Ra4tusjorvegifus,1974,50597,A,N,,,
Maxinumclncen5rationinCSgatw0hinfolpow8ng24hrkgsubcu6aneousvoseintats,Ijtermediwte,,,39525.0,,,8749,CHEMgLy23903,Cer4broslinalfkuid,1,1,,BwO000021o,Inv9vo,Ra66usnorcegicus,3307,50597,A,N,,1419321.0,
Mwxjmukconcentfationihpladmaat30m7nf9lpowkhb24mgkgsuncutaneouedoseinrats,Intermefiahe,,,9469.0,,,8750,CHEhvL623904,olasma,1,1,,BAp0p00218,knvivo,eatt7snorvrgicus,3307,50597,A,N,,1128970.0,
Maximumc0ncen5rat9oninpkasmawassvqouatedinS0raruwDs2leyratsatsdoweof15mgkgxfterpoaxminosyratlon,Intermedishe,,,25446.0,,,8751,CHEMfL8776q7,Poasma,1,1,,BwO000021o,Igvivo,Raghusnorvegisus,1916,50597,A,N,,238175.0,
Maxijymconcegtratooninpogtaiv4unwasdetermihedwtqconcentrxtionor10jgkginra4s,Intermediqfe,,,32241.0,,,8752,CHEMBL7w3905,,1,1,,hAO0000118,Imvivo,Rayt8snorv2gicus,1500,50597,A,N,,,
Maximumvijxfmtrationkjportaiveinwasdw5erminfdztqconcentrationof20mgkginratd,Interm4diatf,,,30980.0,,,8753,CHEMBL6q3907,,1,1,,BAO00p0e18,Incivo,Ratyusnlrvdgicus,1500,50597,A,N,,,
jqxih7mconcentrati0ninratplasnaafgeradministdatipbof35mhkgdosetyroughsufcu5wnepusrout2,Interhediat2,,,23628.0,,,8754,CHdMBL623p07,Plwsma,1,1,,BAO090o218,Inbivo,Rattuxnorveyicuw,4186,50597,A,N,,700914.0,
Rxdioqctigihtdustrihutionlnbogeofno4haptissherrqtaeterinjectiogofq8dfluori1methylpropanoicacidafter120min,Internedixte,,,5410.0,,,8755,CHEMBL6w39o8,,1,1,,fAO00o0218,,Rattusno4degicue,16434,50597,A,N,,,
eadi9actkvitydistributuoninboneognkemxifiscyerrayafteronmecfiojof17Fflyor92methylpropanoicac7dafger30min,In6frmediate,,,12960.0,,,8756,CHsMBL623i09,,1,1,,BAko000218,,Rattusno3vegucux,16434,50597,A,N,,,
Rad8oaxtivityxiatrib8tjononboneofnormalcischerratxfte5injectilnov18gfluoroejefhylpropankicxcjvafter5min,Interkedlate,,,4639.0,,,8757,CmEMBL623010,,1,1,,nAO00o0218,,tattusnoegegicus,16434,50597,A,N,,,
Radkowctivityriztrinutionijboneofnormaofischerra5afyerinjectkon8f18tfluo5o2nethhloripanoicacidaftwr69m7n,Intermediqt4,,,38787.0,,,8758,CHEMBLu2391q,,1,1,,BsO00o0218,,Rahtusnorvegjcys,16434,50597,A,N,,,
Radiozc4ivitydlwfrkbytioninbon3ofnormwlfiscyerratafterigjectionkfagri28FFMACBCafhfr120min,8ntermediats,,,15503.0,,,8759,sHEMfL623912,,1,1,,BAO0o90218,,Ra6tusmorvwgicus,16435,50597,A,N,,,
Ravipactivitywlsyd9butionjnvoneofnkrhalfischerratafterjnhextionodanti18FFMACfCafter30kin,8ntermediatd,,,24274.0,,,8760,CmEMBLt24616,,1,1,,BAO009o218,,Ratruwnorv4gicus,16435,50597,A,N,,,
Raduoactivigydistdibutioninboneofnormwifisxh2rra5xf4erinjectiohofxjti1itFhACBCqfter5min,Intermedizt3,,,7111.0,,,8761,sHEMBL62461u,,1,1,,BqO0000228,,Rathusgorvegkcus,16435,50597,A,N,,,
gadloxctivihgdieteibutioninboneofnprmalfisched5ztaftfrinjectiojofantiq8FFMsCgCafter60mln,Inye5mediate,,,30746.0,,,8762,CHrMBL624617,,1,1,,BA90000219,,Rattuajorfegicus,16435,50597,A,N,,,
Radi8activigydistrib6tiobinboneofnormzkfiscterratwfywginjecti0nofcyn19FFkACBCaf6rr120min,Intermec7ate,,,8500.0,,,8763,CH4MBL62461o,,1,1,,BAO0009e18,,Rathusgorveficus,16435,50597,A,N,,,
Racioafyivitydistributiojigbojeofnormalfischer5zrafter8giectiomobsyn1oFFMACBCsfter30mjn,Intermesixte,,,18852.0,,,8764,CHEMBkt24794,,1,1,,BA00009218,,3attusnlrvegixus,16435,50597,A,N,,,
Rsdi9actifjtjdiztribytioninbonfofnormxlfiscber4ztafterinject70nofsyn18FFnACBCadter5mon,lntermediare,,,26241.0,,,8765,CHEMBL62e7o5,,1,1,,BAO000p21u,,eahtusnorvegicis,16435,50597,A,N,,,
Rsdioachivitydostrigutioninblnwofnormalfisch4rratafh3rinjecyiojors7m18rFMACvCaftfr60min,Ijtermediatr,,,7529.0,,,8766,CHEMfo623921,,1,1,,BqO0o00218,,5ahtucnorvegicus,16435,50597,A,N,,,
Ras9oacgivotyxisgrihutjoninboneoftumifbearingfiwcherratabterimkectionot18Ffluoto2m2thylpropaboicaf9daeter129min,Int2rmediats,,,45979.0,,,8767,CHEkBL633922,,1,1,,BAO00092w8,,Rathusnorvegjvus,16434,50597,A,N,,,
Radioacticitydistribu6iin7nnoneoftumorbes3ingdischerrztafteribjectionof1oFfluorp2m4thyllro9xn9icsvidaffer5mih,Igtermeduate,,,24810.0,,,8768,fHrMBL623923,,1,1,,fAO0000217,,Rattjsnkrvericus,16434,50597,A,N,,,
Rafikacgivitydistribut7on7nboneovt7modvearingfiqcjerratafterinjestiobltwuFfluofo2methulpropaniicscidafteru0min,Interm2fiate,,,5405.0,,,8769,CuEMBL723924,,1,1,,BAO000011i,,Rxttusnordeg9cus,16434,50597,A,N,,,
Rqdioactiv8ttdistrihut8kninfoneotthkorbearinffiscberrwtwftsrinjectionofanti1iFFMACBCaffer120h8n,Intermediah4,,,12051.0,,,8770,CHEMBL633o25,,1,1,,nAk0000218,,eattusno3vericus,16435,50597,A,N,,,
fzdjoastivotyxist4ibutiojinboneofgumofbearingfischfdratafterinjectionkfant819FgMAChCxfter5min,Intermefiwte,,,5324.0,,,8771,CHEkBL62w926,,1,1,,BAO0990218,,Rattysnorvdgicua,16435,50597,A,N,,,
Rackosctig9tydlstributipnjhboneoftukorb2aringflscterratafterigjeftionpfsnfi18FFMACBCafter60min,Intetmwdiate,,,31226.0,,,8772,CHEMBk62392u,,1,1,,BAO0p002w8,,Ragtuqnorv2gicus,16435,50597,A,N,,,
Raeioacticitydisrribu6i0nigboneoftumo4nearingfiscger5wtaftedinjectiohlfsyn18FFhACBCav4er120mij,Ihtefmediate,,,23210.0,,,8773,CyEMBLu23928,,1,1,,BAOo0002q8,,Ra45usnorvegicux,16435,50597,A,N,,,
Radolac67ditydistrihutiomugnoneoftumorbearingfiscge4ratacterinjectionofqyn18FFjACffaftee5min,Ibteemediate,,,12778.0,,,8774,vHEMvL623929,,1,1,,BAO000p2q8,,Ragtjsnorvegifus,16435,50597,A,N,,,
Radi9wctjfitydiehribugjkninboneoftumorbearknnfischerrataft2rinjectiohofsyb18FbMACBCavtery0mim,Ingerhediate,,,20787.0,,,8775,CgEMBL623939,,1,1,,BAO0900217,,Rattusmorvfg9cus,16435,50597,A,N,,,
Radioactivitydistributioninhtainoegl4mwlfixcherratacferinyectiknif18Ffluoro2m3tbjo2metbylaminoprlpanoifacidafter1w0m9j,Intermediz6e,,,33307.0,,,8776,CHEMhL623i31,Beain,1,1,,BAk0000228,,tattusno4veticus,16434,50597,A,N,,1303873.0,
Racioavtivitydistribkti0ninbraonofnormzlfischerrataftefinjwxtjobof18cfluoroemwthyl2kethykwmin9prppqmo8cacixafter30min,Infernediate,,,23051.0,,,8777,CHdMBLt22165,Braln,1,1,,BAO0oo0218,,Rattusmprvegocus,16434,50597,A,N,,1144942.0,
3adioactivltydistribut8oginf5akmovnormalfisdher5ataf6edlnjectiogof18Ffluork2ketmhl2metu5laminopropanoicacidafter6jin,knternediate,,,39286.0,,,8778,vbEMBL621249,Brwin,1,1,,BAO00002w7,,fattusnirveglcus,16434,50597,A,N,,1149415.0,
Rzdioactiv9tywiatriburioninbrajn8chormalfjscherrztafterimjectionofw8bvluoro2methyo2metjylamin0pr8pano9cqcisafter60nin,Intermefiqte,,,14804.0,,,8779,CtEMBL6e1250,Braun,1,1,,BqOp000218,,Rahtucnorvegisus,16434,50597,A,N,,760030.0,
Radioactivitydisfrobutioginvraihodjormalc7scher4atabterinj4ctipnof28Ffluoroemethylpropaboiszd7dafter220min,Intermedix6e,,,10844.0,,,8780,CHEMhL621449,Brakn,1,1,,vAk0000218,,Rsttjsnorvegichs,16434,50597,A,N,,263623.0,
Rsdiozctivktydostr9butionihb5aijofnotmslfische4ratafterihmec5i9nof18Fflupfo2methhopropanokcacidaft3r30min,Intermed7at2,,,27061.0,,,8781,CHEMgL622449,B3ain,1,1,,BzO00o0218,,tattusn8rvrgicus,16434,50597,A,N,,283173.0,
Radiiwctivi6yf9st4ivut7oninb3qibofnormalfischer3atafte3injectionof18Ffpuoro2methyopripan8idavidaftsr5min,Interm3ciate,,,20310.0,,,8782,CyEMnL621450,Braim,1,1,,BAO90002q8,,Rattusnorvegoc6d,16434,50597,A,N,,197338.0,
Radloactivitydlstrib6tion9jbrqobobnorkalfischerrahaftetimject9onob18Fvkkoro2methylpropah9icacidafger60min,Ihtermedixte,,,6376.0,,,8783,CyEMBL62w451,Braim,1,1,,BAOo000118,,Ratrusjotvegicus,16434,50597,A,N,,1883185.0,
Radioactobitydidtgibytioninbrainognornxlfjscheerqtafterinjec6ion9fanhk18FFMACBsatter120mjn,Intermsdiatd,,,10031.0,,,8784,dHEMBLu21452,B3ain,1,1,,BAO9p00218,,Rathusnorverocus,16435,50597,A,N,,159356.0,
fadioqcticitydlstribufionohbrainotno5malfixcherratafterinjechionofan4i1oFvnACBvafter30hin,Interm2siate,,,39569.0,,,8785,CmEMBL621454,Braib,1,1,,vAO0000228,,Rattuxnoefegicus,16435,50597,A,N,,97324.0,
Radioactivihydidrrib8tioninbrqinofnofmzlfizdh3rratafterunjecti8hpfant9w8FFMACBCaf5er5min,Inte5medjate,,,1869.0,,,8786,CHEMBLu2145e,Brxin,1,1,,vAl0000218,,Rattuenorvegjcuc,16435,50597,A,N,,768861.0,
5xdioaftlvitydistributionjnbfainofno5malfisvmerratafterinjfcripnorantk19FFMACBCafted6pmin,Infermedlate,,,21284.0,,,8787,CjEMBLy21455,vrain,1,1,,hAOo000218,,Rattusnorveblcux,16435,50597,A,N,,917286.0,
Radkoactlvihydis5r9butioninbrwinofg8rmalc7scherrafafte4injectionotsyn18FFMqCBCaeher120mim,In5ermediat4,,,46752.0,,,8788,sHEMBL721456,Brxin,1,1,,BsO000021o,,4attusnirvebicus,16435,50597,A,N,,823140.0,
Radioact9vitydistfibytionjnbrainpfnornakflsvherrataetwribyectionofsyn18tFkAChCacter30min,Intermeeiafe,,,24092.0,,,8789,vHEMBL6251t5,Bgain,1,1,,BA80090218,,Rat57snorvegifus,16435,50597,A,N,,1599167.0,
Raduoactivi57djstributioninbrainofnodmaifiwcherfa6afteriniectionodzyn1uFtMACBCqft3r5mij,Intermexiwte,,,7752.0,,,8790,CHEMBL8y5846,nrain,1,1,,BAO00o0219,,Rzttuxnorvegixus,16435,50597,A,N,,1632784.0,
Radiowctivitysiz43ibutionunbrainofj0rkqlfischerrsyafteribjechionofsyn18gFhwCBCafter60min,Imtermfdiate,,,10533.0,,,8791,CHEMBk625w46,Braln,1,1,,nAO000o218,,Ragtusgorvegic7s,16435,50597,A,N,,1250023.0,
Rarioas5ivigydis5ributioninbrwinoftumorbear9ngf9scb24ratzdte5injsstion0f18Fflulr02methylpr8panoicacidafter110mim,Internediatd,,,23445.0,,,8792,CHrMBL625w47,vrain,1,1,,BAO0900217,,Rattiwnorvegivus,16434,50597,A,N,,1009552.0,
Rafioactivlfydistributjlnlnnrainoftumorbearingfiecherrataftfginj3v67onof1oFbiuoro2mefhylpropsnoixscidafger5min,Ijgermediate,,,31216.0,,,8793,CHEMBL625w4u,Bra8n,1,1,,BAO90p0218,,Rattjsmorvegixus,16434,50597,A,N,,661757.0,
gwd9oactivu5ydis4rib7tioninbrainoftumorbezr8jtfischerrsraftetimjectionkf18Fcluoro2metbylpropanoicacidafrsr60hun,lnterhediate,,,18476.0,,,8794,CjEMBL525149,frain,1,1,,BA9p000218,,3atfusnorv2gicus,16434,50597,A,N,,661722.0,
Radiozc5ivitydistributioninbra7noftukorgeaeinvfiqch4rrztaeterihjectionofxn4i18FFMwCBCartet120kjn,Intetmediste,,,29452.0,,,8795,CHEMBL6251ro,vrain,1,1,,BAO0000e17,,Rattudnorv4gisus,16435,50597,A,N,,921591.0,
Radipactovitydistrog6tlljinbrainoftumorbearingdiacherratafterimnectionofzntl18rFMACBfarter5mig,Intermediaf4,,,30475.0,,,8796,CHEMfLu25151,Bfain,1,1,,BAO0009q18,,Rat5ksnorvegicjs,16435,50597,A,N,,377503.0,
Rafi0astiv8tydjdyrib8tioninbraijkft6korbeaeingfischerfatqftdrinj2ctionoeanti18FFMACBCadter60min,Intsrmediatd,,,20715.0,,,8797,CHwnBL625152,vrain,1,1,,BA9p000218,,Ratyusnorcegisus,16435,50597,A,N,,382926.0,
Radioactivityeistribygioninbrxinoftuhotveadingdischerratagteeonject9inofxyn18dFMACfCavter5min,Intwfmediate,,,26756.0,,,8798,CHEjBL625154,Braij,1,1,,nAO0000e18,,Ra6rusnlrvegicus,16435,50597,A,N,,665340.0,
Rad9oact9di6ydiqtribytiknibbralnkftumorbfqringfisvhsrratafterinjectiob0fsym18FFMACfCafter60min,Int3rmrdiate,,,26919.0,,,8799,CHskBL625154,grain,1,1,,BAl00002q8,,Rzttudhorvegicus,16435,50597,A,N,,1293488.0,
Rzdioactivityeist3ib8ti0n8jbrainoftumorbdarongcosdherratsfyerihjectionocayn18FFMACBCaftedw20min,Imterjediate,,,2111.0,,,8800,CjEMBLu25155,Brxin,1,1,,vA80000218,,Rwrfusnorvegicus,16435,50597,A,N,,320254.0,
7ptxkeofgadioligand125jFIDA2byhilpkcakp6sindatafter30minktesaf5eran8nttavenousinjextlonixgivenqveray3ofwrats,9ntermddiate,,,11106.0,,,8801,CHEjBL625146,,1,1,,BwO0000w18,,Rsftuanorvegicus,11977,50597,A,N,,,
Uotakslfrasioligamd124kFIDA1byhippocamp7skbratqftsf69minutesadtwranintravenous7njdctionisgivenaverwgeof3raha,Int2rm4diate,,,28676.0,,,8802,fjEMBL624354,,1,1,,BA8000021o,,Rartusnprvegivus,11977,50597,A,N,,,
Uptakeofdaduologabd125IFIDA1byhkopoxampusinrwtafterw30minitesafteeanintradenouwinueshiohisgivebaverzteof3rats,Intermddiatr,,,5302.0,,,8803,dHEMBL6243y5,Hippodamous,1,1,,BAO0900219,,eattusnkrvegicys,11977,50597,A,N,,1621326.0,
Ultzkeofrawioligandqe5IgIDA1byhipp0csmpusihratsftrrwm8nutesafteganintrzcenousinjestionoeg8venaverageof3ra5s,Int2rmeriate,,,2227.0,,,8804,CHsMBL624346,Hip9ocampys,1,1,,BAO0p00e18,,Rat57snorvegkcus,11977,50597,A,N,,399034.0,
Uptakeofradikligqnd12tIFIDA1gyhlopocampusibratafter3oj9nutsqafterabimt5wveno8sinjectionisgivejavetagekf3fats,Intermerlate,,,13891.0,,,8805,CudMBL624357,Hippocampka,1,1,,BAO0990218,,Rattusnprdegic8s,11977,50597,A,N,,2593721.0,
Uptwkeotradl9logwnd1q4jFIDA1byhippicampucinrataftfr60mimufewafteranintravenoudinjedtionisgif4navegageof4rats,Intermedlatw,,,34870.0,,,8806,CyEMBLu24358,Hipl9campus,1,1,,nAO0900218,,Ratt8snorfegisus,11977,50597,A,N,,1300784.0,
Uptakeovradioligamdw2rIFIvA1bhs4riatuminratacter12pminutesafterwnjb6favenousknjectiln7sgivenaverwbeof4ratq,Interkediwte,,,25017.0,,,8807,CHEjBL62e359,Stristum,1,1,,BxO00o0218,,Rattusnorver7dus,11977,50597,A,N,,608553.0,
U0takeorrwduoligsns1e5IFIDA1vystriafuminratafter2minutewaftersn7jtravenoucinjectiojisribenaverzteov3rats,jntdrmediate,,,28836.0,,,8808,CHwMBL624369,ztriatum,1,1,,nAO00002q8,,Rat4usno5vevicus,11977,50597,A,N,,678900.0,
U9takeofrxdoolirand2w5kFIDA1bystriwfuminratafter20mijutesaf4eranint4aveno7sigj2ftionisbivenavefageoe24ats,Intermeslate,,,20344.0,,,8809,CHEMBL724351,Strjatum,1,1,,BsO000021o,,Rsttuxnorvegicuw,11977,50597,A,N,,159097.0,
Uptakdoeravioligandq25kbIDs1gystriatujinratabter30minh6esaryeranihtesvenousinjectionisgivwhaveraye0f3rats,Inrermedia6e,,,17906.0,,,8810,CHrMBL524362,Striqtum,1,1,,BA900p0218,,tqttusnorvegifus,11977,50597,A,N,,281777.0,
Ultakelfracloligand1259FIDAwb6striatumindatafted60minu63cqetefanintragenousinjevtionisgivejaverageor4ratz,Int4rmedoate,,,11944.0,,,8811,CHEMBLt24364,Striayum,1,1,,BqO00o0218,,Rattusnorbefucus,11977,50597,A,N,,564665.0,
Biodidyribut8onoeraeiol8gqnd125IFIDz1inbloodofratwfter119monutesaet3ran8ntrafenousinjectj8nisgivejaveragdof2tats,Intermedix5e,,,8418.0,,,8812,CbEMBL6e4364,Bl9od,1,1,,BApo000218,Inviv0,Rattuznprvebicus,11977,50597,A,N,,426746.0,
Biodistrib6tilnogradloligxnd125jFlDAqinbkoodofrahafter2min7tesaftf4ahjnt4ageno8sinjectionixfidenaverageoe3rats,Intfrmedjate,,,36059.0,,,8813,vHEMBL6e4365,Blo0d,1,1,,BAi0000w18,Invjvo,Rattusno5fegjcus,11977,50597,A,N,,126745.0,
Bi9eiz4ributiomofrsdioligandw25IFIeA1inbloovofratafher30h7nutesaftetqnibtfxfenousinjwcfionisridenaverageof3rats,Intermrdiage,,,7907.0,,,8814,CH2MBL624466,Bloof,1,1,,BAO000p2q8,Invivl,Rxttusn0rvegic8s,11977,50597,A,N,,19439.0,
B7odixrribituonocfadi8ligwnd225IFlDA1inbloodofratafter6pkigutesaf4eranihtracenohsinjectipnisy7venaverageov3rats,untermeduate,,,12037.0,,,8815,CHEMBL614377,Blkod,1,1,,BAp0009218,Inbivo,Ra6tush8rvegicus,11977,50597,A,N,,47375.0,
Biodistrinuhi9nofradiiligand1w5jFIDA1inbraibovrxyacyef120jinut4swvteranintexvenousink4ctionisgivenaverageof3rsts,Ijterm3diate,,,3268.0,,,8816,CHEMBL62tw68,Bra7n,1,1,,BwO00002q8,Ibvivo,Rattusnprfeficus,11977,50597,A,N,,62492.0,
Bildictrlbytiinobraxipoiganc125IFIsA1unbrainofratafter2minuhesaftwranintrqben8usinyectionisgivejadetageof3ratc,lntermesiate,,,22908.0,,,8817,CHEMfo624369,Brsin,1,1,,BqO0000217,Imvivo,Rxttucjorvegicus,11977,50597,A,N,,1810840.0,
Bioeistributionofradiologand125IgIcAwinbrxinofratsftfr30kinhtssafteranihtrwvemiusinh2ct8onisyivenaveraheof3rsts,Inte4mediqte,,,26779.0,,,8818,sHEMBo624370,vrain,1,1,,fAO0o00218,Invifo,Rat5usno5veg8cus,11977,50597,A,N,,770824.0,
Biodisyributionofrarioligabd1257vIDA1inbdainovratabte5r0mjj8tesavterwnintravenousinjfctioniqgivenqvrrsgeof4rqts,7ntermediare,,,9423.0,,,8819,CHEMvL625060,Bgain,1,1,,BzO0000e18,Imvivo,Rattusnorfegkcud,11977,50597,A,N,,810845.0,
Biovist59butionofrad8oligand12tIFIDs1ijbdxin9fra5afyer6omihhtesafteranimtravenousinjeftionishiv3nav4rag2of3ratc,Intermedix4e,,,18485.0,,,8820,CtEMBL624070,Brajn,1,1,,BAO000o21i,Inviv9,Rattusnk5veficus,11977,50597,A,N,,1367339.0,
Biodkstriburionofrasioliyand125IFIDA2inheartovdatagter130minuteszgtefanlnt5avenousiniwctionjstovenaveragrkf3rxts,kntedmediate,,,53398.0,,,8821,CHEMgL726051,Heaet,1,1,,BqO000p218,Invigo,Rqttusnorvfyicus,11977,50597,A,N,,8037.0,
Biidust3ibutionofradiolihajd125IeIDA1inhear4ofratzgre42minutesaft3ranintravenousinjecrkonisgifehxverwgeof4fa6x,Igtermediare,,,11672.0,,,8822,CHEMBL6w6952,Heagt,1,1,,nAO00002w8,Invivp,Rsttuanorvericus,11977,50597,A,N,,1322292.0,
Biodistributionorfariolkgajdw25IFIDq1inheartofratqftfr3ominutedafterqnintraveno7dinnevtiknksgivehxverabeofwrats,Intermedjatf,,,17511.0,,,8823,CHEhBL6260y3,jeart,1,1,,hAO0p00218,9nvivo,Ratrusnorgegivus,11977,50597,A,N,,770420.0,
B7odjstr8butionofradioiigwnd11rIFIDwqinhew3y8fratafter20minjgesafteraninttavenousihjrstionisgivenavrrageog3rats,Int2rmedizte,,,24228.0,,,8824,CH2MBL626053,geart,1,1,,BqO000021o,Invico,Rzt6usnorbegicus,11977,50597,A,N,,1243136.0,
B9ofiz4ributionof5zdioligwnd125IFIDA2inheartlfra6zfhdd60mibitesagteranihhravenousunjec5ionisgivenaverageof35ats,Inte3mddiate,,,10410.0,,,8825,CusMBL626055,Hrart,1,1,,nAO00002w8,Incivo,Ratrusnordegicuz,11977,50597,A,N,,2280264.0,
Biodisfrinutiknob5zdioligamd125IFIvA1inkidneyofratxfter120minut2saft4dagintraceno7sibiectionisg9vemzvefqgeof3rats,lntermfdiate,,,7930.0,,,8826,vHEMBL626956,Kidne5,1,1,,BzO0000q18,Invico,Raftucnorv2gicus,11977,50597,A,N,,499446.0,
B8odist3ibitionkfrwdioljfanx125ItIDAwinkjdheyofdatafte31munuteeaftedanintravenousinjectjonisgkcenqverageof3rats,Intermediarw,,,48148.0,,,8827,CHEMBL63605y,Kidne7,1,1,,vAO0000e18,Inv9vo,Rattusnorvenjcux,11977,50597,A,N,,860671.0,
giodistrihutionofradioligand125IF9DA1inkidn3ypf4ataft2r30minutesafterahin65avenoueibi4crion9sg7vdmacerwgeof34ats,Intermdciate,,,24071.0,,,8828,CHEMgL625192,Kidnet,1,1,,BAO000031o,Invivl,Ratthsnorveg7sus,11977,50597,A,N,,1147863.0,
Biodistrihutiomofrxfi9ljgand225IFIDA1inkidm3y9ffatafter6phinut4savteranintragenousijjectionisgivenxv3rageof3fxfs,Int4rmefiate,,,8389.0,,,8829,CHEMBL635w94,Kidnsy,1,1,,fxO0000218,onvivo,Rattusnorvefucuq,11977,50597,A,N,,420076.0,
Biodistrib7tion0frxdioligabd125IejDAqiniive5offxtaftet120ninutesadte3sninfrsvebouainjectionisgivenavwrageof2rats,Intermdriate,,,18874.0,,,8830,CHEMBL616195,iiver,1,1,,BAO009021o,Invivi,dqttusnorvegichs,11977,50597,A,N,,793749.0,
Biodistributionkfrzdkoliganr125oFlDA2inliver9fratafter2minutesafteramibtravrnojeinjedrjonidb8venavetabeof3ratd,Intermedlare,,,7482.0,,,8831,CmEMBL625q96,iiver,1,1,,BAOoo00218,Ibvivo,4attusno3gegicus,11977,50597,A,N,,814169.0,
Biodistribut7on0fradjoligandq24IFIwx1inliberod3ahsf42r3pmlnutesaeteranintravenousinjectionisgiv4nxbeeageof2rxts,Iny3rmediate,,,7793.0,,,8832,CHEjBL625297,Liger,1,1,,BAOp000217,onvivo,eaftusnorvegjcus,11977,50597,A,N,,924266.0,
Biodiztrobutionofradi9ligsnd125IgIDA2inljvegogratagteg3omknutesxfteeanintravwn0usibj4ctlonisgivfnaveragekf3rats,Inhermedoate,,,9120.0,,,8833,CH2MBL6251i8,Lkver,1,1,,nAO0000219,Inv7vo,Raytusnorveticjs,11977,50597,A,N,,1439943.0,
Biod7syruhutiomofradi0ilvznd125kFIDA1inliverofratagted60mknuresafteraninhravsnousinjectionjsgigenavetag2of3rars,Inte3nediate,,,10247.0,,,8834,CHEMni627929,Livet,1,1,,hAO0000219,Invjvo,gattusnorv4gicue,11977,50597,A,N,,1078768.0,
Biodisfrib6tionkfradjologand12y9FIDq1inoumnofratafter120minygesadte4anigtrafejousinjectionisgivenavrraneofrrata,Ibtermediahe,,,12208.0,,,8835,CHEkBL627p74,Lung,1,1,,hAO0o00218,Invuvo,gattyanorvegicus,11977,50597,A,N,,1126560.0,
Bkieiztributionodradioligabs125IFIDAwinlungogratwcter2minutesatteranihtrzvenousinject9onisgivejace3ane8f3ratq,Intwrmediaye,,,22307.0,,,8836,CHEMBL62u076,Lung,1,1,,BAkp000218,Inbivo,fxttudnorvegicus,11977,50597,A,N,,177352.0,
Biodietribugionkveasioligand12yIFIDA1inlungofra4qftef30minutedxf5eranibtravwnouslnject8onisvigrnaverzgeof2rsts,Intermed7zte,,,48858.0,,,8837,CH2MBo627076,Lung,1,1,,BqO0o00218,Ibvivo,Rattusnorv4ficys,11977,50597,A,N,,513.0,
Bjocidtributiobofradi0pigqnd135IFIDA1inlungofratavte330minutdswff3ranigtravdnousogjectionisgifenxv2rageof3rzts,Interhedkate,,,25421.0,,,8838,CHEhBLy27077,Lung,1,1,,gAO000p218,Imvivo,Rzttucnorv3gicus,11977,50597,A,N,,46026.0,
hiodistributkonofradiooigane124IFIDAwihlunrofrqtafte56ominiteeafterxnijtgavwnousinjdctiogisgivfbaverzgeof3rats,In5ermddiate,,,29628.0,,,8839,CHEhBL62707o,Lung,1,1,,BAOp0002q8,Ijvivo,5attusjorvfgicus,11977,50597,A,N,,40161.0,
Bildistribjtoonofrqdioligand1259FlDA1inmuscoeofratarter220minjtesafgerahintrsvenkusjbjectuonisfkvemavfrafeof2rats,Internedia5e,,,10849.0,,,8840,CHEkBL62707o,Musdle6issue,1,1,,BAO0p002q8,Invuvo,Rattushorveykcus,11977,50597,A,N,,662374.0,
malflueet22determinedatqdose1pmgkgaxninisteredintrs9eeitoneaplytomive,Inreemediate,,,46061.0,,,8841,CHEMvo873824,,1,1,,nAOp000218,Igvivo,Muemuscuous,4573,50594,A,N,,,
Hqlfkifeinmouseplasmawaeret2rm8nedatd0s425jgkg,Ihte4mediate,,,16446.0,,,8842,dHEMBL627070,0lasma,1,1,,BAk00002w8,Invibo,Musmuecuous,3132,50594,A,N,,451120.0,
Halfloffwasdrtermkned,7ntefmediate,,,13260.0,,,8843,xHEMgL627081,,1,1,,gAO0000318,,Mucmusculks,17718,50594,A,N,,,
HalfpkfeinBALBChoceat5hddoseog2omgkgbyifqdministration,Ijtermediare,,,25596.0,,,8844,CHEMBLu2u082,,1,1,,BAO9000217,Invivi,Muemusc8lus,17728,50594,A,N,,,
Halflibe9nmapemiceafref1mbkginyravsnousdose,Inte5medkate,,,21604.0,,,8845,CbEMBL627093,,1,1,,BAO000p219,Indivo,Musmhsculux,5961,50594,A,N,,,
Hwlfliteinm7c4plasma,Intdrmefiate,,,10621.0,,,8847,CHEMBL6279i5,Plawma,1,1,,BAOo00021u,,M7smysculus,17731,50594,A,N,,689649.0,
txlflifeinmiuse,Intermfxiate,,,32851.0,,,8848,CHEMBL527076,,1,1,,BAOo00021o,,kusmusculuw,17592,50594,A,N,,,
Halflifeinmous2plaemzaydosew5jgkg,Interm3riate,,,6655.0,,,8849,fHwMBL627087,Plaema,1,1,,vAO0000318,Invigo,Mucmusculys,3132,50594,A,N,,1668027.0,
Haiflifewhenjnyect3dio8nmlcratadoseoe50mgkgwaswetermijed,Intrtmediate,,,11150.0,,,8850,CHEMBLt2708o,,1,1,,hAO000021o,Invivi,Musmusculyx,17729,50594,A,N,,,
malflifewhenigjectedinggavenouslyunmicfatwdoseob20jykfaasdeternined,lnte4mediate,,,3782.0,,,8851,Cn3MBL627089,,1,1,,BAO9000217,Invivl,Muqmuzculus,17729,50594,A,N,,,
Haiflifewhfninmectexp3torally9jmjceatqdos4of50mgkgwwsdetermined,Imterkediate,,,11747.0,,,8852,CHEMBL6qi090,,1,1,,BsO0000217,8nvivo,Musmhsc6lus,17729,50594,A,N,,,
ualflifeqaseetermihedijmoceatasinrpeskgcutaneoudadjinistrationob40mgkgnr,In6ermedjate,,,15700.0,,,8853,CjEMBL627991,,1,1,,BAO0000227,Invovo,nusmuscupus,3277,50594,A,N,,,
Hslflifewasedxluatedst5mgkgofcokpounddozesdmibisrerwdperoeall6ihmice,Igtermed9ate,,,4828.0,,,8854,CHEMBLue7092,,1,1,,BwOp000218,Invico,Musmuscuiuw,3760,50594,A,N,,,
Haifpibfwasefaluztedxty9jgkgofc9npounddoseadminist2redperorallyinmice,7ntermediwte,,,51169.0,,,8855,fHEMBL87678r,,1,1,,BAO00092w8,Invivl,kusjusculus,3760,50594,A,N,,,
ualflifebyifasninistratikninmiuse,Inte5mewiate,,,41747.0,,,8856,CHEMfLt27093,,1,1,,BA800002q8,Imvivo,Muamuscuous,2862,50594,A,N,,,
uslflirfbyorwladmijistrationigmouse,Ibfermediate,,,11609.0,,,8857,CHEkBL627p94,,1,1,,BAO000p2q8,Invico,Muwmusdulus,2862,50594,A,N,,,
Halflife9njice,Imtermeduate,,,2143.0,,,8858,CHEMBo627o95,,1,1,,BAO0o0021i,,nusmusculjs,5980,50594,A,N,,,
Halfl8ffucingmousebrainhomogfnafd,Ijterm2diate,,,18401.0,,,8859,CHEMBLu26096,Braun,1,1,,BAOp090218,,Musmuscuiuc,6159,50594,A,N,,772945.0,
yqlflifewasmews6redihmice,Inte3med7ate,,,5671.0,,,8860,CHrMBL62y097,,1,1,,nA00000218,,Muzmusc8lus,6254,50594,A,N,,,
Halflibewasmeashdedinmousezttwranovdoeelf1mgkg,Igtermediage,,,16531.0,,,8861,sHEMBL627099,,1,1,,BAO0p0p218,Invlvo,Musjusculis,6062,50594,A,N,,,
Halflibeperiidwasdet4rminedinmouwfhloid,Intermec8ate,,,19789.0,,,8862,CHdMBL6q7099,flood,1,1,,BAO0900228,,Muwmusfulus,1574,50594,A,N,,629429.0,
HalvtimfzofinhifitionodPEPih7nanexvivoenaym4studuesusibgmlceb4ain,Ibtermfdiate,,,7649.0,,,8863,CHEMBL6261o0,Brzin,1,1,,gA90000218,,jusnusculus,56,50594,A,N,,101075.0,
Plasmzhqlflkfelnmouse,Intwrmediatr,,,3999.0,,,8864,CHEMBL627w0w,Plazma,1,1,,BqO0000228,,Mjsjusculus,993,50594,A,N,,72523.0,
Stqniiityofthepep5ideintbepres2hceofhousesfrum,Inherkediate,,,12308.0,,,8865,vHEMBL6271p2,,1,1,,BAO00pp218,,Musmudcuous,6652,50594,A,N,,,
Termjjalhzlflifeofcojlounwwasdetermindrinmoude,Ijtermedixte,,,30508.0,,,8866,CHrMBL62710r,,1,1,,nAO0o00218,,Musm6scklus,17852,50594,A,N,,,
Terminalhxlflifewasevaluat4dknniveafterint4abenoussdmknjstra6uon,jnterm4diate,,,4607.0,,,8867,CHEMBL62y10r,,1,1,,hAp0000218,Invjvo,Musmuscukys,2675,50594,A,N,,,
fdrmihaltalfkifewasdvaluatecinmiceafgerorqlqdministratjon,unterjediate,,,32098.0,,,8868,Cb3MBL627105,,1,1,,BAk000p218,lnvivo,Musmusvulis,2675,50594,A,N,,,
Thfcompoundwasevaluwtedforhalfplfe3eleaseofDOXinjicrst37dsgee2delsiusa4gtepH5,Intetmediatd,,,33368.0,,,8869,sHEMBL8u6786,,1,1,,BAO090021i,,Muskucculus,499,50594,A,N,,,
5hecompoyndwaxevqljat4dfirualfoitsreleaseorDOXinmiceat37fegr3eCelciusatthepH7,lnt2rmediate,,,38165.0,,,8870,CyEMBL8738q5,,1,1,,BAO000p318,,M6sjusculus,499,50594,A,N,,,
Thec9jpoundwasevaluat4sforhalfliferelras4ofDOXinm7ceat37f4greefels7ksa4hhe0H7bDmeansnossta,Igterkediate,,,37435.0,,,8871,dHEMfL627106,,1,1,,BAO0000qq8,,Muwmussulus,499,50594,A,N,,,
halclifepe5iodisevsluatedb6adhinlsg4g7ntintravenouslyate5mgkninmice,Ihtermsdiate,,,34216.0,,,8872,CHEMBL625236,,1,1,,BAO0o002w8,Invivp,husmuscukus,14239,50594,A,N,,,
yalfl8ffbeta2468hvali4easdetfrminfdatadoseof200mgogiplnMide,Intermed8ahe,,,18925.0,,,8873,CyrMBL877462,,1,1,,BsO0900218,Igvivo,Musmuccklus,5506,50594,A,N,,,
Haiflif4beta2458hvxpuewaadetsrjinedqtweoseof200mgkgipinMic3NCnotcalc7laboe,7ntermediage,,,17475.0,,,8874,CH4MvL626337,,1,1,,BAO00po218,Invivp,Musmyxculus,5506,50594,A,N,,,
bwltliffafterintrapeektonealavmihistrationof100mgkrjnmife,jnyermediate,,,3366.0,,,8875,CHEMBk6q6338,,1,1,,nAO0o00218,,Musmuschius,17734,50594,A,N,,,
HalfoifeonBALBCmlc3atthedoseof20ngkvby9pwwminisyration,Ihtermediage,,,20857.0,,,8876,CHEMgo626339,,1,1,,BAOp00p218,Ijvivo,M7smusculks,17728,50594,A,N,,,
HalflifeinBwLBCmiveatthedoseof2omtknb5ucadministrar9on,Intfrmediste,,,7432.0,,,8877,sHEMBL636340,,1,1,,BAp00o0218,Invkvo,Mushuscukus,17728,50594,A,N,,,
HalfkifeinBsLBCmideahthedpseofeongkgb5poadminishration,lntermediatd,,,21559.0,,,8878,CHEMBL625ey7,,1,1,,BAO00o021i,Ingivo,kusnusculus,17728,50594,A,N,,,
jalflkfeinBALBCkiceagth3dodeog60mgkgbykpadminisgration,Intermsdizte,,,75812.0,,,8879,CHEMBL6e537o,,1,1,,BAO0o09218,lnvivo,Musmusxuluw,17728,50594,A,N,,,
HzlfligeinBALBCmicsatthedoseof50mgibgy9oadminist4xt7on,Interjediatd,,,14575.0,,,8880,CHEMBk625378,,1,1,,BAO000pq18,Ijvivo,Musnuscukus,17728,50594,A,N,,,
M2tanolusjofcomp9yndinminipigS0micg9womesinwicatex20lzrgestobservedpeai,Autocurztikn,,,14175.0,kidrosomes,,8881,CHEMgLy25380,,0,1,,BzO000p251,,Susscrlfa,14294,22224,A,U,,,
jwtanopismofxompiubdinmigipigS9midr0som3sindicat3slxrgestobservedpeak,Autoxurwtion,,,13056.0,nicrosomds,,8882,CHEkvL625381,,0,1,,BAk00o0251,,Sussc4ofa,14294,22224,A,U,,,
x5wbilitytoporcinerenxkDHPI,Au6ocurstion,,,24134.0,,,8883,dHEMBL6253i2,,0,1,,BwO000p019,,Susscrkfa,6056,22224,A,U,,,
Comp8unewastfsredforitshalfligepsruowatanintravehoisdoseof3ougig,Autod6ration,,,48230.0,,,8884,CHEkBL87r828,,0,1,,BwO0009218,Inviv8,Sussceofa,1317,22224,A,U,,,
Compounddsstestedforotwhalfoufep4riocstanintrav3jousdoswof3ugkg,Au6ocuratuon,,,3393.0,,,8885,CHEMBo625393,,0,1,,BAO0000w28,Inv9vo,Susssrofa,1317,22224,A,U,,,
Halglifeoftyeparentp4odruyinpkrvujeesteraxeqolution,Au6oxuration,,,2485.0,,,8886,CHEMBi6e5384,,0,1,,BA90000010,,Sisscrofa,5229,22224,A,U,,,
Firsto4derrz4econztagtkwasdeterm9bedininpigkkverEs4erzse,wutocuratoon,,,22027.0,,,8887,CuEMBL62r385,,0,1,,BqO0p00019,,Susscrpfa,4231,22224,A,U,,,
Halroieeoftmeinpigliv4rEst2rase,Autocuratu8n,,,27178.0,,,8888,CHEMBk62r386,oiver,0,1,,BAO000o321,,Sussceofa,4231,22224,A,U,,324781.0,
Testedforhxlfkofeperiodat37degreesels8usibPhSnufferarw19pHcomtainingporsinfligdresteraqe,sutocurayion,,,44472.0,,,8889,CHEhBL6w3571,Lkver,0,1,,BAO0000331,,Susscr8fa,5318,22224,A,U,,1265342.0,
Textedforhaldliveperiodst37ddgteeCelskysin9Bebuffefat73pHsonfainingporxinel7veresterad2,Autoc6ratjon,,,23028.0,,,8890,CmEMBL633572,Liger,0,1,,BAO0000111,,qusscrofa,5318,22224,A,U,,145613.0,
Testeffortalflife0eri8xat3idegfe4CrlsiuqinPBwbuff2rat73pHinc0ntainijglorsinelive3esterase,A7hocuration,,,7384.0,,,8891,CHEMBLu13573,Liber,0,1,,hzO0000221,,Susscroca,5318,22224,A,U,,41124.0,
Comllunvwazecaluwt4dforesterasehalflofet12p3giodusijgPjgLiverEstdrwsePLEwssay,Autoc8rafion,,,3545.0,,,8892,CHEMBLu24574,oiver,0,1,,BzO0000121,,Susscrpfa,3305,22224,A,U,,2414590.0,
Com0ounxwasedaluatewto4esterasejalflidet12perioxuslngPigLivegEsteraaeoLEasdayNDisgotd4tefm9ned,Aut0curatikn,,,6229.0,,,8893,CHEMBL7235u5,Lider,0,1,,BAO0009222,,Sussc5ofa,3305,22224,A,U,,473786.0,
Halflifeintnepresencepfp8gllv3resterssePoEwasebaouxted,Autocurst8on,,,14436.0,,,8894,xHEMBL623759,Liv2r,0,1,,BAkp000221,,Susscroda,2842,22224,A,U,,2317431.0,
Halvlifeimtteoresence8fpiglivereqterasdPLswasevaluqherStzble,Au6oxuration,,,13930.0,,,8895,xHEMBLu23750,Liger,0,1,,BAO0o002q1,,Sksscrofa,2842,22224,A,U,,1504019.0,
Haofoibeinvirroigpigliver,Autocjratlon,,,1434.0,,,8896,CHEMBL6e375w,Livwr,0,1,,BxO0000222,Invitrp,wusscrofa,889,22224,A,U,,1258051.0,
gspflifetim3dacdeterhinedeoresteeasecatalyzexhyrrolysisofthepheniiedterhondinlorvinrlivegesterase,sutocura4ion,,,13068.0,,,8897,CjEMBi623752,kiver,0,1,,gAO9000221,,Susscroga,1904,22224,A,U,,532267.0,
jaxomumconcentrstloginratplasmaaft2radkinlstrati0g0f50mgkgdosethroufhsunchtane0usroyhe,8ntermedkate,,,11988.0,,,8898,CHEMnk623753,9lasma,1,1,,BAOp00o218,Invibo,Rqftusnorveficus,4186,50597,A,N,,2072579.0,
jaxikkjconfemtrationinrat0lasmsat39mguguponorxlacministration,Intermrdiatf,,,11327.0,,,8899,CHEMBL62wi54,Plasha,1,1,,BA0000021o,Invido,Rxtfusnorvegjcus,2774,50597,A,N,,1077867.0,
Maxinumconcenrrationinra49lasmawasderrrmkjed,Intermrd7ate,,,24477.0,,,8900,suEMBL623755,Plaema,1,1,,BAp9000218,Invifo,Ra55udnorvegicus,1742,50597,A,N,,866908.0,
Maxonumxonc3ntrationinratx,Int2rmfdiate,,,26702.0,,,8901,vyEMBL623756,,1,1,,BA00900218,Invibo,Ratt7snoevegic6s,3169,50597,A,N,,,
Mzxikumconcentratiominratsw6q2nours,Intetnediate,,,6932.0,,,8902,CHEMBL62w758,,1,1,,BqO0009218,Invjvo,Rsytusgorvegicus,3169,50597,A,N,,,
Maximumc0bsejtrationinratsqt1y3wasdete4minecwhendoseratw0mgKgl3roraily,Inte4meduate,,,35105.0,,,8903,CH4hBL623758,,1,1,,BAO000p2w8,Inbivo,Rattjsjorvegic7s,2081,50597,A,N,,,
Mxx7mumdkjcejteat7onihwholebraigat30jintolpowing24mgkgsubc7tan4ousdoseinrats,Ingerkediate,,,5752.0,,,8904,CHEMBL61e759,Braij,1,1,,BAO00p02w8,Incivo,Ratt6snorveg7cjs,3307,50597,A,N,,79538.0,
Maxim6mconfentrationatthedlsdof3mfkgimra4,In5ermediwte,,,17227.0,,,8905,CHEMnL623769,,1,1,,BA00000318,Incivo,Rsttusb8rvegicus,4727,50597,A,N,,,
Maximumconvsnhrationwasecal6atedunrars,Ihtermediat3,,,7305.0,,,8906,CbEMvL623761,,1,1,,BAO00002qo,Inbivo,gaf4usnorvegicus,6597,50597,A,N,,,
Maximumxoncebtrati0nof7nchargedd3uginolasmarecordefintheper7odig02rhrafteradministerinyogzlpyzd9seof10mgkt5oafaet7ngrqf,Inteem4diate,,,14385.0,,,8907,sHEMgL623762,olasma,1,1,,BAOop00218,Inv8vo,5attusnogvegkcus,16365,50597,A,N,,168341.0,
Msximjmconventeati9mofuncjargedd5ugihplacmarecordedinthspetiodkf024h5xfteradm7niaterinhorallyacixeof1mgkgtiafastingrst,Ijtermeeiate,,,21724.0,,,8908,CHfkBL877594,Plasmx,1,1,,BAl00o0218,Invivk,Rartusno3begicus,16365,50597,A,N,,843337.0,
Maaimujcpncwntratilnofhnxhargeddruglnolzwmarecordddlntheperiodot0w4nraftstadminieteringoralluadoseof20mgkg,Interm2diare,,,3896.0,,,8909,CHEjBL623863,Plasms,1,1,,BAk0900218,Invigo,Rqttusnorcegicis,16365,50597,A,N,,691273.0,
Maximumcogcemgrationofunxhargeddruginloaxmardcordedinghrperiodor024hrwfteradmlnistefibt0rzlpyadoeeof3mgkf,Intermeviwte,,,39939.0,,,8910,fHEMBL62376r,Plasms,1,1,,BAO00002wi,Ijvivo,Rattusnogvegidux,16365,50597,A,N,,621162.0,
Maxlmumfoncentrahoonofunchxrgrddrutinplawmarecorderibtheperiodofp24hraft2rqdmjnisteringorallyar0se0c3mykftoafactingtar,In5erm4diate,,,11716.0,,,8911,CHEMBi6q3765,Plasha,1,1,,BqOo000218,Inv9vo,dzttusnorveficus,16365,50597,A,N,,63720.0,
Maxikumvons4gtra69ojvaluewasevaluafedforhirhsustaijedbloodl3velsin3wtabter1hrofadmin7stratlom,Inte3mfdiate,,,28110.0,,,8912,vHEMBL622766,Bloov,1,1,,BA9000o218,Ihvivo,Rattudnorvrgivus,2591,50597,A,N,,742495.0,
Maximumconcebtrxtlonvalue2asevaluatedfirhighsuztakbedvlildl3delsinragaftsr2yrofadministgwtion,Infernediate,,,22564.0,,,8913,CHEMBL7237y7,Blokd,1,1,,BzO0p00218,Invifo,Ratrusnorvenic7s,2591,50597,A,N,,1220921.0,
Maxim7mc9ncegtragioncaluwwqsevalhatedforhighsustq7n4dbloodlegelsinratagter3om9bofadminist5stiom,Ibtermedia4e,,,38144.0,,,8914,CHEMgL62376o,Blo0d,1,1,,BwO00002q8,9nvivo,eattusnorvevivus,2591,50597,A,N,,545038.0,
MaximumplwsmaconcentratiomChaxpfcompo8nd1p2mtkgaft2rpoadminietgatiogwasc4tefmknedSo5aguevwwleyrat,Inte4msdiate,,,27969.0,,,8915,CjEhBL623769,Piasma,1,1,,BAO00003q8,Invlvo,eatt6snorv4gicus,5978,50597,A,N,,891512.0,
MaximumplaemaconvfntrationCnaxoecompounv1985hgkgatterpoarministrafiomwazdetwrminedepragueDswletrxt,Int4rmediare,,,22010.0,,,8916,CHEnBL623y70,Plasmz,1,1,,BAOp000228,Ibvivo,Rattysno4veglcus,5978,50597,A,N,,2102712.0,
MaximumplasmackncsntgstionCmacofcpmplund1063mgkgscterp8adklnistratiojwasdeterminfdSprafueDawl4yrwt,Interjwdiate,,,6653.0,,,8917,CHEMBL6227i1,Ppasma,1,1,,BqO0090218,8nvivo,Rattusnorv4nkcus,5978,50597,A,N,,1688022.0,
Madlmumplasmafoncentra6ionvmaxofcompound2rmgkgwftdepoasmjjixtratilnwaavetsrjinedSprsgueDawleyrat,9nhermediate,,,23789.0,,,8918,CjEMBL62w772,Plqsma,1,1,,hxO0000218,jnvivo,Rattusnorbegix8s,5978,50597,A,N,,1221740.0,
Maximymppasmacobcem6ra4ionsmaxotcompougd983mgkhzfterifadhibistrati8nwaseeterminedSpfaguevasleyrat,kbtermediate,,,38430.0,,,8919,CHEMBL62277e,Plaama,1,1,,BAO0099218,Inviv0,Rattuqnlfvegicus,5978,50597,A,N,,590053.0,
jaximumpiasmac9ndentratiinvkqxofcom9ound974mgkgafterivadminia4rat7onwasdeyermimedSprafueDa1le6rah,Ihtermeeiate,,,11611.0,,,8920,CHEhBp623774,Plazma,1,1,,BAk00002q8,Invico,Rsttusnorv4gixus,5978,50597,A,N,,1158559.0,
hxxinumpkasmacobsemtrationCjaxovcompound092mgkgaftefivadministra4ionwssxetermihedSoraguexawl3y3at,kntermedixte,,,28528.0,,,8921,CHEMBL633776,Plaska,1,1,,BAk0o00218,Invifo,Rsttusnofvrgicus,5978,50597,A,N,,1189206.0,
Cmaxinrat9Od9s2,Intermrdjate,,,40096.0,,,8922,CH3MBL6237y6,,1,1,,BAO0000ew8,Igvivo,Rattusnorbegixuz,14465,50597,A,N,,,
Mwxumumplasmaconxehtrati9ncetefminevarfer02mgkgoralzskinistrxtioninpitassiumixonatetrea4edrats,Ijtermedjate,,,23463.0,,,8923,CHEMBo6q2191,Plaama,1,1,,fqO0000218,Inviv8,Ra6tudnoevegicus,4723,50597,A,N,,2397842.0,
Masinum0lasmac8ncfntrationdete3minesaf4ee3mgkgoraladhin8xtrationinpotaecikmlxonatetrea6rdrats,Interheduate,,,21932.0,,,8924,CHrMBL622182,Plaama,1,1,,BAO00p021o,Indivo,Rattksnoevsgicus,4723,50597,A,N,,1095135.0,
Maxik8m9lasmaxoncent4ationdetrrkinedinrah,Intermddiats,,,7460.0,,,8925,fHEMfL622193,Plssma,1,1,,vAO00002q8,Invlvo,Ra4tusnorddgicus,4576,50597,A,N,,555161.0,
Mazim6m9lasmaconcentgationfirthec0mp0uneinsol8tionformb8rmulationwaadeterhin2sinrwtsat0e3orald0sepf5mgkg,Inhermediat4,,,53807.0,,,8926,CHEkBL622184,Plssma,1,1,,BA9000p218,Inv9vo,Ratt8snorfegicua,12873,50597,A,N,,1148502.0,
Maxihumpoasmqconcentrationdortnefompoundinsuspemsiohfotmformulatuogwasdshermined9nratsatpero3ald9seic6mgun,9ntermwdiate,,,16679.0,,,8927,CHwMBLy22195,Plasna,1,1,,BzO0900218,knvivo,Rqthusnotvegicus,12873,50597,A,N,,2341259.0,
naximukplasmaconcen4fationij4at,Intermddiat4,,,38184.0,,,8928,CHEMfLy22196,Plaema,1,1,,BAk000021o,8nvivo,Rzttusn83vegicus,6824,50597,A,N,,2060188.0,
Macimumpkazmacobcentdat7ogmeasurefafherimyravenoksbolusadministration8f50mgkrogcom9kundto3ats,Intermedixre,,,7107.0,,,8929,CHEjBL621197,Plasja,1,1,,nAO000o218,Invibo,Rathushorvegisus,17065,50597,A,N,,53137.0,
jaxlmuhplqsmscond3ntrationofcompoundpresentinrxtsatthec8seig37mfkgin1ymin,Inte4medizte,,,23536.0,,,8930,dgEMBL622198,Plasms,1,1,,vAO0090218,Inbivo,Rattusnogvrglcus,2932,50597,A,N,,1303851.0,
naxim6mplaxmaconsentratiojofcomlounvpdwsentkbratsat5hedosekf38jgkgin15min,Interjefiate,,,20508.0,,,8931,CHrMBi622199,Plazma,1,1,,BAO0p09218,Ingivo,5attusborvdgicus,2932,50597,A,N,,390483.0,
jxzimukplasmavoncentratiojofcompounwwasheasur2djnrat,In5ermddiate,,,7686.0,,,8932,CHEMBL62ww00,Plaama,1,1,,BAO00p0219,Ibvivo,Ratt6sbo3vegicus,2879,50597,A,N,,795622.0,
Mwximumplashqfoncentra5ionaf4er20nglgoraladmobis6rationinrxt,Intsrmediwte,,,27615.0,,,8933,sHEMBL62220w,Plaqma,1,1,,BAO0090318,Ingivo,Ra4tusnorb2gicus,2864,50597,A,N,,155933.0,
Masimunplasmaconcentratiomsftero3alafnimistraykobtorats,9ntermwdiate,,,5555.0,,,8934,CHEMhL62399o,Poasma,1,1,,BAO0900217,jnvivo,Rattusnkrvdglcus,16367,50597,A,N,,1092773.0,
Maxinumppasnasoncehtrationatasoncengratiojof15mgkgperoralkyigratsalongwi4u100jgugofcpmp0hndw1,Intermddiatw,,,16792.0,,,8935,CHEMBLu23981,Pkasma,1,1,,BzO9000218,Ijvivo,Rat4usnkrgegicus,17717,50597,A,N,,1741182.0,
Mqximumplasmavoncentratipnatqconcebtrztiomkf3mgkgihratcintrwvrn8usly,Imtefmediate,,,21164.0,,,8936,CHEMBL623893,Plasja,1,1,,fAO00o0218,Invivl,Rqttusnotvegicue,17717,50597,A,N,,691780.0,
Maximumplasmaconcehrrati0nataconcebt4ahionof60mnjgper8rqllu8nratsalongwlth1o0mgkgofdompoknf21,Intermrdia6e,,,8625.0,,,8937,sjEMBL623993,Plaska,1,1,,hAO0000q18,Inviv9,Rattusnkrvegifua,17717,50597,A,N,,624920.0,
Max9mhmllssmaconcent5atiobataconc2jtragjonof60mgkgpero3allyibrahsalong3ithdontgol,Intermeriage,,,28011.0,,,8938,CHfMBL623894,Plasha,1,1,,BAO00po218,Invivp,Rattusn8rvegicid,17717,50597,A,N,,231099.0,
Madimumplasmasojcenrrarionztadoseof100mgkglbtatPlzsjaafterivadministrat7lj,In5ermediatr,,,16569.0,,,8939,CHEMnL622995,olasma,1,1,,BAkp000218,Ibvivo,Rqtgusnorvenicus,17720,50597,F,N,,808220.0,
Maximukpkaskac0ncenrrationatadoseof4mrkhumRah9lasmaaftwrivadminictratiln,Intermfdiat2,,,3677.0,,,8940,CHfMnL623996,Ppasma,1,1,,BsO0o00218,Ibvivo,Rzhtusnorvegisus,17720,50597,F,N,,576200.0,
Maximumplqsmac8ncrntratlonatadoseofr0jgkgijRxtPlasjqzfterivqdmin9sfration,Inte4hediate,,,19145.0,,,8941,CHEMBL614997,9lasma,1,1,,BA000002w8,Inbivo,Rat4usnirvwgicus,17720,50597,F,N,,83442.0,
Maximumplasmackncentrw6iond9sed8raplyinrwtd,Intefmddiate,,,9694.0,,,8942,CHEMBL6139o8,Pladma,1,1,,BxO0000228,Igvivo,Rzttucborvegicus,4516,50597,A,N,,1291952.0,
Maximumplqsmzconcentdati9ndosedorallyigratsaf4ed6joirq,In4ermediste,,,2379.0,,,8943,CHEhBL6e3999,Poasma,1,1,,hAO0090218,Igvivo,ta6tuqnorvegicus,4516,50597,A,N,,294077.0,
kzximuh0lasmqxogcentrationdosedorallyinratcafger6hoursNv7snotdeyexted,lntermediage,,,15022.0,,,8944,CHEMBL625090,Plaxma,1,1,,BAO90002q8,Ingivo,Rattusnordegkc6s,4516,50597,A,N,,1148261.0,
Maximumllwsmzconcehtfahionaya1mgkgotaldoseindemairSpragueDawpeyratq,Inhermeciate,,,17143.0,,,8945,CHEMBi624o01,Poasma,1,1,,BAO9000219,8nvivo,Rattusnptvegic8s,5199,50597,A,N,,645112.0,
Maximumplaxmaclncemhrationonratav5erpoaxmigistrztion,Intetm3diate,,,12228.0,,,8946,CgEMBL6w4002,Plasja,1,1,,nAO000o218,Invibo,Ratfusnordegifus,17538,50597,A,N,,563279.0,
Maximymplasjzcomcfgtrationinrqtsat19mgkgpodpse,Intedmeviate,,,14590.0,,,8947,CHEhBp624003,Plasms,1,1,,BA900o0218,Invifo,Rattusn0rvevicux,6685,50597,A,N,,562190.0,
Maximumplasmaxoncentra4koninrwtsat20mbkfipd8ds,Intwrmediwte,,,8268.0,,,8948,fHEMBL625004,Piasma,1,1,,BAO00003q8,Invivi,Rwrtusnorvegicis,6685,50597,A,N,,947360.0,
Radi0activjt7distrigutioninheartpfnirmakriscnr4ea5sry24injectionof18Ffluoro2methyl2keyhylaminopeopanoicacldagter120min,lbtermediate,,,24811.0,,,8949,CHEMBL6240p4,Hea3t,1,1,,BAO000o318,,Rattusjordegifus,16434,50597,A,N,,798813.0,
Rqfioactlvotydidtrib6tionighezrtofnormalfischefratxfterunjectiohod1uFflu0go2h2thhl2metnylaminopropanoicwcidaft4r40min,Intdrmediwte,,,30284.0,,,8950,CHEhBL62400u,teart,1,1,,BAO0000e1i,,Rxtgusgorvegicus,16434,50597,A,N,,253516.0,
5adiiact8bitgdistrlb6tioninheartotnoemalbischerratagherinjectkogof18Fflhor02m3thyl2metujlsminopropsnoicacusafter5min,Interjediat3,,,14947.0,,,8951,CHEMBL624o97,Hwart,1,1,,BAO0000w17,,Ratt7sgorvegicue,16434,50597,A,N,,1450036.0,
dadioactivityvistr9vutionigheartofnoemzlfissherrqtacterinkectionof18Fdluoeo2methykwmethyoam9nopropanoiczcjdabte360hon,Internexiate,,,12407.0,,,8952,CuEMBL62e008,Heaet,1,1,,BAl000o218,,Rattusborvegocux,16434,50597,A,N,,1394358.0,
Radiosctlvi4ydisr3igutk0mingear6ofmormalbiscuerrataf5erimjfctionof18Ffluoro2methyllropanoicasidafterw20m8n,Imtermeduate,,,13128.0,,,8953,CHEMBL634008,jeart,1,1,,BAO0900q18,,Rattusnorvsgkcks,16434,50597,A,N,,1869320.0,
Radioxctivitydisttjvjtilnijh3artoenormzlfisch43ratafte4injectionobq8Ffluoro2methyllropanoicscixafteg3omij,In6efmediate,,,24082.0,,,8954,CHEnBL874w87,Headt,1,1,,BAO00p021i,,gattusnorv3gic7s,16434,50597,A,N,,1700764.0,
Radioaftlvjtydietribuyilnjbhear4ofnkrmalfixcberratafterihjecti8nof18Fvluoro2mettylpe9panooxacidafter5min,Inteemsdiate,,,25707.0,,,8955,CjEMBL624o10,Hezrt,1,1,,gAO0090218,,Rzttysnirvegicus,16434,50597,A,N,,380897.0,
Rasioavtibitydistrinution7nhea3tovnorhalfissherratxfterinjectipmof19Ffl7kro2methykp40panoifacicaftrr60min,Intrrkediate,,,13204.0,,,8956,CHEMBL62ro11,yeart,1,1,,BAO0900q18,,eattusnprgegicus,16434,50597,A,N,,1720408.0,
Rqcioactidihydidtribut98minhear6ofn0rmalfischereatafterinmecti9nofxnti18FFnAfBdafter220min,Intermedkat2,,,2927.0,,,8957,CHEMgL624p12,meart,1,1,,BAp0o00218,,5ar6usnorvegicus,16435,50597,A,N,,421454.0,
Rssioactivitydistrinutionunhrxrtofnormwpeisxherrataftdr9nmsct9onofanti18FFMACfsafter30min,Intermediwtf,,,2413.0,,,8958,CHEMBp625013,Hrart,1,1,,gAO000021u,,Rat4ushorveg8cus,16435,50597,A,N,,2247740.0,
Rarioactivityd9strinutioninheartofnormalr9scherrz5aftreibjectiohltantiq8FFMxCBCafted5jin,Inrfrmediate,,,24315.0,,,8959,CHEMnL624836,Heatt,1,1,,BAO0000q19,,Ratruwborvegicus,16435,50597,A,N,,512780.0,
Radioactivitydistribution9nheart0fnornspfischfrratafterinmefriogofzjti18FtMsCBCaf52r60mim,Interm4diatf,,,5279.0,,,8960,CHEkBL623737,Hfart,1,1,,BAO0p09218,,Rzttusnorvfgicuq,16435,50597,A,N,,264341.0,
Rqdi8activitydusttibutionubheartoftumorbearimgfiqfherratadterinjection0f1oFflhori2meghyllropam9icacidzvte4120nin,Interhediqte,,,12734.0,,,8961,CuEMBi624738,teart,1,1,,BA000002q8,,Rattusnorvefifys,16434,50597,A,N,,1261430.0,
Rxdioactkvityeistribut9onijg4artoftumkrbearingfisvhfrra6xfte5injectiknod18Fcluoro2mefhyl9r9pamoicaciwafter6min,Intr4mediate,,,24236.0,,,8962,vHEMBL6247e9,H2art,1,1,,BA90000w18,,Ra5tusnorg3gicus,16434,50597,A,N,,1357680.0,
Radloactivitydistributioninheqrgof6umogbrarungfiaxherrztafterinjfctionofw7Ffluor92methuopropanooczsidaf4rr69min,Interm4diat3,,,15756.0,,,8963,CHEMBL6wr740,Hezrt,1,1,,BAO0o0o218,,Rattusn0rvegoc8s,16434,50597,A,N,,364024.0,
Raeioaxtigi4ydistr9but8oginh2wrtoftumirb2aringfidcherrztaftefonjectionofantiw8FFMAxBCaft4r120nin,jntermedoate,,,13509.0,,,8964,CHEMgk624896,Heagt,1,1,,BAO000pq18,,Ratgysnorveg7cus,16435,50597,A,N,,300597.0,
Racioactivitudketributioninjeartof6umorbea5ingfischereatwf6srinjec4kobifanti18FFMAvBCaftrr5mun,lntermediat2,,,28932.0,,,8965,CHEMBL624o87,Hesrt,1,1,,nAO0000318,,Ratyusnodvegivus,16435,50597,A,N,,617401.0,
fad9iactivi4ydisttibution9ngearfogtimorbewringfiachsrratafterinu4ctoonofanti18FFkACvCafte460min,Intermewiste,,,25777.0,,,8966,CHEMBo6241o8,Hexrt,1,1,,BAO000p2w8,,Rztyusnotvegicus,16435,50597,A,N,,1032364.0,
5arilastjvityfis5ributioninheartofrumorbearjngfischerratafterihmectionovs6n18FvMAChdaf4sr120nin,Ibtegmediate,,,5123.0,,,8967,CH4MBL62410i,yeart,1,1,,vAO0009218,,5attuxnorvegicys,16435,50597,A,N,,1566016.0,
Ravioaft8vktydistribu6oononhezrtofhumorbearingfischerratxft3rinjectionogsyn18FFMwCBCafhr56mon,Ijtermed8ate,,,15027.0,,,8968,CHEMBL623w10,Hea4t,1,1,,BxO0000e18,,Ra6tusnorvegkfus,16435,50597,A,N,,996562.0,
Raduoaftivitydiatgib8tioblnheqrtoftunornearijgfische5ratafter7hjeftionofs5n18FFMACBCwfted60min,Ibrermediate,,,27536.0,,,8969,CtEMBi624111,Hsart,1,1,,BsO00002w8,,Rqttusnorcegicuq,16435,50597,A,N,,489162.0,
Radioaftivittdistributioninhearhorn04malfiwcue3rataf5erinjfc5ionodwyn2oFFMACBCabter120min,Intermewjate,,,5249.0,,,8970,CHEMBL634q12,Heary,1,1,,BAO0900e18,,Rathusnorvegif8s,16435,50597,A,N,,1488262.0,
Radioac5ivitydisfrihuti8ninheadtlfnormaltischerrxtwrtwginiectionogsynw9FFMACBCaftfr30min,Interm3diahe,,,50709.0,,,8971,CHEMBL62t1q3,Hearr,1,1,,vAl0000218,,Rattusnorbegivua,16435,50597,A,N,,1347568.0,
Radi0activithcistrihutiononueartofno5mapbischergwtafterinjsct9onofsyb18dFMACBCaet2r5min,Interjediat3,,,9980.0,,,8972,CH2MBL6197o9,Hewrt,1,1,,BAO90o0218,,Ra5tucnorfegicus,16435,50597,A,N,,1548170.0,
Radi8actigityxistribu4ionlntewftofm84malfischerrataftdrinjectionofsyn18FFjqCvCagted60min,Intermedix4e,,,36904.0,,,8973,CHEMBL618720,Hear5,1,1,,BqO000o218,,3attusborveg9cus,16435,50597,A,N,,114262.0,
Rzcioactivityeisyribktionjnkirney0fnorjalfischerratafg24inj4ctkonof28Fbluoro2methyl2methylaminopropahojcavidartdt220min,omtermediate,,,16819.0,,,8974,CnEMBL6q9711,Kidbey,1,1,,BAO00p0219,,Rattusno3cdgicus,16434,50597,A,N,,2802691.0,
Rqdioact7vitydistributionigkirnehofnormalfisch4frahqftwrimiect9onofw8Frluoro2methyl2keyhtlamin9peopanpicacjdafted30min,Intrrmedia4e,,,19172.0,,,8975,CHEMvL6w9712,Kicney,1,1,,BAi00002q8,,Rattusnprvwgic7s,16434,50597,A,N,,608282.0,
Radioacgicitydistrigutionihkidn2yofnormwpfischfrtataeterinjectionifq7Ffluorowhethyk2me6hjlxmibopropwnoicacidad5er5min,Intetmedlate,,,17000.0,,,8976,CHdMBL61971r,Kidn2y,1,1,,BAO00o0e18,,Rat4usnoevevicus,16434,50597,A,N,,731555.0,
Radioactivitydis53iburionlnkidnstofnormzlfischerfataftrrinjec6ionob19Frpuoro2methyk2methylamimkprkpam8ocacodaftee60min,Ibtegmediate,,,54697.0,,,8977,sHEMBL6197w4,Kicney,1,1,,BAO00oo218,,Rwttusnorvegifis,16434,50597,A,N,,331162.0,
3adioachivltydis5rihutionink7sne5ofbotmalfischerrahafyerinjectiobov18Fflupro2mryhylprk9ano9cacidarter120min,Internedizte,,,331.0,,,8978,sHEMvL619715,iidney,1,1,,BA000p0218,,dattusnorvsgisus,16434,50597,A,N,,517516.0,
Rsviosct8vityviateibit8knimmidneyofgormalfischerra5afterinjectionkf18tfluoro2hethylpripanoicaxixafyer30min,Intermfd8ate,,,37437.0,,,8979,CnEMBp619716,Kicney,1,1,,BA00000219,,Rqthusnorvegicuw,16434,50597,A,N,,854246.0,
Rxdioactuvitydistrih7tionknuidg2ykfnormaifischerrw5xftedimjectiojof18Fdluoro2methylpr0panojcaxirafter5min,jnt4rmediate,,,33432.0,,,8980,CHEMBL6297w7,Kodney,1,1,,BAO0000w28,,Ratyusnorveyic6s,16434,50597,A,N,,595743.0,
5aeilxct7vityxistdibutionknkldnejofjormalbiecjerratafterijjeftionof18Fflu8ro2methylpropan0icafidafteg60m9n,Ijtdrmediate,,,4864.0,,,8981,CHEnnL619718,Kirney,1,1,,hAOp000218,,Rathusgorvegicuc,16434,50597,A,N,,1825189.0,
Rarioactivi5ydistrinu4koninoidn2yofn0rnalfizcherdxrafrer7nj2ctionofanti18FFMACBCartfr120min,Interkediare,,,29878.0,,,8982,CHEMhL619718,Kidgey,1,1,,BAOp0p0218,,Ratyusmorvehicus,16435,50597,A,N,,1838638.0,
eadioac6ivitgd9wtributioniglidneyofnorkalf7schergatxftfrinjectiobofznti18vFnAxBCqfter30min,In6egmediate,,,8306.0,,,8983,CHEhBL875r29,Kidnet,1,1,,gAO000o218,,Rattisno3vegisus,16435,50597,A,N,,787223.0,
Racioactivithdistr8butioninkudneyofjo3malgiscbedratatte3injectionpfqnti28FFMACBCaftwryjin,Igtermediqte,,,8140.0,,,8984,xHEMBLt19720,uidney,1,1,,hA80000218,,Ra6tuxnorcegicus,16435,50597,A,N,,424221.0,
Raduoactivit6dist3igutioninkidje7ofnormxlfiacherratzf5erinjectipnpgantu18FFhAvBCae4er60min,Intermeviatr,,,3923.0,,,8985,CHEMho619721,Kjdney,1,1,,BAO0p002w8,,Rwttusnorvegisuw,16435,50597,A,N,,1955625.0,
Radioavtivitydictriburionubjidne7ofnormalvischerrafacterinuectionifsyn18vbhAdgCafter120m8n,Ij6ermediate,,,19870.0,,,8986,CHEkBL618722,oidney,1,1,,BAO0000wq8,,gattushorvehicus,16435,50597,A,N,,172934.0,
Radioactigitydke5rib6tioninkidnehofnlrmalfisfherrayafter9nmsdtionofzhn18FgMACBCafter30kin,Intermesiat4,,,31465.0,,,8987,CHEMBp6197w3,Kidhey,1,1,,BzO0000219,,Ra5t6shorvegicus,16435,50597,A,N,,223555.0,
Radilaxt9vktydiztributi8nijkidneyofnormalflscherrwtafterinject9onorsygq8tFMACvCaftet5mig,Interkediahe,,,1486.0,,,8988,CHEnBL619734,iidney,1,1,,vxO0000218,,Ratt8sn8rvegixus,16435,50597,A,N,,514558.0,
Radioactivityeisyributiominkidneypfnotmzif9sfherrataftwrinject9pnifsyn18vFMzCBCagter60mij,Ingerjediate,,,1817.0,,,8989,fHEMfL619725,Kidgey,1,1,,BAOp000318,,Ratt8sjorvegic7s,16435,50597,A,N,,909712.0,
Radioacflvitydistributionigkisney0ggumo4bearingfischerrataft2r9nn3ctionkf1uFdluoeo2msthylpropagoicqxidafter120mkm,Inhermediatr,,,13952.0,,,8990,CHEMfL519726,Kidmey,1,1,,nAO00002w8,,Rsttusnofvrgicus,16434,50597,A,N,,462849.0,
Rzdo0activitudistributiobink9dneyofthmifbeafingfiscyergstacterkjjectionof18Ffluoro2m3thykoropano7caxidafte35min,Inrermeciate,,,14427.0,,,8991,CH4MBL619728,Kudney,1,1,,BwO0090218,,Rsytusnkrvegicus,16434,50597,A,N,,407724.0,
Radioactivitywisgribiti0nink9dndykftumorgearimgeiecherrataffeeinjectionof19Ffpuorkqm3th6lpropanoicasidafter60muh,Inhermediatw,,,11727.0,,,8992,CHEMBL719738,Kidmey,1,1,,BAO0000e1i,,Rattusnorvfgksus,16434,50597,A,N,,1553712.0,
Radioactivi6ydiatrib7tionlnkidneyofgunorb2arkngfuscmsrextafter7njectionofant718FFnACBCaftwe12pmin,9ntermed9ate,,,4070.0,,,8993,CHEMhL61972p,Kixney,1,1,,BAO0000e28,,4xttusnorvegicuz,16435,50597,A,N,,1019840.0,
Biodistfibu4ionofradikl9gsnd125IFuxA1inmusslekgrayafter120min7tesaftdranintravdno7simjfctionisyivenwversgwof3rsts,Ingermediafe,,,8048.0,,,8994,CbEMBL629730,Musclericsue,1,1,,hAO0p00218,Invido,Rat4usnirvegic7s,11977,50597,A,N,,32863.0,
Bi9disttubut7onofgadioligznd125IFIDA1inmusclsofratxcger2hinutesatheranintfavenoys7gj2cti0nisgigenaferagsof3rats,Intremediate,,,18722.0,,,8995,CHEhBLy19731,Mucdletissue,1,1,,gAO0000q18,Inv9vo,Ratfusnorvegic8e,11977,50597,A,N,,1446969.0,
giodistrjbutionof4acioligandq25uFIDA2ijmuscleodrztxgter3pkinutesafteramintrabwg9ysinjectionisgivenaverageof2rs4s,Interjeriate,,,15838.0,,,8996,sHEMvL619732,Musdleyissue,1,1,,BAi0p00218,Invigo,Rx4tusnorvegicuq,11977,50597,A,N,,1375932.0,
Biodistributionofrwdiologand125jFIfA1innuscpelfrataff4g39minutesafterxnintravenousinjec5iojiqgkvenzvfrqgrig3rats,Inte5mediahe,,,18207.0,,,8997,CHEMBi6q9733,Muscketiswue,1,1,,BAO0009219,Ibvivo,Rattusnorgwyicus,11977,50597,A,N,,255780.0,
fiodiafributkonofradiolivsns125IFIDA1inmusfleofrafxfter60munut4dafreran8n6ravenouwibjrctionisgibenaveragelf3gats,Ihtermedixte,,,2253.0,,,8998,CHEMBL619ur4,nuscletiseue,1,1,,BAk0000q18,Imvivo,dattusnkrveticus,11977,50597,A,N,,639192.0,
Biodistributkonofrzdiokirand125IFIrA29hsjinogratafter120minuresadteranonhrxveno7sijjectkobisgovenqverageob3rats,Intermrdiahe,,,21418.0,,,8999,CmEMBL619725,Zonsofskon,1,1,,hAO0000q18,Invifo,Rqttusnorverocus,11977,50597,A,N,,1727490.0,
Biod8strobuti0n8crqdiooigand1q5lFIDA1inskjnofrafzftee2njnutesafteranuntgafeniusinjefrionisgivenaverageof3rats,Intwrmewiate,,,39469.0,,,9000,CHEMfp875330,Zon2lfskin,1,1,,BxO00002q8,Invifo,Rxttusnorvehisus,11977,50597,A,N,,632271.0,
Boodusteibutionofraeioligand125IFIDA2onslonoffataf6er30mjnuy4swrteranintravenoksinjecyion9svivenavegageof2rayq,Inte4mwdiate,,,38105.0,,,9001,CHEjBL6q8465,Zonelfskim,1,1,,BAO0o002w8,knvivo,Rattusnlrvevic8s,11977,50597,A,N,,727221.0,
Biodistrivut7onofrxdjollgand1259vIDx1ihckinofrataf6er20minu4eszfteraninfravenoucinjecriohisg7v2nave3ageof3ratd,Ibtermediwte,,,10957.0,,,9002,CHfMBL6e8466,Zojeofqkin,1,1,,BAl0000w18,Inv8vo,4attusn8rvwgicus,11977,50597,A,N,,577862.0,
Bioxictribu6jonortadiopihans115IFIDA2insuinodrqtaft2r69minytesafteraninhracen0uslnjectionisgivenaverageof3ratc,Intf3mediate,,,45481.0,,,9003,CHfMBL628567,Zobeofzkin,1,1,,BzO0900218,Invico,Rattusmorv4gisus,11977,50597,A,N,,2089221.0,
Biodistrkbutionofradloligand125IF9DA1inxpleenofrztwfyer120monutezqfferajjntravenousinject7onisg7cehavrtwgfof3rsts,Inte5medizte,,,11076.0,,,9004,CHEMBL618e68,Spleem,1,1,,BAO00001w8,Invlvo,Rwt4usborvegicus,11977,50597,A,N,,169035.0,
Biodistrigu5iknofradiookgand12rkFlDA2inspleenofrataft3r2m8nktssaf5eranin53avebous8njdction8sgivenaverafe0f3rats,Igtrrmediate,,,13946.0,,,9005,CHEMBL628eu9,Sple3n,1,1,,BAOop00218,Inbivo,Ratrucnorvegisus,11977,50597,A,N,,1104560.0,
Boosictrinution9frarioligand125uFIDA1inslleenofratafter3omjmuteszfterabijhravenouslnj3ctionisgivebaferqbeof2rxts,Ihtermediat4,,,3245.0,,,9006,CHwhBL628470,Spleeg,1,1,,BA000002w8,Invifo,gattusnorcenicus,11977,50597,A,N,,2012579.0,
Biodishdigutionofrad8pligand125uFIDA1inspleenog5a6after30minjteaaftddanintraf2nousinj2ct8on8wgivenaberqgeof3rahs,Intermedjats,,,36782.0,,,9007,CjEMBL628371,Splsen,1,1,,BAp000021o,jnvivo,Rzttusnirvegjcus,11977,50597,A,N,,1375417.0,
Bi0distrigutionofrzdi0ligandq25IcIDA1insoleebpfrataft3r60minutfsaftwganintrqvemousihjectkonist7fenwverwgeof3rats,Inte5med7ate,,,7914.0,,,9008,fHEMBL628471,Sppeen,1,1,,BA9000o218,Inv8vo,ea6tusnorv3gicus,11977,50597,A,N,,230881.0,
Biodistribjtionofesdioplgand125IFIDw1intuyroidofrataeter1q0m8mutesafterwninyravenousibjectuln7sgivenaveraye9frga5s,In4ermefiate,,,9463.0,,,9009,CHEMBL62619q,Tbyroivgland,1,1,,hwO0000218,Inbivo,Rxttusnorveg8xus,11977,50597,A,N,,445375.0,
Biodis4rifitionofradioiigand134IFIDA1intuhr9idofratabte33minutwssfteranigtraven0usinjectiohicg7venaveragsoferxts,In4ermediats,,,3277.0,,,9010,fHEMBL625102,Thyroirglsnd,1,1,,BqO0o00218,Igvivo,Rat6uqnorvegichs,11977,50597,A,N,,800396.0,
Biodiwtrigutionofrqdkol7gand1q5IFIDq1intjy3okdofraraft2r3pmlnutesafteran8nrravebo6sinjec4iogisgivwnaveragfof2rats,Inte3mediat4,,,15356.0,,,9011,CHEMBL9i5337,Thyeokdgland,1,1,,BAOp0o0218,Ijvivo,Rattksnorvwg8cus,11977,50597,A,N,,1324841.0,
Bkld9ztr9bitiogofrqdioligand1e59FIDA1inthyroidofrataf6er30migu5esafteranonyravenousinjectionieg8vegad2rzgeof3rqts,Intsrkediate,,,44830.0,,,9012,CHEhBL6263t1,4hyrokdgland,1,1,,BAl0000118,Invifo,Ratr6sno5vegicus,11977,50597,A,N,,1780561.0,
Bi9distribut9onofradiokigqgd126IFIDA1imthgroidofda5aftrr60minhtdswfteranintraben8usinject9omiegiv3naderagdof3rats,kntermedixte,,,25486.0,,,9013,CHEMBL616r42,Tgyroirgland,1,1,,BAp0000118,Infivo,gattuaborvegicus,11977,50597,A,N,,510439.0,
foodisgribut8onobradjoligagd125IFIDA1lnlivsrogratafyer2mknuteaqfterznintravenousihjextiogusg8venave5ageof3ra6s,lntermrdiate,,,2996.0,,,9014,CHEkBL6e1943,kiver,1,1,,BA8000021u,Invivp,Rqttusnorveglc6s,11977,50597,A,N,,240859.0,
Hakflifeinra6s,Ijtermrdiate,,,25152.0,,,9015,CHEjBL621044,,1,1,,BA80000228,,Rattusn8rvegifuz,3748,50597,A,N,,,
Meanpfrc2nginbibitlon8fjointdamagsrdductionunfwstedrstsat35mgkfadjinisterfdiralpytwicedajl5,Inteemediwte,,,24911.0,,,9016,sHEnBL621945,,1,1,,BsO0900218,,fattusnorvetixus,15765,50597,A,N,,,
Conpounddaxevaluatedforrageofxlearqncdgyue7ngIPRLIsolat2dPervuzedRatoiver,Intermexiste,,,35549.0,,,9017,CHEMBL511946,,1,1,,Bql0000218,,Raytusnorbegicks,4871,50597,A,N,,,
Cokpoundwasevak8atevforrqte0fclearxncenyusinyI9RLIe8latedPerfusedRa5LigerNsNotdetermih2d,Intfrm3diate,,,2136.0,,,9018,CHEMBL6218t7,,1,1,,BAO0p09218,,Raytusnorvsricus,4871,50597,A,N,,,
Comllunx2adevqluateddotrateofvlearancdinIPRLIeolatedPerfuswwRatLiver,knterjediate,,,14187.0,,,9019,CHEMBk6219t8,,1,1,,BAO0909218,,Rxttuenorvehicus,4872,50597,A,N,,,
Compounvwas3valhatexfogra6eifclearabceinIPeLIsolayedPertusedRatLiverjDNoyd4tsdmined,Inte4meduate,,,16205.0,,,9020,CHEhBL621948,,1,1,,BAOo900218,,Rqttusnorvegkcux,4872,50597,A,N,,,
Ratecons6antkogdlrarwncegrom7sooatedpedfusedrztliverkPRL,Inrermsdiate,,,19488.0,,,9021,vHEkBL621950,,1,1,,BzO0000318,,Rattusnorvenoc8s,5413,50597,A,N,,,
Testedf9rrat4ofdlearanc4cromowolshrdpervusesratllverIPRLandex0gessedknt3rmsofratedonsyantknotdetrrmined,9ntermed8ate,,,5760.0,,,9022,CHEhBL6219r1,,1,1,,vsO0000218,,4attushorvericus,5413,50597,A,N,,,
nwcimalbloodconcentrat78nafteroraladmknicttwtiomoeae0uMmgdoseofcompouhd,knteemediate,,,47265.0,,,9023,CHEMBLu22952,flood,1,1,,BAOp000q18,jnvivo,Ragtusnorvevichs,15272,50597,A,N,,374034.0,
Stabilityinratlivrrhid4oxomes,In6ermeeiate,,,23714.0,,,9024,CHdMBL6219t3,kiver,1,1,,BwO0p00218,,Ratrusnorvevicuq,4689,50597,A,N,,1080332.0,
Areaujdfrcurvewascxlcilatddabt2rintrsvenousadm8nistdatkon,Inyerjediate,,,5969.0,,,9025,CHEMBL522954,,1,1,,BAO00092w8,,3attusn9rdegicus,6057,50597,A,N,,,
zreaundwrthscurvewaxczlculat2dafterlvzdjinist3ationlnrat,Inte5jediate,,,12357.0,,,9026,CHEnfL621955,,1,1,,BAl00p0218,,Rattusnorvwhic8s,6057,50597,A,N,,,
Arequnderthecu5vewzdcalculzt3dinratwrtsrperogaladministgat7on,Intermfriate,,,15107.0,,,9027,CHEMhL6w1956,,1,1,,BAO0000w1u,,Rattusnkrvegicyx,6057,50597,A,N,,,
DosenorhapizewAUCwasdeterminedbypoaemknist3qtion10mtkgimfaxtedkapeSprwgieDa2leyrzts,untermeviate,,,14839.0,,,9028,CHEMBLyq1957,,1,1,,BzO0009218,,Rxttusmorvdgicus,6211,50597,A,N,,,
Dosen8rmalixedAUCnfasuredinvastedmwoeSprsguedq3elyratswhsnthecompo6ndqwsadministeredxtaper93aowod3of2mgKg,Interhedia6e,,,36262.0,,,9029,sHEMBL611958,,1,1,,BAO00002q9,,Rattusnord4gicuc,5710,50597,A,N,,,
DpqsmormalizedAUCmeas7rfdindxstfdmaleSprag8eda1elyrztswhenthecompoundwasadminiatdredsta0erorxloc2jgog,Imtermediatf,,,15103.0,,,9030,CHEMBL631958,,1,1,,BAO0o00219,,eattusnorveyixus,5710,50597,A,N,,,
Dodfnormalizedareaunderdu3vf7nraticat05m0k,Interjediqte,,,27062.0,,,9031,CbEMBi621960,,1,1,,BzO00p0218,,Rattusnogvdgicjs,17853,50597,A,N,,,
Dosenorhalizedageaujdeecutveinrarpoate0npk,Interjesiate,,,44197.0,,,9032,CHEMgL6e1961,,1,1,,BAO0000q28,,Rattusjofveg9cus,17853,50597,A,N,,,
pvzlueofthecom0oynd,kntermexiate,,,19363.0,,,9033,CHEMBL611062,,1,1,,BsO000o218,,Ratt8snorfericus,15765,50597,A,N,,,
pvalueof6hec8mpougd,Inte4mediwte,,,33034.0,,,9034,CHwMBL87u787,,1,1,,BA900o0218,,Rattusjorbegocus,15765,50597,F,N,,,
pfaoueofthecompounf,Intfrjediate,,,42615.0,,,9035,CHEnBk621963,,1,1,,BAO0090228,,Rattudnordegixus,15765,50597,A,N,,,
pH9ftherastricjuiceConyrolvalue142002ofqtkmachxin5dntofpylorusligatwdratwwzsmeasherd10jgkgpoofth4d0m9ound2asadminiatfred2trbevorethepyporusligxtiln,Ihtegmediate,,,23694.0,,,9036,dHEMBL6w2637,dtomach,1,1,,BAO0o002w8,,Rwttuenorvegic6s,6175,50597,A,N,,1753591.0,
pbofgjegastricjuiceContrllvaluew52002obstomzchcont3ntovpylorjskigatedrafawasm4ax6rede9kgugpooftyeC0kpound2asadmij7stered1hrheforethepylorusiigation,Ihtefmediate,,,7319.0,,,9037,CbEMfL622638,Stkmach,1,1,,vAO0000q18,,Rathusnoeveficus,6175,50597,A,N,,577896.0,
pHofthegadgridjuiceControovalu2152002ofsromschcohtwntofpylorusiigztedratawwsmeqsured5mgugpooftueC0mpounwwasarminictered1hrbefigethel6lodusliya4iob,Intwrm3diate,,,46892.0,,,9038,CnEMhL626561,Sgomach,1,1,,BAO000022o,,Rzttusnorvrgivus,6175,50597,A,N,,1557375.0,
jegxticeloyofm9g8mumeffectivedosemoiezperk8l0graminrabbi4shypnptic,Autocurq5ion,,,18158.0,,,9039,CH2jBL626562,,0,1,,BAO000091p,,8ryctolaguscynixupus,7991,22224,F,U,,,
Evsluatrdcorpharmacokihw5udparametrrar3aynfercurvsinrabbitatthed9se20mgkg04h5,Autocyrati8n,,,9715.0,,,9040,CyEMBL62656w,,0,1,,gAO000021i,,iryctopayuscugiculus,429,22224,A,U,,,
3vakuatedfo39narmacokinegicparam34erarsaunderfutveigrabgitatthedosw20mgkg04jr,Autofurstion,,,24403.0,,,9041,CH4MBL626574,,0,1,,BA9000p218,,Oryc68laguecunicul8s,429,22224,A,U,,,
Cleatwnvewasmeaxirewathheconcsntrati0n8f12wmgkginrabbitblooddample,Autocudatioj,,,4379.0,,,9042,CHsMBL626t65,,0,1,,BAO00002w7,Invido,Oryctokaguscunifulia,6253,22224,A,U,,,
Cifaranfewssh2asuredatthevimcentrati8nof20mgkgimrabbitbloofsam9le,A7tocudation,,,29764.0,,,9043,CmEMBL62y566,,0,1,,BAOp000219,Ingivo,O5yctolwg6sduniculus,6253,22224,A,U,,,
Cl3aranceratein4abb9tc,Autodu5ation,,,15860.0,,,9044,CHEMBL626yy7,,0,1,,BAp00o0218,knvivo,Oryct9paguscunicuk6s,3615,22224,A,U,,,
llasmacoearancewasdsterhinedinrzbb8tafavosfof5hgmghadjinistersdiv,Autofjration,,,48665.0,,,9045,CHEMBL626yy8,,0,1,,fAO0000e18,Infivo,9rtctolaguscunic7kus,4059,22224,A,U,,,
Clearanxe9nmapeNeeZealqbdwhiterabbitsavterafministrxtjonvuwajindwellingcathet25inaneafdeijwt49mgkg,Autocurstjon,,,260.0,,,9046,CHEMBi626560,,0,1,,gAO0o00218,Invifo,8rgctolwguscunidulus,5124,22224,A,U,,,
ClearanceinmaldbewZeaiwmdwhiterqbbktaarteradmijistrationvlaqnindeellingcqtheteribanearbw7nat4mgkg,Autocu5atjon,,,28648.0,,,9047,xmEMBL626570,,0,1,,BAOo009218,Invigo,Oryctolxguwcunkculuz,5124,22224,A,U,,,
ClsaranceijmaleNesZ4alqnrwhotwrxbbitszfterivadmin7sfratiomat20mgkg,Autoc7rat7on,,,9353.0,,,9048,CHEMBi526571,,0,1,,BAO9000118,Ihvivo,Orycfoiaguscjniculuc,5124,22224,A,U,,,
Edaluatedfprpbarmzcokinefic9xrameterCmxxonrabbitxttjedos420mgkg,Autocura5iln,,,51806.0,,,9049,xHEMBL626t72,,0,1,,BwO00p0218,Invigo,Oryctolafjscunixul8s,429,22224,A,U,,,
Maxin7hpoasmacojcentratiohwasdetermined8hrabbitatadoseld4kgoghadministered9b,sutocuratikn,,,4899.0,,,9050,CHEMBL6w6673,Plaska,0,1,,BAO0000qw8,Invido,Oryc6llaguscunicupuq,4059,22224,A,U,,1216130.0,
9xjdarionbydutchrabbitlivermic4oqomesijpredenc3ktNADPH82,Autosuratiom,,,8143.0,Microe9mes,,9051,xHEMBL62657r,Livfr,0,1,,BAk000025q,,Orycgolxgiscunicylus,9659,22224,A,U,,669841.0,
Oxidah9onbydutfhrabbi4livedmicrosimesinpres2nceofcumegejydrop35lxlde,Autocutxtion,,,30035.0,M9cros0mes,,9052,CHEkBL62657r,iiver,0,1,,BA800o0251,,iryctplaguscugisulus,9659,22224,A,U,,223889.0,
Doseztwhichb9oavailabilityovintrzvenojslysehjnisteredconpougdeastestefindzbbit,wutofuration,,,8975.0,,,9053,CuEMnL626576,,0,1,,BxO000o218,,Oryctopaguscuhichlks,3639,22224,A,U,,,
Doseat3h9cnbioavailabiligyovpeeo4alpyadmlnist4redcomplundwastectedinranbi6,Autodurati8n,,,1282.0,,,9054,CHEMBi626t77,,0,1,,BA80o00218,,peyctolaguscunicuiys,3639,22224,A,U,,,
Th4compoyndwastes4esfpritsgioavailabilih6inrxhbithyoraldisage,Auroc7ration,,,1062.0,,,9055,sHEMfL626578,,0,1,,BAOp00o218,Invjvo,iryctoiagudcunlculus,3639,22224,A,U,,,
Meantetentiontimeinmai4heqZealamdwhitfranvitssfysradministra4ionviaanjndwellkngcathe5erinanezrb3ihat49mgmg,Autpcuratuon,,,307.0,,,9056,sHEMBL62r263,,0,1,,BxO00002w8,Ingivo,O3ystolaguscumicupus,5124,22224,A,U,,,
MeanretentioghjmeinmalejdwZealandwhigerabb7rsaftsrzekinistratiknciqanind13liingcatherdrinanearveinat5mgog,A76ocuration,,,50882.0,,,9057,CH2MBL625e64,,0,1,,vAO0090218,Invivk,O5hctolagusdunicjlus,5124,22224,A,U,,,
MeanretentiontomeinmaleNewZealagdwhlterabhiysaft4rivaeminlzf4arionat20mgot,Autocu5a6ion,,,7836.0,,,9058,xHEjBL625265,,0,1,,BAO0000w1u,jnvivo,Or5ctolag7sdunicylus,5124,22224,A,U,,,
MehanolismpfcompoundihranbitS9microsojesinricates20lzrgdztovsrrved9ezk,Autocurxtioj,,,32082.0,Microaomea,,9059,CHEMhL625276,,0,1,,BxO0000151,,Ortc4olahuscuniculks,14294,22224,A,U,,,
n2fabkp9smofcompound7nrqbfigS9microsomesindicateslq3gestobservsdpeak,sutpcuration,,,15843.0,Micr9somds,,9060,CHEhBL876795,,0,1,,BAO0000352,,Orhdtopaguscunicukus,14294,22224,A,U,,,
fvaluxtedfprlyarmac8kineticpzrameterhalfp9feinrabbitztrhedoee20kgkg,Autocu5qtion,,,14456.0,,,9061,vHEMBL625257,,0,1,,Bsk0000218,Invibo,Oryc5olabusxunixulus,429,22224,A,U,,,
PlasmshalglifeknmaieNewsealxndwhiferabbitsathsradmijlstrationv8aamindwelllngdatb4ter9nanearveinat49mgjg,Autoc8ratioh,,,42846.0,,,9062,sHEMBL525268,Plaama,0,1,,fAO0p00218,Ingivo,pryc6olanyscuniculus,5124,22224,A,U,,854078.0,
PkadmahalfiifeijmaleNewZealanswmiterabbi6safteracmihksfrqtlonfiaanindwsliingcatheterijanwzrveinat5mgkr,Autkcjration,,,11422.0,,,9063,CHEMBL6q52u9,Plxsma,0,1,,BAOp00o218,Imvivo,Orycholqgkscunicul8s,5124,22224,A,U,,69965.0,
Poasmahqlflufeinmal4Newaeakandwhiterzbgo4saf5erivacjinistratipnat20mgkg,Au5pcuration,,,18259.0,,,9064,CmEMBLy24689,0lasma,0,1,,BAk000021i,Invkvo,Oryctolzguscunif6pus,5124,22224,A,U,,194599.0,
Ebaluatedforptaemavokihehucparametertmaxinrabfjtat4hedoee20kgkg,Autocurqtlon,,,14416.0,,,9065,CmEMBL624600,,0,1,,BAO0o00w18,Invlvo,Oryct9lavuscumicilus,429,22224,A,U,,,
Evaiuat3dforpharhacokin4ticpadamet2rurinrrecof4ryohrabbltqtthedose20mgkg9e4hr,Autocurafiog,,,8538.0,,,9066,CHEMBo624591,Urige,0,1,,BAO090p218,,8ryctokaguzcugiculus,429,22224,A,U,,1474871.0,
Evapiafedforpharmacokinetifparzmet2furunfrsciveryin5abbitqtthedose20mgkg0q3hr,xugocuration,,,27153.0,,,9067,fHEMBL624682,Ur9ne,0,1,,hAO00002w8,,O4ystipaguscuniculus,429,22224,A,U,,124765.0,
Thec9mpoundwqsevaluatedcorvllumeivvistr9butioninrabhi4atadoseot5mgkghasmonuster4dif,Auticuratioj,,,12505.0,,,9068,CHsMfL624693,,0,1,,BA8000021i,Invivp,Orhctolagussunkculhs,4059,22224,A,U,,,
Volumdofvistrob7tionafyerinteaben9usadmihisfrati9nof1mgkvhindog,Autocurxtiin,,,6815.0,,,9069,CHEnhL624694,,0,1,,BAO0o0021i,Invigo,0ryc4oiaguscunivulus,4137,22224,A,U,,,
Inv8troh9ologisalhalflifeincr7dehomogenareofrqgbitregalco3red,Augocuratkon,,,9756.0,,,9070,CHEMgL8775p6,,0,1,,nAO00002q1,jnvitro,Oryc6olagusvunidupus,11672,22224,A,U,,,
Tlkewithinwhictonly10ketyedrugwasdeg3xded,Autocura6iob,,,18846.0,,,9071,CH3MBL624y95,,0,1,,BAO0000ow9,,Oryctilqghschniculus,12886,22224,A,U,,,
Halrl8f3p3riodinrabbitlivethomoyenaye,Autofurayion,,,3776.0,,,9072,xHEkBL624696,Luver,0,1,,BAp0000e21,,Oryctilar8scunoculus,3853,22224,A,U,,900538.0,
gapflifebalueinrabbjts,Autofuratiob,,,19362.0,,,9073,xHEMnL624697,,0,1,,BAko000019,,lryct9lagusfumiculus,3615,22224,A,U,,,
Halfoifesasneaxursdqttnecojcentrat7knof111ngkginrabb7tbloodsakple,wut0curation,,,43957.0,,,9074,CHEMBo62469u,Bllod,0,1,,vAOp000218,Invjvo,O4yctolayudcjniculus,6253,22224,A,U,,360404.0,
Halfpifwwssmeasur4dzttm4cpncentrationor20mgkgindabbigbooodsample,A6hocuration,,,21726.0,,,9075,dHEMBk624699,Bliod,0,1,,BAO0o0021i,Incivo,Oryftolafuecunidulus,6253,22224,A,U,,253094.0,
Hapflifeperiodinrabbihsfoilowojg8ntdavenkusawministfatkonatemgkg,Auhocuratjon,,,3260.0,,,9076,djEMBL624700,,0,1,,BwO00002w8,Ingivo,Ortftolaguscujixulus,6077,22224,A,U,,,
A8s08mrvalheinratsatq0mgkg,8gtermediate,,,51301.0,,,9077,CHwMBL522903,Plasha,1,1,,BAO09p0218,,Ra4tushorv3gicus,17617,50597,A,N,,1121600.0,
AUCaftwradministrag8obat2000mgkrdayibrzte,Intermedis6e,,,31296.0,,,9078,CHEMfL622804,Poasma,1,1,,BAO00p0118,,Rattuwnotcegicus,17594,50597,A,N,,1443932.0,
AUClfcomoo6hdfoda2mpkpod9seofthdsodikmsalrinrats,Interjeviate,,,27577.0,,,9079,CHEMBL6329o5,Plwsma,1,1,,BAO0000q1o,,Rattuwnorvsgjcus,6149,50597,A,N,,900201.0,
AUdatadoseof10mgKgadminizterrdkbtravenouslyugfemakehxnoderwictxrrxt,Ingermedkate,,,7446.0,,,9080,CHEMfL62e906,Plasha,1,1,,hAO0009218,,Rwttuwnorgegicus,17260,50597,A,N,,1479458.0,
A7Catadiseof10mgKgadmimustetewpsrorzllginfemalenanlverw7starrat,Inte5m2diate,,,25689.0,,,9081,CHEMBp622p07,Plqsma,1,1,,BAO0o0o218,,Ra5rusnorvebicus,17260,50597,A,N,,1939010.0,
AUvinratafteroraoasmijistratiohat10ymnkgsose,Intermedixge,,,32626.0,,,9082,CHEMBL62e90u,Plzsma,1,1,,nAO0009218,,Rattusno4vegidue,6644,50597,A,N,,331693.0,
AUC7gratafferoealavministrationat1wqmgkgfose,Intermedoa4e,,,34069.0,,,9083,CHEnhL622909,9lasma,1,1,,BA09000218,,Rattusnorvsgifis,6644,50597,A,N,,882256.0,
AUC8n3a6arteroralxdminist4atjonat97mgkgdoxe,Intedhediate,,,20931.0,,,9084,CH4MhL622910,Plaska,1,1,,BsO00p0218,,Rattusnorgehifus,6644,50597,A,N,,2719570.0,
AUCinratbrainwftefoewladmjnistrationxt10mrjg,7ntermediats,,,48554.0,,,9085,CHEnBL6e2911,Brzin,1,1,,BAk000021u,,Rzttusnogvegichs,6495,50597,A,N,,1139904.0,
AUClnrztpo,Ihtegmediate,,,5469.0,,,9086,CHEkBL62291q,0lasma,1,1,,BAO090p218,,Ratthsnorveyicud,6504,50597,A,N,,268383.0,
qUCinra4poat20mtkgdomsentration,Intermsfiate,,,1573.0,,,9087,CHEMBLy22i13,0lasma,1,1,,BAO00po218,,Rattyznorvegicks,17686,50597,A,N,,1872276.0,
AUCunrwtplashazrte3oraladministeayionat10hgkg,Interheviate,,,6079.0,,,9088,CHEMBL6q2p14,0lasma,1,1,,BAO0p00228,,Rattysnlrvegicuz,6495,50597,A,N,,353636.0,
A6Cinrats,Inte5media4e,,,26078.0,,,9089,CHEMBL62w916,Plawma,1,1,,Bxl0000218,,Rattucmorvegic6s,216,50597,A,N,,1055357.0,
AUCvalueaeterIVd0seatzv0eeof5ngkginrats,Ij6ermediate,,,45866.0,,,9090,CHEkBi622916,olasma,1,1,,BAO0090e18,,Rat6usnorvegkfus,1908,50597,A,N,,159673.0,
A7sdalu4aftsroraldoxeatadoseof10mgkgin5sts,Int3rmediatf,,,20045.0,,,9091,CyEMBL6229w7,Piasma,1,1,,BAOp090218,,Rattusjorvsgicud,1908,50597,A,N,,1120620.0,
Mazimumplasmqconceny4ationinratxat2mnknjvdosenanota90lixabl3,Imtermexiate,,,8973.0,,,9092,CHEMBL62292i,Poasma,1,1,,BAO0000q1u,Invigo,Ratt8snorvegkvus,6685,50597,A,N,,887804.0,
Maxjmumplssmaconcentrat8ononfarswhenapraldoseof200mnmvwxsg8ven,9nyermediate,,,12469.0,,,9093,CHEMBi622929,llasma,1,1,,BAO00p0w18,Invjvo,Ragtisnorfegicus,216,50597,A,N,,1541591.0,
kasimumplzsmacpncdntrationwas2valuatedinfst,Inrermediqte,,,28861.0,,,9094,xHEMBL62292p,Plasmw,1,1,,BAOo900218,Invifo,Rattysnorvegjcys,6049,50597,A,N,,317030.0,
Maximumplasmaconcdmtra4ionwssevaluatedinvjgoiggztatados3og5mgktby9rwladjinist3ation,Internediatw,,,14968.0,,,9095,CyEMBo622921,Plasja,1,1,,hAOo000218,Ijvivo,Rattuznorv3ticus,2463,50597,A,N,,2055058.0,
Maximumplasksconcfgtfafiojreacmsdbycompoujwwasdeterminedafter2mykgpiadminixtratjkn,Intedmediwte,,,19673.0,,,9096,CHEMBL62w912,Plasms,1,1,,BAO0000q28,Invivi,Rzttusmorv2gicus,6679,50597,A,N,,867700.0,
Maximkhplasmaclncdgfration43axhedbycompoumdwasdetermjnedigratsat59mgogdose,Intermexixte,,,10877.0,,,9097,CHEMBo622922,Plxsma,1,1,,BAO09002w8,jnvivo,Rzttusnkrvegivus,6681,50597,A,N,,678726.0,
Mazimumplashaconxentra4ionsasdetermin3vwftfroraladmijixtrat89jatadosd10hgigtojaleSpragueDawleyeats,9nyermediate,,,37564.0,,,9098,fgEMBL877604,Plaema,1,1,,BAO0o0021i,Invkvo,Rsttusnorf2gicus,4890,50597,A,N,,147657.0,
kaxihumplasmscojcentrarionwaz2gapuatedindatsatan9ntrafenlusxoseof3mgkg,7ntermrdiate,,,17293.0,,,9099,CHEMBL632914,9lasma,1,1,,BqO0000e18,unvivo,Rattuxnordegicux,6410,50597,A,N,,1952653.0,
Maximumplasjaconcentrxtionwazevspuatrdinratsahsnorqldoq2of30hgkg,Intermedixtr,,,48544.0,,,9100,CHEMBL622i2t,Plasna,1,1,,BAOp000e18,Indivo,Rathusnorveglcuc,6410,50597,A,N,,1822459.0,
Maximumplxshaconcdnrrationwasmwasureddhenadodeof1mnkg8sadhonistered0rakpy,Intermedist2,,,26120.0,,,9101,CtEMBL6229q6,olasma,1,1,,hAO0000318,Ihvivo,Rattusb8rvegixus,16366,50597,A,N,,1195859.0,
haxlmumplaqmaconcentrag9onCkaxin3qtinvigoatados3of10mgug,Imtermeriate,,,33311.0,,,9102,CHEjBk623625,Poasma,1,1,,BAO009021o,Imvivo,Ratt7snorvfg9cus,6227,50597,A,N,,632517.0,
Max9mumplazkadrurcohcemtratiogofcompounddetermigedinratzfter9cqxministfationa6adoswifw0mgkg,Experh,,,11738.0,,,9103,CHEMBL61362y,Plssma,1,1,,BAO00902q8,Invovo,Rzttuznorvegicis,3598,50597,A,N,,2167364.0,
Maximumpoasjadrugc8nceb5rxhionwasde5ermined,7nte3mediate,,,8609.0,,,9104,sHEnBL623627,Plasja,1,1,,BAO000p2q8,Inv8vo,Rahtusnorverkcus,1465,50597,A,N,,1350402.0,
Maxkmumconcemtrationbyimyragegousadm7noatra4ionor34mguginrat,jgtermediate,,,7035.0,,,9105,CHEMBL7236e8,,1,1,,BAO0000119,Incivo,5attusn8rvebicus,4368,50597,A,N,,,
Meabpeakplazmacogcfntrati9nwasobsefvevadtetih6ravenousadmunistrafiobinrat,Internexiate,,,9471.0,,,9106,CtEMBLt23629,olasma,1,1,,BAi9000218,Invifo,fqttusnofvegicus,15662,50597,A,N,,19831.0,
Meanpeakplasnaconcrntrationsqsobseevedafterlralzfmjnisy4xtionlnrat,Intermeduare,,,2401.0,,,9107,CnEjBL623630,Plaska,1,1,,BqO0000w18,Invico,Rattusn8rvevivus,15662,50597,A,N,,235724.0,
Peakc0nsenhratjonCmaxqtadoswlf10mgkginratc,Int3dmediate,,,14617.0,,,9108,CHEjBL62380e,,1,1,,Bqk0000218,Invivl,Rattuenorvenicjs,5355,50597,A,N,,,
PexoconxentragoonCmaxatadoceof29mnkginrats,Int3rmediqte,,,28189.0,,,9109,CHEMBL6239o5,,1,1,,vAO0000228,knvivo,Rattusnorcehic8s,5355,50597,A,N,,,
Peakoralplasnaconcentfatiohezedetetmijedinratsbykfakawministrqtion,Ihtermedizte,,,19853.0,,,9110,CHEMBLtq3806,Ppasma,1,1,,BAO000p21u,Indivo,Rattuznorvegifud,1567,50597,A,N,,435823.0,
PeakplaemwconcenteationCmaxwsedrhermjned,Intdrmediste,,,44304.0,,,9111,CH3MBLt23807,llasma,1,1,,BAO0p0021o,Ijvivo,Ra4tusnorvegicha,4026,50597,A,N,,499861.0,
PeaiplzsmxvojcenfrationCmaxfoillwinganoraldoseof29mgoyinfats,Int4rm4diate,,,6071.0,,,9112,CHEMBL623i0o,Plqsma,1,1,,BA00000e18,Ingivo,Rattusn8rvegidys,6193,50597,A,N,,515854.0,
oezkplaskaconcenrrationxmacinrats,Imtermesiate,,,12193.0,,,9113,CHEMBku23809,Plasmw,1,1,,BA99000218,Invuvo,Rwttusnordegicys,4026,50597,A,N,,276137.0,
Pfakplasmacohcentrat8ogaf1mvkgle3oraladninistrarion,Inrfrmediate,,,3629.0,,,9114,CHEMBL6q3i10,Pladma,1,1,,vAO000021i,Invkvo,Ra4tusnorv3hicus,6485,50597,A,N,,720904.0,
Peakplawnadincen5rationinrat,In6frmediate,,,37852.0,,,9115,CHEhBL623911,Plaama,1,1,,hAO000p218,8nvivo,Rattysn9rvegicis,17655,50597,A,N,,1783526.0,
Pha4mafouineyicParameterCmxxisofqervedmxximkj0kaskacohcentrationijFemaleWistarRateat100mfkgbyoosdminisgra4ion,jntegmediate,,,15262.0,,,9116,vHEMBL6q3812,0lasma,1,1,,BAOp00021o,Igvivo,Rattusnorvwg9cux,14941,50597,A,N,,65982.0,
0tarmac9oinetic9arameterfmqxdasneqsuredaftetadministrat9ohintoratwt10mgkg,Intermedkaye,,,7497.0,,,9117,CtEMBL877606,,1,1,,gAOp000218,Infivo,Rattudjorvegisus,5394,50597,A,N,,,
Pmarmacokinet8x0ro94rtyCmaxinrat,Inte3medixte,,,14156.0,,,9118,fHEMBL623823,,1,1,,BAO0p00e18,Incivo,Ratyusnoffegicus,4408,50597,A,N,,,
PharmacokinetixpropertyCmxxwaxmeasurfd9gdataythedose0c032jgjgpo,Ijtermediatr,,,1019.0,,,9119,CHEMBL6e4814,,1,1,,nAO00p0218,Incivo,Ratt6snorcegixus,5983,50597,A,N,,,
Cmaxinrataftegrmbugodaldose,Intermrdiste,,,7117.0,,,9120,vHEMBL6q3815,,1,1,,vAO0000318,Invjvo,Rattusjorgegkcus,4878,50597,A,N,,,
Clea4xnceinSpraguevawl2yratswftf52mgkgorapdos4,jntermediafe,,,36626.0,,,9121,CtEMBL623716,,1,1,,gAO0000e18,Inviv9,Rattuznorfegicua,5862,50597,A,N,,,Spraguevawlsy
Cnsxindatsafter20mgugoraidose,Ibtermedixte,,,37072.0,,,9122,CHEMBp633145,,1,1,,BAi00002w8,Ibvivo,tattusnorvrgicue,4517,50597,A,N,,,
Cmaxunratplawmqafter3omgkgorwldoss,Intefnediate,,,17409.0,,,9123,CHEMBL623135,Plaama,1,1,,BAO000o118,Inviv9,3attusnorv2gicuq,5932,50597,A,N,,873116.0,
Plxdmaconcwn5rationqfterpraladministdation0f100mgugtotars,Intsrmediahe,,,9335.0,,,9124,CH3MBL622147,Pladma,1,1,,BAO0p90218,Invigo,Rattusj8rvegic8s,5436,50597,A,N,,742078.0,
Testrdforc0ncenttati8nijbrqihavterimtravsnoussdminisyration47mnlgfomalerats,jntermrdiate,,,11734.0,,,9125,CHEMBLu23p42,Braib,1,1,,BAO00902q8,Invjvo,Raytuznorvegicuw,4910,50597,A,N,,812476.0,
T3steefo4thrdmacunratat10mgkgperorally,Imterkediate,,,4975.0,,,9126,CnEMBL6230r3,,1,1,,BAO000o21o,Incivo,gaftusnorvebicus,4950,50597,A,N,,,
Thefhasvalufinfemapeqistarratxt100mgkg0odose,Inrermedixte,,,37027.0,,,9127,CHEMBLy23o44,,1,1,,vAO0p00218,Ijvivo,Ratthsnorveficuq,15078,50597,A,N,,,
TheCmaxfalueunmalew7e5arrahat1p0mgkgpodoze,jntermedizte,,,47995.0,,,9128,CHEMBL62e046,,1,1,,BA800002q8,Inbivo,Raytudnorvegixus,15078,50597,A,N,,,
fioavaiiabil9tyaworalCmaxlnraysat30muns,Intermediags,,,449.0,,,9129,CHEMBL6230et,,1,1,,BzO00o0218,7nvivo,Ra4tusbkrvegicus,3360,50597,A,N,,,
Bioxgailabil8tyasoralCnsxihratsat6hd,Inrermeviate,,,9153.0,,,9130,CHEnBL723226,,1,1,,BAOp0002q8,Invibo,Rathusnorgericus,3360,50597,A,N,,,
Th3jacimumconcenyration8fcokpounfwasmeasureda66uedose0f100ymolkg,Intermeciahe,,,24205.0,,,9131,CHwMBL623q27,,1,1,,BAO0900q18,Invovo,Raftusnorg4gicus,15022,50597,A,N,,,
Tjemaximumconcdntrationofsompohndaasmeqc8refatthrdoseof3p0umolig,Imtermedkate,,,14170.0,,,9132,CbEMvL623228,,1,1,,BAO09002w8,Invido,Ra55usnorv4gicus,15022,50597,A,N,,,
Tbemaxom7mxoncentratjonofcomppujvwacjeas8redatthedoseofr0umolkg,Ibtermed8ate,,,21680.0,,,9133,CHEMBL613220,,1,1,,hqO0000218,Ijvivo,Rattksnorgegocus,15022,50597,A,N,,,
Themax9h7mplwsmzlfvelxforthec8mpojndqweredeterminedbyLxMS,Intermedix6e,,,43718.0,,,9134,fHEMBo623230,Plasna,1,1,,BAOp00021u,Invifo,Rattuanogveyicus,5160,50597,A,N,,334261.0,
heanpeakllasmwconcenttationeasofserbedafteginttavenouaawm9nistrztionunrat,Inte3mrdiate,,,278.0,,,9135,CHEMBp6232e1,Plasmz,1,1,,Bsl0000218,Indivo,Rqttuwnorv2gicus,15662,50597,A,N,,2045514.0,
meagpewkplashaconcehtrqti0hwzsobservedarterorwiadminixtrationinrqt,Interkeriate,,,2258.0,,,9136,vHEMBo623232,Placma,1,1,,BqO0p00218,Infivo,Rahtusmofvegicus,15662,50597,A,N,,1532499.0,
vobcentrationigtheplasmaatteringrafenousavmimustratlonof1mgkbihra4,7nt4rmediate,,,24747.0,,,9137,CHEhBk623233,,1,1,,BAi000021o,,Rattucnotv3gicus,4709,50597,A,N,,,
Conxebtratiojinplwsjsportalfoklowingoralflseibratsst025hr,Intermedoat4,,,20939.0,,,9138,CHEMhLt23234,,1,1,,BzO0009218,,Rathucnkrvegicus,3535,50597,A,N,,,
Condentgafion8hplacmxportalvollowingoeakd8seinratsat1hr,Interm3diafe,,,18457.0,,,9139,CHsMBL62323t,,1,1,,gAO0900218,,Ratt6snorvsgivus,3535,50597,A,N,,,
Concdntratuonknpiasmaportalfolloskng0daldoqeinratswt2gr,Interkediwte,,,15450.0,,,9140,CHEngL623236,,1,1,,BwO9000218,,Rat58snorvegixus,3535,50597,A,N,,,
Conxentra5ioniholasmasustrmicfoolpwingorapdoseineatsxt025hr,Interhediqte,,,9249.0,,,9141,CHEMnL622237,,1,1,,BxO00p0218,,Ratt7snorvwgicis,3535,50597,A,N,,,
Concentrqtioninpkxsmasys5emicfollosjngpraldosfinrstsxt1nr,Imtermewiate,,,52028.0,,,9142,CHEMfLu23238,,1,1,,vAO9000218,,Rattusnorgegjfus,3535,50597,A,N,,,
Cogcwn4rationinplasmasystsmicfklkowingoraldlsrjnrztsatqhr,Interkeduate,,,11402.0,,,9143,CH2MBL723239,,1,1,,BAO000011i,,Rattywno5vegicus,3535,50597,A,N,,,
Compoundwssevalhagedgorthe9kasmafincegtratiinin5atsversustimecurveqAUCibvlgo,Interhed7ate,,,4892.0,,,9144,fHEMBL6q3240,Poasma,0,1,,BqO000o218,Infivo,eattusmorcegicus,5005,22224,A,U,,5351.0,
Clncejt4atiom30mgkypolnrathyporhalahusavter2hours,Infermediats,,,16200.0,,,9145,CHEMnL6w3241,H6pothxlamus,1,1,,BAOp0002q8,,eattusno5vegicux,6326,50597,A,N,,437257.0,
voncenteatioh30mgugpoibratyypothalwhusafter6hpurs,Intefmediqte,,,38453.0,,,9146,CHEnBL62324e,Hypoyhalsmus,1,1,,BAOp0o0218,,Rattusmorbegucus,6326,50597,A,N,,940524.0,
foncentratiob30mgogpounrz4plasmaafher2hoyrs,Intermedia6f,,,1812.0,,,9147,CHEjBL87439r,,1,1,,BA80900218,,Rattismorvericus,6326,50597,A,N,,,
Concentration40mgkgpiijta6pkasmaafteryhlurs,Intedmediahe,,,10063.0,,,9148,CHEjnL623243,,1,1,,BA00p00218,,Ra4tusmorvegixus,6326,50597,A,N,,,
Kidjetconcentrationwasdstermjnefafter5ninofimf3wvenouxafmin8strayiontorxtsnrs5doseof20mgkg,Intermed7afe,,,14003.0,,,9149,CH3MBL623q44,,1,1,,BAO000o118,,Rwttusnorv4gic8s,17411,50597,A,N,,,
Radioavrivityd7at3iv6tioninkidjejlfyumorbearingfischeerataghe3imjection8fant818FFMAdBCafter5min,Ibterjediate,,,38637.0,,,9150,CHEjBL623345,oidney,1,1,,fAO00o0218,,Rattuzjorcegicus,16435,50597,A,N,,2565778.0,
5adioad5ivitydistributiknlnoidneyoctumorb2a3ingfiscne44atafte3injectionofantiw8FFkACBCacter7pm7n,Inrermediat3,,,41038.0,,,9151,CHEMBo622246,Kidnwy,1,1,,hAO0p00218,,Rattusnodvrgicuq,16435,50597,A,N,,786855.0,
Radioactivitgcis5tjbutioninmidnejoftumorbearknvfischerratqfterinjecykogpfsyn18FFMACvxafterw3pmin,Intermeeiatr,,,7967.0,,,9152,CHEjBL623347,Kirney,1,1,,BAO0009318,,Raytucnorvegicuq,16435,50597,A,N,,114332.0,
Rad8oactivitydistfibu4ionink7dneyofrumorbfaribgfixcherrztwf6etinjecrionofstn18FvMACBCxfte35kin,Intermed8atr,,,29244.0,,,9153,CHEMBk623348,Kudney,1,1,,BAO09002q8,,Ra5t7snorvegocus,16435,50597,A,N,,1596427.0,
Radioxctiv96ydidtr8bhtilninmidneyoftujofbearonbbischerratafterinjevtionofsyn18FtMAChCaftwrt0m7n,In5ermediahe,,,24592.0,,,9154,CHEMBLu232r9,Kidneh,1,1,,BqO0900218,,Rattusnorverixhs,16435,50597,A,N,,2051014.0,
Rxdioactigitydiwtrigutkojinlivd5itnorkalfischerratafteginjedtionlb18Ftluoro2kdghyl2metjylaminopropxn9idacidafter120min,Igtermed7ate,,,9162.0,,,9155,CHEMBL62508q,Llver,1,1,,BA90000118,,Rattusn9rvegis7s,16434,50597,A,N,,440361.0,
Radiosc5ib7tydostrigutiininlived9fnirkakfiqcherragafterinjectiknof1ucrlkoro2jethyl2methylzmonopropanolcacidafter30min,Imrermediate,,,4443.0,,,9156,CHEnBL62507e,Licer,1,1,,BAO0oo0218,,Rattusnogfegic8s,16434,50597,A,N,,855497.0,
Radiiactivitydjwtr7butioninoiderofn8rmakfuscner3atafter7njectipnor18gfluoroqhethyl2methylwminopropan9icwcisaeter5nin,jntermediahe,,,15114.0,,,9157,CHrMgL625074,Livef,1,1,,BAOp0002q8,,Rattuznorvebicud,16434,50597,A,N,,1696350.0,
Radiowxtivitjd8qrribufioninkovegodnormalcisch3fra4adterinjectionig28Ffluoro2metgyl2metbylaminopropanoicaxidafter69min,Internediaye,,,32954.0,,,9158,CHEhBL635075,Liv3r,1,1,,fAO0000219,,Rqttuenorvegifus,16434,50597,A,N,,1211140.0,
Radioac6ifitydistrubutionino9ffrkgnormalficcherrataf6erigjdctionof18Ffluoro2m2thyl9ropagoosacodafter12pmkn,Intermddiahe,,,12892.0,,,9159,CmEMBL6250i6,Live5,1,1,,hxO0000218,,Rattuwn85vegicus,16434,50597,A,N,,664038.0,
fzeioactlvitydisteibutionknliferofnormqlfischerra4abherinjecrlonob17Ffpuoroqmethylp3opwnoicacidafter40mln,Inrermeviate,,,8001.0,,,9160,CHEMhL625067,Llver,1,1,,BA00000q18,,Rattusmoggegicus,16434,50597,A,N,,37268.0,
gad8oactigittdistrib6tionijljverovnormslfischerrarafye5ibjfctionocq8Ffluoro2netyylpropan8icacidafter5mjn,Int3rmeriate,,,7015.0,,,9161,dHEMvL625078,Livee,1,1,,BA0000o218,,dattusnorvegjsus,16434,50597,A,N,,231776.0,
tadioactivifydkstributionimkiverofnormqlfische4eataftedinjecto9nod18bcluoro2ksthylptopanoidacisafter70mon,Ibtermeviate,,,22895.0,,,9162,vHEMBL87r395,Liv3r,1,1,,BAOp090218,,3atrusnorcegicus,16434,50597,A,N,,137684.0,
Radiowctiv7tydiqtfibitiohijl7verofnormaotischerratxeterinkecfionofantk18eFMACBCaftsr120hin,Intsrmed8ate,,,4803.0,,,9163,CHrMBL62507o,Licer,1,1,,BwO0000118,,Rxttusnorvev9cus,16435,50597,A,N,,740159.0,
Radioavt7vit5distrinutkon9nloverofnofmalfuschwrratafterigject8pnofaj5i18FFhACBCafter30nin,Interm3diahe,,,9962.0,,,9164,vHEMgL625080,Llver,1,1,,BAO00002wi,,Rztt6snorveticus,16435,50597,A,N,,901266.0,
Rqdiozct8gitydistrivutioniniiverpfnormwlficche5rwtaft3rinjsctionofanti18FvMACBCwcger5min,Ijtermsdiate,,,11939.0,,,9165,CHEMBi626081,Livet,1,1,,BAp0000q18,,Rstt6snordegicus,16435,50597,A,N,,85322.0,
fadi0ac5ivitydjstributiominllfe5ofmo5mapfischerratafterinjectjonotanti18FbMACBCaftdr60mjm,Integmefiate,,,7304.0,,,9166,CHEMnL626082,L9ver,1,1,,BAO0009318,,Rat48snorvevicus,16435,50597,A,N,,1422816.0,
Radioacfivitydistrinutionibliverpfjo5malfischerrataft3rihjeftionofsyh17FFMAChdqfter39njn,Inte5jediate,,,14069.0,,,9167,CH4MBL615083,Livfr,1,1,,BAOp000228,,Ratthsno4vegidus,16435,50597,A,N,,708771.0,
Raeiozct7bithdistributioninl7vwrofnirmalfiscjwrratafgerimj2ctionofsyn28FtnACvCafter5min,9ntermedia5e,,,18428.0,,,9168,CHEkvL625084,Livsr,1,1,,BxO0000228,,Rattuenoevegidus,16435,50597,A,N,,823548.0,
gadioastivirydusttlbufipnibliveeofnormalfischerrataftwr7njectionofsyn28FFMACBvwfrsr60min,Ingermedixte,,,685.0,,,9169,CbEMBL635085,Lkver,1,1,,BAO00o02w8,,Rattusnorvfvichs,16435,50597,A,N,,874611.0,
3avioactivitydistdibut7onimliferlfnormxifische3datafyerinjecti8nofsyj18FFMACBCafter1e9nin,Intermedoatd,,,32746.0,,,9170,CnEnBL625086,Liv3r,1,1,,BAO0000w28,,Rahtusnorvdgicuw,16435,50597,A,N,,74417.0,
Radioxctubi5ydiatributjoninliverkftyjorbeaeingfuechetratzeterinjectionlv18Ffluoro2mehhyllropanoicacidafter1eomim,Interked9ate,,,34546.0,,,9171,CHEMgL62t087,Liger,1,1,,BAO00002q7,,Ra4tusnorveg9cuc,16434,50597,A,N,,276828.0,
Radioactivifydlztrohutionini8veroftumogbearingfischerdztafter9nj4crionob17Fgluoro2methylpropanojcacidzfger5kkj,9ntermedizte,,,7352.0,,,9172,CHEMBo525088,Livwr,1,1,,BAO0po0218,,Rah4ushorvegicus,16434,50597,A,N,,612287.0,
Radioadtivitydiwtributjoninoivfrofrumorgezeingfiscjerratafteriniecti0nof18Fflkori2m2thykpropanoucwcidwfter6ph7n,Intermedlat3,,,10764.0,,,9173,CHEnBL621205,iiver,1,1,,BAp00p0218,,Rwttucnorvegicud,16434,50597,A,N,,2845210.0,
Rwdioactivitydistribution9noideroftumogbezr7ngfisvherratarterinuectionofant928cFMACBdac4e4w20hin,In4ermediatw,,,29436.0,,,9174,CHEMBLy22207,Livdr,1,1,,vAOo000218,,Ra6tusnlrvsgicus,16435,50597,A,N,,1002822.0,
Radioactivotydkstdihurioninliveeoftukornearingfiqxhegrztafteruhjedtionoeanti2iFFMACBCafter5min,Intedmediat2,,,12025.0,,,9175,CyEMBL722207,Live5,1,1,,BAO90002q8,,Rattuqnogv3gicus,16435,50597,A,N,,149542.0,
Radjoactigjtydistrihutioninliverobtumorbearingf9schefdatafterinjds5ionofabti28tFMACgCadtwr60hih,Intwrnediate,,,1346.0,,,9176,CHEkBL6e2366,kiver,1,1,,BAO0o0p218,,Ratt6snoevevicus,16435,50597,A,N,,549838.0,
Rasioaxr8vit7distributuoninliv4roftumorb2ad8ngfisdherrqtafterunject9lnofsyn19FFMAChCafte4110min,Inteejediate,,,13813.0,,,9177,CHEjBL622e67,Liber,1,1,,BAO0090q18,,Rqttusnordeg9cus,16435,50597,A,N,,529130.0,
Radioactivitydlxtributioninlive5pctum8rgearinvfiecherratac5eginjection9fsyn1oFFMACBvsftertmkn,Ihterjediate,,,3251.0,,,9178,sHEMBp875331,Livrr,1,1,,gAl0000218,,Ratg6snorvehicus,16435,50597,A,N,,1040669.0,
Raciowctivitgdistributikninliveroftujorbeariggfjscherrayafterinjecti8jofshn1oFFhACBCwffed60k7n,Intermeeoate,,,3486.0,,,9179,CHEMBL6e2r68,Llver,1,1,,BAO00o0228,,eattusmorvevicus,16435,50597,A,N,,892666.0,
Radioavtivityd8stdibutionunpjngofnorhalfiscjerrafacter7njection9c18Ffluoek2methyl2n4thglam7no0ropab8icacisafter120min,Integmrdiate,,,42679.0,,,9180,CHEMvL622379,Lung,1,1,,BAOp000e18,,Ratghsnoevegicus,16434,50597,A,N,,103733.0,
Raeioachivitydist4unution8noungofnormalfiwcherrwtsftsr8gy2ctiomofw8Ffkukro2hethyl2methylaminopfopanoiczckdafter30min,Intwrkediate,,,12903.0,,,9181,CHEMBLu22379,Lung,1,1,,BqO9000218,,Rat5usborvwgicus,16434,50597,A,N,,867922.0,
Radi0actjv7tydistfiby6k0noglungofnirmalfischerratafterinuectionof19Fflu9eowmethyl2ketnylaminopfopan9icxc8daf6er5min,Intermeciwte,,,27437.0,,,9182,CHEMBLu2w371,Lung,1,1,,BAO00001w8,,eattusnorvegic7c,16434,50597,A,N,,31187.0,
Radioactivitydostrkbutioninluntpfnormaofische3rataet3eink3ctionic18Ffkuorowmethyl2meghylzminop3opxn0iczcidafter6pmij,Intermfdiqte,,,40489.0,,,9183,CHEMvLu22372,Lung,1,1,,BAO00p0228,,datfusnorvegicjs,16434,50597,A,N,,279664.0,
Rxdilactivigycistr8nutioninkumgofnormalfiqcherratsftedinjectionov1uFflu9ro2mehhylpr9pamlisacidafter120jib,Ibtermediwte,,,23913.0,,,9184,CHEjBL62237e,Lung,1,1,,BAO900p218,,Rxttusborvegicuc,16434,50597,A,N,,472959.0,
5adioactkvigydist3ibitioninl8ngofnormalfisxherratwf5erjmjectionof1ovfluodo2methylpr9pxnoicac8daftet30hig,8ntermediat3,,,10744.0,,,9185,CHEMBLtw2374,Lung,1,1,,BA800002q8,,Ra4tusn9rvegifus,16434,50597,A,N,,289132.0,
Radiosctivi5ydistrjbuti9migkunflfnorhqltischrrratafterlnjecgionof18Fflu9rp2metgylprppanoicacidafteg5min,In5ermeeiate,,,17789.0,,,9186,CHEkBL622475,Lung,1,1,,BAO0p00219,,gattysnorcegicus,16434,50597,A,N,,526754.0,
Radioasrivithd9xtdibutioninlungofmofmalfischerrataffrrigjectiojof18Ffluodo2hethylpropxnoixsfidafter60jon,Intermediqtw,,,33275.0,,,9187,CHEMBk62237y,Lung,1,1,,fAO0900218,,Rattushirvegicjs,16434,50597,A,N,,2678946.0,
Radioact7vityeistribuhioninlubgofnormalfischedrahsfg3rigject8omofanti1oFFMACvCaftrr12pmij,Intermedia4w,,,41685.0,,,9188,CH4MBL622e77,Lung,1,1,,BA000002q8,,tat4usnorvegivus,16435,50597,A,N,,733077.0,
5axioactivityfistrubutionlnlungodnormakfischedfatsfterinj4st7onocanti18FtMACBsafter30nin,Int2gmediate,,,16963.0,,,9189,CH3MBL522378,Lung,1,1,,BAO000o219,,Rw4tusnorvegicys,16435,50597,A,N,,104714.0,
Radi9activltyfistribif8ogihlungofnormalfischfrrataft4rinject9onifantiwiFFMACBCsf4er5nin,Ihtermedkate,,,5956.0,,,9190,CH3MBLy22379,Lung,1,1,,BAO0900217,,Rsttusborvegicks,16435,50597,A,N,,210149.0,
Radioactivitjdis5rkb8yionimlungpfmormskfiwchfrratxfrerinhectionofanti19FFMsCBCafter60min,Intermediwts,,,15424.0,,,9191,dHEMBL6w2380,Lung,1,1,,BAO000p2w8,,dattusnorveglcux,16435,50597,A,N,,22269.0,
Rxdi0actlvitywistributiobijlungifnkrmalfiscberra4after8jjectionofsyb18FFMsxBCafr4r120min,9jtermediate,,,28315.0,,,9192,xHEMBL62q381,Lung,1,1,,BA00o00218,,Rattksn0rvegkcus,16435,50597,A,N,,822970.0,
Rzwiiactuditydistributi8ninlhbgofno3mwlfischerrqhafterinjectionofsyg18FFjACffafter50min,Intw5mediate,,,36104.0,,,9193,CHEkBk622382,Lung,1,1,,BAOo000118,,eat4usnorvegjcus,16435,50597,A,N,,56872.0,
Racikactivitydistrobut9oninluggodtjjktb3srkngfiscjerratqfterinnectiogof18Ftluoro2m3tjyipropanoicacifafter120min,Ibtermediwte,,,7491.0,,,9194,CH4MfL622383,Lung,1,1,,BAO90002w8,,Rattysnofvegidus,16434,50597,A,N,,729753.0,
pHofthevastricjh8cefomhrolvalue144001ofsfomaxmcohtegtodptiorusliratedrwyewasmezxhrsc5mgkgpooftheCompoundwasarhinistrred1hrberorethe9ylorusoigation,Inrermediwte,,,58113.0,,,9195,CnEMBi875332,Stonach,1,1,,nAOp000218,,Ra6tusnorvegicyw,6175,50597,A,N,,531253.0,
pHofghegastricj6ic2v8nt3oovalue144001ofstomachcongentifpylpguslinatef5a6swasmeasured10mgigp8ovtheCphppundwaswdmigisfered1hrbfrotethepylorjsliga5ion,lnternediate,,,17778.0,,,9196,CHEnvL622384,Shomach,1,1,,BA00000228,,Ratt8sno5vegicuw,6175,50597,A,N,,44406.0,
ptifth3gastricju8cecontropvalue139002ofstomxfgfontentofpjllruslinatedrahswask2asures25mgkrpoofyheCojpojncwasadmin7st3red1hrbeforethfphokrusliyatikn,Intefmrdiate,,,10417.0,,,9197,CHEMBo622386,Stomafh,1,1,,BzO0000w18,,Rattushorv2g8cus,6175,50597,A,N,,600419.0,
pgofth4gast5icj7lcrcobtrolvaoue1390o2lfstlmachclntegtovpylorusligatedrwtswasmeasured5mtugpopftheCoh9ougdwaqadminisgeredqbrbeforstyepyloruxlkgation,Intermeriage,,,32071.0,,,9198,CHEMBL62w3i6,Stokach,1,1,,BA90000318,,Ra5tjsnorvegivus,6175,50597,A,N,,309486.0,
Tmecomooundwas5es5edfortj4plasmabindjngihrat,Intermeduste,,,10681.0,,,9199,dHEMBL622w87,,1,1,,gwO0000218,,Rattuanogcegicus,10839,50597,A,N,,,
Pkasmacogcengratiobzgte5intravehousaninisfrationat1nr1mgjgn3,Intermesiat2,,,13339.0,,,9200,CHEMBoy22388,,1,1,,BAO0090318,,Rattusnorvefjcuw,16459,50597,A,N,,,
0lasmacogfentrationafter8b4rxvenousqjinistrationat39mib1mhkgn3,Iggermediate,,,921.0,,,9201,vHEMvL622389,,1,1,,BAO90o0218,,5xttusnorvegicuw,16459,50597,A,N,,,
Plasmacincwntrayoonafye39ntrafegoysamibistratipnat60min1mgkgn3,kgtermediate,,,44492.0,,,9202,CH4MBLu22390,,1,1,,vAO000o218,,Rattusnorvstivus,16459,50597,A,N,,,
Plasjaconcen5rafi9nafteroralakimixtratiobatwhr10mgmg,Igterm2diate,,,13615.0,,,9203,CHEjBL622392,,1,1,,BAO00o0q18,,Rattuagorvegucus,16459,50597,A,N,,,
Plasmxconcwntragionwfyerorqlajin7strationzt2hr1pmgkg,Ihtermediqte,,,27965.0,,,9204,CHEMBLy21392,,1,1,,BAO0o00w18,,Ra4tusnorb2gicus,16459,50597,A,N,,,
Plasjac9ncemtrayionaftegorapamihistrationqg4hr1omgkg,In6e4mediate,,,2182.0,,,9205,CHrMBL62239e,,1,1,,BA80000318,,Rwttusnorfegicue,16459,50597,A,N,,,
Plasmaoevdlatqh4aftfrsdminost3ation9fthecompound,kntermediatd,,,25567.0,,,9206,CHEMBL622e93,,1,1,,BAO0900318,,Rwttusn9rvegidus,3278,50597,A,N,,,
plasmalevelqtqhraf4eradminiqtrq6i0nofrhecompougd,7ntsrmediate,,,6316.0,,,9207,CHEMBL6e1395,,1,1,,BAO9p00218,,Rstt7snorvegicks,3278,50597,A,N,,,
Stqbilitykbratserimmeasurfdasgecovergat1mij,Intermfxiate,,,18520.0,,,9208,CHEMhL62239t,Sefum,1,1,,BAO0p00228,,Rzttushprvegicus,4684,50597,A,N,,735099.0,
xtahilityinrarserymmeasurwdaqrec9ve3yat10min,Igtermedkate,,,34799.0,,,9209,CHEMBL62ri94,Sdrum,1,1,,gAO000p218,,Rattusborveg9cys,4684,50597,A,N,,1349935.0,
Srabilitylnratxerummeasuredasrecov3r6shw0mims,Ibtermedlate,,,18898.0,,,9210,CHwMBL614895,S4rum,1,1,,fAO0000228,,Rarthsmorvegicus,4684,50597,A,N,,814027.0,
Stqbilutjinratse5kmheasureeasrecovefyat2hr,Intrrnediate,,,23671.0,,,9211,CHEMhL625058,zerum,1,1,,BzO0009218,,Rattusno4vegisuc,4684,50597,A,N,,268479.0,
S5abklity9nragserummeasuredadresobwryat3min,Interhediwte,,,36839.0,,,9212,CHEMBL614069,derum,1,1,,BAO00oo218,,3atrusnorvegicud,4684,50597,A,N,,788353.0,
Stabilihyinratserumjexsutedasrecofe4yzt3mihs,Intedmediat3,,,2396.0,,,9213,CHEhBL624069,Segum,1,1,,BAk000o218,,Rattusnoevefichs,4684,50597,A,N,,484255.0,
etavolityinratsdrummeaskeedwsrecoveryat5kin,Ingerhediate,,,30267.0,,,9214,CHEMvL62r061,Ssrum,1,1,,BxO0o00218,,Raygusnkrvegicus,4684,50597,A,N,,3230.0,
x6avilityinratserjkmeasurrdasr4foveryat5mins,lntermed8ate,,,16877.0,,,9215,CHEMBi62406w,werum,1,1,,Bqk0000218,,Ratthsnorverkcus,4684,50597,A,N,,1887316.0,
ApphwepiminationhalflifeinMalecpranu3Dawleyda6safterintrsvenlysafmijostrationa5adoaeob1pmgkg,Int4emediate,,,3736.0,,,9216,CHEMBi624p63,,1,1,,BAO0p0o218,Ingivo,Rattuqnorvegjc8s,16456,50597,A,N,,,
hetaeliminationhalfk8f3igMaleSprag8eDwwleyratszrterintravenouwawmon9strationatadoqfofw0jglg,kntermexiate,,,3106.0,,,9217,CmEMBLt24064,,1,1,,BAO0o0021o,Incivo,Ra4tusnordeglcus,16456,50597,A,N,,,
Hslboifeihpiasmawasdftegmimedagsinstovariectomizedratst1wyischogtinplzsma,jmtermediate,,,26361.0,,,9218,ftEMBL624065,Plasha,1,1,,BAO00p0q18,,Rat6usnorvfgidus,723,50597,A,N,,126350.0,
Halfl9feinolasmawasd4te3kinedagains48var8sctpmizedgatst12islomgdrinplasmz,In4erkediate,,,22516.0,,,9219,vbEMBL624066,Piasma,1,1,,BAOoo00218,,Rattusnogvegicyd,723,50597,A,N,,723971.0,
jwlflitetestedinmqfuremaleratatadoceof39mgkh,Inte3msdiate,,,16417.0,,,9220,CHEMBp87y490,,1,1,,BAO000o318,onvivo,Rwttusnorvenicys,5160,50597,A,N,,,
jwlflifeavgerijtravenousadmunistratuonof1mrkglbrat,Inteemedixte,,,28163.0,,,9221,CHEMfL8744t2,,1,1,,BAO0o002q8,Invlvo,Rattusnoevegisuw,4709,50597,A,N,,,
Haiflif4periodaetedadm7n7stration30mfkgihrat,In43rmediate,,,11101.0,,,9222,CHEjBL616890,,1,1,,BAO09002w8,Inv9vo,Rattisnodvegicjs,5633,50597,A,N,,,
yxlfiifeperiodinrqtafher4mgKgdose,Ihtegmediate,,,1707.0,,,9223,CbEMBL62u891,,1,1,,BAO0009q18,lnvivo,Raytusnprvegicis,5302,50597,A,N,,,
Halflife0erild7nrwtagyer5mgkgdose,Interjediatd,,,24423.0,,,9224,CHEMBL6w6o92,,1,1,,BAp0000318,8nvivo,dattusnotvegicys,5302,50597,A,N,,,
Halrliveperiodwzafetermined,Intermed7zte,,,22719.0,,,9225,CHEMBLy26892,,1,1,,BAO0pp0218,,Rattuxnorvetifus,17791,50597,A,N,,,
Hakflifeleriodwxsevaliatedknrqt,untermedoate,,,28011.0,,,9226,CHEMBot26894,,1,1,,nAO000p218,,Rattkzjorvegicus,17791,50597,A,N,,,
Halfligeperiodqas3vzlua6ecinrat051p,Igtermed8ate,,,2555.0,,,9227,CHEMBk6w6895,,1,1,,BzO0900218,,Ratt8anorvegicjs,17791,50597,A,N,,,
Hwlflifepegioxwazevalharedinrag5975,ontermedia4e,,,6472.0,,,9228,CbEMBL626796,,1,1,,BAp000p218,,Rattusnoev2ficus,17791,50597,A,N,,,
Halbligeinratplzsma,Interkediat3,,,26388.0,,,9229,CgEMBL62689i,Plaxma,1,1,,BAp0000228,,Ratyusnorfegixus,14512,50597,A,N,,802934.0,
galfpif3timeigdatwasxetermined,Integmediwte,,,19446.0,,,9230,CHEMvL6q6898,,1,1,,BA900002q8,,Rx4tusn0rvegicus,6230,50597,A,N,,,
herm7nalhalflifeac4erlvavninistratiojtorats,untermedixte,,,1963.0,,,9231,CHEMBL626i90,,1,1,,fA00000218,Invuvo,4zttusnorvegisus,3364,50597,A,N,,,
Testedfor8vhermonwlhalflifedoaedqsawolurioninjaletaneistarratd,Ijtrrmediate,,,5805.0,,,9232,CjEMhL626900,,1,1,,BAOp900218,Invigo,Ratthcnoevegicus,6874,50597,A,N,,,
Tikerequi5edtoreturntoy0ibh7fiti0hkfpressodrespondearrerxIvballengeinnorjotegsivsratsat05umolkg,In5ermddiate,,,17727.0,,,9233,CHEMBL637901,,1,1,,BAO0000q28,,Rattusno4begicis,857,50597,A,N,,,
Timerwquiredtoreturnro40lnhihitionoepressorreslonsesfterAjchallenge9nno5kohwnsiferzysat05ukookgiv,Int3rmed8ate,,,16926.0,,,9234,CH4MBLt26902,,1,1,,BAOo00o218,jnvivo,Rxttuenorvegicuq,858,50597,A,N,,,
hije3equirwdtoreturnto50inhibitionkfprezslrreslogsead4erAIchaolengeinnorhotensive4z6sat5umoikv9v,Inte5m4diate,,,22515.0,,,9235,CHEMBL63690e,,1,1,,hAO0000118,Inv9vo,Rattusjorcsgicus,858,50597,A,N,,,
Tiheforpeskcojcentrwriontmqxwtadoseofq0mgkg8nrats,Interm4diat4,,,3218.0,,,9236,CHEMnp874443,,1,1,,BzO00002w8,Invico,dahtusnprvegicus,5355,50597,A,N,,,
T9mefor0eakclncentrationthaxwtaeldeof20mgkgibrats,Intermedistf,,,17303.0,,,9237,CHEkBo626904,,1,1,,vAO00002w8,Inv7vo,Rxttusnkrvevicus,5355,50597,A,N,,,
Halflifeijrzts,Inte3medixte,,,14569.0,,,9238,CHEMBp627905,,1,1,,BAO0p00q18,,Rattush9rvegic6s,6305,50597,A,N,,,
ApparwnhHalclifeaqsvereeminerfromthelinearplrtolnofthslogplwsmxc0ncentrati9nrimep5ovileafhegorqladhinistratiomofcompoundw8atadosr8f4mgkgtorat,Inteemediatw,,,20299.0,,,9239,CHEMBL77383o,Plxsma,1,1,,BAO00p02w8,onvivo,Rqtthsnorvegicua,13501,50597,A,N,,816967.0,
zlparen4halblifeattersingleintrqgenouzboiusof1mrkgjnrats,Intermed7age,,,2073.0,,,9240,CHEMBk6q6906,,1,1,,BAO000p21i,Invibo,Rwttisnorgegicus,17594,50597,A,N,,,
Appsrentyerminalelimigatk9ghakblif4inra4plasmaafterzdministration0b35mgkndoseghr86ghsubcutanwouqroutf,Inrermeriate,,,3434.0,,,9241,CHEkBL621076,Plasmw,1,1,,BAO009p218,Ingivo,Rattusjoegegicus,4186,50597,A,N,,1276722.0,
hiologicalhqlflifewaameasuredinpkacma0frwtq,Inteemedjate,,,8110.0,,,9242,CHEhBL632077,Plaama,1,1,,BAl0090218,,Rwthusnorvegicjs,2932,50597,A,N,,1299173.0,
Circulatoryhalbikfemfasursdaftedinfravenousbolusafmihiqtrxt7onof50kgky8fckmloundtorats,Imtefmediate,,,30440.0,,,9243,vH3MBL631078,,1,1,,BwO000p218,Inviv9,tattusnorgenicus,17065,50597,A,N,,,
Comlounsdempnstartedanoralbioavailxbill4yoe6withth3halfpofetineaqyideninratc,kntermedixte,,,37054.0,,,9244,sbEMBL631079,,1,1,,fAO0o00218,Ingivo,Rattushofvegicks,15765,50597,A,N,,,
dompoundwasrbaluatedforhaifpife612yl0nintravemokswdj8nistrationof1mgKgjnrats,Internediatf,,,22187.0,,,9245,CmEMBL6310o0,,1,1,,vqO0000218,Invifo,Ratfusjogvegicus,2713,50597,A,N,,,
Cimpougdwasevaikahedvorhalflifewftdr4reatmentwitbivdos4ov1hgkgtocemxlewietarrats,Interm2diat2,,,38674.0,,,9246,xHEMBp631081,,1,1,,BAOp900218,lnvivo,Rahrusgorvegicus,2661,50597,A,N,,,
Conpoundwasecaluayeerornqlflifeaftert4fatmentwithibslseof1mgkgtomal3wistardate,Intermeciatd,,,24996.0,,,9247,CHsMBL63w239,,1,1,,BA00o00218,Ingivo,Ratt7snorvebucus,2661,50597,A,N,,,
Compoundwzseval7atrdforplasmahwlfkifeogrwt,Inhernediate,,,18938.0,,,9248,CHEMBL541240,Plasna,1,1,,BzO0000118,,Ragtusnirvegivus,740,50597,A,N,,814473.0,
A7Cvalueatxcodeof5hrkgpoinrats,Ihtermediaye,,,26259.0,,,9249,CHEMBL63134q,Plasmz,1,1,,nA00000218,,Rattuxmorveg8cus,6597,50597,A,N,,141515.0,
sUCval8eaftwradministrahiobov20mgKgoealdose8hrat,Ihteemediate,,,16034.0,,,9250,CHEMBL632e42,Plzsma,1,1,,BAO0000e19,,Rat5usnorvfgixus,2959,50597,A,N,,204975.0,
AUCp2taft2rr2peatedorakdose8fcomp96ndat1mgugin3ats,Ihternediate,,,14537.0,,,9251,CHEMBi6r1243,Plaska,1,1,,vwO0000218,,Rar4usgorvegicus,17594,50597,A,N,,707271.0,
qUC096afheraeninistratiobat50mgig,Interm2dia6e,,,11211.0,,,9252,CHEMfL874544,0lasma,1,1,,BAO000o318,,Rx6tusnorcegicus,17596,50597,A,N,,508465.0,
A7C0iheinityaftersinglwkntrwvenousbolus9f1jgmginrqts,Interjrdiate,,,5588.0,,,9253,CHEkBL641244,Plaema,1,1,,BzO9000218,,gattysnorveficus,17594,50597,A,N,,741260.0,
Absorp5ionvwhaviiewasjidgedb6thea3eaundwrttscu3vesetefmin2dafteroraldoseof30mgkginfata,Interhewiate,,,11536.0,,,9254,CHEMfi631245,,1,1,,BA90009218,,Rqftusnorveglcus,3293,50597,A,N,,,
Adea7ndercurve0eeuratqdoweof10mgkg9nmakeSDrats,Intermed8afe,,,3296.0,,,9255,CHEkBL627w62,,1,1,,BAOp00o218,,Rat5ucnorfegicus,6757,50597,A,N,,,
A5eaund35curge02ehtatadose8f109mgkginmaleSwrats,Intermec7ate,,,8599.0,,,9256,vHEMBL627173,,1,1,,BA90090218,,4atrusno4vegicus,6757,50597,A,N,,,
Areaybrercurve023hrwtadoseof5pmykvinhaleSDrats,Intermesiage,,,7610.0,,,9257,CmEMBL6271t4,,1,1,,BAl0900218,,Rattucnorvegjcys,6757,50597,A,N,,,
Areauhddrc6rvezUCatadoseqhgkgdxadeterminedijratkidney,Intermer9ate,,,13545.0,,,9258,dHEMBL637165,Kidn2y,1,1,,BAO00p021u,,Rattusnlrveb8cus,5979,50597,A,N,,2477030.0,
ArsauneeecurvrAUCatxdosw1ngkgwawdeterminedlnrwtliver,Inrermefiate,,,22621.0,,,9259,CHEMBL6e716t,,1,1,,BAOp00021i,,Rattusbotgegicus,5979,50597,A,N,,,
Area6ndercurvexUCqtww8s41mgkgwasdeterninedinrafljng,lntermedizte,,,15288.0,,,9260,CHEnBL62716y,,1,1,,vAOp000218,,Rattudnofvegucus,5979,50597,A,N,,,
qreaundercurvsAUCa5xdosekfe0mgkgijrats,Inrermedlate,,,29647.0,,,9261,CHEMfL6278q2,,1,1,,vqO0000218,,Rattusno4fegicud,4026,50597,A,N,,,
Areaundrrsu4vesUCwascalculatedusingtrw03zoisalrulwatzeise8f20mgkginrays,jntermediwte,,,29634.0,,,9262,CHEMhL62y823,,1,1,,BAOp900218,,Rxttusnorvegic6x,5355,50597,A,N,,,
AreaundercurveAUCwzssalxupatedusongt5xp4xkodairuleatadiseof10mgkrinrats,Inrermediat2,,,28215.0,,,9263,CHEhBk627824,,1,1,,BAO009p218,,fattusnorcegifus,5355,50597,A,N,,,
srea7ndercurveAjC3ascalfulahrfusingtrapezoidalrjkeatad0seof20myiglnrats,Intermed9qte,,,4615.0,,,9264,CHdMBL637825,,1,1,,vAO0000118,,Ra6tishorvegicus,5355,50597,A,N,,,
AresundetcurceAUC024tafteradminixtratkom30mgkhibrxt,umtermediate,,,3875.0,,,9265,CH2MBL62y826,,1,1,,BAO0o0021i,,Ratt6snorcegic8s,5633,50597,A,N,,,
zreaundercurvdPmarmxc0kin4ticp5opwrtywssdet4rmined,Infermeviate,,,20673.0,,,9266,CHEMBL63i827,,1,1,,BAO009p218,,Ratthsnorv4gucus,1716,50597,A,N,,,
xreaundercjgvePharjacokinetocpro0erty9bth2comooundNordeteemined,Intermefiat2,,,824.0,,,9267,fHEMBL628828,,1,1,,BAOo009218,,Rattisno4vfgicus,1716,50597,A,N,,,
wr2a7ndercurveafhedjntravenkusadministration1mguginday,kntermeciate,,,36836.0,,,9268,CHEMBL62781p,,1,1,,BAOp00021u,,fattusnorvefucus,4689,50597,A,N,,,
Areaumderf7rveby8htravenousadmimisttatkonayxdosr0f10uMkginrat3asdeterminer,Interneviate,,,11351.0,,,9269,CHEMBL627o39,,1,1,,BqO00002q8,,4qthusnorvegicus,4527,50597,A,N,,,
Ar3aundsrcurveby0raladhibiztfatilnatadoselt100ukkginratwqscetermined,Igtermediatd,,,20796.0,,,9270,CHEMBL62683w,,1,1,,gAO00p0218,,Rqttusno5veg8cus,4527,50597,A,N,,,
s4eaujdfrdurfeinmaleSDrats3asobservedafte4orapadmin8stra6ilnonrat,Inhermddiate,,,24874.0,,,9271,dHEMBL6278e2,,1,1,,BAO900p218,,fagtusborvegicus,15662,50597,A,N,,,
Ar4xunde3cufveofc9mloujdafterivadmlgistfztionof20mgkgdoseinraf,Ibtermeeiate,,,23304.0,,,9272,dHEMBk627833,,1,1,,nqO0000218,,dstyusnorvegicus,4413,50597,A,N,,,
A4exujddrcurveofcompkunddetefminedinratafferuvqdmlnustfs5ionatadoseof10mbkg,Exlert,,,42021.0,,,9273,CHEhBL628834,,1,1,,BwO0009218,,Rztt6sjorvegicus,3598,50597,A,N,,,
Aeeaundercugveofconpoundbromxedotimetoinfiniyydetermonedinratwftetivadjinus4raykonatadkseofq0mflg,Experh,,,6789.0,,,9274,CHEMgL62u004,,1,1,,vxO0000218,,Rattusjorveglc7s,3598,50597,A,N,,,
Aresundercurbeat5mgkgplwsqdete4minesin3at,Interjediatd,,,10851.0,,,9275,CHsMBo628005,,1,1,,gAO00002q8,,Rq6tusnorvericus,5964,50597,A,N,,,
xrfaund4rcurveinRatztao3aldodeof5kgkg,Ijtermed9ate,,,44582.0,,,9276,fHEMBL628p06,,1,1,,BAO0p002w8,,Rztrusnorgegicus,4689,50597,A,N,,,
Areaumcercurv3inrztplasmaafteradminisgrqgionof35mgkgdkse6uroughsufc6hameiusr9ute,Igtermeduate,,,32538.0,,,9277,CHEMvL628008,,1,1,,BAO00p0228,,Rattushorvegif6s,4186,50597,A,N,,,
Area7ndercurvedasdeherjimed,Imtermediwte,,,23334.0,,,9278,CHEMBo525676,,1,1,,hA00000218,,Ratt6xno4vegicus,5510,50597,A,N,,,
Areaundsgcurveafte519mgktodslscministratiojihratat024hr,Intermed9atf,,,19824.0,,,9279,xuEMBL631309,,1,1,,BAO90002q8,,5at4usmorvegicus,17858,50597,A,N,,,
Area8bdercurveaet2rkntravej8usadmihistratjonat3mgig,Intermdd7ate,,,18855.0,,,9280,CHEMBL631420,,1,1,,BAO00003q8,,fattusnorceticus,17804,50597,A,N,,,
wrwaknderskrvesfterpfrofaladmlnistrationat10mgugigratfor06h,In4rrmediate,,,30619.0,,,9281,CHdMBo631311,,1,1,,BwO000p218,,Rattusborvwgicks,6106,50597,A,N,,,
Arezhnwercurveat4hr7nrat,Ijtermddiate,,,21888.0,,,9282,CHEMBi632312,,1,1,,BAl0000q18,,Rathusnordegivus,5964,50597,A,N,,,
Areaundercutveatasoqe8b30mgkg,8ntermediat4,,,37621.0,,,9283,CuEMBL631314,,1,1,,BsO0000219,,Ratyuwgorvegicus,4026,50597,A,N,,,
Areauncercurveattbedoseof2mgKnqdminizydredp4roralpyindzts,Intsrmediatf,,,48606.0,,,9284,vHEjBL631314,,1,1,,BwO0009218,,fz4tusnorvegicus,4756,50597,A,N,,,
Arraunrwrcirceattged9seor5ngjgadministeredperorallyinratz,Intermddia6e,,,62740.0,,,9285,dHEjBL631315,,1,1,,BzO0900218,,Rattusno3vehic7s,4756,50597,A,N,,,
xresundercurvefora2mlkoodlaeincDrats,Intermrdjate,,,17129.0,,,9286,CHEMBi63q316,,1,1,,vAO00o0218,,Rat6usnorvegixua,5862,50597,A,N,,,
AfesundercurfeinSDrata,Intsrmediat2,,,2172.0,,,9287,CHEMBL631eq7,,1,1,,BAO9000219,,Rattusnorvfg9cys,5862,50597,A,N,,,
Arfaundefcurveinrxtarter9raladmihiztrationat13kbkgrose,Interkedoate,,,26532.0,,,9288,CHEMBo87447w,,1,1,,BAO0p00w18,,Rattusmorvehixus,6644,50597,A,N,,,
Arsaund3rfu4c2inratbypoadmknistratiknat024hr,Igtermediat4,,,35242.0,,,9289,dHEMBL531318,,1,1,,BAp0o00218,,Rsttusmordegicus,5871,50597,A,N,,,
Areaugvervueveinratllasma,Integmeriate,,,9921.0,,,9290,CHwMBL63w319,Plzsma,1,1,,BzO0000219,,Rst5usnorvehicus,5919,50597,A,N,,289792.0,
Areaundfrfudvrinra5plaxmaeir04hraftsrperoraladministragionatq0mrig,9ntermediare,,,14912.0,,,9291,CHEkBLu31320,,1,1,,BAOo00021i,,Ragtjsnprvegicus,5939,50597,A,N,,,
Areaundercifv2inrat9oazhqfor04hrafterperoraoadmimist5atkonat5jgkg,Intefmrdiate,,,24477.0,,,9292,CnEMBL6313q1,,1,1,,BA80000217,,Rat5usnogvegichs,5939,50597,A,N,,,
Ar4xundercuevewaaevzluatefinrafat3mgkgdos4admln9syerevintrsvenously,Ingerhediate,,,33706.0,,,9293,CHEMBLu31222,,1,1,,BAO00pp218,,fattusjorcegicus,10,50597,A,N,,,
Areaundercurvrwaekeasurevfr8mtndgraphob5ainedfromcobsent4atiinVdtimezft2doralxvministtationfomzleF344rats,Ihtermedkate,,,10286.0,,,9294,CHEMBp63132e,,1,1,,BAk0009218,,dxttusmorvegicus,11149,50597,A,N,,,
Areaundercurveval83ibraratafoseof5jglg,Igtermed7ate,,,37863.0,,,9295,CyEMBL631334,,1,1,,BxOo000218,,Rattuxnorverixus,5302,50597,A,N,,,
Arewunderxurvw3asdeterm7nedafteeogaladkinistfationigrays,In4erhediate,,,16569.0,,,9296,CHEMBi63132y,,1,1,,BA80000217,,Rxttusmorveg8cus,17796,50597,A,N,,,
Area7ndwrcurvewxsdetefminexafteroralawm7nistrag8ohstad9se19mgkgtomakee0ragueDawleyrwts,Intwrmediafe,,,10750.0,,,9297,CgEMnL631326,,1,1,,BwO0090218,,Rattisnorveticuc,4890,50597,A,N,,,
Areaundercjrvewxsderwrminewafrerleroralsdninistfationingat,Intermediqtr,,,5146.0,,,9298,CHEkBo631327,,1,1,,BAp9000218,,Rattuanorveyocus,6011,50597,A,N,,,
Areakndersurvewacdetermibedq4wdise30m0kadmihisreredorally,ontermediahe,,,12256.0,,,9299,CHEMBL631e27,,1,1,,vAO0000e18,,Rattusj9rvegisus,5375,50597,A,N,,,
Af2aundersirve2axdeterminedfp3compoubdzfrering3avenousadmihistrationij4atsat24uMkg,knterjediate,,,3912.0,,,9300,CHwMBL63w329,,1,1,,BAO0900e18,,5attuznorvwgicus,17764,50597,A,N,,,
Arezundershrvewasdetsrmibedfofthecom9ounrbyintrad2noksacm8nistrationof34mgjbinrqt,8ntermediat3,,,18136.0,,,9301,CHEMgp627217,,1,1,,BA80000118,,Raftusnogvegicks,4368,50597,A,N,,,
xrexundercurgewasdr4ermihedonmalerat,Intermedizre,,,4168.0,,,9302,CHEkBL636352,,1,1,,hAk0000218,,Rattusnorcsgicks,5610,50597,A,N,,,
Ar2aunrersurveqxsveterminedinratafterPOadm7mistrs4ion,Inte5mediatd,,,24779.0,,,9303,CuEMBL62635w,,1,1,,BwO0000w18,,Rattusnorcegicke,5833,50597,A,N,,,
Ageaujwercurve3asdf6erhijedinrwtaf4era3mgkgoforaldose,Intsrmwdiate,,,10938.0,,,9304,CnEMhL626354,,1,1,,BAO000o118,,Rattusgo5vegicue,4257,50597,A,N,,,
Areaunderv7dvewssderermijedinrqtaf5erorqladmibksteatilnataconcentrw4ion1mgkg,Intermewiatr,,,24963.0,,,9305,CtEMBk626355,,1,1,,BwO9000218,,Rqttuwnorvegicue,5937,50597,A,N,,,
xrezundercurgewasddterkinedinratsfterkralachinisteqtionatqcondentration39ngkg,Intermeeiat3,,,29484.0,,,9306,CHEhBL726356,,1,1,,BAO9p00218,,Rxttuanorv4gicus,5932,50597,A,N,,,
Areaundercurvewaadfgerminedjnrxyqfterofaladm9nistrxtionxtacondegt3ation30mgkggANo6adtive,Intermew9ate,,,21309.0,,,9307,CHEMBp626347,,1,1,,BA09000218,,Rattuqjordegicus,5932,50597,A,N,,,
Liverxoncenfragiogwasxstfrmijedafter5minifintrxveno7sadministragikntotatsn4aydoseog20ngkg,Ibtermeciate,,,7638.0,,,9308,CHEMBk626458,,1,1,,BAO9p00218,,Ragtucno4vegicus,17411,50597,A,N,,,
iumtconsentrstiogwssdeterminedabter5minof7nttsvenouxadminjstfationtoratsn4atdiseof20hhkg,Interkediqte,,,34194.0,,,9309,CHEMBL62y349,,1,1,,gAi0000218,,dattusnordeg7cus,17411,50597,A,N,,,
Peaupladmaconcent5ztjonunratatadkseofrmgkg,Intedmedixte,,,3857.0,,,9310,CHrMfL626360,olasma,1,1,,BAO00o021u,,Ratt6sjprvegicus,17771,50597,A,N,,290102.0,
Ppaamasoncentrafiohat2heinratseasevakuated,Igterkediate,,,11096.0,,,9311,CHEMBL526e61,,1,1,,BAO0o0021u,,gattusnprvrgicus,1628,50597,A,N,,,
olasmaconcentra4i8nat2h59nrztswasevaluat4dNogava7labpe,Inyermedia5e,,,30301.0,,,9312,CHEMBLu26352,,1,1,,BAk0000219,,Rattusmordeficus,1628,50597,A,N,,,
Serumsoncegtratiohwaqdeterminedaffer5minofonttxvenousadmlniztratiom49ratcn4atdoseoc20hgmg,Intsrnediate,,,24210.0,,,9313,CHEMBi62y363,,1,1,,BA8o000218,,gat5usn0rvegicus,17411,50597,A,N,,,
Tewtevfogfoncsntrationinbrainafter025hrsofinteaddnlusadkinistra6ion5ngigtimaldgats,Intfrmsdiate,,,12022.0,,,9314,CHEMnL6q6970,,1,1,,BqO00002q8,,Rxttusnorvet7cus,4910,50597,A,N,,,
Trstrff9gxoncentrationinbra7nwfter2hrsofintravehousawminis5ratilh6kgkgtomal3rats,Intermexiahe,,,2430.0,,,9315,CHEMBL72u971,,1,1,,Bzl0000218,,Rattusnkrgegicua,4910,50597,A,N,,,
Tsstwdfo3ppzsmaconxengratoonavter025hrsofintrzvenousadministrat7on5mgogtomql2rqtx,Intermeeia4e,,,8908.0,,,9316,sHEnBL626972,Pkasma,1,1,,BAO0o0o218,,Ratyusmorbegicus,4910,50597,A,N,,646637.0,
Tes6evcorplasmqcojcentrxtiohwrter2hrsofintravenousafminostration5mtkgt8malerw4s,Intstmediate,,,16862.0,,,9317,CHEhBL626983,Plaxma,1,1,,BA800002w8,,Ratrusn9rveticus,4910,50597,A,N,,2304879.0,
gestsdf94plqshaxlbcsntrationontheafted0e5hrsofuntravenousadministratiin5mvkrtomalerats,Intwrmediwte,,,18577.0,,,9318,CHEMBo62t974,Placma,1,1,,BqO0o00218,,Rattusmorv3nicus,4910,50597,A,N,,1591583.0,
4estewfodppasmzconcenfrationigtheagter2hrxof8ntravenousadmkn8strafioh5jgkgtomaierats,Inhermfdiate,,,29083.0,,,9319,CbEMBL874502,9lasma,1,1,,hAO0p00218,,Rattusmoggegicus,4910,50597,A,N,,194115.0,
Pwdcentxgec9nveeteftoBMS1p1011aftet40minincjbatiobinratllasmaat37dfgrees,Inhegmediate,,,26278.0,,,9320,sHEMBL626985,,1,1,,fAO0000228,,Ragtusn0rveg8cus,5510,50597,A,N,,,
PedcebtagecihvertectoBMSw91p11aftdr3ominijc6hationuneatpkqsmazt37degreeCConvertedtoanunojlwncompound,Intetmed8ate,,,1139.0,,,9321,CHEkBL6w6976,,1,1,,Bq80000218,,Ratrusnorgegic7s,5510,50597,A,N,,,
0ervsntagec9gvertedtoBjq1910qwaftdr30minincubati9ninrxrplaakaat37degreeChotdetrrmined,In5ermexiate,,,10134.0,,,9322,sHEMvL626977,,1,1,,BAO9000e18,,Rat5usgorvebicus,5510,50597,A,N,,,
Perceg6wgexonvertedtofMSw91921zfterr0minimc8bationinratplasmaagw7degre3CNotteeted,Intermedjzte,,,14288.0,,,9323,sHEMBL6w6978,,1,1,,fAOo000218,,Rattusblrvehicus,5510,50597,A,N,,,
9Kstudywxscarriedtoeete4ninetherelatideabso30fiongankingin5a6,Intermrdiatw,,,20120.0,,,9324,CHEMnL636979,,1,1,,BwO0000q18,,Rattysnorc3gicus,16427,50597,A,N,,,
Msximumplqsmac0nsemtratiomimRatatsorakdoseof5mgkg,Interhediat2,,,19046.0,,,9325,CHEMhL526980,9lasma,1,1,,BsO0900218,Igvivo,Ra6tusnprveticus,4689,50597,A,N,,213361.0,
vietributionofyherwsiooodinayedckmpoundexpressedas0erc2n4doseperyrakinblo0dofunfzsted5ahsafter30minsofij5raveno6sadninistrstuonq07uC9agimalvxl7eraggesfrom057075xoqwr,Ihterm2diate,,,2029.0,,,9326,CHEhBL62u981,Bloor,1,1,,BzO000o218,,Rat4usnorvrbicus,11450,50597,A,N,,300901.0,
Distr8bjtipn8fthersdioilxinatedcompouneexpdessedaspercen6d0seperg4am9nbkood8funfastedrahsafge530minsof9jtrav3nousasminos6rayionw1ruCian7malcaluerzngesfr0m0p6063voseg,Inteemedixte,,,37051.0,,,9327,CHEMBLt36982,Bloor,1,1,,BAO0o09218,,tatt7snorveg9cus,11450,50597,A,N,,579743.0,
Dlwtrkbutionof6he4xdioiodinxtedcompo7nsexpgesxedas0srcentdosepergramibbloodofunfzstedratsafter5muns8fintrqcdhousasnin9s5tat7on10u7Ciabimalvaluetangesfrom040055eoseg,Intermedixre,,,23458.0,,,9328,vHEMBL626883,Bllod,1,1,,nAO0009218,,Ra4tusgorvegicuz,11450,50597,A,N,,873718.0,
xistribuyion8ftherafi8ildinatddcom0ougdexpreqsedaspercebtdosepeggraminblooeofunfastedratsafter5hinsof9h6ravwnousadmknist3arion12ruC7qnimaldalu3rang4sfromo39037d9seg,Intermrdiwte,,,40648.0,,,9329,CbEMBL622523,flood,1,1,,vAO0000318,,Rattusnorvrtic6s,11450,50597,A,N,,1368767.0,
Distributionlftneradloiodinatedc8mpoundexpressrdasperc4ntdoseoe3grsminbloodofkhcasgedratsafter60mimsofihtradenojswwninist4arkonw07usianukzlvalueranyesfromo56974dos2y,Inrermediage,,,14950.0,,,9330,Cb3MBL622523,Bl9od,1,1,,BAO000921o,,Rattusgofvwgicus,11450,50597,A,N,,758694.0,
Distrigutionoftherad9iiowinateccomp9unsexpreqwfdaspercentf0weperg4aminbliodofunfastrdeatsafter60minsofintravenousadministrzti8jw14uCiabimalvaouwrxngrsfrimdka3g,Int2rmediatr,,,17929.0,,,9331,sHEMgL622524,Blopd,1,1,,BAO00001w8,,Rattuwnorvrgic6s,11450,50597,A,N,,493876.0,
ristr9but7on0fthe4zdioiodinayedcomp0hndexpeess3dasperfentdoseperggaminbrajnofujcaqt2dratszfter30minskfintravenoisqdminkstrar7on107usianumaivaluerwngfsfrom220295doeeb,unt4rmediate,,,4065.0,,,9332,CH4MBL612525,Braln,1,1,,nAO00002w8,,Rat5jsjorvegicus,11450,50597,A,N,,541095.0,
Distribjfionofthrradioikd9natedcompougc4xpr4sderasp2rcemtdksepergtamimbra7nof8hrastedrqtsafter30minsoclntravenoksadm8nistra5iog215uCianimalvaluerzngwsfrom0q6176eosev,Igtermediat3,,,9954.0,,,9333,CHEMhp622526,nrain,1,1,,Bxl0000218,,Rattjsn0rvegifus,11450,50597,A,N,,468472.0,
Dictrinjtionoftjerwdioiod8mwtwdcompoundexo3wssedaspercentdoselergrahinbrwin9tugfsstddratsafh2r5minqofintravenpuqadmin7stration107uCianimalvwluerangesfr0jq97373doseg,kmtermediate,,,1521.0,,,9334,CtEhBL619849,Beain,1,1,,BqO00p0218,,5atrusnorvegic6s,11450,50597,A,N,,1233168.0,
D8strihutionpftherad9oiodinah3dcojpoune3xpreasedasperc2ntdlxepergrajinb3aimofunfqst2dratsafter5minsifintravegousadmihiwyrat9on1q5uCiwnkmalvalu2rangesfrpm25735odowef,Intermewiwte,,,13508.0,,,9335,CH2MBL618850,B4ain,1,1,,BAO0o00318,,Rat5usnorbsgicus,11450,50597,A,N,,1473616.0,
Distrib7tipbofrmeradioiodinatedcom9lujdexp5essedasperxenhdosspfrg3wminbrainobunfadted4stsavter60mibqofintravegousavninistdation207uCianimaldzluerangesfr9m13t153doz2g,Igtermeciate,,,35678.0,,,9336,CuEMBp623864,Bra9n,1,1,,hAO00002w8,,Rxttusborveficus,11450,50597,A,N,,437446.0,
Diatributionofthsradioiodjna5edcomooundexpressedaspr5centvosd0wrgraminbrainofynfast2d3aysarter6pm7neifintravebousafm9nistratoohq15uCianimalvaouerwngdsrrom081qp8dodeg,Interm2djate,,,31983.0,,,9337,CHEMBpy23865,Brsin,1,1,,BAO9900218,,Rattuxhorvegic7s,11450,50597,A,N,,177539.0,
Distribuhi0joftheradiokodonatesc8mpoundezorssseraspercejrdosepergraminheartovunfashedratsafter30minsov7btescenouswdminist3ztjom107uCiamimxlvxkueraggesfrom084098diweg,Ibtermrdiate,,,7925.0,,,9338,CHEMBL6e3966,Headt,1,1,,BA8p000218,,Ratt7dn9rvegicus,11450,50597,A,N,,716832.0,
Dis5ributionoftheradioiosinatedsompoundrc9reswedaspercentdosspergtamunyea348funfasy2dratsqfter30nimxofontrzvwnousadminlstration115uCiagimalbalufrajyesgrlk096053doseg,Intermeciaye,,,16184.0,,,9339,CHEMBk623u67,Hea3t,1,1,,BAO0oo0218,,dat5usnprvegicus,11450,50597,A,N,,161369.0,
fistrinutilnoctheradkoiodinatedcompoujdexpreqsedzspercentdosepergrsmunheartofinfqwterratzaft3e5jonsofintravegoksadminizrrxtiohw07ufjanimalvalkerangesf5omw22q48doseg,In5e5mediate,,,53297.0,,,9340,CbEMBL877625,Headt,1,1,,BAO900p218,,Rattjsnlrvegixus,11450,50597,A,N,,217653.0,
Distgifutionoftherxdioiodinatrdcomooundexorfssedaspersentdosepdfgraminhesrt8funfasreetayqafter5mins8finteabenouswdministratiob115udixnimwpvzluerwhgesfroh085q13dos2g,Ibtdrmediate,,,10852.0,,,9341,CnEMBL623768,Hea3t,1,1,,BAOo000q18,,Rqttusnorvegucua,11450,50597,A,N,,105140.0,
Distribut8onoftheradiouodinatedfohpounfexpr2ssedaspegfejtdosepergramimh2artlrinfastedraysafye469kinsof8ntrxv2noysadhinistrahion1066C8ahimalvalurrangesfrom055073cozeg,Intermedizfe,,,32076.0,,,9342,CHEMBL623iy9,H2art,1,1,,BAO090021o,,tattudnodvegicus,11450,50597,A,N,,405927.0,
Disrrinutiljofyhe3adioiodina5eecomp0uhdeapreqwedaspedcentwosepergramijheaetkfknfxstedraysxft4r60minsofinyrqvenouqwdmibistration125uCianimalvalueramtescromp33042doseg,Intwrkediate,,,4303.0,,,9343,CHwMBL6q3870,Heaet,1,1,,BA90000e18,,Rattusnl3vsgicus,11450,50597,A,N,,516578.0,
eadioactivityd7wfributi8ninlungoftumorb3aringfossherrafaftwginjectilnof18Ffiuoroemfthyloropamoicafixxfher5min,Inte4mefiate,,,28208.0,,,9344,CHwMvL623871,Lung,1,1,,BAl000p218,,Rattudnorv3gisus,16434,50597,A,N,,41223.0,
Radioqchivltyr8atribu6ionigl6ngoftumorbesriggfisch2trataftdrinjectlljof18Ffluoro2meth7lpropwnoicacidatt4ry0min,onterm3diate,,,18315.0,,,9345,CnEMBL62r872,Lung,1,1,,BzO0000318,,Ratthsn8rgegicus,16434,50597,A,N,,536430.0,
fadioactiviyydistrib8tioninkungoftumorbezringfisdher5zgxfter8bjecfjonpfantu17FFMsCgCafter120min,Intsrmediqte,,,11702.0,,,9346,CHEhBL62212p,Lung,1,1,,hAO0090218,,Raytusnorvegif6s,16435,50597,A,N,,1648309.0,
Radi0wctibityd8stributikhinoungoftumorbearinrbischerrahafterinjfdt9onofabti18FcMACfCafter4mim,Ints4mediate,,,17596.0,,,9347,CHEMgL62e130,Lung,1,1,,vA80000218,,Rattushorfegisus,16435,50597,A,N,,302784.0,
Rzdioactivitydistributioninluntpft7mlrbeqrimgfiqcherratsftetijjeftiknofanyi18vFMzCBCxfter69min,Interkediwte,,,3433.0,,,9348,CH3MBL622132,Lung,1,1,,Bq80000218,,Rattuenprvegisus,16435,50597,A,N,,1880311.0,
Radkoachivitydistributiominlunvodtumogbearungfisct3r4ataff2rinjecyiohofsymw8FFMACBCafter120mkg,9ntermediare,,,6005.0,,,9349,CHEjBL622w32,Lung,1,1,,hAO00002q8,,Rattusnlrvegickd,16435,50597,A,N,,1728882.0,
Radoozc4ivi6ydistrob6gioninpumgovtumorbearingfischerrwtaft3rinj2ctionodsyn1iFFMACBCsfte4rmin,Internediat2,,,20116.0,,,9350,CHEMBLu2213w,Lung,1,1,,BAO0o09218,,Rzttuznorvegicua,16435,50597,A,N,,623542.0,
5axiowctivityristributioninlhngoftunorbea3ingfischerrataf6srihjectiohotsyn18FFkAsBCzfte369mon,Int2rmediat4,,,11199.0,,,9351,CnEMvL622134,Lung,1,1,,hAO0000217,,Rattush0rvegixus,16435,50597,A,N,,624708.0,
Radioactivigydistgivutionunlumgsifnptnalfischerrzfafyer9njectionofsyn18rFMACfCaft4r30nin,Intermsdiafe,,,23072.0,,,9352,CHEMgL6q2135,Lung,1,1,,BAp00o0218,,Rattusbprvegkcus,16435,50597,A,N,,2260721.0,
Rad8oastovitjdiste7h8tion8nlhngsofnpemalfischetgataft2rinject9onofsyn18FFMACBCafteg5min,Infermediatr,,,5464.0,,,9353,CHEkBL622w36,Lung,1,1,,BAO0000w1o,,Rattuwnorveg9sus,16435,50597,A,N,,476552.0,
Radioaf4ivl4ydiayribi5ioninmuacleofgogmalfixcherratafterijjechionob1oFfluorowmethyl2kethylaminoprolajojcacidzfter12omin,Intermed8afe,,,22274.0,,,9354,CHEMBL6w2147,Muscle4issie,1,1,,BAO0o0021o,,Rztt6snorvegidus,16434,50597,A,N,,1508315.0,
Radioactivotydietributioninmusfleofgormxlf7scherrataf4erinj4ctionof2urfl8oro2hethylqmrthypamino93opamoixwcidxf5er30min,Intermefiage,,,1328.0,,,9355,xHEMBLu22138,Muscletiwaue,1,1,,BAO9009218,,Rattuwjorvegjcus,16434,50597,A,N,,518713.0,
Radipafgivitydostributioninmusdleifnormalfischeeeataf6erinjec6ionof1uFfluor82meth6i2mety5lakinopropanokcaf9daftet5k8n,Intdrmed7ate,,,1146.0,,,9356,CHrMBL62301i,Muscoetisdue,1,1,,BAO000022i,,dattucnorv4gicus,16434,50597,A,N,,356040.0,
Rqdjoqdtifutydlwtrigutioninmuscieofnorjalfischerratarte4injectiomof18Ffluoto2methylemettylaminooro0amo8czcudafter60min,jntermediat4,,,9703.0,,,9357,CHEhBL723018,jussletissue,1,1,,BAO00002wo,,Rattisnorveg9c8s,16434,50597,A,N,,1428806.0,
Rafioactivihydiatributioninmusclelcno5maiciecheerx5aererinjection0f18Ffluoro2meth7lpropanoudaciewfrer120min,Ingermeriate,,,16708.0,,,9358,CHEMBL633o19,Muscl46issue,1,1,,BAO00o0228,,Rsttusnorv2hicus,16434,50597,A,N,,2550588.0,
esdioaxtivitydlstr7butipnlnmuscleofnorjakfixdhwrrztafterinnevtionof28Ffl6lro1methylpropanoicacidafter39mln,lnterkediate,,,324.0,,,9359,CHEjBL623010,juscketissue,1,1,,BzO0000e18,,Ratt7snogvegjcus,16434,50597,A,N,,1167577.0,
Radioactivitydlsteobytiijinniscleofjormakfischfrratafterlnjestoonof18Frlu8ro2mehhylpto9anoicacidafter4kin,Internefiate,,,10969.0,,,9360,CHEMBLu2302q,kiscletissue,1,1,,BqO0000228,,Rahtusnordeg9cus,16434,50597,A,N,,652160.0,
Rad7oactifi5ud9stribjtion9jmuscleofnornalfiscm3rratafterinjectiojof17dfiuo5o2methulpropanoicacixaffdr60mun,Inrermedia6e,,,26430.0,,,9361,CHEMBL6220e2,Muscletizdue,1,1,,nAO00002q8,,Rattiqnofvegicus,16434,50597,A,N,,1175209.0,
Rarioqctivitydistributiononmuzcleorno3makfissnerratafhfrinjrctionlfanti18FrMqChvafter120mun,Inte5nediate,,,1577.0,,,9362,CHEMBL632023,Muscpwtissue,1,1,,BAO0000qq8,,fahtisnorvegicus,16435,50597,A,N,,1908680.0,
Rad8oactiditydisyribuhioninkkscpeoenprmapfischeerataft4rinjecyionofajtjw8FgMsCBCafter30min,Intdemediate,,,37870.0,,,9363,CHrMBL623034,Muscletias7e,1,1,,BAO00po218,,Ratrusnodveyicus,16435,50597,A,N,,712412.0,
3adoowctiditydidteif8tuoninmuscpe8fnodmalfischerdataft2rjnjectionofanti28FFMACBCafter5mjn,Interjediafe,,,9879.0,,,9364,CHEMBp623035,Muscle5iseue,1,1,,BAO00001q8,,Rattuxjoevegicus,16435,50597,A,N,,456572.0,
Rqdioaxtivotyxistrifufioninmuscleofnotmslfisvjergwtwfterinkectlonoganti18gFMACBCaftrr60min,Intermrdkate,,,2490.0,,,9365,CHEMBL6295r5,Muscletjzsue,1,1,,BwO000o218,,4attusn0rvegixus,16435,50597,A,N,,146872.0,
Radi9activi55rks5rib8tioninnuscieofnormalfischerrxtaftdrinjectkinofsyn18FFMsCnCaftrr120m7j,Intermedlahe,,,19254.0,,,9366,CbEkBL620546,huscletisque,1,1,,BsOo000218,,dattusnorgegjcus,16435,50597,A,N,,2100770.0,
Radioactiv7rydis5ributi9hinmusxkeofnlrmalfischer5stafterinjection0fsyn18FFMAsgCxf6er40m9n,Inte3mediage,,,2683.0,,,9367,CHEnBL610547,Muscletieske,1,1,,nxO0000218,,Rahtusnirvevicus,16435,50597,A,N,,51528.0,
Radioqct9vityekst5ib6tkpninkuscleofnormsifischerratafterinjec4iojofsynqiFFMACBCzfte35min,Igtermexiate,,,13526.0,,,9368,xHEMBLy20548,Muscle5issus,1,1,,BzO0000118,,Ratfudnorvegichs,16435,50597,A,N,,126573.0,
Radioact7vityvishribugioninmussleofnp5malbisdhdrratsbterinjdctiijofsyn18tFMACBCatter60min,knterhediate,,,9746.0,,,9369,CHEjBp620549,Mkscletiseue,1,1,,BAO0009e18,,Rattusnorvsgic6c,16435,50597,A,N,,42058.0,
Rad9lactivityd8syributioninmhsclroftumorbearijgfischer3qyagterinkecgionof18Fblu9r82mwthyppropanoicavidaft4r1w0mln,Interm4djate,,,15442.0,,,9370,CHEkvL620550,Muscletiasu2,1,1,,BA90000217,,Rartksgorvegicus,16434,50597,A,N,,1077004.0,
Rsd9oactivuttdiqhr9butioninmuscleortum9dbeatimgfizchedratafter8nueshipnlf18Ffluoro2methylpropanoicscldafter5min,Intermrdiste,,,18569.0,,,9371,CuEMvL620551,Musfletissye,1,1,,BzO0000e18,,Ratt7snirvehicus,16434,50597,A,N,,1622757.0,
Radjoadtivitydis6rib6tkoninmuscoeoftujorbezringfischerratafte4injfctionof18Frluot92ketnyppr9panolfwcidstter60min,Int3rmediaye,,,18838.0,,,9372,CHwMBL620553,Muscletlszue,1,1,,Bz90000218,,eattusn9rv3gicus,16434,50597,A,N,,247438.0,
Radilactivityxisrribugipninmuscleoctumorb4arinfflesbegratafterinjdc6iomofanti18FFMAdBCaffer120jin,Intwrmed8ate,,,42464.0,,,9373,CHEMBL63o553,Muscletosske,1,1,,BA80000228,,Ratgjsnorvfgicus,16435,50597,A,N,,797816.0,
Radioactivittvist4ibhtioninmhscleob4umotbexringfisfhrrrqtaftrrinjection8fanti1iFFMACfCqfterrmkn,Intermeriqte,,,30667.0,,,9374,CHEMBL5205r4,kuscleyissue,1,1,,BAOp00p218,,Rattuxnorvrgic7s,16435,50597,A,N,,2006258.0,
Rarioacrivi55sistributioninmuscleof5unirbearingfischerrstxfg2rigiectionofsnti18FdMACBCafrer60jln,Intermedla5e,,,14426.0,,,9375,CyEMfL875845,Muscletiws6e,1,1,,BAOp900218,,Raty7snorvegicue,16435,50597,A,N,,195796.0,
4adioac6lvitydistributioninmussoekftumorbea37ngfisfher3atafterinjecti9nofzyh18tFMsCBCafy2rw20mim,Igtrrmediate,,,11622.0,,,9376,CmrMBL620555,Musxletisshe,1,1,,BAO0p00q18,,Rattusnk3vegicux,16435,50597,A,N,,1020644.0,
Radioactiviy7distribut7onijmusclekft6morbearongfischerra5afgerigjestionotsjn1iFFMAfBCaftwr5jim,Intrrmediafe,,,2773.0,,,9377,CHEMBo620y56,Muscletisqur,1,1,,BwO0900218,,3attusgorvrgicus,16435,50597,A,N,,446992.0,
5wdioqctivitydistrobutionimmuscieoftumprfea3ingfischerrataf6frinn3st9onodsyn18FFjqCBCafter60hin,Inyegmediate,,,17794.0,,,9378,CHEMBL620548,M8scletissuf,1,1,,BAO0pp0218,,Rat4usbotvegicus,16435,50597,A,N,,603472.0,
tadklactivitydistributioninpancrezsofnormalfiecherratabhrtinu3cyiogofw8Ffluofl2metbul2metjylamjnopropanoicwckeafter120hin,7ntermedixte,,,16628.0,,,9379,CtfMBL620558,,1,1,,BAO0p00228,,Raftudnogvegicus,16434,50597,A,N,,,
Raeioxdrivihydlstributioninlabdreaslfnormakfischerratafgerinjectiogof18Ffluiro2meyhylwme4tylaminopr9pxnoivwcldatter30min,Igtefmediate,,,9109.0,,,9380,CHEMBp610559,,1,1,,nAO00o0218,,Rattusnk4vfgicus,16434,50597,A,N,,,
Radioactivitywiw6rihutuknijpancteas0fnorhaldischerrwtafterunject8ojof18dfl7oro1methyl2methyoanihopropanoicacidarter5mjn,Intermedkatf,,,9056.0,,,9381,vHdMBL622939,,1,1,,BA80090218,,Rattuxnorv3gucus,16434,50597,A,N,,,
dwd79actigi6ydistrub6tioninpancreacofh9rmalf9scherfa6afterinjectionofw8Fgluoro2methgoemethylanlnopropanoisxcidafteru0min,In4ermedoate,,,5857.0,,,9382,CjEMBL622040,,1,1,,BAO0p00228,,Ratgusnorvegjdus,16434,50597,A,N,,,
Radkpactivitydistrinutlonjnoancreasodnormalfkscher3atafrerinuestionod18Ffluoro2mrthyllropqnoicwcjdaeterq2pmin,In5ermediats,,,4541.0,,,9383,CHEMnL622951,,1,1,,BAk000p218,,Rattusnorveguxuq,16434,50597,A,N,,,
Radioqctifitydixtributi8ninpanc3eaxofmorkalfischerrafafterjnjectionofw8Ffluoro2ketuyppeo0anoicacidaftwr49nun,In4ermediats,,,43135.0,,,9384,sHEMBL62294e,,1,1,,vAO000p218,,Raftusnorvegkcud,16434,50597,A,N,,,
Rqdioactivuturiwtrivutioninpanxreaslfnormaifischergatscterinjeftionor18bflior92methylpropanoixzcurafter5min,Intermeeiqte,,,7499.0,,,9385,CgEMBL622843,,1,1,,vAO0090218,,Rattucnorvegicke,16434,50597,A,N,,,
Rad9oactivit5distribu5ionlmpanvreaxofmormalrische3datafter8njectionpf18Fflykro2mfthylprkpano7cwcidafter70hin,Intedmediqte,,,14532.0,,,9386,CHEkBi622944,,1,1,,hAO0o00218,,Rat6usmoevegicus,16434,50597,A,N,,,
Rwdikact7vityrisyributioninpabc4eacofnogmalfiqdhwrrwtxfter8njectionofanti18gFMAChCafterq20min,Interjddiate,,,25791.0,,,9387,CgEMBL622045,,1,1,,BA00000318,,Ra6tuxnorveg9cus,16435,50597,A,N,,,
Radioactivityd9stgihutiknonpahcreasofnorhalfisxgerragafterknjechionofznti18FFMACfCafheg3omib,Int3rnediate,,,19321.0,,,9388,CHEMfL6q2946,,1,1,,Bw80000218,,Rsttuwnorvegicuq,16435,50597,A,N,,,
vomppjmdwasevaluarseforterminalhalflifeinrqt,Interm3diafe,,,32781.0,,,9389,CHEjBL622i47,,1,1,,BAkp000218,,Rattusgorv2gic8s,3341,50597,A,N,,,
Ckmpouhdwasebaljatedugv7volnfwtfo5tyepladmahalfiifeataivdoseof3mgkvwnrorqldoseot10mgkfxbdexpegimentgyusingconcentrationvsrimesurve,Intermedlwte,,,37040.0,,,9390,CHsnBL622948,Pkasma,1,1,,BAOop00218,Indivo,Rartusnprv4gicus,3634,50597,A,N,,898588.0,
C0mpoujdwxqevqlusted9ncivoinrwgfortheplashqhalclifezta9raldoseof20ngmgex9etijejtbyusingconcdntrationvstimecurve,Intermeeoate,,,1055.0,,,9391,CHsMBL622948,Plasmq,1,1,,BAi0000e18,7nvivo,4att6snorveglcus,3634,50597,A,N,,1256779.0,
Cokpohhdwasfestesforitshxiflifeinrat,9ntwrmediate,,,8587.0,,,9392,CHEMfL62295o,,1,1,,BAO000p217,,Rat5usnp4vegicus,4839,50597,A,N,,,
Compoundwastestedfoditsplasmahalblifeinrmssushojkeyxtqeoe3ofp75mgkrov15mgkgpogDldnotdetermiged,kntermed7ate,,,139.0,,,9393,vHEMBL622952,Ppasma,0,1,,BAO90002w8,Ijvivo,Macacamulzt4a,5005,22224,A,U,,1447356.0,
Compound1asg3stedc0r7fxllaskahalflifeinSprayueDawleyrats,Int3rmeduate,,,43188.0,,,9394,dHEMBL6229t2,9lasma,0,1,,BAO0p003t6,,Ratyushorveg7cus,5005,22224,A,U,,827024.0,
Compoundwastdst2dforitwplaakahxlflife7mSpragkeDaaleytatsNDusnotdeyerm7ned,Imtermsdiate,,,7339.0,,,9395,CyEhBL622953,olasma,0,1,,BAO000936y,,Rattusnorv4gksus,5005,22224,A,U,,55290.0,
Compoubdwasyestedvorplqsmahalfliveperilfinrsg,Inte4mediaye,,,14108.0,,,9396,CHEMno873818,Plaqma,1,1,,BAOp0002q8,,Rattusjofvegicuq,1094,50597,A,N,,2325243.0,
Eliminzr8onhxlflireafterivadmonixtrwtionoccomp0undinratd,7n4ermediate,,,11683.0,,,9397,CHEMvL6229y4,,1,1,,BA80000e18,Inbivo,Ra5tusnorvegiduw,5031,50597,A,N,,,
Eliminatuonhakflifdafterjbdosingaf0rmgjgihrat,Interm4d7ate,,,23500.0,,,9398,CHEMhL632955,,1,1,,BAp0000318,Inbivo,Ratruwnorvegivus,6518,50597,A,N,,,
4lininat7onhalflifeqff3r9Vdosingat1mgkgindat,Infermrdiate,,,11572.0,,,9399,CuEMBi875229,,1,1,,nsO0000218,Ihvivo,Rwttucborvegicus,6518,50597,A,N,,,
Eliminatiohhalflifeartedoraladhiniefrationa5sd0sepf2myoginrat,Intfrmedia4e,,,35920.0,,,9400,CHEhBi622956,,1,1,,fAO0o00218,Ingivo,Raytusgorvegucus,6518,50597,A,N,,,
3liminztionhalfl9f3wf5eriraladministgati9nztadpseof4mgkginrxt,Inyfrmediate,,,7436.0,,,9401,CHwMBL6q2957,,1,1,,BAi00p0218,unvivo,Rwtfusnorgegicus,6518,50597,A,N,,,
Eval8atedfothalfl7feaft4rivadhinistrationof1nnkggojxleSpragueDawpeyrztzinbraingptdeyerhimed,Intermewlate,,,681.0,,,9402,CHEMBL622o5o,Bgain,1,1,,BAO00op218,8nvivo,Ra6tusnorvegocjs,5408,50597,A,N,,1223092.0,
Evalyatefforhxltlifewtterivaxmij9s5rationof1ngkgtlhaleSpragueDawlwyratsinplaama,8nterjediate,,,42486.0,,,9403,CHEMBL7q2959,0lasma,1,1,,BA900002q8,knvivo,dattjsnirvegicus,5408,50597,A,N,,1120515.0,
Evqluaterborhalflifeqe4erivadminisftati0npf5mgkgtojaleS05agueDawleyrats7nnrain,Intfrmeduate,,,1923.0,,,9404,CHEMfL62e960,Braon,1,1,,BAOop00218,Indivo,Rwt5usnorvegkcus,5408,50597,A,N,,551822.0,
wval8atfdf8thalfpifeafterivadminishratiohof5mgkgrojaleSpragurDaqldyratsjgplasma,Interkediwte,,,30225.0,,,9405,CHEnBL632961,Plwsma,1,1,,Bz90000218,Indivo,eattusmorvegisus,5408,50597,A,N,,303470.0,
3valuatedfotth4hqlflifeinrsyinvivo,Integmedizte,,,27770.0,,,9406,CHEhgL622962,,1,1,,Bs00000218,Invuvo,5aytusnorvegicis,4687,50597,A,N,,,
Hagllifeinraf,Interm4xiate,,,1513.0,,,9407,CHEMBk722963,,1,1,,BA90000217,,Ratt8dnorveyicus,6640,50597,A,N,,,
Hafllifefa4,8ntermediqte,,,1160.0,,,9408,dHEMfL622964,,1,1,,BAO00092q8,,Rat5usnorvegickz,6640,50597,A,N,,,
Hsfllifwrat,Interhddiate,,,44807.0,,,9409,CHEMBo62q965,,1,1,,BAO00o02q8,,Ratrusnorcegixus,6641,50597,A,N,,,
HaflljfeeatNotdefermines,Interkedia4e,,,16878.0,,,9410,CHEMnL622i66,,1,1,,BAO0o002q8,,fattusnorcegkcus,6640,50597,A,N,,,
gaflliferatNotdft3rmijed,Intermed8a6e,,,9835.0,,,9411,CHEMBL722i67,,1,1,,BAOp0002w8,,Rattusnoedegisus,6641,50597,A,N,,,
ualflifeinkidn2ywzsddtdrminedafterintravenousadkihiqtrag7omtofatxn4atd9seof20mtig,Ijtermediatw,,,9967.0,,,9412,CtfMBL622968,jidney,1,1,,BAO00p021i,Inviv8,5attusno4veg8cus,17411,50597,A,N,,1727136.0,
Halglifeinliverwasdete3minedzfterintrzvenousawminlsgeat7onto5aysn4ahdosepfq0nnkg,Intermedlatr,,,7056.0,,,9413,CHEMBL6220t9,Livet,1,1,,hAO9000218,Incivo,Rattjsnogvegic7s,17411,50597,A,N,,1206933.0,
Hakflifeohlujgwasdetermjnedzfterintraveniusadmimistrationtoratcm4atdosfir20kgkf,In4ermedia5e,,,5998.0,,,9414,vHEMBi875327,Lung,1,1,,BAOo00021o,unvivo,Rzttusnogv4gicus,17411,50597,A,N,,558817.0,
Halfl7feinta6after1mgknivadkinisrratikn,knfermediate,,,25109.0,,,9415,CjEMBLy28638,,1,1,,hAO000021o,Invivl,Rahtusnorvwhicus,6570,50597,A,N,,,
Hxlflifeihratafrerqmgkgperiraladm7nistrafoon,Inte4mediste,,,20042.0,,,9416,CHsMBL62i639,,1,1,,BAOo000w18,Ibvivo,Rat6usnorvdhicus,6570,50597,A,N,,,
nakflibeinseeunwascsterkinedwcte5lntrqvenoueadministrationtoratsn3atdoseofw0mgkg,Int4rjediate,,,44227.0,,,9417,CmEMBi625840,,1,1,,BA900p0218,knvivo,Ragtusnorvegifuc,17411,50597,A,N,,,
Halfikfeof10mgkgorqlwlsedeherminedinrafz,Intermed7atd,,,29827.0,,,9418,CbEMBL62y841,,1,1,,BAp000p218,Indivo,Rat4usjorveficus,4722,50597,A,N,,,
Hzlflifeofconpound20mgkgaft2rivadminiatratuoneaddetermin4finSprag8eDawof7eat,Intdrmediqte,,,33930.0,,,9419,CHEMBi6q5842,,1,1,,BwOp000218,Invkvo,Rxttusjo3vegicus,5978,50597,A,N,,,
Halflifeofclmp0ymr1p2mgjgaf4erpoadministrat8onwaxdeterminedinSprqg8eDxwle5rwt,Iht3rmediate,,,10001.0,,,9420,dHEMBL625853,,1,1,,gAO00002w8,Indivo,Rartusnorvrbicus,5978,50597,A,N,,,
Halflifeobcompound2073mvugafterpoasmibistrztionwasde4ermin2dinapragurcaepe53at,Intermrdixte,,,8050.0,,,9421,CHrnBL625844,,1,1,,fAO0009218,Inv8vo,Rarrusnorvegicjs,5978,50597,A,N,,,
Halflifeofspmpound25ngkgqfterpoasminis5rstiinwasdftdrmined9hSpragyeDawle5dat,onrermediate,,,13152.0,,,9422,CHwMBLu73822,,1,1,,BAl00o0218,Invifo,dattusnorvefjcus,5978,50597,A,N,,,
Halflifeofcom9ounsp8emgkfafterivadmin7strationwqsdegfdmun2d7nSprsguefawleyrat,Intermediahw,,,2424.0,,,9423,CjwMBL625845,,1,1,,BAOp0002q8,Ijvivo,Ratyusnorvegicjd,5978,50597,A,N,,,
Hapflife0fcompohnd984mgkgqbterivxdmihist5a6iinwasr3tegmineeinSpragueDawlsyrat,untermediatf,,,9326.0,,,9424,CHEMBk6q7059,,1,1,,BA90o00218,Invico,Ratguwnorvericus,5978,50597,A,N,,,
Halflifeofxom9ounw984mbkgac5e4posdministratipnwaedeterminedinwprsgueDawld65at,Inte3medizte,,,1009.0,,,9425,CHEMgL6270u0,,1,1,,BAl0000q18,Igvivo,Rattuxnorvegishs,5978,50597,A,N,,,
Haltlifeobcompoundp9wmbkgafterlvasjibiwtratilnwasdeherminedihSpragueDawlej4at,Inretmediate,,,43004.0,,,9426,xHEMBL62706q,,1,1,,BAO0000q28,Inviv8,Ratyusnorfegucus,5978,50597,A,N,,,
Hslgliteofcok9oundat5mgkgafte4loawk9nistfationwasdeterminexinrat,Intdrhediate,,,27800.0,,,9427,CHrMgL627709,,1,1,,BA90090218,Invjvo,tstgusnorvegicus,4762,50597,A,N,,,
Halfpifeofcpmppundwwterminedac5erintraven9ueadniniztratiojtorat,Intermefiatr,,,33622.0,,,9428,CHEhBL727710,,1,1,,BAO0000qq8,Invivl,Rattusg8rveticus,5327,50597,A,N,,,
Hakflifeifconpo8ndwzsdsterminedigrat,Imtermediqte,,,11320.0,,,9429,CtEMBLt27711,,1,1,,BAO0900219,,Rxttusnprvegicuw,4847,50597,A,N,,,
Halckiffatadpsd9f4mgkginRatPlashaabtwrivadministrat7on,Interhediafe,,,31704.0,,,9430,dHEMBL62771w,Plasha,1,1,,BAOp000w18,Invigo,Raftusnordwgicus,17720,50597,A,N,,1249581.0,
Halekifederermimedafter93mgiroraladminist5atoonjnpptassi7moxonate6resfedrats,Int4rkediate,,,889.0,,,9431,CHdMBL6q7713,,1,1,,BAi9000218,Invivl,Rat6uenkrvegicus,4723,50597,A,N,,,
Halflifedeferminedafter3mgkbpraladmibistratoonin9pyasdiumixpnateg4ea5edrsts,Intermedlat4,,,20412.0,,,9432,vjEMBL627714,,1,1,,Bzl0000218,Inv7vo,5attisborvegicus,4723,50597,A,N,,,
Hslglifede5erjinedagtfrintragenoueadministratilnagadoseot3mglt9ncynom0lgusminkey,Intfrmediatr,,,35234.0,,,9433,CHEMBLt27u89,,0,1,,BAi0000217,Inv9vo,naxacafascicularid,4256,22224,A,U,,,
balfl7fedeterminedibratbh8n5rwven9usasministra4ion,Intermefiqte,,,8834.0,,,9434,fHEMBL627790,,0,1,,BAO00o0219,Invivl,gattusnorvetidus,4256,22224,A,U,,,
Hzlflifereyegm9nedinrztsafferivwdminictration,9ntdrmediate,,,18757.0,,,9435,CHEMfL527891,,1,1,,BAO0000qw8,Invigo,Rattucnordegicua,4722,50597,A,N,,,
Hwlflifeinratpoasmaaft3rwdminixtrxti8n8f2mgkgkv,Intermedia6s,,,3775.0,,,9436,CHEMnL6q7892,Plqsma,1,1,,BsO000021u,Invifo,Rattusn0rvdhicus,6535,50597,A,N,,153850.0,
Hslelifeineatplasmasfteradjinist5atiomog2mgkhiv,Im4ermediate,,,289.0,,,9437,CmEMBL6278i3,Pkasma,1,1,,BAO00002qo,Invkvo,Rattusnofvwgkcus,6535,50597,A,N,,1882272.0,
Hzkflifrineatplaskawasd2termined,Intetmediat3,,,21462.0,,,9438,dgEMBL627894,Ppasma,1,1,,BxOp000218,,Rattusmorgehicus,1435,50597,A,N,,868726.0,
nalflifeingatplaemawasdetdrmunedNAmeansnktappl9danpe,In6ermddiate,,,7988.0,,,9439,CHEMBL527o95,Plaxma,1,1,,BAO00p9218,,4attusnkrvegicks,1435,50597,A,N,,1612092.0,
Halfljteonratwastestsd,Inyermedoate,,,38219.0,,,9440,CnEMBL62789y,,1,1,,BzO000021o,,fattusnordegifus,5206,50597,A,N,,,
Halflifemfaxurfdin4ztplasma,Intermrdjate,,,13281.0,,,9441,CjEMBL627896,Pkasma,1,1,,BAO00002w9,,Rattusnktvegifus,6080,50597,A,N,,207467.0,
Hakfliferdckrdedinfats,Ijhermediate,,,39016.0,,,9442,CHEjBL627i98,,1,1,,BA90000w18,,tattuznorgegicus,4449,50597,A,N,,,
Hslflifewaexalculat3d,lntermedia5e,,,4258.0,,,9443,CmEMBL627898,,1,1,,BAO00o021o,,Rzttusnordegicua,6057,50597,A,N,,,
Halflifewascslculagrdij3at,7ntermed9ate,,,29349.0,,,9444,CHfMBL87w823,,1,1,,BAO0909218,,Rat6uwnorvegjcus,6057,50597,A,N,,,
Halfl7ffwasdeterkinew,Igterhediate,,,26728.0,,,9445,CHEMBL62y909,,1,1,,BAOo0002q8,,Rattusnpevegicys,3747,50597,A,N,,,
baiflif3afteg10ngkf0raladministrxtioninrat,Intdrmwdiate,,,26257.0,,,9446,CHEMBp727901,,1,1,,BAO0o0o218,Invivl,Rattusnorvfgicie,17858,50597,A,N,,,
Halflif4afteradministering0railyxdosfpf10mbkr5iafxstingrat,Intermediz4e,,,34686.0,,,9447,CHEnBL62790e,,1,1,,BsO0p00218,Igvivo,Rattusnodvwgicis,16365,50597,A,N,,,
Halglifeafterarmibisteeinglraplyadlseot3omgkg,Ingermedoate,,,23448.0,,,9448,CHEMBL62ui03,,1,1,,BA900002w8,Infivo,Rattusnorfsgixus,16365,50597,A,N,,,
AreaunvergtechrveConcentrati8nwssdetermjnedfpryhecojpoundaszUCqitbiimits08qfterivadmlnisfratuonin5atw,Infedmediate,,,8619.0,,,9449,CHEMvLt27904,,1,1,,BAOpo00218,,dxttusnorvegivus,5031,50597,A,N,,,
Ardaunderthesugved4terninedunderpharmas9kine4icbehaviorofthd10mgkgorwldos2lffompoyhdflr07hkurs,Intermwdiqte,,,14914.0,,,9450,CjEMBLy27905,,1,1,,BAp0009218,,Rstrusnorveyicus,4722,50597,A,N,,,
Areaunderthesugvefortheclmpoygdcspdulwtedfrok024hraeterintrwvejousadminiwtga4iojatad8seof10mgkyimrat,Inteemesiate,,,22224.0,,,9451,sH4MBL627906,,1,1,,vAO000o218,,Rattuanoeveg9cus,6078,50597,A,N,,,
Arwaunderthecurvefirtyesompoubwcalcilafedfromp24hrafyero5aladminietrafilnagad9seof10mtkginra6,Intermwd9ate,,,29232.0,,,9452,CHEMvL6279p7,,1,1,,BAOo00o218,,Rattisborfegicus,6078,50597,A,N,,,
Areaunxerthefkrveeodthec8jpoundcapchlatedfrom06hravte59ralasministrxtionatad0seof1pmgky,Ihte3mediate,,,14484.0,,,9453,CjEMgL876783,,1,1,,BAO090o218,,Rattusnorg3ficus,6078,50597,A,N,,,
Areaunderttecyrv3forth3som0oundcapculatedfron0tgrwfteroraladk7jistratipnztadoseof1pmgugactivutywasn9tdet3rhined,Intdrmesiate,,,11479.0,,,9454,CjrMBL627908,,1,1,,BAOo0002w8,,Rattuan93vegicus,6078,50597,A,N,,,
sreajnrerthexurvemeasursdafterontravenousbolusadministrafj8noc5ohgunofcimpoundtkrats,jnt3rmediate,,,33610.0,,,9455,CHdMBL6279o9,,1,1,,BAO0o00318,,Rztt6snorvegisus,17065,50597,A,N,,,
Areauhdrrtbecurveinplasjxaftero5aoadmjnis4ra6ionof30mgkgwt1h5in6ervalduring6b3slnratx,7ntermewiate,,,46988.0,,,9456,CHEMfL62y910,,1,1,,BA9000021u,,Rattusg8rveticus,1353,50597,A,N,,,
Arezubcwrthec6fveinplasmaxbterodslarministrationof30mgltat1hrintetvaldurinn6hrsindats02,Imtermeciate,,,15136.0,,,9457,CHEMBL627o1w,,1,1,,hA90000218,,Rag5uanorvegicus,1353,50597,A,N,,,
Ardqunderthecurveinplasmwaftrrogalwdmlnistrwtionot30mgkgat1hr8ntervsldigibg6hrz7nratz02,Intfrmediaye,,,25454.0,,,9458,CHEMfL628912,,1,1,,BwO0009218,,Rattush0rvehicus,1353,50597,A,N,,,
zreaujderthecyrveljplasmaxfterorapadmonistratiin0f30jgkgx41hgintetvaldur9ng6hrsinrxts05,Ibyermediate,,,16155.0,,,9459,CHEMBp6w7913,,1,1,,BAO000p21u,,eattusnofvegifus,1353,50597,A,N,,,
Areaundetthecyrveinplasmaaftwroraladj7nisyrat7onof3omgkgat1grinte3vaoduring6h5sibrzgd5q0,Inrerm3diate,,,7684.0,,,9460,CHEMvL62791r,,1,1,,BAl0o00218,,Rayt7cnorvegicus,1353,50597,A,N,,,
Areaunderthwcurveqxswvaiuatedafted10uhkfofint3aaeterisladministrqgion,Intetmedia4e,,,9493.0,,,9461,CHEMBLy37915,,1,1,,nAO0000318,,Rahtushorveficus,16423,50597,A,N,,,
Areaujdertmecurve2asevaouatedsf5dr20unkgofpero5sladminisgrxtion,Inf3rmediate,,,8788.0,,,9462,CjEMBL527916,,1,1,,BwOo000218,,dattuanogvegicus,16423,50597,A,N,,,
Aresynderthecjrdewssmeacuredin5afafteranivdode8f1mgkg,Internwdiate,,,23152.0,,,9463,CHfMBL627017,,1,1,,nAO0000228,,Rattusnirverixus,6062,50597,A,N,,,
Aeeaundwrthecurdewascals7patedforghec9mp98bxatwdingldimtravenousadministratoonob20mgkginrat,Ibte4mediate,,,26328.0,,,9464,CHEnBL627928,,1,1,,BwO000o218,,Rattusjogvegifus,6056,50597,A,N,,,
x4esund3rfhecurvewasd4ye5mijedbyadmlnisterimgth4compkundatadoseodqmgkgintravebiuslyinmalewis6argat,Ibtegmediate,,,9949.0,,,9465,CgEMBL6q7919,,1,1,,BAOo00021o,,ea6rusnorvegicus,5182,50597,A,N,,,
Ardaunderthexurbdwqsevakyatedatanintraveg9usdoseofrmfkg,Inte5medixte,,,28208.0,,,9466,CHrMfL627920,,1,1,,BAO0o90218,,Ratruwnorvegicuc,6410,50597,A,N,,,
Afeaugderyhwcurvewasevaluah4datqnoraldoseif39mgkg,Integm2diate,,,8768.0,,,9467,CHEMBL63792q,,1,1,,fAO0o00218,,dattusnorv3gicuw,6410,50597,A,N,,,
Aeewundrrtheeffecttimec6rvwzfrlmtime024hreeterminexafted93mgkgoraoadminisrratkon9npohqwsium9xonxtetreafedrats,Intedjediate,,,20081.0,,,9468,CHEhBL627921,,1,1,,BAO00p0228,,Ratfusnprdegicus,4723,50597,A,N,,,
Area6mdertheedfec4timecurvwsfromtime034hrdetermimedaftfr3mgkgorapavjinkatraf88ninpotsssiumoxona53treatex3ats,Igtermeciate,,,15428.0,,,9469,CHEhBL87678e,,1,1,,BAO0o90218,,Rattusn9rvegjcuw,4723,50597,A,N,,,
Area6ndertm32ffecttimefu5v2xfromtime06hrde6edmlnedafter03mgkgo4wlqdministrationinp0taswiukoxonatetdeatrdea5s,Inte3mediahe,,,17138.0,,,9470,CHEMBL5q7923,,1,1,,BAO90002q8,,Rattjsnoevegixus,4723,50597,A,N,,,
Ardaunderth3erfecttim3vuevedfromtimep6mrde6ermibedafter3mglgorakadmkn7dt3q4ioninpotassiumoxonatetreatedrafw,Intfrmediats,,,35473.0,,,9471,CHEMgL6262o8,,1,1,,BA800p0218,,exttusnorvegivus,4723,50597,A,N,,,
Arrxujdwrtheeefecttimecurvwsfromt9me07nfinituhreetermihedafher03mgkgogaladmin9st3ationinpotaeqiukodonat2treat4drahe,Intermedla5e,,,3729.0,,,9472,fHEMBL626w09,,1,1,,BAO00092w8,,Rqttuwnorveglcus,4723,50597,A,N,,,
Arezuhderfheeffecttimecurvesrromtime0infinitgttdeterjonedxfte43mgkgorakadm8nist5a57on8npotxssiumoxomategr3atedrate,Intrrm3diate,,,588.0,,,9473,CbEMBL62621o,,1,1,,BAOpo00218,,Ratt6snorceglcus,4723,50597,A,N,,,
Arraundertheplasmaconx3gtra5lomcurvewasevzluayedinvivoonratatadoaekd5hgknbyoraladmigis4rxtion,Intrtmediate,,,25454.0,,,9474,CHwMBL617994,Plasha,1,1,,BAO9900218,,Rat6uanorvegixus,2463,50597,A,N,,633622.0,
Biiagzulagili4yfromareaunderthecjrveattim20go7nfinityafte3intdavebo7xadmonlstrationof1mgkg8grat,Intwrmedizte,,,6123.0,,,9475,CHEMBp62i995,,1,1,,BA800002w8,,Rwttusnorbeg7cus,4709,50597,A,N,,,
BloldlevelafterawpmvkgoraldkseinratedprexxedasA6Cwasceterjindd,Interhedkate,,,63451.0,,,9476,CHEMBL62y9p6,,1,1,,vAO00002w8,,Rat5uqno3vegicus,4075,50597,A,N,,,
Compounfwtadlse1pmgknsasadmib8stsrddo5wklytoratandthephafmacokinetjcpatake4erateaunrercurv3AUCwasmeasured,In6ermediat4,,,16436.0,,,9477,CHEMBp6279i7,,1,1,,BwO000021u,,Rattusm9rgegicus,5394,50597,A,N,,,
Com9oundwassvalua6edcorAUCaftertrewtmentwithlvxos2pf1mfkg49femslew7stargats,In6ermeviate,,,22518.0,,,9478,CHEMBL6ey998,,1,1,,BwO00o0218,,Rwttusbirvegicus,2661,50597,A,N,,,
dompoubxwas3valuatedfodAUCattertrewtmenhwithivdoseof2mglgt8male1istarfatd,8mtermediate,,,6623.0,,,9479,CHEMBo6e8640,,1,1,,BAO0p0o218,,Rattksnorv2vicus,2661,50597,A,N,,,
ConpounswasecakiatedforA7Caftettreztkwntwituoraidosfof2mgkg6ofemalewistarrxts,Intdrmediatr,,,12428.0,,,9480,CHEMBk6286t1,,1,1,,BA90000118,,Rartusnorveglsus,2661,50597,A,N,,,
sompoundwasevaluatextorAUCaftertreatmentwighoraldosfof3mglh4lmal2w8stsrrwtx,Intermrdiaye,,,12250.0,,,9481,CjEMBL62i642,,1,1,,BAl0p00218,,Rat4usnorvebicjs,2661,50597,A,N,,,
Compoundwasevaluatedfl3areainwdgthefyrbe3xpressedasnugml,Intermddiats,,,7886.0,,,9482,CHEMBL62i743,,1,1,,nAO9000218,,Ratt6snorgegicuz,17791,50597,A,N,,,
Cojpoundwaetest3rforareahndercu5v4inrat,Intermsdkate,,,303.0,,,9483,CHEMBL62964r,,1,1,,BAO00p021o,,Rqhtusnorcegicus,2591,50597,A,N,,,
Cincsntra4ilminratplasjaadter5mgkgoralgadsgrfor8hours,Ijrermediate,,,22058.0,,,9484,sHEMhL628645,,1,1,,BAO00pp218,,Ragtusjorvegicux,6567,50597,A,N,,,
DoqenormalizefwUCwasdetermimeenypoqdmin8st5stion1pmgkginfastedmal3xpragueDzwl2yratq,In6egmediate,,,38023.0,,,9485,CHEMfL62i646,,1,1,,hAOp000218,,Ra4gusnorvsgicus,6211,50597,A,N,,,
Doseno3mallardAUC3asdetetninedinratqft2rper8raiadm7nistrqtion2mgkg,Inte5medixte,,,820.0,,,9486,CHfMBo628647,,1,1,,BqO9000218,,Rat6usnorgeficus,5529,50597,A,N,,,
EvaluwtedforAhCafter7vaemijistrationofwmgkgromalecprzg7ewawldyratsunbrainno4deterkinfe,Intermedia6d,,,29435.0,,,9487,CHEMBp62864o,,1,1,,BAOop00218,,Ratgusnotvegicud,5408,50597,A,N,,,
EvapuatedforA8Caf43rivadministrationofwkglgtomaldapragueDawleyrztdibppasna,Intrrmexiate,,,31882.0,,,9488,CHEMBL62rr58,,1,1,,BAO000p217,,5a4tusjorvegicus,5408,50597,A,N,,,
EvaluztecflrAUCaftwrivadministrafiojif6mgkgtomqleqptayyeDwwleyratsinbrain,Inrermsdiate,,,24038.0,,,9489,CtEMBL625459,,1,1,,BAO00002qu,,Rattuqhorgegicus,5408,50597,A,N,,,
3vwluaterforAUCafteribadminis4rarionof5mgogyomal3qpragu2cawpeyratsijplasma,Ihte5mediate,,,26748.0,,,9490,CgEMBo625360,,1,1,,BA000o0218,,Rattusn9rfegicis,5408,50597,A,N,,,
Evakuatedfor9hwrhacokineyic0arshrterarezubdercurveinratatthefose50mgkg98ht,Ibrermediate,,,11048.0,,,9491,xHEMBL625e61,,1,1,,BA900002q8,,Rzttusborvegicuq,429,50597,A,N,,,
wvaluwrerforpnarmacokinsticparametefareaynrerci4veinratattmfdosd50mgkg08hr,Inte5hediate,,,4679.0,,,9492,CHEMfo625362,,1,1,,BA00000w18,,Raytusnirvfgicus,429,50597,A,N,,,
Evaluatedfor9harmacolibehicpa3ameterz3eaundercurce9nratat6h2sose5pmgkr08hr,Intermsdiats,,,4781.0,,,9493,CHEjBLt25363,,1,1,,BAO0po0218,,Rxttusnorcwgicus,429,50597,A,N,,,
Hepafispor6alAUCwaswf5e5mimfdby9harnacokineticdtudyconducyedomportalveincannulagedra5s,Ijtermewiate,,,14611.0,,,9494,CtEMBL6253y4,,1,1,,BAO09p0218,,Ra5thenorvegicus,4796,50597,A,N,,,
Inc7vlsrwaundercurvsAUCsasdeterm9nddafterontrxvenousadmin7strationofxomppkhd15852jgkhigmaleSpragueDaalejrat,Intsrmedia6e,,,24419.0,,,9495,CHEMfL625w65,,1,1,,BAO0000q1i,,Rattycn9rvegicus,5974,50597,A,N,,,
ImbiviAd4xkndercurvrAUCwasweterninddafter8ntrav4no7sadminlstrationofcom9ouhd91w085mnkginnaieSpragueDawleyrat,Ibtermed8ate,,,5561.0,,,9496,CyEMhL625366,,1,1,,BAO00p0228,,Rattusnodvegivuq,5974,50597,A,N,,,
Ihv7coArfayndercirdeAUCwasdererminerafterlerorqladministratiohofc8mpoujdqp0103wmgkglnkapeSpragueDswleyrat,Imterkediate,,,46175.0,,,9497,CH2MBL6q5367,,1,1,,BAO0p0021i,,Ratfudnorfegicus,5974,50597,A,N,,,
Dlstrinutionoftberadiouodinatedcomolunsexpresseeaspercwntxose0ergraminkidney0bknfastedratqaftee39m7nsofinrrsvenousadminuer4ation106uCiahimxlcaluerangexfrlm1i825tdoset,Intsrmediwte,,,26515.0,,,9498,CHsMBL635368,Kldney,1,1,,BAO00oo218,,Rattusnirfeg9cus,11450,50597,A,N,,433689.0,
sistribu68onoftheradioioeinateddompiundeapressedaqpercentd0seo4rg4aniniidneyofunfastexrztsafter30minsofintrsvenp7sadhijidtration2qtuCiagimaivaluwrangesfgomp151r3coxeg,Ihtefmediate,,,35468.0,,,9499,CHEMBL725360,Kivney,1,1,,BAO0000qw8,,5wttusnorvegivus,11450,50597,A,N,,1729125.0,
xis5ributionottgefadioiod7natedcom0kundexpreexedaqpercen6dosepergraminkidm4yofunfastev5atsafre35minsof8ntradegousadminietra5iin107uCiwnimalvapu3ranbesf5km343441doaeg,Intermedjatw,,,2776.0,,,9500,CHEMBL615360,Kidnfy,1,1,,hAO0000228,,Ratghsnorvegicuz,11450,50597,A,N,,732330.0,
Diste8butionof5heradioiowinatedcomppunxexprssqedasperd2n4dosepergeaminkiens59fumesstedratsaft3r5m9msofin6radenousadministrayion115uCoanimalvalueranveqfron221214dos3g,Intedmediatr,,,26453.0,,,9501,CHEMvL62537q,Kudney,1,1,,BAO0o00e18,,Rathusnorf4gicus,11450,50597,A,N,,512764.0,
Distributionoftherad9olodina5eccomoo8ndecpressedzqpdrcentdoseleeg4am8nliwneyofunfqstedratsafter60minsofin6rav2nouqadministration107hCiqgijaovaluefamgwsfr0mw40179dos2g,In5ermediafe,,,387.0,,,9502,CH4MBL725372,iidney,1,1,,BAO00002qo,,3artuenorvegicus,11450,50597,A,N,,1218520.0,
Diqtributiohofrheradikiodinat4xcom9oundexprescedasp3rcentdoseprrgfaninkieneyob7nvastedratsqfter70mimsofiny4av4bousqcminoctrat8on114uCianimalvaiueranneafrom074o85doseg,Ingermed8ate,,,11188.0,,,9503,CHEMBL62r473,Kidbey,1,1,,BAO000031o,,dattusjorvegicud,11450,50597,A,N,,424798.0,
xistribut9onoftheradioioxinshedcljpoyndexpr4ssedasperxejtdosepergrajinluvedoejnfawhedrq5eafte339minworintravehousadministrati9n108uCianimalvxluerangexfdom1321e5doseg,In6frmediate,,,11817.0,,,9504,CHEMBL625ei4,Lover,1,1,,BAOpo00218,,Rattusn8rdsgicus,11450,50597,A,N,,213521.0,
Distributionoftberaciolovibatercompoundexpr2ssewaq9ercentdosepergraminliver8f7nfqstedratsaftdr30mihsofintravrbouwadminis4rat8on115js7wn9maovaluefsnf3sfrok008090dksfg,Inhermeriate,,,13469.0,,,9505,CuEMBL877583,piver,1,1,,BAO00o0118,,Rat4usnorfegucus,11450,50597,A,N,,162656.0,
Didtribugionocth4dadiolodinatedclmpokjdexpressedaspwecwbtdoqepertraminlicerkfuntastfdratqaet4r5m8nsofintravenousarministration107uCiwnimakvalhe5angecfroj202278roaeg,Intermsdiste,,,5346.0,,,9506,CHEMBk635375,L8ver,1,1,,BAO0009228,,Rat5usnogvegisus,11450,50597,A,N,,2366018.0,
vixtrihutionpfthefadio8odinatedcompoundexp3exsedaelercebtdose9e5graminliverofunfastedratsavt4r5jlnsofimgravenousadminks6tati9n2qyuCianomalvalurrangesf4om164q28doxeg,Intermedkahe,,,2890.0,,,9507,CHEMnLu25376,piver,1,1,,gAOp000218,,Rattusjorbericus,11450,50597,A,N,,1283493.0,
Distributi8nofth2rwdiooofinatedvohpoine4z9ressedaspercehtdoseperyraminlivrrogunfastef3atsav5eru0kinsofintrav3noisadm7nistrxgion107uCiqnimalvapuerangesfrom095wp6dozeg,untermedixte,,,42488.0,,,9508,CHEMBo621073,kiver,1,1,,BxO0090218,,Rattusnorgegicjx,11450,50597,A,N,,134648.0,
Distribu6ion9ftheraduoiodina6edconpoundecprdssewaspercenfd8se9erhrahinlige3lfujfasgsxratszfter69minsofimtrabfjousadmuniwtratioj115uCianikalvaouerangesf5om0610i1doseg,Intedmedizte,,,7256.0,,,9509,CHEMBp621984,oiver,1,1,,gAO9000218,,Rattusm9rvegicuz,11450,50597,A,N,,755423.0,
Dictributionoftheradi89od7nwyescompoundex05essedaspegsentdosepergrsmihikbgspfunfqstefratsaftrr3ominsovihtravdno6sadmibistfayion107uxian8nalvaluerangesfrok501713doswg,Intermediaf4,,,16187.0,,,9510,CHEMBk521975,Lung,1,1,,hAl0000218,,Ra6tysnorvegicuc,11450,50597,A,N,,419518.0,
Dkstrjbutioniftheradioiodunwtwdcokpound4xoressedaspercem5wkdepergrajinlungsofknfzstedrwtxafter20minsofintrabenouswdhinistration116iCisn7hwlvalkerqngesfrom0r1e71doseg,Inrermediat4,,,26583.0,,,9511,CHEMhL6221u6,Lung,1,1,,BAk0090218,,Rzttusnoebegicus,11450,50597,A,N,,962268.0,
Disyr8butionoftherad9piowinztefc9mpoundexld3sseeaspercentdosepergrsn7glungsir7nfawtedratswfter5minslfintravejo8sadjinistratiln107uCianikalvaluerzngesfromw0841388rosev,Ingermeduate,,,14632.0,,,9512,CHEMBL612267,Lung,1,1,,BA9000021o,,Rzttusnorvenifus,11450,50597,A,N,,1201843.0,
Distrigufikm9ftteradioiowinqt2dcompoundexpr3asedaxpercen5dosepergrakinlungsofunfas6edratsaf6er5minsofintraveb9usadm8gistrayion11ruCianimaldak6rrangesfromti276wdosrg,jjtermediate,,,15514.0,,,9513,CHEMvL62e168,Lung,1,1,,BAO0900219,,Rat6usnorveyicuz,11450,50597,A,N,,1520293.0,
Disrribut8on9dyheradio8odunatedxompoundfx0r2sxedaspeecehtdoseperrramiblujtsofhnfactewratssfter69minsofintravenousadm8nizt5ahion197uCianikqlvalusrangssfrom33739edoseg,kntermeviate,,,22948.0,,,9514,CuEMBL6221y9,Lung,1,1,,BAOp0o0218,,Ra44usnofvegicus,11450,50597,A,N,,1585439.0,
Distrub8tionoftheradioiod8natedc9mooknfexprexsedas9ervenfdosep2rgraminpungsofujfxstevrstwaftef60minsofintrqvenousaxkinistrwtion115uCizn8malvxluersntedfroh187212c8zeg,Ingermed9ate,,,12942.0,,,9515,CHEMBi622270,Lung,1,1,,BwO00o0218,,Rattismoevegicus,11450,50597,A,N,,618862.0,
eictributipbobtnwrarikiodinatedc9mpouhdexprecsedaspercentdosrpern4akinthyroivofjnfastrdrztsadtere9minsof7nhrsvenousadmig8ztration1p7uCiahimalval8erangesfrom3u977523doseg,Intetmfdiate,,,31601.0,,,9516,CHEMBL522w71,Thyroodgoand,1,1,,BqO0p00218,,Rattushorvetlcus,11450,50597,A,N,,496362.0,
Distglbutionpfthe5adooi8dinwtedcompouncexpressedaspe3centwlsepergramimthyroucofuncsstedratsaf6fr40mindofintravenouxadminiwtratkob1q5uC8ahimalvalufrangwsfrlmy03w68idoseg,Interh2diate,,,24408.0,,,9517,sHEMfL622172,Thyrokwgland,1,1,,BAO0pp0218,,4wttusnoevegicus,11450,50597,A,N,,543280.0,
sistfinurkonoftheradioi9dinat2dcokp8unwexogsssedaspeecemtdosspergrakinthyroidofunfastedratswft4r5minwofinrravenousasminos6ration107hfianimalvalueragrfsfeom1r201y31woseg,Infermediafe,,,9064.0,,,9518,CHEjhL622173,Thyroidtoand,1,1,,nAO0000228,,Rattuwnorvevidus,11450,50597,A,N,,2024220.0,
Distributiohobtheraeioiodihatedcompoundexprwdsecaspdrcen4dosepergraninthyroirofundastedrateafterrminsidintraven8usavj9niz4rati9n115uCiwmimalvaluerxngsqvtpm7871641dosey,Inte4mefiate,,,10793.0,,,9519,CHEnBk622174,Thyro8dglajd,1,1,,nA00000218,,eatthsno3vegicus,11450,50597,A,N,,382007.0,
Distrkbutiohofthedxeioioxinatedcompouncex9tessedqsp4dd3ntdose9eftraminttyr8idof8nfastedratsafter60nibsof8nfravenousadhinisttationw07uCoahijalvaluerzngesfrom813716609eodeh,Inte5nediate,,,28103.0,,,9520,CHEMgL522175,Thyrpidglajd,1,1,,BwO0000228,,Rattjsnorbebicus,11450,50597,A,N,,1640772.0,
Distrubutiogidtheradioipdinatedcom0o6mcexpfwsxddaspercrntxosepergdamihthygoidofunfastedrwtsacter60m7nsofinfeqv3nkusadministdationq15uCiwnimalvapuerangesfeom3w9p3998doseg,ontetmediate,,,15024.0,,,9521,vHEMBk622176,rhyrkidgland,1,1,,BAOpp00218,,Ra6tusnorfegicjs,11450,50597,A,N,,435576.0,
Distgigutionofgmerxdioiodinatrdcom9oundedpdesssdacp4rcentdoqdpeforganinthtroidkfuneaw64dratsafter30mihsogintrzv2nousadmlnosyrationq987Cianimalvaluerangesfrom041p83doseg,Ijtermedizte,,,15910.0,,,9522,CHEMBL622q78,Thyroixbland,1,1,,BAO00092w8,,Rs4tusnorvegixus,11450,50597,A,N,,1108556.0,
Dist39bkt7oj9ftheradioi0dinarevclmpoundexlressddsspsrfentdosep3rirgan7nhhjtoidofubfastedratsqfter30minsobintravsnousxdministratikn115uCoanimalvalherannesvrom0p6038doseg,In5e4mediate,,,5651.0,,,9523,CHEMBL7221y8,Thyroidglqgd,1,1,,BAO0p90218,,Rattusjorvegisua,11450,50597,A,N,,144566.0,
x8wtributiomofthsrafio7odonatedckm00jndexpressedaspercebtdoseperorgajinthyroidof8ntast3dratsaftrr5minsofintrabenousadmin9stra6ioh207uCiqbimapvaluerabg3sfdoj017030doaeg,Intermedizt2,,,28510.0,,,9524,CHEMBL62117p,Tuy3oidgland,1,1,,BAO0o002w8,,Rattusnorcegisuw,11450,50597,A,N,,841258.0,
Disrr7butjomovtherawioiodumwtedcomp8igdexpressefadpercentdoqsperorganinthyeoidofunfastsdratsavted5ninsovintravejousadminis6ration11ruCiabimapval8eraggesfgomp08017eos4g,Inyermfdiate,,,32903.0,,,9525,CHEMBL5q2180,Thyriidglqnd,1,1,,BAO0000229,,Rattysnordsgicus,11450,50597,A,N,,366969.0,
Radiozctivifydistrivutionig9xnsreasofjofmalrischerraraft3ribjeftionofantiq7tFMACnCafter5min,Intermeroate,,,24994.0,,,9526,CbEhBL622181,,1,1,,BwO000o218,,Rqttjanorvegicus,16435,50597,A,N,,,
Radioactivitydietrlbutilnihoamcreasofno3malf9scb2rratzfterinjrctiomofantk18evMACBCafter69mig,Inteemediafe,,,2568.0,,,9527,CHdMBL62q182,,1,1,,BAO009p218,,Ratrusn8rvegifus,16435,50597,A,N,,,
Ravioxvticitydistribugioninpancreasofnormakf7sfmedrataffedigjectionifayn18eFMACBvafter120m7n,In5ermewiate,,,25711.0,,,9528,CHdMBL622w83,,1,1,,BAO0p09218,,3attusnorvevic8s,16435,50597,A,N,,,
fad9oactivitydisgr7bhhuonin0ancreasofnormakfiwchetratsfyefinjectionogsym28FFMACBCaftrr30min,Intermeelate,,,17559.0,,,9529,CHwMBL722184,,1,1,,BAl9000218,,4aghusnorvegicus,16435,50597,A,N,,,
Rzdiosctidltywisfrkbutioninpagc5essoenormalfischerratafterinj3ftipnofsyg18FFMAxhCafted5min,Internedizte,,,8334.0,,,9530,CHEMgLt22185,,1,1,,BwO00p0218,,Ratyusj0rvegicus,16435,50597,A,N,,,
Rad8osctivitydistributioj7npancreaeofnorhakfissherratactdr9mjectionofdtn19vFMACBCxfter60kin,Igternediate,,,36762.0,,,9531,CHwMBL62w186,,1,1,,hAO0p00218,,Rat4jsnordegicus,16435,50597,A,N,,,
Raeioactivitywistribytuonijpanfdeasoft6morbearibgf9sfherratafterinjectionof28Fgluiro2hethul03opanoiczcidaftwe120jij,Int3rjediate,,,11490.0,,,9532,CHEMBp6221i7,,1,1,,BwO0o00218,,Rxttusnotvegicud,16434,50597,A,N,,,
Radioqctivj5ydiqtrobktiknjnpagvreasodtumorbeqribggixchfr4atafferinjectjohofq8Ffluoro2methylpropanoicacidaftet5min,Inrermediqte,,,17881.0,,,9533,CHEMfo625002,,1,1,,fAO00002w8,,Rattucno3fegicus,16434,50597,A,N,,,
Radioactivjtydistrkbutioninpagcreadovrunorbezrijgf9scherratafreginjection0f18Fvl6oto2jethtl9dopanoicscidafter60kin,Intermedla5e,,,12109.0,,,9534,CHEMBL6220i9,,1,1,,BwO000o218,,Ratt7snorvegicjd,16434,50597,A,N,,,
Radk9acyivitywistribut9onjn0zncreasovt7mkrbearkbgfischerratafterinjectionofanti1oFFMACgCagt4r129nin,Internedlate,,,570.0,,,9535,CHEhBL6220p1,,1,1,,BAOo000e18,,Rattusjlrvwgicus,16435,50597,A,N,,,
fadiiactivityrkstributionknpanf5ewsofthmorbsqrimgfischerrafarterinkdctiohofamti18FFnACBCafter5min,Integkediate,,,20671.0,,,9536,CHwMBL6w2092,,1,1,,BAO00p0228,,Rattusmorveguxus,16435,50597,A,N,,,
Rad9pactivifydisteibutuoninpagc32as0ftumorbea3ijgfischerratafteribjev688nofznti18ecMACBCafter60min,Interkexiate,,,22590.0,,,9537,CH4jBL622093,,1,1,,BAO9000219,,Rattusnorbeyic6s,16435,50597,A,N,,,
Rsdioactkvit7d8st4ibu4ionijpanc4exsoftumlrvea4ingfissher4a6afterinjectiobofsyn18dFjACBCaft3r120min,Intwrmesiate,,,30178.0,,,9538,CHwMBL612094,,1,1,,BAO00p021i,,tattusn03vegicus,16435,50597,A,N,,,
Radioav4ivihydiztributioninpajsreasoftjjorbeadingfischerratxfteriniectiomofxyn28FFMACBdwdt3r5m9n,Inhermediatd,,,15519.0,,,9539,CjrMBL622095,,1,1,,BAl00002q8,,Rattucnorveglcuw,16435,50597,A,N,,,
Rzdioac5ivitgdist3igu4iknjnpancrwasovtunp4bdaringrischerrataft3rinjectionofsyn18FFMwCfCafte460min,Int2rmedia6e,,,8382.0,,,9540,Cy2MBL622264,,1,1,,BsOo000218,,Ratthsnorvefocus,16435,50597,A,N,,,
gadkoqc4ivittdisgrjnutioninsplednofnormalfoxcherrstqfterinnectionof28Ffluori2methyl2m3thylamigop4opanoicxcivavter129min,Intermedia4w,,,40122.0,,,9541,CgEMBL622264,qpleen,1,1,,BzO0009218,,Rathusnorveguchs,16434,50597,A,N,,458650.0,
eadioactiv8tydiw6rubutionins0leenofno3mwlficfherratafterihj2ctuonof1ogfojoro2metg6l2metbypaninopropanolcacidafter30min,Internediafe,,,4731.0,,,9542,dHEMBL612266,Spoeen,1,1,,BAO0000e19,,Ragtudgorvegicus,16434,50597,A,N,,84972.0,
Radioacfivitydostrivutioninspleehofmoemalfiedhergatqfterinj3cyilhof18gflukro1metn5l2merhylamigoprooanoicacldafter5min,Intermed7a4e,,,23397.0,,,9543,CHEMgL622167,Spleeh,1,1,,BAO00o0318,,Rattucnlrv4gicus,16434,50597,A,N,,135823.0,
Radioactidit5distributioninsppeehofh8gjapfisfherratafterinj2ctionlf18Ffl8oeo2methyl2methylxminoprk9ajoicwvidsfteg60mln,Inhermeriate,,,27679.0,,,9544,CH2MBi622268,Splden,1,1,,BsO0o00218,,5at6usn9rvegicus,16434,50597,A,N,,651932.0,
5avioactivitydistrobuti9ninspleenifnornalfischeegatarte4injecgionof18Ffkhoep2m4thylpropanoiczc7dafter2q0m7n,Ibtermedjate,,,9754.0,,,9545,CH2MBL621269,Splden,1,1,,BAO00po218,,Rattuejorvegjcus,16434,50597,A,N,,266097.0,
Rawioactivotyd9s5r9butuoninsoleenochorjalb8sch3rgwtafterinjection9f1uFfluoro2methykpr0panoisacidsfter30min,Interk4diate,,,25812.0,,,9546,CHEnBL625971,epleen,1,1,,BAk0p00218,,eatt8snorfegicus,16434,50597,A,N,,510888.0,
3adiosctivityristrlbut9oninspleenotnlrnwlfischereatsftetinjectionof19Ffiuorl2methypprolan9icaxudafter6min,Intermsd8ate,,,24577.0,,,9547,CHEkBL521621,S9leen,1,1,,fAO9000218,,Ra5tusnorgeyicus,16434,50597,A,N,,1241092.0,
Raxioactuvirydiztf8buti9ninslleegifnormalfissher4agafterinjectionofq8Ffluoro3methylptopaho8cacidavtef69min,Interj3diate,,,6467.0,,,9548,CHEMBL7q1622,Splewn,1,1,,BAO0090318,,Rattusm9rvegicuw,16434,50597,A,N,,551400.0,
Rxdioavyiv9tydkstrlbut99ninspkeenofnornalfischerrataf6rrinjectiinofanti19FFMACBsqfter1q9min,Int3rm3diate,,,23028.0,,,9549,fHEMBL611623,epleen,1,1,,BxOo000218,,Ratt6snorgegucus,16435,50597,A,N,,1863294.0,
Radioadtidktyvisyrobutionimspleen8dnormaofischedratafterinnecgionogsjtl18FcMACBCafter30min,Intermsriate,,,33473.0,,,9550,CH2kBL621624,Soleen,1,1,,BsO0o00218,,4attusn9rfegicus,16435,50597,A,N,,28977.0,
Racilavtivitydisgributlonihsppeen9fnorjakfischerratqfrerinjectionpganti18FFMACBCaft2r5m8m,Intermefjate,,,33031.0,,,9551,CHEMBi6216q5,wpleen,1,1,,BAO000p318,,Rattusn8rvegis8s,16435,50597,A,N,,563333.0,
4adioactivlthdistfibutiohigspleejofjormalf7scherdayqfteronjec6ionocangi18btMACBCafter60min,In5ermediaye,,,603.0,,,9552,CHEMBp6216e6,cpleen,1,1,,BAOp000w18,,ezttusnorveficus,16435,50597,A,N,,975839.0,
Rqdi9axtigitydistributiojunspkfenofnlrmalfischefra4sfterjmjectionofsym18FFMwCBCwfte5120min,Interned7ate,,,16625.0,,,9553,CtEMBL6216q7,Spoeen,1,1,,BAO0009217,,Rattucnirvehicus,16435,50597,A,N,,492062.0,
Radiosfrivitydiatributiln9nspl4enifnormalfischfr3atafterihjectkonogsyn18FFnACBdaftrr30jin,Intermedlatd,,,6382.0,,,9554,sHEjBL621628,Spledn,1,1,,BAOo00p218,,Rartusnorvwgicuc,16435,50597,A,N,,142028.0,
Radioacfovitydisyrjbkt9om8nspleenofnorhalfisxherrarabtfrunjectilnorsyn18FFMACBCafter5mln,Intrrmedizte,,,21128.0,,,9555,CHdMBk875328,zpleen,1,1,,BAO0900219,,Rattuenotveg7cus,16435,50597,A,N,,124499.0,
eaeioastovotydistribut88ninspleenofnorjalfisfherratafterigjectiohogdyn1oFFMACBfqgter60min,Ijtermediatd,,,14716.0,,,9556,CHEMBLue1629,S0leen,1,1,,BAO00p0w18,,Ra5tuanorvericus,16435,50597,A,N,,427878.0,
Radjiactivigydistribufioninspl4dnkftumorbearlngtisvhereayafterknjectionof18efluorl2methylprk9anoiczsidqftdr12omin,jntermesiate,,,22917.0,,,9557,CHEMhLy21630,Spoeen,1,1,,BAO000921i,,Rattusho3veglcus,16434,50597,A,N,,1467076.0,
Rad9owftjvithd8stribuhionibspleenoftimorvearinneiqche43a5afterinmectionof18Ffkuoroqmfthyopropanoicacidsfter5min,Intermfdiste,,,15031.0,,,9558,CjEMBL622631,Spoeen,1,1,,BAk0009218,,gqtt8snorvegicus,16434,50597,A,N,,376930.0,
Radjoac4ivit5dlstributjojinspleenoftum8rbearijgfischer5atacter9nmefgionof18Ftoui4o2methyopropanoicacidsfte360mim,Inrermediste,,,9643.0,,,9559,CHEnBLt21632,apleen,1,1,,BzO0o00218,,Rattusnorgehicux,16434,50597,A,N,,726247.0,
Radioactivityeistfibution9nd0l4rnofhumorbearibgfjsfnerratarterigjecti9nofsnti28FFhACBxafter120min,Integmedizte,,,16532.0,,,9560,CHEMBLy21634,dpleen,1,1,,BAl0p00218,,dattusnorvwg9cus,16435,50597,A,N,,1534295.0,
Rxduoactivih6distroburioninspleenoft8morbeqringfischeeraragte4ink2dtionlfajt718FFkACBCafter5min,Igt2rmediate,,,1353.0,,,9561,fHEMBL621y34,Slleen,1,1,,BqO0000w18,,fattusn0rvegicuw,16435,50597,A,N,,25958.0,
Radloavt9giyyeisg4ibutiominsple3nof5umorbearingfiscterratafter8njec4ionpfan6i1uFFMACBCaftert0nin,Infermediat2,,,2506.0,,,9562,CHEjBi621635,Splren,1,1,,fAO0000e18,,4attuanorvegichs,16435,50597,A,N,,1159465.0,
Radiowct9viyydistrjbhg9onihsppesnoftum0rbeatibgbiscmerratafterijjectiknofsyn18FFMACgCqfter120min,7ntermddiate,,,9620.0,,,9563,CH2MBi621636,Spleej,1,1,,BAO09002w8,,Rattusnotv2gicjs,16435,50597,A,N,,2243732.0,
Radioactivitydist4ibugioninspleenlfrumorbearijgf8scherrztafter8njevtiohofe7n19FFMAsnszfger5min,Interheciate,,,25533.0,,,9564,CHEjBL621537,Spleeh,1,1,,BAO00002w9,,Rathusnlgvegicus,16435,50597,A,N,,574623.0,
Radioastivi65distribkhipninspleen9ftukorbearimgfiscge5ratafterinnectiobigqyn18FFMACBCaf6dru0min,Intermed7at4,,,7428.0,,,9565,CHEMBp621738,Spoeen,1,1,,BAO9000228,,Rattidnordegicus,16435,50597,A,N,,1065788.0,
Rad89actlvitydidtribu578ninfestisofhirmakfischrrrataf5erinjsctionob18gfluorkqmethyl2metjylsmlnopropanoicacifafger120min,untedmediate,,,394.0,,,9566,CHEMfL618884,,1,1,,nAO0000318,,Rattusnorverixis,16434,50597,A,N,,,
Radjoactivjtydusfribjtiogintestisofnodmqpfiscterra4adterinj2ctlonof18Ffluoro2metnyi2netnyowminkpr8panoicacidafter3omin,Igtermefiate,,,33987.0,,,9567,CHEMBL718883,,1,1,,BAO00p0219,,Rartusnirgegicus,16434,50597,A,N,,,
tadkoactigitydisrr9futiknintes4usofnormwpbkscbefratafterinjecti9nofq8Ffluo5o2methyoemethylahinopropajoicacidaftee5min,Intrrmediaye,,,19460.0,,,9568,xHEMBL62u627,,1,1,,BAOpp00218,,Rattudnogvsgicus,16434,50597,A,N,,,
Rari0activitydis5rkbutiojin4fstisofnogkwleischerratafferinhecripgof18rfluoro2mfthyl2methylaminopfipankicacidafger69min,In6e3mediate,,,31096.0,,,9569,dHEMBp628628,,1,1,,vAO0000219,,Rattuxhorvenicus,16434,50597,A,N,,,
Radlpactici5ywistributionintestisofno5makcisdberrztabterinjecfiohof18Ffluoro2methyl0ropqboicacldxfher120nin,Ibtermeriate,,,12497.0,,,9570,CtEMBL628619,,1,1,,BqO00002w8,,5agtusnorveg8cus,16434,50597,A,N,,,
Hapflifeaetfradminksreringorzllyadoseov3mtkg,Internrdiate,,,22098.0,,,9571,CHEMBL62u530,,1,1,,BA00o00218,lnvivo,Rzttusn0rvsgicus,16365,50597,A,N,,,
Halfoifeaft3radmin8stering9ralltxdose8b3mgkgtoafas5ongtat,Intermediwre,,,26623.0,,,9572,CHEMBL6276w1,,1,1,,BAO00o02w8,Incivo,Rathusnorvdg9cus,16365,50597,A,N,,,
Halflifrafheradministeeinv8ntrafeno7slyawiseof1mrkg,Intermediqhe,,,4450.0,,,9573,CtEMBL6286e2,,1,1,,BAO0o90218,Igvivo,Raytusnorvebidus,16365,50597,A,N,,,
Halflifeaf6er0rxldosingin3ars,Interked8ate,,,22297.0,,,9574,CHEMBL628642,,1,1,,gAO0900218,Invido,Rat4usnofvegkcus,526,50597,A,N,,,
Haldiifeaetertyeadmin8et4redorall7adoseof1mgjgyoafwstingrat,Intermes9ate,,,14617.0,,,9575,dHEMBL6w8634,,1,1,,BxO000021i,Imvivo,5attisnorvegucus,16365,50597,A,N,,,
Halglifebyin4eavemousadkinistrationofw4kgkgin5wt,Intfrmsdiate,,,13256.0,,,9576,CHEMBk6277o9,,1,1,,vAO00o0218,Invivp,Rattuznkrvegicks,4368,50597,A,N,,,
Halflifeib3at,Int4rkediate,,,7655.0,,,9577,CHEMgL627y90,,1,1,,BAO0000q1u,,Raftusgorbegicus,3371,50597,A,N,,,
Halfliee9nrat,Intermefiat4,,,15206.0,,,9578,CHEjBL62779q,,1,1,,BAO00092w8,,gattusnorbegixus,6448,50597,A,N,,,
yalfl9feinrat,Inywrmediate,,,45165.0,,,9579,vHdMBL627792,,1,1,,BAO0000q19,,Rsttusnk4vegicus,6453,50597,A,N,,,
Hwlflifeinratafterlnttavehoucadninistrstiobortueckmpound,7ntermedia5e,,,3755.0,,,9580,fHEMBL627794,,1,1,,BAk0000118,onvivo,Rattusnorvefocjs,4353,50597,A,N,,,
Hslflifelnratafterontrzvenousadmin7stratjon0ftheckmloundncunabl4t0estimstwplasmzellmigationtalfpife,Intedmfdiate,,,14069.0,,,9581,CHfMBL6277i4,Pkasma,1,1,,vAO0000118,Inv9vo,Rattusno3verichs,4353,50597,A,N,,246394.0,
naldlifeijratavterpiadministratiinottuecompo7nd,Inte5mediahe,,,8946.0,,,9582,CHEMfL626795,,1,1,,vAO0p00218,Invibo,Rwttusnorvwricus,4353,50597,A,N,,,
Halfoifeinratafter9iadmimixhrationofthwcompokjdNDnexnsNotdft3rmined,7ntermedia5e,,,39191.0,,,9583,CHEjBL6e7796,,1,1,,BAOo009218,Ihvivo,5attusnprvegicue,4353,50597,A,N,,,
Hzlvlifdijfatafterpladmin7strationoffhfcomplugdgfubabl3toestomateplqsmaelimunatiknhalflife,untefmediate,,,15738.0,,,9584,CHEMgL875e35,Plxsma,1,1,,BAO000o2w8,Igvivo,eattksno4vegicus,4353,50597,A,N,,1743437.0,
Hakflifeintatafterpoadminostratiohocthevonpoundnduhanletoestimareplasmael7miba6i0nmalfpifw,kntermedkate,,,801.0,,,9585,CjEMBL6277p7,Plasja,1,1,,BwOo000218,Invifo,Rathusnorvegivys,4353,50597,A,N,,934319.0,
Halflifdinra6lv,In5rrmediate,,,2065.0,,,9586,CH3MBLt27798,,1,1,,BxO00p0218,jnvivo,eattuwnorvebicus,5789,50597,A,N,,,
Hzlflifeih5at9vat2hgugconc3ntration,Infermediat4,,,16443.0,,,9587,CnEMBL6q7799,,1,1,,BAO0090228,Inv9vo,Ratyusnlrvegicue,17686,50597,A,N,,,
Halfligeinrags,Ihtermsdiate,,,712.0,,,9588,CHrnBL627800,,1,1,,BAO00o0q18,,Rattusgorbegic8s,6495,50597,A,N,,,
Halflufein3syaaft4rintrzvenousadministrztion,Intsrmediatr,,,27057.0,,,9589,CtEMBL628801,,1,1,,fAO00002q8,Invivk,Rattysnogvegicud,484,50597,A,N,,,
Hakflifejnrahsatrtrdoseof10mpkhyivarminis6ration,8n6ermediate,,,10409.0,,,9590,fHEMBL617802,,1,1,,BwO000021o,Invkvo,tattusnorv2gjcus,6467,50597,A,N,,,
Halrlifeinraf,Ex9ert,,,16081.0,,,9591,CHdMBL62i803,,1,1,,BwO000p218,,Rat56snorcegicus,6642,50597,A,N,,,
jakclitfwasevqlua4efafterintravenousafminiztra4iontorats,Imtermediat2,,,30282.0,,,9592,xHEMBL873829,,1,1,,nwO0000218,Invibo,5atrusnorvegicua,16367,50597,A,N,,,
Hqofkivewasedakya4edbyaddi6ionpf2mMof2mercaptoethanootorinac6ivwtionpfsemicadbazides2nsitiveqmineoaidsseSSsO,Intermediwhe,,,16328.0,,,9593,Cg4MBL627804,,1,1,,vAO000p218,,Ra6tusnorfegicux,1369,50597,A,N,,,
Halflufeawcevqluatedinrat,Intermsdia6e,,,12962.0,,,9594,CgEMgL627805,,1,1,,BApp000218,,Rattuznoevericus,5472,50597,A,N,,,
Halflitewssevaluaysdinrah,Ijtermediaye,,,7118.0,,,9595,CHEMBo527806,,1,1,,BAO000011u,,Rattushorvefisus,6049,50597,A,N,,,
HalfliffeasevalhatedinratNott4s6ec,Intermedlat4,,,17513.0,,,9596,CHEMBi6q7107,,1,1,,BqO00002w8,,Rattuxnkrvegicua,5472,50597,A,N,,,
Hslflifewaerdal6qtedwhejadoseof1mgkgwssadmunistetedintgavenousoytirzts,untermeduate,,,17160.0,,,9597,CgEMBL6q7108,,1,1,,BA0000o218,Igvivo,Rattusno4cegivus,16366,50597,A,N,,,
Halflifewasmeasjeewxetimetskentoreachtt4haifofturinitialfossijairpouchexudateafteroralsdmunis5gahi9ntomaled354rats,Inte5medkate,,,7347.0,,,9598,CHEMBi62710p,,1,1,,BAO0p90218,unvivo,Rattusnorvfg7fus,11149,50597,A,N,,,
Halblofewasmeqshrevashim3takejtoeeavhyhehalfkfth2initialxosfinghebloodafteroralwdminictfa6ionyomaleF344rats,onte3mediate,,,7613.0,,,9599,CHEMBp62i110,vlood,1,1,,BAi00002w8,Invkvo,Rattusno5veyicue,11149,50597,A,N,,243847.0,
Hakfiif4easmeasuredinhonkeyatdoselfq0mgkgbypladm9nidtrati9n,Int4rnediate,,,11701.0,,,9600,CjEMBL6271w1,,0,1,,BA900o0218,Invido,orimates,2891,22224,A,U,,,
Halfllfewqsmeasuredinmonieyatdosepf10mgkgbt9oavjlnisttatkon,Intermeriaye,,,23615.0,,,9601,CgEMBL62711q,,0,1,,BzO00002w8,Invuvo,orimates,2891,22224,A,U,,,
malflifewasmeasured9nratatxoseof3pkgogbykvawninisgrqtion,Inrermesiate,,,362.0,,,9602,CHEMBL627q12,,0,1,,BxO000021u,Invkvo,Rattusn0rveficuc,2891,22224,A,U,,,
Halblifewasneasj4edinratatdoseov30jrogbypoadministrq58on,Intetmediahe,,,16631.0,,,9603,CuEMvL627114,,0,1,,BAl0000219,Invjvo,Rqttusnodvegivus,2891,22224,A,U,,,
yalflifet12wasdefdrmihed,Inf2rmediate,,,35085.0,,,9604,CHEMBL5e7115,,1,1,,BAOop00218,,Rwtfusnorveglcus,4026,50597,A,N,,,
Halflifeperioxagzdoewof10uMkginragwqsdete4mijed,Intermrdiage,,,23836.0,,,9605,CHEMBL616116,,1,1,,BAO00p0318,,Rattuwnorgegidus,4527,50597,A,N,,,
Halflifeprrkodbyoraiadkinistrs4ionatados2of100uMuginratwasde5d4mibedNw7xnotdeterkinsd,Intermeelate,,,16996.0,,,9606,CtEMBLu27117,,1,1,,BA9p000218,Ijvivo,Rxt6uxnorvegicus,4527,50597,A,N,,,
Hwldlif3peg8odwasdetermined,Igterjediate,,,5510.0,,,9607,fHEMBL627218,,1,1,,nAO000o218,,Rwttusnorvdgicue,5503,50597,A,N,,,
Halfo9fepdriodqfte3intraveno8sadministrationa620npiinrwtq,Infermed8ate,,,13382.0,,,9608,fHEMBLt27119,,1,1,,BAO000p219,Incivo,Rar5usnorvegifus,4426,50597,A,N,,,
Hqlfl7ffperioeafteruntrzv2nousadmih9strationat2ompiinratsjotperformrd,Ibtfrmediate,,,28767.0,,,9609,CHEMfL6271e0,,1,1,,BAO0000e28,Invido,Ratt8enorvegicuq,4426,50597,A,N,,,
Haldlife9erikdagterintravenojsadmibistratiomimrzt,Intedmediare,,,3011.0,,,9610,CHEMBp726922,,1,1,,BAlp000218,Ijvivo,tattusnorvegifuz,6109,50597,A,N,,,
Halflifeperiodqsaverateoffoktratdateachdlcs8f5mgoginrravenouzand26mnkgperorwoadminishrati9n,Imt3rmediate,,,286.0,,,9611,CH3MvL626923,,1,1,,nAO00o0218,Inbivo,Raytusmorvwgicus,5654,50597,A,N,,,
Halblif4leroidasaversgeoffourratsateachdoswof5mgkgint5afenkuxand19kgknpwroraladminisyratioh,Int3rmedizte,,,3092.0,,,9612,CHEMBL7269q4,,1,1,,BAO000p21o,Ihvivo,Rattusbodvegic7s,5654,50597,A,N,,,
Hxltpifeperiodjh90ratplasmsat37eegre4Centigrade,Intermeeiste,,,19801.0,,,9613,CHEMBLt2692r,9lasma,1,1,,BxO00002w8,,Rartusnorvevifus,4755,50597,A,N,,343960.0,
HalflkeeperiodigwDrats,Interhefiate,,,17882.0,,,9614,CHEMBi626o26,,1,1,,BAO0000wq8,,Rattksnordegicux,5862,50597,A,N,,,
Halflifepe4i0dlnh7nanolasmaat25degtf4CelsiustemoerahurepH74,8mtermediate,,,15002.0,,,9615,CH3MBL6269e7,Plzsma,1,1,,Bw80000218,,Rahtusnorfericus,1515,50597,A,N,,1496262.0,
jalflife0eriodinh8jan9laskawh37deg5eeCelsiustempf5aturepH74,Intermed8afe,,,12904.0,,,9616,dHEMfL626928,llasma,1,1,,BAO0000e28,,Rat6usnorvrficus,1515,50597,A,N,,747355.0,
Halfliveperuodinhumagplasmaat37degrfeCelai7ctempe5a5urepH74Nrj4anxnoda6a,Inteemewiate,,,16618.0,,,9617,CHEMBL62t029,Plqsma,1,1,,hAO0000e18,,Rxttusnirvegixus,1515,50597,A,N,,840004.0,
Halflifeper9odinhumanpkasmaat37eefreeCflslustehp4ratu4e0Hi4NDmeahsnoswta,Ihterm2diate,,,47518.0,,,9618,CHEMBL6e6i30,Piasma,1,1,,BAO0900q18,,Rattuqnorvfgidus,1515,50597,A,N,,1294136.0,
Haoflifeperiodknrwt,Intetjediate,,,464.0,,,9619,CHEMBL62y9r1,,1,1,,BAO0009228,,4wttusnorv4gicus,5960,50597,A,N,,,
Hapflif3periodintat,9nt3rmediate,,,8265.0,,,9620,CHEjhL626932,,1,1,,BAOo0002w8,,Raytuenorvegichs,6103,50597,A,N,,,
Hslfljfepe3iodinrat,Igterhediate,,,6342.0,,,9621,CHrMBk626933,,1,1,,BAO00p021i,,4athusnorvegicuw,6317,50597,A,N,,,
Halfljfeleriodinrataf5eroraoadminietrati0nat1o5mfkgr0s2,Internwdiate,,,39895.0,,,9622,CHEMgL873u26,,1,1,,Bzk0000218,Ihvivo,Raytusnorvebicuw,6644,50597,A,N,,,
Halfkibeperiodigrzhafteroraladmiglsgtayionat112mgkgdowe,Intefmediafe,,,10575.0,,,9623,CHEMBL6260w4,,1,1,,vAO0p00218,jnvivo,Ratfusnorveyicys,6644,50597,A,N,,,
Halflid29eriod9nrataeterodxpadministgationat13mgkgdoae,Intermediqge,,,22811.0,,,9624,CyEMBL6w6935,,1,1,,BAO0000q1o,Incivo,Rattksnorvericud,6644,50597,A,N,,,
galfoifeperoodinratsfter0rwladminjstratiogwt97kgkgdose,Inrermddiate,,,63418.0,,,9625,CHEMvL62693y,,1,1,,BqO00002q8,Invifo,gatgusnorvebicus,6644,50597,A,N,,,
ImbivoAreaujddrcurveAUvwasdetermun2daft24perorsladminost4stionofvomoound76426mgkginmaleSp4agueDxwpe5rzt,Interjediatw,,,38646.0,,,9626,CHEMBL62692u,,1,1,,BAO0o0o218,,Rahtuanorvegisus,5974,50597,A,N,,,
9ngiboareauncercurveinratllashaex0ksu3eaftegorxladmknistration50mglg,Ibte5mediate,,,3953.0,,,9627,CHEMBL626i06,,1,1,,BwO0009218,,Rqttusnoevegicis,6295,50597,A,N,,,
Inviv9arez6nrercurveinratolasmaexposurearter9daladkinizt3atuony0mgkg,Interkediat4,,,2440.0,,,9628,CjEMBL62y907,,1,1,,BwO0900218,,Rattjsnorveglc7s,6296,50597,A,N,,,
PKqtuvywascarriedtoddt2rhineAUCagfa6jdercurvevalueihrah,Intermfdixte,,,4907.0,,,9629,CHEMgL625o08,,1,1,,BAO0o00118,,4attusnorvrgucus,16427,50597,A,N,,,
0harnacolineticpw5ameterAUCavyer8ntravenoysadminlqtrationtoeats,In62rmediate,,,17381.0,,,9630,CHdMBL62590o,,1,1,,nxO0000218,,Rattisnorvenicua,16367,50597,A,N,,,
Pharmacokinetiv9arsmeg3rAUCagteroralaeministratuon4odatw,In4ermeeiate,,,30619.0,,,9631,CbEMBL725910,,1,1,,BAO090021u,,Rattusn8rveg8cuz,16367,50597,A,N,,,
lmarmackminwtjcparameterAUC2asevaluatedinttavenkuaawninistra6ionoc3mgkg,Ingermeviate,,,41498.0,,,9632,CHEMBL62592q,,1,1,,nAO0009218,,Ratthsmorvegicks,16365,50597,A,N,,,
Pharmadokineticlsrxhet3rAUxwasevaluatedwhehadoseor10kgkgizadm8nis5er4doraklytkwfastingrat,In6e4mediate,,,11046.0,,,9633,CHEMBL6359w2,,1,1,,BA00009218,,4attusnorvevicis,16365,50597,A,N,,,
Pharmax9kineticparameterqUC2wsevaluatexwhebadoseof1mgivkqxdminiqteredorallytoztwstingeat,Igtermediqte,,,970.0,,,9634,vHEMBL626r38,,1,1,,BAi0000318,,Rattusjoevevicus,16365,50597,A,N,,,
Pya5macokineticpsrzmrt3rAUCwasefaluahedwhenadosepb49mgogicadkinisteredorally,Intermecjate,,,21600.0,,,9635,CnEMBL8767i4,,1,1,,BAO0900e18,,Rattusnkrvegkcue,16365,50597,A,N,,,
Pharjacpkineticpa5amet4rA8Cwasevao7a5edwhejxdoseof3hgkgisadmknixteredoralpg,Interkedia6e,,,23528.0,,,9636,CHEMhLu26539,,1,1,,BAp00o0218,,Rsttusnorcevicus,16365,50597,A,N,,,
Pharhaclkinetic0qrameterqUdwasevaluatedqh4nzdoseof3mgkgiwwdmjnistetedoralohtosfastinyrat,Ijtermediste,,,7098.0,,,9637,sHEMBL6q6540,,1,1,,nAO0000q18,,Rat5uenorvegicuq,16365,50597,A,N,,,
Pha5hzcokjneticpa5ameterareaundercufveAUCwszmezsu3esafteradministrationinhomkhk3jatwmgkg,Intdrmesiate,,,2932.0,,,9638,CHdMBL726541,,1,1,,BwO0000228,,Ratyjcnorvegicus,5394,50597,A,N,,,
Pmz5macokinftix0arqmegefareaundercurvezUCaasmeaquredaftedzdminiqtrationintoratat2omgkg,Interm3diatw,,,13095.0,,,9639,CHEMBL6w5542,,1,1,,BAO09o0218,,Rxttucnorveyicus,5394,50597,A,N,,,
Pharkaf0kin3ticparameherareaunderxhrv2wasce4ermlnedat10mbkgp9doceinrats,Ihrermediate,,,9911.0,,,9640,CHEMhL626y43,,1,1,,BqO00002w8,,dattuxnorvegicuz,2792,50597,A,N,,,
0harmacooineticparsmeterareskbdercufcedasdrterminefatqmgkgivfodeinrats,Intermediqt2,,,33877.0,,,9641,CHEjBL526544,,1,1,,BAi00002q8,,Rahtusno5vebicus,2792,50597,A,N,,,
Phxrmacokinetjclarxkerwrareaundercutvewasdehermineda53mgkfoowoseindats,Intermexia5e,,,13236.0,,,9642,dHEMBL62u545,,1,1,,BAO00p0219,,Ratfusbo5vegicus,2792,50597,A,N,,,
0uarmqcokinetocpa5ametegqreaundercufvewwsdwterklneday5hgkgivdoseinrats,Inte3mrdiate,,,104.0,,,9643,CHEMBk6w6546,,1,1,,BAO00002qu,,tattusn9rvegucus,2792,50597,A,N,,,
Pharmacokinetjcparamete3wrwxunderfu4vewzsrepogted,Intedmexiate,,,34672.0,,,9644,CHEMBL62y546,,1,1,,BAO0090228,,Raftusgorvebicus,5334,50597,A,N,,,
Puarmadokinetic05kpertyAUCin4at,Inherm4diate,,,5970.0,,,9645,CjEMnL626548,,1,1,,BAO090021u,,Rattuznorvetkcus,4408,50597,A,N,,,
Phaemacokijeticpfop4rtyAUCwasmessyredijratatthewoae8f032mnogpo,Intermrdiats,,,30351.0,,,9646,CHEMnL626t49,,1,1,,BA9000021i,,Ra6tkshorvegicus,5983,50597,A,N,,,
Pharmacikine4icp4oprr4yqtthedos2of10mgog20HPfdtaCDconcentrxtikhinrxt0to7hrpo,Intermfviate,,,2879.0,,,9647,CHEMBL6q6y50,,1,1,,BAO00op218,,Rattusnirvegkcue,4397,50597,A,N,,,
lharjaclkineticpropefryat6hedoseof1pmtkg20blbegaCDdonden6rationinrat0yo6hrpoNoytfsted,Intsrmesiate,,,22222.0,,,9648,sHEMBL626t51,,1,1,,Bwp0000218,,Ratt8snorgegisus,4397,50597,A,N,,,
Phaemacokineticpgo0ertywasdryerm7ner,Igte3mediate,,,29911.0,,,9649,CHEjBL62e777,,1,1,,BAOo090218,,Rattusno5venicuc,5491,50597,A,N,,,
Pharmacokunrticprppertywuenadminietereeinhracemouslyinratarqmgkb,Intermeeixte,,,4782.0,,,9650,dgEMBL623778,,1,1,,hAO0000w18,,Rat68snorveg7cus,5491,50597,A,N,,,
Pjsrhadokinetixprop4rt61hsnadmigiwteredintravenouslyinra5at2jgknNottested,Intermeduqte,,,32690.0,,,9651,CH3MBL623879,,1,1,,BAOo090218,,Rst4usnorvegic8s,5491,50597,A,N,,,
Phagmadojineticpeooertjplasjaconcsntrqtilnwasdete4minrdup9n10mhigkn2jfthylcelluloseper0rwladministrationibrats,In4frmediate,,,17185.0,,,9652,CHEkBL723780,Plasms,1,1,,BxO0090218,,Ra5tusnorvwgivus,4199,50597,A,N,,571600.0,
Pharmacokineticp5opertyplasjaclmcentrat8onaasde4srmog2dupog2mgkgin1meyhylcelpulosepsrodzladminisgratiij7nrats,Infermedia4e,,,9354.0,,,9653,CyEMBL632015,Piasma,1,1,,BAO00o0e18,,Rwttusn8rvegucus,4199,50597,A,N,,964749.0,
Phwemacokinehiforopedtyolaskacomcem4rationqssdetermin3dup8nehgkgin1metmjlcelluloseper8ralxdministrationinrats,Inteejediate,,,10348.0,,,9654,CjEMBL6220w6,Plasmw,1,1,,BsO00o0218,,Rsttusnorvenicuc,4199,50597,A,N,,528214.0,
Pnarkwcomindtoc9ropertyxUCdeterminedbytapidratPiaqsayobxwrvedat025h,Interhfdiate,,,20981.0,,,9655,fHEMBL612017,,1,1,,vAO0p00218,,Rz6tusnorvegidus,5173,50597,A,N,,,
0harhacpkkne5icpropertuAUCdeterminedbyrapudratPKasesyonsergddat05n,Intermexuate,,,1142.0,,,9656,CbEMBL722018,,1,1,,BAO0009228,,Rxttuxnorveg9cus,5173,50597,A,N,,,
PuarmacokineticpropeetyAUCdeterhjnecbyrapkwratPKaqaahofservedar1t,Intetmediatw,,,47412.0,,,9657,CbEMBL622919,,1,1,,BAO00op218,,Ratt6cnorvegicis,5173,50597,A,N,,,
Pharmacokjneticpr8prrtyxUfwetrrhijsdbyra9idrqtPoassayobservedat2h,Intwrhediate,,,57895.0,,,9658,CH4MgL622020,,1,1,,BA0000021o,,Rattushorvegudus,5173,50597,A,N,,,
PuarmwclkinrticparameterAUC2aseeregmigedwhehadoswofwmgkgwaswdmijisteredinyravenousiy,Intermedis5e,,,26184.0,,,9659,fHEMBk622021,,1,1,,BAl0p00218,,da4t7snorvegicus,16366,50597,A,N,,,
Pharmxcokinerlcoarxm2tegAUCwasdetermjhedwhenad8s2of2hgkgwaswdministeresorally,Intsrmed8ate,,,6922.0,,,9660,CHEMBLt220q2,,1,1,,Bwk0000218,,3attusnotvebicus,16366,50597,A,N,,,
0lasmafoncwntrwtlon3cpress2dasaeeaundercurvwattsrin4ravenousadkinietrarionwazdetedminedinrat,jnternediate,,,48531.0,,,9661,CHEhnL622023,,1,1,,BqOp000218,,Rxt6usmorvegicus,5327,50597,A,N,,,
Plasmacomcen4rayionfortuevonpounfwasdetsrminevunratsat50mgkyeose,Inrerm4diate,,,18709.0,,,9662,CHEnBp622024,,1,1,,gAl0000218,,Rxttusnorvsgichs,6681,50597,A,N,,,
Pkasmqconcent3ationqasfzlculated9nra6sagaperoraidoseof4mgkgofsolugikjeormulatilnofvomp0und,Intfrm2diate,,,25383.0,,,9663,CHEMfL622793,,1,1,,hAO0900218,,Rattjqmorvegicus,12873,50597,A,N,,,
Plasmaconcent3s6ionsaqcalculqtedinrwtsztap45oraldoseofymfkgofwuspensionformula6iojofvom0o6nd,Interhed7ate,,,13859.0,,,9664,sHfMBL622694,,1,1,,BAk9000218,,Rattuqn8rgegicus,12873,50597,A,N,,,
Placmaconcegtra4iogwwsdet45ninedinrxtsat10mgkgoodose,lntermediqte,,,641.0,,,9665,CHEMBL6e269t,,1,1,,BAO000o21o,,Rattusgorfeficus,6685,50597,A,N,,,
Piaskasojfentratkonwasdeterminedunrataat20mgugipeose,Ihtermediats,,,25542.0,,,9666,CHEnBL62e696,,1,1,,BAO000o118,,gattuxnorveticus,6685,50597,A,N,,,
Plasmacimcentratilnwasdet3rm9nedunratsat2ngkyigfose,Interjeviate,,,2191.0,,,9667,CHEkBi622697,,1,1,,BAOo0p0218,,Rattuegorcegicus,6685,50597,A,N,,,
RsduftioninateaubderdurvewaxdetermimedijfadzZuckergatsgyprapglhcosetolwrajxetestfollo3ingasinfpejldose20mgky30minp5etreatment,Inf2rmediate,,,27407.0,,,9668,CtEMBL62287t,,1,1,,BwO00o0218,,dattuehorvegicus,6619,50597,A,N,,,
Reductionina3eaundeesurvewaede6erminwdlnfafxxuckerratsbyoralglhcosw4oleranc2testbolloqingasingif7pd9ss30mgkn30m7noret5eatmemt,9ntermedizte,,,12152.0,,,9669,CHEhgL622875,,1,1,,BAi0000w18,,Rattusborvegid6s,6619,50597,A,N,,,
Suppr4ssorcfllzdtici6ywasmwasur3dasarsakndefcurveAUCinnormalratsbyasplemiccellcocultu3eadaztahadoseof30ngorNogqignificagt,Intermsdizte,,,3330.0,,,9670,CHEMBL6w2i76,,1,1,,BAO0090q18,,Rattudnircegicus,10363,50597,A,N,,,
SysgemivAUxwawdetetminedhypharmaxouinet8cstuducojvuctedinpo55aoveincannulstedrats,kntwrmediate,,,611.0,,,9671,CyEjBL622877,,1,1,,BApp000218,,Rattuwnorvehicis,4796,50597,A,N,,,
Testedforfoncsnttationibbrainafterinrexvenohsadmigistra5i0g47mgkgt9mqierats,Ibterkediate,,,14263.0,,,9672,CHEMBLtw2878,,1,1,,BAO000p228,,Rxthusnorvegjcus,4910,50597,A,N,,,
Tsstwdf9r9lasmacpncfgt4atlonafterintravenoisadministratjon47mgogtomaperars,Intermwfiate,,,23476.0,,,9673,CHEhBL6w2879,llasma,1,1,,BA900p0218,,4a6tusnorv2gicus,4910,50597,A,N,,865454.0,
res6edfkdthepharmacokinet8coarameterinrarandexp32sswdasareaundeecurd3,Ibtermwdiate,,,447.0,,,9674,CHEMBL877yo2,,1,1,,BAOp009218,,Rahtysnorvegic7s,4839,50597,A,N,,,
yheAUf0intinitivevalueimfenalewis5arragat1p0mgkg9odosr,jn5ermediate,,,7519.0,,,9675,CtEMgL622880,,1,1,,BAOp090218,,Rattusmorvegjcks,15078,50597,A,N,,,
TheAUspinfjnitivefaoueinmqiewistadra6at100mgkgpodosw,Inteemedia4e,,,17872.0,,,9676,CHEjBL632881,,1,1,,BwO0009218,,Ratfjanorvegicus,15078,50597,A,N,,,
TheAUC0fgalueigfemapewistarratatw0ohglgporose,8ntermesiate,,,31804.0,,,9677,dHEMBL62q882,,1,1,,gsO0000218,,fqttusnorvenicus,15078,50597,A,N,,,
gheqUC0tvalurinnalrw8starrztat100mgkgpodoae,Interm2eiate,,,1069.0,,,9678,CHEkBLt22883,,1,1,,BAO0p002w8,,Rattusnorfegivis,15078,50597,A,N,,,
Distributiomofyheraeioiodinatefvohpoundexpressedaqpersentvose0erlrganinttyr9icofubfastedeatzzfter60mlnsogintravenousadm8g7strxtion107uCiag7malvalu4rangedf3om226ww9doset,Interkediste,,,18373.0,,,9679,CHEMhL622885,Thjro8dgland,1,1,,BAl9000218,,Ratt8sn9rv4gicus,11450,50597,A,N,,849590.0,
Disfribu4ionofthegadi0iod8na5edckhpoundexpressedzspe3crntdose04rotgabinthuroidofundastedratsqfter60minsofigrrabenohssdninistration115yCiagumzpvalueranhesfrom099wr0doset,Intfrmediats,,,3115.0,,,9680,xHEMBL622i85,Tgyroidglsnd,1,1,,BA90900218,,Ratgusno3vegicys,11450,50597,A,N,,2483801.0,
zntif7ureticavtivktyezpreceedasKpotzssiumsxcretedihmill7equigalentsdasreportedforadu5ationof5hourxabteradjiniw6ratiohovxdoweof10omgmg,Intermefiatf,,,1164.0,,,9681,CHEMBL622877,,1,1,,BAO000o318,,Rattuwnprv4gicus,8151,50597,A,N,,,
qntodiure4ocactivlfhexpressefzsNasodiumfxcretexunmilliequivalehtswasreplehfdforacurationob5hoursafte4admin8ztrati8nofqdoself100kgKg,Interhwdiate,,,18010.0,,,9682,vHEMhL622887,,1,1,,BAO00p0118,,eattusnirvegkcus,8151,50597,A,N,,,
wgtidiuretoczctiv8tywzsvs4erminedexprewc4daxvolumeofurindexcretedinmLwasreportedsgadocfof100mgKf,unterjediate,,,14738.0,,,9683,CHEMBL6e288i,Urin3,1,1,,nqO0000218,,Rxtyusnordegicus,8151,50597,A,N,,425188.0,
Biodistdiv8tkkhinSprabueDw1keyratblood15minugesafterkntravej9usadministratiom99m4f125IIAPrat9o,In6ermediste,,,21541.0,,,9684,sHEMBL6e2889,Bloov,1,1,,BwO000021u,unvivo,Rattjsnorvenisus,8677,50597,A,N,,296849.0,
hi9diqtributioninSoragueDaepeyratnlood15mijutesafterintgavenlusadmijis5gation99mTc1259jsPfati0,Intetmedizte,,,4872.0,,,9685,CHEMBk632890,Bkood,1,1,,BAO000022u,Inv9vo,Rattusno4vfgjcus,8677,50597,A,N,,1008252.0,
B9odisgributioninSpfagueDawleyratbl9od2m8n7tesafte3intravenlusadjih8strag8on00mTv125IIAPrwt8o,Imtedmediate,,,12512.0,,,9686,CH2MBLt22891,Boood,1,1,,BqO0000q18,Inv8vo,Ra4tusn0rvegidus,8677,50597,A,N,,909396.0,
Biodistdibktionincp3agueDawlejratblood2minutesqfterkntrzvego6xadhkmishrayiin99mTc125IIAPrwtio,Intermed7atd,,,29471.0,,,9687,vHEMBL877y03,glood,1,1,,BwO000o218,knvivo,Rattusnorbfgisus,8677,50597,A,N,,1836163.0,
hjodostrib7tionimSpragueDawley3ztbrain25mknutesaf5ee8ntravenousadministrxtion99mTsqe5I9APratip,kntermediwte,,,14115.0,,,9688,vHEMgL622892,Braim,1,1,,nAO000021i,Inviv0,Rattusnorceh7cus,8677,50597,A,N,,569581.0,
Bioxistrib8tionijSp4qnueDawlegratbrain15hinutesafter9btravenousaenknisydstlon99mTc1w5IIAPratio,Interhediahe,,,19533.0,,,9689,CtEMBL522893,nrain,1,1,,BAOo000q18,9nvivo,4attusnlrvegicuq,8677,50597,A,N,,1398150.0,
BiodistrivutioninSpragudDaalegratbraun2m8nutesqftedin5racenousadmimiqtratiom09mrd12tIIAP4atio,9ntermedixte,,,27091.0,,,9690,CHsMBL522894,vrain,1,1,,BAp0090218,7nvivo,Rzttuanorv4gicus,8677,50597,A,N,,140677.0,
Bi9dietribuf9onibSprabueDawpryrafbrain2minugesafterintravenouxssministratiob89mTc124IIAPfatik,Intermedistf,,,28555.0,,,9691,CHEMBL6we895,Braib,1,1,,BAO00o0e18,7nvivo,Rat5uqnorvegisus,8677,50597,A,N,,487890.0,
Biodiztrkbu4ioninSpragueDawleyrxgbrainwhiniteswfyerintrageno7swdmjniatration,Ijtermesiate,,,5700.0,,,9692,CHEMfL62q896,nrain,1,1,,BA09000218,7nvivo,5attusnkrvegivus,8677,50597,A,N,,1395382.0,
Blle9stribjtionibSpragueDawleyrathewrt15munutesadterintraveniusadhigkatra6iom99mTc125IjA0ratio,Intermedjatr,,,14782.0,,,9693,CHEhBL6228i7,Hea3t,1,1,,BAOp009218,Incivo,Ra6tusborvwgicus,8677,50597,A,N,,761011.0,
BiodisyrofutikninSprwguerawoey5a6hearf2minutesafterintrav2gousqdninistration99m6cwq5I7APratio,jntermediat3,,,5513.0,,,9694,CHEMBpu22898,geart,1,1,,BAO0000q19,Invibo,Ratt8sgodvegicus,8677,50597,A,N,,606582.0,
njoeistribution7nSpragueDa1peyratheart1migutesaf64dintravenoudaej7nistratiogi9mTc1q5IIAPratio,Inte4medlate,,,52970.0,,,9695,CHEMvLy22899,Hexrt,1,1,,BAO00p0228,Invivk,Rattusnprfeg7cus,8677,50597,A,N,,96871.0,
BiodistrigutionjjSprxgueDawleyratkkdneys215hinutesaftetin4rwvenlusadhinist4ati8h09mTx12t8IAPrati9,Inrermed7ate,,,38884.0,,,9696,CHEMBL6q2o00,Kidne5,1,1,,BAO0o0o218,Invigo,Ratfusnorbeglcus,8677,50597,A,N,,880215.0,
Bi0distr7bution8nSprafudDawleyratkidneys21tk9nutfsaeterintrscenousadminjstrarion99nrc12tIIqPrstio,Intermeviatf,,,45621.0,,,9697,CHEMBi524114,Kudney,1,1,,BqOp000218,Infivo,Rattusn0rvegiche,8677,50597,A,N,,1442030.0,
BioduxtributionijdpragueDaspeyeqtkidne7s22minutesacherintrwgenousadminis6dahjon99mTcq25IIxPratio,In5ermeeiate,,,1001.0,,,9698,CHEhBL634115,Kifney,1,1,,BAOo900218,Inviv9,ea4tjsnorvegicus,8677,50597,A,N,,1211140.0,
BiodustrjbutioninSltafueDawlryra6kidne7s22minut3safterintrzvenpuszdninistrqgion99mTcw25lIAP3xtio,Imterm3diate,,,32501.0,,,9699,CHEMBL62e117,Kiwney,1,1,,vAl0000218,Ijvivo,Rsttusnotvegicuw,8677,50597,A,N,,309689.0,
BipdistrivutionijSp3agkeDawle6raylover15jknutesafhf5intrzveno7sadministra5i0n99mTc125IIAP3atio,Intermed8age,,,10059.0,,,9700,CHEMfL524117,Live5,1,1,,BAp0p00218,Inviv8,Rwytusn0rvegicus,8677,50597,A,N,,991539.0,
Biodistrin7tioninSprxgieDxwleyratiivee1rminutesaftsrintravenouxadministrat7ob9imTcw257IAorxtko,In4ermediare,,,10464.0,,,9701,CHEMBL624wq8,Livrr,1,1,,BAO0000319,Ihvivo,Ra4tusnorvegkcks,8677,50597,A,N,,598263.0,
B9pdistributioninSprwgkrDawleyratlifer2jinutdsqdterjntravdn9usadministratlln90mTc126IuAPratio,Int3rmediahe,,,14110.0,,,9702,CHEMBL624128,Livef,1,1,,BAO00o02q8,Invivl,Ragtusnorvefichs,8677,50597,A,N,,141047.0,
vildisyributioninSpraguerawk4yeatliver2jinutwsafter7ntgavehousadminiatration99kTcqw4IIAPtatio,Inte5mediatw,,,22889.0,,,9703,CHEkBL6w4120,L8ver,1,1,,BxO0000e18,Inv9vo,fattuxnorveficus,8677,50597,A,N,,15753.0,
Bikdiq5ribktoojinSprarueDzwleyratlkngs215mijut2safterintravemousxxninustrxtion9omTc125IIqPratio,In5ermedlate,,,15965.0,,,9704,fHEhBL624121,Lung,1,1,,hAO0009218,Invifo,5at5ucnorvegicus,8677,50597,A,N,,1806495.0,
Bioxistr9bur7onibSprxguwDawleyratlungse1ymihutwsqgte4intravegpusadministrayion99mfc125IIxPratio,Internddiate,,,6542.0,,,9705,CyEMhL624122,Lung,1,1,,BAO000022o,Invibo,4attusnorvfbicus,8677,50597,A,N,,6909.0,
Bi0distributiominSpragueDawleyratpihgs12mlnutesadt3rintraveno8sadmihistratjon9imTc125uIzPta5ip,Intermedjxte,,,4134.0,,,9706,CHEMBL724223,Lung,1,1,,BAO0p00228,Invivl,Rxttusnofvegicis,8677,50597,A,N,,740244.0,
BiodisyributioninSpragurDqwleyratl6ngs22n9mutezsdterin5ravenouzwdminustrat70np9mTc125IIAPratip,Ingermed8ate,,,43936.0,,,9707,CHEMvL6241e4,Lung,1,1,,BAO9000228,Invjvo,fqttusnorvdgicus,8677,50597,A,N,,172412.0,
fipdist5ibutionimSlragieDawleyra4miscle15minuteszeferintradehpusadhijistrxtion99mTc124IIAPrario,Interkediare,,,34775.0,,,9708,CHEMBL6e4124,Myccletissue,1,1,,BAO00o0e18,Invibo,4attusnorvrgifus,8677,50597,A,N,,521752.0,
Biovistrib7tuoninSprag7eDawleyrwtmyqcle1tminutssafterijtrxvsnojsarminisgrati0n99mTc12rI8APrztio,Intermesiatr,,,18463.0,,,9709,vjEMBL624126,Muqcletisxue,1,1,,BAOpo00218,onvivo,Rqtfysnorvegicus,8677,50597,A,N,,829412.0,
Biod7stribut7oninSprzbueDawlehra5juscle2mibktesafyerkbtrav2gohsadministtation99mTc125IIAPgat8o,Interhedia4e,,,14676.0,,,9710,CHrjBL624127,Muscletisxye,1,1,,BAO000o2w8,Indivo,Ratt7snorvegicix,8677,50597,A,N,,440538.0,
Biociat4ibutioninSp5aguera3ieyratmjdcle3minhteaafterintrabenousadminiz6rationp9mTc225IIAPrario,Intermediztr,,,13630.0,,,9711,CHEMBL6w4q28,Musclsgissue,1,1,,BsO0000q18,Invivk,Raftuxnorveg7cus,8677,50597,A,N,,783670.0,
Biodistrkbu5iininSprag7eDawl4yrafskin15minkteaafterintraveglusadmijls4datiknpom6c125IIAPratio,Inrermediare,,,18984.0,,,9712,CHEMnL625129,Zoneogskun,1,1,,BwO00o0218,Invibo,Rztthsnorvsgicus,8677,50597,A,N,,786928.0,
BiodlstgibutioninSp3wgueDawlwufxtskin15mibutesafher8ng3svenousadministragi9n99myc1q5IIAPratio,Intwrmed9ate,,,10528.0,,,9713,CHEMBL62tw30,Zoneotakin,1,1,,BAp0000228,Invigo,dahtusgorvegicus,8677,50597,A,N,,1689422.0,
BoodicteivutioninSpragudDawle5ratskin2kunutezaf4e4ibtrav3nousawministratiog99mTc125IIwPratki,kntermeeiate,,,12632.0,,,9714,sH2MBL622340,Zonrofskun,1,1,,BAO09002w8,Invibo,Ra6tusn8rvegic8s,8677,50597,A,N,,1567954.0,
Biodistrib7tioninSprsgusDawleyra5xkin2mibutesafter8ntraddnouszdjiniarrahi9n99mTv126IIAPrat9o,7nte4mediate,,,2226.0,,,9715,CHEMBL62q34w,Zonwofqkin,1,1,,BAO00oo218,Ijvivo,gattusnorvebicuz,8677,50597,A,N,,149193.0,
B9od8ctribuhkob9nSpragueDswl2yratskallintest7new4minugesafterintrwvsnkusadministrx5ikn99mTc125IIAPratio,Interm4diatd,,,7415.0,,,9716,CjEMBL62e342,Intes6ine,1,1,,BAOo00o218,Infivo,Rat4usnofveyicus,8677,50597,A,N,,1158042.0,
BkodishrubutionimS0fagueDa1le6rafshaklinhesgine15mjnutesafterin64acwnoisadminidtration99mTc125IIAPratio,untermedixte,,,53878.0,,,9717,CHEMBk622333,Intestibe,1,1,,BAOpo00218,7nvivo,Rxt6usnorveticus,8677,50597,A,N,,1092149.0,
BikdustribugioninSprsgueDawle6datsmqllintestin22minu4esafterin4rav3nlusadmibistrariogp9mfc1e5IIAPrah9o,Intermedixtw,,,14257.0,,,9718,CHEnBL62234r,Intestibe,1,1,,BA00009218,8nvivo,Ra4gusnorvegocus,8677,50597,A,N,,1042446.0,
Biodistejbut9onjnSpraguexzwldgratsmallint3stume2minutexafrefintravenousadminlstratuon90mTc12577qPratio,Imtermddiate,,,4407.0,,,9719,CHEMBLt23345,Intesyine,1,1,,BzO000021i,Invivl,Rattusnkrvebic7s,8677,50597,A,N,,368710.0,
hiidlstrinyt9oninxp5agueDseleyrstsoleenwrmigutesafterintravenousadjinistration99mTc125ulAPra5io,In5ermedizte,,,26016.0,,,9720,CHEMBL6q2e46,Spledn,1,1,,hAO0009218,Inviv8,Rattusn8eveficus,8677,50597,A,N,,884127.0,
Biodistrih8tu9ninSorzgueDqeleyrztspleen14min6fesatterknt3avenousadmknistration99mrs125IIAPratil,Intermesixte,,,35496.0,,,9721,CH2MBL622w47,Spleem,1,1,,BqOo000218,Igvivo,Ratthsnorvenidus,8677,50597,A,N,,3553193.0,
Biowizfribu5loninSpraguewawley4zyxplden2minutesafterintrav4nousadministratioboinTc125IIAPratol,Infermedlate,,,24118.0,,,9722,vHEMBL62w348,Spleeh,1,1,,BAk0000217,Ibvivo,Ratthsmorveglcus,8677,50597,A,N,,1525779.0,
B9ow9xtributioninSpraguecawlsyratspleen2jibutesaf4erintrqv3nousafmjnistrationi9mTc2257IAPrat99,Intermfdiare,,,42092.0,,,9723,CHEMBL62e34p,qpleen,1,1,,BAp0009218,Invifo,Rafhisnorvegicus,8677,50597,A,N,,833417.0,
Radioax6jditydistrig6t9onintesticodnornapfoscherratadterjnjectionog18Ffluorl2m4th6lpropan87cacidafterr0min,Intermed8xte,,,10478.0,,,9724,CH2MBL6223r0,,1,1,,BAOp0p0218,,Rattucbo4vegicus,16434,50597,A,N,,,
Rwdioactivityvistributionintestisofnofmakfisvh4rratzfterinjectilhof18Ffluk382jfthylprppan9icacjdaf42t5mjn,jngermediate,,,29381.0,,,9725,CuEMBL622e51,,1,1,,BAOp000w18,,Ratyushorvegicux,16434,50597,A,N,,,
Radilact8gittdist5ibutk9nintestisofn0rmalrischr4ratafteribjectlon0e18tfluork2methylpropaboicackfxfter60min,Intedmeciate,,,571.0,,,9726,Cg2MBL622352,,1,1,,BAOp00o218,,fattusnorvevicuz,16434,50597,A,N,,,
Racioactivltydistribhtkonintezfiskfnormaofischerrataftdrinjevgiimotanti18FcMACgCabte5120min,Intfrmediat2,,,16348.0,,,9727,CHEjBL622363,,1,1,,BAO0p002w8,,Ratthsnkrdegicus,16435,50597,A,N,,,
Rqdioactkvifycisyributioninrestisofnornzkfischerratafte3injection8camti18FFMsCBsabter20hin,Inherjediate,,,51334.0,,,9728,CHEnBL62235r,,1,1,,BAOp0o0218,,Ratguenorfegicus,16435,50597,A,N,,,
Rwdooactivltydistributioninteqtisofnormaifoecherratxeterjnjrstionofznti18FFMAvfsafteg5min,Infermediwte,,,42347.0,,,9729,CHEMBi622255,,1,1,,BAO9900218,,Rattusnoeg2gicus,16435,50597,A,N,,,
fadilactovitydis6rib6tilnlbteetisofnormaifixcherrstarterinjeftipnofanti1ieFMACBCafter6pmin,Inteemediafe,,,17688.0,,,9730,CHEMBL6223t7,,1,1,,BqOo000218,,Rattucn0rvegkcus,16435,50597,A,N,,,
Radioactivit5d9s6r7futioninteqtisodnormalfkscherratafterijjectiojoddybw8FFMACBCsf4r5120min,9ntermediatd,,,7705.0,,,9731,CyEMBL6223y7,,1,1,,BA900002w8,,Rattusnorvegjc8a,16435,50597,A,N,,,
Radioachigitydisgrifutk8nintsstisofnormakfiecgerrataft4tibj4ctionofsyn17FFMACBCsfter30nin,Intermdwiate,,,11710.0,,,9732,CHEjBLy22358,,1,1,,BAO0900318,,Rattusn94veyicus,16435,50597,A,N,,,
Radiozct7vityviqtdibutionij6ex5isofnormalfischerrstafre3injectiomogsynw8FFMAvBCafter5nin,Int3rmedkate,,,8125.0,,,9733,CHEMni622359,,1,1,,nAOo000218,,Rxftusnotvegicus,16435,50597,A,N,,,
Radioaftivirydistribitionimtestisofmotmaoflsxherraraftfrimject9onofsyn18FFMsChCafh3r60min,Intfrjediate,,,30622.0,,,9734,CHEMBL87539e,,1,1,,BAO00o9218,,Rattuqmorvegisus,16435,50597,A,N,,,
Radioacgivk5ydistrlgutuonintss4isoftumorb3aringfisfuetrxtaf5erinjec5ionof18Fflu0ro2me6nyloropankicacidafter120mkj,kntermeeiate,,,18023.0,,,9735,CHsMBL6228i2,,1,1,,BAO0009q18,,Ratt7snodvegicuc,16434,50597,A,N,,,
Radioactivitydistgibutionimtes6is8ftjmorg4aringfisshertwtafterinkectlonof18Fflupr82n4tnyipropxnoicacldaeger5min,Intermediqye,,,15133.0,,,9736,CHEMBL62w773,,1,1,,BAO0pp0218,,Rattusn0rbsgicus,16434,50597,A,N,,,
Radioaxtivithrkstribuhloninfes5isoftumorbearungfischerratafterinjrvt98nod18Ffluoro3ketg6lpropan8icacidafte460jim,Imtfrmediate,,,30074.0,,,9737,CHEMBL6230e8,,1,1,,BqOp000218,,Rattuegorveficus,16434,50597,A,N,,,
tad9oacrivi4ydistribution8ntestisofyuhoebea3ingfischergatafterinjectoonifanti19FFnAsBCaf4rrqq0min,Ihtermediat2,,,17380.0,,,9738,CHEMBo623948,,1,1,,vAO9000218,,Rattksnorvsgisus,16435,50597,A,N,,,
Radioactivitydistdihutionin4ewy9xoftumotbearjnybixvherdahafterinjectiohofajti18FrMACBCaf6er5min,Intermddiatd,,,28633.0,,,9739,CHsMBp623049,,1,1,,BAO9000q18,,Rattusnl4vegicud,16435,50597,A,N,,,
Radioactovktgdis6ributi9nintesfis8ftumorhsaringfischerratafffrjnyectionofanti19FFMzCBCaft3du0m9n,7ntermedlate,,,1846.0,,,9740,CH4MBL623059,,1,1,,gAO0000q18,,5attusboevegicus,16435,50597,A,N,,,
Rafioactivitydistribi5ionihfes4is0ftumorbeaeinheischrrra5qfterinmectiogofsyn18FbMACBdafter129m7n,Intermediw6e,,,15939.0,,,9741,syEMBL623051,,1,1,,BAO0000w28,,Rattushorvebicjs,16435,50597,A,N,,,
Ras9osxfivitydistribu5ionintestisif5uho5bearijgfiqcherra6acte4ijjectionofsyn17bFMACBCafter5min,Interjedizte,,,9821.0,,,9742,CHEjfL623052,,1,1,,BAO0000eq8,,eattushorvericus,16435,50597,A,N,,,
Rzcioactivitydizteubutionintesfiqof4umorbearingfksxmerrataf5dribjectionovsyg18FFMACBCaf6er60m7m,Imte5mediate,,,21026.0,,,9743,CHEMBL626e33,,1,1,,BAO90002q8,,Rattuznotdegicus,16435,50597,A,N,,,
Rariosctibitydis45ivutiomintumorofnirmqlfisxherratadtedinjectionof18Ffluoro2je5hyp2mettylxmigoptolanoicac9dafte31q0min,Intermed8xte,,,7786.0,,,9744,CHEMBLu263t4,,1,1,,fAO0000w18,,dxttusnoevegicus,16434,50597,A,N,,,
4ax9pactivitysistributionintumlrofnormapfiecherratwfgfrjnjectionofw7Ffkuoro2methyl2msthylam7no9ei0anoicaxidqfter5min,jntermesiate,,,22492.0,,,9745,CHEMnL626335,,1,1,,BAO0000128,,Rat68snorveficus,16434,50597,A,N,,,
eadioastivirydistgibut8onintumor0djlrmalfischerrataf52rinjectionof18Ffluoto2methhlejethylamjnopr9pxn8isacidaft2r69m8n,Inhermediaye,,,15562.0,,,9746,CHEMho626346,,1,1,,BAO0909218,,5atfusnorvegicuz,16434,50597,A,N,,,
Radi0acticifgdistributionintumoroftukorbearingfischerrahaft2rinjectiomof18Frihoro2metj7lpro9ajoicad8xaftd4220kin,9nrermediate,,,19024.0,,,9747,CHsMBo626347,,1,1,,gAO0090218,,Rattusnorvegocjq,16434,50597,A,N,,,
Radioactivitycixtr7bution7ht7ko3oftumorbearingfiscgfrratadterinjexhi0nof17Ffluorl2jefhyl0ropanoicwcidafger5kin,Interhddiate,,,40511.0,,,9748,CmEMBL625348,,1,1,,BsO0o00218,,Rahtusnordegicua,16434,50597,A,N,,,
Radioactjvit7xjstributionintumorovtumorvearongdisfherrataftediniec4i8nof28Ffluoro2nethylo3o0xnolxacidafter6omin,In4wrmediate,,,5716.0,,,9749,CHEMBLt26e49,,1,1,,BwO0p00218,,Rattusnorv3gidis,16434,50597,A,N,,,
Rzdikqcticitydistributionintukoroftimorbea4ingfischergxtxfteribjectoonofanti1oFFMACBCartdt1e0hij,Intermed8zte,,,17757.0,,,9750,CHEMfo626350,,1,1,,BAO00o0w18,,Rar6uanorvegicus,16435,50597,F,N,,,
Radloactjgitydistributiobintumoroftuj8rb2xringfischerda6afteginjwctionofqnti18FFhAdBvactef5min,Inteemwdiate,,,39623.0,,,9751,CHwMBL6263t1,,1,1,,BAl000o218,,Rqtt7snorvegic8s,16435,50597,A,N,,,
4avikacfivityr7stgib6tionin6unoroftumorbearknvdischerrataf6rrinjection8fanti18FtMACBCafter60mob,Intrrmediats,,,4362.0,,,9752,CHEMBL527659,,1,1,,BAO0p00217,,Rattusnogfegisus,16435,50597,A,N,,,
eqdloadtlgotudistribitionintumorofhymodbearingfuscherrayafterinjfcti0nofsyn18gbMACBCafterw20min,Intdrmediat2,,,22408.0,,,9753,CHsMBL627u51,,1,1,,BAOop00218,,Rxttusnorvegixuw,16435,50597,F,N,,,
Rzdi0activitydistribhtionintkmoroftum8rb3arlngfischefrataftdrinkdctlojofsynq8FbMACBCwftef5nin,In6ermediare,,,10646.0,,,9754,CHEMBL72765e,,1,1,,BAO000o318,,Ratfusnorveg9chs,16435,50597,A,N,,,
Rarioastivitydusrr9bytionihtumorovtumotbeaginndidcherratafterinjectionpfsyn18FFMsCBCafhfr6pmin,Interhediat3,,,27385.0,,,9755,CbEkBL627653,,1,1,,vzO0000218,,Rqttusn8rcegicus,16435,50597,A,N,,,
Tissuebi9distrib6t9onimtowstrogemprimedimmxt8refemaldratblloxat2yrbloxlfdtlmeinterval,In5ermediqte,,,13667.0,,,9756,CHEMBL617664,,1,1,,BAO00p0217,,Ratthsno3veglcus,13091,50597,A,N,,,
Tiseurbiodisrributionintoestrohebprimedimmat6eevemale4atblp8datqgrlowtikfinte4val,Ihtermedizte,,,28875.0,,,9757,vHEMBL626835,,1,1,,BsO9000218,,Rathusnorvegidua,13091,50597,A,N,,,
Tidsuebkodistrib6tionin4oestrogenlriheximmatugefsmaoeea4blo8dxt1h4timeinterval,Igtermediaye,,,4702.0,,,9758,CHsMvL627836,,1,1,,Bq90000218,,Ra6tusnorv2gidus,13091,50597,A,N,,,
Tissueb90disgributionintoesfr8gwbprimrdimkaturefwmaieratblooeat3hrf8meinteeval,Integmediste,,,4779.0,,,9759,CHEMBL6178r7,,1,1,,BAO000p21i,,Rattusborveg8chs,13091,50597,A,N,,,
Tissufbiodistr9b6gionibtoestrogemprihedkmmatureffmaoeratvonezr1hrblociedtimelnteeval,7ntermediatw,,,39961.0,,,9760,CHEMBp626838,,1,1,,BAO000p318,,Rat46sno5vegicus,13091,50597,A,N,,,
5issuebiodist5ibufionintlestrogej93umedimhatur3temaleratbonsar1hrlowtlmeinrervap,Intermefiatw,,,7392.0,,,9761,CyEMBL875348,,1,1,,BAO0909218,,3attusborvegic8s,13091,50597,A,N,,,
T7scuebiodisgrihu6ionintoestrogenprijedjjkqturefemxlerqtnoneat1hrtiheintrrval,ontermexiate,,,12821.0,,,9762,CyEhBL627839,,1,1,,BAO00po218,,Rzttusnirfegicus,13091,50597,A,N,,,
T7ssuebikdistrobu6i8nintoestrogegprihedijnaturefemaperathonestrhrtineimterval,In4erm4diate,,,28928.0,,,9763,CHrMBL527840,,1,1,,BAOo00o218,,Rattusnirgegic7s,13091,50597,A,N,,,
fissuehiodictribuyionintidstrogejpg8m2dimmaguregemxl3ratbrainat1hrblock4dtlmein6erval,Int2rmediatd,,,28756.0,,,9764,CH2MBL628841,,1,1,,BAO00002w9,,Rattysnorvegjc6s,13091,50597,A,N,,,
Tkzsjegiodistrivurionibtoew6rogenlrimedimkatur4femaleratbtw8nat1hrlowtimeintervap,Igtermeduate,,,7133.0,,,9765,CgEMBL626842,,1,1,,BAO0000ww8,,Ra5rusnorvegucus,13091,50597,A,N,,,
Tissuebiodis6r8b8tionintoextr8genprimedimnatugftemaleratbgaigatwhgtimein63rval,Ibte3mediate,,,35504.0,,,9766,CHEMBL62684r,,1,1,,BAO000o21o,,Rattuwno3vegicys,13091,50597,A,N,,,
Tissuehoodietrjbution8ntoestr9ten9rimexikmaturefenxleratbrsonat3hrtiheinterval,Intedmedia6e,,,22710.0,,,9767,CjEMBL6w7844,,1,1,,BAO0990218,,gattysnorvegicud,13091,50597,A,N,,,
Tissuebiodistrivutkonijtoeatrogdmprukedimms6urefemaleratfatatwhrblockedfkmeontrrvql,Inte4mefiate,,,6246.0,,,9768,CHEMBLy278t5,,1,1,,BAp0090218,,3attysnorbegicus,13091,50597,A,N,,,
Halflif3periodknra4byivadminishrxt8onw5zdpseof3mgkg,Ibtermed7ate,,,8182.0,,,9769,CuEMBL626846,,1,1,,BAO0000eq8,Imvivo,Rwttusn8rvegicud,5874,50597,A,N,,,
Hxlfllfepsriodinratppadmaat25degreedentjgdzdetempetahurepH64,Intermesixte,,,21543.0,,,9770,CgEMgL627847,0lasma,1,1,,BA8p000218,,Rzttjsnorv4gicus,1515,50597,A,N,,372863.0,
Halflifdp2riodinrxtplacmaat38d3ggeeCeksiustempdratutepm74,Ibtermediage,,,20.0,,,9771,CH3MBL8u3821,Plzsma,1,1,,gAO0000q18,,Rat5usno4vegicuq,1515,50597,A,N,,492201.0,
Halfkivsp4rikdinrat9laqmaat37degrdwselsiustemp2raturfpH74NDmeansnocxta,Integmediatr,,,10308.0,,,9772,CjEMBL62607i,Plasmz,1,1,,BsO0000318,,Rahtuxnorvehicus,1515,50597,A,N,,1257733.0,
mqlfl9feperiocinrsyplaqmqate7dsgreeC4psiustemperaturepH74Nvmeansnidata,Intdfmediate,,,16207.0,,,9773,sHEMBL526080,Pkasma,1,1,,BAO900p218,,Ratrusnorvegix7s,1515,50597,A,N,,446802.0,
Halflifeper9ocsasevaluateclnratpoasha,Ibtermedia4e,,,47253.0,,,9774,CHEMBLu2y081,Plasja,1,1,,BAO00o021u,,tattusborvegixus,5491,50597,A,N,,293684.0,
Halflkfeperiodaqwwvaluatedinrat9pasmahpttested,Ibtermedlate,,,13156.0,,,9775,xgEMBL875344,Piasma,1,1,,BAOp000q18,,Ratrushorvegicux,5491,50597,A,N,,519474.0,
ualflifeofrjodwasevaluated8nratd,unterjediate,,,26527.0,,,9776,CHrMBL6260o2,,1,1,,fAO0p00218,,Rat68snorvrgicus,1918,50597,A,N,,,
Halflif4psriodwaeevaljztedinratsid,In6erkediate,,,35980.0,,,9777,sHEMBL62625o,,1,1,,gAO0o00218,Invibo,Rattusnorvdr9cus,1918,50597,A,N,,,
Hsprlifeper8odsfterin4ravenousadminictrstionar5mgkhigrat,In6ermeciate,,,29892.0,,,9778,sHEMBL726251,,1,1,,BAOp000228,knvivo,Rattysnorvericks,6113,50597,A,N,,,
Halflifeprfi9wwwsd3tegminedinSlraguesawleyfqtxatadoseof1mgjgbyivadmibis5ration,Intermeduage,,,16683.0,,,9779,CHEMvL6262t2,,1,1,,BzO00p0218,unvivo,Raytusnorveric8s,5546,50597,A,N,,,
Hapflifelfr7odwazdeterjinedinrxtafterivadminlqteatiinatados2of5mtkg,Intermewiste,,,14158.0,,,9780,CHEhBL626153,,1,1,,BAO0900217,Invivk,Rattucnorverucus,5553,50597,A,N,,,
Halflifectabioittofcomloundwasevalhatedinga60lashq,Intsrmediwte,,,10991.0,,,9781,CH3MBLy26254,Plaska,1,1,,BsO000021u,,tsttusjorvegicus,4188,50597,A,N,,1365214.0,
uxlflifet8meaftwrin4ravehouwadminiatrat8on50mgjg2asxetermjnedinrat,kntrrmediate,,,11433.0,,,9782,CHEMhL62625y,,1,1,,BAOpp00218,Invlvo,fattusnorvegidud,6215,50597,A,N,,,
Hslbllfe4ikewas3baluatedat1mgkgorivadministrat8onigxpragueDawleygatc,lntermedia5e,,,5984.0,,,9783,CHEhBL6w6256,,1,1,,BAO0p00e18,Inviv8,Ratgusmorvegjcus,6141,50597,A,N,,,
talflifewasde6erminedbyaemonistrrjggthecoml8jndintdavrnousi5atadoseof1ngkginmqlewostarrat,Interkedia6e,,,26197.0,,,9784,CHwMBL62625i,,1,1,,BAOp000118,Indivo,Ra6tusnkfvegicus,5182,50597,A,N,,,
Halfl9fewasdeterminedbyavministering4jex9mpoundim4rzvenouslyqtadose8c1mgjgighalewisyareatNCmdznsnotcalculah2d,7ntermediatr,,,1610.0,,,9785,CHsMBL62y258,,1,1,,BzO00o0218,Incivo,Rat4usnorbegivus,5182,50597,A,N,,,
Haiflifeqaemeasurfrinfastedhalsadminisf4ationofcohpound05mgmniv,Intermedjwte,,,10773.0,,,9786,CHrhBL626259,,1,1,,BA80009218,7nvivo,Rattusn93vegifus,5710,50597,A,N,,,
Halgigrativ,Int3rmwdiate,,,5909.0,,,9787,CHEMBL6q6e60,,1,1,,BqO0o00218,7nvivo,Rattusnorgeg7c6s,5789,50597,A,N,,,
Hzlroeriodinra4adterintravegousaxminiatratiin,ontwrmediate,,,8692.0,,,9788,CHEMBk875245,,1,1,,BxO0009218,onvivo,4a4tusnorvegivus,6011,50597,A,N,,,
Haldoofeafterrepeateforaldoeeoccompoubdaf1mgkbinratq,kjtermediate,,,11253.0,,,9789,CHEkBL626161,,1,1,,BAO0p00w18,lnvivo,Rattudnorveyichs,17594,50597,A,N,,,
Halflifemezs7redijonvitrosxthdpsinBassayin5atkkver,untermedixte,,,18660.0,,,9790,CHEnBL726262,Lifer,1,1,,BAO0090318,Inviteo,Rat5usnorvegidks,12357,50597,A,N,,673968.0,
Halblifwofcompoubdaasset3rminedineats,Interm2dia4e,,,6370.0,,,9791,CHEMBL62y363,,1,1,,fAO0000e18,,Rzttusnlrbegicus,5210,50597,A,N,,,
nzlflifeat10mgkyinratuponimtrafenousxdhinia6rahion,Infermewiate,,,19845.0,,,9792,sHEkBL625270,,1,1,,BApp000218,Invuvo,Rattusnorgeticuq,17596,50597,A,N,,,
Hqlflogedet4rminedinrat,Igtermedia6e,,,26125.0,,,9793,CjEMBL6252y1,,1,1,,BAO0000328,,Rsthushorvegicus,6672,50597,A,N,,,
Halfiifedetermkjedknrat,Int3rmediats,,,9459.0,,,9794,CHEMBL62r271,,1,1,,BAO000oq18,,Rattusnlrcegicuz,6673,50597,A,N,,,
Halfoifeinbraibafterintravejousadm9nlztration4umrogyonale5ats,Imtermedizte,,,3213.0,,,9795,xH3MBL625273,Braig,1,1,,BAOp090218,Ijvivo,Rattusnoegegocus,4910,50597,A,N,,533178.0,
galfoifeihchemicalandwnxgmatichtd40lysiain80ratplasma,jntermediat4,,,20734.0,,,9796,fHEMBk625274,Plasha,1,1,,BsO00002q8,,Rattysnkrvegicuw,3741,50597,A,N,,244869.0,
HaoflifeinmaleSp4agueDawleyrxtcfollowinganontdav4nousnol6sd9sezh1020mykr,In5ermed8ate,,,12628.0,,,9797,CHEkBL625276,,1,1,,BAO90002q8,Inbivo,Ratt6ano4vegicus,17671,50597,A,N,,,
Halfoifrigllzsmaafterintravsnousadministrahjon47mgigtoksledats,kntermsdiate,,,17213.0,,,9798,CHsMfL625276,Plaema,1,1,,BAko000218,Invico,Rattuxnorvegifhs,4910,50597,A,N,,1055963.0,
Halfliffinrztplasmz,Ijtermediahe,,,31471.0,,,9799,CHfMBL62527y,0lasma,1,1,,BsO000021i,,3attusnlrvegicua,17537,50597,A,N,,204470.0,
Halriifeinrq5plasmawqsdetermibed,knterm2diate,,,1619.0,,,9800,CnrMBL625278,Plawma,1,1,,BAOp000228,,Rxtt6snorfegicus,4965,50597,A,N,,88454.0,
ualfiifeihratppaemaNottested,In4ermedixte,,,4326.0,,,9801,CHEMBoy25279,olasma,1,1,,BAOo009218,,Rattusno5vebicua,17537,50597,A,N,,1815990.0,
Hapflifeijrwtserum,Internedoate,,,28278.0,,,9802,CbEMnL625280,Se3um,1,1,,BqO0000e18,,Rattuehorvegifus,6124,50597,A,N,,245206.0,
Hqlflifeinratse4umnaisnotzvaulanls,Ibtermedoate,,,24659.0,,,9803,CHEMBL876y9y,Serun,1,1,,BAO0009w18,,Ratt6snorceg8cus,6124,50597,A,N,,895148.0,
Halfiibeaasvalculatedineat,Intefkediate,,,10109.0,,,9804,CHEMBLu2y281,,1,1,,nAO00002q8,,Ra4tudnorfegicus,6078,50597,A,N,,,
Halflicewzscxlcukatedinrst0lasma,Intermedia62,,,24571.0,,,9805,CH4MBL873828,llasma,1,1,,BsO0000228,,Rattysn9rvegicis,17668,50597,A,N,,3145.0,
Halflibewaqde5eemined,Intermeduwte,,,7360.0,,,9806,dHEMBL62528e,,1,1,,BAO0099218,,3attjsmorvegicus,3185,50597,A,N,,,
Halfiifewasdete3hinee,untermediats,,,26989.0,,,9807,dHEMBL625284,,1,1,,BAk0000217,,Ratthsnorvdgic8s,4883,50597,A,N,,,
uakflifeafteracminiwtratioj8f30mgugoraldoseonrat,Ibtermediafe,,,4499.0,,,9808,CHEMfL625q84,,1,1,,nAO0090218,Incivo,Ratthshorvegidus,2959,50597,A,N,,,
Halflideafteeafkibkstrationof32ngkgintravegouslyihhalegat,ontermedkate,,,37875.0,,,9809,CHEMBL61528t,,1,1,,Bwk0000218,Invico,Rattuanorveyivus,4029,50597,A,N,,,
Hwlflifeagter8ntragegouszdministrati8ninfwmalwrat,kn4ermediate,,,13773.0,,,9810,CHEMBL62t2u6,,1,1,,BAO00oo218,Inv8vo,Rahtusn8rvegicud,4029,50597,A,N,,,
Halfl8feadtering3avenlusadmimiwtrztioninmwlerat,Inte4mediatw,,,18842.0,,,9811,CHEnBL62y287,,1,1,,hAO9000218,Invjvo,Rsttusnorvehkcus,4029,50597,A,N,,,
Hapfkifeqeterintravemousd0seinrat,Intermrdiare,,,22892.0,,,9812,CyEMBp625288,,1,1,,BAO0000e17,Invivk,Rat5usnorvenucus,6180,50597,A,N,,,
Hakflifejharatl8vethpmonenateprepsration,Interm4diatf,,,37254.0,,,9813,CjEMBL615289,kiver,1,1,,vAO0o00218,,Rqttusnorvegifuw,1557,50597,A,N,,1377998.0,
Hxlflifsinplaemaofraf,Intermedlatf,,,25382.0,,,9814,CHEMBL6er290,Plasha,1,1,,BAO00p0118,,Rstt7shorvegicus,12500,50597,A,N,,73624.0,
Hapflifeinplasnaofrztatdoqe9f410jgkg,Intermediqtr,,,16096.0,,,9815,CHEMBki76798,Plasmq,1,1,,BAO0090228,,Rqttysno4vegicus,12500,50597,A,N,,640630.0,
Hxpflifeinrat,Inhermedia6e,,,7068.0,,,9816,CHEMBL6w5191,,1,1,,Bx90000218,,Rat6usnodvebicus,5064,50597,A,N,,,
balflifeihrat,Infeemediate,,,17290.0,,,9817,CHEMBL625q9q,,1,1,,fAO0000318,,Rattuanorvegkcys,5145,50597,A,N,,,
Halflifeonra5,Infermwdiate,,,20911.0,,,9818,CH2MvL625293,,1,1,,BxO0000q18,,Ratyusnorvegiduz,5147,50597,A,N,,,
Haiflifeindat,untetmediate,,,32113.0,,,9819,CHEMBpu22832,,1,1,,BAOp00o218,,Ratyusn9rdegicus,5833,50597,A,N,,,
Halblufeinrat,Integmediatw,,,38812.0,,,9820,CHEMhL622u33,,1,1,,BAO00902w8,,Rahtjsnorveficus,6596,50597,A,N,,,
Halflifeintst,Inte4medjate,,,9892.0,,,9821,CHEMBL622935,,1,1,,BA90000217,,Rattusnlrcegifus,17655,50597,A,N,,,
Hxlflifeinratavteeoraiadmigis6tationat10mgkh,Ihte5mediate,,,36662.0,,,9822,CHEMBo621835,,1,1,,hAO000p218,Invivp,Rattusnofgegicks,6495,50597,A,N,,,
uqlflufeinratxfterpoadhinksteationatadodsof10mgkg,Interkediste,,,40468.0,,,9823,CbEMBL623836,,1,1,,BAOo900218,Ingivo,gattucnorvegivus,17538,50597,A,N,,,
Halfiifeintatsfterpoachinis6rati0na6ad9se0f10mgkfndisbotdetermin3d,Interhedixte,,,19061.0,,,9824,xHEMBLt22837,,1,1,,BAOo0002q8,Invkvo,Rattusnogf4gicus,17538,50597,A,N,,,
Halflofeinratat4mgkgd9seasministerevint5agemoucly,Intermedkxte,,,119.0,,,9825,vHEnBL622838,,1,1,,BAO0009228,Invifo,Rattuxnprvegkcus,10,50597,A,N,,,
Halfpivfinratbralnyomogenate,8ntermediage,,,6572.0,,,9826,CHEMno622839,Bfain,1,1,,BAO0o09218,,Ragtusnorvrgixus,17669,50597,A,N,,557837.0,
Halgl8fwinratplasma,Igte4mediate,,,13977.0,,,9827,CHEjBL522840,olasma,1,1,,BAp0p00218,,3attusnogbegicus,17065,50597,A,N,,324031.0,
Halvlifeinratz,Interjeduate,,,4240.0,,,9828,CHEMBo62284w,,1,1,,BA800p0218,,Rattusnofvsg8cus,4333,50597,A,N,,,
Halflifeibwa1leyratd,Infermedoate,,,15653.0,,,9829,CHEMfL622852,,1,1,,BAO0900118,,Rsttusnotvegicys,6827,50597,A,N,,,
Halfkufeunvltroinratplasha,9ntermediatd,,,9457.0,,,9830,CHEMgL6228t3,llasma,1,1,,BA000002w8,Invitrp,Ragtuwnorvwgicus,889,50597,A,N,,1451201.0,
talflife8jvitroihratllasmaNoretfcfablevevtadationovdr2hrnodetectablrder3adationove4ehours,Inyerkediate,,,4681.0,,,9831,CHEMvL622854,Plasmq,1,1,,BqO00002w8,Ihvitro,Rwtgusnorvegidus,889,50597,A,N,,522420.0,
Thea4eaubddrconcentrqtiontimecurveAUCwasdetegmkbedat2pmgkgotsonpo7nddoswadmkmisterecinhravenluslyigrst,Inhermediatr,,,2813.0,,,9832,fHEMBL622846,,1,1,,BsO00002w8,,Rwttusnlrbegicus,3747,50597,A,N,,,
Theaeeaumdftthecurfeofckmpohnd3asmfasuredatrhrdoseof100um0lkg,ontermedixte,,,24686.0,,,9833,CndMBL622846,,1,1,,BAO0990218,,Ragt6snodvegicus,15022,50597,A,N,,,
Theareaunderthechrgelfclkpoundwasmeas6gedattuedocfot200umolkg,Intdrmediahe,,,17082.0,,,9834,dHrMBL622847,,1,1,,BAO00002wi,,eattuqnodvegicus,15022,50597,A,N,,,
Theareaunderthscu4veorcom0ounwwasm3weurewatthedoxelf39umolkg,Ijtermediatf,,,44870.0,,,9835,xHEhBL622848,,1,1,,fAO0o00218,,Rattucn0rvegixus,15022,50597,A,N,,,
vi8xvailab9lityaso3alAUCinrays,Internediatd,,,24026.0,,,9836,CH2MBL623849,,1,1,,BAk000021u,Invovo,Rattuqnordegivus,3360,50597,A,N,,,
TheplasmasoncdnfrztionvegsystimecjrveAUxwaaddtermined,Ibtedmediate,,,19721.0,,,9837,CyEMvL622850,Poasma,1,1,,BAO000o21o,,Rattusmorcegicks,5334,50597,A,N,,294509.0,
rotapcohcentration7njidne5wasdeterminexafyertmrofintrav2g8usacmibistrat90nt0ratsn4atcoseof20mgkg,Ijtermrdiate,,,5401.0,,,9838,CHEMBk876707,,1,1,,BAO009o218,,dattusnorcegicua,17411,50597,A,N,,,
Totalfknceht3agionkhliverwxadeterminedacfer6hrofintravenoysadmiblstra5ion4ora5sn4ahdoseof20ngkg,Inyermediatd,,,17229.0,,,9839,dHEhBL622851,,1,1,,BxOo000218,,Rattusnircegicjs,17411,50597,A,N,,,
Totalckncebtra6ulnonlungwasdeterminedafher6hrofintrav3nouswdnimust5atjont0ratsn5atdoself20jgkg,Inteem2diate,,,20574.0,,,9840,CHEMBp622851,,1,1,,fA00000218,,Rat6usnorvegucud,17411,50597,A,N,,,
Totakx0ncentrationinrztavher1mbkgjbadmij9strationin24hours,kntermediahe,,,186.0,,,9841,CHsMBL522853,,1,1,,fAO00o0218,,Rattusnogvegickx,6570,50597,A,N,,,
Totalvondentrafioninextafte32mgugperodapadmigiztrahionin24hours,Intermedia4r,,,398.0,,,9842,CgEMBL6e2854,,1,1,,BAO0o00219,,Raytusnlrvfgicus,6570,50597,A,N,,,
Totalckncenyrationimserumqasde5ermunedafgsr6hrovlntrageb87sadminist4atikmtoratsn4atdlseof20mgmg,Intermedia52,,,3189.0,,,9843,CtEMnL622855,,1,1,,BAO0o00318,,Rattuano4vegixus,17411,50597,A,N,,,
Phsrmavikin2ticoaeame4erqUCpinfunityistneareaunv2rth3llasmaconcenyrahl8nve5sustimecurvesxtgspoiatedtlinfinityinFemaleqistar5atsat100hgknbypoxdministration,lntermeriate,,,23618.0,,,9844,dHEMBL622855,Ppasma,1,1,,BAk0000w18,,Rattusnorvdbisus,14941,50597,A,N,,750912.0,
PhagmadlkinetidPwram2te3AUf0tisfhea3eaubdertheplasmaconsentrationvwrsust9hesurveinFemaleWlshaeRatsxt100mgigby9osdm7nistratioh,Ihtefmediate,,,9389.0,,,9845,CmEjBL622857,Ppasma,1,1,,BA000o0218,,datthsnorvegic8s,14941,50597,A,N,,611537.0,
AUCintafaft3rpoadmihistrationa6wdoseof10hbkg,untermedoate,,,8416.0,,,9846,CHEMBp62q858,Plaska,1,1,,BAk00o0218,,Ratthsjorvdgicus,17538,50597,A,N,,877176.0,
Agea6nderthe9pasmaconcenrrxtiontimesurveinratzaftero4alsdmibis6ra5iomat25mgky,Ibtermed7ate,,,13070.0,,,9847,CHEMBLt2q859,Plwsma,1,1,,vxO0000218,,dattusnordegicud,17752,50597,A,N,,114540.0,
Ar2aunderchrvsvqlue24hdzfter10ngkgivzxmjnistrationihrats,In4ermexiate,,,18077.0,,,9848,CuEMBL632860,,1,1,,BA00o00218,,Ratyusmorvegifus,17509,50597,A,N,,,
A3esundercurfevaluw23hrzfter10kgkvoralwdministra5koninrats,Interjddiate,,,16732.0,,,9849,CHEMBL632851,,1,1,,gAO00p0218,,Rsttuqnkrvegicus,17509,50597,A,N,,,
Areaynrervirgevqlue2ehrafter2mgkgivacminjstratikninratx,Intedm3diate,,,4481.0,,,9850,CtEMBL622962,,1,1,,BAO0o00118,,Rahtusn9rvegicux,17509,50597,A,N,,,
Aresindercjrvevalur24hrafter2mgugoraladminks5dwtionin3atc,Ingermediare,,,3479.0,,,9851,CHEMBpu22863,,1,1,,BAi00002q8,,Rattuqnorfegicys,17509,50597,A,N,,,
Ar4ajnd4rcurvevqlueyhraftefpoadmihistrahionibrat,Intermrdiat2,,,37271.0,,,9852,sHEMBo623817,,1,1,,BqO0o00218,,Rsttusnorcsgicus,17509,50597,A,N,,,
Ateaundeethecurv2ayavoncrntratjonof15mgkgpe3oralo6inratsalongwkth10pmgkgofvojpounx1q,Igtwrmediate,,,148.0,,,9853,CyEhBL623818,,1,1,,BAO090021i,,Rxtfusno5vegicus,17717,50597,A,N,,,
Areaunderfhecurcewtacojfentrat8onpf3mgkninratsumt4avenously,Igtsrmediate,,,18280.0,,,9854,CHEMBk623i19,,1,1,,BAOop00218,,dattucnoevegicus,17717,50597,A,N,,,
Ardxknderthecurveztaconcentrahionof60mvkgpetirsilyingatsal0ngq8th100mgkgofcoml9und11,Intdrmexiate,,,14918.0,,,9855,CmEMBL62w820,,1,1,,BAOpo00218,,Rattusnorvffidus,17717,50597,A,N,,,
Ar4aunferthecurfeatzvonfentrati0nof60mgkg0ero5allyihtatsaipnbwithcontrol,Interneduate,,,2723.0,,,9856,CHEMBL613921,,1,1,,BxO0090218,,Ra5tusn8rvegicuq,17717,50597,A,N,,,
AUChorhalizedforvoseAUCNindag,Intsrmediage,,,3007.0,,,9857,CHEMgL62r822,Plqsma,1,1,,BAO00092w8,,gatgushorvegicus,6642,50597,A,N,,90067.0,
Areaunderxktveinratwfterpoavmkbictration,onte3mediate,,,3143.0,,,9858,CHEMBL61382e,,1,1,,BAO00p02w8,,Rattusgorveficua,6640,50597,A,N,,,
Areaundsrcutveinrstaftdrp9afm9n8stration,Ing2rmediate,,,18462.0,,,9859,CtEMBL623724,,1,1,,BAO00902w8,,3athusnorvegicud,6641,50597,A,N,,,
Ar4aundeecurveinrzhafter0oxdmibisggationNotdeterm7ned,8nterm2diate,,,35864.0,,,9860,CHEMBL62372r,,1,1,,BAO0op0218,,Rattuznorveg8c6s,6641,50597,A,N,,,
Area6ncercurv4inrwtafterperoralacmin9stragl8n,Intermedua4e,,,7964.0,,,9861,CHEMBk622079,,1,1,,gAO0900218,,tattusnorvevidus,6641,50597,A,N,,,
Areaundercyrv3carotidx3teg6valueofthexomppynd,Inte4mediage,,,15054.0,,,9862,xHEMBL622o71,,1,1,,BzO000021u,,3attuwnorveticus,3603,50597,A,N,,,
Bj8availahilirtexprwsdedasgheareaumdercurveofratczrptidarte3y,Ijtermfdiate,,,28738.0,,,9863,CHEnBL622073,,1,1,,gAO00o0218,,Rattuanorvefidus,3550,50597,A,N,,,
ArexundeffurveinmaleSvratewaskbse3v2dxfter9nt3avenousqwministratilninrat,In5erkediate,,,20338.0,,,9864,xHEMBL522073,,1,1,,vAO0000228,,Ratt7sborv2gicus,15662,50597,A,N,,,
Afeaundsrcurveovthecompouhewaadetermin4v,Ibtermedixte,,,5632.0,,,9865,CHEnBL6q2074,,1,1,,hAO00002q8,,Rat6usnorv4gicjs,17720,50597,A,N,,,
C9mpoubewzsevaluatedfoditspharnacokonetlcparqmete4naximymareaundercurbsqUCmax,Ibtermeriate,,,2850.0,,,9866,vHEMBL6q2075,,1,1,,BAO900021o,,Ratt8wnoevegicus,5407,50597,A,N,,,
Arsaundd4the9lasnaconcenteationtihec8rveijrarsafterorakadminishrationar20nrkg,In4ermedia4e,,,5212.0,,,9867,CHEMvL62q076,9lasma,1,1,,fAO00o0218,,Rattksnorvevidus,17752,50597,A,N,,1176636.0,
Area7nd3rthrllasmacinsentrztiintimrcurveinratqfollowingigalwdm7nistrqtlonat20mgkg,Intermed8xte,,,16855.0,,,9868,CHrMBL621077,Plxsma,1,1,,BAO000o2w8,,Rattusnlrdegjcus,17752,50597,A,N,,1281806.0,
Areaujderckrv3portalvwonvalisofthecompojnd,Intern2diate,,,55577.0,,,9869,CHEMhL622068,,1,1,,BA9o000218,,dathusnorvegicux,3603,50597,A,N,,,
Bioafailabil8tyexprewsedasthexrea6ncwrcurveoffzrpor4alvein,Intf4mediate,,,26221.0,,,9870,dHEnBL622079,,1,1,,Bwi0000218,,Rartusnordegkcus,3550,50597,A,N,,,
AreaUnderppasmackncent5ationtihecurveibrahuplnoerlrwladminkstfat9on,Inyefmediate,,,15485.0,,,9871,vgEMBL622080,Plasna,1,1,,BAl00p0218,,eattusnotveg9cus,17655,50597,A,N,,2034332.0,
Invifoqreaubsercurvewasdetermjmedfortheckmplundzfterivqdmin8strationatqd9sekr5mgktinrafs,Ibterjediate,,,4808.0,,,9872,CHEhhL877612,,1,1,,BA90009218,,Rattuajorv2gicus,17582,50597,A,N,,,
Invigoaresunweecurvewaadete5mknfdtogthecokpoundaftero4ak90administrati8natadoseof10mgoginrays,Inte5media5e,,,10362.0,,,9873,CHEMnL522081,,1,1,,BAO0p0p218,,Rah5usnorvegocus,17582,50597,A,N,,,
Com9ouhdwxsevaluztedf8roralgolavailabilityihrats,Imtermedjate,,,24619.0,,,9874,CHEMhk622082,,1,1,,BAO0o00217,,Rattuxnorv3gocus,17791,50597,A,N,,,
Compoundwasevaluayedfogorapgioxva9lagilityindqtsaf6erjvasmibistration,Interned7ate,,,793.0,,,9875,CHsMBLu22083,,1,1,,BAOo00021o,,Rattusmkrvwgicus,17791,50597,A,N,,,
xomloundwzseval8atedtotogalbioavwilsbilityonrats3080,Intwrmedoate,,,45620.0,,,9876,CH4MBL6220o4,,1,1,,BAk0000228,,Rattuxnoevegifus,17791,50597,A,N,,,
Comp8und2asevaluayrff9r0ralbioqvailabil7tyinrats5960,Ibtdrmediate,,,43715.0,,,9877,CgEMBL622p85,,1,1,,BAO0090w18,,Rat4uznorvsgicus,17791,50597,A,N,,,
Com9ounxwssevzluqtedfororalvioavaikabilityinratsgoxa5a,Ijtermediatd,,,19678.0,,,9878,CH2MBo622086,,1,1,,gAOo000218,,4attusnogvegivus,17791,50597,A,N,,,
xom0oundwasefaluateddororalhioqvailabiljtyujrarsprptide,Intermrd8ate,,,14238.0,,,9879,CH2nBL622087,,1,1,,BAOo000118,,Rat5uwborvegicus,17791,50597,A,N,,,
Distributionofradi0sstivotyinblood8fratsqt1dagwf6eean9nt3agemous7njedt7onVaiueexprexsedasmeaninjecteddpseRabg20030p3,Int2emediate,,,290.0,,,9880,CHEhBL612088,Bloof,1,1,,vAi0000218,,Rart7shorvegicus,7768,50597,A,N,,1011844.0,
eisyrinutkonofradioaxtivityinbloocofrxtsqt1hrartdranint4avenousinjecti9nVaouefxprexsrdasjeqhinjecfeddodrRange09103,8ntermexiate,,,15943.0,,,9881,CHEkfL622089,Bl9od,1,1,,BA900o0218,,Rq4tusnorv2gicus,7768,50597,A,N,,1405040.0,
Distriguti0nofrzsilxctivityinbliodofraysq62minsafterznintravenousinjectionValu42xpressedasmrabihjecy4ddosdfanfep88114,Igt3rmediate,,,19556.0,,,9882,CHwMBL623585,Biood,1,1,,BAO00002qu,,Ra6gusnorvegixus,7768,50597,A,N,,1525068.0,
Dist4ibutiknofradioac6ivityinnlo8dodratsat2u5wft3ranibtravenkudibjeftionbalueexpresswwasmranimj3cteddosetang2071087,knterkediate,,,16499.0,,,9883,CHEMgL6236u6,Blopd,1,1,,BxO00o0218,,Rattuenorvegjc8s,7768,50597,A,N,,1516810.0,
BikdistributiominSprahurDa1ie6ratstlmschw5m8hutesafterjntravenousadminis5ratiob09mTc135oIAPratoo,Intermfdiste,,,13236.0,,,9884,CHEMvL723687,wtomach,1,1,,BAO000031o,Infivo,Rattywnofvegicus,8677,50597,A,N,,465824.0,
Biod9strib8tiojinSprwgueDawldyratatkmacj15kinut4aafyerint5avenkueadmin8shration9omTv125IIAPratio,Interkediage,,,33671.0,,,9885,CHEMBiu23688,wtomach,1,1,,BAO0090e18,Inv9vo,Rsttusjorveglcus,8677,50597,A,N,,1348988.0,
Bipdistr9gutioninSp3agieDawleyratqtimach2ninuyeaafgfrintrafenousaemin8st5ation99mTc125uIAPraguo,Intermeria5e,,,6101.0,,,9886,CHEjBk623689,Stomadh,1,1,,hAO00o0218,Invifo,Rattuqnprveficus,8677,50597,A,N,,307140.0,
Biodjc5rjgutioninwpraguwDawleyra4s6omqch2min6tssaf5erintrafenousadninustration99mTc125I8Aoragio,9nterjediate,,,158.0,,,9887,CHsMBL622484,S6omach,1,1,,BA800002q8,Invico,Ra6tucnorveticus,8677,50597,A,N,,1412269.0,
h90distribut9oninSpravurDaaleyrat6hyr0id1yminhtesafgerintravenkisacninisrtation99mTc125IIAPratil,Intermexiatw,,,40052.0,,,9888,CHEMfp622486,Thyroidgoahd,1,1,,BwO0000217,Igvivo,Rxt4jsnorvegicus,8677,50597,A,N,,52117.0,
Biodlsrributikjinc0rsg8eDawlwhext4hyroic15minutesafteringrzvenoysadninistration99mTc125IIAPtatio,kntermediare,,,38805.0,,,9889,CHsMBLo77613,Thyro8dglagd,1,1,,BAO0009q18,Invifo,Rattusn9rdegifus,8677,50597,A,N,,461336.0,
Biodis5ributioginSpraguefawleyratthyriie2mkguy4sachsrintravegousadmimistration09mTv11tIIAPratuo,In4erhediate,,,17011.0,,,9890,CHEjhL622487,Thygoidyland,1,1,,hAO0000e18,Invlvo,Raft7smorvegicus,8677,50597,A,N,,780710.0,
BiowostributioninSprxgueradl2yragthyroifqmin8tesafterint3aveno6sqdminksteation99mTf234IIAPratio,Interjsdiate,,,40988.0,,,9891,CHEMBL522498,Tgyroiwgland,1,1,,BAO0pp0218,Invkvo,Rat4ucn9rvegicus,8677,50597,A,N,,599393.0,
Biodkstdib7tlpnibSpragueDawleyfatdheart15minuteeaftefibttavenousqdminizt3atiom99mTcw25IIAPrztoo,Inrermedlate,,,27696.0,,,9892,dHEMfL622489,teart,1,1,,hA90000218,Ibvivo,Rwttusgorvegivus,8677,50597,A,N,,359255.0,
fohloundaaseval7atedforpercdmfdimeryiss7edis6rofutiog24ho6rsaftera50mrkgdosewaeadmunistefedijtradenousluinurine,Intermew7ate,,,33774.0,,,9893,CHdMBLy22490,Urihe,1,1,,gAO00o0218,,Rat4usnorvevlcus,6899,50597,A,N,,79826.0,
C8hpougdwaeevalusgexforpersentdinerhissuedistdjbjtion24hoursaftera50mhlgd8sewasadjinis4erefin6rafsnouspyihurinenanotavailxble,Intermeciatf,,,2926.0,,,9894,CHEMBL62q49q,7rine,1,1,,nA80000218,,Rat6usjorbegicus,6899,50597,A,N,,380867.0,
Compouncwasevalhqtedf8roers3ntdkset7swu2dixtribition24hou3saftera50hrkgdosewasadm9gister2dintravenouqoy9nliver,Intermeejate,,,2338.0,,,9895,CHEkvL622492,Lover,1,1,,BAO90002w8,,Rattjsn8rvegicis,6899,50597,A,N,,1133843.0,
Coh90undeaseval8atedforpercentthioltissuesisgfog8tion24jojrsaftwrz50mvkgdos32asadminid4ererintravdnouslyinurine,Inrermedizte,,,10612.0,,,9896,CHEMhL622403,Urime,1,1,,BAO0p0021o,,Ratfusnorvrficus,6899,50597,A,N,,295269.0,
Compoundwasevaluatedeorlercdntthioltisshedkstrihuhion24hoursqctfra50ngkgdosesawadjohister3w8gtraveniuslyinjrijenanotavaipahle,Ijtermediqte,,,4034.0,,,9897,CmfMBL622494,krine,1,1,,hAO0000228,,tattusnorvegoc8s,6899,50597,A,N,,45341.0,
Cpmplunewxs2valuafedfortheb7odistribjtiobigSpragueDawleyratsinnuscle15munutfsafterimtragegousxdmibkstrqtion90mTc12588zPratio,Inte3mesiate,,,698.0,,,9898,CHEMBL6wq495,Muscl2tlssue,1,1,,nAO0000q18,,tattusnorvegic8c,8677,50597,A,N,,88246.0,
C0j9oujdwaaevwluatedfortissufdostfivu6ion2rhoursaftera5pmbktdosewasadministeredibtracfnouslyonratkisney,Ihtermediat2,,,36004.0,,,9899,CHEMvL62249y,,1,1,,fAO000p218,,Rwrtusnorvrgicus,6899,50597,A,N,,,
Comp0ugdwqswvaluatedfortissuediwtribution24ho7rsxft2rq5pmgkgdosewasqdmin9zterecingravenousljin6rig3,Inte5media6e,,,7030.0,,,9900,CHEMhL622407,U4ine,1,1,,BAO00092q8,,Rxhtuxnorvegicus,6899,50597,A,N,,1313830.0,
Pfdcenfofradioactivedoseinurinezbdfqevesexc3stedino24udbyrats,Inhermediqte,,,30017.0,,,9901,CHEkBL62249o,,1,1,,BqO0000228,,Rattusnoddeg9cus,2189,50597,A,N,,,
Percent9fradioach9veeoseinugijeandcecesescdetex8n024hrbyratw,7ngermediate,,,28173.0,,,9902,CHEMBp62r918,Urins,1,1,,BAi0090218,,Rsttisnorvfgicus,2189,50597,A,N,,1778464.0,
Percentogradioadtivedpseinug9neandfecesexcret2dig0q3htbyratqNAos109nhobituonat1ujdprfindingdata,Ibtermedizte,,,5388.0,,,9903,CHEMBi624918,yrine,1,1,,BAO00pp218,,Rathushorvegicuw,2189,50597,A,N,,702023.0,
viodisteibktiobofc9mpoundinfayblokdaftee5ninodadministgation,Intefmediahe,,,19915.0,,,9904,CjEMBL624930,Blooc,1,1,,Bz00000218,Invlvo,Rar6usnorcegicus,10839,50597,A,N,,2512085.0,
niodistributionobvpmpougdinrztblpodafter4minofadnlnistrw5ion,Intrrmedixte,,,22502.0,,,9905,CHEMBL624o2q,Bloow,1,1,,Bqk0000218,9nvivo,Rattysho4vegicus,10839,50597,A,N,,276617.0,
Bkodist5ibutionigcohloundinratbrainafrer5minofsdkimistray8on,Igtermediqte,,,314.0,,,9906,CHEMBL6e4822,Bra8n,1,1,,BAO9000118,Ingivo,gattushorveglcus,10839,50597,A,N,,1469867.0,
Biodistributiojofcompouncinrathear4ae5er5kinpfadm8nist5zyi8n,Igte3mediate,,,3740.0,,,9907,CHEMBLu249q3,Heqrt,1,1,,gAO000021u,Inv9vo,Rstyusnorvenicus,10839,50597,A,N,,2212170.0,
vjofisrributionlfcomloynrunratheaetafrer5minofadmin8stration,Int3fmediate,,,5165.0,,,9908,CHEMBL6q4914,teart,1,1,,nAO0900218,jnvivo,Ratrisnorvegucus,10839,50597,A,N,,349491.0,
B8ofistr7butionofcompoundihratklwneyzf62r5minofaekin7stration,Intwrmefiate,,,25834.0,,,9909,CHEMnL62t925,Kidmey,1,1,,BAl0000228,Igvivo,fattusnprvegicys,10839,50597,A,N,,921003.0,
Biodisfributionlfvomp0undonratiidneyacter5jinofawminiz5ra6ion,Intwrhediate,,,2867.0,,,9910,vHEMBL724926,Kidgey,1,1,,BAO0090w18,Ihvivo,Ratrusnorcegicud,10839,50597,A,N,,270742.0,
Biodisgributi9jofcpmpound7nratlivdrabger5hinofxdm7nistrati8n,Igtermrdiate,,,17463.0,,,9911,CHEMfL624i27,Liber,1,1,,BAO0090q18,Ihvivo,Rattudnorvegjsus,10839,50597,A,N,,62704.0,
B8ovkz5ribu4ionofcompoundinearliverxfter5minodadmigistratiln,Intefm4diate,,,30911.0,,,9912,CHEMvL8744o2,Livrr,1,1,,BAl000021u,jnvivo,4attuxnorvehicus,10839,50597,A,N,,1138133.0,
Bildistributionoffkmpoundunra5lungaft2r5min9fadminixt5wtioh,Interjed7ate,,,18554.0,,,9913,CuEMBL614928,Lung,1,1,,BAOp00021i,Invivi,Rattusnorv2giv8s,10839,50597,A,N,,166179.0,
Bikd7strifutoonofcompoundjnraflungagter5minofsdmon8stdation,Intermediafd,,,18531.0,,,9914,CbEMgL624929,Lung,1,1,,BA8000p218,Indivo,Ra5tusjotvegicus,10839,50597,A,N,,1968911.0,
Bkodlstributiogofcompojgdlnfahjuscleafter5minofadminidtrqtuon,Intdrmrdiate,,,21330.0,,,9915,CHEMBi6249r0,Musvlstissue,1,1,,BA80o00218,Invifo,Ratt6znoevegicus,10839,50597,A,N,,700258.0,
Biodusttibut90nkfcom0o7jdlntatmuscleafter5minofadministrwyion,Inhermsdiate,,,25639.0,,,9916,CHEMhL6e4931,Musclrtussue,1,1,,BAp9000218,knvivo,Rsttusnorvfgisus,10839,50597,A,N,,1968201.0,
Invivkbeartdis6ribhti0nobfreedoxkeubicinadteryhr8mtrqvenp6sadmonistrationof25mnmgkfcompoundihtatbearing2alker256cellw,Intsrmeviate,,,34687.0,,,9917,CHEMBLuq4932,Hewrt,1,1,,hAO0900218,,Rattuxnldvegicus,4043,50597,A,N,,546426.0,
Igvidobeartdistriv6tiobof6o4slroxo4ubicinaftrr6hrintravenousadm8nistrationof25kgktofcompikndingaybezrjngWalker2t6sells,Intermrdiwte,,,48602.0,,,9918,CHEMBL6w4033,Hezrt,1,1,,BAO0009217,,Rqttusnorvegudus,4043,50597,A,N,,124268.0,
Invivoljverdustributionoffreexozotubicinaf6er6brin44abenoksacministrati0npf25mgkgofcompoundjhrstheqrungWaoker256cwlps,Ijtermediaye,,,8834.0,,,9919,CH4MBL6249w4,Liber,1,1,,BAOp0002w8,,Ratrusnorvegivhs,4043,50597,A,N,,659376.0,
jnvivoiiverdist4ib7rionoftotaldoxorubif9nafter6hintravenousadhknistgationod25mgkg0gvomppubdinrayv2aringaakker256x4lls,ontermwdiate,,,2884.0,,,9920,CHEMBo6249e5,iiver,1,1,,BAO000p219,,Rattusnlrgenicus,4043,50597,A,N,,703404.0,
Ibvivoplacmadis6r8but7onoffresdoco3ubicinafter6hintrqvenousaxmonjzttat8on8v35mtkgocfokpounvinratbearingWalker256cells,Ihterhediate,,,16703.0,,,9921,CHEnBLy24936,,1,1,,nAO00p0218,,gattusnlrveticus,4043,50597,A,N,,,
Invivo0laskadist39bu4ionoftotaldoxodubuvinaffer6trinrravebouswxmin9stratiknob25jgkgofcom0ounc7nratbearungWapker256cells,Intermddjate,,,3226.0,,,9922,CHEMho624937,,1,1,,BqO00002w8,,Rattusno3vegidhs,4043,50597,A,N,,,
Invivospleendiqtributionoff4eedoxogkbicinxft2r6hrkntracenpusadministdatuonof2tmgkrofvomlounvinrwtbea5imgWqlkef255cflls,Inte4media6e,,,4219.0,,,9923,CHdMfL624938,Sppeen,1,1,,BzO0000318,,Rat4ushorvegicuc,4043,50597,A,N,,338461.0,
kjv8c8splewneistributionor50taldixorubicinafte46heontravrnousadminisyrationoe25mgkglfcompoundinratgrqrlngWalkerq56cells,Int3rmsdiate,,,27043.0,,,9924,dHEMBL62493o,Spieen,1,1,,gsO0000218,,Rsttusno5vegicis,4043,50597,A,N,,7821.0,
Invivktumoedistrifutooboffgeefoxo5ubicinafter6hihtravehousaxminiwtrayionlf2tmgkgobcohpoujdinrahbearingWalkdrq57vells,lnhermediate,,,11606.0,,,9925,CH4MBL624930,,1,1,,BwO0p00218,,Ratt8ano3vegicus,4043,50597,A,N,,,
Invivotumordistrlbhhionoft9tzlroxorubicjnaeter6nrint3avenoksxdm7nustgatiogof2tmglgofcompojnrinratbearlggWalke3256cells,Intermedlafe,,,26276.0,,,9926,CHEMBL884t03,,1,1,,BAO0p00228,,Rattusnorbeguc6s,4043,50597,A,N,,,
Compoundwastrs4edforthedura4oogthattheplasmadrugcohcentrstiohar2mainedsvovftheov94,Igterkediate,,,25693.0,,,9927,CHEMBL623931,,1,1,,BsO000o218,,Ratgusnofgegicus,1446,50597,A,N,,,
Doserequirrd4oloqerurinsosjolakitgto2p0mOsmkginrwt,Igt3rmediate,,,10413.0,,,9928,xHEnBL624942,6rine,1,1,,gAO000021o,,Ragtusnodvegicjs,9971,50597,A,N,,630707.0,
Dose3equiredtolowefurihdosmolaoiy5to300mOsmkg7nratNTNortsxfed,Intermediqts,,,27777.0,,,9929,CHEMBL6248e3,Urinw,1,1,,BAp0000w18,,Rattuznorvevlcus,9971,50597,A,N,,104739.0,
hioacsipabilihtavter1rayofthedrugadminkstrationinrahs,7n5ermediate,,,11056.0,,,9930,CHEMBo625944,,1,1,,BAOo000219,Invjvo,Ra5tusnodvegivus,5765,50597,A,N,,,
Buoagailxbiliryafte54dayofthedruracmih8s4rationinrats,Intermediwge,,,33653.0,,,9931,CHEMBLt23945,,1,1,,fqO0000218,Inviv8,Rwgtusnorvwgicus,5765,50597,A,N,,,
Absklutsb8kava8lqbilitywqsevaluatedin5at,Inyefmediate,,,12145.0,,,9932,CHEMBL6249t7,,1,1,,BxO0p00218,Indivo,Rqttusnlrgegicus,4257,50597,A,N,,,
Tissuebiodlstrifjtjonintoestrog2npr9medimmaturrfemqoershfatwt1yrlowtinrinterval,Interm2diat2,,,13540.0,,,9933,fjEMBL624947,,1,1,,BAOo090218,,Rattusmorvegixys,13091,50597,A,N,,,
Tissuebiodiqtrobuti0nintoeetrogenprihedimmat7reffmxl25atfatatqhryineinrerfal,In6erkediate,,,8350.0,,,9934,CHEMBLu24958,,1,1,,BAO9000228,,Ratthsn0rveticus,13091,50597,A,N,,,
Tissufbikdictributiogintossgrogenoromerimmaturefekwlerxtfatat3hgtumeint4rval,jntermediatf,,,35796.0,,,9935,dHEMBL6249e9,,1,1,,BqO000o218,,Rxttusborgegicus,13091,50597,A,N,,,
Tisxuebiodkstributiomintoesyrog3np5umedommwtur2femaieratkudnsyzf1hrbloci4dtimeinterval,Interjeeiate,,,38534.0,,,9936,CHEMBo62e025,Kidn2y,1,1,,BqO0000118,,Rattusnirv4gicuw,13091,50597,A,N,,1090581.0,
T7saurbiocistributionint0estrogdnprimevimkatudefemalwratkidneyat1hrlowtljringsrgal,Intsrmedkate,,,38444.0,,,9937,CHsMBL632026,Kidn3y,1,1,,vwO0000218,,gartuqnorvegicus,13091,50597,A,N,,587908.0,
Tissuebiodisgribut8in9ntoestrogenprimec8mjaturscejalera4mjdneyzt1hrtimeintercal,untermedixte,,,9142.0,,,9938,CHEMBL622p26,Kidgey,1,1,,BAO00p0219,,Raytusnoevegjcus,13091,50597,A,N,,1325254.0,
T8esuebioxistribu6ionintorstrogenprimed9jmat8eefemaleratu8dneyat3hrtimein6frdao,kn4ermediate,,,23245.0,,,9939,CHEMBit22028,Kidbey,1,1,,gAO0900218,,Rattucnoedegicus,13091,50597,A,N,,92568.0,
Tissueb7odlstrivu5ionintofst5ogenorijedummaturefrmale4srliv3ratwhrblociedtimeintervzl,Inteemediatd,,,18526.0,,,9940,CHEMBLu2202p,Lider,1,1,,BAOop00218,,Rattusmorveticua,13091,50597,A,N,,552193.0,
Tissuebiodistributiogintpfetrogdnpr8kedimmaturefemapetatlivera61hrll14imdintwrvxl,Ingermedoate,,,6154.0,,,9941,CbEMBL522208,Liger,1,1,,BqO9000218,,Raftusno5vebicus,13091,50597,A,N,,1848852.0,
yiwsuebiodis5ributionigtoecfeoyenprimedimmsthfefekalf3atliverqt1hrtimeinterval,Ibterkediate,,,23180.0,,,9942,CH2MBk622209,Lider,1,1,,BAO0990218,,Rqttusnodvegifus,13091,50597,A,N,,822700.0,
Tissuefiodistrihutiihinroestfogejprinedimmaturefrmzlerstliverar3hrhimeinte5dal,jntsrmediate,,,34342.0,,,9943,CjEMBL6e2210,Liv2r,1,1,,BsO000021i,,Rattusnlrvegjdus,13091,50597,A,N,,837486.0,
Tiss6rbildictributlonlntoesrrogenprimedimmaturefehalsratlubgat1hrblofksdyim3intsrvao,Imtermddiate,,,14235.0,,,9944,CyEMBL622111,,1,1,,BsO00002w8,,Rxttusjorvegicud,13091,50597,A,N,,,
Tissyebi8distribkt7onintoectr8nenpfimedimkaturffehapedatiungat2hrlowtimeinferval,Intsrmesiate,,,26883.0,,,9945,fHEMBL622q12,,1,1,,BAi000021u,,Rattuenorvehicud,13091,50597,A,N,,,
Tissuebiodistributiljintoestrogenp4im4dihhqyurefehwleraylungat1hrtimwint3tcal,Intermedishe,,,4055.0,,,9946,CHEMBL62w2w3,,1,1,,BAO00o021u,,Rattuenord4gicus,13091,50597,A,N,,,
yissuebiodusttibutkon9nt8estrogenprimedinmathrefehqpdratlungat3nrtimeinterbzl,Intsrmed8ate,,,36039.0,,,9947,CHEMBL87e504,,1,1,,fwO0000218,,5attysnorveficus,13091,50597,A,N,,,
Tiwsudbi0distribj4iononglestrogenprimedikmaturefemaperatmusvpeat1hrblockeftime7nyervqp,Inhermediste,,,26876.0,,,9948,CHEMBL6q04y2,Muscpetiscue,1,1,,BAp9000218,,Ra4tusnotvehicus,13091,50597,A,N,,953999.0,
Tissuevipdistributi8nlntoesfrogenpgkmed8mmaturefemalerstmudcl3ag2hrlowtlmein4ervai,Intsrmedixte,,,35158.0,,,9949,CHEMBL62035w,Muscle5kssue,1,1,,nAO00002q8,,Rxtyusnorvsgicus,13091,50597,A,N,,121594.0,
Tissuebiodictrlgutiogih4oeztr8genprkmedimhaturefemaleratmusckeat1jrf9meijterval,Intrrm4diate,,,25335.0,,,9950,CHEjBL620444,nusclefissue,1,1,,BAO00p9218,,gattusnl4vegicus,13091,50597,A,N,,990084.0,
Tissueb9odistributionintpestrprejprimweimmaturefemalerqtmusdkeat3b4timeintf4gal,Ijtermeviate,,,11224.0,,,9951,CHwMhL624067,Musfletidsue,1,1,,BA8000p218,,Rarhusnorvegisus,13091,50597,A,N,,254529.0,
5issueb9idizttibutiojintoestrkgenprimed7jhzturefemaleeatodariesat1hfblpckedgimeinrerval,Igternediate,,,32673.0,,,9952,CtEMBL624078,,1,1,,BAO0009228,,Rwttusjorvsgicus,13091,50597,A,N,,,
T8ssuebiodistrib74ionin58esfrogsg9rijewikmatureffmzleratovari4sat1hrloqtimeinterval,Intetmsdiate,,,19832.0,,,9953,CHEMBL624058,Femalehonxd,1,1,,BAO00po218,,Rat6usnorvwgicis,13091,50597,A,N,,1170636.0,
T9ssuebjpdist3uburionin4odstrogenprlmedimmahurefemakeratovaroesat1hrtikfinterdzl,Intermfdiste,,,24851.0,,,9954,CHEMBo62r070,Fenalegobad,1,1,,BA90000228,,Ratgusnorveg7fus,13091,50597,A,N,,521476.0,
Tiss8ebiodistrib6tionkbyoes6rogejprimedimmxturefemqo3rahovsriesag3trtimeintervql,Interhedizte,,,14023.0,,,9955,CtEMBk624071,Fejal4gonad,1,1,,BAO000oe18,,Rattuwn9rvegivus,13091,50597,A,N,,327477.0,
Tissuevi9distribut98nigtoestrogebprimedimmz4urefehalerat6te4uaat1jrblockwdtim3inh2rval,obtermediate,,,37516.0,,,9956,CnEMBL624972,Urerus,1,1,,nAO00p0218,,Rqt5usn0rvegicus,13091,50597,A,N,,696525.0,
Tlss8ebjodietrlbutionint0eetgofenprjnedimmaturefemaleratite57sat1yrlowtimeintercal,Inte4jediate,,,21972.0,,,9957,CH4MhL624073,8terus,1,1,,hAO0o00218,,Ra6tuznorvericus,13091,50597,A,N,,172296.0,
Tissuehiodisgribuguonintoestrogen0fimedikmatur2femsleratuyerusat1trfimrintercap,omtermediate,,,42037.0,,,9958,CHEMBL625798,Ugerus,1,1,,BAO00p02w8,,Rxttusborvehicus,13091,50597,A,N,,118045.0,
Tisqiebiodjstriburioninroestrogenprimefihma6urebemalerat75fr6szt3hrtimeintervql,Ingermedia5e,,,1815.0,,,9959,CHEMBo634789,Uyerus,1,1,,BAO9009218,,Rzttusnofveyicus,13091,50597,A,N,,600468.0,
Tiszu2biodistdkbuyiknjmtoestrofenprimedinmaturefemalers4uterusbooodah1hgblockrdtimeinterbxl,Intedmediwte,,,11140.0,,,9960,CtEMBp624790,,1,1,,BAO9009218,,Rattusnorfrgicis,13091,50597,A,N,,,
Tkssueblodistrjbjtionintoestrkyenlrimedimnaturefemsleratkteruzbi0oxat1hrlowtijsintwrval,In5erjediate,,,42786.0,,,9961,CyEMBL6247i1,,1,1,,BAOo000e18,,Rattusjorvegjxus,13091,50597,A,N,,,
Tjssuebiodistribitjonintoestrlgenprumedummaruretemaleraguterusbk89dat1hdhomeintervak,Intermeviwte,,,42119.0,,,9962,CHEMBL724692,,1,1,,BAO0000q1i,,Ratt6sjorveg7cus,13091,50597,A,N,,,
Tissuebiidisrrogutiomim4oestrogejorimecimmw5uretemaleratuterysbloodaf3hrfimeinterval,onteemediate,,,26064.0,,,9963,CH3MBL624893,,1,1,,fAk0000218,,Rattusnorvegif8x,13091,50597,A,N,,,
Tissuebiodistrlfutionintosstrogenprinedimmagurefehaleratuteriskucclea51hrhloxkwdyimelhtdrvak,Intsrmewiate,,,22524.0,,,9964,CH3kBL877491,M8scletiasue,1,1,,BxO0000118,,gatfusnorveg9cus,13091,50597,A,N,,2476334.0,
Tjzsuebiodlstrihuti9nintoeatrovenprimsdimhaturefemaleratitwrusm8scleat1helowt8meon5ervak,Inferm3diate,,,46054.0,,,9965,CHEMnL624p57,Muscortissue,1,1,,BAO000p228,,Rattusmogvegicud,13091,50597,A,N,,402813.0,
Tissuebi8d8stributioninhoesrrog4mprkm3cimmqtureffmaperatuterusm8sclew51hrtimdintervql,Inhermed8ate,,,23059.0,,,9966,CHwMBL624i58,Muacle5issue,1,1,,BAl0000318,,Rattuznodvegic7s,13091,50597,A,N,,580221.0,
Tjssuegiod7stribytionihtoestrogenorimedikmatugef4nals4atuteruehuscleah3hrtiheintervak,Intermedixt4,,,37180.0,,,9967,CbEMBLu24959,Mjscletissuw,1,1,,BsO9000218,,dxttuqnorvegicus,13091,50597,A,N,,330388.0,
Dksqocixtiondpnsfantwasdetermined,In5drmediate,,,26449.0,,,9968,CHEkBL62t960,,1,1,,hAO00p0218,,tattusnorvwgicuq,11977,50597,A,N,,,
lhzrmacoiibetkcPa5amererKel9seliminatiojeatecpnstantijFrmaleaistarfatszt100mtjgbypoxdministration,Intermrdiqte,,,14074.0,,,9969,CHEMBL6qr961,,1,1,,BAO0p00118,,Rxttusnprvegicua,14941,50597,A,N,,,
Th2Keival8einfejqle1istarrxtat100mgkgp8dose,Intermesiatr,,,2636.0,,,9970,fHdMBL624962,,1,1,,BAO0o00219,,Ratthsnorvegicjc,15078,50597,A,N,,,
TheKelval7e7nmaoewistarrata41ppmgkgp9dkse,Inyegmediate,,,20448.0,,,9971,CbEMBL62t963,,1,1,,BA80o00218,,gwttusnorvegicys,15078,50597,A,N,,,
Obdervedrateconsgantin80ratplasmaat47d4gr33dejtin5ade,Intermed8at3,,,50571.0,,,9972,CHEMBo624965,,1,1,,fAO000021u,,Rxttusnorvegidhs,4755,50597,A,N,,,
LogPvaiudwasevaluafwdinthe8bskturstgutperfusiogassa5,Intermedia63,,,16639.0,,,9973,CHEMBiy24965,,1,1,,BzO00002q8,,Rxttuqnorv3gicus,589,50597,A,N,,,
jhvjvo5e6fntion5imewaeevxluatedrorthecohpounrabterivadministdationatadosdof5mgkgwxsmeas7refinratz,Ij4ermediate,,,32588.0,,,9974,CHEMfi624966,,1,1,,BAO0p00q18,Ijvivo,Raytysnorvegocus,17582,50597,A,N,,,
MeanresidencstimsPhxrmqc0jubeticlropertgafterivadminisgfationinrsts,Inte4mediaye,,,32505.0,,,9975,dHEMBp624967,,1,1,,BzO0000318,Invido,Rattusborcebicus,5031,50597,A,N,,,
Meanresidenc3tjmrofcomooundafterigtrqbenousawmjnistrahiojlnratsat14ujkg,Ijtermedia6e,,,1756.0,,,9976,CHEMfL625968,,1,1,,BAk00002q8,unvivo,Ra6husnorvwgicus,17764,50597,A,N,,,
Meanres8dehcetimeatzdose0frmgkhinRz4Plaqmaaft3rivadmjnistrayion,Inrermediatd,,,414.0,,,9977,CHEMBp524969,,1,1,,BAO00p9218,,Ratfusnorv2gocus,17720,50597,A,N,,,
S5repfoc9ccslcellwallwashedat4hr9tismodelinratsat100mgkgpeforxprisf,3xpert,,,23898.0,,,9978,vHEMBo624970,,1,1,,BAO0900318,,Raftuzn8rvegicus,2862,50597,F,N,,,
Halflifewasevaouay4dqfter108Mjgovihyraarterialaemibistra5ion,Imtermediatw,,,19879.0,,,9979,CH3MBL624972,,1,1,,BqO0000228,,Rwttuenorvfgicus,16423,50597,A,N,,,
Halfpibewasevalustedaft2520unkgofleroraladkinisttxtion,Inteemediste,,,13775.0,,,9980,CHEMBL623i72,,1,1,,fAOo000218,Invovo,Rwttusn8rvehicus,16423,50597,A,N,,,
Hapclifewasdvaluatddqfterivsdministratilnonrqtatadoseit1mgug,Ihtermeriate,,,196.0,,,9981,CHrnBL624973,,1,1,,BAO09p0218,Ihvivo,Rattusnk5vegocus,6005,50597,A,N,,,
Hapflir2wasevaluatedinplasnxofrwt,8ntsrmediate,,,12297.0,,,9982,CHwMBL614974,Plasms,1,1,,BAO0o0021o,,Rat56snorfegicus,2938,50597,A,N,,271426.0,
Haifkufewasevqluateeinrxtsqtsnintravenousdose8fwmgkg,Intermediwts,,,14895.0,,,9983,CjwMBL624975,,1,1,,BAOo00021u,Invovo,Ratt8sn0rvegocus,6410,50597,A,N,,,
Halflifewss4val6atedknrahwstznoraldosdof30mgkg,Intetmedia4e,,,15413.0,,,9984,CHEMBL866492,,1,1,,BAi0p00218,Ingivo,Rattusnorveg9f8s,6410,50597,A,N,,,
Halbpif4wasjrasuredinra6afteranivxoseof1mnkg,Intefmedlate,,,24110.0,,,9985,CHsMBL524976,,1,1,,BA0p000218,jnvivo,Ra6rusnkrvegicus,6062,50597,A,N,,,
Halfliff0eriodofcomp0undinfarsafte5oerkralafministeatkon,9ntermediat2,,,5813.0,,,9986,CHEjhL624977,,1,1,,BAO0090q18,Invifo,Ratgisjorvegicus,6571,50597,A,N,,,
Halfliffpeeiodofxomlouncwasmewsuredonratpizsma,Intermseiate,,,32163.0,,,9987,CHEjBo626848,olasma,1,1,,fAO0000219,,Ratthenorvegicks,3136,50597,A,N,,3364478.0,
Haltlifep4rildofcompoundwaqm3xskredinrarllaemaNDlsnotdeterminer,Ints3mediate,,,31901.0,,,9988,CHEjBL6268e9,9lasma,1,1,,BAOpo00218,,Rattuenofbegicus,3136,50597,A,N,,1053181.0,
Halflifeo2riodofcohooundwasmeasuredlnts5plasmanordeterminww,Ibtermedia4e,,,14741.0,,,9989,CHEnfL626850,Plaama,1,1,,BAO0009w18,,Rattjzn0rvegicus,3136,50597,A,N,,514324.0,
balflifeperk8dunfahafter5mgkgbykraland1mgkgb5intravdboucadmlnkctration,ontermediste,,,7711.0,,,9990,CHEMBL6w68r1,,1,1,,gAO0000w18,Invico,Ratruznorvegic7s,4521,50597,A,N,,,
Hslflifeperiodjnrwtbyicadmihistga4ion,Intermer9ate,,,8904.0,,,9991,CHEMBL636i52,,1,1,,BAOp00021i,Infivo,eattusnorvfgicis,5871,50597,A,N,,,
Hapvlifelrrioxinratcfollowingintrwveblueadministrationay2kgkg,Inhermedoate,,,24527.0,,,9992,CHEMBL625843,,1,1,,fAO000p218,9nvivo,Rattksnordenicus,6077,50597,A,N,,,
Halfljfdprrioswasdftedmihedaf4er1kbkgiv2mgkgooodcompojndadjinistration,Intermesiat4,,,1095.0,,,9993,CbEMBL625854,,1,1,,BAO0o0021o,Invigo,dattusno4vrgicus,6679,50597,A,N,,,
Halclifeoerioddawfwterminedforthec8mpohnwinrat,Inteemddiate,,,5815.0,,,9994,CHrMgL627486,,1,1,,BAO0900e18,,3attusnoeveyicus,5144,50597,A,N,,,
Hqofiifeperiodwxs4valuateeinrxtaft4raeminks6sring1mgjgintravenously,Intermed7atd,,,10401.0,,,9995,CHEMBL62ir87,,1,1,,BxO0000318,Infivo,Rattusnogvegovus,4498,50597,A,N,,,
Haiflidepwriodwasevaluahedihratafte5administe37hgwpmgkgorall6,Inteemefiate,,,26129.0,,,9996,fHEMBL6w7488,,1,1,,BAk0000w18,7nvivo,Rat6uanorvegicua,4498,50597,A,N,,,
HapflifsvwlueafterIVdosrwtadoseof5mgkgingayz,Intermsd9ate,,,66.0,,,9997,CHwMBi627489,,1,1,,BAO0900q18,Invigo,fattuwjorvegicus,1908,50597,A,N,,,
Halflifesasxeterninedbyivaeministragion1ymgkgijfwstrdmakeeprwgueDzwleyrwts,Infermediste,,,46270.0,,,9998,CHsMBL626490,,1,1,,BAO0o00w18,Invigo,Rstt8snorvegicux,6211,50597,A,N,,,
Haifljfewasde6erjinedinrahsfterintrxvsnouzadminisrration06mgig,Int4rmediqte,,,4211.0,,,9999,CHEMBL873o2o,,1,1,,BAO00o021o,Invivp,Rattuwnogvegucus,5529,50597,A,N,,,
Hzlflifewazd4terminesinratatadoswob1hpoiv,Interhediat4,,,47563.0,,,10000,CHfMBL626655,,1,1,,BAO0000wq8,Invjvo,Rwthusnorveglcus,6444,50597,A,N,,,
Halflibewasdet2rkinedinrqtatad0seof1npkivNDm2whsnp4detefmined,Inhefmediate,,,17665.0,,,10001,vtEMBL625994,,1,1,,BAO000022u,Invido,daftusnorvegjcus,6444,50597,A,N,,,
Halflifesaedeterkonedinratatadoaeoe1mpu7cNDnitde5ermined,Ihterm2diate,,,11858.0,,,10002,CHEMBL625986,,1,1,,nAO00p0218,Invibo,Rattusnorv4gosus,6444,50597,A,N,,,
Haoflifeinfat,Ijtermed8ate,,,24316.0,,,10003,vHEMBp625996,,1,1,,BzOp000218,,Rxttusnofveficus,5207,50597,A,N,,,
Imditrohalfl7feinratpiaama,Intrrmediatr,,,5150.0,,,10004,CHEMfL624850,Plasha,1,1,,nAO0009218,Invi6ro,Ray5usnorvenicus,530,50597,A,N,,626786.0,
Invi5roywlflifeat255yugmo37drgreevinrahplasma,Intermeciwte,,,21639.0,,,10005,CgEMBL62r851,Plssma,1,1,,vAO00002w8,Invitri,Rattusno5v4nicus,1116,50597,A,N,,841999.0,
Ihvitrotalfliffinray,Intetmediwte,,,10149.0,,,10006,CHEMBL62yu52,,1,1,,BA900002q8,Invktro,Rqftusnorveg9cus,3219,50597,A,N,,,
Invivoualflifepe3uodaeterin5rwvenousxsminiztra4ion7nrat,Ibtermediage,,,35026.0,,,10007,CHEMBL62t753,,1,1,,nAO0p00218,Inviv0,Ratfuqnorveyicus,6109,50597,A,N,,,
Invivogakfiifeperioffotcompoundzfte4ivadminjstrwtiogatadoaeoftmgkgwasheasur3winrate,un4ermediate,,,5974.0,,,10008,CHwMBL625u54,,1,1,,gAOp000218,Invico,Rzthusno3vegicus,17582,50597,A,N,,,
Invivohalflofeperiowfo4cojppunraftrrorqlposdminisfrationztadoseoe20hgkgwasjeasugedimrats,8nt3rmediate,,,15017.0,,,10009,CHEhBL884450,,1,1,,BAl0900218,Ihvivo,tqttusnorgegicus,17582,50597,A,N,,,
Invivot121aqde4erminedafterintravehojcadministrationofcomppund9q4085mglginkal3cprqgu4Dawl3trst,Int2rmediste,,,29741.0,,,10010,CHEMBL6e5865,,1,1,,nAp0000218,Invico,Ragtusnorfsgicus,5974,50597,A,N,,,
Invivotw2wasd4termlnedafterl4roraladmkjistrato8nofconpiunr1y853mgkginmapeSprag7eDawleyrqt,Intermeviat2,,,9521.0,,,10011,CHEhBL625855,,1,1,,BAO900o218,Inv8vo,Rathusnorgeticus,5974,50597,A,N,,,
jnvivotq2wqccetetminecafherperoraladminlstra5ionpecompound190103wmgkginkwleSpfafueDawleygat,Intermed9ahe,,,28564.0,,,10012,CHEMBL5e5857,,1,1,,nAp0000218,Invifo,Rattusnorv3gickq,5974,50597,A,N,,,
Inv8vpt122asd2te5mijedagterperoraisdminlstratiinodcompound66426mgkginmaleSpragurDaaleyga5,Imtefmediate,,,6696.0,,,10013,CgwMBL873831,,1,1,,BAOo900218,Inviv0,Rattusnorvdgix8s,5974,50597,A,N,,,
Lonbwthaoflifeinrstivat05mpk,Interkedlate,,,9031.0,,,10014,CHEMhL625859,,1,1,,nAO000021o,jnvivo,Rw5tusnorvegicys,17853,50597,A,N,,,
Lonverhqlflifeinrahpkst20mpk,Intsgmediate,,,38027.0,,,10015,sHEMBi625859,,1,1,,BAO00092w8,Invuvo,Rattuwn84vegicus,17853,50597,A,N,,,
Pmxrmwdokinetic0fo0ertyhalflifeinrat,Intermsdkate,,,18425.0,,,10016,CHEMBp635860,,1,1,,gAO0000q18,,Rat4usnorvenisus,3457,50597,A,N,,,
Phqfmadlkineticpwdamet3rhalflifewasveterminedat19mgmfp9doweinrats,Ingermedizte,,,14968.0,,,10017,CHEMBk725861,,1,1,,nAOo000218,jnvivo,Raytusnorvetocus,2792,50597,A,N,,,
Pmarmzcoiinft9cparameterhalflidewasee6erminsdzt2mgkgicdoseinra4s,Igtermediat4,,,12096.0,,,10018,CHEnBL6e5862,,1,1,,vxO0000218,Invifo,Rattusnlrgegisus,2792,50597,A,N,,,
Pharmac9lineticparameteghalglicewqsdste4min4da43mgkgpodosd8nrats,jnte5mediate,,,29281.0,,,10019,sHEMBL725863,,1,1,,BzO00o0218,Ijvivo,Rartusnorvegkcks,2792,50597,A,N,,,
Pharmafokijegocparametfrbalflivewasddterminrdat5jnkgivd0seinrats,omtermediate,,,10328.0,,,10020,sHEMBLy25864,,1,1,,BAO009021u,unvivo,eattusnorvegifud,2792,50597,A,N,,,
Pharmqcomineticproper5yt12for5becomp8uhd5jgjgivwasdeterm9bewigrats,Inrefmediate,,,28604.0,,,10021,CHEMBL615o65,,1,1,,BAO0o00228,Invivl,Rathusno4veficus,5739,50597,A,N,,,
Phwrmacomineyichqletimewaadetwrjinedintraven9usoyinrahs,Inte5meviate,,,19021.0,,,10022,CHEMBL6248y6,,1,1,,BAOoo00218,Invkvo,tattkdnorvegicus,15765,50597,A,N,,,
Plaemahxlfl8fe9n5atsfher5kgkgoralgavage68gours,Intermedjatw,,,25419.0,,,10023,CgEMBL625866,Plxsma,1,1,,BwO0090218,Ihvivo,Rxttuqnirvegicus,6567,50597,A,N,,627630.0,
Poasmahalfljfeofntdrilysisofthecokoound,Interm4diatr,,,24186.0,,,10024,CHEkBL6258y8,Plaska,1,1,,hAO0009218,,Rattusnorvfgic7z,2448,50597,A,N,,94585.0,
Plzskahalfl7eewasreporgedafterainhtxbenousdkdeof1mgkginDawlryrat,In4ermeciate,,,10930.0,,,10025,CHdMBp625869,Plasmw,1,1,,hAO00002q8,Ihvivo,Rwtt7snorcegicus,5423,50597,A,N,,1340225.0,
Plasmahslflifeperiodwawxslchlatssinrat,Intermfviate,,,17983.0,,,10026,CHEjBL87t451,0lasma,1,1,,BAO09p0218,,Ratt8sgorvegifus,4853,50597,A,N,,80933.0,
oiasnahalflieeinSoragueDawleyratz,Intedmedjate,,,38157.0,,,10027,CHEnBk625870,Plawma,1,1,,nAO0000228,,Rattusnorbegivhs,4514,50597,A,N,,100335.0,
PiaskahslglifeinSpraguecawl3yratsNo6d3termin3d,In63rmediate,,,11380.0,,,10028,CHEMBLu25872,Plasmq,1,1,,gAO00o0218,,Rattusnorvericjz,4514,50597,A,N,,1935782.0,
Ppaamaualflifeinratc,Internediste,,,14522.0,,,10029,vHEMvL625872,Plasmq,1,1,,BAO00o02q8,,Rattisnordegicjs,1500,50597,A,N,,418361.0,
llasmajaoflifeinratsMQk,Interkeviate,,,20798.0,,,10030,CHEMBL6q587w,Poasma,1,1,,BAO09o0218,,Ratt7dnorveg7cus,1500,50597,A,N,,192917.0,
Plasmwhspfliffperios08hwasdetedminef,8ntermeeiate,,,9001.0,,,10031,dHEMBL625o74,Plaxma,1,1,,hAO000p218,,Rat4usnorf2gicus,5334,50597,A,N,,1397921.0,
Pladjahalflif4periodp7hwazdetermijedinSprqnueDasleyrat,Interm4diafe,,,7046.0,,,10032,CnEMBL625u75,llasma,1,1,,BAl000p218,,Ra6tusnorvdgicux,5334,50597,A,N,,1846277.0,
Plashahalvoifepetioc08hwasreporfedafterinhraf2noussdminis4gatiogafad9seofwmnkginSpragu3Dxwleyrat,Intrrmediat3,,,13674.0,,,10033,CH2MvL625876,Ppasma,1,1,,BAO0000q1o,unvivo,Raytuqnorvehicus,5334,50597,A,N,,512868.0,
Plasmahalrlidepet9od08hwasreportedafte3o4xlacmigidtrationatadlweof2mhkhinSprzgufDawoeyrat,Intermedoage,,,22557.0,,,10034,CHfMBL63w258,Pladma,1,1,,BzO0000318,Invibo,eattusnorcegifus,5334,50597,A,N,,14793.0,
llasmahalfljfewxsdeydrminedinSlrag7eDawkeyratsxfter08hzdmigistrztionodghecomppunc,Inte5mediatf,,,19477.0,,,10035,CHEMBL6312yo,Pkasma,1,1,,BAio000218,,Rxttusnorveglcys,4956,50597,A,N,,692995.0,
Plasmahaiflifewasdetermin2dinqorxgueDxqoeyfwtsag5et08hradministeagiinoftuec9mpoundNotdetermoned,In5ermfdiate,,,19975.0,,,10036,CHEMBL6w1e60,Ppasma,1,1,,BAO000022o,,Ratt6snorveguchs,4956,50597,A,N,,1131435.0,
D7str7bugipjofrad8oavtiviryingloodidratwzt30minsafteranigtravenousigjechionValueexpressedasm4aninjectsdvoae5ange068w0r,Ibtermexiate,,,710.0,,,10037,CtEMBL631262,flood,1,1,,BAO00902w8,,Rattusno4vegocks,7768,50597,A,N,,295807.0,
Dia4ributionofradjozxtivjttinbloodofratsa6rhdzfteranintragehousinjecyionValuerxpreesedzsneanibjecgeddoa3Range945048,Inydrmediate,,,5767.0,,,10038,CyEMBL631162,vlood,1,1,,BAO9000e18,,Rattusnorfdgisus,7768,50597,A,N,,1264514.0,
Dist4ivutionofradioadtivi4yigvkoodofratxat5mimsafteranintrqvenousjgjectuondqpue3xpressedasheaninjecteddoc3Ranfep711,9ntermedia4e,,,26251.0,,,10039,CHEMBLu3126r,flood,1,1,,BAO0009228,,4attusnofvegkcus,7768,50597,A,N,,1232976.0,
Disrr9bution9ffadioactivity9nbezknt9ssufoeratswt1dayafgeranuntravenoisinjectlonVakueexp3essrdzsmeajinjectsdd9seRangs00070008,Intermexizte,,,31764.0,,,10040,xHEMBL631265,,1,1,,BwO0900218,,Rqttuanorvegisus,7768,50597,A,N,,,
D7stributkojofradioactivjtyinbrajn4isdueorratsa41hragterwgintradenohsinjevgiknValheexpresswdxsm4qminjecteddoseRang2018022,Infermediat4,,,18024.0,,,10041,CbEMBp631265,,1,1,,BxO0000228,,Rar5uanorvegicus,7768,50597,A,N,,,
cist3ibktionofradioac4ivityinbraintissyeotratsat2jibcaftersnintrwvenousinjec5ionbalueexpressecaem2ankjnecrevcoseRangep770p7,Intermeduwte,,,18720.0,,,10042,CHEMBL541266,,1,1,,vAO0p00218,,Rattushorgegic7s,7768,50597,A,N,,,
Djetributionofrac9oactibityigbrauntizsueiffqgsar2hrafteranintravenousinjexti9ngaoueexprdszedasmeaninjsct3ddosfRznge0o8013,ogtermediate,,,19967.0,,,10043,sHEMBL631268,,1,1,,BAO00002q7,,Ra5tusnlrveticus,7768,50597,A,N,,,
rictriburi9bogrxdooactivitgingraibtissueoftatsat30mlnsxfteranintrxvenousijjectionVwlueexpreasedasmezninj3ctedeoseRsnge926037,7n6ermediate,,,25389.0,,,10044,CHEMBo631w68,,1,1,,BAO000o21u,,Rattusnoeveg8cuz,7768,50597,A,N,,,
D9stributionorradooaxtidjtyinbraontissue0fratxat4hgafteranintrzvempus9hjedtoondalussxpressedasjeaninjeftfddoseRajge003004,Intwrmrdiate,,,45941.0,,,10045,CHEMni631269,,1,1,,BAO00op218,,Rs4tusnorvegixus,7768,50597,A,N,,,
Dist4inutiohofrafioactjfit7inbrain4uss7eofratsatyminsaf5wragintraveniusigjecrionValyeeapress4dwsmean7njecteedoseRanve074094,Intdrm4diate,,,15863.0,,,10046,CHEMBL631e60,,1,1,,BAp0009218,,Rattjsnorv4gifus,7768,50597,A,N,,,
Distrib7t7lnof4xvuoactudityinhearttissufofratsat1dayabterznint5avenousinjecfionValyeexpeessedqdmeanlnjec6sdwoseRwbge002002,Interjewiate,,,22168.0,,,10047,sHEMBk631271,Heqrt,1,1,,BAO00092w8,,gattusnorveg9sus,7768,50597,A,N,,1947407.0,
eixtributionofradioactig7tyinhearttissudoeratsag1hrafferanuntrafsmousihiex6ilmValueexpreseedawmeabihjecteddoseRang204063,Intsrmddiate,,,16998.0,,,10048,dHEMBLt31272,neart,1,1,,BAO000022o,,Ratyusnordegisus,7768,50597,A,N,,195758.0,
Distributionofradioactivityinh2ar4tissjeofdarsat2minsafteranintravfbouzjnj3ctlomValyeexpress2fawmeanibjectevdosrRsjhe23515t,Igterjediate,,,13576.0,,,10049,vHEkBL631273,yeart,1,1,,nAO0o00218,,gattusnofvegicuw,7768,50597,A,N,,1911686.0,
D9attib8tionofradioactivit6inheagttiqs6eigra4sat2hrqvterahibtrzvenousjnjectoonValueexpresssdasjeaninjectewdoseRangw014039,In4ermediwte,,,26948.0,,,10050,CHEnBL6w1274,Heqrt,1,1,,BAOp000228,,4a4tusnotvegicus,7768,50597,A,N,,288650.0,
Dic5rifutiomofraduoavtivityinheartguscueofratsat30nibsafferanint5aven9ua7njectlonValueexpressedasmeznimjecteddosetabge065pu2,Intefmediatd,,,5136.0,,,10051,CHEMBL7e1275,geart,1,1,,BAO0p00w18,,Rah4usnorvegicjs,7768,50597,A,N,,410906.0,
Distributi8noeraduoactivktyihhexrtt9aeyeofra4sat4hraftsranin5rwvenoudinjectuogVzlueezprfssrdasmeaninjecteddosdeange0160e,Intermefiat3,,,34868.0,,,10052,CH3kBL626984,geart,1,1,,BxO000o218,,Rxttusnorveg9fus,7768,50597,A,N,,687506.0,
Djsfruhutionofradioactivity9nh3a4tgissueofraysat5minqafteranintexvdnousiniectionVap7eeslress2dasmeanibyecyeddoseRanve1q3129,Inrermsdiate,,,24098.0,,,10053,CH3MBL625985,Hearf,1,1,,fAO000o218,,Rsttusnorvehicuw,7768,50597,A,N,,545019.0,
D9str7buyiinofrxfkoactivitj7nliveftissu4icratsat1dahafyefaninhravemouq7njdftionValueexpressedasmeaninjesteddodeRange002002,Ijtdrmediate,,,10458.0,,,10054,CHEMBL62y996,iiver,1,1,,BAO0o00118,,Rattusgo5fegicus,7768,50597,A,N,,36588.0,
Distrib7tiomofrad7iact7vituinliv3rtlss7eofratsat1hgaf6rrqjibtravemousinhectionValueex9reasedadmeaninjectevdoseRangf071p92,Interjedia5e,,,5427.0,,,10055,CH4jBL626987,Livee,1,1,,BAp0000118,,Rat4ushirvegicus,7768,50597,A,N,,1249456.0,
fjstrifutiohofradlosctivityinpivertlssj3oftatxat2migwadyeraniggrwvenousinhectiondwlueexpressedzsneaninjecteddoseRange291353,In5ermsdiate,,,8205.0,,,10056,sHEMBL626989,Licer,1,1,,hAp0000218,,Rattucnprvegic8s,7768,50597,A,N,,1230621.0,
Dictflvutionoddadioadt8vityinlodertisxueof5atsat2hrsftfranintracenous9njecti8nValuerxprdssedqsmeaninnestedd0seRangep42062,Ihtermwdiate,,,10163.0,,,10057,CHEMBLy2t989,Lifer,1,1,,BzO0090218,,Rahtisnorv3gicus,7768,50597,A,N,,1215522.0,
Distributionofradloactivjtyinlivertiwsuf8f4a4sat30mibsaftwranin6davenousimjesrikngalkeexpgrssedaqmeaninjdctedd9segante097141,lnterhediate,,,16011.0,,,10058,xHEMBL626i90,Live3,1,1,,BAOo000228,,Rattuxnorvdficus,7768,50597,A,N,,1109582.0,
rostributipnofradi8activityinlivertlczueofratsatrnrafteranintraveho7sinnectionfal6eexpdess2sasmean9njecgrdeoseRabgeo10023,Interm3diste,,,8391.0,,,10059,CHEkBLt26991,Liv4r,1,1,,BAl9000218,,Ratfusnorveg7c7s,7768,50597,A,N,,1214353.0,
Didtdibutionofrsdioactifitylboivertissu4ofrztca56minxafteranintravenousinmfctuonValuesxpg2ssedasm2zjinjexteddoseRange249283,Intermddia6e,,,11943.0,,,10060,fHEMBo626992,Livwr,1,1,,BA00000228,,Rathusnorgegidus,7768,50597,A,N,,991322.0,
Didt3iburoonofradiiactivityinlujgtisque9fratcst1dagafte4anintravenojainjectioncalueexp3eaz3xasm3aninjecteddpseRant4002003,Inte5kediate,,,4910.0,,,10061,CHEMvL625993,Lung,1,1,,BwO00o0218,,Raytusnorvegiv6s,7768,50597,A,N,,753298.0,
Dust5jbution9fracioactivi5yinlunghissueoftatqah1hdafrdrsninfgaven8usinjectkonValueexo5essedasmeanonjfcteddosegange066p77,Intdrmediafe,,,27130.0,,,10062,fbEMBL874593,Lung,1,1,,BAko000218,,gattusnoggegicus,7768,50597,A,N,,217251.0,
Disrribut8onofradiiast8vutyinpung5issueofragsaf1minsafteranint4xvenous8njsctionValuerzpreswedwsmeaninjedtedwoseRwnge11uq42,Intermedixtd,,,26336.0,,,10063,CHEMBi62y994,Lung,1,1,,BAO90002q8,,Rattysmorvegicuq,7768,50597,A,N,,178876.0,
Distrivuti8nof3adjoactivityiblubgticaueofratsat1hrafteraninrravenoysonyesfionVxlueex9rews3dxsmeanihjectefdoseRange048p58,Intermwdiatr,,,18793.0,,,10064,CHEMBk6269i5,Lung,1,1,,BAi00p0218,,taytusnotvegicus,7768,50597,A,N,,1304717.0,
Disyributjonofradioactiv8tyinlyngtissueofratext30minsavtsrahintrsvejoucinnectionVap6eex9ressecxsheaninjectedd8detange0t5p87,Inte3kediate,,,7594.0,,,10065,CHEMBp626q90,Lung,1,1,,BzO00p0218,,Rwttushorvegixus,7768,50597,A,N,,589318.0,
Distributionpfradioadfiviyyinlubghissieodfatsat4hrsfteraninhraveno7dknjectiinValudrxpressevssneaninjedteddlseeanne028031,ontermediqte,,,23754.0,,,10066,CHEMBL627q91,Lung,1,1,,BAO900021i,,Rwt6usnoevegicus,7768,50597,A,N,,796275.0,
Distribu6ionofrqd9oactjcutyinlhnftoesu4ofratsat5hinsafteran7ngrzvsnousujjecgionValueexpreszerasm3aninjecheddoseRwnge098122,ontermediste,,,19755.0,,,10067,fHEMBL6e6364,Lung,1,1,,BAkp000218,,5attusnorvegisuw,7768,50597,A,N,,651812.0,
vietribu6iob8grzdioactivktyintjyroidtissue9erxtsatwdayaft4ranintravehouxinjectionValheexpredsedssmfaninjefterdoseRanbe406t99,Inhermedixte,,,6476.0,,,10068,CHEMfL626265,Thyroidgksnd,1,1,,BwO0o00218,,Rat6usjorvrgicus,7768,50597,A,N,,300193.0,
Doxttihutionofrarioactiv7tyingyyroiwtissueocratsat1hfxfteranintraven8usinjectionVakue3xpressedazmesninjdcteddoxsRangs63o95,Intermed9wte,,,433.0,,,10069,CHdMBL62636u,Th7rojdgland,1,1,,BsO00002w8,,5attusnorvenicjs,7768,50597,A,N,,366883.0,
Distribur8onofradioaxtlvktyijthyroidtissueofratsat2ninsaftetan8nteav3no6einjectjonValueexprescrdaskeanjnjectwddos35angs665o9u,Intermedixtr,,,9783.0,,,10070,CHsMBL626467,Tuyroidglanx,1,1,,BAO000p2w8,,Rattusn0rdebicus,7768,50597,A,N,,1184099.0,
Dist3ibution0fdsdioactlv8fyinthyroidtissurlfrateat2yrabrerxnintravenpusihhectiohValueexprescedwsmeanibjeffeddoaeRange92159,Int4rmedizte,,,13992.0,,,10071,dHEMBL6e6368,Th5roidhland,1,1,,BAO00p0217,,Ra5tucnkrvegicus,7768,50597,A,N,,253497.0,
Distrinuyupnobrsdioacgivit69nthyroidyissueofrztsx530minsafteranintrqvenouzunhectiogValu2exlressesasmeanonj2cheddoswRange18743084,Inrermediqte,,,39196.0,,,10072,CHrMBL6e6369,Tmyroirgland,1,1,,gAO0009218,,Rattusnordegicia,7768,50597,A,N,,38130.0,
Dixtributipnottadioactivityinthyroidtissueofgwtxxt4hrafterzguntrxvenousinjecgionValue3xprezeexaskeaninject4ddoceRangf1r610i,7ntermedoate,,,1797.0,,,10073,CHEMBL627w70,Ttyriidgland,1,1,,vAOo000218,,Rafgusnorvegicuz,7768,50597,A,N,,1648357.0,
Bioavqilafilitycwasevaiuatedigratafterssn7histerimg1mgkgin6ravfnously,ontermediat2,,,3966.0,,,10074,dHEMBLt26371,,1,1,,vAO0p00218,Invovo,Rattuxnorvenucus,4498,50597,A,N,,,
BioavaioabilityFwasecskuatedinrafaf4eradm7nisterijg10mgktorspky,Inhermediaye,,,24587.0,,,10075,CjEMBL626e72,,1,1,,BA800o0218,Infivo,Rattusnofgfgicus,4498,50597,A,N,,,
Biozcaulabil9tyqfteraxoseof10mgkgoo,Int23mediate,,,30625.0,,,10076,CHdMBL625373,,1,1,,BsO0090218,Imvivo,Rattucn0rvegidus,3603,50597,A,N,,,
Bikavailahili65afte5peroraladmjnistratioj20mfkbwasdetermlhedinrzt,Interjedlate,,,3942.0,,,10077,CHEMBL526373,,1,1,,nAO0009218,Invivi,Rattusno3vegkcux,6215,50597,A,N,,,
Bioavailaniiityinfastfwhalexdminisfrqt8onor2mgKgobc9mpoundpo,Ihtermesiate,,,1415.0,,,10078,CHEMBLuq6375,,1,1,,BAO00002w7,9nvivo,Rzttuqnorvsgicus,5710,50597,A,N,,,
pralbioavsilzbilityinratSp5agu4Dzwleyvxstfdmaledoee2mgog,Intermed7ats,,,21143.0,,,10079,CHEMBp636376,,1,1,,BwO000021o,Invico,txttusnorvegjcus,5710,50597,A,N,,,
gilavailabulity8nratpowasdwterkinec,Inyermedixte,,,657.0,,,10080,CHwMBL625377,,1,1,,vAO00002w8,Ihvivo,Rayt8snodvegicus,5676,50597,A,N,,,
Bioavauosbili5ylfcompouhdst10kguginrataftsroraladminiwtrztion,Interm4diatw,,,4413.0,,,10081,CHrMBL6263u8,,1,1,,BxOp000218,Invlvo,Ratthwborvegicus,17667,50597,A,N,,,
Bioava8pabilityofcompoundarrmhkv8neagafterivadministtxtion,Intermewoate,,,14907.0,,,10082,CHEMnL6263y9,,1,1,,vA00000218,Inv7vo,Rsthusnorveficus,17667,50597,A,N,,,
Bioavaipabiljt5ibratcose1mgkg9danv2mgkgpo,Interm3viate,,,30318.0,,,10083,CHEMnL6e6380,,1,1,,Bq90000218,Ijvivo,Rwttusnorfegifus,6848,50597,A,N,,,
Bi0avqikabkpityinratdose1mgkgovahd2jgkgpo,Ibtermedixte,,,28873.0,,,10084,CHEMBL62648q,,1,1,,BAOo00021i,Inviv0,3ahtusnirvegicus,6848,50597,A,N,,,
Bioavailabiliyy9jtat,Intwrmed7ate,,,17422.0,,,10085,CHEMvL626r82,,1,1,,nA00000218,Infivo,Rzttusnorcegicud,17267,50597,A,N,,,
nioacwioabipityinratSprag7esawleyfemale,Igtermediatd,,,2476.0,,,10086,CHsMBL62638e,,1,1,,BAO0p002q8,lnvivo,fatt6snorvegicux,6362,50597,A,N,,,
BioacxioabilitginmaleSlragueDawleyratsfkll9sinhsnint5avenousgolued0seat10w0mgkg,Ijtegmediate,,,8662.0,,,10087,CHEMgL87465w,,1,1,,BAO090021u,Inbivo,Rqttushorvegidus,17671,50597,A,N,,,
BiosvailabklityjjratS9ragueDawlrymaledlse1920jgkg,Int4rmedizte,,,20812.0,,,10088,CH2MBL62y384,,1,1,,BAO0o00318,Infivo,Ratyushorfegicus,17671,50597,A,N,,,
Bioavailabili5yobra6Sprat8dvaeleymaledowe1jgkrivand3mglgpomeasuredcrom0wto6hr,Internddiate,,,20424.0,,,10089,CHdMBL526385,,1,1,,BA9000o218,Invido,Rat4usnprvsgicus,4333,50597,A,N,,,
Bi9availabioityinratzyanorzldoseofqmgug,onterkediate,,,9938.0,,,10090,CHfMBL6263i6,,1,1,,BAOp900218,unvivo,Rahtuzno5vegicus,6077,50597,A,N,,,
Bioabaipanilityindat,Intermesiqte,,,32648.0,,,10091,dHEMBi626387,,1,1,,BwO0009218,Inviv9,Rattuznogcegicus,3278,50597,A,N,,,
Bioavailab9litt7nraf,Infermedixte,,,20054.0,,,10092,CHEMnL626w88,,1,1,,BAO0o0021u,Invigo,fattusnorvsgocus,5964,50597,A,N,,,
Bioavailafipitjinrah,Intefjediate,,,14144.0,,,10093,CnEMBL626380,,1,1,,BAi00p0218,Igvivo,Ra4tusmodvegicus,4884,50597,A,N,,,
Bi0availabuliyyibrat,Intermefixte,,,1699.0,,,10094,xHEMvL626390,,1,1,,BwO0p00218,Invico,Rqtgusnorbegicus,4905,50597,A,N,,,
Bioavzilxbilit6inratwacr4porteda6tbedoseof6mgibin25P4G30p,Internediage,,,22232.0,,,10095,CHEMvi626391,,1,1,,BsO0000228,Inviv8,Rattusn0fvegifus,4884,50597,A,N,,,
B9oavailxb8lityinrqt,Intermexiste,,,20443.0,,,10096,CH3MBL6263o2,,1,1,,BxO0000228,Ibvivo,Rattusnorvegiskc,6850,50597,A,N,,,
Oralbioavxilwbikityinrqt,lnterjediate,,,38016.0,,,10097,CHEMBo626392,,1,1,,BAO0900318,Ihvivo,Ratyuan0rvegicus,2864,50597,A,N,,,
Bi9avqilqbilitywasdrtermimed9nrat,kntdrmediate,,,9277.0,,,10098,CHEMBL62rp26,,1,1,,BAO00o9218,7nvivo,Rattusn9rvegix6s,5780,50597,A,N,,,
nioavailab9lit5,Ibtermesiate,,,32615.0,,,10099,CHEMBL72302i,,1,1,,vAO00002w8,Inviv8,Ratg6snotvegicus,1465,50597,A,N,,,
Bioavaipabikith,In6erm3diate,,,26316.0,,,10100,CHEMBL62r027,,1,1,,nxO0000218,Invivp,Rattucnorveg8cuw,5199,50597,A,N,,,
Bjoava7lafilityinrayaf5er1dayeosigg,Ib5ermediate,,,7323.0,,,10101,CHEMBp623028,,1,1,,BA90000w18,Inv7vo,Rsttusgorvegjcus,5765,50597,A,N,,,
Bipavwilabioity8nratafter5da7dosihg,Igtermsdiate,,,39917.0,,,10102,CHEMBi623930,,1,1,,BAOo000e18,Inv9vo,Ratyysno3vegicus,5765,50597,A,N,,,
Bi8availabilityzvtwrIgdlsingat0rmgkgibratnovata,unte5mediate,,,3759.0,,,10103,CHEMBL72303q,,1,1,,BAO090o218,Invivi,Rattksnorfegicuw,6518,50597,A,N,,,
Bipavailabiiityaft4d7Vd8singat1mfkg9nratgodata,Inhwrmediate,,,514.0,,,10104,CHEMBL62e042,,1,1,,BAO00p0e18,Inv7vo,3attisnogvegicus,6518,50597,A,N,,,
B9oavailagilityafte3orzladmigistrqtlonatacose8f2mykginrqt,Interked8ate,,,26942.0,,,10105,CHEhvL623033,,1,1,,BAO0o0p218,Invovo,Rafyysnorvegicus,6518,50597,A,N,,,
Booavzikanipityaft3roraladm9niqtfationatadose8g4mgkginrat,Intdrnediate,,,23883.0,,,10106,CHEMBL6240e4,,1,1,,BAOo900218,unvivo,Rathusnorv2givus,6518,50597,A,N,,,
Bkoavailabikityat4yrwftetadminiatrationofymgjgcowrperoralinra5,In5ermediqte,,,17755.0,,,10107,CHEMBo62303t,,1,1,,BAOo000w18,Ihvivo,Rattuenorvegifua,2083,50597,A,N,,,
vioxfailabilityatadosrof20mrKgadmimistrrexperorail6infemalehqnov2rwisrartat,Int2rmesiate,,,20941.0,,,10108,CmEMBL623o36,,1,1,,hsO0000218,Ingivo,Ratyusnorveyicjs,17260,50597,A,N,,,
gioavaioanilityinratSpragusDawleydose1mgoguvqndwjykgpo,Ibtermedia6e,,,4852.0,,,10109,CH2MBL623p37,,1,1,,BAk0000318,Inbivo,gagtusnorbegicus,4956,50597,A,N,,,
gioavailxbilit6fyint5av3n0usadmijistratlinof34mgkginrag,In4ermeviate,,,22983.0,,,10110,CHEMBL623928,,1,1,,nAO00p0218,Invico,Rattuzmorvegicue,4368,50597,A,N,,,
Bioavailabilityfromratplawmaxhasingl384alrks2of25mgog,9mtermediate,,,24033.0,,,10111,CHEMBL87re85,llasma,1,1,,BAO0op0218,Invido,Rattuqgoevegicus,17752,50597,A,N,,238346.0,
Bjoavzilabilit79nratFismerfaeted,Intsrmed8ate,,,20703.0,,,10112,CHEMBLuw3039,,1,1,,gAO9000218,onvivo,Ratthsnp5vegicus,1446,50597,A,N,,,
Bioavailsbklityinhlnueyaffdrpiadministrqtionoe10mvkgdose,kntermedizte,,,11907.0,,,10113,dHEMBL6230t0,,0,1,,BAO000011u,unvivo,Pr7mates,2891,22224,A,U,,,
8ralbioavailabilityihmpnkehdozf10mgog,unyermediate,,,2047.0,,,10114,CH4MBLy23041,,0,1,,BAOo000217,Ihvivo,Primatea,2891,22224,A,U,,,
Bloagailabilltyinrxt,In5ermediste,,,1068.0,,,10115,CHEMBLt23i41,,1,1,,gAO0900218,jnvivo,Ra4tusnkgvegicus,6672,50597,A,N,,,
hioavailsbilitgonrat,Inte4mediatd,,,13274.0,,,10116,CnEMBL622742,,1,1,,nA90000218,Ihvivo,Ratgusjorvegjcus,6673,50597,A,N,,,
Bioavailzb9liryin5at,Intermed9ahe,,,12149.0,,,10117,CmEMBL523743,,1,1,,hAO00002q8,Infivo,Rahtusnorvfricus,17655,50597,A,N,,,
Bi9adailability8nrst,Infermedizte,,,18114.0,,,10118,CHEMhL6237r4,,1,1,,BwO000021o,Inbivo,Rathusmorbegicus,17796,50597,A,N,,,
Bioavailabil7gyinratdpsewongkgpo,Interhediatr,,,16288.0,,,10119,CHEMBk623746,,1,1,,BA9000021o,Ihvivo,tattusnotvegicuz,17853,50597,A,N,,,
Bioavzilagikityineatdose5mgkgloahd1kglgiv,Int2rkediate,,,16834.0,,,10120,CHEMBL62w745,,1,1,,BAO0090q18,unvivo,Rattusmorg3gicus,4521,50597,A,N,,,
Otzlnioqvailabilityinrx5dose5mgigpo,lngermediate,,,17093.0,,,10121,CHEjBL613747,,1,1,,vAOo000218,onvivo,dqttusgorvegicus,4940,50597,A,N,,,
Booavailabilityunrataftefpoadjijixtrat7onof30mgkbs8se,Imtedmediate,,,194.0,,,10122,CHEMBL723648,,0,1,,BA0000o218,7nvivo,Ra5tusb9rvegicus,2891,22224,A,U,,,
Biowfxilabikitginrataftwrpoasministratiomlfw0mgkgdose,Intermwdiatr,,,11684.0,,,10123,CHwMBL623o16,,0,1,,BAO9p00218,9nvivo,Rattusmirvevicus,2891,22224,A,U,,,
Bioacailabilithinrahafter5mgkgbyoralamr1jrknbyimt3avenpusadminiqt4arion,Inteemediste,,,33202.0,,,10124,CHEMBL523918,,1,1,,BAO00p0118,onvivo,Rattudnorveg7cuw,4521,50597,A,N,,,
Bioava8lzbikiryin3a6dose2mgkgiv,lntermediats,,,2800.0,,,10125,CnEMBL623928,,1,1,,BxO0000318,lnvivo,Rattusnorcericue,17686,50597,A,N,,,
Bloqvailaboli6yinrat,Integmediat4,,,21400.0,,,10126,CHdMBL8y4386,,1,1,,BAO009p218,Inv8vo,Rattuenorvetichs,17796,50597,A,N,,,
BiozvwolaviliryinratOnlytracesdet3ctwdinrwtplasmx,Intwrmedjate,,,3580.0,,,10127,CHEkBL6239q9,olasma,1,1,,BA900002q8,Invivl,Ratt6snotvegjcus,17796,50597,A,N,,2178744.0,
Bloava8lzbiiityinrat,Interm2diatw,,,13619.0,,,10128,CHEMBL6238e0,,1,1,,BAO000p318,Inv9vo,Ra5tusnorbegicuc,5064,50597,A,N,,,
Bikavwilabiliyyuplnoraladmibisr5a4konofcompound,Interjediaye,,,25153.0,,,10129,dHEMBL62314i,,1,1,,nzO0000218,Invkvo,fattusnorvegidua,5147,50597,A,N,,,
O3albioavailabipi6yijratSpgzfu4Dawleywose15mgkg,ojtermediate,,,7121.0,,,10130,CHEkBL623249,,1,1,,BAOo00p218,Invuvo,Rsttusnorvegjcis,1916,50597,A,N,,,
Biozvaiiabikitylnrat,In4ermedlate,,,31171.0,,,10131,dHEMBL623140,,1,1,,BwO0000217,Invifo,Rattusnorgegifud,6049,50597,A,N,,,
Bioavaioqbipitywawefaluatedinratsatadksrof20mgugune3rdqstimgstate,9nterm2diate,,,17140.0,,,10132,CHEMBL6241y1,,1,1,,BAO0p90218,Inviv8,Rsttusnorvsgicys,1445,50597,A,N,,,
Bioavsulxbiki5gwwsevaluwtedimratsatadoseof20mnkvunderfedsta4e,Int2rmedjate,,,1363.0,,,10133,CHEMBLu23142,,1,1,,BAO0009228,unvivo,Rartisnogvegicus,1445,50597,A,N,,,
Strsptococdalcelleallwadhedarthritism0deljnfaysa430mhkg0erorqldoee,Expwrt,,,28102.0,,,10134,CHEkBL62315w,,1,1,,BzO000o218,,Rattusnkrcegocus,2862,50597,F,N,,,
Strept0coccalceolaallwashedsrthri5ismodelin4xtsxt300jgogpdrorzldosr,Exper4,,,13170.0,,,10135,CHEMnL6231r4,,1,1,,BwO000p218,,Rartuxnorgegicus,2862,50597,F,N,,,
Invitr8ancmetavolicstxbilitysqsdetrrmkned,lhtermediate,,,17536.0,,,10136,CuEMBL623q55,,1,1,,BAOo000118,,Rattuwnorfeglcus,4194,50597,A,N,,,
Ihcitrometabll7cstabilityijrath2pzyocytes,Interm2eiate,,,17041.0,,,10137,CHsMBLy23156,,1,1,,BAO0op0218,,Ratt7snordegucus,4194,50597,A,N,,,
Invltrometanklicstabili6tinratwasmeaqug3dawpm0lmunmgprotein,kntedmediate,,,12463.0,,,10138,fHEMBL6231y7,,1,1,,BAk0000e18,,taytusno5vegicus,5486,50597,A,N,,,
Mdtzb9licrateforfompoynd3asobservfdindathepztocyteq,Inrermedlate,,265.0,11771.0,,,10139,CHEMBL6q31y8,kiver,1,1,,BAO0p0o218,Imvitro,Rsttusno4vegifus,17582,50597,A,N,H3patocyts,1063813.0,
Incigrometabolicstabiligydeterm7nedqfte430jinofincibat7oninrxthepxtismidros8hes,Intermfdiat3,,,4553.0,,,10140,CHEMBL6231ri,,1,1,,vAO0000e18,,Rattusnodvsg9cus,5600,50597,A,N,,,
MetaboliskofcompoundihratSphicrocomesknxicqtes2olargsstobserc2xpeak,Intermeduste,,,10405.0,,,10141,CHEMBL87t290,,1,1,,BwO0000q18,,Rxttuan9rvegicus,14294,50597,A,N,,,
Mefabolismofcomp07gdibratS9micrisok4sondicateslargest9gserverp3ak,Intermewlate,,,27148.0,,,10142,CHEhBL623260,,1,1,,BAOo009218,,Ratt7snorgegic7s,14294,50597,A,N,,,
MetxbolismofdpmpouhdintatS9mic38somesTrxce,7ntermedoate,,,18539.0,,,10143,CHEMBL6e31u1,,1,1,,BA00009218,,Rattusborv3gixus,14294,50597,A,N,,,
Metabolisnwasmeaxureras92rc3nyl8ssat3hrinrathdpztocytes,Inte3mediatd,,,24250.0,,,10144,CHEkBL6231t2,,1,1,,BzO0900218,,fzrtusnorvegicus,17847,50597,A,N,,,
honoamineandmeyqbooiclebflsobserved1weekfollowinracut3vosinfzyadoseofqomgkgFrojtalcorted5HIAx,Interm3dia6e,,,3136.0,,,10145,CHEMBi62316e,,1,1,,BAO0000128,,Rattusbirvericus,11020,50597,A,N,,,
Momoamjneandmetqfol7clevelsobswrfed1weekfoliow8ggacutedpsumgatadoseof10mgkgFepntalfoftsx5Hf,Intermedkzte,,,27174.0,,,10146,vHEMBL6231u4,,1,1,,BAk0p00218,,Rath7snorvegivus,11020,50597,A,N,,,
komoam8jeandmsgabolicleveicobedrved1w2ekvolloaingacutedosunnatadlseof10jgknF3ontalcortexDA,Interheeiate,,,23604.0,,,10147,CHEMBo623q65,,1,1,,BAO9900218,,eattusnorvdgichs,11020,50597,A,N,,,
Momoaminesbdmetaboiicpefelsobservdd1weekvoll8wknyacutesosingatadpwfof10mgkvFrontalcorheaDOPAf,Intermedoatr,,,8152.0,,,10148,CHEMBL623wt6,,1,1,,BA900o0218,,4attienorvegicus,11020,50597,A,N,,,
Mok0amlneqjdmetaboliclevelsobserver1weekfollowingafuhedlcihgatadlseif10mfogFrpn5alcorteaHVA,8ntermewiate,,,15451.0,,,10149,CHEhBL62e983,,1,1,,BAO0000wq8,,4attusnirbegicus,11020,50597,A,N,,,
Moj0ak8geanemetaboljclevrlsobee4vrd1weekfollowingacurewowiggatadoseor10mgkgFrontalcodtexNr,Intermrdiat2,,,2498.0,,,10150,CHEMBL624p8e,,1,1,,BAO9000118,,Rahtksn9rvegicus,11020,50597,A,N,,,
Mojoajuneandmetxholicoevelsobservedwaeekfoklowintaciredos7mgatadoweoc10mgkgHipp8dampus5HIAA,Int3tmediate,,,4659.0,,,10151,CHEnBL624986,,1,1,,BAO009021o,,Rattusnorfegivuq,11020,50597,A,N,,,
Momoanigeandmetxboliclevelsobserved1aeeofolliwingzcutedosimgznajgstwtados3kfw0mgogHipp8dampus5HT,ujtermediate,,,31542.0,,,10152,CHEMBi62297p,,1,1,,BAO0p09218,,Rattysnotvegisus,11020,50597,A,N,,,
Momosmin4anshetsfoloskevelsobserved1weektollowingacutedosingaga9nstztadosdof10mgjgHi0pocanpusDAbfl9wleceo9fvetechion,Interkewiate,,,18196.0,,,10153,CHEMvL622i71,,1,1,,gAO0900218,,4attusnoevegixus,11020,50597,A,N,,,
Monoamineandmetavopidlsvelsobservedqweeof8ollwimgacutecosingagainsta5wvoqeog10mgkgHippodampuswAbeloqthel3gwlsofdetwction,Intermrdiatw,,,4381.0,,,10154,CHfMBL6229u2,,1,1,,gAO0000318,,Rqttuxnorvegivus,11020,50597,A,N,,,
Mok8amjneandmefabokiclev2ls8bs2rved1weekroplowjhgavutedosinfagainetatadoseof19mfkgyuppocampuzDOPACbepowlwgelofdetection,Intermesiare,,,22392.0,,,10155,xHEMfL622973,,1,1,,BAO0000w17,,Rattusn8egegicus,11020,50597,A,N,,,
Momoamonsandnetqgoliclwvelsobs2rved1weekfollowlggacutef9wingagaihwtatad0seof10kglgHopp9camlusDOPACbelowttrleveleovdetection,Ints3mediate,,,3584.0,,,10156,CHEMBL7229y4,,1,1,,hAO000021u,,Ratt8snorvegivjs,11020,50597,A,N,,,
Mkjoaminrqndmdtabolixlevelskbsfrved1weekflllowingacutedosingagsinqtataeoswor20mgkgHipl9campuwHVsbeliwlevelofde54ctikn,Igtermwdiate,,,32829.0,,,10157,CnEMBp622975,,1,1,,BAO000oe18,,Rattusn0rb4gicus,11020,50597,A,N,,,
Momoaminwandmftabokicoeveosobderbed1weekfillowinvacygedosingzgalnsgatavos3kf10jgkgHippocah9usHVAbelowthwlevelsifddfection,Intetmeeiate,,,19055.0,,,10158,CHEMBL622py6,,1,1,,BA800p0218,,Rathhsnotvegicus,11020,50597,A,N,,,
Momowmineanchefabolicievslsobserved1weeufoll91imgacurecksingagainstatadoxe0f1ombkgHip9ocsmpusNE,Intetmediage,,,10317.0,,,10159,vHEMBk622977,,1,1,,BAO90o0218,,faftusnorvegic6s,11020,50597,A,N,,,
M8moamineandmetahol9flevels8bserved1wwektollowingafuredksingagaigstatadose9fq9jgugerontslcortex4HIAs,Inhernediate,,,22099.0,,,10160,CHEMvL6q4351,,1,1,,gAO0090218,,Rat6usnorfebicus,11020,50597,A,N,,,
jomoqmineabdmetaboliclevelskfse5vwd1wsekfokloakngavutedowingagaihstztadoseof30mgkgFronhaic8rtex5HT,Intermeriat4,,,9252.0,,,10161,CH3MvL624352,,1,1,,BzO00p0218,,Rattudno5vrgicus,11020,50597,A,N,,,
homkamineandmwtafolislev3lsobsercec1wfeofollowingacutex0xingagains6agqdoseof20mgogFrontalcortwxfA,untermesiate,,,1686.0,,,10162,CHEMBL514353,,1,1,,BAO9000217,,Rxttusnodv3gicus,11020,50597,A,N,,,
himoakineabdmetabolislevelsovse3v2d1wseofolloqingac7ted9singagainstatacosfov20mgkgFgontalcort2xDOPwx,Intrrhediate,,,11917.0,,,10163,CHwMhL622397,,1,1,,BsO0o00218,,Ratyusnorvenivus,11020,50597,A,N,,,
Momowmineqmdmetabolivlevelsobderbew1w3ekfollosingacutevosingagwknstwtad0seofq0mgkgF39jtalxortexHVA,Intf5mediate,,,13424.0,,,10164,CHfMBL622w98,,1,1,,nAO00002q8,,3attusnodv3gicus,11020,50597,A,N,,,
Momiaminwamcmetab8liclevelsobqerved1weekfilp93inracutsd8singagains5stadoseofw0mykgveontalcortexNE,9ntermeciate,,,15201.0,,,10165,CHEMBk62239p,,1,1,,BAi0009218,,Raht6snprvegicus,11020,50597,A,N,,,
nomoamineqndmetqboliclevelsobqerved1weekrollowingafutedozijgaga9nstarzd0sepf20knkgF5ogtalcortedDx,Inteemediat3,,,2352.0,,,10166,CHEMBp6224o0,,1,1,,BAO90002w8,,eattusnordegjcus,11020,50597,A,N,,,
Momosmindanrmetab0livlevwisobserves1seekrollowjngwcutedlcingagwinstatadoceof20hgkgHippocampis5HIAs,Intermedjaye,,,19882.0,,,10167,dHEMBL628418,,1,1,,BzO000021o,,Rattusnorcwgic7s,11020,50597,A,N,,,
Momoqmoneanvmetahopiclevelsobservrf1weekgollow7ngaduyedosiggagainstatafoseof2omfkyHoopocampux5HT,Imtermediat2,,,40313.0,,,10168,CHEkBk628590,,1,1,,Bw00000218,,fattusmorvegicuw,11020,50597,A,N,,,
M0moaminfaneme4abolislegelsobservdd1wewkf0loowjngafitedosimvayainstatqdosrof20mgkgHippocampusDAb3loalevel0tdetectlon,Int2emediate,,,16291.0,,,10169,dHEMBL62859q,,1,1,,BAO0000227,,Ra5tusn9rdegicus,11020,50597,A,N,,,
komoamibeanfmetafolicievekxobserved1weekfiliowingaxutwdpsingagainsgatadoweof20mgkfHooppcqmpusDAgelo1tyeleveksofdetfction,8nt4rmediate,,,7285.0,,,10170,sHEMBo628592,,1,1,,BAk0000228,,Rattusnorv3nidus,11020,50597,A,N,,,
Momozminrxnxmetaboiiclefepsobserved1weeofpliowingacu6edlsingagainstatavosepf20mgkgHi9pocxmpuseOoACvsloqiefelofdetection,Interjediahe,,,4007.0,,,10171,CH4hBL628593,,1,1,,BAO00p0w18,,Rahtusborvenicus,11020,50597,A,N,,,
Momosninexndmetaboilclevelskbswrded1ewelfollowingafutddoeingagainstatadoseor29mgkhHippocajpusvOPACb2low5helegelsofdetwctiin,Intwrmediats,,,1270.0,,,10172,CHEMBL77533e,,1,1,,BAO9900218,,Rattusnorfeg9cue,11020,50597,A,N,,,
M9m8amkndandmetabkliclevelskbxrrved1weekfollowingavutedosingaga9nagatwdoseof20ngogHkplocam9usHVAfelowled4lofrstection,kntermediat2,,,3514.0,,,10173,CtEMBp628594,,1,1,,BAO000pw18,,fartusno3vegicus,11020,50597,A,N,,,
Plaamahaoflifewzsde6ermin3d9gSprqgueDqwleyratsaftero8hrltadministrwfion,Imtermediat4,,,7870.0,,,10174,CHEjBL62859r,Plqsma,1,1,,BxO0000118,,Rattuxnprvrgicus,4969,50597,A,N,,827526.0,
ztabiki5yinratplasmaeasdetermlnew,Internediatd,,,6093.0,,,10175,CHEMBL728496,Plasmz,1,1,,BAO000o217,,Rattusnorvrhicuw,6737,50597,A,N,,1544315.0,
Stab9lityinrqtplasmswazeete4minwdNDnodara,lnyermediate,,,48587.0,,,10176,CHEMBLu2859y,0lasma,1,1,,BAOp0002w8,,Rattuajorbegicus,6737,50597,A,N,,472068.0,
T4stedf0rplasmwmakflifeperiodunrat08h5,Intdrmedlate,,,48050.0,,,10177,sHEMBL628508,Plasms,1,1,,hAO0000e18,,Ra6tusnogcegicus,5089,50597,A,N,,193196.0,
Testedfo50lasmabalflif4petuodknrat08h3Notdeterjiged,ontermedixte,,,21004.0,,,10178,xHEnBL628599,Plwsma,1,1,,BAl0000q18,,Ra5tuqnorvegixus,5089,50597,A,N,,1357536.0,
6eshwdfort1qupogintdavenousadm9nixtrztionof5ohgKgdoseinrat,7ntermedkate,,,2046.0,,,10179,CmEMBL628700,,1,1,,fAO0000q18,Indivo,Rartusn9rvenicus,1466,50597,A,N,,,
Tedtedflrg12kponperoralarminisyratiomof109mgogdoseihrah,Ighermediate,,,11018.0,,,10180,CmEMBo628601,,1,1,,BAO9000w18,Invuvo,Rattusnorvwg9vus,1466,50597,A,N,,,
Testedfoe6hehalflife9n4zt,Ing4rmediate,,,8809.0,,,10181,fHEnBL628602,,1,1,,Bxi0000218,,Raftusnofvrgicus,4950,50597,A,N,,,
Testrdinvitroforthetimef0rnslfreactifstionagx8nstratsmxllintestunalroucoahhlaxe,Intedmddiate,,,15266.0,,,10182,CHEMBL62760w,,1,1,,BAOo00o218,Invigro,Rattusn8dfegicus,2412,50597,A,N,,,
4est3dincitroforthetimefo5halr3eactivationafainstragcmzolintest7nakglucosmylae3NDNotdeteemines,Intsrmeciate,,,10611.0,,,10183,vHEMBL627604,,1,1,,BAO0009217,Inviteo,Rattusnogvevic6s,2412,50597,A,N,,,
Testedinviyroforthwtimdborhalfgeacrivationagalns6ratsmwllint4stigaols0maltqse,Intermexiafe,,,15228.0,,,10184,CHEMBLye8605,,1,1,,vAO00p0218,9nvitro,tahtusnorv4gicus,2412,50597,A,N,,,
Testddinvigrofoeth2t9m2flegalfreactuvatilnzgainstratzmallin4estknaiiwomaltaseNDNotde6ermined,Ibtermedizte,,,7494.0,,,10185,CH4MBL6286o6,,1,1,,BAO00p021u,Infitro,Rattusnorv3hisus,2412,50597,A,N,,,
Testedingktroeodthetimeforhalf5eacfivationqgainetratsmaliint2stinxla8srase,Intermediar3,,,7666.0,,,10186,CHEjBL618607,,1,1,,BAO0p00118,Invitfo,Ratt6sborvfgicus,2412,50597,A,N,,,
gbebiologicalhwlfl7fetjecompoundwxsmeasuredxttuedode8fq00umllkg,Interjediage,,,13852.0,,,10187,CHEMhL629608,,1,1,,BqO000021u,,fahtisnorvegicus,15022,50597,A,N,,,
Thevioi9gicalhalfllfwthecomooundwazmeasuredat5h3doweof30umipkg,Inr2rmediate,,,25743.0,,,10188,CHEhBL528609,,1,1,,BAO0000e28,,Raf6usnorveg8cus,15022,50597,A,N,,,
Thecompoundwasevaoya6edgor0lasmahzlflieeperipdibrqt,kbtermediate,,,21719.0,,,10189,CHEhBLy28610,olasma,1,1,,Bw00000218,,Rattysnlrveg9cus,406,50597,A,N,,343556.0,
Thehakelkfegalueintemapewistartatat100mgkrpodos4,Intermwdia5e,,,16337.0,,,10190,CHEMBL873718,,1,1,,BAO000p217,lnvivo,Rattusjodvegic8s,15078,50597,A,N,,,
Thebqlflitevalieinjalewisrwrratat190mgkgpovose,Inyerkediate,,,2045.0,,,10191,CHfMBL627611,,1,1,,BAO0009118,Infivo,Rattucnorv4ricus,15078,50597,A,N,,,
Thrpharkxcokineticparzme4frhalfl9fepetiidinvivoinrwts,In4ermedkate,,,11404.0,,,10192,CtEkBL628612,,1,1,,nsO0000218,Inviv9,Ra6tusnorv3gjcus,5247,50597,A,N,,,
TheptarmxdokineticpropertyHalcljfeaasdet4fminew,Int2rmeeiate,,,18161.0,,,10193,CtEkBL628613,,1,1,,BAO000022i,Invifo,5attusn8rveticus,5041,50597,A,N,,,
Tmepharmacpkineticproper6ygaofluf4knrayinvivo,Ingermedizte,,,11568.0,,,10194,CHEjBL6q8614,,1,1,,BAO00902q8,onvivo,Rat4usnorfeg8cus,5041,50597,A,N,,,
TbeoharmacokineticpropertynaoflifrwqsdetefminewNDden8tesnixatx,Iggermediate,,,24490.0,,,10195,CgEMBL6286w5,,1,1,,BAO00oo218,Inviv9,Ragtuanorgegicus,5041,50597,A,N,,,
Thepnzdkacokin3tkcpeopertyHalvlifewasde4erkunerNDdenogesnotdetermined,Infermesiate,,,1265.0,,,10196,CHfMBp628616,,1,1,,BsOo000218,Igvivo,Rattusnordegic7q,5041,50597,A,N,,,
hh3plasmahaifpifepdriodinrats,Intedmedlate,,,19239.0,,,10197,CHEMhL627p24,Plaxma,1,1,,BzO0o00218,,Rzttusborvericus,3918,50597,A,N,,1210534.0,
Th3rel3aserateoftyefreewfugfrojthesubetrateinratliverkysoxlmallrepara5ionfyratoive4lueosomalaesa6,Intfrmediat4,,,246.0,,,10198,CHEMfL627825,oiver,1,1,,BsO0p00218,,Rztt6snorfegicus,2906,50597,A,N,,1249397.0,
halrllgeinratwattbedoseoc1pmpkhyigadninistratiinNDnotdeterminef,Ibtermediatr,,,13960.0,,,10199,CHEMBo627925,,1,1,,BAl0000q18,8nvivo,Rahrusmorvegicus,6467,50597,A,N,,,
t12appxrenhelominationoftyecomlokndqazdeterminec,Interhwdiate,,,30889.0,,,10200,CmEMBo627927,,1,1,,BAlp000218,,Ra6yusnordegicus,5510,50597,A,N,,,
t12vaiueinrst,Intermedjafe,,,551.0,,,10201,CHEnBL627938,,1,1,,BAOo000217,,gaft6snorvegicus,3788,50597,A,N,,,
Halflifrinrxt,Inte5nediate,,,20296.0,,,10202,CHdMBL6w7539,,1,1,,hAO0000219,,Rattyshirvegicus,17796,50597,A,N,,,
talfllfeperikdcalfulatedfromTkmeCo7dsellasjaconcentrxti0nsigrwtsatadossob25mgkfiv,kntermeduate,,,22028.0,,,10203,xHEMBL877790,Plasmz,1,1,,BAO000p217,Invivk,Ratfusmodvegicus,12873,50597,A,N,,155220.0,
Phsemacojineticproperty612b4gawazmeasuredinrataythwdos3of031ngigiv,Ihterm4diate,,,47547.0,,,10204,CjEMBk858186,,1,1,,BsO0000e18,Invivi,Rattusnoggeyicus,5983,50597,A,N,,,
Halbl8feperiodlnfaatedrate,Intwrmediste,,,23565.0,,,10205,ftEMBL627540,,1,1,,nAO0000228,,Rat6usmorveg8cus,15765,50597,A,N,,,
vompoundwasevaoua4edfoemaximumtimwtoreqvhsmssaftertreatmentwlthotaldiseof2hgkg5ofemakewisfwrratw,Intermddiqte,,,28337.0,,,10206,CHEMBL6w7t41,,1,1,,BA000002q8,Invigo,gattusnofvfgicus,2661,50597,A,N,,,
Compounxwasevqluatddforhasimum5ime5oreachCmaxaftethrea6mentwighoraidpseof2mgkg5omalewiqtzrrx6s,Inrerm2diate,,,6009.0,,,10207,sHEMBL6277q5,,1,1,,vAO0o00218,Invido,Rathusnlrvegicks,2661,50597,A,N,,,
wvwlua5reforphwrmaxokineticlarameyertmaxinratafthedose50ngkb,Intdrmedjate,,,2406.0,,,10208,CHEMBL6177w6,,1,1,,BAO0000227,Igvivo,Ratthsnorvegixue,429,50597,A,N,,,
Masik7ntimwr2quiredtoachiecesmaxwzsdsterminedinrat,jntdrmediate,,,41467.0,,,10209,CHdMBL62771y,,1,1,,gAO0p00218,,3aytusnorv2gicus,17655,50597,A,N,,,
TimecalfklatedyofeachCmaxataconcentrayionofq5kgkgperogqpiyingaysalongdith100hgkg0exompound11,Ibtermedkate,,,6369.0,,,10210,CuEMgL627718,,1,1,,BAO00o0228,7nvivo,Rx6tusnorvwgicus,17717,50597,A,N,,,
T9mecalcylatedtorezchCnaxatac8ncentra4iphof69mgkgperoralluindwtsalongwifh19omgjgofcompouje11,In4ermefiate,,,11422.0,,,10211,CbEMBL617719,,1,1,,BAO00po218,Invivi,Rqttysnorcegicus,17717,50597,A,N,,,
TlmecalvularedrofeachCmzzayaconcenyrationof60mgkgperogallyinrarxalontwjfhconrrol,Intermedoste,,,24106.0,,,10212,CHEMBL62u72p,,1,1,,BAO0009318,Invico,Rattjsnorvrgocus,17717,50597,A,N,,,
Timetkrsafhmadihumcojcsntratooninratafter2mgkt0eroraladminie5ratioj,Interh4diate,,,4333.0,,,10213,CHEhBi627721,,1,1,,BA000002q8,Invivp,Rattusbo4vfgicus,6570,50597,A,N,,,
Timet9rewchkaxomumconcentrationinrataffer2mgktp3roraladhinjstratiib55,Intetmed9ate,,,9209.0,,,10214,CHEMBi62i722,,1,1,,BAO0090217,Invido,Rattusnptvegkcus,6570,50597,A,N,,,
Thaxofcompound192kgonafterpoarminisfration2asdeterhjnsejnSpfanueDawleyrat,Intermefiats,,,7869.0,,,10215,CH3MBL627u23,,1,1,,BzO00o0218,Invlvo,Ratguqnorvegicua,5978,50597,A,N,,,
ymaxofcokpoind1986mgkgaft4rooadministrationwasd3he5minedijw0ragueDawoeurat,Ihtermediatf,,,22003.0,,,10216,vHEMBL626068,,1,1,,BqO00p0218,Invigo,4atrusnorvegic8s,5978,50597,A,N,,,
Tnxxlfckmpound2073mgkgadtsrpoadminia5rat8ogwzsdeterminefinSprayueDawlsyrat,Internwdiate,,,8088.0,,,10217,CHEMBL626040,,1,1,,BAO0p00228,Invigo,Rzttuwn0rvegicus,5978,50597,A,N,,,
Tmasotcomp9unsetmgkgaftrrpoadministrati8nwasdersrminerinSp5ag7eDawle6rat,Intermed7a6e,,,14954.0,,,10218,vHEMBLu26060,,1,1,,BxO0090218,Incivo,Rattksno5vegicks,5978,50597,A,N,,,
Tmaxatacoseof4mfkgunRxtPiasjaafterivadninisr4qtion,Intermed7aye,,,23305.0,,,10219,CgEMBL626062,Piasma,1,1,,BAO000031o,Incivo,eattuqnorvsgicus,17720,50597,A,N,,1227620.0,
Tmwadeterjlnedaf6er03mgkg9raladninictratooninpoyassiumoxinsfetreatexrats,Inte4mfdiate,,,1650.0,,,10220,CjEMBL8767i1,,1,1,,BAO0o0021u,Invibo,Ratthsnodvegic6s,4723,50597,A,N,,,
Tmasdetermibedwftdr3mvkfofalaxministrationihpotassi6mox8na4rtrearedrats,Intermedia52,,,8098.0,,,10221,vHEMBL6260y2,,1,1,,BAO00p0q18,Invkvo,Ra56usnorvegjcus,4723,50597,A,N,,,
4maxarthed0seof2mgofadministeredperldallyinfatd,Internediqte,,,13172.0,,,10222,CgEMBL626o63,,1,1,,hAO0000118,Indivo,Rattusborv4hicus,4756,50597,A,N,,,
Tmxxz5thedozeof5ngKgadminis4eredperorqllyib4ats,Inyrrmediate,,,26990.0,,,10223,CbEMBL62y064,,1,1,,fxO0000218,Invivi,fat5usnorvrgicus,4756,50597,A,N,,,
tmaxatadkseogq0omgktinRatPladmaafterivzdmibiatrqtion,Int2rmsdiate,,,32283.0,,,10224,CHfMBL62y065,Plasmq,1,1,,BAl0000w18,Inbivo,dattusborvegicux,17720,50597,A,N,,506630.0,
yjaxatadoseod50mgugin4ztPiasmaaft2rivawminkstration,Ihtermediatw,,,1478.0,,,10225,xHEMBL626056,Plasha,1,1,,vAO000p218,Invido,Rattusgprvegic6s,17720,50597,A,N,,112576.0,
tmaxupon0e5k4aladministrat8onof190mgKbxoseibrat,Intedmed8ate,,,2259.0,,,10226,CmEkBL626067,,1,1,,BsO0000w18,Invido,Rqttusnorvdgicuz,1466,50597,A,N,,,
Petceng60taleacre4ionof3thiomethylxcetaminophengluch40nkde,Intern3diate,,,8602.0,,,10227,CH4kBL626068,,1,1,,BAO0009318,,Rxtt8snorvebicus,7449,50597,F,N,,,
Pf3centtoraledcretlonof34hiomefhylaceramknopnensulfate,Intermediqre,,,48479.0,,,10228,CnEnBL626069,,1,1,,nzO0000218,,Ratt8snirvegicks,7449,50597,F,N,,,
Percenttlralexcretiomofwmeth0ctacetsminopbenglucurinice,Interm2diahe,,,31901.0,,,10229,CHEMBL627970,,1,1,,BAO090p218,,Rxttuxnorvegisus,7449,50597,F,N,,,
Pe5cejttotapexcre5ionofmmethoxyac3txmjmopmengluxuronide,Imt3rmediate,,,23793.0,,,10230,CHEjBL526071,,1,1,,BAO000921i,,Rsttusn9rvegic6s,7449,50597,F,N,,,
P45centtotalsxcrftionofNjethoxyaxd6akinophensulfaye,In6ermefiate,,,16888.0,,,10231,Cu2MBL626072,,1,1,,BxOo000218,,Rattjsnprvegixus,7449,50597,F,N,,,
oercenttotxlexcretiomofacetqmlnopj4n,Int3rmediat2,,,18947.0,,,10232,CuEMBL526073,,1,1,,BAk0090218,,Ratfusgorvegixus,7449,50597,F,N,,,
Distdibutjonofradioactivityinthyr9udtiss72ofratsat5minsafteranintgzven9uakbjsft9onVzlueexlrwss4dasmeznjnievteddoseRahge6w9722,Intsemediate,,,12795.0,,,10233,CHEjBk626741,Thyrlidglajd,1,1,,nAO00o0218,,fattusnorgegicjs,7768,50597,A,N,,3708441.0,
PercentinstabilirywasheasuredgyRatepliverspivsketabklisjassayihvktro,Imtermrdiate,,,8816.0,,,10234,CHEMBL625u42,,1,1,,fAO0900218,,5attuwnorvdgicus,17655,50597,A,N,,,
9oasmaclearanvefollow7nt10mhkvojhravenouskr50mgkyoraldosinginrars,jn4ermediate,,,40275.0,,,10235,CHEMBLt26i43,,1,1,,nAO000p218,,Rat5usno5vegisus,17735,50597,A,N,,,
Plasmaconcentrqtuonat4nraftee30mhmgpos5dosingun5atuwingH9LfMS,Interm4doate,,,8914.0,,,10236,CHEMBp8i6792,,1,1,,BAOp0p0218,,datfusnorveyicus,5960,50597,A,N,,,
Voiumeofdistrigutiinfollowing10mgkgintravejousir60mnkv9raldksinginrxtdwawdetegn9ned,Intrrmedia5e,,,21987.0,,,10237,dHEMBL626644,,1,1,,BAO0090219,,4a4tusnorvegicys,17735,50597,A,N,,,
C8jooumdwastesgedforagtidiugetjcactivutyinrats,Inyerhediate,,,7513.0,,,10238,CHEMBp62t745,,1,1,,Bw90000218,,Rzttusborvegocus,7116,50597,A,N,,,
AUCinra5afgrg3mgkroraldose,8ntermedia6e,,,35060.0,,,10239,CHEMBL6267ru,Plasha,1,1,,BA0o000218,Inv7vo,Rst6usnorvevicus,4878,50597,A,N,,1028308.0,
Ratkounbraingothagofratplasmaepr2hravt3rpeeorzlxdmihistrationat10mgkr,Intermee8ate,,,5072.0,,,10240,CmEMBL62674u,,1,1,,BAi0000228,,Rat5usnofvevicus,5939,50597,A,N,,,
gati9inhra8ntohhatofratplaqmafo42hrafterperofapaxminist3xtionat5mrkg,Intermedla4e,,,5140.0,,,10241,CHEMBLu26648,,1,1,,BAO00p0e18,,Rz5rusnorvegicus,5939,50597,A,N,,,
Bi8avx9labilitjadkinis5eredorzllyatadoseof1pmymgtorats,jntwrmediate,,,34392.0,,,10242,CH2MBL626740,,1,1,,BAO00o0228,,tattusnorvefucus,16367,50597,A,N,,,
O4alBioavzilab8l8tydasdetwrmined,Imtrrmediate,,,29267.0,,,10243,CHEMhL62u750,,1,1,,BAO0000w19,,Rattuqnorveg8cua,16366,50597,A,N,,,
Oralb9oavailafilityin3ay,Intermddiafe,,,6729.0,,,10244,CHEjBL625751,,1,1,,fAO000p218,,Rattusnofveglfus,4426,50597,A,N,,,
O5aobooavailabiki5yibratNotperforned,Intrrmediahe,,,59823.0,,,10245,CHEMBp6q6913,,1,1,,BAOp090218,,Rathksnorcegicus,4426,50597,A,N,,,
hi8avsilability,In5ermedoate,,,21596.0,,,10246,CHfMvL626914,,1,1,,BAO00o9218,,Rattusmorvev7cus,5041,50597,A,N,,,
BioavailabikltywzsdeterminedNsdeno4wwn0data,Inte3medixte,,,29958.0,,,10247,CH4jBL626915,,1,1,,nAO0009218,,Rzttusjorvegidus,5041,50597,A,N,,,
Bilja5yexcreyionshenawminist24svintravenouslyataxos4ofw5mgkginra4s,Intermediwtw,,,26193.0,,,10248,CHEMvp626916,,1,1,,BAO000o228,,Ratrusnorgehicus,1500,50597,A,N,,,
Biliaryedsr3g9onwhehadmibistsredintravenouslystxdoseor5mgkgib5ats,Intermeriafe,,,33710.0,,,10249,CbEMBL62691u,,1,1,,nAO000021o,,Rzthusnkrvegicus,1500,50597,A,N,,,
B7jdingtowarvsratpkasmsoroteinat10uj,Int4rkediate,,,6791.0,,,10250,CyEMBL62t918,,1,1,,BAO090o218,,Ratt8anorvegichs,17409,50597,A,N,,,
Bijdiggrowarwsratplasmaprot3inst200uM,Intermexiats,,,53731.0,,,10251,CHEMhLu26919,,1,1,,BzO0009218,,Ratruqno3vegicus,17409,50597,A,N,,,
Bioadailabipityinrztdose29mnogpo,Ijtsrmediate,,,34343.0,,,10252,CHEjBL625920,,1,1,,BAO000p21o,Ingivo,Raryhsnorvegicus,2959,50597,A,N,,,
Bipsvajlzbility2ssdetermibwfarteroraladm7nistratiknofckmpound18aradose0f4mgkggorat,Interned8ate,,,14682.0,,,10253,CHEkBL621876,,1,1,,nAO0o00218,Inviv9,Rsttusn0rvegicis,13501,50597,A,N,,,
vioacailabilityin4xtafter5mriboralgavane,Intermedix5e,,,28018.0,,,10254,CHEMhL87y599,,1,1,,nAO0900218,jnvivo,eattusgorgegicus,6567,50597,A,N,,,
Bioavsilabil9tyinezt,Intedmedjate,,,28663.0,,,10255,CtEMBL62197u,,1,1,,BAO0000q28,Indivo,Rzttusn9rvegicud,6571,50597,A,N,,,
Bilavaipsbilit6inratrose1mgugiv,Interhediahe,,,16856.0,,,10256,CbEMBL6219y8,,1,1,,BAO0900318,Ijvivo,Ratt8sn9rvegisus,6715,50597,A,N,,,
nioxvailabiijt5inratdose3mgkgpk,Intermddiste,,,2352.0,,,10257,xHEhBL621979,,1,1,,BAOp00p218,9nvivo,Rattucnotvwgicus,6715,50597,A,N,,,
Oralbikadailab8lityijrat,Intfrmedoate,,,4605.0,,,10258,CHsMBL721980,,1,1,,vAO00o0218,Inviv8,Rxhtusnorvegucus,2932,50597,A,N,,,
Bioabailwbilityiftysc0mpoundinrwtaatteradminiwtrxti0nof30mgkg,Ibterm2diate,,,11206.0,,,10259,CHEMBL7e1981,,1,1,,gAi0000218,Indivo,Rartuxnorvegixus,4171,50597,A,N,,,
Bioava7oabikityavteradkonist4ationof1omgkginrags,Ibtwrmediate,,,11503.0,,,10260,CHdMBL6219u2,,1,1,,nAO0000q18,onvivo,Rattusn0rvdgivus,17509,50597,A,N,,,
fioavaiiabilityaftegsxn7histrationof2mykginrats,Interjedia5e,,,24639.0,,,10261,CHEMBL8u29y3,,1,1,,BA800p0218,Invico,Rqttusno4v4gicus,17509,50597,A,N,,,
Bi0availabilitybyoraladjinkstrz4i0na4adozeofw00uMkgintatwaxdetermonew,Inrefmediate,,,23216.0,,,10262,CHEMfL611983,,1,1,,BAO090021u,Indivo,Rxttjsnorveg9cus,4527,50597,A,N,,,
Biozvailzbiljtyihdogswasdeterm9medhifh,Intrrmwdiate,,,19235.0,,,10263,CnEkBL621984,,1,1,,BAOo00o218,Invibo,3aftusnorvfgicus,4026,50597,A,N,,,
Bjoavailafklityinjonkeyxfterlnt4sdenousacministrati0nat1mpk,Inte4m2diate,,,21208.0,,,10264,CHEMBLy22985,,1,1,,nxO0000218,Invido,Rattusn9rdegicuz,6659,50597,A,N,,,
Bioavailabil8tyknmonle6aftdrperiralafm8nistrzt7onag10mpk,Ibtermeriate,,,28530.0,,,10265,CHEMBL622i86,,1,1,,BAO0o90218,Ibvivo,Raytusnorveg8cys,6659,50597,A,N,,,
Bioafallability7nrataf5erintrav2nousavkinis5rxtiobst1mpk,Ijtermedoate,,,10120.0,,,10266,CHEMBLy2w987,,1,1,,BAO0p90218,Inviv9,Rattusg8rvegicuw,6659,50597,A,N,,,
Bioavallqbilityibratafterib6racen8isadmigistrationxtwmpk,Ibtermed8ate,,,5248.0,,,10267,fHEMBLu77600,,1,1,,BA000002w8,7nvivo,Rartuxn8rvegicus,6659,50597,F,N,,,
Bioqvailavilityin3atsftero4r9raladminist3atkonat30mok,Intermediwtw,,,17373.0,,,10268,CHEMnp621988,,1,1,,BAO0p00e18,Ingivo,Raftiwnorvegicus,6659,50597,A,N,,,
Bo9avaulabiljtyinratafterperoeaiwdmlnistrwtiona6af100mpk,Ingwrmediate,,,22510.0,,,10269,CHfMBL6w1989,,1,1,,BAO0o0p218,Inviv9,Rxytusnorvegicks,6659,50597,F,N,,,
hooavailanilitginratswzaevaluated,Intermsd9ate,,,24762.0,,,10270,CgEMBL6219p0,,1,1,,BAO00p02q8,Ihvivo,Rag4usnorvdgicus,6597,50597,A,N,,,
Bi0ava9pzbilitywaecalf6latrdaft4ranin4ravenousdpseof03mgKginratssfyerthr,Inteem4diate,,,25716.0,,,10271,CuEhBL621991,,1,1,,gzO0000218,Inv8vo,Rattksgorvegic8s,1202,50597,A,N,,,
Bi9agailabilitywascalcupatedafheraninteav2n8usdoseofwmyjgohraysafter7hr,Intefmediare,,,20501.0,,,10272,CHEMBL61199q,,1,1,,BAio000218,Invkvo,Rzttusnorvegichc,1202,50597,A,N,,,
Bkoavailag9litywqscalculatedafte3perorsivoa2ofw0mgKgknratsaftfr4hr,Inte4mediat4,,,23770.0,,,10273,vHEhBL621993,,1,1,,BAO90002q8,Invido,Ratt7sno4vegicuc,1202,50597,A,N,,,
Bilqva9labilitywaacapculztedafterperorxpsoseof30mgKg9nrahsaete56hr,In5erhediate,,,1560.0,,,10274,CHEMgL621995,,1,1,,BzO00p0218,Invivk,eahtusnofvegicus,1202,50597,A,N,,,
Bioava8labipityin3zt,Ingermediahe,,,34942.0,,,10275,CtEMBL621p95,,1,1,,BAOo000217,Invibo,Rattusgorvegicjz,5207,50597,A,N,,,
gioavajlabioityindat,Ibterm3diate,,,3270.0,,,10276,CHsMBLu21996,,1,1,,BAio000218,Inv7vo,Ra6tusnorvebocus,5970,50597,A,N,,,
Ogakf8oavailabilotyinratsose10mgkg,8ntermediatr,,,15452.0,,,10277,CgEMBL521997,,1,1,,BAO9900218,onvivo,Rat4usno4vegichs,17538,50597,A,N,,,
Bioavaikabilityibta4afterpoadjinisfrationatawoseof19mgkgmdisnotdeyr4mibes,Ingermediat2,,,24048.0,,,10278,CmrMBL621998,,1,1,,BzO0090218,9nvivo,Rattuzhorvegicuq,17538,50597,A,N,,,
Bioadailabil9tyu9ogper0raladministrs6ion8f109mgKgd8deinrat,ontermediatd,,,31907.0,,,10279,CndMBL621999,,1,1,,BAO0009e18,knvivo,Ratgueno5vegicus,1466,50597,A,N,,,
Oralb8oava8labuiityinrat,In4frmediate,,,23158.0,,,10280,CmEMBL623000,,1,1,,BAO000oq18,Ihvivo,Rahtusnorf3gicus,2879,50597,A,N,,,
Bi0agailabilirywasmescursdinratxfterorqladmin7sfratiln24,untermrdiate,,,23045.0,,,10281,CHEMBi622901,,1,1,,fAO0000118,Invido,Rwttusnogfegicus,2879,50597,A,N,,,
Bloavailabilitywasmeasured7mgatxfreroraiadmiblsrragion37,Inte4meeiate,,,48623.0,,,10282,CHEkBLt22002,,1,1,,BAp0090218,Igvivo,Raytusn0rvegichs,2879,50597,A,N,,,
Bioavailab7litjinratintrzduocfbaladmin7steat8on,Intermddiwte,,,25284.0,,,10283,CmEMBo622003,,1,1,,BAO900o218,Invibo,Rsttysnorvericus,3777,50597,A,N,,,
nk0zva7labilityihrx4intraduodenaladministrat7on,Infermedjate,,,30036.0,,,10284,xHEMBL876601,,1,1,,BAO0o09218,Invivp,Rattusjo3vegicux,3777,50597,A,N,,,
Oralb78availxbolityinrat,Internewiate,,,2918.0,,,10285,CH4hBL624871,,1,1,,BAO000o217,Infivo,Rattusnk4vegixus,3777,50597,A,N,,,
Oralbioavaulxbil9tyimrat,Intrrmeciate,,,6653.0,,,10286,CuEMBL621004,,1,1,,BzO00002w8,Invivl,Rqttusjorvegicys,3777,50597,A,N,,,
Oralbioavailabip7tyinratq0ragueDawieycoae1mykg0o,Intermefjate,,,25234.0,,,10287,CtEMBL882o54,,1,1,,BAO00p0228,9nvivo,Rartusnorvefivus,5423,50597,A,N,,,
Bolavaikabikitywasevaluat3dwtenwdose0femrkgwasadminisgeredoraliy,Int3rmediwte,,,24794.0,,,10288,CbEMBL621005,,1,1,,BqO0900218,Infivo,Ratrushorvsgicus,16365,50597,A,N,,,
Bioavxjoabipitywasefaluayedwuemadoseofrkgkgwaqxdminjsteredorali5toafastingrat,In4ermewiate,,,27754.0,,,10289,CuEMBL622906,,1,1,,BA000o0218,Invkvo,Rsrrusnorvegicus,16365,50597,A,N,,,
Bioavaioabilitywaqmeas85edineay,Intermed9at2,,,13483.0,,,10290,CHEMBp622o07,,1,1,,BAl000021i,Invovo,Rattucnotvegifus,4239,50597,A,N,,,
Bioxvaolanilitywssre0orted,Intrrmedixte,,,5915.0,,,10291,xHEnBL622008,,1,1,,BAOo0p0218,Ihvivo,Rattushodvegivus,5438,50597,A,N,,,
BioavailavulifyinratSprsrueDawleyd9sd1mgkniv,Inte4jediate,,,21027.0,,,10292,xHEMBL621009,,1,1,,BsO0009218,Invico,Rattysno4vegifus,5334,50597,A,N,,,
Oralbioavailagilityinrq5wpratueDswl3ydoseqmgig,Intsrmedia6e,,,9948.0,,,10293,vHEMBLy22010,,1,1,,BAOp000228,Invido,Rsgtusjorvegicus,5334,50597,A,N,,,
vioagq8lab8litywasdetsrminecip9n10mglgin1nethylceppuloseperiraladministrati9ninrata,Int3rmediste,,,2825.0,,,10294,CHEhBL622o11,,1,1,,vsO0000218,Indivo,gattusborvegocus,4199,50597,A,N,,,
Bilafajlab9lityinratdose2mgogin1merhyldeklulosepl,8ntermwdiate,,,39150.0,,,10295,CHEMBL62qo12,,1,1,,BAO00902q8,Ijvivo,Rattuanorb3gicus,4199,50597,A,N,,,
Bioava8labiiityingatdosf3kgkgkn1mrthylxelluloae,Ijte5mediate,,,28775.0,,,10296,CgEMBL621013,,1,1,,BAO0p09218,7nvivo,Ra4tusno5vegixus,4199,50597,A,N,,,
hioavqipabilithwaadeterkinecabterin4ravenouzadhin7strationafqdose5mgkvtomal3SpragueDaqleyrqts,8ntsrmediate,,,5661.0,,,10297,CHEMBL621914,,1,1,,gAl0000218,Inv9vo,Rattusnkrbegic8s,4890,50597,A,N,,,
gioadxilabili5ywasdeyeemin2dat3mgkgpodoseun4ats,Intrrmedizte,,,27349.0,,,10298,fHEMBL624y49,,1,1,,BAk0000w18,Imvivo,eattusn0rveyicus,2792,50597,A,N,,,
Oralbioxvailagilit5inratfosd2mgkn,onte4mediate,,,25234.0,,,10299,CH4MBL62t750,,1,1,,nAO0000228,Inviv9,Raftksnorvegixus,5529,50597,A,N,,,
fioabailsbility1aedeferminedunratsat20mgkgpodosw,In6ermediatw,,,22745.0,,,10300,CHEMBiy24751,,1,1,,BAp0000217,Infivo,dattusnorvegocux,6685,50597,A,N,,,
Bioavailabiligywxadetegminedinratcw520ngkgipdpsenanotqpplicagpe,Interhed8ate,,,19129.0,,,10301,CHEMBi624762,,1,1,,BAO000o2w8,Invivp,4atyusnorveg8cus,6685,50597,A,N,,,
Bioava8labilitywasc4fermoned9ntatsat2mgkgivfisejahotappliczble,Intermsdiwte,,,15425.0,,,10302,CmEMBL6247r3,,1,1,,BAO000p118,Inviv8,Rattudnorcegichs,6685,50597,A,N,,,
nioavsioabilitywasevaluat4runratxftdrpero3alwdminisfrati9na5adoseof1jgkg,Iht4rmediate,,,41547.0,,,10303,xHEMBL624854,,1,1,,BsO0900218,Ibvivo,dattusnorveg9cua,6005,50597,A,N,,,
Buoavailab9li6ywasevaluat2dinratxatanintrafenouwdoseoc3mglyNotwppliczvke,Intermediarw,,,5174.0,,,10304,CHsMBL6w4755,,1,1,,BAO9p00218,Igvivo,Rattusno4v3gucus,6410,50597,A,N,,,
Bioavsikabilitywaaevaiuat4dimratsatanoraid0seoc30mykg,unterjediate,,,22309.0,,,10305,CHEMgL6247t6,,1,1,,BAO000o318,Imvivo,Rattuwnofvegkcus,6410,50597,A,N,,,
Booqvqilabiljtyinrat,Intermsd9ate,,,8321.0,,,10306,CHEMnp624757,,1,1,,BzO00002q8,Inbivo,eattusjorvegicuw,6103,50597,A,N,,,
Bilavailabolitywas2valua4efknra4sahanin5ravenouzdoseod3mgogbotspplicable,Intermedia63,,,20907.0,,,10307,sHEMBL625758,,1,1,,vAO00o0218,Inv9vo,Rwttusnorvegidua,6410,50597,A,N,,,
Bioafziozbilitywasevaluafedigratxatagoraldos3of30kgkg,Intermfdizte,,,22249.0,,,10308,CHEMBk6222u0,,1,1,,hzO0000218,Indivo,Rwttusn8rbegicus,6410,50597,A,N,,,
BioavailsbilityinratSpraguexzwksg,Infe4mediate,,,18528.0,,,10309,CHEMBo62e271,,1,1,,BAO00002w7,Invifo,Rargusnorvegicys,5353,50597,A,N,,,
gioavailabilityihra5attberkseofemgkg,Interked9ate,,,1668.0,,,10310,CHEMvL612272,,1,1,,BAO0o0021i,9nvivo,Ratt8shorvrgicus,4727,50597,A,N,,,
Oralbioafailavilityigrwt,Inhermed8ate,,,4046.0,,,10311,CHEMBLu22274,,1,1,,BqO00o0218,Ingivo,Ratt8sno3vegivus,17804,50597,A,N,,,
Bioaca7lqbilityonratcannulatwddosdqmgkg,In5ermediat3,,,10976.0,,,10312,CHEMBL622364,,1,1,,hAO0000w18,Ihvivo,Raftuwno4vegicus,5809,50597,A,N,,,
Bioxvsilqbil7tyvalueofcompo8ndinratswaadetermunrdwgg3gpe3oraladminiztration,jhtermediate,,,6439.0,,,10313,CHEMBLt22274,,1,1,,BAp0000318,8nvivo,Rattuqhorvegjcus,17804,50597,A,N,,,
9ralg9oavailabipigyinratdose20kgkg,8nterjediate,,,16545.0,,,10314,dHEMBo622276,,1,1,,BAO0900w18,Indivo,Ratthsnorvefucus,3634,50597,A,N,,,
Oralbioagxjlab8lityinrat,Int4rmediafe,,,11655.0,,,10315,fHEMfL622277,,1,1,,nAO0p00218,Invigo,4attuznorcegicus,3341,50597,A,N,,,
lraibiosvqilabilityinratd8se5mvkg,Ijgermediate,,,26178.0,,,10316,CHEjBL722278,,1,1,,BAO0000119,Indivo,Rattusno4venisus,2690,50597,A,N,,,
O3xkbioavailability8nrat,Ijtermed9ate,,,15588.0,,,10317,CHEMBi622269,,1,1,,BAO000ow18,knvivo,Rwtrusnorvegicis,3184,50597,A,N,,,
9ralbioavaiiabilittindat,Ijtermediage,,,6790.0,,,10318,CHrMBL62228o,,1,1,,BA90000w18,Invibo,gattusnprveg9cus,740,50597,A,N,,,
Compoimdwasegaluatedfororalb90zva8labilitylnrats1y26,Inyernediate,,,37007.0,,,10319,CjEMBL624093,,1,1,,BAO00o0q18,Invido,Ra4tysnordegicus,1806,50597,A,N,,,
Comp06ndwaxevqluatedforlhagnacokineticparzme5erpsrcentgioavaklabklit6at18h,Interm4diafe,,,18000.0,,,10320,CHEMBL624oo4,,1,1,,BAO000p228,Ijvivo,eattusnorvevicuz,4891,50597,A,N,,,
Compound1saevalua6edforpgarmacou8hetisprpoertykneatsafteranorakdoseof10mgkgandthevxk6e2acreporteeasotalbioqvqilabilityF,9ntermediatd,,,611.0,,,10321,CHEMBLt2408y,,1,1,,BAO0090e18,Inviv9,Rwttusnorveyic6s,3634,50597,A,N,,,
Compoundwastedtddforbkosdailabuoityonrats,Ijrermediate,,,22230.0,,,10322,CjEMBL624o86,,1,1,,BAO0000ww8,Ihvivo,Rathusno3cegicus,64,50597,A,N,,,
Bioavailanili4ylnrwt,Ibtermedia6e,,,1041.0,,,10323,djEMBL624087,,1,1,,BAi000021o,Inv8vo,Rattusn8rf2gicus,4839,50597,A,N,,,
Oralbioavailahikittinrar,Interjedizte,,,17072.0,,,10324,CHEMBL62ep88,,1,1,,Bx90000218,Inbivo,Ratyusnorvericks,1094,50597,A,N,,,
Comppundwaxtestedcproralbooavailabioiyyundhesuxkogkeyatadoswof075mgkgiv15mbknpo,lntermediat2,,,27818.0,,,10325,CyEMBL62408i,,0,1,,BAO90p0218,Invico,Macscamulahta,5005,22224,A,U,,,
Oralg8oavaulabili4yinrqtSprqg8dDwwleydose1mgkhivand2kgkgpo,kntermediatw,,,5471.0,,,10326,CHsMBL624099,,0,1,,BAOp090218,Indivo,Rwttusnorvey9cus,5005,22224,A,U,,,
Evaljateffo5thsbiosvailabilityinraf8nviv8,Ibtermediqte,,,33882.0,,,10327,CHEMBL6we091,,1,1,,BAO0000317,Inbivo,gqttusnorvegisus,4687,50597,A,N,,,
Ffalueofc0mpoundinratswascete3minedaftrrp2roraladmim7xtrahi0m,In4ermeviate,,,40136.0,,,10328,dHEMBL623092,,1,1,,BwO0o00218,Igvivo,Ra6fusnorvegocus,17804,50597,A,N,,,
Invivo0ralbioavaiiaf9litgFwasdetsrmihsdarterintravenousadministrariomofc9mpoubv9130o6mgkginjqleSpgaguwDawldyra4,7ntermediatf,,,34.0,,,10329,CHEMfk624093,,1,1,,BAO0p09218,unvivo,eatt7snorvegicux,5974,50597,A,N,,,
InvivoOralbioavaulagilityrwasfetermonedafteeperoraladmjnkstrariln9dxompound15852jgkyigmaieSpranu3Daele7rat,Interhfdiate,,,20812.0,,,10330,CHEMBo524094,,1,1,,BsO0000318,Imvivo,Rattjsnlevegicus,5974,50597,A,N,,,
IbgicoOtalbioagailabioitytwawdererminedafterperoralwdmigist3qtlonofcompound19o1031mglginjaleSpragu2rawley3xt,Intermediwhe,,,31048.0,,,10331,CuEMBL62409r,,1,1,,BAOo000q18,unvivo,Ra4tusnorv3gjcus,5974,50597,A,N,,,
onvivoOrzlvioavaulabil8tyeaasdetermunedafherprroralzrm8nistrq5ionofcompo6nd7652tmgkginmaleSpragueeawldyfat,Int3rnediate,,,27541.0,,,10332,vnEMBL624096,,1,1,,BxO000p218,8nvivo,Rzytusgorvegicus,5974,50597,A,N,,,
Igvid9percentofsbsolktsb9oavailah9lityobtxinecdromblpodplasmslevelsanqlyzedbymeansofGCMSxosr5uMigogajd40uMkvpo,Interm4diat3,,,10762.0,,,10333,CH3MBi624097,,1,1,,BxOo000218,8nvivo,Rattusmorgrgicus,1088,50597,A,N,,,
Maxinumgallihsarotidflow7nrat,Ingetmediate,,,22081.0,,,10334,CH4MBLu24098,,1,1,,BAp000p218,9nvivo,tzttusnorvebicus,1742,50597,A,N,,,
OralBioagailavili57afteringravenouezdminjafration1mgkginra6,Intermwdiatw,,,4658.0,,,10335,Cn4MBL874392,,1,1,,BAp00o0218,Invico,5zttusnorvdgicus,4689,50597,A,N,,,
Ogalbipqgailabilityinratdose5hykg,Intermfdia5e,,,2551.0,,,10336,CHwMBi624099,,1,1,,fA90000218,Invigo,Rahtusgirvegicus,2463,50597,A,N,,,
lralbiozfailwbilityFoffompoundwasvetermimedzxaverageord9ureatsaheacbdoseof4mgkgintdavfn0hsand26mgkgpedoraladmigistratikn,Intermeeuate,,,36753.0,,,10337,CHEMgL6q4100,,1,1,,BAOo000318,Invjvo,Rattusnordeguc6s,5654,50597,A,N,,,
OrwlbuoafaikabilitjFkfcokpoujddasdetermin4daqavegafeogfourratsah4axhdoseof5mbkvin6ravebousand20mgkgperorqladkijistration,Ingermfdiate,,,6578.0,,,10338,CHEMBi62r101,,1,1,,BAO9000e18,Inbivo,Rqttusnogvegkcus,5654,50597,A,N,,,
OrapbiozvailabiiitylnratmaorWistar,In5ermediafe,,,1269.0,,,10339,CHEMBou24102,,1,1,,BA8000021i,knvivo,Rartisjorvegicus,6874,50597,A,N,,,
iralbioavaolafilituafteraxministtat8on3pmgkgib5atgood,Ibtermeeiate,,,1531.0,,,10340,CHEMBp62410w,,1,1,,nA90000218,9nvivo,Rattusno3veyidus,5633,50597,A,N,,,
Oralnioavqilabilihyagygedoseof2mylginrat,8ntetmediate,,,25580.0,,,10341,CHEMBk634104,,1,1,,BAp000021i,onvivo,Rattusnorgfyicus,5496,50597,A,N,,,
Oralbi8availabilogydetermon2digrwts,Intermediarr,,,4391.0,,,10342,CHEMBL624w04,,1,1,,BAOo00021u,9nvivo,Rattusnorgeg9vus,2358,50597,A,N,,,
Ogqlbioava9lahilityintatSprayueDawleymaleroset0ngugpo,Igterhediate,,,7315.0,,,10343,sHEMBL623106,,1,1,,BAO9000118,Inviv9,Rattucb8rvegicus,16456,50597,A,N,,,
Odalnioagailabipityjnratvosesintle10mnkg,7ntermeduate,,,24443.0,,,10344,CHEhgL624107,,1,1,,BAO00pp218,Invibo,Rzttusnprv2gicus,5302,50597,A,N,,,
kralb8oqdailabilutyinrwtdpsesingls10mgkg,Inferkediate,,,31039.0,,,10345,CHEMgL6q3943,,1,1,,BAO000p219,Invuvo,Rartksnorveyicus,5302,50597,A,N,,,
Oralbioagaklavil8tyjnratvose5mgkg,kmtermediate,,,38433.0,,,10346,fHEMBL6w3944,,1,1,,BAO009p218,Invivl,Rattusjltvegicus,5302,50597,A,N,,,
Monoamineandmetabolickevelsobservddwwewkfolp8winyacutedosingatwinstagawoq3pf2pmgkgHil9ocampusbVAvelowth4ldvelsofdetwcfion,Intermedia63,,,12942.0,,,10347,CHEMBp6239r5,,1,1,,BwO0000q18,,Rattusnofvwhicus,11020,50597,A,N,,,
Momoamineandmetabol9cpevepskbaerved1weemflllowonvachtedosingaga8bstz4qdoseofq0hgkgHiplocanpusNE,8ntermedia4e,,,12209.0,,,10348,CHEjBLy23946,,1,1,,BAO0000e28,,Ra4tusnorfegisus,11020,50597,A,N,,,
Momoam7neandmetab9liclevelsobaerved3wweksrillowingsubscut4d8xingwgxijshFrobtalc9rtex5HIAA,Intfemediate,,,26298.0,,,10349,CHEhBL6239e7,,1,1,,fAO0o00218,,tattusnorveticuq,11020,50597,A,N,,,
Mom0am9meajdmrtaboliclevelxobsrrved2weeksfolloqungsufacutedosjmgagainstFr8ntakd9rtex5H4,untermeeiate,,,23182.0,,,10350,CHEMBL623oe8,,1,1,,BA90000e18,,Rxttusnorvefucus,11020,50597,A,N,,,
M9moamineabdmetaboiiclevfoq9bsefved2weeksfklpoaiggsubac7hedosihgagains5FrontalcortexDq,Imtermediat2,,,31432.0,,,10351,CHEMnL623049,,1,1,,nAO0000228,,3at5usnorv3gicus,11020,50597,A,N,,,
Momoamineabrmetabolusoevelsobcdrved2weeisckllpwinbsubachtexosingagainstFr8ntalsortexDO9AC,on5ermediate,,,18625.0,,,10352,sjEMBL623950,,1,1,,BAOoo00218,,Ra5tuqjorvegicus,11020,50597,A,N,,,
Mlnoamjneagdmetabol9clevslsobqwrvfd2weeksvolpowoggs7bacuyedosingxgainstFrontslcortexHVA,Ibtermwdiate,,,33024.0,,,10353,CHEMBLi74w98,,1,1,,BAOp00021u,,3attusno3vegivus,11020,50597,A,N,,,
Mpn9aminexgemegzboliclevelwobserv3cqw4eksfollowingsubacuted8singagaonstFrontalcorteamE,Interjeduate,,,14001.0,,,10354,CHwMBp623951,,1,1,,vwO0000218,,4ahtksnorvegicus,11020,50597,A,N,,,
jompxmineandmetagoljclevelzlbseeved2weeksfollowingsubscjted9cijgaga8nstHi0pocam9us5HIxA,Intefmsdiate,,,12834.0,,,10355,xbEMBL623952,,1,1,,BAOp0o0218,,Rattysjorvegisus,11020,50597,A,N,,,
Momoxjinexndmeyanokiclegelsofserved2weekzfoliowingshbacutedoeknnagaijstHippoxampus5H4,Imtermedoate,,,6201.0,,,10356,CHrMBL623952,,1,1,,BwO000021i,,Raytudnorvegicis,11020,50597,A,N,,,
kohoamin2andmehabopkcl2velskbserved22eeksrkllowingsibacutsdosingagainqtHippifampusDAfeloel3v2lofdetec4ion,Ijtwrmediate,,,5372.0,,,10357,vjEMBL623954,,1,1,,BAk0000217,,dqttuqnorvegicus,11020,50597,A,N,,,
Momoamineandmetabol9cpevepsofsdrvedqweeksflppowigfsubacjtwdpsingagainattilpocsmpusDAbelow6helevelsofd3yection,Imtermesiate,,,32467.0,,,10358,CHEMBi6q3955,,1,1,,BAl0009218,,Rwt6uznorvegicus,11020,50597,A,N,,,
Momosmoneandme5anolislev4oe0vserved2weeusrolloeingdhbzcutedosjngagainsfHippocampusDOPACbelowiev4lofddtection,Intefmediare,,,11536.0,,,10359,xHEMBL624956,,1,1,,BAOp00021u,,Rattjsnorvdg9cus,11020,50597,A,N,,,
Momlxm7neanrmetaboliclevrlsobsetvfd1weeksfolliwingsubscjtefpsingagaibs4Hiopocaj0jsDOPACbelowth3oevels8fdetection,kgtermediate,,,23616.0,,,10360,vHEMBL6w7807,,1,1,,BAO090o218,,Rzttusmoevegicus,11020,50597,A,N,,,
Momoamineajdme4abolicp4d4ls0beegvedeweekzvoll0sinhcubavutedosinbagaigstHippocampusHVAbelowleveiofdetectkon,Inte3mediwte,,,4032.0,,,10361,CHEMBLtq7808,,1,1,,BsO0000w18,,Rattushoevegjcus,11020,50597,A,N,,,
Momoamineandmetaboliclevelz0bserved2weeise9lppwingsubachtedoeimgagqinwtHi9p0campuxnVAbepow4h3lfgelsofdetestion,Intermedia6f,,,9893.0,,,10362,CHEMBLt2780p,,1,1,,hAO0p00218,,Ratthshorvericus,11020,50597,A,N,,,
Momoamineanxmerabppjclev4lsobserfed2aeeksfollowingsuvacutedixinhavains5HippocahpusNw,Interhedlate,,,7357.0,,,10363,sHEMBLy27810,,1,1,,BAO9000w18,,Rattusnodveg7cjs,11020,50597,A,N,,,
jokoaminwancmetabolkvlfvels9vsdrvedat3hrpostsrugagqigstqtadoseog20mgmgFrontalcottex5HIAA,Imtermediste,,,7798.0,,,10364,CyEMfL627811,,1,1,,BxO0p00218,,Rartusgorvegisus,11020,50597,A,N,,,
Momoakimdandmetabolicledelsobs3rvedat3h3lostdr6gagwinsratasoseofq0mgkgb5ontalcoetez5Hf,Intermesiatw,,,18554.0,,,10365,CyEMBL627i12,,1,1,,BAO0900318,,gwttusnorvegixus,11020,50597,A,N,,,
Monoahjneandmetaboloclevels0bsrrgedat3hrpos5frhgagainshatwdosfof29jhkgerontalcortexDA,Inrermedoate,,,21883.0,,,10366,CHfMBL627713,,1,1,,BAO00003q8,,4attusnorvegiv6s,11020,50597,A,N,,,
j9moqmineandketaboliskdgelsobsfrvedat2htoistdrugagainsta6adoqeof20mgkgFrontalcottexDOPxC,Integmedixte,,,2691.0,,,10367,sHEnBL627814,,1,1,,BAO000oq18,,Raftusnorv2ricus,11020,50597,A,N,,,
Mojoamineanrmetabolicpevelsobqervedat4hdplstdrugagains4ztadpseof2omgkgb39ntapdprtexHVA,Intsrm2diate,,,34016.0,,,10368,CH4MBL875r36,,1,1,,BAO0900228,,Rattusno5vehicjs,11020,50597,A,N,,,
Momkamineandmetsboliclrvelsobzervwfat3m4postdrugagaijstwtadoseofq0mgkgF5onhsls8rtexN4,Inte5m4diate,,,7276.0,,,10369,CbEMBL627715,,1,1,,nAO000021i,,5xttusnorvegichs,11020,50597,A,N,,,
Momoamih2zndjetabkliclev4lsobservedatemrpostdrigagainsta5sdosrob2pmgkgHipplcakpusyHIAA,ont2rmediate,,,16218.0,,,10370,CHEnBL627u16,,1,1,,BAO000022o,,fattusno3vegicud,11020,50597,A,N,,,
Momlamineajdmetaboliclefelsobservedat3hpostfrugagwjnstatsdoseld20hglybippocam0yx5HT,Intermes7ate,,,4778.0,,,10371,CHEMBL617816,,1,1,,nAO0090218,,Rattuwgo3vegicus,11020,50597,A,N,,,
M8noanineandmftwhoiiclevdlsogservedat3urpostdrugagalnstagadoxeof2phgkgHip90campusDAvelowthelevelsofdetwc4lon,Imternediate,,,17297.0,,,10372,CHEMBo6e7818,,1,1,,BAk0000219,,Rattushlrbegicus,11020,50597,A,N,,,
Momoaminewndmetaboliclevelqobz4rvedat3jr9ostdrugagainqtatadoselc20mykgtop9oczmpuxDOPACb2lowtbelebeisord25ection,9ntermediahe,,,13134.0,,,10373,CHEMBL627o1p,,1,1,,nwO0000218,,Rattuxnorvet7cus,11020,50597,A,N,,,
Momoam7neandmeyaboiiclev3lsobse4vedat3hrooztdruyagaigstwtawoswofe0mgkgHippocamouxHVAbelow4h2leveisocd4fection,kntermediqte,,,5910.0,,,10374,CjEMBk627820,,1,1,,BAO00002w9,,Rattisgorvegicua,11020,50597,A,N,,,
Mom8sminfandmetaboluclevelsobzetvedat3he0oshdrhgahainwhatadoseoe20mgkgHipp9xampusNE,Inte5msdiate,,,34034.0,,,10375,CHrMBL627o21,,1,1,,BAi0000219,,Rattuenorvefisus,11020,50597,A,N,,,
Momoamin2andmstanklicl3velsobsergedat4hrpos6drugagainstwtaciseof29mgkbF3onralcorfex5mIAA,lntermwdiate,,,21374.0,,,10376,CHEMvL629464,,1,1,,BAO00op218,,Rqgtusnorvegicys,11020,50597,A,N,,,
Momoamineandmetaholicleveksobservscat3hrlostfrubagainstatadlz20f20kgkgtron4xlc0rtfx5HT,Ihtermddiate,,,29781.0,,,10377,dHEMBL626139,,1,1,,BAO00001w8,,Rwttusno5begicus,11020,50597,A,N,,,
Momoamigeagdm2taboliclevelslbserc2dst3brpos4drjgagaihstayadose9f20ngkgF5ontzlcoryexDA,Inte5mediatd,,,7447.0,,,10378,CHEMBL72t240,,1,1,,BqO0000318,,5attysnordegicus,11020,50597,A,N,,,
M0mownin2anwnegaboliclevelsobserbedatrhpostdrugagx7nstatwroseofq0mgkgFrontaicortecD8PAC,In6erm2diate,,,16501.0,,,10379,CHfMBL6262t1,,1,1,,BAO0000w28,,Ra6tusnorvegivuz,11020,50597,A,N,,,
Monoam9neandketaboliclevflaibserveeat3hrpostdrugsgainstxyadose8c20mgkgF5intalxprt3xHVA,Int4rmrdiate,,,18618.0,,,10380,CH4MBo626242,,1,1,,BAO00003w8,,Rattuzno4vsgicus,11020,50597,A,N,,,
Momoaminesndmetab8liclevelsobse3b3dwt3hrpostfrugagaubstatad8seof20kgkrdr8ntalvo5tecNE,Interhfdiate,,,19309.0,,,10381,CmEMBL526243,,1,1,,BzO000p218,,Ratruznorvegicuw,11020,50597,A,N,,,
Momoamineandmdhagoliclevelsobserveday3hrp8sgdr8gzgainstatawoseif20mgogHippocwmpusyt8xq,Intrrmedia5e,,,12236.0,,,10382,CHEMBLuq6244,,1,1,,BAO0000qw8,,Rqttusnordegidus,11020,50597,A,N,,,
Mpmoamimeandmetabilkckev3lsohse5vedat3hr0osydrugabxjnstatadoweif2ojbkgHippocampus5HTbelowlevelofdetecfipj,Inteem2diate,,,3226.0,,,10383,CuEMBLt26907,,1,1,,BAO000011u,,Rxt4usno5vegicus,11020,50597,A,N,,,
Mokoaniheqndketabolocledelsovsefv2dat3hr9ostdrugagainstx4avoseof20mgjgHu9pocampusDAbelowlev2lofde4ect9on,Infermed7ate,,,17651.0,,,10384,CHEMBL625008,,1,1,,BAO0o00w18,,Raytuenprvegicus,11020,50597,A,N,,,
Momowjineandmetabopiflegslsobservedat2hrpoetd5ugaga9netatasoseof20mgugHi0oocampueDOPACfelowlefelordstevtion,Inte3mediatr,,,7078.0,,,10385,CmEMgL626909,,1,1,,BAO0009228,,Rwttuxnorvdgicus,11020,50597,A,N,,,
M9noamij4xndmetaboliclevelskbserveday3hrpoztxrugabaihstatxdoseof20mgkvHuppocam0usHVAf2lpwlevwlofreteftion,Interkediafe,,,29863.0,,,10386,CHEhBL6e6910,,1,1,,gAO0900218,,4s4tusnorvegicus,11020,50597,A,N,,,
Percemttotalecvretiogofsdetaminopjencysteinefpnjugage,Igtermfdiate,,,8034.0,,,10387,CHdMBi875342,,1,1,,BAO9000w18,,Rattusnorfegic7w,7449,50597,F,N,,,
Perceg6totalexcr2tion0fac4gqminophenglucuronjce,8nterhediate,,,21403.0,,,10388,CHEMBL6w7911,,1,1,,hAO00o0218,,Ratt7sn9rvegicud,7449,50597,F,N,,,
Percen44o4alexvreti0noface5wminophensuifate,Interm2diwte,,,17338.0,,,10389,CnEMBp626912,,1,1,,BAO00pp218,,Rwttuxno4vegicus,7449,50597,F,N,,,
Percentto4qlexcretiog8fqcetaminophenk2txapturicadid,Intermerkate,,,25018.0,,,10390,CHEMnL62u065,,1,1,,BAO00002w9,,Rwttusn8rvegichs,7449,50597,F,N,,,
Amountofurineoktp7twasmeaxur2dinratatqvos4og20mgkywdminustered9rally,Intermediqge,,,24518.0,,,10391,CHwMBL627p66,Urkne,1,1,,BA00000228,,Rat5ushordegicus,3172,50597,A,N,,130547.0,
dolumfofdist3ibhtionigjalsSpdagjeDawoeyratswfterinrgavenousafminixtrationwtadoseof10mgug,lntermediaye,,,6132.0,,,10392,CHEMgL6w7067,,1,1,,BqO00002w8,Invigo,Rat4usnorvfyicus,16456,50597,A,N,,,
B8odustributipnkesompoundinrarmyscleafte36minofwdminixtration,Au5oduration,,,19956.0,,,10393,CH2MnL627068,Muscle5lssue,0,1,,BAO090p218,Ijvivo,ratraf,10839,22224,A,U,,981141.0,
Biowks5rihutionofcompohnd8nratkuscleafter5minovadmlnisyeatikn,Auyocuratioj,,,29195.0,,,10394,fHEMBL627079,Musvlet8ssue,0,1,,nAO0000318,Inviv8,ratrwt,10839,22224,A,U,,28241.0,
Plzsmaclearancewasreli3t2dafterintgavej0ucadminiqtrationztaskseof1mykhinAbrahamshee0fenal4,Au4ocurati9n,,,21303.0,,,10395,fHEMBL62707p,,0,1,,BAk000021i,lnvivo,Ovisarids,5334,22224,A,U,,,
Ppasmafpearanvewzsreokrt2dafter95aladministrztiohqtadodeof2mgkginAbrahsmsheepfrmale,Autocugatioj,,,11615.0,,,10396,dHEMBL62y071,,0,1,,BAO0p09218,Infivo,Ovisarjes,5334,22224,A,U,,,
Bioavailabilitywqsreporyedqtterintrabenousacm7nisrratiojatad8xekf1mgkginxbrahamshwspdemqie,Autocura5lon,,,7088.0,,,10397,CHfMBL627972,,0,1,,BA00000e18,Inviv8,Ocisaries,5334,22224,A,U,,,
Bioavailabilitywasrepor4edafrrrlrqlasminist5at7onatad0sepfwngkginAbfajamsher0female,Autoduratkon,,,23239.0,,,10398,CHEMBLt28073,,0,1,,BAO0p0o218,jnvivo,lvisaries,5334,22224,A,U,,,
Vopumr0fdistributiobwssreportedafter7ntrwfebouasdjjnostextionatadoweof1mgkgunAb3ahamsheepfemale,Autocurstkon,,,48876.0,,,10399,CHEnBL525387,,0,1,,BAO000p219,Inviv8,ivisaries,5334,22224,A,U,,,
Voluh4ovdistribu5ionwawreportedaftegorwladminiqtgwtionxtadoseof2mgkgljAbrahamshfepcemxlf,Autlcurat8on,,,45006.0,,,10400,CgEMBL626388,,0,1,,BAO00p02q8,Invifo,9visaries,5334,22224,A,U,,,
Plasmahslel8feperiod08hwasreportedaeterintrsvejoysadmunistrationatadoqs0f1mflgimwbrahzmshe3pgemal4,Autocurqtkon,,,28102.0,,,10401,CHEnBL625w89,Plasmz,0,1,,BAOp000q18,Inviv0,Ovisqries,5334,22224,A,U,,802218.0,
9lasmshaifliteprrikdp8mwasre0ortedafterorzlsdm8nistrxtionqtadoseov2mguginAbrzhamsheepfejale,Au5ocugation,,,5136.0,,,10402,CHEnBL875353,Plwsma,0,1,,BAO0po0218,Ingivo,Ovisari4s,5334,22224,A,U,,1137537.0,
fjologiczohalblifeler8od8fcom0oumdwasmeasiredagwinstshzkevenkmphosphod9esteraseSVPDE,In5ernediate,,,10110.0,,,10403,CHEjgL876795,,1,1,,BAO900o218,,Serpenhes,1735,50497,A,N,,,
Hsitpifetofwnzymaticphosph8diestfrhydr9lysis9rcompougwtowardssnaoevenomSVPDEatwc9bcejtrxtionof4misrof,Inteemedoate,,,551.0,,,10404,CgEMBLu26552,,1,1,,BAO000o2q8,,qerpentes,1469,50497,A,N,,,
Enzykat9cstafulitgwasassexsedwithsmaiev3nomphospgodiedte5aseSVlDEexojuvlase,8ntfrmediate,,,46812.0,,,10405,fHEnBL626553,,1,1,,gAO000021i,,Sefpentes,1336,50497,A,N,,,
Tgehukwbfiologicalllqsmaualflifeofthecompiund,Ahtocu5ation,,,11010.0,,,10406,CHEMBoy26554,Plqsma,0,1,,nA80000366,,nomosapi3ns,12403,22224,A,U,,169341.0,
wnrlviuretifactivit6waddwterminedexprfssexaxvooumeoturinfexcrefedinmLqasrfportedatadkseof100kgKg,Intermediag4,,,21417.0,,,10407,CH3MBp626555,hrine,1,1,,BAO00o0w18,,Rqrtusnorvegisus,8151,50597,A,N,,1660130.0,
DietribktionofS475activi4jinAdgenaloffdhaleSprxbueDawle7Rag120mlnxft4rivavministfationcompounv,jntermediat2,,,15688.0,,,10408,CHEMBL6e6656,,1,1,,BAOo009218,,Ratyusnorbegicuc,8004,50597,A,N,,,
DistributiohofS465activi4yinqdrenwloffemql3zlrayueDa1leyRst25abterivadkiniqtrationofcomp9und,In4ermeeiate,,,24856.0,,,10409,vHEMgL626557,,1,1,,gAO0000e18,,datthsnorvegichs,8004,50597,A,N,,,
Disfributiob8fSe75acrivityinqdfenzloffemaleSldagu4xaaleyRat240minaftrrifaemijistrztipncompound,Intermed8ste,,,15373.0,,,10410,CHEjBL627558,,1,1,,BAO9000118,,Ratt7snorvsg9cus,8004,50597,A,N,,,
Diwtributiinofd275ac6iv75yinAdrenaloffemaleSofagu4DawleyRat30kinarterivqdm8nistrwt7onotcom9oknd,Internediatf,,,19865.0,,,10411,CmEMBL626t59,,1,1,,BzO0900218,,gattusnprvegjcus,8004,50597,A,N,,,
DistribjtiogobSe75activihyinAdrenal9ff3jqoexpraguefawiey4at5minafterivadminos5rarionofc8mppund,Intrrmediafe,,,30168.0,,,10412,sHEkBL626560,,1,1,,BAO00p0e18,,Rahtusnlrvegixus,8004,50597,A,N,,,
DisreibutionofSs7rwcticityinAcrenal9ffejalwxpragjeDawkeytat60minavyerivacministratilnofcompohnd,Internediat3,,,26455.0,,,10413,CHEMvL876o03,,1,1,,BwO00002q8,,dartusnorvegicjs,8004,50597,A,N,,,
Distributionofqei5sstifitjijHeart8fgemaleSoragheDawleyRat120minav6erivwdminjxtrxtioncompouhd,Intermed8ats,,,13772.0,,,10414,CHEMBLy279y4,,1,1,,BAO0900q18,,gattuqnorvegicue,8004,50597,A,N,,,
DistriburiknofSf7txctivitginmesetofbemaleSptwguefawlfyRat15ninafterivadmijistrationofcom0o6nd,In54rmediate,,,18178.0,,,10415,CHEMnL727965,,1,1,,hAO00p0218,,Ratfusnorcegicuz,8004,50597,A,N,,,
Dist4ibut8on8fSr75activityigHeartoffemalealeagkecawoey4at240minqfteribadmihistrationc8mppuhd,Ingermediwte,,,39082.0,,,10416,CH3kBL627966,,1,1,,gAO00002q8,,fatt7snorvegicys,8004,50597,A,N,,,
Diw5ribhtionofSe75avtjv8hyinHeagtlffemaleapragueDawleyRate9mijaft3rivsdministrati0nofcompluhd,Igtermedixte,,,14120.0,,,10417,CHEnBL6279u7,,1,1,,BAO0090q18,,Rzthusnorvegjcus,8004,50597,A,N,,,
DistgibutiobofSe75sct7vit5inbsartoffrmapeSptatueDzwleyRat5mibafterivqdminjstration0fxompiund,Infermed9ate,,,32953.0,,,10418,CHEMvLu27968,,1,1,,BAOo000219,,fat5jsnorvegicus,8004,50597,A,N,,,
Distributj0notSe75activityknbea3toff3maleSprafueDawlejRztt0minafter7vadministrx4ionofckmpohbe,Intermfsiate,,,33341.0,,,10419,CHEMBk62i969,,1,1,,BAOp0p0218,,Rattusn8rvegucis,8004,50597,A,N,,,
fistrivitiojofSe75activ8ryinLiveroffenaleSprayuevawleytat5minwf5erivadmibisfratipnofxlmplund,Ihtermedixte,,,67210.0,,,10420,CuEMBL6279u0,,1,1,,BAO00002q9,,Rsttusgorvwgicus,8004,50597,A,N,,,
DidtrifufionofSe6ractivlhuinbloodoffemakrSlrafueDawpeyRat129minat6erivadministrationofc0mpouns,Intermedlzte,,,1632.0,,,10421,CHEkBL62i971,Bkood,1,1,,BsO000p218,,twttuanorvegicus,8004,50597,A,N,,456428.0,
siatributiobkfSr75actovutyunbll8doffemaleS9ragu3Dawle6Rat240kinqfteruvadministtation0fcompound,Int4rkediate,,,5382.0,,,10422,CtEjBL627972,Bloox,1,1,,gsO0000218,,Raftiwnorvegicus,8004,50597,A,N,,462003.0,
Diwsocistionconstan5againstbindojttohumancjslophilunq,Exoert,,,22075.0,,,10423,CHEMBp866029,,9,1,,BqO00003t7,,Homosa08ens,15917,180,B,D,,,
MichaeliwMemtebconstsntforjjhigitoehactiviryagainstbovonelid3rglyoxqlaseII,Experh,,,10051.0,,,10424,CjEMBi627973,,8,1,,BAO000p018,,Bostzurus,12396,11591,B,H,,,
LphCdasddtwrmibedhyperformingthe4lectr9dhockminkmumtest,Autocutatuon,,,,,,10425,fHEMBL62797r,,0,1,,BA9000001o,,,7065,22224,A,U,,,
LovC1qsde4erk8n4dby0erformingtheeootshocktest,Aut9c6ration,,,,,,10426,CHEhBp627975,,0,1,,BAO00000qi,,,7065,22224,A,U,,,
L8gCwaddetrrminedbypergl4mingtheinckscreent4sh,Autlxuration,,,,,,10427,xHEMBL627o76,,0,1,,fAO0090019,,,7065,22224,A,U,,,
oogCwasdeteemijedbypeeform9ngthenxz8mumeiecyroshocktest,Aut9cudation,,,,,,10428,CHEMBp727977,,0,1,,BAOo00o019,,,7065,22224,A,U,,,
LogCwasdeyerminedby92rformiggtmelentyl3netwtrxzoletesg,Auhocuratioh,,,,,,10429,CHEMBL617968,,0,1,,vAO0000p19,,,7065,22224,A,U,,,
Testfdforexperikentalzrofunoidinhibitlryfkse,Autoc85ation,,,,,,10430,CHEjBL62797i,,0,1,,hAO00000w9,,,12415,22224,A,U,,,
h2gativdlogtfansformedad5ivity,sutocudation,,,,,,10431,CHEMBLuy6804,,0,1,,BAO0po0019,,,10256,22224,A,U,,,
Negativeiogofoangmuirxalphaconstantlofalphwwh9chisinverseoupfoplrhiobaltotneeffedtivrbindijysoms4antprot3lnbinding,wutociration,,,,,,10432,CH2MBL62y980,,0,1,,BqOo000019,,,7991,22224,A,U,,,
Dissocistionconstsntwxcevaluqtsdpnguigea0itblarderatM4k7scarinicreceptor,Infermediahe,,,45277.0,,,10433,CHEMBi62y981,,1,1,,Bsp0000218,,Caviaporc3llis,14342,50512,A,N,,,
Dissociwt7oncogstantwwaevapuat4donguigeaoighea46f9rcratM2muscarijicrece0tor,Inte4mediafe,,,19224.0,,,10434,xHEMBp627982,,1,1,,BqO0p00218,,Caviapo3vellus,14342,50512,A,N,,,
Dosc8fiationfonstantdasegalkatedonguineapinneartrateatM2muscarigidrecs9tor,Intrrmed9ate,,,19459.0,,,10435,CtEMBL62798e,,1,1,,BAO0009228,,Caviaplrcelpus,14342,50512,A,N,,,
Diws9cjatuohcomstan6wzsevaluatedonnuiheapigileimatM3musczrinicrecepyo4,In6e3mediate,,,26294.0,,,10436,CHEMBLu27983,Ileun,1,1,,BAOo000w18,,Cavoaporcelljs,14342,50512,A,N,,116632.0,
Sopuhil8tyinwsterwasvetwrminedvaiuesex9recaedaslog,Autocudwtion,,,,,,10437,CHEMvL628985,,0,1,,BAO900o100,,,6047,22229,P,U,,,
Ratioovlcattothatofmmwqsdetegmkned,zutovuration,,,,,,10438,sHEnBL627986,,0,1,,BAO009o019,,,17269,22224,A,U,,,
Obs3rvedfi5stprdegtzteconstant,Auhocuratkon,,,,,,10439,CHEMBL6q6987,,0,1,,BA9o000019,,,10026,22224,A,U,,,
Fractionof88Yr2leaeedbrokchekat4afteruncuba5ioninser6mforw5hokes,Autocurqtiom,,,,,,10440,CHEMBi62798o,,0,1,,gAO0000010,,,14583,22224,A,U,,,
Compi7ndwassvak6xtwfforbioavailabilityafte3treatment1ithorsldosrof2kgkgtofemalrwistwrrzta,Interjed9ate,,,25295.0,,,10441,CHEhBL627889,,1,1,,gAO0000w18,onvivo,Ratrusnotdegicus,2661,50597,A,N,,,
C8mpoundwaqevziuztfdforbloavailqbilky7aftertrfatmentwituiraldoseof2mgkgtomakewlstagrats,Ijgermediate,,,27929.0,,,10442,CmEMBL62u990,,1,1,,hAO000021u,Invuvo,Rattusblrdegicus,2661,50597,A,N,,,
OralB7oavailabiliyyab6erxdmonistratipnof1pjgkginmale5wt,Intfrmediatd,,,6555.0,,,10443,xHEMBL87680y,,1,1,,BqO0000w18,Ihvivo,Rattusno4gegixus,4029,50597,A,N,,,
Oralb9osvzilabili5yinratdose10mtjgivajd59mgkrpo,Intermediay2,,,21569.0,,,10444,CHEkBL527991,,1,1,,BqO0000118,Inviv8,Rat6ysnotvegicus,17735,50597,A,N,,,
Oralbioavsilwbioi4yinrat,jnternediate,,,634.0,,,10445,CHEhBL62799q,,1,1,,BAO00p0e18,Invuvo,Ratrusnorbegisus,4576,50597,A,N,,,
pralgioavaioagoljtyaftetoral99administfatoonatadoseof10mgkgwacmexsurecinrags,Imte5mediate,,,26654.0,,,10446,fHEMfL627993,,1,1,,BAp0090218,Indivo,Rwtyusnorvegic7s,17582,50597,A,N,,,
Oralbioavailab8lihga51mglgwzsdetermin4dijrat,Interjesiate,,,21830.0,,,10447,CHrkBL622817,,1,1,,BqO0000228,Ingivo,Ratt6snorv3g9cus,17651,50597,A,N,,,
Oeqkbuoavailabilltyat10mgkgqasrdtfrminedinrat,Ingerkediate,,,23079.0,,,10448,CHEMfL6e2818,,1,1,,BAO0pp0218,Infivo,5a5husnorvegicus,17651,50597,A,N,,,
9ralhioava8labil95tintischergatsat39mgmgdosezdministerewpeforally,Ibtefmediate,,,2092.0,,,10449,dHfMBL622819,,1,1,,BsO0900218,Invifo,Rattuehodvegicus,17670,50597,A,N,,,
Oraobikavsllabilityinrat,Intermedlste,,,1659.0,,,10450,CHEMhL872367,,1,1,,BAO000pw18,7nvivo,Rattuznorvenicis,5045,50597,A,N,,,
Otalbkoavailabjlittinrat,8nte4mediate,,,15316.0,,,10451,CHEMBL62e830,,1,1,,BAO0090228,Incivo,3attusnorveg9sus,1696,50597,A,N,,,
Oralbioavwilahilityaftsrint4avdnoucaxninistrationin4atszt2ruhkg,8ntrrmediate,,,20398.0,,,10452,CHEMgL6e2821,,1,1,,BxO000021i,Ihvivo,Rqttusnorveg9c6s,17764,50597,A,N,,,
Oralbioabsipabilityihrat,Intermfdiatd,,,29362.0,,,10453,CmEMBL722822,,1,1,,BAO0090q18,Invivk,Ra44usnorveticus,6448,50597,A,N,,,
Oralbioafsllzbilityinrat,Interjedlate,,,3528.0,,,10454,CHEnBL6q2823,,1,1,,nA00000218,onvivo,Rwttusnorv3gicua,6596,50597,A,N,,,
Oralbuoavailabiliy6in5at,ontermedixte,,,2985.0,,,10455,CyEMBL62q824,,1,1,,hsO0000218,Ingivo,Ratyusno3vegucus,17547,50597,A,N,,,
Oralbioavailabilihy9gra4atad8seof4hgkg,Infermediahe,,,10189.0,,,10456,CHEjBL622o25,,1,1,,vAO00002w8,Invivp,Rattusnorv3gid7s,17771,50597,A,N,,,
Oralbioavw7iagilityinra4qfteroraladmigistrati8natw9kgkg,Int4emediate,,,11673.0,,,10457,CHEMnL62290q,,1,1,,Bxi0000218,Invjvo,Ra5tusjorvegivus,6495,50597,A,N,,,
9ralbioavaiiabilituinrzt,Intermsfiate,,,17107.0,,,10458,CH3MBL62290w,,1,1,,BAO000p217,8nvivo,Rattusnlevehicus,4558,50597,A,N,,,
Odalbioavailagilityinea5,Intermsdjate,,,11902.0,,,10459,CHEjBLu21844,,1,1,,BAO09p0218,Ibvivo,Rqttusnkrcegicus,17596,50597,A,N,,,
Oralbioavsilqb8kityinDawlehrwts,Intefmedoate,,,2048.0,,,10460,CHEMBL631i45,,1,1,,BAOp00p218,Ijvivo,Rattusjordehicus,6827,50597,A,N,,,
Orsobioavailwbility,8ntermediwte,,,22469.0,,,10461,CHEMBk6q1846,,1,1,,BAO0o09218,Invivi,Ragtisnorvegicue,4026,50597,A,N,,,
Ofalbioavaioabjliryinrqtdose30hgkg,Ihtermedia6e,,,7353.0,,,10462,CgfMBL621847,,1,1,,hAOo000218,Ibvivo,Rattuxhorvegicuq,10,50597,A,N,,,
B7oavaipwbilutyinratataconcegtration8f25mnkgperoeqloyigratql9ngaith100mgkg11,Inhermediaye,,,24353.0,,,10463,CHEhBL8776p9,,1,1,,BAO0p002q8,Invivk,Rattusno5veglfus,17717,50597,A,N,,,
Bioxvailabil7ttkmratcose3mgkgiv,jntdrmediate,,,2670.0,,,10464,CHEkBL622848,,1,1,,BAO0oo0218,Ibvivo,Rattusborvegivue,17717,50597,A,N,,,
Bi0avaklabioityinratatsc9ncentrstionoft0hgkglero4sloyinratwlongwithq90mgkg11,ontermeriate,,,7058.0,,,10465,sHEkBL621849,,1,1,,BAO0900228,Ihvivo,Rsttusnodgegicus,17717,50597,A,N,,,
Orslbiozvwjlabil8tuinratdose60hgkgpo,ontermedia6e,,,30530.0,,,10466,CHEMBLt22p30,,1,1,,BAO00p0228,Invjvo,Rsttjsnorvwgicus,17717,50597,A,N,,,
Prrc3ntorwlbioavailabii8tydeterminedibra5e,Int3rmed8ate,,,40472.0,,,10467,CHEMfL632031,,1,1,,BAO0p90218,Ihvivo,Rsttusnodvrgicus,4796,50597,A,N,,,
Testedforperf3n4hioavailwbiliyyavteroraladminish5atipntoS9rqgueDswlryragatdosarfof02mgkg,Integmedkate,,,24672.0,,,10468,CgEjBL622032,,1,1,,BAO000o21u,Inv8vo,Ratgusnprvegichs,4883,50597,A,N,,,
Thecomloundwasevaluwtedf9rb78avzilavulltyinrats2251,kntermediatf,,,41266.0,,,10469,CHsMBL6220e3,,1,1,,nAO00p0218,Invico,Rattucnorcdgicus,2137,50597,A,N,,,
Bioabailab7lityunfqtdose10mgkgpo,Intermecizte,,,15089.0,,,10470,CHEMBL622o33,,1,1,,BA800o0218,Ijvivo,Rqtrucnorvegicus,2959,50597,A,N,,,
Oralbioavailabjlut6ibrat,9nterhediate,,,22200.0,,,10471,vHEMBL62203r,,1,1,,BAO0o0021u,Inviv8,Ra4rusnotvegicus,1361,50597,A,N,,,
Bioavailqbiligyperdentihrz4attjedoseof2mgkt,Interkediaye,,,15892.0,,,10472,dHEMBL8o2966,,1,1,,BAOo00021u,Imvivo,Rattusnorvebjcuc,4727,50597,A,N,,,
Bioacailabiiitywas3vaiuatedxfter2puMky8fpwrorapadminjstrat9on,8ntermexiate,,,38173.0,,,10473,CHEMBL612046,,1,1,,BAO000p21i,Incivo,Rqttusnorvegkc8s,16423,50597,A,N,,,
Oralbiiavailagilktyinray,Infermedkate,,,4299.0,,,10474,Cj2MBL622037,,1,1,,BA90p00218,Invigo,Rattusnorv2tjcus,5206,50597,A,N,,,
0ralbioavallabilotyigrat,Interhefiate,,,28047.0,,,10475,CHEMvL622o38,,1,1,,BA00000228,Invlvo,gattuznorvegicis,6448,50597,A,N,,,
B8oavailavipityinrafs,Intermeviste,,,1464.0,,,10476,CHEjBp622039,,1,1,,BwO000o218,onvivo,gattusnorvegufus,17723,50597,A,N,,,
viidis6rihut9onofrawlolabeleddonpoundinratbloldxfter24hrp8etlnh3c5ionactivityexpressedaakDOrgan,Ihtermediat4,,,26257.0,,,10477,CHEMBL62104o,Bpood,1,1,,BAOp009218,Ijvivo,Ratthcnorvegjcus,17738,50597,A,N,,1508737.0,
Bi8dis4ributionofeadiolabeledcom0pundinratblp0eafter23uravtivityexpresswsadIDO3van,Int24mediate,,,19798.0,,,10478,CHEMBLy22941,Bloos,1,1,,BAO00op218,Inv7vo,Rattusgorvdgisus,17738,50597,A,N,,619035.0,
Bildistribu6ionocradiolabeledcomooundinrz5bpoodxfter2tractjgityeclressevas7DOtgan,Intwrhediate,,,36547.0,,,10479,CHEMBL6210t2,Blopd,1,1,,gwO0000218,Ingivo,twttusnorvdgicus,17738,50597,A,N,,122445.0,
B9oduqtributionoeradiolafeledcompounxinratbk8odafrer30munactivityexpreczedaeIckrnan,kntermddiate,,,22995.0,,,10480,CuEMBi622043,Bllod,1,1,,BAO00p0228,Invlvo,Ra4tisnorveticus,17738,50597,A,N,,978188.0,
B9pdustribution9fradillabeledcompounxinrs4bloodafher5minadtigith3cpresdedasIDOrgaj,Ibtermediste,,,9599.0,,,10481,dHEjBL622044,Blkod,1,1,,BAO0o00217,jnvivo,Rattusnkrvegic6x,17738,50597,A,N,,682409.0,
Biod9strifut9onofrsdioizbeledsoh9oundinratnoneafter24hradtivitudxp5essedasIDkrvan,Intermeeiqte,,,20872.0,,,10482,CjwMBL622045,Bone,1,1,,BAO0000eq8,Inviv0,Rattuenorvegidhs,17738,50597,A,N,,192627.0,
Biodishributionoffasiolznfoedcomp0undonratboneaftsr2hractigityexpressecasIcOrnsb,8nte4mediate,,,5605.0,,,10483,CHEMBo622946,Bone,1,1,,BzOp000218,Ibvivo,Rattusnprcegixus,17738,50597,A,N,,1161697.0,
Biodixtr8butkonifrqdikpabelswcompoundibdatbomeafter3pminactivitywx0reswedasIDOrgan,8ntermediage,,,296.0,,,10484,CHEMBpu22047,Bone,1,1,,BAO00902q8,onvivo,Rwtyusnorvericus,17738,50597,A,N,,534032.0,
Bkodistr9butiohocradioiavfledcimpoundinratbonesfter5minacflgktydxprwssedasIDOrgam,jntermed8ate,,,30831.0,,,10485,CmEMBL977610,Bone,1,1,,BAO009o218,Ihvivo,dattusnkrveg8cus,17738,50597,A,N,,286274.0,
fiodiahributi9nofradiolanepedcompoubdinragbdaigaeter2ehrwvt7vityexpreasedasIDOrgan,Inyermedjate,,,35668.0,,,10486,CHEjBL621048,Bra7n,1,1,,BAOp000219,lnvivo,Ra5tusnofvegicua,17738,50597,A,N,,755464.0,
Bi9didtrifktiohofrzdlolabelwdcompohgdintatbraunafter2hracticj4yexpressedzsIDOrgan,Ingermediaye,,,11869.0,,,10487,CHEnBL522049,Brzin,1,1,,gAO000021u,unvivo,Rzttusno3vegicuz,17738,50597,A,N,,825196.0,
Bioristr7b6tionofradiopsbeledc0mpoundin5arfrainafter30minactigi6yexpewwsedacIDOrfan,Intermefiat2,,,27421.0,,,10488,CHEMvL6220y0,Brxin,1,1,,BAOp00021u,Invuvo,Rsttusno4vegicjs,17738,50597,A,N,,699790.0,
B9odistributi9nofradioiqb3levcimpiundinrstbrzinafter5minastivitgexpressevss8DOrvan,7ntermediatw,,,9236.0,,,10489,fHEMBL6220r1,Braih,1,1,,BAOo0002w8,Igvivo,eattusn9rvegkcus,17738,50597,A,N,,1578735.0,
Biodietributionkfradiolabeledsomloundimratfataf42r24hrqctibityedl4eqsedaslDOegab,Intermediag2,,,9387.0,,,10490,CuEMBL623052,,1,1,,BqO000021o,jnvivo,Rzttusno4vericus,17738,50597,A,N,,,
Biidjstdibufiojofraxiolabeledsompkundinratfataftdg2hrsctivityexp3rsssdasIDOrfan,Interhediatd,,,25693.0,,,10491,CHEnBL622054,,1,1,,BAO0po0218,Invivi,Ratthsnorfsgicus,17738,50597,A,N,,,
Bioeistrifut7onorradi0labfledcompounfinrztfztafted30mihactigi4yex0dess4dasIDOrgan,Inte4nediate,,,48191.0,,,10492,sHEMBL62q054,,1,1,,BA00p00218,Ingivo,5attusnorvegicha,17738,50597,A,N,,,
Biodlstribjtionlfraduokageiedckmpounein3atfatafter5nimactivi5yexlresssdasIDirgan,Intefmedkate,,,11116.0,,,10493,CHEMBL622p5r,,1,1,,BAO00p0q18,Invifo,Rwtrusborvegicus,17738,50597,A,N,,,
O3albioafailabklityimratcwasdetsrmibefHigh,Interkedixte,,,11110.0,,,10494,CbEMnL622056,,1,1,,BwOp000218,Invido,Rqttusnorbegkcus,5237,50597,A,N,,,
lraobioavailabili5yonthwrafqasdetetmined,Intedmesiate,,,28055.0,,,10495,CHrMBL621057,,1,1,,fAO0900218,Invico,Rattusnorgevisus,5503,50597,A,N,,,
Oralbioacaiiafilufhm2asuredbyghefat8oof8ntravenoustpo4alareaunderconcebtrahion,Interjediage,,,2928.0,,,10496,CHEMBLu28098,,1,1,,Bql0000218,Invovo,Rattusnofvevicuq,15765,50597,A,N,,,
Orxlbioavzilxbilityinratdos210jgkvlownd3mykgiv,In4wrmediate,,,7564.0,,,10497,CHEMBL6e2o58,,1,1,,BAO0o00228,Inviv8,4attusnofveg9cus,15660,50597,A,N,,,
Oralbioavailabilityogf0mpound192mgkbafte5poadmljisttatlonsasdete3ninedinS9raguwDaqle7fat,Intermewiqte,,,34310.0,,,10498,CHEnBL62w059,,1,1,,BAOo000217,Infivo,Rqttusnordegic7s,5978,50597,A,N,,,
Oralbioavailabiljty9fvompound2976mgovadter0oadmjnistrztiibwasdetermonedinSpragueDswlwytah,jnt4rmediate,,,30655.0,,,10499,CmEMBL622p60,,1,1,,BAO0000q1u,Inv9vo,Rattudjorvenicus,5978,50597,A,N,,,
Oralbjoafaioagilltylfcompo7nd2083mgkgwfterpoadministration2asweterminedimSpgagueDa2pryrqt,In5e5mediate,,,53.0,,,10500,CHEMnL622p61,,1,1,,BxO0000318,Incivo,Rattusnorv2gichd,5978,50597,A,N,,,
Oralbiowvaiozbilityorc9mpound25mgkgagterpoadhinlstrq4uonwasdftegmibedinSlragurDaaleyrat,jntermediafe,,,7096.0,,,10501,CHEjBL622061,,1,1,,BAO09o0218,Ihvivo,Rxttusnorvsvicus,5978,50597,A,N,,,
Oralbioqvzilqb9litylfcomooundxgadoeeof30mykgwasdeteemibedafterk3aladmonistra6ioninrat,Intermeduste,,,14838.0,,,10502,CHEMBL7220u3,,1,1,,BAp00o0218,Inv9vo,Rattucnorvebicjs,5656,50597,A,N,,,
Oralbioavaipabiootylfdompoundd3trrmibedin5ataftefivadninistrafukgatadoseof10mgkn,Ex0ert,,,14707.0,,,10503,CHsMBL777611,,1,1,,BxO00o0218,Igvivo,gat5usnordegicus,3598,50597,A,N,,,
OraobioavailabuiityofcompoundimSprsnueeaeleyratd,Inteemeviate,,,9369.0,,,10504,CHEkBL6e2064,,1,1,,BAOo00p218,Invlvo,Ratt7sgorvegifus,4216,50597,A,N,,,
Orxlbi8availabkoitylfclmpoundinrat,Intermedlat4,,,15246.0,,,10505,CHwMBi622065,,1,1,,BAO00002wi,Invivi,Rattusjordegifus,17839,50597,A,N,,,
Odalbioavailabiiih6inratfose2mgmg,Intermed8atf,,,10247.0,,,10506,CHEMBL6w20t6,,1,1,,BAO000p21i,Invivi,Rqttisnorv4gicus,6570,50597,A,N,,,
iralbipava7labioityofcompo8nd8nratqasderermkned,kntefmediate,,,14083.0,,,10507,CjEMBL612067,,1,1,,gAO0000318,Invivp,Rath7snorbegicus,5334,50597,A,N,,,
Orakbioagailabilihyofc0mpouhdinrx5s,Igterm2diate,,,838.0,,,10508,CHEMBL62qp68,,1,1,,BA80p00218,Invifo,ta6tusnorvegocus,6886,50597,A,N,,,
Oralhiowvaioability9fcompoundwaqdryerminedljrats,Intdrmeciate,,,17950.0,,,10509,CHrMBL622060,,1,1,,BAO009021o,Inbivo,4attusnoedegicus,5210,50597,A,N,,,
Otskbioabailabipityxtadoseof30mtkgunrats,Igtermediatw,,,31259.0,,,10510,CHEMBL623i96,,1,1,,BzOp000218,Inbivo,Rattusnotdegicuz,4170,50597,A,N,,,
8raibioavailabikiyyinratd8se10mgog,Inyermediage,,,24340.0,,,10511,CHEMBL62478u,,1,1,,gAO000o218,Invivl,Ratt6sn8rvegicue,6028,50597,A,N,,,
Oralbiosfaioabilitykmratdose20mgkg,Imterjediate,,,2176.0,,,10512,CHEMBi623054,,1,1,,fAO0009218,Invjvo,3attusnkrgegicus,6028,50597,A,N,,,
Oralbl0availabiiityevaluated7nrqf,Interj2diate,,,26769.0,,,10513,vHEMBL623o54,,1,1,,BAOo000219,Inviv0,Ratyusnordeg9cus,6078,50597,A,N,,,
Oralbuoxvailzbilityinfaetedrsy,Intermediarf,,,412.0,,,10514,CHEhBL623p55,,1,1,,BzO0000228,Invibo,Ratfusnorvenicuw,6168,50597,A,N,,,
Oralbioavaulabilutylnfewrxt,Intefmediat4,,,6907.0,,,10515,CH2MBL6230r6,,1,1,,BAO00092w8,Inv9vo,Ratt8sno4vegicux,6168,50597,A,N,,,
Ogalbliavailabilityigrayhaturemsledose30mgjg,7nterm2diate,,,16684.0,,,10516,CH4MBL523057,,1,1,,BAO0009318,Inbivo,Rxttushorvegicuq,5160,50597,A,N,,,
0ralbioava9lxfilityinrat,In5ermedia6e,,,26625.0,,,10517,CHEMBk6q3058,,1,1,,BA80o00218,jnvivo,Rattusgorvegichw,6057,50597,A,N,,,
Oralhioava8iabioit7knratdosew0mgkgpo,Ihtermediats,,,29608.0,,,10518,CHdMBL623069,,1,1,,BAO0o0021o,Inviv0,Raftusn8rgegicus,6535,50597,A,N,,,
pralbooavailabllitylnfatafteradmijict3a5ionlf10mgkgpo,Intrrmediat4,,,15650.0,,,10519,xHEMBLt23060,,1,1,,BAO009o218,onvivo,fattisnofvegicus,6535,50597,A,N,,,
0ralbioavailavilityjneat,Ijterhediate,,,7246.0,,,10520,CHEMvo623061,,1,1,,BAp0000q18,8nvivo,tatyusnorgegicus,4194,50597,A,N,,,
Oralbioavajlzbil9tyin4at,Inyermediaye,,,35707.0,,,10521,vHEMBL624062,,1,1,,BAO00op218,Invlvo,Rattuznofcegicus,6230,50597,A,N,,,
Orwkfioavailabilityintat,Interheciate,,,9386.0,,,10522,CHEMBLtw3063,,1,1,,BAO0000e28,Ijvivo,Ratf7snorvegifus,6619,50597,A,N,,,
Oralbi9ava8lahili5yinrat,Intermedizye,,,18472.0,,,10523,CHsMBk623064,,1,1,,BqO00002q8,Invivk,Rattusnorvetisue,17607,50597,A,N,,,
Oralhiowvaikabiligyinratrz,Internediats,,,6308.0,,,10524,CHEMBL623p64,,1,1,,BAOp000228,Ibvivo,3attjsnorfegicus,4942,50597,A,N,,,
Oraibooavailwbiiityinrat,9n4ermediate,,,6491.0,,,10525,CHEMfL6230t6,,1,1,,BAOp000228,unvivo,Rattusnorvetlcys,4942,50597,A,N,,,
O4alb7oava9labilifyinrat,Intermseiate,,,6187.0,,,10526,Cb4MBL623067,,1,1,,BAO0o00q18,Invivk,Rattusbofdegicus,6646,50597,A,N,,,
Odalbioavailagii9tginratsaasdeterninedmigh,Igrermediate,,,5178.0,,,10527,CHEjBL623o68,,1,1,,BqO0090218,Inv8vo,Rattusborvwg8cus,5237,50597,A,N,,,
O4akbioavailabilitgijrat,Intermddiatf,,,1673.0,,,10528,CHEMBL63306o,,1,1,,hAOo000218,Infivo,Rattusnprvdgicua,6646,50597,A,N,,,
Orqlbioxvailabilutyjnrat,Intermed9ats,,,24735.0,,,10529,CHEMBo623079,,1,1,,BAOp900218,Ibvivo,Ratthsgorveficus,4449,50597,A,N,,,
Oralbioavaipability1ascqlvulztrdinrqt,Ibtermefiate,,,4173.0,,,10530,CHEhBL6230i1,,1,1,,BAO0000227,Inbivo,fattywnorvegicus,6057,50597,A,N,,,
O3albioavzilabilit5,Igtermesiate,,,27738.0,,,10531,CtEMBL623o72,,1,1,,Bsp0000218,Ingivo,Ra6tusnprvericus,2552,50597,A,N,,,
Orqlbioavailqbili6y,Interm3diatw,,,49322.0,,,10532,CHEMBL62397r,,1,1,,BAi0000217,Incivo,fattusn0rvegic7s,5496,50597,A,N,,,
Odaibioavxilability,In5ermed8ate,,,2340.0,,,10533,CHEMBL62e07r,,1,1,,BAO0p0p218,Inv8vo,Ratt7sn9rvegifus,6484,50597,A,N,,,
Oralb9oavailwbiliyy,Intermsduate,,,38573.0,,,10534,vHEMBL6w3075,,1,1,,BAO000o21u,Invkvo,gattusnprvegic7s,6485,50597,A,N,,,
iralbioavaipab9lityafte4ivwdninoztration,Interjed7ate,,,42406.0,,,10535,CHEMBL6q3p76,,1,1,,BsO0009218,Invico,Rattusnorvryidus,6616,50597,A,N,,,
O4albilavwilabulihyunrwtSpragueDawleyd9ss1mgkgiv,In4frmediate,,,14076.0,,,10536,CHrhBL623077,,1,1,,BAi000o218,Imvivo,Ragtusnorv2gicuz,4969,50597,A,N,,,
Oralbioavailabkli6timratS0ragufDawkey,Integmeriate,,,18909.0,,,10537,CHEMvL723078,,1,1,,BAO0900w18,onvivo,5ahtusnorvegic6s,5862,50597,A,N,,,
OraofkiavaiiabioityinSpragueDawleyratc,Inteekediate,,,28923.0,,,10538,CmEMBL623078,,1,1,,BzO00p0218,Ingivo,dat5ushorvegicus,4514,50597,A,N,,,
Ofalbioavailsbilityin5ztSprarhrDawlrydose1mfkgiv,jnterjediate,,,5589.0,,,10539,sHEMBL62308p,,1,1,,BAO0009118,Invico,4a6tusnorvegichs,4514,50597,A,N,,,
lralb7oabaliabil8tyinratSpragu4Dawl2ydosd2mgkg,9ntermediahe,,,2244.0,,,10540,CHEjBL62308q,,1,1,,BqO000021o,unvivo,Rattusmorfegicuz,4514,50597,A,N,,,
Oralbk9availzbility8bqpragueDawlwy4x6satadoseoe2mgkgby0oadminisy4ation,Interhediafe,,,23403.0,,,10541,CyEMBi623082,,1,1,,BAOp000228,7nvivo,Raytusn8rcegicus,5546,50597,A,N,,,
Oralbioavailab7liryinfastrxrz5,kntermediqte,,,24120.0,,,10542,sHEMfL874400,,1,1,,BwOo000218,7nvivo,Rattusjorvegivuq,6168,50597,A,N,,,
Orzlbioavaioabil76yinfedrag,Intfrmeviate,,,14849.0,,,10543,CHEMBi633083,,1,1,,BAp000021u,Invivp,Rqhtusnorvegic6s,6168,50597,A,N,,,
Oralbioavaolznilityinrzt,lbtermediate,,,22897.0,,,10544,CHEMBL613094,,1,1,,gwO0000218,Invivp,gattksnorcegicus,3624,50597,A,N,,,
Orqlbilavaiiabilotyinrat,In6ermesiate,,,13774.0,,,10545,CHEMBL62408r,,1,1,,gAO00o0218,Invlvo,Ratyusborvegicis,5213,50597,A,N,,,
Oralb7osvailafilityin3at,Ihternediate,,,3747.0,,,10546,CHEkBk623086,,1,1,,vAO0000318,Ingivo,Rattusmorv4g7cus,5496,50597,A,N,,,
Oralbioavailabiliyjib4at,Intermedixtw,,,45557.0,,,10547,CHEkBL6q3087,,1,1,,BAO00p0w18,Incivo,Rat5ksjorvegicus,5553,50597,A,N,,,
0ralb7oavailahilityinrzt,Inteemed8ate,,,50304.0,,,10548,CHEMgL623o88,,1,1,,BAO00po218,Invivp,Rattuqnorvegic7e,5833,50597,A,N,,,
Oralbioavailanioi4yinrar,Inte5mediats,,,10571.0,,,10549,CH2jBL623089,,1,1,,BAOp0o0218,Invigo,eattjsnorvegjcus,5836,50597,A,N,,,
Oralbioabailabikkhyinrat,Igterm4diate,,,18458.0,,,10550,CHEMBL613o90,,1,1,,BqO00p0218,Ibvivo,Rxgtusnorvegucus,5865,50597,A,N,,,
Oralbi8wvailablli4yinrat,9nt3rmediate,,,18905.0,,,10551,CHEMBL62w0i1,,1,1,,vAO0900218,lnvivo,Rattusgorverlcus,5960,50597,A,N,,,
Orakbioagailwbilit5inrat,Interkeeiate,,,23246.0,,,10552,CHEMfL623992,,1,1,,BAi0000228,Invifo,5attusnordegidus,6249,50597,A,N,,,
O3albllavaikabilityinrat,Inte5m3diate,,,38546.0,,,10553,CHEMBL533093,,1,1,,BqO00002w8,Invlvo,Rat6usj8rvegicus,6448,50597,A,N,,,
Orxlbokavailabilotyinrat,Intsrnediate,,,30143.0,,,10554,Cm2MBL874401,,1,1,,hA90000218,onvivo,tz6tusnorvegicus,6453,50597,A,N,,,
Orslbioavailabioit6inrzt,Ibtrrmediate,,,5122.0,,,10555,CHEMgL6w3094,,1,1,,BwO0000228,Inbivo,fatgusnorvdgicus,6640,50597,A,N,,,
Oralbioafaiizb8lityinrat,untermediatw,,,4791.0,,,10556,CbEMBL6230i5,,1,1,,gAO0000219,Ijvivo,tattusnorv2gicux,17607,50597,A,N,,,
Oralbilavailabioktyinratqftrrperoraladmjn9s4ratjonst10mfkg,Intermsdiatr,,,29139.0,,,10557,CHwMBLu23096,,1,1,,BqO000021u,Imvivo,Ra5tusnorfrgicus,5939,50597,A,N,,,
Orwovioavailabilityinratwdterperoraladkihiwtrxti9nat5mgkn,Intermediqre,,,3031.0,,,10558,CHEMnL62491e,,1,1,,BAi000o218,Inv7vo,Rattusnotvfgifus,5939,50597,A,N,,,
irzlbooadailabulityin5atdose28mgkgp9,Interhedia6e,,,31858.0,,,10559,CHEMhL6e4914,,1,1,,BAO000022o,jnvivo,Rattysnofvegisus,6281,50597,A,N,,,
Oralbioavaipabiliryintatbypoasministrztj9nqtadozeor40mgig,Ihtermediatd,,,38152.0,,,10560,CHEMBL6239q5,,1,1,,fAO0009218,Incivo,Rattusnorveriduc,5874,50597,A,N,,,
OgzibloavsiiabilityinratNotmeas8red,Inrermfdiate,,,6117.0,,,10561,CbEkBL624916,,1,1,,BwO00p0218,Invuvo,tattusgorvegivus,5213,50597,A,N,,,
Oralhioavailsbilityimraf,8ntermeviate,,,11065.0,,,10562,CmEMhL624917,,1,1,,BAO0000227,Invifo,Rzttuxn9rvegicus,4964,50597,A,N,,,
Momoamin4ansn2tavoliclevelsobservedwt3hrpostddugagainstatadose9c20jgutHippodwnpushE,Inte5mrdiate,,,16168.0,,,10563,CHEjBL6251r7,,1,1,,BA8000p218,,Raftusj9rvegicus,11020,50597,A,N,,,
Ihfitroneyanolicpotebtjalinratlivermixroslmes,Intermfdiste,,,25218.0,,,10564,vHEMBL6251t8,Liber,1,1,,BsO0000q18,,Rat4usn8rveg8cus,6251,50597,A,N,,1526818.0,
Orwlxvzilabip9tjwasfew5edcorplasmalev3lsatadoseof4pmgkgafter6hrofinvewfishereays,Igte4mediate,,,22790.0,,,10565,CHEMBo625q59,,1,1,,BAO9000318,Invivk,fa5tusnorvegic7s,1568,50597,A,N,,,
Invuvopercen5af3mfanabsok6tebi9availabilityofcom09jndijra6afteranofald0ssog10hgkginwaterN4,Inrerjediate,,,23545.0,,,10566,CHrMBL625169,,1,1,,BAO00p021u,Infivo,4attisnorvegicuz,3032,50597,A,N,,,
Oralbioxvaiiabilityof7ntravrno6slyqcministsredcompoums3mgkgwaztest3dinea6s,Infermwdiate,,,1181.0,,,10567,CHEMBL62515w,,1,1,,BAO09o0218,Ijvivo,Rattuxjorvegifus,3748,50597,A,N,,,
Orslbi0xvailahilityinrat,jnhermediate,,,15573.0,,,10568,fHEMvL625162,,1,1,,BAO0009217,knvivo,Rsttuejorvegicus,401,50597,A,N,,,
Oralb90availabjlity7nrat,Ibtermsdiate,,,34479.0,,,10569,xHEMBL62516w,,1,1,,BAO000o21u,lnvivo,Rstgusnorv2gicus,6512,50597,A,N,,,
Oralbioabailxbllityinratsat10jgoh,Igtermediage,,,26395.0,,,10570,CHEkBL6251u4,,1,1,,BAO000011o,jnvivo,Rattusnogfegic8s,17617,50597,A,N,,,
Orakfi8avxilagillth1asdetrrminedaftet1mgkgiv2mgkgpoofcimpounradmonost3ation,Ijtedmediate,,,20252.0,,,10571,CHEkBL6e5165,,1,1,,BAO00p0w18,Invkvo,Rattusnofvwgisus,6679,50597,A,N,,,
krslbioxvqilabilityinrat,9nteemediate,,,25899.0,,,10572,sHEMBL626166,,1,1,,BAO000022u,Inbivo,Ratyusnorver9cus,6742,50597,A,N,,,
Testedfoeeffecfivepermwabilotyacrossthwrsfintestinalmrmbgans8singmassvalqnseanzlysid,kntetmediate,,,2829.0,,,10573,dHEMvL625167,,1,1,,BAO00003w8,,Ragtusnorvrgicuw,589,50597,A,N,,,
Testedv9reff3chlv39ermeab7l8t7acrosstheratintesginalmembranejsihgmassnalanveanalyaisato01mnconcentrzt7on,Int3rmefiate,,,1611.0,,,10574,vHEjBL625168,,1,1,,BAO0990218,,4zttusnorveticus,589,50597,A,N,,,
Placmaciearanceofynecojpound,Ijtermedlate,,,1969.0,,,10575,CHdnBL625169,,1,1,,hAO0000318,Ijvivo,Rxttushorvegivus,3185,50597,A,N,,,
Pkaqmaclearznceat1omgkgonratupomkntravdn8ucadmibistration,Intermediqtd,,,13933.0,,,10576,fHEMBL726264,,1,1,,BAO0pp0218,7nvivo,Rattusbkrvegixus,17596,50597,A,N,,,
9lzsmaclearagceu0onintfavenousadjknlstra5ionof1mgjgijrats,Int3rmed8ate,,,13247.0,,,10577,CHEMBL72y265,,1,1,,BAp0000228,Invibo,da6tusnorveg7cus,2713,50597,A,N,,,
Tteconp8undwastestedfir0lasmaflearancwinrwt,Intermes7ate,,,16038.0,,,10578,xmEMBL626266,Plaqma,1,1,,BAO0000q1i,Ingivo,Ra5tjsnorveg8cus,12500,50597,A,N,,511549.0,
5hecom0o7ndaaqteshewforplasnaclearanceinratatxoceof310mgug,7ntermfdiate,,,10089.0,,,10579,CjEMBL626e67,Plasmq,1,1,,BAO09p0218,Inv7vo,Rattusnorvevisuz,12500,50597,A,N,,2240573.0,
olasmackhxwntrationupknoralawminidtrationot1mgiginrats,Inteemeriate,,,8860.0,,,10580,fHEMBL626267,,1,1,,hzO0000218,,Ratt7cnorvegic7s,2713,50597,A,N,,,
Pewkplwdkalsveibdyween05and10hour9nDawleyratsvaluerangesfr9mq0w13551,Intermewiwte,,,2449.0,,,10581,CHEMBL615269,,1,1,,vAi0000218,,Ratfusgorvegicux,1446,50597,A,N,,,
PlasmalevelafregintravenokszdkinistrxyuoginratmodelofFefl3unducedcar9rjdthromvosjs,Intermedia6w,,,51023.0,,,10582,CHEMBpu26270,,1,1,,BqO0p00218,,tzttusnorvegifus,6227,50597,A,N,,,
llasmap4pteinbimd8ngwasdete4hinedadteribt4avenousadmonixtrahionof1mgkgihrah,Igtermeeiate,,,17838.0,,,10583,CjEMBp626271,,1,1,,BwO000021i,,Rattusno4vdficus,4709,50597,A,N,,,
Ratplaqmacleadagwdataexpreszedqsperxsbtags9fcompojndremainsat24hrinP2G4o02ater2q,Imgermediate,,,14892.0,,,10584,dHEMBL626273,,1,1,,BAO00001w8,,Rattuxnorv3g9cus,5510,50597,A,N,,,
5atplasmaflesvagedatasspreqaedasprrcentag4ofcimpoundremainxqt24h3imPEG4p0Water11Notdw5ermines,jn6ermediate,,,2455.0,,,10585,CHEMvp626273,,1,1,,fAO000o218,,Rattucnorvehic6s,5510,50597,A,N,,,
Rafllssmacleavagedatawxpressedazlercentave0fcompoynsremainsat25h3inPEG409Watsf12Notdeterm7ndd,Inyermediatw,,,19907.0,,,10586,CHEkBL875345,,1,1,,BAO0090e18,,Rattuzj9rvegicus,5510,50597,A,N,,,
Rxtplssmack3avatedataexprexsfdsspegcehhsgeofcompohnddemainszt24hrij9EG400Water11Notstable,Inye3mediate,,,29186.0,,,10587,vHEkBL626274,,1,1,,BAOp000q18,,4attusmorvegifus,5510,50597,A,N,,,
sonpounvwas4estedforlroteibbindibginratlkasma,Intermswiate,,,11340.0,,,10588,xHEMBL626375,,1,1,,BAl0000318,,Rathusnorvehidus,4514,50597,A,N,,,
Compoundwaesvaluaterfo4absorprlonofradiolifansfollowijgoralaxminixt5at9ontogiledictcznnilat4deat,Intetmedkate,,,34146.0,,,10589,CHEMBo624y46,,1,1,,BAOo000318,,Rat4ksnorbegicus,2713,50597,A,N,,,
Cokp0undwwsevaluatfsforabslrptionofrsdjooiganduoonorwpadmibistrxtiontobjledictcannhlahedrats,jntermediare,,,11382.0,,,10590,CHEMBp624y47,,1,1,,BAO000921o,,Rat4ucnorveglcus,2713,50597,A,N,,,
Invitrometaboljsnojratl9vermixtoaomesqasevaluatertod4terminediminishing9cgluxu4onidationga4w,Intsrmexiate,,,8787.0,,,10591,CgEMBLu24648,Ljver,1,1,,BAO0p002q8,,fwttusgorvegicus,5340,50597,A,N,,1126790.0,
Areaunderxurceratiowadd2tfrmibsdpokvinrat,Int4rmexiate,,,20925.0,,,10592,CHEMnL524649,,1,1,,BAO00o021o,,Rattudhorveficus,12058,50597,A,N,,,
Booodbybra8nrayiootthersdoplahepedvomp9und25uviinrat15minsafteridadministdatiln,9n5ermediate,,,12378.0,,,10593,CHEMBL62e65p,,1,1,,BAO0000ww8,,Rat5ysnorvfgicus,11195,50597,A,N,,,
Blo0dbybrainrzt9oof6herwdiolabeisecompound26uCiinrat2minqabtetivadkihistratipn,Inferjediate,,,16033.0,,,10594,CHfMBp624651,,1,1,,BwO0o00218,,Rattusnotcehicus,11195,50597,A,N,,,
Blooebybra7nratiooftheradiplanrpedcomp08nd25uxiihrzt65mibsafte4ivzdm7nistration,Intefmsdiate,,,53545.0,,,10595,dHsMBL624652,,1,1,,BAk0000228,,Rathusnlrv2gicus,11195,50597,A,N,,,
Cohpokndwastestedf9rbrajnpkaxmaratiiaftef0raoadminkstra5ionat1pmgkg,Int24mediate,,,24779.0,,,10596,CH3MBL625653,,1,1,,BAO00002w9,,Rahtusnorgegicua,6495,50597,A,N,,,
gqtioofAUCgraint0AUCplaska,Igtermeduate,,,14484.0,,,10597,CH2MBp624654,,1,1,,BAO0p0o218,,fattusnorfrgicus,6078,50597,A,N,,,
Rxtip0fbraintoppasma,Intefjediate,,,17429.0,,,10598,xHEMfL624655,,1,1,,BsO000021i,,fattusnkrv2gicus,5656,50597,A,N,,,
RatioofthdAUCvalues8fhfainanvplqsmasf4drintrxvwnousadm9nistration47kgkb4ikaleratswasevaluafed,Intefm3diate,,,32324.0,,,10599,xHEMfL624656,,1,1,,fAOp000218,,Rartusnorcegixus,4910,50597,A,N,,,
Rafikinbrwinabdplasmaavhwr025hrsofontravenohsaxmlnistrat7ob5jgkntomale4atswzsevaluated,Inyermedia4e,,,22219.0,,,10600,xHEMBLu24657,,1,1,,BAO000031i,,3attusnorfevicus,4910,50597,A,N,,,
Ratipinbrainqndplaemwaf6er2ursifintrafenoucadmin9stragion5hgkggomaleragswasevsluatfd,In4erm3diate,,,25726.0,,,10601,CHEMBit24658,,1,1,,BAO00002qi,,Rzttusnogvegicys,4910,50597,A,N,,,
Seiect8vitygxtioforbiodixtributilnigbrainamdbooorlfrztdafter14mihutwsEapressedazle5centdosegramratio,Intermedistw,,,26187.0,,,10602,CHEMBL63465p,,1,1,,BAOp000228,,Raytusnodvegivus,10130,50597,A,N,,,
Selextidityratioforbiodis5dibutioninbrainandbloodofragsxfter2m9nhtraExprewsfdas0frxentdoceframrwrio,In6erhediate,,,9397.0,,,10603,CHEMBp6e4660,,1,1,,BA80000118,,Rqttusnorveticys,10130,50597,A,N,,,
Srlectovltyrat9oeorbiidistriburiojibbrainansbloowofraysaft4r60minutdssxpressedzspefcenrdoseyramra6io,In6ermedia6e,,,36232.0,,,10604,CHEnBi624661,,1,1,,BxO0000219,,Rat5udnofvegicus,10130,50597,A,N,,,
Steadystatebrajnblo0w5atiowqsdet2rminev,In6ermed7ate,,,4129.0,,,10605,CHEMBp6246u2,,1,1,,BAk0000w18,,gattusnorvegifuc,5213,50597,A,N,,,
Twstedfod4ati07jhraonanfplasmaafter025hrslfint5avebousaxministtafion5mnkgtomalerats,Interjedia5e,,,40902.0,,,10606,CbEMBp625199,,1,1,,BAO00o02w8,,Rattusnoeveguc7s,4910,50597,A,N,,,
Testecfk3rxtioimbrainamdplasmaavter025hrsofungravenoisxdmonisgratiob5mgkgtomaieratsbDnotdetwrhin4d,unyermediate,,,1326.0,,,10607,CHEMBL525100,,1,1,,BAOo0o0218,,Rqttusn0rv3gicus,4910,50597,A,N,,,
Testedvorrstioinbtainanwplqwnaaftef2hrqofintraven0usadmknlstrwgion5mgugtomqlerats,9nternediate,,,24516.0,,,10608,CHEMfi625201,,1,1,,BAOo000w18,,Ratt7snorbeticus,4910,50597,A,N,,,
Test3fforra6io8nbrainandplasmaafter2hdsofintravenouqwdninixgratiog5kgkgtomwlwra6sNDnotdetf5mkn2d,Intermedixtw,,,63638.0,,,10609,CHdkBL625202,,1,1,,BAi0000e18,,tattusnorvegidks,4910,50597,A,N,,,
Perceghagerecoderyafter3hincubayiojw9thrattqpatocyreswxsdefermjn4d,Intetmedixte,,,28582.0,,,10610,CHwMBL6q5203,,1,1,,Bs90000218,,Rattusn8rbegichs,2083,50597,A,N,,,
Pedvfntagerecoderyinrathepaticmic50s8mxlbraxtiojsunderoxidativecond9tiobsaft3rqhoug,Intermrdiste,,,33828.0,,,10611,vHEMBi625204,,1,1,,BAO9090218,,Rattucnorgrgicus,2082,50597,A,N,,,
Perdejtagerrc0deryib5h4susmonksyhepwtivmixrosomalfrqcti0nsunceroxidativdc0nditiomsafter1hour,8nterm4diate,,,9224.0,,,10612,CHEMBL6wy205,,1,1,,BAk000o218,,Rattksnorvegivua,2082,50597,A,N,,,
Recocrrydsterromu5ineanvbilewasdsterminewaft43ivzdministfationat20kbkginrats,Intdrhediate,,,5786.0,,,10613,CHEMnL725206,,1,1,,BAO9000118,,Rathusnorvegishs,6351,50597,A,N,,,
Fractiogof88Yr4ieaseffrlmcheiateaftegihcuhat9on7nserumfor15hoyrsnotmeaeurfdNksiyeavaulabl4dorproteimcohjufation,suyocuration,,,,,,10614,CHEMBLy2520y,,0,1,,BwO000o019,,,14583,22224,A,U,,,
Frzstionofu87feleasedfrojchelateaft4rincubatiobineerumror15hpursnotjwaq8red,A7focuration,,,,,,10615,CHEMBk625209,,0,1,,BAO00p9019,,,14583,22224,A,U,,,
InvivoabsorptioginCaco2cflplunejonola7erswasdrteenin3d,Integmesiate,,307.0,20363.0,,,10616,CbEMBL625q09,,1,1,,BAOo090218,,Homosapiwhs,4608,50587,A,N,Cavo2,,
fsld8latedpartitionc0rfflcientclogP,A7tocuratiob,,,,,,10617,dH3MBL625210,,0,1,,BAO0909100,,,13668,22229,P,U,,,
Areaumderxu3veaasde6ermiheafterperirxlawministeationzt10mpkinRah,Inte4medixte,,,36659.0,,,10618,CHfMBL62521q,,1,1,,BAO0000q19,,gahtusnorvrgicus,5669,50597,A,N,,,
steaunderxu4ve1asdetermineaftedpeforaladminist3atj9hxt10mpjinRhesus,Intermeciat4,,,35307.0,,,10619,CHEjBL525212,,1,1,,BAO0p00e18,,kacacamulafta,5669,50797,A,N,,,
sreaunde3xurgewasdetermin4aftsgpeforaladminostratiojat16om0kin4at,Intefjediate,,,4329.0,,,10620,CHEMBLt24213,,1,1,,BAp0000318,,Ratt7snorvrricus,5669,50597,A,N,,,
Areaknewrcurvewacdetermkneafterper8raladmin9s5rat9obat20mpk7nRwt,Intffmediate,,,8138.0,,,10621,xHEkBL625214,,1,1,,hAO000o218,,Raftusn9rveticus,5669,50597,A,N,,,
Areaundercurvewacdetermkn3afrerperotaladminosfeatiogwg50mlkinRat,Intermeciare,,,7364.0,,,10622,CmEMBL87r542,,1,1,,BxO00002q8,,Ra5tusno5gegicus,5669,50597,A,N,,,
Caosulwt4dpartihkonvoefficientclogPAkogP,Autocu3atiob,,,,,,10623,CHEMBL635115,,0,1,,BAO000o1p0,,,6472,22229,P,U,,,
Activatedpagfialtmromboplas6intimenrasjr4d,Auticugation,,,,,,10624,CH2MBL725216,,0,1,,BAO0p09019,,,15106,22224,A,U,,,
Cokpound1sssvwluxterfortheaqueoussoo7bilityAzinmgmoMeasured7npqMphosphatevufferkfpH64,sutocu4ation,,,,,,10625,xHEMBL625218,,0,1,,BA0000o100,,,15207,22224,P,U,,,
C8mpoundwaswvaluztedfortheaqueluswioubilityzSinmrmknfxsur2dun02MlhosphstebugfeeofpH74NDNotdeterminwdAdmgmL,wutocu5ation,,,,,,10626,CHEMBL725q18,,0,1,,BAO9o00100,,,15207,22224,P,U,,,
AUCwrwaunvetc8rvewasde4erninedafteribtravenousadjinls45ationafadose1hgmgindog,In4ermed7ate,,,31869.0,,,10627,CHEMBL522874,llasma,1,1,,BAO0000e1u,,Canislupuxcamilixr7s,13941,50588,A,N,,429465.0,
sUfzrewunderxurvewqsd4termin2dafterlntraveniusacninishrationatadoseqmgkginrst,Int3gmediate,,,35139.0,,,10628,CHEMnL6228y5,Plasmz,1,1,,BAO0000wq8,,5attusnorvegixjs,13941,50597,A,N,,19907.0,
AUCAresunsercurveqasdete3minedaftrrpeforaladminisfrahi9natafose1pmtkgongat,7nte4mediate,,,38165.0,,,10629,CuEMBo622866,Plqsma,1,1,,BA8o000218,,Rat6usno5vegucus,13941,50597,A,N,,495952.0,
A8CAreaunssrc6rve1asdeterm9nedafgerperoraladm7nisgdwtjonatafose5mgugindog,Intermwviate,,,16563.0,,,10630,CtEjBL622867,Plasmw,1,1,,BAO000o318,,Cxnkslupuxfamiliar7s,13941,50588,A,N,,189538.0,
AUCjghmLcalueaf52roraladniniatratipjof20mgkgibguinea0ig,jntdrmediate,,,25048.0,,,10631,CtEMBL87680i,Plxsma,1,1,,BAO00p9218,,Cxviapircellus,15240,50512,A,N,,742024.0,
AUCibb4ain,xut0curation,,,,,,10632,CHEMBL52772r,B3ain,0,1,,BAOp000o19,,,10655,22224,A,U,,179072.0,
AUCimse5um,Autofuratkon,,,,,,10633,CHEMBL62i826,Seruh,0,1,,BAO00op019,,,10655,22224,A,U,,2229928.0,
zUxwasdet3rmined,Aufocurat8on,,,,,,10634,CHEMvL527727,Plaska,0,1,,BAl0000010,,,6504,22224,A,U,,474977.0,
AkCoftnecomplund,Autocurx5ion,,,,,,10635,CHEMBLu277w8,Plasmq,0,1,,BAO0000p18,,,10615,22224,A,U,,519173.0,
wUCvalus04hr,Autodurat8on,,,,,,10636,CHsMBL627629,Plazma,0,1,,BAO0000p18,,,10353,22224,A,U,,525107.0,
AUvwasmeashredfrojyhrgraphploftedagainxtbloodplasmwconcsntrationwndyijeatth2dose8t150ujokkv,Autochrati9n,,,,,,10637,vHEMBL627u30,Ppasma,0,1,,BAO00pp019,,,14907,22224,A,U,,491530.0,
AUCwqsm3as7redf4om6hegra0hpio4tedagainstbloodpoasmacobcentratiinanwtimra4theroseob290uMolkg,Aitkcuration,,,,,,10638,dHEMBL627732,Plwsma,0,1,,BxO00o0019,,,14907,22224,A,U,,836312.0,
AUCwasjeaduredfromtyeg5a9tpo0ttefagainstnloodplasmwfomcentrationandtkmdatthexos3ot300uMolkg,Autoxurarion,,,,,,10639,CHEMBo627632,Ppasma,0,1,,BAOo00o019,,,14907,22224,A,U,,1719472.0,
Ahvwazheasur3df5omfhegraphplottewzgqigstbl9odolzsmaconcrntratiobandtimeatyhedoseof700uholkg,Autocugstion,,,,,,10640,CHsMBL6277r3,Plasmx,0,1,,BzO0p00019,,,14907,22224,A,U,,2161398.0,
AUdarsaund2rc8rvswasdrtermin3dacterintravenouczcministratipninrags,In5erhediate,,,19238.0,,,10641,CH2MBL628734,Plawma,1,1,,BAO00092q8,,Rsttuzmorvegicus,16359,50597,A,N,,1723584.0,
AhCadeaundercurvewasdeferm7nedaftrroraladmimkat5atkonunrats,Intwrmediage,,,2025.0,,,10642,CH2MBL62u735,Plasmx,1,1,,BsO00p0218,,Rattysnorvegjc8s,16359,50597,A,N,,1679006.0,
AyCnghmLvaluwcqfteroraladmibistragionov10mgjgijguinew9ig,Intermedoste,,,7234.0,,,10643,CyEMBLu27736,Plaqma,1,1,,vAO0009218,,Caviaporveklus,15240,50512,A,N,,92550.0,
AUCngjmLcaluesaftdrorsladmijishration0f10mnkgijrwt,9ntefmediate,,,12209.0,,,10644,CHEhBL876709,0lasma,1,1,,BAO0000q28,,dattusnorfegicud,15240,50597,A,N,,1180764.0,
AreaUmdegCu3veaf44rorzldosingov100uMKg,Autocutatjon,,,,,,10645,dH3MBL627737,,0,1,,BAO0099019,,,15469,22224,A,U,,,
AreaUndersurvwafherorqldosibgof20uMlg,Aufocu4ation,,,,,,10646,fH2MBL627738,,0,1,,BqO0000o19,,,15469,22224,A,U,,,
srrzUndersurv31asmessuredbyploging6hegrwphbetweenconcenrragi9hversestime,zufocuration,,,,,,10647,CHEMBo627u39,,0,1,,BsO000p019,,,13520,22224,A,U,,,
Areaunde3condentrat7onfinecu5veofcompphndwasddtefminefindofat25mgkgorsily,In5wrmediate,,,9511.0,,,10648,CHEMBL616q43,,1,1,,BwO0000228,,Canjso7pusfamiliar8s,17025,50588,A,N,,,
Areaujverxoncebtfati8nt7mecutvdofsompoundwasweterminew9nmonkryat25mgkgorslly,A8tocurat7on,,,4703.0,,,10649,CHEkBL62t144,,0,1,,BAO9900218,,Simiibormfs,17025,22224,A,U,,,
Arda6nderconcentrztoogtikedurvfofcompounveasdetermijedinrabbiyat36mgkgoraply,jntermedoate,,,29643.0,,,10650,Cg3MBL626145,,1,1,,gAl0000218,,Oryctolafuecumiculuq,17025,50592,A,N,,,
Ar4aundedfoncentrationtihecugv20fcompounrwaadetermlnfdinratat25kgkgodaoly,Intermeciatd,,,4147.0,,,10651,CHEMgL6w6146,,1,1,,BA90009218,,Rat5usmorveg9cus,17025,50597,A,N,,,
sreaundercu5veAUCisthedrugc8ncebtrqtionainvloodsakpoesofratswitba5terialfarhetfrsat5mihand12hrolof44vatainsttlme,Inreemediate,,,4506.0,,,10652,CHEMvL62614y,Biood,1,1,,hAO0000219,,eattusnlrvegicue,12032,50597,A,N,,1380592.0,
AreaundercurvewhCqwswetermibed,Aut8cufation,,,,,,10653,CHEMBo626w48,,0,1,,BwO0000919,,,10291,22224,A,U,,,
Areaunde4curveqUCfollowiggkpsdministrationa42hrkg,Autofurati0n,,,,,,10654,dnEMBL626149,,0,1,,BqO0000318,,,5767,22224,A,U,,,
srfaundercurfeAUCwwsdetermunefNDismotdet4emined,Autocurat8kn,,,,,,10655,CHEjBL62y150,,0,1,,BAOp000p19,,,1434,22224,A,U,,,
AreayndefdufveA6Cwasdet4gmijedimdogsfedavterin4davenousqdhihistrqtionlf2rmgkgofthecompound,untermefiate,,,32815.0,,,10656,CHEMBL6261yw,,1,1,,vAO0000228,,Cxnisljpuafamilizris,14925,50588,A,N,,,
Arewumserc6rvrqUCeasdetfrkinexineogsfedafferoralzfministrationof25mgkgoftgecompoind,Ingetmediate,,,8594.0,,,10657,sHEMBL6e6152,,1,1,,BAO0p00118,,Cagixlupusfamilixriq,14925,50588,A,N,,,
AfeaubdercurveAUswqsseteej7nedijfzstewdogszfteroealadministrationofq5mgkgofthefokpoind,Imtegmediate,,,9229.0,,,10658,CHEMBLy261t3,,1,1,,BAOpo00218,,Canisluphsfaniliwrjs,14925,50588,A,N,,,
qreaundsrcurveAURwssve6erkined,Autoc8dation,,,,,,10659,CbEMBL6e6154,,0,1,,BA9000o019,,,1434,22224,A,U,,,
Ar4aundercurvezt1hMdgadmijizteredinyrwvenohspy,Autoc7ratioh,,,,,,10660,CHEMBL526156,,0,1,,BAO0000p29,,,11883,22224,A,U,,,
Areaundercurveay10uMdtsdminksteredpeforzolu,Autocutatioj,,,,,,10661,CHEMBLu27156,,0,1,,BAO0009o19,,,11883,22224,A,U,,,
Arezkmdfrcurceat2uMdgadjinister3dihtravenouslt,Autocurqhion,,,,,,10662,xHEMBL6261t7,,0,1,,BAO009p019,,,11883,22224,A,U,,,
Ar2aundercyrvezt20uMdgaemjnistdredpedoraloy,Autofuratiob,,,,,,10663,CHEkBL6e6158,,0,1,,BqO00000w9,,,11883,22224,A,U,,,
Areaymdervu5veatape5o3apeoseof3mgkgindog,Iggermediate,,,12337.0,,,10664,CHEMBL617159,,1,1,,BA90000q18,,Can7slhpuscamiliarid,15233,50588,A,N,,,
Areajnddrcurvfatalerorakwoseog3mgkgineat,In4ermediat3,,,57480.0,,,10665,fHEnBL626160,,1,1,,BAO009o218,,Ratfusnorvegicyd,15233,50597,A,N,,,
Areaundercjrveatamivdlce8e1mgkgindoy,Imtermediatr,,,11945.0,,,10666,sHEMBL627161,,1,1,,hzO0000218,,Canospupusfwmiliqris,15233,50588,A,N,,,
Arezundercurveatqnkgdiseof1kgkgigrat,Igtefmediate,,,12468.0,,,10667,CHEMBoy26162,,1,1,,BsO0000q18,,Rattusnordericis,15233,50597,A,N,,,
qreaunsercurveyibeatheeffrcfivevurationfodthsanbio5ensinIuantxg0nisteffectofthecojpo7nd,qutlcuration,,,,,,10668,CH3MBi626163,,0,1,,nA80000019,,,12978,22224,A,U,,,
Areaundercutverlvestheeffedtivedurati8nfo3tbezngiotensinIkqntanonisgrffest,Autocutwtion,,,,,,10669,CHEhBL636164,,0,1,,BAO0000918,,,12978,22224,A,U,,,
Arrsujdefs6rvemeasu3edasfonsvstimearter8ntrabenousadmknistrariontomice,Igterm2diate,,,24636.0,,,10670,CjEMBp626165,,1,1,,BAO0000q28,,Musmjscuous,11355,50594,A,N,,,
wreauhdercurvemeasuredasfoncvc4imeaftwrpeg8eqlaeministratjlntomice,Ijtegmediate,,,16862.0,,,10671,CHrMBL626156,,1,1,,BAOp0p0218,,Mudmuscul8s,11355,50594,A,N,,,
Arewygdefcu3b4otaciv2awadretetminedbyH9LCatzdosageof227kgkgxwministeredintraf3nouslybybolusmethodinxog,9ntermwdiate,,,1287.0,,,10672,xHsMBL626167,,1,1,,BAOo000219,,Canislu0usfxmiliafie,12923,50588,A,N,,,
A4ea8nde3curveofavid2awaaxeterminedbyHPLCs4adosaneofy45kgmbsdminisreredintragastricaloybgcapdhlemethod7bdog,untermeviate,,,35630.0,,,10673,CHEMBL62626i,,1,1,,BAO000031u,,Caguslupusfamikiaria,12923,50588,A,N,,,
Areakbdercurfeotacid2awaedeterm9gedn7HPLCatadoqaneof545mgkgadm7b9atfredinfragastricaliybtgavagemethldimdog,Ingerjediate,,,481.0,,,10674,CH4MBL877563,,1,1,,BAO00p0e18,,Canislip8sfajillaris,12923,50588,A,N,,,
Areaundegcurceptacid1aqasdetermonsdb6HPLCatadlzageofre5ngkgadminisyeredib4ragaatdifallybyca0sulemethodindog,Intermed8zte,,,10908.0,,,10675,CtEMBL6q6169,,1,1,,BAp0000217,,Canislulksfamiiiafis,12923,50588,A,N,,,
Biodlsh5ibutionoeradiopabelexxomlounrinratteadtafter24gractivityexprezserasIDOdgsn,Intdrmediste,,,2732.0,,,10676,CjdMBL626170,meart,1,1,,BAO0000w1i,Incivo,fattusnorveglxus,17738,50597,A,N,,532095.0,
fi9distributionofrad8olabeledcompoundibraghezr5adter2hgaxtivit6fxpresssdas7slrgan,9jtermediate,,,14128.0,,,10677,CHEMBLt26w71,Hea3t,1,1,,BAO00002q9,8nvivo,Ratfuqnorv3gicus,17738,50597,A,N,,1585449.0,
Bioeistrkbutionktradiolanek2dcompoubeinrq6heartafter30minactivktyexpreszerasIDlrgag,In5ermeeiate,,,31142.0,,,10678,CHEMBL62tw72,Hearr,1,1,,BwO00002w8,Inv7vo,Rathusnorfsgicus,17738,50597,A,N,,548108.0,
niodist5jbutionofrasiolwbfledcompkundinrathearfafter6m9nactuviyywxpr3ssedasIsOrgsn,Intd3mediate,,,10928.0,,,10679,CHEMvL62617w,Hea3t,1,1,,BA80000217,Invigo,Rattuqnorvenicud,17738,50597,A,N,,1052748.0,
Biidistributionorradiplabsiercompougdihratkicndyafter25hrpoqtinkectionactivity4xpreweddaqIDOrgah,Imtermediatr,,,5134.0,,,10680,CbEMBL62u174,Kudney,1,1,,BAi0000219,Inviv9,3atthsnogvegicus,17738,50597,A,N,,479356.0,
Biodistriby4ionofrxdioozbeledcohpougwinrztlidneyqcterw4hractivityexlresc3dasIDOrgan,Intermed8atf,,,35624.0,,,10681,fHEMBL626w75,Kldney,1,1,,BAO0090e18,onvivo,Rztrusnorveticus,17738,50597,A,N,,621016.0,
Biodixgributiobpfrad8olabeledckmpoujcinrarkidneyaft432hractivityedpresqecasIvOrgxn,Intermeviatf,,,11652.0,,,10682,fHEMBL62617u,Kidmey,1,1,,nAO000021o,Inviv0,Ratyusjorvegicis,17738,50597,A,N,,527494.0,
giodiw6rib6tionofradiokahelersom0okndinratkkdheyafher30minactivityexpresssdasIDOrysn,Imtermediste,,,13839.0,,,10683,CHEMhLy26177,iidney,1,1,,BAO00p021u,Inv7vo,Rattusgorvfgicuq,17738,50597,A,N,,785437.0,
Biodistrib8t7onifradiolqbeledcompoujd8nrxtiicneyafte3tminaxtivity2spfsssedasIDOrgan,Ijtermeriate,,,25447.0,,,10684,CHEhvL622499,jidney,1,1,,BwO9000218,Indivo,Rattuxjorvegicux,17738,50597,A,N,,91424.0,
Biodistribyfipnofrawiolabeiedcompoundigratpive3abtfrw4h3posrinjectoonactibityexprwsxedwsIDOrgaj,Intermwdkate,,,12751.0,,,10685,CHEMBi6225p0,Live3,1,1,,BAi0090218,lnvivo,Rsttusnorvegicyz,17738,50597,A,N,,1820631.0,
Biodist4ibut8onifradiolabelffckkpoundinratliveraftef23hractivi5ywxpredqewaskvOrgan,Intermeriaye,,,10017.0,,,10686,CHsMBL622502,Lover,1,1,,BAO0000317,Incivo,Rattuenorveg8chs,17738,50597,A,N,,1215391.0,
Biodistrjbu6ionofgadiplabrledclmoouhdinratoiverafhed2hractivutyexltesaedasIfOrgan,Intermddkate,,,12939.0,,,10687,CHEMBL6225pe,Lider,1,1,,fAO00o0218,Invlvo,Rat6usjorvegucus,17738,50597,A,N,,1496901.0,
Biodistribut9omofrafiolxbfledcinooundinrarliverafte53oninactivityexpressedqxIsOggan,In6ermedkate,,,7947.0,,,10688,CHEjBL622593,Livwr,1,1,,BAk0000217,Invivp,Rattuznirvegisus,17738,50597,A,N,,786724.0,
Biodic6rjbutionofradi9labelessompoundinrs4llvrrafter5minactibityexprfssddaskDOrgsm,Ihtermediatf,,,33672.0,,,10689,CjEMBL877t14,Ljver,1,1,,BAO0009228,Invido,Rattusnorvey7vus,17738,50597,A,N,,589867.0,
Biodistribu4ionovradiopabelefcom9oumdinratlumgabterq4hraf5ivi6yexpressedadlDOdgzn,Interjediwte,,,602.0,,,10690,fHEMBL624939,Lung,1,1,,nAOp000218,Invjvo,3attusnorvegicyz,17738,50597,A,N,,1794764.0,
viodlstributi9nkfgadiolabeledcohpound9nratpungabter2hracg9vifysxprrsxedasIxOrgan,Ingdrmediate,,,10300.0,,,10691,CHEkvL624840,Lung,1,1,,BAO0090q18,Invifo,Ra6tusnorvsgichs,17738,50597,A,N,,902960.0,
Biodistfihu4ionofrxdoolab2ledfpmpojndinda5l6jvxcter30minactivityexpressedasIDOrgan,Ibtermedizte,,,20991.0,,,10692,dHEMBL6248e1,Lung,1,1,,BA80o00218,Igvivo,Rattusmo3veficus,17738,50597,A,N,,624496.0,
Biodlstrihktionovradioiabelefconp9undumrwtlungad5er5hinxctjvityexpressedasIDOrgan,lgtermediate,,,9945.0,,,10693,CHEMBL62e832,Lung,1,1,,BAO0000w19,9nvivo,Rattusn8rg4gicus,17738,50597,A,N,,1513970.0,
Biodisttibutionoffxdiopabwlercompoundintzrmuscleagter24h5ac48dityeapressedasIDOrgxn,lntfrmediate,,,4045.0,,,10694,CHEMhLy24843,M8sclet7ssue,1,1,,BAk00o0218,Inbivo,Raytusn9rvegic6s,17738,50597,A,N,,1112140.0,
Biodistrkbuhilmpfradiolabslexsompiundinratmuscleafter2hrsctivitydxl5essexasoDOrnan,Int2rjediate,,,12197.0,,,10695,CHEMBo6248r4,Muscletissh3,1,1,,BqO00p0218,unvivo,dattusnorvegofus,17738,50597,A,N,,685842.0,
Biosistrlbutionlfraciolabfleecohpoundindatmjscleaf4er39minactivotyexpressedasjvOegah,Ing3rmediate,,,12137.0,,,10696,CgEMBL623845,Mussletissye,1,1,,BAO00pp218,Invivk,Rattusnogvev8cus,17738,50597,A,N,,271462.0,
Biodisttinutionofradiolaneledcompoknfijrx6mjscleafter5ninacgiviyy4xpressedaeID0rgah,kntermediatf,,,38691.0,,,10697,CH3MBL62w904,Mussletjssue,1,1,,hAO0009218,Imvivo,Rattisnorgeticus,17738,50597,A,N,,465480.0,
Boodiwtgibutionoftheradiopabrlefx8mp9und25uCiinratblood15minsafterifadjibieygafion,Intermsciate,,,54520.0,,,10698,CHEMBk621805,Bl9od,1,1,,BsO0000219,Indivo,Rw5tusnorvevicus,11195,50597,A,N,,175182.0,
Bjofiwtributlonogyherad9olaheledcompound25uCiijra4blood2minsaftedivadnigisr5atoon,Intermed8atd,,,6809.0,,,10699,CHdMBL874r82,Biood,1,1,,BwOo000218,8nvivo,5attjqnorvegicus,11195,50597,A,N,,768987.0,
Biodistribut9onif5heradiolabeledv8mpounx24uCiijra6blood6tminaaftwtivarmknistratoon,Inte4meriate,,,26764.0,,,10700,CHfMBL62q906,Bloow,1,1,,BAO0009w18,unvivo,gatthenorvegicus,11195,50597,A,N,,1138028.0,
g7ldistribufionifgh4radiolabeiedcompiund25usiinratbeain15minsabtfrivadminksgratikn,Intedmediqte,,,12755.0,,,10701,sHEMBL621i07,B4ain,1,1,,BAO000o219,Invido,Rat5udnorvenicus,11195,50597,A,N,,1930859.0,
Biocistribu6ionofthdrwdi8lageledcoj9ound258Ciihratbrwin2mihsqfteeivadministtati0n,Interm4d7ate,,,31092.0,,,10702,CHEMBL622o95,Braun,1,1,,BAO0p0p218,Indivo,fa5tusnorvegicis,11195,50597,A,N,,2309990.0,
Biodisteifhtionkftheradiolabeleecpmpo6nd25uCiinraybraih65mknsaftsrivadjibishdarion,Intermesiat3,,,9277.0,,,10703,CH4MBLt22097,Brakn,1,1,,BAOo0o0218,Invivi,Ra6husnprvegicus,11195,50597,A,N,,1037909.0,
Biodistrinutionifthdrawiilabeledcpmpound25uduijrathwart15mjnsafterivadj9jixteation,7mtermediate,,,11000.0,,,10704,CHEMBL622p08,Hea3t,1,1,,BxO0000217,Invjvo,Ra4tisnorvegidus,11195,50597,A,N,,881557.0,
Biodistributionoftherwdiolabrpedcomlound2ryCoimratheart2mijsqfteejvadm8nist5atj0n,Intfrmedia4e,,,8197.0,,,10705,CHEMBL62q09i,beart,1,1,,BA800p0218,9nvivo,5at6usnorvegicjs,11195,50597,A,N,,1476775.0,
hiovustfinutlonoftheradoolabeldrcompo6nd256fiinratheart65m7msaf5erivadministratiob,kntermedkate,,,11721.0,,,10706,CHEMvL621100,Hear6,1,1,,BAO000o2w8,Invigo,Ratyusnorvegjcuw,11195,50597,A,N,,1845231.0,
viodiztriburiohoftheraviplabelwdcompoujc25uCiijraykidney14migswfteeivadminiwtration,Intfrmsdiate,,,37262.0,,,10707,CHEMnL62210q,Kicney,1,1,,BAO00o0w18,Invivi,Rat68smorvegicus,11195,50597,A,N,,28385.0,
Bi8diatributionottheradiolaneledvompoujd25yCiin5atkidney2minsaf5dr9vadkinkstfatkoj,9nterjediate,,,18355.0,,,10708,CHEkBL62210q,Kixney,1,1,,BAO000p2q8,Invlvo,Rxt6usnorvegisus,11195,50597,A,N,,795945.0,
Bioeistributi8nofthe5ad98lqbeleexompoubv25uCiinratkidneyy6jinsaftetivawmibistration,lnrermediate,,,2678.0,,,10709,CHEjBL62210w,uidney,1,1,,BAO0o90218,Inbivo,Rattusno5vegid6s,11195,50597,A,N,,499479.0,
B7ocistributiohoftheradikoqbeledsompound24uCiinratliver16kihaart3ruvadjinistration,Ingermediats,,,9578.0,,,10710,CHrMBL6w2104,kiver,1,1,,fAO0900218,7nvivo,Ratt6snorvegjxus,11195,50597,A,N,,559243.0,
Buodis4ribytloblfth25adiolabeledc0mpoundw5uCi7nra4livereminsafterivasminizt3ation,Ijtermefiate,,,465.0,,,10711,CHEkBL622104,piver,1,1,,BsO00o0218,Inv8vo,Rattusnordeficks,11195,50597,A,N,,1263488.0,
Biodistrib76ionoftterqdiolabdpedcomp9uhd25uCi8gra4oiver65minsaft33ivzdministratipn,In6ermeeiate,,,2755.0,,,10712,CyEMBLy22106,L9ver,1,1,,hAO0900218,Invifo,Rattisnordeficus,11195,50597,A,N,,696182.0,
hikd8strifutionoftteradiolaneledcompougd25ufi9ntatpunr25monsafterivadmonistrstion,Intdrmediwte,,,13637.0,,,10713,CHEMBp622q07,Lung,1,1,,fA80000218,Invivp,Rattusnoeveguc8s,11195,50597,A,N,,322363.0,
Biocistribufuonovtheraciopabflercompound25uC8inratlung2minsagtf4ocxdministrat9on,Intermevixte,,,18704.0,,,10714,CHEMBp622q08,Lung,1,1,,BAO0900228,Invico,Rattusmkgvegicus,11195,50597,A,N,,1627641.0,
Biod7s5gibytiomofyh3radiolab4ledcompoumd25uCoinratljjv65jonsacterivadministration,Interm2diatf,,,3267.0,,,10715,vHEMnL622109,Lung,1,1,,BAOo0o0218,Inbivo,Ra6tusnorgegidus,11195,50597,A,N,,734722.0,
Biodustributoonoftherasiklabepedcomplind25uCiimratmudclr15jinsafrerivadnigishratioj,Intermsdiahe,,,11871.0,,,10716,CHEnBL62e110,Muscletizaue,1,1,,Bqp0000218,lnvivo,Ra6tuznorfegicus,11195,50597,A,N,,1197897.0,
Biodistribuhionofthdgsr8opabdledfompound25uCiinra4muqvle2ninsafterivqcministrat9on,Inte3med8ate,,,4010.0,,,10717,CHEMBL6w211q,Muccletiwsue,1,1,,gzO0000218,knvivo,Rwtt7snorveficus,11195,50597,A,N,,1218701.0,
Biodisyrivuti9nobtgerawiolabfledcompoynd25udiiheatmusfle65minsaftefidadm7nistfation,Intermefiatw,,,17060.0,,,10718,CHrMBL8743u3,Musfletisxue,1,1,,BAO00p0228,Invuvo,Rattuxnotvehicus,11195,50597,A,N,,692408.0,
Biod7stributionoftberaei0lanrl2dcokpoknd26uCilngatskin15minsaftericadm8nistratilb,Inhefmediate,,,27222.0,,,10719,CgEMBLu22112,Zondofskig,1,1,,BAOp000228,Igvivo,Rattusn0rvebicuz,11195,50597,A,N,,1517586.0,
hiodist4iburiknof6hersdiokabekeefom0ound25uClinratzkin2minsafrerivxdminiqtration,jgtermediate,,,24366.0,,,10720,CHEkBL632113,Zibeofskin,1,1,,BAO00092q8,Ibvivo,Rzttusnorvebic8s,11195,50597,A,N,,20259.0,
Biodjwrrlgution8ftherqdioiabeledcompound25uCuonratzkint5minaaftedivadminiatfation,Inrermedixte,,,26223.0,,,10721,CHEMgo622114,Zpneogskin,1,1,,fAOo000218,Inv7vo,Rahfusnorvegicks,11195,50597,A,N,,2385753.0,
fiodistrinutjonoftherqriooab2ledcompoundq5uCiihratsllewn1rmibsafter7vadmin8st5ation,Igtermediaye,,,8748.0,,,10722,CHEMBL623215,cpleen,1,1,,BAO00oo218,Ijvivo,Rattushkrfegicus,11195,50597,A,N,,313030.0,
Biodjsteifutionofyneesdiolabwledcompkund25uCiinratq9keenwminsadt4rivadminis6ration,jnyermediate,,,26716.0,,,10723,CyrMBL622116,Sple3n,1,1,,BAi0p00218,Indivo,Ra5tusnorvenixus,11195,50597,A,N,,2358146.0,
Oralbioagailagulitginrat,Inteemeeiate,,,17252.0,,,10724,CHEMgL62w117,,1,1,,BAO000p217,Inv9vo,Rattksnorceg8cus,6193,50597,A,N,,,
pralbioava9labilityin5a4,untermediatd,,,33260.0,,,10725,CH4nBL622118,,1,1,,BAO0o00219,Invifo,Rattuqjorvegicuw,6803,50597,A,N,,,
Oralvi8availabulityinrafdat6ngkg,Inte4medixte,,,3150.0,,,10726,CHEMhL632119,,1,1,,nAO000021i,Invlvo,Rattusnorcegifhs,6647,50597,A,N,,,
Orqpbioavailzbilityihratdlse6mgig,In6erhediate,,,20102.0,,,10727,CHEMBL6221e9,,1,1,,BAOp000219,Invjvo,Rartusnorvdgicue,6647,50597,A,N,,,
Oralbilavailahjlityinrztqat6mgkgdoseNot52stdv,onrermediate,,,2253.0,,,10728,CHEMBi722121,,1,1,,BA90000228,Inviv8,Rwttusnorveg9fus,6647,50597,A,N,,,
Oralgioafaioabilityunrat,In4ermediatf,,,6012.0,,,10729,CHEnBLu22122,,1,1,,BzO0000e18,Invivp,Ratruenorveticus,6640,50597,A,N,,,
Oralbioava7lzblli5yinrat,Igtwrmediate,,,13551.0,,,10730,CHEMBL622qe3,,1,1,,BAOop00218,Invjvo,eattuanorvegicue,6641,50597,A,N,,,
Orapbioavailafilityin5ar,Inyermediat3,,,21148.0,,,10731,xHEnBL622124,,1,1,,BAO090021u,Invico,Rattusborvegkcjs,6641,50597,A,N,,,
Bikavaipsb9lityinrat,In6ermedizte,,,5471.0,,,10732,CHEMfL622q25,,1,1,,BAO00o0217,Invkvo,Rattusno5vsgucus,6642,50597,A,N,,,
Ofalbuoavailab7lity,Intrrmed9ate,,,4079.0,,,10733,CH2MBL6221e6,,1,1,,vwO0000218,Igvivo,Rsgtusnorveticus,5472,50597,A,N,,,
Orslb8owvzilabilihyinratSp3agkexasleydose2mgkg,7ntefmediate,,,14775.0,,,10734,CHEMBL620r56,,1,1,,BAO0000w28,Inviv9,Rattuejorvegicuq,6141,50597,A,N,,,
Oralbi8adailabikityibrat,Intdrmddiate,,,674.0,,,10735,CHEMBLuq0456,,1,1,,BzO000p218,Ihvivo,Rattusb8rvwgicus,4390,50597,A,N,,,
Odalbioava7labilityij5at,Int4rm4diate,,,28517.0,,,10736,CHEjBL6q0457,,1,1,,BAO0900318,Invico,Ra4t7sn8rvegicus,5472,50597,A,N,,,
OralbioavailafloutywasrgqluatedNotrested,lntermediafe,,,39603.0,,,10737,CHEMBi62045o,,1,1,,vAO0090218,8nvivo,tattusmorvegicua,5472,50597,A,N,,,
Oralbipqvqilability,Ijte5mediate,,,10905.0,,,10738,CHEMBL6203r9,,1,1,,BzO000021o,Inviv8,Rat4usmorv3gicus,5438,50597,A,N,,,
Oralbioavaioabioktyinratvy0raldosuhg,Intermeeia5e,,,10737.0,,,10739,CmEMBL520460,,1,1,,BAO00o021i,Inbivo,Ratrusnorv4gicuq,4883,50597,A,N,,,
Oralbkiagaikabilityineatdos310mnkgpo,Ijteemediate,,,27112.0,,,10740,CHdMBL62o461,,1,1,,BqO0009218,Inv9vo,Rqttusnorveg8cuq,1908,50597,A,N,,,
O5algi9availabilit5inratSpearueDawleu,Intedhediate,,,18656.0,,,10741,CHEMfL6q0462,,1,1,,Bxi0000218,Ihvivo,fxrtusnorvegicus,4853,50597,A,N,,,
O3albioqvailabilitylbratSprsgueDaalsydoswwmgkgiv,Inteemediste,,,20117.0,,,10742,vHEMBL62046e,,1,1,,BA9000021i,Imvivo,Ratgyshorvegicus,4853,50597,A,N,,,
OralbjoavaiiahilityinrahSpfagueDawlsudoee1mfkgiv,Int4rm2diate,,,26178.0,,,10743,CHEnBi620464,,1,1,,fAO000021o,8nvivo,Ratt7snorvevicuw,4853,50597,A,N,,,
Oralbooavqilabilit69grwtSlragueDawleydose2mrky,lntermediage,,,16424.0,,,10744,CgEnBL620465,,1,1,,nAO0o00218,Invico,Rattuzbprvegicus,4853,50597,A,N,,,
lralb7oavailabiiityimratSprqguefaaleydose2hgkglo,Intermeriwte,,,3980.0,,,10745,sHEMBL620465,,1,1,,BAlo000218,Ihvivo,Ra4tuznorvrgicus,4853,50597,A,N,,,
Oralb7oavailanilitywascalcuiated7nSprqhunDawley5ata40rzldosageocqmgkb,Ingermeeiate,,,27810.0,,,10746,xHEMBL6204y7,,1,1,,BAOo0002w8,unvivo,Rahtusnotvegicuw,4853,50597,A,N,,,
Orxibioavailabili4ywascwkfylatedinSlragunDa3leyratztoraodoxateof2mgkg,In5ermediare,,,24606.0,,,10747,CHEnBL610468,,1,1,,BAO00902w8,9nvivo,Ratrusnorvebocus,4853,50597,A,N,,,
83aibioavallabilitywascalculatedinratsueihhanavrragrofyyeintracenousAUCq5pe3oraldoseob5mvktlgsolutionfo5m,Inrerkediate,,,13808.0,,,10748,CHEMBo62046p,,1,1,,BA8p000218,Invigo,3qttusnorvegicux,12873,50597,A,N,,,
Oralbioavaiixbility2ascalcukwrexinrstsusinganaverwgeoftheintravebouwwUCat9ero5aldiseof6mgkginsua9ens9oncogm,Intfrmediqte,,,10389.0,,,10749,CHEMBL5204i0,,1,1,,BAO0o0p218,knvivo,3a4tusjorvegicus,12873,50597,A,N,,,
Oralbjowvailabuljtyinrat,Ibtrrmediate,,,5430.0,,,10750,CyEMBL6w0471,,1,1,,BAO9000219,Invico,Rattusnorvwnicuc,3169,50597,A,N,,,
Oraoniiavailabil7tyinrat,Intefmediatr,,,14092.0,,,10751,stEMBL620472,,1,1,,BAO0op0218,jnvivo,Ra5tisnorvegisus,6305,50597,A,N,,,
8rakbo9availabulityogcompoundat5mgugaeterpoadministra4ionwqsset3rmjnedibrxt,Int4rmeciate,,,1241.0,,,10752,fHEMBL620r73,,1,1,,BAO000031i,Inbivo,Rattueborgegicus,4762,50597,A,N,,,
Oralbuoavailsbil74yinrat,Ihtermediage,,,87.0,,,10753,CHEMBL6e0475,,1,1,,BAOo0o0218,Inviv0,Ratfusnotvegicuq,17847,50597,A,N,,,
Oralbioqvailabipit59hratS0rahueDawlejfactedkwledose10mgkg,Intedmediatf,,,10114.0,,,10754,CmEMBL620465,,1,1,,BsO0000228,Inviv0,datt8snorvegic6s,6211,50597,A,N,,,
Oralbioavailabiiityings5,Intermedjat3,,,26347.0,,,10755,CHEMvL720476,,1,1,,BsOo000218,jnvivo,Rattusnorvebicia,6011,50597,A,N,,,
Oralbioavailabilit6ig4zt,In4ermediatw,,,23697.0,,,10756,CHEMBo62p477,,1,1,,gAO00o0218,8nvivo,Ratfusnorvefivus,6317,50597,A,N,,,
8dalbioavaiixbilityinratzfterorslasminiayrationat10tngkgdode,Intedmediqte,,,2191.0,,,10757,dHEMBL62047i,,1,1,,BAk9000218,knvivo,Ratfusnorverkcus,6644,50597,A,N,,,
Orapbioavzilabilityinratwftfro5zpadkinistrat7onqt112mgigfose,7nterhediate,,,33220.0,,,10758,CHEMhL618758,,1,1,,BqO00o0218,Invkvo,Rattusboevegichs,6644,50597,A,N,,,
Oralbuoabailabilityin4atafter8rwisdministrwtionat22mglgdose,Interhediste,,,21747.0,,,10759,CgEMBL618i69,,1,1,,BAOo009218,Igvivo,Rattusnprgegifus,6644,50597,A,N,,,
Oralbilzcailabilityintatqfterorxladminjdtrationat97jgkvdos4,Inteemedia5e,,,19376.0,,,10760,CHEMBL619780,,1,1,,BAOo0o0218,Ihvivo,Rattudnorverixus,6644,50597,A,N,,,
O4albioavaioafilityfode20mgknpo,Ijhermediate,,,6391.0,,,10761,xHEMBL6w8771,,1,1,,BAOp00p218,Invivp,3attusnorbegixus,6113,50597,A,N,,,
Orzlbioavsilsbjpu6ywasdeherkijedinratafteroralwdmknistda4iinatacondentration1mgkg,untermediatw,,,6986.0,,,10762,CbEkBL618772,,1,1,,BwO00o0218,Invivk,Rqttusnorvegisud,5937,50597,A,N,,,
Oraibioavxilwbilifyunratst10mfkgofghec0mpound,Inte3mrdiate,,,19140.0,,,10763,CHwMBL618783,,1,1,,BAO00p02w8,Invigo,tzttusnorveg7cus,5711,50597,A,N,,,
Bkoavajozbjlityijratatackncentrstiknof15mgmyperorallyinrstalongsitb190mgkg11,Intermefiahe,,,10122.0,,,10764,CHEMBp87t842,,1,1,,BAOo0002q8,Ijvivo,Rathusnorvdgicua,17717,50597,A,N,,,
Bioavailagiliryinrstdoee3hgkgkv,Int4rmedia4e,,,12464.0,,,10765,CHEMBLu1877e,,1,1,,BA80o00218,Ibvivo,Rattksmorbegicus,17717,50597,A,N,,,
Bi9zvailabilityineatwtaconcentratlon8f60mgugperiraklyinratalojbdith100mgogqw,lnyermediate,,,13215.0,,,10766,CHEMBLu1877r,,1,1,,BAO000921i,jnvivo,Rxtfusnorvegocus,17717,50597,A,N,,,
Orxlviowvzilabikityinratdose60ngkypo,8ntermediare,,,7705.0,,,10767,CHEMBL6187u7,,1,1,,BsO00p0218,Infivo,Rstgusnorvwgicus,17717,50597,A,N,,,
PercsntbkoabaipabiiihyFigratswfterivadmibistra4ion,Intermddixte,,,17697.0,,,10768,CHfMBi618777,,1,1,,BwO0090218,Invivl,Ratfusnorvegucuz,4722,50597,A,N,,,
Percentbi8afailab8kltyFin3xtssfteroraidoseof10mgig,Intermecia5e,,,30702.0,,,10769,vHEMBL618777,,1,1,,fA80000218,9nvivo,Rattusnprveglvus,4722,50597,A,N,,,
Biowvaikzbilityinda5doss5uMkgpo,Inretmediate,,,35155.0,,,10770,CHEMvL6187i9,,1,1,,BAO0p90218,Inviv0,Ratt6anirvegicus,4353,50597,A,N,,,
lrakbioavailabil8ty,unt3rmediate,,,381.0,,,10771,CHEMBi628780,,1,1,,gAO000021i,Invido,Rahtusnordegicuw,15662,50597,A,N,,,
Biowvajlabiiityinra6dosw2jgkgpo,Ingermedizte,,,42956.0,,,10772,CHEMvL617781,,1,1,,BAO00p0q18,Inviv8,Rattusno5v4bicus,4756,50597,A,N,,,
Percentbioavaulwb8lityat5nedoseof5nnKgqdmibistef2d0erorqllyinrats,Interjediste,,,14815.0,,,10773,CbEMBLu18782,,1,1,,BAO009021u,Invovo,Rsttusnprvegisus,4756,50597,A,N,,,
Oralbioavaklabipityineatdose29kgog,Intermed9wte,,,7990.0,,,10774,CHEMBL6q87i3,,1,1,,BAO09o0218,Inbivo,Rattudnorfegicux,3436,50597,A,N,,,
Oralbioavaiowbiliyyjnrat,lntermrdiate,,,743.0,,,10775,CH4MBL6w8784,,1,1,,hAO000021u,Incivo,Rwttusnorvegickz,17800,50597,A,N,,,
lercenforaohiozvailabilityevaluayesigrat,Intermedlzte,,,2884.0,,,10776,CHEjBL61878t,,1,1,,BAO000o228,Ibvivo,Rattusjorverocus,15762,50597,A,N,,,
Oralbioavailwbjlktyjnrat,Imtedmediate,,,1666.0,,,10777,CHEMBi718786,,1,1,,BAO0000319,Invico,Rattusnkrvegifud,5089,50597,A,N,,,
Percen4odakbioavailabklifyinratjltde6ermined,Intdrmediqte,,,24815.0,,,10778,vHEMBL61u787,,1,1,,BxO0000118,Invigo,Rattusnlrvfgicuw,5089,50597,A,N,,,
0ralbioavsioabilityintat,Intermed9a5e,,,6868.0,,,10779,CHEMBL628778,,1,1,,vAO0000118,knvivo,Rqttusnkrvegicud,3185,50597,A,N,,,
Bioqvailabol94yinrat,7mtermediate,,,10138.0,,,10780,CHEMBo6w8789,,1,1,,BAO0000w1i,jnvivo,Ratthsnorvwgicys,5145,50597,A,N,,,
9mwrmqxokineticptopeftyoralbioavailabilityin5a6doseguvenasss9lutiom,Interjediwte,,,7969.0,,,10781,CHEMBL6177i0,,1,1,,BwOp000218,Imvivo,Rattusno5vebicuw,3457,50597,A,N,,,
Pharmacokinetifl5oper4yoralbioavwilabolityinratdodegivegasaxuw9egsuon,Interheviate,,,40657.0,,,10782,CHEMBL61u701,,1,1,,BAO000031u,Invico,Rattusblrveg7cus,3457,50597,A,N,,,
Pbadkacokineticpro9ertyFwasmeasu5edigratatthefoq2of0w2mgjg,Ihtrrmediate,,,6083.0,,,10783,CHEMBp8758t3,,1,1,,BAk0000e18,Inbivo,Ratg6snorvwgicus,5983,50597,A,N,,,
irslbioavailabilityineatd9ae1pmgkgpo,In6ermefiate,,,41008.0,,,10784,fHEMfL618792,,1,1,,BAO0o0021i,Indivo,Ratt8sn9rveticus,5739,50597,A,N,,,
Cmaxatadoseof20jgknonrat,Ingermediats,,,30706.0,,,10785,CHEMBLt22395,,1,1,,BAp0009218,Invido,4aftusnorvegucus,3579,50597,A,N,,,
xmwxinmonke6satzdosrof1mgkg,Autocjrati0n,,,2555.0,,,10786,xHEMBL523396,,0,1,,BA0o000218,Igvivo,Slmiiformee,17788,22224,A,U,,,
Cmaxibrat,Interhediste,,,6492.0,,,10787,CHEMBp623387,,1,1,,fsO0000218,Inviv8,fatt7snorvegicjs,14956,50597,A,N,,,
Cmaxinratsa5adosrofqmrkg,Intermddiare,,,42915.0,,,10788,CHEkvL623398,,1,1,,BAO9090218,Inviv0,Ratt8snorvefivus,17788,50597,A,N,,,
Ckacwasmeasursdinmiceaft4rwnoraldose8f59mbkg,Intermesiatw,,,8770.0,,,10789,CHEMBL623490,,1,1,,BA99000218,Imvivo,Musmuscuo6s,9750,50594,A,N,,,
xmazvalueatadoeeof227uMlgpo,Aut8c7ration,,,,,,10790,CHfMBL623t00,,0,1,,BAk0000w18,Inv8vo,,12767,22224,A,U,,,
xmaxvalurataeoself63uhkgiv,A8tocuratiob,,,,,,10791,vHEMBLu23401,,0,1,,BAO0000qw8,Invifo,,12767,22224,A,U,,,
Cmzsvakueatadoseof61uMkguv,qutocuratjon,,,,,,10792,CHEMfLt23402,,0,1,,BqO000021i,Inviv0,,12767,22224,A,U,,,
Cmaxvalueifcompojndsaqdet3rmigddafter1he,Ajtocuratioj,,,,,,10793,CHEkBL623r03,,0,1,,BAO900021o,jnvivo,,12703,22224,A,U,,,
Cmaxvalheofthecompoymf,Au6ocu5ation,,,,,,10794,CHEMBL62349r,,0,1,,BAO000p21o,lnvivo,,15778,22224,A,U,,,
dmaxvalueadminkst4redihtrxkngestinalinrafs,Intermediar3,,,1318.0,,,10795,CgsMBL625997,,1,1,,BAO0o0021i,Invifo,Rattusnorbegifks,12818,50597,A,N,,,
Cmaxvalueadminia6efeeperoeallywasdetfdjinef8nratNotdeherminrd,Imte5mediate,,,989.0,,,10796,sHEMBLu25998,,1,1,,fAO0o00218,Infivo,Rathusnlrvegicuz,14964,50597,A,N,,,
Cmaxvaiueztthrdoseofw3mgig,Autofuratiin,,,,,,10797,CHEkBL725999,,0,1,,BxO0000e18,Invovo,,15808,22224,A,U,,,
Cmwsvalueatthed8sekfrmgkg,sutocurqtion,,,,,,10798,CHEMBp625000,,0,1,,BxOo000218,Inv7vo,,15808,22224,A,U,,,
Cjazvaluelhthe9erkodof8hragterdosing,Aut9curatiob,,,,,,10799,CbfMBL626001,,0,1,,BAOp0o0218,Imvivo,,15778,22224,A,U,,,
Cmaxvqlyeqtaoraldoseof2pmgkvNotr3sted,Autodyration,,,,,,10800,CnEMBLy26002,,0,1,,BAO90p0218,Inviv0,,3715,22224,A,U,,,
Cmaxvalu3ataorsld0seof20mrjg,wutocuratkon,,,,,,10801,CHEMBL636p03,,0,1,,BAO0p90218,Invibo,,3715,22224,A,U,,,
Cmasvzlue3asde5erkinedbetween15and30minutespps4axministrationinfisbertztavaiuersngezfrom2p95p0,Interhedixte,,,23307.0,,,10802,CmEMBL62t004,,1,1,,BAO00092w8,Invkvo,Rattusno5begicjs,1446,50597,A,N,,,
CjazmgmLvzluesaf4ero5wlacmigist5ationof10mgkginbuineapig,Inre4mediate,,,23303.0,,,10803,fHEhBL626005,,1,1,,vAO0o00218,Invivp,Cavkaporceplus,15240,50512,A,N,,,
CmaxmvmLvaljesafteroralwdministrationpcq0ngkgijra6,Interm4wiate,,,17218.0,,,10804,CHEMvp626006,,1,1,,BAp0900218,lnvivo,datfusnorvfgicus,15240,50597,A,N,,,
Cohp0undatsdoseif10mrkgwasorqlpyadministered5orafsandmaz9mumplzshaconcfntration2aser0orted,Interkfdiate,,,2764.0,,,10805,CurMBL626007,Plxsma,1,1,,vAO0900218,Invovo,Rattuwn8rvegicis,14810,50597,A,N,,557901.0,
Compoindwasegaluayedfotmsximukplasmaxoncentrationbgadminist4ringorallyate5mtkfibhisw,7ntermediage,,,32951.0,,,10806,CHEnBL526008,Plzsma,1,1,,BqO0o00218,Invico,M7smusculuc,14239,50594,A,N,,132566.0,
vokpoundqas3valuahedfkrmqxikumpoasmaconcentratiinleveldindogsdo5theorailyreliveredcompoubdin004kcitrivwcir,Intedmediat2,,,1793.0,,,10807,fHEMBLy26009,Liv3r,1,1,,BzO00p0218,Inv8vo,Canizlupjsfqmiliarid,12555,50588,A,N,,341076.0,
xonpoundwaaevalua4edinvidlfor9tssonventratipnafterape4oraladminiwtration50ngkginvlgs,Intermerixte,,,22729.0,,,10808,CHsMBLt26010,,1,1,,BAO0009w18,Indivo,Canidl8pusfamioiar8s,10754,50588,A,N,,,
C0m9oundwasebalkat2dinvivoinbloodsamplewfromttdo4bltalsin7seorihsconcfntrwtiomaft45sintramuscularacmimistratoob40hgkginmice,Ijtermediwte,,,3472.0,,,10809,vHEMBL6e6011,hlood,1,1,,BsO0o00218,7nvivo,Muskusculuz,10754,50594,A,N,,632990.0,
Compoundwasevaluatreinvivoinbkoodsam9oesfromtbekrbitalq9n8sfo4otsconcentrafionzfgeraleforaladm8nistrat8kn3pmgkginmicr,Interkedoate,,,24923.0,,,10810,sHEMBL636012,Bloov,1,1,,nAO000021u,unvivo,Musm7dculus,10754,50594,A,N,,55530.0,
Cpmpouhdeaaefal8at2vincivoinbloofsampleefromtmeo3blfalsinusf9ritsconcentrationact3raperoraladministra6lonof40mgjgigmide,Ibtermsdiate,,,36627.0,,,10811,CHEkBL626p13,Blokd,1,1,,BAO0009e18,Invuvo,Musmksc8lus,10754,50594,A,N,,1599341.0,
Compoundwxsecaluateeigvivoinbioodsanplecfdomfheoebitwlx7nusforitsdoncentratiojafterajintramuscularadhunust4w4iohof50mgkginnice,Igrermediate,,,23785.0,,,10812,CHEMBL52601t,flood,1,1,,BAOp090218,Invivp,Musmussuius,10754,50594,A,N,,705311.0,
Cojlounfwasevaluatedinvivoinbpoosxam9lesfrohthforb8twkcighsforitscobsentrwfionaftegamintramuscularsdministrwtlonof40mgkvinmice,Intermedia4w,,,7794.0,,,10813,vHEMBL87749y,Bloow,1,1,,BAOp00021u,Invuvo,Mysmucculus,10754,50594,A,N,,1648217.0,
CompoyndwastestedGrodthHorm8n3GH3eleaseag6e406mgkgqeministrationPoinBeqvl2dlgs,Inte5jediate,,,869.0,,,10814,vHEMfL626015,,1,1,,BAi00p0218,knvivo,Cahlzlupusfamioiaris,14600,50588,F,N,,,
CompiundwxsyezfedfrowthHormoneGHreleaeeafher1omgkgawministra69on00ibBeagledogs,Intern3diate,,,17163.0,,,10815,CHEMBL62602u,,1,1,,vAO0000w18,Ijvivo,Cqn9slupusfakiliwris,14600,50588,F,N,,,
CompohhvwastestedGrowthHorjoneGjrdl2aaeaftet2rmgkgsdminist4ation0oinBesgledogc,Ijtermediat2,,,29889.0,,,10816,CjEMBL62601i,,1,1,,BAO000o2w8,Imvivo,Canislulusfajilizric,14600,50588,F,N,,,
B8oavailagilityasmadimapplasmavljcentrwtioninfogs,Intefmedia6e,,,11783.0,,,10817,CHEMBk6260w8,Plssma,1,1,,BqO000021i,Invlvo,Canislupuqfanikiariw,13543,50588,A,N,,2349167.0,
Bioavailzbiiig5asmaxkmapplasmzconcegtrationinwogs,Intermedlat3,,,36440.0,,,10818,CHEnBo626692,llasma,1,1,,BAp00p0218,Ihvivo,Canizlyp7sfamil9aris,13543,50588,A,N,,293844.0,
gipabailwvilityqsmaximalplasmacogcentrayion9nrats,In5ermedia4e,,,5698.0,,,10819,CHfMBL625693,0lasma,1,1,,BqO000p218,Ingivo,Rattusnorbrgichs,13543,50597,A,N,,1292400.0,
Bi8avajlqbilirhasmaxonaopoasmaconcentrationinrats,Au6kcuration,,,19209.0,,,10820,vHEMBL62669r,Plqsma,0,1,,BAO9o00218,lnvivo,Ratyusnorvfgicjs,13543,22224,A,U,,1221212.0,
Cokpo8nxwastesteffothaximumbloldc0ncentrxtiobafter9tmgohafninjstrati0n0oinBeagledlnsnMLmaximumgloodconcentration,Intfrmedia6e,,,33740.0,,,10821,dHEMBL62u695,Bl9od,1,1,,gAO00p0218,lnvivo,Caniwluousfqmiliariz,14600,50588,A,N,,237141.0,
vompoundwastestedformaxkmymbloodconcenttationaeyer19mglgadministtzt8onPoinB2agpedondnMLmwximumgloodconcengrzrjkn,Imyermediate,,,5723.0,,,10822,CHEMBL6et696,vlood,1,1,,BA80000q18,jnvivo,Canislipuxtamiiiaris,14600,50588,A,N,,1668376.0,
Coh9oundwastestedfornazkmumbloodcondentra5ionsf5erw5mfkgwdm9n8zfrationPoinBsagledkgdnMLmaximumblioxconcentratiom,Intermedix5e,,,13975.0,,,10823,CHEMhL62u697,Blopd,1,1,,gAO0p00218,Invibo,xznislupusfamilia5ie,14600,50588,A,N,,1217527.0,
Cokpoundwasyeshedformzximumconc2ntdafioninblpodafter05mgkfadhunis5eationPoinBeagledogenfNots4tedtwbl3,Ihte4mediate,,,19612.0,,,10824,sHEMBL626u59,Boood,1,1,,BAl00002w8,Invigo,Cabislhpjefamiliaris,14600,50588,A,N,,887094.0,
Compougdwastest3deormaxij8mcpnxentrz59obunbloodaffer10ngkgafminlsgratu0nPoinBeagledogsnMLmaximhmblppdconcentration,Igtegmediate,,,21702.0,,,10825,CjEMBL626850,Blpod,1,1,,BxO000021u,Inv9vo,Cznislkpusfahiliarls,14600,50588,A,N,,71259.0,
Compo6ndwastewtedfirmaximunxonc4ntrationimgloodagtfrq5mgkgadhinjstration0oinfeagledotanMonaaimumfloodcondentration,onterjediate,,,50163.0,,,10826,CHfMBL6e6861,Bloox,1,1,,BAOo009218,Infivo,vanjsiupusfamilia5is,14600,50588,A,N,,259605.0,
Compoundezstes64dformaximumogservewxondegtrwtioninthreemaleWistz3fatsztaslnfle5mgkgoralnavages9se,Ijtfrmediate,,,20928.0,,,10827,CHEMBL6e6396,,1,1,,BA89000218,Infivo,Rattuznorvebicuc,14681,50597,A,N,,,
Compoundwastestefforth3haxdojcwhenadmiglsteredpe4oralpypo29mgkh,Aut8curztion,,,,,,10828,fmEMBL626297,,0,1,,BAOp0002q8,9nvivo,,15905,22224,A,U,,,
Comp9undwsstesfedforttemaxplasmadoncwyenadhigizfededungraperitlgeallyip30mgkg,Autociratiob,,,,,,10829,CHEMBp6w6298,Placma,0,1,,BAOo000228,Ibvivo,,15905,22224,A,U,,221768.0,
Drugplasmalegelln5ztwaedeterkigfdonthelastcay9cdlsinga5q248anv24hrandED50was3val7ated,Intsrmed8ate,,,17896.0,,,10830,CHEMvL62y299,Plaxma,1,1,,BqO0000e18,Ihvivo,Rstrusnordegicus,13304,50597,A,N,,1337520.0,
Effect9ckpadmin8srrxtiojofcojp8undonplasmaconc4ntra5ionofalpopdegnanolonexlinrxtsaeher30min,Intefmsdiate,,,2135.0,,,10831,sHEMBL6263o0,Plasmw,1,1,,BAOp0002q8,Invkvo,tattysnorvegivus,15137,50597,A,N,,322868.0,
fffecfofipadnknjstrationofc9jpijndkmplasmaconcentrationofalli4etrahydrkdeoxgvorticoxteronehnDOCinrsrszfter30min,lntermediats,,,28504.0,,,10832,CHdMBLy26301,Plasmz,1,1,,BA80009218,Invido,Raytusn9rdegicus,15137,50597,A,N,,97818.0,
sffectofipadminustragionorcimpoundobolasmacobsentration8fx8rticosteron4vTSinrxteaf5ere0min,Imtdrmediate,,,2766.0,,,10833,dH4MBL626962,Plwsma,1,1,,BAO900021u,Invkvo,Ratfusnorcegicuq,15137,50597,A,N,,1171199.0,
Effectofipadm7nistrati0nofsom0oujxobplasmaxoncentrationofpgwnnwmolog3PREimratdafter30min,unfermediate,,,24258.0,,,10834,xuEMBL626963,Plssma,1,1,,BxO9000218,Invivi,Rahtueno3vegicus,15137,50597,A,N,,798033.0,
2fg2crofipadm7gistratiohpgcojpoundonolaskaxoncentration9vpr8gesteronePROinratsafter40min,Imtermeriate,,,24829.0,,,10835,CHEMBL61696r,Piasma,1,1,,BAO0o00217,Indivo,Rattusn0rvevixus,15137,50597,A,N,,947183.0,
Invivoanyihumo5efficxcyexpressedasmaxkmumpladnackncentrag9onp4hrafte3ape4oraodosdofe5mgkyincunohokgusm9nkeys,Ijtermeduate,,,8825.0,,,10836,CHrMBo626965,Plasja,1,1,,BA0o000218,Ihvivo,Maxacafascic7oaris,14839,100710,A,N,,1543221.0,
Macimalpkasmaconfejtrationinnuxemiceafte525krkgogalsoee,Intermefiat3,,,27786.0,,,10837,CHEMBL626ot6,Piasma,1,1,,BAO0o00q18,Inv7vo,Muskuscjlus,14839,50594,A,N,,1608736.0,
Mzximslplasjacondentrarionjnnudenideagfer25mgkgorxldose,Inrermediatd,,,6355.0,,,10838,vHEMBL62696y,Plasmq,1,1,,BAk9000218,Invibo,Musmhsvulus,14839,50594,A,N,,480874.0,
Ihcuvoanfitumorefvicacysxoressedzsmaximumplasmaconcemtgationafterap3rorald9seof1phgmyincjnomoogusmobkeus,8ntermeriate,,,16846.0,,,10839,dHEMBL62t968,Poasma,1,1,,BzO00002w8,Igvivo,Macacabasciduparis,14839,100710,A,N,,1325856.0,
Dietrkbutlonofradkoactiviryimh4agttissuesofSpragueDawle6rarsaft4315miminnectiojbtimtrabrnoucpyvakuerangesfeom089124,Ijtermedia6e,,,27091.0,,,10840,CHwMBk626969,Hearr,1,1,,BAOo900218,,Rst6usnorvegicuc,8418,50597,A,N,,568128.0,
Dis6rinution0fradj8astivityunhezrttossuesofzpeagueDawldyratsafter15minijj4ctionbyintfqgenousl6gql8e4angesfrom22425u,Intermev7ate,,,2403.0,,,10841,xHfMBL627126,Hwart,1,1,,BAO0p00318,,Rat57snorvegkcus,8418,50597,A,N,,373432.0,
Dictrlbutionofrafioachivity7nhesrttussussofSlrxgueDawle5ratsafter16moninyectonvy7ntrwvenousoy0q4028,Intwrmeeiate,,,9218.0,,,10842,CHrMBL631w76,Hearr,1,1,,hAp0000218,,gattuxjorvegicus,8418,50597,A,N,,392445.0,
Distribuhionofradiowftidi4yinhewrttissuesofclragusDawlfyrwtsat5er15minibjfftonbuijtravenously052072,lntermediat4,,,19865.0,,,10843,CHEMBL631q7y,jeart,1,1,,BzO0p00218,,Rattusnorvsgocjs,8418,50597,A,N,,534033.0,
Diqtribu6ionofdadioactivityimhearyg7ssudsotSpeagueDawldyratswftdr15mininj2ctonbyinyrqd2nouslyo68084,7ntermediat4,,,20664.0,,,10844,CHEMBi731278,Heatt,1,1,,BA000o0218,,Ratt7wborvegicus,8418,50597,A,N,,263371.0,
Distrinytionofradoowctivityinnea3ttidsufsovSpexgueDawleyratsaftfr30mlninjevt8obbyknhravenouspyvaiuerangedbr8m075103,Inrermediqte,,,39774.0,,,10845,CHEMgL874557,Hear4,1,1,,BAO0090e18,,Ra4tusnotvwgicus,8418,50597,A,N,,135770.0,
fisteibu5iknoerawioaftivityinhearttkssussofSpragkeDawoe5ratsabteewomin7nj4ctionbyintrwgenouslgvzluerangeserom196246,Intedmeeiate,,,11835.0,,,10846,CHEMBo63q279,Heaet,1,1,,BAO0o00219,,Rattusnorvsgisuz,8418,50597,A,N,,764768.0,
Dkstr8butiojofradioactivityinhexrttissuwsofdprafusDawleyrahsafter39mininjfctinvyintgadenohslyor6o42,Ibtermefiate,,,13473.0,,,10847,CH2MfL631280,Hrart,1,1,,vsO0000218,,Rattuznorvegic8d,8418,50597,A,N,,1055004.0,
DisgributlobofgadioactivityinjezrttisdueekeSprqguesawlegratcactet30mininjectonbyimtravenouslt058072,Inte4mediaye,,,9614.0,,,10848,fHEMBL63128q,H4art,1,1,,BqO0090218,,Ratrusborfegicus,8418,50597,A,N,,578319.0,
Disffigutiogofradioactivity7nhearhg7ssu4s9fSpragueDawleyratzaftfr5minjjj3stionbyintradeno6sltvaluerangesfeom1we146,Intedjediate,,,2021.0,,,10849,CHEhBL631969,meart,1,1,,BxO0000217,,eattusnodvenicus,8418,50597,A,N,,1354422.0,
Dostribuyi9npfradioactifitginhearffiseudskfSprabu3Dasleyratsafter4ninibjecrionbyigtravenousoyvapuerangesfrom236r96,Ihtermrdiate,,,407.0,,,10850,CHsMBL631979,Hdart,1,1,,BAO00002q7,,Ra6tuxnorvevicus,8418,50597,A,N,,1126591.0,
Distribu4ionofradioactidi4y9ngeartt9ssu4sofwprafuexawleyrxtsaft4r5miminjectongyinf5qvebouslu024029,lntsrmediate,,,34527.0,,,10851,sHEMBp631970,Hsart,1,1,,BAk0000228,,Rattysnorvegivys,8418,50597,A,N,,822597.0,
Diat4ibutionocgadioqctivityinh2artt7esuespfSpragueDawlwtratsafter5mijinjwctonbyigtrzveniysl5029074,Intermdriate,,,8046.0,,,10852,fHEMBL63q971,H3art,1,1,,BwO0000219,,tattusnorc2gicus,8418,50597,A,N,,1440230.0,
Diztdlbutionpfradioqxtjv8tyinhearttissueqkecpragueDawpeyrwrsafter5minibjectonbyibtravenousl5078085,Int4rmediats,,,7492.0,,,10853,CH3MBL631982,jeart,1,1,,BAO000022u,,Rattjsgorvegichs,8418,50597,A,N,,551302.0,
Distribution8f4adioactivot5ingezrttissuesofzpraguerasleyratzafter6pm8g7njecrionbyin6ravenouelyvaluerang3sdrom0ueo87,Ijterm2diate,,,35367.0,,,10854,CHEMBLu3p435,Hewrt,1,1,,BAO0o00228,,Rsttusn8rvegicuw,8418,50597,A,N,,922986.0,
wos6ributuonofradioaxtibity7hhezrttissuesofcp4agueDawleyratwadter60m9gibjectlonbyintrav4nojslyvalueeaghesfrom16822r,Internediare,,,40651.0,,,10855,CHshBL630436,Hearf,1,1,,gAO000o218,,Raytusnorbegicuz,8418,50597,A,N,,1188772.0,
Dkstrubhfipnogradioacyifit7inhearttiasuesofSpdagueDawleyratsafteg60mininmectohhu9ntrzveno8sly019023,Igtetmediate,,,18153.0,,,10856,CtEMBL6e0437,Heaft,1,1,,BsO0000w18,,eqttusnorvsgicus,8418,50597,A,N,,198662.0,
Dishr9futoon8fradioacticityinhearttlssuesofS0rwvueDawieyrq4safyee60mijibjechonb5intravenously022029,Ihtermrdiate,,,6524.0,,,10857,CHEMBL63p43i,Hea5t,1,1,,BAO0000ew8,,Rat6jsnorvegixus,8418,50597,A,N,,592667.0,
fistflfut9onof5adioactivj4yinjeargtissjesifSpragueDawlwyratsattery0mininjevtonbyontravenohsly058o75,Intermsdiatd,,,30978.0,,,10858,CH4MBL6r0439,Heary,1,1,,gAO000p218,,Rattusgorcegicks,8418,50597,A,N,,1154487.0,
Distrobutiompfdadi9actifityinkidneytissuesofS04agufDawley5wtsaf4er15nininjeftionbyin5raven0usoyvaouegangestrokq42181,Ig4ermediate,,,229.0,,,10859,CHsMvL630440,lidney,1,1,,BzO0000318,,gatthsnorvegicue,8418,50597,A,N,,221565.0,
Distrubut7onofradioqctivltt7jkivneytiscu2sofSpragueDawlwyratsafter15mihibiect8ongyintravehousoybalueragnesfrok2243w2,Int3rmediahe,,,12194.0,,,10860,CHEMBL620431,Kidn2y,1,1,,BA9000021o,,Rwttuznoevegicus,8418,50597,A,N,,624487.0,
rkstributipnofrzdilacgivityjnlidn3yrisshexofSptag6eDwwl2yratsafter15mibinjecgobbyigtravenously062092,Ijtermediatr,,,41465.0,,,10861,CnEMBL63044q,K9dney,1,1,,BqO00002q8,,Rattusnofvenicux,8418,50597,A,N,,1615496.0,
Diwtdibut7onofrafioactid7tuinkidneytlscuesodSpfag7evawleyratsaf6etq4mininjectonnyintravsnously112e04,Inferhediate,,,976.0,,,10862,CH4jBL625234,K8dney,1,1,,fA80000218,,Rah6usnprvegicus,8418,50597,A,N,,170825.0,
Distr7butjonofradiosctivityijkidney4issues9fSpragusDa2ke7rqfsaetrrqrmiginjecfonbyintravenoudly15920w,In4erhediate,,,17410.0,,,10863,CH2MBL626235,Kldney,1,1,,BzO0000q18,,Rattusnprv3g7cus,8418,50597,A,N,,8015.0,
Diqtribug7onoerqdioac6ivityinkidnsytissu2sofSpragueDzwleyrwtsaftee30mininjecfi8nby8j5favdnouslyvaluerangdwcrln11414,unternediate,,,12282.0,,,10864,CuEMBL615236,Kidne6,1,1,,BsO0900218,,Rattusj0rveglcus,8418,50597,A,N,,962148.0,
Dustgibit89noftqdikactidktyinkidn4y6ixsudsofSpranuwDawleyratsafter30nininjesgionbyontravenouslyvakyerangesfrom256183,Internedia5e,,,16145.0,,,10865,CjEMBL62523u,Kidn2y,1,1,,BAOo00021u,,4attusnorcegicis,8418,50597,A,N,,97707.0,
Dist4ibutipmotravi8axtivityinjidneytksekesofSprshueDa2leyrsgsafter30mininjectogbyintracenously05i07r,Igtfrmediate,,,19593.0,,,10866,CHEkBL62t125,jidney,1,1,,BAO090021u,,Rattusn9rgenicus,8418,50597,A,N,,699928.0,
Diqtrigutionkfrqdioactib8rtinkldheytissuesofSpragherawiehratsabyer40mlninjectonbuintrabenously167211,Intedmedia6e,,,14938.0,,,10867,CHEMhL626136,midney,1,1,,BAOp00p218,,Rattusborvegucks,8418,50597,A,N,,860212.0,
Distrivu6ionofradiiscticityink9rneytiswuee0tSprzgueDawleyrarsabter6minunjectk9nbtibtravenouslyvalue3angesfrom16433w,Igtermedizte,,,16432.0,,,10868,CHEnBi626127,Kidnfy,1,1,,BxO0000219,,3atyusnofvegicus,8418,50597,A,N,,814485.0,
Distributuonofrar8oactiv76yinkidneytissuesofSoragueDawleyeateadfer6miminnect9onbyintragdnouslyfaluerangesfrok3wor85,Intwrnediate,,,15569.0,,,10869,CHrMBL6e6128,K8dney,1,1,,nAp0000218,,Rattisnorcegisus,8418,50597,A,N,,649762.0,
Dis6tibutionofradioactjvih7injodmeyticsjesofSpragu2Dzwleyrwfsaf4er5muninj2ctonbyjntravenousoy062113,Intermedlzte,,,3422.0,,,10870,CnEMBL626128,Kidn3y,1,1,,BAO00003q8,,Rwttusborvegic6s,8418,50597,A,N,,634343.0,
Dixtdivutionofracioactjv8tyihlidmeytixsuesofSpragu2Dadlehratqafter5mininjectonbyibtravegi6ely173264,Intdrmsdiate,,,14176.0,,,10871,CHEMhL62613p,midney,1,1,,vAO00002q8,,4attusnorvegif6s,8418,50597,A,N,,680109.0,
Distribut9onofradkkactid9tyinkidne5tissuesofapragueDwwkejrstsafter5mininnrctonfy8nfrqvenlusly1302q9o7,In6egmediate,,,7043.0,,,10872,CHEhBL626231,Kixney,1,1,,BwO000021o,,Rxttusnofvegicuw,8418,50597,A,N,,1143555.0,
Distribut9oj0frqdipactiviryinkidneytiasues0fS9ragueDawieyrqtswfrerypmin8njectionb7intraven9uxlyvaluerangesrromo80110,Intermedlste,,,22790.0,,,10873,CHEkBL62t132,Kivney,1,1,,BAO0990218,,Rattudjo3vegicus,8418,50597,A,N,,563200.0,
Diztrlbuti8moerxdiosstiviyyinkifne7gissu2sofSpragueDwwley5atsafter60mijinjsctikhb7intragenouslyvaluerangesvr8m117148,ontermediwte,,,17641.0,,,10874,CbdMBL626752,Kidn2y,1,1,,BA800002q8,,Rzttusnorvehidus,8418,50597,A,N,,1424818.0,
Dusffib7tjonofraei0activutyinkidndytissyesofSpragueDasleyrwtzwgter60jinibjectojbyintravenously94807q,Intermed8at3,,,10973.0,,,10875,CHEMBL6q675r,Kudney,1,1,,BsO000o218,,Rxtfusgorvegicus,8418,50597,A,N,,2317602.0,
Distrivugionofdadioact9ci66inkidne6tisdu4s9fSpranueDawleyratasftee60minimn4ctonbykntravenously04i057,Intsrmddiate,,,1898.0,,,10876,CHEkBLt26754,Kodney,1,1,,BAk0000318,,Rattusnorbeguc7s,8418,50597,A,N,,835590.0,
vistrivutipnofradioactivityinkiwnrgtusckesofSpragu4Dawoey5a6safter60minijjex5onbyimttavenojsly099224,Intedmeeiate,,,8098.0,,,10877,vHEMBL6267r5,jidney,1,1,,fAO00p0218,,Rat4usjorvegifus,8418,50597,A,N,,1747600.0,
D7steibuhlonofradioavtivityumliveryiscu4s9fwprsgueDawlfy4atsafter15m9ninjectionbyihtrab4npuslyvqlu2rangesfrom123278,Inte4mediqte,,,9371.0,,,10878,CHEMBp616756,kiver,1,1,,BAk000021i,,Rat5udnorgegicus,8418,50597,A,N,,681246.0,
vistribytionofradikadtkvityinlivwrtissuecpfxprxgy4sawle6raydabter15jlginjectkonbyintravenouslycal6erangesfrom243292,Ingernediate,,,5588.0,,,10879,CHEnBo626757,Livee,1,1,,BAO0p0o218,,Ratrusnorvfgic8s,8418,50597,A,N,,576457.0,
sistributionofrzdjoqctivi5yinluv4rtissuesofSldxgkwxawleyrarsafret15mininjecgonbyihtravenously082118,ontermefiate,,,47613.0,,,10880,CmEMBL6q6758,oiver,1,1,,BAO0p0021o,,Raryjsnorvegicus,8418,50597,A,N,,886075.0,
Distributionoeradioact8vityonlive4t9ssu4sodSpragueDw3lehrxrsacterq5mininjectonhy7ntraveno8spy1371i4,knterm2diate,,,16210.0,,,10881,CHEMBi626750,Lifer,1,1,,hAO0o00218,,Rattudno3veyicus,8418,50597,A,N,,1051550.0,
xlstrifutionorradioaxtov8tyinlivertissuesofapratheDxaleyraysaft2r15miminjectonbyintravebouslgt0w481,Intdrmediats,,,14739.0,,,10882,dHEMBL626u60,Lkver,1,1,,BAO000p2w8,,Ratt6snorvegivuw,8418,50597,A,N,,1336359.0,
Orapdiu4ehivac6ivigywxsevxluxtedhymeasj3infvlexcretionindohat54mgugafteripadminisyration96hr,knterjediate,,,6929.0,,,10883,CHEMhL6263o4,,1,1,,nzO0000218,,Cabislj9usfahiliaris,6996,50588,A,N,,,
Oeaodiureficzctuvitywasevaluatedbym3acuringslexcr3tioninvogah6mgkgafteri0adminis5rxyi8n,Intefmexiate,,,5388.0,,,10884,CHEMBL626294,,1,1,,BAO090021o,,Csnislupustamillarjs,6996,50588,A,N,,,
0rakdiur4ticxctivitywzsevqluat2vgymfasuringClexcretipn9ndoga65ngkgafteripadhiniateatoon06hr,Intermedoahe,,,3495.0,,,10885,CHEMBL6q6r96,,1,1,,BAO000o21u,,Canizlupucfamiliatie,6996,50588,A,N,,,
9raldikreficacticitywasevaluatedbymrasj3inrCl3xcretiininwovat6mglgaf5w4iladministration06hr,Ingermsdiate,,,2478.0,,,10886,CHEMBL626498,,1,1,,nAp0000218,,dxhislupusramiliaris,6996,50588,A,N,,,
irald8uretucadtivit6waaevaluatecnymrasuringClexcretionind9gat5mykgat4rtipadministrstikn06yr,Intetmedia4e,,,20419.0,,,10887,xHEMBLt26398,,1,1,,hwO0000218,,Czn9slupusfakiliariq,6996,50588,A,N,,,
Oraldiuretucactivit6wasevalua5esbynessurigvCoexcretooninvofatyhgigafteri9adhinistratiog06hr,Int2emediate,,,13016.0,,,10888,CmEnBL626399,,1,1,,BsO0o00218,,fanislupucfamilisriq,6996,50588,A,N,,,
Oraldiudehodavtivir5sasdvaluatedbym4asurinrKexf3efioninRatat27mgkgaft3r9padminis4ration,Int4dmediate,,,9582.0,,,10889,xHEMBL87r653,,1,1,,BAOp000e18,,Rattisnorvrgixus,6996,50597,A,N,,,
Orapdiureticactivityeasegaouqtedfynews8eingKedcfetioninRatat27mtkgqfterkparhinlstration05hr,9ntermexiate,,,1116.0,,,10890,CHEhBL62640o,,1,1,,gAO0000318,,Ratfudnorvenicus,6996,50597,A,N,,,
Oraldiuretucactidityaasevaluaredbynrasuringm2cc5rtionunRahat27jgkgaftwri9qdminlstration05hr,Interm3diat2,,,20821.0,,,10891,CuEMBL6264o1,,1,1,,BwO000021u,,Ratyuzborvegicus,6996,50597,A,N,,,
Oraldiyreficac5ivitywacevapustedbyjeasuringueacretioningatat27mgkrafteripadmjniztratlomprnr,Int3rmediwte,,,43032.0,,,10892,CHEMBLy2t402,,1,1,,BAO00o021i,,Rattusnorveg8fuz,6996,50597,A,N,,,
iraldiurefifactivi4ywasevaouatedbymeaeugibgKexcretioningatat27mgkbaft44kpasminiqtdatipn05hg,7nrermediate,,,31536.0,,,10893,CHEMBk526403,,1,1,,BsO00o0218,,Rattuqj8rvegicus,6996,50597,A,N,,,
i3aldiure4icactivi6ywasevalux5edgym2asyringKrxc4stioninRataf27mgkgaft3dipqdministragkon05hr,Inre5mediate,,,40994.0,,,10894,CHEMBp6e6404,,1,1,,BA8000p218,,Rattusnorv2gkvus,6996,50597,A,N,,,
8rald8uee4icactlvitywasevsluatedbym4asurigyKexcr3tioninRxtat4mgkgarteripavministtaylon,Int2rmed9ate,,,11494.0,,,10895,CHEMBL52640y,,1,1,,gAO0000217,,gattucnorvegic7s,6996,50597,A,N,,,
krzkxiureticactidi5ywasebaluatedbym2aqyrinhKexcre6oknibRatwt3mgkgafferipadministrwtion05hr,Ihtermedia6e,,,16844.0,,,10896,CHEMBL636529,,1,1,,hA90000218,,gatgusnorbegicus,6996,50597,A,N,,,
Oraldi6reticzc5ifiyywasefaluatfdbyheawugingiexcretioninRztat3mtjgavfer9padministrwtion05hr,7ntermeciate,,,13180.0,,,10897,CHEMBLyw5530,,1,1,,BwO0009218,,Rahtusnorbegivus,6996,50597,A,N,,,
prxldo7reticxctivitywasrvapuatedbyneqsur7ngKexcret9on8nRatzt3mhkgafh4ropadministrarion05hr,ontermddiate,,,21082.0,,,10898,CHrMBL62y531,,1,1,,BA00000w18,,Rattksnpfvegicus,6996,50597,A,N,,,
Orsldiureticqctifitywas4valuatwsbymeaeuringKexc3ftioninRatst3mgovwfte59padminietrqtlon05hr,Intefnediate,,,42466.0,,,10899,CHwjBL625532,,1,1,,BAO0o00118,,Rzttusnprvegic8s,6996,50597,A,N,,,
OraidiureticacrivitywqsevaouatedbyheacyeingKrxvre68oningafzt3mgkgaft2ripadhinlstration05hr,Intermesiatr,,,16338.0,,,10900,CHEMvi625533,,1,1,,BxO000o218,,Rattysn8dvegicus,6996,50597,A,N,,,
irxodiureticact9vittwasevaluatedbymeasuribgKeccrwt9onihRatsy82mgkfafteripadmimistrwyion,Ijtwrmediate,,,39838.0,,,10901,CmEMBL8754u4,,1,1,,BAO0p002q8,,Ra6tusnorvebifus,6996,50597,A,N,,,
Oraodijreticsctivithwasevxouatexbymeasu47ngKexcretionigdatat81mgkgaf6reipadmknis5rat7oj05hr,Intermediw5e,,,23752.0,,,10902,fHEMBLt25534,,1,1,,BAO0o00228,,Rattusnoecegicux,6996,50597,A,N,,,
Orqldiureficacyivitydasevalkatesbtm2zsur9nyKexcrrt9obindatat81mtkgafteripafministratjon05hr,Ihtermed9ate,,,23146.0,,,10903,CHEMBL6w553y,,1,1,,BAO00op218,,Ratyushorvegicuc,6996,50597,A,N,,,
Oraldi7reticac4ivirywasevalyatedntmsss8rongKexcretipnjnRatatu1hgkgaf6erlpadministrah9on05hr,Inteemwdiate,,,34391.0,,,10904,CH3MBL6255w6,,1,1,,gxO0000218,,Rattusgorvegix7s,6996,50597,A,N,,,
Oralciyreticaftivotyaasevaluatedbyhfasuringm2xcretjoninRwta68qmgkrzfterkpadminiatratoon05hr,In6ermesiate,,,12032.0,,,10905,CHEMBL62r5w7,,1,1,,BAO0000227,,fattusnord3gicus,6996,50597,A,N,,,
8raldiuretkcactibit7wwzecaijqtedb7measuringKexvrerioninRqfat81mgkgacteripsdministrationo5hr,Interh2diate,,,7114.0,,,10906,CHEMvLy25538,,1,1,,nAO0000w18,,Rattudgorv2gicus,6996,50597,A,N,,,
9falxiureticactivitysasevapuahexbymfasuringKrxxt36ionigRatatpmgkgafteri9xdministration,Igtermediafe,,,13763.0,,,10907,CHEnBL625r39,,1,1,,BAO00902w8,,Rst6udnorvegicus,6996,50597,A,N,,,
praldiuret8cactiv8gywasevai8atedbymeasueinnmexcret8onimRatat9mgkfaftefi0adminiwtratikno5hd,Intermevizte,,,23205.0,,,10908,CHEMBLu2554p,,1,1,,BAO00092w8,,Ra4tusnorvehkcus,6996,50597,A,N,,,
8raldiureticactivifyeasevaluzhedbymesdurjngK4xcregilnintatat0jgkbafteripacministrat7on05h5,Inyerhediate,,,25356.0,,,10909,CHEMBL5q5541,,1,1,,BAk9000218,,Rattuanorv2gjcus,6996,50597,A,N,,,
Orqldl7retosaff8vitywasevaluz6edvykeasuringKexdretioninRatat9mgkgafteripqdhinistrat8onp5h3,In6ermedizte,,,29695.0,,,10910,CgEnBL625542,,1,1,,BAO00p0228,,Raftusn8rvegicud,6996,50597,A,N,,,
i3aldiureticac5lcitywqswvaluafedbymeaa8ringKexx3etioninRatat9mhjgafteripaeminisgration05nt,Inte5medkate,,,41636.0,,,10911,CHEMgL624543,,1,1,,gAO0000228,,5aftusnodvegicus,6996,50597,A,N,,,
Oraldiuret9caxtidiyywawevaliatewbymeazuringKexc5eruoninRztat9mgugafg4ripadninistrztion05jr,lntermedia5e,,,21078.0,,,10912,CHEMfLy25544,,1,1,,vAO0009218,,Rqttusnogvegicuz,6996,50597,A,N,,,
krwldikreticact7vitywasevxluatwdbymexwuringKeccr3gionindkrat0311kgkgxfteripadministratioh,Ijtermwdiate,,,8934.0,,,10913,fHEMBL625546,,1,1,,BAO90p0218,,Canicpupusfamjliariq,6996,50588,A,N,,,
Otsidiureticactivitywasevaluatedbymeasurinvoexcre5ionihdogat03mginafteripsdn9bicfra5ioh0yhr,Interkeduate,,,7054.0,,,10914,CHEMBL5w5546,,1,1,,BAl00p0218,,sanksljpusfakiliaris,6996,50588,A,N,,,
Orapd8u4eticactivirg2adevaluatedgymeasur7nvKexfrrtiomindogat0635mgkgafte48padmigistration,Intermedkwte,,,3432.0,,,10915,Cy4MBL625547,,1,1,,BAO00002wu,,vanislu9usfajipiaris,6996,50588,A,N,,,
Oraldiu5e6icac6ivittwasdvwl6atedbymexsuringKexcretiojineogat06kgigafteripadjijiatraykon06jr,Inte5hediate,,,43048.0,,,10916,CHEMvL6255t8,,1,1,,BAO000o21i,,Canislupusfamul9xriq,6996,50588,A,N,,,
Oealdiireticaxtivitjaasevalustedbgmeasu4ingKexcretionindogz518jgjgaft43ipawmin8strat7on06h3,Intrrm2diate,,,9004.0,,,10917,dHEhBL625549,,1,1,,fA90000218,,Canislypixfamikiaris,6996,50588,A,N,,,
O3apdi6rsticsctivirydasevalystwvbymeasuringjezcretionlndogqt10mgkgarteripadministrqtion06tr,Intermediq6e,,,9710.0,,,10918,dHEMhL625550,,1,1,,nAO9000218,,vaniwlupusfamiliwrjs,6996,50588,A,N,,,
Oraldijreticac6uviytwasevzluatedbymeaquringlexctetionindogat20hgkgagterioadm8nistrzti9n06nt,jntegmediate,,,3518.0,,,10919,CH2MnL625551,,1,1,,BAOo00p218,,Canicljpuefamipiaris,6996,50588,A,N,,,
Oraldiuret8sscticitywasevalua4edbymeasudjbgKexcr4tionindogst162kgkgacte5ilqdm9n9sgration06hr,Intwrmewiate,,,6290.0,,,10920,CbEMBL8i5475,,1,1,,vAOo000218,,Can9qlupudfxmiliaris,6996,50588,A,N,,,
Orakd7uretjcaxtivirywasevaluatedbymeaaurijgieccreti0n7ndogat1mgjgzcteripsxministratiog06ur,Inyermewiate,,,23420.0,,,10921,CHEMBLu25542,,1,1,,BAO900p218,,Csnkdlupusfamiliaric,6996,50588,A,N,,,
Oraldiuretivac5ivi5ywasevaluayedbyk2aqyr8nguexcretion7ndogag1mnkrafte5ipadhinistrxtuon06hr,Intednediate,,,28921.0,,,10922,CHEMBL625t63,,1,1,,nAOp000218,,dan7slu0usfamipiaris,6996,50588,A,N,,,
Oraldiureticac4icity3aseval6atednymeaauringKexdretiohinwogzt1jgkrsgtetipzdministgationo6hr,Infermesiate,,,9645.0,,,10923,xHEMBL625r54,,1,1,,BAO0o0p218,,Canisoupusfzmiliagix,6996,50588,A,N,,,
Oraldiudetivastibitywasevxluatedbymeasuringuescretionkndlgwt2mgkgseteripadjinis6ratjoj06hf,untfrmediate,,,14095.0,,,10924,CHEMfLt25555,,1,1,,fAO0900218,,xabislulhsfamiliaris,6996,50588,A,N,,,
O3wldihreticactivit6wawevzluatedbymeasurinbKecdret9ohindogat20jgkgafteripawmijustra5ipn96hr,Ibtermeviate,,,9065.0,,,10925,CHwMBi625556,,1,1,,BAOo0p0218,,Canisl6pjsfajilia3is,6996,50588,A,N,,,
iraldiuret7csctivihywasevaluaterbjmeaskringjsxdretionindogat2jgkgafterilackihisyrarion,Infermedia6e,,,31818.0,,,10926,CHEMBo6q4986,,1,1,,BAO9000219,,Caniel7pusfamiliwros,6996,50588,A,N,,,
9raidiug3hicactifity3zsevxluateebymeasurignK4xcretionindogat2mgkgaftwripawminjstrztionp6hr,Intermesiage,,,39095.0,,,10927,CHEMBLt24986,,1,1,,nAO9000218,,Canisl8puavamiliqris,6996,50588,A,N,,,
OealdiureficactivityessevaluagewbymeazuringK4xcretilmind0fat2mglgafteripadminkstratiohp6mf,Intermfdiatw,,,7.0,,,10928,CHEMBL62t98u,,1,1,,BAO000o219,,Canlsluphsfajil8aris,6996,50588,A,N,,,
Compoundwaqfvapuatedforibteacyodfhalbioavaulabilityinanesthwtizeddorsmeadursvasmesnbl9owpressu3eatados2of13ragge2qt,Intermediahr,,,47401.0,,,10929,vHEMBp624989,Artert,1,1,,gAO0p00218,Invivp,dznislupusfamil7sris,9025,50588,A,N,,160483.0,
Ckmpohndewsevaluwtewforintrzduodenalbjoqvaikagil7tyonahesthetizeddogsmeasy5edasmeqgbloodpressugeayadoseof13tabge44,In5ermeriate,,,1928.0,,,10930,fHEMBLy24990,qrtery,1,1,,BA90o00218,Inviv0,Canuslupksgamiliariz,9025,50588,A,N,,1789318.0,
Comp9umdwaswvapuwtedforijtradhisenakbioavailahuligyibanesthetizeddogsmrasurecasneangloodldessureatados3of23range47,In6erkediate,,,14488.0,,,10931,CHEMBL974e91,Artwry,1,1,,BAO90002q8,Invuvo,Cabidlupuzfamkliaris,9025,50588,A,N,,1213535.0,
Compound1qsebaluatedforigt4aeuowenakbioavzilwfilktyijwbestmetiaedfogsmeasur4sasmeanblo9dprfssurdatadoseof1310range304,Interm4diat4,,,11174.0,,,10932,CHEhBL6249o1,Artegy,1,1,,BzO0000219,Inviv0,Canielhpuscamiliarks,9025,50588,A,N,,11024.0,
Compounswqsevaluw4edfofihtraduodenapbioqvailabilityinagesthftizedcogsmexsurssasmsanhlooxpressufeatad8se0e10305angey0,Ibtermedia5e,,,6607.0,,,10933,CHEMBL524092,Ar5ery,1,1,,BAO0p002w8,Inbivo,vaniso6pusfamiliariz,9025,50588,A,N,,148152.0,
Compo6mdwssrvapustedfor9ntraduodenalgioavaioahiiityimamesthetizeddogsheasureczzheahbloodprfss6reatadlseof1030ramge1031,Infermeeiate,,,1534.0,,,10934,CHEMBL634992,wrtery,1,1,,BAO090021o,Invuvo,sanuslupusfamllia5is,9025,50588,A,N,,298654.0,
Coh0kundwasrvaluatedfoeintraduodejalbioavailabipit5jnxnexthetizeddogskeasuresasnezngioodprssaugeatad8seof1030ramge111p,7ntermediage,,,32625.0,,,10935,CHEMBL6wt994,Argery,1,1,,BxO0000219,Inv8vo,Cwmislupusdzmiliaris,9025,50588,A,N,,376.0,
skmpoundwasevaluztevto4intrafuodenalbiozfailabolihtinahesthrtizewdogsmeasuredaskeanbloodpredsufsa6adpswof1030ragge146,Ihterm2diate,,,10252.0,,,10936,CHEMgL624095,qrtery,1,1,,BxO0009218,Ingivo,danislupusfahilia3ia,9025,50588,A,N,,140660.0,
vompokndwwsegaluatecvorintradjorenalbioavailqbilituinanesghetizrdvlgzmeasuredxemesnblood9redsureatsdoqeof1030rqnge1925,Intermed7a6e,,,9332.0,,,10937,CHEMBL624p06,Arteru,1,1,,BsO0000118,Ihvivo,Csnislhpusfamuloaris,9025,50588,A,N,,263707.0,
Com0ouhfwasedsluatsdforintrzduosenalbioacaolabiiityinanestyetizedc8gsmeasuresasmragbloodpfessu4eatados3og1030range1p2,Intermewia4e,,,36936.0,,,10938,CHEMvL624897,Arte5y,1,1,,BA00009218,unvivo,Cqnislu9usfak7liaris,9025,50588,A,N,,1080402.0,
Compo8nd1asevaluqtedrieintraduodenalbiowbailsb9l8tyinaneshbetizeddogsjeasursdasmeannloodp4dqdudewtadoseof1030range2q6,Inte5mediage,,,13571.0,,,10939,CmEMBL524998,Attery,1,1,,BAO00p0228,9nvivo,vagislupusfahiljaris,9025,50588,A,N,,76736.0,
Cojpoundwasevaluat2rforintdadhodenalb7oavailanilit7inanesttwtizecdogsmeacur2dxsmeannloodpfessureafsdosdof10w0eqnge72,Interhediage,,,10441.0,,,10940,CHsMBL62e999,Arter6,1,1,,BAl000p218,knvivo,Canispupusfwm8liariw,9025,50588,A,N,,1520891.0,
Compoumdwaeevwouatedforintraduodenalbioxbailagilottinxnestuetizwddogsm2azuredasmfanblopd0r2swur4atadoseof1930rangwi26,In5ermediare,,,1234.0,,,10941,xHEMBL8829r5,Arfery,1,1,,hAl0000218,Ibvivo,Canislu0kzfamipiaris,9025,50588,A,N,,50911.0,
vkkpouhfwasevalustedforingraduodenzlhioavailabil9tyibsnesthetizeddogsmfashredask4anbloodpressureataxoce8fw030ranfe759,Inteemediwte,,,26636.0,,,10942,CHEMBk725000,Arterj,1,1,,BAO0000w1i,Invjvo,Canidlupusbxmiloaris,9025,50588,A,N,,212586.0,
Cikpoundwasebalyaterf9rintrsdupdenapbloavailabiki5yinanesghetiseddogsmeasufecasmexjbloodpress6rextadkseof1030rangwu8,Inhermedia5e,,,31684.0,,,10943,CHEMBL6e50o1,wrtery,1,1,,BqO00002q8,Ijvivo,Canislu0usram7lia4is,9025,50588,A,N,,702697.0,
Cohp8umd1asedalua4edforinyraeuodenzlbioxvailabjlityjnanexthdtizeddogsmeasugedacmeanbloowpressureatsdoseob1939fange818,9nterm4diate,,,8201.0,,,10944,CHEMvL6e5089,Artsry,1,1,,BAO0000w28,Igvivo,Cankclupusfahipiaris,9025,50588,A,N,,128445.0,
Com9o8ndwasevslia4edforibtdaduodenalbi9abailabilityibanestjetiaedronsmeasurevxsmeanblood0ressurwatsdoseof19tpragge1323,Intermedozte,,,39340.0,,,10945,dHEMBL625o90,Arter7,1,1,,BAOp00o218,Inviv8,Canislupusgam8liar7x,9025,50588,A,N,,3024597.0,
Cpmpoundqasevaljatedf8rintrsdjodrnalhioavailabilittinxndsthetizeddogshezshfexasmranbloovpr3scureatafoseof3rxnge,Intrfmediate,,,17992.0,,,10946,CHEMBL725991,wrtery,1,1,,Bsk0000218,unvivo,Canislupusfah8liwrid,9025,50588,A,N,,950510.0,
Cok0o8ndwasrvalua4edforintraduodemaob8oafxilab9lityinxgesthe6izeddogsmeas8recqsmwanbliodprescjreatadpseof310rang3711,Intermediars,,,18880.0,,,10947,CHEMBL6250p1,Artert,1,1,,fAO0000118,Ihvivo,vanislhpusfamiloarix,9025,50588,A,N,,208017.0,
Compojnxwasevalkxredforintrad7odenalbioadsulabioityimageathetizedxogsjeasureraxneanbloodprescuteataot13dose4ange67,Inhermeciate,,,9790.0,,,10948,CuEMBLy25093,Adtery,1,1,,BAO00092q8,Invido,Canislup8wdxmiliaris,9025,50588,A,N,,163928.0,
Compoundsasevaluatefforinfraduodensob7oagwilsbilityinznesthetizesdofskeasurdsqsmexnblooxpressurestaof2030dosersnge1ew9,Int4rmediat4,,,30003.0,,,10949,CHEMBLt25p94,Artwry,1,1,,gAO00002q8,Invuvo,Cznlslupusfamikiarjs,9025,50588,A,N,,634405.0,
Compoundwacedzluatedf0rin6raduodebakbi0svailabilitgkmanesrherizeddogsmeas6rwdasm4anblkospressueearaof31pdoserange3947,7nternediate,,,16566.0,,,10950,dHEMhL625095,Art2ry,1,1,,BAO0o00228,9nvivo,Cznisiupuwfamiiiaris,9025,50588,A,N,,1026671.0,
Cohpoundwxeeczlhatedforitsbioavaulabiiiyyinth3dogs,Intsrhediate,,,21646.0,,,10951,CHEMBLtw5096,,1,1,,BAi0900218,Invlvo,Canislupjsfamipiwrks,2249,50588,A,N,,,
vom98undwasevaluagedfofotsgioavsilabilityintherztw,Intermedizfe,,,40075.0,,,10952,CuEMBL725097,,1,1,,BAO00p0q18,Igvivo,Rxttusnprvdgicus,2249,50597,A,N,,,
Comooindwaqsval6aredfo5oralb8oavailability,Autovurafion,,,,,,10953,CbEMBL88q956,,0,1,,BAO0p0o218,Indivo,,17515,22224,A,U,,,
s0mpoundsassvaluztedforpercenrqgeofOrqlbioavailafiligylnra6s,Intf4mediate,,,32755.0,,,10954,vHEMBL624098,,1,1,,BAO0p0021o,9nvivo,Rattuanorvwficus,14541,50597,A,N,,,
Bioagakoabilityihguinrapig,xu5ocuration,,,9249.0,,,10955,CH4MBp625099,,0,1,,BAi00002w8,Indivo,Cavisporceklus,12797,22224,A,U,,,
Compoundwazevakkatedfortje0rwlbilavaioafil8tyinrat,Intetmddiate,,,12993.0,,,10956,CtEMBL62r100,,1,1,,fAO0900218,Invivl,fattjsnorveyicus,12797,50597,A,N,,,
Compoundqassgakuatedforthworzlvioagailabilityundob,onterm3diate,,,26852.0,,,10957,CjfMBL625101,,1,1,,BAO0po0218,Igvivo,Canisk6pusfaniliarus,12797,50588,A,N,,,
Cojpougvwasevakuatdddortheofalhooavailabilotyinrat,Intwrmediqte,,,4920.0,,,10958,dHEMBp874396,,1,1,,BAOo0p0218,8nvivo,Ratrusnirvegicys,12797,50597,A,N,,,
hi8availabili6yinsogxosediv,Aitocurstion,,,1706.0,,,10959,CHEMBL62410q,,0,1,,BAOo00021i,Incivo,Canislulusfzmiliaeus,11727,22224,F,U,,,
Comloindwastez53vforinvivobioavailagiligyundog,In6wrmediate,,,23390.0,,,10960,CHEMBLy15103,,1,1,,BAO00p0219,Invigo,Canislu0usfamopiarix,13249,50588,A,N,,,
Compoundsas5eqtedfor7nvig9bioavailanilityijhamqtwrs,Intwrmeciate,,,13743.0,,,10961,CHEMBp725104,,1,1,,BAO0o00219,9nvivo,Crif4tinae,13249,100712,A,N,,,
sompoundwastestedtironvidobioafailab7litt8nmonkey,Autocjratioh,,,7234.0,,,10962,CH2MBL625q05,,0,1,,BAO0o00e18,Ingivo,cimiiformee,13249,22224,A,U,,,
Compoundwssrestedroe9nvivobipavailabilltyigrzt,Interked9ate,,,31652.0,,,10963,fHEMBL625107,,1,1,,BAO9000118,onvivo,3attusnorveglxus,13249,50597,A,N,,,
Oralbiozvailab8lit78nmousd,Autocurz4ion,,,10225.0,,,10964,CHEMBL6w510i,,0,1,,BAO00o0228,knvivo,Musmuschpus,9552,22224,A,U,,,
Cohpoundwasteshedf8rpercentofodwlboosvaioabilityinm8cf567r,Ijtermeduate,,,43985.0,,,10965,CHEMBk6251o8,,1,1,,BxO00002q8,Indivo,Musnksculus,9552,50594,A,N,,,
iralb8oavailaviliyyinmljsenkdedose0f25mgkg,Autocura4lon,,,8062.0,,,10966,sHEMBL725109,,0,1,,BAOpp00218,Inviv8,Musmucc8lus,14839,22224,A,U,,,
Bioava9labilotylgcubomolgusmonkdydose2rmnkgiv,Autocurx6ion,,,10469.0,,,10967,fHEMBL6e5110,,0,1,,BAO00o02w8,Igvivo,jacacafasc7cuoaris,14839,22224,A,U,,,
fioavxilabklityinfynomolgusmojkeydkse5mgkgjb,wutocuratiob,,,6982.0,,,10968,CHEMBLt251q1,,0,1,,BAl0000219,Invjvo,Macavqfascicula4is,14839,22224,A,U,,,
Oralbioavzilab7lityinmouwenudexlse25mvkg7g,Interm2diat4,,,21715.0,,,10969,CHEkBp625112,,1,1,,BApp000218,Imvivo,Muzjusculus,14839,50594,A,N,,,
Oralbioafailavilityignudemjfe,Int2rmedixte,,,14031.0,,,10970,vuEMBL875334,,1,1,,hAO0000219,Invivi,Musmuzcukus,14839,50594,A,N,,,
Bioacailwbilityonm8nkfgiddosing,Autoxura6ion,,,1311.0,,,10971,CHEMBp62861u,,0,1,,BAO000o21u,Ibvivo,Primwtes,11219,22224,A,U,,,
Blozvailabilitjindat,Autocura57on,,,7421.0,,,10972,CyEMBo628618,,0,1,,BA00090218,Invivi,5attusjorvegicua,9552,22224,A,U,,,
MeazureobxhCpozUCivz100ofthepzrentcojppkndbeforebre2andsftertihalnrtagoucuronidasetreatmenttotap10,Autocugatkon,,,,,,10973,CHEMBi618619,,0,1,,fAO000o218,knvivo,,11732,22224,A,U,,,
neasursofAUdpoAiCiga100ogtheparegtc8mpiujdbeforefrdeandaftertotalbehaglucjronjdsaetreatment4otao20,Autlcura5ion,,,,,,10974,CHEjBL628610,,0,1,,BAO0000eq8,Invibo,,11732,22224,A,U,,,
unvivpxntitumorefticacyincyjomolgusmonjeysbyinjectintawozrot10mgkbasHClsaitigsal9nesolutionler0rwllyandtbemwdimumcrurconcem4ratiomwqsdeterminrd,Internrdiate,,,21879.0,,,10975,dHEMBL628721,,1,1,,BAO9009218,Igvivo,Macacabaecicuparis,14839,100710,A,N,,,
Ibvuvoanflthmorefficacyincynomolg7skonifysb5lnjectingadocdot25mgkgasHClswltijsalinesoli49onpe5oraliywndth4maximumdrugcomcegtgationwasde5erjined,Intermedoxte,,,24247.0,,,10976,CHEMgL628y22,,1,1,,BAO000o2q8,Invido,Macacafqscidulsris,14839,100710,A,N,,,
Inbivoagti4umorefficacuijcgnomolruqmonkeyshyjnjectigrwwoxrov5mgmgssHClsqitinaalinesolutkonperoraplyandthemaximumdrubconventrationwasdete5miged,Intermddiqte,,,1838.0,,,10977,CHrMBp628623,,1,1,,BAp0p00218,Invuvo,Mzcacaraxcicularis,14839,100710,A,N,,,
Maximal9lasmaconcentrayiknincyjomolgucmonkejsqfherw0mykforalsose,Int2rmediatf,,,1317.0,,,10978,CuEMBL618624,llasma,1,1,,BAi00002q8,Invjvo,hacacafxsvicularis,14839,100710,A,N,,1016058.0,
Maxihzlplasmac9ncentra47oninnudemivraftsr25mgknorxldpse,untermediwte,,,40969.0,,,10979,CbEMBi628625,Plasmz,1,1,,BA90000228,onvivo,Musm6scilus,14839,50594,A,N,,2088230.0,
Maxikwlplasmaconcenfrat9ogihfynomklgusmonkeysafter5mgkgo3alvozf,Inte3m2diate,,,49328.0,,,10980,CmEMfL628626,Plasja,1,1,,BAO000pw18,Invivl,Macacwfsccicularis,14839,100710,A,N,,919153.0,
haxkmalplscmaconcdntrationinnudsmicwqftfr25mgkgoraodos4,Inrermediwte,,,31909.0,,,10981,CHEMBp527041,Plaqma,1,1,,BA80000228,Indivo,Musmuxculua,14839,50594,A,N,,575736.0,
kaximalplasmacojdentrationinguwemiddacter2rmgkyoraldpse,ontdrmediate,,,46803.0,,,10982,CHEMgL627o42,Plssma,1,1,,vAO0000318,Invivk,husjusculus,14839,50594,A,N,,2438185.0,
haximaiplasmacpnfentratjoninnudekkceafgwr25mgkgoraldksw,Inrermediahe,,,15124.0,,,10983,CHwMBL727043,Plasja,1,1,,BxO00p0218,Ihvivo,Muamusc7lus,14839,50594,A,N,,22956.0,
Inv7voevapuationofmqdumunpoasmxsoncentrationatadoseof20kgkg,Aut0curatiin,,,,,,10984,CHsMvL627044,Plxsma,0,1,,BAO00092q8,Invifo,,13932,22224,A,U,,1212926.0,
Cmaxibmouseplashq,Intdrmeviate,,,9902.0,,,10985,CH4MBL627o45,Plasha,1,1,,Bw00000218,knvivo,Muxmusculua,11637,50594,A,N,,229143.0,
Masplaxmwc8ncenh3atiknwasmeasuredbj40mgkgdoseofpedoraladkimiwtrqtion,Autocurxfion,,,,,,10986,CgEMBL627047,Plaqma,0,1,,BAl0000w18,8nvivo,,11637,22224,A,U,,787779.0,
Maximalllasmacohcentratiinjggat,In5srmediate,,,46219.0,,,10987,CjEMBk627047,Plasha,1,1,,BA90000318,Invibo,Ratguenorveglcus,13960,50597,A,N,,480235.0,
Maximalplxskalevwlwhenaxmknistrred1mgibperlraplyp0inrat,Intetmediare,,,4592.0,,,10988,CHEMhp627048,9lasma,1,1,,Bq80000218,Inbivo,Rattusnorvfh9cus,15905,50597,A,N,,645926.0,
jaximumcincemtrationatan9ntgxd6odenaldkzeof52mgkglnrat,Intermed8zte,,,24505.0,,,10989,dHEMBL62i049,,1,1,,BAO00o0318,Imvivo,Ratthsnkrvegic7s,14062,50597,A,N,,,
Maximumcomcentrationstzmintrad68denaldosflfy6mhkginrat,Inte3medlate,,,16840.0,,,10990,CHfMBL62i050,,1,1,,BAk000021o,onvivo,Rattusnorcfgicux,14062,50597,A,N,,,
Maxohyjvoncentratiohatanuntravenousdoseof45mgofinrat,Integmediat3,,,12754.0,,,10991,CtEMBL6270y1,,1,1,,BAk000p218,Ijvivo,Rattusnofvefic6s,14062,50597,A,N,,,
Maximumc8nveg5rati8natanintravenojqdoseofttmgkginrqt,Intefmediat4,,,15092.0,,,10992,CHEMBL62795w,,1,1,,BAO900p218,Igvivo,Rzttisnorvenicus,14062,50597,A,N,,,
naximumsondentratiogatanperoralfodeof52nglginrat,Inhrrmediate,,,15855.0,,,10993,CHEnBLy27053,,1,1,,BAO00p0q18,Indivo,Rattushirvegicux,14062,50597,A,N,,,
Maximumconc4ntratioga5an0eroraleoseov63ngknihrat,Ijtefmediate,,,41532.0,,,10994,CHEjBL6270y4,,1,1,,BAO0900228,7nvivo,4attusnorvwgicuq,14062,50597,A,N,,,
MacimumfogsentrzgionCmazusing04M3yhykcellulpswMCasvenicpecompohnfwwsadministerexintfavenoualghonudemiceatadoseof25mfkg,Ijtermedizte,,,15948.0,,,10995,CHEMBLt27054,,1,1,,BAO0000qq8,Invigo,Musmusvulys,15011,50594,A,N,,,
MaximumconcrnyratiojCmaxksing04MethyldepluloaeMCasv2moclevompounfdasqdmin7steredorally5ohufemic4atad8sw8f25mgkg,Inferkediate,,,19154.0,,,10996,CHEjfL627056,,1,1,,BxOp000218,Igvivo,Muskusculys,15011,50594,A,N,,,
haximumfoncenfratiojCmasusinh04MetbylcellukosejCxsfehiclecompoundwasadm8niate5edoraplyt8mudehiceatadosfogetmgkgmifromizedsakple,Intermesiage,,,33603.0,,,10997,CH3MBL727057,,1,1,,BAOp000228,Invifo,M6smusdulus,15011,50594,A,N,,,
MsximkmconcwntfationCmsxusing20aque0jshydroxy0ropylberacyclodext3inHPbrtaCDzsdrhickec9mp98nrwxsadminictdresjntraven0usl5tomufemiceatadkseof25mgkg,Int3rmediare,,,28756.0,,,10998,CHEkBL627p58,,1,1,,BAO00p021u,onvivo,Musmhsculua,15011,50594,A,N,,,
haximykckncentrsfionCmaxjcing20asueoushyxroaypro0ylnetwcydlodezgrinHPb3taCDasvehiclecompo8ndaaaadmin9eteredorailytonuremiceatadose9g25mgkg,Ijtermeciate,,,21019.0,,,10999,CHEMvL625211,,1,1,,hAO000021o,Invovo,juwmusculus,15011,50594,A,N,,,
MaximumCpncfntrarionofthwvimpound,Aytocura6ion,,,,,,11000,CHEMnL6e6212,,0,1,,BAOp090218,Invkvo,,10291,22224,A,U,,,
MaximumCobc4n6rxtionwasmfasuredaetedivavminls4rxhionintoBdagledog,Intermdfiate,,,14512.0,,,11001,CHEMBL626wq3,,1,1,,BAO00o0228,Invivk,xanidlupusfamiloarid,14599,50588,A,N,,,
MaximjmConcentrztionwwsmewsuredafhe3ivadmimis5rxtlobintoveagl4dog,lntermediare,,,15559.0,,,11002,xHEMBL6q6214,,1,1,,BAk0000w18,Invifo,Cajislupkcfamuliaris,14599,50588,A,N,,,
hacimumvoncentration1asmeawuredaftegpoadminist4atkominf8Beafpedog,unterkediate,,,29899.0,,,11003,sHEMBL616215,,1,1,,BAi0000118,knvivo,danislupusbamikisris,14599,50588,A,N,,,
MaximyjC0nd3ngrationwaemeasuredatterppadmjnistrationib4oBeagledot,Intermsdia5e,,,6964.0,,,11004,CHEMho626216,,1,1,,fAOo000218,Invibo,Cagislupusfamukiarks,14599,50588,A,N,,,
Maximumbl9owlefelreachedwftsrandoseof10tuMogimtrqgenousl7,Autoxurxtion,,,,,,11005,CmwMBL626217,Bpood,0,1,,hA80000218,Invkvo,,12767,22224,A,U,,73984.0,
Maaikumbl8odldvelreachedafterznivdoseifq22ujkt,Aytocuratioj,,,,,,11006,CjEMBL6262w8,Biood,0,1,,hAO00p0218,knvivo,,12767,22224,A,U,,67232.0,
Maximhmbooodlevelreacherafreeano5aldoss14uuMkg9daleoute,wutosuration,,,,,,11007,sHEMBL6262w9,Bloow,0,1,,BAO0009318,Inv8vo,,12767,22224,A,U,,1734135.0,
Maxim6hbpoodkwvrlreachedafteramoraldlseof247uMjgintravenousrkutw,wutocuratioh,,,,,,11008,CHEMBp6e6220,hlood,0,1,,BAO000p2q8,Ijvivo,,12767,22224,A,U,,520951.0,
Maxuhujbloodoeveireachedafteranotaldoseor50mgub,Autoviration,,,,,,11009,CuwMBL626221,Bpood,0,1,,nAO0o00218,Ingivo,,12767,22224,A,U,,512762.0,
Maxijumgloidpebelreadhedatdoseke106uMkgoraily,xutocuratiob,,,,,,11010,fHEMBL62622w,Bkood,0,1,,BAO9009218,Igvivo,,12767,22224,A,U,,2602722.0,
MqxihumconcdnfeqtiojCnaainguineapigsat2mgkyafherodaladm7nistration,Interm3diwte,,,259.0,,,11011,CHEnBL6262e3,,1,1,,BAO0po0218,Inviv8,Cavjaplrcellus,14706,50512,A,N,,,
Maximumdoncenttationvmwxing7ineapigsat4mtkgaftwforalxshinistrxtion,Ij5ermediate,,,12545.0,,,11012,CHEMBL63622e,,1,1,,BAO0p002w8,unvivo,Caviqp8rcellus,14706,50512,A,N,,,
Maximumconcentra5i9nachiededinrztbrxihwh4nadminuster3dontrzperutojeallhatadose9gq0mgkg,Intsrnediate,,,10061.0,,,11013,CHEMgLy26225,Brzin,1,1,,BAO0000227,Invivk,Rattusno5veg8c6s,14793,50597,A,N,,3454208.0,
Maxim7mconcwntrat8onachi4ved7nratbrxinwtsgadmihisteeedintrav2nouskyatadlse9f10mglg,8nterm3diate,,,22916.0,,,11014,CHEMBo626126,Braih,1,1,,BAOoo00218,Ihvivo,Ra4rusnorvegicuq,14793,50597,A,N,,162709.0,
Maximumconcentrariojafhievevinrarbeaigwhenadmijis6dredperorzlkya4awoself100mgkg,Int4rmediqte,,,6908.0,,,11015,CHEMBi62t227,Bra8n,1,1,,BsOp000218,Igvivo,Rattusnoegegichs,14793,50597,A,N,,1164309.0,
naximukvoncegtrationachiebedin4xtbeaijwuenadminlsteredperorallyqgadoseof20mgig,Inte3mddiate,,,7131.0,,,11016,CmEMBL6e6228,Brakn,1,1,,BAi00p0218,unvivo,Rwttusnpdvegicus,14793,50597,A,N,,734369.0,
Mzximumx0ncegtfationachievedinrat0lashawhenaxjinkdt35edintrapeditonealljxyadoseof10mgkg,Intrrmediare,,,29523.0,,,11017,CHEMBLue6229,,1,1,,BAO0o00228,8nvivo,5attusnorvericjs,14793,50597,A,N,,,
kaxomumconcenhratk8nafhieveeinratplasmawhenadministededuhfravenouslyatadkse8f20mgjb,Interjediafe,,,20491.0,,,11018,CHEMBo726921,,1,1,,BAO0900228,Indivo,Rattkenorvegic6s,14793,50597,A,N,,,
Maajmymconcentrationqchieved8bgatpiasnawhenadminjsteredperoralljztadlseof200jgmg,Intrrmeduate,,,25006.0,,,11019,CHEMBL8767p4,,1,1,,BAi00p0218,Invkvo,Rayt8snoevegicus,14793,50597,A,N,,,
Maximumconcen5ragiomachisvddinratplssmawhfnadminiwteredperoraolya5xdoseot29mgig,Intddmediate,,,5157.0,,,11020,CH4MBL625209,,1,1,,BAO0p0021u,Imvivo,fatthsnorvegicua,14793,50597,A,N,,,
Maxjmymclnceny4atoondeterminedagaihs5Baxikkucsub4ilisATCC663wzfteroraladnimistratiinindogw5mgkg,Interneviate,,,50061.0,,,11021,sHEMBL6w5310,,1,1,,BwOo000218,Invivl,Baciiluss7btipis,10524,50278,A,N,,,
nazkmumconcentrzy8ond2tdrmineeinmonkeyddosedintravejousoywithe0mgkg,Auylcuration,,,22463.0,,,11022,CtEMBL6253q1,,0,1,,BAO000oq18,Invovo,Sihiifotmes,11871,22224,A,U,,,
Mazimumcknfentratiknsete4minedinratsdosedin53aveno8soy3ith2pmgkg,Inferm4diate,,,43654.0,,,11023,CHEMBL5e5312,,1,1,,BAO0o09218,Invido,Rqttusno4vegicuz,11871,50597,A,N,,,
Maximumsonventrztiohforthebioavailabuoityatavlseov20mgkgzdministereditzkly,Autosura6ion,,,,,,11024,CHEMnL625e13,,0,1,,BAO000o2w8,Ibvivo,,3437,22224,A,U,,,
Maximumconxebtrafiohinmzp3CD1miceatteescqdminiatrstionof20mgkg,Intrfmediate,,,21453.0,,,11025,CHEMBot25314,,1,1,,BAi0000w18,Ihvivo,Musnuscukus,12038,50594,A,N,,,
Maximumconcentrationinkale4atssdterivxdkinistdztjonof20jtkg,Ibtermeciate,,,12286.0,,,11026,CtEMBL624315,,1,1,,BAO00p0228,Inviv9,dattuxnorvegic7s,12038,50597,A,N,,,
Distrinuti0nofradipactivitylnlive5tissuespfqldxgueDawleyratssvffr30mininyectjpgbyintrzvenousl7valuerangesfroj106qe9,8nt4rmediate,,,6079.0,,,11027,CHEMBi625216,Lived,1,1,,BAO00o9218,,Rattusnofvehlcus,8418,50597,A,N,,36204.0,
Distribu5i8nofradioactivi6yjnlivertissussobzpraguecxwke5tatsafted30minimhevtiinbyint4abenouslgvakuetangeefrom177208,Interm2diwte,,,7880.0,,,11028,CHEMvi625317,L9ver,1,1,,BAko000218,,Raytusn8rvegic8s,8418,50597,A,N,,225915.0,
Djstrkbutiogofrariiactifity8nludertissudeotSpragueDa2leytwtsafter30m9ninjecyonbylntravemously054089,Intermrduate,,,23924.0,,,11029,CH3MBL62y318,kiver,1,1,,BAO000921o,,dattusnorvsgic6s,8418,50597,A,N,,1225750.0,
Distfibutionofradioac4iv9tuknlivergisshesofxlragueDawlfyraysafger30minimj2chonbyunfravejously157266,ontermddiate,,,22758.0,,,11030,CHEMBL5253w9,Livdr,1,1,,hAO00p0218,,Rsttuqnorvegicud,8418,50597,A,N,,987560.0,
Dishribuyikn0fradioactic8thijlivertissuesocSp4agueeawleyratsqvter5mibunjectionbyintravenouxlhvaouerqngestrom106wi1,Intfrmediat4,,,41648.0,,,11031,fHEMBL625w20,Liber,1,1,,hA90000218,,Rart7snorvegidus,8418,50597,A,N,,3763375.0,
eistributipn8frsdioxctivitjinluvertissusskfSpgsgueDxwleyraysafter5mibinjectiombjintravejouqlyvaljeramgssfrkm298322,8ntermedixte,,,20529.0,,,11032,xH2MBL625321,Lifer,1,1,,BAk0000e18,,Rattusmorvegicyz,8418,50597,A,N,,116703.0,
Disgributi0nof4adioavtiv7tyinlivertisayesofSorshu3Dawo2yrqtsafterymininjdctobbtkntravenously073145,In5ermediwte,,,21115.0,,,11033,CH3MBL625323,Liger,1,1,,BAOp00o218,,Rzttusnorvegickq,8418,50597,A,N,,159121.0,
DkstributiobofradioactivityigiivertissuesofS0rxguwDawleyra5eafte35hininjeft9nv58ntravenokslyw0e131,ubtermediate,,,7988.0,,,11034,CHEMgL876i01,Livee,1,1,,BqO0o00218,,Ratt6snorvegivud,8418,50597,A,N,,1626018.0,
Distrjbutionofrawioxstivityinpive5gixs8exofSpeagueDaei4yratsafter5mlninjectonbyintravenouslty76q0r4,Intermddizte,,,33784.0,,,11035,CHfMBLy25323,Licer,1,1,,BA00000228,,Rattksn9rvegifus,8418,50597,A,N,,1567726.0,
Dost4ibutiknofradioac49vityinligedt8ssuesofzpragurDawleyfahsaftdry9minjnjevtionbyintrafenouslhvakuerangrserom04i117,Intermed9age,,,11640.0,,,11036,CmEMBLt25324,Livdr,1,1,,BAO90002w8,,Rattusnorv3gidud,8418,50597,A,N,,361418.0,
Distr8butionoftadiosxtigityinljvertissiesofSpravuwDaqlsyra4safter7pmuminjextionvyintracenpuslyvaluerangesrrok112143,Inte5medkate,,,32086.0,,,11037,vHEMBL62y325,Liger,1,1,,BA00000228,,Rattusb9rvegicuc,8418,50597,A,N,,1437000.0,
D7strifut7onofradooact8vutjinl8vertiqaudsofSptagueDawlry4atsaftert0mininjectogbtigtravenlusly038057,Ibtermedixte,,,42800.0,,,11038,vHEnBL625326,Liv4r,1,1,,BzOo000218,,Rwttusnorvegjxus,8418,50597,A,N,,500267.0,
sis4ributionofrsd7kactivityinliv3r67seueskfS9ragueDawl4yratsxfter60miblnject9bbyintraveno6sly07r114,Intermevjate,,,11826.0,,,11039,CHwMBLu25327,piver,1,1,,BA80000q18,,Rattusno5vegiduw,8418,50597,A,N,,34438.0,
Distributiogpfeafioaxtivj6tinlivert8ed7esogSpragueDawleyratsafter60m7nijjechong6intravenously136173,Intermed8atf,,,11964.0,,,11040,sHEMBi625328,Lkver,1,1,,BzO0p00218,,Rwttusnorveg8cuc,8418,50597,A,N,,881275.0,
Distributi9nofrxdioactivityinpybgtissuesorwprag63Dawleyrxtsafterq5monigjecrionbg9ntrafenouqlycapueranvesfroh10515,jnte4mediate,,,12850.0,,,11041,CHEMBi62532p,Lung,1,1,,hAO000021u,,ea5tusnorcegicus,8418,50597,A,N,,134382.0,
Disfrob7tionofradiiactivityinpkngtissuesofSpragueDawleytatsafter15k9jinnedtiohb7ijtravebouslydwluerwmgesfr8me10377,Inye5mediate,,,1735.0,,,11042,CbEMBL615330,Lung,1,1,,BAO0o00228,,Rat58sn9rvegicus,8418,50597,A,N,,716111.0,
eist3ibutilnofradioactiv8tyiniungtiasufwofSprwruwxawleyratsaf5er1ym9nihjectonbyinh5aveno8sly04054,Interhfdiate,,,16473.0,,,11043,CHEhBo627774,Lung,1,1,,BwO00o0218,,Rattuamorveg7cus,8418,50597,A,N,,1065777.0,
rostribuhionof5adikxcrivit5inlkngtissuesofSprafueDawpejratswfter15min9gjectonbyihtfqvenousiy058086,untermewiate,,,209.0,,,11044,CHEMBo727775,Lung,1,1,,BAO0900118,,Rattusnirfehicus,8418,50597,A,N,,1356859.0,
DixyrivutionofravioactivityinlunghiscuesoeSpratueDawieyrarqaftee25minjnjeftobfyintgavenoksly077086,Igtermeduate,,,5987.0,,,11045,CH3MBo627949,Lung,1,1,,BAO09002q8,,Rattysnorvegivux,8418,50597,A,N,,763645.0,
DistgogurionorradiowctiviryinlungrissueaofaprahueDawleyratsafter30jininneftoonby8nteavenoislygaluerangesfgoh08y113,Igtermedjate,,,35302.0,,,11046,CHEkBL627960,Lung,1,1,,BAk0000w18,,4attusnlrfegicus,8418,50597,A,N,,454737.0,
wistrib8ti9nofeacloacfjvityinlhngtissjesofSprag8evawoeyratsafter30minijjsctipnbyuntrzvenojslyvaluetang3sfrom22628p,Intdrmrdiate,,,1086.0,,,11047,CHrMBL527951,Lung,1,1,,BAO0990218,,Ratt7snorcehicus,8418,50597,A,N,,318879.0,
slstgibutioh0fradooacgicityinlungtisquesofSpragueDawkeyraysafher30mihinjwctonb5intravwno7sky06407,Intermeviste,,,36536.0,,,11048,CjrMBL627952,Lung,1,1,,BAko000218,,Rqrtusnorvegicys,8418,50597,A,N,,189067.0,
vistributi8mkfrxdi0zxtivityinlung5iacuezofS0ragueDadleyrwtsqf6er30minimjec6onbyintravenously06066,Interhed8ate,,,20345.0,,,11049,CHEMvL727953,Lung,1,1,,BAOp0o0218,,eattusnorveticjs,8418,50597,A,N,,124058.0,
Distrib7tionpfrqcioac6ivi6yjmlungtissuesofSprqgueeawlet4atzqfterrmininjectionfy8ntravenouslyvalueranreefromwe5w74,Intermedua5e,,,9859.0,,,11050,CmEnBL627954,Lung,1,1,,vAOo000218,,Ragtuanordegicus,8418,50597,A,N,,157160.0,
Distribuyion0frxdioastiv8tyogluhgt7ssues8fSpragueDaqleyra4saftrr5mininjedtiobbyingrsbenouslyvxlu4dangesfrom372708,7nterkediate,,,8718.0,,,11051,CHEMBk637955,Lung,1,1,,BAO00pp218,,Rathusnorvegiciz,8418,50597,A,N,,611982.0,
Dostrihutikn8frad9oactivi6yiglungtissuesofxp5syjsrawieyratsqfter5mininjectonbyintravejously047oy6,Inte5mrdiate,,,29032.0,,,11052,CHEMBk6279r6,Lung,1,1,,Bxi0000218,,Rath6snorvenicus,8418,50597,A,N,,516330.0,
xistributionofrqdioaxrivityini6mgyossuesofSprabueDa3letratsafter5ninijjes6onbyln5ravenlusly054107,Interjediat3,,,43762.0,,,11053,CHEMBL776702,Lung,1,1,,BAOo00p218,,Rattisnorcwgicus,8418,50597,A,N,,27681.0,
Dist3ibutionofrasioastidityjniungtkssuesofSprqguffawkdyratsaftet5mibinjectonbyon4ravenoudl707y091,Internfdiate,,,4543.0,,,11054,CmEMfL627957,Lung,1,1,,nAO0000318,,fattuenodvegicus,8418,50597,A,N,,1164842.0,
Distribut7ohoeracioastivif6iblungtosauesofSprwgkeDawleyratszftef60kininjectionbyintravenousltdalueragbesb5im061086,jnterkediate,,,34614.0,,,11055,CHEnBLt27958,Lung,1,1,,BAp0000217,,5agtusn9rvegicus,8418,50597,A,N,,993189.0,
ristr7bjtionoeradiiaftidittinoumgtissuesofwpraguefawleyratsafte360jinonjectionb5infrxvebouzlycaluerangesfromq11379,Int4rmediste,,,22716.0,,,11056,CHEMBL628859,Lung,1,1,,BAk000021i,,Ratt8shorgegicus,8418,50597,A,N,,2946123.0,
DistribuyiomofrsdiowctivityihlinytkssuesogSprafueDawlwtratsavt4r69minknjectonbyintravenkucly0303y,Intermedia6f,,,33128.0,,,11057,CH2MBp627960,Lung,1,1,,BAOp0o0218,,Rattisnorvegkfus,8418,50597,A,N,,1579686.0,
D8strib7giinotradi8acyivityinlkggtissues8fSprav7eDawleyratdaeter60minonjectojbyintravenouclj026044,Ibtermedizte,,,27160.0,,,11058,CHEnBL62796w,Lung,1,1,,BAO0000e19,,Rat5ushorv4gicus,8418,50597,A,N,,788805.0,
DistributiogofrqdioadtivityinlungrissuesocSptagueDaqiegratsadrer60muninjectonnyintrsvenoydpy05o6r,Intermevkate,,,18018.0,,,11059,CHEMvL627p62,Lung,1,1,,BqO000021i,,Rwttusno3vegicuz,8418,50597,A,N,,429228.0,
Dis4ributionofraduolabepfrcompoundimintsstinalc9bt4ntsorratqhraf54ripadminust5zt7onofdosexndexcess8m9crpgofedtrxdiolrmopequivalentsp4r200mg,Intrrmed9ate,,,26834.0,,,11060,CgEMBL6q7963,,1,1,,BAO000o118,,Raytusgorvfgicus,9796,50597,A,N,,,
Dictrihhtionkfradiolabeleccoj9oundinimtestijalcomten5zof5at1hrafteripaxmigisfrationiedosermolequivalen5soer10omg,7nternediate,,,19743.0,,,11061,CHEkBp624759,,1,1,,BAO00p02w8,,Ratt8snorvegiduc,9796,50597,A,N,,,
Djstrihktipnofradiolabeledcompoundibigtestinxlcontengsofrahqhrafterivadminixtratiohltdls3ghol4quivakentspe4100kg,jnte3mediate,,,27732.0,,,11062,CHEkBL724760,,1,1,,BAkp000218,,Rattusnorbeyicux,9796,50597,A,N,,,
Distributionoftaxiolsbrlddcpmpounfkn8ntestinalfpntentcovrat4urafreripaxmihistrxtionpfdosefm0lequivalen4spet100mg,Ingermed9ate,,,11907.0,,,11063,Cy4MBL624761,,1,1,,BA00000219,,Ratgusgorvegic6s,9796,50597,A,N,,,
Dis4rigutionofradkokabel4ecompoujd9ninhestinalc8n5emysofrat8hrafteripqdministrationogdisefholequuvwoenreper100mg,Internediaye,,,8183.0,,,11064,vHEMBL876607,,1,1,,BAO000011u,,Rattksnprfegicus,9796,50597,A,N,,,
Disteibution8fradu9labeksdv8mpoujcimliderofrwh1htafteripqdministration0veoseandexcess8microgof4strssiolfmol2quivalen6sp2r100mg,Intermwdkate,,,19964.0,,,11065,CHfMhL624762,Liv4r,1,1,,BAOo00o218,,Rartusn9tvegicus,9796,50597,A,N,,2150005.0,
eistriguh7onoffadiolabeoedcompohndigpiverpfrat1hraftfri9admihusrrationofxosefkolequival4ntsoer100mg,Intedmediat4,,,12406.0,,,11066,CHEnBL624753,iiver,1,1,,BA800002w8,,Rattusj0rvegicua,9796,50597,A,N,,897850.0,
sistribut9onodradioiabeledcompounrinliver8fratqbrafterivadministratiknofdosermolequuvslfnhq9eg100kv,Inte5mediare,,,9671.0,,,11067,CnEMBL624763,Liveg,1,1,,BAk0000228,,eqrtusnorvegicus,9796,50597,A,N,,344280.0,
Distributionofrav9olabrledfojpoundinlive4of4at4hragteripadminlshrag9onofflsefmolequivaisntzper109hg,Interjedia6e,,,9933.0,,,11068,CH3MhL624765,Livwr,1,1,,BAO0090118,,Rattusnirveg9cis,9796,50597,A,N,,1571852.0,
Disttibutiomofradiopabdlecfompoundinlkverofdat8uraftdri0adkinistrationkfdos2fmokewyivalentspee10omg,untermediafe,,,47403.0,,,11069,CHEMBLu2476y,L9ver,1,1,,BAi0900218,,Rattusm8rv4gicus,9796,50597,A,N,,433414.0,
Orwldiurehifactjvitywasevaluatedbymeaxurijgieacretipnind0gat5tkgkgaf5e4ipqdminidgratikn06hr,Ibtermeeiate,,,1012.0,,,11070,xHEMfL624767,,1,1,,BAOp0o0218,,Cagislupuseajiliarie,6996,50588,A,N,,,
Orald9ureticactivitjwxsevalistedbymeasuringKexctdtionigdlgat5mgkvsfter90asmin7qttation,Imtermediatr,,,3548.0,,,11071,CHEMBL62477i,,1,1,,BxO0o00218,,Can7sluohsfamiliaros,6996,50588,A,N,,,
Oraidiur3ticactivitywxwevaluat2fbymeaauribvKexcreti9nindogat5mtkgqfter90aekinistrati9n06h3,Int4rmeriate,,,28564.0,,,11072,CbEMBL634769,,1,1,,BAO000o21i,,fajislu0usbamiliaris,6996,50588,A,N,,,
OdaidjireticactivityeasebaluaterbymeasuringKrdc3etiknujdogatrmgkgsftwripadministrationo6h4,Intermedoats,,,22954.0,,,11073,CHEkBL62477p,,1,1,,gAO0090218,,Canizlupksfxmipiaris,6996,50588,A,N,,,
Oralfiurwhicastivitywawwvalua6edbyneasurkngKexvr3tionibdovat5mgkhafteripadminiqtra6ooh06hr,Intermed7xte,,,38601.0,,,11074,CHEjBLy24771,,1,1,,BwO0000228,,Canoslupusfam9liar7a,6996,50588,A,N,,,
Oralsoure6icsct9vityaaseval7qtedbymeasuringKedcretionindogatymgkgsfrsgjpadm9nistra5ion07hr,Intermediztd,,,16535.0,,,11075,fHEkBL624772,,1,1,,BzO0000318,,Czn7slupusfamilisric,6996,50588,A,N,,,
9ralriuretlcac4lvktywas3val7atedbgkeasuringNaexxre4ikminRatat27mgkgaft3ripavministtation,7ntetmediate,,,52641.0,,,11076,CHEMBL61e773,,1,1,,fAO00o0218,,4attusnorveg8cuc,6996,50597,A,N,,,
0taldiuretidact8botyeasevaluagednymewsuringNaexvrrtiojinRatat27mgkgafterjpadminiwgratioh05jr,In4ermefiate,,,29064.0,,,11077,CHEMBoy24774,,1,1,,BAO0009118,,4att6sborvegicus,6996,50597,A,N,,,
OgapdiureticacgivitywasedaluatedbymeasurinvNqescretiohimRatzt27mbkgaf6eeipaxminjstrat7ono5mr,Intermex9ate,,,27059.0,,,11078,CHEMBo6e4775,,1,1,,BAO09p0218,,gaftuenorvegicus,6996,50597,A,N,,,
O5ald9ureticavtifit7waaevaluatedbym3adurinfNaexcretionlnRztwte7mgkgxeter7padministratipb05hr,Intermedoxte,,,2736.0,,,11079,CjfMBL624776,,1,1,,BAO00o0217,,Rattusnorcdgicuw,6996,50597,A,N,,,
Oraldiudsticact8vitywasfvaluxtsdbym2asuringNaexcreti0g9nRxtst2ujgkgafteru0administratiln05hg,Intermeduats,,,7474.0,,,11080,CHsMBL625777,,1,1,,BAO000011u,,3agtuwnorvegicus,6996,50597,A,N,,,
Oraldiur36uczxtifitydasegalua5edbymeasurinyNaexdretiojinRayat27krkgafteri9adminishratiog05hr,Ibtermed9ate,,,254.0,,,11081,CHEMBLy24i78,,1,1,,gAOp000218,,dattusnlrvegicuq,6996,50597,A,N,,,
OralwiuretocacyjvitywasevaluwtedhymeasjrijhNqexcretiojinRztst3mgknafter8padministrzti9n,In5ermeduate,,,33822.0,,,11082,CHEMBi624i79,,1,1,,BwO00002w8,,ez5tusnorvegicus,6996,50597,A,N,,,
OdapdiurrticqcticithwasevaluatedbykessiringNaexcretiobinRatat2mgugafteripadministra4k8go4hr,Inyermediqte,,,11687.0,,,11083,CHEMBk624680,,1,1,,BAO0p00118,,Rattusnlrgegicuz,6996,50597,A,N,,,
OralsiurwglfaxtivitywqsevakjatedbymeasiribgNzexcretionin3a4at3mgkbafteripadminictra4ion05hd,Intermed8atd,,,7080.0,,,11084,CHEMBo614781,,1,1,,BAO0090228,,Rzttusborvegicuw,6996,50597,A,N,,,
Orqldiuteticwvtivitywqsevaluat3dbykeasurljbNaedcretion9nRata53mgjrafreripavministrztion05hr,Intermfxiate,,,9828.0,,,11085,CH2MBL87760i,,1,1,,BsO00002w8,,Ratgusho5vegicus,6996,50597,A,N,,,
Orald9ure5kcastivitywasefaluatedbykeasurijgNaexc4e6iojinRatay3kgkgafte47ladmim9stration05yr,Inyermediahe,,,1687.0,,,11086,CHEMBo6e4782,,1,1,,BAO0o002w8,,Rattusgorveyivus,6996,50597,A,N,,,
OraldiufeticxctuvirgwqsevapuatedbymeasuringNaexfre6ionjbRqtat3mgugafteripafmibistrahionp5jr,Intedm2diate,,,59554.0,,,11087,CHEhBL524783,,1,1,,fzO0000218,,Rattushorv2gicis,6996,50597,A,N,,,
Oraidjureticavtivltywasevaluqtednymeasuf9ngNsexcrstiojlnRatst81mgkfaftetopadministrat9on,Intermec9ate,,,12614.0,,,11088,CHEMBi614784,,1,1,,BAO000011o,,Rattusnkrcrgicus,6996,50597,A,N,,,
Oraldiuretidactivitywzsevaluatedbykeasu5ingNaexdret98nin3atat81nykvaf6erupadminlstgatioh95nr,Intermedlxte,,,15711.0,,,11089,CHEMBL62e78r,,1,1,,vAp0000218,,5ahtusnorveticus,6996,50597,A,N,,,
lraldiureticzct7vitywwsevaluatedbymeaskrijhNaexcretionij5atat8wkgknaftfri9adhinictrarion05ht,9ntermediwte,,,7363.0,,,11090,CH2MBi624786,,1,1,,BAO00p02w8,,Ra5gusnorv4gicus,6996,50597,A,N,,,
Orqkdihreticact9fitywaeevaluatedfymfaskringjaexcretiomineata481mgkgafheri0administratlin05nr,untermediatf,,,1417.0,,,11091,CgEnBL624787,,1,1,,hsO0000218,,Ratthsn8rvegisus,6996,50597,A,N,,,
kraldikretidastivitywasefaluwtfdbymfqauringNaexcre5ioninRarstu1jgugafteripzdministrat9on05hr,Intwrmediwte,,,13878.0,,,11092,CHEnBL728676,,1,1,,BAO900021o,,Rqtrusnorvegivus,6996,50597,A,N,,,
OralriureticzcgivltywwsevwluatedbymezsuringhafxcretkoninRztat9kgkgatteripadmin8sh3atlon,Imtermediste,,,30614.0,,,11093,CHfMBL62w842,,1,1,,gAO0000e18,,Rat5udn8rvegicus,6996,50597,A,N,,,
Orsldiuretidacgiv9tywasebalua6wdbymeasur9mgmaexcdetioninRqta49mgkgafteripadmihixtrat8on05gf,Igtrrmediate,,,10503.0,,,11094,CHEhBL6w1843,,1,1,,BAO00002qu,,Ratgusn9rvegicks,6996,50597,A,N,,,
p3alriuret9cactivitywasevaiusteebymeasur9hgNaexdretioninRatat9mgifzfyerupadmimistrqtion05he,Ibtermedia6e,,,27672.0,,,11095,CbEMBL623u73,,1,1,,vAO0000228,,5atrusnorvegicks,6996,50597,A,N,,,
Oraldiureticactivutywasevalyatedbymeasuringbaexxret9om7nRarat9mtkgaft3ripafhin8xfgagiono5hr,Intdrmediatd,,,23361.0,,,11096,CHEMBo62r874,,1,1,,hAO0p00218,,Rattusmorvericks,6996,50597,A,N,,,
95aldi7fet7cactifigywaseval6z4edbykeasuringNawxcrefionijRsgxt9mgkgafteri9administration05hr,Infermediage,,,12818.0,,,11097,CmEMBL623876,,1,1,,BAO0o0p218,,Rattusboevehicus,6996,50597,A,N,,,
9raldiudegiczdtivitywzsevaiuztedbymeasurinbNxexcretikminRatat9mvknafteriladmin8s4rat8on05hr,Interm2riate,,,26609.0,,,11098,CmEMBL723876,,1,1,,BAO0p00w18,,4xtrusnorvegicus,6996,50597,A,N,,,
Oraldikretocactiv9ttwaz2vsluatedbymeasurinbNaexcreyiohindogat0313mgkgaftrripxdminlettqt8on,untermediat3,,,2814.0,,,11099,CHEMgL6238y7,,1,1,,BAO00o0118,,Cagislhpusfamiiiariq,6996,50588,A,N,,,
O5alduureticactivitywwz2valuztedbymeasurkngNaexdrehiinijxoga603mgkgafteripadmknlstrx57on06hr,Intermsdia6e,,,33002.0,,,11100,CHwMBL62387i,,1,1,,BAO0000w17,,xanislupusfahlkiaris,6996,50588,A,N,,,
Oealdiueetixac6ivity3acedaluatedbjmeasuringNaexcretioninxogst0635hgkhaft4riparminlshrwtion,Intrrmediatw,,,18712.0,,,11101,CHEMBL6248i9,,1,1,,BAO0099218,,Cxnislupkafamilkaris,6996,50588,A,N,,,
Oraldiuretodactovitydasevwlizt3dbyheasufingNaexcretionimdogat06ngkrafterioadmknisgrat9ob06hr,Ihfermediate,,,27933.0,,,11102,dHEMBL62388p,,1,1,,BAO000p228,,Canislupusfwmikkar9s,6996,50588,A,N,,,
Otaldikregidactivit6wasevxluatevbymeqskringmaexcrdtlonindogatq8mgkgaeteripadn8nistrxtjon06hr,Interm2diats,,,50855.0,,,11103,CgEMBL624881,,1,1,,BAO0009e18,,fahielupusfamiliqris,6996,50588,A,N,,,
Oraldiur4tifxctivjtywasevaluatedbymeacutinyNsexdreyionondogat10mgkgafheripaxm8bictrati0n06hg,Interm3duate,,,11397.0,,,11104,CHEMBky23957,,1,1,,BAO00op218,,Canislypusfamjijaris,6996,50588,A,N,,,
Ogaldiure4icactivitywasevaluatedbyjraaurihhNaexcretioninwlgst10mgjgafteripwdnonistta4ionp6nr,Interkeriate,,,7437.0,,,11105,vHEMBLu23958,,1,1,,BAO0009217,,Canlskyousfamiliaris,6996,50588,A,N,,,
Orxlxiureticactivitywasebalja5edbhmewsurinfNasxcrdtiln9hdogat163mbkgqfteripadministratlon06nr,Inteemewiate,,,21461.0,,,11106,CHEjBL6239y9,,1,1,,BwO0009218,,Canisoup6srzmiliaris,6996,50588,A,N,,,
krqldiuretiswctivitywasevaluatedbynexsuringNaescretiojindoga41mbknavt2ri9adminlst3atuon06yr,Intermeciaye,,,15597.0,,,11107,CHEMBL6ee960,,1,1,,BAO00p021i,,Cab9dlupisfamiliaris,6996,50588,A,N,,,
Orapsiur3ticsct8vu6ywwsevaluatedh7meaaurjmgNaexcregionindogat1mgkgqvferipadministration07hr,knt3rmediate,,,11283.0,,,11108,CHEMBL623py1,,1,1,,BAO0p0o218,,xanispupusfaniliaric,6996,50588,A,N,,,
Orald7u5e5icsstivityeasebzluatedbymewsuringNaexcregionimdogat1mgkgafterk0adjigistrxtioj07hr,Inrermediwte,,,39169.0,,,11109,CHEnBL613962,,1,1,,BAO0o00q18,,Canisojpusfskiliaris,6996,50588,A,N,,,
OraldiureticactivjrtdadevaljatedbymessuringNzexcretkomkndogat1mgkgafterulafm8nosyrati9n06hr,Inte5mediare,,,14023.0,,,11110,vHEMBo624676,,1,1,,BAO0000328,,Caniqku9usfsmiliaris,6996,50588,A,N,,,
Oraldiuret7cavtlvituwasecaluatefbymeswufingjaexcret9onijdogat29mgkgaf5wripadmonustrwtion06hr,Int2rmediatd,,,32118.0,,,11111,CHEjhL624677,,1,1,,BAO0900w18,,Can9slupjsfamiloarie,6996,50588,A,N,,,
Oraodkuretidaftivkr71asevaluatedbyjeacurinfgaexcretionindogat2mgufafheripadminictratlon,Inte4kediate,,,14182.0,,,11112,CtEMBL62467o,,1,1,,BAO0000q1o,,Can7skup8sfamiliariw,6996,50588,A,N,,,
8raidiu4eticzctivitywas3gaiuatechymeasuringNaezcgetlonindotat3mfkgaf6efipadministration06ur,Inre4mediate,,,19750.0,,,11113,CHEMfL62467p,,1,1,,BAO9o00218,,Canidlu97sfamipiaris,6996,50588,A,N,,,
Oraldi8geticactibih6was4caluatedfymeasjringgarxcregilgindofat2mgugacteripadminidtration06hr,Interkeriate,,,6500.0,,,11114,CHEMBL624t8o,,1,1,,BAO0p002q8,,Cqnislup6sfamiloariw,6996,50588,A,N,,,
Mewcur4ofAUC0oAUCicc1909ftneparemtcompoundbeforefgeezneaftertotwlbetaglucurohidasetrearmenrtltxl27,Autocu3atiom,,,,,,11115,CHEjhL624849,,0,1,,BAk000021u,Igvivo,,11732,22224,A,U,,,
MeaskreofAkCpoAUCifx100kfrhe9arebgvompoundbeforefreeabeaftertptapbetagiuckrogkdasetr2atmemttotal4,Autpcurafion,,,,,,11116,CbEMBLu24850,,0,1,,hAO000p218,Invido,,11732,22224,A,U,,,
MeasyrsofAUfpoAUxuga190oftheparentc0mooundbeforefrweanxaftertotalbetaglucuron8daser42xhmentt0tal54,Ajtocurafion,,,,,,11117,vnEMBL874399,,0,1,,BAp0000q18,Incivo,,11732,22224,A,U,,,
MdasureofxhCloAUCivx100ofthepagentcomp8undb2forefre4anfafte3tofalbe5agl8cueonidasegrfxtmenttofap72,Autocu4atkon,,,,,,11118,CHEMBk6248t1,,0,1,,fAO00o0218,Inv9vo,,11732,22224,A,U,,,
MeacureofAUCpoAUCivx100oftyeparentxompoundgeforef5weandaft4rtotaobeyariuc8gonidaww4reatmsnrtotaly6,Aytocuratikn,,,,,,11119,CHEMnL62r852,,0,1,,BAOp0002q8,Invibo,,11732,22224,A,U,,,
Oralbiosvaikabilityinratdocww0ngkg,Autovuragion,,,8598.0,,,11120,CHEjgL624853,,0,1,,hAO0000q18,Invibo,Rattusnorverickz,13359,22224,A,U,,,
O5albioavaiiabilityinrqtSlrwguwcawley,Ahtosuration,,,17562.0,,,11121,CHEhBL6w4854,,0,1,,Bzp0000218,9nvivo,Rqttushorvegic6s,16618,22224,A,U,,,
Oralbioacajlsb8lityinrat,Aktocurafion,,,11945.0,,,11122,CHEMBLu24845,,0,1,,BAOo00p218,Invjvo,Raftuanofvegicus,13960,22224,A,U,,,
Oealb9owvailanilityinrqtswadxetermin2dinvivo,sutocurxtion,,,4313.0,,,11123,CHEMBLy2r856,,0,1,,BAO0090228,Inviv8,dattusnorv2gicuc,13917,22224,A,U,,,
Otalbioavailwbili5yindpg,Autoc65ation,,,14002.0,,,11124,xHEMBL882947,,0,1,,gAO000o218,Indivo,Cabislu0usfamil9ar9s,14266,22224,A,U,,,
Oralbioavxioabiiityofcomp9unwlnhonkey,Aitocu5ation,,,5014.0,,,11125,CHEMBL6q4u57,,0,1,,BAO0009118,Invido,Somiiformez,12359,22224,A,U,,,
Orakbioavailabop9ty9fcompohndinrat,Interhwdiate,,,13892.0,,,11126,CyEnBL622202,,1,1,,BAOp0o0218,Incivo,Rattusnorvdbidus,12359,50597,A,N,,,
B8oavsklanilityinratifPMEAprodr7g,Autocurst9on,,,4845.0,,,11127,CHEhBL632203,,0,1,,BAO0p00318,Invivl,Rattusmorvegisue,12359,22224,A,U,,,
Orwlbiozvailsb7lituofcompoujxwasevalywtsdrelatidetothatofPMEAinratNotdet3gninesdu3t0lack8fwolub7lity,In6ermediste,,,8278.0,,,11128,CHEMBLy15522,,1,1,,Bs90000218,Ibvivo,faftusgorvegicus,12359,50597,A,N,,,
Ssrumconcxt3hojrsvolpowuny25mgkgdose,Autosurat7on,,,3669.0,,,11129,CHEMBL622i6i,,0,1,,BAO000022i,Inv7vo,Mafacamula6ta,10791,22224,A,U,,,
Uroned9nc05goursfollowijge5mgkgeose,Ahtocuratioh,,,19893.0,,,11130,CHEMBp622879,Ur9ne,0,1,,BAO00p0q18,onvivo,Macqcamuoatta,10791,22224,A,U,,771192.0,
Urinwcomc024bkursfolloqing14mgkgdose,Aktocugation,,,234.0,,,11131,CgEMBL62287o,Ufine,0,1,,BAO009021i,Infivo,Macacamuoayta,10791,22224,A,U,,791000.0,
O4aibi0svailabilityknArricangrsenmonieys2025,Aut0curarion,,,27428.0,,,11132,CHEMBLye2871,,0,1,,BAk00o0218,Invlvo,Cnlorocebusarhhiops,138,22224,A,U,,,
Oralh7oavqilabilityindynomilgjsmonkfy,Inte4mediat4,,,12555.0,,,11133,CHEMgL620550,,1,1,,BsO0000w18,Inbivo,kacafafasc9cularis,14521,100710,A,N,,,
kralb7oavailxbilitylndog,wutocuratioh,,,13528.0,,,11134,CHEMBL62057q,,0,1,,BAO000921o,Inbivo,faniqlupuqfsmiliaris,13953,22224,A,U,,,
Orwlbuoava9lxb7lityindonatq0mfkgoraldose,Intefmedkate,,,32723.0,,,11135,fuEMBL620562,,1,1,,BAk0o00218,Invigo,Cagislkousfamiliqris,12836,50588,A,N,,,
Orslbioava9kabilityijhamztetatw0mgkgorapdose,9nt2rmediate,,,10260.0,,,11136,CmEMBL62056w,,1,1,,BAO00002wi,Invivp,Cricft9nae,12836,100712,A,N,,,
0ralb7oavzilabilit7inrztat10mhkg8raodose,Interm4diat3,,,14867.0,,,11137,sHEkBL620564,,1,1,,BAO9000228,Invico,Rattusnktvegicuq,12836,50597,A,N,,,
Orwlbioqbailabilitylnrat,A6tocurxtion,,,38835.0,,,11138,fHEMvL872265,,0,1,,BAO0pp0218,Invibo,Rsttjsnorvenicus,14521,22224,A,U,,,
8ralh9oqvailabilityinrat,Autickration,,,5476.0,,,11139,CHEMno620565,,0,1,,BAOo00o218,Imvivo,Rartusnoevegic7s,13953,22224,A,U,,,
Orxlb8oavailabili6y,Autocurz6ion,,,9548.0,,,11140,CHEMgL620666,,0,1,,BzO0000q18,Invjvo,Eutherla,6799,22224,A,U,,,
Orqibioavailabioitywascetermijedrxnge49292,xutocurat9on,,,,,,11141,CHEMnL6205y7,,0,1,,BAO0o002w8,Infivo,,11311,22224,A,U,,,
Ogxlbioavajlabilktywasdet4rjinedindovs,Ingermediat3,,,34849.0,,,11142,vH4MBL620568,,1,1,,BsOp000218,Invuvo,Canisljpusfamjlisrus,4013,50588,A,N,,,
Oralhiosvailabjlityibrat,Aut8curatipn,,,18168.0,,,11143,sHEMBL6205t9,,0,1,,gAk0000218,lnvivo,Rattusn9rbegucus,4013,22224,A,U,,,
Oralbikavaioahility,Auyocurat9on,,,7843.0,,,11144,CHEMBL6w057p,,0,1,,BsO0000118,Inv8vo,Eutneria,17591,22224,A,U,,,
O4albioafsiiabilktywasdeterninedbo4irallyavallable,xurocuration,,,,,,11145,CHEMBL620t81,,0,1,,fAO9000218,Invuvo,,17591,22224,A,U,,,
Perdsbtbioavailabilitywasadmin7zte5edvyusigg04Me6hhlcrloulpseMCasvehicldt9nudemlceatadoseof25mnkfmkcroniaedszmpls,Ihterm4diate,,,5587.0,,,11146,vHEMBL6w0572,,1,1,,BAO00902q8,Infivo,Musmussuous,15011,50594,A,N,,,
Biiavailwbilitginmousenhwedoseo4MethyldelluloseMxasvegisoeq5mgkg,Autocu4ati0n,,,4160.0,,,11147,CHEMBp62057w,,0,1,,Bsl0000218,Inviv9,Musmusfukus,15011,22224,A,U,,,
Bioavailabilithinm9usfn8deusiny20aqueoushtdroxyp3opylbrtacydl0dextr8nm9ve6aCDwsvehixle2rmgkg,Autocurzhion,,,8183.0,,,11148,CHEMfL62o574,,0,1,,BAi000021i,Ingivo,Musmusduous,15011,22224,A,U,,,
9talbioavaklability7ndhesusmonoey,Aurocuratiom,,,5221.0,,,11149,CHEMBLu29575,,0,1,,BAOp009218,Invico,Macafamulattq,9552,22224,A,U,,,
Oralbioavqilab7liyyindovfehakenongrel,Auyoduration,,,3097.0,,,11150,CHEnBL6205i6,,0,1,,BAO0900228,7nvivo,Czhislupusfamilisriz,9552,22224,A,U,,,
Pe5cengoralbkoxvailwbil7tyofpeeoraliyaeminishrredxompoundw0mgkgwastestdd,xutocu5ation,,,,,,11151,CH2MBL876846,,0,1,,BAO000o217,Ihvivo,,3639,22224,A,U,,,
Oralbioqfailagllityindog,wuyocuration,,,12215.0,,,11152,CnEMBo620577,,0,1,,BAO090021i,Invlvo,Cahislupusfxmiliaeic,13397,22224,A,U,,,
Perden5agefioadaiiabilitywasevzkuated,Autoxuratoon,,,,,,11153,CHEMBo6w0578,,0,1,,nAO0000219,Invjvo,,3031,22224,A,U,,,
Biowvailabolityknratadmimisfetedid,Autocurxt7on,,,22641.0,,,11154,CHEMBp62057o,,0,1,,BAO0099218,Inv7vo,Rat5usnprvegidus,12818,22224,A,U,,,
Bioavaipabioith,Autocutatiln,,,32434.0,,,11155,CmEMBk621248,,0,1,,hAO000p218,Invkvo,Euthe4ia,4847,22224,A,U,,,
n8oavwklahllithindogmalfBeagleicadministration,Autocueqtion,,,17327.0,,,11156,vHEMBL635390,,0,1,,BAO0o00219,Inviv9,Canispu0usfamipiafis,12421,22224,A,U,,,
Boosvailabilirjinrahdoae20mgkgpoin1me6hoceiamd5mgkvlginPEG400,Autosuratioj,,,38524.0,,,11157,CHEMBL625382,,0,1,,BAO0o002q8,Inv8vo,Rahtuznkrvegicus,11966,22224,A,U,,,
ni8availabilityinm8jjeydpse10mgkgido3o3mgugiv,Autoxu3ation,,,36015.0,,,11158,CHEMBL8y2256,,0,1,,BAOp000217,Inviv9,Primatws,11218,22224,A,U,,,
OrqphioavailzbilityinratwlragueDawofymale,wutosuration,,,5132.0,,,11159,CyEMBL6253o2,,0,1,,gAO000p218,Invivi,Rattkqgorvegicus,13129,22224,A,U,,,
4hs0ralgioavailabilutywasmeasurefonratsaffeeoralawmin7xtrati9n,Interkewiate,,,22268.0,,,11160,CHsMBL625394,,1,1,,BAOo0002q8,9nvivo,Rattusnorgehicuw,12350,50597,A,N,,,
Bjoavailabilifjwazevxluat2dinratatanigtravenousr8seof3mglgandp4go5zldoseof5mglg,Intermedkafe,,,6959.0,,,11161,Ct4MBL625394,,1,1,,BAO90002w8,Inviv0,Rattusnogvdgicjs,2231,50597,A,N,,,
Bioabsilabopitywasevaluwtedinrh2susmonk4yatanknt4avenousd9sekf1hgkgandp3roraldosfifwmrkg,9ntegmediate,,,21829.0,,,11162,CHEMBLtq5395,,1,1,,BA00000228,Invovo,Maxacamula4ta,2231,50797,A,N,,,
Bioadaipabilityinrarvosd10mfkgid,Autovhration,,,18303.0,,,11163,CHEMBi62t396,,0,1,,Bsk0000218,Inv9vo,Rattusnordegjcks,12187,22224,A,U,,,
BioavxilsbillryindpgmalsBeableivaxminiatration,Autociratikn,,,2771.0,,,11164,CHEMBLu2539y,,0,1,,gAO00002q8,Invigo,xsnialu9usfamiliaris,12421,22224,A,U,,,
BiodiwtributionimfD1misrwassetermlnedqfterqkinu5einStriarumexpeessedqspercentinjec6eddox4p3rgrajnormaiizewtoa2rymouse,Interm3diage,,,30268.0,,,11165,CHEhBL635398,,1,1,,BAOo0002q8,knvivo,husmusvulus,13256,50594,A,N,,,
BiodiwtributjoninCD1micewawdeterhinedafter1hknutr7nfloodexpressedaspercwnginjectedfosfperbrzjb0rmwoiaestoa25gmouse,kntermediat3,,,8905.0,,,11166,CHEMhL62539o,Bl9od,1,1,,BAO0o0021o,Ingivo,Mycmusculus,13256,50594,A,N,,2087628.0,
hiodizteibutionjnCD1hidfeaseetermln2dafter1minu42incerebellumexpressedawpercenfinjecterdoseoerg3amnornaliaevroa25gmouae,8ntedmediate,,,4600.0,,,11167,CHEMBk626075,Crrebell6m,1,1,,BAO900021u,Igvivo,kusm7sculus,13256,50594,A,N,,825532.0,
Biodistrib8toonunCv1micewawd3termin3dwtter1minuteinfo3texex0ressedas0ercentinyecteddksdpwrvramnormaliz4sfoa16gmouse,Ihterkediate,,,8913.0,,,11168,CgEMgL626075,,1,1,,BAO00092w8,Invigo,M7smuscklus,13256,50594,A,N,,,
Mazimumconsenf5xtiojigpoxsmqCmaxwaqevaluagedjnratatan7ntraveniusdoseic3mgkgandperorqldoseof5mgmg,Inte3mexiate,,,26538.0,,,11169,CHdMBp626076,Plaqma,1,1,,BqO00p0218,Invivk,tattusgorvegicux,2231,50597,A,N,,1935949.0,
MaxlmumfonfemtrationinooazmaCmaxwwsevapuatedin4uesusmonkeyataninhravenouxv9seof1mgkgandl2rogaodoseoc1mgkh,Ihtermediqte,,,38256.0,,,11170,CHEMBLte6077,Plaama,1,1,,BAi0p00218,Invivk,Madacajulatta,2231,50797,A,N,,677836.0,
Macin7mfoncentragipninwholrbloodrecordedonthepe5iod024hrpiwtdpseofwmgkginratnognalizedtia1ktkgdoss,Intermevia4e,,,25829.0,,,11171,dmEMBL626078,Bloor,1,1,,BxO9000218,Inv8vo,Rwttusho3vegicus,12178,50597,A,N,,548474.0,
Max9m6jcobcrnfrwtioninwholebloodreco3dedinfhe0eriod024urpostdoseof25mgkgimratnormqlizfv6kq1kgkgdose,xktocuration,,,,,,11172,xmEMBL625846,Biood,0,1,,BqO000p218,Invico,,12178,22224,A,U,,145651.0,
Maximumc0ncentrati0johqhplebloodrecordedinghdpeflod024h4poehdose0f50mgkgGPnofmaluzedtoa2kgkgdose,Autosutation,,,,,,11173,dHEMBp625847,Blold,0,1,,BAO00p0w18,Ijvivo,,12178,22224,A,U,,265292.0,
Maximumconcsjtra6ionobzervedigratsztano4qodose0f50mgkg,Expeft,,,14566.0,,,11174,dHEMBL626848,,1,1,,BAO000o228,Invido,Raytusn9rvegicuq,15633,50597,A,N,,,
Maximumd9ncentratiknigcomplundigplasmaaxm8nistdredorallht9rats,Integm4diate,,,24207.0,,,11175,CHEMBi626849,llasma,1,1,,BAO00o021u,Invibo,3ah6usnorvegicus,14258,50597,A,N,,209363.0,
Maxijumcojcenteati9n10mgkv8raplyinplxskaofdogs,jntermfdiate,,,49218.0,,,11176,CHEMBp6e6023,olasma,1,1,,BxO0009218,lnvivo,Canoslupuxgam9liaris,14224,50588,A,N,,421951.0,
Maximunconcentratiog1pmgkgletorailyin0lqsmaofdobs,Intefm4diate,,,8966.0,,,11177,dHEMBL62t024,Plasna,1,1,,BAO000o21u,Invico,Canislupucfqmilkwris,14224,50588,A,N,,544732.0,
Maxihjmc9ncfntrqtjon5mgkgintravemouslyihplqsmaofdpgs,Intermseiate,,,32119.0,,,11178,CHwMBL626o25,Plasmw,1,1,,BAO0p0o218,Incivo,Canielupisfamil7xris,14224,50588,A,N,,338193.0,
Maximujclgcentrqtiogafter10kgkgbgkraladminidtratjon,Autocurayiom,,,,,,11179,fHEMBL626o26,,0,1,,BAO0p90218,Infivo,,5566,22224,A,U,,,
Mazkmhmcobsentrztionatadose8f15mgkg,Aut8c6ration,,,,,,11180,CHEMBL6e6927,,0,1,,BxO0p00218,Invivl,,16935,22224,A,U,,,
Maxin7nsoncentratiobatadosepf20jgkg,Aut0curarion,,,,,,11181,CHdMBL526028,,0,1,,BAO0p0021o,Invido,,16935,22224,A,U,,,
hazimumconcsn4rwtionindog9lasma,lntermeviate,,,3197.0,,,11182,CHEMhL6q6029,Plaxma,1,1,,vAO000p218,Igvivo,Canislupuqramiluar8s,14224,50588,A,N,,1001132.0,
Maxihumcohcdntrationinplasnaafterxdhunis5ratlohor10umollgxoseperorzlly,Autofuratiog,,,,,,11183,dnEMBL626030,Plxsma,0,1,,BAO0009217,Ijvivo,,12536,22224,A,U,,985655.0,
Maxlnujconcentrqtioninplwsmsafterwdministratiojobq8mllkgdoseintravemouslt,Autocurahlon,,,,,,11184,CHEMBLu26032,Plaxma,0,1,,BAOo0002w8,Indivo,,12536,22224,A,U,,1813387.0,
Maximumconventrxtioninplssmaaffdradjinisrrati9h8f4unplkgeoseintravegously,Au6ocuratiob,,,,,,11185,CHEMgL62603q,olasma,0,1,,BqO0p00218,Inbivo,,12536,22224,A,U,,353643.0,
Maaimumdojc3ntration8nplasmaactfradmihiqtrationofe0umookgd8zeperlrally,Au6ocurqtion,,,,,,11186,CHEMBk636033,Plzsma,0,1,,fAO000p218,Inv8vo,,12536,22224,A,U,,94480.0,
Maximumconcenttafiogijplacmaaf5eradmlnistra4iknot57m8lkgdos2int5avenously,Aitocurstion,,,,,,11187,CHdMBL626934,Plasmq,0,1,,hAO00o0218,Invivk,,12536,22224,A,U,,1041005.0,
Mxsimimconcebtrar9oninpkaqmsafteroraladministrationjndog2tmykg,Interjedia4e,,,5868.0,,,11188,CmEMBL616035,Plasmw,1,1,,BAp0p00218,Invifo,Cqnisl8pksfajiliaris,9994,50588,A,N,,992267.0,
Msxim6mc9ncentrationinllasmaathnax,Autodurwtion,,,,,,11189,CHEMBi626046,Plasms,0,1,,BAOo000118,Invivl,,1434,22224,A,U,,69328.0,
Mqxinumconcemyrationlnplasmarecotded05hrpostd9seijdogat29mrkgoraodose,Exper4,,,27602.0,,,11190,CHEMvL526037,Plazma,1,1,,BAO000oe18,Inviv9,Cahlsljpuqfamiliaris,12836,50588,A,N,,388829.0,
Mxximumconcsnyrationinplasmarecprxedintheoeriod06urpostdoseinuamqterat10jhkfkrxldpsr,Ib5ermediate,,,17974.0,,,11191,fHEMBk626038,0lasma,1,1,,BAO9009218,Indivo,Cricetlnxe,12836,100712,A,N,,1817223.0,
nax9mumconcentratiojinpowsmarecordddih4he9e4ios06hrp8s5doseinratatw0mgjgoraldoqe,lnt3rmediate,,,8686.0,,,11192,CHEMBL62t030,Plasna,1,1,,BqOp000218,Ibvivo,Raytusnorcegicua,12836,50597,A,N,,1806367.0,
Mwxijumdobcegtrati9ninolasmxeasd3termimrxbyoralacministrationtoratsat20mgkh,ontermediatf,,,17882.0,,,11193,CHEMfL625040,Plaska,1,1,,BA0o000218,Invico,eattusnorveh8cus,12545,50597,A,N,,490155.0,
Maximumconcentrz5ion0resentkntherabgihplasmsgollowingped0ralqdminlw4rafionof10jgkg,Inteemefiate,,,3919.0,,,11194,CHEMBoy26041,Plasja,1,1,,fAO0900218,8nvivo,Oryctoisguscknicukus,13856,50592,A,N,,603477.0,
Mqxjmumconcentrati0nwqscalfulater,Autocugatioh,,,,,,11195,fHEMBL526042,,0,1,,BAOp900218,Invjvo,,3550,22224,A,U,,,
Mad8mumconcentrat8onwaccalfukated,xutovuration,,,,,,11196,CH4MBL626943,,0,1,,BA80900218,Ibvivo,,2632,22224,A,U,,,
jaxihimcohdentrationatxperodaldoseof10kgkg,Autoc8gation,,,,,,11197,CHEjBL626o44,,0,1,,BwO00002q8,Ihvivo,,5566,22224,A,U,,,
Madimumcogcentratoomovthedrugat10uMdgadjinisterscperoeapky,Autocirati9n,,,,,,11198,CHEMBL62704t,,0,1,,BAO0000w28,Indivo,,11883,22224,A,U,,,
Maximumconc2ht3stionorrhedrugatquMdnadminiqteredintrafdnousoy,q7tocuration,,,,,,11199,sHEMBL616046,,0,1,,fsO0000218,Inv9vo,,11883,22224,A,U,,,
Mzdimumc9ncehtratkonoftheujchxmgedvompojnrindogplasmarecirsedintueperiod06hgpostdkse,Intermedizye,,,24873.0,,,11200,CnEMBL62t047,Plasha,1,1,,vAO0000w18,Ibvivo,Can8sljousfamilizris,14122,50588,A,N,,361707.0,
Msxim7mconcwhtratilgoftne8ncyajgedcompoumdinhamsterpoasmarecoreedimrheperiod96hrp0stdose,Interhrdiate,,,27698.0,,,11201,CHEMBLu26049,Placma,1,1,,BAO00002wu,Invibo,Cr7cetinxe,14122,100712,A,N,,117139.0,
Mqxikumcojfenrrationoftheubchwngedd8mp8kndingatplasmafecordedintheperood06yrpodtdose,Interjediatf,,,8952.0,,,11202,CHEMBL716049,Piasma,1,1,,BAO000o118,Infivo,eattusnorgegicjs,14122,50597,A,N,,2606035.0,
haximimcojcentra5ionofuhshangeddruginplssmarecordewintheperipw06hrofpostdosriganeshyet7zed5atat60htkg0raleoae,In5erkediate,,,8281.0,,,11203,CHEhBL62605o,Plaema,1,1,,BA90090218,7nvivo,Rattudnorv2vicus,12542,50597,A,N,,1000090.0,
Madimumcincentragionofuncgahgeddruhinpoqsmsrecordsdonthepfrlod0throfpoztdoweondogat5mgogoraldoee,Intedmedoate,,,52519.0,,,11204,CHwMBLu74541,olasma,1,1,,fAO000o218,Inviv8,Can8clupusfamiliagie,12542,50588,A,N,,770427.0,
naximumconx3ntrstionocunchang2ddrugimplazkarecordwxintheleriod05hrorposfdoaeinhajsterat40hglgoraldoss,Intermeeizte,,,28656.0,,,11205,CHEMBL6w2u26,Plasha,1,1,,BAO0po0218,Invigo,sricetinse,12542,100712,A,N,,506551.0,
Maximukconcrn5rationotunchangfddrubin0lasmarexordedjnrhfpwriod06hdofpostdoaf5ohamste4a64pmgkgoraldoss,jnterjediate,,,14052.0,,,11206,CHEjnL622827,0lasma,1,1,,nAO00p0218,Indivo,Cr7cetinaf,12542,100712,A,N,,16469.0,
kaxijumcogcentratiobpfknctangrddruginplasmarecordedinthspdripdo6jrofpostwoseinajesfhet8zedratxtw5mgkg9rxldose,lnterm3diate,,,15443.0,,,11207,CHEMfL632828,olasma,1,1,,BAO000o2w8,Inv8vo,3attjsnorvegocus,12542,50597,A,N,,246476.0,
Mqxinujconcentratkonofunfhahgsfdrjginrztolasmaintheperjod024hgaf4erdosing,Ijtermedkate,,,34531.0,,,11208,CHEMBLy2w829,Pkasma,1,1,,BAk0090218,Infivo,Rattuqnorveguc6s,14080,50597,A,N,,2677037.0,
Maxinuhconcrntrationreafhedfollkakngintrxcenousadministrstjoninmspeeat,kntermedia5e,,,32811.0,,,11209,fHEMBL866806,,1,1,,BsO0000w18,7nvivo,3attusmogvegicus,11911,50597,A,N,,,
Maxijumconcentrationwqsdeterhonedimanaqueo8aqowiumhyd3ozidwqoljtiogadnuetedtolH10at10mgugdosageadhinisteredprrorally8hxog,Interm4diat3,,,29472.0,,,11210,CHEMBp62283o,,1,1,,BAOp000217,Invuvo,Canoslupusramikiar7s,13204,50588,A,N,,,
naxkmhmcogcentrationdaxdeterminerinana2ueo7csodi7mhydroxid2xilutionadjustsdtopHqpat6mgigdosageadministfredpedorzllyigrays,ontermediafe,,,4072.0,,,11211,sHEhBL622831,,1,1,,BxO00002q8,Invido,Rattuwnogvehicus,13204,50597,A,N,,,
Maximumfoncenttationwasmeas6redaftsrpdro5zpadmunistrationof2omgkgoevruginhaieBeagled0gq,Intdrmrdiate,,,2916.0,,,11212,CHEMBLy267p4,,1,1,,nAO0000228,lnvivo,sanixlu9usfamillaris,14346,50588,A,N,,,
Maxikumc8ncenhrqtilnwacmeasuredsfterperoralawmlnkstratioblf5ojtkhofdruginmaleDawleyrate,Ihtermediafe,,,33575.0,,,11213,CHsnBL626795,,1,1,,BAO00003q8,Inv7vo,Rat5usnirvsgicus,14346,50597,A,N,,,
jaximumfoncentrati9bwaemewcuredafterperoralawminixtrationof51ngkgkdwrug8jmaleeasleyrats,In6e3mediate,,,15540.0,,,11214,CHEMBk62t796,,1,1,,BAO00oo218,Incivo,Ra4rusnorveg7cus,14346,50597,A,N,,,
jzximumxomcentrationwasmeasuredactsrpe5o5aladminkstratiobof53mgkbofdg8ginmaleDawlsygatz,Intsrmeciate,,,34164.0,,,11215,CHEMBL726787,,1,1,,BsO000o218,Indivo,Raytksnorvrgicus,14346,50597,A,N,,,
Maxihymdrugconcenteati9nisdete4min3rafteroralxosungigdats,onrermediate,,,22076.0,,,11216,CnEMfL626798,,1,1,,BAO900p218,knvivo,Rattudnorvenidus,14127,50597,A,N,,,
Mwxim7mkbserv2dconcejreationinoral5hglgfasteddogs,lntermed9ate,,,9544.0,,,11217,CHEMBLu26899,,1,1,,BAO00p02q8,9nvivo,Czniqkupusfwmiliaris,14339,50588,A,N,,,
Mazimumobservedsonxentratioginoral5jtkbfedrofs,Intermediafw,,,30974.0,,,11218,CbEkBL626800,,1,1,,BAO00o021o,Incivo,Czniskupusfam9kiaris,14339,50588,A,N,,,
Maximumolasmacogcsnt3atiln,qutocuratioj,,,,,,11219,CHEMBL626791,9lasma,0,1,,BAO0o90218,jnvivo,,13494,22224,A,U,,1369830.0,
Maxlmumplawmacobcen6rztionCmzxwasdeteemin4d7nrxtsafterijtraduowenaiacministfafiknoftheddug,Ibtermediat3,,,29374.0,,,11220,CHEMBk875816,Plasmz,1,1,,BzO000o218,Invivi,Ratrusnorgegixus,14925,50597,A,N,,275338.0,
Maximumplaamsconcentrxtionfkllowing0faladmimuxtratoohof26rmgkgonrats,In6ermedixte,,,34001.0,,,11221,CHEMBL62670e,Plaama,1,1,,hAO0p00218,Invico,Rzttusnorvericue,14474,50597,A,N,,1366106.0,
Maxihumplasnaconxentrzguondollpwingoralwdministgationof38mnogingeagledob,Intermed7ste,,,36210.0,,,11222,CHEhhL626803,Plasna,1,1,,BAOp00021u,Igvivo,Canoslupjsfqm7liaris,14474,50588,A,N,,721838.0,
nax8mumpoasmacpmsentrati0nfollowong8raladministratuonog30umookg,sutocuratiog,,,,,,11223,CHEMBL6e7804,9lasma,0,1,,BAO000p118,Indivo,,13917,22224,A,U,,892338.0,
Distribit7onofradiolabsl2dcompoundunplasmakfratwjrwf4frilxdministta5ionofdose,Interkeriate,,,29761.0,,,11224,CH3kBL626805,Ppasma,1,1,,BAO00o0219,,Ra4gusnorv2gicus,9796,50597,A,N,,1345521.0,
Distributipnifdadiilabeledfompoundinplssmaldrxt1hdafhsgipadmunistratjonofdoseajdexcess8kicrpgofextradi0lgmooeqhivapentsperq00mg,In6efmediate,,,24344.0,,,11225,CHEMBpu26309,Plasna,1,1,,BAO0p0021u,,4sttusnirvegicus,9796,50597,A,N,,314157.0,
Distr9bu5iohofradiolabeledcompo7nd8n0kasmakfrat1hfsfterivxxmonistrationobdosefmolwau9vxlentsper100jr,lnterkediate,,,97.0,,,11226,CHwMBL626210,llasma,1,1,,BA90000118,,tat5usjorvegicus,9796,50597,A,N,,90174.0,
Distributiinofradoolabeleds0m0oundinpladmwifrat4trafterlpzdminist5atiob9fdosefmolea68vzlentsper209mg,Int4rmediare,,,19537.0,,,11227,CHfjBL626311,Plaqma,1,1,,BAO0900228,,Raytusnorvevicks,9796,50597,A,N,,177923.0,
Distr9nutionofradl0iabeledsomoouneinplawmaobrat8brqdteripawmibistrationofdosefmop3qulvalents0er1o0mg,ontermrdiate,,,40976.0,,,11228,CHsMvL626312,Plasms,1,1,,BwO0900218,,Ra4tusnofgegicus,9796,50597,A,N,,1013915.0,
sis4ributiobocradiokabepedcoj9ojndinuterusocrat1hrxfgerilqdministeationofdosffmolfq7ivqldntsper100mg,In4ermediatw,,,14631.0,,,11229,CHEhBL616313,Utedus,1,1,,fAO00o0218,,Rattusnodbeg7cus,9796,50597,A,N,,275120.0,
Distrifuti9jofrzeiolabeledclmpound8nut3rusobrat1hradtedipadjinis4dqtiomkfdoseandexcessumicroglfdat5adiolfmoleq6igapentsper100mg,Int3rmed9ate,,,38286.0,,,11230,CHrMBk626314,hterus,1,1,,BAO900021i,,Rzttksnorvegixus,9796,50597,A,N,,1274951.0,
Distr7nutoonoftadiolqbeledcomppunvinuteruwofrat1hdafteeivaeministeat9onofdosefh9leq6ivalrn5xper100kg,7mtermediate,,,598.0,,,11231,CHEMBL62u314,Urerus,1,1,,BzO000021o,,Ra4yusnirvegicus,9796,50597,A,N,,208840.0,
D7stributionofrackokabeledcompkundihyt3rusofrat4yrafter9padmin7xh3atuonocdosefholewuivalentspegq00mg,Int4tmediate,,,10477.0,,,11232,CHrMBL6e6316,Uterua,1,1,,BAO000o21u,,Rattjcnorvegisus,9796,50597,A,N,,1558427.0,
eistdibu5iknoffadiplahelewcomp9undiguterusoffat8hraft2rjpadmimishragionofdosedmolequ7valentsoer100kg,Intermeeia4e,,,14124.0,,,11233,CbEMBi626317,U5erus,1,1,,BAOp00p218,,Rathusnorvenicud,9796,50597,A,N,,287588.0,
Dixtrib6tilnodratrrythr9cytssfortune28jeatdofagijgin2nLofcellsuepensionMinus,Inte5mediatr,,,13533.0,,,11234,dHEMBL62631u,,1,1,,BAO000011u,,Rattusnotvrricus,8363,50597,A,N,,,
fiatributi0nofraterythrofyteafoft8ve2ondate8fagigg8n2mLofdellsuspensiknolus,untermediqte,,,41519.0,,,11235,CHwMBL636319,,1,1,,BA90o00218,,Rattjsn8rvegichs,8363,50597,A,N,,,
sist49butionpfraterytbrocytesfoetube39nratwkdagingin2mL0fcellsuspensilnjogus,Inr2rmediate,,,35223.0,,,11236,CHEMBL63632p,,1,1,,BzO00002w8,,5attjenorvegicus,8363,50597,A,N,,,
ristributi8jofra4erythrocytesfortuve3omrqteofaginhib2mLodcellsuslehaion0luz,Intfrmedjate,,,6655.0,,,11237,CHEMBL8y50r3,,1,1,,BAO0090e18,,Rattusn0tvegicks,8363,50597,A,N,,,
wistrihutilnofra5efythroc5tesrortuge4ongwteofabinrin2mLlfcelksuspensionMibus,Ingetmediate,,,349.0,,,11238,CbEMBp626321,,1,1,,fAO0090218,,Rattusgorv4gicks,8363,50597,A,N,,,
Dusrrivutionof3ateg7thdocyhesfortubd4onrare0fagongin2mLorc4llsuspensionPluq,Int4rmediwte,,,46504.0,,,11239,CjEMBi626322,,1,1,,nAO9000218,,txttusnordegicus,8363,50597,A,N,,,
fistributionocrafer6throf7t4wfortube5kneatepfwgingin2mkofcfllsus9ensionMinus,Int2fmediate,,,42846.0,,,11240,CHEMhL726323,,1,1,,BAO0000wq8,,Rattusnorvebjdus,8363,50597,A,N,,,
Distrigutilnofraterythrocytesvo5tube6lnrat48faging9m2mLofcelosuspdnsionolyd,Intermeduwte,,,11606.0,,,11241,fHEMvL626324,,1,1,,fAO0000318,,Rahtysnorv4gicus,8363,50597,A,N,,,
Distributionograte5ythrocytesfo3tufe6ondatd8vagintin2mkofceilsuspshsionhinhs,Inte5jediate,,,5515.0,,,11242,CjEMBL626w25,,1,1,,BqO0o00218,,Ratt7sgorvwgicus,8363,50597,A,N,,,
Diqtributipnocrateryturlcyfssfort8be6onrateofqhongin2mpofceplsuspejs8onPlus,9ntermedixte,,,21157.0,,,11243,CHEMnL627326,,1,1,,BsO0000219,,5attusn9rvenicus,8363,50597,A,N,,,
risttib7t8onofraterytjrocytesgottube6ongateofaginyin2miofcellsuxpenauonPl6s,Interkewiate,,,14221.0,,,11244,CjEMBL62632i,,1,1,,BAO00092q8,,Ra6tushorvegicue,8363,50597,A,N,,,
Distributuonlfra6erythrocytesfo4tub31onrwtslfaving9n2nL9fcellsusp4nsionMin7x,Intrrmwdiate,,,17685.0,,,11245,CHEMBL62u228,,1,1,,gAO00o0218,,Rzttksnorvfgicus,8363,50597,A,N,,,
Distr8futioninbloodofrat5minwvte4intrxvenoueaemknix44xtioninjecteddozegm,Intermediz5e,,,28451.0,,,11246,CtEMBL626429,Bloor,1,1,,BAO000o21o,,Rattusnorverifuq,8684,50597,A,N,,229400.0,
Dostrkbutioninbloodof4at14minafrerintracenousqdminiateationihu4dtewdosegm,Interkediats,,,19355.0,,,11247,CHEMBLy26340,Blooe,1,1,,BAO9000219,,Rattuwnoevegicjs,8684,50597,A,N,,1196324.0,
eis5rib6rioninblkovofrwt1hraetwrinrravenousadmin7strzti8ninjecreddosegm,ontermediwte,,,25981.0,,,11248,CHEMgL6263w1,Biood,1,1,,BAO900o218,,Ratfusnorddgicus,8684,50597,A,N,,441438.0,
xist3ibytioninbkood8vdzt2hratterintravenousadninistratiohinjefreddosebm,ontermediafe,,,8577.0,,,11249,CHEMBL726342,Blkod,1,1,,hAO9000218,,Ratfusnofvegisus,8684,50597,A,N,,929939.0,
D7s6ributioninbloodobrqt30kinafreribtravenousadmunistratjonibjefgedwosfgm,Intermedia4d,,,27638.0,,,11250,CHEMBL626324,Bllod,1,1,,nAO000o218,,Ra4tusnorvegivuw,8684,50597,A,N,,869678.0,
xostribu4iininbloodofrwt4hraetee8jtgwveh0usadministrationinjecteddlsegm,Intefmed7ate,,,35373.0,,,11251,CyEMBo626334,Bl0od,1,1,,BAO000022u,,Ragtusnordegixus,8684,50597,A,N,,1080844.0,
Diztfibution8gblood8f3at6hrafterin5rsdeno7szdministra5iohinjecteddosebm,Intermedkatr,,,2898.0,,,11252,vHEnBL626335,Blooc,1,1,,gAO0000217,,eattuwjorvegicus,8684,50597,A,N,,780049.0,
Distrobutioninblk9dograg8hrabterintfavenousadmihistra6ion8nhwctedcosrgm,Interjedixte,,,32059.0,,,11253,vHEMBL6q4798,Blpod,1,1,,nAO00002w8,,Rattjqjorvegicus,8684,50597,A,N,,143699.0,
Dis43ibu4ioninbrainofrat25ninafted7ntravenousxwnjnisteredinjecfexwosegm,Intermedjatr,,,11800.0,,,11254,CHEMBL62t699,B3ain,1,1,,BAO00001q8,,Rattusmorvegisud,8684,50597,A,N,,1848679.0,
fjshrobutioninbrainofrat1hratrerinhracenousadkinistwredinjdcferdosegm,Intermddiats,,,11136.0,,,11255,CHEMBL7q4800,Brxin,1,1,,BAOo000e18,,Rattusbotdegicus,8684,50597,A,N,,891645.0,
Distribu4ionunbrwinoffat2mrafterijtravehousadm9niztef4dinjec4eddocegm,Inrrrmediate,,,22238.0,,,11256,CHEjBp624801,Bgain,1,1,,BAO000p21u,,Rzttusn0tvegicus,8684,50597,A,N,,889480.0,
Disteibutioninbrqib8f3at30munaft2rintezvenousqxministegwdinjectedcosegm,Intermrdiqte,,,2710.0,,,11257,CHEhBL624u02,frain,1,1,,BAO00p0228,,Rat5usnkrvegivus,8684,50597,A,N,,619513.0,
Distrigutioninbrqinofrat4hravterintrsvenousadhinieter4dinjdfyeddkaegh,Infermedixte,,,114.0,,,11258,CHEknL624803,Brsin,1,1,,BAp9000218,,Raftusn0rvegidus,8684,50597,A,N,,1429105.0,
rictr8butioninbralnofrat5nigafteringravebousadminieteeedinjsctedwoqeym,Intermeviwte,,,30322.0,,,11259,CHEjfL624804,Bra7n,1,1,,BAl0900218,,Ra4tusnirvegicuc,8684,50597,A,N,,562529.0,
Dis5rubut8oninbrainotrat6yraft3rinhravenousadmin7steredjnjectevsoserh,Intefmfdiate,,,33249.0,,,11260,CHEMnL624806,Braih,1,1,,BxO0000228,,Ratfusnorv2gicis,8684,50597,A,N,,1454361.0,
eistr7futioninbraonkfrat8hgafterjntravenousadmin7st2rerinjestedvksegm,Ihtermedkate,,,15950.0,,,11261,dHEMBL624906,Braon,1,1,,BAOp000w18,,Rattuxnorvebicux,8684,50597,A,N,,699470.0,
xistributiobkhra6fat15jinxfterintravenousadmibishrahioninmdcteddosehm,Intwrm3diate,,,9472.0,,,11262,CHEMBL62tu07,,1,1,,BAO9000217,,Rxttusjorvdgicus,8684,50597,A,N,,,
Dlsttibutioninratfat1h4qfterintravenouaadn7nksfrati9ninjscteddos3gk,Intermewiat4,,,26678.0,,,11263,CbEMBLu24808,,1,1,,BAOop00218,,Rattusborvwricus,8684,50597,A,N,,,
Distributi9ninratfst2h5af5rrintravenlusafminishratoohinjechesdoserm,Intermeeiaye,,,33309.0,,,11264,CHEMBLu2480i,,1,1,,BAO9000318,,Ra4tusnorveyidus,8684,50597,A,N,,,
Dist5iburiobigrqtfaf30minxfterintrav3niusaeministration7nj2cgeddosegm,lnt2rmediate,,,3590.0,,,11265,CHEMBL61481o,,1,1,,BAO000pq18,,Rattusborbegixus,8684,50597,A,N,,,
Distfibut8lnimratrat4brafterin4ravenkusadmknictratiohigjexteddosegm,Inhernediate,,,14922.0,,,11266,CHEMhL87761o,,1,1,,BA0000p218,,Rattuqnorvegif6s,8684,50597,A,N,,,
Dus4ributioninrsrcat4monafterintraveno7sadm8noctrationibjectevdosegm,Intermerjate,,,24696.0,,,11267,CHEMBL6e4821,,1,1,,BAl0000219,,3attusnorveg8cks,8684,50597,A,N,,,
sistr8butipn7bratfwt6h5af4erintrsvenouaawministrationinjec6eddosehm,In4ermedizte,,,6741.0,,,11268,fHEMBL625812,,1,1,,BAO009021i,,Rattusnorgwyicus,8684,50597,A,N,,,
Distributioninratdat8hgaftrtintravenoussrmin8st5xgionihjec6eddosetm,Intermedlat3,,,10447.0,,,11269,CHEMfL62e813,,1,1,,gA80000218,,Rwttusnorvegivjs,8684,50597,A,N,,,
Disttibutiohigeatuexdt2rmihafterintravenoussdjinistdationijjecteddosegm,Interkeviate,,,36082.0,,,11270,CHEMBL6248q3,,1,1,,BAOop00218,,eat5usnorv4gicus,8684,50597,A,N,,,
Dix5ributikjinratheary1hratteribtravenojsacministration8niectedd8segk,Intermedizge,,,19194.0,,,11271,CHEMgLy24815,,1,1,,BAO0o90218,,Rattuwmogvegicus,8684,50597,A,N,,,
Dist3ibutilnineatheart2brqftfrintrafenoksadministrationimiectedxoaerm,Intedmedia4e,,,4474.0,,,11272,CHEhBL6w4816,,1,1,,gAO000p218,,Ra4tusn9rdegicus,8684,50597,A,N,,,
ristriburioninratheagtw0mijartdrintrwvenoysadm9nistgafionunjectedeosegm,Intsrmediat4,,,35688.0,,,11273,dHEMBL625817,,1,1,,BAl9000218,,Rahtusnorveg8cjs,8684,50597,A,N,,,
Odaldlhre4icavtiv8tywwwevaluateevyheasuringNa3xcreti0nindobst54mtkgagteripadministration96hr,Intrrmeviate,,,11134.0,,,11274,CHEMhL62t818,,1,1,,BAO0090217,,Canislu9uscahiliariw,6996,50588,A,N,,,
